PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Bonfoco, E; Li, E; Kolbinger, F; Cooper, NR				Bonfoco, E; Li, E; Kolbinger, F; Cooper, NR			Characterization of a novel proapoptotic caspase-2-and caspase-9-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS; ACTIVATION; DEATH; GENE; PROCASPASE-9; RECRUITMENT; ENCODES; COMPLEX; FAMILY; MEMBER	Caspases play important roles in regulating apoptotic signaling pathways. Here we report the cloning, by the yeast two hybrid system with dominant negative caspase-2 as "bait," of a proapoptotic molecule named proapoptotic caspase adaptor protein (PACA-P), encoded by a 372-base pair open reading frame. Binding of this novel protein to caspase-2 (casp-2) was confirmed in yeast two hybrid, in vitro, and in vivo assays. The deduced amino acid sequence revealed homology to functional motifs, including ATP and cytochrome c binding sites. PACAP mRNA was widely expressed in most human tissues; in transfected cells, PACAP was diffusely expressed in the cytoplasm. Bindings studies with the PACAP recombinant protein demonstrated specific binding to casp-2 and casp-9 but not to casp-3, -4, -7, or -8 in cell extracts. Cotransfection experiments showed that PACAP binds to casp-2 and -9 in 293T cells. In addition, studies with truncated PACAP demonstrated a requirement for residues 39-72 of PACAP for specific binding to casp-2 and -9. Transient transfection of PACAP into 293T human kidney cells and rat-1 fibroblasts triggered apoptosis at 24 h, which was at least in part prevented by an inhibitor of casp-3-like enzymes. Transfection of PACAP into human B cell lines using a retroviral system also triggered apoptotic cell death. In addition, transcription of PACAP in primary human B cells was dramatically down-regulated early after cellular activation by CD40L and Staphylococcus aureus and markedly up-regulated as the cells apoptose. These findings identify a novel proapoptotic caspase adaptor protein.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Novartis Pharma AG, CH-4002 Basel, Switzerland	Scripps Research Institute; Novartis	Cooper, NR (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ebonfoco@scripps.edu	Li, Erguang/N-7676-2019; Li, Erguang/C-2782-2013	Li, Erguang/0000-0002-3065-1336; Li, Erguang/0000-0002-3065-1336				Ahmad M, 1997, CANCER RES, V57, P615; ARMITAGE RJ, 1993, J IMMUNOL, V150, P3671; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bonfoco E, 1996, J NEUROCHEM, V67, P2484; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Chen WP, 1999, J IMMUNOL, V163, P2483; Chu ZL, 2001, J BIOL CHEM, V276, P9239, DOI 10.1074/jbc.M006309200; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; GREEN DR, 1994, CURR OPIN IMMUNOL, V6, P476, DOI 10.1016/0952-7915(94)90130-9; Grignani F, 1998, CANCER RES, V58, P14; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; Harvey NL, 1996, GENES CELLS, V1, P673, DOI 10.1046/j.1365-2443.1996.00255.x; Haviv R, 1998, J NEUROSCI RES, V52, P491, DOI 10.1002/(SICI)1097-4547(19980601)52:5<491::AID-JNR1>3.0.CO;2-7; Hlaing T, 2001, J BIOL CHEM, V276, P9230, DOI 10.1074/jbc.M009853200; Ito A, 2000, FEBS LETT, V470, P360, DOI 10.1016/S0014-5793(00)01351-X; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRISTIANSEN SV, 1994, J IMMUNOL, V153, P2974; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kumar S, 1997, CELL DEATH DIFFER, V4, P378, DOI 10.1038/sj.cdd.4400251; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; MCGEOCH DJ, 1985, VIRUS RES, V3, P271, DOI 10.1016/0168-1702(85)90051-6; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Rothstein TL, 1996, CURR OPIN IMMUNOL, V8, P362, DOI 10.1016/S0952-7915(96)80126-9; RUSSELL DM, 1991, NATURE, V354, P308, DOI 10.1038/354308a0; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Troy CM, 2000, J NEUROSCI, V20, P1386; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	39	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29242	29250		10.1074/jbc.M100684200	http://dx.doi.org/10.1074/jbc.M100684200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11350957	hybrid			2022-12-25	WOS:000170346000082
J	Moroni, A; Gorza, L; Beltrame, M; Gravante, B; Vaccari, T; Bianchi, ME; Altomare, C; Longhi, R; Heurteaux, C; Vitadello, M; Malgaroli, A; DiFrancesco, D				Moroni, A; Gorza, L; Beltrame, M; Gravante, B; Vaccari, T; Bianchi, ME; Altomare, C; Longhi, R; Heurteaux, C; Vitadello, M; Malgaroli, A; DiFrancesco, D			Hyperpolarization-activated cyclic nucleotide-gated channel 1 is a molecular determinant of the cardiac pacemaker current I-f	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SINOATRIAL NODE; MESSENGER-RNA; CATION CHANNEL; INWARD CURRENT; CURRENT I(F); CELLS; HEART; MODULATION; EXPRESSION; HOMOLOGY	The pacemaker current If of the sinoatrial node (SAN) is a major determinant of cardiac diastolic depolarization and plays a key role in controlling heart rate and its modulation by neurotransmitters. Substantial expression of two different mRNAs (HCN4, HCN1) of the family of pacemaker channels (HCN) is found in rabbit SAN, suggesting that the native channels may be formed by different isoforms. Here we report the cloning and heterologous expression of HCN1 from rabbit SAN and its specific localization in pacemaker myocytes. rbHCN1 is an 822-amino acid protein that, in human embryonic kidney 293 cells, displayed electrophysiological properties similar to those of I-f suggesting that HCN1 can form a pacemaker channel. The presence of HCN1 in the SAN myocytes but not in nearby heart regions, and the electrophysiological properties of the channels formed by it, suggest that HCN1 plays a central and specific role in the formation of SAN pacemaker currents.	Univ Milan, Dipartimento Fisiol & Biochim Gen, Sez Fisiol Mol & Neurobiol, I-20133 Milan, Italy; Univ Milan, Dipartimento Biol, I-20133 Milan, Italy; Univ Milan, Dipartimento Genet & Biol Microrganismi, I-20133 Milan, Italy; Univ Padua, Ctr Studio Biol & Fisiopatol Muscolare, CNR, I-35121 Padua, Italy; Univ Padua, Dipartimento Sci Biomed Sperimentali, I-35121 Padua, Italy; Ist Sci San Raffaele, HSR, DIBIT, Dipartimento Ric Sci & Tecnol, I-20123 Milan, Italy; CNR, Ist Biocatalisi & Riconoscimento Mol, I-20131 Milan, Italy; Univ Nice, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France	University of Milan; University of Milan; University of Milan; Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); UDICE-French Research Universities; Universite Cote d'Azur	Moroni, A (corresponding author), Univ Milan, Dipartimento Fisiol & Biochim Gen, Sez Fisiol Mol & Neurobiol, Via Celoria 26, I-20133 Milan, Italy.	anna.moroni@unimi.it	HEURTEAUX, Catherine/M-4947-2016; Beltrame, Monica/D-8093-2017; Malgaroli, Antonio/I-5090-2013; Bianchi, Marco Emilio/K-3417-2018; DiFrancesco, Dario/G-8408-2017; Vaccari, Thomas/B-1945-2015; moroni, anna/H-2097-2014	HEURTEAUX, Catherine/0000-0002-9741-9777; Malgaroli, Antonio/0000-0003-3758-7477; Bianchi, Marco Emilio/0000-0002-5329-6445; DiFrancesco, Dario/0000-0002-7322-1790; Vaccari, Thomas/0000-0002-6231-7105; moroni, anna/0000-0002-1860-406X; GORZA, LUISA/0000-0003-4897-400X; Beltrame, Monica/0000-0001-5094-3494; Altomare, Claudia/0000-0001-8743-9080	Telethon [971] Funding Source: Medline	Telethon(Fondazione Telethon)		Accili EA, 1996, PFLUG ARCH EUR J PHY, V431, P757; Baker K, 1997, P NATL ACAD SCI USA, V94, P4554, DOI 10.1073/pnas.94.9.4554; Baruscotti M, 1997, J PHYSIOL-LONDON, V498, P641, DOI 10.1113/jphysiol.1997.sp021889; Bois P, 1997, J PHYSIOL-LONDON, V501, P565, DOI 10.1111/j.1469-7793.1997.565bm.x; BROWN HF, 1979, NATURE, V280, P235, DOI 10.1038/280235a0; Clapham DE, 1998, NEURON, V21, P5, DOI 10.1016/S0896-6273(00)80508-5; DAMIANI RD, 1993, P NATL ACAD SCI USA, V90, P8244, DOI 10.1073/pnas.90.17.8244; DENYER JC, 1990, J PHYSIOL-LONDON, V428, P405, DOI 10.1113/jphysiol.1990.sp018219; DIFRANCESCO D, 1986, J PHYSIOL-LONDON, V377, P61, DOI 10.1113/jphysiol.1986.sp016177; DIFRANCESCO D, 1988, J PHYSIOL-LONDON, V405, P493, DOI 10.1113/jphysiol.1988.sp017344; DIFRANCESCO D, 1986, NATURE, V324, P470, DOI 10.1038/324470a0; DIFRANCESCO D, 1981, J PHYSIOL-LONDON, V314, P377, DOI 10.1113/jphysiol.1981.sp013714; DIFRANCESCO D, 1994, J PHYSIOL-LONDON, V474, P473, DOI 10.1113/jphysiol.1994.sp020038; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; DiFrancesco D., 1989, NEURONAL CELLULAR OS, P31; EARM YE, 1983, J PHYSIOL-LONDON, V342, P569, DOI 10.1113/jphysiol.1983.sp014869; Gauss R, 1998, NATURE, V393, P583, DOI 10.1038/31248; GORZA L, 1989, CIRC RES, V65, P360, DOI 10.1161/01.RES.65.2.360; HAGIWARA N, 1989, J PHYSIOL-LONDON, V409, P121, DOI 10.1113/jphysiol.1989.sp017488; Ishii TM, 1999, J BIOL CHEM, V274, P12835, DOI 10.1074/jbc.274.18.12835; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Korschen HG, 1999, NATURE, V400, P761, DOI 10.1038/23468; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Ludwig A, 1999, EMBO J, V18, P2323, DOI 10.1093/emboj/18.9.2323; Luthi A, 1998, NEURON, V21, P9, DOI 10.1016/S0896-6273(00)80509-7; MASSONPEVET M, 1979, J MOL CELL CARDIOL, V11, P555, DOI 10.1016/0022-2828(79)90430-9; Moorman AFM, 1998, CIRC RES, V82, P629, DOI 10.1161/01.RES.82.6.629; Moroni A, 2000, PFLUG ARCH EUR J PHY, V439, P618, DOI 10.1007/s004240050985; Moroni A, 1999, BIOPHYS J, V76, pA210; Nitabach MN, 2001, P NATL ACAD SCI USA, V98, P705, DOI 10.1073/pnas.031446198; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; Santoro B, 1997, P NATL ACAD SCI USA, V94, P14815, DOI 10.1073/pnas.94.26.14815; Seifert R, 1999, P NATL ACAD SCI USA, V96, P9391, DOI 10.1073/pnas.96.16.9391; Shi WM, 1999, CIRC RES, V85, pE1; Simpson L, 1996, ANNU REV NEUROSCI, V19, P27, DOI 10.1146/annurev.ne.19.030196.000331; Vaccari T, 1999, BBA-GENE STRUCT EXPR, V1446, P419, DOI 10.1016/S0167-4781(99)00092-5; VANGINNEKEN ACG, 1991, J PHYSIOL-LONDON, V434, P57, DOI 10.1113/jphysiol.1991.sp018459; Verheijck EE, 1998, CIRCULATION, V97, P1623, DOI 10.1161/01.CIR.97.16.1623; Vitadello M, 1996, J MOL CELL CARDIOL, V28, P1833, DOI 10.1006/jmcc.1996.0176; YU HG, 1995, J PHYSIOL-LONDON, V485, P469, DOI 10.1113/jphysiol.1995.sp020743; Zaza A, 1996, J PHYSIOL-LONDON, V491, P347, DOI 10.1113/jphysiol.1996.sp021220	45	77	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29233	29241		10.1074/jbc.M100830200	http://dx.doi.org/10.1074/jbc.M100830200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11328811	hybrid, Green Published			2022-12-25	WOS:000170346000081
J	Chang, CS; Mooser, A; Pluckthun, A; Wlodawer, A				Chang, CS; Mooser, A; Pluckthun, A; Wlodawer, A			Crystal structure of the dimeric C-terminal domain of TonB reveals a novel fold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI TONB; OUTER-MEMBRANE; ENERGY TRANSDUCTION; CYTOPLASMIC MEMBRANE; LIGAND-BINDING; BTUB AFFECT; IN-VIVO; PROTEIN; TRANSPORT; RECEPTOR	The TonB-dependent complex of Gram-negative bacteria couples the inner membrane proton motive force to the active transport of iron siderophore and vitamin B-12 across the outer membrane. The structural basis of that process has not been described so far in full detail. The crystal structure of the C-terminal domain of TonB from Escherichia coli has now been solved by multi-wavelength anomalous diffraction and refined at 1.55-Angstrom resolution, providing the first evidence that this region of TonB (residues 164-239) dimerizes. Moreover, the structure shows a novel architecture that has no structural homologs among any known proteins. The dimer of the C-terminal domain of TonB is cylinder-shaped with a length of 65 Angstrom and a diameter of 25 Angstrom. Each monomer contains three beta strands and a single alpha helix. The two monomers are intertwined with each other, and all six beta -strands of the dimer make a large antiparallel beta -sheet. We propose a plausible model of binding of TonB to FhuA and FepA, two TonB-dependent outer-membrane receptors.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland; NCI, Mol Crystallog Lab, NIH, Frederick, MD 21702 USA	University of Zurich; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pluckthun, A (corresponding author), Univ Zurich, Inst Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	plueckthun@biocfebs.unizh.ch	Plückthun, Andreas/C-2746-2009; Chang, Changsoo/X-3271-2018	Plückthun, Andreas/0000-0003-4191-5306; Chang, Changsoo/0000-0003-1860-2969				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRADBEER C, 1993, J BACTERIOL, V175, P3146, DOI 10.1128/JB.175.10.3146-3150.1993; Braun M, 1999, MOL MICROBIOL, V33, P1037, DOI 10.1046/j.1365-2958.1999.01546.x; Braun V, 1998, MET IONS BIOL SYST, V35, P67; BRAUN V, 1995, FEMS MICROBIOL REV, V16, P295, DOI 10.1111/j.1574-6976.1995.tb00177.x; BREWER S, 1990, J MOL BIOL, V216, P883, DOI 10.1016/S0022-2836(99)80008-4; Buchanan SK, 2001, TRENDS BIOCHEM SCI, V26, P3, DOI 10.1016/S0968-0004(00)01733-3; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; Cadieux N, 1999, P NATL ACAD SCI USA, V96, P10673, DOI 10.1073/pnas.96.19.10673; Cadieux N, 2000, J BACTERIOL, V182, P5954, DOI 10.1128/JB.182.21.5954-5961.2000; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Dauter Z, 2000, ACTA CRYSTALLOGR D, V56, P232, DOI 10.1107/S0907444999016352; Dauter Z, 2001, ACTA CRYSTALLOGR D, V57, P239, DOI 10.1107/S0907444900015249; Ehrmann M, 1998, MOL MICROBIOL, V29, P685, DOI 10.1046/j.1365-2958.1998.00915.x; EICKHELMERICH K, 1989, J BACTERIOL, V171, P5117, DOI 10.1128/jb.171.9.5117-5126.1989; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Forrer P, 1998, GENE, V224, P45, DOI 10.1016/S0378-1119(98)00538-1; Groeger W, 1998, MICROBIOL-SGM, V144, P2759, DOI 10.1099/00221287-144-10-2759; GUDMUNDSDOTTIR A, 1989, J BACTERIOL, V171, P6526, DOI 10.1128/jb.171.12.6526-6533.1989; HANCOCK REW, 1976, J BACTERIOL, V125, P409, DOI 10.1128/JB.125.2.409-415.1976; Higgs PI, 1998, J BACTERIOL, V180, P6031, DOI 10.1128/JB.180.22.6031-6038.1998; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; Jiang XQ, 1997, SCIENCE, V276, P1261, DOI 10.1126/science.276.5316.1261; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KADNER RJ, 1990, MOL MICROBIOL, V4, P2027, DOI 10.1111/j.1365-2958.1990.tb00562.x; KARLSSON M, 1993, MOL MICROBIOL, V8, P379, DOI 10.1111/j.1365-2958.1993.tb01581.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LARSEN RA, 1994, MOL MICROBIOL, V13, P627, DOI 10.1111/j.1365-2958.1994.tb00457.x; LARSEN RA, 1993, MOL MICROBIOL, V10, P943, DOI 10.1111/j.1365-2958.1993.tb00966.x; Larsen RA, 1997, J BACTERIOL, V179, P3213, DOI 10.1128/jb.179.10.3213-3221.1997; Larsen RA, 1996, J BACTERIOL, V178, P1363, DOI 10.1128/jb.178.5.1363-1373.1996; Larsen RA, 1999, MOL MICROBIOL, V31, P1809, DOI 10.1046/j.1365-2958.1999.01317.x; Larsen RA, 2001, J BIOL CHEM, V276, P8111, DOI 10.1074/jbc.M007479200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lazdunski CJ, 1998, J BACTERIOL, V180, P4993, DOI 10.1128/JB.180.19.4993-5002.1998; Letain TE, 1997, MOL MICROBIOL, V24, P271, DOI 10.1046/j.1365-2958.1997.3331703.x; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; Lubkowski J, 1999, STRUCTURE, V7, P711, DOI 10.1016/S0969-2126(99)80092-6; Merianos HJ, 2000, NAT STRUCT BIOL, V7, P205; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moeck GS, 1997, J BIOL CHEM, V272, P28391, DOI 10.1074/jbc.272.45.28391; Moeck GS, 2001, J BACTERIOL, V183, P2755, DOI 10.1128/JB.183.9.2755-2764.2001; Newton SMC, 1997, P NATL ACAD SCI USA, V94, P4560, DOI 10.1073/pnas.94.9.4560; NIKAIDO H, 1992, SCIENCE, V258, P936, DOI 10.1126/science.1279804; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pluckthun A, 1996, ANTIBODY ENG PRACTIC, P203; POSTLE K, 1988, J BIOL CHEM, V263, P11000; POSTLE K, 1993, J BIOENERG BIOMEMBR, V25, P591; REYNOLDS PR, 1980, J BIOL CHEM, V255, P4313; Schirmer T, 1998, J STRUCT BIOL, V121, P101, DOI 10.1006/jsbi.1997.3946; SCHRAMM E, 1987, J BACTERIOL, V169, P3350, DOI 10.1128/jb.169.7.3350-3357.1987; Scott DC, 2001, J BIOL CHEM, V276, P13025, DOI 10.1074/jbc.M011282200; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Sheldrick GM, 1997, METHOD ENZYMOL, V276, P628, DOI 10.1016/S0076-6879(97)76083-X; SKARE JT, 1993, J BIOL CHEM, V268, P16302; Terwilliger TC, 1996, ACTA CRYSTALLOGR D, V52, P749, DOI 10.1107/S0907444996000832; WOOLDRIDGE KG, 1992, J GEN MICROBIOL, V138, P597, DOI 10.1099/00221287-138-3-597	60	102	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27535	27540		10.1074/jbc.M102778200	http://dx.doi.org/10.1074/jbc.M102778200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11328822	hybrid			2022-12-25	WOS:000169966900105
J	Tosaka, A; Ogawa, M; Yoshida, S; Suzuki, M				Tosaka, A; Ogawa, M; Yoshida, S; Suzuki, M			O-helix mutant T664P of Thermus aquaticus DNA polymerase I - Altered catalytic properties for incorporation of incorrect nucleotides but not correct nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FIDELITY; CRYSTAL-STRUCTURES; KLENOW FRAGMENT; ALPHA-HELICES; EXTENSION	Previous studies:indicate that the O-helix of Thermus aquaticus (Taq) DNA polymerase I (pol I) plays an important role in the replication fidelity of the enzyme. This study examines the role of Thr-664, which lies in the middle of the O-helix of Tag pol I. A mutant of Tag Pol I with a proline substitution of Thr-664 (T664P) exhibits much lower replication fidelity than the wildtype enzyme in a forward mutation assay. T664P produces base substitution, single-base deletion, and single-base insertion errors at 20-, 5, and 50-fold higher rates than mild type, respectively. In specific activity and steady-state kinetic experiments, T664P was catalytically robust for insertion of correct nucleotides. In contrast, it incorporated incorrect nucleotides 6.1- to 10-fold more efficiently than wild type at a template dC. Mismatched primer termini were extended by T664P 4.2- to 9.5 fold more efficiently than wild type. These data imply that the O-helix with a proline at position 664 functions like wild type Tag pol I for correct nucleotide incorporations, but bends and enlarges the catalytic pocket of the enzyme and increases the rate of nucleotide misincorporation.	Nagoya Univ, Canc Cell Biol Lab, Dis Mechanism & Control Res Inst, Sch Med, Nagoya, Aichi 4668550, Japan	Nagoya University	Suzuki, M (corresponding author), Nagoya Univ, Canc Cell Biol Lab, Dis Mechanism & Control Res Inst, Sch Med, Nagoya, Aichi 4668550, Japan.	msuzuki@tsuru.med.nagoya-u.ac.jp	Suzuki, Motoshi/I-7246-2014	Suzuki, Motoshi/0000-0003-0682-5006				Astatke M, 1998, P NATL ACAD SCI USA, V95, P3402, DOI 10.1073/pnas.95.7.3402; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; BERNSTEIN FC, 1977, EUR J BIOCHEM, V80, P319, DOI 10.1111/j.1432-1033.1977.tb11885.x; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; BRANDEN C, 1998, INTRO PROTEIN STRUCT, P16; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; ECKERT KA, 1990, NUCLEIC ACIDS RES, V18, P3739, DOI 10.1093/nar/18.13.3739; Gao GX, 1997, P NATL ACAD SCI USA, V94, P407, DOI 10.1073/pnas.94.2.407; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; HUANG MM, 1992, NUCLEIC ACIDS RES, V20, P4567, DOI 10.1093/nar/20.17.4567; Kim MK, 1999, PROTEIN SCI, V8, P1492, DOI 10.1110/ps.8.7.1492; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Li Y, 1998, PROTEIN SCI, V7, P1116, DOI 10.1002/pro.5560070505; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Patel PH, 2000, J BIOL CHEM, V275, P40266, DOI 10.1074/jbc.M005757200; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; Suzuki M, 1996, P NATL ACAD SCI USA, V93, P9670, DOI 10.1073/pnas.93.18.9670; Suzuki M, 2000, J BIOL CHEM, V275, P32728, DOI 10.1074/jbc.M000097200; Suzuki M, 1997, J BIOL CHEM, V272, P11228; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; YOSHIDA S, 1974, BIOCHIM BIOPHYS ACTA, V353, P463, DOI 10.1016/0005-2787(74)90052-5	22	20	23	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27562	27567		10.1074/jbc.M010635200	http://dx.doi.org/10.1074/jbc.M010635200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11346641	hybrid			2022-12-25	WOS:000169966900109
J	Foschi, M; Franchi, F; Han, JH; La Villa, G; Sorokin, A				Foschi, M; Franchi, F; Han, JH; La Villa, G; Sorokin, A			Endothelin-1 induces serine phosphorylation of the adaptor protein p66(Shc) and its association with 14-3-3 protein in glomerular mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE; KINASE; SHC; SIGNAL; PATHWAY; RECOGNITION; ACTIVATION; EXPRESSION; APOPTOSIS; P21(RAS)	Endothelin-1 (ET-1) is a vasoconstrictor peptide known to be a potent mitogen for glomerular mesangial cells (GMC). In the current study, it is demonstrated that ET-1 treatment of GMC results in serine phosphorylation of the 66-kDa isoform of the adapter protein She (p66(Shc)). ET-l-induced serine phosphorylation of p66(Shc) requires activation of the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signaling module and is efficiently inhibited by both a MAPK/ERK kinase (MEK)-selective inhibitor and adenovirus-mediated transfer of a dominant interfering MEK1 mutant. Furthermore, adenovirus-mediated transfer of a constitutively active MEK1 mutant was found to markedly increase p66(Shc) serine phosphorylation. Adenoviruses encoding constitutively active mutants of MAPK kinases 3 and 6 (upstream kinases of p38(MAPK)) and 7 (upstream kinase of c-Jun NH2-terminal kinase) failed to induce serine phosphorylation of this adaptor protein. Serine phosphorylation of p66(Sh)c resulted in its association with the serine binding motif-containing protein 14-3-3. ET-l-induced phosphorylation of a serine encompassed in the 14-3-3 binding motif of p66(Shc) Was confirmed in experiments employing anti-phospho-14-3-3 binding motif antibodies. These studies are the first to demonstrate that G protein-coupled receptors stimulate serine phosphorylation of p66(Shc) and the first to report the formation of a signaling complex between p66(Shc) and 14-3-3.	Univ Florence, Dept Internal Med, I-50141 Florence, Italy; Scripps Res Inst, La Jolla, CA 92037 USA; Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Cardiovasc Res Ctr, Milwaukee, WI 53226 USA	University of Florence; Scripps Research Institute; Medical College of Wisconsin; Medical College of Wisconsin	Foschi, M (corresponding author), Univ Florence, Dept Internal Med, V Le Morgagni 85, I-50141 Florence, Italy.	m.foschi@dfc.unifi.it; sorokin@mcw.edu	Han, J/G-4671-2010	Sorokin, Andrey/0000-0002-5660-0190	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022563, R37HL022563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041684] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 22563] Funding Source: Medline; NIDDK NIH HHS [DK 41684] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Araki S, 1997, KIDNEY INT, V51, P631, DOI 10.1038/ki.1997.92; Bokemeyer D, 1996, KIDNEY INT, V49, P1187, DOI 10.1038/ki.1996.172; Borg JP, 1998, CURR TOP MICROBIOL, V228, P23; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Clerk A, 2001, MOL CELL BIOL, V21, P1173, DOI 10.1128/MCB.21.4.1173-1184.2001; COBB MH, 1995, PROTEIN KINASE FACTS, P214; Decker ER, 1998, CONT BIOMED, P93; Denhardt DT, 1999, MOLECULAR BASIS OF CELL CYCLE AND GROWTH CONTROL, P225; Dudley DT, 2000, CANC DRUG DISC DEV, V5, P467; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; ERIKSON RL, 1995, PROTEIN KINASE FACTS, P275; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Force T, 1998, CONT BIOMED, P121; Foschi M, 2001, J AM SOC NEPHROL, V12, P1137, DOI 10.1681/ASN.V1261137; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; HABIB T, 1994, J BIOL CHEM, V269, P25243; Heeneman S, 2000, J BIOL CHEM, V275, P15926, DOI 10.1074/jbc.M909616199; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Kao AW, 1997, ENDOCRINOLOGY, V138, P2474, DOI 10.1210/en.138.6.2474; Kelly K, 2000, CANC DRUG DISC DEV, V5, P165; Lee CH, 1998, METH MOL B, V84, P3; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Mayer BJ, 1998, CURR TOP MICROBIOL, V228, P1; McGinty A, 2000, BIOCHEM J, V352, P419, DOI 10.1042/0264-6021:3520419; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Muda M, 1996, J BIOL CHEM, V271, P4319; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nissenson AR, 1998, KIDNEY INT, V53, pS7; Okada S, 1997, J BIOL CHEM, V272, P28042, DOI 10.1074/jbc.272.44.28042; Okamoto Y, 2000, J BIOL CHEM, V275, P6439, DOI 10.1074/jbc.275.9.6439; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SCHRAMEK H, 1997, ENDOTHELINS BIOL MED, P81; Shichiri M, 2000, ARTERIOSCL THROM VAS, V20, P989, DOI 10.1161/01.ATV.20.4.989; SIMONSON MS, 1990, METHOD ENZYMOL, V187, P544; Skulachev VP, 2000, IUBMB LIFE, V49, P177; Sraer JD, 1996, KIDNEY INT, V49, P267, DOI 10.1038/ki.1996.38; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Young PR, 2000, CANC DRUG DISC DEV, V5, P483	52	41	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26640	26647		10.1074/jbc.M102008200	http://dx.doi.org/10.1074/jbc.M102008200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11342545	hybrid			2022-12-25	WOS:000169823300129
J	Hamilton, MH; Tcherepanova, I; Huibregtse, JM; McDonnell, DP				Hamilton, MH; Tcherepanova, I; Huibregtse, JM; McDonnell, DP			Nuclear import/export of hRPF1/Nedd4 regulates the ubiquitin-dependent degradation of its nuclear substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; EPITHELIAL NA+ CHANNEL; PROTEIN LIGASE NEDD4; WW DOMAINS; LARGE SUBUNIT; SUBCELLULAR-LOCALIZATION; COVALENT MODIFICATION; PROTEASOME PATHWAY; LIDDLES-SYNDROME; EXPORT SIGNALS	The ubiquitin-protein ligase (E3), hRPF1/Nedd4, is a component of the ubiquitin-proteasome pathway responsible for substrate recognition and specificity, Although previously characterized as a regulator of the stability of cytoplasmic proteins, hRPF1/Nedd4 has also been suggested to have a role in the nucleus. However, in light of the cytoplasmic localization of hRPF1/Nedd4, it is unclear whether bona fide nuclear substrates of hRPF1/Nedd4 exist, and if so, what mechanism may allow a cytoplasmic ubiquitin ligase to manifest nuclear activity. Our search for nuclear substrates led to the identification of the human proline-rich transcript, brain-expressed (hPRTB) protein, the ubiquitination and degradation of which is regulated by hRPF1/Nedd4. interestingly; hPRTB colocalizes with the splicing factor SC35 in nuclear speckles. Finally, we demonstrate that hRPF1/Nedd4 is indeed capable of entering the nucleus; however, the presence of a functional Rev-like nuclear export sequence in hRPF1/Nedd4 ensures a predominant cytoplasmic localization, Cumulatively, these findings highlight a nuclear role for the ubiquitin ligase hRPF1/Nedd4 and underscore cytoplasmic/nuclear localization as an important regulatory component of hRPF1/Nedd4-substrate recognition.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Univ Texas, Inst Cellular & Mol Biol, Austin, TX 78712 USA	Duke University; University of Texas System; University of Texas Austin	McDonnell, DP (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.				NIDDK NIH HHS [DK50494] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050494] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Anan T, 1998, GENES CELLS, V3, P751, DOI 10.1046/j.1365-2443.1998.00227.x; Beaudenon SL, 1999, MOL CELL BIOL, V19, P6972; Bedford MT, 1998, P NATL ACAD SCI USA, V95, P10602, DOI 10.1073/pnas.95.18.10602; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FUKADA M, 1997, NATURE, V390, P308; Gavva NR, 1997, J BIOL CHEM, V272, P24105, DOI 10.1074/jbc.272.39.24105; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Harvey KF, 1998, J BIOL CHEM, V273, P13524, DOI 10.1074/jbc.273.22.13524; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Imhof MO, 1996, MOL CELL BIOL, V16, P2594; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Kumar S, 1997, GENOMICS, V40, P435, DOI 10.1006/geno.1996.4582; Meyer BE, 1996, J VIROL, V70, P2350, DOI 10.1128/JVI.70.4.2350-2359.1996; Morrione A, 1999, J BIOL CHEM, V274, P24094, DOI 10.1074/jbc.274.34.24094; Mosser EA, 1998, BIOCHEMISTRY-US, V37, P13686, DOI 10.1021/bi981310l; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Yang W, 1999, DEV DYNAM, V215, P108, DOI 10.1002/(SICI)1097-0177(199906)215:2<108::AID-DVDY3>3.3.CO;2-9; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	43	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26324	26331		10.1074/jbc.M101205200	http://dx.doi.org/10.1074/jbc.M101205200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11342538	hybrid			2022-12-25	WOS:000169823300091
J	Kim, SJ; Rahbar, R; Hegde, RS				Kim, SJ; Rahbar, R; Hegde, RS			Combinatorial control of prion protein biogenesis by the signal sequence and transmembrane domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES; HUMAN P-GLYCOPROTEIN; CHARGED RESIDUES; HYDROPHOBIC DOMAIN; TERMINAL DOMAIN; ANCHOR PROTEINS; STOP-TRANSFER; ER MEMBRANE; ORIENTATION	The prion protein (PrP) is synthesized in three topologic forms at the endoplasmic reticulum, (PrP)-Pr-sec is fully translocated into the endoplasmic reticulum lumen, whereas (NPrP)-Pr-tm and (PrP)-Pr-Ctm are single-spanning membrane proteins of opposite orientation. Increased generation of (PrP)-Pr-Ctm in either transgenic mice or humans is associated with the development of neurodegenerative disease, To study the mechanisms by which PrP can achieve three topologic outcomes, we analyzed the translocation of proteins containing mutations introduced into either the N-terminal signal sequence or potential transmembrane domain (TMD) of PrP, Although mutations in either domain were found to affect PrP topogenesis, they did so in qualitatively different ways. In addition to its traditional role in mediating protein targeting, the signal was found to play a surprising role in determining orientation of the PrP N terminus. By contrast, the TMD was found to influence membrane integration. Analysis of various signal and TMD double mutants demonstrated that the topologic consequence of TMD action was directly dependent on the previous, signal-mediated step. Together, these results reveal that PrP topogenesis is controlled at two discrete steps during its translocation and provide a framework for understanding how these steps act coordinately to determine the final topology achieved by PrP.	NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Hegde, RS (corresponding author), NCI, Cellular Oncol Lab, NIH, Bldg 36,Rm 1D32,9000 Rockville Pike, Bethesda, MD 20892 USA.			Hegde, Ramanujan/0000-0001-8338-852X				BELTZER JP, 1991, J BIOL CHEM, V266, P973; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Borel AC, 1996, CELL, V85, P379, DOI 10.1016/S0092-8674(00)81116-2; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DEFEA KA, 1994, J BIOL CHEM, V269, P16810; Denzer AJ, 1995, EMBO J, V14, P6311, DOI 10.1002/j.1460-2075.1995.tb00321.x; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; Eusebio A, 1998, EXP CELL RES, V241, P181, DOI 10.1006/excr.1998.4042; Falcone D, 1999, J BIOL CHEM, V274, P33661, DOI 10.1074/jbc.274.47.33661; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Harley CA, 1998, J BIOL CHEM, V273, P24963, DOI 10.1074/jbc.273.38.24963; Hegde RS, 1999, NATURE, V402, P822, DOI 10.1038/45574; Hegde RS, 1998, MOL CELL, V2, P85, DOI 10.1016/S1097-2765(00)80116-1; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Heinrich SU, 2000, CELL, V102, P233, DOI 10.1016/S0092-8674(00)00028-3; HSIAO KK, 1991, NEUROLOGY, V41, P681, DOI 10.1212/WNL.41.5.681; Johnson RT, 1998, NEW ENGL J MED, V339, P1994, DOI 10.1056/NEJM199812313392707; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; Ma JY, 1999, NAT CELL BIOL, V1, P358, DOI 10.1038/14053; Mallucci GR, 1999, BRAIN, V122, P1823, DOI 10.1093/brain/122.10.1823; MASTRIANNI JA, 1995, NEUROLOGY, V45, P2042, DOI 10.1212/WNL.45.11.2042; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHATZL HM, 1995, J MOL BIOL, V245, P362, DOI 10.1006/jmbi.1994.0030; SILHAVY TJ, 1983, MICROBIOL REV, V47, P313, DOI 10.1128/MMBR.47.3.313-344.1983; SKACH WR, 1993, J BIOL CHEM, V268, P23552; SKACH WR, 1993, J BIOL CHEM, V268, P6903; SPIESS M, 1995, FEBS LETT, V369, P76, DOI 10.1016/0014-5793(95)00551-J; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; Stewart RS, 2001, J BIOL CHEM, V276, P2212, DOI 10.1074/jbc.M006763200; Tector M, 1999, EMBO J, V18, P6290, DOI 10.1093/emboj/18.22.6290; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRANCHANT C, 1992, J NEUROL NEUROSUR PS, V55, P185, DOI 10.1136/jnnp.55.3.185; Voigt S, 1996, J CELL BIOL, V134, P25, DOI 10.1083/jcb.134.1.25; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Wahlberg JM, 1997, J CELL BIOL, V137, P555, DOI 10.1083/jcb.137.3.555; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Weissmann C, 1999, J BIOL CHEM, V274, P3, DOI 10.1074/jbc.274.1.3; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; Wopfner F, 1999, J MOL BIOL, V289, P1163, DOI 10.1006/jmbi.1999.2831; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0	48	84	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26132	26140		10.1074/jbc.M101638200	http://dx.doi.org/10.1074/jbc.M101638200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11359769	hybrid			2022-12-25	WOS:000169823300067
J	Mooney, RA; Senn, J; Cameron, S; Inamdar, N; Boivin, LM; Shang, Y; Furlanetto, RW				Mooney, RA; Senn, J; Cameron, S; Inamdar, N; Boivin, LM; Shang, Y; Furlanetto, RW			Suppressors of cytokine signaling-1 and-6 associate with and inhibit the insulin receptor - A potential mechanism for cytokine-mediated insulin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED STAT INHIBITOR; TUMOR-NECROSIS-FACTOR; FACTOR-I RECEPTOR; SOCS-BOX MOTIF; MOLECULAR MECHANISMS; PROTEIN; FAMILY; GENE; TRANSCRIPTION; PROLIFERATION	Insulin resistance contributes to a number of metabolic disorders, including type II diabetes, hypertension, and atherosclerosis. Cytokines, such as tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6, and hormones, such as growth hormone, are known to cause insulin resistance, but the mechanisms by which they inhibit the cellular response to insulin have not been elucidated. One mechanism by which these agents could cause insulin resistance is by inducing the expression of cellular proteins that inhibit insulin receptor (IR) signaling. Suppressors of cytokine signaling (SOCS) proteins are negative regulators of cytokine signaling pathways, the expression of which is regulated by certain cytokines, SOCS proteins are therefore attractive candidates as mediators of cytokine-induced insulin resistance. We have found that SOCS-1 and SOCS-6 interact with the IR when expressed in human hepatoma cells (HepG2) or in rat hepatoma cells overexpressing the human IR In SOCS-1-expressing cells, insulin treatment increases the extent of interaction with the IR, whereas in SOCS-6-expressing cells the association with the IR appears to require insulin treatment. SOCS-1 and SOCS-6 do not inhibit insulin-dependent IR autophosphorylation, but both proteins inhibit insulin-dependent activation of ERK1/2 and protein kinase B in vivo and IR-directed phosphorylation of IRS-1 in vitro. These results suggest that SOCS proteins may be inhibitors of IR signaling and could mediate cytokine-induced insulin resistance and contribute to the pathogenesis of type II diabetes.	Univ Rochester, Sch Med, Dept Pediat, Rochester, NY 14642 USA; Univ Rochester, Sch Med, Dept Pathol, Rochester, NY 14642 USA; Univ Rochester, Sch Med, Grad Program Cell Regulat & Mol Pharmacol, Rochester, NY 14642 USA; Univ Rochester, Sch Med, Grad Program Biol & Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester	Furlanetto, RW (corresponding author), Univ Rochester, Sch Med, Dept Pediat, Box 777,601 Elmwood Ave, Rochester, NY 14642 USA.	richard_furlanetto@URMC.rochester.edu						Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Boisclair YR, 2000, J BIOL CHEM, V275, P3841, DOI 10.1074/jbc.275.6.3841; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; Colson A, 2000, ENDOCRINOLOGY, V141, P3687, DOI 10.1210/en.141.10.3687; De Sepulveda P, 1999, EMBO J, V18, P904; Dey BR, 1998, J BIOL CHEM, V273, P24095, DOI 10.1074/jbc.273.37.24095; Dey BR, 2000, BIOCHEM BIOPH RES CO, V278, P38, DOI 10.1006/bbrc.2000.3762; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; GOLEMIS EA, 1995, CURRENT PROTOCOLS MO, V2; Hansen JA, 1999, MOL ENDOCRINOL, V13, P1832, DOI 10.1210/me.13.11.1832; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Krebs DL, 2000, J CELL SCI, V113, P2813; Kruszynska YT, 1996, J INVEST MED, V44, P413; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; KULL FC, 1983, J BIOL CHEM, V258, P6561; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LING PR, 1994, METABOLISM, V43, P279, DOI 10.1016/0026-0495(94)90093-0; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Minamoto S, 1997, BIOCHEM BIOPH RES CO, V237, P79, DOI 10.1006/bbrc.1997.7080; Mora-Garcia P, 1998, BLOOD, V92, p193A; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Pickup JC, 2000, LIFE SCI, V67, P291, DOI 10.1016/S0024-3205(00)00622-6; Saito H, 2000, J IMMUNOL, V164, P5833, DOI 10.4049/jimmunol.164.11.5833; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Strathdee CA, 1999, GENE, V229, P21, DOI 10.1016/S0378-1119(99)00045-1; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	39	200	212	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25889	25893		10.1074/jbc.M010579200	http://dx.doi.org/10.1074/jbc.M010579200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11342531	hybrid			2022-12-25	WOS:000169823300035
J	Schotte, P; Van Loo, G; Carpentier, I; Vandenabeele, P; Beyaert, R				Schotte, P; Van Loo, G; Carpentier, I; Vandenabeele, P; Beyaert, R			Lithium sensitizes tumor cells in an NF-kappa B-independent way to caspase activation and apoptosis induced by tumor necrosis factor (TNF) - Evidence for a role of the TNF receptor-associated death domain protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; CYTOCHROME-C; SIGNAL-TRANSDUCTION; FACTOR-ALPHA; INHIBITION; PATHWAYS; COMPLEX; COMBINATION; EXPRESSION; INDUCTION	We have previously shown that lithium salts can considerably increase the direct cytotoxic effect of tumor necrosis factor (TNF) on various tumor cells in vitro and in vivo. However, the underlying mechanism has remained largely unknown. Here we show that the TNF-sensitizing effect of lithium chloride (LiCl) is independent of the type of cell death, either necrosis or apoptosis. In the case of apoptosis, TNF-lithium synergism is associated with an enhanced activation of caspases and mitochondrial cytochrome c release. Sensitization to apoptosis is specific for TNF-induced apoptosis, whereas Fas-mediated or etoposide-induced apoptosis remains unaffected. LiCl also potentiates cell death induced by artificial oligomerization of a fusion protein between FKBP and the TNF receptor-associated death domain protein. TNF-induced activation of NF-KB-dependent gene expression is not modulated by LiCl treatment. These results indicate that LiCl enhances TNF-induced cell death in an NF-KB-independent way, and suggest that the TNF receptor-associated death domain protein plays a crucial role in the TNF-sensitizing effect of LiCl.	Flanders Interuniv Inst Biotechnol, Unit Mol Signal Transduct Inflammat, Dept Mol Biol, B-9000 Ghent, Belgium; State Univ Ghent, B-9000 Ghent, Belgium	Ghent University	Beyaert, R (corresponding author), Flanders Interuniv Inst Biotechnol, Unit Mol Signal Transduct Inflammat, Dept Mol Biol, KL Ledeganckstr 35, B-9000 Ghent, Belgium.		van Loo, Geert/C-1505-2009; Vandenabeele, Peter/C-8597-2009; Beyaert, Rudi/B-2589-2009; Vandenabeele, Peter/AAD-5793-2022; , van Loo Geert/AAD-1220-2019	Vandenabeele, Peter/0000-0002-6669-8822; , van Loo Geert/0000-0002-8427-4775; Beyaert, Rudi/0000-0002-5704-582X				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BALKWILL FR, 1986, CANCER RES, V46, P3990; BEYAERT R, 1991, CYTOKINE, V3, P284, DOI 10.1016/1043-4666(91)90496-Z; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BEYAERT R, 1989, P NATL ACAD SCI USA, V86, P9494, DOI 10.1073/pnas.86.23.9494; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; Chcialowski A, 1997, Pol Merkur Lekarski, V2, P392; Chen G, 1999, J NEUROCHEM, V72, P1327, DOI 10.1046/j.1471-4159.2000.0721327.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DENECKER G, 2001, IN PRESS CELL DEATH, V8; DeValck D, 1997, BIOCHEM BIOPH RES CO, V238, P590, DOI 10.1006/bbrc.1997.7343; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Erhardt P, 1996, J BIOL CHEM, V271, P17601, DOI 10.1074/jbc.271.30.17601; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hers I, 1999, FEBS LETT, V460, P433, DOI 10.1016/S0014-5793(99)01389-7; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; KETTELHUT IC, 1987, P NATL ACAD SCI USA, V84, P4273, DOI 10.1073/pnas.84.12.4273; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIENARD D, 1992, J CLIN ONCOL, V10, P52, DOI 10.1200/JCO.1992.10.1.52; Magnusson C, 1999, IMMUNOL CELL BIOL, V77, P41, DOI 10.1046/j.1440-1711.1999.00800.x; Medema JP, 1997, EUR J IMMUNOL, V27, P3492, DOI 10.1002/eji.1830271250; Muenchen HJ, 2000, CLIN CANCER RES, V6, P1969; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; RUFF MR, 1981, INFECT IMMUN, V31, P380, DOI 10.1128/IAI.31.1.380-385.1981; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Spencer DM, 1996, CURR BIOL, V6, P839, DOI 10.1016/S0960-9822(02)00607-3; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; TADA H, 1986, J IMMUNOL METHODS, V93, P157, DOI 10.1016/0022-1759(86)90183-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tondo L, 2000, J CLIN PSYCHIAT, V61, P97; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Van de Craen M, 1997, FEBS LETT, V403, P61, DOI 10.1016/S0014-5793(97)00026-4; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; VANHOENACKER P, 1999, GENE THER MOL BIOL, V3, P301; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vercammen D, 1997, CYTOKINE, V9, P801, DOI 10.1006/cyto.1997.0252; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	48	37	38	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25939	25945		10.1074/jbc.M104014200	http://dx.doi.org/10.1074/jbc.M104014200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11342564	hybrid			2022-12-25	WOS:000169823300041
J	Wilce, JA; Love, SG; Richardson, SJ; Alewood, PF; Craik, DJ				Wilce, JA; Love, SG; Richardson, SJ; Alewood, PF; Craik, DJ			Synthesis of an analog of the thyroid hormone-binding protein transthyretin via regioselective chemical ligation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID FIBRIL FORMATION; PHASE PEPTIDE-SYNTHESIS; RAY CRYSTAL-STRUCTURE; THYROXINE-BINDING; PLASMA-PROTEINS; ALTERNATIVE CONFORMATIONS; HIV-1 PROTEASE; PRE-ALBUMIN; RESOLUTION; EVOLUTION	Transthyretin is an essential protein responsible for the transport of thyroid hormones and retinol in human serum and is also implicated in the amyloid diseases familial amyloidotic polyneuropathy and senile systemic amyloidosis. Its folding properties and stabilization by ligands are of current interest due to their importance in understanding and combating these diseases, Here we report the solid phase synthesis of the monomeric unit of a transthyretin analog (equivalent to 127 amino acids) using t-Boc chemistry and peptide ligation and its folding to form a functional 54-kDa tetramer, The monomeric unit of the protein was chemically synthesized in three parts (positions 1-51, 54-99, and 102-127) and ligated using a chemoselective thioether ligation chemistry. The synthetic protein was folded and assembled to a tetrameric structure in the presence of transthyretin's native ligand, thyroxine, as shown by gel filtration chromatography, native gel electrophoresis, transthyretin antibody recognition, and thyroid hormone binding. Other folding products included a high molecular weight aggregate as well as a transient dimeric species. This represents one of the largest macromolecules chemically synthesized to date and demonstrates the potential of protein chemical synthesis for investigations of protein-ligand interactions.	Univ Western Australia, Dept Biochem Chem, Nedlands, WA 6907, Australia; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia	University of Western Australia; University of Queensland; University of Melbourne	Craik, DJ (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	d.craik@imb.uq.edu.au	Wilce, Jacqueline/N-5018-2017; Craik, David/B-1695-2010	Wilce, Jacqueline/0000-0002-8344-2626; Craik, David/0000-0003-0007-6796; Richardson, Samantha/0000-0002-1708-9430				Alewood P, 1997, METHOD ENZYMOL, V289, P14; Ball H L, 1994, Biomed Pept Proteins Nucleic Acids, V1, P39; Benson MD, 1996, AMYLOID, V3, P44, DOI 10.3109/13506129609014354; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; BRANCH WT, 1972, ARCH BIOCHEM BIOPHYS, V152, P144, DOI 10.1016/0003-9861(72)90202-0; CANNE LE, 1995, J AM CHEM SOC, V117, P2998, DOI 10.1021/ja00116a005; Chang L, 1999, EUR J BIOCHEM, V259, P534, DOI 10.1046/j.1432-1327.1999.00076.x; CISZAK E, 1992, P NATL ACAD SCI USA, V89, P6644, DOI 10.1073/pnas.89.14.6644; Damas AM, 1996, ACTA CRYSTALLOGR D, V52, P966, DOI 10.1107/S0907444996003307; Dawson PE, 1997, J AM CHEM SOC, V119, P4325, DOI 10.1021/ja962656r; DWULET FE, 1983, BIOCHEM BIOPH RES CO, V114, P657, DOI 10.1016/0006-291X(83)90831-8; ENGLEBRETSEN DR, 1995, TETRAHEDRON LETT, V36, P8871, DOI 10.1016/0040-4039(95)01843-7; Hackeng TM, 1997, P NATL ACAD SCI USA, V94, P7845, DOI 10.1073/pnas.94.15.7845; HAMILTON JA, 1993, J BIOL CHEM, V268, P2416; Jacobson D R, 1991, Adv Hum Genet, V20, P69; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; Klabunde T, 2000, NAT STRUCT BIOL, V7, P312; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; Lai ZH, 1997, BIOCHEMISTRY-US, V36, P10230, DOI 10.1021/bi963195p; Lai ZH, 1996, BIOCHEMISTRY-US, V35, P6470, DOI 10.1021/bi952501g; Lu WY, 1996, J AM CHEM SOC, V118, P8518, DOI 10.1021/ja960812o; Lu WY, 1998, FEBS LETT, V429, P31, DOI 10.1016/S0014-5793(98)00547-X; Lu WY, 1997, BIOCHEMISTRY-US, V36, P673, DOI 10.1021/bi9625612; MCCUTCHEN SL, 1995, BIOCHEMISTRY-US, V34, P13527, DOI 10.1021/bi00041a032; MENDEL CM, 1989, J CLIN INVEST, V83, P143, DOI 10.1172/JCI113851; Miroy GJ, 1996, P NATL ACAD SCI USA, V93, P15051, DOI 10.1073/pnas.93.26.15051; MONACO HL, 1995, SCIENCE, V268, P1039, DOI 10.1126/science.7754382; MUNRO SL, 1989, J CLIN ENDOCR METAB, V68, P1141, DOI 10.1210/jcem-68-6-1141; NILSSON SF, 1975, J BIOL CHEM, V250, P8554; PARDRIDGE WM, 1980, J CLIN INVEST, V66, P367, DOI 10.1172/JCI109865; Peterson SA, 1998, P NATL ACAD SCI USA, V95, P12956, DOI 10.1073/pnas.95.22.12956; Rajarathnam K, 1997, METHOD ENZYMOL, V287, P89; Richardson SJ, 1996, ENDOCRINOLOGY, V137, P3507, DOI 10.1210/en.137.8.3507; RICHARDSON SJ, 1994, AM J PHYSIOL, V266, pR1359, DOI 10.1152/ajpregu.1994.266.4.R1359; Saraiva M J, 1996, J Peripher Nerv Syst, V1, P179; SCHNEIDER J, 1988, CELL, V54, P363, DOI 10.1016/0092-8674(88)90199-7; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; SIPE JD, 1994, CRIT REV CL LAB SCI, V31, P325, DOI 10.3109/10408369409084679; STEINRAUF LK, 1993, J BIOL CHEM, V268, P2425; Wilken J, 1998, CURR OPIN BIOTECH, V9, P412, DOI 10.1016/S0958-1669(98)80016-5; Wojtczak A, 1996, ACTA CRYSTALLOGR D, V52, P758, DOI 10.1107/S0907444996003046; WOJTCZAK A, 1992, J BIOL CHEM, V267, P353; Xu R, 1999, P NATL ACAD SCI USA, V96, P388, DOI 10.1073/pnas.96.2.388	45	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25997	26003		10.1074/jbc.M101228200	http://dx.doi.org/10.1074/jbc.M101228200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11352912	hybrid			2022-12-25	WOS:000169823300049
J	Luo, Y; Liang, CP; Tall, AR				Luo, Y; Liang, CP; Tall, AR			The orphan nuclear receptor LRH-1 potentiates the sterol-mediated induction of the human CETP gene by liver X receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTER TRANSFER PROTEIN; MESSENGER-RNA LEVELS; CHOLESTEROL 7-ALPHA-HYDROXYLASE GENE; DENSITY-LIPOPROTEIN RECEPTOR; BILE-ACID; LXR-ALPHA; DIETARY-CHOLESTEROL; TANGIER-DISEASE; TRANSGENIC MICE; PLASMA-MEMBRANE	The human cholesteryl ester transfer protein (CETP) transfers cholesteryl esters from high density lipoproteins to triglyceride-rich lipoproteins, indirectly facilitating cholesteryl esters uptake by the liver. Hepatic CETP gene expression is increased in response to dietary hypercholesterolemia, an effect that is mediated by the activity of liver X receptor/retinoid X receptor (LXR/RXR) on a direct repeat 4 element in the CETP promoter. In this study we show that the orphan nuclear receptor LRH-1 also transactivates the CETP promoter by binding to a proximal promoter element distinct from the DR4 site. LRH-1 potentiates the sterol-dependent regulation of the wild type CETP promoter by LXR/RXR. Small heterodimer partner, a repressor of LRH-1, abolishes the potentiation effect of LRH-1 but not its basal transactivation of the CETP promoter. Since this mode of regulation of CETP is very similar to that recently reported for the bile salt-mediated repression of Cyp7a (encoding the rate-limiting enzyme for conversion of cholesterol into bile acid in the liver), we examined the effects of bile salt feeding on CETP mRNA expression in human CETP transgenic mice. Hepatic CETP mRNA expression was repressed by a diet containing 1% cholic acid in male mice but was induced by the same diet in female mice. Microarray analysis of hepatic mRNA showed that about 1.5% of genes were repressed, and 2.5% were induced by the bile acid diet. However, the sexually dimorphic regulatory pattern of the CETP gene was an unusual response. Our data provide further evidence for the regulation of CETP and Cyp7a genes by similar molecular mechanisms, consistent with coordinate transcriptional regulation of sequential steps of reverse cholesterol transport. However, differential effects of the bile salt diet indicate additional complexity in the response of these two genes.	Columbia Univ, Coll Phys & Surg, Dept Med, Div Mol Med, New York, NY 10032 USA	Columbia University	Luo, Y (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Med, Div Mol Med, 8-401, New York, NY 10032 USA.		Tall, Alan/AAT-8528-2021					Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; Chouinard RA, 1998, J BIOL CHEM, V273, P22409, DOI 10.1074/jbc.273.35.22409; Costet P, 2000, J BIOL CHEM, V275, P28240; de Urquiza AM, 2000, SCIENCE, V290, P2140, DOI 10.1126/science.290.5499.2140; del Castillo-Olivares A, 2000, J BIOL CHEM, V275, P17793, DOI 10.1074/jbc.M000996200; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Feingold KR, 1996, J LIPID RES, V37, P223; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Hardardottir I, 1996, J CLIN INVEST, V97, P2585, DOI 10.1172/JCI118707; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; JIANG XC, 1992, J CLIN INVEST, V90, P1290, DOI 10.1172/JCI115993; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Luo Y, 2000, J CLIN INVEST, V105, P513, DOI 10.1172/JCI8573; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; MasucciMagoulas L, 1996, J CLIN INVEST, V97, P154, DOI 10.1172/JCI118384; Miyake JH, 2000, J BIOL CHEM, V275, P21805, DOI 10.1074/jbc.C000275200; NELSON JA, 1981, J BIOL CHEM, V256, P1067; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; Oliveira HCF, 1996, J BIOL CHEM, V271, P31831, DOI 10.1074/jbc.271.50.31831; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Parker KL, 1999, ANNU REV PHYSIOL, V61, P417, DOI 10.1146/annurev.physiol.61.1.417; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; QUINET EM, 1990, J CLIN INVEST, V85, P357, DOI 10.1172/JCI114446; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Seel WG, 1998, MOL ENDOCRINOL, V12, P1551, DOI 10.1210/mend.12.10.0184; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wiebel FF, 1999, MOL ENDOCRINOL, V13, P1105, DOI 10.1210/me.13.7.1105	46	121	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24767	24773		10.1074/jbc.M100912200	http://dx.doi.org/10.1074/jbc.M100912200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11331284	hybrid			2022-12-25	WOS:000169800700048
J	Tom, S; Henricksen, LA; Park, MS; Bambara, RA				Tom, S; Henricksen, LA; Park, MS; Bambara, RA			DNA ligase I and proliferating cell nuclear antigen form a functional complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; REPLICATION-FACTOR-C; PURIFIED HUMAN PROTEINS; DOUBLE-STRANDED DNA; ENDONUCLEASE ACTIVITY; FLAP ENDONUCLEASE-1; POLYMERASES DELTA; MAMMALIAN-CELLS; PCNA; BINDING	DNA ligase I is responsible for joining Okazaki fragments during DNA replication. An additional proposed role for DNA ligase I is sealing nicks generated during excision repair, Previous studies have shown that there is a physical interaction between DNA ligase I and proliferating cell nuclear antigen (PCNA), another important component of DNA replication and repair. The results shown here indicate that human PCNA enhances the reaction rate of human DNA ligase I up to 5-fold. The stimulation is specific to DNA ligase I because T4 DNA ligase is not affected. Electrophoretic mobility shift assays indicate that PCNA improves the binding of DNA ligase I to the ligation site. Increasing the DNA ligase I concentration leads to a reduction in PCNA stimulation, consistent with PCNA-directed improvement of DNA ligase I binding to its DNA substrate. Two experiments show that PCNA is required to encircle duplex DNA to enhance DNA ligase I activity. Biotin-streptavidin conjugations at the ends of a linear substrate inhibit PCNA stimulation. PCNA cannot enhance ligation on a circular substrate without the addition of replication factor C, which is the protein responsible for loading PCNA onto duplex DNA. These results show that PCNA is responsible for the stable association of DNA ligase I to nicked duplex DNA.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Sch Med & Dent, Rochester, NY 14642 USA; Univ Calif Los Alamos Natl Lab, Biosci Div, Los Alamos, NM 87545 USA	University of Rochester; United States Department of Energy (DOE); Los Alamos National Laboratory	Bambara, RA (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Sch Med & Dent, 601 Elmwood Ave,Box 712, Rochester, NY 14642 USA.		Park, Min Sung/HCH-2207-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441, R01GM059301] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24441, GM59301] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bae SH, 1998, J BIOL CHEM, V273, P26880, DOI 10.1074/jbc.273.41.26880; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; Cai JS, 1996, P NATL ACAD SCI USA, V93, P12896, DOI 10.1073/pnas.93.23.12896; Cardoso MC, 1997, J CELL BIOL, V139, P579, DOI 10.1083/jcb.139.3.579; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; DeMott MS, 1998, J BIOL CHEM, V273, P27492, DOI 10.1074/jbc.273.42.27492; ELDER RH, 1990, BIOCHEMISTRY-US, V29, P6009, DOI 10.1021/bi00477a019; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gomes XV, 2000, EMBO J, V19, P3811, DOI 10.1093/emboj/19.14.3811; HARRINGTON JJ, 1995, J BIOL CHEM, V270, P4503, DOI 10.1074/jbc.270.9.4503; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HENDERSON LM, 1985, P NATL ACAD SCI USA, V82, P2044, DOI 10.1073/pnas.82.7.2044; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kang HY, 2000, GENETICS, V155, P1055; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; Kim CY, 2001, BIOCHEMISTRY-US, V40, P3208, DOI 10.1021/bi002100n; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; LASKO DD, 1990, J BIOL CHEM, V265, P12618; Lee KH, 2000, NUCLEIC ACIDS RES, V28, P2873, DOI 10.1093/nar/28.15.2873; LEE SH, 1991, J BIOL CHEM, V266, P594; Levin DS, 2000, CURR BIOL, V10, P919, DOI 10.1016/S0960-9822(00)00619-9; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; LI CG, 1994, NUCLEIC ACIDS RES, V22, P632, DOI 10.1093/nar/22.4.632; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; Liu QQ, 2000, J BIOL CHEM, V275, P1615, DOI 10.1074/jbc.275.3.1615; LONN U, 1989, CARCINOGENESIS, V10, P981, DOI 10.1093/carcin/10.6.981; Mackenney VJ, 1997, J BIOL CHEM, V272, P11550; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; MONTECUCCO A, 1992, NUCLEIC ACIDS RES, V20, P6209, DOI 10.1093/nar/20.23.6209; MONTECUCCO A, 1995, EMBO J, V14, P5379, DOI 10.1002/j.1460-2075.1995.tb00222.x; Montecucco A, 1998, EMBO J, V17, P3786, DOI 10.1093/emboj/17.13.3786; Mossi R, 1998, J BIOL CHEM, V273, P14322, DOI 10.1074/jbc.273.23.14322; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; Pascucci B, 1999, J BIOL CHEM, V274, P33696, DOI 10.1074/jbc.274.47.33696; PETRINI JH, 1995, MOL CELL BIOL, V14, P4303; PODUST LM, 1995, MOL CELL BIOL, V15, P3072; PRIGENT C, 1994, MOL CELL BIOL, V14, P310, DOI 10.1128/MCB.14.1.310; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; Rossi R, 1999, EMBO J, V18, P5745, DOI 10.1093/emboj/18.20.5745; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; Tomkinson AE, 1998, MUTAT RES-DNA REPAIR, V407, P1, DOI 10.1016/S0921-8777(97)00050-5; Tomkinson AE, 1997, BIOESSAYS, V19, P893, DOI 10.1002/bies.950191009; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; WAGA S, 1994, J BIOL CHEM, V269, P10923; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; WEI YF, 1995, MOL CELL BIOL, V15, P3206; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; WU Y, 1994, J CELL BIOCHEM, V54, P32, DOI 10.1002/jcb.240540105; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; Zhang G, 1999, P NATL ACAD SCI USA, V96, P1869, DOI 10.1073/pnas.96.5.1869	62	83	86	34	168	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24817	24825		10.1074/jbc.M101673200	http://dx.doi.org/10.1074/jbc.M101673200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11331287	hybrid			2022-12-25	WOS:000169800700054
J	Turner, J; Anderson, R; Guo, J; Beraud, C; Fletterick, R; Sakowicz, R				Turner, J; Anderson, R; Guo, J; Beraud, C; Fletterick, R; Sakowicz, R			Crystal structure of the mitotic spindle kinesin Eg5 reveals a novel conformation of the neck-linker	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-MOLECULE INHIBITOR; MOTOR DOMAIN; BIPOLAR KINESIN; PROTEIN; MOTILITY; GENE; NCD; ENCODES	Success of mitosis depends upon the coordinated and regulated activity of many cellular factors, including kinesin motor proteins, which are required for the assembly and function of the mitotic spindle. Eg5 is a kinesin implicated in the formation of the bipolar spindle and its movement prior to and during anaphase. We have determined the crystal structure of the Eg5 motor domain with ADP-Mg bound. This structure revealed a new intramolecular binding site of the neck-linker. In other kinesins, the neck-linker has been shown to be a critical mechanical element for force generation. The neck-linker of conventional kinesin is believed to undergo an ordered-to-disordered transition as it translocates along a microtubule. The structure of Eg5 showed an ordered neck-linker conformation in a position never observed previously. The docking of the neck-linker relies upon residues conserved only in the Eg5 subfamily of kinesin motors. Based on this new information, we suggest that the neck-linker of Eg5 may undergo an ordered-to-ordered transition during force production. This ratchet-like mechanism is consistent with the biological activity of Eg5.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Cytokinet Inc, S San Francisco, CA 94080 USA	University of California System; University of California San Francisco	Turner, J (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, Box 0448, San Francisco, CA 94143 USA.							Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Case RB, 2000, CURR BIOL, V10, P157, DOI 10.1016/S0960-9822(00)00316-X; Crevel IMTC, 1997, J MOL BIOL, V273, P160, DOI 10.1006/jmbi.1997.1319; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; Gulick AM, 1998, BIOCHEMISTRY-US, V37, P1769, DOI 10.1021/bi972504o; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; Heald R, 2000, CELL, V102, P399, DOI 10.1016/S0092-8674(00)00044-1; HECK MM, 1993, J CELL BIOL, V123, P655; Hirose K, 2000, EMBO J, V19, P5308, DOI 10.1093/emboj/19.20.5308; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; Kashina AS, 1996, NATURE, V379, P270, DOI 10.1038/379270a0; Kikkawa M, 2001, NATURE, V411, P439, DOI 10.1038/35078000; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LEGUELLEC R, 1991, MOL CELL BIOL, V11, P3395, DOI 10.1128/MCB.11.6.3395; Lockhart A, 1996, BIOCHEMISTRY-US, V35, P2365, DOI 10.1021/bi952318n; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; Sharp DJ, 1999, NAT CELL BIOL, V1, P51, DOI 10.1038/9025; Sharp DJ, 1999, J CELL BIOL, V144, P125, DOI 10.1083/jcb.144.1.125; SWAIN KE, 1995, P NATL ACAD SCI USA, V92, P4289; SWAIN KE, 1992, NATURE, V359, P540; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; Walczak CE, 1998, CURR BIOL, V8, P903, DOI 10.1016/S0960-9822(07)00370-3	29	188	198	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25496	25502		10.1074/jbc.M100395200	http://dx.doi.org/10.1074/jbc.M100395200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11328809	hybrid			2022-12-25	WOS:000169800700140
J	List, HJ; Lauritsen, KJ; Reiter, R; Powers, C; Wellstein, A; Riegel, AT				List, HJ; Lauritsen, KJ; Reiter, R; Powers, C; Wellstein, A; Riegel, AT			Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL COACTIVATOR; GENE-EXPRESSION; BINDING PROTEIN; IN-VIVO; AMPLIFICATION; ACTIVATION; COMPLEX; TRANSACTIVATION; FAMILY; SRC-1	Human breast tumorigenesis is promoted by the estro gen receptor pathway, and nuclear receptor coactivators are thought to participate in this process. Here we studied whether one of these coactivators, AIB1 (amplified in breast cancer (1) under bar), was rate-limiting for hormone-dependent growth of human MCF-7 breast cancer cells. We developed MCF-7 breast cancer cell lines in which the expression of AIB1 can be modulated by regulatable ribozymes directed against AIB1 mRNA, We found that depletion of endogenous AIB1 levels reduced steroid hormone signaling via the estrogen receptor Lu or progesterone receptor p on transiently transfected reporter templates. Down-regulation of AIB1 levels in MCF-7 cells did not affect estrogen-stimulated cell cycle progression but reduced estrogen-mediated inhibition of apoptosis and cell growth. Finally, upon reduction of endogenous AIB1 expression, estrogen-dependent colony formation in soft agar and tumor growth of MCF-7 cells in nude mice was decreased. From these findings we conclude that, despite the presence of different estrogen receptor coactivators in breast cancer cells, AIB1 exerts a rate-limiting role for hormone-dependent hu. man breast tumor growth.	Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Washington, DC 20007 USA	Georgetown University	Riegel, AT (corresponding author), Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Bldg E307,3970 Reservoir Rd, Washington, DC 20007 USA.		Powers, Ciaran/E-3890-2011	Wellstein, Anton/0000-0002-0570-4950				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bai JW, 2000, CELL, V103, P1047, DOI 10.1016/S0092-8674(00)00208-7; Bautista S, 1998, CLIN CANCER RES, V4, P2925; Belandia B, 2000, J BIOL CHEM, V275, P30801, DOI 10.1074/jbc.C000484200; Berns EMJJ, 1998, BREAST CANCER RES TR, V48, P87, DOI 10.1023/A:1005903226483; Bouras T, 2001, CANCER RES, V61, P903; CATHERINO WH, 1995, CANCER LETT, V92, P39, DOI 10.1016/0304-3835(95)03755-L; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Dilworth FJ, 1999, P NATL ACAD SCI USA, V96, P1995, DOI 10.1073/pnas.96.5.1995; Ghadimi BM, 1999, AM J PATHOL, V154, P525, DOI 10.1016/S0002-9440(10)65298-4; Glass CK, 2000, GENE DEV, V14, P121; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Harris VK, 1998, J BIOL CHEM, V273, P19130, DOI 10.1074/jbc.273.30.19130; HOERLEIN AJ, 1995, NATURE, V377, P397; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kurebayashi J, 2000, CLIN CANCER RES, V6, P512; Lee SK, 1999, MOL ENDOCRINOL, V13, P1924, DOI 10.1210/me.13.11.1924; Lee SK, 1999, J BIOL CHEM, V274, P34283, DOI 10.1074/jbc.274.48.34283; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Leygue E, 1999, CANCER RES, V59, P4190; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; LIPPMAN ME, 1975, NATURE, V256, P592, DOI 10.1038/256592a0; LIST HJ, 2001, IN PRESS BREAST CANC; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Murphy LC, 2000, CANCER RES, V60, P6266; ONATE SA, 1995, SCIENCE, V270, P1354; OSBORNE CK, 1984, CANCER RES, V44, P1433; Qi C, 1999, P NATL ACAD SCI USA, V96, P1585, DOI 10.1073/pnas.96.4.1585; Sakakura C, 2000, INT J CANCER, V89, P217; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; Shim WS, 1999, P NATL ACAD SCI USA, V96, P208, DOI 10.1073/pnas.96.1.208; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; SUTHERLAND RL, 1983, EUR J CANCER CLIN ON, V19, P615, DOI 10.1016/0277-5379(83)90177-3; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Tikkanen MK, 2000, P NATL ACAD SCI USA, V97, P12536, DOI 10.1073/pnas.220427297; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; VINDELOV LL, 1983, CYTOMETRY, V3, P328, DOI 10.1002/cyto.990030504; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WANG TTY, 1995, CANCER RES, V55, P2487; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; Werbajh S, 2000, FEBS LETT, V485, P195, DOI 10.1016/S0014-5793(00)02223-7; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848	49	115	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23763	23768		10.1074/jbc.M102397200	http://dx.doi.org/10.1074/jbc.M102397200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11328819	hybrid			2022-12-25	WOS:000169531100073
J	Berjukow, S; Marksteiner, R; Sokolov, S; Weiss, RG; Margreiter, E; Hering, S				Berjukow, S; Marksteiner, R; Sokolov, S; Weiss, RG; Margreiter, E; Hering, S			Amino acids in segment IVS6 and beta-subunit interaction support distinct conformational changes during Ca(v)2.1 inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HEMIPLEGIC MIGRAINE; ISOFORM-SPECIFIC INTERACTION; CHANNEL ALPHA(1A) SUBUNIT; CARBOXYL-TERMINAL REGION; BI CALCIUM CHANNELS; CA2+ CHANNEL; MOLECULAR DETERMINANTS; PHARMACOLOGICAL PROPERTIES; VOLTAGE; SENSITIVITY	Ca(v)2.1 mediates voltage-gated Ca2+ entry into neurons and the release of neurotransmitters at synapses of the central nervous system. An inactivation process that is modulated by the auxiliary beta -subunits regulates Ca2+ entry through Ca(v)2.1. However, the molecular mechanism of this alpha (1)-beta -subunit interaction remains unknown. Herein we report the identification of new determinants within segment IVS6 of the alpha (1)2.1-subunit that markedly influence channel inactivation. Systematic substitution of residues within IVS6 with amino acids of different size, charge, and polarity resulted in mutant channels with rates of fast inactivation (k(inact)) ranging from a 1.5-fold slowing in V1818I (k(inact) = 0.98 +/- 0.09 s(-1) compared with wild type alpha (1)2.1/alpha (2)-delta/beta (1a) k(inact) = 1.35 +/- 0.25 -1) to a 75-fold acceleration in mutant M1811Q (k(inact) 102 +/- 3 s(-1)). Coexpression of mutant alpha (1)2.1-subunits with beta (2a) resulted in two different phenotypes of current inactivation: 1) a pronounced reduction in the rate of channel inactivation or 2) an attenuation of a slow component in I-Ba inactivation. Simulations revealed that these two distinct inactivation phenotypes arise from a beta (2a)-subunit-induced destabilization of the fast-inactivated state. The IVS6- and beta (2a)-subunit-mediated effects on Ca(v)2.1 inactivation are likely to occur via independent mechanisms.	Inst Biochem Pharmakol, A-6020 Innsbruck, Austria		Hering, S (corresponding author), Inst Biochem Pharmakol, Peter Mayr Str 1, A-6020 Innsbruck, Austria.							Berjukow S, 1999, J BIOL CHEM, V274, P6154, DOI 10.1074/jbc.274.10.6154; Berjukow S, 2000, J BIOL CHEM, V275, P22114, DOI 10.1074/jbc.M908836199; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; Bourinet E, 1999, NAT NEUROSCI, V2, P407, DOI 10.1038/8070; Catterall WA, 1998, CELL CALCIUM, V24, P307, DOI 10.1016/S0143-4160(98)90055-0; Cens T, 1999, J BIOL CHEM, V274, P5483, DOI 10.1074/jbc.274.9.5483; DEWAARD M, 1995, J PHYSIOL-LONDON, V485, P619, DOI 10.1113/jphysiol.1995.sp020757; Doring F, 1996, J BIOL CHEM, V271, P11745, DOI 10.1074/jbc.271.20.11745; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; GRABNER M, 1991, P NATL ACAD SCI USA, V88, P727, DOI 10.1073/pnas.88.3.727; Hans M, 1999, J NEUROSCI, V19, P1610; Hans M, 1999, BIOPHYS J, V76, P1384, DOI 10.1016/S0006-3495(99)77300-5; Hering S, 2000, J PHYSIOL-LONDON, V528, P237, DOI 10.1111/j.1469-7793.2000.t01-1-00237.x; Hering S, 1996, J BIOL CHEM, V271, P24471, DOI 10.1074/jbc.271.40.24471; Herlitze S, 1997, P NATL ACAD SCI USA, V94, P1512, DOI 10.1073/pnas.94.4.1512; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Jen J, 1999, CURR OPIN NEUROBIOL, V9, P274, DOI 10.1016/S0959-4388(99)80040-3; Jun K, 1999, P NATL ACAD SCI USA, V96, P15245, DOI 10.1073/pnas.96.26.15245; Kraus RL, 1998, J BIOL CHEM, V273, P5586, DOI 10.1074/jbc.273.10.5586; Kraus RL, 2000, J BIOL CHEM, V275, P9239, DOI 10.1074/jbc.275.13.9239; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Liu HY, 1996, J BIOL CHEM, V271, P13804, DOI 10.1074/jbc.271.23.13804; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; Perez-Reyes E, 1999, ANN NY ACAD SCI, V868, P131, DOI 10.1111/j.1749-6632.1999.tb11283.x; Pichler M, 1997, J BIOL CHEM, V272, P13877, DOI 10.1074/jbc.272.21.13877; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Rettig J, 1996, P NATL ACAD SCI USA, V93, P7363, DOI 10.1073/pnas.93.14.7363; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; Sokolov S, 2000, J PHYSIOL-LONDON, V527, P445, DOI 10.1111/j.1469-7793.2000.t01-1-00445.x; Sokolov S, 1999, J PHYSIOL-LONDON, V519, P315, DOI 10.1111/j.1469-7793.1999.0315m.x; Soldatov NM, 1998, J BIOL CHEM, V273, P957, DOI 10.1074/jbc.273.2.957; Soldatov NM, 1997, J BIOL CHEM, V272, P3560, DOI 10.1074/jbc.272.6.3560; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; Stotz SC, 2000, J BIOL CHEM, V275, P24575, DOI 10.1074/jbc.M000399200; TANAKA O, 1995, BRAIN RES MOL BRAIN, V30, P10; Walker D, 1999, J BIOL CHEM, V274, P12383, DOI 10.1074/jbc.274.18.12383; Walker D, 1998, J BIOL CHEM, V273, P2361, DOI 10.1074/jbc.273.4.2361; WESTENBROEK RE, 1995, J NEUROSCI, V15, P6403; Wu LG, 1999, J NEUROSCI, V19, P726; Yellen G, 1999, CURR OPIN NEUROBIOL, V9, P267, DOI 10.1016/S0959-4388(99)80039-7; ZHANG JF, 1994, NATURE, V372, P97, DOI 10.1038/372097a0; Zhong HJ, 1999, NAT NEUROSCI, V2, P939, DOI 10.1038/14721; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	47	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17076	17082		10.1074/jbc.M010491200	http://dx.doi.org/10.1074/jbc.M010491200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11350979	hybrid			2022-12-25	WOS:000168730400064
J	Ihara, H; Urano, T; Takada, A; Loskutoff, DJ				Ihara, H; Urano, T; Takada, A; Loskutoff, DJ			Induction of plasminogen activator inhibitor 1 gene expression in adipocytes by thiazolidinediones	FASEB JOURNAL			English	Article									Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Hamamatsu Univ Sch Med, Dept Physiol, Hamamatsu, Shizuoka 4313192, Japan	Scripps Research Institute; Hamamatsu University School of Medicine	Loskutoff, DJ (corresponding author), Scripps Res Inst, Dept Vasc Biol, VB-3,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	loskutof@scripps.edu							0	29	32	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1233	1235		10.1096/fj.00-0570fje	http://dx.doi.org/10.1096/fj.00-0570fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344098				2022-12-25	WOS:000168655200020
J	O'Brien, CD; Ji, GJ; Wang, YX; Sun, J; Krymskaya, VP; Ruberg, FL; Kotlikoff, MI; Albelda, SM				O'Brien, CD; Ji, GJ; Wang, YX; Sun, J; Krymskaya, VP; Ruberg, FL; Kotlikoff, MI; Albelda, SM			PECAM-1 (CD31) engagement activates a phosphoinositide-independent, nonspecific cation channel in endothelial cells	FASEB JOURNAL			English	Article									Univ Penn, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA; Cornell Univ, Coll Vet Med, Dept Biomed Sci, Ithaca, NY 14853 USA	University of Pennsylvania; Cornell University	O'Brien, CD (corresponding author), Univ Penn, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, 838 BRB2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.			Ruberg, Frederick/0000-0002-6424-4413; Ji, Guangju/0000-0001-8626-3490					0	19	19	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1257	1260		10.1096/fj.00-0467fje	http://dx.doi.org/10.1096/fj.00-0467fje			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344106				2022-12-25	WOS:000168655200028
J	Samuel, BU; Mohandas, N; Harrison, T; McManus, H; Rosse, W; Reid, M; Haldar, K				Samuel, BU; Mohandas, N; Harrison, T; McManus, H; Rosse, W; Reid, M; Haldar, K			The role of cholesterol and glycosylphosphatidylinositol-anchored proteins of erythrocyte rafts in regulating raft protein content and malarial infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE CHOLESTEROL; BETA-CYCLODEXTRIN; CELLS; COMPLEMENT; INVASION; RECEPTOR; CAVEOLAE; MICRODOMAINS; ACTIVATION; TRANSPORT	Human erythrocytes are terminally differentiated, non-endocytic cells that lack all intracellular organelles. Here we show that their plasma membranes contain detergent-resistant membrane rafts that constitute a small fraction (4%) of the total membrane protein, with a complex mixture of proteins that differentially associate with rafts. Depletion of raft-cholesterol abrogates association of all proteins with no significant effect on cholesterol:protein ratios in the rest of the membrane, lipid asymmetry, deformability, or transport properties of the bilayer, indicating that cholesterol is critical for protein assembly into rafts and suggesting that rafts have little influence on several erythrocyte functions. Erythrocytes from patients with paroxysmal nocturnal hemoglobinuria, which lack glycosylphosphatidylinositol-anchored proteins, show significant elevation in raft-cholesterol but no increase in raft protein association, suggesting that raft assembly does not require glycosylphosphatidylinositol-anchored proteins, raft proteins do not bind directly to cholesterol, and only threshold levels of raft-cholesterol are critical for protein recruitment. Loss of glycosylphosphatidylinositol-anchored proteins had no effect on erythrocytic infection by malarial parasite or movement of raft markers into the parasite's vacuole. However, infection is blocked following raft-cholesterol disruption, suggesting that erythrocyte rafts can be functionally exploited and providing the first evidence for the involvement of host rafts in an apicomplexan infection.	Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA; Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Duke Univ, Med Ctr, Dept Med, Div Hematol, Durham, NC 27710 USA; New York Blood Ctr, New York, NY 10021 USA	Northwestern University; Northwestern University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; Duke University; New York Blood Center	Haldar, K (corresponding author), Northwestern Univ, Sch Med, Dept Pathol, 303 E Chicago Ave,Ward 3210, Chicago, IL 60611 USA.	k-haldar@nwu.edu	Haldar, Kasturi/C-6685-2014		NIAID NIH HHS [AI39071] Funding Source: Medline; NIDDK NIH HHS [DK 32094] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK032094] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; CHASIS JA, 1989, BLOOD, V74, P1112, DOI 10.1182/blood.V74.3.1112.1112; Civenni G, 1998, BLOOD, V91, P1784, DOI 10.1182/blood.V91.5.1784.1784_1784_1792; CLARK MR, 1983, BLOOD, V61, P899, DOI 10.1182/blood.V61.5.899.899; DLUZEWSKI AR, 1985, PARASITOLOGY, V91, P273, DOI 10.1017/S003118200005736X; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; GOCKERMAN JP, 1978, AM J HEMATOL, V5, P323, DOI 10.1002/ajh.2830050407; HADLEY TJ, 1987, J CLIN INVEST, V80, P1190, DOI 10.1172/JCI113178; HALDAR K, 1994, METHOD CELL BIOL, V45, P221; HALDAR K, 1989, J CELL BIOL, V108, P2183, DOI 10.1083/jcb.108.6.2183; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Hiraoka Y, 1991, Semin Cell Biol, V2, P153; Holowka D, 2000, J CELL SCI, V113, P1009; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; Lauer S, 2000, EMBO J, V19, P3556, DOI 10.1093/emboj/19.14.3556; Lauer SA, 1997, SCIENCE, V276, P1122, DOI 10.1126/science.276.5315.1122; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; MAYER MM, 1972, P NATL ACAD SCI USA, V69, P2954, DOI 10.1073/pnas.69.10.2954; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; MOHANDAS N, 1980, BLOOD CELLS, V6, P329; Niculescu F, 1999, IMMUNOPHARMACOLOGY, V42, P187, DOI 10.1016/S0162-3109(99)00014-4; NICULESCU F, 1994, J BIOL CHEM, V269, P4417; Niculescu F, 1997, J IMMUNOL, V158, P4405; Okoyeh JN, 1999, INFECT IMMUN, V67, P5784, DOI 10.1128/IAI.67.11.5784-5791.1999; Ostermeyer AG, 1999, J BIOL CHEM, V274, P34459, DOI 10.1074/jbc.274.48.34459; Page E, 1998, AM J PHYSIOL-HEART C, V274, pH1988, DOI 10.1152/ajpheart.1998.274.6.H1988; PASVOL G, 1983, CIBA F SYMP, V94, P174; Rosse WF, 1997, MEDICINE, V76, P63, DOI 10.1097/00005792-199703000-00001; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Schnitzer JE, 1996, AM J PHYSIOL-HEART C, V270, pH416, DOI 10.1152/ajpheart.1996.270.1.H416; SHIN ML, 1978, J IMMUNOL, V120, P1996; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Soubes SC, 1999, VOX SANG, V76, P107, DOI 10.1159/000031029; Stewart GW, 1997, INT J BIOCHEM CELL B, V29, P271, DOI 10.1016/S1357-2725(96)00072-6; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VANVIANEN PH, 1993, CYTOMETRY, V14, P276, DOI 10.1002/cyto.990140307; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Verkade P, 1997, HISTOCHEM CELL BIOL, V108, P211, DOI 10.1007/s004180050161; Volonte D, 1999, J BIOL CHEM, V274, P12702, DOI 10.1074/jbc.274.18.12702; Wiesner J, 1997, EUR J IMMUNOL, V27, P2708, DOI 10.1002/eji.1830271034; Zager RA, 2000, KIDNEY INT, V58, P193, DOI 10.1046/j.1523-1755.2000.00154.x	49	150	155	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29319	29329		10.1074/jbc.M101268200	http://dx.doi.org/10.1074/jbc.M101268200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11352913	hybrid			2022-12-25	WOS:000170346000092
J	Wang, Y; Dulubova, I; Rizo, J; Sudhof, TC				Wang, Y; Dulubova, I; Rizo, J; Sudhof, TC			Functional analysis of conserved structural elements in yeast syntaxin Vam3p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNARE COMPLEX; SACCHAROMYCES-CEREVISIAE; MEMBRANE-FUSION; 3-DIMENSIONAL STRUCTURE; VACUOLAR MEMBRANE; PROTEIN-TRANSPORT; VESICLE FUSION; IN-VITRO; T-SNARE; HOMOLOG	Vam3p, a syntaxin-like SNARE protein involved in yeast vacuole fusion, is composed of a three-helical N-terminal domain, a canonical SNARE motif, and a C-terminal transmembrane region (TMR). Surprisingly, we find that the N-terminal domain of Vam3p is not essential for fusion, although analogous domains in other syntaxins are indispensible for fusion and/or protein-protein interactions. In contrast to the N-terminal domain, mutations in the SNARE motif of Vam3p or replacement of the SNARE motif of Vam3p with the SNARE motif from other syntaxins inhibited fusion. Furthermore, the precise distance between the SNARE motif and the TMR was critical for fusion. Insertion of only three residues after the SNARE motif significantly impaired fusion and insertion of 12 residues abolished fusion. As judged by co-immunoprecipitation experiments, the SNARE motif mutations and the insertions did not alter the association of Vam3p with Vam7p, Vti1p, Nyv-1p, and Ykt6p, other vacuolar SNARE proteins implicated in fusion. In contrast, the SNARE motif substitutions interfered with the stable formation of Vam3p complexes with Nyv1p and Vti1p, although Vam3p complexes with Vam7p and Ykt6p were still present. Our data suggest that in contrast to previously characterized syntaxins, Vam3p contains only two domains essential for fusion, the SNARE motif and the TMR, and these domains have to be closely coupled to function in fusion.	Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75390 USA.	Thomas.Sudhof@UTSouthwestem.edu			NINDS NIH HHS [NS372000] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Carr CM, 1999, J CELL BIOL, V146, P333, DOI 10.1083/jcb.146.2.333; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Conibear E, 1998, BBA-MOL CELL RES, V1404, P211, DOI 10.1016/S0167-4889(98)00058-5; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Dulubova I, 2001, NAT STRUCT BIOL, V8, P258, DOI 10.1038/85012; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; Gerhardt B, 1998, J BIOL CHEM, V273, P15818, DOI 10.1074/jbc.273.25.15818; Gerrard SR, 2000, TRAFFIC, V1, P45, DOI 10.1034/j.1600-0854.2000.010108.x; Gotte M, 1997, FEBS LETT, V411, P48, DOI 10.1016/S0014-5793(97)00575-9; HAAS A, 1994, J CELL BIOL, V126, P87, DOI 10.1083/jcb.126.1.87; Haas Albert, 1995, Methods in Cell Science, V17, P283, DOI 10.1007/BF00986234; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Katz L, 2000, MOL BIOL CELL, V11, P3849, DOI 10.1091/mbc.11.11.3849; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; Lerman JC, 2000, BIOCHEMISTRY-US, V39, P8470, DOI 10.1021/bi0003994; McNew JA, 1999, MOL CELL, V4, P415, DOI 10.1016/S1097-2765(00)80343-3; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Munson M, 2000, NAT STRUCT BIOL, V7, P894; Nichols BJ, 1998, BBA-MOL CELL RES, V1404, P9, DOI 10.1016/S0167-4889(98)00044-5; Ossig R, 2000, EMBO J, V19, P6000, DOI 10.1093/emboj/19.22.6000; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; Piper RC, 1997, J CELL BIOL, V138, P531, DOI 10.1083/jcb.138.3.531; ROBINSON JS, 1998, MOL CELL BIOL, V12, P5813; Sato TK, 1998, MOL CELL BIOL, V18, P5308, DOI 10.1128/MCB.18.9.5308; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Srivastava A, 1998, GENETICS, V148, P85; Sudhof TC, 2001, SYNAPSES, P177; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Ungermann C, 1999, J CELL BIOL, V145, P1435, DOI 10.1083/jcb.145.7.1435; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; von Mollard GF, 1999, MOL BIOL CELL, V10, P1719, DOI 10.1091/mbc.10.6.1719; WADA Y, 1992, J BIOL CHEM, V267, P18665; Wada Y, 1997, J CELL SCI, V110, P1299; Weimbs T, 1998, TRENDS CELL BIOL, V8, P260, DOI 10.1016/S0962-8924(98)01285-9; Wendland B, 1998, CURR OPIN CELL BIOL, V10, P513, DOI 10.1016/S0955-0674(98)80067-7; Wickner W, 2000, ANNU REV BIOCHEM, V69, P247, DOI 10.1146/annurev.biochem.69.1.247; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247	48	45	47	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28598	28605		10.1074/jbc.M101644200	http://dx.doi.org/10.1074/jbc.M101644200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11349128	hybrid			2022-12-25	WOS:000170093400113
J	Banerjee, RR; Lazar, MA				Banerjee, RR; Lazar, MA			Dimerization of resistin and resistin-like molecules is determined by a single cysteine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL TREFOIL FACTOR; ACTIVIN-A; GENE	Resistin is a peptide hormone secreted by adipocytes, Cysteine residues comprise 11 of 94 (12%) amino acids in resistin, The arrangement of these cysteines is unique to resistin and its recently discovered family of tissue-specific secreted proteins, which have been independently termed resistin-like molecules (RELMs) and the FIZZ (found in inflammatory zone) family. Here we show that resistin is a disulfide-linked homodimer that can be converted to a monomer by reducing conditions. The intestine-specific RELM beta has similar characteristics. Remarkably, however, the adipose-enriched RELM alpha is a monomer under non-reducing conditions. We note that RELM alpha lacks a cysteine residue, closest to the cleaved N terminus, that is present in resistin and RELM beta in multiple species. Conversion of this cysteine to alanine abolishes dimerization of resistin, Thus, a single disulfide bond is necessary to connect two resistin subunits in a homodimer. The additional 10 cysteines most likely participate in intramolecular disulfide bonds that define the conserved structure of the family members. The monomeric nature of RELM alpha suggests structural and potentially functional divergence between resistin and this close family member.	Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Penn Diabet Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Lazar, MA (corresponding author), Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, Dept Med, 611 CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.		Lazar, Mitchell A/AAF-3738-2019; Banerjee, Ronadip/U-6649-2019		NIDDK NIH HHS [DK50306, DK49780, DK49210, DK19525] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK049210, P30DK019525, R01DK049780, P30DK050306] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHAWLA A, 1993, J BIOL CHEM, V268, P16265; CHINERY R, 1995, FEBS LETT, V357, P50, DOI 10.1016/0014-5793(94)01297-E; Holcomb IN, 2000, EMBO J, V19, P4046, DOI 10.1093/emboj/19.15.4046; Huang EY, 2000, GENE DEV, V14, P45; HUSKENHINDI P, 1994, J BIOL CHEM, V269, P19380; Kim KH, 2001, J BIOL CHEM, V276, P11252, DOI 10.1074/jbc.C100028200; Kinoshita K, 2000, MOL CELL BIOL, V20, P4680, DOI 10.1128/MCB.20.13.4680-4690.2000; MASON AJ, 1994, MOL ENDOCRINOL, V8, P325, DOI 10.1210/me.8.3.325; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Steppan CM, 2001, P NATL ACAD SCI USA, V98, P502, DOI 10.1073/pnas.98.2.502; Wedemeyer WJ, 2000, BIOCHEMISTRY-US, V39, P4207, DOI 10.1021/bi992922o; Wittrup K. Dane, 1995, Current Opinion in Biotechnology, V6, P203, DOI 10.1016/0958-1669(95)80033-6	13	110	150	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25970	25973		10.1074/jbc.M103109200	http://dx.doi.org/10.1074/jbc.M103109200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11358969	hybrid			2022-12-25	WOS:000169823300045
J	Cheng, A; Bal, GS; Kennedy, BP; Tremblay, ML				Cheng, A; Bal, GS; Kennedy, BP; Tremblay, ML			Attenuation of adhesion-dependent signaling and cell spreading in transformed fibroblasts lacking protein tyrosine phosphate-1B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC-FAMILY KINASES; FOCAL ADHESION; C-SRC; INSULIN SENSITIVITY; HUMAN-PLACENTA; PTP-PEST; INTEGRIN; PHOSPHORYLATION; P130(CAS); GROWTH	Previous biochemical evidence has yielded conflicting models for the role of protein tyrosine phosphatase-1B (PTP-1B) in the regulation of integrin signaling, Thus, to establish the physiological relevance for such a role, we employed a genetic approach by generating embryonic fibroblasts from PTP-1B knockout mice. Both primary fibroblasts and their derived cell lines were used in this study. Immortalization of wild-type primary cells with the SV40 Large T antigen resulted in a dramatic increase in the endogenous expression of PTP-1B, suggesting a role during transformation. Moreover, the absence of PTP-1B in the transformed cell lines led to a more pronounced effect on different pathways of fibronectin-mediated signaling compared with the untransformed state. Specifically, p130(Cas) phosphorylation, Erk activation as well as cell spreading were delayed in PTP-1B-deficient cells, compared with their wild-type counterparts. Interestingly, this attenuation in integrin-mediated events closely resembles that of Src-deficient fibroblasts, Indeed, PTP-1B deficient, transformed fibroblasts held in suspension do exhibit a hyperphosphorylation of the inhibitory site (Tyr-527) of Src, compared with their wild-type counterparts. These results establish PTP-1B as a positive physiological regulator of integrin signaling in transformed cells, acting upstream of Src Tyr-527 dephosphorylation that leads to several adhesion-dependent events.	McGill Univ, Ctr Canc, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada	McGill University; McGill University; Merck & Company			Cheng, Alan/M-9319-2013	Cheng, Alan/0000-0001-7897-4751				Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Angers-Loustau A, 1999, BIOCHEM CELL BIOL, V77, P493, DOI 10.1139/bcb-77-6-493; Aplin AE, 1999, J CELL SCI, V112, P695; Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; Barberis L, 2000, J BIOL CHEM, V275, P36532, DOI 10.1074/jbc.M002487200; Bjorge JD, 2000, J BIOL CHEM, V275, P41439, DOI 10.1074/jbc.M004852200; Broome MA, 2000, ONCOGENE, V19, P2867, DOI 10.1038/sj.onc.1203608; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; Cote JF, 1998, BIOCHEMISTRY-US, V37, P13128, DOI 10.1021/bi981259l; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; ILIE D, 1995, NATURE, V377, P539; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; LaMontagne KR, 1998, MOL CELL BIOL, V18, P2965, DOI 10.1128/MCB.18.5.2965; LaMontagne KR, 1998, P NATL ACAD SCI USA, V95, P14094, DOI 10.1073/pnas.95.24.14094; Liu F, 1997, BIOCHEM J, V327, P139, DOI 10.1042/bj3270139; Liu F, 1998, CURR BIOL, V8, P173, DOI 10.1016/S0960-9822(98)70066-1; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; MACAULEY A, 1989, MOL CELL BIOL, V9, P2648, DOI 10.1128/MCB.9.6.2648; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; YouTen KE, 1997, J EXP MED, V186, P683, DOI 10.1084/jem.186.5.683; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125	54	92	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25848	25855		10.1074/jbc.M009734200	http://dx.doi.org/10.1074/jbc.M009734200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11346638	hybrid			2022-12-25	WOS:000169823300029
J	Kroger, N; Deutzmann, R; Sumper, M				Kroger, N; Deutzmann, R; Sumper, M			Silica-precipitating peptides from diatoms - The chemical structure of silaffin-1A from Cylindrotheca fusiformis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE FAMILY	Two silica-precipitating peptides, silaffin-1A(1) and-1A(2), both encoded by the sill gene from the diatom Cylin-drotheca fusiformis, were extracted from cell walls and purified to homogeneity, The chemical structures were determined by protein chemical methods combined with mass spectrometry, Silaffin-1A(1) and -1A(2) consist of 15 and 18 amino acid residues, respectively. Each peptide contains a total of four lysine residues, which are all found to be post-translationally modified. In silaffin-1A(2) the lysine residues are clustered in two pairs in which the e-amino group of the first residue is linked to a linear polyamine consisting of 5 to 11 N-methylated propylamine units, whereas the second lysine is converted to epsilon -N,N-dimethyllysine. Silaffin-1A(1) contains only a single lysine pair exhibiting the same structural features. One of the two remaining lysine residues was identified as epsilon -N,N,N-trimethyl-delta -hydroxylysine, a lysine derivative containing a quaternary ammonium group. The fourth lysine residue again is linked to a long-chain polyamine, Silaffin-1A(1) is the first peptide shown to contain epsilon -N,N,N-trimethyl-delta -hydroxylysine. In vitro, both peptides precipitate silica nanospheres within seconds when added to a monosilicic acid solution.	Univ Regensburg, Lehrstuhl Biochem 1, D-95053 Regensburg, Germany	University of Regensburg	Sumper, M (corresponding author), Univ Regensburg, Lehrstuhl Biochem 1, D-95053 Regensburg, Germany.							BURKETT SL, 1996, COMPREHENSIVE SUPRAM, V7, P465; Cha JN, 2000, NATURE, V403, P289, DOI 10.1038/35002038; Hildebrand M, 1998, MOL GEN GENET, V260, P480, DOI 10.1007/s004380050920; Hildebrand M, 1997, NATURE, V385, P688, DOI 10.1038/385688b0; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; Kroger N, 1999, SCIENCE, V286, P1129, DOI 10.1126/science.286.5442.1129; Kroger N, 2000, P NATL ACAD SCI USA, V97, P14133, DOI 10.1073/pnas.260496497; KROGER N, 1994, EMBO J, V13, P4676, DOI 10.1002/j.1460-2075.1994.tb06791.x; Kroger N, 1996, EUR J BIOCHEM, V239, P259, DOI 10.1111/j.1432-1033.1996.0259u.x; Kroger N., 2000, BIOMINERALISATION, P151; LOWENSTAM HA, 1981, SCIENCE, V211, P1126, DOI 10.1126/science.7008198; Mann S, 1996, NATURE, V382, P313, DOI 10.1038/382313a0; MORT AJ, 1977, ANAL BIOCHEM, V82, P289, DOI 10.1016/0003-2697(77)90165-8; NACHBAUR E, 1971, MONATSH CHEM, V102, P1718, DOI 10.1007/BF00905645; NAKAJIMA T, 1970, BIOCHEM BIOPH RES CO, V39, P28, DOI 10.1016/0006-291X(70)90752-7; NARITA K, 1975, PROTEIN SEQUENCE DET, P30; Parkinson J, 1999, TRENDS BIOTECHNOL, V17, P190, DOI 10.1016/S0167-7799(99)01321-9; ROBINSON DH, 1987, TRENDS BIOCHEM SCI, V12, P151, DOI 10.1016/0968-0004(87)90072-7; Round F.E., 1990, DIATOMS; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TREGUER P, 1995, SCIENCE, V268, P375, DOI 10.1126/science.268.5209.375; VOLCANI B E, 1978, P177; Vrieling EG, 1999, J PHYCOL, V35, P548, DOI 10.1046/j.1529-8817.1999.3530548.x	23	245	257	1	83	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26066	26070		10.1074/jbc.M102093200	http://dx.doi.org/10.1074/jbc.M102093200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11349130	hybrid			2022-12-25	WOS:000169823300058
J	Shin, D; Lim, S; Seok, Y; Ryu, S				Shin, D; Lim, S; Seok, Y; Ryu, S			Heat shock RNA polymerase (E sigma(32)) is involved in the transcription of mlc and crucial for induction of the Mlc regulon by glucose in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR GLUCOSE; SIGMA-FACTOR; EXPRESSION; GENE; TRANSPORTER; REPRESSOR; PROTEIN; CAMP; REGULATOR; PROMOTER	Mlc is a global regulator of carbohydrate metabolism. Recent studies have revealed that Mlc is depressed by protein-protein interaction with enzyme IICBGlc, a glucose-specific permease, which is encoded by ptsG, The mlc gene has been previously known to be transcribed by two promoters, P1(+1) and P2(+13), and have a binding site of its own gene product at +16, However, the mechanism of transcriptional regulation of the gene has not yet been established. In vitro transcription assays of the mlc gene showed that Pa promoter could be recognized by RNA polymerase containing the heat shock sigma factor sigma (32) (E sigma (32)) as well as E sigma (70), while P1 promoter is only recognized by E sigma (70). The cyclic AMP receptor protein and cyclic AMP complex (CRP cAMP) increased expression from P2 but showed negative effect on transcription from P1 by E sigma (70), although it had little effect on transcription from P2 by E sigma (32) in vitro, Purified Mlc repressed transcription from both promoters, but with different degrees of inhibition. In vivo transcription assays using wild type and mlc strains indicated that the level of mlc expression was modulated less than 2-fold by glucose in the medium with concerted action of CRP cAMP and Mlc. A dramatic increase in mlc expression was observed upon heat shock or in cells overexpressing sigma (32), confirming that E sigma (32) is involved in the expression of mlc. Induction of ptsG P1 and pts P0 transcription by glucose was also dependent on E sigma (32). These results indicate that E sigma (32) plays an important role in balancing the relative concentration of Mlc and EIICBGlc in response to availability of glucose in order to maintain inducibility of the Mle regulon at high growth temperature.	Seoul Natl Univ, Dept Food Sci & Technol, Res Ctr New Bio Mat Agr, Suwon 441744, South Korea; Seoul Natl Univ, Sch Agr Biotechnol, Suwon 441744, South Korea; Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Ryu, S (corresponding author), Seoul Natl Univ, Dept Food Sci & Technol, Res Ctr New Bio Mat Agr, Suwon 441744, South Korea.	sangryu@snu.ac.kr		Seok, Yeong-Jae/0000-0003-0379-3619				Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; CHARPENTIER B, 1994, J BACTERIOL, V176, P830, DOI 10.1128/jb.176.3.830-839.1994; CHUANG SE, 1993, J BACTERIOL, V175, P5242, DOI 10.1128/JB.175.16.5242-5252.1993; Decker K, 1998, MOL MICROBIOL, V27, P381, DOI 10.1046/j.1365-2958.1998.00694.x; ERICKSON JW, 1989, GENE DEV, V3, P1462, DOI 10.1101/gad.3.9.1462; GROSSMAN AD, 1984, CELL, V38, P383, DOI 10.1016/0092-8674(84)90493-8; HARGER DA, 1990, BIOCHEMISTRY-US, V29, P7890; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HIRSCHMAN J, 1985, P NATL ACAD SCI USA, V82, P7525, DOI 10.1073/pnas.82.22.7525; HOSONO K, 1995, BIOSCI BIOTECH BIOCH, V59, P256, DOI 10.1271/bbb.59.256; ISHIZUKA H, 1993, MOL MICROBIOL, V10, P341, DOI 10.1111/j.1365-2958.1993.tb01960.x; KELLEY RL, 1982, P NATL ACAD SCI-BIOL, V79, P3120, DOI 10.1073/pnas.79.10.3120; Kim SY, 1999, J BIOL CHEM, V274, P25398, DOI 10.1074/jbc.274.36.25398; Kimata K, 1998, MOL MICROBIOL, V29, P1509, DOI 10.1046/j.1365-2958.1998.01035.x; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KUSUKAWA N, 1988, GENE DEV, V2, P874, DOI 10.1101/gad.2.7.874; Lee SJ, 2000, EMBO J, V19, P5353, DOI 10.1093/emboj/19.20.5353; MENG LM, 1990, EUR J BIOCHEM, V187, P373, DOI 10.1111/j.1432-1033.1990.tb15314.x; MORRIS PW, 1985, J BACTERIOL, V163, P785, DOI 10.1128/JB.163.2.785-786.1985; MULVEY MR, 1989, NUCLEIC ACIDS RES, V17, P9979, DOI 10.1093/nar/17.23.9979; Nam TW, 2001, EMBO J, V20, P491, DOI 10.1093/emboj/20.3.491; NEWLANDS JT, 1993, J BACTERIOL, V175, P661, DOI 10.1128/JB.175.3.661-668.1993; Plumbridge J, 1999, MOL MICROBIOL, V33, P260, DOI 10.1046/j.1365-2958.1999.01462.x; Plumbridge J, 1998, MOL MICROBIOL, V29, P1053, DOI 10.1046/j.1365-2958.1998.00991.x; Plumbridge J, 1998, MOL MICROBIOL, V27, P369, DOI 10.1046/j.1365-2958.1998.00685.x; Plumbridge J, 1996, J BACTERIOL, V178, P2629, DOI 10.1128/jb.178.9.2629-2636.1996; ROEHL RA, 1980, J BACTERIOL, V142, P120, DOI 10.1128/JB.142.1.120-130.1980; RYU S, 1994, J BIOL CHEM, V269, P4767; RYU S, 1993, P NATL ACAD SCI USA, V90, P75, DOI 10.1073/pnas.90.1.75; Ryu S, 1998, MOL CELLS, V8, P614; RYU S, 1995, J BIOL CHEM, V270, P2489, DOI 10.1074/jbc.270.6.2489; Sambrook J, 2001, MOL CLONING LAB MANU; STRAUS DB, 1987, NATURE, V329, P348, DOI 10.1038/329348a0; Sukhodolets MV, 1998, J BIOL CHEM, V273, P7018, DOI 10.1074/jbc.273.12.7018; Tanaka Y, 1999, GENES CELLS, V4, P391, DOI 10.1046/j.1365-2443.1999.00268.x; Tanaka Y, 2000, EMBO J, V19, P5344, DOI 10.1093/emboj/19.20.5344; WEICKERT MJ, 1993, J BACTERIOL, V175, P251, DOI 10.1128/JB.175.1.251-258.1993; YURA T, 1993, ANNU REV MICROBIOL, V47, P321, DOI 10.1146/annurev.mi.47.100193.001541	38	35	35	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25871	25875		10.1074/jbc.M101757200	http://dx.doi.org/10.1074/jbc.M101757200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11340070	hybrid			2022-12-25	WOS:000169823300032
J	Choi, YH; Kim, KB; Kim, HH; Hong, GS; Kwon, YK; Chung, CW; Park, YM; Shen, ZJ; Kim, BJ; Lee, SY; Jung, YK				Choi, YH; Kim, KB; Kim, HH; Hong, GS; Kwon, YK; Chung, CW; Park, YM; Shen, ZJ; Kim, BJ; Lee, SY; Jung, YK			FLASH coordinates NF-kappa B activity via TRAF2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CELL-DEATH; TNF RECEPTOR; INTERLEUKIN-1-BETA-CONVERTING ENZYME; SIGNALING COMPLEX; ACTIVATION; PROTEIN; APOPTOSIS; KINASE; CASPASE-8; ALPHA	FLASH is a protein recently shown to interact with the death effector domain of caspase-8 and is likely to be a component of the death-inducing signaling complex in receptor-mediated apoptosis, Here we show that antisense oligonucleotide-induced inhibition of FLASH expression abolished TNF-ru-induced activation of NF-KB in HEK293 cells, as determined by luciferase reporter gene expression driven by a NF-KB responsive promoter. Conversely, overexpression of FLASH dose-dependently activated NF-KB, an effect suppressed by dominant negative mutants of TRAF2, NIK, and IKK alpha, and partially by those of TRAF5 and TRAF6, TRAF2 was co-immunoprecipitated with FLASH from the cell extracts of HEK293 cells or HeLa cells stably expressing exogenous FLASH (HeLa/HA-FLASH), Furthermore, serial deletion mapping demonstrated that a domain spanning the residues 856-1191 of FLASH activated NF-KB as efficiently as the full-length and could directly bind to TRAF2 in vitro and in the transfected cells. Taken together, these results suggest that FLASH coordinates downstream NF-KB activity via a TRAF2-dependent pathway in the TNF-alpha signaling.	Kwangju Inst Sci & Technol, Dept Life Sci, Puk Gu, Kwangju 500712, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea	Gwangju Institute of Science & Technology (GIST); Ewha Womans University	Jung, YK (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, Puk Gu, 1 Oryong Dong, Kwangju 500712, South Korea.			Jung, Yong-Keun/0000-0002-9686-3120				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Chung CW, 2001, NEUROBIOL DIS, V8, P162, DOI 10.1006/nbdi.2000.0335; COA Z, 1996, NATURE, V383, P443; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; Inohara N, 2000, J BIOL CHEM, V275, P27823; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Jung YK, 1996, J BIOL CHEM, V271, P5112; Kim IK, 2000, BIOCHEM BIOPH RES CO, V277, P311, DOI 10.1006/bbrc.2000.3673; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Ling L, 2000, P NATL ACAD SCI USA, V97, P9567, DOI 10.1073/pnas.170279097; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Medema JP, 1999, NATURE, V398, P756, DOI 10.1038/19638; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Reuther JY, 1999, J BIOL CHEM, V274, P20664, DOI 10.1074/jbc.274.29.20664; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Serfas MS, 1997, CELL GROWTH DIFFER, V8, P951; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	38	40	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25073	25077		10.1074/jbc.M102941200	http://dx.doi.org/10.1074/jbc.M102941200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11340079	hybrid			2022-12-25	WOS:000169800700086
J	Ellerbroek, SM; Wu, YI; Overall, CM; Stack, MS				Ellerbroek, SM; Wu, YI; Overall, CM; Stack, MS			Functional interplay between type I collagen and cell surface matrix metalloproteinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GELATINASE-A; EXTRACELLULAR-MATRIX; TISSUE INHIBITOR; FOCAL CONTACTS; CONCANAVALIN-A; ACTIVATION; INTEGRIN; CLEAVAGE; EXPRESSION; INVASION	Type I collagen stimulation of pro-matrix metalloproteinase (pro-MMP)-2 activation by ovarian cancer cells involves beta (1) integrin receptor clustering; however, the specific cellular and biochemical events that accompany MMP processing are not well characterized. Collagenolysis is not required for stimulation of pro-MMP-2 activation, and denatured collagen does not elicit an MMP-2 activation response. Similarly, DOV13 cells bind to intact collagen utilizing both alpha (2)beta (1) and alpha (3)beta (1) integrins but interact poorly with collagenase-treated or thermally denatured collagen. Antibody-induced clustering of alpha (3)beta (1) strongly promotes activation of pro-MMP-2, whereas alpha (2)beta (1) integrin clustering has only marginal effects. Membrane-type 1 (MT1)-MMP is present on the DOV13 cell surface as both an active 55-kDa TIMP-2-binding species and a stable catalytically inactive 43-kDa form. Integrin clustering stimulates cell surface expression of MT1-MMP and co-localization of the proteinase to aggregated integrin complexes. Furthermore, cell surface proteolysis of the 55-kDa MT1-MMP species occurs in the absence of active MMP-2, suggesting MT1-MMP autolysis, Cellular invasion of type I collagen matrices requires collagenase activity, is blocked by tissue inhibitor of metalloproteinases-2 (TIMP-2) and collagenase-resistant collagen, is unaffected by TIMP-1, and is accompanied by pro-MMP-2 activation. Together, these data indicate that integrin stimulation of MT1-MMP activity is a rate-limiting step for type I collagen invasion and provide a mechanism by which this activity can be down-regulated following collagen clearance.	Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Obstet & Gynecol, Chicago, IL 60611 USA; Univ British Columbia, Fac Med, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Fac Dent, Vancouver, BC V6T 1Z3, Canada	Northwestern University; Northwestern University; University of British Columbia; University of British Columbia	Stack, MS (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave,Tarry 8-715, Chicago, IL 60611 USA.	mss130@northwestern.edu			NCI NIH HHS [R01 CA86984] Funding Source: Medline; NIGMS NIH HHS [5T32 GM08061] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086984] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008061] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; AZZAM HS, 1992, CANCER RES, V52, P4540; Bafetti LM, 1998, J BIOL CHEM, V273, P143, DOI 10.1074/jbc.273.1.143; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Cockett MI, 1998, BIOCHEM SOC SYMP, P295; Corcoran ML, 1996, ENZYME PROTEIN, V49, P7, DOI 10.1159/000468613; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; DANIELSEN CC, 1987, BIOCHEM J, V247, P725, DOI 10.1042/bj2470725; DIPERSIO CM, 1995, J CELL SCI, V108, P2321; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; Ellerbroek SM, 1999, CANCER RES, V59, P1635; Ellerbroek SM, 1998, INT J CANCER, V78, P331, DOI 10.1002/(SICI)1097-0215(19981029)78:3<331::AID-IJC13>3.0.CO;2-9; GRENZ H, 1993, J CELL SCI, V105, P739; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Lichtner RB, 1998, EXP CELL RES, V240, P368, DOI 10.1006/excr.1998.4012; LIU X, 1995, J CELL BIOL, V130, P227, DOI 10.1083/jcb.130.1.227; Messent AJ, 1998, J CELL SCI, V111, P1127; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Moser TL, 1996, INT J CANCER, V67, P695, DOI 10.1002/(SICI)1097-0215(19960904)67:5<695::AID-IJC18>3.3.CO;2-2; Mueller SC, 1999, J BIOL CHEM, V274, P24947, DOI 10.1074/jbc.274.35.24947; Nagase H, 1997, BIOL CHEM, V378, P151; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Nguyen M, 2000, INT J BIOCHEM CELL B, V32, P621, DOI 10.1016/S1357-2725(00)00013-3; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; PineiroSanchez ML, 1997, J BIOL CHEM, V272, P7595, DOI 10.1074/jbc.272.12.7595; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SELTZER JL, 1994, EXP CELL RES, V213, P365, DOI 10.1006/excr.1994.1211; Steffensen B, 1998, J BIOL CHEM, V273, P20622, DOI 10.1074/jbc.273.32.20622; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; Theret N, 1999, HEPATOLOGY, V30, P462, DOI 10.1002/hep.510300236; Tomasek JJ, 1997, J BIOL CHEM, V272, P7482, DOI 10.1074/jbc.272.11.7482; Urena JM, 1999, J CELL SCI, V112, P773; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119	45	140	147	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24833	24842		10.1074/jbc.M005631200	http://dx.doi.org/10.1074/jbc.M005631200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11331272	hybrid			2022-12-25	WOS:000169800700056
J	Hoffmeister, KM; Falet, H; Toker, A; Barkalow, KL; Stossel, TP; Hartwig, JH				Hoffmeister, KM; Falet, H; Toker, A; Barkalow, KL; Stossel, TP; Hartwig, JH			Mechanisms of cold-induced platelet actin assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; FILAMENT BARBED ENDS; ARP2/3 COMPLEX; N-WASP; CAPPING PROTEIN; KINASE-C; GELSOLIN; CALCIUM; CDC42; NUCLEATION	Various agonists but also chilling cause blood platelets to increase cytosolic calcium, polymerize actin, and change shape. We report that cold increases barbed end nucleation sites in octyl glucoside-permeabilized platelets by 3-fold, enabling analysis of the intermediates of this response. Although chilling does not change polyphosphoinositide (ppI) levels, a ppI-binding peptide completely inhibits cold-induced nucleation. The C terminus of N-WASp, which inhibits the Arp2/3 complex, blocks nucleation by 40%; GDP betaS, N17Rac and N17Cdc42 have no effects. Some gelsolin translocates to the detergent-insoluble cytoskeleton after cooling. Chilled platelets from gelsolin-deficient mice have similar to 50% fewer new actin nuclei compared with platelets from wild-type mice. EGTA completely inhibits gelsolin translocation into the cytoskeleton, and the small amount of gelsolin initially there becomes soluble. Chilling releases adducin from the detergent-resistant cytoskeleton. We conclude that platelet actin filament assembly induced by cooling involves ppI-mediated actin filament barbed end uncapping and de novo nucleation independently of surface receptors or downstream signaling intermediates besides calcium, The actin-related changes occur in platelets at temperatures below 37 degreesC, suggesting that the platelet may be more activable at temperatures at the body surface than at core temperature, thereby favoring superficial hemostasis over internal thrombosis.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Hartwig, JH (corresponding author), Brigham & Womens Hosp, Div Hematol, LMRC 301,221 Longwood Ave, Boston, MA 02115 USA.	hartwig@calvin.bwh.harvard.edu		Falet, Herve/0000-0003-0788-9204	NHLBI NIH HHS [HL56993, HL56949] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056993, P01HL056949] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; Barkalow K, 1996, J CELL BIOL, V134, P389, DOI 10.1083/jcb.134.2.389; BENNETT WF, 1980, J CELL BIOL, V86, P280, DOI 10.1083/jcb.86.1.280; CHAPONNIER C, 1987, J EXP MED, V165, P97, DOI 10.1084/jem.165.1.97; CHERNOFF A, 1992, TRANSFUSION, V32, P386, DOI 10.1046/j.1537-2995.1992.32492263456.x; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Eddy RJ, 1997, J CELL BIOL, V139, P1243, DOI 10.1083/jcb.139.5.1243; Falet H, 2000, BLOOD, V96, P3786, DOI 10.1182/blood.V96.12.3786.h8003786_3786_3792; Glogauer M, 2000, J CELL BIOL, V150, P785, DOI 10.1083/jcb.150.4.785; Gross BS, 1999, BLOOD, V94, P4166, DOI 10.1182/blood.V94.12.4166.424k36_4166_4176; HARTWIG J H, 1992, P23; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HARTWIG JH, 1991, J CELL BIOL, V112, P407, DOI 10.1083/jcb.112.3.407; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; Hartwig JH, 1996, J BIOL CHEM, V271, P32986, DOI 10.1074/jbc.271.51.32986; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; Kolluri R, 1996, P NATL ACAD SCI USA, V93, P5615, DOI 10.1073/pnas.93.11.5615; Kuhlman PA, 1996, J BIOL CHEM, V271, P7986, DOI 10.1074/jbc.271.14.7986; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XL, 1998, J BIOL CHEM, V273, P19329, DOI 10.1074/jbc.273.30.19329; LIND SE, 1987, J CELL BIOL, V105, P833, DOI 10.1083/jcb.105.2.833; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Ma L, 1998, P NATL ACAD SCI USA, V95, P15362, DOI 10.1073/pnas.95.26.15362; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Machesky LM, 1999, CURR OPIN CELL BIOL, V11, P117, DOI 10.1016/S0955-0674(99)80014-3; Matsuoka Y, 2000, CELL MOL LIFE SCI, V57, P884, DOI 10.1007/PL00000731; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; MOROFF G, 1994, TRANSFUSION, V34, P317, DOI 10.1046/j.1537-2995.1994.34494233579.x; Mullins RD, 1999, CURR BIOL, V9, P405, DOI 10.1016/S0960-9822(99)80187-0; Nachmias VT, 1996, FEBS LETT, V378, P258, DOI 10.1016/0014-5793(95)01474-8; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Tablin F, 1996, J CELL PHYSIOL, V168, P305, DOI 10.1002/(SICI)1097-4652(199608)168:2<305::AID-JCP9>3.0.CO;2-T; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; WHITE JG, 1967, BLOOD-J HEMATOL, V30, P625, DOI 10.1182/blood.V30.5.625.625; WHITE JG, 1968, AM J PATHOL, V53, P281; WINOKUR R, 1995, BLOOD, V85, P1796, DOI 10.1182/blood.V85.7.1796.bloodjournal8571796; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0	50	66	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24751	24759		10.1074/jbc.M011642200	http://dx.doi.org/10.1074/jbc.M011642200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11328807	hybrid			2022-12-25	WOS:000169800700046
J	Zhang, F; Romano, PR; Nagamura-Inoue, T; Tian, B; Devert, TE; Mathews, MB; Ozato, K; Hinnebusch, AG				Zhang, F; Romano, PR; Nagamura-Inoue, T; Tian, B; Devert, TE; Mathews, MB; Ozato, K; Hinnebusch, AG			Binding of double-stranded RNA to protein kinase PKR is required for dimerization and promotes critical autophosphorylation events in the activation loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION FACTOR-2-ALPHA; PHOSPHORYLATION SITES; TRANSLATIONAL CONTROL; INTERFERON ACTION; MOLECULAR-BASIS; IN-VIVO; DOMAIN; MECHANISM; YEAST; INHIBITION	Protein kinase PKR is activated by double-stranded RNA (dsRNA) and phosphorylates translation initiation factor 2 alpha to inhibit protein synthesis in virus-infected mammalian cells. PKR contains two dsRNA binding motifs (DRBMs I and II) required for activation by dsRNA, There is strong evidence that PKR activation requires dimerization, but the role of dsRNA in dimer formation is controversial. By making alanine substitutions predicted to remove increasing numbers of side chain contacts between the DRBMs and dsRNA we found that dimerization of full-length PKR in yeast was impaired by the minimal combinations of mutations required to impair dsRNA binding in vitro. Mutation of Ala-67 to Glu in DRBM-I, reported to abolish dimerization without affecting dsRNA binding, destroyed both activities in our assays. By contrast, deletion of a second dimerization region that overlaps the kinase domain had no effect on PKR dimerization in yeast, Human PKR contains at least 15 autophosphorylation sites, but only Thr-446 and Thr-451 in the activation loop were found here to be critical for kinase activity in yeast. Using an antibody specific for phosphorylated Thr-451, we showed that Thr-451 phosphorylation is stimulated by dsRNA binding, Our results provide strong evidence that dsRNA binding is required for dimerization of full-length PKR molecules in vivo, leading to autophosphorylation in the activation loop and stimulation of the eIF2 alpha kinase function of PKR.	NICHHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA; NICHHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; Thomas Jefferson Univ, Jefferson Ctr Biomed Res, Doylestown, PA 18901 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Rutgers State University New Brunswick; Rutgers State University Medical Center; Jefferson University	Hinnebusch, AG (corresponding author), NICHHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA.	ahinnebusch@nih.gov	Dever, Thomas/GSE-0966-2022	Dever, Thomas/0000-0001-7120-9678; Tian, Bin/0000-0001-8903-8256	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001310, Z01HD001004, Z01HD001010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034552] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI34552] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; Bevilacqua PC, 1996, BIOCHEMISTRY-US, V35, P9983, DOI 10.1021/bi9607259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BYCROFT M, 1995, EMBO J, V14, P3563, DOI 10.1002/j.1460-2075.1995.tb07362.x; Carpick BW, 1997, J BIOL CHEM, V272, P9510, DOI 10.1074/jbc.272.14.9510; Cesareni G, 1987, GENETIC ENG PRINCIPL, V9, P135, DOI DOI 10.1007/978-1-4684-5377-5_9; CHIU YS, 1978, J BIOL CHEM, V253, P7145; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; COSENTINO GP, 1995, P NATL ACAD SCI USA, V92, P9445, DOI 10.1073/pnas.92.21.9445; Craig AWB, 1996, J BIOL CHEM, V271, P24526, DOI 10.1074/jbc.271.40.24526; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; Fierro-Monti I, 2000, TRENDS BIOCHEM SCI, V25, P241, DOI 10.1016/S0968-0004(00)01580-2; GALABRU J, 1989, EUR J BIOCHEM, V178, P581, DOI 10.1111/j.1432-1033.1989.tb14485.x; GALABRU J, 1987, J BIOL CHEM, V262, P15538; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; GREEN SR, 1995, MOL CELL BIOL, V15, P358, DOI 10.1128/MCB.15.1.358; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; HUNTER T, 1975, J BIOL CHEM, V250, P409; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGLAND JO, 1992, J BIOL CHEM, V267, P10729; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; MATHEWS MB, 1993, SEMIN VIROL, V4, P247, DOI 10.1006/smvy.1993.1021; Nanduri S, 2000, EMBO J, V19, P5567, DOI 10.1093/emboj/19.20.5567; Nanduri S, 1998, EMBO J, V17, P5458, DOI 10.1093/emboj/17.18.5458; Ortega LG, 1996, VIROLOGY, V215, P31, DOI 10.1006/viro.1996.0004; PATEL RC, 1995, P NATL ACAD SCI USA, V92, P8283, DOI 10.1073/pnas.92.18.8283; Patel RC, 1998, MOL CELL BIOL, V18, P7009, DOI 10.1128/MCB.18.12.7009; Patel RC, 1996, J BIOL CHEM, V271, P25657, DOI 10.1074/jbc.271.41.25657; Pavitt GD, 1997, MOL CELL BIOL, V17, P1298, DOI 10.1128/MCB.17.3.1298; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Ramos A, 2000, EMBO J, V19, P997, DOI 10.1093/emboj/19.5.997; Romano PR, 1998, MOL CELL BIOL, V18, P7304, DOI 10.1128/MCB.18.12.7304; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Ryter JM, 1998, EMBO J, V17, P7505, DOI 10.1093/emboj/17.24.7505; SCHMEDT C, 1995, J MOL BIOL, V249, P29, DOI 10.1006/jmbi.1995.0278; Sharp TV, 1998, VIROLOGY, V250, P302, DOI 10.1006/viro.1998.9365; Sherman F., 1974, METHODS YEAST GENETI; SHOJI S, 1979, J BIOL CHEM, V254, P6211; SIKORSKI RS, 1989, GENETICS, V122, P19; Tan SL, 1998, MOL CELL BIOL, V18, P2431, DOI 10.1128/MCB.18.5.2431; Taylor DR, 2001, J VIROL, V75, P1265, DOI 10.1128/JVI.75.3.1265-1273.2001; Taylor DR, 1996, MOL CELL BIOL, V16, P6295; THOMIS DC, 1995, J VIROL, V69, P5195, DOI 10.1128/JVI.69.8.5195-5198.1995; Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291; Wu SY, 1996, J BIOL CHEM, V271, P1756, DOI 10.1074/jbc.271.3.1756; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; Zhang XL, 1998, ANAL CHEM, V70, P2050, DOI 10.1021/ac971207m; Zhu SH, 1997, J BIOL CHEM, V272, P14434, DOI 10.1074/jbc.272.22.14434	56	152	160	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24946	24958		10.1074/jbc.M102108200	http://dx.doi.org/10.1074/jbc.M102108200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11337501	hybrid			2022-12-25	WOS:000169800700069
J	Descamps, S; Toillon, RA; Adriaenssens, E; Pawlowski, V; Cool, SM; Nurcombe, V; Le Bourhis, XF; Boilly, B; Peyrat, JP; Hondermarck, H				Descamps, S; Toillon, RA; Adriaenssens, E; Pawlowski, V; Cool, SM; Nurcombe, V; Le Bourhis, XF; Boilly, B; Peyrat, JP; Hondermarck, H			Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; FACTOR-LIKE PROTEIN; HUMAN PROSTATE; P75 RECEPTOR; PC12 CELLS; ACTIVATION; NGF; AFFINITY; DEATH; APOPTOSIS	We show here that the neurotrophin nerve growth factor (NGF), which has been shown to be a mitogen for breast cancer cells, also stimulates cell survival through a distinct signaling pathway. Breast cancer cell lines (MCF-7, T47-D, BT-20, and MDA-MB-231) were found to express both types of NGF receptors: p140(trkA) and p75(NTR). The two other tyrosine kinase receptors for neurotrophins, TrkB and TrkC, were not expressed. The mitogenic effect of NGF on breast cancer cells required the tyrosine kinase activity of p140(trkA) as well as the mitogen-activated protein kinase (MAPK) cascade, but was independent of p75(NTR). I, contrast, the anti-apoptotic effect of NGF (studied using the ceramide analogue C2) required p75(NTR) as well as the activation of the transcription factor NF-kB, but neither p140(trkA) nor MAPK was necessary. Other neurotrophins (BDNF, NT-3, NT-4/5) also induced cell survival, although not proliferation, emphasizing the importance of p75(NTR) in NGF-mediated survival. Both the pharmacological NF-KB inhibitor SN50, and cell transfection with IkBm, resulted in a diminution of NGF anti-apoptotic effect. These data show that two distinct signaling pathways are required for NGF activity and confirm the roles played by p75(NTR) and NF-kappaB in the activation of the survival pathway in breast cancer cells.	Univ Sci & Technol Lille, Equipe facteurs Croissance, UPRES EA Biol Dev 1033, F-59655 Villeneuve Dascq, France; Inst Biol, CNRS, UMR 8527, F-59000 Lille, France; Univ Queensland, Dept Anat Sci, St Lucia, Qld 4072, Australia; Ctr Oscar Lambret, Lab Oncol Mol Humaine, F-59020 Lille, France	Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); University of Queensland; UNICANCER; Centre Oscar Lambret	Hondermarck, H (corresponding author), Univ Sci & Technol Lille, Equipe facteurs Croissance, UPRES EA Biol Dev 1033, F-59655 Villeneuve Dascq, France.		Cool, Simon/W-1257-2018; Cool, Simon McKenzie/AAG-4346-2021; Toillon, Robert-Alain/Q-2286-2018; Le+Bourhis, Xuefen/AAL-5141-2021	Cool, Simon/0000-0001-8543-3056; Toillon, Robert-Alain/0000-0001-5483-2118; 				ANTON ES, 1994, P NATL ACAD SCI USA, V91, P2795, DOI 10.1073/pnas.91.7.2795; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; Barker PA, 1998, CELL DEATH DIFFER, V5, P346, DOI 10.1038/sj.cdd.4400375; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; Bhakar AL, 1999, J BIOL CHEM, V274, P21443, DOI 10.1074/jbc.274.30.21443; Carter BD, 1997, NEURON, V18, P187, DOI 10.1016/S0896-6273(00)80259-7; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; Casaccia-Bonnefil P, 1998, CELL DEATH DIFFER, V5, P357, DOI 10.1038/sj.cdd.4400377; Chou TT, 2000, J BIOL CHEM, V275, P565, DOI 10.1074/jbc.275.1.565; Descamps S, 1998, J BIOL CHEM, V273, P16659, DOI 10.1074/jbc.273.27.16659; DIMARCO E, 1993, J BIOL CHEM, V268, P22838; DJAKIEW D, 1993, CANCER RES, V53, P1416; DJAKIEW D, 1991, CANCER RES, V51, P3304; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P5423, DOI 10.1073/pnas.90.12.5423; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; Foehr ED, 2000, J NEUROSCI, V20, P7556; Frade JM, 1996, NATURE, V383, P166; Friedman WJ, 1999, EXP CELL RES, V253, P131, DOI 10.1006/excr.1999.4705; Gentry JJ, 2000, J BIOL CHEM, V275, P7558, DOI 10.1074/jbc.275.11.7558; Gill ZP, 1997, J BIOL CHEM, V272, P25602, DOI 10.1074/jbc.272.41.25602; GRUETERS A, 1985, PEDIATR RES, V19, P934, DOI 10.1203/00006450-198509000-00014; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Herrmann JL, 1997, EXP CELL RES, V237, P101, DOI 10.1006/excr.1997.3737; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; Le Bourhis X, 2000, BREAST CANCER RES TR, V60, P251, DOI 10.1023/A:1006461621905; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Lievremont JP, 1999, J BIOL CHEM, V274, P15466, DOI 10.1074/jbc.274.22.15466; LILLIEN LE, 1985, NATURE, V317, P632, DOI 10.1038/317632a0; Longo FM, 1997, J NEUROSCI RES, V48, P1, DOI 10.1002/(SICI)1097-4547(19970401)48:1<1::AID-JNR1>3.0.CO;2-K; LOSSING C, 1993, PLAST RECONSTR SURG, V91, P1277, DOI 10.1097/00006534-199306000-00014; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; Pflug B, 1998, MOL CARCINOGEN, V23, P106, DOI 10.1002/(SICI)1098-2744(199810)23:2<106::AID-MC7>3.0.CO;2-W; Pirianov G, 1999, CELL DEATH DIFFER, V6, P890, DOI 10.1038/sj.cdd.4400563; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Rabizadeh S, 1999, CELL DEATH DIFFER, V6, P1222, DOI 10.1038/sj.cdd.4400614; RAKOWICZSZULCZYNSKA EM, 1993, J CELL PHYSIOL, V154, P64, DOI 10.1002/jcp.1041540109; ROSS AH, 1984, P NATL ACAD SCI-BIOL, V81, P6681, DOI 10.1073/pnas.81.21.6681; Sortino MA, 2000, MOL ENDOCRINOL, V14, P124, DOI 10.1210/me.14.1.124; Tagliabue E, 2000, J BIOL CHEM, V275, P5388, DOI 10.1074/jbc.275.8.5388; YAAR M, 1991, J CELL BIOL, V115, P821, DOI 10.1083/jcb.115.3.821; YAOZHONG L, 1995, J BIOL CHEM, V270, P14255	42	178	191	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17864	17870		10.1074/jbc.M010499200	http://dx.doi.org/10.1074/jbc.M010499200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11359788	Green Published, hybrid			2022-12-25	WOS:000168866500035
J	Martin, CB; Mahon, GM; Klinger, MB; Kay, RJ; Symons, M; Der, CJ; Whitehead, IP				Martin, CB; Mahon, GM; Klinger, MB; Kay, RJ; Symons, M; Der, CJ; Whitehead, IP			The thrombin receptor, PAR-1, causes transformation by activation of Rho-mediated signaling pathways	ONCOGENE			English	Article						PAR-1; thrombin; transformation; RhoA	PROTEIN-COUPLED RECEPTOR; NUCLEOTIDE EXCHANGE FACTORS; ACTIN STRESS FIBERS; NIH 3T3 CELLS; RAS TRANSFORMATION; EXPRESSION CLONING; MALIGNANT TRANSFORMATION; STRUCTURAL SIMILARITIES; INDEPENDENT PATHWAYS; FAMILY PROTEINS	We utilized a cDNA expression library derived from the B6SutA(1) mouse myeloid progenitor cell line to search for novel oncogenes that promote growth transformation of NIH3T3 cells. A 2.2 kb transforming cDNA was recovered that encodes the wild type thrombin-stimulated G protein-coupled receptor PAR-I, In addition to its potent focus forming activity, constitutive overexpression of PAR-1 in NIH3T3 cells promoted the loss of anchorage- and serum-dependent growth. Although inhibitors of thrombin failed to block PAR-I transforming activity, a PAR-1 mutant that cannot be cleaved by thrombin was nontransforming. Since the foci of transformed cells induced by PAR-1 bear a striking resemblance to those induced by activated RhoA, we determined if PAR-1 transformation was due to the aberrant activation of a specific Rho family member. Like RhoA, PAR-I cooperated with activated Raf-l and caused synergistic enhancement of transforming activity, induced stress fibers when microinjected into porcine aortic endothelial cells, stimulated the activity of the serum response factor and NF-kappaB transcription factors, and PAR-1 transformation was blocked by co-expression of dominant negative RhoA, Finally, PAR-I transforming activity was blocked by pertussis toxin and by coexpression of the RGS domain of Lsc, implicating G alpha (i) and G alpha (12)/G alpha (13) subunits, respectively, as mediators of PAR-I transformation. Taken together, these observations suggest that PAR-1 growth transformation is mediated, in part, by activation of RhoA.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA; Univ N Carolina, Sch Med, Lineberger Canc Res Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Picower Inst Med Res, Mol Oncol Lab, Manhasset, NY 11030 USA; British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 4E6, Canada	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Northwell Health; British Columbia Cancer Agency	Whitehead, IP (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, 185 S Orange Ave, Newark, NJ 07103 USA.			Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA42978, CA55008, CA63071, CA77493] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA077493, R01CA055008, R01CA063071, R01CA042978] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; Betuing S, 1998, J BIOL CHEM, V273, P15804, DOI 10.1074/jbc.273.25.15804; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COUGHLIN SR, 1993, THROMB HAEMOSTASIS, V70, P184; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dhanasekaran N, 1998, ONCOGENE, V17, P1383, DOI 10.1038/sj.onc.1202242; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Fareed J, 1999, CLIN APPL THROMB-HEM, V5, pS45, DOI 10.1177/10760296990050S109; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Genda T, 1999, HEPATOLOGY, V30, P1027, DOI 10.1002/hep.510300420; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Henrikson KP, 1999, BRIT J CANCER, V79, P401, DOI 10.1038/sj.bjc.6690063; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Macey MG, 1996, LEUKEMIA, V10, P687; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; TORDAI A, 1993, J IMMUNOL, V150, P4876; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANOBBERGHENSCH.E, 1998, THROMBIN ITS RECEPTO; VANOBBERGHENSCHILLING E, 1993, THROMB HAEMOSTASIS, V70, P163; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead IP, 1998, MOL CELL BIOL, V18, P4689, DOI 10.1128/MCB.18.8.4689; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; YOUNG D, 1988, P NATL ACAD SCI USA, V85, P5339, DOI 10.1073/pnas.85.14.5339; Zohn IE, 2000, ONCOGENE, V19, P3866, DOI 10.1038/sj.onc.1203731; Zohn IE, 1998, MOL CELL BIOL, V18, P1225, DOI 10.1128/MCB.18.3.1225; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	61	102	106	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2001	20	16					1953	1963		10.1038/sj.onc.1204281	http://dx.doi.org/10.1038/sj.onc.1204281			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360179				2022-12-25	WOS:000168043800003
J	Arnaudeau, S; Kelley, WL; Walsh, JV; Demaurex, N				Arnaudeau, S; Kelley, WL; Walsh, JV; Demaurex, N			Mitochondria recycle Ca2+ to the endoplasmic reticulum and prevent the depletion of neighboring endoplasmic reticulum regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTACT HELA-CELLS; CALCIUM OSCILLATIONS; GENE-EXPRESSION; INOSITOL TRISPHOSPHATE; RECOMBINANT AEQUORIN; TARGETED AEQUORIN; RELEASE; STORES; HOMEOSTASIS; WAVES	To study Ca2+ fluxes between mitochondria and the endoplasmic reticulum (ER), we used "cameleon" indicators targeted to the cytosol, the ER lumen, and the mitochondrial matrix. High affinity mitochondrial probes saturated in similar to 20% of mitochondria during histamine stimulation of HeLa cells, whereas a low affinity probe reported averaged peak values of 106 +/- 5 muM, indicating that Ca2+ transients reach high levels in a fraction of mitochondria. In concurrent ER measurements, [Ca2+](ER) averaged 371 +/- 21 muM: at rest and decreased to 133 +/- 14 muM and 59 +/- 5 muM upon stimulation with histamine and thapsigargin, respectively, indicating that substantial ER refilling occur during agonist stimulation. A larger ER depletion was observed when mitochondrial Ca2+ uptake was prevented by oligomycin and rotenone or when Ca2+ efflux from mitochondria was blocked by CGP 37157, indicating that some of the Ca2+ taken up by mitochondria is re-used for ER refilling. Accordingly, ER regions close to mitochondria released less Ca2+ than ER regions lacking mitochondria. The ER heterogeneity was abolished by thapsigargin, oligomycin/rotenone, or CGP 37157, indicating that mitochondrial Ca2+ uptake locally modulate ER refilling. These observations indicate that some mitochondria are very close to the sites of Ca2+ release and recycle a substantial portion of the captured Ca2+ back to vicinal ER domains. The distance between the two organelles thus determines both the amplitude of mitochondrial Ca2+ signals and the filling state of neighboring ER regions.	Univ Geneva, Dept Physiol, CH-1211 Geneva 4, Switzerland; Univ Hosp Geneva, Div Infect Dis, CH-1211 Geneva, Switzerland; Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01605 USA	University of Geneva; University of Geneva; University of Massachusetts System; University of Massachusetts Worcester				Demaurex, Nicolas/0000-0002-9933-6772	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061297] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61297] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alonso MT, 1999, J CELL BIOL, V144, P241, DOI 10.1083/jcb.144.2.241; Babcock DF, 1998, CURR OPIN NEUROBIOL, V8, P398, DOI 10.1016/S0959-4388(98)80067-6; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Barrero MJ, 1997, J BIOL CHEM, V272, P27694, DOI 10.1074/jbc.272.44.27694; Berridge M, 1999, CURR BIOL, V9, pR157, DOI 10.1016/S0960-9822(99)80101-8; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Boitier E, 1999, J CELL BIOL, V145, P795, DOI 10.1083/jcb.145.4.795; Button D, 1996, MOL BIOL CELL, V7, P419, DOI 10.1091/mbc.7.3.419; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; Emmanouilidou E, 1999, CURR BIOL, V9, P915, DOI 10.1016/S0960-9822(99)80398-4; Fan GY, 1999, BIOPHYS J, V76, P2412, DOI 10.1016/S0006-3495(99)77396-0; FULCERI R, 1991, CELL CALCIUM, V12, P431, DOI 10.1016/0143-4160(91)90069-Q; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; Gurney AM, 2000, CELL CALCIUM, V27, P339, DOI 10.1054/ceca.2000.0124; Hajnoczky G, 1999, J BIOL CHEM, V274, P14157, DOI 10.1074/jbc.274.20.14157; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HIROSE K, 1994, NATURE, V372, P791; Hofer AM, 1998, J CELL BIOL, V140, P325, DOI 10.1083/jcb.140.2.325; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; Kaftan EJ, 2000, J BIOL CHEM, V275, P25465, DOI 10.1074/jbc.M000903200; Kim JH, 1998, P NATL ACAD SCI USA, V95, P2997, DOI 10.1073/pnas.95.6.2997; Landolfi B, 1998, J CELL BIOL, V142, P1235, DOI 10.1083/jcb.142.5.1235; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MOHR FC, 1990, AM J PHYSIOL, V258, pC217, DOI 10.1152/ajpcell.1990.258.2.C217; Montero M, 1997, FASEB J, V11, P881, DOI 10.1096/fasebj.11.11.9285486; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; Park MK, 2000, EMBO J, V19, P5729, DOI 10.1093/emboj/19.21.5729; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1993, CYTOTECHNOLOGY, V11, P44; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; RIZZUTO R, 1994, METHOD CELL BIOL, V40, P339; Rutter GA, 2000, TRENDS BIOCHEM SCI, V25, P215, DOI 10.1016/S0968-0004(00)01585-1; Rutter GA, 1996, P NATL ACAD SCI USA, V93, P5489, DOI 10.1073/pnas.93.11.5489; Simpson PB, 1996, J BIOL CHEM, V271, P33493, DOI 10.1074/jbc.271.52.33493; Simpson PB, 1997, J BIOL CHEM, V272, P22654, DOI 10.1074/jbc.272.36.22654; Tinel H, 1999, EMBO J, V18, P4999, DOI 10.1093/emboj/18.18.4999; TSE A, 1993, SCIENCE, V260, P82, DOI 10.1126/science.8385366; TSE A, 1994, J PHYSIOL-LONDON, V477, P511, DOI 10.1113/jphysiol.1994.sp020212; Wu MM, 2000, CHEM BIOL, V7, P197, DOI 10.1016/S1074-5521(00)00088-0; Yu R, 2000, J BIOL CHEM, V275, P23648, DOI 10.1074/jbc.M002684200	58	215	217	3	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29430	29439		10.1074/jbc.M103274200	http://dx.doi.org/10.1074/jbc.M103274200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11358971	Green Published, hybrid			2022-12-25	WOS:000170346000105
J	Li, WG; Miller, FJ; Zhang, HJ; Spitz, DR; Oberley, LW; Weintraub, NL				Li, WG; Miller, FJ; Zhang, HJ; Spitz, DR; Oberley, LW; Weintraub, NL			H2O2-induced O-2(radical anion) production by a non-phagocytic NAD(P)H oxidase causes oxidant injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SUPEROXIDE-DISMUTASE; CRITICAL COMPONENT; ANGIOTENSIN-II; APOPTOSIS; H2O2; LUCIGENIN; TOXICITY; RELEASE	Non-phagocytic NAD(P)H oxidases have been implicated as major sources of reactive oxygen species in blood vessels. These oxidases can be activated by cytokines, thereby generating O-2(radical anion), which is subsequently converted to H2O2 and other oxidant species. The oxidants, in turn, act as important second messengers in cell signaling cascades. We hypothesized that reactive oxygen species, themselves, can activate the non-phagocytic NAD(P)H oxidases in vascular cells to induce oxidant production and, consequently, cellular injury. The current report demonstrates that exogenous exposure of non-phagocytic cell types of vascular origin (smooth muscle cells and fibroblasts) to H2O2 activates these cell types to produce O-2* via an NAD(P)H oxidase. The ensuing endogenous production of O-2* contributes significantly to vascular cell injury following exposure to H2O2. These results suggest the existence of a feed-forward mechanism, whereby reactive oxygen species such as H2O2 can activate NAD(P)H oxidases in non-phagocytic cells to produce additional oxidant species, thereby amplifying the vascular injury process. Moreover, these findings implicate the non-phagocytic NAD(P)H oxidase as a novel therapeutic target for the amelioration of the biological effects of chronic oxidant stress.	Univ Iowa, Dept Internal Med, Coll Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Biochem, Coll Med, Iowa City, IA 52242 USA; Univ Iowa, Free Rad & Radiat Biol Program, Coll Med, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Weintraub, NL (corresponding author), Univ Iowa, Dept Internal Med, Coll Med, 200 Hawkins Dr,E329-GH, Iowa City, IA 52242 USA.	Neal-weintraub@uiowa.edu	Miller Jr, Francis/N-7312-2015; Miller, Francis J/F-3801-2017	Miller Jr, Francis/0000-0001-5822-0549; Miller, Francis J/0000-0001-5822-0549; Weintraub, Neal/0000-0002-5138-3705; Spitz, Douglas/0000-0002-1254-8765	NCI NIH HHS [P01 CA066081, CA66081] Funding Source: Medline; NHLBI NIH HHS [R01 HL51469, K08 HL003669-05, HL49264, P01 HL062984, R01 HL051469, K08 HL003669-03, K08 HL003669-04, HL62984] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA066081] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049264, R01HL051469, P01HL062984, K08HL003669] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; Brown MR, 1999, CIRC RES, V85, P524, DOI 10.1161/01.RES.85.6.524; Cane A, 1998, AM J PHYSIOL-CELL PH, V274, pC1040, DOI 10.1152/ajpcell.1998.274.4.C1040; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; Carlsson LM, 1996, P NATL ACAD SCI USA, V93, P5219, DOI 10.1073/pnas.93.11.5219; CASTILHO RF, 1995, FREE RADICAL BIO MED, V18, P479, DOI 10.1016/0891-5849(94)00166-H; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; Fridovich I, 1998, J EXP BIOL, V201, P1203; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HIRAISHI H, 1992, J BIOL CHEM, V267, P14812; Hoyt KR, 1997, NEUROCHEM RES, V22, P333, DOI 10.1023/A:1022403224901; Hu QH, 1998, CIRCULATION, V97, P268, DOI 10.1161/01.CIR.97.3.268; Kim KS, 1998, J CLIN INVEST, V101, P1821, DOI 10.1172/JCI1830; Li PF, 1997, FEBS LETT, V404, P249, DOI 10.1016/S0014-5793(97)00093-8; Li WG, 2000, ARTERIOSCL THROM VAS, V20, P1473, DOI 10.1161/01.ATV.20.6.1473; Li YB, 1998, J BIOL CHEM, V273, P2015, DOI 10.1074/jbc.273.4.2015; Lynn S, 2000, CIRC RES, V86, P514, DOI 10.1161/01.RES.86.5.514; Marumo T, 1997, CIRCULATION, V96, P2361; Miller FJ, 1998, CIRC RES, V82, P1298, DOI 10.1161/01.RES.82.12.1298; Pagano PJ, 1997, P NATL ACAD SCI USA, V94, P14483, DOI 10.1073/pnas.94.26.14483; Patterson C, 1999, J BIOL CHEM, V274, P19814, DOI 10.1074/jbc.274.28.19814; POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tarpey MM, 1999, CIRC RES, V84, P1203, DOI 10.1161/01.RES.84.10.1203; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; Zhang HJ, 1999, CANCER RES, V59, P6276	31	219	239	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29251	29256		10.1074/jbc.M102124200	http://dx.doi.org/10.1074/jbc.M102124200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11358965	Green Accepted, hybrid			2022-12-25	WOS:000170346000083
J	Campos, F; Garcia-Gomez, BI; Solorzano, RM; Salazar, E; Estevez, J; Leon, P; Alvarez-Buylla, ER; Covarrubias, AJ				Campos, F; Garcia-Gomez, BI; Solorzano, RM; Salazar, E; Estevez, J; Leon, P; Alvarez-Buylla, ER; Covarrubias, AJ			A cDNA for nuclear-encoded chloroplast translational initiation factor 2 from a higher plant is able to complement an infB Escherichia coli null mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASEOLUS-VULGARIS L; EUGLENA-GRACILIS; GENE-EXPRESSION; FACTOR-II; TRANSIT PEPTIDES; GENOME SEQUENCE; FACTOR IF2; EVOLUTION; PROTEIN; ORIGIN	Formation of the initiation translation complex containing the three initiation factors, IF1, IF2, and IF3, tRNA(fMet), and GTP constitutes the earliest event in the protein synthesis. IF2, a GTP-binding protein, is the principal factor involved in selecting and binding fMet-tRNA(fMet) the 30 S ribosomal subunit. Although some chloroplast initiation translational factors have been identified and purified from algae, none of these factors have been characterized from plants. In this work, we report the molecular characterization of a nuclear-encoded chloroplastic IF2 gene from common bean (PvIF2cp). We show that the PvIF2cp gene encodes a protein containing a chloroplast translocation signal peptide, able to target a green fluorescent protein fusion protein to chloroplasts. A high accumulation of PvIF2cp transcript was found in photosynthetic tissues, whereas low mRNA levels were detected in etiolated plants and in nonphotosynthetic organs. Additional data indicate that the PvIF2cp transcript accumulation is modulated by light. The PvIF2cp gene encodes a functional factor, since the PvIF2cp conserved region, containing the G-domain and the C-terminal end, complements an Escherichia coli infB null mutation. Phylogenetic analysis using the PvIF2cp conserved region suggests that the PvIF2cp gene originated via endosymbiotic gene transfer to the nucleus and that it may be a useful marker for phylogeny reconstruction.	Univ Nacl Autonoma Mexico, Inst Biotecnol, Dept Biol Mol Plantas, Cuernavaca 62250, Morelos, Mexico; Univ Nacl Autonoma Mexico, Inst Ecol, Lab Genet Mol & Evoluc Plantas, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico	Covarrubias, AJ (corresponding author), Univ Nacl Autonoma Mexico, Inst Biotecnol, Dept Biol Mol Plantas, AP 510-3, Cuernavaca 62250, Morelos, Mexico.	crobles@ibt.unam.mx		Alvarez-Buylla Roces, Maria Elena/0000-0002-7938-6473				ABEL S, 1994, PLANT J, V5, P421, DOI 10.1111/j.1365-313X.1994.00421.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V2; Bhattacharya D, 1998, PLANT PHYSIOL, V116, P9, DOI 10.1104/pp.116.1.9; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Bray E. A, 1991, ABSCISIC ACID PHYSL, P81; Bremaud L, 1997, J BACTERIOL, V179, P2348, DOI 10.1128/jb.179.7.2348-2355.1997; Bruce BD, 2000, TRENDS CELL BIOL, V10, P440, DOI 10.1016/S0962-8924(00)01833-X; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; ColmeneroFlores JM, 1997, PLANT MOL BIOL, V35, P393, DOI 10.1023/A:1005802505731; COVARRUBIAS AA, 1994, P 2 INT SCI M PHAS B; Danon A, 1997, PLANT PHYSIOL, V115, P1293, DOI 10.1104/pp.115.4.1293; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; GILLHAM NW, 1994, ANNU REV GENET, V28, P71, DOI 10.1146/annurev.ge.28.120194.000443; HARRIS EH, 1994, MICROBIOL REV, V58, P700, DOI 10.1128/MMBR.58.4.700-754.1994; Hirose T, 1999, FEBS LETT, V445, P169, DOI 10.1016/S0014-5793(99)00123-4; HOWE CJ, 1992, TRENDS ECOL EVOL, V7, P378, DOI 10.1016/0169-5347(92)90008-Y; HSIAO TC, 1973, ANNU REV PLANT PHYS, V24, P519, DOI 10.1146/annurev.pp.24.060173.002511; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KRAUS BL, 1988, PLANT PHYSIOL, V88, P993, DOI 10.1104/pp.88.4.993; LAALAMI S, 1991, BIOCHIMIE, V73, P1557, DOI 10.1016/0300-9084(91)90191-3; LAALAMI S, 1991, J MOL BIOL, V220, P335, DOI 10.1016/0022-2836(91)90017-Z; LARA M, 1984, PLANT PHYSIOL, V76, P1019, DOI 10.1104/pp.76.4.1019; LIN Q, 1994, J BIOL CHEM, V269, P9436; MA L, 1995, J BIOL CHEM, V270, P1859, DOI 10.1074/jbc.270.4.1859; Ma L, 1996, J BIOL CHEM, V271, P10528, DOI 10.1074/jbc.271.18.10528; MA L, 1992, J BIOL CHEM, V267, P18356; MA L, 1990, J BIOL CHEM, V265, P13560; Margulis L, 1970, ORIGIN EUKARYOTIC CE; Martin W, 1998, PLANT PHYSIOL, V118, P9, DOI 10.1104/pp.118.1.9; Moreira D, 2000, NATURE, V405, P69, DOI 10.1038/35011054; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEVERINI M, 1991, J BIOL CHEM, V266, P22800; SHEEN J, 1995, PLANT J, V8, P777, DOI 10.1046/j.1365-313X.1995.08050777.x; Shilperoort, 1994, PLANT MOL BIOL MAN D, P1, DOI 10.1007/978-94-011-0511-8_16; SHIMADA H, 1991, NUCLEIC ACIDS RES, V19, P983, DOI 10.1093/nar/19.5.983; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Spurio R, 2000, J BIOL CHEM, V275, P2447, DOI 10.1074/jbc.275.4.2447; Stern DB, 1997, TRENDS PLANT SCI, V2, P308, DOI 10.1016/S1360-1385(97)89953-0; Sugiura M, 1998, ANNU REV GENET, V32, P437, DOI 10.1146/annurev.genet.32.1.437; SUGIURA M, 1992, PLANT MOL BIOL, V19, P149, DOI 10.1007/BF00015612; Swofford D. L., 2011, PAUP PHYLOGENETIC AN; TOBIN EM, 1985, ANNU REV PLANT PHYS, V36, P569, DOI 10.1146/annurev.pp.36.060185.003033; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAMBUTAS SH, 1991, EUR J BIOCHEM, V201, P543; Villanueva MA, 1999, PLANTA, V207, P582, DOI 10.1007/s004250050521; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535	52	8	10	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28388	28394		10.1074/jbc.M100605200	http://dx.doi.org/10.1074/jbc.M100605200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11356831	hybrid			2022-12-25	WOS:000170093400086
J	Ludlam, AV; McNatt, MW; Carr, KM; Kaguni, JM				Ludlam, AV; McNatt, MW; Carr, KM; Kaguni, JM			Essential amino acids of Escherichia coli DnaC protein in an N-terminal domain interact with DnaB helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN; CHROMOSOMAL ORIGIN; GENE-PRODUCT; SALMONELLA-TYPHIMURIUM; NUCLEOTIDE COFACTORS; COMPLEX; BINDING; INITIATION; EXPRESSION; SEQUENCES	Escherichia coli DnaC protein bound to ATP forms a complex with DnaB protein. To identify the domain of DnaC that interacts with DnaB, a genetic selection was used based on the lethal effect of induced dnaC expression and a model that inviability arises by the binding of DnaC to DnaB to inhibit replication fork movement, The analysis of dnaC alleles that preserved viability under elevated expression revealed an N-terminal domain of DnaC involved in binding to DnaB, Mutant proteins bearing single amino acid substitutions (R10P, L11Q, L29Q, S41P, W32G, and L44P) that reside in regions of predicted secondary structure were inert in DNA replication activity because of their inability to bind to DnaB, but they retained ATP binding activity, as indicated by UV cross-linking to [alpha-P-32]ATP. These alleles also failed to complement a dnaC28 mutant. Other selected mutations that map to regions carrying Walker A and B boxes are expected to be defective in ATP binding, a required step in DnaB-DnaC complex formation. Lastly, we found that the sixth codon from the N terminus encodes aspartate, resolving a reported discrepancy between the predicted amino acid sequence based on DNA sequencing data and the results from N-terminal amino acid sequencing.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University	Kaguni, JM (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.			Kaguni, Jon/0000-0002-3096-4447	NIGMS NIH HHS [R01 GM033992, GM33992] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN GC, 1991, J BIOL CHEM, V266, P22096; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; ARAI K, 1979, P NATL ACAD SCI USA, V76, P4308, DOI 10.1073/pnas.76.9.4308; ARAI K, 1981, J BIOL CHEM, V256, P5253; BISWAS SB, 1987, J BIOL CHEM, V262, P7831; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; CARL PL, 1970, MOL GEN GENET, V109, P107, DOI 10.1007/BF00269647; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; Fang LH, 1999, MOL CELL, V4, P541, DOI 10.1016/S1097-2765(00)80205-1; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; Galletto R, 2000, BIOCHEMISTRY-US, V39, P12959, DOI 10.1021/bi0012484; HWANG DS, 1988, J BIOL CHEM, V263, P10633; Ishimi Y, 1998, J BIOL CHEM, V273, P8369, DOI 10.1074/jbc.273.14.8369; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Jezewska MJ, 1997, BIOPHYS CHEM, V64, P253, DOI 10.1016/S0301-4622(96)02221-1; Jezewska MJ, 1996, BIOPHYS J, V71, P2075, DOI 10.1016/S0006-3495(96)79406-7; JOHNSTON S, 1985, GENE, V34, P137, DOI 10.1016/0378-1119(85)90121-0; Kaguni J. M., 1997, EXPT MOL BIOL BIOCH; Kaguni JM, 1997, MOL CELLS, V7, P145; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; KOBORI JA, 1982, J BIOL CHEM, V257, P13770; KOBORI JA, 1982, J BIOL CHEM, V257, P13757; LANKA E, 1982, NUCLEIC ACIDS RES, V11, P257; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; MALLORY JB, 1990, J BIOL CHEM, V265, P13297; Marszalek J, 1996, J BIOL CHEM, V271, P18535, DOI 10.1074/jbc.271.31.18535; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; MARSZALEK J, 1992, J BIOL CHEM, V267, P19334; MASAI H, 1990, J BIOL CHEM, V265, P15134; MAURER R, 1984, GENETICS, V108, P1; MESSER W, 1996, ESCHERICHIA COLI SAL, V2, P1579; NAKAYAMA N, 1987, J BIOL CHEM, V262, P10475; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; San Martin C, 1998, STRUCTURE, V6, P501; Sandler SJ, 2000, J BACTERIOL, V182, P9, DOI 10.1128/JB.182.1.9-13.2000; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHUBACH WH, 1973, J MOL BIOL, V74, P205, DOI 10.1016/0022-2836(73)90107-1; Siegele DA, 1997, P NATL ACAD SCI USA, V94, P8168, DOI 10.1073/pnas.94.15.8168; Sutton MD, 1998, J BIOL CHEM, V273, P34255, DOI 10.1074/jbc.273.51.34255; UEDA K, 1978, J BIOL CHEM, V253, P261; WAHLE E, 1989, J BIOL CHEM, V264, P2469; WAHLE E, 1989, J BIOL CHEM, V264, P2463; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WECHSLER JA, 1975, J BACTERIOL, V121, P594, DOI 10.1128/JB.121.2.594-599.1975; WECHSLER JA, 1971, MOL GEN GENET, V113, P273, DOI 10.1007/BF00339547; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P921, DOI 10.1073/pnas.72.3.921; You ZY, 1999, MOL CELL BIOL, V19, P8003; Yu X, 1996, J MOL BIOL, V259, P7, DOI 10.1006/jmbi.1996.0297	50	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27345	27353		10.1074/jbc.M101940200	http://dx.doi.org/10.1074/jbc.M101940200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11333269	hybrid			2022-12-25	WOS:000169966900082
J	Wu, CG; Stojanov, T; Chami, O; Ishii, S; Shimuzu, T; Li, AG; O'Neill, C				Wu, CG; Stojanov, T; Chami, O; Ishii, S; Shimuzu, T; Li, AG; O'Neill, C			Evidence for the autocrine induction of capacitation of mammalian spermatozoa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; PROTEIN-TYROSINE PHOSPHORYLATION; MOUSE PREIMPLANTATION EMBRYOS; BOVINE SEMINAL PLASMA; FACTOR-ACETYLHYDROLASE; FACTOR RECEPTOR; IN-VITRO; INVITRO FERTILIZATION; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE A(2)	Mammalian spermatozoa require a maturational event after ejaculation that allows them to acquire the capacity for fertilization. This process, known as capacitation, occurs spontaneously in simple defined medium implicating a potential role of autocrine induction. This study shows that the ether phospholipid 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphocholine (PAF) meets the criteria for an autocrine mediator of capacitation. Sperm released PAF after their dilution into capacitation medium and expressed a receptor for PAF on their membranes. PAF stimulated changes in the motility of sperm and enhanced fertilization in vitro. These actions were inhibited by a PAF receptor antagonist (UR-12519) and by extracellular recombinant PAF:acetylhydrolase (an enzyme that degrades PAF to a biologically inert form). Seminal plasma contained an acid-labile PAF: acetylhydrolase, whereas capacitation was inhibited by an acid-labile factor within seminal plasma, implicating this factor as a potential decapacitation factor within seminal plasma. Sperm from a PAF receptor knock-out mouse strain failed to express the receptor and displayed a significantly (p < 0.01) reduced rate of capacitation, as assessed by the spontaneous onset of the acrosome reaction in vitro. When used for in vitro fertilization, sperm from PAF receptor knock-out mice gave a significantly lower rate of fertilization (21.5%) than did wild-type sperm (66.7%). The study shows for the first time the operation of an autocrine Poop that induces capacitation in sperm in vitro and shows that this loop acts in concert with other mediators of capacitation to promote efficient fertilization.	Univ Sydney, Human Reprod Unit, Dept Physiol, Royal N Shore Hosp, St Leonards, NSW 2065, Australia; Univ Tokyo, CREST, Japan Sci & Technol Corp, Dept Biochem & Mol Biol,Fac Med,Bunkyo Ku, Tokyo 1130033, Japan	Royal North Shore Hospital; University of Sydney; Japan Science & Technology Agency (JST); University of Tokyo	O'Neill, C (corresponding author), Univ Sydney, Human Reprod Unit, Dept Physiol, Royal N Shore Hosp, St Leonards, NSW 2065, Australia.			O'Neill, Christopher/0000-0003-4003-8727				AITKEN RJ, 1977, J REPROD FERTIL, V50, P29; Ammit AJ, 1997, J REPROD FERTIL, V109, P309, DOI 10.1530/jrf.0.1090309; Ammit AJ, 1997, J BIOL CHEM, V272, P18772, DOI 10.1074/jbc.272.30.18772; Ammit AJ, 1997, HUM REPROD, V12, P785, DOI 10.1093/humrep/12.4.785; AMMIT AJ, 1995, PLATELET ACTIVATING, P263; ANGLE MJ, 1991, FERTIL STERIL, V56, P314; BEDFORD JM, 1962, AM J PHYSIOL, V202, P179, DOI 10.1152/ajplegacy.1962.202.1.179; Cahana A, 1999, FEBS LETT, V451, P99, DOI 10.1016/S0014-5793(99)00548-7; CLAY KL, 1990, BIOCHIM BIOPHYS ACTA, V1046, P309, DOI 10.1016/0005-2760(90)90246-T; COLLIER M, 1990, HUM REPROD, V5, P323, DOI 10.1093/oxfordjournals.humrep.a137098; DAVIS BK, 1979, BIOCHIM BIOPHYS ACTA, V558, P257, DOI 10.1016/0005-2736(79)90260-8; DAVIS BK, 1980, ARCH ANDROLOGY, V5, P249, DOI 10.3109/01485018008986993; DOHERTY AS, 1994, MOL REPROD DEV, V37, P21, DOI 10.1002/mrd.1080370104; EISENBACH M, 1992, AM J PHYSIOL, V262, pC1095, DOI 10.1152/ajpcell.1992.262.5.C1095; Emerson M, 2000, J BIOL CHEM, V275, P21905, DOI 10.1074/jbc.M001719200; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; Ishii S, 2000, PROG LIPID RES, V39, P41, DOI 10.1016/S0163-7827(99)00016-8; Ishii S, 1998, J EXP MED, V187, P1779, DOI 10.1084/jem.187.11.1779; Ishii S, 1996, BIOCHEM J, V314, P671, DOI 10.1042/bj3140671; Jones RE, 1997, ARCH ANDROLOGY, V38, P181; KUMAR R, 1988, ARCH BIOCHEM BIOPHYS, V260, P497, DOI 10.1016/0003-9861(88)90474-2; KUZAN FB, 1990, PROSTAGLANDINS, V39, P61, DOI 10.1016/0090-6980(90)90095-D; Larson JL, 1999, MOL REPROD DEV, V52, P445, DOI 10.1002/(SICI)1098-2795(199904)52:4&lt;445::AID-MRD14&gt;3.0.CO;2-6; Luconi M, 1998, BIOL REPROD, V58, P1476, DOI 10.1095/biolreprod58.6.1476; LUDWIG JC, 1985, ARCH BIOCHEM BIOPHYS, V241, P337, DOI 10.1016/0003-9861(85)90555-7; Muguruma K, 1997, BIOL REPROD, V56, P529, DOI 10.1095/biolreprod56.2.529; ONeill C, 1997, BIOL REPROD, V56, P229, DOI 10.1095/biolreprod56.1.229; ONEILL C, 1995, BIOL REPROD, V52, P965, DOI 10.1095/biolreprod52.5.965; Osheroff JE, 1999, MOL HUM REPROD, V5, P1017, DOI 10.1093/molehr/5.11.1017; PARKS JE, 1993, J ANDROL, V14, P335; QUINN P, 1985, ANN NY ACAD SCI, V442, P195, DOI 10.1111/j.1749-6632.1985.tb37520.x; Reinhardt JC, 1999, FERTIL STERIL, V71, P941, DOI 10.1016/S0015-0282(99)00096-5; Roudebush WE, 2000, FERTIL STERIL, V73, P967, DOI 10.1016/S0015-0282(00)00485-4; ROUDEBUSH WE, 1993, J ASSIST REPROD GEN, V10, P91, DOI 10.1007/BF01204447; ROUDEBUSH WE, 1990, AM J OBSTET GYNECOL, V163, P1670, DOI 10.1016/0002-9378(90)90648-Q; SENGOKU K, 1993, HUM REPROD, V8, P1443, DOI 10.1093/oxfordjournals.humrep.a138276; SINGH J, 1995, ENDOCRINOLOGY, V136, P5311, DOI 10.1210/en.136.12.5311; Soubeyrand S, 1998, BIOCHEM J, V329, P41, DOI 10.1042/bj3290041; Stojanov T, 1999, BIOL REPROD, V60, P674, DOI 10.1095/biolreprod60.3.674; TJOELKER LW, 1995, J BIOL CHEM, V270, P25481, DOI 10.1074/jbc.270.43.25481; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; Visconti PE, 1999, J BIOL CHEM, V274, P3235, DOI 10.1074/jbc.274.5.3235; VISCONTI PE, 1995, DEVELOPMENT, V121, P1129; Yanagimachi R., 1994, P189	44	48	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26962	26968		10.1074/jbc.M103107200	http://dx.doi.org/10.1074/jbc.M103107200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11350972	hybrid			2022-12-25	WOS:000169966900032
J	van Dijk, TH; van der Sluijs, FH; Wiegman, CH; Baller, JFW; Gustafson, LA; Burger, HJ; Herling, AW; Kuipers, F; Meijer, AJ; Reijngoud, DJ				van Dijk, TH; van der Sluijs, FH; Wiegman, CH; Baller, JFW; Gustafson, LA; Burger, HJ; Herling, AW; Kuipers, F; Meijer, AJ; Reijngoud, DJ			Acute inhibition of hepatic glucose-6-phosphatase does not affect gluconeogenesis but directs gluconeogenic flux toward glycogen in fasted rats - A pharmacological study with the chlorogenic acid derivative S4048	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOTOPOMER DISTRIBUTION ANALYSIS; REQUIRES GLUCOSE-METABOLISM; IN-VIVO; GENE-EXPRESSION; PHOSPHOENOLPYRUVATE CARBOXYKINASE; SECRETED GLUCURONATE; LIVER-GLYCOGEN; DIABETIC RATS; SUBSTRATE; TURNOVER	Effects of acute inhibition of glucose-6-phosphatase activity by the chlorogenic acid derivative S4048 on hepatic carbohydrate fluxes were examined in isolated rat hepatocytes and in vivo in rats. Fluxes were calculated using tracer dilution techniques and mass isotopomer distribution analysis in plasma glucose and urinary paracetamol-glucuronide after infusion of [U-C-13]glucose, [2-C-13]glycerol, [1-H-2]galactose, and paracetamol, In hepatocytes, glucose-g-phosphate (Glc-6-P) content, net glycogen synthesis, and lactate production from glucose and dihydroxyacetone increased strongly in the presence of S4048 (10 muM) In livers of S4048-treated rats (0.5 mg kg(-1) min(-1); 8 h) Glc-6-P content increased strongly (+440%), and massive glycogen accumulation (+1260%) was observed in periportal areas. Total glucose production was diminished by 50%, The gluconeogenic flux to Glc-6-P was unaffected (i,e, 33.3 +/- 2.0 versus 33.2 +/- 2.9 mu mol kg(-1) min(-1) in control and S4048-treated rats, respectively). Newly synthesized Glc-6-P was redistributed from glucose production (62 +/- 1 Dersus 38 +/- 1%; p < 0.001) to glycogen synthesis (35 +/- 5% versus 65 +/- 5%; p < 0.005) by S4048, This was associated with a strong inhibition (-82%) of the flux through glucokinase and an increase (+83%) of the flux through glycogen synthase, while the flux through glycogen phosphorylase remained unaffected. In livers from S4048-treated rats, mRNA levels of genes encoding Glc-6-P hydrolase (similar to4-fold), Glc-6-P translocase (similar to4-fold), glycogen synthase (similar to7-fold) and L-type pyruvate kinase (similar to4-fold) were increased, whereas glucokinase expression was almost abolished. In accordance with unaltered gluconeogenic flux, expression of the gene encoding phosphoenolpyruvate carboxykinase was unaffected in the S4048-treated rats. Thus, acute inhibition of glucose-6-phosphatase activity by S4048 elicited 1) a repartitioning of newly synthesized Glc-6-P from glucose production into glycogen synthesis without affecting the gluconeogenic flux to Glc-6-P and 2) a cellular response aimed at maintaining cellular Glc-6-P homeostasis.	Univ Groningen Hosp, Ctr Liver Digest & Metab Dis, Pediat Lab, NL-9700 RB Groningen, Netherlands; Acad Med Ctr, Dept Biochem, NL-1105 AZ Amsterdam, Netherlands; Aventis Pharma Deutschland GmbH, D-65926 Frankfurt, Germany	University of Groningen; University of Amsterdam; Academic Medical Center Amsterdam; Sanofi-Aventis	Reijngoud, DJ (corresponding author), Univ Groningen Hosp, Ctr Liver Digest & Metab Dis, Pediat Lab, NL-9700 RB Groningen, Netherlands.	d.j.reijngoud@med.rug.nl		Kuipers, Folkert/0000-0003-2518-737X; Reijngoud, Dirk-Jan/0000-0003-1157-4491; Wiegman, Coen/0000-0001-9161-0581				Ackermans MT, 2001, J CLIN ENDOCR METAB, V86, P2220, DOI 10.1210/jc.86.5.2220; Aiston S, 1999, J BIOL CHEM, V274, P24559, DOI 10.1074/jbc.274.35.24559; Bergmeyer H.U., 1974, METHODS ENZYMATIC AN; Bollen M, 1998, BIOCHEM J, V336, P19, DOI 10.1042/bj3360019; Christiansen MP, 2000, DIABETES, V49, P1691, DOI 10.2337/diabetes.49.10.1691; Clore JN, 2000, DIABETES, V49, P969, DOI 10.2337/diabetes.49.6.969; CONSOLI A, 1987, J CLIN INVEST, V80, P1303, DOI 10.1172/JCI113206; Cournarie F, 1999, FEBS LETT, V460, P527, DOI 10.1016/S0014-5793(99)01407-6; DAVID M, 1990, J CLIN INVEST, V86, P612, DOI 10.1172/JCI114752; EKBERG K, 1995, J BIOL CHEM, V270, P21715, DOI 10.1074/jbc.270.37.21715; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; GIACCARI A, 1992, J CLIN INVEST, V89, P36, DOI 10.1172/JCI115583; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GROEN AK, 1983, J BIOL CHEM, V258, P4346; Guillam MT, 1998, P NATL ACAD SCI USA, V95, P12317, DOI 10.1073/pnas.95.21.12317; Hellerstein M, 2000, METABOLISM, V49, P1375; Hellerstein M, 2000, DIABETES NUTR METAB, V13, P46; Hellerstein MK, 1999, AM J PHYSIOL-ENDOC M, V276, pE1146, DOI 10.1152/ajpendo.1999.276.6.E1146; Hellerstein MK, 1997, AM J PHYSIOL-ENDOC M, V272, pE155, DOI 10.1152/ajpendo.1997.272.1.E155; Hellerstein MK, 1997, METABOLISM, V46, P1390, DOI 10.1016/S0026-0495(97)90137-2; Hellerstein MK, 1997, J CLIN INVEST, V100, P1305, DOI 10.1172/JCI119644; HELLERSTEIN MK, 1992, AM J PHYSIOL, V263, pE988; Hellerstein MK, 1997, AM J PHYSIOL-ENDOC M, V272, pE163, DOI 10.1152/ajpendo.1997.272.1.E163; Hemmerle H, 1997, J MED CHEM, V40, P137, DOI 10.1021/jm9607360; Herling AW, 1998, AM J PHYSIOL-GASTR L, V274, pG1087, DOI 10.1152/ajpgi.1998.274.6.G1087; Herling AW, 1999, EUR J PHARMACOL, V386, P75, DOI 10.1016/S0014-2999(99)00748-7; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; KACSER H, 1993, EUR J BIOCHEM, V216, P361, DOI 10.1111/j.1432-1033.1993.tb18153.x; KATZ J, 1984, J CLIN INVEST, V74, P1901, DOI 10.1172/JCI111610; KUIPERS F, 1985, GASTROENTEROLOGY, V88, P403, DOI 10.1016/0016-5085(85)90499-8; Kurland IJ, 2000, J BIOL CHEM, V275, P36787, DOI 10.1074/jbc.M004739200; LANDAU BR, 1993, AM J PHYSIOL, V265, pE636, DOI 10.1152/ajpendo.1993.265.4.E636; LANDAU BR, 1995, AM J PHYSIOL-ENDOC M, V269, pE18, DOI 10.1152/ajpendo.1995.269.1.E18; LANDAU BR, 1995, J CLIN INVEST, V95, P172, DOI 10.1172/JCI117635; Lei KJ, 1996, NAT GENET, V13, P203, DOI 10.1038/ng0696-203; MAGNUSSON I, 1994, AM J PHYSIOL, V266, pE796, DOI 10.1152/ajpendo.1994.266.5.E796; MEIJER AJ, 1985, EUR J BIOCHEM, V148, P189, DOI 10.1111/j.1432-1033.1985.tb08824.x; NEESE RA, 1995, J BIOL CHEM, V270, P14452, DOI 10.1074/jbc.270.24.14452; Newsholme E A, 1976, Biochem Soc Symp, P61; O'Doherty RM, 1999, DIABETES, V48, P2022, DOI 10.2337/diabetes.48.10.2022; PERONI O, 1995, AM J PHYSIOL-ENDOC M, V269, pE516, DOI 10.1152/ajpendo.1995.269.3.E516; Peroni O, 1997, METABOLISM, V46, P1358, DOI 10.1016/S0026-0495(97)90244-4; Peroni O, 1996, METABOLISM, V45, P897, DOI 10.1016/S0026-0495(96)90166-3; Previs SF, 1998, J BIOL CHEM, V273, P16853, DOI 10.1074/jbc.273.27.16853; PREVIS SF, 1995, J BIOL CHEM, V270, P19806, DOI 10.1074/jbc.270.34.19806; Previs SF, 1999, AM J PHYSIOL-ENDOC M, V277, pE154, DOI 10.1152/ajpendo.1999.277.1.E154; Scott DK, 1998, J BIOL CHEM, V273, P24145, DOI 10.1074/jbc.273.37.24145; She P, 2000, MOL CELL BIOL, V20, P6508, DOI 10.1128/MCB.20.17.6508-6517.2000; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; SHULMAN RG, 1995, P NATL ACAD SCI USA, V92, P8535, DOI 10.1073/pnas.92.19.8535; Shulman RG, 1996, P NATL ACAD SCI USA, V93, P7491, DOI 10.1073/pnas.93.15.7491; Siler SQ, 1998, AM J PHYSIOL-ENDOC M, V275, pE897, DOI 10.1152/ajpendo.1998.275.5.E897; Simon C, 2000, ARCH BIOCHEM BIOPHYS, V373, P418, DOI 10.1006/abbi.1999.1560; Sunehag AL, 1999, DIABETES, V48, P791, DOI 10.2337/diabetes.48.4.791; Trinh KY, 1998, J BIOL CHEM, V273, P31615, DOI 10.1074/jbc.273.47.31615; WANG W, 1999, AM J PHYSIOL, V279, pE50; WOLFE RR, 1992, PRINCIPLES PRACTICE, P117	58	74	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25727	25735		10.1074/jbc.M101223200	http://dx.doi.org/10.1074/jbc.M101223200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11346646	hybrid			2022-12-25	WOS:000169823300014
J	Danilczyk, UG; Williams, DB				Danilczyk, UG; Williams, DB			The lectin chaperone calnexin utilizes polypeptide-based interactions to associate with many of its substrates in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; HISTOCOMPATIBILITY COMPLEX-MOLECULES; NICOTINIC ACETYLCHOLINE-RECEPTOR; N-LINKED OLIGOSACCHARIDES; TCR-ALPHA-PROTEINS; ENDOPLASMIC-RETICULUM; CALRETICULIN FUNCTIONS; RIBONUCLEASE-B; LIVING CELLS; GLYCOPROTEIN	Calnexin and calreticulin are molecular chaperones of the endoplasmic reticulum that bind to newly synthesized glycoproteins in part through a lectin site specific for monoglucosylated (Glc(1)Man(7-9)GlcNAc(2)) oligosaccharides. In addition to this lectin-oligosaccharide interaction, in vitro studies have demonstrated that calnexin and calreticulin can bind to polypeptide segments of both glycosylated and nonglycosylated proteins. However, the in vivo relevance of this latter interaction has been questioned. We examined whether polypeptide-based interactions occur between calnexin and its substrates in vivo using the glucosidase inhibitor castanospermine or glucosidase-deficient cells to prevent the formation of monoglucosylated oligosaccharides. We show that if care is taken to preserve weak interactions, the block in lectin-oligosaccharide binding leads to the loss of some calnexin-substrate complexes, but many others remain readily detectable. Furthermore, we demonstrate that calnexin is capable of associating in vivo with a substrate that completely lacks Asn-linked oligosaccharides. The binding of calnexin to proteins that lack monoglucosylated oligosaccharides could not be attributed to nonspecific adsorption nor to its inclusion in protein aggregates. We conclude that both lectin-oligosaccharide and polypeptide-based interactions occur between calnexin and diverse proteins in vivo and that the strength of the latter interaction varies substantially between protein substrates.	Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Williams, DB (corresponding author), Univ Toronto, Dept Biochem, Med Sci Bldg, Toronto, ON M5S 1A8, Canada.							ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; ARUNACHALAM B, 1995, J BIOL CHEM, V270, P2784, DOI 10.1074/jbc.270.6.2784; BALOW JP, 1995, J BIOL CHEM, V270, P29025, DOI 10.1074/jbc.270.48.29025; Basu S, 1999, J EXP MED, V189, P797, DOI 10.1084/jem.189.5.797; Bouvier M, 2000, BIOCHEMISTRY-US, V39, P14950, DOI 10.1021/bi0019545; Cannon KS, 1999, J BIOL CHEM, V274, P7537, DOI 10.1074/jbc.274.11.7537; Cannon KS, 1996, J BIOL CHEM, V271, P14280, DOI 10.1074/jbc.271.24.14280; CARRENO BM, 1995, J IMMUNOL, V154, P5173; Chang W, 1997, J BIOL CHEM, V272, P28925, DOI 10.1074/jbc.272.46.28925; Christodoulou S, 1997, GENE, V191, P143, DOI 10.1016/S0378-1119(97)00025-5; Danilczyk UG, 2000, J BIOL CHEM, V275, P13089, DOI 10.1074/jbc.275.17.13089; Gething MJ., 1997, GUIDEBOOK MOL CHAPER; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; High S, 2000, FEBS LETT, V476, P38, DOI 10.1016/S0014-5793(00)01666-5; Ihara Y, 1999, MOL CELL, V4, P331, DOI 10.1016/S1097-2765(00)80335-4; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; Jannatipour M, 1998, BIOCHEMISTRY-US, V37, P17253, DOI 10.1021/bi981785c; Jorgensen CS, 2000, EUR J BIOCHEM, V267, P2945, DOI 10.1046/j.1432-1033.2000.01309.x; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; Keller SH, 1998, J BIOL CHEM, V273, P17064, DOI 10.1074/jbc.273.27.17064; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; Labriola C, 1999, MOL BIOL CELL, V10, P1381, DOI 10.1091/mbc.10.5.1381; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Nair S, 1999, J IMMUNOL, V162, P6426; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; ORA A, 1995, J BIOL CHEM, V270, P26060, DOI 10.1074/jbc.270.44.26060; OSAWA T, 1987, ANNU REV BIOCHEM, V56, P21, DOI 10.1146/annurev.biochem.56.1.21; Otteken A, 1996, J BIOL CHEM, V271, P97, DOI 10.1074/jbc.271.1.97; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PARKER CG, 1995, EMBO J, V14, P1294, DOI 10.1002/j.1460-2075.1995.tb07115.x; Parodi AJ, 2000, BIOCHEM J, V348, P1, DOI 10.1042/0264-6021:3480001; Patil AR, 2000, J BIOL CHEM, V275, P24348, DOI 10.1074/jbc.M003102200; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; Pipe SW, 1998, J BIOL CHEM, V273, P8537, DOI 10.1074/jbc.273.14.8537; Popov M, 1999, J BIOL CHEM, V274, P17635, DOI 10.1074/jbc.274.25.17635; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; RAY MK, 1991, J BIOL CHEM, V266, P22818; REITMAN ML, 1982, J BIOL CHEM, V257, P357; Rodan AR, 1996, EMBO J, V15, P6921, DOI 10.1002/j.1460-2075.1996.tb01084.x; Saito Y, 1999, EMBO J, V18, P6718, DOI 10.1093/emboj/18.23.6718; Smith M J, 1992, DNA Seq, V3, P247, DOI 10.3109/10425179209034025; Spee P, 1999, BIOCHEMISTRY-US, V38, P10559, DOI 10.1021/bi990321r; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; Suh WK, 1999, J IMMUNOL, V162, P1530; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; Toyofuku K, 1999, J BIOCHEM, V125, P82, DOI 10.1093/oxfordjournals.jbchem.a022272; Van der Wal FJ, 1998, EUR J BIOCHEM, V256, P51, DOI 10.1046/j.1432-1327.1998.2560051.x; vanLeeuwen JEM, 1996, J BIOL CHEM, V271, P9660, DOI 10.1074/jbc.271.16.9660; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; Wada I, 1997, EMBO J, V16, P5420, DOI 10.1093/emboj/16.17.5420; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009; Zhang Q, 1998, J IMMUNOL, V160, P831; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944	60	85	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25532	25540		10.1074/jbc.M100270200	http://dx.doi.org/10.1074/jbc.M100270200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11337494	hybrid			2022-12-25	WOS:000169800700144
J	Sloane, V; Blanchard, CZ; Guillot, F; Waldrop, GL				Sloane, V; Blanchard, CZ; Guillot, F; Waldrop, GL			Site-directed mutagenesis of ATP binding residues of biotin carboxylase - Insight into the mechanism of catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMOYL-PHOSPHATE SYNTHETASE; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; ENZYME CATALYSIS; B-DOMAIN; LIGASE; SUPERFAMILY; RESOLUTION; SUBSTRATE	Acetyl-CoA carboxylase catalyzes the first committed step in fatty acid synthesis in all plants, animals, and bacteria. The Escherichia coli form is a multimeric protein complex consisting of three distinct and separate components: biotin carboxylase, carboxyltransferase, and the biotin carboxyl carrier protein. The biotin carboxylase component catalyzes the ATP-dependent carboxylation of biotin using bicarbonate as the carboxylate source and has a distinct architecture that is characteristic of the ATP-grasp superfamily of enzymes. Included in this superfamily are D-Ala D-Ala ligase, glutathione synthetase, carbamyl phosphate synthetase, N-5-carboxyaminoimidazole ribonucleotide synthetase, and glycinamide ribonucleotide transformylase, all of which have known three-dimensional structures and contain a number of highly conserved residues between them. Four of these residues of biotin carboxylase, Lys-116, Lys-159, His-209, and Glu-276, were selected for site-directed mutagenesis studies based on their structural homology with conserved residues of other ATP-grasp enzymes. These mutants were subjected to kinetic analysis to characterize their roles in substrate binding and catalysis, In all four mutants, the K-m value for ATP was significantly increased, implicating these residues in the binding of ATP, This result is consistent with the crystal structures of several other ATP-grasp enzymes, which have shown specific interactions between the corresponding homologous residues and cocrystallized ADP or nucleotide analogs. In addition, the maximal velocity of the reaction was significantly reduced (between 30- and 260-fold) in the 4 mutants relative to wild type. The data suggest that the mutations have misaligned the reactants for optimal catalysis.	Louisiana State Univ, Dept Sci Biol, Div Biochem & Mol Biol, Baton Rouge, LA 70803 USA	Louisiana State University System; Louisiana State University	Waldrop, GL (corresponding author), Louisiana State Univ, Dept Sci Biol, Div Biochem & Mol Biol, Rm 508,Life Sci Bldg, Baton Rouge, LA 70803 USA.	gwaldro@lsu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051261] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51261] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artymiuk PJ, 1996, NAT STRUCT BIOL, V3, P128, DOI 10.1038/nsb0296-128; Blanchard CZ, 1999, BIOCHEMISTRY-US, V38, P3393, DOI 10.1021/bi982660a; Blanchard CZ, 1999, BIOCHEM BIOPH RES CO, V266, P466, DOI 10.1006/bbrc.1999.1844; Bruice TC, 1999, ACCOUNTS CHEM RES, V32, P127, DOI 10.1021/ar960131y; Bruice TC, 2000, BIOCHEMISTRY-US, V39, P6267, DOI 10.1021/bi0003689; FAN C, 1994, SCIENCE, V266, P439, DOI 10.1126/science.7939684; Galperin MY, 1997, PROTEIN SCI, V6, P2639; GUCHHAIT RB, 1974, J BIOL CHEM, V249, P6633; Kanai S, 1999, J MOL EVOL, V48, P482, DOI 10.1007/PL00006492; KNOWLES JR, 1989, ANNU REV BIOCHEM, V58, P195, DOI 10.1146/annurev.bi.58.070189.001211; Kohen A, 2000, J AM CHEM SOC, V122, P10738, DOI 10.1021/ja002229k; KOSHLAND DE, 1994, ANGEW CHEM INT EDIT, V33, P2375; Koshland DE, 1998, NAT MED, V4, P1112, DOI 10.1038/2605; Levert KL, 2000, BIOCHEMISTRY-US, V39, P4122, DOI 10.1021/bi992662a; OGITA T, 1988, BIOCHEMISTRY-US, V27, P8028, DOI 10.1021/bi00421a009; POLAKIS SE, 1974, J BIOL CHEM, V249, P6657; SHI Y, 1995, BIOCHEMISTRY-US, V34, P2768, DOI 10.1021/bi00009a005; Stapleton MA, 1996, BIOCHEMISTRY-US, V35, P14352, DOI 10.1021/bi961183y; Sutcliffe MJ, 2000, TRENDS BIOCHEM SCI, V25, P405, DOI 10.1016/S0968-0004(00)01642-X; Thoden JB, 2000, J BIOL CHEM, V275, P16183, DOI 10.1074/jbc.275.21.16183; Thoden JB, 2000, BIOCHEMISTRY-US, V39, P8791, DOI 10.1021/bi000926j; Thoden JB, 1999, BIOCHEMISTRY-US, V38, P15480, DOI 10.1021/bi991618s; Thoden JB, 1999, BIOCHEMISTRY-US, V38, P2347, DOI 10.1021/bi982517h; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WALDROP GL, 1994, BIOCHEMISTRY-US, V33, P10249, DOI 10.1021/bi00200a004; YAMAGUCHI H, 1993, J MOL BIOL, V229, P1083, DOI 10.1006/jmbi.1993.1106	27	29	30	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24991	24996		10.1074/jbc.M101472200	http://dx.doi.org/10.1074/jbc.M101472200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11346647	hybrid			2022-12-25	WOS:000169800700075
J	Takagi, M; Sueishi, M; Saiwaki, T; Kametaka, A; Yoneda, Y				Takagi, M; Sueishi, M; Saiwaki, T; Kametaka, A; Yoneda, Y			A novel nucleolar protein, NIFK, interacts with the forkhead associated domain of Ki-67 antigen in mitosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; FHA DOMAIN; FACTOR SL1; GENE; SPECIFICITY; RAD53; IDENTIFICATION; TRANSCRIPTION; PHOSPHATASE; MUTATIONS	In a previous study, we demonstrated that the fork-head associated (FHA) domain of pKi-67 interacts with the novel kinesin-like protein, Hklp2 (Sueishi, M., Takagi, M., and Yoneda, Y. (2000) J. Biol. Chem. 275, 28888-28892), In this study, we report on the identification of a putative RNA-binding protein of 293 residues as another binding partner of the FHA domain of pKi-67 (referred to as NIFK for nucleolar protein interacting with the FHA domain of pKi-67), Human NIFK (hNIFK) interacted with the FHA domain of pKi-67 (Ki-FHA) efficiently in vitro when hNIFK was derived from mitotically arrested cells. In addition, a moiety of hNIFK was co-localized with pKi-67 at the peripheral region of mitotic chromosomes. The hNIFK domain that interacts with Ki-FHA was mapped in the yeast two-hybrid system to a portion encompassed by residues 226-269, In a binding assay utilizing Xenopus egg extracts, it was found that the mitosis-specific environment and two threonine residues within this portion of hNIFK (Thr-234 and Thr238) were crucial for the efficient interaction of hNIFK and Ki-FHA, suggesting that hNIFK interacts with KiFHA in a mitosis-specific and phosphorylation-dependent manner. These findings provide a new clue to our understanding of the cellular function of pKi-67.	Osaka Univ, Grad Sch Med, Dept Cell Biol & Neurosci, Suita, Osaka 5650871, Japan; Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan	Osaka University; Osaka University	Yoneda, Y (corresponding author), Osaka Univ, Grad Sch Med, Dept Cell Biol & Neurosci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	yyoneda@anat3.med.osaka-u.ac.jp	Kametaka, Ai/AAA-6869-2020	Kametaka, Ai/0000-0002-5648-9373				ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Boudrez A, 2000, J BIOL CHEM, V275, P25411, DOI 10.1074/jbc.M001676200; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Carninci P, 2000, GENOME RES, V10, P1617, DOI 10.1101/gr.145100; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; GERDES J, 1984, J IMMUNOL, V133, P1710; GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; Heix J, 1998, EMBO J, V17, P7373, DOI 10.1093/emboj/17.24.7373; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; Kawai J, 2001, NATURE, V409, P685, DOI 10.1038/35055500; Kuhn A, 1998, J MOL BIOL, V284, P1, DOI 10.1006/jmbi.1998.2164; Li J, 2000, J CELL SCI, V113, P4143; Liao H, 1999, J MOL BIOL, V294, P1041, DOI 10.1006/jmbi.1999.3313; Liao H, 2000, J MOL BIOL, V304, P941, DOI 10.1006/jmbi.2000.4291; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nishijima H, 1997, J CELL BIOL, V138, P1105, DOI 10.1083/jcb.138.5.1105; SEKI T, 1992, MOL BIOL CELL, V3, P1373, DOI 10.1091/mbc.3.12.1373; Sirri V, 2000, J CELL BIOL, V148, P259, DOI 10.1083/jcb.148.2.259; STONE JM, 1994, SCIENCE, V266, P793, DOI 10.1126/science.7973632; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; Sueishi M, 2000, J BIOL CHEM, V275, P28888, DOI 10.1074/jbc.M003879200; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Takagi M, 1999, J CELL SCI, V112, P2463; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wang P, 2000, J MOL BIOL, V302, P927, DOI 10.1006/jmbi.2000.4095; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901	31	51	56	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25386	25391		10.1074/jbc.M102227200	http://dx.doi.org/10.1074/jbc.M102227200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342549	hybrid			2022-12-25	WOS:000169800700127
J	Henao, F; Delavoie, F; Lacapere, JJ; McIntosh, DB; Champeil, P				Henao, F; Delavoie, F; Lacapere, JJ; McIntosh, DB; Champeil, P			Phosphorylated Ca2+-ATPase stable enough for structural studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; ATPASE	The atomic structure of sarcoplasmic reticulum Ca2+-ATPase, in a Ca2+-bound conformation, has recently been elucidated (Toyoshima, C., Nakasako, M, Nomura, H. & Ogawa, H, (2000) Nature 405, 647-655). Important steps for further understanding the mechanism of ion pumps will be the atomic structural characterization of different key conformational intermediates of the transport cycle, including phosphorylated intermediates. Following our previous report (Champeil, P., Henao, F., Lacapere, J.-J, & McIntosh, D. B, (2000) J. Biol. Chem, 276, 5795-5803), we show here that it is possible to prepare a phosphorylated form of sarcoplasmic reticulum Ca2+-ATPase (labeled with fluorescein isothiocyanate) with a meek-long stability both in membranes anal in mixed lipid-detergent micelles. We show that this phosphorylated fluorescein isothiocyanate-ATPase can form two-dimensional arrays in membranes, similar to those that were used previously to reconstruct from cryoelectron microscopy images the three-dimensional structure of Ca2+-free unphosphorylated ATPase. The results also provide hope that crystals of phosphorylated Ca2+- ATPase suitable for x-ray crystallography will be achieved.	Ctr Etud Saclay, Dept Biol Cellulaire & Mol, Sect Biophys Prot & Membranes, F-91191 Gif Sur Yvette, France; Ctr Etud Saclay, CNRS, URA 2096, F-91191 Gif Sur Yvette, France; Ctr Etud Saclay, CEA, F-91191 Gif Sur Yvette, France; Univ Extremadura, Dept Bioquim & Biol Mol, E-06080 Badajoz, Spain; Fac Xavier Bichat, INSERM, Unite U410, F-75870 Paris 18, France; Univ Cape Town, Sch Med, Dept Chem Pathol, ZA-7925 Cape Town, South Africa	Centre National de la Recherche Scientifique (CNRS); CEA; UDICE-French Research Universities; Universite Paris Saclay; Universidad de Extremadura; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Cape Town	Champeil, P (corresponding author), Ctr Etud Saclay, Dept Biol Cellulaire & Mol, Sect Biophys Prot & Membranes, F-91191 Gif Sur Yvette, France.	champeil@dsvidf.cea.fr	DELAVOIE, Franck/AAP-3126-2021; Henao, Fernando/F-6694-2016	DELAVOIE, Franck/0000-0001-9692-0386; Henao, Fernando/0000-0003-1117-8544				Champeil P, 2001, J BIOL CHEM, V276, P5795, DOI 10.1074/jbc.M006980200; DUX L, 1983, J BIOL CHEM, V258, P2599; HARDWICKE PMD, 1989, J MUSCLE RES CELL M, V10, P245, DOI 10.1007/BF01739814; HIGHSMITH S, 1985, BIOCHIM BIOPHYS ACTA, V817, P123, DOI 10.1016/0005-2736(85)90074-4; Lacapere JJ, 2001, BIOPHYS J, V80, p35A; MacLennan DH, 2000, NATURE, V405, P633, DOI 10.1038/35015206; McIntosh DB, 2000, NAT STRUCT BIOL, V7, P532, DOI 10.1038/76735; PICK U, 1981, FEBS LETT, V123, P131, DOI 10.1016/0014-5793(81)80036-1; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; STOKES DL, 1994, J BIOL CHEM, V269, P11606; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	12	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24284	24285		10.1074/jbc.M103905200	http://dx.doi.org/10.1074/jbc.M103905200			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11337512	hybrid, Green Published			2022-12-25	WOS:000169531100138
J	Marbach, I; Licht, R; Frohnmeyer, H; Engelberg, D				Marbach, I; Licht, R; Frohnmeyer, H; Engelberg, D			Gcn2 mediates Gcn4 activation in response to glucose stimulation or UV radiation not via GCN4 translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-PROTEIN GENES; RAS/CYCLIC AMP PATHWAY; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; DNA-REPAIR; C-JUN; CELLULAR STRESS; YEAST; KINASE	In mammalian cells transcription factors of the AP-1 family are activated by either stress signals such as W radiation, or mitogenic signals such as growth factors. Here we show that a similar situation exists in the yeast Saccharomyces cerevisiae, The AP-1 transcriptional activator Gcn4, known to be activated by stress signals such as UV radiation and amino acids starvation, is also induced by growth stimulation such as glucose. We show that glucose-dependent Gcn4 activation is mediated through the Ras/cAMP pathway. This pathway is also responsible for UV-dependent Gcn4 activation but is not involved in Gcn4 activation by amino acid starvation. Thus, the unusual phenomenon of activation of mitogenic pathways and AP-1 factors by contradictory stimuli through Has is conserved from yeast to mammals. We also show that activation of Gcn4 by glucose and W requires Gcn2 activity. However, in contrast to its role in amino acid starvation, Gcn2 does not increase eIF2 alpha phosphorylation or translation of GCN4 mRNA in response to glucose or UV. These findings suggest a novel mechanism of action for Gcn2, The finding that Gcn4 is activated in response to glucose via the Ras/cAMP pathway suggests that this cascade coordinates glucose metabolism with amino acids and purine biosynthesis and thereby ensures availability of both energy and essential building blocks for continuation of the cell cycle.	Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Univ Freiburg, Inst Biol 2, D-79104 Freiburg, Germany	Hebrew University of Jerusalem; University of Freiburg	Engelberg, D (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.							ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BARONI MD, 1994, NATURE, V371, P339, DOI 10.1038/371339a0; Blattner C, 2000, MOL CELL BIOL, V20, P3616, DOI 10.1128/MCB.20.10.3616-3625.2000; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BoyMarcotte E, 1996, MICROBIOL-UK, V142, P459, DOI 10.1099/13500872-142-3-459; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; Broach JR, 1991, CURR OPIN GENET DEV, V1, P370, DOI 10.1016/S0959-437X(05)80302-8; COFFER PJ, 1995, ONCOGENE, V11, P561; Colombo S, 1998, EMBO J, V17, P3326, DOI 10.1093/emboj/17.12.3326; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; ENGELBERG D, 1994, MOL CELL BIOL, V14, P4929, DOI 10.1128/MCB.14.7.4929; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; ERASO P, 1985, FEBS LETT, V191, P51, DOI 10.1016/0014-5793(85)80991-1; FOIANI M, 1994, MOL CELL BIOL, V14, P923, DOI 10.1128/MCB.14.2.923; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HERRLICH P, 1994, CURR OPIN CELL BIOL, V6, P425, DOI 10.1016/0955-0674(94)90036-1; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; HINNEBUSCH AG, 1985, MOL CELL BIOL, V5, P2349, DOI 10.1128/MCB.5.9.2349; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; Hoffmann B, 1999, MOL MICROBIOL, V31, P807, DOI 10.1046/j.1365-2958.1999.01219.x; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jiang Y, 1998, EMBO J, V17, P6942, DOI 10.1093/emboj/17.23.6942; KAIBUCHI K, 1986, P NATL ACAD SCI USA, V83, P8172, DOI 10.1073/pnas.83.21.8172; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KLEIN C, 1994, MOL CELL BIOL, V14, P1920, DOI 10.1128/MCB.14.3.1920; LUCCHINI G, 1984, MOL CELL BIOL, V4, P1326, DOI 10.1128/MCB.4.7.1326; MAGER WH, 1995, MICROBIOL REV, V59, P506, DOI 10.1128/MMBR.59.3.506-531.1995; MBYONI K, 1988, MOL CELL BIOL, V8, P3051; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; NEUMANSILBERBERG FS, 1995, MOL CELL BIOL, V15, P3187; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Stanhill A, 1999, MOL CELL BIOL, V19, P7529; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0; Takemaru K, 1998, MOL CELL BIOL, V18, P4971, DOI 10.1128/MCB.18.9.4971; THEVELEIN JM, 1994, YEAST, V10, P1753, DOI 10.1002/yea.320101308; TOKIWA G, 1994, NATURE, V371, P342, DOI 10.1038/371342a0; WALKER GC, 1995, TRENDS BIOCHEM SCI, V20, P416, DOI 10.1016/S0968-0004(00)89091-X; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Yang RJ, 2000, MOL CELL BIOL, V20, P2706, DOI 10.1128/MCB.20.8.2706-2717.2000	54	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16944	16951		10.1074/jbc.M100383200	http://dx.doi.org/10.1074/jbc.M100383200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11350978	hybrid			2022-12-25	WOS:000168730400046
J	O'Callaghan, BL; Koo, SH; Wu, Y; Freake, HC; Towle, HC				O'Callaghan, BL; Koo, SH; Wu, Y; Freake, HC; Towle, HC			Glucose regulation of the acetyl-CoA carboxylase promoter PI in rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEINS; COENZYME-A CARBOXYLASE; CARBOHYDRATE RESPONSE ELEMENT; FATTY-ACID BIOSYNTHESIS; LIPOGENIC ENZYME GENES; STEROL REGULATION; TRANSCRIPTION FACTOR; DIFFERENTIATION FACTOR-1; SYNTHASE PROMOTER; INSULIN ACTION	The rat acetyl-CoA carboxylase (ACC) alpha gene is transcribed from two promoters, denoted PI and PII, that direct regulated expression in a tissue-specific manner. Induction of ACC, the rate-controlling enzyme of fatty acid biosynthesis, occurs in the liver in response to feeding of a high carbohydrate, low fat diet, conditions that favor enhanced lipogenesis. This induction is mainly due to increases in PI promoter activity. We have used primary cultured hepatocytes from the rat to investigate glucose regulation of ACC expression. Glucose and insulin synergistically activated expression of ACC mRNAs transcribed from the PI promoter with little or no effect on PII mRNAs. Glucose treatment stimulated PI promoter activity in transfection assays and a glucose-regulated element was identified (-126/-102), homologous to those previously described in other responsive genes, including L-type pyruvate kinase, S-14 and fatty acid synthase. Mutation of this element eliminated the response to glucose. This region of the ACC PI promoter was able to bind a liver nuclear factor designated ChoRF that interacts with other conserved glucose-regulated elements. This ACC PI element is also capable of conferring a strong response to glucose when linked to a heterologous promoter. We conclude that induction of ACC gene expression under lipogenic conditions in hepatocytes is mediated in part by the activation of a glucose-regulated transcription factor, ChoRF, which stimulates transcription from the PI promoter. Similar mechanisms operate on related genes permitting the coordinate induction of the lipogenic pathway.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Univ Connecticut, Dept Nutr Sci, Storrs, CT 06269 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Connecticut	Towle, HC (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 6-155 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.		Koo, Seung-Hoi/E-2763-2015	Koo, Seung-Hoi/0000-0001-8769-2879; O'Callaghan, Brennon L/0000-0002-0800-5856	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026919] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK26919] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Cunningham BA, 1998, THYROID, V8, P815, DOI 10.1089/thy.1998.8.815; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; Daniel S, 1996, J BIOL CHEM, V271, P1385, DOI 10.1074/jbc.271.3.1385; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; FOUFELLE F, 1994, EUR J BIOCHEM, V223, P893, DOI 10.1111/j.1432-1033.1994.tb19066.x; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; HARDIE DG, 1989, PROG LIPID RES, V28, P117, DOI 10.1016/0163-7827(89)90010-6; Hillgartner FB, 1996, BIOCHEM J, V319, P263, DOI 10.1042/bj3190263; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 1999, CURR OPIN LIPIDOL, V10, P143, DOI 10.1097/00041433-199904000-00008; Huang CL, 1998, BIOCHEM BIOPH RES CO, V249, P704, DOI 10.1006/bbrc.1998.9217; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; Kaytor EN, 1997, J BIOL CHEM, V272, P7525, DOI 10.1074/jbc.272.11.7525; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kim KH, 1997, ANNU REV NUTR, V17, P77, DOI 10.1146/annurev.nutr.17.1.77; Kim TS, 1996, J NUTR, V126, P611, DOI 10.1093/jn/126.3.611; Kim TS, 1996, BIOCHEM BIOPH RES CO, V225, P647, DOI 10.1006/bbrc.1996.1224; Koo SH, 2000, J BIOL CHEM, V275, P5200, DOI 10.1074/jbc.275.7.5200; Koo SH, 2001, J BIOL CHEM, V276, P9437, DOI 10.1074/jbc.M010029200; LIU ZR, 1993, J BIOL CHEM, V268, P12787; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; LOPEZCASILLAS F, 1991, ENDOCRINOLOGY, V129, P1049, DOI 10.1210/endo-129-2-1049; LUO XC, 1989, P NATL ACAD SCI USA, V86, P4042, DOI 10.1073/pnas.86.11.4042; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Magana MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; SHIH HM, 1994, J BIOL CHEM, V269, P9380; SHIH HM, 1992, J BIOL CHEM, V267, P13222; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Tabor DE, 1998, J BIOL CHEM, V273, P22052, DOI 10.1074/jbc.273.34.22052; Towle HC, 1997, ANNU REV NUTR, V17, P405, DOI 10.1146/annurev.nutr.17.1.405; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; Yin LY, 2000, BBA-GENE STRUCT EXPR, V1517, P91, DOI 10.1016/S0167-4781(00)00267-0	44	70	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16033	16039		10.1074/jbc.M101557200	http://dx.doi.org/10.1074/jbc.M101557200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11340083	hybrid			2022-12-25	WOS:000168623100063
J	Fitzgerald, ML; Mendez, AJ; Moore, KJ; Andersson, LP; Panjeton, HA; Freeman, MW				Fitzgerald, ML; Mendez, AJ; Moore, KJ; Andersson, LP; Panjeton, HA; Freeman, MW			ATP-binding cassette transporter A1 contains an NH2-terminal signal anchor sequence that translocates the protein's first hydrophilic domain to the exoplasmic space	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANGIER-DISEASE; CHOLESTEROL EFFLUX; MONOCLONAL-ANTIBODIES; CELLULAR CHOLESTEROL; HDL CHOLESTEROL; ABCA1 GENE; MUTATIONS; RECEPTOR; PROMOTER; CLONING	Mutations in the ATP-binding cassette transporter A1 (ABCA1) transporter are associated with Tangier disease and a defect in cellular cholesterol efflux, The amino terminus of the ABCA1 transporter has two putative in-frame translation initiation sites, 60 amino acids apart. A cluster of hydrophobic amino acids form a potentially cleavable signal sequence in this 60-residue extension. We investigated the functional role of this extension and found that it was required for stable protein expression of transporter constructs containing any downstream transmembrane domains. The extension directed transporter translocation across the ER membrane with an orientation that resulted in glycosylation of amino acids immediately distal to the signal sequence. Neither the native signal sequence nor a green fluorescent protein tag, fused at the amino terminus, was cleaved from ABCA1. The green fluorescent protein fusion protein had efflux activity comparable with wild type ABCA1 and demonstrated a predominantly plasma membrane distribution in transfected cells. These data establish a requirement for the upstream 60 amino acids of ABCA1. This region contains an uncleaved signal anchor sequence that positions the amino terminus in a type II orientation leading to the extracellular presentation of an similar to 600-amino acid loop in which loss-of-function mutations cluster in Tangier disease patients.	Massachusetts Gen Hosp, Lipid Metab Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Univ Miami, Sch Med, Diabet Res Inst, Miami, FL 33101 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Miami	Freeman, MW (corresponding author), Massachusetts Gen Hosp, Lipid Metab Unit, Boston, MA 02114 USA.		Moore, Kathryn/ABE-6416-2020	Moore, Kathryn/0000-0003-2505-2547	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL066678, P50HL056985, R01HL045098, R29HL053451, F32HL010398] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53451, UO1-HL-66678, HL10398, HL56985, HL45098] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andersson L, 1998, J BIOL CHEM, V273, P19592, DOI 10.1074/jbc.273.31.19592; ARTISS JD, 1980, MICROCHEM J, V25, P535, DOI 10.1016/0026-265X(80)90219-2; ASSMANN G, 1995, METABOLIC MOL BASES, P2053; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Broccardo C, 1999, BBA-BIOMEMBRANES, V1461, P395, DOI 10.1016/S0005-2736(99)00170-4; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brousseau ME, 2000, J LIPID RES, V41, P433; CHAMBENOIT O, 2001, J BIOL CHEM     0109; Clee SM, 2000, J CLIN INVEST, V106, P1263, DOI 10.1172/JCI10727; Costet P, 2000, J BIOL CHEM, V275, P28240; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HODGES RS, 1988, J BIOL CHEM, V263, P11768; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; Mendez AJ, 1997, J LIPID RES, V38, P1807; Mendez AJ, 2001, J BIOL CHEM, V276, P3158, DOI 10.1074/jbc.M007717200; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; Mott S, 2000, ATHEROSCLEROSIS, V152, P457, DOI 10.1016/S0021-9150(99)00498-0; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 2000, BBA-MOL CELL BIOL L, V1529, P321, DOI 10.1016/S1388-1981(00)00157-8; Pullinger CR, 2000, BIOCHEM BIOPH RES CO, V271, P451, DOI 10.1006/bbrc.2000.2652; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; ROGLER G, 1995, ARTERIOSCL THROM VAS, V15, P683, DOI 10.1161/01.ATV.15.5.683; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Santamarina-Fojo S, 2000, P NATL ACAD SCI USA, V97, P7987, DOI 10.1073/pnas.97.14.7987; Wang J, 2000, ARTERIOSCL THROM VAS, V20, P1983, DOI 10.1161/01.ATV.20.8.1983; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; WARNER GJ, 1995, J BIOL CHEM, V270, P5772, DOI 10.1074/jbc.270.11.5772; Zhao LX, 2000, BIOCHEM J, V350, P865, DOI 10.1042/0264-6021:3500865	39	102	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15137	15145		10.1074/jbc.M100474200	http://dx.doi.org/10.1074/jbc.M100474200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11328826	hybrid			2022-12-25	WOS:000168528800082
J	Gimm, O; Dziema, H; Brown, J; Cuong, HV; Hinze, R; Dralle, H; Mulligan, LM; Eng, C				Gimm, O; Dziema, H; Brown, J; Cuong, HV; Hinze, R; Dralle, H; Mulligan, LM; Eng, C			Over-representation of a germline variant in the gene encoding RET co-receptor GFR alpha-1 but not GFR alpha-2 or GFR alpha-3 in cases with sporadic medullary thyroid carcinoma	ONCOGENE			English	Article						MEN 2; RET; common low penetrance alleles; polymorphisms; thyroid	ENDOCRINE-NEOPLASIA TYPE-2B; TYROSINE KINASE; NEUROTROPHIC FACTOR; GDNF FAMILY; HIRSCHSPRUNG-DISEASE; FUNCTIONAL RECEPTOR; CODON-918 MUTATION; MICE LACKING; PROTOONCOGENE; PROTEIN	In contrast to the hereditary form of medullary thyroid carcinoma (MTC), little is known about the etiology of sporadic MTC, Somatic gain-of-function mutations in the RET proto-oncogene, encoding a receptor tyrosine kinase, are found in an average of 40% of sporadic MTC, We analysed 31 sporadic MTC for somatic and germline variants in GFRA1, GFRA2 and GFRA3 which encode the co-receptors of RET, Although there were no somatic mutations in any of the three genes, a sequence variant (-193C>G) in the 5'-UTR of GFRA1 was found in 15% of cases. Three patients were heterozygous (het); another three patients homozygous (hom) for the G variant. The G allele was not observed in 31 race-matched normal controls. Hence, the relative frequency of this variant in sporadic MTC cases and controls differed significantly (P<0.05). Since this variant lies in the 5' UTR, likely at the transcriptional start site, we analysed for differential expression of GFR<alpha>-1 at the transcript and protein levels. At the mRNA level, GFRA1 was over-expressed in tumors harboring the rare variant (P=0.06), The presence of the G polymorphic allele seemed to be associated with increased expression by immunostaining for GFR alpha -1. Interestingly, cytoplasmic staining was stronger in intensity for het patients and nuclear staining predominant in hom cases. In conclusion, mutation analysis of GFRA1, GFRA2 and GFRA3 revealed over-representation of a rare variant in GFRA1 (- 193C > G) in the germline of sporadic MTC cases. Our data suggest that the mechanism is related to over-expression of GFR alpha -1 and differential subcellular compartmentalization but the precise mechanism as to how it acts as a low penetrance susceptibility allele for the development of sporadic MTC remains to be elucidated.	Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Clin Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Div Human Genet, Columbus, OH 43210 USA; Univ Halle Wittenberg, Inst Pathol, Halle, Germany; Queens Univ, Dept Pathol, Kingston, ON K7L 3NR, Canada; Queens Univ, Dept Paediat, Kingston, ON K7L 3NR, Canada; Univ Cambridge, Canc Res Campaign, Human Canc Genet Res Grp, Cambridge CB2 2QQ, England; Univ Halle Wittenberg, Dept Gen Surg, Halle, Germany	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Martin Luther University Halle Wittenberg; Queens University - Canada; Queens University - Canada; CRUK Cambridge Institute; University of Cambridge; Martin Luther University Halle Wittenberg	Eng, C (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, 420 W 12th Ave,Suite 690 TMRF, Columbus, OH 43210 USA.		Dralle, Henning/ABD-4454-2020	Eng, Charis/0000-0002-3693-5145	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD039058] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA16058] Funding Source: Medline; NICHD NIH HHS [1RO1HD39058-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Angrist M, 1998, GENOMICS, V48, P354, DOI 10.1006/geno.1997.5191; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Baloh RH, 1998, NEURON, V21, P1291, DOI 10.1016/S0896-6273(00)80649-2; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; Ceccherini I, 1999, AM J HUM GENET, V65, pA266; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Eng C, 1996, CANCER RES, V56, P2167; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; Eng C, 1997, HUM MUTAT, V9, P97, DOI 10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.3.CO;2-Q; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; Enokido Y, 1998, CURR BIOL, V8, P1019, DOI 10.1016/S0960-9822(07)00422-8; Gimm O, 1999, ONCOGENE, V18, P1369, DOI 10.1038/sj.onc.1202418; Gimm O, 2000, HUM MOL GENET, V9, P1633, DOI 10.1093/hmg/9.11.1633; Gimm O, 1997, J CLIN ENDOCR METAB, V82, P3902, DOI 10.1210/jc.82.11.3902; Gimm O, 1999, BRIT J CANCER, V80, P383, DOI 10.1038/sj.bjc.6690367; Gimm O, 1999, J CLIN ENDOCR METAB, V84, P2784, DOI 10.1210/jc.84.8.2784; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Jing SQ, 1997, J BIOL CHEM, V272, P33111, DOI 10.1074/jbc.272.52.33111; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Jordanova A, 1997, HUM MUTAT, V10, P65, DOI 10.1002/(SICI)1098-1004(1997)10:1<65::AID-HUMU9>3.3.CO;2-9; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; Masure S, 1999, EUR J BIOCHEM, V266, P892, DOI 10.1046/j.1432-1327.1999.00925.x; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; Myers SM, 1999, J MED GENET, V36, P217; Naveilhan P, 1998, P NATL ACAD SCI USA, V95, P1295, DOI 10.1073/pnas.95.3.1295; ONOCHIE CI, 2000, IN PRESS J MED GENET; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; Thompson J, 1998, MOL CELL NEUROSCI, V11, P117, DOI 10.1006/mcne.1998.0682; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Trupp M, 1998, MOL CELL NEUROSCI, V11, P47, DOI 10.1006/mcne.1998.0667	37	25	27	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2001	20	17					2161	2170		10.1038/sj.onc.1204289	http://dx.doi.org/10.1038/sj.onc.1204289			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360200				2022-12-25	WOS:000168116700011
J	Tsai, HF; Fujii, I; Watanabe, A; Wheeler, AH; Chang, YC; Yasuoka, Y; Ebizuka, Y; Kwon-Chung, KJ				Tsai, HF; Fujii, I; Watanabe, A; Wheeler, AH; Chang, YC; Yasuoka, Y; Ebizuka, Y; Kwon-Chung, KJ			Pentaketide melanin biosynthesis in Aspergillus fumigatus requires chain-length shortening of a heptaketide precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYKETIDE SYNTHASE GENE; NIDULANS WA GENE; COLLETOTRICHUM-LAGENARIUM; HETEROLOGOUS EXPRESSION; VIRULENCE; CLONING; ORYZAE; PKS1; IDENTIFICATION; TRANSFORMATION	Chain lengths and cyclization patterns of microbial polyketides are generally determined by polyketide synthases alone. Fungal polyketide melanins are often derived from a pentaketide 1,8-dihydroxynaphthalene, and pentaketide synthases are used for synthesis of the upstream pentaketide precursor, 1,3,6,8-tetrahydroxynaphthalene (1,3,6,8-THN). However, Aspergillus fumigatus, a human fungal pathogen, uses a heptaketide synthase (Alb1p) to synthesize its conidial pigment through a pentaketide pathway similar to that which produces 1,8-dihydroxynaphthalene-melanin. In this study we demonstrate that a novel protein, Ayg1p, is involved in the formation of 1,3,6,8-THN by chain-length shortening of a heptaketide precursor in A. fumigatus. Deletion of the ayg1 gene prevented the accumulation of 1,3,6,8-THN suggesting the involvement of ayg1 in 1,3,6,8-THN production. Genetic analyses of double-gene deletants suggested that Ayg1p catalyzes a novel biosynthetic step downstream of Alb1p and upstream of Arp2p (1,3,6,8-THN reductase). Further genetic and biochemical analyses of the reconstituted strains carrying alb1, ayg1, or alb1 + ayg1 indicated that Ayg1p is essential for synthesis of 1,3,6,8-THN in addition to Alb1p. Cell-free enzyme assays, using the crude Ayg1p protein extract, revealed that Ayg1p enzymatically shortened the heptaketide product of Alb1p to 1,3,6,8-THN. Thus, the protein Ayg1p facilitates the participation of a heptaketide synthase in a pentaketide pathway via a novel polyketide-shortening mechanism in A fumigatus.	NIAID, Clin Invest Lab, NIH, Bethesda, MD 20892 USA; Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; USDA ARS, Cotton Pathol Res Unit, College Stn, TX 77845 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Tokyo; United States Department of Agriculture (USDA)	Kwon-Chung, KJ (corresponding author), NIAID, Clin Invest Lab, NIH, Bldg 10,Rm 11C304,10 Ctr Dr,MSC 1882, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000657, Z01AI000057, ZIAAI000657, ZIAAI000057] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECK J, 1990, EUR J BIOCHEM, V192, P487, DOI 10.1111/j.1432-1033.1990.tb19252.x; Butler MJ, 1998, CAN J MICROBIOL, V44, P1115, DOI 10.1139/cjm-44-12-1115; CHANG PK, 1995, MOL GEN GENET, V248, P270, DOI 10.1007/BF02191593; DIXON DM, 1987, J MED VET MYCOL, V25, P97; FENG GH, 1995, J BACTERIOL, V177, P6246, DOI 10.1128/jb.177.21.6246-6254.1995; Fujii I, 1996, MOL GEN GENET, V253, P1, DOI 10.1007/s004380050289; Fujii I, 1999, BIOSCI BIOTECH BIOCH, V63, P1445, DOI 10.1271/bbb.63.1445; Fujii I, 2000, BIOCHEMISTRY-US, V39, P8853, DOI 10.1021/bi000644j; Fujii I., 1999, COMPREHENSIVE NATURA, V1, P409, DOI [10.1016/B978-0-08-091283-7.00016-3, DOI 10.1016/B978-0-08-091283-7.00016-3]; FUJII T, 1995, BIOSCI BIOTECH BIOCH, V59, P1869, DOI 10.1271/bbb.59.1869; Funa N, 1999, NATURE, V400, P897, DOI 10.1038/23748; GOMI K, 1987, AGR BIOL CHEM TOKYO, V51, P2549; Hendrickson L, 1999, CHEM BIOL, V6, P429, DOI 10.1016/S1074-5521(99)80061-1; HUTCHINSON CR, 1995, ANNU REV MICROBIOL, V49, P201; Kafer E, 1977, Adv Genet, V19, P33, DOI 10.1016/S0065-2660(08)60245-X; Keller NP, 1997, FUNGAL GENET BIOL, V21, P17, DOI 10.1006/fgbi.1997.0970; Kennedy J, 1999, SCIENCE, V284, P1368, DOI 10.1126/science.284.5418.1368; LUNDQVIST T, 1994, STRUCTURE, V2, P937, DOI 10.1016/S0969-2126(94)00095-6; MAYORGA ME, 1992, MOL GEN GENET, V235, P205, DOI 10.1007/BF00279362; Perpetua NS, 1996, MOL PLANT MICROBE IN, V9, P323, DOI 10.1094/MPMI-9-0323; Proctor RH, 1999, FUNGAL GENET BIOL, V27, P100, DOI 10.1006/fgbi.1999.1141; RAPER KB, 1965, GENUS ASPERGILLUS, P36; Sambrook J., 2002, MOL CLONING LAB MANU; TAKANO Y, 1995, MOL GEN GENET, V249, P162, DOI 10.1007/BF00290362; Thompson JE, 2000, J BIOL CHEM, V275, P34867, DOI 10.1074/jbc.M006659200; TIMBERLAKE WE, 1986, ANNU REV GENET, V24, P5; Tsai HF, 1999, J BACTERIOL, V181, P6469, DOI 10.1128/JB.181.20.6469-6477.1999; Tsai HF, 1997, MOL MICROBIOL, V26, P175, DOI 10.1046/j.1365-2958.1997.5681921.x; Tsai HF, 1998, J BACTERIOL, V180, P3031, DOI 10.1128/JB.180.12.3031-3038.1998; Watanabe A, 1999, TETRAHEDRON LETT, V40, P91, DOI 10.1016/S0040-4039(98)80027-0; Watanabe A, 2000, FEMS MICROBIOL LETT, V192, P39, DOI 10.1111/j.1574-6968.2000.tb09356.x; Wheeler M H, 1988, Curr Top Med Mycol, V2, P338; WHEELER MH, 1979, EXP MYCOL, V3, P340, DOI 10.1016/S0147-5975(79)80037-7; WHEELER MH, 1995, PESTIC BIOCHEM PHYS, V52, P125, DOI 10.1006/pest.1995.1037; Yang G, 1996, PLANT CELL, V8, P2139, DOI 10.1105/tpc.8.11.2139; YELTON MM, 1984, P NATL ACAD SCI-BIOL, V81, P1470, DOI 10.1073/pnas.81.5.1470; YU JH, 1995, J BACTERIOL, V177, P4792, DOI 10.1128/jb.177.16.4792-4800.1995	37	109	118	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29292	29298		10.1074/jbc.M101998200	http://dx.doi.org/10.1074/jbc.M101998200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11350964	hybrid			2022-12-25	WOS:000170346000088
J	Xiong, YM; Tanaka, H; Richardson, JA; Williams, SC; Slaughter, CA; Nakamura, M; Chen, JL; Yanagisawa, M				Xiong, YM; Tanaka, H; Richardson, JA; Williams, SC; Slaughter, CA; Nakamura, M; Chen, JL; Yanagisawa, M			Endothelin-1 stimulates leptin production in adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OBESE GENE-EXPRESSION; OB MESSENGER-RNA; GLUCOSE-UPTAKE; PHOSPHATIDYLINOSITOL 3-KINASE; GLUT4 TRANSLOCATION; PROTEIN EXPRESSION; RECEPTOR GENE; FEMALE MICE; FOOD-INTAKE; EARLY-ONSET	Leptin is an adipocyte-derived hormone that regulates body fat stores and feeding behavior. In an effort to identify endogenous diffusible modulators of leptin production, we found that endothelin-1 (ET-1) up-regulates leptin expression in adipocytes. ET-1 is as potent and efficacious as insulin in stimulating leptin production in two different adipocyte cell lines. Endothelins stimulate leptin production via the endothelin-A receptor (ETA), as judged by a potency rank order of ET-1 >> ET-3. We detected expression of ETA but not ETB in both cell lines by Northern blot analysis. In addition, the ETA-selective antagonist FR139317 inhibited ET-1-induced leptin expression more potently than did the ETB-selective antagonist BQ788. ET-1 and insulin positively interact with each other in increasing leptin production in adipocytes. In primary mouse white fat cells, we detected expression of both ETA and ETB by Northern blot and in situ hybridization analyses. We conclude that ET-1 stimulates leptin production via the ETA receptor in cultured adipocytes.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Donald W Reynolds Cardiovasc Clin Res Ctr, Dallas, TX 75390 USA; Tularik Inc, San Francisco, CA 94040 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yanagisawa, M (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd,Rm Y5-224, Dallas, TX 75390 USA.	myanagisawa@aol.com						Aizawa-Abe M, 2000, J CLIN INVEST, V105, P1243, DOI 10.1172/JCI8341; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; Bado A, 1998, NATURE, V394, P790, DOI 10.1038/29547; Benjamin IJ, 1997, DEV DYNAM, V208, P75; Bennett BD, 1996, CURR BIOL, V6, P1170, DOI 10.1016/S0960-9822(02)70684-2; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chehab FF, 1997, SCIENCE, V275, P88, DOI 10.1126/science.275.5296.88; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; CHOU YC, 1994, BIOCHEM BIOPH RES CO, V202, P688, DOI 10.1006/bbrc.1994.1985; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; DELABROUSSE FC, 1998, Patent No. 5780258; Dupuis J, 1998, AM HEART J, V135, P614, DOI 10.1016/S0002-8703(98)70276-5; FERRI C, 1995, J CLIN ENDOCR METAB, V80, P829, DOI 10.1210/jc.80.3.829; FRANK HJL, 1993, ENDOCRINOLOGY, V133, P1092, DOI 10.1210/en.133.3.1092; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; Grunfeld C, 1996, J CLIN INVEST, V97, P2152, DOI 10.1172/JCI118653; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; HAUNER H, 1994, METABOLISM, V43, P227, DOI 10.1016/0026-0495(94)90250-X; Haynes WG, 1997, J CLIN INVEST, V100, P270, DOI 10.1172/JCI119532; Hocher B, 1997, EUR J CLIN CHEM CLIN, V35, P175; Hoggard N, 1997, P NATL ACAD SCI USA, V94, P11073, DOI 10.1073/pnas.94.20.11073; Hu J, 1998, BIOCHEM BIOPH RES CO, V245, P894, DOI 10.1006/bbrc.1998.8543; HU RM, 1993, DIABETES, V42, P351, DOI 10.2337/diabetes.42.2.351; IMAI T, 1992, HYPERTENSION, V19, P753, DOI 10.1161/01.HYP.19.6.753; Imamura T, 1999, J BIOL CHEM, V274, P33691, DOI 10.1074/jbc.274.47.33691; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; Jiang ZY, 1999, DIABETES, V48, P1120, DOI 10.2337/diabetes.48.5.1120; Kamohara S, 1997, NATURE, V389, P374, DOI 10.1038/38717; Kolaczynski JW, 1996, DIABETES, V45, P699, DOI 10.2337/diabetes.45.5.699; KURIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P1435, DOI 10.1016/0006-291X(89)92270-5; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Lee YC, 1998, METABOLISM, V47, P1468, DOI 10.1016/S0026-0495(98)90071-3; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; MALEK AM, 1993, P NATL ACAD SCI USA, V90, P5999, DOI 10.1073/pnas.90.13.5999; Mandrup S, 1997, P NATL ACAD SCI USA, V94, P4300, DOI 10.1073/pnas.94.9.4300; Mantzoros CS, 1996, DIABETES, V45, P909, DOI 10.2337/diabetes.45.7.909; Mark AL, 1999, HYPERTENSION, V33, P537, DOI 10.1161/01.HYP.33.1.537; MARSDEN PA, 1992, AM J PHYSIOL, V262, pC854, DOI 10.1152/ajpcell.1992.262.4.C854; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; MOORE K, 1992, NEW ENGL J MED, V327, P1774, DOI 10.1056/NEJM199212173272502; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V214, P1260, DOI 10.1006/bbrc.1995.2422; RODBELL M, 1964, J BIOL CHEM, V239, P375; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; Satoh H, 1999, BIOCHEM BIOPH RES CO, V254, P757, DOI 10.1006/bbrc.1998.0126; Shih KC, 2000, J CELL BIOCHEM, V78, P231, DOI 10.1002/(SICI)1097-4644(20000801)78:2<231::AID-JCB6>3.0.CO;2-O; SHINOHARA O, 1992, ENDOCRINOLOGY, V130, P2031, DOI 10.1210/en.130.4.2031; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Slieker LJ, 1996, J BIOL CHEM, V271, P5301, DOI 10.1074/jbc.271.10.5301; TAKAHASHI K, 1990, DIABETOLOGIA, V33, P306, DOI 10.1007/BF00403325; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TOMITA K, 1989, NEW ENGL J MED, V321, P1127; Wang JL, 1998, NATURE, V393, P684, DOI 10.1038/31474; WEIGLE DS, 1995, J CLIN INVEST, V96, P2065, DOI 10.1172/JCI118254; Wu-Wong JSR, 1999, J BIOL CHEM, V274, P8103, DOI 10.1074/jbc.274.12.8103; Yamada H, 1998, J CARDIOVASC PHARM, V31, pS215, DOI 10.1097/00005344-199800001-00060; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YANAGISAWA M, 1994, CIRCULATION, V89, P1320, DOI 10.1161/01.CIR.89.3.1320; Zhang B, 1996, J BIOL CHEM, V271, P9455, DOI 10.1074/jbc.271.16.9455	64	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28471	28477		10.1074/jbc.M103478200	http://dx.doi.org/10.1074/jbc.M103478200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11359784	hybrid			2022-12-25	WOS:000170093400097
J	Delmolino, LM; Saha, P; Dutta, A				Delmolino, LM; Saha, P; Dutta, A			Multiple mechanisms regulate subcellular localization of human CDC6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; DNA-REPLICATION; BUDDING YEAST; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; FISSION YEAST; S-PHASE; INITIATION; PROTEINS	CDC6 is a protein essential for DNA replication, the expression and abundance of which are cell cycle-regulated in Saccharomyces cerevisiae. We have demonstrated previously that the subcellular localization of the human CDC6 homolog, HsCDC6, is cell cycle-dependent: nuclear during G(1) phase and cytoplasmic during S phase. Here we demonstrate that endogenous HsCDC6 is phosphorylated during the G(1)/S transition. The N-terminal region contains putative cyclin-dependent kinase phosphorylation sites adjoining nuclear localization sequences (NLSs) and a cyclin-docking motif, whereas the C-terminal region contains a nuclear export signal (NES). In addition, we show that the observed regulated subcellular localization depends on phosphorylation status, NLS, and NES. When the four putative substrate sites (serines 45, 54, 74, and 106) for cyclin-dependent kinases are mutated to alanines, the resulting HsCDC6A4 protein is localized predominantly to the nucleus. This localization depends upon two functional NLSs, because expression of HsCDC6 containing mutations in the two putative NLSs results in predominantly cytoplasmic distribution. Furthermore, mutation of the four serines to phosphate-mimicking aspartates (HsCDC6D4) results in strictly cytoplasmic localization. This cytoplasmic localization depends upon the C-terminal NES. Together these results demonstrate that HsCDC6 is phosphorylated at the G(1)/S phase of the cell cycle and that the phosphorylation status determines the subcellular localization.	Harvard Univ, Brigham & Womens Hosp, Dept Pathol, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Dutta, A (corresponding author), Harvard Univ, Brigham & Womens Hosp, Dept Pathol, Sch Med, Boston, MA 02115 USA.		Dutta, Anindya/P-3203-2016	Dutta, Anindya/0000-0002-4319-0073; Saha, Partha/0000-0002-4514-6391	NATIONAL CANCER INSTITUTE [R01CA060499] Funding Source: NIH RePORTER; NCI NIH HHS [CA60499] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Dhar SK, 2000, J BIOL CHEM, V275, P34983, DOI 10.1074/jbc.M006069200; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Fujita M, 1999, J BIOL CHEM, V274, P25927, DOI 10.1074/jbc.274.36.25927; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; Herbig U, 2000, MOL BIOL CELL, V11, P4117, DOI 10.1091/mbc.11.12.4117; Ishiai M, 1997, GENOMICS, V46, P294, DOI 10.1006/geno.1997.5003; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; NEWLON CS, 1993, COLD SPRING HARB SYM, V58, P415, DOI 10.1101/SQB.1993.058.01.048; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; Pinto S, 1999, NEURON, V23, P45, DOI 10.1016/S0896-6273(00)80752-7; Quintana DG, 1997, J BIOL CHEM, V272, P28247, DOI 10.1074/jbc.272.45.28247; Quintana DG, 1998, J BIOL CHEM, V273, P27137, DOI 10.1074/jbc.273.42.27137; Saha P, 1997, MOL CELL BIOL, V17, P4338, DOI 10.1128/MCB.17.8.4338; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Takahara K, 1996, GENOMICS, V31, P119, DOI 10.1006/geno.1996.0018; Takeda DY, 2001, J BIOL CHEM, V276, P1993, DOI 10.1074/jbc.M005719200; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	30	71	72	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26947	26954		10.1074/jbc.M101870200	http://dx.doi.org/10.1074/jbc.M101870200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11346650	hybrid			2022-12-25	WOS:000169966900030
J	Hu, MC; Fan, LZ; Crowder, LA; Karim-Jimenez, Z; Murer, H; Moe, OW				Hu, MC; Fan, LZ; Crowder, LA; Karim-Jimenez, Z; Murer, H; Moe, OW			Dopamine acutely stimulates Na+/H+ exchanger (NHE3) endocytosis via clathrin-coated vesicles - Dependence on protein kinase A-mediated NHE3 phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							RENAL BRUSH-BORDER; PROXIMAL CONVOLUTED TUBULE; K+-ATPASE ACTIVITY; SPONTANEOUSLY HYPERTENSIVE RATS; SODIUM-EXCRETION; NA+,K+-ATPASE ACTIVITY; PARATHYROID-HORMONE; VOLUME EXPANSION; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSPORT VESICLES	Dopamine (DA) is a key hormone in mammalian sodium homeostasis. DA induces natriuresis via acute inhibition of the renal proximal tubule apical membrane Na+/H+ exchanger NHE3. We examined the mechanism by which DA inhibits MHE3 in a renal cell line. DA acutely decreases surface NHE3 antigen in dose- and time-dependent fashion without altering total cellular NHE3. Although DA, receptor agonist alone decreases surface NHE3, simultaneous DA, agonist synergistically enhances the effect of DA,, Decreased surface NHE3 antigen, caused by stimulation of NHE3 endocytosis, is dependent on intact functioning of the GTPase dynamin and involves increased binding of NHE3 to the adaptor protein AP2, DA-stimulated NHE3 endocytosis can be blocked by pharmacologic or genetic protein kinase A inhibition or by mutation of two protein kinase A target serines (Ser-560 and Ser-613) on NRE3, We conclude that one mechanism by which DA induces natriuresis is via protein kinase A-mediated phosphorylation of proximal tubule NHE3 leading to endocytosis of NHE3 via clathrin-coated vesicles.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Dept Vet Affairs Med Ctr, Med Serv, Dallas, TX 75216 USA; Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Zurich	Moe, OW (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			KARIM, Zoubida/0000-0002-3724-5592	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK048482, R01DK048482, R01DK054396] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-48482, DK-54396] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akhter S, 2000, BIOCHEMISTRY-US, V39, P1990, DOI 10.1021/bi991739s; Albrecht FE, 2000, AM J PHYSIOL-REG I, V278, pR1064, DOI 10.1152/ajpregu.2000.278.4.R1064; ALEXANDER RW, 1974, J CLIN INVEST, V54, P194, DOI 10.1172/JCI107743; AMEMIYA M, 1995, KIDNEY INT, V48, P1206, DOI 10.1038/ki.1995.404; Amenta F, 1997, CLIN EXP HYPERTENS, V19, P27, DOI 10.3109/10641969709080802; APERIA A, 1987, AM J PHYSIOL, V252, pF39, DOI 10.1152/ajprenal.1987.252.1.F39; BAINES AD, 1980, LIFE SCI, V26, P253, DOI 10.1016/0024-3205(80)90334-3; Baines AD, 1998, J AM SOC NEPHROL, V9, P1604; BALL SG, 1977, BRIT J CLIN PHARMACO, V4, P115, DOI 10.1111/j.1365-2125.1977.tb00681.x; BARBEAU A, 1970, CAN MED ASSOC J, V103, P824; Baum M, 1998, KIDNEY INT, V54, P1593, DOI 10.1046/j.1523-1755.1998.00156.x; BELLOREUSS E, 1977, AM J PHYSIOL, V232, pF26, DOI 10.1152/ajprenal.1977.232.1.F26; BERTORELLO A, 1988, AM J PHYSIOL, V254, pF795, DOI 10.1152/ajprenal.1988.254.6.F795; BERTORELLO A, 1990, AM J HYPERTENS, V3, pS51, DOI 10.1093/ajh/3.6.51S; BERTORELLO A, 1990, AM J PHYSIOL, V259, pF924, DOI 10.1152/ajprenal.1990.259.6.F924; BERTORELLO A, 1988, ACTA PHYSIOL SCAND, V132, P441, DOI 10.1111/j.1748-1716.1988.tb08350.x; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; Biemesderfer D, 1997, AM J PHYSIOL-RENAL, V273, pF289, DOI 10.1152/ajprenal.1997.273.2.F289; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CHAN YL, 1976, J PHARMACOL EXP THER, V199, P17; CHAPMAN BJ, 1980, J PHYSIOL-LONDON, V298, P437, DOI 10.1113/jphysiol.1980.sp013093; Chow CW, 1999, J BIOL CHEM, V274, P37551, DOI 10.1074/jbc.274.53.37551; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; Collazo R, 2000, J BIOL CHEM, V275, P31601, DOI 10.1074/jbc.M000600200; CORRUZI P, 1986, CLIN SCI, V70, P523; D'Souza S, 1998, J BIOL CHEM, V273, P2035, DOI 10.1074/jbc.273.4.2035; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAVIS BB, 1968, P SOC EXP BIOL MED, V129, P210; DEFEO ML, 1987, CLIN EXP HYPERTENS A, V9, P2049, DOI 10.3109/10641968709159074; Fan LZ, 1999, J BIOL CHEM, V274, P11289, DOI 10.1074/jbc.274.16.11289; FELDER CC, 1989, KIDNEY INT, V36, P183, DOI 10.1038/ki.1989.178; FELDER CC, 1990, AM J PHYSIOL, V259, pF297, DOI 10.1152/ajprenal.1990.259.2.F297; FELDER CC, 1993, AM J PHYSIOL, V263, pF1031; FELDER RA, 1993, AM J PHYSIOL, V264, pR726, DOI 10.1152/ajpregu.1993.264.4.R726; FELDER RA, 1990, AM J HYPERTENS, V3, pS96, DOI 10.1093/ajh/3.6.96S; Ferguson SSG, 1998, SEMIN CELL DEV BIOL, V9, P119, DOI 10.1006/scdb.1997.0216; GESEK FA, 1990, AM J PHYSIOL, V258, pF514, DOI 10.1152/ajprenal.1990.258.3.F514; GLAHN RP, 1993, AM J PHYSIOL, V264, pF614; GOLDSTEIN DS, 1989, CLIN SCI, V76, P517, DOI 10.1042/cs0760517; GOTTARDI CJ, 1995, AM J PHYSIOL-RENAL, V268, pF285, DOI 10.1152/ajprenal.1995.268.2.F285; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; HAGIWARA N, 1990, JPN J PHYSIOL, V40, P351, DOI 10.2170/jjphysiol.40.351; HANSELL P, 1991, KIDNEY INT, V39, P253, DOI 10.1038/ki.1991.30; HAYASHI M, 1991, AM J PHYSIOL, V260, pE675, DOI 10.1152/ajpendo.1991.260.5.E675; HAYASHI M, 1990, AM J PHYSIOL, V258, pF28, DOI 10.1152/ajprenal.1990.258.1.F28; HEDGE SS, 1989, HYPERTENSION, V13, P828; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; HOLLENBERG NK, 1980, KIDNEY INT, V17, P423, DOI 10.1038/ki.1980.50; HOLLENBERG NK, 1973, CLIN SCI MOL MED, V45, P733, DOI 10.1042/cs0450733; HORIUCHI A, 1992, AM J PHYSIOL, V263, pF1105, DOI 10.1152/ajprenal.1992.263.6.F1105; IMURA O, 1996, JPN HEART J, V37, P815; JADHAV AL, 1992, CLIN EXP HYPERTENS A, V14, P653, DOI 10.3109/10641969209036213; Janecki AJ, 2000, J BIOL CHEM, V275, P8133, DOI 10.1074/jbc.275.11.8133; Janecki AJ, 1998, J BIOL CHEM, V273, P8790, DOI 10.1074/jbc.273.15.8790; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; JOSE PA, 1988, NEPHRON, V48, P54, DOI 10.1159/000184869; JOSE PA, 1986, AM J PHYSIOL, V250, P1033, DOI 10.1152/ajprenal.1986.250.6.F1033; Jose PA, 1996, AM J HYPERTENS, V9, P400, DOI 10.1016/0895-7061(95)00351-7; JOSE PA, 1992, J AM SOC NEPHROL, V2, P1265; Karim-Jimenez Z, 2000, P NATL ACAD SCI USA, V97, P12896, DOI 10.1073/pnas.220394197; KINOSHITA S, 1989, J CLIN INVEST, V84, P1849, DOI 10.1172/JCI114371; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; KRISHNA GG, 1985, J LAB CLIN MED, V105, P214; Kurashima K, 1999, J BIOL CHEM, V274, P29843, DOI 10.1074/jbc.274.42.29843; Kurashima K, 1997, J BIOL CHEM, V272, P28672, DOI 10.1074/jbc.272.45.28672; Kurashima K, 1998, J BIOL CHEM, V273, P20828, DOI 10.1074/jbc.273.33.20828; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; LARADI A, 1986, MINER ELECTROL METAB, V12, P303; Lederer ED, 1998, J AM SOC NEPHROL, V9, P975; LEE MR, 1993, CLIN SCI, V84, P357, DOI 10.1042/cs0840357; LEE MR, 1989, CLIN EXP HYPERTENS A, V11, P149, DOI 10.3109/10641968909045420; LOKHANDWALA MF, 1991, FASEB J, V5, P3023, DOI 10.1096/fasebj.5.15.1683844; Magyar CE, 2000, AM J PHYSIOL-RENAL, V279, pF358, DOI 10.1152/ajprenal.2000.279.2.F358; MCDONALD RH, 1964, J CLIN INVEST, V43, P1116, DOI 10.1172/JCI104996; Moe OW, 1997, CURR OPIN NEPHROL HY, V6, P440, DOI 10.1097/00041552-199709000-00006; Moe OW, 1999, J AM SOC NEPHROL, V10, P2412; MOE OW, 1995, J CLIN INVEST, V96, P2187, DOI 10.1172/JCI118273; NISHI A, 1993, HYPERTENSION, V21, P767, DOI 10.1161/01.HYP.21.6.767; Ogimoto G, 2000, P NATL ACAD SCI USA, V97, P3242, DOI 10.1073/pnas.060025597; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; OHBU K, 1995, AM J PHYSIOL-REG I, V268, pR231, DOI 10.1152/ajpregu.1995.268.1.R231; PELAYO JC, 1983, AM J PHYSIOL, V245, pF247, DOI 10.1152/ajprenal.1983.245.2.F247; Peng Y, 1999, AM J PHYSIOL-CELL PH, V276, pC938, DOI 10.1152/ajpcell.1999.276.4.C938; PERRICHOT R, 1995, BIOCHEM J, V312, P433, DOI 10.1042/bj3120433; RACZ K, 1986, CIRC RES, V58, P889; RECTOR FC, 1983, AM J PHYSIOL, V244, pF461, DOI 10.1152/ajprenal.1983.244.5.F461; ROBINSON MS, 1998, BIOCHIM BIOPHYS ACTA, V1404, P173; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SHEIKHHAMAD D, 1993, AM J PHYSIOL, V264, pF737, DOI 10.1152/ajprenal.1993.264.4.F737; SIDHU A, 1992, J CLIN INVEST, V89, P789, DOI 10.1172/JCI115657; SIMPSON FO, 1988, LANCET, V2, P25; SIRAGY HM, 1989, AM J PHYSIOL, V257, pF469, DOI 10.1152/ajprenal.1989.257.3.F469; SOWERS JR, 1984, ENDOCRINOLOGY, V115, P2085, DOI 10.1210/endo-115-6-2085; Szaszi K, 2000, J BIOL CHEM, V275, P28599, DOI 10.1074/jbc.M001193200; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; TAKEMOTO F, 1991, PFLUG ARCH EUR J PHY, V419, P243, DOI 10.1007/BF00371102; VALLEE RB, 1993, CIBA F SYMP, V176, P185; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; Wiederkehr MR, 2001, KIDNEY INT, V59, P197, DOI 10.1046/j.1523-1755.2001.00480.x; Wiederkehr MR, 1999, AM J PHYSIOL-CELL PH, V276, pC1205, DOI 10.1152/ajpcell.1999.276.5.C1205; WILLIAMS GH, 1990, AM J HYPERTENS, V3, pS112, DOI 10.1093/ajh/3.6.112S; WINAVER J, 1990, KIDNEY INT, V38, P1133, DOI 10.1038/ki.1990.323; Yang XJ, 2000, AM J PHYSIOL-CELL PH, V279, pC410, DOI 10.1152/ajpcell.2000.279.2.C410; Yip KP, 1998, AM J PHYSIOL-RENAL, V275, pF565, DOI 10.1152/ajprenal.1998.275.4.F565; YOSHIDA Y, 1990, CHIRALITY, V2, P10, DOI 10.1002/chir.530020103; Zhang YB, 1996, AM J PHYSIOL-RENAL, V270, pF1004, DOI 10.1152/ajprenal.1996.270.6.F1004; Zhang YB, 1999, AM J PHYSIOL-RENAL, V276, pF711, DOI 10.1152/ajprenal.1999.276.5.F711; Zhang YB, 1998, AM J PHYSIOL-CELL PH, V274, pC1090, DOI 10.1152/ajpcell.1998.274.4.C1090; Zhang YBB, 1998, J AM SOC NEPHROL, V9, P531; Zhao H, 1999, J BIOL CHEM, V274, P3978, DOI 10.1074/jbc.274.7.3978; Zhu YX, 1999, MOL BIOL CELL, V10, P537, DOI 10.1091/mbc.10.3.537	114	120	119	4	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26906	26915		10.1074/jbc.M011338200	http://dx.doi.org/10.1074/jbc.M011338200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11328806	hybrid, Green Accepted			2022-12-25	WOS:000169966900025
J	Sakamoto, N; Ohshima, K; Montermini, L; Pandolfo, M; Wells, RD				Sakamoto, N; Ohshima, K; Montermini, L; Pandolfo, M; Wells, RD			Sticky DNA, a self-associated complex formed at long GAA center dot TTC repeats in intron 1 of the frataxin gene, inhibits transcriptions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRIEDREICH ATAXIA GENE; ELONGATION IN-VITRO; RNA-POLYMERASE; BINDING PROTEIN; STRANDED DNA; CIRCULAR DNA; EXPRESSION; EXPANSION; SEQUENCES; PATHOGENESIS	Friedreich's ataxia (FRDA) is an autosomal recessive neurodegenerative disease caused by the expansion of GAA.TTC repeats in the first intron of the frataxin (X25) gene. FRDA patients carrying two expanded GAA.TTC repeats show very low levels of mature frataxin mRNA and protein. A novel type of unusual DNA structure, sticky DNA, was previously found in the expanded GAA.TTC repeats from FRDA patients, To evaluate the effect of sticky DNA on transcription, in vitro transcription studies of (GAA.TTC), repeats (where n = 9-150) were carried out using T7 or SP6 RNA polymerase, When a gel-isolated sticky DNA template was transcribed, the amount of full-length RNA synthesized was significantly reduced compared with the transcription of the linear template, Surprisingly, transcriptional inhibition was observed not only for the sticky DNA template but also another DNA molecule used as an internal control in an orientation-independent manner. The molecular mechanism of transcriptional inhibition by sticky DNA was a sequestration of the RNA polymerases by direct binding to the complex DNA structure. Moreover, plasmids containing the (GAAGGA.TCCTTC)(65) repeat, which does not form sticky DNA, did not inhibit in vitro transcription, as expected. These results suggest that the role of sticky DNA in FRDA may be the sequestration of transcription factors.	Texas A&M Univ, Inst Biosci & Technol, Ctr Genome Res, Texas Med Ctr, Houston, TX 77030 USA; Ctr Hosp Univ Montreal, Montreal, PQ H2L 4M1, Canada	Baylor College of Medicine; Texas A&M University System; Universite de Montreal	Wells, RD (corresponding author), Texas A&M Univ, Inst Biosci & Technol, Ctr Genome Res, Texas Med Ctr, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	rwells@ibt.tamu.edu	Pandolfo, Massimo/B-2853-2010		NIGMS NIH HHS [GM52982] Funding Source: Medline; NINDS NIH HHS [NS37554, NS34192] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034192, R01NS037554] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ashley C, 2000, DNA CELL BIOL, V19, P235, DOI 10.1089/104454900314500; Bidichandani SI, 1998, AM J HUM GENET, V62, P111, DOI 10.1086/301680; Bidichandani SI, 1997, AM J HUM GENET, V60, P1251; BUTLER ET, 1982, J BIOL CHEM, V257, P5772; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Campuzano V, 1997, HUM MOL GENET, V6, P1771, DOI 10.1093/hmg/6.11.1771; Chen S, 1997, MOL ENDOCRINOL, V11, P3, DOI 10.1210/me.11.1.3; Cossee M, 1997, NAT GENET, V15, P337, DOI 10.1038/ng0497-337; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; Delatycki MB, 2000, J MED GENET, V37, P1, DOI 10.1136/jmg.37.1.1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Durr A, 1996, NEW ENGL J MED, V335, P1169, DOI 10.1056/NEJM199610173351601; Epplen C, 1997, HUM GENET, V99, P834, DOI 10.1007/s004390050458; Filla A, 1996, AM J HUM GENET, V59, P554; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; FUJITA R, 1989, GENOMICS, V4, P110, DOI 10.1016/0888-7543(89)90323-6; Giovannangeli C, 1996, J MOL BIOL, V261, P386, DOI 10.1006/jmbi.1996.0471; Grabczyk E, 2000, NUCLEIC ACIDS RES, V28, P2815, DOI 10.1093/nar/28.14.2815; Gray JV, 1997, NAT GENET, V16, P323, DOI 10.1038/ng0897-323; GRIGORIEV M, 1993, P NATL ACAD SCI USA, V90, P3501, DOI 10.1073/pnas.90.8.3501; HAMPEL KJ, 1993, BIOCHEMISTRY-US, V32, P1072, DOI 10.1021/bi00055a012; HANAUER A, 1990, AM J HUM GENET, V46, P133; Jimenez-Garcia E, 1998, J BIOL CHEM, V273, P24640, DOI 10.1074/jbc.273.38.24640; Kaplan J, 1999, P NATL ACAD SCI USA, V96, P10948, DOI 10.1073/pnas.96.20.10948; KOHWI Y, 1991, GENE DEV, V5, P2547, DOI 10.1101/gad.5.12b.2547; Kovacs A, 1996, J BIOL CHEM, V271, P1805, DOI 10.1074/jbc.271.3.1805; LEE JS, 1995, J MOL BIOL, V252, P283, DOI 10.1006/jmbi.1995.0495; Mariappan SVS, 1999, J MOL BIOL, V285, P2035, DOI 10.1006/jmbi.1998.2435; Montermini L, 1997, ANN NEUROL, V41, P675, DOI 10.1002/ana.410410518; Montermini L, 1997, HUM MOL GENET, V6, P1261, DOI 10.1093/hmg/6.8.1261; MORGAN AR, 1968, J MOL BIOL, V37, P63, DOI 10.1016/0022-2836(68)90073-9; Nelson LD, 2000, J BIOL CHEM, V275, P5573, DOI 10.1074/jbc.275.8.5573; NISHIMURA S, 1965, J MOL BIOL, V13, P302, DOI 10.1016/S0022-2836(65)80098-5; OAKLEY JL, 1975, BIOCHEMISTRY-US, V14, P4684, DOI 10.1021/bi00692a019; Ohshima K, 1998, J BIOL CHEM, V273, P14588, DOI 10.1074/jbc.273.23.14588; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; Ohshima K, 1999, NEUROLOGY, V53, P1854, DOI 10.1212/WNL.53.8.1854; Pandolfo M, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P373; Puccio H, 2000, HUM MOL GENET, V9, P887, DOI 10.1093/hmg/9.6.887; Sakamoto N, 1999, MOL CELL, V3, P465, DOI 10.1016/S1097-2765(00)80474-8; Sambrook J., 2002, MOL CLONING LAB MANU; SARKAR PS, 1992, NUCLEIC ACIDS RES, V20, P5713, DOI 10.1093/nar/20.21.5713; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; Soyfer V.N., 1996, TRIPLE HELICAL NUCL; Vasquez KM, 1998, TRENDS BIOCHEM SCI, V23, P4, DOI 10.1016/S0968-0004(97)01158-4; Wells R.D., 1998, GENETIC INSTABILITIE; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; YOUNG SL, 1991, P NATL ACAD SCI USA, V88, P10023, DOI 10.1073/pnas.88.22.10023	48	141	146	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27171	27177		10.1074/jbc.M101879200	http://dx.doi.org/10.1074/jbc.M101879200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11340071	hybrid			2022-12-25	WOS:000169966900060
J	Shu, WG; Yang, HH; Zhang, LL; Lu, MM; Morrisey, EE				Shu, WG; Yang, HH; Zhang, LL; Lu, MM; Morrisey, EE			Characterization of a new subfamily of winged-helix/forkhead (Fox) genes that are expressed in the lung and act as transcriptional repressors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACTANT PROTEIN-B; HEPATOCYTE NUCLEAR FACTOR-3-BETA; GATA-6 ACTIVATES TRANSCRIPTION; DEVELOPING MOUSE LUNG; FACTOR-I; RESPIRATORY EPITHELIUM; TRANSGENIC MICE; CELL LINEAGES; SPINAL-CORD; FORK HEAD	Epithelial gene expression in the lungis thought to be regulated by the coordinate activity of several different families of transcription factors including the Fox family of winged-helix/forkhead DNA-binding proteins. In this report, we have identified and characterized two members of this Fox gene family Foxp1 and Foxp2, and show that they comprise a new subfamily of Fox genes expressed in the lung, Foxp1 and Foxp2 are expressed at high levels in the lung as early as E12.5 of mouse development with Foxp2 expression restricted to the airway epithelium. In addition, Foxp1 and Foxp2 are expressed at lower levels in neural, intestinal, and cardiovascular tissues during development. Upon differentiation of the airway epithelium along the proximal-distal axis, Foxp2 expression becomes restricted to the distal alveolar epithelium whereas Foxp1 expression is observed in the distal epithelium and mesenchyme. Foxp1 and Foxp2 can regulate epithelial lung gene transcription as was demonstrated by their ability to dramatically repress the mouse CC10 promoter and, to a lesser extent, the human surfactant protein C promoter. In addition, GAL4 fusion proteins encoding subdomains of Foxp1 and Foxp2 demonstrate that an independent and homologous transcriptional repression domain lies within the N-terminal end of the proteins. Together, these studies suggest that Foxp1 and Foxp2 are important regulators of lung epithelial gene transcription.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Morrisey, EE (corresponding author), Univ Penn, Dept Med, 953 BRB II-III,421 Curie Blvd, Philadelphia, PA 19104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064632] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL64632] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aitola M, 2000, DEV DYNAM, V218, P136, DOI 10.1002/(SICI)1097-0177(200005)218:1<136::AID-DVDY12>3.0.CO;2-U; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Bruno MD, 2000, J BIOL CHEM, V275, P1043, DOI 10.1074/jbc.275.2.1043; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; Chen JC, 1998, J CLIN INVEST, V102, P1077, DOI 10.1172/JCI4786; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; Hao ZL, 1999, DEV DYNAM, V216, P201, DOI 10.1002/(SICI)1097-0177(199910)216:2<201::AID-DVDY10>3.0.CO;2-6; He GP, 1999, J BIOL CHEM, V274, P14678, DOI 10.1074/jbc.274.21.14678; Hellqvist M, 1996, J BIOL CHEM, V271, P4482; Hoch M, 1996, MECH DEVELOP, V58, P3, DOI 10.1016/S0925-4773(96)00541-2; Iida K, 1997, DEVELOPMENT, V124, P4627; Ikeda K, 1996, MOL CELL BIOL, V16, P3626; Kaestner KH, 1997, GENE DEV, V11, P1583, DOI 10.1101/gad.11.12.1583; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Kelly SE, 1996, J BIOL CHEM, V271, P6881, DOI 10.1074/jbc.271.12.6881; LICHT JD, 1994, MOL CELL BIOL, V14, P4057, DOI 10.1128/MCB.14.6.4057; MADDEN SL, 1993, ONCOGENE, V8, P1713; Margana RK, 1997, J BIOL CHEM, V272, P3083, DOI 10.1074/jbc.272.5.3083; Matise MP, 1997, J NEUROSCI, V17, P7805; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1997, J BIOL CHEM, V272, P8515, DOI 10.1074/jbc.272.13.8515; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; Motoyama J, 1998, NAT GENET, V20, P54, DOI 10.1038/1711; Perrone L, 2000, BIOCHEM BIOPH RES CO, V275, P203, DOI 10.1006/bbrc.2000.3232; RAY MK, 1993, BIOCHEM BIOPH RES CO, V197, P163, DOI 10.1006/bbrc.1993.2455; RAY MK, 1995, J BIOL CHEM, V270, P2689, DOI 10.1074/jbc.270.6.2689; Ray MK, 1996, MOL CELL BIOL, V16, P2056; SAWAYA PL, 1993, MOL CELL BIOL, V13, P3860, DOI 10.1128/MCB.13.7.3860; Shaw-White JR, 1999, J BIOL CHEM, V274, P2658, DOI 10.1074/jbc.274.5.2658; SOLWAY J, 1995, J BIOL CHEM, V270, P13460, DOI 10.1074/jbc.270.22.13460; Sutton J, 1996, J BIOL CHEM, V271, P23126, DOI 10.1074/jbc.271.38.23126; Svensson EC, 2000, J BIOL CHEM, V275, P20762, DOI 10.1074/jbc.M001522200; Tichelaar JW, 1999, J HISTOCHEM CYTOCHEM, V47, P823, DOI 10.1177/002215549904700612; Tichelaar JW, 1999, DEV BIOL, V213, P405, DOI 10.1006/dbio.1999.9380; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; Warburton D, 2000, MECH DEVELOP, V92, P55, DOI 10.1016/S0925-4773(99)00325-1; Warburton D, 1998, BIOCHEM CELL BIOL, V76, P971, DOI 10.1139/bcb-76-6-971; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; Winnier GE, 1999, DEV BIOL, V213, P418, DOI 10.1006/dbio.1999.9382; Xiao H, 1998, J BIOL CHEM, V273, P22873, DOI 10.1074/jbc.273.36.22873; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; Zhou L, 1997, DEV DYNAM, V210, P305, DOI 10.1002/(SICI)1097-0177(199711)210:3<305::AID-AJA10>3.0.CO;2-9; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084	47	270	284	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27488	27497		10.1074/jbc.M100636200	http://dx.doi.org/10.1074/jbc.M100636200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11358962	hybrid			2022-12-25	WOS:000169966900100
J	Cavaille, J; Vitali, P; Basyuk, E; Huttenhofer, A; Bachellerie, JP				Cavaille, J; Vitali, P; Basyuk, E; Huttenhofer, A; Bachellerie, JP			A novel brain-specific box C/D small nucleolar RNA processed from tandemly repeated introns of a noncoding RNA gene in rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNORNA HOST GENE; 2'-O-RIBOSE METHYLATION; RIBOSE METHYLATION; MESSENGER-RNA; TRYPANOSOMA-BRUCEI; ENCODED U16; GUIDE RNA; COMPLEMENTARITIES; TRANSCRIPT; LONG	Antisense box C/D small nucleolar RNAs (snoRNAs) guide the 2 ' -O-ribose methylations of eukaryotic rRNAs and small nuclear RNAs (snRNAs) through formation of a specific base pairing at each RNA methylation site. By analysis of a box C/D snoRNA cDNA library constructed from rat brain RNAs, we have identified a novel box C/D snoRNA, RBII-36, which is devoid of complementarity to rRNA or an snRNA and exhibits a brain-specific expression pattern. It is uniformly expressed in all major areas of adult rat brain (except for choroid plexus) and throughout rat brain ontogeny but exclusively detected in neurons in which it exhibits a nucleolar localization. In vertebrates, known methylation guide snoRNAs are intron-encoded and processed from transcripts of housekeeping genes. In contrast, RBII-36 snoRNA is intron-encoded in a gene preferentially expressed in the rat central nervous system and not in proliferating cells. Remarkably, this host gene, which encodes a previously reported noncoding RNA, Bar, spans tandemly repeated 0.9-kilobase units including the snoRNA-containing intron. The novel brain-specific snoRNA appears to result not only from processing of the debranched lariat but also from endonucleolytic cleavages of unspliced Bar RNA (i.e. an alternative splicing-independent pathway unreported so far for mammalian intronic snoRNAs), Sequences homologous to RBII-36 snoRNA were exclusively detected in the Rattus genus of rodents, suggesting a very recent origin of this brain-specific snoRNA.	Univ Toulouse 3, UMR5099, Lab Biol Mol Eucaryote, CNRS, F-31062 Toulouse, France; CNRS, UPR 9023, F-34094 Montpellier 05, France; Zentrum Mol Biol Entzundung, Inst Expt Pathol, D-48149 Munster, Germany	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Cavaille, J (corresponding author), Univ Toulouse 3, UMR5099, Lab Biol Mol Eucaryote, CNRS, 118 Route de Narbonne, F-31062 Toulouse, France.	cavaille@ibcg.biotoul.fr; bachel@ibcg.biotoul.fr	cavaille, jerome/AAM-8047-2020	vitali, patrice/0000-0001-8178-9004; CAVAILLE, Jerome/0000-0003-2833-6836; Basyuk, Eugenia/0000-0001-9768-4557				Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; ARMOFONSECA M, 2000, NAT CELL BIOL, V2, pE107; Bachellerie JP, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P191; BACHELLERIE JP, 1995, TRENDS BIOCHEM SCI, V20, P261, DOI 10.1016/S0968-0004(00)89039-8; Bachellerie JP, 1997, TRENDS BIOCHEM SCI, V22, P257, DOI 10.1016/S0968-0004(97)01057-8; Balakin AG, 1996, CELL, V86, P823, DOI 10.1016/S0092-8674(00)80156-7; Basyuk E, 2000, Nucleic Acids Res, V28, pE46, DOI 10.1093/nar/28.10.e46; Bortolin ML, 1998, RNA, V4, P445; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; Caffarelli E, 1996, EMBO J, V15, P1121, DOI 10.1002/j.1460-2075.1996.tb00450.x; CAFFARELLI E, 1994, MOL CELL BIOL, V14, P2966, DOI 10.1128/MCB.14.5.2966; Cavaille J, 1996, NATURE, V383, P732, DOI 10.1038/383732a0; Cavaille J, 1998, NUCLEIC ACIDS RES, V26, P1576, DOI 10.1093/nar/26.7.1576; Cavaille J, 1996, BIOCHIMIE, V78, P443, DOI 10.1016/0300-9084(96)84751-1; Cavaille J, 2000, P NATL ACAD SCI USA, V97, P14311, DOI 10.1073/pnas.250426397; Chanfreau G, 1998, J MOL BIOL, V284, P975, DOI 10.1006/jmbi.1998.2237; Chanfreau G, 1998, EMBO J, V17, P3726, DOI 10.1093/emboj/17.13.3726; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; de los Santos T, 2000, AM J HUM GENET, V67, P1067, DOI 10.1086/303106; Dunbar DA, 2000, NUCLEIC ACIDS RES, V28, P2855, DOI 10.1093/nar/28.15.2855; Dunbar DA, 2000, J BIOL CHEM, V275, P14767, DOI 10.1074/jbc.M001180200; Fatica A, 2000, EMBO J, V19, P6218, DOI 10.1093/emboj/19.22.6218; FRAGAPANE P, 1993, EMBO J, V12, P2921, DOI 10.1002/j.1460-2075.1993.tb05954.x; Ganot P, 1999, MOL CELL BIOL, V19, P6906; Gaspin C, 2000, J MOL BIOL, V297, P895, DOI 10.1006/jmbi.2000.3593; Huttenhofer A, 2001, EMBO J, V20, P2943, DOI 10.1093/emboj/20.11.2943; Jady BE, 2000, NUCLEIC ACIDS RES, V28, P1348, DOI 10.1093/nar/28.6.1348; Jady BE, 2001, EMBO J, V20, P541, DOI 10.1093/emboj/20.3.541; Kelley RL, 2000, CELL, V103, P9, DOI 10.1016/S0092-8674(00)00099-4; KISS T, 1995, GENE DEV, V9, P1411, DOI 10.1101/gad.9.11.1411; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; KLOC M, 1994, SCIENCE, V265, P1101, DOI 10.1126/science.7520603; Komine Y, 1999, MOL BRAIN RES, V66, P1, DOI 10.1016/S0169-328X(98)00343-X; Leader DJ, 1997, EMBO J, V16, P5742, DOI 10.1093/emboj/16.18.5742; Leader DJ, 1999, PLANT MOL BIOL, V39, P1091, DOI 10.1023/A:1006157022319; Liang-Hu Qu, 2001, Nucleic Acids Research, V29, P1623, DOI 10.1093/nar/29.7.1623; Maden B E, 1990, Prog Nucleic Acid Res Mol Biol, V39, P241, DOI 10.1016/S0079-6603(08)60629-7; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; NEUMANN B, 1995, NAT GENET, V9, P12, DOI 10.1038/ng0195-12; Nicoloso M, 1996, J MOL BIOL, V260, P178, DOI 10.1006/jmbi.1996.0391; Omer AD, 2000, SCIENCE, V288, P517, DOI 10.1126/science.288.5465.517; Ooi SL, 1998, RNA, V4, P1096, DOI 10.1017/S1355838298980785; Paul MS, 1998, EMBO J, V17, P1120, DOI 10.1093/emboj/17.4.1120; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; Pelczar P, 1998, MOL CELL BIOL, V18, P4509, DOI 10.1128/MCB.18.8.4509; QU LH, 1995, NUCLEIC ACIDS RES, V23, P2669, DOI 10.1093/nar/23.14.2669; QU LH, 1994, NUCLEIC ACIDS RES, V22, P4073, DOI 10.1093/nar/22.20.4073; Qu LH, 1999, MOL CELL BIOL, V19, P1144; Roberts TG, 1998, MOL CELL BIOL, V18, P4409, DOI 10.1128/MCB.18.8.4409; Samarsky DA, 1998, EMBO J, V17, P3747, DOI 10.1093/emboj/17.13.3747; Sleutels F, 2000, CURR OPIN GENET DEV, V10, P229, DOI 10.1016/S0959-437X(00)00062-9; Smith CM, 1998, MOL CELL BIOL, V18, P6897, DOI 10.1128/MCB.18.12.6897; Smith CM, 1997, CELL, V89, P669, DOI 10.1016/S0092-8674(00)80247-0; SOLLNERWEBB B, 1993, CELL, V75, P403, DOI 10.1016/0092-8674(93)90374-Y; Tanaka R, 2000, GENES CELLS, V5, P277, DOI 10.1046/j.1365-2443.2000.00325.x; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; TYCOWSKI KT, 1993, GENE DEV, V7, P1176, DOI 10.1101/gad.7.7a.1176; Tycowski KT, 1998, MOL CELL, V2, P629, DOI 10.1016/S1097-2765(00)80161-6; Tycowski KT, 1996, NATURE, V379, P464, DOI 10.1038/379464a0; Van Hoof A, 2000, MOL CELL BIOL, V20, P441, DOI 10.1128/MCB.20.2.441-452.2000; Verneau O, 1997, J MOL EVOL, V45, P424, DOI 10.1007/PL00006247; Villa T, 2000, MOL CELL BIOL, V20, P1311, DOI 10.1128/MCB.20.4.1311-1320.2000; Villa T, 1998, MOL CELL BIOL, V18, P3376, DOI 10.1128/MCB.18.6.3376; Wevrick R, 1997, HUM MOL GENET, V6, P325, DOI 10.1093/hmg/6.2.325; Yi-Brunozzi HY, 1999, NUCLEIC ACIDS RES, V27, P2912, DOI 10.1093/nar/27.14.2912	66	61	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26374	26383		10.1074/jbc.M103544200	http://dx.doi.org/10.1074/jbc.M103544200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11346658	hybrid			2022-12-25	WOS:000169823300097
J	Dong, H; Light, PE; French, RJ; Lytton, J				Dong, H; Light, PE; French, RJ; Lytton, J			Electrophysiological characterization and ionic stoichiometry of the rat brain K+-dependent Na+/Ca2+ exchanger, NCKX2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGE; ROD OUTER SEGMENTS; NA-CA EXCHANGER; FUNCTIONAL EXPRESSION; NA+-CA2+ EXCHANGE; DYNAMIC PROPERTIES; MOLECULAR-CLONING; RETINAL CONE; STEADY-STATE; TRANSPORT	We have recently described a novel K+-dependent Na+/Ca2+ exchanger, NCKX2, that is abundantly expressed in brain neurons (Tsoi, M,, Rhee, IL-H., Bungard, D,, Li, X-F,, Lee, S,-L,, Auer, R, N,, and Lytton, J, (1998) J, Biol, Chem, 273, 4115-4162), The precise role for NCKX2 in neuronal Ca2+ homeostasis is not yet clearly understood but will depend upon the functional properties of the molecule. Here, we have performed whole-cell patch clamp analysis to characterize cation dependences and ion stoichiometry for rat brain NCKX2, heterologously expressed in HEK293 cells. Outward currents generated by reverse NCKX2 exchange depended on external Ca2+ with a K-1/2 of 1.4 or 101 muM without or with 1 mM Mg2+, and on external K+ with a K-1/2 of about 12 or 36 mM with choline or Li+ as counter ion, respectively. Na+ inhibited outward currents with a K-1/2 of about 60 mM, Inward currents generated by forward NCKX2 exchange depended upon external Na+ with a K-1/2 of 30 mM and a Hill coefficient of 2.8. K+ inhibited the inward currents by a maximum of 40%, with a K-1/2 of 2 mM or less, depending upon the conditions. The transport stoichiometry of NCKX2 was determined by observing the change in reversal potential as individual ion gradients were altered. Our data support a stoichiometry for rat brain NCKX2 of 4 Na+:(1 Ca2+ + 1 K+), These findings provide the first electrophysiological characterization of rat brain NCKX2, and the first evidence that a single recombinantly expressed NCKX polypeptide encodes a K+-transporting Na+/Ca2+ exchanger with a transport stoichiometry of 4 Na+:(1 Ca2+ + 1 K+).	Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary	Lytton, J (corresponding author), Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	jlytton@ucalgary.ca		Lytton, Jonathan/0000-0003-4770-2512				Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; CERVETTO L, 1989, NATURE, V337, P740, DOI 10.1038/337740a0; COOK NJ, 1988, J BIOL CHEM, V263, P11382; Cooper CB, 1999, BIOCHEMISTRY-US, V38, P6276, DOI 10.1021/bi983068o; DAHAN D, 1991, J BIOL CHEM, V266, P2067; EHARA T, 1989, J PHYSIOL-LONDON, V410, P227, DOI 10.1113/jphysiol.1989.sp017530; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FONTANA G, 1995, J PHYSIOL-LONDON, V485, P349, DOI 10.1113/jphysiol.1995.sp020734; FRIEDEL U, 1991, BIOCHIM BIOPHYS ACTA, V1061, P247, DOI 10.1016/0005-2736(91)90290-O; Fujioka Y, 2000, J PHYSIOL-LONDON, V523, P339, DOI 10.1111/j.1469-7793.2000.t01-2-00339.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Haug-Collet K, 1999, J CELL BIOL, V147, P659, DOI 10.1083/jcb.147.3.659; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P933, DOI 10.1085/jgp.100.6.933; KIMURA J, 1987, J PHYSIOL-LONDON, V384, P199, DOI 10.1113/jphysiol.1987.sp016450; KIMURA M, 1993, J BIOL CHEM, V268, P6874; Kimura M, 1999, AM J PHYSIOL-HEART C, V277, pH911, DOI 10.1152/ajpheart.1999.277.3.H911; KOFUJI P, 1992, AM J PHYSIOL, V263, pC1241, DOI 10.1152/ajpcell.1992.263.6.C1241; KRAEV A, 2001, IN PRESS J BIOL CHEM, V276; LEE SL, 1994, J BIOL CHEM, V269, P14849; LI ZP, 1994, J BIOL CHEM, V269, P17434; Lytton J, 2001, BIOPHYS J, V80, p18A; MARLIER LNJL, 1993, MOL BRAIN RES, V20, P21, DOI 10.1016/0169-328X(93)90107-Z; MATSUOKA S, 1992, J GEN PHYSIOL, V100, P963, DOI 10.1085/jgp.100.6.963; MIURA Y, 1989, J GEN PHYSIOL, V93, P1129, DOI 10.1085/jgp.93.6.1129; Navangione A, 1997, BIOPHYS J, V73, P45, DOI 10.1016/S0006-3495(97)78046-9; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; Philipson KD, 2000, ANNU REV PHYSIOL, V62, P111, DOI 10.1146/annurev.physiol.62.1.111; Prinsen CFM, 2000, J NEUROSCI, V20, P1424; Ransom CB, 2000, J PHYSIOL-LONDON, V522, P427, DOI 10.1111/j.1469-7793.2000.00427.x; REILANDER H, 1992, EMBO J, V11, P1689, DOI 10.1002/j.1460-2075.1992.tb05219.x; SCHNETKAMP PPM, 1991, J GEN PHYSIOL, V98, P555, DOI 10.1085/jgp.98.3.555; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P189; SCHNETKAMP PPM, 1995, AM J PHYSIOL-CELL PH, V269, pC1153, DOI 10.1152/ajpcell.1995.269.5.C1153; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P22975; SCHNETKAMP PPM, 1989, AM J PHYSIOL, V257, pC153, DOI 10.1152/ajpcell.1989.257.1.C153; SCHNETKAMP PPM, 1995, CELL CALCIUM, V18, P322, DOI 10.1016/0143-4160(95)90028-4; SCHNETKAMP PPM, 1986, J PHYSIOL-LONDON, V373, P25, DOI 10.1113/jphysiol.1986.sp016033; Schwarz EM, 1997, P NATL ACAD SCI USA, V94, P10249, DOI 10.1073/pnas.94.19.10249; Seiler EP, 2000, EUR J BIOCHEM, V267, P2461, DOI 10.1046/j.1432-1327.2000.01279.x; Sheng JZ, 2000, BIOPHYS J, V79, P1945, DOI 10.1016/S0006-3495(00)76443-5; SLAUGHTER RS, 1983, J BIOL CHEM, V258, P3183; Szerencsei RT, 2000, J BIOL CHEM, V275, P669, DOI 10.1074/jbc.275.1.669; Tsoi M, 1998, J BIOL CHEM, V273, P4155, DOI 10.1074/jbc.273.7.4155; Yu L, 1997, MOL BRAIN RES, V50, P285, DOI 10.1016/S0169-328X(97)00202-7	47	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25919	25928		10.1074/jbc.M103401200	http://dx.doi.org/10.1074/jbc.M103401200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11342562	hybrid			2022-12-25	WOS:000169823300039
J	Eguchi, A; Akuta, T; Okuyama, H; Senda, T; Yokoi, H; Inokuchi, H; Fujita, S; Hayakawa, T; Takeda, K; Hasegawa, M; Nakanishi, M				Eguchi, A; Akuta, T; Okuyama, H; Senda, T; Yokoi, H; Inokuchi, H; Fujita, S; Hayakawa, T; Takeda, K; Hasegawa, M; Nakanishi, M			Protein transduction domain of HIV-1 Tat protein promotes efficient delivery of DNA into mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-TRANSFER; BASIC DOMAIN; BACTERIOPHAGE; BINDING; PHAGE; MEMBRANE; PEPTIDE; DISPLAY; SURFACE; INTERNALIZATION	The plasma membrane of mammalian cells is one of the tight barriers against gene transfer by synthetic delivery systems. Various agents have been used to facilitate gene transfer by destabilizing the endosomal membrane under acidic conditions, but their utility is limited, especially for gene transfer in vivo, In this article, we report that the protein transduction domain of human immunodeficiency virus type 1 Tat protein (Tat peptide) greatly facilitates gene transfer via membrane destabilization, We constructed recombinant h phage particles displaying Tat peptide on their surfaces and carrying mammalian marker genes as part of their genomes (Tat-phage), We demonstrate that, when animal cells are briefly exposed to Tat-phage, significant expression of phage marker genes is induced with no harmful effects to the cells. In contrast, recombinant phage displaying other functional peptides, such as the integrin-binding domain or a nuclear localization signal, could not induce detectable marker gene expression. The expression of marker genes induced by Tat-phage is not affected by endosomotropic agents but is partially impaired by inhibitors of caveolae formation. These data suggest that Tat peptide will become a useful component of synthetic delivery vehicles that promote gene transfer independently of the classical endocytic pathway.	Osaka Univ, Dept Neurovirol, Res Inst Microbial Dis, Suita, Osaka 5650871, Japan; DNAVEC Res Inc, Tsukuba, Ibaraki 3050856, Japan; Tanabe Seiyaku Co Ltd, Discovery Res Lab, Osaka 5328505, Japan; Sumitomo Pharmaceut Co Ltd, Osaka 5540022, Japan; Fujita Hlth Univ, Sch Med, Dept Anat 1, Toyoake, Aichi 47011, Japan; Kyowa Hakko Kogyo Co Ltd, Machida, Tokyo 1940023, Japan; Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan; Osaka Univ, Sch Med, Dept Surg 1, Suita, Osaka 5650871, Japan; Natl Inst Hlth Sci, Dept Biochem & Biol, Tokyo 1588501, Japan; Natl Inst Adv Ind Sci & Technol, Gene Discovery Res Ctr, Tsukuba, Ibaraki 3058566, Japan	Osaka University; DNAVEC Corporation; Mitsubishi Tanabe Pharma Corporation; Fujita Health University; Kyowa Kirin Ltd; Kyoto University; Osaka University; National Institute of Health Sciences - Japan; National Institute of Advanced Industrial Science & Technology (AIST)	Nakanishi, M (corresponding author), Osaka Univ, Dept Neurovirol, Res Inst Microbial Dis, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.	mahito@biken.osaka-u.ac.jp	Eguchi, Akiko/E-3086-2010; Nakanishi, Mahito/I-9888-2018	Nakanishi, Mahito/0000-0002-7068-7587				ALLINQUANT B, 1995, J CELL BIOL, V128, P919, DOI 10.1083/jcb.128.5.919; Anderson HA, 1996, MOL BIOL CELL, V7, P1825, DOI 10.1091/mbc.7.11.1825; Arber W., 1983, LAMBDA, P433; CAMPBELL A, 1961, VIROLOGY, V14, P22, DOI 10.1016/0042-6822(61)90128-3; COTTEN M, 1990, P NATL ACAD SCI USA, V87, P4033, DOI 10.1073/pnas.87.11.4033; COTTEN M, 1999, COLD SPRING HARBOR M, V36, P261; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; DANG CV, 1989, J BIOL CHEM, V264, P18019; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Dunn IS, 1996, GENE, V183, P15, DOI 10.1016/S0378-1119(96)00400-3; Dunn IS, 1996, BIOCHIMIE, V78, P856, DOI 10.1016/S0300-9084(97)84338-6; Efthymiadis A, 1998, J BIOL CHEM, V273, P1623, DOI 10.1074/jbc.273.3.1623; Eguchi A, 2000, J BIOL CHEM, V275, P17549, DOI 10.1074/jbc.M910004199; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Georgopoulos C., 1983, LAMBDA 2, P279; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Harbottle RP, 1998, HUM GENE THER, V9, P1037, DOI 10.1089/hum.1998.9.7-1037; HART SL, 1994, J BIOL CHEM, V269, P12468; Houshmand H, 1999, ANAL BIOCHEM, V268, P363, DOI 10.1006/abio.1998.3076; JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864; Kasamatsu H, 1998, ANNU REV MICROBIOL, V52, P627, DOI 10.1146/annurev.micro.52.1.627; Kassner PD, 1999, BIOCHEM BIOPH RES CO, V264, P921, DOI 10.1006/bbrc.1999.1603; KATAHIRA J, 1995, J VIROL, V69, P3125, DOI 10.1128/JVI.69.5.3125-3133.1995; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Larocca D, 1998, HUM GENE THER, V9, P2393, DOI 10.1089/hum.1998.9.16-2393; Larocca D, 1999, FASEB J, V13, P727, DOI 10.1096/fasebj.13.6.727; LEVENTIS R, 1990, BIOCHIM BIOPHYS ACTA, V1023, P124, DOI 10.1016/0005-2736(90)90017-I; Lewin M, 2000, NAT BIOTECHNOL, V18, P410, DOI 10.1038/74464; Lin JT, 1999, MOL CELL BIOL, V19, P3237; Liu Y, 2000, NAT MED, V6, P1380, DOI 10.1038/82199; Luo D, 2000, NAT BIOTECHNOL, V18, P33, DOI 10.1038/71889; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; MARUYAMA IN, 1994, P NATL ACAD SCI USA, V91, P8273, DOI 10.1073/pnas.91.17.8273; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Mikawa YG, 1996, J MOL BIOL, V262, P21; Mizuguchi H, 1996, BIOCHEM BIOPH RES CO, V218, P402, DOI 10.1006/bbrc.1996.0070; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Okabe J, 2000, HUM MOL GENET, V9, P2639, DOI 10.1093/hmg/9.18.2639; OKAYAMA H, 1985, MOL CELL BIOL, V5, P1136, DOI 10.1128/MCB.5.5.1136; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Pouton CW, 1998, J CONTROL RELEASE, V53, P289, DOI 10.1016/S0168-3659(98)00015-7; Rusnati M, 1998, J BIOL CHEM, V273, P16027, DOI 10.1074/jbc.273.26.16027; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Simpson JC, 1998, EXP CELL RES, V239, P293, DOI 10.1006/excr.1997.3921; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; STERNBERG N, 1977, J MOL BIOL, V117, P733, DOI 10.1016/0022-2836(77)90067-5; STERNBERG N, 1995, P NATL ACAD SCI USA, V92, P1609, DOI 10.1073/pnas.92.5.1609; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; Yang F, 2000, NAT STRUCT BIOL, V7, P230; YONEDA Y, 1992, EXP CELL RES, V201, P313, DOI 10.1016/0014-4827(92)90279-H; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; ZENKE M, 1990, P NATL ACAD SCI USA, V87, P3655, DOI 10.1073/pnas.87.10.3655	61	254	290	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26204	26210		10.1074/jbc.M010625200	http://dx.doi.org/10.1074/jbc.M010625200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11346640	hybrid			2022-12-25	WOS:000169823300076
J	Hogan, A; Shepherd, L; Chabot, J; Quenneville, S; Prescott, SM; Topham, MK; Gee, SH				Hogan, A; Shepherd, L; Chabot, J; Quenneville, S; Prescott, SM; Topham, MK; Gee, SH			Interaction of gamma 1-syntrophin with diacylglycerol kinase-zeta - Regulation of nuclear localization by PDZ interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-ASSOCIATED PROTEIN; CENTRAL-NERVOUS-SYSTEM; NEUROMUSCULAR-JUNCTION; SODIUM-CHANNELS; SYNTROPHIN; DOMAIN; FAMILY; CLONING; MUSCLE; ALPHA-1-SYNTROPHIN	Syntrophins are modular adapter proteins that link ion channels and signaling proteins to dystrophin and its homologues, A yeast two-hybrid screen of a human brain cDNA library using the PDZ domain of gamma1-syntrophin, a recently identified brain-specific isoform, yielded overlapping clones encoding the C terminus of diacylglycerol kinase-zeta (DGK-zeta), an enzyme that converts diacylglycerol into phosphatidic acid, In biochemical assays, the C terminus of DGK-zeta, which contains a consensus PDZ-binding motif, was found to be necessary and sufficient for association with gamma1-syntrophin, When coexpressed in HeLa cells. DGK-zeta and gamma1-syntrophin formed a stable complex that partitioned between the cytoplasm and nucleus. DGK-zeta translocates from the cytosol to the nucleus, a process negatively regulated by protein kinase C phosphorylation, We found that DGK-zeta recruits gamma1-syntrophin into the nucleus and that the PDZ-binding motif is required. Disrupting the interaction altered the intracellular localization of both proteins; DGK-zeta accumulated in the nucleus, whereas gamma1-syntrophin remained in the cytoplasm, The level of endogenous syntrophins in the nucleus of HeLa cells also reflected the amount of nuclear DGK-zeta, In the brain, DGK-zeta and gamma1-syntrophin were colocalized in cell bodies and dendrites of cerebellar Purkinjie neurons and other neuronal cell types, suggesting that their interaction is physiologically relevant. Moreover, coimmunoprecipitation and pull-down experiments from brain extracts and cells suggest that DGK-zeta, gamma1-syntrophin, and dystrophin form a ternary complex. Collectively, our results suggest that gamma1-syntrophin participates in regulating the subcellular localization of DGK-zeta to ensure correct termination of diacylglycerol signaling.	Univ Ottawa, Dept Cellular & Mol Med, Ctr Neuromusc Dis, Ottawa, ON K1H 8M5, Canada; Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA	University of Ottawa; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Gee, SH (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, Ctr Neuromusc Dis, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.							Adams ME, 2000, J CELL BIOL, V150, P1385, DOI 10.1083/jcb.150.6.1385; ADAMS ME, 1995, J BIOL CHEM, V270, P25859, DOI 10.1074/jbc.270.43.25859; ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; AHN AH, 1994, P NATL ACAD SCI USA, V91, P4446, DOI 10.1073/pnas.91.10.4446; Ahn AH, 1996, J BIOL CHEM, V271, P2724, DOI 10.1074/jbc.271.5.2724; Blake DJ, 2000, TRENDS NEUROSCI, V23, P92, DOI 10.1016/S0166-2236(99)01510-6; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Ding L, 1998, FEBS LETT, V429, P109, DOI 10.1016/S0014-5793(98)00490-6; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Froehner SC, 1997, SOC GEN PHY, V52, P197; Gee SH, 2000, BIOCHEMISTRY-US, V39, P14638, DOI 10.1021/bi001633t; Gee SH, 1998, J BIOL CHEM, V273, P21980, DOI 10.1074/jbc.273.34.21980; Gee SH, 1998, J NEUROSCI, V18, P128; Gorecki DC, 1997, EUR J NEUROSCI, V9, P965, DOI 10.1111/j.1460-9568.1997.tb01447.x; Goto K, 1996, P NATL ACAD SCI USA, V93, P11196, DOI 10.1073/pnas.93.20.11196; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; HARLOW E, 1988, ANTIBODIES LAB MANUA, P314; Hasegawa M, 1999, J BIOL CHEM, V274, P12626, DOI 10.1074/jbc.274.18.12626; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Kachinsky AM, 1999, J CELL BIOL, V145, P391, DOI 10.1083/jcb.145.2.391; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KRAMARCY NR, 1994, J BIOL CHEM, V269, P2870; Kramarcy NR, 2000, MOL CELL NEUROSCI, V15, P262, DOI 10.1006/mcne.1999.0823; Lee SH, 2000, CURR OPIN NEUROBIOL, V10, P125, DOI 10.1016/S0959-4388(99)00046-X; LIDOV HGW, 1990, NATURE, V348, P725, DOI 10.1038/348725a0; LIDOV HGW, 1993, NEUROSCIENCE, V54, P167, DOI 10.1016/0306-4522(93)90392-S; Lumeng C, 1999, NAT NEUROSCI, V2, P611, DOI 10.1038/10165; Miller KG, 2000, NEURON, V27, P289, DOI 10.1016/S0896-6273(00)00037-4; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Nurrish S, 1999, NEURON, V24, P231, DOI 10.1016/S0896-6273(00)80835-1; PETERS MF, 1994, NEUROREPORT, V5, P1577, DOI 10.1097/00001756-199408150-00009; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Piluso G, 2000, J BIOL CHEM, V275, P15851, DOI 10.1074/jbc.M000439200; Poulat F, 1997, J BIOL CHEM, V272, P7167, DOI 10.1074/jbc.272.11.7167; Sanjuan MA, 2001, J CELL BIOL, V153, P207, DOI 10.1083/jcb.153.1.207; Schultz J, 1998, NAT STRUCT BIOL, V5, P19, DOI 10.1038/nsb0198-19; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; Topham MK, 2001, J CELL BIOL, V152, P1135, DOI 10.1083/jcb.152.6.1135; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; YANG B, 1994, J BIOL CHEM, V269, P6040; Zhang YJ, 2001, J BIOL CHEM, V276, P1299, DOI 10.1074/jbc.M008513200	51	87	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26526	26533		10.1074/jbc.M104156200	http://dx.doi.org/10.1074/jbc.M104156200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11352924	hybrid			2022-12-25	WOS:000169823300116
J	Seko, A; Hara-Kuge, S; Yamashita, K				Seko, A; Hara-Kuge, S; Yamashita, K			Molecular cloning and characterization of a novel human galactose 3-O-sulfotransferase that transfers sulfate to Gal beta 1 -> 3GalNAc residue in O-glycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED CARBOHYDRATE CHAINS; HUMAN COLONIC ADENOCARCINOMAS; RESPIRATORY MUCINS; CYSTIC-FIBROSIS; CANCER-CELLS; PORCINE THYROGLOBULIN; H-1-NMR SPECTROSCOPY; OLIGOSACCHARIDES; EXPRESSION; PATIENT	We have identified a novel galactose 3-O-sulfotransferase, termed Gal3ST-4, by analysis of an expression sequence tag using the amino acid sequence of human cerebroside 3 ' -sulfotransferase (Gal3ST-1), The isolated cDNA contains a single open reading frame coding for a protein of 486 amino acids with a type II transmembrane topology. The amino acid sequence of Gal3ST-4 revealed 33%, 39%, and 30% identity to human Gal3ST-1, Gal beta1 -->3/ 4GlcNAc -->3 ' -sulfotransferase (Gal3ST-2) and Gal beta1 --> 4GlcNAc -->3 ' -sulfotransferase (Gal3ST-3), respectively. The Gal3ST-4 gene comprised at least four exons and was located on human chromosome 7q22, Expression of Gal3ST-4 in COS-7 cells produced a sulfotransferase activity that catalyzes the transfer of [S-35]sulfate to the C-3 ' position of Gal beta1 --> 3GalNAc alpha1-O-Bn. Gal3ST-4 recognizes Gal beta1 --> 3GalNAc and Gal beta1 -->3 (GlcNAc beta1 -->6)GalNAc as good substrates, but not Gal beta1 --> 3GalNAc(OH) or Gal beta1 -->3/4GlcNAc. Asialofetuin is also a good substrate, and the sulfation was found exclusively in O-linked glycans that consist of the Gal beta1 --> 3GalNAc moiety, suggesting that the enzyme is specific for O-linked glycans, Northern blot analysis revealed that 2.5-kilobase mRNA for the enzyme is expressed extensively in various tissues. These results suggest that Gal3ST-4 is the fourth member of a Gal:-->3-sulfotransferase family and that the four members, Gal3ST-1, GalST-2, Gal3ST-3, and Gal3ST-4, are responsible for sulfation of different acceptor substrates.	Sasaki Inst, Dept Biochem, Chiyoda Ku, Tokyo 1010062, Japan; Japan Sci & Technol Corp, CREST, Chiyoda Ku, Tokyo 1010062, Japan	Japan Science & Technology Agency (JST)	Yamashita, K (corresponding author), Sasaki Inst, Dept Biochem, Chiyoda Ku, 2-2 Kanda Surugadai, Tokyo 1010062, Japan.	yamashita@sasaki.or.jp						Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Brockhausen I, 1997, TRENDS GLYCOSCI GLYC, V9, P379, DOI 10.4052/tigg.9.379; BROCKHAUSEN I, 1995, EUR J BIOCHEM, V233, P607, DOI 10.1111/j.1432-1033.1995.607_2.x; Capon C, 1997, J BIOL CHEM, V272, P31957, DOI 10.1074/jbc.272.51.31957; CAPON C, 1989, EUR J BIOCHEM, V182, P139, DOI 10.1111/j.1432-1033.1989.tb14810.x; Chance DL, 1996, CARBOHYD RES, V295, P157, DOI 10.1016/S0008-6215(96)90136-6; Chandrasekaran EV, 1997, GLYCOBIOLOGY, V7, P753, DOI 10.1093/glycob/7.6.753; Coppin A, 1999, EUR J BIOCHEM, V266, P370, DOI 10.1046/j.1432-1327.1999.00862.x; DEWAARD P, 1991, J BIOL CHEM, V266, P4237; EDGE ASB, 1987, J BIOL CHEM, V262, P16135; GREEN ED, 1988, J BIOL CHEM, V263, P18253; Habuchi O, 2000, BBA-GEN SUBJECTS, V1474, P115, DOI 10.1016/S0304-4165(00)00016-7; Honke K, 1996, J BIOCHEM-TOKYO, V119, P421; Honke K, 1997, J BIOL CHEM, V272, P4864, DOI 10.1074/jbc.272.8.4864; Honke K, 2001, J BIOL CHEM, V276, P267, DOI 10.1074/jbc.M005666200; Hooper LV, 1996, FASEB J, V10, P1137, DOI 10.1096/fasebj.10.10.8751716; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; KAMERLING JP, 1988, FEBS LETT, V241, P246, DOI 10.1016/0014-5793(88)81070-6; KAWANO M, 1989, ANAL BIOCHEM, V182, P9, DOI 10.1016/0003-2697(89)90709-4; KOBATA A, 1972, METHOD ENZYMOL, V28, P262; KOCHIBE N, 1989, J BIOL CHEM, V264, P173; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUHNS W, 1995, GLYCOBIOLOGY, V5, P689, DOI 10.1093/glycob/5.7.689; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMBLIN G, 1991, BIOCHEM J, V275, P199, DOI 10.1042/bj2750199; LOGUIDICE JM, 1994, J BIOL CHEM, V269, P18794; LoGuidice JM, 1997, GLYCOCONJUGATE J, V14, P113, DOI 10.1023/A:1018525318185; LOTAN R, 1975, J BIOL CHEM, V250, P8518; Loveless RW, 1998, GLYCOBIOLOGY, V8, P1237, DOI 10.1093/glycob/8.12.1237; Okamura A, 2000, CLIN EXP METASTAS, V18, P37, DOI 10.1023/A:1026526829010; Segrest J P, 1971, Biochem Biophys Res Commun, V44, P390; Roussel P, 1996, GLYCOPROTEINS DIS, P351; Seko A, 1996, CANCER RES, V56, P3468; Seko A, 2000, GLYCOBIOLOGY, V10, P919, DOI 10.1093/glycob/10.9.919; Seko A, 1997, BBA-GEN SUBJECTS, V1335, P23, DOI 10.1016/S0304-4165(96)00118-3; SPIRO RG, 1988, J BIOL CHEM, V263, P14351; Suzuki A, 2001, J BIOL CHEM, V276, P24388, DOI 10.1074/jbc.M103135200; Tsuda M, 2000, EUR J BIOCHEM, V267, P2672, DOI 10.1046/j.1432-1327.2000.01281.x; Van Rooijen JJM, 1998, EUR J BIOCHEM, V256, P471, DOI 10.1046/j.1432-1327.1998.2560471.x; YAMASHITA K, 1981, J BIOL CHEM, V256, P4789; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003	42	35	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25697	25704		10.1074/jbc.M101558200	http://dx.doi.org/10.1074/jbc.M101558200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11333265	hybrid			2022-12-25	WOS:000169823300011
J	Tang, HB; Sun, ZX; Goldman, D				Tang, HB; Sun, ZX; Goldman, D			CaM kinase II-dependent suppression of nicotinic acetylcholine receptor delta-subunit promoter activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASES; ELEMENT-BINDING PROTEIN; E-BOX ELEMENTS; GENE-EXPRESSION; ELECTRICAL-ACTIVITY; SKELETAL-MUSCLE; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; RESPONSE ELEMENT; EPSILON-SUBUNIT	Nerve-induced muscle activity suppresses nicotinic acetylcholine receptor (nAChR) gene expression by increasing intracellular calcium levels. This suppression is mediated by nAChR promoter sequences harboring at least 1 E-box (CANNTG) that bind myogenic helix-loop-helix transcription factors, How muscle depolarization or increased calcium mediates changes in nAChR promoter activity is not well understood. In chick muscle, protein kinase C (PKC) activation is necessary for activity-dependent nAChR gene suppression. Similar effects of PKC activation have not been found in mammalian skeletal muscle. Therefore, we used rat primary muscle cultures to screen for other calcium-regulated enzymatic activities that may mediate the effects of muscle activity and calcium on nAChR promoter activity. We report here that calcium/calmodulin-dependent protein kinase II (CaM kinase II) can specifically suppress nAChR promoter activity in mammalian muscle. This regulation was mediated by a single E-box sequence residing in the previously characterized nAChR delta -subunit genes 47-base pair activity-dependent enhancer. In vitro protein/DNA interaction studies suggest that CaM kinase ii inhibits binding of the myogenic factor, myogenin, to the delta -promoter 47-base pair activity-dependent enhancer, CaM kinase activity is increased in active muscle and inhibition of this enzymatic activity results in increased nAChR delta -promoter activity. Therefore, CaM kinase II may represent a previously unappreciated activity that participates in coupling muscle depolarization to nAChR gene expression.	Univ Michigan, Mental Hlth Res Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Goldman, D (corresponding author), Univ Michigan, Mental Hlth Res Inst, 205 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG010821] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG10821] Funding Source: Medline; NINDS NIH HHS [R01 NS25153] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABMAYR SM, 1990, CURRENT PROTOCOLS MO; Adams L, 1998, J NEUROBIOL, V35, P245, DOI 10.1002/(SICI)1097-4695(19980605)35:3<245::AID-NEU2>3.0.CO;2-Z; ADAMS L, 1995, J CELL BIOL, V131, P1341, DOI 10.1083/jcb.131.5.1341; Altiok N, 2001, FEBS LETT, V487, P333, DOI 10.1016/S0014-5793(00)02311-5; Altiok N, 1997, EMBO J, V16, P717, DOI 10.1093/emboj/16.4.717; Antipenko A, 1999, INT J BIOCHEM CELL B, V31, P303, DOI 10.1016/S1357-2725(98)00112-5; Bayer KU, 1998, EMBO J, V17, P5598, DOI 10.1093/emboj/17.19.5598; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BERBERICH C, 1993, EUR J BIOCHEM, V216, P395, DOI 10.1111/j.1432-1033.1993.tb18157.x; BESSEREAU JL, 1994, P NATL ACAD SCI USA, V91, P1304, DOI 10.1073/pnas.91.4.1304; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; CHAHINE KG, 1992, DEVELOPMENT, V115, P213; CHODOSH LA, 1990, CURRENT PROTOCOLS MO; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUCLERT A, 1991, NEUROREPORT, V2, P25, DOI 10.1097/00001756-199101000-00006; DURR I, 1994, EUR J BIOCHEM, V224, P353, DOI 10.1111/j.1432-1033.1994.00353.x; FLUCK M, 2000, BIOCHEM BIOPH RES CO, V274, P803; FONTAINE B, 1987, J CELL BIOL, V105, P1337, DOI 10.1083/jcb.105.3.1337; Fromm L, 1998, GENE DEV, V12, P3074, DOI 10.1101/gad.12.19.3074; GILMOUR BP, 1995, DEV BIOL, V168, P416, DOI 10.1006/dbio.1995.1091; Goldman D, 1998, CAN J APPL PHYSIOL, V23, P390, DOI 10.1139/h98-023; GOLDMAN D, 1991, NEURON, V7, P649, DOI 10.1016/0896-6273(91)90377-C; GUNDERSEN K, 1995, MOL CELL BIOL, V15, P7127; Heist EK, 1998, CELL CALCIUM, V23, P103; HUANG CF, 1992, NEURON, V9, P671, DOI 10.1016/0896-6273(92)90030-H; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KLARSFELD A, 1989, NEURON, V2, P1229, DOI 10.1016/0896-6273(89)90307-3; Kostrominova TY, 2000, AM J PHYSIOL-REG I, V279, pR179, DOI 10.1152/ajpregu.2000.279.1.R179; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; MENDELZON D, 1994, BIOCHEMISTRY-US, V33, P2568, DOI 10.1021/bi00175a028; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MUKHERJI S, 1994, J BIOL CHEM, V269, P13744; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NEVILLE CM, 1992, CELL MOL NEUROBIOL, V12, P511, DOI 10.1007/BF00711232; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Schaeffer L, 1998, EMBO J, V17, P3078, DOI 10.1093/emboj/17.11.3078; Shimomura A, 1996, J BIOL CHEM, V271, P17957, DOI 10.1074/jbc.271.30.17957; Si JT, 1996, J BIOL CHEM, V271, P19752, DOI 10.1074/jbc.271.33.19752; Si JT, 1999, J NEUROSCI, V19, P8498; SIMON AM, 1993, MOL CELL BIOL, V13, P5133, DOI 10.1128/MCB.13.9.5133; SU CT, 1995, FEBS LETT, V366, P131, DOI 10.1016/0014-5793(95)00496-V; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; Takeuchi Y, 2000, J NEUROCHEM, V74, P1913, DOI 10.1046/j.1471-4159.2000.0741913.x; TANG JC, 1994, DEVELOPMENT, V120, P1799; Tansey MG, 1996, J CELL BIOL, V134, P465, DOI 10.1083/jcb.134.2.465; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; TOBIMATSU T, 1988, J BIOL CHEM, V263, P16082; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; WALKE W, 1994, J BIOL CHEM, V269, P19447; Walke W, 1996, J NEUROSCI, V16, P3641; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104	58	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26057	26065		10.1074/jbc.M101670200	http://dx.doi.org/10.1074/jbc.M101670200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11350961	hybrid			2022-12-25	WOS:000169823300057
J	Lavrik, OI; Prasad, R; Sobol, RW; Horton, JK; Ackermann, EJ; Wilson, SH				Lavrik, OI; Prasad, R; Sobol, RW; Horton, JK; Ackermann, EJ; Wilson, SH			Photoaffinity labeling of mouse fibroblast enzymes by a base excision repair intermediate - Evidence for the role of poly(ADP-ribose) polymerase-1 in DNA repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR NICK-SENSOR; REVERSE-TRANSCRIPTASE; INDUCED CYTOTOXICITY; MAMMALIAN-CELLS; BOVINE TESTIS; SITE REPAIR; BETA; PROTEIN; DAMAGE; STEP	To examine the interaction of mammalian base excision repair (BER) enzymes with DNA intermediates formed during BER, we used a novel photoaffinity labeling probe and mouse embryonic fibroblast cellular extracts. The probe was formed in situ, using an end-labeled oligonucleotide containing a synthetic abasic site; this site was incised by apurinic/apyrimidinic endonuclease creating a nick with 3 ' -hydroxyl and 5 ' -reduced sugar phosphate groups at the margins, and then a dNMP carrying a photoreactive adduct was added to the 3 ' -hydroxyl group. With near-UV light (312 nm) exposure of the extract/probe mixture, six proteins were strongly labeled. Four of these include poly(ADP-ribose) polymerase-1 (PARP-1) and the BER participants flap endonuclease-1, DNA polymerase beta, and apurinic/apyrimidinic endonuclease, The amount of the probe cross-linked to PARP-1 was greater than that cross-linked to the other proteins. The specificity of PARP-1 labeling was examined using various competitor oligonucleotides and DNA probes with alternate structures. PARP-1 labeling was stronger with a DNA representing a BER intermediate than with a nick in double-stranded DNA, These results indicate that proteins interacting preferentially with a photoreactive BER intermediate can be selected from the crude cellular extract.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; Russian Acad Sci, Siberian Div, Novosibirsk Bioorgan Chem Inst, Novosibirsk 630090, Russia; Pacific NW Natl Lab, Richland, WA 99352 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Institute of Chemical Biology & Fundamental Medicine, Siberian Branch of the RAS; Russian Academy of Sciences; United States Department of Energy (DOE); Pacific Northwest National Laboratory	Wilson, SH (corresponding author), NIEHS, Struct Biol Lab, NIH, 111 TW Alexandra Dr, Res Triangle Pk, NC 27709 USA.		Wilson, Samuel H/E-6644-2019; Sobol, Robert W./E-4125-2013; Lavrik, Olga I/G-4641-2013	Wilson, Samuel H/0000-0002-1702-5293; Sobol, Robert W./0000-0001-7385-3563; 	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050158, ZIAES050158] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Beard WA, 1995, METHOD ENZYMOL, V262, P98; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Berghammer H, 1999, FEBS LETT, V449, P259, DOI 10.1016/S0014-5793(99)00448-2; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; BUTLER WB, 1984, ANAL BIOCHEM, V141, P70, DOI 10.1016/0003-2697(84)90426-3; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; CREISSEN D, 1982, NATURE, V296, P271, DOI 10.1038/296271a0; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dantzer F, 2000, BIOCHEMISTRY-US, V39, P7559, DOI 10.1021/bi0003442; Dantzer F, 1999, BIOCHIMIE, V81, P69, DOI 10.1016/S0300-9084(99)80040-6; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; DORONIN SV, 1994, FEBS LETT, V354, P200, DOI 10.1016/0014-5793(94)01110-9; DORONIN SV, 1992, FEBS LETT, V313, P31, DOI 10.1016/0014-5793(92)81177-N; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Horton JK, 2000, J BIOL CHEM, V275, P2211, DOI 10.1074/jbc.275.3.2211; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1999, MOL CELL, V3, P33, DOI 10.1016/S1097-2765(00)80172-0; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Lavrik OI, 1996, J BIOL CHEM, V271, P21891, DOI 10.1074/jbc.271.36.21891; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; Maniatis T., 1989, MOL CLONING LAB MANU; MARSISCHKY GT, 1995, J BIOL CHEM, V270, P3247, DOI 10.1074/jbc.270.7.3247; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; Nicholl ID, 1997, BIOCHEMISTRY-US, V36, P7557, DOI 10.1021/bi962950w; Ochs K, 1999, CANCER RES, V59, P1544; Oei SL, 2000, J BIOL CHEM, V275, P23234, DOI 10.1074/jbc.M002429200; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; Sallmann FR, 2000, J BIOL CHEM, V275, P15504, DOI 10.1074/jbc.275.20.15504; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Strauss PR, 1997, J BIOL CHEM, V272, P1302, DOI 10.1074/jbc.272.2.1302; Thompson LH, 2000, MUTAT RES-DNA REPAIR, V459, P1, DOI 10.1016/S0921-8777(99)00058-0; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0; WLASSOFF WA, 1995, BIOCONJUGATE CHEM, V6, P352, DOI 10.1021/bc00034a003	52	161	171	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25541	25548		10.1074/jbc.M102125200	http://dx.doi.org/10.1074/jbc.M102125200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11340072	hybrid			2022-12-25	WOS:000169800700145
J	Mongay, L; Plaza, S; Vigorito, E; Serra-Pages, C; Vives, J				Mongay, L; Plaza, S; Vigorito, E; Serra-Pages, C; Vives, J			Association of the cell cycle regulatory proteins p45(SKP2) and CksHs1 - Functional effect on CDK2 complex formation and kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS SUC1/CKS PROTEIN; F-BOX PROTEIN; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; DEPENDENT-KINASE; HUMAN CUL-1; S-PHASE; SCHIZOSACCHAROMYCES-POMBE; MUTATIONAL ANALYSIS; YEAST	In mammalian cells, CDK2 is part of a multiprotein complex that includes Cyclin A or E and cell cycle regulatory proteins such as p21(Cip1), PCNA, p27(Kip1), p45(SKP2) p19(SKP1), and CksHs1/CksHs2. While the role of some of these proteins has been well studied, the function of other proteins in the complex remains unclear. In this study, we showed that the carboxyl-terminal region of p45(SKP2) associates directly with CksHs1 and that CksHs1 negatively regulated the interaction between p45(SKP2) and CDK2, Moreover, we showed that overexpression of CksHs1 inhibits CDK2 kinase activity and that additional expression of p45(SKP2) overcame this inhibition and restored CDK2 kinase activity. We proposed that the association of CksHs1 and p45(SKP2) prevented CksHs1 from binding CDK2 and negatively regulating the CDK2 kinase activity.	Hosp Clin & Prov Barcelona, Serv Immunol, ICII, Barcelona 08036, Spain	University of Barcelona; Hospital Clinic de Barcelona	Serra-Pages, C (corresponding author), Hosp Clin & Prov Barcelona, Serv Immunol, ICII, Villarroel 170, Barcelona 08036, Spain.							ARVAI AS, 1995, J MOL BIOL, V249, P835, DOI 10.1006/jmbi.1995.0341; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Bourne Y, 2000, STRUCT FOLD DES, V8, P841, DOI 10.1016/S0969-2126(00)00175-1; Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Charrasse S, 2000, ONCOGENE, V19, P2986, DOI 10.1038/sj.onc.1203618; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Kaiser P, 1999, GENE DEV, V13, P1190, DOI 10.1101/gad.13.9.1190; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Lyapina SA, 1998, P NATL ACAD SCI USA, V95, P7451, DOI 10.1073/pnas.95.13.7451; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Medley QG, 2000, J BIOL CHEM, V275, P36116, DOI 10.1074/jbc.M003775200; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1996, CURR OPIN CELL BIOL, V8, P767, DOI 10.1016/S0955-0674(96)80076-7; Patra D, 1996, GENE DEV, V10, P1503, DOI 10.1101/gad.10.12.1503; Patra D, 1999, J BIOL CHEM, V274, P36839, DOI 10.1074/jbc.274.52.36839; Patra D, 1998, GENE DEV, V12, P2549, DOI 10.1101/gad.12.16.2549; Pines J, 1996, CURR BIOL, V6, P1399, DOI 10.1016/S0960-9822(96)00741-5; Reynard GJ, 2000, MOL CELL BIOL, V20, P5858, DOI 10.1128/MCB.20.16.5858-5864.2000; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Shteinberg M, 1999, BIOCHEM BIOPH RES CO, V257, P12, DOI 10.1006/bbrc.1999.0409; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; TANG Y, 1993, GENE DEV, V7, P822, DOI 10.1101/gad.7.5.822; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	38	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25030	25036		10.1074/jbc.M102184200	http://dx.doi.org/10.1074/jbc.M102184200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11349131	hybrid			2022-12-25	WOS:000169800700080
J	Ramandeep; Hwang, KW; Raje, M; Kim, KJ; Stark, BC; Dikshit, KL; Webster, DA				Ramandeep; Hwang, KW; Raje, M; Kim, KJ; Stark, BC; Dikshit, KL; Webster, DA			Vitreoscilla hemoglobin - Intracellular localization and binding to membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMERIC BACTERIAL HEMOGLOBIN; ESCHERICHIA-COLI; GLOBIN GENE; PRIMARY SEQUENCE; EXPRESSION; CYTOCHROME; CLONING; IMPROVES; FLAVOHEMOGLOBIN; IDENTIFICATION	The obligate aerobic bacterium, Vitreoscilla, synthesizes elevated quantities of a homodimeric hemoglobin (VHb) under hypoxic growth conditions, Expression of VHb in heterologous hosts often enhances growth and product formation. A role in facilitating oxygen transfer to the respiratory membranes is one explanation of its cellular function. Immunogold labeling of VHb in both Vitreoscilla and recombinant Escherichia coli bearing the VHb gene clearly indicated that VHb has a cytoplasmic (not periplasmic) localization and is concentrated near the periphery of the cytosolic face of the cell membrane. OmpA signal-peptide VHb fusions were transported into the periplasm in E. coli, but this did not confer any additional growth advantage. The interaction of VHb with respiratory membranes was also studied. The K-d values for the binding of VHb to Vitreoscilla and E. coli cell membranes were similar to5-6 muM, a 4-8-fold higher affinity than those of horse myoglobin and hemoglobin for these same membranes. VHb stimulated the ubiquinol-l oxidase activity of inverted Vitreoscilla membranes by 68%. The inclusion of Vitreoscilla cytochrome bo in proteoliposomes led to 2.4- and 8-fold increases in VHb binding affinity and binding site number, respectively, relative to control liposomes, suggesting a direct interaction between VHb and cytochrome bo.	Inst Microbial Technol, Sector 39, Chandigarh 160014, India; IIT, Dept Biol Chem & Phys Sci, Chicago, IL 60616 USA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH); Illinois Institute of Technology	Webster, DA (corresponding author), Inst Microbial Technol, Sector 39, Chandigarh 160014, India.	kanak@imtech.res.in; dale.webster@iit.edu						ANDREWS SC, 1992, FEBS LETT, V302, P247, DOI 10.1016/0014-5793(92)80452-M; BOERMAN SJ, 1982, J GEN APPL MICROBIOL, V28, P35, DOI 10.2323/jgam.28.35; CLARK JM, 1977, EXPT BIOCH, P159; Couture M, 1999, P NATL ACAD SCI USA, V96, P11223, DOI 10.1073/pnas.96.20.11223; CRAMM R, 1994, J BIOL CHEM, V269, P7349; DEMODENA JA, 1993, BIO-TECHNOL, V11, P926, DOI 10.1038/nbt0893-926; DENG T, 1994, GENE, V93, P224; DIKSHIT KL, 1990, NUCLEIC ACIDS RES, V18, P4149, DOI 10.1093/nar/18.14.4149; DIKSHIT KL, 1989, J GEN MICROBIOL, V135, P2601; DIKSHIT KL, 1988, GENE, V70, P377, DOI 10.1016/0378-1119(88)90209-0; DIKSHIT RP, 1992, ARCH BIOCHEM BIOPHYS, V293, P241, DOI 10.1016/0003-9861(92)90391-9; FUNG LWM, 1981, BIOCHEMISTRY-US, V20, P7162, DOI 10.1021/bi00528a017; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; GEORGIOU CD, 1987, BIOCHEMISTRY-US, V26, P6521, DOI 10.1021/bi00394a035; GEORGIOU CD, 1987, ARCH MICROBIOL, V148, P328, DOI 10.1007/BF00456712; HIROSE M, 1971, BIOCHIM BIOPHYS ACTA, V251, P376, DOI 10.1016/0005-2795(71)90125-5; HOCKNEY RC, 1994, TRENDS BIOTECHNOL, V12, P456, DOI 10.1016/0167-7799(94)90021-3; Iijima M, 2000, CELL STRUCT FUNCT, V25, P47, DOI 10.1247/csf.25.47; JOSHI M, 1994, BIOCHEM BIOPH RES CO, V202, P535, DOI 10.1006/bbrc.1994.1961; Joshi M, 1998, APPL ENVIRON MICROB, V64, P2220; KALLIO PT, 1994, EUR J BIOCHEM, V219, P201, DOI 10.1111/j.1432-1033.1994.tb19931.x; KHOSLA C, 1989, J MOL BIOL, V210, P79, DOI 10.1016/0022-2836(89)90292-1; KHOSLA C, 1989, J BACTERIOL, V171, P5995, DOI 10.1128/jb.171.11.5995-6004.1989; KHOSLA C, 1990, BIO-TECHNOL, V8, P849, DOI 10.1038/nbt0990-849; KHOSLA C, 1988, NATURE, V331, P633, DOI 10.1038/331633a0; KHOSRAVI M, 1990, PLASMID, V24, P190, DOI 10.1016/0147-619X(90)90002-T; Liu SC, 1996, BIOTECHNOL BIOENG, V49, P101, DOI 10.1002/(SICI)1097-0290(19960105)49:1&lt;101::AID-BIT13&gt;3.0.CO;2-L; Liu SC, 1995, APPL MICROBIOL BIOT, V44, P419; NARRO ML, 1990, J BACTERIOL, V172, P4549, DOI 10.1128/jb.172.8.4549-4554.1990; ORII Y, 1986, J BIOL CHEM, V261, P3544; Park C, 1996, BIOCHEMISTRY-US, V35, P11895, DOI 10.1021/bi9530503; Patel SM, 2000, BIOTECHNOL PROGR, V16, P26, DOI 10.1021/bp9901421; Ramandeep, 2001, J HISTOCHEM CYTOCHEM, V49, P355; Riistama S, 1996, BBA-BIOENERGETICS, V1275, P1, DOI 10.1016/0005-2728(96)00040-0; Tarricone C, 1997, STRUCTURE, V5, P497, DOI 10.1016/S0969-2126(97)00206-2; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; TYREE B, 1978, J BIOL CHEM, V253, P7635; VASUDEVAN SG, 1995, FEMS MICROBIOL LETT, V125, P219, DOI 10.1016/0378-1097(94)00501-H; WAKABAYASHI S, 1986, NATURE, V322, P481, DOI 10.1038/322481a0; WEBSTER DA, 1988, ADV INORG BIOCHEM, V7, P245; WITTENBERG JB, 1974, J BIOL CHEM, V249, P4057; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5015, DOI 10.1073/pnas.89.11.5015	42	114	120	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24781	24789		10.1074/jbc.M009808200	http://dx.doi.org/10.1074/jbc.M009808200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11331274	hybrid			2022-12-25	WOS:000169800700050
J	Fukushi, S; Okada, M; Stahl, J; Kageyama, T; Hoshino, FB; Katayama, K				Fukushi, S; Okada, M; Stahl, J; Kageyama, T; Hoshino, FB; Katayama, K			Ribosomal protein S5 interacts with the internal ribosomal entry site of hepatitis C virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRACT-BINDING-PROTEIN; 25-KILODALTON CELLULAR PROTEIN; ESCHERICHIA-COLI RIBOSOME; DIRECTED CROSS-LINKING; MESSENGER-RNA ANALOGS; TRANSLATION INITIATION; MEDIATED TRANSLATION; POLIOVIRUS RNA; DECODING SITE; REGION	Translational initiation of hepatitis C virus (HCV) genome RNA occurs via its highly structured 5' noncoding region called the internal ribosome entry site (IRES), Recent studies indicate that HCV IRES and 40 S ribosomal subunit form a stable binary complex that is believed to be important for the subsequent assembly of the 48 S initiation complex. Ribosomal protein (rp) S9 has been suggested as the prime candidate protein for binding of the HCV IRES to the 40 S subunit. RpS9 has a molecular mass of similar to 25 kDa in UV cross-linking experiments. In the present study, we examined the similar to 25-kDa proteins of the 40 S ribosome that form complexes with the HCV IRES upon UV cross-linking. Immunoprecipitation with specific antibodies against two 25-kDa 40 S proteins, rpS5 and rpS9, clearly identified rpS5 as the protein bound to the IRES. Thus, our results support rpS5 as the critical element in positioning the HCV RNA on the 40 S ribosomal subunit during translation initiation.	Biomed Labs, Ctr Res & Dev, Kawagoe, Saitama 3501101, Japan; Osaka Univ, Res Inst Microbial Dis, Suita, Osaka 5650871, Japan; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany	Osaka University; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Fukushi, S (corresponding author), Biomed Labs, Ctr Res & Dev, 1361-1 Matoba, Kawagoe, Saitama 3501101, Japan.			Katayama, Kazuhiko/0000-0002-7692-1151				Ali N, 2000, J BIOL CHEM, V275, P27531; Anwar A, 2000, J BIOL CHEM, V275, P34231, DOI 10.1074/jbc.M006343200; Blyn LB, 1997, J VIROL, V71, P6243, DOI 10.1128/JVI.71.8.6243-6246.1997; BORMAN A, 1993, J GEN VIROL, V74, P1775, DOI 10.1099/0022-1317-74-9-1775; DONTSOVA O, 1991, EMBO J, V10, P2613, DOI 10.1002/j.1460-2075.1991.tb07803.x; Fukushi S, 1997, J VIROL, V71, P1662, DOI 10.1128/JVI.71.2.1662-1666.1997; FUKUSHI S, 1994, BIOCHEM BIOPH RES CO, V199, P425, DOI 10.1006/bbrc.1994.1246; Fukushi S, 1999, VIRUS GENES, V19, P153, DOI 10.1023/A:1008131325056; Fukushi S, 2001, VIRUS RES, V73, P67, DOI 10.1016/S0168-1702(00)00228-8; GIMAUTDINOVA OI, 1981, NUCLEIC ACIDS RES, V9, P3465, DOI 10.1093/nar/9.14.3465; HARTZ D, 1991, J MOL BIOL, V218, P99, DOI 10.1016/0022-2836(91)90876-8; HELLEN CUT, 1994, J VIROL, V68, P941, DOI 10.1128/JVI.68.2.941-950.1994; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; Jackson RJ, 1995, RNA, V1, P985; Kaminski A, 1995, RNA, V1, P924; Kamoshita N, 1997, VIROLOGY, V233, P9, DOI 10.1006/viro.1997.8600; Kolupaeva VG, 2000, J VIROL, V74, P6242, DOI 10.1128/JVI.74.14.6242-6250.2000; KUWANO Y, 1992, J BIOL CHEM, V267, P25304; LUTSCH G, 1983, BIOMED BIOCHIM ACTA, V42, P705; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; Niepmann M, 1997, J VIROL, V71, P8330, DOI 10.1128/JVI.71.11.8330-8339.1997; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; RIJNBRAND R, 1995, FEBS LETT, V365, P115, DOI 10.1016/0014-5793(95)00458-L; ROJASEISENRING IA, 1995, J VIROL, V69, P6819, DOI 10.1128/JVI.69.11.6819-6824.1995; Spahn CMT, 2001, SCIENCE, V291, P1959, DOI 10.1126/science.1058409; Spiridonova VA, 1999, FEBS LETT, V460, P353, DOI 10.1016/S0014-5793(99)01351-4; STADE K, 1989, NUCLEIC ACIDS RES, V17, P9889, DOI 10.1093/nar/17.23.9889; THEISE H, 1978, ACTA BIOL MED GER, V37, P1353; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VLADIMIROV SN, 1990, BIOCHIM BIOPHYS ACTA, V1048, P245, DOI 10.1016/0167-4781(90)90063-8; Wang C, 1995, CURR TOP MICROBIOL, V203, P99	32	95	102	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					20824	20826		10.1074/jbc.C100206200	http://dx.doi.org/10.1074/jbc.C100206200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11331271	hybrid			2022-12-25	WOS:000169297900006
J	Byun, T; Tang, M; Sloma, A; Brown, KM; Marumoto, C; Fujii, M; Blinkovsky, AM				Byun, T; Tang, M; Sloma, A; Brown, KM; Marumoto, C; Fujii, M; Blinkovsky, AM			Aminopeptidase from Sphingomonas capsulata	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIFICITY	A novel aminopeptidase with unique substrate specificity was purified from a culture broth of Sphingomonas capsulata, This is the first reported aminopeptidase to demonstrate broad substrate specificity and yet release glycine and alanine with the highest efficacy. On a series of pentapeptide amides with different N-terminal amino acids, this enzyme efficiently releases glycine, alanine, leucine, proline, and glutamate with the lowest turnover value of 370 min(-1) for glutamate, At pH 7.5 (pH optimum) and 25 degreesC, the kinetic parameters for alanine para-nitroanilide were found to be k(cat) = 7600 min(-1) and K-m = 14 mM. For alanine beta -naphthylamide, they were k(cat) = 860 min(-1) and K-m = 6.7 mm, Polymerase chain reaction primers were designed based upon obtained internal sequences of the wild type enzyme. The subsequent product was then used to acquire the full-length gene from an S, capsulata genomic library. An open reading frame encoding a protein of 670 amino acids was obtained. The translated protein has a putative signal peptide that directs the enzyme into the supernatant, A search of the amino acid sequence revealed no significant homology to any known aminopeptidases in the available data bases.	Novozymes Biotech Inc, Davis, CA 95616 USA; Japan Tobacco Inc, Foods Technol Ctr, Ohito, Shizuoka 4102318, Japan	Novozymes; Japan Tobacco Inc.	Blinkovsky, AM (corresponding author), Novozymes Biotech Inc, 1445 Drew Ave, Davis, CA 95616 USA.							Adler-Nissen J, 1985, ENZYMIC HYDROLYSIS F; Alan Sloma, 1999, US Patent, Patent No. 5958728; Blinkovsky AM, 2000, BBA-PROTEIN STRUCT M, V1480, P171, DOI 10.1016/S0167-4838(00)00064-9; CHAPPELETTORDO D, 1977, EUR J BIOCHEM, V81, P299, DOI 10.1111/j.1432-1033.1977.tb11952.x; Cunningham DF, 1997, BBA-PROTEIN STRUCT M, V1343, P160, DOI 10.1016/S0167-4838(97)00134-9; FERSHT A, 1985, ENZYME STRUCTURE MEC, P405; Gonzales T, 1996, FEMS MICROBIOL REV, V18, P319, DOI 10.1111/j.1574-6976.1996.tb00247.x; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; NISHIMURA T, 1988, Food Reviews International, V4, P175; OSADA H, 1986, BIOCHEM J, V233, P459, DOI 10.1042/bj2330459; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOMBURG D, 1991, ENZYME HDB CLASS 3 H, V5; SLOMA AP, 1997, Patent No. 5622850; TAN PST, 1993, J DAIRY RES, V60, P69; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; WATSON RR, 1976, METHOD MICROBIOL, V9, P1	18	6	6	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17902	17907		10.1074/jbc.M010608200	http://dx.doi.org/10.1074/jbc.M010608200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11359790	hybrid			2022-12-25	WOS:000168866500040
J	Pirok, EW; Henry, J; Schwartz, NB				Pirok, EW; Henry, J; Schwartz, NB			cis elements that control the expression of chick aggrecan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE PROTEIN; GENE; IDENTIFICATION; DEGRADATION; PROMOTER; OPERON	Aggrecan is a large chondroitin sulfate proteoglycan whose expression is both cell-specific and developmentally regulated. Cloning and sequencing of the 1.8-kilo-base genomic 5'-flanking sequence of the chick aggrecan gene revealed the presence of potential tissue-specific control elements including a consensus sequence found in the cartilage-associated silencers, CSIIS1 and CSIIS2, that were first characterized in the type II collagen promoter sequences, as well as numerous other cis elements. Transient transfections of chick sternal chondrocytes and fibroblasts with reporter plasmids bearing progressively deleted portions of the chick aggrecan promoter and enhancer region demonstrated cell type-specific promoter activity and identified a 420-base pair region in the genomic Fi-flanking region responsible for negative regulation of the aggrecan gene. In this report, three complementary methods, DNase I footprinting assays, transient transfections, and electrophoretic mobility shift assays (EMSA), provided an integral approach to better understand the regulation of the aggrecan gene. DNase I footprinting revealed that six regions of this genomic sequence bind to nuclear proteins in a tissue-specific manner. Transient transfection of reporter constructs bearing ablations of these protected sequences showed that four of the six protected sequences, which contain the sequence TCCTCC or TCCCCT, had repressor activities in transfected chick chondrocytes, Cross-competition EMSA using nuclear protein extracted from chondrocytes or fibroblasts explored the contributions of the different sequence elements in formation of DNA-protein complexes specific to cell type. This is the first parallel examination of the EMSA patterns for six functionally defined cis elements with highly similar sequences, using protein from primary cultured cells.	Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Schwartz, NB (corresponding author), Univ Chicago, Dept Pediat, 5841 S Maryland Ave,MC 5058, Chicago, IL 60637 USA.				NHLBI NIH HHS [HL-07237] Funding Source: Medline; NIAMS NIH HHS [AR-19622] Funding Source: Medline; NICHD NIH HHS [HD-09402] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD009402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR019622, R37AR019622] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Boos W, 1998, MICROBIOL MOL BIOL R, V62, P204, DOI 10.1128/MMBR.62.1.204-229.1998; BREMER E, 1985, J BACTERIOL, V162, P1092, DOI 10.1128/JB.162.3.1092-1099.1985; CAHN RD, 1967, METHODS DEVELOPMENTA, P493; CAMPBELL SC, 1988, J CELL BIOL, V106, P2191, DOI 10.1083/jcb.106.6.2191; DANOT O, 1994, MOL MICROBIOL, V14, P335, DOI 10.1111/j.1365-2958.1994.tb01294.x; EWULONU UK, 1991, P NATL ACAD SCI USA, V88, P4675, DOI 10.1073/pnas.88.11.4675; GEETHAHABIB M, 1984, J BIOL CHEM, V259, P7300; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HOUGHTON M J, 1989, Pediatric Pathology, V9, P501; Ihn H, 1996, J BIOL CHEM, V271, P26717, DOI 10.1074/jbc.271.43.26717; KLEIN W, 1993, J BACTERIOL, V175, P1682, DOI 10.1128/JB.175.6.1682-1686.1993; Krueger RC, 1999, MAMM GENOME, V10, P1119, DOI 10.1007/s003359901176; Lark MW, 1995, ACTA ORTHOP SCAND, V66, P92, DOI 10.3109/17453679509157660; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; Li H, 1995, J MOL EVOL, V41, P878; LI H, 1993, J BIOL CHEM, V268, P23504; Pirok EW, 1997, J BIOL CHEM, V272, P11566, DOI 10.1074/jbc.272.17.11566; PLUMBRIDGE J, 1995, EMBO J, V14, P3958, DOI 10.1002/j.1460-2075.1995.tb00067.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAVAGNER P, 1990, J BIOL CHEM, V265, P6669; Schwartz NB, 2000, FRONT BIOSCI, V5, pD649; Schwartz NB, 1999, PROG NUCLEIC ACID RE, V62, P177; Schwartz NB, 1998, SKELETAL GROWTH AND DEVELOPMENT: CLINICAL ISSUES AND BASIC SCIENCE ADVANCES, P413; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1	24	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16894	16903		10.1074/jbc.M009944200	http://dx.doi.org/10.1074/jbc.M009944200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11350977	hybrid			2022-12-25	WOS:000168730400040
J	Fletcher, CF; Tottene, A; Lennon, VA; Wilson, SM; Dubel, SJ; Paylor, R; Hosford, DA; Tessarollo, L; Tessarollo, L; McEnery, MW; Pietrobon, D; Copeland, NG; Jenkins, NA				Fletcher, CF; Tottene, A; Lennon, VA; Wilson, SM; Dubel, SJ; Paylor, R; Hosford, DA; Tessarollo, L; Tessarollo, L; McEnery, MW; Pietrobon, D; Copeland, NG; Jenkins, NA			Dystonia and cerebellar atrophy in Cacna1a null mice lacking P/Q calcium channel activity	FASEB JOURNAL			English	Article									NCI, Mouse Canc Genet Program, FCRDC, Frederick, MD 21702 USA; Univ Padua, Ctr Biomembranes, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, Ctr Biomembranes, CNR, I-35121 Padua, Italy; Mayo Clin, Mayo Grad Sch, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin, Mayo Grad Sch, Dept Neurol, Rochester, MN 55905 USA; Mayo Clin, Mayo Med Sch, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin, Mayo Med Sch, Dept Neurol, Rochester, MN 55905 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Glaxo Wellcome Res & Dev Ltd, Clin Genet Dis Sci, Stevenage SG1 2NY, Herts, England	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Case Western Reserve University; Baylor College of Medicine; GlaxoSmithKline	Fletcher, CF (corresponding author), GNF, 3118 Merryfield Row, San Diego, CA 92121 USA.			Wilson, Scott/0000-0001-9376-9430	Telethon [E.1297] Funding Source: Medline	Telethon(Fondazione Telethon)			0	140	146	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1288	1290		10.1096/fj.00-0562fje	http://dx.doi.org/10.1096/fj.00-0562fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344116				2022-12-25	WOS:000168655200038
J	Lebrin, F; Chambaz, EM; Bianchini, L				Lebrin, F; Chambaz, EM; Bianchini, L			A role for protein kinase CK2 in cell proliferation: evidence using a kinase-inactive mutant of CK2 catalytic subunit alpha	ONCOGENE			English	Article						proliferation; casein kinase 2; BrdU; dominant-negative	CASEIN KINASE-2; SACCHAROMYCES-CEREVISIAE; REGULATORY SUBUNIT; BETA-SUBUNIT; MOLECULAR-CLONING; NA+/H+ ANTIPORTER; CRYSTAL-STRUCTURE; MAMMALIAN-CELLS; PHOSPHATASE 2A; GROWTH	Protein kinase CK2 is an ubiquitous and pleiotropic Ser/Thr protein kinase composed of two catalytic (alpha and/or alpha') and two regulatory (B) subunits generally combined to form alpha (2)beta (2), alpha alpha'beta (2), or alpha'(2)beta (2) heterotetramers, To gain more insight into the role of CK2 in the control of proliferation in mammalian cells, overexpression of isolated CK2 subunits alpha, alpha', or beta was carried out in two fibroblast cell lines: NIH3T3 and CCL39, To interfere with CK2 cellular functions, cells were also transfected with a kinase-inactive mutant of CK2 alpha catalytic subunit: CK2 alpha -K68A. In NIH3T3 cells, overexpression of either wild-type subunit (alpha, alpha' or beta) had no effect on cell proliferation, In contrast, overexpression of the CK2 alpha kinase-deficient mutant induced a marked inhibition of cell proliferation, This resulted from a defect in G1/S progression as demonstrated in transient transfection experiments in both NIH3T3 and CCL39 cells using BrdU incorporation measurements and in CCL39 clones stably overexpressing the CK2 alpha -K68A mutant by growth curve analysis. We demonstrated that the kinase-negative mutant has the capacity to integrate the endogenous CK2 subunit pool both as an isolated kinase-inactive alpha subunit and as associated to the beta subunit in a kinase-inactive tetramer. Finally we showed that expression of the kinase-inactive mutant interferes with phosphorylation of an endogenous CK2 substrate; we speculate that optimal phosphorylation of target proteins by CK2 is required to achieve optimal cell cycle progression.	CEA, BRCE, DBMS, INSERM U244, F-38054 Grenoble 9, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm)	Bianchini, L (corresponding author), Fac Sci, Ctr Biochim, UMR 6543 CNRS, Parc Valrose, F-06108 Nice 2, France.			lebrin, franck/0000-0002-1650-6757				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; BIDWAI AP, 1993, ARCH BIOCHEM BIOPHYS, V300, P265, DOI 10.1006/abbi.1993.1037; Boldyreff B, 1997, FEBS LETT, V403, P197, DOI 10.1016/S0014-5793(97)00010-0; Chantalat L, 1999, EMBO J, V18, P2930, DOI 10.1093/emboj/18.11.2930; Chen MZ, 1997, MOL CELL BIOL, V17, P1904, DOI 10.1128/MCB.17.4.1904; Cosmelli D, 1997, FEBS LETT, V410, P391, DOI 10.1016/S0014-5793(97)00625-X; DOBROWOLSKA G, 1992, EUR J BIOCHEM, V204, P299, DOI 10.1111/j.1432-1033.1992.tb16637.x; Egyhazi E, 1999, MOL CELL BIOCHEM, V191, P149; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Hagemann C, 1997, FEBS LETT, V403, P200, DOI 10.1016/S0014-5793(97)00011-2; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; Korn I, 1999, MOL CELL BIOCHEM, V191, P75, DOI 10.1023/A:1006818513560; Lebrin F, 1999, MOL CELL BIOCHEM, V191, P207, DOI 10.1023/A:1006888228156; Li DX, 1999, J BIOL CHEM, V274, P32988, DOI 10.1074/jbc.274.46.32988; LITCHFIELD DW, 1994, CELL MOL BIOL RES, V40, P373; Lorenz P, 1999, FEBS LETT, V448, P283, DOI 10.1016/S0014-5793(99)00388-9; LORENZ P, 1993, J BIOL CHEM, V268, P2733; MEGGIO F, 1994, BIOCHEMISTRY-US, V33, P4336, DOI 10.1021/bi00180a030; Niefind K, 1998, EMBO J, V17, P2451, DOI 10.1093/emboj/17.9.2451; Orlandini M, 1998, J BIOL CHEM, V273, P21291, DOI 10.1074/jbc.273.33.21291; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; Penner CG, 1997, J CELL BIOCHEM, V64, P525; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SNELL V, 1994, EMBO J, V13, P2066, DOI 10.1002/j.1460-2075.1994.tb06481.x; ULLOA L, 1993, EMBO J, V12, P1633, DOI 10.1002/j.1460-2075.1993.tb05808.x; Vilk G, 1999, J BIOL CHEM, V274, P14406, DOI 10.1074/jbc.274.20.14406; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; Zeng YX, 1997, BIOTECHNIQUES, V23, P88, DOI 10.2144/97231bm19	39	60	63	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 12	2001	20	16					2010	2022		10.1038/sj.onc.1204307	http://dx.doi.org/10.1038/sj.onc.1204307			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360185				2022-12-25	WOS:000168043800009
J	Matharu, AL; Mundell, SJ; Benovic, JL; Kelly, E				Matharu, AL; Mundell, SJ; Benovic, JL; Kelly, E			Rapid agonist-induced desensitization and internalization of the A(2B) adenosine receptor is mediated by a serine residue close to the COOH terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; CYTOPLASMIC TAIL; NG108-15 CELLS; PHOSPHORYLATION; ENDOCYTOSIS; TRAFFICKING; EXPRESSION; BINDING; KINASES	The G.-coupled rat A(2B) adenosine receptor (A(2B)-AR) was epitope-tagged at the NH2 terminus with hemagglutinin (HA) and subjected to progressive deletions or point mutations of the COOH terminus in order to determine regions of the receptor that contribute to agonist-induced desensitization and internalization. When expressed stably in Chinese hamster ovary cells, a mutant receptor in which the final 2 amino acids were deleted, the Leu(330)-stop mutant, underwent rapid agonist-induced desensitization and internalization as did the wild type (WT) receptor. However, the Phe(328) and the Gln(325)-stop mutants were resistant to rapid agonist-induced desensitization and internalization. Co-expression of arrestin-2-green fluorescent protein (arrestin-2-GFP) with WT receptor or Leu(330)-stop mutant resulted in rapid translocation of arrestin-2-GFP from cytosol to membrane upon agonist addition. On the other hand, agonist activation of the Phe(328)-stop or Gln(325)-stop mutant did not result in translocation of arrestin-2-GFP from cytosol. A COOH terminus point mutant, S329G, was also unable to undergo rapid agonist-induced desensitization and internalization, indicating that Ser(329) is a critical residue for these processes. A further deletion mutant (Ser(326)- stop) unexpectedly underwent rapid agonist-induced desensitization and internalization. However, activation of this mutant did not promote translocation of arrestin-2-GFP from cytosol to membrane. In addition, whereas WT receptor internalization was markedly inhibited by co-expression of dominant negative mutants of arrestin-2 (arrestin-2-(319-418)), dynamin (dynamin K44A), or Eps-15 (E Delta 95-295), Ser(326)-stop receptor internalization was only inhibited by dominant negative mutant dynamin. Taken together these results indicate that Ser(329), close to the COOH terminus of the rat A2B-AR, is critical for the rapid agonist-induced desensitization and internalization of the receptor. However, deletion of the COOH terminus also uncovers a motif that is able to redirect internalization of the receptor to an arrestin- and clathrin-independent pathway.	Univ Bristol, Sch Med Sci, Dept Pharmacol, Bristol BS8 1TD, Avon, England; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	University of Bristol; Jefferson University	Kelly, E (corresponding author), Univ Bristol, Sch Med Sci, Dept Pharmacol, Bristol BS8 1TD, Avon, England.							Beaumont V, 1998, J BIOL CHEM, V273, P33174, DOI 10.1074/jbc.273.50.33174; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Benmerah A, 2000, J BIOL CHEM, V275, P3288, DOI 10.1074/jbc.275.5.3288; Blomenrohr M, 1999, MOL PHARMACOL, V56, P1229, DOI 10.1124/mol.56.6.1229; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bunemann M, 1999, J PHYSIOL-LONDON, V517, P5, DOI 10.1111/j.1469-7793.1999.0005z.x; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Daunt DA, 1997, MOL PHARMACOL, V51, P711, DOI 10.1124/mol.51.5.711; Feoktistov I, 1997, PHARMACOL REV, V49, P381; FERGUSON SSG, 1996, SCIENCE, V271, P383; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Hammes SR, 1999, BIOCHEMISTRY-US, V38, P9308, DOI 10.1021/bi9902236; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; Haynes J, 1999, AM J PHYSIOL-HEART C, V276, pH1877, DOI 10.1152/ajpheart.1999.276.6.H1877; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Ji X D, 1999, Drug Des Discov, V16, P217; KOJRO E, 1995, J BIOL CHEM, V270, P6476, DOI 10.1074/jbc.270.12.6476; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Mundell SJ, 1998, BIOCHEM PHARMACOL, V55, P595, DOI 10.1016/S0006-2952(97)00466-8; Mundell SJ, 2000, BIOCHEMISTRY-US, V39, P12828, DOI 10.1021/bi0010928; Mundell SJ, 1999, BIOCHEMISTRY-US, V38, P8723, DOI 10.1021/bi990361v; Mundell SJ, 1997, MOL PHARMACOL, V51, P991, DOI 10.1124/mol.51.6.991; OLAH ME, 1995, ANNU REV PHARMACOL, V35, P581, DOI 10.1146/annurev.pa.35.040195.003053; Palmer TM, 1997, BIOCHEMISTRY-US, V36, P832, DOI 10.1021/bi962290v; Peters DM, 1998, BIOCHEM PHARMACOL, V55, P873, DOI 10.1016/S0006-2952(97)00560-1; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Schulte G, 2000, MOL PHARMACOL, V58, P477, DOI 10.1124/mol.58.3.477; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; Sitaraman SV, 2000, AM J PHYSIOL-CELL PH, V278, pC1230, DOI 10.1152/ajpcell.2000.278.6.C1230; Smith RD, 1998, MOL PHARMACOL, V54, P935, DOI 10.1124/mol.54.6.935; Tsao P, 2000, CURR OPIN NEUROBIOL, V10, P365, DOI 10.1016/S0959-4388(00)00096-9	35	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30199	30207		10.1074/jbc.M010650200	http://dx.doi.org/10.1074/jbc.M010650200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11333255	hybrid			2022-12-25	WOS:000170558000080
J	Coussen, F; Ayon, A; Le Goff, A; Leroy, J; Massoulie, J; Bon, S				Coussen, F; Ayon, A; Le Goff, A; Leroy, J; Massoulie, J; Bon, S			Addition of a glycophosphatidylinositol to acetylcholinesterase - Processing, degradation, and secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; MEMBRANE ANCHOR; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR; ENDOPLASMIC-RETICULUM; TORPEDO-CALIFORNICA; MUTATIONAL ANALYSIS; PHOSPHOLIPASE-C; MAMMALIAN-CELLS; SIGNAL PEPTIDE	We introduced various mutations and modifications in the GPI anchoring signal of rat acetylcholinesterase (AChE). 1) The resulting mutants, expressed in transiently transfected COS cells, were initially produced at the same rate, in an active form, but the fraction of GPI-anchored ACNE and the steady state level of ACNE activity varied over a wide range. 2) Productive interaction with the GPI addition machinery led to GPI anchoring, secretion of uncleaved protein, and secretion of a cleaved protein, in variable proportions. Unproductive interaction led to degradation; poorly processed molecules were degraded rather than retained intracellularly or secreted. 3) An efficient glypiation appeared necessary but not sufficient for a high level of secretion; the cleaved, secreted protein was possibly generated as a by-product of transamidation. 4) Glypiation was influenced by a wider context than the triplet omega/omega + 1/omega + 2, particularly omega - 1. 5) Glypiation was not affected by the closeness of the w site to the alo helix of the catalytic domain. 6) A cysteine could simultaneously form a disulfide bond and serve as an co site; however, there was a mutual interference between glypiation and the formation of an intercatenary disulfide bond, at a short distance upstream of omega. 7) Glypiation was not affected by the presence of an N-glycosylation site at co or in its vicinity or by the addition of a short hydrophilic, highly charged peptide (FLAG; DYKDDDDK) at the C terminus of the hydrophobic region.	Ecole Normale Super, Mol & Cellular Neurobiol Lab, CNRS, UMR 8544, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Bon, S (corresponding author), Ecole Normale Super, Mol & Cellular Neurobiol Lab, CNRS, UMR 8544, 46 Rue Ulm, F-75005 Paris, France.	jean.massoulie@biologie.ens.fr						Bon S, 1997, J BIOL CHEM, V272, P3007, DOI 10.1074/jbc.272.5.3007; BON S, 1988, J NEUROCHEM, V51, P786, DOI 10.1111/j.1471-4159.1988.tb01813.x; Bucht C, 1996, BBA-PROTEIN STRUCT M, V1292, P223, DOI 10.1016/0167-4838(95)00205-7; Bucht G, 1999, BBA-PROTEIN STRUCT M, V1431, P471, DOI 10.1016/S0167-4838(99)00079-5; CARAS IW, 1991, J CELL BIOL, V113, P77, DOI 10.1083/jcb.113.1.77; DELAHUNTY MD, 1993, J BIOL CHEM, V268, P12017; Doering TL, 1996, EMBO J, V15, P182, DOI 10.1002/j.1460-2075.1996.tb00346.x; DUVAL N, 1992, EMBO J, V11, P3255, DOI 10.1002/j.1460-2075.1992.tb05403.x; Eisenhaber B, 1998, PROTEIN ENG, V11, P1155, DOI 10.1093/protein/11.12.1155; Eisenhaber B, 1999, J MOL BIOL, V292, P741, DOI 10.1006/jmbi.1999.3069; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Ferguson MAJ, 1999, J CELL SCI, V112, P2799; FERGUSON MAJ, 1986, J BIOL CHEM, V261, P356; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Furukawa Y, 1997, BBA-BIOMEMBRANES, V1328, P185, DOI 10.1016/S0005-2736(97)00084-9; FUTERMAN AH, 1983, NEUROSCI LETT, V40, P85, DOI 10.1016/0304-3940(83)90097-6; FUTERMAN AH, 1985, BIOCHEM BIOPH RES CO, V129, P312, DOI 10.1016/0006-291X(85)91439-1; Haas R, 1996, BIOCHEM J, V314, P817, DOI 10.1042/bj3140817; HAAS R, 1986, BIOCHEMISTRY-US, V25, P3098, DOI 10.1021/bi00359a005; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; Kenworthy AK, 2000, MOL BIOL CELL, V11, P1645, DOI 10.1091/mbc.11.5.1645; KODUKULA K, 1993, J CELL BIOL, V120, P657, DOI 10.1083/jcb.120.3.657; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; LI Y, 1991, J BIOL CHEM, V266, P23083; LOW MG, 1987, BIOCHEM J, V244, P1; MARSH D, 1984, J NEUROCHEM, V43, P204, DOI 10.1111/j.1471-4159.1984.tb06698.x; Massoulie J, 1998, STRUCTURE AND FUNCTION OF CHOLINESTERASES AND RELATED PROTEINS, P3; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MAXWELL SE, 1995, P NATL ACAD SCI USA, V92, P1550, DOI 10.1073/pnas.92.5.1550; Meyer U, 2000, BIOCHEMISTRY-US, V39, P3461, DOI 10.1021/bi992186o; MICANOVIC R, 1990, P NATL ACAD SCI USA, V87, P157, DOI 10.1073/pnas.87.1.157; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORAN P, 1992, J CELL BIOL, V119, P763, DOI 10.1083/jcb.119.4.763; MORAN P, 1991, J CELL BIOL, V115, P1595, DOI 10.1083/jcb.115.6.1595; MORAN P, 1994, J CELL BIOL, V125, P333, DOI 10.1083/jcb.125.2.333; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Ohishi K, 2000, MOL BIOL CELL, V11, P1523, DOI 10.1091/mbc.11.5.1523; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Ramalingam S, 1996, P NATL ACAD SCI USA, V93, P7528, DOI 10.1073/pnas.93.15.7528; RIEZMAN H, 1998, HDB PROTEOLYTIC ENZY, P756; ROBERTS WL, 1986, BIOCHEMISTRY-US, V25, P3091, DOI 10.1021/bi00359a004; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; Sharma DK, 1999, J BIOL CHEM, V274, P16479, DOI 10.1074/jbc.274.23.16479; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; Tomassetti A, 1999, J CELL BIOCHEM, V72, P111, DOI 10.1002/(SICI)1097-4644(19990101)72:1<111::AID-JCB12>3.0.CO;2-1; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; YAN W, 1995, BIOCHEMISTRY-US, V34, P14594, DOI 10.1021/bi00044a039	48	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27881	27892		10.1074/jbc.M010817200	http://dx.doi.org/10.1074/jbc.M010817200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11337488	hybrid			2022-12-25	WOS:000170093400020
J	Odermatt, A; Arnold, P; Frey, FJ				Odermatt, A; Arnold, P; Frey, FJ			The intracellular localization of the mineralocorticoid receptor is regulated by 11 ss-hydroxysteroid dehydrogenase type 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL 7-ALPHA-HYDROXYLASE GENE; 11-BETA-HYDROXYSTEROID DEHYDROGENASE; HUMAN KIDNEY; CORTICOSTEROID 11-BETA-DEHYDROGENASE; HIGH-AFFINITY; GUINEA-PIG; BILE-ACID; RAT; ALDOSTERONE; INHIBITION	11 beta -Hydroxysteroid dehydrogenase (11 beta -HSD) type 2 has been considered to protect the mineralocorticoid receptor (MR) by converting 11 beta -hydroxyglucocorticoids into their inactive 11-keto forms, thereby providing specificity to the TMR for aldosterone. To investigate the functional protection of the MR by 11 beta -HSD2, we coexpressed epitope-tagged MR and 11 beta -HSD2 in HEK-293 cells lacking 11 beta -HSD2 activity and analyzed their subcellular localization by fluorescence microscopy. When expressed alone in the absence of hormones, the MR was both cytoplasmic and nuclear. However, when coexpressed with 11 beta -HSD2, the MR displayed a reticular distribution pattern, suggesting association with 11 beta -HSD2 at the endoplasmic reticulum membrane. The endoplasmic reticulim membrane localization of the AM was observed upon coexpression only with 11 beta -HSD2, but not with 11 beta -HSD1 or other steroid-metabolizing enzymes. Aldosterone induced rapid nuclear translocation of the AM whereas moderate cortisol concentrations (10-200 nM) did not activate the, receptor, due to 11 beta -HSD2-dependent oxidation to cortisone. Compromised 11 beta -HSD2 activity (due to genetic mutations, the presence of inhibitors, or saturating cortisol concentrations) led to cortisol-induced nuclear accumulation of the MR. Surprisingly, the 11 beta -HSD2 product cortisone blocked the aldosterone-induced MR activation by a strictly 11 beta -HSD2-dependent mechanism. Our results provide evidence that 11 beta -HSD2, besides inactivating 11 beta -hydroxyglucocorticoids, functionally interacts with the MR and directly regulates the magnitude of aldosterone-induced MR activation.	Univ Bern, Dept Clin Res, Div Nephrol & Hypertens, CH-3010 Bern, Switzerland	University of Bern	Odermatt, A (corresponding author), Univ Bern, Dept Clin Res, Div Nephrol & Hypertens, Freiburgstr 15, CH-3010 Bern, Switzerland.			Odermatt, Alex/0000-0002-6820-2712				Ackermann D, 1999, HEPATOLOGY, V30, P623, DOI 10.1002/hep.510300303; AGARWAL AK, 1989, J BIOL CHEM, V264, P18939; ALBISTON AL, 1994, MOL CELL ENDOCRINOL, V105, pR11, DOI 10.1016/0303-7207(94)90176-7; ALNEMRI ES, 1991, J BIOL CHEM, V266, P18072; ANDERSSON S, 1990, P NATL ACAD SCI USA, V87, P3640, DOI 10.1073/pnas.87.10.3640; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BEAUMONT K, 1983, ENDOCRINOLOGY, V113, P2043, DOI 10.1210/endo-113-6-2043; BINART N, 1991, P NATL ACAD SCI USA, V88, P10681, DOI 10.1073/pnas.88.23.10681; BREM AS, 1991, AM J PHYSIOL, V261, pF873, DOI 10.1152/ajprenal.1991.261.5.F873; BUHLER H, 1994, STEROIDS, V59, P131, DOI 10.1016/0039-128X(94)90090-6; Couette B, 1996, BIOCHEM J, V315, P421, DOI 10.1042/bj3150421; ESCHER G, 1995, ENDOCRINOLOGY, V136, P1759, DOI 10.1210/en.136.4.1759; Escher G, 1998, GASTROENTEROLOGY, V114, P175, DOI 10.1016/S0016-5085(98)70645-6; FARMAN N, 1991, AM J PHYSIOL, V260, pC226, DOI 10.1152/ajpcell.1991.260.2.C226; Fejes-Toth G, 1998, P NATL ACAD SCI USA, V95, P2973, DOI 10.1073/pnas.95.6.2973; Funder JW, 2000, KIDNEY INT, V57, P1358, DOI 10.1046/j.1523-1755.2000.00975.x; FUNDER JW, 1990, FASEB J, V4, P3234, DOI 10.1096/fasebj.4.14.2172062; Fuster D, 1998, ENDOCRINOLOGY, V139, P3849, DOI 10.1210/en.139.9.3849; Gao HB, 1997, ENDOCRINOLOGY, V138, P156, DOI 10.1210/en.138.1.156; GOMEZSANCHEZ EP, 1992, AM J PHYSIOL, V263, pE1125; GuiochonMantel A, 1996, J STEROID BIOCHEM, V56, P3, DOI 10.1016/0960-0760(95)00268-5; HOLBROOK MM, 1980, J STEROID BIOCHEM, V13, P1355, DOI 10.1016/0022-4731(80)90097-7; Ishibashi S, 1996, J BIOL CHEM, V271, P18017, DOI 10.1074/jbc.271.30.18017; KENYON CJ, 1984, CLIN SCI, V67, P329, DOI 10.1042/cs0670329; Kotelevtsev Y, 1997, P NATL ACAD SCI USA, V94, P14924, DOI 10.1073/pnas.94.26.14924; Kotelevtsev Y, 1999, J CLIN INVEST, V103, P683, DOI 10.1172/JCI4445; KROZOWSKI ZS, 1983, P NATL ACAD SCI-BIOL, V80, P6056, DOI 10.1073/pnas.80.19.6056; KROZOWSKI ZS, 1989, ENDOCRINOLOGY, V125, P192, DOI 10.1210/endo-125-1-192; Kyossev Z, 1996, KIDNEY INT, V49, P271, DOI 10.1038/ki.1996.39; LAKSHMI V, 1988, ENDOCRINOLOGY, V123, P2390, DOI 10.1210/endo-123-5-2390; Lindsay RS, 1996, HYPERTENSION, V27, P1200, DOI 10.1161/01.HYP.27.6.1200; LOMBES M, 1994, BIOCHEM J, V302, P191, DOI 10.1042/bj3020191; LOMBES M, 1990, P NATL ACAD SCI USA, V87, P1086, DOI 10.1073/pnas.87.3.1086; MONDER C, 1989, ENDOCRINOLOGY, V125, P1046, DOI 10.1210/endo-125-2-1046; Morris DJ, 2000, KIDNEY INT, V57, P1370, DOI 10.1046/j.1523-1755.2000.00977.x; MYLES K, 1994, AM J PHYSIOL, V267, pE268, DOI 10.1152/ajpendo.1994.267.2.E268; Mziaut H, 1999, J BIOL CHEM, V274, P14122, DOI 10.1074/jbc.274.20.14122; Naray-Fejes-Toth A, 1998, ENDOCRINOLOGY, V139, P2955, DOI 10.1210/en.139.6.2955; Odermatt A, 1999, J BIOL CHEM, V274, P28762, DOI 10.1074/jbc.274.40.28762; Odermatt A, 1998, J BIOL CHEM, V273, P12360, DOI 10.1074/jbc.273.20.12360; Odermatt A, 2001, J CLIN ENDOCR METAB, V86, P1247, DOI 10.1210/jc.86.3.1247; PAWLOWSKI JE, 1991, J BIOL CHEM, V266, P8820; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Quinkler M, 1999, J CLIN ENDOCR METAB, V84, P4165, DOI 10.1210/jc.84.11.4165; ROBERTSON NM, 1993, MOL ENDOCRINOL, V7, P1226, DOI 10.1210/me.7.9.1226; SASANO H, 1992, J ENDOCRINOL, V132, P305, DOI 10.1677/joe.0.1320305; SATOH K, 1993, NUCLEIC ACIDS RES, V21, P4429, DOI 10.1093/nar/21.18.4429; Schwarz M, 1996, J BIOL CHEM, V271, P18024, DOI 10.1074/jbc.271.30.18017; SOUNESS GW, 1989, ENDOCRINOLOGY, V124, P1588, DOI 10.1210/endo-124-3-1588; SOUNESS GW, 1995, ENDOCRINOLOGY, V136, P1809, DOI 10.1210/en.136.4.1809; Stewart PM, 1999, VITAM HORM, V57, P249; STEWART PM, 1994, J CLIN ENDOCR METAB, V79, P480, DOI 10.1210/jc.79.2.480; Trapp T, 1996, TRENDS PHARMACOL SCI, V17, P145, DOI 10.1016/0165-6147(96)81590-2; Voice MW, 1996, BIOCHEM J, V317, P621, DOI 10.1042/bj3170621; White PC, 1997, ENDOCR REV, V18, P135, DOI 10.1210/er.18.1.135; WILSON RC, 1995, J CLIN ENDOCR METAB, V80, P2263, DOI 10.1210/jc.80.7.2263; Windle RJ, 1998, ENDOCRINOLOGY, V139, P4044, DOI 10.1210/en.139.10.4044; YOUNG M, 1994, J CLIN INVEST, V93, P2578, DOI 10.1172/JCI117269; Young MJ, 1996, AM J PHYSIOL-ENDOC M, V271, pE883, DOI 10.1152/ajpendo.1996.271.5.E883; ZHANG YD, 1994, J STEROID BIOCHEM, V49, P81, DOI 10.1016/0960-0760(94)90304-2	60	109	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28484	28492		10.1074/jbc.M100374200	http://dx.doi.org/10.1074/jbc.M100374200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11350956	hybrid			2022-12-25	WOS:000170093400099
J	Yamashita, A; Kawagishi, N; Miyashita, T; Nagatsuka, T; Sugiura, T; Kume, K; Shimizu, T; Waku, K				Yamashita, A; Kawagishi, N; Miyashita, T; Nagatsuka, T; Sugiura, T; Kume, K; Shimizu, T; Waku, K			ATP-independent fatty acyl-coenzyme A synthesis from phospholipid - Coenzyme A-dependent transacylation activity toward lysophosphatidic acid catalyzed by acyl-coenzyme A : lysophosphatidic acid acyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; ARACHIDONIC-ACID; RAT-LIVER; MEMBRANE PHOSPHOLIPIDS; CDNA CLONING; COA; METABOLISM; LYSOPHOSPHOLIPIDS; EXPRESSION; ACYLATION	CoA-dependent transacylation activity in microsomes is known to catalyze the transfer of fatty acids between phospholipids and lysophospholipids in the presence of CoA without the generation of free fatty acids. We previously found a novel acyl-CoA synthetic pathway, ATP-independent acyl-CoA synthesis from phospholipids. We proposed that: 1) the ATP-independent acyl-CoA synthesis is due to the reverse reaction of acyl-CoA:lysophospholipid acyltransferases and 2) the reverse and forward reactions of acyltransferases can combine to form a CoA-dependent transacylation system. To test these proposals, we examined whether or not recombinant mouse acyl-CoA:1-acyl-sn-glycero-3-phosphate (lysophosphatidic acid, LPA) acyltransferase (LPAAT) could catalyze ATP-independent acyl-CoA synthetic activity and CoA-dependent transacylation activity. ATP-independent acyl-CoA synthesis was indeed found in the membrane fraction from Escherichia coli cells expressing mouse LPAAT, whereas negligible activity was observed in mock-transfected cells. Phosphatidic acid (PA), but not free fatty acids, served as an acyl donor for the reaction, and LPA was formed from PA in a CoA-dependent manner during acyl-CoA synthesis. These results indicate that the ATP-independent acyl-CoA synthesis was due to the reverse reaction of LPAAT, In addition, bacterial membranes containing LPAAT catalyzed CoA-dependent acylation of LPA; PA but not free fatty acid served as an acyl donor. These results indicate that the CoA-dependent transacylation of LPA consists of 1) acyl-CoA synthesis hom PA through the reverse action of LPAAT and 2) the transfer of the fatty acyl moiety of the newly formed acyl-CoA to LPA through the forward reaction of LPAAT.	Teikyo Univ, Fac Pharmaceut Sci, Kanagawa 1990195, Japan; Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Hongo, Japan; Japan Sci & Technol Corp, CREST, Bunkyo Ku, Tokyo 1130033, Japan	Teikyo University; University of Tokyo; Japan Science & Technology Agency (JST)	Yamashita, A (corresponding author), Teikyo Univ, Fac Pharmaceut Sci, Kanagawa 1990195, Japan.	ayamashi@pharm.teikyo-u.ac.jp		Kume, Kazuhiko/0000-0003-4232-1657; Yamashita, Atsushi/0000-0002-2544-2134				Aguado B, 1998, J BIOL CHEM, V273, P4096, DOI 10.1074/jbc.273.7.4096; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRONFMAN M, 1988, BIOCHEM BIOPH RES CO, V152, P987, DOI 10.1016/S0006-291X(88)80381-4; BURSTEN S, 1994, CIRC SHOCK, V44, P14; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; COLARD O, 1984, BIOCHIM BIOPHYS ACTA, V793, P42, DOI 10.1016/0005-2760(84)90051-1; COLEMAN J, 1990, J BIOL CHEM, V265, P17215; COLEMAN J, 1992, MOL GEN GENET, V232, P295, DOI 10.1007/BF00280009; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; DEENEY JT, 1992, J BIOL CHEM, V267, P19840; Eberhardt C, 1997, J BIOL CHEM, V272, P20299, DOI 10.1074/jbc.272.32.20299; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Holub B J, 1978, Adv Lipid Res, V16, P1; HUANG WH, 1989, J BIOL CHEM, V264, P2605; IRVINE RF, 1979, BIOCHEM BIOPH RES CO, V91, P1399, DOI 10.1016/0006-291X(79)91222-1; KRAMER RM, 1984, J BIOL CHEM, V259, P2403; KRAMER RM, 1984, J BIOL CHEM, V259, P3316; KRAMER RM, 1983, J BIOL CHEM, V258, P3806; Kume K, 1997, BIOCHEM BIOPH RES CO, V237, P663, DOI 10.1006/bbrc.1997.7214; Lands W., 1976, ENZYMES BIOL MEMBRAN, V2, P3; LANDS WEM, 1960, J BIOL CHEM, V235, P2233; LANDS WEM, 1965, J BIOL CHEM, V240, P1905; LI QL, 1990, J BIOCHEM-TOKYO, V107, P699, DOI 10.1093/oxfordjournals.jbchem.a123111; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD JIS, 1991, BIOCHIM BIOPHYS ACTA, V1084, P105, DOI 10.1016/0005-2760(91)90209-Z; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; NAKAGAWA Y, 1989, PROG LIPID RES, V28, P205, DOI 10.1016/0163-7827(89)90013-1; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; ROBINSON M, 1985, J BIOL CHEM, V260, P7889; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SEUBERT W, 1960, BIOCHEM PREP, V7, P80; Singer J. W., 1994, EXPERT OPIN INV DRUG, V3, P631; SNYDER F, 1992, PROG LIPID RES, V31, P65, DOI 10.1016/0163-7827(92)90016-C; Stamps AC, 1997, BIOCHEM J, V326, P455, DOI 10.1042/bj3260455; STEINMAN HM, 1973, J BIOL CHEM, V248, P892; STYMNE S, 1985, BIOCHIM BIOPHYS ACTA, V837, P239, DOI 10.1016/0005-2760(85)90047-5; SUGIURA T, 1995, J LIPID RES, V36, P440; SUGIURA T, 1995, BBA-LIPID LIPID MET, V1255, P167, DOI 10.1016/0005-2760(94)00237-S; SUGIURA T, 1987, J BIOL CHEM, V262, P1199; SUGIURA T, 1988, J BIOL CHEM, V263, P17490; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; TOKUMURA A, 1995, PROG LIPID RES, V34, P151, DOI 10.1016/0163-7827(95)00001-G; TROTTER J, 1982, J BIOL CHEM, V257, P1816; Uchiyama A, 1996, J BIOL CHEM, V271, P30360, DOI 10.1074/jbc.271.48.30360; WAKU K, 1992, BIOCHIM BIOPHYS ACTA, V1124, P101, DOI 10.1016/0005-2760(92)90085-A; West J, 1997, DNA CELL BIOL, V16, P691, DOI 10.1089/dna.1997.16.691; YAMASHITA A, 1995, BIOCHEM J, V312, P301, DOI 10.1042/bj3120301; Yamashita A, 1997, J BIOCHEM-TOKYO, V122, P1	48	23	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26745	26752		10.1074/jbc.M101795200	http://dx.doi.org/10.1074/jbc.M101795200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11352914	hybrid			2022-12-25	WOS:000169966900004
J	Canobbio, I; Bertoni, A; Lova, P; Paganini, S; Hirsch, E; Sinigaglia, F; Balduini, C; Torti, M				Canobbio, I; Bertoni, A; Lova, P; Paganini, S; Hirsch, E; Sinigaglia, F; Balduini, C; Torti, M			Platelet activation by von Willebrand Factor requires coordinated signaling through thromboxane A(2) and Fc gamma IIA receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHORYLATION; GLYCOPROTEIN-IB; PHOSPHOLIPASE C-GAMMA-2; COLLAGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; IX; SYK; CYTOSKELETON; ASSOCIATION; ALPHA	Interaction of von Willebrand Factor with glycoprotein Ib-M-V induces platelet activation through a still poorly defined mechanism. Previous studies have suggested a possible role for the low affinity receptor for immunoglobulin, Fc gamma RIIA, in GPIb-IX-V signaling. Here we show that binding of VWF to platelets induces the tyrosine phosphorylation of Fc gamma RIIA by a Src kinase, Treatment of platelets with the anti-Fc gamma RIIA monoclonal antibody IV.3 specifically inhibits vWF-induced but not thrombin-induced pleckstrin phosphorylation and serotonin secretion. Moreover, VWF fails to induce pleckstrin phosphorylation in mouse platelets, lacking Fc gamma RIIA, and serotonin secretion is impaired. Pleckstrin phosphorylation and serotonin secretion in human platelets stimulated with vWF are blocked by the cyclooxygenase inhibitor acetylsalicylic acid. However, release of arachidonic acid and synthesis of TxA(2) induced by vWF are not affected by the anti-Fc gamma RIIA monoclonal antibody IV.3, Similarly, vWF-induced tyrosine phosphorylation of Fc gamma RIIA, as well as of Syk and PLC gamma2, occurs normally in aspirinized platelets. Inhibition of the tyrosine kinase Syk by piceatannol does not affect vWF-induced tyrosine phosphorylation of Fc gamma RIIA but prevents phosphorylation of PLC gamma2, Pleckstrin phosphorylation and platelet secretion induced by VWF, but not by thrombin, are also inhibited by piceatannol, Pleckstrin phosphorylation is also sensitive to the phosphatidylinositol 3-kinase inhibitor wortmannin. These results indicate that PLC gamma2 plays a central role in platelet activation by vWF and that the stimulation of this enzyme requires coordinated signals through endogenous TxA(2) and Fc gamma RIIA.	Univ Pavia, Dept Biochem, I-27100 Pavia, Italy; Univ A Avogadro, Dept Med Sci, I-28100 Novara, Italy; Univ Turin, Dept Genet Biol & Biochem, Turin, Italy	University of Pavia; University of Eastern Piedmont Amedeo Avogadro; University of Turin	Torti, M (corresponding author), Univ Pavia, Dept Biochem, Via Bassi 21, I-27100 Pavia, Italy.		Canobbio, Ilaria/L-7414-2013; Hirsch, Emilio/F-4848-2013	Canobbio, Ilaria/0000-0002-9643-3403; Hirsch, Emilio/0000-0002-9073-6024				ANDERSON CL, 1995, SEMIN THROMB HEMOST, V21, P1, DOI 10.1055/s-2007-1000374; Asazuma N, 1997, BLOOD, V90, P4789, DOI 10.1182/blood.V90.12.4789.4789_4789_4798; Bergmeier W, 2000, BLOOD, V95, P886, DOI 10.1182/blood.V95.3.886.003k45_886_893; BLAKE RA, 1994, FEBS LETT, V353, P212, DOI 10.1016/0014-5793(94)01037-4; Briddon SJ, 1999, BIOCHEM J, V338, P203, DOI 10.1042/0264-6021:3380203; CHACKO GW, 1994, J BIOL CHEM, V269, P32435; Cunningham JG, 1996, J BIOL CHEM, V271, P11581, DOI 10.1074/jbc.271.19.11581; DU XP, 1994, J BIOL CHEM, V269, P18287; Falati S, 1999, BLOOD, V94, P1648, DOI 10.1182/blood.V94.5.1648.417k31_1648_1656; Gratacap MP, 1998, J BIOL CHEM, V273, P24314, DOI 10.1074/jbc.273.38.24314; Gross BS, 1999, J BIOL CHEM, V274, P5963, DOI 10.1074/jbc.274.9.5963; JACKSON SP, 1994, J BIOL CHEM, V269, P27093; KROLL MH, 1991, J CLIN INVEST, V88, P1568, DOI 10.1172/JCI115468; Law DA, 1999, BLOOD, V93, P2645, DOI 10.1182/blood.V93.8.2645.408k13_2645_2652; MEYER D, 1993, THROMB HAEMOSTASIS, V70, P99; OZAKI Y, 1995, BBA-GEN SUBJECTS, V1243, P482, DOI 10.1016/0304-4165(94)00178-Z; Pasquet JM, 1999, MOL CELL BIOL, V19, P8326; Pasquet JM, 1999, BIOCHEM J, V342, P171, DOI 10.1042/0264-6021:3420171; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Sullam PM, 1998, J BIOL CHEM, V273, P5331, DOI 10.1074/jbc.273.9.5331; Sun B, 1999, BIOCHEM BIOPH RES CO, V266, P24, DOI 10.1006/bbrc.1999.1761; Torti M, 1999, J BIOL CHEM, V274, P13690, DOI 10.1074/jbc.274.19.13690; TORTI M, 1993, P NATL ACAD SCI USA, V90, P7553, DOI 10.1073/pnas.90.16.7553; Tsakiris DA, 1999, THROMB HAEMOSTASIS, V81, P177, DOI 10.1055/s-0037-1614439; WARE J, 1993, J BIOL CHEM, V268, P8376; Ware J, 1998, THROMB HAEMOSTASIS, V79, P466; YANAGA F, 1995, BIOCHEM J, V311, P471, DOI 10.1042/bj3110471; Zaffran Y, 2000, J BIOL CHEM, V275, P16779, DOI 10.1074/jbc.275.22.16779	28	65	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26022	26029		10.1074/jbc.M102639200	http://dx.doi.org/10.1074/jbc.M102639200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11344169	hybrid			2022-12-25	WOS:000169823300052
J	Huang, CF; De Sanctis, GT; O'Brien, PJ; Mizgerd, JP; Friend, DS; Drazen, JM; Brass, LF; Stevens, RL				Huang, CF; De Sanctis, GT; O'Brien, PJ; Mizgerd, JP; Friend, DS; Drazen, JM; Brass, LF; Stevens, RL			Evaluation of the substrate specificity of human mast cell tryptase beta I and demonstration of its importance in bacterial infections of the lung	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINASE-ACTIVATED RECEPTOR-2; VEIN ENDOTHELIAL-CELLS; CHONDROITIN SULFATE-E; MOLECULAR-CLONING; AIRWAY HYPERRESPONSIVENESS; FUNCTIONAL EXPRESSION; THROMBIN RECEPTORS; GRANULE PROTEASES; COMPLEMENTARY-DNA; SERINE PROTEASES	Human pulmonary mast cells (MCs) express tryptases alpha and betaI, and both granule serine proteases are exocytosed during inflammatory events. Recombinant forms of these tryptases were generated for the first time to evaluate their substrate specificities at the biochemical level and then to address their physiologic roles in pulmonary inflammation. Analysis of a tryptase-specific, phage display peptide library revealed that tryptase betaI prefers to cleave peptides with 1 or more Pro residues flanked by 2 positively charged residues. Although recombinant tryptase betaI was unable to activate cultured cells that express different types of protease-activated receptors, the numbers of neutrophils increased > 100-fold when enzymatically active tryptase betaI was instilled into the lungs of mice, In contrast, the numbers of lymphocytes and eosinophils in the airspaces did not change significantly. More important, the tryptase betaI-treated mice exhibited normal airway responsiveness. Neutrophils did not extravasate into the lungs of tryptase alpha -treated mice, Thus, this is the first study to demonstrate that the two nearly identical human MC tryptases are functionally distinct in vivo. When MC-deficient W/W-nu mice were given enzymatically active tryptase betaI or its inactive zymogen before pulmonary infection with Klebsiella prteumoniae, tryptase betaI-treated W/W-nu mice had fewer viable bacteria in their lungs relative to zymogen-treated W/W-nu mice, Because neutrophils are required to combat bacterial infections, human tryptase betaI plays a critical role in the antibacterial host defenses of the lung by recruiting neutrophils in a manner that does not alter airway reactivity,	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Brigham & Womens Hosp, Combined Program Pulm & Crit Care Med, Boston, MA 02115 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Harvard Univ, Sch Publ Hlth, Physiol Program, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; University of Pennsylvania; Harvard University; Harvard T.H. Chan School of Public Health	Stevens, RL (corresponding author), Brigham & Womens Hosp, Dept Med, Smith Bldg,Rm 616B,1 Jimmy Fund Way, Boston, MA 02115 USA.	rstevens@rics.bwh.harvard.edu	Drazen, Jeffrey M/E-5841-2012; Mizgerd, Joseph/GRY-6369-2022; O'Brien, Peter J/B-5182-2013	O'Brien, Peter J/0000-0003-4127-2718; Mizgerd, Joseph/0000-0002-4042-3169	NATIONAL CANCER INSTITUTE [P30CA016520] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063284, R01HL052132, R29HL052132, P01HL040387, P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK019525] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16520] Funding Source: Medline; NHLBI NIH HHS [HL-63284, HL-52132, HL-40387, HL-36110] Funding Source: Medline; NIAID NIH HHS [AI-23483] Funding Source: Medline; NIDDK NIH HHS [DK-19525] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRASS LF, 1991, J BIOL CHEM, V266, P958; BULLARD DC, 1995, J CLIN INVEST, V95, P1782, DOI 10.1172/JCI117856; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; Cairns JA, 1996, J IMMUNOL, V156, P275; Caughey GH, 2000, J IMMUNOL, V164, P6566, DOI 10.4049/jimmunol.164.12.6566; Compton SJ, 1998, J IMMUNOL, V161, P1939; Corvera CU, 1997, J CLIN INVEST, V100, P1383, DOI 10.1172/JCI119658; CROMLISH JA, 1987, J BIOL CHEM, V262, P1363; Dary O, 1999, BIOCHEM SOC T, V27, P246, DOI 10.1042/bst0270246; de Sanctis GT, 1999, J CLIN INVEST, V103, P507, DOI 10.1172/JCI4017; DESANCTIS GT, 1995, NAT GENET, V11, P150, DOI 10.1038/ng1095-150; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Galli SJ, 1999, CURR OPIN IMMUNOL, V11, P53, DOI 10.1016/S0952-7915(99)80010-7; GHILDYAL N, 1994, J IMMUNOL, V153, P2624; Ghildyal N, 1996, J EXP MED, V184, P1061, DOI 10.1084/jem.184.3.1061; GREENBERG SM, 1988, BLOOD, V72, P1968; GURISH MF, 1991, J IMMUNOL, V146, P1527; GURISH MF, 1994, MAMM GENOME, V5, P656, DOI 10.1007/BF00411467; GURISH MF, 1993, J BIOL CHEM, V268, P11372; Hallgren J, 2000, BIOCHEMISTRY-US, V39, P13068, DOI 10.1021/bi000973b; HARTMANN T, 1994, AM J PHYSIOL, V267, pL113, DOI 10.1152/ajplung.1994.267.2.L113; He SH, 1997, J IMMUNOL, V159, P6216; Hollenberg MD, 1999, CAN J PHYSIOL PHARM, V77, P458, DOI 10.1139/cjpp-77-6-458; Howells GL, 1997, J CELL SCI, V110, P881; Huang C, 2000, J BIOL CHEM, V275, P351, DOI 10.1074/jbc.275.1.351; Huang CF, 1997, J BIOL CHEM, V272, P31885, DOI 10.1074/jbc.272.50.31885; Huang CF, 1998, J IMMUNOL, V160, P1910; Huang CF, 1999, J BIOL CHEM, V274, P19670, DOI 10.1074/jbc.274.28.19670; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Hunt JE, 1996, J BIOL CHEM, V271, P2851, DOI 10.1074/jbc.271.5.2851; Inoue M, 1999, BIOCHEM BIOPH RES CO, V266, P564, DOI 10.1006/bbrc.1999.1870; Kahn ML, 1999, J CLIN INVEST, V103, P879, DOI 10.1172/JCI6042; Kawabata A, 1998, BRIT J PHARMACOL, V125, P419, DOI 10.1038/sj.bjp.0702063; Lukacs NW, 1996, PATHOBIOLOGY, V64, P308, DOI 10.1159/000164065; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; Maurer M, 1998, J EXP MED, V188, P2343, DOI 10.1084/jem.188.12.2343; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; MILLER JS, 1990, J CLIN INVEST, V86, P864, DOI 10.1172/JCI114786; MILLER JS, 1989, J CLIN INVEST, V84, P1188, DOI 10.1172/JCI114284; Mirza H, 1997, BLOOD, V90, P3914, DOI 10.1182/blood.V90.10.3914; Mizgerd JP, 1999, J IMMUNOL, V163, P995; Mizgerd JP, 1997, J EXP MED, V186, P1357, DOI 10.1084/jem.186.8.1357; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; NAGAI H, 1991, INFLAMMATION, V15, P317, DOI 10.1007/BF00917316; NILSSON G, 1994, SCAND J IMMUNOL, V39, P489, DOI 10.1111/j.1365-3083.1994.tb03404.x; NYSTEDT S, 1995, J BIOL CHEM, V270, P5950, DOI 10.1074/jbc.270.11.5950; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; O'Brien PJ, 2000, J BIOL CHEM, V275, P13502, DOI 10.1074/jbc.275.18.13502; Pallaoro M, 1999, J BIOL CHEM, V274, P3355, DOI 10.1074/jbc.274.6.3355; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; PERONA JJ, 1995, PROTEIN SCI, V4, P337; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; Prodeus AP, 1997, NATURE, V390, P172, DOI 10.1038/36586; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; Schechter NM, 1998, J CELL PHYSIOL, V176, P365, DOI 10.1002/(SICI)1097-4652(199808)176:2<365::AID-JCP15>3.0.CO;2-2; SHUSTER DE, 1995, SCIENCE, V269, P1590, DOI 10.1126/science.7667641; STACK MS, 1994, J BIOL CHEM, V269, P9416; Steinhoff M, 1999, EXP DERMATOL, V8, P282; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; STEVENS RL, 1994, P NATL ACAD SCI USA, V91, P128, DOI 10.1073/pnas.91.1.128; STEVENS RL, 1988, P NATL ACAD SCI USA, V85, P2284, DOI 10.1073/pnas.85.7.2284; THOMPSON HL, 1988, J IMMUNOL, V140, P2708; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; Wang HW, 2000, FASEB J, V14, pA1239; WONG GW, J BIOL CHEM, V276, P20464; Wong UW, 1999, J BIOL CHEM, V274, P30784, DOI 10.1074/jbc.274.43.30784; WOOLKALIS MJ, 1995, J BIOL CHEM, V270, P9868, DOI 10.1074/jbc.270.17.9868	72	120	123	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26276	26284		10.1074/jbc.M102356200	http://dx.doi.org/10.1074/jbc.M102356200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11335723	hybrid			2022-12-25	WOS:000169823300085
J	Millman, JS; Qi, HY; Vulcu, F; Bernstein, HD; Andrews, DW				Millman, JS; Qi, HY; Vulcu, F; Bernstein, HD; Andrews, DW			FtsY binds to the Escherichia coli inner membrane via interactions with phosphatidylethanolamine and membrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; SEQUENCE RECOGNITION; ACIDIC PHOSPHOLIPIDS; TARGETING PATHWAYS; NONBILAYER LIPIDS; PLASMA-MEMBRANE; ALPHA-SUBUNIT; BETA-SUBUNIT; NG DOMAIN; RECEPTOR	Targeting of many polytopic proteins to the inner membrane of prokaryotes occurs via an essential signal recognition particle-like pathway. FtsY, the Escherichia coli homolog of the eukaryotic signal recognition particle receptor alpha -subunit, binds to membranes via its amino-terminal AN domain. We demonstrate that FtsY assembles on membranes via interactions with phosphatidylethanolamine and with a trypsin-sensitive component. Both interactions are mediated by the AN domain of FtsY, In the absence of phosphatidylethanolamine, the trypsin-sensitive component is sufficient for binding and function of FtsY in the targeting of membrane proteins. We propose a two-step mechanism for the assembly of FtsY on the membrane similar to that of SecA on the E, coli inner membrane.	McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; NIDDK, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA	McMaster University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Andrews, DW (corresponding author), McMaster Univ, Dept Biochem, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.			Millman, Jonathan/0000-0002-1766-2348; Andrews, David/0000-0002-9266-7157; Vulcu, Felicia/0000-0002-6426-6823				ANDREWS DW, 1989, J CELL BIOL, V108, P797, DOI 10.1083/jcb.108.3.797; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; de Leeuw E, 2000, EMBO J, V19, P531, DOI 10.1093/emboj/19.4.531; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P5323; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; DUZGUNES N, 1981, BIOCHIM BIOPHYS ACTA, V642, P182, DOI 10.1016/0005-2736(81)90148-6; GILL DR, 1990, MOL MICROBIOL, V4, P575; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; HUGHES MJ, 1996, BIOTECHNIQUES, V20, P192; Jander G, 1996, J BACTERIOL, V178, P3049, DOI 10.1128/jb.178.11.3049-3058.1996; Kholodenko BN, 2000, TRENDS CELL BIOL, V10, P173, DOI 10.1016/S0962-8924(00)01741-4; Koch HG, 1999, MOL BIOL CELL, V10, P2163, DOI 10.1091/mbc.10.7.2163; Legate KR, 2000, J BIOL CHEM, V275, P27439; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; Mac Millan SV, 2000, EUR J CELL BIOL, V79, P327, DOI 10.1078/S0171-9335(04)70036-9; MACFARLANE J, 1995, EUR J BIOCHEM, V233, P766, DOI 10.1111/j.1432-1033.1995.766_3.x; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; Millman JS, 1999, J BIOL CHEM, V274, P33227, DOI 10.1074/jbc.274.47.33227; Montoya G, 1997, NATURE, V385, P365, DOI 10.1038/385365a0; OHTA A, 1977, J BACTERIOL, V132, P434, DOI 10.1128/JB.132.2.434-443.1977; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; Powers T, 1997, EMBO J, V16, P4880, DOI 10.1093/emboj/16.16.4880; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; Qi HY, 1999, J BIOL CHEM, V274, P8993, DOI 10.1074/jbc.274.13.8993; RIETVELD AG, 1993, J BIOL CHEM, V268, P12427; RIETVELD AG, 1995, EMBO J, V14, P5506, DOI 10.1002/j.1460-2075.1995.tb00237.x; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; Scotti PA, 1999, J BIOL CHEM, V274, P29883, DOI 10.1074/jbc.274.42.29883; Seluanov A, 1997, J BIOL CHEM, V272, P2053; STRUCK JCR, 1988, NUCLEIC ACIDS RES, V16, P7740, DOI 10.1093/nar/16.15.7740; Tian HP, 2000, P NATL ACAD SCI USA, V97, P4730, DOI 10.1073/pnas.090087297; TRAXLER B, 1992, J BIOL CHEM, V267, P5339; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; van der Does C, 2000, J BIOL CHEM, V275, P2472, DOI 10.1074/jbc.275.4.2472; YOUNG JC, 1995, J BIOL CHEM, V270, P15650, DOI 10.1074/jbc.270.26.15650; Zelazny A, 1997, P NATL ACAD SCI USA, V94, P6025, DOI 10.1073/pnas.94.12.6025	40	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25982	25989		10.1074/jbc.M011331200	http://dx.doi.org/10.1074/jbc.M011331200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11353766	hybrid			2022-12-25	WOS:000169823300047
J	Murnion, ME; Adams, RR; Callister, DM; Allis, CD; Earnshaw, WC; Swedlow, JR				Murnion, ME; Adams, RR; Callister, DM; Allis, CD; Earnshaw, WC; Swedlow, JR			Chromatin-associated protein phosphatase 1 regulates aurora-B and histone H3 phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE-II; CHROMOSOME CONDENSATION; STRUCTURAL-CHANGES; MITOTIC CHROMOSOMES; CENTRAL SPINDLE; OKADAIC ACID; KINASE; XENOPUS; MITOSIS; INTERPHASE	Proper chromosome condensation requires the phosphorylation of histone and nonhistone chromatin proteins. We have used an in vitro chromosome assembly system based on Xenopus egg cytoplasmic extracts to study mitotic histone H3 phosphorylation, We identified a histone H3 Ser(10) kinase activity associated with isolated mitotic chromosomes. The histone H3 kinase was not affected by inhibitors of cyclin-dependent kinases, DNA-dependent protein kinase, p90(rsk), or cAMP-dependent protein kinase, The activity could be selectively eluted from mitotic chromosomes and immunoprecipitated by specific anti-X aurora-B/AIRK2 antibodies. This activity was regulated by phosphorylation. Treatment of X aurora-B immunoprecipitates with recombinant protein phosphatase 1 (PP1) inhibited kinase activity. The presence of PP1 on chromatin suggested that PP1 might directly regulate the X aurora-B associated kinase activity. Indeed, incubation of isolated interphase chromatin with the PP1-specific inhibitor I2 and ATP generated an H3 kinase activity that was also specifically immunoprecipitated by anti-X aurora-B antibodies. Nonetheless, we found that stimulation of histone H3 phosphorylation in interphase cytosol does not drive chromosome condensation or targeting of 13 S condensin to chromatin, In summary, the chromosome-associated mitotic histone H3 Ser(10) kinase is associated with X aurora-B and is inhibited directly in interphase chromatin by PP1.	Univ Dundee, Sch Life Sci, Div Mol Cell Biol, Dundee DD1 5EH, Scotland; Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Inst Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Univ Virginia, Charlottesville, VA 22908 USA	University of Dundee; University of Edinburgh; University of Virginia	Swedlow, JR (corresponding author), Univ Dundee, Sch Life Sci, Div Mol Cell Biol, MSI-WTB Complex,Dow St, Dundee DD1 5EH, Scotland.	j.swedlow@dundee.ac.uk	Earnshaw, William/AAY-7438-2020	Adams, Richard/0000-0003-1501-0941; Swedlow, Jason/0000-0002-2198-1958; Earnshaw, William/0000-0002-7191-0621	Wellcome Trust [073915] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; Adams RR, 2000, CURR BIOL, V10, P1075, DOI 10.1016/S0960-9822(00)00673-4; Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Ajiro K, 1996, J BIOL CHEM, V271, P13197, DOI 10.1074/jbc.271.22.13197; Andreassen PR, 1998, J CELL BIOL, V141, P1207, DOI 10.1083/jcb.141.5.1207; Andresson T, 1998, EMBO J, V17, P5627, DOI 10.1093/emboj/17.19.5627; BARRATT MJ, 1994, P NATL ACAD SCI USA, V91, P4781, DOI 10.1073/pnas.91.11.4781; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; BRADBURY EM, 1992, BIOESSAYS, V14, P9; CARDENAS ME, 1993, J CELL SCI, V104, P219; CHAN CSM, 1993, GENETICS, V135, P677; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; de la Barre AE, 2000, EMBO J, V19, P379, DOI 10.1093/emboj/19.3.379; EARNSHAW WC, 1991, J CELL SCI, V98, P443; Field CM, 1998, METHOD ENZYMOL, V298, P525, DOI 10.1016/S0076-6879(98)98043-0; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Giet R, 1999, J CELL SCI, V112, P3591; Giet R, 1999, J BIOL CHEM, V274, P15005, DOI 10.1074/jbc.274.21.15005; Giet R, 2001, J CELL BIOL, V152, P669, DOI 10.1083/jcb.152.4.669; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gross SD, 2000, CURR BIOL, V10, P430, DOI 10.1016/S0960-9822(00)00425-5; GUO XW, 1995, EMBO J, V14, P976, DOI 10.1002/j.1460-2075.1995.tb07078.x; GURLEY LR, 1973, BIOCHEM BIOPH RES CO, V50, P744, DOI 10.1016/0006-291X(73)91307-7; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hardie DG, 1999, PROTEIN PHOSPHORYLAT, P201; HECK MMS, 1989, J BIOL CHEM, V264, P15161; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; HELPS NR, 1994, FEBS LETT, V340, P93, DOI 10.1016/0014-5793(94)80179-7; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; Hirano T, 1998, CURR OPIN CELL BIOL, V10, P317, DOI 10.1016/S0955-0674(98)80006-9; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; Hoque MT, 2001, J BIOL CHEM, V276, P5059, DOI 10.1074/jbc.M007809200; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Jin Y, 2000, J CELL BIOL, V149, P1005, DOI 10.1083/jcb.149.5.1005; Kaitna S, 2000, CURR BIOL, V10, P1172, DOI 10.1016/S0960-9822(00)00721-1; Kaszas E, 2000, J CELL SCI, V113, P3217; Kim JH, 1999, J CELL BIOL, V145, P1381, DOI 10.1083/jcb.145.7.1381; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; Kimura K, 2000, P NATL ACAD SCI USA, V97, P11972, DOI 10.1073/pnas.220326097; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LOHKA MJ, 1984, J CELL BIOL, V98, P1222, DOI 10.1083/jcb.98.4.1222; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MARION C, 1985, J MOL BIOL, V186, P367, DOI 10.1016/0022-2836(85)90111-1; MAZEN A, 1987, J MOL BIOL, V194, P741, DOI 10.1016/0022-2836(87)90251-8; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; PAULSON JR, 1982, J BIOL CHEM, V257, P6064; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Roghi C, 1998, J CELL SCI, V111, P557; Sagata N, 1997, BIOESSAYS, V19, P13, DOI 10.1002/bies.950190105; Schumacher JM, 1998, DEVELOPMENT, V125, P4391; Schumacher JM, 1998, J CELL BIOL, V143, P1635, DOI 10.1083/jcb.143.6.1635; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; SMITH RC, 1988, GENE DEV, V2, P1284, DOI 10.1101/gad.2.10.1284; Speliotes EK, 2000, MOL CELL, V6, P211, DOI 10.1016/S1097-2765(00)00023-X; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Swedlow JR, 1999, PRACT APPROACH SER, P165; Tate P, 1998, J CELL SCI, V111, P2575; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Tomonaga T, 2000, GENE DEV, V14, P2757, DOI 10.1101/gad.832000; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; WILSON KL, 1988, J CELL BIOL, V107, P57, DOI 10.1083/jcb.107.1.57; Zweidler A, 1978, Methods Cell Biol, V17, P223, DOI 10.1016/S0091-679X(08)61145-0	74	202	206	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26656	26665		10.1074/jbc.M102288200	http://dx.doi.org/10.1074/jbc.M102288200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11350965	hybrid			2022-12-25	WOS:000169823300131
J	Schaerer, MT; Kannenberg, K; Hunziker, P; Baumann, SW; Sigel, E				Schaerer, MT; Kannenberg, K; Hunziker, P; Baumann, SW; Sigel, E			Interaction between GABA(A) receptor beta subunits and the multifunctional protein gC1q-R	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C PHOSPHORYLATION; A-RECEPTOR; BENZODIAZEPINE RECEPTOR; MITOCHONDRIAL MATRIX; INTRACELLULAR DOMAINS; P-32 PROTEIN; ACID; BRAIN; EXPRESSION; CELLS	gamma -Aminobutyric acid type A (GABA,) receptors were immunopurified from bovine brain using a monoclonal antibody directed against the alpha1 subunit, Of the several proteins that copurified, a 34-kDa protein was analyzed further. After enrichment and tryptic proteolysis, the resulting fragments were sequenced, and the protein was identified as gC1q-R. Using anti-gC1q-R and anti-GABA(A) receptor antibodies, mutual coimmunoprecipitation could be demonstrated from solubilized rat brain membranes. The stability of this interaction was estimated to be very high, Using the yeast two-hybrid system, various GABAA receptor subunit intracellular loop constructs were tested for an interaction with gC1q-R. All beta subunits, but not alpha1 and gamma2 subunits, were found to bind to gC1q-R, NH2- and COOH-terminally truncated beta2 subunit loops were used to find the region responsible for the interaction with gC1q-R, A stretch of 15 amino acids containing 7 positively charged residues was identified (amino acids 399-413), This region contains residue Ser-410, which is a protein kinase substrate, and it is known that phosphorylation of this residue leads to an alteration in receptor activity. Localization studies suggested a predominantly intracellular localization. Our observations therefore suggest a tight interaction between gC1q-R and the GABA(A) receptor which might be involved in receptor biosynthesis or modulation of the mature function.	Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland; Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland	University of Bern; University of Zurich	Sigel, E (corresponding author), Univ Bern, Dept Pharmacol, Friedbuhlstr 49, CH-3010 Bern, Switzerland.	Erwin.Sigel@pki.unibe.ch	Sigel, Erwin/F-7736-2015					Barnard EA, 1998, PHARMACOL REV, V50, P291; BENNETT V, 1986, METHOD ENZYMOL, V134, P55; BERTOCCI B, 1991, P NATL ACAD SCI USA, V88, P1416, DOI 10.1073/pnas.88.4.1416; BLOUNT P, 1991, J CELL BIOL, V113, P1125, DOI 10.1083/jcb.113.5.1125; Bonnert TP, 1999, P NATL ACAD SCI USA, V96, P9891, DOI 10.1073/pnas.96.17.9891; Brandon NJ, 1999, J NEUROSCI, V19, P9228; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen L, 2000, P NATL ACAD SCI USA, V97, P11557, DOI 10.1073/pnas.190133497; CRAIG AM, 1994, P NATL ACAD SCI USA, V91, P12373, DOI 10.1073/pnas.91.26.12373; Davies PA, 1997, NATURE, V385, P820, DOI 10.1038/385820a0; Dedio J, 1998, J IMMUNOL, V160, P3534; EWERT M, 1990, J CELL BIOL, V110, P2043, DOI 10.1083/jcb.110.6.2043; FORSAYETH JR, 1992, J CELL BIOL, V117, P841, DOI 10.1083/jcb.117.4.841; GHEBREHIWET B, 1994, J EXP MED, V179, P1809, DOI 10.1084/jem.179.6.1809; HARING P, 1985, P NATL ACAD SCI USA, V82, P4837, DOI 10.1073/pnas.82.14.4837; Hedblom E, 1997, J BIOL CHEM, V272, P15346, DOI 10.1074/jbc.272.24.15346; Jiang JZ, 1999, P NATL ACAD SCI USA, V96, P3572, DOI 10.1073/pnas.96.7.3572; Kannenberg K, 1997, J NEUROCHEM, V68, P1352; Kannenberg K, 1999, EUR J NEUROSCI, V11, P1256, DOI 10.1046/j.1460-9568.1999.00533.x; KELLENBERGER S, 1992, J BIOL CHEM, V267, P25660; Kneussel M, 2000, P NATL ACAD SCI USA, V97, P8594, DOI 10.1073/pnas.97.15.8594; KRISHEK BJ, 1994, NEURON, V12, P1081, DOI 10.1016/0896-6273(94)90316-6; Lin YF, 1996, MOL PHARMACOL, V50, P185; LOLAIT SJ, 1989, FEBS LETT, V246, P145, DOI 10.1016/0014-5793(89)80271-6; Lynch NJ, 1997, FEBS LETT, V418, P111, DOI 10.1016/S0014-5793(97)01348-3; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MALHERBE P, 1990, J NEUROSCI, V10, P2330; MALHERBE P, 1990, MOL BRAIN RES, V8, P199, DOI 10.1016/0169-328X(90)90017-8; Matthews DA, 1998, J GEN VIROL, V79, P1677, DOI 10.1099/0022-1317-79-7-1677; MCDONALD BJ, 1994, J BIOL CHEM, V269, P18111; McDonald BJ, 1998, NAT NEUROSCI, V1, P23, DOI 10.1038/223; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; MOSS SJ, 1995, NATURE, V377, P344, DOI 10.1038/377344a0; MOSS SJ, 1992, J BIOL CHEM, V267, P14470; MOSS SJ, 1992, SCIENCE, V257, P661, DOI 10.1126/science.1323140; Muta T, 1997, J BIOL CHEM, V272, P24363, DOI 10.1074/jbc.272.39.24363; NUSSER Z, 1995, J NEUROSCI, V15, P2948; NUSSER Z, 1995, EUR J NEUROSCI, V7, P630, DOI 10.1111/j.1460-9568.1995.tb00667.x; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; Scotti AL, 1999, PHILOS T ROY SOC B, V354, P357, DOI 10.1098/rstb.1999.0387; Seytter T, 1998, YEAST, V14, P303, DOI 10.1002/(SICI)1097-0061(19980315)14:4<303::AID-YEA217>3.0.CO;2-N; SIEGHART W, 1995, PHARMACOL REV, V47, P181; SIGEL E, 1987, J PHYSIOL-LONDON, V386, P73, DOI 10.1113/jphysiol.1987.sp016523; SIGEL E, 1983, J BIOL CHEM, V258, P6965; Sigel E, 1997, TRENDS PHARMACOL SCI, V18, P425, DOI 10.1016/S0165-6147(97)90675-1; Sinkkonen ST, 2000, J NEUROSCI, V20, P3588, DOI 10.1523/JNEUROSCI.20-10-03588.2000; Soltys BJ, 2000, HISTOCHEM CELL BIOL, V114, P245; Storz P, 2000, J BIOL CHEM, V275, P24601, DOI 10.1074/jbc.M002964200; Tretter V, 1997, J NEUROSCI, V17, P2728; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Xu ZJ, 1999, J BIOL CHEM, V274, P21149, DOI 10.1074/jbc.274.30.21149; YMER S, 1989, EMBO J, V8, P1665, DOI 10.1002/j.1460-2075.1989.tb03557.x	52	20	26	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26597	26604		10.1074/jbc.M102534200	http://dx.doi.org/10.1074/jbc.M102534200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11350968	hybrid			2022-12-25	WOS:000169823300124
J	Tanoue, T; Yamamoto, T; Maeda, R; Nishida, E				Tanoue, T; Yamamoto, T; Maeda, R; Nishida, E			A novel MAPK phosphatase MKP-7 acts preferentially on JNK/SAPK and p38 alpha and beta MAPKs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; DUAL-SPECIFICITY PHOSPHATASE; IMMEDIATE-EARLY GENE; KINASE PHOSPHATASE; PTP-SL; SELECTIVELY DEPHOSPHORYLATES; SUBSTRATE-SPECIFICITY; CATALYTIC ACTIVATION; SIGNAL-TRANSDUCTION; CELLULAR STRESSES	Mitogen-activated protein kinases (MAPKs) are inactivated via dephosphorylation of either the threonine or tyrosine residue or both in the P-loop catalyzed by protein phosphatases which include serine/threonine phosphatases, tyrosine phosphatases, and dual specificity phosphatases. Nine members of the dual specificity phosphatases specific for MAPKs, termed MKPs, have been reported. Each member has its own substrate specificity, tissue distribution, and subcellular localization. In this study, we have cloned and characterized a novel MKP, designated MKP-7. MKP-7 is most similar to hVH5, a member of previously known MKPs, in the primary structure. MKP-7 is predominantly localized in the cytoplasm when expressed in cultured cells, whereas hVH5 is both in the nucleus and the cytoplasm, MKP-7 binds to and inactivates p38 MAPK and JNK/SAPK, but not ERK, Furthermore, we have found that MKPs have the substrate specificity toward the isoforms of the p38 family (alpha, beta, gamma, and delta). MKP-7 binds to and inactivates p38 alpha and -beta, but not gamma or delta. MKP-5 and CL100/MKP-1 also bind to p38 alpha and -beta, but not gamma or delta. Finally, we propose a tentative classification of MKPs based on the sequence characteristics of their MAPK-docking site.	Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan; Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University; Kyoto University	Nishida, E (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan.	L50174@sakura.kudpc.kyoto-u.ac.jp	Yamamoto, Takuya/H-2792-2017	Yamamoto, Takuya/0000-0002-0022-3947; Maeda, Ryota/0000-0002-1514-1071				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALESSI DR, 1993, ONCOGENE, V8, P2015; Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/S0968-0004(96)30032-7; Blanco-Aparicio C, 1999, J CELL BIOL, V147, P1129, DOI 10.1083/jcb.147.6.1129; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; CHARLES CH, 1992, ONCOGENE, V7, P187; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; Dowd S, 1998, J CELL SCI, V111, P3389; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; Hasegawa M, 1999, J BIOL CHEM, V274, P12626, DOI 10.1074/jbc.274.18.12626; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Hutter D, 2000, BIOCHEM J, V352, P155, DOI 10.1042/0264-6021:3520155; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; King AG, 1995, ONCOGENE, V11, P2553; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Theodosiou A, 1999, ONCOGENE, V18, P6981, DOI 10.1038/sj.onc.1203185; Theodosiou AM, 1996, HUM MOL GENET, V5, P675, DOI 10.1093/hmg/5.5.675; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900	58	127	138	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26629	26639		10.1074/jbc.M101981200	http://dx.doi.org/10.1074/jbc.M101981200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11359773	hybrid			2022-12-25	WOS:000169823300128
J	Bartoli, M; Ramarao, MK; Cohen, JB				Bartoli, M; Ramarao, MK; Cohen, JB			Interactions of the rapsyn RING-H2 domain with dystroglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR CLUSTERS; BETA-DYSTROGLYCAN; NEUROMUSCULAR-JUNCTIONS; FINGER DOMAIN; 43-KD PROTEIN; 43K PROTEIN; DYSTROPHIN; ASSOCIATION; LINKING; COMPLEX	Rapsyn, a peripheral membrane protein of skeletal muscle, is necessary for the formation of the highly organized structure of the vertebrate neuromuscular junction. For mice lacking rapsyn, there is a failure of postsynaptic specialization characterized by an absence of nicotinic acetylcholine receptors (nAChRs) and other integral and peripheral membrane proteins such as beta -dystroglycan and utrophin, Dystroglycan is necessary for the formation of the mature neuromuscular junction and has been shown to interact directly with rapsyn, Previous studies with rapsyn fragments and mutants, expressed in 293T cells along with nAChRs, establish that the rapsyn tetratricopeptide repeat (TPR) domain is involved in self-association and its coiled-coil domain is necessary for nAChR clustering, The function of the rapsyn RING-MS domain, which is not necessary for rapsyn self-association or nAChR clustering, is unknown. To further characterize these domains, we have used a yeast two-hybrid assay to test for interactions at the plasma membrane between rapsyn domains and a nAChR beta -subunit fragment, the beta -dystroglycan cytoplasmic domain, or rapsyn domains. The rapsyn coiled-coil domain interacts with the nAChR beta -subunit cytoplasmic domain, but not with itself, other rapsyn domains, or beta -dystroglycan, The RING-MS domain interacts only with the beta -dystroglycan cytoplasmic domain. Furthermore, when expressed in 293T cells, a rapsyn construct containing as few as two TPRs and the RING-MS domain self-associates and clusters dystroglycan, but not nAChRs, These results emphasize the modular character of the rapsyn structural domains.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Cohen, JB (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA.	jonathan_cohen@hms.harvard.edu	Bartoli, Marc/O-8893-2016; Bartoli, Marc/Q-5979-2017	Bartoli, Marc/0000-0003-3339-9858; Bartoli, Marc/0000-0003-3339-9858	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018458] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 18458] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; Bewick GS, 1996, J NEUROCYTOL, V25, P367; Bezakova G, 1998, MOL CELL NEUROSCI, V11, P274, DOI 10.1006/mcne.1998.0688; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; BURDEN SJ, 1983, CELL, V35, P687, DOI 10.1016/0092-8674(83)90101-0; CARR C, 1989, J CELL BIOL, V109, P1753, DOI 10.1083/jcb.109.4.1753; Cartaud A, 1998, J BIOL CHEM, V273, P11321, DOI 10.1074/jbc.273.18.11321; FLUCHER BE, 1989, NEURON, V3, P163, DOI 10.1016/0896-6273(89)90029-9; FRAIL DE, 1988, J BIOL CHEM, V263, P15602; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; FROEHNER SC, 1990, NEURON, V5, P403, DOI 10.1016/0896-6273(90)90079-U; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; Glass DJ, 1997, CURR OPIN NEUROBIOL, V7, P379, DOI 10.1016/S0959-4388(97)80066-9; Grady RM, 2000, NEURON, V25, P279, DOI 10.1016/S0896-6273(00)80894-6; Henry MD, 1999, CURR OPIN CELL BIOL, V11, P602, DOI 10.1016/S0955-0674(99)00024-1; Huang X, 2000, NAT STRUCT BIOL, V7, P634, DOI 10.1038/77923; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Jacobson C, 2001, J CELL BIOL, V152, P435, DOI 10.1083/jcb.152.3.435; James M, 2000, J CELL SCI, V113, P1717; JUNG D, 1995, J BIOL CHEM, V270, P27305, DOI 10.1074/jbc.270.45.27305; Kentsis A, 2000, CURR PROTEIN PEPT SC, V1, P49, DOI 10.2174/1389203003381478; MAIMONE MM, 1993, NEURON, V11, P53, DOI 10.1016/0896-6273(93)90270-2; Maimone MM, 1999, MOL CELL NEUROSCI, V14, P340, DOI 10.1006/mcne.1999.0779; Moukhles H, 2000, J COMP NEUROL, V420, P182, DOI 10.1002/(SICI)1096-9861(20000501)420:2<182::AID-CNE3>3.0.CO;2-2; NOAKES PG, 1993, DEV BIOL, V155, P275, DOI 10.1006/dbio.1993.1025; Okumoto K, 2000, J BIOL CHEM, V275, P25700, DOI 10.1074/jbc.M003303200; PHILLIPS WD, 1993, J CELL BIOL, V123, P729, DOI 10.1083/jcb.123.3.729; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; Ponting CCP, 1996, BIOCHEM J, V314, P1053, DOI 10.1042/bj3141053; Ramarao MK, 2001, J BIOL CHEM, V276, P7475, DOI 10.1074/jbc.M009888200; Ramarao MK, 1998, P NATL ACAD SCI USA, V95, P4007, DOI 10.1073/pnas.95.7.4007; Rosa G, 1996, BIOCHEM BIOPH RES CO, V223, P272, DOI 10.1006/bbrc.1996.0883; Russo K, 2000, BIOCHEM BIOPH RES CO, V274, P93, DOI 10.1006/bbrc.2000.3103; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; SCOTLAND PB, 1993, J CELL BIOL, V123, P719, DOI 10.1083/jcb.123.3.719; Winder SJ, 2001, TRENDS BIOCHEM SCI, V26, P118, DOI 10.1016/S0968-0004(00)01731-X; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	39	79	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24911	24917		10.1074/jbc.M103258200	http://dx.doi.org/10.1074/jbc.M103258200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342559	hybrid			2022-12-25	WOS:000169800700064
J	Cao, MY; Shinjo, F; Heinrichs, S; Soh, JW; Jongstra-Bilen, J; Jongstra, J				Cao, MY; Shinjo, F; Heinrichs, S; Soh, JW; Jongstra-Bilen, J; Jongstra, J			Inhibition of anti-IgM-induced translocation of protein kinase C beta I inhibits ERK2 activation and increases apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; JUN NH2-TERMINAL KINASE; LYMPHOCYTE-SPECIFIC PROTEIN-1; CA-2+-BINDING PROTEIN; WEHI-231 CELLS; CROSS-LINKING; B-LYMPHOCYTES; RECEPTOR; LSP1; TRANSDUCTION	Expression of the COOH-terminal residues 179-330 of the LSP1 protein in the LSP1(+) B-cell line W10 increases anti-IgM- or ionomycin-induced apoptosis, suggesting that expression of this LSP1 truncate (B-LSP1) interferes with a Ca2+-dependent step in anti-IglM signaling. Here we show that inhibition of Ca2+-dependent conventional protein kinase C (cPKC) isoforms with Go6976 increases anti-IgM-induced apoptosis of W10 cells and that expression of B-LSP1 inhibits translocation of PKC betaI but not of PKC beta II or PKC alpha to the plasma membrane. The increased anti-IgM-induced apoptosis is partially reversed by overexpression of PKC betaI, This shows that the B-LSP1-mediated inhibition of PKC betaI leads to increased anti-IgM-induced apoptosis, Expression of constitutively active PKC betaI protein in W10 cells activates the mitogen-activated protein kinase ERK2, whereas expression of B-LSP1 inhibits anti-IgM-induced activation of ERK2, suggesting that anti-IgM-activated PKC betaI is involved in the activation of ERK2 and that inhibition of ERK2 activation contributes to the increased anti-IgM-induced apoptosis, Pull-down assays show that LSP1 interacts with PKC betaI but not with PKC beta II or PKC alpha in W10 cell lysates, while in vitro LSP1 and B-LSP1 bind directly to PKC betaI, Thus, B-LSP1 is a unique reagent that binds PKC betaI and inhibits anti-IgM-induced PKC betaI translocation, leading to inhibition of ERK2 activation and increased apoptosis.	Univ Toronto, Toronto Western Res Inst, Div Cell & Mol Biol, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5T 2S8, Canada; Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Columbia University	Jongstra, J (corresponding author), Toronto Western Hosp, Rm 13-419,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	jongstra@uhnres.utoronto.ca						ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Andjelic S, 1998, EUR J IMMUNOL, V28, P570, DOI 10.1002/(SICI)1521-4141(199802)28:02<570::AID-IMMU570>3.0.CO;2-M; BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; Campbell KS, 1999, CURR OPIN IMMUNOL, V11, P256, DOI 10.1016/S0952-7915(99)80042-9; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Davis TA, 1998, BLOOD, V92, P1184, DOI 10.1182/blood.V92.4.1184.416k05_1184_1190; DeFranco AL, 1997, CURR OPIN IMMUNOL, V9, P296, DOI 10.1016/S0952-7915(97)80074-X; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FANG W, 1995, J IMMUNOL, V155, P66; GENESTIER L, 1995, INT IMMUNOL, V7, P533, DOI 10.1093/intimm/7.4.533; GIMBLE JM, 1993, J IMMUNOL, V150, P115; Gold MR, 1999, J IMMUNOL, V163, P1894; Graves JD, 1998, J IMMUNOL, V161, P168; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; Hashimoto A, 1998, J EXP MED, V188, P1287, DOI 10.1084/jem.188.7.1287; Hsu FJ, 1997, BLOOD, V89, P3129, DOI 10.1182/blood.V89.9.3129; Jiang A, 1998, J EXP MED, V188, P1297, DOI 10.1084/jem.188.7.1297; JONGSTRA J, 1994, MOL IMMUNOL, V31, P1125, DOI 10.1016/0161-5890(94)90026-4; JONGSTRA J, 1988, J IMMUNOL, V141, P3999; Jongstra-Bilen J, 1999, MOL IMMUNOL, V36, P349, DOI 10.1016/S0161-5890(99)00055-3; JONGSTRABILEN J, 1992, J CELL BIOL, V118, P1443, DOI 10.1083/jcb.118.6.1443; Kaptein JS, 1996, J BIOL CHEM, V271, P18875, DOI 10.1074/jbc.271.31.18875; King LB, 1999, J IMMUNOL, V162, P2655; KLEIN DP, 1989, MOL CELL BIOL, V9, P3043, DOI 10.1128/MCB.9.7.3043; KLEIN DP, 1990, J IMMUNOL, V145, P2967; KNOX KA, 1992, INT J CANCER, V52, P959, DOI 10.1002/ijc.2910520622; Lee JR, 1998, J IMMUNOL, V161, P1637; LI Y, 1995, J IMMUNOL, V155, P3563; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; MCCONKEY DJ, 1991, J IMMUNOL, V146, P1072; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Pulford K, 1999, IMMUNOLOGY, V96, P262; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; TORDAI A, 1994, J BIOL CHEM, V269, P7538; TSUTSUMI A, 1992, CELL IMMUNOL, V142, P303, DOI 10.1016/0008-8749(92)90292-W; WENZELSEIFERT K, 1994, BIOCHEM BIOPH RES CO, V200, P1536, DOI 10.1006/bbrc.1994.1625; Wiesner DA, 1997, J BIOL CHEM, V272, P9868; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	42	19	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24506	24510		10.1074/jbc.M103883200	http://dx.doi.org/10.1074/jbc.M103883200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11333276	hybrid			2022-12-25	WOS:000169800700013
J	Kim, CH; Ardayfio, P; Kim, KS				Kim, CH; Ardayfio, P; Kim, KS			An E-box motif residing in the exon/intron 1 junction regulates both transcriptional activation and splicing of the human norepinephrine transporter gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-HYDROXYLASE GENE; MAJOR LATE PROMOTER; SPONTANEOUSLY HYPERTENSIVE RAT; LOOP-HELIX PROTEINS; RNA POLYMERASE-II; HEAVY-CHAIN GENE; TYROSINE-HYDROXYLASE; MESSENGER-RNA; FIRST INTRON; UPSTREAM ELEMENT	The norepinephrine transporter (NET) is responsible for the rapid NaCl-dependent uptake of norepinephrine into presynaptic noradrenergic nerve endings, Recently, we have characterized the structural organization of the 5 ' upstream promoter region of the human NET (hNET) gene. A new intron of 476 base pairs was found in the middle of the 5 ' -untranslated leader sequence and was shown to robustly enhance the promoter activity. Here, we show that the first hNET intron enhances both the homologous hNET and the heterologous thymidine kinase promoter activities in an orientation- and position-dependent manner. The first hNET intron exhibited a similar promoter-enhancing effect in both SK-N-BE(2)C (NET-positive) and HeLa (NET-negative) cell lines, showing that its function is not cell-specific. Transient transfection assays of a series of deletional constructs show that the first hNET intron contains subdomains with either positive or negative regulatory functions. Furthermore, DNase I footprinting analysis demonstrated that the 5 ' side of the intron, encompassing the splice donor site, is prominently protected by nuclear proteins isolated from both SK-N-BE(B)C and HeLa cells. The protected nucleotide sequence contains a consensus E-box motif, known to regulate diverse eukaryotic genes, which overlaps with the splice donor site of the first intron, We demonstrate that two basic helix-loop-helix proteins, upstream stimulatory factors 1 and 2, are major proteins interacting at this site and that the E-box is at least in part responsible for the promoter-enhancing activity of the first intron, Furthermore, site-directed mutagenesis of the splice donor site of the first intron affects both correct splicing and transcriptional activity. Taken together, our results indicate that a cis-element residing at the first exon/intron junction, encompassing an E-box motif, has a unique dual role in basal transcriptional activation and splicing of hNET mRNA.	Harvard Univ, Sch Med, McLean Hosp, Mol Neurobiol Lab, Belmont, MA 02478 USA; Univ Tennessee, Coll Med, Dept Anat & Neurobiol, Memphis, TN 38163 USA	Harvard University; McLean Hospital; University of Tennessee System; University of Tennessee Health Science Center	Kim, KS (corresponding author), Harvard Univ, Sch Med, McLean Hosp, Mol Neurobiol Lab, 115 Mill St, Belmont, MA 02478 USA.	kskim@mclean.harvard.edu			NIMH NIH HHS [MH48866] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH048866, R29MH048866] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Axelrod J, 1969, Prog Brain Res, V31, P21; Bengzon J, 1999, BRAIN RES, V842, P239, DOI 10.1016/S0006-8993(99)01874-0; BORNSTEIN P, 1988, MOL CELL BIOL, V8, P4851, DOI 10.1128/MCB.8.11.4851; Bradford MM, 1976, ANAL BIOCHEM, V112, P195; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; Charron G, 1995, J BIOL CHEM, V270, P30604, DOI 10.1074/jbc.270.51.30604; CHUNG S, 1989, MOL CELL BIOL, V9, P2075, DOI 10.1128/MCB.9.5.2075; CUBELLS JF, 1995, J NEUROCHEM, V65, P502; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Figlewicz DP, 1999, EPILEPSY RES, V37, P203, DOI 10.1016/S0920-1211(99)00072-8; FRANKLIN GC, 1991, EMBO J, V10, P1365, DOI 10.1002/j.1460-2075.1991.tb07656.x; Gemel J, 1999, J BIOL CHEM, V274, P6020, DOI 10.1074/jbc.274.9.6020; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Gregori C, 1998, J BIOL CHEM, V273, P25237, DOI 10.1074/jbc.273.39.25237; GREMKE L, 1993, DEV BIOL, V159, P513, DOI 10.1006/dbio.1993.1260; Handen JS, 1997, J BIOL CHEM, V272, P1665, DOI 10.1074/jbc.272.3.1665; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; KAWAMOTO S, 1994, J BIOL CHEM, V269, P15101; Kim CH, 1999, J BIOL CHEM, V274, P6507, DOI 10.1074/jbc.274.10.6507; Kim HS, 1998, J NEUROSCI, V18, P8247; KIM KS, 1994, J NEUROSCI, V14, P7200; KIM KS, 1995, PRACTICAL APPROACH G, V2, P151; Klimek V, 1997, J NEUROSCI, V17, P8451; Lambert G, 2000, ARCH GEN PSYCHIAT, V57, P787, DOI 10.1001/archpsyc.57.8.787; LEFRANC G, 1990, BIOCHIMIE, V72, P7, DOI 10.1016/0300-9084(90)90167-F; Lu D, 1996, ENDOCRINOLOGY, V137, P763, DOI 10.1210/en.137.2.763; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Matsuoka I, 1997, BRAIN RES, V776, P181, DOI 10.1016/S0006-8993(97)01016-0; Melkonyan H, 1998, J BIOL CHEM, V273, P27026, DOI 10.1074/jbc.273.41.27026; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Oskouian B, 1997, BIOCHEM J, V324, P113, DOI 10.1042/bj3240113; PORZGEN P, 1995, BIOCHEM BIOPH RES CO, V215, P1145, DOI 10.1006/bbrc.1995.2582; Rao E, 1997, J BIOL CHEM, V272, P6722, DOI 10.1074/jbc.272.10.6722; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHILDKRAUT JJ, 1965, AM J PSYCHIAT, V122, P509, DOI 10.1176/ajp.122.5.509; SCHLOKAT U, 1986, ONCOGENES GROWTH CON, P226; Seo HM, 1996, J NEUROSCI, V16, P4102; Shannon JR, 2000, NEW ENGL J MED, V342, P541, DOI 10.1056/NEJM200002243420803; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; SUN ZM, 1995, J BIOL CHEM, V270, P20962, DOI 10.1074/jbc.270.36.20962; Szot P, 1997, MOL BRAIN RES, V44, P46, DOI 10.1016/S0169-328X(96)00217-3; TEJANIBUTT SM, 1994, NEUROENDOCRINOLOGY, V59, P235, DOI 10.1159/000126664; TELLIEZ JB, 1995, MOL CARCINOGEN, V12, P137, DOI 10.1002/mc.2940120305; Vallet VS, 1997, J BIOL CHEM, V272, P21944, DOI 10.1074/jbc.272.35.21944; Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175; Wakade AR, 1996, J PHYSIOL-LONDON, V494, P67, DOI 10.1113/jphysiol.1996.sp021476; Wang D, 1997, J BIOL CHEM, V272, P26367, DOI 10.1074/jbc.272.42.26367; Yang CY, 1998, J NEUROCHEM, V71, P1813; Yang H, 1999, J NEUROSCI, V19, P2413; Yang SP, 1997, J NEUROENDOCRINOL, V9, P763, DOI 10.1046/j.1365-2826.1997.00641.x	53	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24797	24805		10.1074/jbc.M101279200	http://dx.doi.org/10.1074/jbc.M101279200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11333263	hybrid			2022-12-25	WOS:000169800700052
J	Ruban, AV; Pascal, AA; Robert, B; Horton, P				Ruban, AV; Pascal, AA; Robert, B; Horton, P			Configuration and dynamics of xanthophylls in light-harvesting antennae of higher plants - Spectroscopic analysis of isolated light-harvesting complex of photosystem II and thylakoid membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPHYLL FLUORESCENCE; EXCITATION TRANSFER; ENERGY-DISSIPATION; BINDING-PROTEINS; BETA-CAROTENE; PHOTOPROTECTION; STATE; RAMAN; OLIGOMERIZATION; IDENTIFICATION	Resonance Raman excitation spectroscopy combined with ultra low temperature absorption spectral analysis of the major xanthophylls of higher plants in isolated antenna and intact thylakoid membranes was used to identify carotenoid absorption regions and study their molecular configuration. The major electronic transitions of the light-harvesting complex of photosystem II (LHCIIb) xanthophylls have been identified for both the monomeric and trimeric states of the complex. One long wavelength state of lutein with a 0-0 transition at 510 nm was detected in LHCIIb trimers, The short wavelength 0-0 transitions of lutein and neoxanthin were located at 495 and 486 nm, respectively. In monomeric LHCIIb, both luteins absorb around 495 nm, but slight differences in their protein environments give rise to a broadening of this band. The resonance Raman spectra of violaxanthin and zeaxanthin in intact thylakoid membranes was determined. The broad 0-0 absorption transition for zeaxanthin was found to be located in the 503-511 nm region. Violaxanthin exhibited heterogeneity, having two populations with one absorbing at 497 nm (0-0), 460 nm (0-1), and 429 nm (0-2), and the other major pool absorbing at 488 nm (0-0), 452 nm (0-1), and 423 nm (0-2), The origin of this heterogeneity is discussed. The configuration of zeaxanthin and violaxanthin in thylakoid membranes was different from that of free pigments, and both xanthophylls (notably, zeaxanthin) were found to be well coordinated within the antenna proteins in vivo, arguing against the possibility of their free diffusion in the membrane and supporting our recent biochemical evidence of their association with intact oligomeric light-harvesting complexes.	Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Univ Verona, Fac Sci MM FF NN, I-37134 Verona, Italy; CE Saclay, Sect Biophys Prot & Membranes, Dept Biol, Cellulaire & Mol Sect Biophys Prot & Mol, F-91191 Gif Sur Yvette, France; CE Saclay, CNRS, Unite Rech Associee 2096, F-91191 Gif Sur Yvette, France	University of Sheffield; University of Verona; CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Ruban, AV (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England.	a.ruban@sheffield.ac.uk	pascal, andrew a/B-6186-2014; Horton, Peter/A-3958-2012; Robert, Bruno/D-1264-2012	pascal, andrew a/0000-0002-1844-6065; Horton, Peter/0000-0002-6095-1460; Robert, Bruno/0000-0001-5999-4538				Bassi R, 1999, P NATL ACAD SCI USA, V96, P10056, DOI 10.1073/pnas.96.18.10056; BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; Connelly JP, 1997, J PHYS CHEM B, V101, P1902, DOI 10.1021/jp9619651; Croce R, 1999, FEBS LETT, V456, P1, DOI 10.1016/S0014-5793(99)00907-2; DAVIDOV AS, 1962, THEORY MOL EXCITONS; DEMMIGADAMS B, 1990, BIOCHIM BIOPHYS ACTA, V1020, P1, DOI 10.1016/0005-2728(90)90088-L; DEMMIGADAMS B, 1992, ANNU REV PLANT PHYS, V43, P599, DOI 10.1146/annurev.pp.43.060192.003123; Farber A, 1997, PLANT PHYSIOL, V115, P1609, DOI 10.1104/pp.115.4.1609; Gilmore AM, 1997, PHYSIOL PLANTARUM, V99, P197, DOI 10.1034/j.1399-3054.1997.990127.x; Giuffra E, 1996, EUR J BIOCHEM, V238, P112, DOI 10.1111/j.1432-1033.1996.0112q.x; Gradinaru CC, 2000, J PHYS CHEM B, V104, P9330, DOI 10.1021/jp001752i; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; KENKRE VM, 1974, PHYS REV LETT, V33, P803, DOI 10.1103/PhysRevLett.33.803; Koyama Y, 1999, ADV PHOTOSYNTH, V8, P161; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; LEE AL, 1995, PLANT PHYSIOL, V85, P495; NOGUCHI T, 1991, J PHYS CHEM-US, V95, P3167, DOI 10.1021/j100161a040; Paulsen H, 1999, ADV PHOTOSYNTH, V8, P123; PETER GF, 1991, J BIOL CHEM, V266, P16745; Peterman EJG, 1997, CHEM PHYS LETT, V264, P279, DOI 10.1016/S0009-2614(96)01334-6; Peterman EJG, 1997, BIOCHEMISTRY-US, V36, P12208, DOI 10.1021/bi9711689; Phillip D, 1996, P NATL ACAD SCI USA, V93, P1492, DOI 10.1073/pnas.93.4.1492; RIMAI L, 1973, J AM CHEM SOC, V95, P4493, DOI 10.1021/ja00795a005; Robert B, 1999, ADV PHOTOSYNTH, V8, P189; Ruban AV, 2000, FEBS LETT, V477, P181, DOI 10.1016/S0014-5793(00)01799-3; Ruban AV, 1999, J BIOL CHEM, V274, P10458, DOI 10.1074/jbc.274.15.10458; RUBAN AV, 1994, PLANT PHYSIOL, V104, P227, DOI 10.1104/pp.104.1.227; Ruban AV, 1996, BIOCHEMISTRY-US, V35, P674, DOI 10.1021/bi9524878; RUBAN AV, 1994, BBA-BIOENERGETICS, V1186, P123, DOI 10.1016/0005-2728(94)90143-0; Ruban AV, 1997, BIOCHEMISTRY-US, V36, P7855, DOI 10.1021/bi9630725; RUBAN AV, 1993, PLANT PHYSIOL, V102, P741, DOI 10.1104/pp.102.3.741; Ruban AV, 1997, BBA-BIOENERGETICS, V1321, P61, DOI 10.1016/S0005-2728(97)00047-9; SAITO S, 1983, J RAMAN SPECTROSC, V14, P310, DOI 10.1002/jrs.1250140504; Sandona D, 1998, BBA-BIOENERGETICS, V1365, P207, DOI 10.1016/S0005-2728(98)00068-1; STURGIS JN, 1994, J MOL BIOL, V238, P445, DOI 10.1006/jmbi.1994.1303; Verhoeven AS, 1999, PLANT PHYSIOL, V120, P727, DOI 10.1104/pp.120.3.727; Wentworth M, 2000, FEBS LETT, V471, P71, DOI 10.1016/S0014-5793(00)01369-7; YAMAMOTO HY, 1972, PLANT PHYSIOL, V49, P224, DOI 10.1104/pp.49.2.224	38	100	101	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24862	24870		10.1074/jbc.M103263200	http://dx.doi.org/10.1074/jbc.M103263200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11331293	hybrid			2022-12-25	WOS:000169800700059
J	Svergun, DI; Zaccai, G; Malfois, M; Wade, RH; Koch, MHJ; Kozielski, F				Svergun, DI; Zaccai, G; Malfois, M; Wade, RH; Koch, MHJ; Kozielski, F			Conformation of the Drosophila motor protein non-claret disjunctional in solution from x-ray and neutron scattering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-ANGLE-SCATTERING; SINGLE KINESIN MOLECULES; CRYSTAL-STRUCTURE; DIMERIC KINESIN; SYNCHROTRON RADIATION; NCD; DOMAINS; MICROTUBULES; RESOLUTION; MOVEMENT	The quaternary structures of monomeric and dimeric Drosophila non-claret disjunctional (ncd) constructs were investigated using synchrotron x-ray and neutron solution scattering, and their low resolution shapes were restored ab initio from the scattering data, The experimental curves were further compared with those computed from crystallographic models of one monomeric and three available dimeric ncd structures in the microtubule-independent ADP-bound state, These comparisons indicate that accounting for the missing parts in the crystal structures for all these constructs is indispensable to obtain reasonable fits to the scattering patterns. A ncd construct (MC6) lacking the coiled-coil region is monomeric in solution, but the calculated scattering from the crystallographic monomer yields a poor fit to the data. A tentative configuration of the missing C-terminal residues in the form of an antiparallel beta -sheet was found that significantly improves the fit. The atomic model of a short dimeric ncd construct (MC5) without 2-fold symmetry is found to fit the data better than the symmetric models, Addition of the C-terminal residues to both head domains gives an excellent fit to the x-ray and neutron experimental data, although the orientation of the beta -sheet differs from that of the monomer, The solution structure of the long ncd construct (MC1) including complete N-terminal coiled-coil and motor domains is modeled by adding a straight coiled-coil section to the model of MC5.	DESY, European Mol Biol Lab, D-22603 Hamburg, Germany; Russian Acad Sci, Inst Crystallog, Moscow 117333, Russia; CEA, CNRS, Inst Biol Struct, Lab Mol Biophys, F-38000 Grenoble 01, France; Inst Max Von Laue Paul Langevin, F-38042 Grenoble 9, France	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Russian Academy of Sciences; FSRC Crystallography & Photonics RAS; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Institut Laue-Langevin (ILL)	Svergun, DI (corresponding author), DESY, European Mol Biol Lab, Notkestr 85, D-22603 Hamburg, Germany.	Svergun@EMBL-Hamburg.DE	Malfois, Marc/L-2974-2014	Malfois, Marc/0000-0001-5231-1896; Svergun, Dmitri/0000-0003-0830-5696				Arnal I, 1996, CURR BIOL, V6, P1265, DOI 10.1016/S0960-9822(02)70712-4; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; BOULIN C, 1986, NUCL INSTRUM METH A, V249, P399, DOI 10.1016/0168-9002(86)90694-7; BOULIN CJ, 1988, NUCL INSTRUM METH A, V269, P312, DOI 10.1016/0168-9002(88)90895-9; BUTTNER HG, 1996, YELLOW BOOK GUIDE NE, P76; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; deCastro MJ, 1999, BIOCHEMISTRY-US, V38, P5076, DOI 10.1021/bi9829175; FEIGIN LA, 1987, STRUCTURE ANAL XRAY; Foster KA, 1998, J BIOL CHEM, V273, P35307, DOI 10.1074/jbc.273.52.35307; Foster KA, 2000, BIOCHEMISTRY-US, V39, P1784, DOI 10.1021/bi991500b; GABRIEL A, 1982, NUCL INSTRUM METHODS, V201, P223, DOI 10.1016/0167-5087(82)90031-X; Gulick AM, 1998, BIOCHEMISTRY-US, V37, P1769, DOI 10.1021/bi972504o; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; JACROT B, 1981, BIOPOLYMERS, V20, P2413, DOI 10.1002/bip.1981.360201110; Kim AJ, 2000, J CELL SCI, V113, P3681; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; Kozielski F, 1999, STRUCTURE, V7, P1407, DOI 10.1016/S0969-2126(00)80030-1; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Kozielski F, 2001, J BIOL CHEM, V276, P1267, DOI 10.1074/jbc.M007169200; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; Porod G., 1982, SMALL ANGLE XRAY SCA, P17, DOI DOI 10.1002/ACTP.1985.010360520; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Sablin EP, 1998, NATURE, V395, P813, DOI 10.1038/27463; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; Stone DB, 1999, BIOCHEMISTRY-US, V38, P4938, DOI 10.1021/bi982374z; STUHRMAN.HB, 1970, ACTA CRYSTALL A-CRYS, VA 26, P297, DOI 10.1107/S0567739470000748; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 2000, J BIOL CHEM, V275, P4210, DOI 10.1074/jbc.275.6.4210; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; Svergun DI, 2000, J BIOL CHEM, V275, P297, DOI 10.1074/jbc.275.1.297; SVERGUN DI, 1988, ACTA CRYSTALLOGR A, V44, P244, DOI 10.1107/S0108767387011255; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Svergun DI, 1997, PROTEINS, V27, P110; SVERGUN DI, 1993, J APPL CRYSTALLOGR, V26, P258, DOI 10.1107/S0021889892011828; Svergun DI, 1998, P NATL ACAD SCI USA, V95, P2267, DOI 10.1073/pnas.95.5.2267; Trewhella J, 1997, CURR OPIN STRUC BIOL, V7, P702, DOI 10.1016/S0959-440X(97)80081-4; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; ZACCAI G, 1983, ANNU REV BIOPHYS BIO, V12, P139, DOI 10.1146/annurev.bb.12.060183.001035	43	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24826	24832		10.1074/jbc.M103618200	http://dx.doi.org/10.1074/jbc.M103618200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11335729	hybrid			2022-12-25	WOS:000169800700055
J	Methot, N; Ritchie, BD; Blanton, MP; Baenziger, JE				Methot, N; Ritchie, BD; Blanton, MP; Baenziger, JE			Structure of the pore-farming transmembrane domain of a ligand-gated ion channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; TRANSFORM INFRARED-SPECTROSCOPY; EXCHANGE-RESISTANT CORE; SECONDARY STRUCTURE; TORPEDO-CALIFORNICA; ALPHA-SUBUNIT; SPATIAL STRUCTURE; GLYCINE RECEPTOR; GAMMA-SUBUNIT; PROTEINS	The structure of the pore-forming transmembrane domain of the nicotinic acetylcholine receptor from Torpedo has been investigated by infrared spectroscopy. Treatment of affinity-purified receptor with either Pronase or proteinase K digests the extramembranous domains (roughly 75% of the protein mass), leaving hydrophobic membrane-imbedded peptides 3-6 kDa in size that are resistant to peptide H-1/H-2 exchange, Infrared spectra of the transmembrane domain preparations exhibit relatively sharp and symmetric amide I and amide II band contours centered near 1655 and 1545 cm(-1) respectively, in both (H2O)-H-1 and (H2O)-H-2. The amide I band is very similar to the amide I bands observed in the spectra of alpha -helical proteins, such as myoglobin and bacteriorhodopsin, that lack P structure and exhibit much less p-sheet character than is observed in proteins with as little as 20% P sheet. Curve-fitting estimates 75-80% cy-helical character, with the remaining peptides likely adopting extended and/or turn structures at the bilayer surface. Infrared dichroism spectra are consistent with transmembrane alpha -helices oriented perpendicular to the bilayer surface. The evidence strongly suggests that the transmembrane domain of the nicotinic receptor, the most intensively studied ligand-gated ion channel, is composed of five bundles of four transmembrane alpha-helices.	Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada; Texas Tech Univ, Hlth Sci Ctr, Dept Anesthesiol, Lubbock, TX 79430 USA; Texas Tech Univ, Hlth Sci Ctr, Dept Pharmacol, Lubbock, TX 79430 USA	University of Ottawa; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Baenziger, JE (corresponding author), Univ Ottawa, Dept Biochem Microbiol & Immunol, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	jebaenz@uottawa.ca		Baenziger, John/0000-0002-2888-5328	NINDS NIH HHS [NS35786] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS035786] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKABAS MH, 1995, BIOCHEMISTRY-US, V34, P12496, DOI 10.1021/bi00039a002; Baenziger JE, 1997, BIOCHEMISTRY-US, V36, P3617, DOI 10.1021/bi962845m; BAENZIGER JE, 1995, J BIOL CHEM, V270, P29129, DOI 10.1074/jbc.270.49.29129; Barrantes FJ, 2000, J BIOL CHEM, V275, P37333, DOI 10.1074/jbc.M005246200; BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; BLANTON MP, 1992, BIOCHEMISTRY-US, V31, P3738, DOI 10.1021/bi00130a003; BLANTON MP, 2001, IN PRESS BIOCH BIOPH; BRUNNER J, 1993, ANNU REV BIOCHEM, V62, P483, DOI 10.1146/annurev.bi.62.070193.002411; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; Cascio M, 2001, J BIOL CHEM, V276, P20981, DOI 10.1074/jbc.M010968200; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; CLAUDIO T, 1983, P NATL ACAD SCI-BIOL, V80, P1111, DOI 10.1073/pnas.80.4.1111; Corbin J, 1998, J BIOL CHEM, V273, P771, DOI 10.1074/jbc.273.2.771; DOUSSEAU F, 1990, BIOCHEMISTRY-US, V29, P8771, DOI 10.1021/bi00489a038; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; GORNETSCHELNOKOW U, 1994, EMBO J, V13, P338, DOI 10.1002/j.1460-2075.1994.tb06266.x; GUNTHARD HH, 1981, MEMBRANE SPECTROSCOP, P270; HUBNER W, 1991, BIOPHYS J, V59, P1261, DOI 10.1016/S0006-3495(91)82341-4; HUCHO F, 1994, TRENDS BIOCHEM SCI, V19, P383, DOI 10.1016/0968-0004(94)90116-3; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; KUHSE J, 1995, CURR OPIN NEUROBIOL, V5, P318, DOI 10.1016/0959-4388(95)80044-1; Leite JF, 2000, J BIOL CHEM, V275, P13683, DOI 10.1074/jbc.275.18.13683; Lugovskoy AA, 1998, EUR J BIOCHEM, V255, P455, DOI 10.1046/j.1432-1327.1998.2550455.x; Marsh D, 1997, BIOPHYS J, V72, P2710, DOI 10.1016/S0006-3495(97)78914-8; MCCARTHY MP, 1992, J BIOL CHEM, V267, P7655; Methot N, 1998, BIOCHEMISTRY-US, V37, P14815, DOI 10.1021/bi980848o; METHOT N, 1994, BIOCHEMISTRY-US, V33, P7709, DOI 10.1021/bi00190a026; NAUMANN D, 1993, BIOCHEMISTRY-US, V32, P3162, DOI 10.1021/bi00063a031; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; Opella SJ, 1999, NAT STRUCT BIOL, V6, P374, DOI 10.1038/7610; Ortells MO, 1996, PROTEIN ENG, V9, P51, DOI 10.1093/protein/9.1.51; Pashkov VS, 1999, FEBS LETT, V457, P117, DOI 10.1016/S0014-5793(99)01023-6; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; SHAGGER H, 1987, ANAL BIOCHEM, V166, P368; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; Tamamizu S, 2000, BIOCHEMISTRY-US, V39, P4666, DOI 10.1021/bi992835w; Tamm LK, 1997, Q REV BIOPHYS, V30, P365, DOI 10.1017/S0033583597003375; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107	39	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23726	23732		10.1074/jbc.M102101200	http://dx.doi.org/10.1074/jbc.M102101200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11328815	hybrid			2022-12-25	WOS:000169531100068
J	Sumi, T; Matsumoto, K; Shibuya, A; Nakamura, T				Sumi, T; Matsumoto, K; Shibuya, A; Nakamura, T			Activation of LIM kinases by myotonic dystrophy kinase-related Cdc42-binding kinase alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN CYTOSKELETAL DYNAMICS; CONTAINING PROTEIN-KINASE; ZINC-FINGER; COFILIN PHOSPHORYLATION; GENOMIC ORGANIZATION; CELL MOTILITY; CDNA CLONING; FAMILY; MOTIF; RHO	LIM kinases (LIMK1 and LIMK2) regulate actin cytoskeletal reorganization through cofilin phosphorylation downstream of distinct Rho family GTPases. Pak1 and ROCK, respectively, activate LIMK1 and LIMK2 downstream of Rac and Rho; however, an effector protein kinase for LIMKs downstream of Cdc42 remains to be defined. We now report evidence that LIMK1 and LIMK2 activities toward cofilin phosphorylation are stimulated in cells by the co-expression of myotonic dystrophy kinase-related Cdc42-binding kinase alpha (MRCK alpha), an effector protein kinase of Cdc42. In vitro, MRCK alpha phosphorylated the protein kinase domain of LIM kinases, and the site in LIMK2 phosphorylated by MRCK alpha proved to be threonine 505 within the activation segment. Expression of MRCK alpha induced phosphorylation of actin depolymerizing factor (ADF)/cofilin in cells, whereas MRCK alpha -induced ADF/cofilin phosphorylation was inhibited by the co expression with the protein kinase-deficient form of LIM kinases. These results indicate that MRCK alpha phosphorylates and activates LIM kinases downstream of Cdc42, which in turn regulates the actin cytoskeletal reorganization through the phosphorylation and inactivation of ADF/cofilin.	Osaka Univ, Grad Sch Med, Div Mol Regenerat Med, Course Adv Med, Suita, Osaka 5650871, Japan	Osaka University	Nakamura, T (corresponding author), Osaka Univ, Grad Sch Med, Div Mol Regenerat Med, Course Adv Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		MATSUMOTO, Kunio/D-8441-2015	MATSUMOTO, Kunio/0000-0002-6532-4482				Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Bamburg JR, 1999, TRENDS CELL BIOL, V9, P364, DOI 10.1016/S0962-8924(99)01619-0; BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; Carlier MF, 1999, J BIOL CHEM, V274, P33827, DOI 10.1074/jbc.274.48.33827; Chen XQ, 1999, J BIOL CHEM, V274, P19901, DOI 10.1074/jbc.274.28.19901; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Ikebe C, 1997, GENOMICS, V46, P504, DOI 10.1006/geno.1997.5060; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Koshimizu U, 1997, BIOCHEM BIOPH RES CO, V241, P243, DOI 10.1006/bbrc.1997.7795; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Leung T, 1998, MOL CELL BIOL, V18, P130, DOI 10.1128/MCB.18.1.130; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MIZUNO K, 1994, ONCOGENE, V9, P1605; Nakamura N, 2000, GENES CELLS, V5, P571, DOI 10.1046/j.1365-2443.2000.00348.x; NUNOUE K, 1995, ONCOGENE, V11, P701; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OHASHI K, 1994, J BIOCHEM, V116, P636, DOI 10.1093/oxfordjournals.jbchem.a124573; OHASHI K, 2000, J BIOL CHEM, V249, P138; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Sumi T, 1999, J CELL BIOL, V147, P1519, DOI 10.1083/jcb.147.7.1519; Sumi T, 2001, J BIOL CHEM, V276, P670, DOI 10.1074/jbc.M007074200; Takahashi T, 1997, DEV DYNAM, V209, P196, DOI 10.1002/(SICI)1097-0177(199706)209:2<196::AID-AJA5>3.0.CO;2-D; Takahashi T, 2001, DEV BIOL, V229, P554, DOI 10.1006/dbio.2000.9999; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735	29	73	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					23092	23096		10.1074/jbc.C100196200	http://dx.doi.org/10.1074/jbc.C100196200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11340065	hybrid			2022-12-25	WOS:000169412700147
J	Barber, A; Robson, SC; Myatt, L; Bulmer, JN; Lyall, F				Barber, A; Robson, SC; Myatt, L; Bulmer, JN; Lyall, F			Heme oxygenase expression in human placenta and placental bed: reduced expression of placenta endothelial HO-2 in preeclampsia and fetal growth restriction	FASEB JOURNAL			English	Article						pregnancy; HO-1; HO-2; trophoblast; carbon monoxide	NITRIC-OXIDE SYNTHASE; HSP32 MESSENGER-RNA; SPIRAL ARTERIES; CARBON-MONOXIDE; TROPHOBLAST INVASION; MORPHOLOGICAL-CHANGES; PULSATILITY INDEX; OXIDATIVE STRESS; PRE-ECLAMPSIA; BIRTH-WEIGHT	In this study we tested the hypothesis that expression of heme oxygenases HO-1 and HO-2, which are responsible for the production of carbon monoxide, are reduced in the placenta and placental bed of pregnancies complicated by preeclampsia (PE) and fetal growth restriction (FGR) compared with control third-trimester pregnancies. Placental protein expression was determined by Western blotting (n=10 in each group) and immunohistochemistry (controls n=18, PE n=19, FGR n=10), Extravillous trophoblast expression was determined by immunohistochemistry of placental bed biopsy samples (controls n=17, PE n=19, FGR n=10), Western blot analysis of placental homogenates showed no overall differences in HO-2 among groups. However, immunohistochemical analysis showed a reduction in HO-2 expression in endothelial cells in both abnormal groups (PE P<0.01; FGR P<0.0005 vs. control group) but no differences in villous trophoblast staining. HO-I was undetectable by Western blotting in control and abnormal pregnancies and immunoreactivity was very low, suggesting that there is little HO-I in the placenta. Within the placental bed, HO-2 but not HO-1 was detected on all populations of extravillous trophoblast, but expression of HO-2 or HO-1 did not change in PE or FGR, The reduced expression of HO-2 on endothelial cells in PE and FGR may be responsible for reduced placental blood flow in these conditions. The data do not show changes in HO in the placental bed in PE or FGR.	Inst Med Genet, Maternal & Fetal Med Sect, Glasgow G3 8SJ, Lanark, Scotland; Royal Victoria Infirm, Dept Pathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Royal Victoria Infirm, Dept Obstet & Gynaecol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Univ Cincinnati, Coll Med, Dept Obstet & Gynecol, Cincinnati, OH 45267 USA	University of Glasgow; Newcastle University - UK; Newcastle University - UK; University System of Ohio; University of Cincinnati	Lyall, F (corresponding author), Inst Med Genet, Maternal & Fetal Med Sect, Glasgow G3 8SJ, Lanark, Scotland.							ARDUINI D, 1990, J PERINAT MED, V18, P165, DOI 10.1515/jpme.1990.18.3.165; Barber A, 1999, AM J PATHOL, V155, P831, DOI 10.1016/S0002-9440(10)65182-6; BLANKENSHIP TN, 1993, CELL TISSUE RES, V274, P135, DOI 10.1007/BF00327994; BOWER S, 1993, OBSTET GYNECOL, V82, P78; BROSENS I, 1967, J PATHOL BACTERIOL, V93, P568; BROSENS IA, 1977, CLIN OBSTET GYNAECOL, V4, P573; Conrad KP, 1995, PLACENTA, V16, P691, DOI 10.1016/0143-4004(95)90013-6; CONRAD KP, 1993, FASEB J, V7, P1269, DOI 10.1096/fasebj.7.13.7691671; Craven CM, 1998, PLACENTA, V19, P241, DOI 10.1016/S0143-4004(98)90055-8; CRUSE I, 1988, J BIOL CHEM, V263, P3348; DEWOLF F, 1980, BRIT J OBSTET GYNAEC, V87, P678; DEWOLF F, 1973, AM J OBSTET GYNECOL, V117, P833, DOI 10.1016/0002-9378(73)90500-0; Elbirt KK, 1999, P ASSOC AM PHYSICIAN, V111, P438, DOI 10.1111/paa.1999.111.5.438; EWING JF, 1993, J NEUROCHEM, V60, P1512, DOI 10.1111/j.1471-4159.1993.tb03315.x; GERRETSEN G, 1981, BRIT J OBSTET GYNAEC, V88, P876, DOI 10.1111/j.1471-0528.1981.tb02222.x; GHABOUR MS, 1995, AM J OBSTET GYNECOL, V173, P687, DOI 10.1016/0002-9378(95)90324-0; Hubel CA, 1999, P SOC EXP BIOL MED, V222, P222, DOI 10.1046/j.1525-1373.1999.d01-139.x; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KHONG TY, 1986, BRIT J OBSTET GYNAEC, V93, P1049, DOI 10.1111/j.1471-0528.1986.tb07830.x; KHONG TY, 1987, BRIT J OBSTET GYNAEC, V94, P649, DOI 10.1111/j.1471-0528.1987.tb03169.x; KHONG TY, 1995, FETUS NEONATE CHANGE, P177; Kingdom J, 1998, PLACENTA, V19, P347, DOI 10.1016/S0143-4004(98)90073-X; Kingdom JCP, 1997, PLACENTA, V18, P613, DOI 10.1016/S0143-4004(97)90000-X; KUTTY RK, 1989, ARCH BIOCHEM BIOPHYS, V268, P100, DOI 10.1016/0003-9861(89)90569-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVERE RD, 1993, AM J HEMATOL, V43, P19, DOI 10.1002/ajh.2830430106; LUNELL NO, 1979, GYNECOL OBSTET INVES, V10, P106, DOI 10.1159/000299924; Lyall F, 2000, FASEB J, V14, P208, DOI 10.1096/fasebj.14.1.208; Lyall F, 1996, PLACENTA, V17, P165, DOI 10.1016/S0143-4004(96)80009-9; LYALL F, 1995, AM J OBSTET GYNECOL, V173, P714, DOI 10.1016/0002-9378(95)90328-3; Lyall F, 1999, AM J PATHOL, V154, P1105, DOI 10.1016/S0002-9440(10)65363-1; Lyall F, 2000, PLACENTA BASIC SCI C, P79; MAINES MD, 1993, MOL CELL NEUROSCI, V4, P389, DOI 10.1006/mcne.1993.1049; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MAINES MD, 1993, J PHARMACOL EXP THER, V264, P457; MANSOURI A, 1982, THROMB HAEMOSTASIS, V48, P286; MATIJEVIC R, 1995, OBSTET GYNECOL, V86, P289, DOI 10.1016/0029-7844(95)00129-F; MCFADYEN IR, 1986, BRIT J OBSTET GYNAEC, V93, P476, DOI 10.1111/j.1471-0528.1986.tb07933.x; MCFAUL SJ, 1987, TOXICOL APPL PHARM, V87, P464, DOI 10.1016/0041-008X(87)90252-3; McLaughlin BE, 2000, PLACENTA, V21, P870, DOI 10.1053/plac.2000.0574; MEEKINS JW, 1994, BRIT J OBSTET GYNAEC, V101, P669, DOI 10.1111/j.1471-0528.1994.tb13182.x; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; MYATT L, 1992, PLACENTA, V13, P329, DOI 10.1016/0143-4004(92)90057-Z; MYATT L, 1993, PLACENTA, V14, P487, DOI 10.1016/S0143-4004(05)80202-4; MYATT L, 1997, HUM REPROD, V12, P67; OLOFSSON P, 1993, EUR J OBSTET GYN R B, V49, P161, DOI 10.1016/0028-2243(93)90265-E; PIJNENBORG R, 1991, BRIT J OBSTET GYNAEC, V98, P648, DOI 10.1111/j.1471-0528.1991.tb13450.x; PIJNENBORG R, 1983, PLACENTA, V4, P397, DOI 10.1016/S0143-4004(83)80043-5; PIJNENBORG R, 1980, PLACENTA, V1, P3, DOI 10.1016/S0143-4004(80)80012-9; ROBERTS JM, 1993, LANCET, V341, P1447, DOI 10.1016/0140-6736(93)90889-O; Robson SC, 1995, FETUS NEONATE, P297; SHEPPARD BL, 1981, BRIT J OBSTET GYNAEC, V88, P695, DOI 10.1111/j.1471-0528.1981.tb01268.x; SHEPPARD BL, 1976, BRIT J OBSTET GYNAEC, V83, P948, DOI 10.1111/j.1471-0528.1976.tb00781.x; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; Tin W, 1997, BRIT J OBSTET GYNAEC, V104, P180, DOI 10.1111/j.1471-0528.1997.tb11041.x; TRAKSHEL GM, 1989, J BIOL CHEM, V264, P1323; TRUDINGER BJ, 1985, BRIT J OBSTET GYNAEC, V92, P23, DOI 10.1111/j.1471-0528.1985.tb01044.x; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; VOIGT HJ, 1992, J PERINAT MED, V20, P139, DOI 10.1515/jpme.1992.20.2.139; Walsh SW, 1998, SEMIN REPROD ENDOCR, V16, P93, DOI 10.1055/s-2007-1016256; Zakhary R, 1996, P NATL ACAD SCI USA, V93, P795, DOI 10.1073/pnas.93.2.795; [No title captured]	62	99	107	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1158	1168		10.1096/fj.00-0376com	http://dx.doi.org/10.1096/fj.00-0376com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344084				2022-12-25	WOS:000168655200006
J	Hoebertz, A; Meghji, S; Burnstock, G; Arnett, TR				Hoebertz, A; Meghji, S; Burnstock, G; Arnett, TR			Extracellular ADP is a powerful osteolytic agent: evidence for signaling through the P2Y(1) receptor on bone cells	FASEB JOURNAL			English	Article						P2 receptors; ADP; ATP; osteoclast; bone resorption; P2Y(1)	PHARMACOLOGICAL CHARACTERIZATION; PURINERGIC RECEPTORS; NONSELECTIVE CATION; ADENINE-NUCLEOTIDES; HUMAN OSTEOBLASTS; RAT OSTEOCLASTS; P2 RECEPTORS; ATP; RESORPTION; PH	There is increasing evidence that extracellular nucleotides act on bone cells via P2 receptors, This study investigated the action of ADP and 2-methylthioADP, a potent ADP analog with selectivity for the P2Y(1) receptor, on osteoclasts, the bone-resorbing multinuclear cells. Using three different assays, we show that ADP and 2-methylthioADP at nanomolar to submicromolar levels caused up to fourfold to sixfold increases in osteoclastic bone resorption, On mature rat osteoclasts, cultured for 1 day on polished dentine disks, peak effects on resorption pit formation were observed between 20 nM and 2 muM of ADP, The same concentrations of ADP also stimulated osteoclast and resorption pit formation in 10-day mouse marrow cultures on dentine disks. In 3-day explant cultures of mouse calvarial bones, the stimulatory effect of ADP on osteoclast-mediated Ca2+ release was greatest at 5-50 muM and equivalent to the maximal effects of prostaglandin E-2. The ADP effects were blocked in a nontoxic manner by MRS 2179, a P2Y(1) receptor antagonist. Using in situ hybridization and immunocytochemistry, we found evidence for P2Y(1) receptor expression on both osteoclasts and osteoblasts; thus, ADP could exert its actions both directly on osteoclasts and indirectly via P2Y(1) receptors on osteoblasts, As a major ATP degradation product, ADP is a novel stimulator of bone resorption that could help mediate inflammatory bone loss in vivo.	UCL, Dept Anat & Dev Biol, London WC1E 6BT, England; UCL, Eastman Dent Inst, Cellular Microbiol Res Grp, London WC1E 6BT, England; UCL, Auton Neurosci Inst, London WC1E 6BT, England	University of London; University College London; University of London; University College London; University of London; University College London	Arnett, TR (corresponding author), UCL, Dept Anat & Dev Biol, Mortimer St, London WC1E 6BT, England.	t.arnett@ucl.ac.uk	Arnett, Tim/AAW-4445-2021					Arnett TR, 1996, BONE, V18, P277, DOI 10.1016/8756-3282(95)00486-6; ARNETT TR, 1986, ENDOCRINOLOGY, V119, P119, DOI 10.1210/endo-119-1-119; Bianchi BR, 1999, EUR J PHARMACOL, V376, P127, DOI 10.1016/S0014-2999(99)00350-7; Bodin P, 1998, INFLAMM RES, V47, P351, DOI 10.1007/s000110050341; Bowler WB, 1999, J BIOL CHEM, V274, P14315, DOI 10.1074/jbc.274.20.14315; Bowler WB, 1998, BONE, V22, P195, DOI 10.1016/S8756-3282(97)00280-9; Boyer JL, 1998, BRIT J PHARMACOL, V124, P1, DOI 10.1038/sj.bjp.0701837; Brown CJ, 1997, BBA-MOL BASIS DIS, V1362, P208, DOI 10.1016/S0925-4439(97)00080-X; Burnstock G, 1997, NEUROPHARMACOLOGY, V36, P1127, DOI 10.1016/S0028-3908(97)00125-1; COADE SB, 1989, CIRC RES, V65, P531, DOI 10.1161/01.RES.65.3.531; Dixon CJ, 2000, BRIT J PHARMACOL, V130, P664, DOI 10.1038/sj.bjp.0703350; Dixon CJ, 1997, BRIT J PHARMACOL, V120, P777; Dixon SJ, 2000, DRUG DEVELOP RES, V49, P187, DOI 10.1002/(SICI)1098-2299(200003)49:3<187::AID-DDR9>3.0.CO;2-F; EVANS RJ, 1995, MOL PHARMACOL, V48, P178; Filippov AK, 2000, BRIT J PHARMACOL, V129, P1063, DOI 10.1038/sj.bjp.0703185; Fuller K, 2000, J CELL SCI, V113, P2445; GOLDHABER P, 1987, AM J PHYSIOL, V253, pE90, DOI 10.1152/ajpendo.1987.253.1.E90; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; Hechler B, 1998, MOL PHARMACOL, V53, P727, DOI 10.1124/mol.53.4.727; Hoebertz A, 2000, BONE, V27, P503, DOI 10.1016/S8756-3282(00)00351-3; Jacobson KA, 1999, PROG BRAIN RES, V120, P119; King BF, 1996, BRIT J PHARMACOL, V117, P1371, DOI 10.1111/j.1476-5381.1996.tb15293.x; King BF, 1998, DEV CARDIOVASC MED, V209, P159; KUMAGAI H, 1991, J BONE MINER RES, V6, P697; LEONG WS, 1994, BBA-GEN SUBJECTS, V1201, P298, DOI 10.1016/0304-4165(94)90054-X; Meghji S, 2001, AM J PHYSIOL-ENDOC M, V280, pE112, DOI 10.1152/ajpendo.2001.280.1.E112; MEGHJI S, 1998, METHODS BONE BIOL, P106; Moran-Jimenez MJ, 2000, MOL BRAIN RES, V78, P50, DOI 10.1016/S0169-328X(00)00067-X; Morrison MS, 1998, J PHYSIOL-LONDON, V511, P495, DOI 10.1111/j.1469-7793.1998.495bh.x; MORRISON MS, 1998, BONE, V22, pS30; MURRILLS RJ, 1998, METHODS BONE BIOL, P64; Naemsch LN, 1999, J CELL SCI, V112, P4425; NEEDLEMAN P, 1974, CIRC RES, V34, P455, DOI 10.1161/01.RES.34.4.455; Ogilvie ALJ, 2000, J INVEST DERMATOL, V114, P226; PEEL NFA, 1991, BRIT J RHEUMATOL, V30, P84; Peerschke EIB, 1998, IMMUNOBIOLOGY, V199, P239, DOI 10.1016/S0171-2985(98)80030-2; RABADJIJA L, 1990, BONE MINER, V11, P295, DOI 10.1016/0169-6009(90)90026-C; Ralevic V, 1998, PHARMACOL REV, V50, P413; REIMER WJ, 1992, AM J PHYSIOL, V263, pC1040, DOI 10.1152/ajpcell.1992.263.5.C1040; SCHOFL C, 1992, J BONE MINER RES, V7, P485; SISTARE FD, 1994, J PHARMACOL EXP THER, V269, P1049; Vigne P, 1998, BRIT J PHARMACOL, V125, P675, DOI 10.1038/sj.bjp.0702115; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; Weidema AF, 1997, J PHYSIOL-LONDON, V503, P303, DOI 10.1111/j.1469-7793.1997.303bh.x; Wildman SS, 1997, BRIT J PHARMACOL, V120, P221, DOI 10.1038/sj.bjp.0700903; YU HS, 1995, J CELL SCI, V108, P3051; YU HS, 1994, CELL SIGNAL, V6, P905, DOI 10.1016/0898-6568(94)90023-X; YU HS, 1993, BIOCHEM BIOPH RES CO, V191, P357, DOI 10.1006/bbrc.1993.1225; Zanellato N, 2000, J BONE MINER RES, V15, pS387	49	68	70	1	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2001	15	7					1139	1148		10.1096/fj.00-0395com	http://dx.doi.org/10.1096/fj.00-0395com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344082				2022-12-25	WOS:000168655200004
J	Lee, SL; Wang, WW; Fanburg, BL				Lee, SL; Wang, WW; Fanburg, BL			Dexfenfluramine as a mitogen signal via the formation of superoxide anion	FASEB JOURNAL			English	Article									Tufts Univ, Sch Med, New England Med Ctr, Dept Med,Tupper Res Inst,Pulm & Crit Care Div, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	Fanburg, BL (corresponding author), Tufts Univ, Sch Med, New England Med Ctr, Dept Med,Tupper Res Inst,Pulm & Crit Care Div, 750 Washington St,257, Boston, MA 02111 USA.								0	28	30	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1324	1325		10.1096/fj.00-0431fje	http://dx.doi.org/10.1096/fj.00-0431fje			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344128				2022-12-25	WOS:000168655200050
J	Salven, P; Anttonen, K; Repo, H; Joensuu, H; Orpana, A				Salven, P; Anttonen, K; Repo, H; Joensuu, H; Orpana, A			Endotoxins induce and interferon alpha suppresses vascular endothelial growth factor (VEGF) production in human peripheral blood mononuclear cells	FASEB JOURNAL			English	Article									NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; Univ Helsinki, Cent Hosp, Dept Clin Chem, FIN-00290 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Med Genet, FIN-00290 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Med, Infect Dis Unit, FIN-00290 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Oncol, FIN-00290 Helsinki, Finland; Haartman Inst, Dept Bacteriol & Immunol, Helsinki 00290, Finland	New York University; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital	Salven, P (corresponding author), Cornell Univ, Weill Med Coll, Div Hematol Oncol, 1300 York Ave, New York, NY 10021 USA.			Joensuu, Heikki/0000-0003-0281-2507					0	17	19	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1318	1320		10.1096/fj.00-0627fje	http://dx.doi.org/10.1096/fj.00-0627fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344126				2022-12-25	WOS:000168655200048
J	Iwanaga, R; Ohtani, K; Hayashi, T; Nakamura, M				Iwanaga, R; Ohtani, K; Hayashi, T; Nakamura, M			Molecular mechanism of cell cycle progression induced by the oncogene product Tax of human T-cell leukemia virus type I	ONCOGENE			English	Article						cell cycle; E2F; HTLV-I; NF-kappa B; tax; cyclin D2	RETINOBLASTOMA PROTEIN; TRANSCRIPTIONAL ACTIVATOR; HTLV-I; E2F; EXPRESSION; FAMILY; LINE; ACCUMULATION; GROWTH; GENES	The trans-activator protein Tax of human T-cell leukemia virus type I(HTLV-I) plays an important role in the development of adult T-cell leukemia through, at least in part, its ability to stimulate cell growth. We previously reported that Tax induced cell cycle progression from G0/G1 phase to S and G2/M phases in human T-cell line Kit 225 cells. To elucidate molecular mechanism of Tax-induced cell cycle progression, we systematically examined the effects of Tax on biochemical events associated with cell cycle progression, Introduction of Tax into resting Kit 225 cells induced activation of the G1/S transition regulation cascade consisting of activation of cyclin dependent kinase 2 (CDK2) and CDK4, phosphorylation of the Rb family proteins and an increase in free E2F, The kinase activation was found to result from Tax-induced expression of genes for cell cycle regulatory molecules including cyclin D2, cyclin E, E2F1, CDK2, CDK4 and CDK6, and Tax-induced reduction of CDK inhibitors p19(INK4d) and p27(Kip1), These modulations by Tax always paralleled the ability of Tax to activate the NF-kappaB transcription pathway. These results indicate the important role of Tax-mediated trans-activation of the genes for cell cycle regulatory molecules in Tax-induced cell cycle progression.	Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU)	Ohtani, K (corresponding author), Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, 1-4-45 Yushima, Tokyo 1138510, Japan.							AKAGI T, 1995, BLOOD, V86, P4243, DOI 10.1182/blood.V86.11.4243.bloodjournal86114243; Akagi T, 1996, ONCOGENE, V12, P1645; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; GESSAIN A, 1985, LANCET, V2, P407; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HIRAI H, 1992, ONCOGENE, V7, P1737; HORI T, 1987, BLOOD, V70, P1069; Hoshikawa Y, 1998, P NATL ACAD SCI USA, V95, P8574, DOI 10.1073/pnas.95.15.8574; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; Iwanaga Y, 1999, J VIROL, V73, P1271, DOI 10.1128/JVI.73.2.1271-1277.1999; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lauper N, 1998, ONCOGENE, V17, P2637, DOI 10.1038/sj.onc.1202477; LEE B, 1989, TOHOKU J EXP MED, V157, P1, DOI 10.1620/tjem.157.1; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; MINOWADA J, 1972, J NATL CANCER I, V49, P891; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NEVINS JR, 1992, SCIENCE, V258, P424; Ohtani K, 2000, J BIOL CHEM, V275, P11154, DOI 10.1074/jbc.275.15.11154; OSAME M, 1986, LANCET, V1, P1031; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; Suzuki T, 1999, VIROLOGY, V259, P384, DOI 10.1006/viro.1999.9760; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; YOSHIDA M, 1995, J CANCER RES CLIN, V121, P521, DOI 10.1007/BF01197764; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	43	109	110	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2001	20	17					2055	2067		10.1038/sj.onc.1204304	http://dx.doi.org/10.1038/sj.onc.1204304			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360190				2022-12-25	WOS:000168116700001
J	Sharma, SV; Oneyama, C; Yamashita, Y; Nakano, H; Sugawara, K; Hamada, M; Kosaka, N; Tamaoki, T				Sharma, SV; Oneyama, C; Yamashita, Y; Nakano, H; Sugawara, K; Hamada, M; Kosaka, N; Tamaoki, T			UCS15A, a non-kinase inhibitor of Src signal transduction	ONCOGENE			English	Article						Src; UCS15A; bone resorption inhibitor; protein-protein interaction	PP60C-SRC PROTEIN-KINASE; FOCAL ADHESION KINASE; RESORPTION IN-VITRO; C-SRC; BONE-RESORPTION; SH3 DOMAIN; OSTEOCLAST FUNCTION; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; GROWTH-FACTOR	Src tyrosine kinase plays key roles in signal transduction following growth factor stimulation and integrin-mediated cell-substrate adhesion. Since src-signal transduction defects are implicated in a multitude of human diseases, we have sought to develop new ways to identify small molecule inhibitors using a yeast-based, activated-src over-expression system, In the present study, we describe the identification of a unique src-signal transduction inhibitor, UCS15A, UCS15A was found to inhibit the src specific tyrosine phosphorylation of numerous proteins in v-src-transformed cells, Two of these phosphoproteins were identified as bona-fide src substrates, cortactin and Sam68, UCS15A differed from conventional src-inhibitors in that it did not inhibit the tyrosine kinase activity of src, In addition, UCS15A appeared to differ from src-destabilizing agents such as herbimycin and radicicol that destabilize src by interfering with Hsp90. Our studies suggest that UCS15A exerted its src-inhibitory effects by a novel mechanism that involved disruption of protein-protein interactions mediated by src, One of the biological consequences of src-inhibition by UCS15A was its ability to inhibit the bone resorption activity of osteoclasts in vitro, These data suggest that UCS15A may inhibit the bone resorption activity of osteoclasts, not by inhibiting src tyrosine kinase activity, but by disrupting the interaction of proteins associated with src, thereby modulating downstream events in the src signal transduction pathway.	Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Machida, Tokyo 194, Japan; Kyowa Hakko Kogyo Co Ltd, Pharmaceut Res Labs, Nagaizumi, Shizuoka 411, Japan; Natl Inst Basic Biol, Okazaki Natl Res Inst, Div Morphogenesis, Okazaki, Aichi 4448585, Japan	Kyowa Kirin Ltd; Kyowa Kirin Ltd; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Okazaki Institute for Integrative Bioscience (OIIB)	Sharma, SV (corresponding author), Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, 3-6-6 Asahimachi, Machida, Tokyo 194, Japan.							AKATSU T, 1992, J BONE MINER RES, V7, P1297; Blair HC, 1996, J CELL BIOCHEM, V61, P629, DOI 10.1002/(SICI)1097-4644(19960616)61:4<629::AID-JCB17>3.0.CO;2-A; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BRUGGE JS, 1987, MOL CELL BIOL, V7, P2180, DOI 10.1128/MCB.7.6.2180; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHENG HC, 1992, J BIOL CHEM, V267, P9248; Dalgarno DC, 1997, BIOPOLYMERS, V43, P383; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; Fischer RS, 2000, VIROLOGY, V269, P404, DOI 10.1006/viro.2000.0232; FUKAZAWA H, 1991, BIOCHEM PHARMACOL, V42, P1661; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; HALL GE, 1987, CALCIFIED TISSUE INT, V40, P212, DOI 10.1007/BF02556624; HALL TJ, 1994, BIOCHEM BIOPH RES CO, V199, P1237, DOI 10.1006/bbrc.1994.1363; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Huang JQ, 1999, ONCOGENE, V18, P4099, DOI 10.1038/sj.onc.1202779; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JACOBS C, 1983, CANCER RES, V43, P1696; KAMPS MP, 1988, ONCOGENE, V2, P305; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; KORNBLUTH S, 1987, P NATL ACAD SCI USA, V84, P4455, DOI 10.1073/pnas.84.13.4455; KURIHARA N, 1990, ENDOCRINOLOGY, V126, P2733, DOI 10.1210/endo-126-5-2733; KWON HJ, 1995, J BIOCHEM-TOKYO, V118, P221, DOI 10.1093/oxfordjournals.jbchem.a124882; KWON HJ, 1992, CANCER RES, V52, P6926; KWON HJ, 1992, BIOSCI BIOTECH BIOCH, V56, P538; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; Missbach M, 1999, BONE, V24, P437, DOI 10.1016/S8756-3282(99)00020-4; Miyazaki T, 2000, J BONE MINER RES, V15, P41, DOI 10.1359/jbmr.2000.15.1.41; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OKAMURA H, 1994, ONCOGENE, V9, P2293; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301-472X(99)00061-2; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schulte TW, 1999, MOL ENDOCRINOL, V13, P1435, DOI 10.1210/me.13.9.1435; Schulte TW, 1998, CELL STRESS CHAPERON, V3, P100, DOI 10.1379/1466-1268(1998)003<0100:ARBTTN>2.3.CO;2; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; Sharma SV, 1998, ONCOGENE, V16, P2639, DOI 10.1038/sj.onc.1201790; Shen ZW, 1999, ONCOGENE, V18, P4647, DOI 10.1038/sj.onc.1203079; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; Sugawara K, 1998, ANAL BIOCHEM, V255, P204, DOI 10.1006/abio.1997.2474; SUZUKI G, 1983, Patent No. 58116686; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; UEHARA Y, 1985, JPN J CANCER RES, V76, P672; UEHARA Y, 1988, J ANTIBIOT, V41, P831, DOI 10.7164/antibiotics.41.831; Viola R, 1999, KNEE SURG SPORT TR A, V7, P25, DOI 10.1007/s001670050116; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; YONEDA T, 1993, J CLIN INVEST, V91, P2791, DOI 10.1172/JCI116521; ZHAO JF, 1995, ONCOGENE, V11, P161; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; Zhu T, 1998, J BIOL CHEM, V273, P33864, DOI 10.1074/jbc.273.50.33864	69	45	48	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2001	20	17					2068	2079		10.1038/sj.onc.1204296	http://dx.doi.org/10.1038/sj.onc.1204296			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360191				2022-12-25	WOS:000168116700002
J	Gensure, RC; Gardella, TJ; Juppner, H				Gensure, RC; Gardella, TJ; Juppner, H			Multiple sites of contact between the carboxyl-terminal binding domain of PTHrP-(1-36) analogs and the amino-terminal extracellular domain of the PTH/PTHrP receptor identified by photoaffinity cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PARATHYROID-HORMONE; PTH-RELATED PEPTIDE; PROTEIN-RECEPTOR; REGION; LIGAND; LOOP; MUTAGENESIS; FRAGMENTS; RESIDUES; COMPLEX	The carboxyl-terminal portions of parathyroid hormone (PTH)-(1-34) and PTH-related peptide (PTHrP)-(1-36) are critical for high affinity binding to the PTH/ PTHrP receptor (P1R), but the mechanism of receptor interaction for this domain is largely unknown. To identify interaction sites between the carboxyl-terminal region of PTHrP-(1-36) and the P1R, we prepared analogs of [I-5,W-23,Y-36]PTHrP-(1-36)-amide with individual p-benzoyl-L-phenylalanine (Bpa) substitutions at positions 22-35. When tested with LLC-PK1 cells stably transfected with human P1R (hP1R), the apparent binding affinity and the EC50 of agonist-stimulated cAMP accumulation for each analog was, with the exception of the Bpa(24)-substituted analog, similar to that of the parent compound. The radiolabeled Bpa(23)-, Bpa(27)-, Bpa (28)-, and Bpa(33)-substituted compounds affinity-labeled the hP1R sufficiently well to permit subsequent mapping of the cross-linked receptor region. Each of these peptides cross-linked to the amino-terminal extracellular domain of the P1R: [I-5,Bpa(23),Y-36]PTHrP-(1-36)-amide crosslinked to the extreme end of this domain (residues 33-63); [I-5,W-23 Bpa(27),Y-36]PTHrP-(1-36)-amide cross-linked to residues 96-102; [1(5),W-23 Bpa (28),Y-36] PTHrP-(1-36). amide cross-linked to residues 64-95; and [15,W23, Bpa(33),Y-36]PTHrP-(1-36)-amide cross-linked to residues 151-172. These data thus predict that residues 23, 279 28, and 33 of native PTHrP are each near to different regions of the amino-terminal extracellular receptor domain of the P1R. This information helps define sites of proximity between several ligand residues and this large receptor domain, which so far has been largely excluded from models of the hormone-receptor complex.	Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Pediat Endocrine Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Juppner, H (corresponding author), Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.				NIDDK NIH HHS [DK11794, 1F32DK10034-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794, F32DK010034] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams AE, 1998, MOL ENDOCRINOL, V12, P1673, DOI 10.1210/me.12.11.1673; Barbier JR, 1997, J MED CHEM, V40, P1373, DOI 10.1021/jm960743o; Behar V, 2000, J BIOL CHEM, V275, P9, DOI 10.1074/jbc.275.1.9; Bergwitz C, 1997, J BIOL CHEM, V272, P28861, DOI 10.1074/jbc.272.46.28861; Bergwitz C, 1998, ENDOCRINOLOGY, V139, P723, DOI 10.1210/en.139.2.723; Bergwitz C, 1996, J BIOL CHEM, V271, P26469, DOI 10.1074/jbc.271.43.26469; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; Carter PH, 1999, ENDOCRINOLOGY, V140, P4972, DOI 10.1210/en.140.11.4972; Dong MQ, 1999, J BIOL CHEM, V274, P903, DOI 10.1074/jbc.274.2.903; EPAND RM, 1985, INT J PEPT PROT RES, V25, P594; Gardella T J, 2000, Rev Endocr Metab Disord, V1, P317, DOI 10.1023/A:1026522619828; Gardella TJ, 1996, J BIOL CHEM, V271, P19888, DOI 10.1074/jbc.271.33.19888; GARDELLA TJ, 1993, ENDOCRINOLOGY, V132, P2024, DOI 10.1210/en.132.5.2024; Grauschopf U, 2000, BIOCHEMISTRY-US, V39, P8878, DOI 10.1021/bi0001426; Greenberg Z, 2000, BIOCHEMISTRY-US, V39, P8142, DOI 10.1021/bi000195n; GREMLICH HU, 1983, BIOCHEMISTRY-US, V22, P4257, DOI 10.1021/bi00287a015; Hoare SRJ, 2000, J BIOL CHEM, V275, P27274; Jin L, 2000, J BIOL CHEM, V275, P27238; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; JUPPNER H, 1988, J BIOL CHEM, V263, P8557; Juppner H., 2000, ENDOCRINOLOGY, P969; KEMP BE, 1987, SCIENCE, V238, P1568, DOI 10.1126/science.3685995; KONG XF, 1994, BIOCHEM BIOPH RES CO, V200, P1290, DOI 10.1006/bbrc.1994.1591; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CW, 1995, MOL ENDOCRINOL, V9, P1269, DOI 10.1210/me.9.10.1269; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; Mannstadt M, 1998, J BIOL CHEM, V273, P16890, DOI 10.1074/jbc.273.27.16890; Pellegrini M, 1998, J BIOL CHEM, V273, P10420, DOI 10.1074/jbc.273.17.10420; Piserchio A, 2000, BIOCHEMISTRY-US, V39, P8153, DOI 10.1021/bi000196f; Rolz C, 1999, BIOCHEMISTRY-US, V38, P6397, DOI 10.1021/bi9829276; Rubin DA, 1999, J BIOL CHEM, V274, P28185, DOI 10.1074/jbc.274.40.28185; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIPANI E, 1995, J CLIN ENDOCR METAB, V80, P1611, DOI 10.1210/jc.80.5.1611; Shimizu M, 2000, J BIOL CHEM, V275, P21836, DOI 10.1074/jbc.M909861199; Shimizu M, 2000, J BIOL CHEM, V275, P19456, DOI 10.1074/jbc.M001596200; Takasu H, 1999, BIOCHEMISTRY-US, V38, P13453, DOI 10.1021/bi990437n; Turner PR, 1998, J BIOL CHEM, V273, P3830, DOI 10.1074/jbc.273.7.3830; Zhou AT, 2000, BIOCHEMISTRY-US, V39, P6514, DOI 10.1021/bi992706f	39	55	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28650	28658		10.1074/jbc.M100717200	http://dx.doi.org/10.1074/jbc.M100717200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11356832	hybrid			2022-12-25	WOS:000170346000004
J	Planque, N; Leconte, L; Coquelle, FM; Martin, P; Saule, S				Planque, N; Leconte, L; Coquelle, FM; Martin, P; Saule, S			Specific Pax-6/microphthalmia transcription factor interactions involve their DNA-binding domains and inhibit transcriptional properties of both proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROPHTHALMIA GENE-PRODUCT; RETINAL-PIGMENT EPITHELIUM; PAX6 PAIRED DOMAIN; WAARDENBURG-SYNDROME; NEURAL RETINA; IN-VITRO; EXPRESSION; MITF; HELIX; HOMEODOMAIN	Pax-6 and microphthalmia transcription factor (Mitf) are required for proper eye development. Pax-6, expressed in both the neuroretina and pigmented retina, has two DNA-binding domains: the paired domain and the homeodomain. Mice homozygous for Pax-6 mutations are anophthalmic. Mitf, a basic helix-loop-helix leucine zipper (b-HLH-LZ) transcription factor associated with the onset and maintenance of pigmentation, identifies the retinal pigmented epithelium during eye development. Loss of Mitf function results in the formation of an ectopic neuroretina at the expense of the dorsal retinal pigmented epithelium. In the present study, we investigated the interaction between Pax-6 and Mitf. In transient transfection-expression experiments, we found that transactivating effects of Pax-6 and Mitf on their respective target promoters were strongly inhibited by co-transfection of both transcription factors. This repression was due to direct protein/protein interactions involving both Pax-6 DNA-binding domains and the Mitf b-HLH-LZ domain. These results suggest that Pax-6/Mitf interactions may be critical for retinal pigmented epithelium development.	Inst Curie Sect Rech, CNRS, UMR 146, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Saule, S (corresponding author), Inst Curie Sect Rech, CNRS, UMR 146, Ctr Univ Batiment 110, F-91405 Orsay, France.	Simon.Saule@curie.u-psud.fr		COQUELLE, Frederic/0000-0002-5483-8787				AGATA K, 1993, DEVELOPMENT, V118, P1025; Aksan I, 1998, MOL CELL BIOL, V18, P6930, DOI 10.1128/MCB.18.12.6930; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; BOISSY RE, 1993, J SUBMICR CYTOL PATH, V25, P319; Bumsted KM, 2000, INVEST OPHTH VIS SCI, V41, P903; Callaerts P, 1997, ANNU REV NEUROSCI, V20, P483, DOI 10.1146/annurev.neuro.20.1.483; CARRIERE C, 1995, CELL GROWTH DIFFER, V6, P1531; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; Chow RL, 1999, DEVELOPMENT, V126, P4213; Cvekl A, 1999, INVEST OPHTH VIS SCI, V40, P1343; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; GLASER T, 1995, MOL GENETICS OCULAR, P55; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Hussain MA, 1999, J BIOL CHEM, V274, P28950, DOI 10.1074/jbc.274.41.28950; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; Knoepfler PS, 1999, NUCLEIC ACIDS RES, V27, P3752, DOI 10.1093/nar/27.18.3752; Lam PYP, 1999, MOL CELL BIOL, V19, P594; MACDONALD R, 1995, DEVELOPMENT, V121, P3267; MARTIN P, 1992, ONCOGENE, V7, P1721; Mikkola I, 2001, J BIOL CHEM, V276, P4109, DOI 10.1074/jbc.M008882200; Mochii M, 1998, DEV BIOL, V196, P145, DOI 10.1006/dbio.1998.8864; Nakayama A, 1998, MECH DEVELOP, V70, P155, DOI 10.1016/S0925-4773(97)00188-3; Nguyen MTT, 2000, DEVELOPMENT, V127, P3581; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; Okada T S, 1980, Curr Top Dev Biol, V16, P349; PARK CM, 1989, DEV BIOL, V134, P201, DOI 10.1016/0012-1606(89)90089-4; PITTACK C, 1991, DEVELOPMENT, V113, P577; Planque N, 1999, CELL GROWTH DIFFER, V10, P525; PLAZA S, 1993, CELL GROWTH DIFFER, V4, P1041; Plaza S, 1997, CELL GROWTH DIFFER, V8, P1115; Potterf SB, 2000, HUM GENET, V107, P1, DOI 10.1007/s004390050001; Poulin G, 2000, MOL CELL BIOL, V20, P4826, DOI 10.1128/MCB.20.13.4826-4837.2000; Ritz-Laser B, 1999, J BIOL CHEM, V274, P4124, DOI 10.1074/jbc.274.7.4124; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; Sato S, 1997, ONCOGENE, V14, P3083, DOI 10.1038/sj.onc.1201298; Schedl A, 1996, CELL, V86, P71, DOI 10.1016/S0092-8674(00)80078-1; Singh S, 2000, J BIOL CHEM, V275, P17306, DOI 10.1074/jbc.M000359200; Singh S, 2001, HUM MOL GENET, V10, P911, DOI 10.1093/hmg/10.9.911; TACHIBANA M, 1994, HUM MOL GENET, V3, P553, DOI 10.1093/hmg/3.4.553; Takebayashi K, 1996, MOL CELL BIOL, V16, P1203; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; Torres MA, 1996, DEVELOPMENT, V122, P3381; Turque N, 1996, EMBO J, V15, P3338, DOI 10.1002/j.1460-2075.1996.tb00699.x; Wakamatsu Y, 1997, DEVELOPMENT, V124, P3449; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; Xu HE, 1999, GENE DEV, V13, P1263, DOI 10.1101/gad.13.10.1263; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058; YAVUZER U, 1995, ONCOGENE, V10, P123	54	47	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29330	29337		10.1074/jbc.M101812200	http://dx.doi.org/10.1074/jbc.M101812200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11350962	hybrid			2022-12-25	WOS:000170346000093
J	van der Merwe, GK; Cooper, TG; van Vuuren, HJJ				van der Merwe, GK; Cooper, TG; van Vuuren, HJJ			Ammonia regulates VID30 expression and Vid30p function shifts nitrogen metabolism toward glutamate formation especially when Saccharomyces cerevisiae is grown in low concentrations of ammonia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL KINASE HOMOLOG; CATABOLIC GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; TOR; RAPAMYCIN; REPRESSION; PRODUCT; GLN3P; PROTEIN; URE2P	The GATA family proteins Gln3p and Gat1p mediate nitrogen catabolite repression (NCR)-sensitive transcription in Saccharomyces cerevisiae. When cells are cultured with a good nitrogen source (glutamine, ammonia), Gln3p and Gat1p are restricted to the cytoplasm, whereas with a poor nitrogen source (proline), they localize to the nucleus, bind to the GATA sequences of NCR-sensitive gene promoters, and activate transcription. The target of rapamycin-signaling cascade and Ure2p participate in regulating the cellular localization of Gln3p and Gat1p. Rapamycin, a Tor protein inhibitor, like growth with a poor nitrogen source, promotes nuclear localization of Gln3p and Gat1p. gln3 Delta and ure2 Delta mutants are partially resistant and hypersensitive to growth inhibition by rapamycin, respectively. We show that a vid30 Delta is more rapamycin-sensitive than wild type but less so than a ure2 Delta. VID30 expression is modestly NCR-sensitive, responsive to deletion of URE2, and greatly increases in low ammonia medium. Patterns of gene expression in a vid30 Delta suggest that the Vid30p function shifts the balance of nitrogen metabolism toward the production of glutamate, especially when cells are grown in low ammonia. CAN1, DAL4, DAL5, MEP2, DAL1, DAL80, and GDH3 transcription is down-regulated by Vid30p function with proline as the nitrogen source. An effect, however, that could easily be indirect.	Univ British Columbia, Fac Agr Sci, Wine Res Ctr, Vancouver, BC V6T 1Z4, Canada; Univ Tennessee, Ctr Hlth Sci, Dept Microbiol & Immunol, Memphis, TN 38163 USA	University of British Columbia; University of Tennessee System; University of Tennessee Health Science Center	van Vuuren, HJJ (corresponding author), Univ British Columbia, Fac Agr Sci, Wine Res Ctr, Vancouver, BC V6T 1Z4, Canada.	hjjvv@interchange.ubc.ca		Cooper, Terrance G./0000-0002-7651-9963	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035642] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM035642, GM-35642-14] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F. M., 1995, CURRENT PROTOCOLS MO, P241; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bertram PG, 2000, J BIOL CHEM, V275, P35727, DOI 10.1074/jbc.M004235200; Blinder D, 1996, J BACTERIOL, V178, P4734, DOI 10.1128/jb.178.15.4734-4736.1996; BLINDER D, 1995, J BACTERIOL, V177, P4190, DOI 10.1128/jb.177.14.4190-4193.1995; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Chan TF, 2001, J BIOL CHEM, V276, P6463, DOI 10.1074/jbc.M008162200; Choi JH, 2000, CURR BIOL, V10, P861, DOI 10.1016/S0960-9822(00)00599-6; Coffman JA, 1996, MOL CELL BIOL, V16, P847; COFFMAN JA, 1994, J BACTERIOL, V176, P7476, DOI 10.1128/JB.176.24.7476-7483.1994; COGONI C, 1995, J BACTERIOL, V177, P792, DOI 10.1128/jb.177.3.792-798.1995; Cooper T., 1982, MOL BIOL YEAST SACCH, P39, DOI DOI 10.1101/087969180.11B.39; COOPER TG, 1990, J BACTERIOL, V172, P1014, DOI 10.1128/jb.172.2.1014-1018.1990; Cooper TG, 1996, MYCOTA, V3, P139; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P4455, DOI 10.1128/MCB.11.9.4455; COURCHESNE WE, 1988, J BACTERIOL, V170, P708, DOI 10.1128/jb.170.2.708-713.1988; CUNNINGHAM TS, 1991, MOL CELL BIOL, V11, P6205, DOI 10.1128/MCB.11.12.6205; Cunningham TS, 1996, J BACTERIOL, V178, P3470, DOI 10.1128/jb.178.12.3470-3479.1996; Cunningham TS, 2000, J BIOL CHEM, V275, P14408, DOI 10.1074/jbc.275.19.14408; DAUGHERTY JR, 1993, J BACTERIOL, V175, P64, DOI 10.1128/JB.175.1.64-73.1993; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LAW DTS, 1988, MOL CELL BIOL, V8, P912, DOI 10.1128/MCB.8.2.912; MAGASANIK B, 1992, MOL CELLULAR BIOL YE, V2, P283; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; REITZER LJ, 1987, ESCHERICHIA COLI SAL, P301; Schmidt A, 1998, EMBO J, V17, P6924, DOI 10.1093/emboj/17.23.6924; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; STANBROUGH M, 1995, J BACTERIOL, V177, P94, DOI 10.1128/jb.177.1.94-102.1995; Stanbrough M, 1996, J BACTERIOL, V178, P2465, DOI 10.1128/jb.178.8.2465-2468.1996; ter Schure EG, 2000, FEMS MICROBIOL REV, V24, P67, DOI 10.1016/S0168-6445(99)00030-3	34	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28659	28666		10.1074/jbc.M102280200	http://dx.doi.org/10.1074/jbc.M102280200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11356843	Green Accepted, hybrid			2022-12-25	WOS:000170346000005
J	Rodrigues, RG; Guo, NH; Zhou, LG; Sipes, JM; Williams, SB; Templeton, NS; Gralnick, HR; Roberts, DD				Rodrigues, RG; Guo, NH; Zhou, LG; Sipes, JM; Williams, SB; Templeton, NS; Gralnick, HR; Roberts, DD			Conformational regulation of the fibronectin binding and alpha(3)beta(1) integrin-mediated adhesive activities of thrombospondin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; CELL LUNG-CARCINOMA; GROWTH-FACTOR; MONOCLONAL-ANTIBODIES; PLATELET THROMBOSPONDIN; PLASMA FIBRONECTIN; ENDOTHELIAL-CELLS; TUMOR-GROWTH; GPIIB-IIIA; I REPEAT	The recognition of extracellular matrix components can be regulated by conformational changes that alter the activity of cell surface integrins. We now demonstrate that conformational regulation of the matrix glycoprotein thrombospondin-1 (TSP1) can also modulate its binding to an integrin receptor. F18 1G8 is a conformation-sensitive TSP1 antibody that binds weakly to soluble TSP1 in the presence of divalent cations. However, binding of the antibody to melanoma cells was strongly stimulated by adding exogenous TSP1 in the presence of calcium, suggesting that TSP1 undergoes a conformational change following its binding to the cell surface. This conformation was not induced by known cell surface TSP1 receptors, whereas binding of F18 was stimulated when TSP1 bound to fibronectin but not to heparin or fibrinogen. Conversely, binding of F18 to TSP1 enhanced TSP1 binding to fibronectin. Exogenous fibronectin also stimulated TSP1-dependent binding of F18 to melanoma cells. Binding of the fibronectin-TSP1 complex to melanoma cells was mediated by alpha (4)beta (1) and alpha (5)beta (1) integrins. Furthermore, binding to F18 or fibronectin strongly enhanced the adhesive activity of immobilized TSP1 for some cell types. This enhancement of adhesion was mediated by alpha (3)beta (1) integrin and required that the alpha (3)beta (1) integrin be in an active state. Fibronectin also enhanced TSP1 binding to purified alpha (3)beta (1) integrin. Therefore, both fibronectin and the F18 antibody induce conformational changes in TSP1 that enhance the ability of TSP1 to be recognized by alpha (3)beta (1) integrin. The conformational and functional regulation of TSP1 activity by fibronectin represents a novel mechanism for extracellular signal transduction.	NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; NIH, Hematol Serv, Ctr Clin, Bethesda, MD 20892 USA; Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Baylor College of Medicine; Baylor College of Medicine	Roberts, DD (corresponding author), NCI, Pathol Lab, NIH, Bldg 10,Rm 2A33,10 Ctr DR,MSC 1500, Bethesda, MD 20892 USA.		Templeton, Nancy S/C-9565-2011; Roberts, David D./A-9699-2008	Roberts, David D./0000-0002-2481-2981				Adams JC, 1997, MOL BIOL CELL, V8, P2345, DOI 10.1091/mbc.8.11.2345; AIKEN ML, 1986, J CLIN INVEST, V78, P1713, DOI 10.1172/JCI112767; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; BENEZRA D, 1993, INVEST OPHTH VIS SCI, V34, P3601; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; BUEE L, 1992, AM J PATHOL, V141, P783; CASTLE V, 1991, J CLIN INVEST, V87, P1883, DOI 10.1172/JCI115212; Castle VP, 1997, LAB INVEST, V77, P51; Chandrasekaran L, 2000, MOL BIOL CELL, V11, P2885, DOI 10.1091/mbc.11.9.2885; Chandrasekaran S, 1999, J BIOL CHEM, V274, P11408, DOI 10.1074/jbc.274.16.11408; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DARDIK R, 1989, EUR J BIOCHEM, V185, P581, DOI 10.1111/j.1432-1033.1989.tb15153.x; Dardik R, 1999, EXP CELL RES, V248, P407, DOI 10.1006/excr.1999.4415; DEFREITAS MF, 1995, NEURON, V15, P333, DOI 10.1016/0896-6273(95)90038-1; DIXIT VM, 1986, J BIOL CHEM, V261, P1962; Eble JA, 1998, BIOCHEMISTRY-US, V37, P10945, DOI 10.1021/bi980175+; GINSBERG MH, 1983, J CELL BIOL, V97, P571, DOI 10.1083/jcb.97.2.571; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GOODWIN G, 1982, CANCER RES, V42, P1361; GRALNICK HR, 1992, BRIT J HAEMATOL, V80, P347, DOI 10.1111/j.1365-2141.1992.tb08144.x; Guo NH, 2000, CANCER RES, V60, P457; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; Guo NH, 1997, CANCER RES, V57, P1735; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HOMANDBERG GA, 1987, THROMB RES, V48, P329, DOI 10.1016/0049-3848(87)90445-2; Hotchkiss KA, 1996, BIOCHEMISTRY-US, V35, P9761, DOI 10.1021/bi9603938; Hotchkiss KA, 1998, BBA-PROTEIN STRUCT M, V1388, P478, DOI 10.1016/S0167-4838(98)00211-8; Huang EM, 1997, BLOOD, V89, P3205, DOI 10.1182/blood.V89.9.3205; Huang S, 1999, NAT CELL BIOL, V1, pE131, DOI 10.1038/13043; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; KARCZEWSKI J, 1989, J BIOL CHEM, V264, P21322; Keenan RM, 1997, J MED CHEM, V40, P2289, DOI 10.1021/jm970205r; Krutzsch HC, 1999, J BIOL CHEM, V274, P24080, DOI 10.1074/jbc.274.34.24080; LAHAV J, 1984, EUR J BIOCHEM, V145, P151, DOI 10.1111/j.1432-1033.1984.tb08534.x; LAHAV J, 1982, CELL, V31, P253, DOI 10.1016/0092-8674(82)90425-1; LAWLER J, 1989, BLOOD, V74, P2022; LAWLER J, 1982, J BIOL CHEM, V257, P2257; Lin KC, 1999, J MED CHEM, V42, P920, DOI 10.1021/jm980673g; Matthias LJ, 1996, BBA-PROTEIN STRUCT M, V1296, P138, DOI 10.1016/0167-4838(96)00060-X; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHYULLRICH JE, 1989, J CELL BIOL, V109, P1309, DOI 10.1083/jcb.109.3.1309; NICOSIA RF, 1994, J CELL BIOL, V124, P183, DOI 10.1083/jcb.124.1.183; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; Pijuan-Thompson V, 1999, EXP CELL RES, V249, P86, DOI 10.1006/excr.1999.4458; Porter JC, 1998, TRENDS CELL BIOL, V8, P390, DOI 10.1016/S0962-8924(98)01344-0; Roberts David D., 1994, Journal of Tissue Culture Methods, V16, P217, DOI 10.1007/BF01540654; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; Shi SR, 1999, J HISTOCHEM CYTOCHEM, V47, P463, DOI 10.1177/002215549904700404; SIPES JM, 1993, J CELL BIOL, V121, P469, DOI 10.1083/jcb.121.2.469; SLANE JMK, 1988, FEBS LETT, V229, P363, DOI 10.1016/0014-5793(88)81157-8; SUN X, 1992, J CELL BIOL, V118, P693, DOI 10.1083/jcb.118.3.693; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; TUSZYNSKI GP, 1987, CANCER RES, V47, P4130; VOLPERT OV, 1995, BREAST CANCER RES TR, V36, P119, DOI 10.1007/BF00666034; Watanabe K, 2000, BIOCHEMISTRY-US, V39, P7138, DOI 10.1021/bi992670r; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; YABKOWITZ R, 1993, J IMMUNOL, V151, P149; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209; ZAFAR RS, 1992, ARCH BIOCHEM BIOPHYS, V297, P271, DOI 10.1016/0003-9861(92)90672-J	65	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27913	27922		10.1074/jbc.M009518200	http://dx.doi.org/10.1074/jbc.M009518200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11358957	hybrid			2022-12-25	WOS:000170093400024
J	Cuevas, BD; Lu, YL; Mao, ML; Zhang, JY; LaPushin, R; Siminovitch, K; Mills, GB				Cuevas, BD; Lu, YL; Mao, ML; Zhang, JY; LaPushin, R; Siminovitch, K; Mills, GB			Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT; FACTOR-RECEPTOR; CELL-SURVIVAL; PROTEIN; BINDING; KINASE; SH2; PROLIFERATION; ASSOCIATION; ACTIVATION	Under resting conditions, the p85 regulatory subunit of phosphatidylinositol S-kinase (PI3K) serves to both stabilize and inactivate the p110 catalytic subunit. The inhibitory activity of p85 is relieved by occupancy of the NH2-terminal SH2 domain of p85 by phosphorylated tyrosine. Src family kinases phosphorylate tyrosine 688 in p85, a process that we have shown to be reversed by the activity of the p85-associated SH2 domain-containing phosphatase SHP1. We demonstrate that phosphorylation of the downstream PI3K target Akt is increased in cells lacking SHP1, implicating phosphorylation of p85 in the regulation of PI3K activity. Furthermore, the in vitro specific activity of PI3K associated with tyrosine-phosphorylated p85 is higher than that associated with nonphosphorylated p85, Expression of wild-type p85 inhibits PI3K enzyme activity as indicated by PI3K-dependent Akt phosphorylation. The inhibitory activity of p85 is accentuated by mutation of tyrosine 688 to alanine and reversed by mutation of tyrosine 688 to aspartic acid, changes that block and mimic tyrosine phosphorylation, respectively. Strikingly, mutation of tyrosine 688 to aspartic acid completely reverses the inhibitory activity of p85 on cell viability and activation of the downstream targets Akt and NF kappaB, indicative of the physiological relevance of p85 phosphorylation, Tyrosine phosphorylation of Tyr(688) or mutation of tyrosine 688 to aspartic acid is sufficient to allow binding to the NH2-terminal SH2 domain of p85. Thus an intramolecular interaction between phosphorylated Tyr(688) and the NH2-terminal SH2 domain of p85 can relieve the inhibitory activity of p85 on p110. Taken together, the data indicate that phosphorylation of Tyr(688) in p85 leads to a novel mechanism of PI3K regulation.	Univ Texas, MD Anderson Canc Ctr, Div Med, Dept Mol Therapeut, Houston, TX 77030 USA; Univ Toronto, Dept Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1X5, Canada	University of Texas System; UTMD Anderson Cancer Center; University of Toronto; University of Toronto; University of Toronto	Mills, GB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Med, Dept Mol Therapeut, 1515 Holcombe Blvd,Box 317, Houston, TX 77030 USA.		Siminovitch, Katherine/K-1475-2013		NATIONAL CANCER INSTITUTE [R01CA074247, P01CA064602, P50CA083639] Funding Source: NIH RePORTER; NCI NIH HHS [CA64602, CA74247, CA83639] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blalock WL, 1999, LEUKEMIA, V13, P1109, DOI 10.1038/sj.leu.2401493; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cuevas B, 1999, J BIOL CHEM, V274, P27583, DOI 10.1074/jbc.274.39.27583; delPeso L, 1997, SCIENCE, V278, P687; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Harpur AG, 1999, J BIOL CHEM, V274, P12323, DOI 10.1074/jbc.274.18.12323; HE TC, 1993, BLOOD, V82, P3530; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; Martinez-Lorenzo MJ, 2000, INT J BIOCHEM CELL B, V32, P435, DOI 10.1016/S1357-2725(99)00142-9; Mayer BJ, 1998, CURR TOP MICROBIOL, V228, P1; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; von Willebrand M, 1998, J BIOL CHEM, V273, P3994, DOI 10.1074/jbc.273.7.3994; VONWILLEBRAND M, 1994, EUR J IMMUNOL, V24, P234, DOI 10.1002/eji.1830240137; Wu Y, 1998, J BIOL CHEM, V273, P5765, DOI 10.1074/jbc.273.10.5765; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; Yu ZB, 1998, J BIOL CHEM, V273, P3687, DOI 10.1074/jbc.273.6.3687	24	192	194	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27455	27461		10.1074/jbc.M100556200	http://dx.doi.org/10.1074/jbc.M100556200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11337495	hybrid			2022-12-25	WOS:000169966900096
J	Horer, S; Stoop, J; Mooibroek, H; Baumann, U; Sassoon, J				Horer, S; Stoop, J; Mooibroek, H; Baumann, U; Sassoon, J			The crystallographic structure of the mannitol 2-dehydrogenase NADP(+) binary complex from Agaricus bisporus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; 3-ALPHA,20-BETA-HYDROXYSTEROID DEHYDROGENASE; 17-BETA-HYDROXYSTEROID DEHYDROGENASE; 3-DIMENSIONAL STRUCTURE; COENZYME SPECIFICITY; ANGSTROM RESOLUTION; COMMON MUSHROOM; REDUCTASE; BINDING; METABOLISM	Mannitol, an acyclic six-carbon polyol, is one of the most abundant sugar alcohols occurring in nature, In the button mushroom, Agaricus bisporus, it is synthesized from fructose by the enzyme mannitol a dehydrogenase (MtDH; EC 1.1.1.138) using NADPH as a cofactor. Mannitol serves as the main storage carbon (up to 50% of the fruit body dry weight) and plays a critical role in growth, fruit body development, osmoregulation, and salt tolerance. Furthermore, mannitol dehydrogenases are being evaluated for commercial mannitol production as alternatives to the less efficient chemical reduction of fructose, Given the importance of mannitol metabolism and mannitol dehydrogenases, MtDH was cloned into the pET28 expression system and overexpressed in Escherichia coli, Kinetic and physicochemical properties of the recombinant enzyme are indistinguishable hom the natural enzyme. The crystal structure of its binary complex with NADP was solved at 1.5-Angstrom resolution and refined to an R value of 19.3%. It shows MtDH to be a tetramer and a member of the short chain dehydrogenase/reductase family of enzymes. The catalytic residues forming the so-called catalytic triad can be assigned to Ser(149), Tyr(169), and Lys(173).	Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland; DuPont Crop Genet, Wilmington, DE 19880 USA; Univ Wageningen & Res Ctr, Dept Bioconvers, Agrotechnol Res Inst, ATO BV, NL-6700 AA Wageningen, Netherlands	University of Bern; DuPont; Wageningen University & Research	Baumann, U (corresponding author), Univ Bern, Dept Chem & Biochem, Freiestr 3, CH-3012 Bern, Switzerland.	ulrich.baumann@ibc.unibe.ch; sassoon@ibc.unibe.ch	Baumann, Ulrich/B-1220-2013					Auerbach G, 1997, EMBO J, V16, P7219, DOI 10.1093/emboj/16.24.7219; Azzi A, 1996, NAT STRUCT BIOL, V3, P665, DOI 10.1038/nsb0896-665; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benach J, 1998, J MOL BIOL, V282, P383, DOI 10.1006/jmbi.1998.2015; Breton R, 1996, STRUCTURE, V4, P905, DOI 10.1016/S0969-2126(96)00098-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cornish-Bowden A., 1995, ANAL ENZYME KINETIC; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Duax WL, 1996, CURR OPIN STRUC BIOL, V6, P813, DOI 10.1016/S0959-440X(96)80012-1; DUTSCH GA, 1972, PHYTOCHEMISTRY, V11, P2677, DOI 10.1016/S0031-9422(00)86496-1; Evans W, 1997, CHEM BRIT, V33, P22; GHOSH D, 1994, STRUCTURE, V2, P973, DOI 10.1016/S0969-2126(94)00099-9; GHOSH D, 1991, P NATL ACAD SCI USA, V88, P10064, DOI 10.1073/pnas.88.22.10064; GHOSH D, 1994, STRUCTURE, V2, P629, DOI 10.1016/S0969-2126(00)00064-2; HAMMOND JBW, 1975, J SCI FOOD AGR, V26, P835, DOI 10.1002/jsfa.2740260615; Hery S, 1998, J MOL BIOL, V279, P303, DOI 10.1006/jmbi.1998.1754; HOLTZ RB, 1971, J AGR FOOD CHEM, V19, P1272, DOI 10.1021/jf60178a052; Hulsmeyer M, 1998, PROTEIN SCI, V7, P1286; IUPAC-IUB Joint Commission on Biochemical Nomeclature (JCBN), 1983, EUR J BIOCHEM, V131, P9, DOI DOI 10.1021/IC2011716; JENNINGS DH, 1984, ADV MICROB PHYSIOL, V25, P149; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; KLEYWEGT GJ, 1996, CCP4 ESF EACBM NEWSL, V32, P32; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Lesk AM, 1995, CURR OPIN STRUC BIOL, V5, P775, DOI 10.1016/0959-440X(95)80010-7; LESLIE AGW, 1996, PROTEIN CRYSTALLOGR, V32, P7; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Mazza C, 1998, J BIOL CHEM, V273, P8145, DOI 10.1074/jbc.273.14.8145; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MOOIBROEK H, 1996, PROGR TRANSFORMATION; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; OPPENHEIMER NJ, 1992, MECH NAD DEPENDENT E, V20; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; RAST D, 1965, PLANTA, V64, P81, DOI 10.1007/BF00518625; ROSSMANN MG, 1975, EVOLUTIONARY STRUCTU; RUFFNER HP, 1978, PHYTOCHEMISTRY, V17, P865, DOI 10.1016/S0031-9422(00)88635-5; Sassoon J, 2001, ACTA CRYSTALLOGR D, V57, P711, DOI 10.1107/S0907444901002542; Schwede T, 2000, RES MICROBIOL, V151, P107, DOI 10.1016/S0923-2508(00)00121-2; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; STOOP JMH, 1994, PLANT PHYSIOL, V106, P503, DOI 10.1104/pp.106.2.503; Stoop JMH, 1996, TRENDS PLANT SCI, V1, P139, DOI 10.1016/S1360-1385(96)80048-3; Stoop JMH, 1998, APPL ENVIRON MICROB, V64, P4689; SU Y, 1993, J BIOL CHEM, V268, P26836; Tanaka N, 1996, BIOCHEMISTRY-US, V35, P7715, DOI 10.1021/bi951904d; Tanaka N, 1996, STRUCTURE, V4, P33, DOI 10.1016/S0969-2126(96)00007-X; vandeRhee MD, 1996, CURR GENET, V30, P166, DOI 10.1007/s002940050116; vandeRhee MD, 1996, MOL GEN GENET, V250, P252, DOI 10.1007/BF02174382; VARUGHESE KI, 1992, P NATL ACAD SCI USA, V89, P6080, DOI 10.1073/pnas.89.13.6080; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Yamamoto K, 2001, J BIOCHEM, V129, P303, DOI 10.1093/oxfordjournals.jbchem.a002858; Yamashita A, 1999, BIOCHEMISTRY-US, V38, P7630, DOI 10.1021/bi9825044	53	53	56	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27555	27561		10.1074/jbc.M102850200	http://dx.doi.org/10.1074/jbc.M102850200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11335726	hybrid			2022-12-25	WOS:000169966900108
J	D'Amico, S; Gerday, C; Feller, G				D'Amico, S; Gerday, C; Feller, G			Structural determinants of cold adaptation and stability in a large protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HALOPLANCTIS ALPHA-AMYLASE; ALTEROMONAS-HALOPLANCTIS; DIRECTED EVOLUTION; CONFORMATIONAL FLEXIBILITY; DEHYDROGENASE; ENZYME; DENATURATION; TEMPERATURE; ENVIRONMENTS; DYNAMICS	The heat-labile alpha -amylase from an antarctic bacterium is the largest known protein that unfolds reversibly according to a two-state transition as shown by differential scanning calorimetry, Mutants of this enzyme were produced, carrying additional weak interactions found in thermostable alpha -amylases, It is shown that single amino acid side chain substitutions can significantly modify the melting point T-m, the calorimetric enthalpy DeltaH(cal) the cooperativity and reversibility of unfolding, the thermal inactivation rate constant, and the kinetic parameters k(cat) and K-m. The correlation between thermal inactivation and unfolding reversibility displayed by the mutants also shows that stabilizing interactions increase the frequency of side reactions during refolding, leading to intramolecular mismatches or aggregations typical of large proteins. Although all mutations were located far from the active site, their overall trend is to decrease both k(cat) and K-m by rigidifying the molecule and to protect mutants against thermal inactivation. The effects of these mutations indicate that the cold-adapted alpha -amylase has lost a large number of weak interactions during evolution to reach the required conformational plasticity for catalysis at low temperatures, thereby producing an enzyme close to the lowest stability allowing maintenance of the native conformation.	Univ Liege, Inst Chem B6, Biochem Lab, B-4000 Liege, Belgium	University of Liege	Feller, G (corresponding author), Univ Liege, Inst Chem B6, Biochem Lab, B-4000 Liege, Belgium.	gfeller@ulg.ac.be						Aghajari N, 1998, STRUCTURE, V6, P1503, DOI 10.1016/S0969-2126(98)00149-X; Aghajari N, 1998, PROTEIN SCI, V7, P564, DOI 10.1002/pro.5560070304; ANDERSON DE, 1990, BIOCHEMISTRY-US, V29, P2403, DOI 10.1021/bi00461a025; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; Cambillau C, 2000, J BIOL CHEM, V275, P32383, DOI 10.1074/jbc.C000497200; Cherry JR, 1999, NAT BIOTECHNOL, V17, P379, DOI 10.1038/7939; D'Amico S, 2000, GENE, V253, P95, DOI 10.1016/S0378-1119(00)00229-8; Feller G, 1999, BIOCHEMISTRY-US, V38, P4613, DOI 10.1021/bi982650+; Feller G, 1996, J BIOL CHEM, V271, P23836, DOI 10.1074/jbc.271.39.23836; Feller G, 1998, APPL ENVIRON MICROB, V64, P1163; FELLER G, 1994, EUR J BIOCHEM, V222, P441, DOI 10.1111/j.1432-1033.1994.tb18883.x; Fields PA, 1998, P NATL ACAD SCI USA, V95, P11476, DOI 10.1073/pnas.95.19.11476; FUKADA H, 1987, BIOCHEMISTRY-US, V26, P4063, DOI 10.1021/bi00387a048; Giver L, 1998, P NATL ACAD SCI USA, V95, P12809, DOI 10.1073/pnas.95.22.12809; Holland LZ, 1997, BIOCHEMISTRY-US, V36, P3207, DOI 10.1021/bi962664k; Jaenicke R, 1999, PROG BIOPHYS MOL BIO, V71, P155, DOI 10.1016/S0079-6107(98)00032-7; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; Kohen A, 1999, NATURE, V399, P496, DOI 10.1038/20981; Lebbink JHG, 2000, BIOCHEMISTRY-US, V39, P3656, DOI 10.1021/bi991483q; Lonhienne T, 2001, BBA-PROTEIN STRUCT M, V1545, P349, DOI 10.1016/S0167-4838(00)00296-X; LUMRY R, 1954, J PHYS CHEM-US, V58, P110, DOI 10.1021/j150512a005; Ma BY, 1999, PROTEIN ENG, V12, P713, DOI 10.1093/protein/12.9.713; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; MATOUSCHEK A, 1994, PROTEIN ENG, V7, P1089, DOI 10.1093/protein/7.9.1089; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; Merz A, 2000, BIOCHEMISTRY-US, V39, P880, DOI 10.1021/bi992333i; Miyazaki K, 2000, J MOL BIOL, V297, P1015, DOI 10.1006/jmbi.2000.3612; Pappenberger G, 1997, J MOL BIOL, V274, P676, DOI 10.1006/jmbi.1997.1421; Petrounia IP, 2000, CURR OPIN BIOTECH, V11, P325, DOI 10.1016/S0958-1669(00)00107-5; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; Privalov Peter L., 1992, P83; PRIVALOV PL, 1990, CRIT REV BIOCHEM MOL, V25, P281, DOI 10.3109/10409239009090612; QIAN MX, 1994, BIOCHEMISTRY-US, V33, P6284, DOI 10.1021/bi00186a031; Roovers H, 2001, J BACTERIOL, V183, P1101, DOI 10.1128/JB.183.3.1101-1105.2001; Rumbley J, 2001, P NATL ACAD SCI USA, V98, P105, DOI 10.1073/pnas.98.1.105; SOMERO GN, 1995, ANNU REV PHYSIOL, V57, P43, DOI 10.1146/annurev.ph.57.030195.000355; Strop P, 2000, BIOCHEMISTRY-US, V39, P1251, DOI 10.1021/bi992257j; VARLEY PG, 1991, J MOL BIOL, V220, P531, DOI 10.1016/0022-2836(91)90028-5; Vetriani C, 1998, P NATL ACAD SCI USA, V95, P12300, DOI 10.1073/pnas.95.21.12300; Wintrode PL, 2000, J BIOL CHEM, V275, P31635, DOI 10.1074/jbc.M004503200; Zavodszky P, 1998, P NATL ACAD SCI USA, V95, P7406, DOI 10.1073/pnas.95.13.7406	41	100	104	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25791	25796		10.1074/jbc.M102741200	http://dx.doi.org/10.1074/jbc.M102741200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11325973	Green Submitted, Green Published, hybrid			2022-12-25	WOS:000169823300022
J	Dunn, R; Hicke, L				Dunn, R; Hicke, L			Multiple roles for Rsp5p-dependent ubiquitination at the internalization step of endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; LIGAND-INDUCED INTERNALIZATION; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; ALPHA-FACTOR; WW DOMAINS; DEUBIQUITINATING ENZYME; MULTIUBIQUITIN CHAIN; TRANSCRIPTION FACTOR; PHEROMONE RECEPTOR	Ubiquitination of integral plasma membrane proteins triggers their rapid internalization into the endocytic pathway. The yeast ubiquitin ligase Rsp5p, a homologue of mammalian Nedd4 and Itch, is required for the ubiquitination and subsequent internalization of multiple plasma membrane proteins, including the cu-factor receptor (Ste2p), Here we demonstrate that Rsp5p plays multiple roles at the internalization step of endocytosis, Temperature-sensitive rsp5 mutant cells were defective in the internalization of a-factor by a Ste2p-ubiquitin chimera, a receptor that does not require post-translational ubiquitination, Similarly, a modified version of Ste2p bearing a NPFXD linear peptide sequence as its only internalization signal was not internalized in rsp5 cells, Internalization of these variant receptors was dependent on the catalytic cysteine residue of Rsp5p and on ubiquitin-conjugating enzymes that bind Rsp5p, Thus, a Rsp5p-dependent ubiquitination event is required for internalization mediated by ubiquitin-dependent and -independent endocytosis signals, Constitutive Ste2p-ubiquitin internalization and fluid-phase endocytosis also required active ubiquitination machinery, including Rsp5p, These observations indicate that Rsp5p-dependent ubiquitination of a transacting protein component of the endocytosis machinery is required for the internalization step of endocytosis.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Hicke, L (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.	l-hicke@northwestern.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053257] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008061] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 53257] Funding Source: Medline; NIGMS NIH HHS [T32GM08061] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Cadavid ALM, 2000, DEVELOPMENT, V127, P1727; Chang A, 2000, J BIOL CHEM, V275, P20562, DOI 10.1074/jbc.M002479200; CHANG A, 1995, J CELL BIOL, V128, P39, DOI 10.1083/jcb.128.1.39; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; D'Hondt K, 2000, ANNU REV GENET, V34, P255, DOI 10.1146/annurev.genet.34.1.255; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; DULIC V, 1991, METHOD ENZYMOL, V194, P697; Dunn R, 2001, MOL BIOL CELL, V12, P421, DOI 10.1091/mbc.12.2.421; Gajewska B, 2001, GENETICS, V157, P91; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; Horak J, 2001, J BACTERIOL, V183, P3083, DOI 10.1128/JB.183.10.3083-3088.2001; HORVATH A, 1994, YEAST, V10, P1305, DOI 10.1002/yea.320101007; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Lucero P, 2000, J BACTERIOL, V182, P241, DOI 10.1128/JB.182.1.241-243.2000; Medintz I, 1998, J BIOL CHEM, V273, P34454, DOI 10.1074/jbc.273.51.34454; Nakatsu F, 2000, J BIOL CHEM, V275, P26213, DOI 10.1074/jbc.M907720199; NICKEL BE, 1989, BIOCHEMISTRY-US, V28, P958, DOI 10.1021/bi00429a006; Paoluzi S, 1998, EMBO J, V17, P6541, DOI 10.1093/emboj/17.22.6541; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; ROHRER J, 1993, MOL BIOL CELL, V4, P511, DOI 10.1091/mbc.4.5.511; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; SCHANDEL KA, 1994, MOL CELL BIOL, V14, P7245, DOI 10.1128/MCB.14.11.7245; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGER B, 1990, J CELL BIOL, V110, P1911, DOI 10.1083/jcb.110.6.1911; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Springael JY, 1999, BIOCHEM BIOPH RES CO, V257, P561, DOI 10.1006/bbrc.1999.0505; Springael JY, 1999, J CELL SCI, V112, P1375; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Strous GJ, 1999, J CELL SCI, V112, P1417; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Tan PK, 1996, J CELL BIOL, V135, P1789, DOI 10.1083/jcb.135.6.1789; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; Wang GL, 1999, MOL CELL BIOL, V19, P342; Wang GL, 2001, MOL CELL BIOL, V21, P3564, DOI 10.1128/MCB.21.10.3564-3575.2001; Wendland B, 1998, CURR OPIN CELL BIOL, V10, P513, DOI 10.1016/S0955-0674(98)80067-7; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; Zoladek T, 1997, GENETICS, V145, P595	63	122	126	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25974	25981		10.1074/jbc.M104113200	http://dx.doi.org/10.1074/jbc.M104113200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11356856	hybrid			2022-12-25	WOS:000169823300046
J	Kimura, M; Mizukami, Y; Miura, T; Fujimoto, K; Kobayashi, S; Matsuzaki, M				Kimura, M; Mizukami, Y; Miura, T; Fujimoto, K; Kobayashi, S; Matsuzaki, M			Orphan G protein-coupled receptor, GPR41, induces apoptosis via a p53/bax pathway during ischemic hypoxia and reoxygenation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENES; TUMOR-SUPPRESSOR P53; INTERLEUKIN-8 RECEPTOR; NUCLEAR TRANSLOCATION; KINASE ACTIVATION; MOLECULAR-CLONING; LEUKOTRIENE B-4; AMINO-TERMINUS; HEART-FAILURE; GROWTH-FACTOR	Orphan receptors that couple to G protein without known ligands are considered to relate directly to drug discovery, Here, we examine the expression of various orphan receptors in H9c2 cells during ischemic hypoxia and reoxygenation. Among orphan receptors examined, the level of G protein-coupled receptor 41 (GPR41) mRNA increases significantly, with a peak at 2 h after reoxygenation, and recovers to the control level by 3 h after reoxygenation. The level of glyceraldehyde-3-phosphate dehydrogenase mRNA used as an internal control remains almost constant. The levels of c-fos and c-jun mRNA increase significantly with ischemic hypoxia and reoxygenation. The transfection of GPR41 into H9c2 cells results in a significant decrease in cell number, with DNA fragmentation observed by in vitro and in situ assay. The amount of p53 protein increases significantly in the nuclei of cells expressing GPR41, accompanying an increase in the transcriptional activity of p53. Consistent with the activation of p53, the level of bat mRNA is significantly increased, which leads to an increase in Bax protein. Furthermore, the expression of a deletion mutant of a GPR41, which lacks the G protein binding site and shows an attenuation of intracellular phosphorylation signals to H9c2 cells, inhibits cell death and the increase in p53 protein within 24 h after reoxygenation, These observations demonstrate that GPR41 is a novel receptor that activates p53 leading to apoptosis during reoxygenation after ischemic hypoxia in H9c2 cells. We have designated GPR41 as the hypoxia-induced apoptosis receptor, HIA-R.	Yamaguchi Univ, Sch Med, Dept Physiol 1, Ube, Yamaguchi 7558505, Japan; Yamaguchi Univ, Sch Med, Dept Internal Med 2, Ube, Yamaguchi 7558505, Japan	Yamaguchi University; Yamaguchi University	Mizukami, Y (corresponding author), Yamaguchi Univ, Sch Med, Dept Physiol 1, 1-1-1 Minami Kogushi, Ube, Yamaguchi 7558505, Japan.	mizukami@po.cc.yamaguchi-u.ac.jp	Kobayashi, Sei/E-7175-2010	Mizukami, Yoichi/0000-0002-3290-0754				Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; Aloyz RS, 1998, J CELL BIOL, V143, P1691, DOI 10.1083/jcb.143.6.1691; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Bialik S, 1997, J CLIN INVEST, V100, P1363, DOI 10.1172/JCI119656; BING OHL, 1994, J MOL CELL CARDIOL, V26, P943, DOI 10.1006/jmcc.1994.1115; Bonini JA, 1997, BIOCHEM BIOPH RES CO, V234, P190, DOI 10.1006/bbrc.1997.6591; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cheng W, 1996, EXP CELL RES, V226, P316, DOI 10.1006/excr.1996.0232; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Dobrzynski E, 2000, HYPERTENSION, V36, P995, DOI 10.1161/01.HYP.36.6.995; Drews J, 1996, NAT BIOTECHNOL, V14, P1516, DOI 10.1038/nbt1196-1516; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Fujimoto K, 2001, BBA-GENE STRUCT EXPR, V1518, P173, DOI 10.1016/S0167-4781(00)00309-2; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Hagan JJ, 1999, P NATL ACAD SCI USA, V96, P10911, DOI 10.1073/pnas.96.19.10911; Hansen S, 1996, J BIOL CHEM, V271, P30922, DOI 10.1074/jbc.271.48.30922; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Kawata Y, 1998, J BIOL CHEM, V273, P16905, DOI 10.1074/jbc.273.27.16905; Kobayashi S, 1999, J BIOL CHEM, V274, P20358, DOI 10.1074/jbc.274.29.20358; Ladoux A, 2000, J BIOL CHEM, V275, P39914, DOI 10.1074/jbc.M006512200; Landau E, 2000, J BIOL CHEM, V275, P2281, DOI 10.1074/jbc.275.4.2281; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEONG SR, 1994, J BIOL CHEM, V269, P19343; LEVY AP, 1995, CIRC RES, V76, P758, DOI 10.1161/01.RES.76.5.758; Lin L, 1999, CELL, V98, P365, DOI 10.1016/S0092-8674(00)81965-0; Long XL, 1997, J CLIN INVEST, V99, P2635, DOI 10.1172/JCI119452; Lowman HB, 1996, J BIOL CHEM, V271, P14344, DOI 10.1074/jbc.271.24.14344; Lund PE, 2000, J BIOL CHEM, V275, P30806, DOI 10.1074/jbc.M002603200; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MIYASHITA T, 1995, CELL, V80, P293; Mizukami Y, 1997, BIOCHEM J, V323, P785, DOI 10.1042/bj3230785; Mizukami Y, 2000, J BIOL CHEM, V275, P19921, DOI 10.1074/jbc.M907901199; Mizukami Y, 1997, FEBS LETT, V401, P247, DOI 10.1016/S0014-5793(96)01481-0; Mizukami Y, 1997, J BIOL CHEM, V272, P16657, DOI 10.1074/jbc.272.26.16657; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; Noiri E, 2000, P NATL ACAD SCI USA, V97, P823, DOI 10.1073/pnas.97.2.823; Oie E, 2000, CIRCULATION, V101, P415; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Ono K, 1997, CIRCULATION, V95, P2552, DOI 10.1161/01.CIR.95.11.2552; OUELLETTE AJ, 1990, J CLIN INVEST, V85, P766, DOI 10.1172/JCI114502; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; SCHRAUFSTATTER IU, 1995, J BIOL CHEM, V270, P10428, DOI 10.1074/jbc.270.18.10428; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Terui Y, 1998, BLOOD, V92, P2672, DOI 10.1182/blood.V92.8.2672.420k40_2672_2680; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; WEBSTER KA, 1994, CIRC RES, V74, P679, DOI 10.1161/01.RES.74.4.679; Webster KA, 1999, J CLIN INVEST, V104, P239; Xie W, 1997, J BIOL CHEM, V272, P24948, DOI 10.1074/jbc.272.40.24948; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Ziesche R, 1996, P NATL ACAD SCI USA, V93, P12478, DOI 10.1073/pnas.93.22.12478	62	46	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26453	26460		10.1074/jbc.M101289200	http://dx.doi.org/10.1074/jbc.M101289200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11335718	hybrid			2022-12-25	WOS:000169823300107
J	Briggs, SD; Scholtz, B; Jacque, JM; Swingler, S; Stevenson, M; Smithgall, TE				Briggs, SD; Scholtz, B; Jacque, JM; Swingler, S; Stevenson, M; Smithgall, TE			HIV-1 Nef promotes survival of myeloid cells by a stat3-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; COLONY-STIMULATING FACTOR; SH3 DOMAIN; IMMUNODEFICIENCY-VIRUS; STAT3 ACTIVATION; GENE HCK; FIBROBLAST TRANSFORMATION; SRC ONCOPROTEIN; IN-VIVO; BINDING	Human immunodeficiency virus Nef is a small myristylated protein that plays a critical role in AIDS progression. Nef binds with high affinity to the SH3 domain of the myeloid-restricted tyrosine kinase Hck in vitro, identifying this Src-related kinase as a possible cellular target for Nef in macrophages. Here we show that Nef activates endogenous Hck in the granulocyte-macrophage colony-stimulating factor-dependent myeloid cell line, TF-1. Unexpectedly, Nef induced cytokine-independent TF-1 cell outgrowth and constitutive activation of the Stat3 transcription factor. Induction of survival required the Nef SH3 binding and membrane-targeting motifs and was blocked by dominant-negative Stat3 mutants. Nef also stimulated Stat3 activation in primary human macrophages, providing evidence for Stat3 as a Nef effector in a target cell for human immunodeficiency virus.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Massachusetts System; University of Massachusetts Worcester	Smithgall, TE (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, E1240 Biomed Sci Tower, Pittsburgh, PA 15261 USA.	tsmithga@pitt.edu	Jacque, Jean-Marc/B-6875-2008	Briggs, Scott D/0000-0003-2852-3594; Scholtz, Beata/0000-0002-2737-5027	NCI NIH HHS [R01 CA081398, CA81398] Funding Source: Medline; NCRR NIH HHS [RR11589, R01 RR011589] Funding Source: Medline; NHLBI NIH HHS [R01 HL057880] Funding Source: Medline; NIAID NIH HHS [R01 AI032890, R01 AI049152] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081398] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR011589] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Alexander L, 1997, J VIROL, V71, P6094, DOI 10.1128/JVI.71.8.6094-6099.1997; ANDERSON SM, 1995, J IMMUNOL, V155, P1660; Arold S, 1998, BIOCHEMISTRY-US, V37, P14683, DOI 10.1021/bi980989q; BAHNSON AB, 1995, J VIROL METHODS, V54, P131, DOI 10.1016/0166-0934(95)00035-S; Balter M, 1996, SCIENCE, V274, P1464, DOI 10.1126/science.274.5292.1464; BOULET I, 1992, ONCOGENE, V7, P703; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; Briggs SD, 1999, J BIOL CHEM, V274, P26579, DOI 10.1074/jbc.274.37.26579; Briggs SD, 2000, BIOCHEMISTRY-US, V39, P489, DOI 10.1021/bi992504j; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Burton EA, 1997, J BIOL CHEM, V272, P16189, DOI 10.1074/jbc.272.26.16189; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; DURDEN DL, 1995, J IMMUNOL, V154, P4039; ENGLISH BK, 1993, J EXP MED, V178, P1017, DOI 10.1084/jem.178.3.1017; Ernst M, 1999, J BIOL CHEM, V274, P9729, DOI 10.1074/jbc.274.14.9729; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; Fackler OT, 1999, MOL CELL, V3, P729, DOI 10.1016/S1097-2765(01)80005-8; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1; Hirsch VM, 1998, NAT MED, V4, P1401, DOI 10.1038/3992; HITT M, 1995, METH MOL G, V7, P13; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KALTER DC, 1991, J IMMUNOL, V146, P298; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; Li JZ, 1998, J BIOL CHEM, V273, P13828, DOI 10.1074/jbc.273.22.13828; LINNEKIN D, 1994, BLOOD, V84, P94, DOI 10.1182/blood.V84.1.94.bloodjournal84194; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; Rajotte D, 1996, BLOOD, V88, P2906, DOI 10.1182/blood.V88.8.2906.bloodjournal8882906; Renkema GH, 2000, FRONT BIOSCI-LANDMRK, V5, pD268, DOI 10.2741/Renkema; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; Rogers JA, 1996, J BIOL CHEM, V271, P17519, DOI 10.1074/jbc.271.29.17519; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; Sawai ET, 1996, CURR BIOL, V6, P1519, DOI 10.1016/S0960-9822(96)00757-9; SAWAI ET, 1994, P NATL ACAD SCI USA, V91, P1539, DOI 10.1073/pnas.91.4.1539; SHUGARS DC, 1993, J VIROL, V67, P4639, DOI 10.1128/JVI.67.8.4639-4650.1993; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; Stevenson M, 1996, NAT STRUCT BIOL, V3, P303, DOI 10.1038/nsb0496-303; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; TORIGOE T, 1992, BLOOD, V80, P617; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Wei S, 1996, J IMMUNOL, V157, P5155; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZIEGLER SF, 1988, J EXP MED, V168, P1801, DOI 10.1084/jem.168.5.1801; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	65	71	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25605	25611		10.1074/jbc.M103244200	http://dx.doi.org/10.1074/jbc.M103244200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11328823	hybrid, Green Accepted			2022-12-25	WOS:000169800700152
J	Jiang, QJ; Taupenot, L; Mahata, SK; Mahata, M; O'Connor, DT; Miles, LA; Parmer, RJ				Jiang, QJ; Taupenot, L; Mahata, SK; Mahata, M; O'Connor, DT; Miles, LA; Parmer, RJ			Proteolytic cleavage of chromogranin A (CgA) by plasmin - Selective liberation of a specific bioactive CgA fragment that regulates catecholamine release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZATION MASS-SPECTROMETRY; PARATHYROID CELL SECRETION; N-TERMINAL FRAGMENT; PHEOCHROMOCYTOMA CELLS; RECOMBINANT PROTEINS; MOLECULAR-CLONING; MESSENGER-RNA; A FRAGMENT; PEPTIDE; DESORPTION	Chromogranin A (CgA), the major soluble protein in catecholamine storage vesicles, serves as a prohormone that is cleaved into bioactive peptides that inhibit catecholamine release, providing an autocrine, negative feedback mechanism for regulating catecholamine responses during stress. However, the proteases responsible for the processing of CgA and release of bioactive peptides have not been established. Recently, we found that chromaffin cells express components of the plasmin(ogen) system, including tissue plasminogen activator, which is targeted to catecholamine storage vesicles and released with CgA and catecholamines in response to sympathoadrenal stimulation, and high affinity cell surface receptors for plasminogen, to promote plasminogen activation at the cell surface. In the present study, we investigated processing of CgA by plasmin and sought to identify specific bioactive CgA peptides produced by plasmin proteolysis, Highly purified human CgA (hCgA) was produced by expression in Escherichia coli and purification using metal affinity chromatography, hCgA was digested with plasmin, Matrix-assisted laser desorption/ionization mass spectrometry identified a major peptide produced with a mass/charge ratio (m/z) of 1546, corresponding uniquely to hCgA-(360-373), the identity of which was confirmed by reverse phase high pressure liquid chromatography and amino-terminal microsequencing, hCgA-(360-373) was selectively liberated by plasmin from hCgA at early time points and was stable even after prolonged exposure to plasmin, The corresponding synthetic peptide markedly inhibited nicotine-induced catecholamine release from pheochromocytoma cells. These results identify plasmin as a protease, present in the local environment of the chromaffin cell, that selectively cleaves CgA to generate a bioactive fragment, hCgA-(360-373), that inhibits nicotinic-mediated catecholamine release. These results suggest that the plasminogen/plasmin system through its interaction with CgA may play a major role in catecholaminergic function and suggest a specific mechanism as well as a discrete CgA peptide through which this effect is mediated.	Univ Calif San Diego, Dept Med, San Diego, CA 92161 USA; Dept Vet Affairs Med Ctr, San Diego, CA 92161 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	University of California System; University of California San Diego; Scripps Research Institute	Parmer, RJ (corresponding author), Univ Calif San Diego, Dept Med, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.		Mahata, Sushil/AAF-8781-2021	Taupenot, Laurent/0000-0003-2316-3825	NHLBI NIH HHS [HL-07261, HL-38272, HL-50398, HL-58120] Funding Source: Medline; NIDDK NIH HHS [DK-07671] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038272, R01HL050398, P01HL058120, R29HL038272] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AARDAL S, 1992, REGUL PEPTIDES, V41, P9, DOI 10.1016/0167-0115(92)90509-S; BENEDUM UM, 1986, EMBO J, V5, P1495, DOI 10.1002/j.1460-2075.1986.tb04388.x; BILLECI TM, 1993, ANAL CHEM, V65, P1709, DOI 10.1021/ac00061a013; COLLEN D, 1975, THROMB DIATH HAEMOST, V34, P403, DOI 10.1055/s-0038-1651399; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DREES BM, 1991, ENDOCRINOLOGY, V129, P3381, DOI 10.1210/endo-129-6-3381; ELICONE C, 1994, J CHROMATOGR A, V676, P121, DOI 10.1016/0021-9673(94)00089-1; FASCIOTTO BH, 1993, ENDOCRINOLOGY, V133, P461, DOI 10.1210/en.133.2.461; GALINDO E, 1991, P NATL ACAD SCI USA, V88, P1426, DOI 10.1073/pnas.88.4.1426; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HELMAN LJ, 1988, J BIOL CHEM, V263, P11559; Hervio LS, 2000, CHEM BIOL, V7, P443, DOI 10.1016/S1074-5521(00)00125-3; HUTTON JC, 1987, BIOCHEM J, V244, P457, DOI 10.1042/bj2440457; IACANGELO A, 1986, NATURE, V323, P82, DOI 10.1038/323082a0; IACANGELO AL, 1988, ENDOCRINOLOGY, V122, P2339, DOI 10.1210/endo-122-5-2339; KONECKI DS, 1987, J BIOL CHEM, V262, P17026; Kriwacki RW, 1996, J AM CHEM SOC, V118, P5320, DOI 10.1021/ja960752m; LI KW, 1994, J BIOL CHEM, V269, P30288; Mahata SK, 1997, J CLIN INVEST, V100, P1623, DOI 10.1172/JCI119686; METZBOUTIGUE MH, 1993, EUR J BIOCHEM, V217, P247, DOI 10.1111/j.1432-1033.1993.tb18240.x; MILES LA, 1985, J BIOL CHEM, V260, P4303; OCONNOR DT, 1984, T ASSOC AM PHYSICIAN, V97, P242; PARMER RJ, 1993, J CLIN INVEST, V92, P1042, DOI 10.1172/JCI116609; PARMER RJ, 1989, HYPERTENSION, V14, P435, DOI 10.1161/01.HYP.14.4.435; Parmer RJ, 2000, J CLIN INVEST, V106, P907, DOI 10.1172/JCI7394; Parmer RJ, 1997, J BIOL CHEM, V272, P1976, DOI 10.1074/jbc.272.3.1976; SIMON JP, 1988, P NATL ACAD SCI USA, V85, P1712, DOI 10.1073/pnas.85.5.1712; SIUZDAK G, 1994, P NATL ACAD SCI USA, V91, P11290, DOI 10.1073/pnas.91.24.11290; Siuzdak G., 1996, MASS SPECTROMETRY BI; STULTS JT, 1995, CURR OPIN STRUC BIOL, V5, P691, DOI 10.1016/0959-440X(95)80063-8; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; Taylor JA, 1996, RAPID COMMUN MASS SP, V10, P679, DOI 10.1002/(SICI)1097-0231(199604)10:6<679::AID-RCM528>3.0.CO;2-Q; TSARBOPOULOS A, 1994, ANAL CHEM, V66, P2062, DOI 10.1021/ac00085a022; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WALLEN P, 1972, BIOCHIM BIOPHYS ACTA, V257, P122, DOI 10.1016/0005-2795(72)90261-9; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; WEINSTEI.MJ, 1972, BIOCHIM BIOPHYS ACTA, V258, P577, DOI 10.1016/0005-2744(72)90250-1; WIGHTMAN RM, 1995, 8 INT S CHROM CELL S, V25, P66; WINKLER H, 1976, NEUROSCIENCE, V1, P65, DOI 10.1016/0306-4522(76)90001-4; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WU HJ, 1991, J BIOL CHEM, V266, P13130	41	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25022	25029		10.1074/jbc.M101545200	http://dx.doi.org/10.1074/jbc.M101545200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342539	hybrid			2022-12-25	WOS:000169800700079
J	Craddock, BL; Hobbs, J; Edmead, CE; Welham, MJ				Craddock, BL; Hobbs, J; Edmead, CE; Welham, MJ			Phosphoinositide 3-kinase-dependent regulation of interleukin-3-induced proliferation - Involvement of mitogen-activated protein kinases, SHP2 and Gab2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; COLONY-STIMULATING FACTOR; CELL-CYCLE PROGRESSION; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; T-CELL; NUCLEAR TRANSLOCATION; LYSOPHOSPHATIDIC-ACID; SIGNAL-TRANSDUCTION	We have demonstrated previously that class I,phosphoinositide 3-kinases play a major role in regulation of interleukin-3 (IL)-3-dependent proliferation. Investigations into the downstream targets involved have identified the MAPK cascade as a target. Expression of Delta p85 and incubation with LY294002 both inhibited IL-S-induced activation of Mek, Erk1, and Erk2, This was most pronounced during the initial phase of Erk activation. The Mek inhibitor, PD98059, blocked IL-3-driven proliferation, an effect enhanced by Delta p85 expression, suggesting that inhibition of Mek and Erks by Delta p85 contributes to the decrease in IL-3-induced proliferation in these cells but that additional pathways may also be involved. To investigate the mechanism leading to decreased activation of Erks, me investigated effects on SHP2 and Gab2, both implicated in IL-3 regulation of Erk activation. Expression of Delta p85 led to a reduction in SHP2 tyrosine phosphorylation and its ability to interact with Grb2 and Gab2 but increased overall tyrosine phosphorylation of Gab2. LY294002 did not perturb SHP2 interactions, potentially related to differences in the effects of these inhibitors on levels of phosphoinositides. These results imply that the regulation of Erks by class I, phosphoinositide 3-kinase may contribute to IL-3-driven proliferation and that both SHP2 and Gab2 are possibly involved in this regulation.	Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England	University of Bath	Welham, MJ (corresponding author), Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England.	M.J.Welham@bath.ac.uk						Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; Bacqueville D, 1998, BIOCHEM BIOPH RES CO, V244, P630, DOI 10.1006/bbrc.1997.7885; Bavelloni A, 2000, CELL DEATH DIFFER, V7, P112, DOI 10.1038/sj.cdd.4400591; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Bone H, 1997, J BIOL CHEM, V272, P14470, DOI 10.1074/jbc.272.22.14470; Bone H, 2000, CELL SIGNAL, V12, P183, DOI 10.1016/S0898-6568(99)00088-1; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Casagrande F, 1998, FEBS LETT, V422, P385, DOI 10.1016/S0014-5793(98)00043-X; Chantry D, 1997, J BIOL CHEM, V272, P19236, DOI 10.1074/jbc.272.31.19236; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Conway AM, 1999, BIOCHEM J, V337, P171, DOI 10.1042/0264-6021:3370171; Craddock BL, 1997, J BIOL CHEM, V272, P29281, DOI 10.1074/jbc.272.46.29281; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Feng LX, 2000, J BIOL CHEM, V275, P25572, DOI 10.1074/jbc.M002218200; Ferby IM, 1996, J BIOL CHEM, V271, P11684, DOI 10.1074/jbc.271.20.11684; FERBY IM, 1994, J BIOL CHEM, V269, P30485; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; GOLD MR, 1994, J BIOL CHEM, V269, P5403; Greulich H, 1998, J BIOL CHEM, V273, P13280, DOI 10.1074/jbc.273.21.13280; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gu HH, 1997, J BIOL CHEM, V272, P16421, DOI 10.1074/jbc.272.26.16421; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Hinton HJ, 1999, J IMMUNOL, V162, P7002; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; IHLE JN, 1992, CHEM IMMUNOL, V51, P65; IZOH M, 2000, MOL CELL BIOL, V20, P3695; Jascur T, 1997, J BIOL CHEM, V272, P14483, DOI 10.1074/jbc.272.22.14483; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Lantz CS, 1998, NATURE, V392, P90, DOI 10.1038/32190; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MACHIDE M, 1995, ONCOGENE, V11, P619; MANO H, 1995, BLOOD, V85, P343; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Perkins GR, 1996, BLOOD, V87, P3669, DOI 10.1182/blood.V87.9.3669.bloodjournal8793669; Phillips-Mason PJ, 2000, J BIOL CHEM, V275, P18046, DOI 10.1074/jbc.M909194199; Rausch O, 1999, J BIOL CHEM, V274, P4096, DOI 10.1074/jbc.274.7.4096; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Rojnuckarin P, 1999, BLOOD, V94, P1273, DOI 10.1182/blood.V94.4.1273.416k04_1273_1282; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Scheid MP, 1996, J BIOL CHEM, V271, P18134, DOI 10.1074/jbc.271.30.18134; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; TakahashiTezuka M, 1997, ONCOGENE, V14, P2273, DOI 10.1038/sj.onc.1201071; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Treinies I, 1999, MOL CELL BIOL, V19, P321; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; vonWillebrand M, 1996, EUR J BIOCHEM, V235, P828; WARD SG, 1995, EUR J IMMUNOL, V25, P526, DOI 10.1002/eji.1830250233; WARD SG, 2000, METHODS MOL BIOL; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WELHAM MJ, 1992, J IMMUNOL, V149, P2772; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Yart A, 2001, J BIOL CHEM, V276, P8856, DOI 10.1074/jbc.M006966200; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	75	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24274	24283		10.1074/jbc.M009098200	http://dx.doi.org/10.1074/jbc.M009098200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11335710	hybrid			2022-12-25	WOS:000169531100137
J	Nakamura, M; Nishida, W; Mori, S; Hiwada, K; Hayashi, K; Sobue, K				Nakamura, M; Nishida, W; Mori, S; Hiwada, K; Hayashi, K; Sobue, K			Transcriptional activation of beta-tropomyosin mediated by serum response factor and a novel barx homologue, Barx1b, in smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN GENE-TRANSCRIPTION; HOMEO BOX GENES; HOMEODOMAIN PROTEINS; MOLECULAR-CLONING; DEVELOPING HEART; CALDESMON GENE; EXPRESSION; SKELETAL; DROSOPHILA; MESODERM	Tropomyosin (TM) is a regulatory protein of actomyosin system. Muscle type-specific expression of TM isoforms is generated from different genes and by alternative splicing. beta -TM isoforms in chicken skeletal and smooth muscles are encoded by a single gene and transcribed from the same promoter. We previously reported a smooth muscle cell (SMC) phenotype-dependent change in beta -TM expression (Kashiwada, K., Nishida, W,, Hayashi, K,, Ozawa, K., Yamanaka, Y,, Saga, H,, Yamashita, T,, Tohyama, M,, Shimada, S,, Sate, K,, and Sobue, K, (1997) J. Biol. Chem. 272, 15396-15404), and identified beta -TM as an SMC-differentiation marker. Here, we characterized the transcriptional machinery of the beta -TM gene in SMCs. Promoter and gel mobility shift analyses revealed an obligatory role for serum response factor and its interaction with the CArG box sequence in the SMC-specific transcription of the beta -TM gene in differentiated SMCs, We further isolated a novel homologue of the Barx homeoprotein family, Barx1b, from chicken gizzard, Barx1b was exclusively localized to SMCs of the upper digestive organs and their attached arteries and to craniofacial structures. Serum response factor and Barx1b bound each other directly, coordinately transactivated the beta -TM gene in differentiated SMCs and heterologous cells, and formed a ternary complex with a CArG probe. Taken together, these results suggest that SRF and Barx1b are coordinately involved in the SMC-specific transcription of the beta -TM gene in the upper digestive organs and their attached arteries.	Osaka Univ, Grad Sch Med, Biomed Res Ctr, Dept Neurosci D13, Suita, Osaka 5650871, Japan; Ehime Univ, Sch Med, Dept Internal Med 2, Matsuyama, Ehime 7910295, Japan	Osaka University; Ehime University	Sobue, K (corresponding author), Osaka Univ, Grad Sch Med, Biomed Res Ctr, Dept Neurosci D13, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.			Nakamura, Mako/0000-0002-6129-7560				Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; Barlow AJ, 1999, DEV DYNAM, V214, P291, DOI 10.1002/(SICI)1097-0177(199904)214:4<291::AID-AJA2>3.0.CO;2-E; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; BUCKINGHAM ME, 1985, ESSAYS BIOCHEM, V20, P77; Carson JA, 2000, J BIOL CHEM, V275, P39061, DOI 10.1074/jbc.M006532200; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DEJONG R, 1993, NUCLEIC ACIDS RES, V21, P4711, DOI 10.1093/nar/21.20.4711; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; EBASHI S, 1991, ANNU REV PHYSIOL, V53, P1, DOI 10.1146/annurev.ph.53.030191.000245; FORRYSCHAUDIES S, 1990, J MOL BIOL, V211, P321, DOI 10.1016/0022-2836(90)90354-O; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GORSKI DH, 1993, MOL CELL BIOL, V13, P3722, DOI 10.1128/MCB.13.6.3722; Gould DB, 2000, GENOMICS, V68, P336, DOI 10.1006/geno.2000.6307; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; Hautmann MB, 1997, CIRC RES, V81, P600, DOI 10.1161/01.RES.81.4.600; Hayashi K, 1999, J CELL BIOL, V145, P727, DOI 10.1083/jcb.145.4.727; Herring BP, 1997, AM J PHYSIOL-CELL PH, V272, pC1394, DOI 10.1152/ajpcell.1997.272.4.C1394; HERRING BP, 2001, J BIOL CHEM     0129; HIGASHIJIMA SI, 1992, GENE DEV, V6, P50, DOI 10.1101/gad.6.1.50; Jones FS, 1997, P NATL ACAD SCI USA, V94, P2632, DOI 10.1073/pnas.94.6.2632; Kashiwada K, 1997, J BIOL CHEM, V272, P15396, DOI 10.1074/jbc.272.24.15396; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; Li L, 1997, DEV BIOL, V187, P311, DOI 10.1006/dbio.1997.8621; LINTS TJ, 1993, DEVELOPMENT, V119, P419; Mack CP, 2000, CIRC RES, V86, P221, DOI 10.1161/01.RES.86.2.221; Mericskay M, 2000, DEV BIOL, V226, P192, DOI 10.1006/dbio.2000.9865; Miano JM, 2000, J BIOL CHEM, V275, P9814, DOI 10.1074/jbc.275.13.9814; Miano JM, 1996, P NATL ACAD SCI USA, V93, P900, DOI 10.1073/pnas.93.2.900; Momiyama T, 1998, BIOCHEM BIOPH RES CO, V242, P429, DOI 10.1006/bbrc.1997.7959; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Obata H, 1997, J BIOL CHEM, V272, P26643, DOI 10.1074/jbc.272.42.26643; ORKIN SH, 1992, BLOOD, V80, P575; PATEL CV, 1992, J BIOL CHEM, V267, P26085; Ranganayakulu G, 1998, DEVELOPMENT, V125, P3037; Saito T, 1998, DEV BIOL, V199, P216, DOI 10.1006/dbio.1998.8889; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; Sciavolino PJ, 1997, DEV DYNAM, V209, P127, DOI 10.1002/(SICI)1097-0177(199705)209:1<127::AID-AJA12>3.0.CO;2-Z; SELLERS JR, 1985, CURR TOP CELL REGUL, V27, P51; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; SOBUE K, 1991, J BIOL CHEM, V266, P12115; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; TISSIERSETA JP, 1995, MECH DEVELOP, V51, P3, DOI 10.1016/0925-4773(94)00343-L; Topouzis S, 1996, DEV BIOL, V178, P430, DOI 10.1006/dbio.1996.0229; TOUTANT M, 1994, NUCLEIC ACIDS RES, V22, P1838, DOI 10.1093/nar/22.10.1838; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Tribioli C, 1997, MECH DEVELOP, V65, P145, DOI 10.1016/S0925-4773(97)00067-1; YANO H, 1995, J BIOL CHEM, V270, P23661, DOI 10.1074/jbc.270.40.23661; Zilberman A, 1998, CIRC RES, V82, P566, DOI 10.1161/01.RES.82.5.566	56	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18313	18320		10.1074/jbc.M101127200	http://dx.doi.org/10.1074/jbc.M101127200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11359793	hybrid			2022-12-25	WOS:000168866500094
J	Qi, MS; Ikematsu, S; Maeda, N; Ichihara-Tanaka, K; Sakuma, S; Noda, M; Muramatsu, T; Kadomatsu, K				Qi, MS; Ikematsu, S; Maeda, N; Ichihara-Tanaka, K; Sakuma, S; Noda, M; Muramatsu, T; Kadomatsu, K			Haptotactic migration induced by midkine - Involvement of protein-tyrosine phosphatase xi, mitogen-activated protein kinase, and phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULE HB-GAM; CHONDROITIN SULFATE PROTEOGLYCAN; GROWTH-DIFFERENTIATION FACTOR; ACID-RESPONSIVE GENE; NEURITE OUTGROWTH; CELL-MIGRATION; ZETA/RPTP-BETA; SIGNALING PATHWAY; CARCINOMA-CELLS; BINDING	Midkine, a heparin-binding growth factor, plays a critical role in cell migration causing suppression of neointima formation in midkine-deficient mice. Here we have determined the molecules essential for midkine-induced migration. Midkine induced haptotaxis of osteoblast-like cells, which was abrogated by the soluble form of midkine or pleiotrophin, a midkine-homologous protein. Chondroitin sulfate B, E, chondroitinase ABC, B, and orthovanadate, an inhibitor of protein-tyrosine phosphatase, suppressed the migration. Supporting these data, the cells examined expressed PTP zeta, a receptor-type protein-tyrosine phosphatase that exhibits high affinity to both midkine and pleiotrophin and harbors chondroitin sulfate chains. Furthermore, strong synergism between midkine and platelet-derived growth factor in migration was detected. The use of specific inhibitors demonstrated that mitogen-activated protein (MAP) kinase and protein-tyrosine phosphatase were involved in midkine-induced haptotaxis but not PDGF-induced chemotaxis, whereas phosphatidylinositol 3 (PI3)-kinase and protein kinase C were involved in both functions. Midkine activated both PI3-kinase and MAP kinases, the latter activation was blocked by a PI3-kinase inhibitor. Midkine further recruited PTP zeta and PI3-kinase. These results indicate that PTP zeta and concerted signaling involving PI3-kinase and MAP kinase are required for midkine-induced migration and demonstrate for the first time the synergism between midkine and platelet-derived growth factor in cell migration.	Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, Nagoya, Aichi 4668550, Japan; Meiji Milk Prod Co Ltd, Pharmaceut Dev Dept, Odawara, Kanagawa 2500862, Japan; Natl Inst Basic Biol, Div Mol Neurobiol, Okazaki, Aichi 4448585, Japan	Nagoya University; Meiji Holdings Co., Ltd.; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Kadomatsu, K (corresponding author), Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		Kadomatsu, Kenji/G-8083-2012; Noda, Masaharu/D-7146-2016	Noda, Masaharu/0000-0002-3796-524X				ANDREW JG, 1995, BONE, V16, P455; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Choudhuri R, 1997, CANCER RES, V57, P1814; Cospedal R, 1999, CARDIOVASC RES, V41, P708, DOI 10.1016/S0008-6363(98)00232-6; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; HIYAMA K, 1975, J BIOL CHEM, V250, P1824; Horiba M, 2000, J CLIN INVEST, V105, P489, DOI 10.1172/JCI7208; Imai S, 1998, J CELL BIOL, V143, P1113, DOI 10.1083/jcb.143.4.1113; Imai Y, 1999, ENDOCRINOLOGY, V140, P4228, DOI 10.1210/en.140.9.4228; Iwashita N, 1999, BURNS, V25, P119, DOI 10.1016/S0305-4179(98)00120-X; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; Kadomatsu K, 1997, BRIT J CANCER, V75, P354, DOI 10.1038/bjc.1997.58; Kaneda N, 1996, J BIOCHEM-TOKYO, V119, P1150; Kaneda N, 1996, BIOCHEM BIOPH RES CO, V220, P108, DOI 10.1006/bbrc.1996.0365; Kim BC, 1999, J BIOL CHEM, V274, P24372, DOI 10.1074/jbc.274.34.24372; Kinnunen T, 1998, J BIOL CHEM, V273, P10702, DOI 10.1074/jbc.273.17.10702; Kojima T, 1996, J BIOL CHEM, V271, P5914, DOI 10.1074/jbc.271.10.5914; Kurosawa N, 2000, EUR J BIOCHEM, V267, P344, DOI 10.1046/j.1432-1327.2000.01005.x; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; MAEDA N, 1994, FEBS LETT, V354, P67, DOI 10.1016/0014-5793(94)01093-5; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; MICHELACCI YM, 1975, BIOCHEM J, V151, P121, DOI 10.1042/bj1510121; MITSIADIS TA, 1995, DEVELOPMENT, V121, P37; MURAMATSU H, 1993, DEV BIOL, V159, P392, DOI 10.1006/dbio.1993.1250; MURAMATSU T, 1993, INT J DEV BIOL, V37, P183; Nakanishi T, 1997, J BIOCHEM-TOKYO, V121, P197; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; Nishiwaki T, 1998, J BIOCHEM-TOKYO, V123, P458; Obama H, 1998, ANTICANCER RES, V18, P145; Ohta S, 1999, J BONE MINER RES, V14, P1132, DOI 10.1359/jbmr.1999.14.7.1132; Rameshwar P, 1997, J IMMUNOL, V158, P3417; Ratovitski EA, 1998, J BIOL CHEM, V273, P3654, DOI 10.1074/jbc.273.6.3654; Revest JM, 1999, EUR J NEUROSCI, V11, P1134, DOI 10.1046/j.1460-9568.1999.00521.x; Rigot V, 1998, J CELL SCI, V111, P3119; Rosenkranz S, 1999, GROWTH FACTORS, V16, P201, DOI 10.3109/08977199909002130; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SAITO H, 1968, J BIOL CHEM, V243, P1536; Sakai T, 1999, J BIOL CHEM, V274, P15480, DOI 10.1074/jbc.274.22.15480; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Souttou B, 1997, J BIOL CHEM, V272, P19588, DOI 10.1074/jbc.272.31.19588; Suga J, 1997, DIABETES, V46, P735, DOI 10.2337/diabetes.46.5.735; Sumi Y, 2000, J BIOCHEM-TOKYO, V127, P247, DOI 10.1093/oxfordjournals.jbchem.a022601; Takada T, 1997, J BIOCHEM-TOKYO, V122, P453; TOMOMURA M, 1990, J BIOL CHEM, V265, P10765; TSUKAMOTO T, 1991, BIOCHEM BIOPH RES CO, V175, P745, DOI 10.1016/0006-291X(91)91629-Q; Ueoka C, 2000, J BIOL CHEM, V275, P37407, DOI 10.1074/jbc.M002538200; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Yahiro K, 1999, J BIOL CHEM, V274, P36693, DOI 10.1074/jbc.274.51.36693; YOSHIDA Y, 1995, DEV BRAIN RES, V85, P25, DOI 10.1016/0165-3806(94)00183-Z; Zou K, 2000, EUR J BIOCHEM, V267, P4046, DOI 10.1046/j.1432-1327.2000.01440.x	60	132	139	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					15868	15875		10.1074/jbc.M005911200	http://dx.doi.org/10.1074/jbc.M005911200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11340082	hybrid			2022-12-25	WOS:000168623100041
J	Grishko, V; Solomon, M; Breit, JF; Killilea, DW; Ledoux, SP; Wilson, GL; Gillespie, MN				Grishko, V; Solomon, M; Breit, JF; Killilea, DW; Ledoux, SP; Wilson, GL; Gillespie, MN			Hypoxia promotes oxidative base modifications in the pulmonary artery endothelial cell VEGF gene	FASEB JOURNAL			English	Article									Univ S Alabama, Coll Med, Dept Pharmacol & Cell Biol, Mobile, AL 36688 USA; Univ S Alabama, Coll Med, Dept Neurosci, Mobile, AL 36688 USA	University of South Alabama; University of South Alabama	Gillespie, MN (corresponding author), Univ S Alabama, Coll Med, Dept Pharmacol, MSB 3130, Mobile, AL 36688 USA.	mgillesp@jaguar1.usouthal.edu		Killilea, David/0000-0002-8929-6527				CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253	1	62	63	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2001	15	7					1267	1269		10.1096/fj.00-0755fje	http://dx.doi.org/10.1096/fj.00-0755fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344109	Bronze			2022-12-25	WOS:000168655200031
J	Leitinger, N; Huber, J; Rizza, C; Mechtcheriakova, D; Bochkov, V; Koshelnick, Y; Berliner, JA; Binder, BR				Leitinger, N; Huber, J; Rizza, C; Mechtcheriakova, D; Bochkov, V; Koshelnick, Y; Berliner, JA; Binder, BR			The isoprostane 8-iso-PGF(2 alpha) stimulates endothelial cells to bind monocytes: differences from thromboxane-mediated endothelial activation	FASEB JOURNAL			English	Article									Univ Vienna, Dept Vasc Biol & Thrombosis Res, A-1090 Vienna, Austria; Univ Calif Los Angeles, Dept Med Cardiol, Los Angeles, CA 90095 USA	University of Vienna; University of California System; University of California Los Angeles	Leitinger, N (corresponding author), Univ Vienna, Dept Vasc Biol & Thrombosis Res, Schwarzspanierstr 17, A-1090 Vienna, Austria.			Mechtcheriakova, Diana/0000-0002-8737-3592					0	53	53	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1254	1256		10.1096/fj.00-0498fje	http://dx.doi.org/10.1096/fj.00-0498fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344105				2022-12-25	WOS:000168655200027
J	Masaki, I; Yonemitsu, Y; Komori, K; Ueno, H; Nakashima, Y; Nakagawa, K; Fukumura, M; Kato, A; Hasan, MK; Nagai, Y; Sugimachi, K; Hasegawa, M; Sueishi, K				Masaki, I; Yonemitsu, Y; Komori, K; Ueno, H; Nakashima, Y; Nakagawa, K; Fukumura, M; Kato, A; Hasan, MK; Nagai, Y; Sugimachi, K; Hasegawa, M; Sueishi, K			Recombinant Sendai virus-mediated gene transfer to vasculature: a new class of efficient gene transfer vector to the vascular system	FASEB JOURNAL			English	Article									Kyushu Univ, Grad Sch Med Sci, Dept Pathol, Div Pathophysiol & Expt Pathol,Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Higashi Ku, Fukuoka 8128582, Japan; DNAVEC Res Inc, Tsukuba, Ibaraki, Japan; Natl Inst Infect Dis, Dept Viral Infect & Vaccine Control, Tokyo, Japan; Natl Inst Infect Dis, AIDS Res Ctr, Tokyo, Japan	Kyushu University; Kyushu University; Kyushu University; DNAVEC Corporation; National Institute of Infectious Diseases (NIID); National Institute of Infectious Diseases (NIID)	Yonemitsu, Y (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Pathol, Div Pathophysiol & Expt Pathol,Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.		KOMORI, Kimihiro/M-8870-2014						0	60	65	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1294	1296		10.1096/fj.00-0460fje	http://dx.doi.org/10.1096/fj.00-0460fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344118				2022-12-25	WOS:000168655200040
J	Rappsilber, J; Ajuh, P; Lamond, AI; Mann, M				Rappsilber, J; Ajuh, P; Lamond, AI; Mann, M			SPF30 is an essential human splicing factor required for assembly of the U4/U5/U6 tri-small nuclear ribonucleoprotein into the spliceosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; DISEASE GENE-PRODUCT; MASS-SPECTROMETRY; U2 SNRNP; POLYACRYLAMIDE GELS; SEQUENCE DATABASES; COILED BODIES; U4/U6 SNRNP; BRANCH SITE; 2'-OME RNA	Spliceosome assembly involves the sequential recruitment of small nuclear ribonucleoproteins (snRNPs) onto a pre-mRNA substrate. Although several non-snRNP proteins function during the binding of U1 and U2 snRNP's, little is known about the subsequent binding of the U4/U5/U6 tri-snRNP. A recent proteomic analysis of the human spliceosome identified SPF30 (Neubauer, G., King, A., Rappsilber, J., Calvio, C., Watson, M., Ajuh, P., Sleeman, J., Lamond, A., and Mann, M. (1998) Nat. Genet. 20, 46-50), a homolog of the survival of motor neurons (SMN) protein, as a spliceosome factor. We show here that SPF30 is a nuclear protein that associates with both U4/U5/U6 and U2 snRNP components. In the absence of SPF30, the preformed tri-snRNP fails to assemble into the spliceosome. Mass spectrometric analysis shows that a recombinant glutathione S-transferase-SPF30 fusion protein associates with complexes containing core Sm and U4/U5/U6 tri-snRNP proteins when added to HeLa nuclear extract, most strongly to U4/U6-90. The data indicate that SPF30 is an essential human splicing factor that may act to dock the U4/U5/U6 tri-snRNP to the A complex during spliceosome assembly or, alternatively, may act as a late assembly factor in both the tri-snRNP and the A-complex.	Univ So Denmark, Prot Interact Lab, DK-5230 Odense M, Denmark; European Mol Biol Lab, D-69117 Heidelberg, Germany; Univ Dundee, Dept Biochem, Dundee DD1 4HN, Scotland	University of Southern Denmark; European Molecular Biology Laboratory (EMBL); University of Dundee	Mann, M (corresponding author), Univ So Denmark, Prot Interact Lab, Campusvej 55, DK-5230 Odense M, Denmark.	mann@bmb.sdu.dk	Mann, Matthias/A-3454-2013; Rappsilber, Juri/B-7265-2015; Rappsilber, Juri/ABF-3328-2020	Mann, Matthias/0000-0003-1292-4799; Rappsilber, Juri/0000-0001-5999-1310; Lamond, Angus/0000-0001-6204-6045				ABOVICH N, 1990, MOL CELL BIOL, V10, P6417, DOI 10.1128/MCB.10.12.6417; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Arenas JE, 1997, P NATL ACAD SCI USA, V94, P11798, DOI 10.1073/pnas.94.22.11798; Arning S, 1996, RNA, V2, P794; Ayadi L, 1997, RNA, V3, P197; BACH M, 1991, BIOCHIM BIOPHYS ACTA, V1088, P139, DOI 10.1016/0167-4781(91)90164-H; BANROQUES J, 1989, MOL CELL BIOL, V9, P3710, DOI 10.1128/MCB.9.9.3710; BARABINO SML, 1990, CELL, V63, P293, DOI 10.1016/0092-8674(90)90162-8; BARABINO SML, 1989, EMBO J, V8, P4171, DOI 10.1002/j.1460-2075.1989.tb08602.x; BEHRENS SE, 1991, GENE DEV, V5, P1439, DOI 10.1101/gad.5.8.1439; BEHRENS SE, 1993, MOL CELL BIOL, V13, P307, DOI 10.1128/MCB.13.1.307; Bertrandy S, 1999, HUM MOL GENET, V8, P775, DOI 10.1093/hmg/8.5.775; BLANTON S, 1992, MOL CELL BIOL, V12, P3939, DOI 10.1128/MCB.12.9.3939; BLENCOWE BJ, 1989, CELL, V59, P531, DOI 10.1016/0092-8674(89)90036-6; Bohmann K, 1995, J CELL SCI, P107; BROWN JD, 1992, EMBO J, V11, P3721, DOI 10.1002/j.1460-2075.1992.tb05457.x; Carvalho T, 1999, J CELL BIOL, V147, P715, DOI 10.1083/jcb.147.4.715; CHAMPIONARNAUD P, 1994, GENE DEV, V8, P1974, DOI 10.1101/gad.8.16.1974; Charroux B, 2000, J CELL BIOL, V148, P1177, DOI 10.1083/jcb.148.6.1177; Charroux B, 1999, J CELL BIOL, V147, P1181, DOI 10.1083/jcb.147.6.1181; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; Fetzer S, 1997, RNA, V3, P344; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; FU XD, 1995, RNA, V1, P663; GALISSON F, 1993, NUCLEIC ACIDS RES, V21, P1555, DOI 10.1093/nar/21.7.1555; Gall JG, 1999, MOL BIOL CELL, V10, P4385, DOI 10.1091/mbc.10.12.4385; Gee S, 1997, P NATL ACAD SCI USA, V94, P11803, DOI 10.1073/pnas.94.22.11803; Gottschalk A, 1999, EMBO J, V18, P4535, DOI 10.1093/emboj/18.16.4535; Gozani O, 1996, GENE DEV, V10, P233, DOI 10.1101/gad.10.2.233; HABETS WJ, 1989, J IMMUNOL, V143, P2560; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KRAMER A, 1991, EMBO J, V10, P1503, DOI 10.1002/j.1460-2075.1991.tb07670.x; Kreivi JP, 1997, FEBS LETT, V420, P57, DOI 10.1016/S0014-5793(97)01485-3; Kuster B, 2001, PROTEOMICS, V1, P641; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; LAMOND AI, 1987, GENE DEV, V1, P532, DOI 10.1101/gad.1.6.532; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; Lorson CL, 1998, HUM MOL GENET, V7, P1269, DOI 10.1093/hmg/7.8.1269; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; Lygerou Z, 1999, MOL CELL BIOL, V19, P2008; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; MANN M, 1993, BIOL MASS SPECTROM, V22, P338, DOI 10.1002/bms.1200220605; Matera AG, 1999, TRENDS CELL BIOL, V9, P302, DOI 10.1016/S0962-8924(99)01606-2; Meister G, 2001, EMBO J, V20, P2304, DOI 10.1093/emboj/20.9.2304; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; Nishikimi A, 1999, BBA-PROTEIN STRUCT M, V1435, P147, DOI 10.1016/S0167-4838(99)00203-4; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; PETTERSSON I, 1984, J BIOL CHEM, V259, P5907; PIKIELNY CW, 1986, NATURE, V324, P341, DOI 10.1038/324341a0; Ponting CP, 1997, TRENDS BIOCHEM SCI, V22, P51, DOI 10.1016/S0968-0004(96)30049-2; ROSCIGNO RF, 1995, RNA, V1, P692; RYDER U, 1990, NUCLEIC ACIDS RES, V18, P7373, DOI 10.1093/nar/18.24.7373; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shichijo S, 1998, J EXP MED, V187, P277, DOI 10.1084/jem.187.3.277; Sleeman JE, 1999, CURR OPIN CELL BIOL, V11, P372, DOI 10.1016/S0955-0674(99)80052-0; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Stevens SW, 1999, P NATL ACAD SCI USA, V96, P7226, DOI 10.1073/pnas.96.13.7226; Talbot K, 1998, HUM MOL GENET, V7, P2149, DOI 10.1093/hmg/7.13.2149; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; VORM O, 1994, ANAL CHEM, V66, P3281, DOI 10.1021/ac00091a044; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Young PJ, 2000, EXP CELL RES, V256, P365, DOI 10.1006/excr.2000.4858; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	74	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31142	31150		10.1074/jbc.M103620200	http://dx.doi.org/10.1074/jbc.M103620200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11331295	hybrid			2022-12-25	WOS:000170472900073
J	Lin, JQ; Hutchinson, L; Gaston, SM; Raab, G; Freeman, MR				Lin, JQ; Hutchinson, L; Gaston, SM; Raab, G; Freeman, MR			BAG-1 is a novel cytoplasmic binding partner of the membrane form of heparin-binding EGF-like growth factor - A unique role for proHB-EGF in cell survival regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN RECEPTOR; APOPTOTIC PROTEIN BAG-1; DEATH ACTIVITY; EXPRESSION; ALPHA; PROLIFERATION; ACTIVATION; CLONING; RAP46; BCL-2	Several cell functions related to growth and survival regulation have been attributed specifically to the membrane form of heparin-binding EGF-like growth factor (proHB-EGF), rather than to the diffusible, processed HB-EGF isoform. These findings suggest the existence of a functional binding partner specifically for the membrane form of the growth factor. In this study we have identified the prosurvival cochaperone, BAG-1, as a protein that interacts with the cytoplasmic tail domain of proHB-EGF. Interaction between BAG-1 and the 24-amino acid proHB-EGF cytoplasmic tail was initially identified in a yeast two-hybrid screen and was confirmed in mammalian cells. The proHB-EGF tail bound BAG-1 in an hsp70-independent manner and within a 97-amino acid segment that includes the ubiquitin homology domain in BAG-1 but does not include the hsp70 binding site. Effects of BAG-1 and proHB-EGF co-expression were demonstrated in cell adhesion and cell survival assays and in quantitative assays of regulated secretion of soluble HB-EGF. Because the BAG-1 binding site is not present on the mature, diffusible form of the growth factor, these findings suggest a new mechanism by which proHB-EGF, in isolation from the diffusible form, can mediate cell signaling events. In addition, because effects of BAG-1 on regulated secretion of soluble I-IB-EGF were also identified, this interaction has the potential to alter the signaling capabilities of both the membrane-anchored and the diffusible forms of the growth factor.	Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Urol, Boston, MA 02115 USA; Childrens Hosp, Surg Res Lab, Boston, MA 02115 USA; Childrens Hosp, Urol Lab, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital	Freeman, MR (corresponding author), Enders Res Labs, Rm 1161,300 Longwood Ave, Boston, MA 02115 USA.		Gaston, Sandra/AAN-4088-2021		NATIONAL CANCER INSTITUTE [R01CA077386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057691, R01DK047556] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA77386] Funding Source: Medline; NIDDK NIH HHS [R01 DK47556, R01 DK57691] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Dethlefsen SM, 1998, J CELL BIOCHEM, V69, P143, DOI 10.1002/(SICI)1097-4644(19980501)69:2<143::AID-JCB5>3.0.CO;2-S; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; Iwamoto R, 1999, J BIOL CHEM, V274, P25906, DOI 10.1074/jbc.274.36.25906; Lin JQ, 1999, CANCER RES, V59, P2891; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; Miyoshi E, 1997, J BIOL CHEM, V272, P14349, DOI 10.1074/jbc.272.22.14349; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; Naishiro Y, 1999, ONCOGENE, V18, P3244, DOI 10.1038/sj.onc.1202661; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; Raab G, 1996, DEVELOPMENT, V122, P637; RAAB G, 1997, BIOCHIM BIOPHYS ACTA, V1333, P179; Schneikert J, 1999, J CELL BIOL, V146, P929, DOI 10.1083/jcb.146.5.929; Schulz JB, 1997, J NEUROCHEM, V69, P2075; Shi W, 2000, J CELL BIOL, V148, P591, DOI 10.1083/jcb.148.3.591; Takaoka A, 1997, ONCOGENE, V14, P2971, DOI 10.1038/sj.onc.1201147; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Takayama S, 1998, CANCER RES, V58, P3116; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Takemura T, 1997, J BIOL CHEM, V272, P31036, DOI 10.1074/jbc.272.49.31036; Takemura T, 1999, KIDNEY INT, V55, P71, DOI 10.1046/j.1523-1755.1999.00259.x; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang JY, 1998, J BIOL CHEM, V273, P20525, DOI 10.1074/jbc.273.32.20525; Zeiner M, 1999, P NATL ACAD SCI USA, V96, P10194, DOI 10.1073/pnas.96.18.10194; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483	29	53	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30127	30132		10.1074/jbc.M010237200	http://dx.doi.org/10.1074/jbc.M010237200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11340068	hybrid			2022-12-25	WOS:000170558000071
J	Denk, A; Goebeler, M; Schmid, S; Berberich, I; Ritz, O; Lindemann, D; Ludwig, S; Wirth, T				Denk, A; Goebeler, M; Schmid, S; Berberich, I; Ritz, O; Lindemann, D; Ludwig, S; Wirth, T			Activation of NF-kappa B via the I kappa B kinase complex is both essential and sufficient for proinflammatory gene expression in primary endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC FINGER PROTEIN; E-SELECTIN; IKK-ALPHA; TRANSCRIPTIONAL ACTIVATION; BETA; A20; INHIBITION; PHOSPHORYLATION; EPSILON; ADHESION	Activation of the transcription factor NF-kappaB is necessary for full expression of tumor necrosis factor alpha (TNF-alpha)-inducible endothelial chemokines and adhesion molecules. However, a detailed analysis regarding contribution of the different NF-kappaB upstream components to endothelial activation has not been performed yet. We employed a retroviral infection approach to stably express transdominant (TD) mutants of I kappaB alpha, I kappaB beta, or I kappaB epsilon and dominant negative (dn) versions of I kappaB kinases (IKK) 1 or 2 as well as a constitutively active version of IKK2 in human endothelial cells. TD I kappaB alpha, I kappaB beta, and I kappaB epsilon were not degraded upon TNF-alpha exposure, and each prevented NF-kappaB activation. These TD I kappaB mutants almost completely inhibited the induction of monocyte chemoattractant protein-1, interleukin-8, intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin expression by TNF-alpha, whereas interferon-gamma -mediated up-regulation of intercellular adhesion molecule-1 and HLA-DR was not affected. Expression of dn IKK2 completely blocked TNF-alpha -induced up-regulation, whereas dn IKK1 showed a partial inhibition of expression of these molecules. Importantly, expression of constitutively active IKK2 was sufficient to drive full expression of all chemokines and adhesion molecules in the absence of cytokine. We conclude that the IKK/I kappaB/NF-kappaB pathway is crucial and sufficient for proinflammatory activation of endothelium.	Univ Ulm, Dept Physiol Chem, D-89081 Ulm, Germany; Wuerzburg Univ, Dept Dermatol, D-97078 Wuerzburg, Germany; Wuerzburg Univ, Inst Med Strahlenkunde & Zellforsch, MSZ, D-97078 Wuerzburg, Germany; Wuerzburg Univ, Inst Virol & Immunol, D-97078 Wuerzburg, Germany	Ulm University; University of Wurzburg; University of Wurzburg; University of Wurzburg	Wirth, T (corresponding author), Univ Ulm, Dept Physiol Chem, Albert Einstein Allee 11, D-89081 Ulm, Germany.		Goebeler, Matthias/F-7118-2013; Lindemann, Dirk/H-5857-2013; Goebeler, Matthias/P-3612-2019; Wirth, Thomas/X-7172-2019	Lindemann, Dirk/0000-0002-0320-4223; Ludwig, Stephan/0000-0003-4490-3052				Badrichani AZ, 1999, J CLIN INVEST, V103, P543, DOI 10.1172/JCI2517; CHEN CC, 1995, J IMMUNOL, V155, P3538; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Cooper JT, 1996, J BIOL CHEM, V271, P18068, DOI 10.1074/jbc.271.30.18068; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Denk A, 2000, CYTOKINE GROWTH F R, V11, P303, DOI 10.1016/S1359-6101(00)00009-5; DiChiara MR, 2000, J EXP MED, V192, P695, DOI 10.1084/jem.192.5.695; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; Ebnet K, 1999, HISTOCHEM CELL BIOL, V112, P1, DOI 10.1007/s004180050387; Ferran C, 1998, BLOOD, V91, P2249, DOI 10.1182/blood.V91.7.2249.2249_2249_2258; Gerszten RE, 1999, NATURE, V398, P718, DOI 10.1038/19546; Goebeler M, 2001, BLOOD, V97, P46, DOI 10.1182/blood.V97.1.46; Goodman DJ, 1996, TRANSPLANTATION, V62, P967, DOI 10.1097/00007890-199610150-00016; Grignani F, 1998, CANCER RES, V58, P14; Heilker R, 1999, BIOCHEMISTRY-US, V38, P6231, DOI 10.1021/bi990220t; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Johnson DR, 1996, J BIOL CHEM, V271, P16317, DOI 10.1074/jbc.271.27.16317; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Kuss AW, 1999, EUR J IMMUNOL, V29, P3077, DOI 10.1002/(SICI)1521-4141(199910)29:10<3077::AID-IMMU3077>3.0.CO;2-R; LAHERTY CD, 1993, J BIOL CHEM, V268, P5032; Lakshminarayanan V, 1998, J BIOL CHEM, V273, P32670, DOI 10.1074/jbc.273.49.32670; LEMBECHER T, 1993, NATURE, V365, P767; Li Z, 1997, MOL CELL BIOL, V17, P6184, DOI 10.1128/MCB.17.10.6184; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Min W, 1997, J IMMUNOL, V159, P3508; Nolan GP, 1998, CURR OPIN BIOTECH, V9, P447, DOI 10.1016/S0958-1669(98)80027-X; O'Mahony A, 2000, MOL CELL BIOL, V20, P1170, DOI 10.1128/MCB.20.4.1170-1178.2000; Oitzinger W, 2001, BLOOD, V97, P1611, DOI 10.1182/blood.V97.6.1611; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Simeonidis S, 1997, P NATL ACAD SCI USA, V94, P14372, DOI 10.1073/pnas.94.26.14372; Spiecker M, 2000, J IMMUNOL, V164, P3316, DOI 10.4049/jimmunol.164.6.3316; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stroka DM, 1999, BLOOD, V93, P3803, DOI 10.1182/blood.V93.11.3803.411a27_3803_3810; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; True AL, 2000, AM J PHYSIOL-LUNG C, V279, pL302, DOI 10.1152/ajplung.2000.279.2.L302; VANHUIJSDUIJNEN RH, 1993, NUCLEIC ACIDS RES, V21, P3711, DOI 10.1093/nar/21.16.3711; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Wrighton CJ, 1996, J EXP MED, V183, P1013, DOI 10.1084/jem.183.3.1013; Yamamoto Y, 2000, MOL CELL BIOL, V20, P3655, DOI 10.1128/MCB.20.10.3655-3666.2000; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	43	174	183	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28451	28458		10.1074/jbc.M102698200	http://dx.doi.org/10.1074/jbc.M102698200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11337506	hybrid			2022-12-25	WOS:000170093400094
J	Neufeld, EB; Remaley, AT; Demosky, SJ; Stonik, JA; Cooney, AM; Comly, M; Dwyer, NK; Zhang, M; Blanchette-Mackie, J; Santamarina-Fojo, S; Brewer, HB				Neufeld, EB; Remaley, AT; Demosky, SJ; Stonik, JA; Cooney, AM; Comly, M; Dwyer, NK; Zhang, M; Blanchette-Mackie, J; Santamarina-Fojo, S; Brewer, HB			Cellular localization and trafficking of the human ABCA1 transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER-1; LOW-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; TANGIER-DISEASE; CHOLESTEROL EFFLUX; PLASMA-MEMBRANE; BREFELDIN-A; CELLS; REMOVAL; FIBROBLASTS	ABCA1, the ATP-binding cassette protein,mutated in Tangier disease, mediates the efflux of,excess cellular sterol to apoA-I and thereby the formation of high density lipoprotein. The intracellular localization and trafficking of ABCA1 was examined in stably and transiently transfected HeLa cells expressing a functional human ABCA1-green fluorescent protein (GFP) fusion protein. The fluorescent chimeric ABCA1 transporter was found to reside on the cell surface and on intracellular vesicles that include a novel subset of early endosomes, as well as late endosomes and lysosomes, Studies of the localization and trafficking of ABCA1-GFP in the presence of brefeldin A or monensin, agents known to block intracellular vesicular trafficking as well as apoA-I-mediated cellular lipid efflux, showed that: (i) ABCA1 functions in lipid efflux at the cell surface, and (ii) delivery of ABCA1 to lysosomes for degradation may serve as a mechanism to modulate its surface expression. Time-lapse fluorescence microscopy revealed that ABCA1-GFP-containing early endosomes undergo fusion, fission,: and tubulation and transiently interact with one another, late endocytic vesicles, and the cell surface, These studies establish a complex intracellular trafficking pathway for human ABCA1 that may play important roles in modulating ABCA1 transporter activity and cellular cholesterol homeostasis.	NHLBI, NIH, Bethesda, MD 20892 USA; NIDDK, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Neufeld, EB (corresponding author), NHLBI, NIH, 10-7N115,10 Ctr Dr, Bethesda, MD 20892 USA.		Neufeld, Edward/R-3819-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK060003, ZIADK060003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Assmann G, 2001, METABOLIC MOL BASES, P2937; BIELICKI JK, 1992, J LIPID RES, V33, P1699; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BREWER HB, 1986, METHOD ENZYMOL, V128, P223; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Chen CS, 1998, P NATL ACAD SCI USA, V95, P6373, DOI 10.1073/pnas.95.11.6373; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; Fitzgerald ML, 2001, J BIOL CHEM, V276, P15137, DOI 10.1074/jbc.M100474200; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; GHOSH RN, 1994, J CELL SCI, V107, P2177; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Heeren J, 1999, J CELL SCI, V112, P349; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; LISCUM L, 1989, J BIOL CHEM, V264, P11796; MENDEZ AJ, 1995, J BIOL CHEM, V270, P5891, DOI 10.1074/jbc.270.11.5891; Mendez AJ, 1997, J LIPID RES, V38, P1807; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; ORAM JF, 1991, ARTERIOSCLER THROMB, V11, P403, DOI 10.1161/01.ATV.11.2.403; Oram JF, 1996, J LIPID RES, V37, P2473; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Remaley AT, 1999, P NATL ACAD SCI USA, V96, P12685, DOI 10.1073/pnas.96.22.12685; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Zhang F, 2000, J BIOL CHEM, V275, P23287, DOI 10.1074/jbc.M001819200; Zhang M, 2001, J BIOL CHEM, V276, P3417, DOI 10.1074/jbc.M005393200; Zhou CJ, 2001, J NEUROSCI, V21, P849, DOI 10.1523/JNEUROSCI.21-03-00849.2001	36	269	272	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27584	27590		10.1074/jbc.M103264200	http://dx.doi.org/10.1074/jbc.M103264200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11349133	hybrid			2022-12-25	WOS:000169966900112
J	Segev, DL; Hoshiya, Y; Stephen, AE; Hoshiya, M; Tran, TT; MacLaughlin, DT; Donahoe, PK; Maheswaran, S				Segev, DL; Hoshiya, Y; Stephen, AE; Hoshiya, M; Tran, TT; MacLaughlin, DT; Donahoe, PK; Maheswaran, S			Mullerian inhibiting substance regulates NF kappa B signaling and growth of mammary epithelial cells in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; II RECEPTOR; FEMALE RATS; EXPRESSION; GLAND; APOPTOSIS; HORMONE; SURVIVAL; PUBERTY; ONSET	Mullerian inhibiting substance (MIS) inhibits breast cancer cell growth in vitro through interference with cell cycle progression and induction of apoptosis, a process associated with NF kappaB activation and up-regulation of one of its important target genes, IEX-1S (Segev, D. L., Ha, T., Tran, T. T., Kenneally, M., Harkin, P., Jung, M., MacLaughlin, D. T., Donahoe, P. K., and Maheswaran, S. (2000) J. Biol. Chem. 275, 28371-28379). Here we demonstrate that MIS activates the NF kappaB signaling cascade, induces IEX-1S mRNA, and inhibits the growth of MCF10A, an immortalized human breast epithelial cell line with characteristics of normal cells. In vivo an inverse correlation was found to exist between various stages of mammary growth and MIS type II receptor expression. Receptor mRNA significantly diminished during puberty, when the ductal system branches and invades the adipose stroma and during the expansive growth at lactation, but it was up-regulated during involution, a time of regression and apoptosis. Peripartum variations in MIS type II receptor expression correlated with NF kappaB activation and IEX-1S mRNA expression. Administration of MIS to female mice induced NF kappaB DNA binding and IEX-1S mRNA expression in the breast. Furthermore, exposure to MIS in vivo increased apoptosis in the mouse mammary ductal epithelium. Thus, MIS may function as an endogenous hormonal regulator of NF kappaB signaling and growth in the breast.	Massachusetts Gen Hosp, Pediat Surg Res Labs, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Maheswaran, S (corresponding author), Massachusetts Gen Hosp, Pediat Surg Res Labs, WRN1024,55 Fruit St, Boston, MA 02114 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032112] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA071345, R01CA017393, F32CA077945] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA-71345-04, F32 CA77945-01A1, CA17393] Funding Source: Medline; NICHD NIH HHS [HD32112] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arlt A, 2001, ONCOGENE, V20, P69, DOI 10.1038/sj.onc.1204061; BAARENDS WM, 1994, DEVELOPMENT, V120, P189; Baichwal V. R., 1997, CURR BIOL, V7, P94; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Brantley DM, 2000, MECH DEVELOP, V97, P149, DOI 10.1016/S0925-4773(00)00405-6; Clarke TR, 2001, MOL ENDOCRINOL, V15, P946, DOI 10.1210/me.15.6.946; Clarkson RWE, 2000, J BIOL CHEM, V275, P12737, DOI 10.1074/jbc.275.17.12737; DICLEMENTE N, 1994, MOL ENDOCRINOL, V8, P1006, DOI 10.1210/me.8.8.1006; Geymayer S, 2000, FASEB J, V14, P1159, DOI 10.1096/fasebj.14.9.1159; Gouedard L, 2000, J BIOL CHEM, V275, P27973; Han ZS, 1999, J BIOL CHEM, V274, P21355, DOI 10.1074/jbc.274.30.21355; HOWLETT AR, 1995, J CELL SCI, V108, P1945; HUDSON PL, 1990, J CLIN ENDOCR METAB, V70, P16, DOI 10.1210/jcem-70-1-16; Juarez J, 2000, ALCOHOL, V21, P181, DOI 10.1016/S0741-8329(00)00086-0; Kleinberg DL, 1998, BREAST CANCER RES TR, V47, P201, DOI 10.1023/A:1005998832636; Lee MM, 1996, J CLIN ENDOCR METAB, V81, P571, DOI 10.1210/jc.81.2.571; Masso-Welch PA, 2000, J MAMMARY GLAND BIOL, V5, P165, DOI 10.1023/A:1026491221687; MCGIVERN RF, 1992, ALCOHOL, V9, P335, DOI 10.1016/0741-8329(92)90077-N; Meng XJ, 1999, GENE DEV, V13, P792, DOI 10.1101/gad.13.7.792; Nguyen AV, 2000, DEVELOPMENT, V127, P3107; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; RAGIN RC, 1992, PROTEIN EXPRES PURIF, V3, P236, DOI 10.1016/1046-5928(92)90020-W; Schafer H, 1998, FEBS LETT, V436, P139, DOI 10.1016/S0014-5793(98)01109-0; Segev DL, 2000, J BIOL CHEM, V275, P28371, DOI 10.1074/jbc.M004554200; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; SINHA YN, 1966, AM J PHYSIOL, V210, P601, DOI 10.1152/ajplegacy.1966.210.3.601; SOULE HD, 1990, CANCER RES, V50, P6075; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; Teixeira J, 1996, ENDOCRINOLOGY, V137, P160, DOI 10.1210/en.137.1.160; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; Visser JA, 2001, MOL ENDOCRINOL, V15, P936, DOI 10.1210/me.15.6.936; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998	34	57	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26799	26806		10.1074/jbc.M103092200	http://dx.doi.org/10.1074/jbc.M103092200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356848	hybrid			2022-12-25	WOS:000169966900011
J	Burchett, SA; Scott, A; Errede, B; Dohlman, HG				Burchett, SA; Scott, A; Errede, B; Dohlman, HG			Identification of novel pheromone-response regulators through systematic overexpression of 120 protein kinases in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE; SACCHAROMYCES-CEREVISIAE; MATING PHEROMONE; FEEDBACK PHOSPHORYLATION; MUTATIONAL ANALYSIS; INVASIVE GROWTH; FACTOR RECEPTOR; TRANSCRIPTION; STE12	Protein kinases are well known to transmit and regulate signaling pathways. To identify additional regulators of the pheromone signaling apparatus in yeast, we evaluated an array of 120 likely protein kinases encoded by the yeast genome. Each kinase was fused to glutathione S-transferase, overexpressed, and tested for changes in pheromone responsiveness in vivo, As expected, several known components of the pathway (YCK1, STE7 STE11, FUS3, and KSS1) impaired the growth arrest response. Seven other kinases also interfered with pheromone-induced growth arrest; in rank order they are as follows: YKL116c (renamed PRR1) = YDL214c (renamed PRR2) > YJL141c (YAK1, SRA1) > YNR047w = YCR091w (KIN82) = YIL095w (PRK1) > YCL024w (KCC4). Inhibition of pheromone signaling by PRR1, but not PRR2, required the glutathione S-transferase moiety, Both kinases inhibited gene transcription after stimulation with pheromone, a constitutively active kinase mutant STE11-4, or overexpression of the transcription factor STE12. Neither protein altered the ability of the mitogen-activated protein kinase (MAPK) Fus3 to feedback phosphorylate a known substrate, the MAPK kinase Ste7, These results reveal two new components of the pheromone-signaling cascade in yeast, each acting at a point downstream of the MAPK.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06536 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	Yale University; University of North Carolina; University of North Carolina Chapel Hill	Dohlman, HG (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, 295 Congress Ave,Rm 436,POB 9812, New Haven, CT 06536 USA.	henrik.dohlman@yale.edu		Dohlman, Henrik/0000-0003-2443-0729	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039852, R01GM059167, R29GM055316, R01GM055316] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39852, GM55316, R01 GM059167, R01 GM055316, GM59167] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Bardwell L, 1998, P NATL ACAD SCI USA, V95, P15400, DOI 10.1073/pnas.95.26.15400; Bardwell L, 1998, GENE DEV, V12, P2887, DOI 10.1101/gad.12.18.2887; BARDWELL L, 1994, DEV BIOL, V166, P363, DOI 10.1006/dbio.1994.1323; Baur M, 1997, MOL CELL BIOL, V17, P4330, DOI 10.1128/MCB.17.8.4330; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cook JG, 1997, NATURE, V390, P85, DOI 10.1038/36355; Cook JG, 1996, GENE DEV, V10, P2831, DOI 10.1101/gad.10.22.2831; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; Dohlman HG, 1998, SEMIN CELL DEV BIOL, V9, P135, DOI 10.1006/scdb.1998.0218; DOLAN JW, 1991, BIOCHIM BIOPHYS ACTA, V1088, P155, DOI 10.1016/0167-4781(91)90051-M; DOLAN JW, 1990, GENE DEV, V4, P492, DOI 10.1101/gad.4.4.492; Elion EA, 2000, CURR OPIN MICROBIOL, V3, P573, DOI 10.1016/S1369-5274(00)00143-0; ELION EA, 1993, MOL BIOL CELL, V4, P495, DOI 10.1091/mbc.4.5.495; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Farley FW, 1999, GENETICS, V151, P1425; Feng Y, 2000, MOL CELL BIOL, V20, P5350, DOI 10.1128/MCB.20.14.5350-5359.2000; Feng Y, 2000, MOL CELL BIOL, V20, P563, DOI 10.1128/MCB.20.2.563-574.2000; Feng YY, 1998, CURR BIOL, V8, P267, DOI 10.1016/S0960-9822(98)70108-3; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Garrison TR, 1999, J BIOL CHEM, V274, P36387, DOI 10.1074/jbc.274.51.36387; Gartner A, 1998, MOL CELL BIOL, V18, P3681, DOI 10.1128/MCB.18.7.3681; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Haynes PA, 2000, YEAST, V17, P81, DOI 10.1002/1097-0061(20000630)17:2<81::AID-YEA22>3.3.CO;2-Q; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; Hudson JR, 1997, GENOME RES, V7, P1169, DOI 10.1101/gr.7.12.1169; Hung W, 1997, EUR J BIOCHEM, V245, P241, DOI 10.1111/j.1432-1033.1997.00241.x; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; Inouye C, 1997, GENETICS, V147, P479; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; Martzen MR, 1999, SCIENCE, V286, P1153, DOI 10.1126/science.286.5442.1153; Mitchell DA, 2001, MOL CELL BIOL, V21, P488, DOI 10.1128/MCB.21.2.488-500.2001; MUELLER CGF, 1991, EMBO J, V10, P4219, DOI 10.1002/j.1460-2075.1991.tb05000.x; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Olson KA, 2000, MOL CELL BIOL, V20, P4199, DOI 10.1128/MCB.20.12.4199-4209.2000; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PARKER MW, 1990, J MOL BIOL, V213, P221, DOI 10.1016/S0022-2836(05)80183-4; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PFEIFER K, 1987, CELL, V49, P9, DOI 10.1016/0092-8674(87)90750-1; PFEIFER K, 1987, CELL, V49, P19, DOI 10.1016/0092-8674(87)90751-3; PRINTEN JA, 1994, GENETICS, V138, P609; SENGUPTA P, 1990, MOL CELL BIOL, V10, P6809, DOI 10.1128/MCB.10.12.6809; Sette C, 2000, MOL BIOL CELL, V11, P4033, DOI 10.1091/mbc.11.11.4033; SONG OK, 1991, GENE DEV, V5, P741, DOI 10.1101/gad.5.5.741; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; Tedford K, 1997, CURR BIOL, V7, P228, DOI 10.1016/S0960-9822(06)00118-7; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yablonski D, 1996, P NATL ACAD SCI USA, V93, P13864, DOI 10.1073/pnas.93.24.13864; Yesilaltay A, 2000, MOL BIOL CELL, V11, P2873, DOI 10.1091/mbc.11.9.2873; YUAN YLO, 1993, GENE DEV, V7, P1584, DOI 10.1101/gad.7.8.1584; ZHOU ZQ, 1993, MOL CELL BIOL, V13, P2069, DOI 10.1128/MCB.13.4.2069	66	14	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26472	26478		10.1074/jbc.M103436200	http://dx.doi.org/10.1074/jbc.M103436200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11337509	hybrid, Green Published			2022-12-25	WOS:000169823300109
J	Raman, CS; Li, HY; Martasek, P; Babu, BR; Griffith, OW; Masters, BSS; Poulos, TL				Raman, CS; Li, HY; Martasek, P; Babu, BR; Griffith, OW; Masters, BSS; Poulos, TL			Implications for isoform-selective inhibitor design derived from the binding mode of bulky isothioureas to the heme domain of endothelial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ARGININE; POTENT; PTERIN; MECHANISM; PARADIGM; CYCLASE; OXYGEN; SYSTEM; ENZYME; DIMER	Nitric oxide produced by nitric-oxide synthase (NOS) is not only involved in a wide range of physiological functions but also in a variety of pathological conditions, Isoform-selective NOS inhibitors are highly desirable to regulate the NO production of one isoform beneficial to normal physiological functions from. the uncontrolled NO production of another isoform that accompanies certain pathological states. Crystal structures of the heme domain of the three NOS isoforms have revealed a very high degree of similarity in the immediate vicinity of the heme active site illustrating the challenge of isoform-selective inhibitor design, Isothioureas are potent NOS inhibitors, and the structures of the endothelial NOS heme domain complexed with isothioureas bearing small S-alkyl substituents have been determined (Li, H,, Raman, C,S,, Martasek, P,, Kral, V., Masters, B.S.S., and Poulos, T.L. (2000) J. Inorg. Biochem, 81, 133-139), In the present communication, the binding mode of larger bisisothioureas complexed to the endothelial NOS heme domain has been determined, These structures afford a structural rationale for the known inhibitory activities, In addition, these structures provide clues on how to exploit the longer inhibitor substituents that extend out of the active site pocket for isoform-selective inhibitor design.	Univ Calif Irvine, Dept Molec Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Program Macromol Struct, Irvine, CA 92697 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of Texas System; University of Texas Health San Antonio; Medical College of Wisconsin	Poulos, TL (corresponding author), Univ Calif Irvine, Dept Molec Biol & Biochem, Irvine, CA 92697 USA.		Martásek, Pavel/G-6622-2017	Martásek, Pavel/0000-0001-6165-4444; Raman, C. S./0000-0002-1036-3193	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048423] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052419, R01GM057353] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48423] Funding Source: Medline; NIGMS NIH HHS [GM52419, GM 57353] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babu BR, 1998, CURR OPIN CHEM BIOL, V2, P491, DOI 10.1016/S1367-5931(98)80125-7; Babu BR, 1999, J BIOL CHEM, V274, P25218, DOI 10.1074/jbc.274.36.25218; BABU BR, 1999, 6 INT M BIOL NITR OX, P145; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chabrier PE, 1999, P NATL ACAD SCI USA, V96, P10824, DOI 10.1073/pnas.96.19.10824; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; Collins JL, 1998, J MED CHEM, V41, P2858, DOI 10.1021/jm980072p; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; GARVEY EP, 1994, J BIOL CHEM, V269, P26669; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Huang H, 1999, J MED CHEM, V42, P3147, DOI 10.1021/jm990111c; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KERWIN JF, 1995, J MED CHEM, V38, P4343, DOI 10.1021/jm00022a001; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; Li HY, 1999, J BIOL CHEM, V274, P21276, DOI 10.1074/jbc.274.30.21276; Li HY, 2000, J INORG BIOCHEM, V81, P133, DOI 10.1016/S0162-0134(00)00099-4; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; MAYER B, 1989, BIOCHEM BIOPH RES CO, V164, P678, DOI 10.1016/0006-291X(89)91513-1; Mayer B, 1998, N-S ARCH PHARMACOL, V358, P127, DOI 10.1007/PL00005233; MONCADA S, 1991, PHARMACOL REV, V43, P109; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Reif DW, 2000, FREE RADICAL BIO MED, V28, P1470, DOI 10.1016/S0891-5849(00)00250-1; Shearer BG, 1997, J MED CHEM, V40, P1901, DOI 10.1021/jm960785c; Southan GJ, 1996, BIOCHEM PHARMACOL, V51, P383, DOI 10.1016/0006-2952(95)02099-3; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Zhang ZG, 1996, J CEREBR BLOOD F MET, V16, P599, DOI 10.1097/00004647-199607000-00009	31	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26486	26491		10.1074/jbc.M102255200	http://dx.doi.org/10.1074/jbc.M102255200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11331290	hybrid			2022-12-25	WOS:000169823300111
J	Qu, W; Bradbury, JA; Tsao, CC; Maronpot, R; Harry, GJ; Parker, CE; Davis, LS; Breyer, MD; Waalkes, MP; Falck, JR; Chen, JY; Rosenberg, RL; Zeldin, DC				Qu, W; Bradbury, JA; Tsao, CC; Maronpot, R; Harry, GJ; Parker, CE; Davis, LS; Breyer, MD; Waalkes, MP; Falck, JR; Chen, JY; Rosenberg, RL; Zeldin, DC			Cytochrome P450CYP2J9, a new mouse arachidonic acid omega-1 hydroxylase predominantly expressed in brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-SITU HYBRIDIZATION; ARTERIAL SMOOTH-MUSCLE; RAT-BRAIN; EPOXYEICOSATRIENOIC ACIDS; MOLECULAR-CLONING; CDNA CLONING; 5,6-EPOXYEICOSATRIENOIC ACID; MONOOXYGENASE ACTIVITIES; MULTIPLE FORMS; MESSENGER-RNA	A cDNA encoding a new cytochrome P450 was isolated from a mouse brain library. Sequence analysis reveals that this 1,958-base pair cDNA encodes a 57-58-kDa 502-amino acid polypeptide that is 70-91% identical to CYP2J subfamily P450s and is designated CYP2J9. Recombinant CYP2J9 was co-expressed with NADPH-cytochrome P450 oxidoreductase (CYPOR) in Sf9 cells using a baculovirus system. Microsomes of CYP2J9/CYPOR-transfected cells metabolize arachidonic acid to 19-hydroxyeicosatetraenoic acid (HETE) thus CYP2J9 is enzymologically distinct from other P450s. Northern analysis reveals that CYP2J9 transcripts are present at high levels in mouse brain. Mouse brain microsomes biosynthesize 19-HETE. RNA polymerase chain reaction analysis demonstrates that CYP2J9 mRNAs are widely distributed in brain and most abundant in the cerebellum. Immunoblotting using an antibody raised against human CYP2J2 that cross-reacts with CYP2J9 detects a 56-kDa protein band that is expressed in cerebellum and other brain segments and is regulated during postnatal development. In situ hybridization of mouse brain sections with a CYP2J9-specific riboprobe and immunohistochemical staining with the anti-human CYP2J2 IgG reveals abundant CYP2J9 mRNA and protein in cerebellar Purkinje cells. Importantly, 19-HETE inhibits the activity of recombinant P/Q-type Ca2+ channels that are known to be expressed preferentially in cerebellar Purkinje cells and are involved in triggering neurotransmitter release. Based on these data, we conclude that CYP2J9 is a developmentally regulated P450 that is abundant in brain, localized to cerebellar Purkinje cells, and active in the biosynthesis of 19-HETE, an eicosanoid that inhibits activity of P/Q-type Ca2+ channels. We postulate that CYP2J9 arachidonic acid products play important functional roles in the brain.	NIEHS, Pulm Pathobiol Lab, Div Intramural Res, NIH, Res Triangle Pk, NC 27709 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA; NIEHS, Inorgan Carcinogensis Sect, NCI, NIH, Res Triangle Pk, NC 27709 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); NIH National Institute of Environmental Health Sciences (NIEHS); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of North Carolina; University of North Carolina Chapel Hill	Zeldin, DC (corresponding author), NIEHS, Pulm Pathobiol Lab, Div Intramural Res, NIH, Bldg 101,Rm D236,111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	zeldin@niehs.nih.gov	Harry, Gaylia Jean/AAC-1171-2022; Zeldin, Darryl C/Y-7091-2018	Harry, Gaylia Jean/0000-0002-0829-7318; Zeldin, Darryl C/0000-0002-2087-7307; Breyer, Matthew/0000-0003-1880-371X; Falck, John/0000-0002-9219-7845	NHLBI NIH HHS [HL49449] Funding Source: Medline; NIDDK NIH HHS [P01-DK38226] Funding Source: Medline; NIGMS NIH HHS [GM-31278] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049449] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038226] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES021164, Z01ES025041, Z01ES050106, Z01ES021164, Z01ES025034, ZIAES025043, ZIAES025034, ZIAES025041, Z01ES025044, Z01ES025043] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alkayed NJ, 1996, STROKE, V27, P971, DOI 10.1161/01.STR.27.5.971; AMRUTHESH SC, 1993, J NEUROCHEM, V61, P150, DOI 10.1111/j.1471-4159.1993.tb03550.x; Bhagwat SV, 2000, BIOCHEM PHARMACOL, V59, P573, DOI 10.1016/S0006-2952(99)00362-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREYER MD, 1993, KIDNEY INT, V44, P1372, DOI 10.1038/ki.1993.391; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; CAPDEVILA JH, 1991, METHOD ENZYMOL, V206, P441; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; Carroll MA, 1996, AM J PHYSIOL-REG I, V271, pR863, DOI 10.1152/ajpregu.1996.271.4.R863; CARROLL MA, 1993, J BIOL CHEM, V268, P12260; Chen JY, 1999, MOL PHARMACOL, V55, P288, DOI 10.1124/mol.55.2.288; CLARE RA, 1991, J CHROMATOGR-BIOMED, V562, P237, DOI 10.1016/0378-4347(91)80581-V; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; ESCALANTE B, 1988, BIOCHEM BIOPH RES CO, V152, P1269, DOI 10.1016/S0006-291X(88)80422-4; ESCALANTE B, 1993, J CARDIOVASC PHARM, V22, pS106, DOI 10.1097/00005344-199322002-00034; ESCALANTE B, 1993, EUR J PHARMACOL, V235, P1, DOI 10.1016/0014-2999(93)90812-V; FALCK JR, 1983, BIOCHEM BIOPH RES CO, V114, P743, DOI 10.1016/0006-291X(83)90843-4; FALCK JR, 1990, METHOD ENZYMOL, V187, P357; Gebremedhin D, 1998, J PHYSIOL-LONDON, V507, P771, DOI 10.1111/j.1469-7793.1998.771bs.x; GEBREMEDHIN D, 1992, AM J PHYSIOL, V263, pH519, DOI 10.1152/ajpheart.1992.263.2.H519; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; HAMMONDS TD, 1989, ANAL BIOCHEM, V182, P300, DOI 10.1016/0003-2697(89)90598-8; Harder DR, 1998, STROKE, V29, P229, DOI 10.1161/01.STR.29.1.229; HARRIS RC, 1990, J CELL PHYSIOL, V144, P429, DOI 10.1002/jcp.1041440310; Hua JY, 1995, TOXICOLOGY, V104, P83, DOI 10.1016/0300-483X(95)03143-4; JUNIER MP, 1990, ENDOCRINOLOGY, V126, P1534, DOI 10.1210/endo-126-3-1534; Kawashima H, 1995, BIOCHEM BIOPH RES CO, V217, P1137, DOI 10.1006/bbrc.1995.2887; Kawashima H, 1996, J BIOL CHEM, V271, P28176, DOI 10.1074/jbc.271.45.28176; KIKUTA Y, 1991, J BIOL CHEM, V266, P17821; KOMORI M, 1993, BIOCHEM BIOPH RES CO, V196, P721, DOI 10.1006/bbrc.1993.2309; LAETHEM RM, 1992, J PHARMACOL EXP THER, V262, P433; LAETHEM RM, 1993, J BIOL CHEM, V268, P12912; LEE CA, 1995, ARCH BIOCHEM BIOPHYS, V319, P157, DOI 10.1006/abbi.1995.1278; Lin ZX, 1997, NEURON, V18, P153, DOI 10.1016/S0896-6273(01)80054-4; Luo G, 1998, ARCH BIOCHEM BIOPHYS, V357, P45, DOI 10.1006/abbi.1998.0806; Ma JX, 1999, J BIOL CHEM, V274, P17777, DOI 10.1074/jbc.274.25.17777; MANNA S, 1983, TETRAHEDRON LETT, V24, P33, DOI 10.1016/S0040-4039(00)81319-2; McFadyen MCE, 1998, BIOCHEM PHARMACOL, V55, P825, DOI 10.1016/S0006-2952(97)00516-9; MCGIFF JC, 1991, ANNU REV PHARMACOL, V31, P339, DOI 10.1146/annurev.pa.31.040191.002011; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MOSSET P, 1986, TETRAHEDRON LETT, V27, P6035, DOI 10.1016/S0040-4039(00)85391-5; MOUSTAKIS CA, 1985, J AM CHEM SOC, V107, P5283, DOI 10.1021/ja00304a048; NASLUND BMA, 1988, MOL PHARMACOL, V33, P31; NEGROVILAR A, 1985, ENDOCRINOLOGY, V116, P2663, DOI 10.1210/endo-116-6-2663; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; Nguyen X, 1999, AM J PHYSIOL-REG I, V276, pR1691; Node K, 1999, SCIENCE, V285, P1276, DOI 10.1126/science.285.5431.1276; NORRIS PJ, 1994, NEUROSCIENCE, V61, P331, DOI 10.1016/0306-4522(94)90235-6; OLIW EH, 1994, PROG LIPID RES, V33, P329, DOI 10.1016/0163-7827(94)90029-9; OLIW EH, 1990, J CHROMATOGR-BIOMED, V526, P525, DOI 10.1016/S0378-4347(00)82534-7; OMURA T, 1964, J BIOL CHEM, V239, P2370; Petratos S, 2000, DEV BRAIN RES, V123, P81, DOI 10.1016/S0165-3806(00)00076-6; PROCTOR KG, 1987, CIRC RES, V60, P50, DOI 10.1161/01.RES.60.1.50; Riedl AG, 2000, SYNAPSE, V38, P392, DOI 10.1002/1098-2396(20001215)38:4<392::AID-SYN4>3.0.CO;2-Z; RIFKIND AB, 1995, ARCH BIOCHEM BIOPHYS, V320, P380, DOI 10.1016/0003-9861(95)90023-3; Rose KA, 1997, P NATL ACAD SCI USA, V94, P4925, DOI 10.1073/pnas.94.10.4925; Rzigalinski BA, 1999, J BIOL CHEM, V274, P175, DOI 10.1074/jbc.274.1.175; SAKAIRI Y, 1995, AM J PHYSIOL-RENAL, V268, pF931, DOI 10.1152/ajprenal.1995.268.5.F931; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Scarborough PE, 1999, DRUG METAB REV, V31, P205, DOI 10.1081/DMR-100101915; Schilter B, 2000, J PHARMACOL EXP THER, V294, P916; SMITH SJ, 1985, P NATL ACAD SCI USA, V82, P622, DOI 10.1073/pnas.82.2.622; SNYDER GD, 1983, P NATL ACAD SCI-BIOL, V80, P3504, DOI 10.1073/pnas.80.11.3504; SNYDER GD, 1989, AM J PHYSIOL, V265, pE221; STAPLETON G, 1995, J BIOL CHEM, V270, P29739, DOI 10.1074/jbc.270.50.29739; Thompson CM, 2000, J PHARMACOL EXP THER, V294, P1120; Tirumalai PS, 1998, BIOCHEM PHARMACOL, V56, P371, DOI 10.1016/S0006-2952(98)00036-7; Upadhya SC, 2000, ARCH BIOCHEM BIOPHYS, V373, P23, DOI 10.1006/abbi.1999.1477; WARNER M, 1993, J STEROID BIOCHEM, V47, P191, DOI 10.1016/0960-0760(93)90074-7; White JA, 2000, P NATL ACAD SCI USA, V97, P6403, DOI 10.1073/pnas.120161397; Wu S, 1996, J BIOL CHEM, V271, P3460; Wu S, 1997, J BIOL CHEM, V272, P12551, DOI 10.1074/jbc.272.19.12551; ZELDIN DC, 1993, J BIOL CHEM, V268, P6402; Zhang QY, 1997, ARCH BIOCHEM BIOPHYS, V340, P270, DOI 10.1006/abbi.1997.9922; ZOU A, 2000, AM J PHYSIOL, V278, pL335; Zou AP, 1996, AM J PHYSIOL-RENAL, V270, pF822, DOI 10.1152/ajprenal.1996.270.5.F822; Zou AP, 1996, AM J PHYSIOL-REG I, V270, pR228, DOI 10.1152/ajpregu.1996.270.1.R228	77	71	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25467	25479		10.1074/jbc.M100545200	http://dx.doi.org/10.1074/jbc.M100545200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11328810	hybrid			2022-12-25	WOS:000169800700137
J	Yao, XY; Rubenstein, PA				Yao, XY; Rubenstein, PA			F-actin-like ATPase activity in a polymerization-defective mutant yeast actin (V266G/L267G)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERELY DECREASED HYDROPHOBICITY; FILAMENT; STABILITY; DYNAMICS	Polymerization increases a low level G-actin ATPase activity yielding ADP-P-i F-actin and then ADP F-actin following release of P-i. By monitoring P-i release, we explored the relationship between the ATPase activity and polymerization characteristics of a mutant yeast actin, GG. In this mutant, two hydrophobic residues at the tip of a proposed hydrophobic plug between actin subdomains 3 and 4, Val(266) and Leu(267), were mutated to Gly. Although GG-actin does not polymerize by itself in vitro, GG cells are viable. We show that GG-actin ATPase activity increases under normal polymerization conditions, although stable filaments do not form. A plot of P-i release rate versus actin concentration yields an apparent critical concentration, like that seen for actin polymerization, of similar to8 muM for Mg2+ GG-actin and 11 muM for Ca2+ GG-actin, In contrast to WT-actin, P-i release from GG-actin is cold-sensitive, reflecting the temperature sensitivity associated with mutations that decrease hydrophobicity in this region. Thus, under polymerization conditions, GG-actin exhibits a continuous F-actin-like ATPase activity resulting from the temperature-sensitive formation of unstable cycling F-actin oligomers, Tropomyosin limits the extent and rate of this activity and restores polymerization by capturing and stabilizing these oligomers rather than enhancing filament nucleation.	Univ Iowa, Coll Med, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa	Rubenstein, PA (corresponding author), Univ Iowa, Coll Med, Dept Biochem, Iowa City, IA 52242 USA.	peter-rubenstein@uiowa.edu		Rubenstein, Peter/0000-0003-1225-4414	NIGMS NIH HHS [GM-33689] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033689] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; Buzan JM, 1996, P NATL ACAD SCI USA, V93, P91, DOI 10.1073/pnas.93.1.91; Carlier M F, 1990, Adv Biophys, V26, P51, DOI 10.1016/0065-227X(90)90007-G; CHEN X, 1993, J CELL BIOL, V123, P1185, DOI 10.1083/jcb.123.5.1185; Cheng DM, 1999, J BIOL CHEM, V274, P35873, DOI 10.1074/jbc.274.50.35873; COOK RK, 1992, J BIOL CHEM, V267, P9430; HESTERKAMP T, 1993, EUR J BIOCHEM, V218, P507, DOI 10.1111/j.1432-1033.1993.tb18403.x; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Kuang B, 1997, J BIOL CHEM, V272, P1237, DOI 10.1074/jbc.272.2.1237; Kuang B, 1997, J BIOL CHEM, V272, P4412, DOI 10.1074/jbc.272.7.4412; Melki R, 1996, BIOCHEMISTRY-US, V35, P12038, DOI 10.1021/bi961325o; MILLONIG R, 1988, J CELL BIOL, V106, P785, DOI 10.1083/jcb.106.3.785; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; Pollard TD, 2001, J CELL SCI, V114, P3; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; RICH SA, 1976, J MOL BIOL, V104, P777, DOI 10.1016/0022-2836(76)90181-9; SELDEN LA, 1983, BIOCHEM BIOPH RES CO, V116, P478, DOI 10.1016/0006-291X(83)90548-X; SHU WP, 1992, BIOCHEM J, V283, P567, DOI 10.1042/bj2830567; Steinmetz MO, 1997, J CELL BIOL, V138, P559, DOI 10.1083/jcb.138.3.559; TOBACMAN LS, 1983, J BIOL CHEM, V258, P3207; Wen KK, 2000, BIOCHEMISTRY-US, V39, P8638, DOI 10.1021/bi000241j; Wen KK, 2000, J BIOL CHEM, V275, P40594, DOI 10.1074/jbc.M007201200; Yao XY, 1999, J BIOL CHEM, V274, P37443, DOI 10.1074/jbc.274.52.37443	23	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25598	25604		10.1074/jbc.M011797200	http://dx.doi.org/10.1074/jbc.M011797200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11328808	hybrid			2022-12-25	WOS:000169800700151
J	Smart, DE; Vincent, KJ; Arthur, MJP; Eiekelberg, O; Castellazzi, M; Mann, J; Mann, DA				Smart, DE; Vincent, KJ; Arthur, MJP; Eiekelberg, O; Castellazzi, M; Mann, J; Mann, DA			JunD regulates transcription of the tissue inhibitor of metalloproteinases-1 and interleukin-6 genes in activated hepatic stellate cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; MESSENGER-RNA; LIVER-INJURY; C-FOS; EXPRESSION; PROMOTER; AP-1; INDUCTION; PROTEIN-1; FIBROSIS	Activation of hepatic stellate cells (HSCs) to a myofibroblast-like phenotype is the pivotal event in hepatic wound healing and fibrosis. Rat HSCs activated in vitro express JunD, Fra2, and FosB as the predominant AP-1 DNA-binding proteins, and all three associate with an AP-I sequence that is essential for activity of the tissue inhibitor of metalloproteinases-1 (TIMP-1) promoter. In this study, we used expression vectors for wild-type, dominant-negative, and forced homodimeric (Jun/eb1 chimeric factors) forms of JunD and other Fos and Jun proteins to determine the requirement for JunD in the transcriptional regulation of the TIMP-1 and interleukin-6 (IL-6) genes. JunD activity was required for TIMP-1 gene promoter activity, whereas overexpression of Fra2 or FosB caused a repression of promoter activity. The ability of homodimeric JunD/eb1 to elevate TIMP-1 promoter activity supports a role for JunD homodimers as the major AP-1-dependent transactivators of the TIMP-1 gene. IL-6 promoter activity was induced upon activation of HSCs and also required JunD activity; however, expression of JunD/eb1 homodimers resulted in transcriptional repression, Mutagenesis of the IL-6 promoter showed that an AP-1 DNA-binding site previously reported to be an activator of transcription in fibroblasts functions as a suppressor of promoter activity in HSCs, We conclude that JunD activates IL-6 gene transcription as a heterodimer and operates at an alternative DNA-binding site in the promoter. The relevance of these findings to events occurring in the injured Liver was addressed by showing that AP-I DNA-binding complexes are induced during HSC activation and contain JunD as the predominant Jun family protein. JunD is therefore an important transcriptional regulator of genes responsive to Jun homo- and heterodimers in activated HSCs.	Univ Southampton, Southampton Gen Hosp, Liver Grp, Div Infect Inflammat & Repair, Southampton SO16 6YD, Hants, England; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Ecole Normale Super Lyon, Unite Virol Humaine, INSERM U 412, F-69364 Lyon 07, France	University of Southampton; Yale University; Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Mann, DA (corresponding author), Univ Southampton, Southampton Gen Hosp, Liver Grp, Div Infect Inflammat & Repair, Southampton SO16 6YD, Hants, England.	dam2@soton.ac.uk		smart, David/0000-0002-1411-723X; Mann, Derek/0000-0003-0950-243X				ARMENDARIZBORUNDA J, 1994, BIOCHEM J, V304, P817, DOI 10.1042/bj3040817; Arthur MJP, 1998, J GASTROEN HEPATOL, V13, pS33; Asschert JGW, 1999, INT J CANCER, V81, P236, DOI 10.1002/(SICI)1097-0215(19990412)81:2<236::AID-IJC12>3.0.CO;2-R; Bahr MJ, 1999, HEPATOLOGY, V29, P839, DOI 10.1002/hep.510290333; CHEN A, 1999, J BIOL CHEM, V271, P25994; Chen AP, 2000, MOL CELL BIOL, V20, P2818, DOI 10.1128/MCB.20.8.2818-2826.2000; CHOI I, 1994, CLIN EXP IMMUNOL, V95, P530; Coulson EJ, 1999, J BIOL CHEM, V274, P16387, DOI 10.1074/jbc.274.23.16387; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; Elsharkawy AM, 1999, HEPATOLOGY, V30, P761, DOI 10.1002/hep.510300327; Franchimont N, 1999, J BIOL CHEM, V274, P6783, DOI 10.1074/jbc.274.10.6783; Franchimont N, 1997, J CLIN INVEST, V100, P1797, DOI 10.1172/JCI119707; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Grassl C, 1999, J AM SOC NEPHROL, V10, P1466; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HARRISON RJ, 1995, MOL ENDOCRINOL, V9, P981, DOI 10.1210/me.9.8.981; Hellerbrand C, 1998, HEPATOLOGY, V27, P1285, DOI 10.1002/hep.510270514; Hellerbrand C, 1999, J HEPATOL, V30, P77, DOI 10.1016/S0168-8278(99)80010-5; Iredale JP, 1996, HEPATOLOGY, V24, P176, DOI 10.1002/hep.510240129; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Knittel T, 1999, AM J PATHOL, V155, P1841, DOI 10.1016/S0002-9440(10)65502-2; Kovalovich K, 2000, HEPATOLOGY, V31, P149, DOI 10.1002/hep.510310123; Lang A, 2000, J HEPATOL, V33, P49, DOI 10.1016/S0168-8278(00)80159-2; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Okazaki S, 1998, BIOCHEM BIOPH RES CO, V250, P347, DOI 10.1006/bbrc.1998.9331; Papanicolaou DA, 1998, ANN INTERN MED, V128, P127, DOI 10.7326/0003-4819-128-2-199801150-00009; Rutberg SE, 1997, ONCOGENE, V15, P1337, DOI 10.1038/sj.onc.1201293; SONOBE MH, 1995, ONCOGENE, V10, P689; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; TANABE O, 1988, J IMMUNOL, V141, P3875; Tao JC, 1999, J BIOL CHEM, V274, P23761, DOI 10.1074/jbc.274.34.23761; TIGGELMAN AMB, 1995, J HEPATOL, V23, P295, DOI 10.1016/0168-8278(95)80474-9; Toda K, 2000, J GASTROENTEROL, V35, P214, DOI 10.1007/s005350050333; Trim JE, 2000, J BIOL CHEM, V275, P6657, DOI 10.1074/jbc.275.9.6657; Tsukamoto H, 1999, ALCOHOL CLIN EXP RES, V23, P911, DOI 10.1111/j.1530-0277.1999.tb04202.x; Vandel L, 1996, MOL CELL BIOL, V16, P1881; Weiner JK, 1998, J BIOL CHEM, V273, P15913, DOI 10.1074/jbc.273.26.15913; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	41	80	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24414	24421		10.1074/jbc.M101840200	http://dx.doi.org/10.1074/jbc.M101840200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11337499	hybrid			2022-12-25	WOS:000169531100157
J	Stephen, AG; Raval-Fernandes, S; Huynh, T; Torres, M; Kickhoefer, VA; Rome, LH				Stephen, AG; Raval-Fernandes, S; Huynh, T; Torres, M; Kickhoefer, VA; Rome, LH			Assembly of vault-like particles in insect cells expressing only the major vault protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-LIKE PARTICLES; RIBONUCLEOPROTEIN-PARTICLES; SMALL RNA; RESISTANCE; POLYMERASE; DISRUPTION; COMPLEX; CONTAIN	Vaults are the largest (13 megadalton) cytoplasmic ribonucleoprotein particles known to exist in eukaryotic cells. They have a unique barrel-shaped structure with 8-fold symmetry. Although the precise function of vaults is unknown, their wide distribution and highly conserved morphology in eukaryotes suggests that their function is essential and that their structure must be important for their function. The 100-kDa major vault protein (MVP) constitutes similar to 75% of the particle mass and is predicted to form the central barrel portion of the vault. To gain insight into the mechanisms for vault assembly, we have expressed rat MVP in the Sf9 insect cell line using a baculovirus vector. Our results show that the expression of the rat MVP alone can direct the formation of particles that have biochemical characteristics similar to endogenous rat vaults and display the distinct vault-like morphology when negatively stained and examined by electron microscopy. These particles are the first example of a single protein polymerizing into a non-spherically, non-cylindrically symmetrical structure. Understanding vault assembly will enable us to design agents that disrupt vault formation and hence aid in elucidating vault function in vivo.	Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; NCI, Frederick Canc Res & Dev Ctr, SAIC Frederick, Frederick, MD 21702 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Rome, LH (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Biol Chem, 33-131 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA.		Stephen, Andrew/W-2636-2019; Rome, Leonard H/E-8786-2016	Stephen, Andrew/0000-0002-8259-621X; Rome, Leonard H/0000-0002-1236-2063; Kickhoefer, Valerie/0000-0002-0048-0580	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038097] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38097] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHUGANI DC, 1993, J CELL SCI, V106, P23; GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8; Herrmann C, 1999, J CELL BIOL, V144, P1163, DOI 10.1083/jcb.144.6.1163; Izquierdo MA, 1998, CYTOTECHNOLOGY, V27, P137, DOI 10.1023/A:1008004502861; KEDERSHA NL, 1991, J CELL BIOL, V112, P225, DOI 10.1083/jcb.112.2.225; KEDERSHA NL, 1990, J CELL BIOL, V110, P895, DOI 10.1083/jcb.110.4.895; KEDERSHA NL, 1986, J CELL BIOL, V103, P699, DOI 10.1083/jcb.103.3.699; KICKHOEFER VA, 1994, GENE, V151, P257, DOI 10.1016/0378-1119(94)90667-X; KICKHOEFER VA, 1993, J BIOL CHEM, V268, P7868; Kickhoefer VA, 1999, J BIOL CHEM, V274, P32712, DOI 10.1074/jbc.274.46.32712; Kickhoefer VA, 1998, J BIOL CHEM, V273, P8971, DOI 10.1074/jbc.273.15.8971; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Kickhoefer VA, 2001, J CELL BIOL, V152, P157, DOI 10.1083/jcb.152.1.157; KIRNBAUER R, 1993, J VIROL, V67, P6929, DOI 10.1128/JVI.67.12.6929-6936.1993; Kitazono M, 1999, JNCI-J NATL CANCER I, V91, P1647, DOI 10.1093/jnci/91.19.1647; Kong LB, 2000, RNA, V6, P890, DOI 10.1017/S1355838200000157; Kong LB, 1999, STRUCT FOLD DES, V7, P371, DOI 10.1016/S0969-2126(99)80050-1; Li TC, 1997, J VIROL, V71, P7207, DOI 10.1128/JVI.71.10.7207-7213.1997; Roy P, 1997, GENE, V190, P119, DOI 10.1016/S0378-1119(96)00619-1; Siva AC, 2001, INT J CANCER, V92, P195, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1168>3.0.CO;2-7; VASU SK, 1995, J BIOL CHEM, V270, P16588, DOI 10.1074/jbc.270.28.16588; VASU SK, 1993, J BIOL CHEM, V268, P15356; Wang MY, 2000, BIOTECHNOL BIOENG, V67, P104, DOI 10.1002/(SICI)1097-0290(20000105)67:1&lt;104::AID-BIT12&gt;3.0.CO;2-I	23	107	117	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23217	23220		10.1074/jbc.C100226200	http://dx.doi.org/10.1074/jbc.C100226200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11349122	hybrid			2022-12-25	WOS:000169531100002
J	Srinivas, V; Leshchinsky, I; Sang, N; King, MP; Minchenko, A; Caro, J				Srinivas, V; Leshchinsky, I; Sang, N; King, MP; Minchenko, A; Caro, J			Oxygen sensing and HIF-1 activation does not require an active mitochondrial respiratory chain electron-transfer pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR 1-ALPHA; TUMOR-SUPPRESSOR PROTEIN; DEGRADATION DOMAIN; HYPOXIA; ERYTHROPOIETIN; CELLS; MECHANISM; HIF-1-ALPHA; INDUCTION; ALPHA	Hypoxia induces the stabilization and transcriptional activation of the hypoxia-inducible factor 1 alpha (HIF-1 alpha) protein, the regulatory member of the HIF-1 complex, The molecular mechanisms that are responsible for oxygen sensing and the downstream pathways utilized by the hypoxic signal are still poorly understood, One hypothesis for oxygen sensing has postulated that reactive oxygen species generated at mitochondrial complex III are the initiators of the hypoxic signal. Here we find that mitochondrial DNA-less (rho degrees) cells have a normal response to hypoxia, measured at the level of HIF-1 alpha protein stabilization, nuclear translocation, and its transcriptional activation activity. Furthermore, overexpression of catalase, either in the mitochondria or in the cytosol, fails to modify the hypoxia response indicating that hydrogen peroxide is not a signaling molecule in the hypoxic signaling cascade that culminates with HIF-1 activation.	Thomas Jefferson Univ, Cardeza Fdn Hematol Res, Jefferson Med Coll, Dept Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Srinivas, V (corresponding author), Thomas Jefferson Univ, Cardeza Fdn Hematol Res, Jefferson Med Coll, Dept Med, 1015 Walnut St, Philadelphia, PA 19107 USA.		Minchenko, Oleksandr/AAV-5742-2020	Minchenko, Oleksandr/0000-0002-7093-5173	NATIONAL CANCER INSTITUTE [K01CA098809, R01CA089212] Funding Source: NIH RePORTER; NCI NIH HHS [1RO1 CA89212-02, K01 CA098809, R01 CA089212] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKER H, 1994, ANN NY ACAD SCI, V718, P1; Bai JX, 1999, J BIOL CHEM, V274, P26217, DOI 10.1074/jbc.274.37.26217; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; FANDREY J, 1994, BIOCHEM J, V303, P507, DOI 10.1042/bj3030507; GLEADLE JM, 1995, EUR J BIOCHEM, V234, P92, DOI 10.1111/j.1432-1033.1995.092_c.x; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Han D, 2001, BIOCHEM J, V353, P411, DOI 10.1042/0264-6021:3530411; Horiguchi H, 2000, BBA-MOL CELL RES, V1495, P231, DOI 10.1016/S0167-4889(99)00169-X; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Liu ZD, 2001, BIOCHEM PHARMACOL, V61, P285, DOI 10.1016/S0006-2952(00)00551-7; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MINCHENKO A, 1994, LAB INVEST, V71, P374; NECAS E, 1972, AM J PHYSIOL, V222, P1187, DOI 10.1152/ajplegacy.1972.222.5.1187; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Srinivas V, 1998, J BIOL CHEM, V273, P18019, DOI 10.1074/jbc.273.29.18019; Srinivas V, 1999, J BIOL CHEM, V274, P1180; Srinivas V, 1999, BIOCHEM BIOPH RES CO, V260, P557, DOI 10.1006/bbrc.1999.0878; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 2000, J EXP BIOL, V203, P1253	26	120	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					21995	21998		10.1074/jbc.C100177200	http://dx.doi.org/10.1074/jbc.C100177200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11342528	Green Accepted, hybrid			2022-12-25	WOS:000169412700002
J	Bacolla, A; Pradhan, S; Larson, JE; Roberts, RJ; Wells, RD				Bacolla, A; Pradhan, S; Larson, JE; Roberts, RJ; Wells, RD			Recombinant human DNA (cytosine-5) methyltransferase - III. Allosteric control, reaction order, and influence of plasmid topology and triplet repeat length on methylation of the fragile X CGG center dot CCG sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO; ICF SYNDROME; FMR1 GENE; MAINTENANCE METHYLATION; HISTONE DEACETYLASE; DELAYED REPLICATION; SATELLITE DNA; STEADY-STATE; CELLS; DOMAIN	Steady-state kinetic analyses revealed that the methylation reaction of the human DNA (cytosine-5) methyltransferase 1 (DNMT1) is repressed by the N-terminal domain comprising the first 501 amino acids, and that repression is relieved when methylated DNA binds to this region. DNMT1 lacking the first 501 amino acids retains its preference for hemimethylated DNA, The methylation reaction proceeds by a sequential mechanism, and either substrate (S-adenosyl-L-methionine and unmethylated DNA) may be the first to bind to the active site. However, initial binding of S-adenosyl-L-methionine is preferred. The binding affinities of DNA for both the regulatory and the catalytic sites increase in the presence of methylated CpG; dinucleotides and vary considerably (more than one hundred times) according to DNA sequence. DNA topology strongly influences the reaction rates, which increased with increasing negative superhelical tension. These kinetic data are consistent with the role of DNMT1 in maintaining the methylation patterns throughout development and suggest that the enzyme may be involved in the etiology of fragile X, a syndrome characterized by de novo methylation of a greatly expanded CGG.CCG triplet repeat sequence.	Texas A&M Univ, Hlth Sci Ctr, Texas Med Ctr, Ctr Genome Res,Inst Biosci & Technol, Houston, TX 77030 USA; New England Biolabs Inc, Beverly, MA 01915 USA	Baylor College of Medicine; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston	Wells, RD (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Texas Med Ctr, Ctr Genome Res,Inst Biosci & Technol, 2121 Holcombe Blvd, Houston, TX 77030 USA.		Bacolla, Albino/N-3877-2013; Bacolla, Albino/AAP-1727-2020	Bacolla, Albino/0000-0003-0206-8423; Bacolla, Albino/0000-0003-0206-8423; Roberts, Richard/0000-0002-4348-0169	NIGMS NIH HHS [GM46127, GM52982] Funding Source: Medline; NINDS NIH HHS [NS37554] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046127, P01GM052982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037554] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bacolla A, 1999, J BIOL CHEM, V274, P33011, DOI 10.1074/jbc.274.46.33011; Bacolla A, 1997, J BIOL CHEM, V272, P16783, DOI 10.1074/jbc.272.27.16783; BACOLLA A, 1995, J BIOL CHEM, V270, P24556, DOI 10.1074/jbc.270.41.24556; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bonfils C, 2000, J BIOL CHEM, V275, P10754, DOI 10.1074/jbc.275.15.10754; BOWATER R, 1991, BIOCHEMISTRY-US, V30, P11495, DOI 10.1021/bi00113a003; Boyer P.D., 1990, ENZYMES, V19, P99; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; Carotti D, 1998, BIOCHEMISTRY-US, V37, P1101, DOI 10.1021/bi971031i; Chuang LSH, 1996, J MOL BIOL, V257, P935, DOI 10.1006/jmbi.1996.0213; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Cleland W. W, 1970, ENZYMES, V2, P1; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; deVries BBA, 1996, J MED GENET, V33, P1007, DOI 10.1136/jmg.33.12.1007; Eberhart DE, 1996, SOMAT CELL MOLEC GEN, V22, P435, DOI 10.1007/BF02369435; Flynn J, 1998, BIOCHEMISTRY-US, V37, P15162, DOI 10.1021/bi9810609; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gellibolian R, 1997, J BIOL CHEM, V272, P16793, DOI 10.1074/jbc.272.27.16793; Ghosh AK, 1999, BIOCHEM BIOPH RES CO, V260, P405, DOI 10.1006/bbrc.1999.0921; Glickman JF, 1997, J BIOL CHEM, V272, P17851, DOI 10.1074/jbc.272.28.17851; GRANT RC, 1968, J AM CHEM SOC, V90, P4474, DOI 10.1021/ja01018a060; GRUNWALD S, 1984, INT J BIOCHEM, V16, P883, DOI 10.1016/0020-711X(84)90147-2; Hagerman R, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P15; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; Hansen RS, 1997, P NATL ACAD SCI USA, V94, P4587, DOI 10.1073/pnas.94.9.4587; HITT MM, 1988, J BIOL CHEM, V263, P4392; Imbert G, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P27; Ivanchenko M, 1997, BIOPHYS J, V72, P1388, DOI 10.1016/S0006-3495(97)78785-X; JEANPIERRE M, 1993, HUM MOL GENET, V2, P731, DOI 10.1093/hmg/2.6.731; Ji WZ, 1997, MUTAT RES-FUND MOL M, V379, P33, DOI 10.1016/S0027-5107(97)00088-2; Klein CB, 1997, MUTAT RES-REV MUTAT, V386, P163, DOI 10.1016/S1383-5742(96)00052-X; Kondo T, 2000, HUM MOL GENET, V9, P597, DOI 10.1093/hmg/9.4.597; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Lyko F, 1999, NAT GENET, V23, P363, DOI 10.1038/15551; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; Margot JB, 2000, J MOL BIOL, V297, P293, DOI 10.1006/jmbi.2000.3588; Mariappan SVS, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P647; Merenstein SA, 1996, AM J MED GENET, V64, P388, DOI 10.1002/(SICI)1096-8628(19960809)64:2<388::AID-AJMG31>3.3.CO;2-S; Mertineit C, 1998, DEVELOPMENT, V125, P889; Morales V, 2000, MOL CELL BIOL, V20, P7230, DOI 10.1128/MCB.20.19.7230-7237.2000; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; ONEILL LP, 1995, EMBO J, V14, P3946, DOI 10.1002/j.1460-2075.1995.tb00066.x; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P124; PATTERTON HG, 1993, J MOL BIOL, V229, P623, DOI 10.1006/jmbi.1993.1068; Pearson CE, 1998, BIOCHEMISTRY-US, V37, P2701, DOI 10.1021/bi972546c; Pearson CE, 1996, BIOCHEMISTRY-US, V35, P5041, DOI 10.1021/bi9601013; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Pradhan S, 1997, NUCLEIC ACIDS RES, V25, P4666, DOI 10.1093/nar/25.22.4666; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; RUCHIRAWAT M, 1987, MOL CELL BIOCHEM, V76, P45; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUFFENHAUER S, 1995, HUM GENET, V96, P562, DOI 10.1007/BF00197412; Segel I. H., 1975, ENZYME KINETICS BEHA, P505; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; Steyaert J, 1996, AM J MED GENET, V64, P274, DOI 10.1002/(SICI)1096-8628(19960809)64:2<274::AID-AJMG8>3.0.CO;2-U; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; Wells R.D., 1988, UNUSUAL DNA STRUCTUR; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287; Yeshaya J, 1999, HUM GENET, V105, P86, DOI 10.1007/s004390051068; Yeshaya J, 1998, HUM GENET, V102, P6, DOI 10.1007/s004390050647; Yoder JA, 1998, HUM MOL GENET, V7, P279, DOI 10.1093/hmg/7.2.279; ZHENG GX, 1991, J MOL BIOL, V221, P107, DOI 10.1016/0022-2836(91)80208-C; Zimmermann C, 1997, BIOL CHEM, V378, P393, DOI 10.1515/bchm.1997.378.5.393	71	53	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18605	18613		10.1074/jbc.M100404200	http://dx.doi.org/10.1074/jbc.M100404200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11359795	hybrid			2022-12-25	WOS:000168866500131
J	Saeger, B; Schmitt-Wrede, HP; Dehnhardt, M; Benten, WPM; Krucken, J; Harder, A; Von Samson-Himmelstjerna, G; Wiegand, H; Wunderlich, F				Saeger, B; Schmitt-Wrede, HP; Dehnhardt, M; Benten, WPM; Krucken, J; Harder, A; Von Samson-Himmelstjerna, G; Wiegand, H; Wunderlich, F			Latrophilin-like receptor from the parasitic nematode Haemonchus contortus as target for the anthelmintic depsipeptide PF1022A	FASEB JOURNAL			English	Article									Univ Dusseldorf, Div Mol Parasitol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Ctr Biol & Med Res, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Med Inst Environm Hyg, D-40225 Dusseldorf, Germany; Bayer AG, Biol Technol Ctr, Res & Dev, Business Grp Anim Hlth, D-51368 Leverkusen, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Bayer AG	Wunderlich, F (corresponding author), Univ Dusseldorf, Div Mol Parasitol, Univ Str 1, D-40225 Dusseldorf, Germany.		Krücken, Jürgen/AAE-3133-2021; Krücken, Jürgen/B-6794-2009; Krücken, Jürgen/CAF-6903-2022; Schmitt-Wrede, Hans-Peter/ABD-6206-2021; von Samson, Georg/R-1123-2016	Krücken, Jürgen/0000-0002-2842-8100; Krücken, Jürgen/0000-0002-2842-8100; Krücken, Jürgen/0000-0002-2842-8100; 					0	65	69	3	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1332	1334		10.1096/fj.00-0664fje	http://dx.doi.org/10.1096/fj.00-0664fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344131				2022-12-25	WOS:000168655200053
J	Wuttge, DM; Romert, A; Eriksson, U; Torma, H; Hansson, GK; Sirsjo, A				Wuttge, DM; Romert, A; Eriksson, U; Torma, H; Hansson, GK; Sirsjo, A			Induction of CD36 by all-trans retinoic acid: retinoic acid receptor signaling in the pathogenesis of atherosclerosis	FASEB JOURNAL			English	Article									Karolinska Inst, Ctr Mol Med, Stockholm, Sweden; Karolinska Inst, Dept Med, Stockholm, Sweden; Ludwig Inst Canc Res, Stockholm Branch, S-10401 Stockholm, Sweden; Univ Uppsala Hosp, Dept Med Sci, Dermatol Sect, Uppsala, Sweden	Karolinska Institutet; Karolinska Institutet; Ludwig Institute for Cancer Research; Uppsala University; Uppsala University Hospital	Sirsjo, A (corresponding author), Karolinska Hosp, Ctr Mol Med, Cardiovasc Res Unit, S-17176 Stockholm, Sweden.		Hansson, Goran K/B-7423-2012; Törmä, Hans/F-8152-2011	Törmä, Hans/0000-0002-3617-8551; Hansson, Goran/0000-0003-4148-5190					0	35	35	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1221	1223		10.1096/fj.00-0488fje	http://dx.doi.org/10.1096/fj.00-0488fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344094				2022-12-25	WOS:000168655200016
J	Brooks, DG; James, RM; Patek, CE; Williamson, J; Arends, MJ				Brooks, DG; James, RM; Patek, CE; Williamson, J; Arends, MJ			Mutant K-ras enhances apoptosis in embryonic stem cells in combination with DNA damage and is associated with increased levels of p19(ARF)	ONCOGENE			English	Article						K-ras; DNA damage; ES cells; apoptosis	ONCOGENIC RAS; N-RAS; TUMOR SUPPRESSION; MATRIX ADHESION; PLASMA-MEMBRANE; C-MYC; P53; ACTIVATION; TRANSFORMATION; KINASE	The roles of K-ras in neoplasia are not entirely understood, although there is evidence that K-ras affects susceptibility to apoptosis, modulating survival of DNA damaged cells which would otherwise be eliminated. In this study, we investigated the effects of mutant K-ras on apoptosis in vitro following DNA damage. To avoid complications resulting from mutations in other cancer-related genes and from the presence of endogenous K-ras, we derived K-ras null embryonic stem cells. Expression of either wild-type or mutant K-vas was reconstructed by stable plasmid transfection, The cell lines were treated with etoposide, cisplatin and UV radiation and apoptosis measured flow cytometrically. Mutant K-ras potentiated the effect of etoposide-derived DNA damage by increasing apoptosis, whereas absence of K-ras had the opposite effect. This pattern was similar but less marked with cisplatin, whereas UV yielded no difference in apoptosis with regard to K-ras status, suggesting that the effect of K-ras on apoptosis is dependent on the nature of the DNA damage, To investigate possible mechanisms, we examined the expression of p19(ARF) mRNA by RT-PCR, Cells expressing mutant K-ras produced elevated levels of p19(ARF) mRNA, which could link K-ras status with p53 expression and hence susceptibility to DNA damage-induced apoptosis.	Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Cambridge CB2 2QQ, England; Univ Edinburgh, Mol Med Ctr, Sir Alastair Currie CRC Labs, Edinburgh EH4 2XU, Midlothian, Scotland	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Edinburgh	Arends, MJ (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Hills Rd, Cambridge CB2 2QQ, England.							Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; ARENDS MJ, 1994, AM J PATHOL, V144, P1045; ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; BREIVIK J, 1994, BRIT J CANCER, V69, P367, DOI 10.1038/bjc.1994.67; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; Chang MY, 1999, EXP CELL RES, V248, P589, DOI 10.1006/excr.1999.4436; CHEN F, 1994, PROCESS BIOCHEM, V29, P245, DOI 10.1016/0032-9592(94)80064-2; Chen G, 1997, ONCOGENE, V15, P1643, DOI 10.1038/sj.onc.1201347; Corbet SW, 1999, ONCOGENE, V18, P1537, DOI 10.1038/sj.onc.1202436; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Koo HM, 1999, JNCI-J NATL CANCER I, V91, P236, DOI 10.1093/jnci/91.3.236; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MacKenzie KL, 1999, BLOOD, V93, P2043, DOI 10.1182/blood.V93.6.2043.406k17_2043_2056; Magee T, 1999, CELL, V98, P9, DOI 10.1016/S0092-8674(00)80601-7; McGill G, 1997, J CELL BIOL, V138, P901, DOI 10.1083/jcb.138.4.901; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; Navarro P, 1999, J BIOL CHEM, V274, P18857, DOI 10.1074/jbc.274.27.18857; Oliff A, 1999, BBA-REV CANCER, V1423, pC19, DOI 10.1016/S0304-419X(99)00007-4; Orecchia R, 2000, J PATHOL, V190, P423; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Peli J, 1999, EMBO J, V18, P1824, DOI 10.1093/emboj/18.7.1824; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; REIHSAUS E, 1990, ONCOGENE, V5, P137; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; Vater CA, 1996, ONCOGENE, V13, P739; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Wolfman JC, 2000, J BIOL CHEM, V275, P19315, DOI 10.1074/jbc.M000250200; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	46	29	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2001	20	17					2144	2152		10.1038/sj.onc.1204309	http://dx.doi.org/10.1038/sj.onc.1204309			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360198				2022-12-25	WOS:000168116700009
J	Wasmeier, C; Hutton, JC				Wasmeier, C; Hutton, JC			Secretagogue-dependent phosphorylation of the insulin granule membrane protein phogrin is mediated by cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; ALPHA-AMIDATING MONOOXYGENASE; TYROSINE-PHOSPHATASE HOMOLOG; GLUCAGON-LIKE PEPTIDE-1; SECRETORY GRANULES; CYTOSOLIC DOMAIN; SYNAPSIN-I; EXOCYTOSIS; ACTIVATION; CALCIUM	Phogrin, a 60/64-kDa integral membrane protein of dense-core granules in neuroendocrine cells, is phosphorylated in a Ca2+-sensitive manner in response to secretagogue stimulation of pancreatic beta -cells. Phosphorylation of the phogrin cytosolic domain by beta -cell homogenates was Ca2+-independent but stimulated by cAMP. Recombinant protein kinase A (PKA) could phosphorylate phogrin directly. High performance liquid chromatography analysis of tryptic phosphopeptides, combined with site-directed mutagenesis of candidate sites, revealed the presence of two phosphorylation sites at Ser-680 and Thr-699, located in the juxtamembrane region between the transmembrane span and the protein-tyrosine phosphatase homology domain of phogrin. Full-length wild-type phogrin, as well as mutant versions where Ser-680 and Thr-699 had been replaced either by alanines or by aspartic acid residues, were targeted to secretory granules in transfected AtT20 neuroendocrine cells. Stimulation of these cells with a range of secretagogues, including K+, BaCl2, and forskolin, demonstrated that the in vivo phosphorylation sites are the same as those identified in vitro. In MIN6 beta -cells, the PKA inhibitor H-89 prevented Ca2+-dependent phogrin phosphorylation in response to glucose, suggesting that Ca2+ exerts its effect on phogrin phosphorylation through regulating the activity of PKA.	Univ Colorado, Hlth Sci Ctr, Barbara Davis Ctr Childhood Diabet, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Hutton, JC (corresponding author), Univ Colorado, Hlth Sci Ctr, Barbara Davis Ctr Childhood Diabet, 4200 E 9th Ave, Denver, CO 80262 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052068, R56DK052068, P30DK057516, R01DK055597] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 57516-02, DK 52068-02, DK 55597-02] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMMALA C, 1993, NATURE, V363, P356, DOI 10.1038/363356a0; AMMALA C, 1994, P NATL ACAD SCI USA, V91, P4343, DOI 10.1073/pnas.91.10.4343; ASHCROFT SJH, 1994, DIABETOLOGIA, V37, pS21, DOI 10.1007/BF00400822; Bhatt HS, 2000, BIOCHEM PHARMACOL, V60, P1655, DOI 10.1016/S0006-2952(00)00483-4; Brandon EP, 1997, CURR OPIN NEUROBIOL, V7, P397, DOI 10.1016/S0959-4388(97)80069-4; Easom RA, 1999, DIABETES, V48, P675, DOI 10.2337/diabetes.48.4.675; Eliasson L, 1997, J PHYSIOL-LONDON, V503, P399, DOI 10.1111/j.1469-7793.1997.399bh.x; GROMADA J, 1995, DIABETES, V44, P767, DOI 10.2337/diabetes.44.7.767; Gromada J, 1998, PFLUG ARCH EUR J PHY, V435, P583, DOI 10.1007/s004240050558; Guenifi A, 2000, HISTOCHEM CELL BIOL, V113, P81, DOI 10.1007/s004180050010; Hisatomi M, 1996, ENDOCRINOLOGY, V137, P4644, DOI 10.1210/en.137.11.4644; HOLZ GG, 1993, NATURE, V361, P362, DOI 10.1038/361362a0; HOLZ GG, 1995, J BIOL CHEM, V270, P17749, DOI 10.1074/jbc.270.30.17749; HOWELL SL, 1994, DIABETOLOGIA, V37, P30; Jones PM, 1998, ENDOCR REV, V19, P429, DOI 10.1210/er.19.4.429; Krueger KA, 1999, DIABETES, V48, P499, DOI 10.2337/diabetes.48.3.499; Krueger KA, 1997, J BIOL CHEM, V272, P27464, DOI 10.1074/jbc.272.43.27464; Lang JC, 1999, EUR J BIOCHEM, V259, P3, DOI 10.1046/j.1432-1327.1999.00043.x; Lester LB, 1997, P NATL ACAD SCI USA, V94, P14942, DOI 10.1073/pnas.94.26.14942; LIDA Y, 1997, AM J PHYSIOL, V273, pE782; MATSUMOTO K, 1995, ENDOCRINOLOGY, V136, P3784, DOI 10.1210/en.136.9.3784; METZ SA, 1988, DIABETES, V37, P3, DOI 10.2337/diabetes.37.1.3; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; PEARSON RB, 1992, PROTEIN PHOSPHORYLAT, P265; Pouli AE, 1998, BIOCHEM J, V333, P193, DOI 10.1042/bj3330193; RAJAN AS, 1990, DIABETES CARE, V13, P340, DOI 10.2337/diacare.13.3.340; RAJAN AS, 1989, DIABETES, V38, P874, DOI 10.2337/diabetes.38.7.874; Renstrom E, 1997, J PHYSIOL-LONDON, V502, P105, DOI 10.1111/j.1469-7793.1997.105bl.x; Steveson TC, 1999, J BIOL CHEM, V274, P21128, DOI 10.1074/jbc.274.30.21128; Takahashi N, 1999, P NATL ACAD SCI USA, V96, P760, DOI 10.1073/pnas.96.2.760; Thorens B, 1996, J BIOL CHEM, V271, P8075, DOI 10.1074/jbc.271.14.8075; Wasmeier C, 1999, BIOCHEM J, V341, P563, DOI 10.1042/0264-6021:3410563; Wasmeier C, 1996, J BIOL CHEM, V271, P18161, DOI 10.1074/jbc.271.30.18161; WENHAM RM, 1994, J BIOL CHEM, V269, P4947; Xia ZG, 1997, CURR OPIN NEUROBIOL, V7, P391, DOI 10.1016/S0959-4388(97)80068-2; Yaekura K, 1996, DIABETES, V45, P295, DOI 10.2337/diabetes.45.3.295; YUN HY, 1995, J BIOL CHEM, V270, P30075	37	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31919	31928		10.1074/jbc.M102580200	http://dx.doi.org/10.1074/jbc.M102580200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11353772	hybrid			2022-12-25	WOS:000170613500063
J	Xu, Y; Potapova, O; Leschziner, AE; Grindley, NDF; Joyce, CM				Xu, Y; Potapova, O; Leschziner, AE; Grindley, NDF; Joyce, CM			Contacts between the 5 ' nuclease of DNA polymerase I and its DNA substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FLAP ENDONUCLEASE-1; BACTERIOPHAGE-T4 RNASE-H; SINGLE-STRANDED-DNA; CALF RTH-1 NUCLEASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; 5'-NUCLEASE DOMAIN; KLENOW FRAGMENT; EXONUCLEASE; REPLICATION	The 5 ' nuclease of DNA polymerase I (Pol I) of Escherichia coli is a member of an important class of prokaryotic and eukaryotic nucleases, involved in DNA replication and repair, with specificity for the junction between single-stranded and duplex DNA. We have investigated the interaction of the 5 ' nuclease domain with DNA substrates from the standpoint of both the protein and the DNA. Phosphate ethylation interference showed that the nuclease binds to the nucleotides immediately surrounding the cleavage site and also contacts the complementary strand one-half turn away, indicating that contacts are made to one face only of the duplex portion of the DNA substrate. Phosphodiester contacts were investigated further using DNA substrates carrying unique methylphosphonate substitutions, together with mutations in the 5 ' nuclease. These experiments suggested that two highly conserved basic residues, Lys(78) and Arg(81), are close to the phosphodiester immediately 5 ' to the cleavage site, while a third highly conserved residue, Arg(20), may interact with the phosphodiester 3 ' to the cleavage site. Our results provide strong support for a DNA binding model proposed for the related exonuclease from bacteriophage T5, in which the conserved basic residues mentioned above define the two ends of a helical arch that forms part of the single-stranded DNA-binding region. The nine highly conserved carboxylates in the active site region appear to play a relatively minor role in substrate binding, although they are crucial for catalysis. In addition to binding the DNA backbone around the cleavage point, the 5 ' nuclease also has a binding site for one or two frayed bases at the 3 ' end of an upstream primer strand. In agreement with work in related systems, 5 ' nuclease cleavage is blocked by duplex DNA in the 5 ' tag, but the enzyme is quite tolerant of abasic DNA or polarity reversal within the 5 ' tail.	Yale Univ, Dept Mol Biophys & Biochem, Bass Ctr Mol & Struct Biol, New Haven, CT 06520 USA	Yale University	Joyce, CM (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, Bass Ctr Mol & Struct Biol, 266 Whitney Ave,POB 208114, New Haven, CT 06520 USA.	catherine.joyce@yale.edu		Leschziner, Andres/0000-0002-7732-7023	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019025, R01GM028550] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-19025, GM-28550] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTAO VP, 1992, NUCLEIC ACIDS RES, V20, P819, DOI 10.1093/nar/20.4.819; ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Bhagwat M, 1997, J BIOL CHEM, V272, P28523, DOI 10.1074/jbc.272.45.28523; Bhagwat M, 1997, J BIOL CHEM, V272, P28531, DOI 10.1074/jbc.272.45.28531; Bornarth CJ, 1999, BIOCHEMISTRY-US, V38, P13347, DOI 10.1021/bi991321u; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; Garforth SJ, 1999, P NATL ACAD SCI USA, V96, P38, DOI 10.1073/pnas.96.1.38; GUTMAN PD, 1993, NUCLEIC ACIDS RES, V21, P4406, DOI 10.1093/nar/21.18.4406; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Huang L, 1996, BIOCHEMISTRY-US, V35, P9266, DOI 10.1021/bi9603074; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Kaplan DL, 2000, J MOL BIOL, V301, P285, DOI 10.1006/jmbi.2000.3965; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Kornberg A., 1992, DNA REPLICATION; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; LONGLEY MJ, 1990, NUCLEIC ACIDS RES, V18, P7317, DOI 10.1093/nar/18.24.7317; LUNDQUIST RC, 1982, CELL, V31, P53, DOI 10.1016/0092-8674(82)90404-4; Lyamichev V, 1999, P NATL ACAD SCI USA, V96, P6143, DOI 10.1073/pnas.96.11.6143; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MERKENS LS, 1995, BBA-GENE STRUCT EXPR, V1264, P243, DOI 10.1016/0167-4781(95)00153-8; Mizrahi V, 1996, NUCLEIC ACIDS RES, V24, P4845, DOI 10.1093/nar/24.24.4845; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; Murante RS, 1996, J BIOL CHEM, V271, P25888, DOI 10.1074/jbc.271.42.25888; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Pickering TJ, 1999, NUCLEIC ACIDS RES, V27, P730, DOI 10.1093/nar/27.3.730; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; Riggs MG, 1996, BBA-GENE STRUCT EXPR, V1307, P178, DOI 10.1016/0167-4781(96)00051-6; RIMPHANITCHAYAK.V, 1991, LAB GUIDE IN VITRO S, V5, P111; ROBINS P, 1994, J BIOL CHEM, V269, P28535; Sayers JR, 1998, NAT STRUCT BIOL, V5, P668, DOI 10.1038/1358; Setlow P, 1974, Methods Enzymol, V29, P3; Shafritz KM, 1998, NUCLEIC ACIDS RES, V26, P2593, DOI 10.1093/nar/26.11.2593; Shen BH, 1998, TRENDS BIOCHEM SCI, V23, P171, DOI 10.1016/S0968-0004(98)01199-2; Shen BH, 1997, NUCLEIC ACIDS RES, V25, P3332, DOI 10.1093/nar/25.16.3332; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; WISSMANN A, 1991, METHOD ENZYMOL, V208, P365; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; Xu Y, 1997, J MOL BIOL, V268, P284, DOI 10.1006/jmbi.1997.0967; Xu Y, 2000, J BIOL CHEM, V275, P20949, DOI 10.1074/jbc.M909135199	52	30	32	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30167	30177		10.1074/jbc.M100985200	http://dx.doi.org/10.1074/jbc.M100985200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11349126	hybrid			2022-12-25	WOS:000170558000076
J	Chan, SW; Hong, WJ				Chan, SW; Hong, WJ			Retinoblastoma-binding protein 2 (Rbp2) potentiates nuclear hormone receptor-mediated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE; GENE-PRODUCT; CELL-CYCLE; COACTIVATOR; COMPLEX; ACTIVATION; REPRESSION; SEQUENCE; CBP; IDENTIFICATION	Retinoblastoma-binding protein 2 (Rbp2) was originally identified as a retinoblastoma protein (RB) pocket domain-binding protein. Although Rbp2 has been shown to interact with RB, p107, TATA-binding protein, and T-cell oncogene rhombotin-2, the physiological function of Rbp2 remains unclear. Here we demonstrate that Rbp2 not only binds to nuclear receptors (NRs) but also enhances the transcription mediated by them. Rbp2 interacts with the DNA-binding domains of NRs and potentiates NR-mediated transcription in an AF-2-dependent manner. Both the N-terminal and C-terminal domains of Rbp2 are critical for the transactivation activity of Rbp2 on NRs. The C terminus is the NR-interacting region. In addition, RB functions in maximizing the effect of Rbp2 on the transcription by NRs. These results suggest that Rbp2 is a coregulator of NRs and define a potential role for Rbp2 in NR-mediated transcription.	Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Hong, WJ (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.		HONG, Wanjin/E-9927-2010					AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; Dallas PB, 2000, MOL CELL BIOL, V20, P3137, DOI 10.1128/MCB.20.9.3137-3146.2000; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; FATTAEY AR, 1993, ONCOGENE, V8, P3149; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Gregory SL, 1996, MOL CELL BIOL, V16, P792; Heery DM, 2001, J BIOL CHEM, V276, P6695, DOI 10.1074/jbc.M009404200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HUANG HJ, 1998, SCIENCE, V242, P1563; Ichinose H, 1997, GENE, V188, P95, DOI 10.1016/S0378-1119(96)00785-8; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KIM YW, 1994, MOL CELL BIOL, V14, P7256, DOI 10.1128/MCB.14.11.7256; Kortschak RD, 2000, TRENDS BIOCHEM SCI, V25, P294, DOI 10.1016/S0968-0004(00)01597-8; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Lowe SL, 1997, NATURE, V389, P881, DOI 10.1038/39923; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mao SF, 1997, ONCOGENE, V14, P1531, DOI 10.1038/sj.onc.1200988; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; ONATE SA, 1995, SCIENCE, V270, P1354; OTTERSON GA, 1993, ONCOGENE, V8, P949; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; Singh P, 2001, J BIOL CHEM, V276, P13762, DOI 10.1074/jbc.M100137200; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Takemaru K, 1997, P NATL ACAD SCI USA, V94, P7251, DOI 10.1073/pnas.94.14.7251; TAVOSIAN SG, 1997, GENE DEV, V11, P383; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; VOEGEL JJ, 1996, EMBO J, V15, P8667; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	50	65	69	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28402	28412		10.1074/jbc.M100313200	http://dx.doi.org/10.1074/jbc.M100313200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11358960	hybrid			2022-12-25	WOS:000170093400088
J	Chen, S; Zhou, DJ; Yang, C; Sherman, M				Chen, S; Zhou, DJ; Yang, C; Sherman, M			Molecular basis for the constitutive activity of estrogen-related receptor alpha-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN RECEPTOR; IDENTIFICATION; ANTAGONISM; ASSAY	Some orphan nuclear receptors, including estrogen-related receptor alpha -1 (ERR alpha -1), can activate gene transcription in a constitutive manner. Little is known about the molecular basis of the constitutive activity of these receptors. Our results from site-directed mutagenesis experiments have revealed that Phe-329 (analogous to Ala-350 in estrogen receptor alpha (ER alpha)) is responsible for the constitutive activity of ERR alpha -1. The ERR alpha -1 mutant F329A lost the transactivation activity and acted as a dominant negative mutant. The mammalian cell transfection experiments revealed that the ERR alpha -1 mutant F329A, like wild-type ER alpha, recognized toxaphene (an organochlorine pesticide) as an agonist. This compound was previously shown to be an antagonist of wild-type ERR alpha -1. On the other hand, like wild-type ERR alpha -1, the ER alpha mutant A350F was found to be constitutively active (as demonstrated by mammalian cell transfection and yeast two-hybrid assays). These results indicate that Phe-329 in ERR alpha -1 and Ala-350 in ER alpha play important roles in both ligand binding and transactivation function.	City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope	Chen, S (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA.				NCI NIH HHS [CA44735] Funding Source: Medline; NIEHS NIH HHS [ES08258] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008258] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BLUNDELL TL, 1987, NATURE, V326, P347, DOI 10.1038/326347a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Norris JD, 1997, MOL ENDOCRINOL, V11, P747, DOI 10.1210/me.11.6.747; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P705; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.1289/ehp.95103s7113; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; Vanacker JM, 1999, MOL ENDOCRINOL, V13, P764, DOI 10.1210/me.13.5.764; Yang C, 1999, CANCER RES, V59, P4519; Yang C, 1998, CANCER RES, V58, P5695	14	58	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28465	28470		10.1074/jbc.M102638200	http://dx.doi.org/10.1074/jbc.M102638200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11356845	hybrid			2022-12-25	WOS:000170093400096
J	El-Fasakhany, FM; Uchimura, K; Kannagi, R; Muramatsu, T				El-Fasakhany, FM; Uchimura, K; Kannagi, R; Muramatsu, T			A novel human Gal-3-O-sulfotransferase - Molecular cloning, characterization, and its implication in biosynthesis of (SO4-3)Gal beta 1-4(Fuc alpha 1-3)GlcNAc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-SELECTIN LIGAND; HIGH ENDOTHELIAL VENULES; CARBOHYDRATE UNITS; SULFOTRANSFERASE; EXPRESSION; SPECIFICITIES; RESIDUES; SULFATE; CDNA; IDENTIFICATION	Based on sequence homology with the previously cloned human cerebroside sulfotransferase (CST) cDNA, a novel sulfotransferase was cloned by screening a human fetal brain cDNA library. The novel sulfotransferase gene was present on human chromosome 11q13; the location was different from human CST and from that of the recently cloned human beta -Gal 3'-sulfotransferase (GP3ST). The isolated cDNA contained an open reading frame that encoded a predicted protein of 431 amino acid residues with type II transmembrane topology. The amino acid sequence showed 33% identity with that of human CST and 38% with that of human GP3ST. The recombinant enzyme expressed in Chinese hamster ovary cells catalyzed transfer of sulfate to position 3 of non-reducing beta -galactosyl residues in Gal beta1-4GlcNAc. Type 2 chains served as good accepters, whereas type 1 chains served as poor accepters, and intermediate activity was found toward Gal beta1-3GalNAc. Therefore, the substrate specificity was different from that of GP3ST. CST activity was not detected in the newly cloned enzyme. Northern blotting analysis showed that the sulfotransferase mRNA was strongly expressed in the thyroid and moderately expressed in the brain, heart, kidney, and spinal cord. Co-transfection of the enzyme cDNA and fucosyltransferase III into COS-7 cells resulted in expression of (SO4-3) Gal beta1- 4(Fuc alpha1-3) GlcNAc and a small amount of (SO4-3) Gal beta1-3(Fuc alpha1-4)GlcNAc. These results indicated that the newly cloned enzyme is a novel Gal-3-O-sulfotransferase and is involved in biosynthesis of the (SO4-3)Gal beta1-4(Fuc alpha1-3)GlcNAc structure.	Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, Nagoya, Aichi 4668550, Japan; Aichi Canc Ctr, Res Inst, Program Expt Pathol, Nagoya, Aichi 4648681, Japan	Nagoya University; Aichi Cancer Center	Uchimura, K (corresponding author), Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	ihcu@med.nagoya-u.ac.jp	Uchimura, Kenji/AFV-1802-2022; Kannagi, Reiji/Q-6459-2018; Uchimura, Kenji/C-9635-2014	Uchimura, Kenji/0000-0003-3009-248X; Kannagi, Reiji/0000-0003-4202-2921; Uchimura, Kenji/0000-0003-3009-248X				Akama TO, 2000, NAT GENET, V26, P237, DOI 10.1038/79987; Altschul Stephen F., J MOL BIOL, V215, P403, DOI [10.1016/S0022-2836(05)80360-2, DOI 10.1016/S0022-2836(05)80360-2]; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Chai WG, 1997, GLYCOBIOLOGY, V7, P861, DOI 10.1093/glycob/7.6.861; Chandrasekaran EV, 1997, GLYCOBIOLOGY, V7, P753, DOI 10.1093/glycob/7.6.753; Chandrasekaran EV, 1999, GLYCOCONJUGATE J, V16, P523, DOI 10.1023/A:1007074005371; ENDO A, 1995, CARBOHYD RES, V270, pC9, DOI 10.1016/0008-6215(95)00112-7; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; Galustian C, 1999, J BIOL CHEM, V274, P18213, DOI 10.1074/jbc.274.26.18213; GOLDSTEIN I. J., 1965, METHOD CARBOHYD CHEM, V5, P361; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; Habuchi O, 2000, BBA-GEN SUBJECTS, V1474, P115, DOI 10.1016/S0304-4165(00)00016-7; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; Honke K, 1997, J BIOL CHEM, V272, P4864, DOI 10.1074/jbc.272.8.4864; Honke K, 2001, J BIOL CHEM, V276, P267, DOI 10.1074/jbc.M005666200; Hooper LV, 1996, FASEB J, V10, P1137, DOI 10.1096/fasebj.10.10.8751716; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; KATO Y, 1989, J BIOL CHEM, V264, P3364; KAWANO M, 1989, ANAL BIOCHEM, V182, P9, DOI 10.1016/0003-2697(89)90709-4; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUHNS W, 1995, GLYCOBIOLOGY, V5, P689, DOI 10.1093/glycob/5.7.689; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; Lee JK, 1999, BIOCHEM BIOPH RES CO, V263, P543, DOI 10.1006/bbrc.1999.1324; LOGUIDICE JM, 1994, J BIOL CHEM, V269, P18794; LOGUIDICE JM, 1995, J BIOL CHEM, V270, P27544, DOI 10.1074/jbc.270.46.27544; Mitsuoka C, 1997, BIOCHEM BIOPH RES CO, V230, P546, DOI 10.1006/bbrc.1996.6012; Mitsuoka C, 1997, BIOCHEM BIOPH RES CO, V233, P576, DOI 10.1006/bbrc.1997.6463; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; Muramatsu T, 2000, J BIOCHEM, V127, P171, DOI 10.1093/oxfordjournals.jbchem.a022590; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NUMOMURA S, 1994, CARBOHYD RES, V263, pC1, DOI 10.1016/0008-6215(94)00264-9; OBAMA H, 1995, GLYCOCONJUGATE J, V12, P795, DOI 10.1007/BF00731241; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Rosen SD, 1999, AM J PATHOL, V155, P1013, DOI 10.1016/S0002-9440(10)65201-7; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; SPIRO RG, 1988, J BIOL CHEM, V263, P14351; SUZUKI A, 2001, J BIOL CHEM; Uchimura K, 2000, BIOCHEM BIOPH RES CO, V274, P291, DOI 10.1006/bbrc.2000.3141; Uchimura K, 1998, J BIOL CHEM, V273, P22577, DOI 10.1074/jbc.273.35.22577; Veerman ECI, 1997, GLYCOBIOLOGY, V7, P37, DOI 10.1093/glycob/7.1.37; WESTON BW, 1992, J BIOL CHEM, V267, P4152; YUEN CT, 1994, J BIOL CHEM, V269, P1595	42	22	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26988	26994		10.1074/jbc.M100348200	http://dx.doi.org/10.1074/jbc.M100348200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356829	hybrid			2022-12-25	WOS:000169966900035
J	Grimme, SJ; Westfall, BA; Wiedman, JM; Taron, CH; Orlean, P				Grimme, SJ; Westfall, BA; Wiedman, JM; Taron, CH; Orlean, P			The essential Smp3 protein is required for addition of the side-branching fourth mannose during assembly of yeast glycosylphosphatidylinositols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHOR BIOSYNTHESIS; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; MEMBRANE ANCHORS; 3RD MANNOSE; FIRST STEP; TRANSFERRING PHOSPHOETHANOLAMINE; PLASMODIUM-FALCIPARUM; MAMMALIAN-CELLS; CORE STRUCTURE	The major glycosylphosphatidylinositols (GPIs) transferred to protein in mammals and trypanosomes contain three mannoses, In Saccharomyces cerevisiae, however, the GPI transferred to protein bears a fourth, alpha1,2-linked Man on the alpha1,2-Man that receives the phosphoethanolamine (EthN-P) moiety through which GPIs become linked to protein. We report that temperature-sensitive smp3 mutants accumulate a GPI containing three mannoses and that smp3 is epistatic to the gpi11, gpi13, and gaa1 mutations, which normally result in the accumulation of Man(4)-GPIs, including the presumed substrate for the yeast GPI transamidase. The Smp3 protein, which is encoded by an essential gene, is therefore required for addition of the fourth Man to yeast GPI precursors. The finding that smp3 prevents the formation of the Man(4)-GPI that accumulates when addition of EthN-P to Man-3 is blocked in a gpi13 mutant suggests that the presence of the fourth Man is important for transfer of EthN-P to Man-3 of yeast GPIs, The Man(3)-GPI that accumulates in smp3 is a mixture of two dominant isoforms, one bearing a single EthN-P side branch on Man-1, the other with EthN-P on Man-2, and these isoforms can be placed in separate arms of a branched GPI assembly pathway. Smp3-related proteins are encoded in the genomes of Schizosaccharomyces pombe, Candida albicans, Drosophila melanogaster, and Homo sapiens and form a subgroup of a family of proteins, the other groups of which are defined by the Pig-B(Gpi10) protein, which adds the third GPI mannose, and by the Alg9 and Alg12 proteins, which act in the dolichol pathway for N-glycosylation, Because Man(4)-containing GPI precursors are normally formed in yeast and Plasmodium falciparum, whereas addition of a fourth Man during assembly of mammalian GPIs is rare and not required for GPI transfer to protein, Smp3p-dependent addition of a fourth Man represents a target for antifungal and antimalarial drugs.	Univ Illinois, Dept Biochem, Roger Adams Lab 309, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Orlean, P (corresponding author), Univ Illinois, Dept Biochem, Roger Adams Lab 309, 606 S Mathews Ave, Urbana, IL 61801 USA.	p-orlean@uiuc.edu		Taron, Christopher/0000-0001-8149-4556	NIGMS NIH HHS [GM46220] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046220] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Benachour A, 1999, J BIOL CHEM, V274, P15251, DOI 10.1074/jbc.274.21.15251; BENGHEZAL M, 1995, J CELL BIOL, V130, P1333, DOI 10.1083/jcb.130.6.1333; BREWIS IA, 1995, J BIOL CHEM, V270, P22946, DOI 10.1074/jbc.270.39.22946; Burda P, 1999, GLYCOBIOLOGY, V9, P617, DOI 10.1093/glycob/9.6.617; Canivenc-Gansel E, 1998, GLYCOBIOLOGY, V8, P761, DOI 10.1093/glycob/8.8.761; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Colussi PA, 1997, YEAST, V13, P139, DOI 10.1002/(SICI)1097-0061(199702)13:2<139::AID-YEA69>3.3.CO;2-J; FANKHAUSER C, 1993, J BIOL CHEM, V268, P26365; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Ferguson MAJ, 1999, BBA-MOL BASIS DIS, V1455, P327, DOI 10.1016/S0925-4439(99)00058-7; Flury I, 2000, J BIOL CHEM, V275, P24458, DOI 10.1074/jbc.M003844200; Fujii T, 1999, BBA-GEN SUBJECTS, V1427, P133, DOI 10.1016/S0304-4165(99)00012-4; Gaynor EC, 1999, MOL BIOL CELL, V10, P627, DOI 10.1091/mbc.10.3.627; GEROLD P, 1994, J BIOL CHEM, V269, P2597; GERRING SL, 1990, EMBO J, V9, P4347, DOI 10.1002/j.1460-2075.1990.tb07884.x; HAMBURGER D, 1995, J CELL BIOL, V129, P629, DOI 10.1083/jcb.129.3.629; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; Hong Y, 2000, J BIOL CHEM, V275, P20911, DOI 10.1074/jbc.M001913200; Hong YJ, 1999, J BIOL CHEM, V274, P35099, DOI 10.1074/jbc.274.49.35099; Ilgoutz SC, 1999, EMBO J, V18, P2746, DOI 10.1093/emboj/18.10.2746; INOUE N, 1993, J BIOL CHEM, V268, P6882; IRIE K, 1991, MOL GEN GENET, V225, P257, DOI 10.1007/BF00269857; KAMITANI T, 1992, J BIOL CHEM, V267, P24611; Kawagoe K, 1996, BLOOD, V87, P3600, DOI 10.1182/blood.V87.9.3600.bloodjournal8793600; LEIDICH SD, 1994, J BIOL CHEM, V269, P10193; Leidich SD, 1996, J BIOL CHEM, V271, P27829, DOI 10.1074/jbc.271.44.27829; Lipke PN, 1998, J BACTERIOL, V180, P3735, DOI 10.1128/JB.180.15.3735-3740.1998; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; McConville MJ, 2000, MOL MEMBR BIOL, V17, P1; MOHNEY RP, 1994, J BIOL CHEM, V269, P6536; Nagamune K, 2000, P NATL ACAD SCI USA, V97, P10336, DOI 10.1073/pnas.180230697; Naik RS, 2000, J BIOL CHEM, V275, P24506, DOI 10.1074/jbc.M002151200; NUOFFER C, 1993, J BIOL CHEM, V268, P10558; Ohishi K, 2000, MOL BIOL CELL, V11, P1523, DOI 10.1091/mbc.11.5.1523; Orlean P., 1997, MOL CELLULAR BIOL YE, V21, P229; PUOTI A, 1993, J BIOL CHEM, V268, P7215; PUOTI A, 1992, J BIOL CHEM, V267, P22673; SCHNEIDER P, 1995, METHOD ENZYMOL, V250, P614; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIPOS G, 1994, EMBO J, V13, P2789, DOI 10.1002/j.1460-2075.1994.tb06572.x; Smith TK, 1997, EMBO J, V16, P6667, DOI 10.1093/emboj/16.22.6667; STEVENS VL, 1995, BIOCHEM J, V310, P361, DOI 10.1042/bj3100361; Sutterlin C, 1998, BIOCHEM J, V332, P153; Sutterlin C, 1997, EMBO J, V16, P6374, DOI 10.1093/emboj/16.21.6374; Takahashi M, 1996, EMBO J, V15, P4254, DOI 10.1002/j.1460-2075.1996.tb00800.x; TAKEDA J, 1995, TRENDS BIOCHEM SCI, V20, P367, DOI 10.1016/S0968-0004(00)89078-7; Taron CH, 2000, MOL BIOL CELL, V11, P1611, DOI 10.1091/mbc.11.5.1611; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tiede A, 1999, BIOL CHEM, V380, P503, DOI 10.1515/BC.1999.066; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; UEDA E, 1993, J BIOL CHEM, V268, P9998; Watanabe R, 1998, EMBO J, V17, P877, DOI 10.1093/emboj/17.4.877; ZIELER HA, 1995, MOL CELL BIOL, V15, P3227	56	57	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27731	27739		10.1074/jbc.M101986200	http://dx.doi.org/10.1074/jbc.M101986200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356840	hybrid			2022-12-25	WOS:000169966900131
J	Park, K; Evans, RL; Watson, GE; Nehrke, K; Richardson, L; Bell, SM; Schultheis, PJ; Hand, AR; Shull, GE; Melvin, JE				Park, K; Evans, RL; Watson, GE; Nehrke, K; Richardson, L; Bell, SM; Schultheis, PJ; Hand, AR; Shull, GE; Melvin, JE			Defective fluid secretion and NaCl absorption in the parotid glands of Na+/H+ exchanger-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANDIBULAR SALIVARY-GLAND; THICK ASCENDING LIMB; ACINAR-CELLS; INTRACELLULAR PH; TARGETED DISRUPTION; MUSCARINIC AGONIST; APICAL MEMBRANE; RAT; ACTIVATION; AMILORIDE	Multiple Na+/H+ exchangers (NHEs) are expressed in salivary gland cells; however, their functions in the secretion of saliva by acinar cells and the subsequent modification of the ionic composition of this-fluid by the ducts are unclear. Mice with targeted disruptions of the Nhe1, Nhe2, and Nhe3 genes were used to study the,in vivo functions of these exchangers in parotid glands. Immunohistochemistry indicated that NHE1 was localized to the basolateral and NHE2 to apical membranes of both acinar and duct cells, whereas NHE3 was restricted to the apical region of duct cells. Na+/H+ exchange was reduced more than 95% in acinar cells and greater than 80% in duet cells of NKE1-deficient mice (Nhe1(-/-)). Salivation in response to pilocarpine stimulation was reduced significantly in both Nhe1(-/-) and Nhe2(-/-) mice, particularly during prolonged stimulation, whereas the loss of NHE3 had no effect on secretion. Expression of Na+/K+/2Cl(-) cotransporter mRNA increased dramatically in Nhe1(-/-) parotid glands but not in those of Nhe2(-/-) or Nhe3(-/-) mice, suggesting that compensation occurs for the Loss of NHE1. The sodium content, chloride activity and osmolality of saliva in Nhe2(-/-) or Nhe3(-/-) mice were comparable with those of wild-type mice. In contrast, Nhe1(-/-) mice displayed impaired NaCl absorption. These results suggest that in parotid duct cells apical NHE2 and NHE3 do not play a major role in Na+ absorption. These results also demonstrate that basolateral NHE1 and apical NHE2 modulate saliva secretion in viva, especially during sustained stimulation when secretion depends less on Na+/K+/2Cl(-) cotransporter activity.	Univ Rochester, Med Ctr, Ctr Oral Biol, Rochester Inst Biomed Sci, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Eastman Dept Dent, Rochester, NY 14642 USA; Univ Connecticut, Dept Pediat Dent, Farmington, CT 06030 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Childrens Hosp Res Fdn, Div Dev Biol, Cincinnati, OH 45229 USA	University of Rochester; University of Rochester; University of Connecticut; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Melvin, JE (corresponding author), Univ Rochester, Med Ctr, Ctr Oral Biol, Rochester Inst Biomed Sci, Box 611,601 Elmwood Ave, Rochester, NY 14642 USA.			Nehrke, Keith/0000-0001-9697-726X; Bell, Sheila/0000-0002-1946-0969; Watson, Gene/0000-0002-3397-1116	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE008921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE009692, R37DE008921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK050594, R01DK050594] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE09692, DE08921] Funding Source: Medline; NIDDK NIH HHS [DK50594] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMEMIYA M, 1995, KIDNEY INT, V48, P1206, DOI 10.1038/ki.1995.404; ARREOLA J, 1995, J MEMBRANE BIOL, V147, P95; Bell SM, 1999, AM J PHYSIOL-CELL PH, V276, pC788, DOI 10.1152/ajpcell.1999.276.4.C788; Bookstein C, 1997, AM J PHYSIOL-CELL PH, V273, pC1496, DOI 10.1152/ajpcell.1997.273.5.C1496; Brooks HL, 2001, J PHYSIOL-LONDON, V530, P359, DOI 10.1111/j.1469-7793.2001.0359k.x; Cook D. I., 1994, P1061; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; Cox GA, 1997, CELL, V91, P139, DOI 10.1016/S0092-8674(01)80016-7; DINUDOM A, 1993, PFLUG ARCH EUR J PHY, V423, P164, DOI 10.1007/BF00374977; DISSING S, 1990, AM J PHYSIOL, V259, pG1044, DOI 10.1152/ajpgi.1990.259.6.G1044; Evans RL, 1999, J BIOL CHEM, V274, P29025, DOI 10.1074/jbc.274.41.29025; Evans RL, 2000, J BIOL CHEM, V275, P26720; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Good DW, 1995, P NATL ACAD SCI USA, V92, P12525, DOI 10.1073/pnas.92.26.12525; He XJ, 1997, PFLUG ARCH EUR J PHY, V433, P260; Ishikawa T, 1998, J GEN PHYSIOL, V111, P825, DOI 10.1085/jgp.111.6.825; LAU KR, 1989, AM J PHYSIOL, V256, pC288, DOI 10.1152/ajpcell.1989.256.2.C288; LAU KR, 1990, J PHYSIOL-LONDON, V425, P407, DOI 10.1113/jphysiol.1990.sp018111; Lee MG, 1998, J PHYSIOL-LONDON, V513, P341, DOI 10.1111/j.1469-7793.1998.341bb.x; MANGANEL M, 1989, J MEMBRANE BIOL, V111, P191, DOI 10.1007/BF01871782; MARMARY Y, 1987, COMP BIOCHEM PHYS A, V88, P307, DOI 10.1016/0300-9629(87)90488-9; MARTINEZ JR, 1966, PFLUG ARCH GES PHYS, V290, P124, DOI 10.1007/BF00363690; MARTINEZ JR, 1985, ARCH ORAL BIOL, V30, P797, DOI 10.1016/0003-9969(85)90134-7; McSwine RL, 1998, AM J PHYSIOL-CELL PH, V275, pC693, DOI 10.1152/ajpcell.1998.275.3.C693; MELVIN JE, 1988, J BIOL CHEM, V263, P19564; Melvin JE, 1999, CRIT REV ORAL BIOL M, V10, P199, DOI 10.1177/10454411990100020601; Nguyen HV, 2000, J PHYSIOL-LONDON, V523, P139, DOI 10.1111/j.1469-7793.2000.t01-2-00139.x; OKADA M, 1991, PFLUG ARCH EUR J PHY, V419, P338, DOI 10.1007/BF00371116; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; PARK K, 1995, AM J PHYSIOL-CELL PH, V268, pC647, DOI 10.1152/ajpcell.1995.268.3.C647; Park K, 1999, AM J PHYSIOL-GASTR L, V276, pG470, DOI 10.1152/ajpgi.1999.276.2.G470; PIRANI D, 1987, PFLUG ARCH EUR J PHY, V408, P178, DOI 10.1007/BF00581349; ROBERTSON MA, 1994, AM J PHYSIOL, V267, pC146, DOI 10.1152/ajpcell.1994.267.1.C146; Robertson MA, 1997, J BIOL CHEM, V272, P287; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Schultheis PJ, 1998, J CLIN INVEST, V101, P1243, DOI 10.1172/JCI1249; SEO JT, 1995, J PHYSIOL-LONDON, V487, P185, DOI 10.1113/jphysiol.1995.sp020870; SOLTOFF SP, 1989, J GEN PHYSIOL, V93, P285, DOI 10.1085/jgp.93.2.285; THAYSEN JH, 1954, AM J PHYSIOL, V178, P155, DOI 10.1152/ajplegacy.1954.178.1.155; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; YOUNG JA, 1966, PFLUG ARCH GES PHYS, V291, P85, DOI 10.1007/BF00362654; YU FH, 1993, J BIOL CHEM, V268, P25536; YUN CH, 1995, AM J PHYSIOL, V269, pGY1	45	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27042	27050		10.1074/jbc.M102901200	http://dx.doi.org/10.1074/jbc.M102901200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11358967	hybrid			2022-12-25	WOS:000169966900042
J	Kappes, F; Burger, K; Baack, M; Fackelmayer, FO; Gruss, C				Kappes, F; Burger, K; Baack, M; Fackelmayer, FO; Gruss, C			Subcellular localization of the human proto-oncogene protein DEK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINICHROMOSOME MAINTENANCE PROTEINS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ACUTE MYELOID-LEUKEMIA; A SAF-A; DNA-REPLICATION; HISTONE H1; CHROMATIN; TRANSCRIPTION; ONCOPROTEIN; BINDING	Recent data revealed that DEK associates with splicing complexes through interactions mediated by serine/arginine-repeat proteins. However, the DEK protein has also been shown to change the topology of DNA in chromatin in vitro, This could indicate that the DEK protein resides on cellular chromatin, To investigate the in vivo localization of DEK, we performed cell fractionation studies, immunolabeling, and micrococcal nuclease digestion analysis. Most of the DEK protein was found to be released by DNase treatment of nuclei, and only a small amount by treatment with RNase, Furthermore, micrococcal nuclease digestion of nuclei followed by glycerol gradient sedimentation revealed that DEK cosedimentates with oligonucleosomes, clearly demonstrating that DEK is associated with chromatin in vivo. Additional chromatin fractionation studies, based on the different accessibilities to micrococcal nuclease, showed that DEK is associated both with extended, genetically active and more densely organized, inactive chromatin, We found no significant change in the amount and localization of DEK in cells that synchronously traversed the cell cycle. In summary these data demonstrate that the major portion of DEK is associated with chromatin in vivo and suggest that it might play a role in chromatin architecture.	Univ Konstanz, Dept Biol, D-78457 Constance, Germany	University of Konstanz	Gruss, C (corresponding author), Univ Konstanz, Dept Biol, D-78457 Constance, Germany.	claudia.gruss@uni-konstanz.de	Ferdinand, Kappes/H-4445-2014	Ferdinand, Kappes/0000-0002-0369-0065				ADAM SA, 1992, METHOD ENZYMOL, V219, P97; Alexiadis V, 2000, GENE DEV, V14, P1308; Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; BLENCOWE BJ, 1995, RNA, V1, P852; CLARK RJ, 1971, NATURE-NEW BIOL, V229, P101, DOI 10.1038/newbio229101a0; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; Dong XW, 1998, ARTHRITIS RHEUM-US, V41, P1505, DOI 10.1002/1529-0131(199808)41:8<1505::AID-ART23>3.0.CO;2-N; FORNEROD M, 1995, ONCOGENE, V10, P1739; Fu GK, 1997, P NATL ACAD SCI USA, V94, P1811, DOI 10.1073/pnas.94.5.1811; Gohring F, 1997, EMBO J, V16, P7361, DOI 10.1093/emboj/16.24.7361; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; HALMER L, 1995, NUCLEIC ACIDS RES, V23, P773, DOI 10.1093/nar/23.5.773; Johnson R. T., 1993, CELL CYCLE PRACTICAL, P1; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kipp M, 2000, MOL CELL BIOL, V20, P7480, DOI 10.1128/MCB.20.20.7480-7489.2000; Kipp M, 2000, J BIOL CHEM, V275, P5031, DOI 10.1074/jbc.275.7.5031; KLEMPNAUER KH, 1980, J MOL BIOL, V136, P359, DOI 10.1016/0022-2836(80)90395-2; Kreitz S, 2001, J BIOL CHEM, V276, P6337, DOI 10.1074/jbc.M009473200; Krude T, 1996, J CELL SCI, V109, P309; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Lever MA, 2000, NATURE, V408, P873, DOI 10.1038/35048603; McGarvey T, 2000, J CELL BIOL, V150, P309, DOI 10.1083/jcb.150.2.309; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; Peterson CL, 2000, J CELL BIOCHEM, V78, P179, DOI 10.1002/(SICI)1097-4644(20000801)78:2<179::AID-JCB1>3.0.CO;2-E; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; Richter A, 1998, BIOL CHEM, V379, P1181; Ritzi M, 1998, J BIOL CHEM, V273, P24543, DOI 10.1074/jbc.273.38.24543; ROSE SM, 1984, J BIOL CHEM, V259, P8534; SZER IS, 1994, J RHEUMATOL, V21, P2136; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wichmann I, 2000, CLIN EXP IMMUNOL, V119, P530, DOI 10.1046/j.1365-2249.2000.01154.x; Yang L, 1998, J BIOL CHEM, V273, P27761, DOI 10.1074/jbc.273.43.27761	38	83	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26317	26323		10.1074/jbc.M100162200	http://dx.doi.org/10.1074/jbc.M100162200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11333257	hybrid			2022-12-25	WOS:000169823300090
J	Ito, K; Inoue, T; Takahashi, T; Huang, HS; Esumi, T; Hatakeyama, S; Tanaka, N; Nakamura, KT; Yoshimoto, T				Ito, K; Inoue, T; Takahashi, T; Huang, HS; Esumi, T; Hatakeyama, S; Tanaka, N; Nakamura, KT; Yoshimoto, T			The mechanism of substrate recognition of pyroglutamyl-peptidase I from Bacillus amyloliquefaciens as determined by x-ray crystallography and site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRROLIDONE CARBOXYL PEPTIDASE; PROLYL AMINOPEPTIDASE; CRYSTAL-STRUCTURE; GENE; PCP; INHIBITOR; CLONING	Pyroglutamyl-peptidase is able to specifically remove the amino-terminal pyroglutamyl residue protecting proteins or peptides from aminopeptidases. To clarify the mechanism of substrate recognition for the unique structure of the pyrrolidone ring, x-ray crystallography and site-directed mutagenesis were applied. The crystal structure of pyroglutamyl-peptidase bound to a transition state analog inhibitor (Inh), pyroglutaminal, was determined. Two hydrogen bonds were located between the main chain of the enzyme and the inhibitor (71:O . . .H-N:Inh and Gln71:N-H . . . OE:Inh and the pyrrolidone ring of the inhibitor was inserted into the hydrophobic pocket composed of Phe-10, Phe-13, Thr-45, Ile-92, Phe-142, and Val-143, To study in detail the hydrophobic pocket, Phe-10, Phe-13, and Phe-142 were selected for mutation experiments. The k(cat) value of the F10Y mutant decreased, but the two phenylalanine mutants F13Y and F142Y did not exhibit significant changes in kinetic parameters compared with the wild-type enzyme, The catalytic efficiencies (K-cat/K-m) for the F13A and F142A mutants were less than 1000-fold that of the wild-type enzyme. The x-ray crystallographic study of the F142A mutant showed no significant change except for a minor one in the hydrophobic pocket compared with the wild type. These findings indicate that the molecular recognition of pyroglutamic acid is achieved through two hydrogen bonds and an insertion in the hydrophobic pocket. In the pocket, Phe-10 is more important to the hydrophobic interaction than is Phe-142, and furthermore Phe-13 serves as an "induced fit" mechanism.	Nagasaki Univ, Fac Pharmaceut Sci, Nagasaki 8528521, Japan; Showa Univ, Sch Pharmaceut Sci, Shinagawa Ku, Tokyo 1428555, Japan	Nagasaki University; Showa University	Yoshimoto, T (corresponding author), Nagasaki Univ, Fac Pharmaceut Sci, Bunkyo Machi 1-14, Nagasaki 8528521, Japan.	t-yoshimoto@cc.nagasaki-u.ac.jp	Ito, Kiyoshi/E-9652-2011	Tanaka, Nobutada/0000-0001-5365-4698				AWADE A, 1992, FEBS LETT, V305, P67, DOI 10.1016/0014-5793(92)80656-2; BRUGER AT, 1989, X PLOR VERSION 3 1 S; CLEUZIAT P, 1992, MOL MICROBIOL, V6, P2051, DOI 10.1111/j.1365-2958.1992.tb01378.x; Daveran-Mingot ML, 1998, J BACTERIOL, V180, P4834, DOI 10.1128/JB.180.18.4834-4842.1998; FRIEDMAN TC, 1985, BIOCHEMISTRY-US, V24, P3907, DOI 10.1021/bi00336a015; FRIGERIO M, 1995, J ORG CHEM, V60, P7272, DOI 10.1021/jo00127a036; FUJIWARA K, 1982, BIOCHIM BIOPHYS ACTA, V702, P149; FUJIWARA K, 1981, J BIOCHEM-TOKYO, V90, P433, DOI 10.1093/oxfordjournals.jbchem.a133490; FUJIWARA K, 1981, BIOCHIM BIOPHYS ACTA, V658, P10, DOI 10.1016/0005-2744(81)90244-8; Fulop V, 1998, CELL, V94, P161, DOI 10.1016/S0092-8674(00)81416-6; GONZALES T, 1994, J BACTERIOL, V176, P2569, DOI 10.1128/JB.176.9.2569-2576.1994; Ito K, 2000, J BIOCHEM, V128, P673, DOI 10.1093/oxfordjournals.jbchem.a022800; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; Odagaki Y, 1999, STRUCTURE, V7, P399, DOI 10.1016/S0969-2126(99)80053-7; PATTI JM, 1995, GENE, V166, P95, DOI 10.1016/0378-1119(95)00561-0; Robert-Baudouy J., 1998, HDB PROTEOLYTIC ENZY, P791; ROUSSEL A, 1992, TURBO FRODO; Singleton MR, 1999, STRUCT FOLD DES, V7, P237, DOI 10.1016/S0969-2126(99)80034-3; Tsunasawa S, 1998, J BIOCHEM, V124, P778, DOI 10.1093/oxfordjournals.jbchem.a022179; TSURU D, 1978, J BIOCHEM, V84, P467, DOI 10.1093/oxfordjournals.jbchem.a132148; YOSHIMOTO T, 1993, J BIOCHEM-TOKYO, V113, P67; Yoshimoto T, 1999, J BIOCHEM, V126, P559, DOI 10.1093/oxfordjournals.jbchem.a022486	22	12	12	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18557	18562		10.1074/jbc.M011724200	http://dx.doi.org/10.1074/jbc.M011724200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11359794	hybrid			2022-12-25	WOS:000168866500125
J	Noma, T; Nishiyama, A; Mizushige, K; Murakami, K; Tsuji, T; Kohno, M; Rahman, M; Fukui, T; Abe, Y; Kimura, S				Noma, T; Nishiyama, A; Mizushige, K; Murakami, K; Tsuji, T; Kohno, M; Rahman, M; Fukui, T; Abe, Y; Kimura, S			Possible role of uncoupling protein in regulation of myocardial energy metabolism in aortic regurgitation model rats	FASEB JOURNAL			English	Article									Kagawa Med Univ, Dept Pharmacol, Kagawa 7610793, Japan; Kagawa Med Univ, Dept Internal Med 2, Kagawa 7610793, Japan	Kagawa University; Kagawa University	Kimura, S (corresponding author), Kagawa Med Univ, Dept Pharmacol, 1750-1 Miki, Kagawa 7610793, Japan.		Rahman, Moazur/C-5515-2019	Rahman, Moazur/0000-0003-2892-1250					0	33	34	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1206	1208		10.1096/fj.000569fje	http://dx.doi.org/10.1096/fj.000569fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344089				2022-12-25	WOS:000168655200011
J	Reinmuth, N; Liu, WB; Jung, YD; Ahmad, SA; Shaheen, RM; Fan, F; Bucana, CD; McMahon, G; Gallick, GE; Ellis, LM				Reinmuth, N; Liu, WB; Jung, YD; Ahmad, SA; Shaheen, RM; Fan, F; Bucana, CD; McMahon, G; Gallick, GE; Ellis, LM			Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival	FASEB JOURNAL			English	Article									Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; SUGEN Inc, S San Francisco, CA 94080 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Pfizer	Ellis, LM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holcombe Blvd,Box 444, Houston, TX 77030 USA.								0	185	195	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1239	1241		10.1096/fj.00-0693fje	http://dx.doi.org/10.1096/fj.00-0693fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344100				2022-12-25	WOS:000168655200022
J	Adam, L; Vadlamudi, RK; McCrea, P; Kumar, R				Adam, L; Vadlamudi, RK; McCrea, P; Kumar, R			Tiam1 overexpression potentiates heregulin-induced lymphoid enhancer factor-1/beta-catenin nuclear signaling in breast cancer cells by modulating the intercellular stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; NUCLEOTIDE EXCHANGE FACTOR; N-TERMINAL PLECKSTRIN; PROTEIN-KINASE-C; BETA-CATENIN; GROWTH-FACTOR; EPITHELIAL-CELLS; ALPHA-CATENIN; E-CADHERIN; TYROSINE PHOSPHORYLATION	Heregulin-beta1 (HRG) promotes motility, scattering, and invasiveness of breast cancer cells. Tiam1, a newly identified guanine nucleotide exchange factor, has been shown to inhibit or promote cell migration in a cell type-dependent manner. In this study, we identified Tiam1 as a target of HRG signaling. HRG stimulation of breast cancer epithelial cells induced the phosphorylation and redistribution of Tiam1 to the membrane ruffles and the loosening of intercellular junctions. In addition, HRG-mediated scattering of breast epithelial cells was accompanied by stimulation of tyrosine phosphorylation and redistribution of beta -catenin from the cell junctions to the cytosol and, finally, entry into the nucleus. Decompaction of breast cancer epithelial cells by HRG was accompanied by a transient physical association of the tyrosine-phosphorylated beta -catenin with the activated human epidermal growth factor receptor 2 and subsequent nuclear translocation of beta -catenin, as well as beta -catenin-dependent transactivation of T-cell factor-lymphoid enhancer factor-1. All of these HRG-induced phenotypic changes were regulated in a phosphatidylinositol-3 kinase-sensitive manner. HRG-induced cellular ruffles, loss of intercellular adhesiveness, and increased cell migration could be mimicked by overexpression of a fully functional Tiam1 construct. Furthermore, ectopic expression of Tiam1 or of an active beta -catenin mutant led to potentiation of the beta -catenin-dependent T-cell factor-lymphoid enhancer factor-1 transactivation and invasiveness of HRG-treated cells. We also found preliminary evidence suggesting a close correlation between the status of Tiam1 expression and invasiveness of human breast tumor cells with the degree of progression of breast tumors. Together, these findings suggest that HRG regulate Tiam1 activation and lymphoid enhancer factor/beta -catenin nuclear signaling via phosphatidylinositol-3 kinase in breast cancer cells.	Univ Texas, MD Anderson Canc Ctr 108, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr 108, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA65746, CA16672, CA80066] Funding Source: Medline; NIGMS NIH HHS [R01 GM052112] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA080066, U01CA065746, R01CA065746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139; Baeckstrom D, 2000, INT J ONCOL, V16, P1081; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Buchanan FG, 2000, J BIOL CHEM, V275, P9742, DOI 10.1074/jbc.275.13.9742; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; Bullions Linda C., 1998, Current Opinion in Oncology, V10, P81, DOI 10.1097/00001622-199801000-00013; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Crompton AM, 2000, J BIOL CHEM, V275, P25751, DOI 10.1074/jbc.M002050200; Fleming IN, 1997, J BIOL CHEM, V272, P33105, DOI 10.1074/jbc.272.52.33105; Fleming IN, 1998, FEBS LETT, V429, P229, DOI 10.1016/S0014-5793(98)00566-3; Fukata M, 1999, J BIOL CHEM, V274, P26044, DOI 10.1074/jbc.274.37.26044; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GUMBINER BM, 1997, CURR BIOL, V7, P443; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; KANAI Y, 1995, BIOCHEM BIOPH RES CO, V208, P1067, DOI 10.1006/bbrc.1995.1443; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kumar R, 2000, J CLIN LIGAND ASSAY, V23, P233; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Liu W, 1999, BIOCHEM BIOPH RES CO, V261, P897, DOI 10.1006/bbrc.1999.1144; Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784; McGrew LL, 1999, MECH DEVELOP, V87, P21, DOI 10.1016/S0925-4773(99)00136-7; Menard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Miller JR, 1997, J CELL BIOL, V139, P229, DOI 10.1083/jcb.139.1.229; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; Nieset JE, 1997, J CELL SCI, V110, P1013; Orsulic S, 1999, J CELL SCI, V112, P1237; Pinkas-Kramarski R, 1997, J MAMMARY GLAND BIOL, V2, P97, DOI 10.1023/A:1026343528967; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; Porfiri E, 1997, ONCOGENE, V15, P2833, DOI 10.1038/sj.onc.1201462; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; SINKOVICS JG, 1988, CRC CR REV IMMUNOL, V8, P217; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Stewart DB, 1997, J BIOL CHEM, V272, P29652, DOI 10.1074/jbc.272.47.29652; Takahashi K, 1997, ONCOGENE, V15, P71, DOI 10.1038/sj.onc.1201160; Vadlamudi R, 1999, CANCER RES, V59, P2843; Vadlamudi R, 1999, ONCOGENE, V18, P7253, DOI 10.1038/sj.onc.1203163; White P, 1998, J CELL BIOL, V140, P183, DOI 10.1083/jcb.140.1.183; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3	52	73	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28443	28450		10.1074/jbc.M009769200	http://dx.doi.org/10.1074/jbc.M009769200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11328805	hybrid			2022-12-25	WOS:000170093400093
J	Jeanclos, EM; Lin, L; Treuil, MW; Rao, J; DeCoster, MA; Anand, R				Jeanclos, EM; Lin, L; Treuil, MW; Rao, J; DeCoster, MA; Anand, R			The chaperone protein 14-3-3 eta interacts with the nicotinic acetylcholine receptor alpha 4 subunit - Evidence for a dynamic role in subunit stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRONTAL-LOBE EPILEPSY; GATED ION CHANNELS; ENDOPLASMIC-RETICULUM; MUSCLE-CELLS; GENE YWHAH; PHOSPHORYLATION; 14-3-3-PROTEINS; EXPRESSION; KINASE; MUTATION	By using the large cytoplasmic domain of the nicotinic acetylcholine receptor (AChR) alpha4 subunit as a bait in the yeast two-hybrid system, we isolated the first cytosolic protein, 14-3-3-eta, known to interact directly with neuronal AChRs. 14-3-3-eta is a member of a family of proteins that function as regulatory or chaperone/scaffolding/adaptor proteins. 14-3-3-eta interacted with the recombinant alpha4 subunit alone in tsA 201 cells following activation of cAMP-dependent protein kinase by forskolin. The interaction of 14-3-3-eta with recombinant alpha4 subunits was abolished when serine 441 of the alpha4 subunit was mutated to alanine (alpha4(S441A)). The surface levels of recombinant wild-type alpha4 beta2 AChRs were similar to2-fold higher than those of mutant alpha4(S441A)beta2 AChRs. The interaction significantly increased the steady state levels of the alpha4 subunit and alpha4 beta2 AChRs but not that of the mutant alpha4(S441A) subunit or mutant alpha4(S441A)beta2 AChRs. The EC50 values for activation by acetylcholine were not significantly different for alpha4 beta2 AChRs and alpha4(S441A)beta2 AChRs coexpressed with 14-3-3-eta in oocytes following treatment with forskolin. 14-3-3 coimmunopurified with native alpha4 AChRs from brain. These results support a role for 14-3-3 in dynamically regulating the expression levels of alpha4 beta2 AChRs through its interaction with the alpha4 subunit.	Louisiana State Univ, Hlth Sci Ctr, Neurosci Ctr Excellence, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Neurol, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Anand, R (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Neurosci Ctr Excellence, 2020 Gravier St,Ste D, New Orleans, LA 70112 USA.		DeCoster, Mark/AAF-5224-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS033625] Funding Source: NIH RePORTER; NINDS NIH HHS [NS33625] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; Anand R, 1998, J PHARMACOL EXP THER, V287, P469; Autieri MV, 1996, CELL GROWTH DIFFER, V7, P1453; BARNARD EA, 1992, TRENDS BIOCHEM SCI, V17, P368, DOI 10.1016/0968-0004(92)90002-Q; BENWELL MEM, 1988, J NEUROCHEM, V50, P1243, DOI 10.1111/j.1471-4159.1988.tb10600.x; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; Breese CR, 2000, NEUROPSYCHOPHARMACOL, V23, P351, DOI 10.1016/S0893-133X(00)00121-4; Broadie K, 1997, NEURON, V19, P391, DOI 10.1016/S0896-6273(00)80948-4; BURGOYNE RD, 1993, J ANAT, V183, P309; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; Cooper ST, 1999, J BIOL CHEM, V274, P27145, DOI 10.1074/jbc.274.38.27145; DENERIS ES, 1991, TRENDS PHARMACOL SCI, V12, P34, DOI 10.1016/0165-6147(91)90486-C; Dubois T, 1997, J PROTEIN CHEM, V16, P513, DOI 10.1023/A:1026321813463; Eertmoed AL, 1999, J NEUROSCI, V19, P6298; FRAIL DE, 1987, P NATL ACAD SCI USA, V84, P6302, DOI 10.1073/pnas.84.17.6302; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; GELPERIN D, 1995, P NATL ACAD SCI USA, V92, P11539, DOI 10.1073/pnas.92.25.11539; Gopalakrishnan M, 1997, MOL PHARMACOL, V52, P524, DOI 10.1124/mol.52.3.524; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; Hirose S, 1999, NEUROLOGY, V53, P1749, DOI 10.1212/WNL.53.8.1749; Keller SH, 1996, J BIOL CHEM, V271, P22871, DOI 10.1074/jbc.271.37.22871; Keller SH, 1999, J GEN PHYSIOL, V113, P171, DOI 10.1085/jgp.113.2.171; Keller SH, 1998, J BIOL CHEM, V273, P17064, DOI 10.1074/jbc.273.27.17064; Kuwana T, 1998, P NATL ACAD SCI USA, V95, P1056, DOI 10.1073/pnas.95.3.1056; Lindstrom J, 1996, Ion Channels, V4, P377; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; Marubio LM, 1999, NATURE, V398, P805, DOI 10.1038/19756; MCCONNELL JE, 1995, DEV BIOL, V169, P218, DOI 10.1006/dbio.1995.1139; Megidish T, 1998, J BIOL CHEM, V273, P21834, DOI 10.1074/jbc.273.34.21834; Muratake T, 1996, GENOMICS, V36, P63, DOI 10.1006/geno.1996.0426; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NIGAM SK, 1989, J BIOL CHEM, V264, P16927; Olsson A, 1998, PLANT PHYSIOL, V118, P551, DOI 10.1104/pp.118.2.551; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; PAULSON HL, 1991, J CELL BIOL, V113, P1371, DOI 10.1083/jcb.113.6.1371; PHILLIPS HA, 1995, NAT GENET, V10, P117, DOI 10.1038/ng0595-117; PHILLIPS WD, 1991, J CELL BIOL, V115, P1713, DOI 10.1083/jcb.115.6.1713; Picciotto MR, 1998, NATURE, V391, P173, DOI 10.1038/34413; PICCIOTTO MR, 1995, NATURE, V374, P65, DOI 10.1038/374065a0; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ramarao MK, 1998, P NATL ACAD SCI USA, V95, P4007, DOI 10.1073/pnas.95.7.4007; ROSS AF, 1991, J CELL BIOL, V113, P623, DOI 10.1083/jcb.113.3.623; ROSS AF, 1987, J BIOL CHEM, V262, P14640; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SIVILOTTI L, 1995, SCIENCE, V269, P1681, DOI 10.1126/science.7569892; Skoulakis EMC, 1998, MOL NEUROBIOL, V16, P269, DOI 10.1007/BF02741386; STEINLEIN OK, 1995, NAT GENET, V11, P201, DOI 10.1038/ng1095-201; Steinlein OK, 1997, HUM MOL GENET, V6, P943, DOI 10.1093/hmg/6.6.943; Toyooka K, 1999, AM J MED GENET, V88, P164, DOI 10.1002/(SICI)1096-8628(19990416)88:2<164::AID-AJMG13>3.0.CO;2-3; Wang WF, 1996, J MOL EVOL, V43, P384; WATANABE M, 1993, DEV BRAIN RES, V73, P225, DOI 10.1016/0165-3806(93)90142-W; WHITING PJ, 1988, J NEUROSCI, V8, P3395; WILLIAMS BM, 1999, NATURE, V1, P557; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zoli M, 1999, EMBO J, V18, P1235, DOI 10.1093/emboj/18.5.1235	56	129	137	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28281	28290		10.1074/jbc.M011549200	http://dx.doi.org/10.1074/jbc.M011549200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11352901	hybrid			2022-12-25	WOS:000170093400073
J	Matter, ML; Ruoslahti, E				Matter, ML; Ruoslahti, E			A signaling pathway from the alpha(5)beta 1 and alpha(v)beta(3) integrins that elevates bcl-2 transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; NF-KAPPA-B; PROTEIN-KINASE; CELL-SURVIVAL; PHOSPHATIDYLINOSITOL 3-KINASE; FIBRONECTIN RECEPTOR; TYROSINE PHOSPHORYLATION; TRANSDUCTION PATHWAY; MEDIATED ACTIVATION; MAP KINASE	Integrin-mediated cell adhesion is necessary for the survival of many cell types, and loss of adhesion causes apoptosis. We have previously shown that the alpha (5)beta (1) integrin supports cell survival on fibronectin and increases Bcl-2 protein expression. Here we show that bcl-2 transcription is elevated in cells that attach to fibronectin through alpha (v)beta (1) or to vitronectin through alpha (v)beta (1) but is not elevated in cells attaching through the alpha (v)beta (1) integrin. Bcl-2 protein expression and protection from apoptosis under serum-free conditions correlated with bcl-2 transcription. This integrin-mediated regulation of bcl-2 is She- and FAK-dependent, and activation of Ras by FAK is required. Furthermore, Ras mediates this up-regulation of bcl-2 by activating the phosphatidylinositol 3-kinase-AKT pathway. Mitogen-activated protein kinase did not appear to be necessary for the activation of bcl-2 transcription. Therefore, our work characterizes the pathway that mediates the effect of integrins on bcl-2 transcription and cell survival.	Burnham Inst, Ctr Canc Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Ruoslahti, E (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 90237 USA.		Matter, Michelle/GSN-9703-2022	Matter, Michelle/0000-0002-5988-9663	NATIONAL CANCER INSTITUTE [T32CA009579, R01CA079984, R01CA074238] Funding Source: NIH RePORTER; NCI NIH HHS [CA79984, CA74238, CA09579] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; Brassard DL, 1999, EXP CELL RES, V251, P33, DOI 10.1006/excr.1999.4559; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Downward J, 1998, NATURE, V396, P416, DOI 10.1038/24743; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Farrelly N, 1999, J CELL BIOL, V144, P1337, DOI 10.1083/jcb.144.6.1337; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; Harigai M, 1996, ONCOGENE, V12, P1369; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Matter ML, 1998, J CELL BIOL, V141, P1019, DOI 10.1083/jcb.141.4.1019; OBrien V, 1996, EXP CELL RES, V224, P208, DOI 10.1006/excr.1996.0130; Ozes ON, 1999, NATURE, V401, P82; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; REY I, 1994, ONCOGENE, V9, P685; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; SCHREINER CL, 1989, J CELL BIOL, V109, P3157, DOI 10.1083/jcb.109.6.3157; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TADA H, 1986, J IMMUNOL METHODS, V93, P157, DOI 10.1016/0022-1759(86)90183-3; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235; Zheng DQ, 2000, J BIOL CHEM, V275, P24565, DOI 10.1074/jbc.M002646200	48	197	222	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27757	27763		10.1074/jbc.M102014200	http://dx.doi.org/10.1074/jbc.M102014200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11333270	hybrid			2022-12-25	WOS:000170093400004
J	Carrick, FE; Forbes, BE; Wallace, JC				Carrick, FE; Forbes, BE; Wallace, JC			BIAcore analysis of bovine insulin-like growth factor (IGF)-binding protein-2 identifies major IGF binding site determinants in both the amino- and carboxyl-terminal domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I; FACTOR BINDING-PROTEIN-4; STRUCTURAL ANALOGS; ESCHERICHIA-COLI; AFFINITY; REGION; FRAGMENTS; SERUM; LOCALIZATION; SUPERFAMILY	In the absence of a complete tertiary structure to define the molecular basis of the high affinity binding interaction between insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs), we have investigated binding of IGFs by discrete amino-terminal domains (amino acid residues 1-93, 1-104, 1-132, and 1-185) and carboxyl-terminal domains (amino acid residues 96-279, 136-279, and 182-284) of bovine IGFBP-2 (bIGFSP-2). Both halves of bIGFBP-2 bound IGF-I and IGF-II in BIAcore studies, albeit with different affinities ((1-132)IGFBP-2, K(D) = 36.3 and 51.8 nM; (136-279)IGFBP-2HIS, K(D) = 23.8 and 16.3 nM, respectively). The amino-terminal half appears to contain components responsible for fast association. In contrast, IGF binding by the carboxyl-terminal fragment results in a more stable complex as reflected by its K(D). Furthermore, des(1-3)IGF-I and des(1-6)IGF-II exhibited reduced binding affinity to (1-279)IGFBP-2HIS, (1-132)IGFBP-2, and (136-279)IGFBP-2HIS biosensor surfaces compared with wild-type IGF. A charge reversal at positions 3 and 6 of IGF-I and IGF-II, respectively, affects binding interactions with the amino-terminal fragment and full-length bPGFBP-2 but not the carboxyl-terminal fragment.	Univ Adelaide, Cooperat Res Ctr Tissue Growth & Repair, Dept Mol Biosci, Adelaide, SA 5005, Australia	University of Adelaide	Carrick, FE (corresponding author), Univ Adelaide, Cooperat Res Ctr Tissue Growth & Repair, Dept Mol Biosci, N Terrace, Adelaide, SA 5005, Australia.	francine.carrick@adelaide.edu.au	Forbes, Briony/R-1838-2019; , John/AAP-5150-2020	Forbes, Briony/0000-0003-4360-9927				ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004; BACH LA, 1993, J BIOL CHEM, V268, P9246; BAGLEY CJ, 1989, BIOCHEM J, V259, P665, DOI 10.1042/bj2590665; Baxter RC, 2000, AM J PHYSIOL-ENDOC M, V278, pE967, DOI 10.1152/ajpendo.2000.278.6.E967; BAXTER RC, 1994, HORM RES, V42, P140, DOI 10.1159/000184186; BAYNE ML, 1988, J BIOL CHEM, V263, P6233; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BOURNER MJ, 1992, J CELL BIOCHEM, V48, P215; Bramani S, 1999, J MOL ENDOCRINOL, V23, P117, DOI 10.1677/jme.0.0230117; BRINKMAN A, 1991, MOL ENDOCRINOL, V5, P987, DOI 10.1210/mend-5-7-987; BRINKMAN A, 1991, FEBS LETT, V291, P264, DOI 10.1016/0014-5793(91)81298-M; BUCK MA, 1989, ANAL BIOCHEM, V182, P295, DOI 10.1016/0003-2697(89)90597-6; CASCIERI MA, 1989, J BIOL CHEM, V264, P2199; CHERNAUSEK SD, 1995, J BIOL CHEM, V270, P11377, DOI 10.1074/jbc.270.19.11377; CONOVER CA, 1995, J BIOL CHEM, V270, P4395, DOI 10.1074/jbc.270.9.4395; Conover CA, 1998, INT CONGR SER, V1151, P107; DURHAM SK, 1995, ENDOCRINOLOGY, V136, P1374, DOI 10.1210/en.136.4.1374; Firth SM, 1998, J BIOL CHEM, V273, P2631, DOI 10.1074/jbc.273.5.2631; Forbes BE, 1998, J BIOL CHEM, V273, P4647, DOI 10.1074/jbc.273.8.4647; FRANCIS GL, 1993, BIOCHEM J, V293, P713, DOI 10.1042/bj2930713; Galanis M, 2001, J ENDOCRINOL, V169, P123, DOI 10.1677/joe.0.1690123; Hashimoto R, 1997, J BIOL CHEM, V272, P27936, DOI 10.1074/jbc.272.44.27936; Ho PJ, 1997, ENDOCRINOLOGY, V138, P3811, DOI 10.1210/en.138.9.3811; Hobba GD, 1996, J BIOL CHEM, V271, P30529, DOI 10.1074/jbc.271.48.30529; Hobba GD, 1998, J BIOL CHEM, V273, P19691, DOI 10.1074/jbc.273.31.19691; Horney MJ, 2001, J BIOL CHEM, V276, P2880, DOI 10.1074/jbc.M007526200; HUHTALA ML, 1986, BIOCHEM BIOPH RES CO, V141, P263, DOI 10.1016/S0006-291X(86)80363-1; Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761; Imai Y, 2000, J BIOL CHEM, V275, P18188, DOI 10.1074/jbc.M000070200; Jones JC, 1998, J FIRE SCI, V16, P3, DOI 10.1177/073490419801600101; Kalus W, 1998, EMBO J, V17, P6558, DOI 10.1093/emboj/17.22.6558; Kim HS, 1997, P NATL ACAD SCI USA, V94, P12981, DOI 10.1073/pnas.94.24.12981; KING R, 1992, J MOL ENDOCRINOL, V8, P29, DOI 10.1677/jme.0.0080029; KUBLER B, 1999, GROWTH HORM IGF RES, V9, P362; Landale EC, 1995, GROWTH FACTORS, V12, P245, DOI 10.3109/08977199509028963; LOFAS S, 1990, J CHEM SOC CHEM COMM, P1526, DOI 10.1039/c39900001526; LUCIC M, 2000, THESIS ADELAIDE U; Lucic MR, 1998, J BIOTECHNOL, V61, P95, DOI 10.1016/S0168-1656(98)00012-1; Magee BA, 1999, BIOCHEMISTRY-US, V38, P15863, DOI 10.1021/bi9910070; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; Qin XZ, 1998, J BIOL CHEM, V273, P23509, DOI 10.1074/jbc.273.36.23509; Rajaram S, 1997, ENDOCR REV, V18, P801, DOI 10.1210/er.18.6.801; SOMMER A, 1991, MODERN CONCEPTS INSU, P715; Spencer E. Martin, 1995, Progress in Growth Factor Research, V6, P209; Standker L, 1998, FEBS LETT, V441, P281, DOI 10.1016/S0014-5793(98)01497-5; Standker L, 2000, BIOCHEMISTRY-US, V39, P5082, DOI 10.1021/bi992513s; SUN Y, 1993, BIOTECHNIQUES, V15, P372; WANG JF, 1988, BIOCHEM BIOPH RES CO, V157, P718, DOI 10.1016/S0006-291X(88)80309-7; ZAPF J, 1988, BIOCHEM BIOPH RES CO, V156, P1187, DOI 10.1016/S0006-291X(88)80758-7	49	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27120	27128		10.1074/jbc.M101317200	http://dx.doi.org/10.1074/jbc.M101317200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356837	hybrid			2022-12-25	WOS:000169966900053
J	Ikuta, M; Kamata, K; Fukasawa, K; Honma, T; Machida, T; Hirai, H; Suzuki-Takahashi, I; Hayama, T; Nishimura, S				Ikuta, M; Kamata, K; Fukasawa, K; Honma, T; Machida, T; Hirai, H; Suzuki-Takahashi, I; Hayama, T; Nishimura, S			Crystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; CRYSTAL-STRUCTURES; CDC2 KINASE; GENE; COMPLEX; CANCER; G1; PHOSPHORYLATION; FLAVOPIRIDOL; SPECIFICITY	Genetic alteration of one or more components of the P16(INK4A)-CDK4,6/cyclin D-retinoblastoma pathway is found in more than half of all human cancers. Therefore, CDR4 is an attractive target, for the development of a novel anticancer agent. However, it is difficult to make CDK4-specific inhibitors that do not possess activity for other kinases, especially CDK2, because the CDH family has high structural homology, The three-dimensional structure of CDK2, particularly that bound with the inhibitor, has provided useful information for the synthesis of CDK2-specific inhibitors. The same approach used to make CDK4-specific inhibitors was hindered by the failure to obtain a crystal structure of CDK4, To overcome this problem, we synthesized a CDK4 mimic CDK2 protein in which the ATP binding pocket of CDK2 was replaced with that of CDK4, This CDK4 mimic CDK2 was crystallized both in the free and inhibitor-bound form. The structural information thus obtained was found to be useful for synthesis of a CDK4-specific inhibitor that does not, have substantial CDK2 activity. Namely, the data suggest that CDK4 has additional space that will accommodate a large substituent such as the CDK4 selective inhibitor. Inhibitors designed to bind into this large cavity should be selective for CDK4 without having substantial CDK2 activity. This design principle was confirmed in the x-ray crystal structure of the CDK4 mimic CDK2 with a new CDK4 selective inhibitor bound.	Merck Res Labs, Banyu Tsukuba Res Inst, Tsuchiura, Ibaraki 3002611, Japan	Merck & Company	Nishimura, S (corresponding author), Merck Res Labs, Banyu Tsukuba Res Inst, Okubo 3, Tsuchiura, Ibaraki 3002611, Japan.							BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Carlson BA, 1996, CANCER RES, V56, P2973; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; deAzevedo WF, 1996, P NATL ACAD SCI USA, V93, P2735, DOI 10.1073/pnas.93.7.2735; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; GLAB N, 1994, FEBS LETT, V353, P207, DOI 10.1016/0014-5793(94)01035-8; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HIGASHI H, 1995, BIOCHEM BIOPH RES CO, V216, P520, DOI 10.1006/bbrc.1995.2653; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kelland LR, 2000, EXPERT OPIN INV DRUG, V9, P2903, DOI 10.1517/13543784.9.12.2903; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KITAGAWA M, 1992, ONCOGENE, V7, P1067; KITAGAWA M, 1993, ONCOGENE, V8, P2425; Lawrie AM, 1997, NAT STRUCT BIOL, V4, P796, DOI 10.1038/nsb1097-796; LESLIE AGW, 1990, CRYSTALLOGRAPHIC COM, P50; LOSIEWICZ MD, 1994, BIOCHEM BIOPH RES CO, V201, P589, DOI 10.1006/bbrc.1994.1742; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; ROSENBLATT J, 1993, J MOL BIOL, V230, P1317, DOI 10.1006/jmbi.1993.1248; SCHULZEGAHMEN U, 1995, PROTEINS, V22, P378, DOI 10.1002/prot.340220408; Senderowicz AM, 1999, INVEST NEW DRUG, V17, P313, DOI 10.1023/A:1006353008903; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	41	99	123	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27548	27554		10.1074/jbc.M102060200	http://dx.doi.org/10.1074/jbc.M102060200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11335721	hybrid			2022-12-25	WOS:000169966900107
J	Skipper, L; Campbell, WH; Mertens, JA; Lowe, DJ				Skipper, L; Campbell, WH; Mertens, JA; Lowe, DJ			Pre-steady-state kinetic analysis of recombinant arabidopsis NADP : Nitrate reductase - Rate-limiting processes in catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; FLAVOPROTEIN REDUCTASES; CHLORELLA-VULGARIS; MOLYBDENUM CENTER; PROSTHETIC GROUPS; SULFITE OXIDASE; PICHIA-PASTORIS; PH-DEPENDENCE; WILD-TYPE; FRAGMENT	Recombinant Arabidopsis NADH:nitrate reductase was expressed in Pichia pastoris using fermentation. Large enzyme quantities were purified for pre-steady-state kinetic analysis, which had not been done before with any eukaryotic nitrate reductase, Basic biochemical properties of recombinant nitrate reductase were similar to natural enzyme forms. Molybdenum content was lower than expected, which was compensated for by activity calculation on molybdenum basis. Stopped-flow rapid-scan spectrophotometry showed that the enzyme FAD and heme were rapidly reduced by NADH with and without nitrate present. NADPH reduced FAD at less than one-tenth of NADH rate. Reaction of NADH-reduced enzyme with nitrate yielded rapid initial oxidation of heme with slower oxidation of flavin, Rapid-reaction freeze-quench EPR spectra revealed molybdenum was maintained in a partially reduced state during turnover. Rapid-reaction chemical quench for quantifying nitrite production showed that the rate of nitrate reduction was initially greater than the steady-state rate, but rapidly decreased to near steady-state turnover rate. However, rates of internal electron transfer and nitrate reduction were similar in magnitude with no one step in the catalytic process appearing to be much slower than the others. This leads to the conclusion that the catalytic rate is determined by a combination of rates with no overall rate-limiting individual process.	Michigan Technol Univ, Dept Biol Sci, Houghton, MI 49931 USA; John Innes Inst, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England	Michigan Technological University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Campbell, WH (corresponding author), Michigan Technol Univ, Dept Biol Sci, Houghton, MI 49931 USA.			Campbell, Wilbur/0000-0001-6432-7537				Abraham ZHL, 1997, BIOCHEM J, V324, P511, DOI 10.1042/bj3240511; BARBER MJ, 1989, PLANT PHYSIOL, V90, P70, DOI 10.1104/pp.90.1.70; Barber MJ, 1997, ARCH BIOCHEM BIOPHYS, V345, P88, DOI 10.1006/abbi.1997.0223; Boll M, 2000, J BIOL CHEM, V275, P31857, DOI 10.1074/jbc.M001508200; BRAY RC, 1961, BIOCHEM J, V81, P189, DOI 10.1042/bj0810189; Campbell WH, 1999, ANNU REV PLANT PHYS, V50, P277, DOI 10.1146/annurev.arplant.50.1.277; CORRELL CC, 1993, PROTEIN SCI, V2, P2112, DOI 10.1002/pro.5560021212; George GN, 1999, J AM CHEM SOC, V121, P9730, DOI 10.1021/ja990310l; Gray HB, 1996, ANNU REV BIOCHEM, V65, P537, DOI 10.1146/annurev.bi.65.070196.002541; GUTTERIDGE S, 1983, BIOCHEM J, V213, P137, DOI 10.1042/bj2130137; KAY CJ, 1990, BIOCHEMISTRY-US, V29, P10823, DOI 10.1021/bi00500a015; KAY CJ, 1989, BIOCHEMISTRY-US, V28, P5750, DOI 10.1021/bi00440a008; KAY CJ, 1991, BIOCHEMISTRY-US, V30, P11445, DOI 10.1021/bi00112a011; KAY CJ, 1988, BIOCHEMISTRY-US, V27, P6142, DOI 10.1021/bi00416a047; KAY CJ, 1986, J BIOL CHEM, V261, P14125; Kisker C, 1997, CELL, V91, P973, DOI 10.1016/S0092-8674(00)80488-2; LU GG, 1995, J MOL BIOL, V248, P931, DOI 10.1006/jmbi.1995.0273; LU GG, 1994, STRUCTURE, V2, P809, DOI 10.1016/S0969-2126(94)00082-4; Mertens J.A., 1999, FLAVINS FLAVOPROTEIN, P131; Mertens JA, 2000, PLANT PHYSIOL, V123, P743, DOI 10.1104/pp.123.2.743; Pacheco A, 1999, J BIOL INORG CHEM, V4, P390, DOI 10.1007/s007750050325; RATNAM K, 1995, J BIOL CHEM, V270, P24067, DOI 10.1074/jbc.270.41.24067; Ratnam K, 1997, J BIOL CHEM, V272, P2122; REDINBAUGH MG, 1985, J BIOL CHEM, V260, P3380; Schwarz G, 1997, J BIOL CHEM, V272, P26811, DOI 10.1074/jbc.272.43.26811; SOLOMONSON LP, 1990, ANNU REV PLANT PHYS, V41, P225, DOI 10.1146/annurev.pp.41.060190.001301; SOLOMONSON LP, 1984, J BIOL CHEM, V259, P849; SOLOMONSON LP, 1975, J BIOL CHEM, V250, P4120; Su WP, 1997, PLANT PHYSIOL, V115, P1135, DOI 10.1104/pp.115.3.1135	29	38	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26995	27002		10.1074/jbc.M100356200	http://dx.doi.org/10.1074/jbc.M100356200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356830	hybrid			2022-12-25	WOS:000169966900036
J	Urbatsch, IL; Gimi, K; Wilke-Mounts, S; Lerner-Marmarosh, N; Rousseau, ME; Gros, P; Senior, AE				Urbatsch, IL; Gimi, K; Wilke-Mounts, S; Lerner-Marmarosh, N; Rousseau, ME; Gros, P; Senior, AE			Cysteines 431 and 1074 are responsible for inhibitory disulfide cross-linking between the two nucleotide-binding sites in human P-glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATPASE ACTIVITY; CATALYTIC CYCLE; PURIFICATION; IDENTIFICATION; EXPRESSION; MUTATIONS; TRANSPORT; AZIDOPINE; RESIDUES; PASTORIS	Human wild-type and Cys-less P-glycoproteins were expressed in Pichia pastoris and purified in high yield in detergent-soluble form. Both ran on SDS gels as a single 140-kDa band in the presence of reducing agent and showed strong verapamil-stimulated ATPase activity in the presence of added lipid. The wild type showed spontaneous formation of higher molecular mass species in the absence of reducing agent, and its ATPase was activated by dithiothreitol. Oxidation with Cu2+ generated the same higher molecular mass species, primarily at 200 and similar to 300 kDa, in high yield. Cross-linking was reversed by dithiothreitol and prevented by pretreatment with N-ethylmaleimide. Using proteins containing different combinations of naturally occurring Cys residues, it was demonstrated that an inhibitory intramolecular disulfide bond forms between Cys-431 and Cys-1074 (located in the Walker A sequences of nucleotide-binding sites 1 and 2, respectively), giving rise to the 800-kDa species, in addition, dimeric P-glycoprotein species (similar to 300 kDa) form by intermolecular disulfide bonding between Cys-431 and Cys-1074. The ready formation of the intramolecular disulfide between Cys-431 and Cys-1074 establishes that the two nucleotide-binding sites of P-glycoprotein are structurally very close and capable of intimate functional interaction, consistent with available information on the catalytic mechanism. Formation of such a disulfide in vivo could,in principle,underlie a regulatory mechanism and might provide a means of intervention to inhibit P-glycoprotein.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	University of Rochester; McGill University	Senior, AE (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Box 712, Rochester, NY 14642 USA.	alan_senior@urmc.rochester.edu		Rousseau, Marc-Etienne/0000-0001-6281-1691	NIGMS NIH HHS [GM50156] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050156] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; Beaudet L, 1998, METHOD ENZYMOL, V292, P397; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; Demeule M, 1998, BIOCHEMISTRY-US, V37, P18110, DOI 10.1021/bi981992c; Demmer A, 1999, EUR J BIOCHEM, V264, P800, DOI 10.1046/j.1432-1327.1999.00702.x; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; Figler RA, 2000, ARCH BIOCHEM BIOPHYS, V376, P34, DOI 10.1006/abbi.2000.1712; Forgac M, 1999, J BIOL CHEM, V274, P1301, DOI 10.1074/jbc.274.3.1301; Goodfellow HR, 1996, J BIOL CHEM, V271, P13668, DOI 10.1074/jbc.271.23.13668; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HINNEBUSCH AG, 1991, MOL CELLULAR BIOL YE, V1, P625; Hrycyna CA, 1998, J BIOL CHEM, V273, P16631, DOI 10.1074/jbc.273.27.16631; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Innis A. M., 1990, PCR PROTOCOLS GUIDE, P3; *INV CORP, 1999, PICH EXPR KIT VERS J, P2; Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269; Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x; Lerner-Marmarosh N, 1999, J BIOL CHEM, V274, P34711, DOI 10.1074/jbc.274.49.34711; Loo TW, 2000, J BIOL CHEM, V275, P19435, DOI 10.1074/jbc.C000222200; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; Oluwatosin YE, 1997, J BIOL CHEM, V272, P28149, DOI 10.1074/jbc.272.44.28149; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Sankaran B, 1997, BIOCHEMISTRY-US, V36, P6847, DOI 10.1021/bi970034s; Sauna ZE, 2000, P NATL ACAD SCI USA, V97, P2515, DOI 10.1073/pnas.97.6.2515; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; Sharom FJ, 1997, J MEMBRANE BIOL, V160, P161, DOI 10.1007/s002329900305; Stein WD, 1997, PHYSIOL REV, V77, P545, DOI 10.1152/physrev.1997.77.2.545; Szabo K, 1998, J BIOL CHEM, V273, P10132, DOI 10.1074/jbc.273.17.10132; Urbatsch IL, 2000, J BIOL CHEM, V275, P25031, DOI 10.1074/jbc.M003962200; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441; Zhou TQ, 2000, EMBO J, V19, P4838, DOI 10.1093/emboj/19.17.4838	42	68	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26980	26987		10.1074/jbc.M010829200	http://dx.doi.org/10.1074/jbc.M010829200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356825	hybrid			2022-12-25	WOS:000169966900034
J	Adimoolam, S; Lin, CX; Ford, JM				Adimoolam, S; Lin, CX; Ford, JM			The p53-regulated cyclin-dependent kinase inhibitor, p21 (cip1, waf1, sdi1), is not required for global genomic and transcription-coupled nucleotide excision repair of UV-induced DNA photoproducts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOBUTANE PYRIMIDINE DIMERS; P53 TUMOR-SUPPRESSOR; HUMAN CANCER-CELLS; XERODERMA-PIGMENTOSUM; HUMAN FIBROBLASTS; IN-VITRO; PREFERENTIALLY AFFECTS; NONTRANSCRIBED STRAND; GENE; DAMAGE	The p53 tumor suppressor gene is a transcriptional activator involved in cell cycle regulation, apoptosis, and DNA repair. We have shown that p53 is required for efficient nucleotide excision repair of UV-induced DNA photoproducts from global genomic DNA but has no effect on transcription-coupled repair. In order to evaluate whether p53 influences repair indirectly through cell cycle arrest following DNA damage or plays a direct role, we examined repair in vivo in human cells genetically altered to disrupt or regulate the function of p53 and p21, Both primary human fibroblasts and HCT116 colon carcinoma cells wild type for p53 but in which the p21 gene was inactivated through targeted homologous recombination showed no decrease in global repair of W photoproducts, Human bladder carcinoma cells mutant for p53 and containing a tetracycline-regulated p21 cDNA showed no significant enhancement of repair upon induction of p21 expression. All of the cell lines, including the mismatch repair-deficient, MLH1 mutant HCT116 cells, were proficient for transcription-coupled repair. Clonogenic survival of HCT116 cells following W irradiation showed no dependence on p21, Therefore, our results indicate that p53-dependent nucleotide excision repair does not require the function of the p21 gene product and is independent of p53-regulated cell cycle checkpoints.	Stanford Univ, Sch Med, Dept Med, Div Oncol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Div Oncol, Stanford, CA 94305 USA	Stanford University; Stanford University	Ford, JM (corresponding author), Stanford Univ, Sch Med, Dept Med, Div Oncol, 1115 CCSR Bldg, Stanford, CA 94305 USA.	jmf@stanford.edu		Ford, James/0000-0002-2513-7025	NATIONAL CANCER INSTITUTE [R01CA083889] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA83889] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1999, MOL CELL BIOL, V19, P1068; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Balajee AS, 1998, MUTAT RES-DNA REPAIR, V409, P135, DOI 10.1016/S0921-8777(98)00051-2; Bowman KK, 2000, MOL CARCINOGEN, V29, P17, DOI 10.1002/1098-2744(200009)29:1<17::AID-MC3>3.3.CO;2-5; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cooper MP, 1999, MOL BIOL CELL, V10, P2119, DOI 10.1091/mbc.10.7.2119; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; El-Mahdy MA, 2000, MUTAT RES-DNA REPAIR, V459, P135, DOI 10.1016/S0921-8777(99)00066-X; Fang L, 1999, ONCOGENE, V18, P2789, DOI 10.1038/sj.onc.1202615; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; Ford JM, 1997, CURR TOP MICROBIOL, V221, P47; Ford JM, 1998, CANCER RES, V58, P599; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FORD JM, 2000, P AM ASSOC CANC RES, V41, P1131; FOX M, 1981, DNA REPAIR, P523; Ganesan AK, 1999, MUTAT RES-DNA REPAIR, V433, P117, DOI 10.1016/S0921-8777(98)00070-6; HARPER JW, 1993, CELL, V75, P805; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Leadon SA, 1997, CANCER RES, V57, P3784; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LOMMEL L, 1995, MUTAT RES-DNA REPAIR, V336, P181, DOI 10.1016/0921-8777(94)00055-B; McDonald E, 1996, CANCER RES, V56, P2250; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557; MORI T, 1991, PHOTOCHEM PHOTOBIOL, V54, P225, DOI 10.1111/j.1751-1097.1991.tb02010.x; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Petit C, 1999, BIOCHIMIE, V81, P15, DOI 10.1016/S0300-9084(99)80034-0; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; Shivji MKK, 1998, ONCOGENE, V17, P2827, DOI 10.1038/sj.onc.1202352; SMITH ML, 1995, ONCOGENE, V10, P1053; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Spivak Graciela, 1995, Methods (Orlando), V7, P147, DOI 10.1006/meth.1995.1021; Stewart ZA, 1999, CANCER RES, V59, P3831; Sugasawa K, 1996, MOL CELL BIOL, V16, P4852; Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X; Therrien JP, 1999, P NATL ACAD SCI USA, V96, P15038, DOI 10.1073/pnas.96.26.15038; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; van Steeg H, 1999, MOL MED TODAY, V5, P86, DOI 10.1016/S1357-4310(98)01394-X; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wani MA, 1999, CARCINOGENESIS, V20, P765, DOI 10.1093/carcin/20.5.765; Wood RD, 1999, BIOCHIMIE, V81, P39, DOI 10.1016/S0300-9084(99)80036-4; Zhu QZ, 2000, J BIOL CHEM, V275, P11492, DOI 10.1074/jbc.275.15.11492	52	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25813	25822		10.1074/jbc.M102240200	http://dx.doi.org/10.1074/jbc.M102240200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11331289	hybrid			2022-12-25	WOS:000169823300025
J	Braun, P; Ockhuijsen, C; Eppens, E; Koster, M; Bitter, W; Tommassen, J				Braun, P; Ockhuijsen, C; Eppens, E; Koster, M; Bitter, W; Tommassen, J			Maturation of Pseudomonas aeruginosa elastase - Formation of the disulfide bonds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; GRAM-NEGATIVE BACTERIA; ACTIVE-SITE HIS-223; SECRETION; PROPEPTIDE; CLONING; MUTANTS; BINDING; GENES; TRANSLOCATION	Elastase of Pseudomonas aeruginosa is synthesized as a preproenzyme. After propeptide-mediated folding in the periplasm, the proenzyme is autoproteolytically processed, prior to translocation of both the mature enzyme and the propeptide across the outer membrane. The formation of the two disulfide bonds present in the mature enzyme was examined by studying the expression of the wild-type enzyme and of alanine for cysteine mutant derivatives in the authentic host and in dsb mutants of Escherichia coli. It appeared that the two disulfide bonds are formed successively. First, DsbA catalyzes the formation of the disulfide bond between Cys-270 and Cys-297 within the proenzyme, This step is essential for the subsequent autoproteolytic processing to occur, The second disulfide bond between Cys-30 and Cys-57 is formed more slowly and appears to be formed after processing of the proenzyme, and its formation is catalyzed by DsbA as well. This second disulfide bond appeared to be required for the full proteolytic activity of the enzyme and contributes to its stability.	Univ Utrecht, Dept Mol & Cell Biol, NL-3584 CH Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, NL-3584 CH Utrecht, Netherlands	Utrecht University; Utrecht University	Tommassen, J (corresponding author), Univ Utrecht, Dept Mol & Cell Biol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	j.p.m.tommassen@bio.uu.nl	Bitter, W/CAJ-5778-2022; Bitter, Wilbert/AAA-6872-2019; Bitter, Wilbert/ABG-3726-2020; Koster, Margot/D-1261-2011; Tommassen, Jan/I-1690-2016	Bitter, Wilbert/0000-0001-8347-6511; Tommassen, Jan/0000-0001-7633-4945; Braun, Peter/0000-0002-9870-465X				BEVER RA, 1988, J BACTERIOL, V170, P4309, DOI 10.1128/jb.170.9.4309-4314.1988; BORTOLIGERMAN I, 1994, MOL MICROBIOL, V11, P545, DOI 10.1111/j.1365-2958.1994.tb00335.x; Braun P, 2000, MICROBIOL-UK, V146, P2565, DOI 10.1099/00221287-146-10-2565; Braun P, 1998, J BACTERIOL, V180, P3467, DOI 10.1128/JB.180.13.3467-3469.1998; Braun P, 1996, MOL MICROBIOL, V19, P297, DOI 10.1046/j.1365-2958.1996.381908.x; DEGROOT A, 1991, MOL GEN GENET, V229, P278, DOI 10.1007/BF00272167; Eppens EF, 1997, EMBO J, V16, P4295, DOI 10.1093/emboj/16.14.4295; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; FILLOUX A, 1987, FEMS MICROBIOL LETT, V40, P159; Filloux A, 1998, FEMS MICROBIOL REV, V22, P177, DOI 10.1016/S0168-6445(98)00013-8; Folders J, 2000, J BACTERIOL, V182, P1257, DOI 10.1128/JB.182.5.1257-1263.2000; Frank DW, 1997, MOL MICROBIOL, V26, P621, DOI 10.1046/j.1365-2958.1997.6251991.x; Frech C, 1996, EMBO J, V15, P392, DOI 10.1002/j.1460-2075.1996.tb00369.x; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GUZZO J, 1990, J BACTERIOL, V172, P942, DOI 10.1128/jb.172.2.942-948.1990; HAAS D, 1976, MOL GEN GENET, V144, P243, DOI 10.1007/BF00341722; HARDIE KR, 1995, MOL MICROBIOL, V17, P1035, DOI 10.1111/j.1365-2958.1995.mmi_17061035.x; HEKSTRA D, 1993, J BACTERIOL, V175, P6546, DOI 10.1128/jb.175.20.6546-6552.1993; HERRERO M, 1990, J BACTERIOL, V172, P6557, DOI 10.1128/jb.172.11.6557-6567.1990; HIRST TR, 1987, P NATL ACAD SCI USA, V84, P7418, DOI 10.1073/pnas.84.21.7418; KANIGA K, 1991, GENE, V109, P137, DOI 10.1016/0378-1119(91)90599-7; KESSLER E, 1988, J BACTERIOL, V170, P5241, DOI 10.1128/jb.170.11.5241-5247.1988; Kessler E, 1998, J BIOL CHEM, V273, P30225, DOI 10.1074/jbc.273.46.30225; KESSLER E, 1994, J BIOL CHEM, V269, P22726; KING EO, 1954, J LAB CLIN MED, V44, P301; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; MCIVER K, 1991, J BACTERIOL, V173, P7781, DOI 10.1128/jb.173.24.7781-7789.1991; McIver KS, 1995, MOL MICROBIOL, V18, P877, DOI 10.1111/j.1365-2958.1995.18050877.x; MCIVER KS, 1993, J BACTERIOL, V175, P4008, DOI 10.1128/JB.175.13.4008-4015.1993; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; PUGSLEY AP, 1992, P NATL ACAD SCI USA, V89, P12058, DOI 10.1073/pnas.89.24.12058; Raina S, 1997, ANNU REV MICROBIOL, V51, P179, DOI 10.1146/annurev.micro.51.1.179; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAD PA, 1987, J BACTERIOL, V169, P2691, DOI 10.1128/jb.169.6.2691-2696.1987; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; THAYER MM, 1991, J BIOL CHEM, V266, P2864; TOMMASSEN J, 1992, FEMS MICROBIOL LETT, V103, P73; TOMMASSEN J, 1983, EMBO J, V2, P1275, DOI 10.1002/j.1460-2075.1983.tb01581.x; Wilhelm S, 1999, J BACTERIOL, V181, P6977, DOI 10.1128/JB.181.22.6977-6986.1999; WRETLIND B, 1984, J BACTERIOL, V158, P801, DOI 10.1128/JB.158.3.801-808.1984; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019	43	42	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26030	26035		10.1074/jbc.M007122200	http://dx.doi.org/10.1074/jbc.M007122200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11350952	hybrid			2022-12-25	WOS:000169823300053
J	Lai, A; Sarcevic, B; Prall, OWJ; Sutherland, RL				Lai, A; Sarcevic, B; Prall, OWJ; Sutherland, RL			Insulin/Insulin-like growth factor-I and estrogen cooperate to stimulate cyclin E-Cdk2 activation and cell cycle progression in MCF-7 breast cancer cells through differential regulation of cyclin E and p21(WAF1/Cip1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; RETINOBLASTOMA PROTEIN-PHOSPHORYLATION; ALPHA GENE-EXPRESSION; PHOSPHATIDYLINOSITOL 3-KINASE; MITOGENIC STIMULATION; CARCINOMA CELLS; CDK INHIBITORS; KINASE; PROLIFERATION; COMPLEX	Estrogens and insulin/insulin-like growth factor-I (IGF-I) are potent mitogens for breast epithelial cells and, when co-administered, induce synergistic stimulation of cell proliferation. To investigate the molecular basis of this effect, a MCF-7 breast cancer cell model was established where serum deprivation and concurrent treatment with the pure estrogen antagonist, ICI 182780, inhibited growth factor and estrogen action and arrested cells in G(0)/G(1) phase. Subsequent stimulation with insulin or IGF-I alone failed to induce significant S-phase entry. However, these treatments increased cy. clin D1, cyclin E, and p21 gene expression and induced the formation of active Cdk4 complexes but resulted in only minor increases in cyclin E-Cdk2 activity, likely due to recruitment of the cyclin-dependent kinase (CDK) inhibitor p21(WAF1/Cip1) into these complexes. Treatment with estradiol alone resulted in a greater increase in cyclin D1 gene expression but markedly decreased p21 expression, with a concurrent increase in Cdk4 and Cdk2 activity and subsequent synchronous entry of cells into S phase. Go-administration of insulin/ IGF-I and estrogen induced synergistic stimulation of S-phase entry coincident with synergistic: activation of high molecular mass (similar to 350 kDa) cyclin E-Cdk2 complexes lacking p21, To determine if the ability of estrogen to deplete p21 was central to these effects, cells stimulated with insulin and estradiol were infected with an adenovirus expressing p21, Induction of p21 to levels equivalent to those following treatment with insulin alone markedly inhibited the synergism between estradiol and insulin on S-phase entry. Thus the ability of estradiol to antagonize the insulin-induced increase in p21 gene expression, with consequent activation of cy. clin E-Cdk2, is a central component of the synergistic stimulation of breast epithelial cell proliferation induced by simultaneous activation of the estrogen and insulin/IGF-I signaling pathways.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney	Sutherland, RL (corresponding author), Garvan Inst Med Res, Canc Res Program, 384 Victoria St,Darlinghurst, Sydney, NSW 2010, Australia.		Sutherland, Robert L/A-8378-2008	Sarcevic, Boris/0000-0002-8063-1050				ADAMO M, 1992, BIOFACTORS, V3, P151; Adams PD, 1996, MOL CELL BIOL, V16, P6623; Ahmad S, 1999, BIOCHEM PHARMACOL, V58, P425, DOI 10.1016/S0006-2952(99)00125-2; Altucci L, 1996, ONCOGENE, V12, P2315; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; Colditz GA, 1998, JNCI-J NATL CANCER I, V90, P814, DOI 10.1093/jnci/90.11.814; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Daws MR, 1996, ENDOCRINOLOGY, V137, P1177, DOI 10.1210/en.137.4.1177; Dufourny B, 2000, J ENDOCRINOL, V166, P329, DOI 10.1677/joe.0.1660329; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Dupont J, 2000, J BIOL CHEM, V275, P35893, DOI 10.1074/jbc.M006741200; FALCKPEDERSEN E, 1998, CELLS LAB MANUAL; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Guvakova MA, 1997, CANCER RES, V57, P2606; HARLOW E, 1988, ANTIBODIES LAB MANUA, P526; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; Jackson JG, 1998, J BIOL CHEM, V273, P9994, DOI 10.1074/jbc.273.16.9994; Kahlert S, 2000, J BIOL CHEM, V275, P18447, DOI 10.1074/jbc.M910345199; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; Lee AV, 1997, J ENDOCRINOL, V152, P39, DOI 10.1677/joe.0.1520039; Lukas J, 1996, MOL CELL BIOL, V16, P6917; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MA ZQ, 1994, MOL ENDOCRINOL, V8, P910, DOI 10.1210/me.8.7.910; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; MILAZZO G, 1992, J CLIN INVEST, V89, P899, DOI 10.1172/JCI115670; Molloy CA, 2000, J BIOL CHEM, V275, P12565, DOI 10.1074/jbc.275.17.12565; MUSGROVE EA, 1989, CANCER RES, V49, P2398; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nicholson RI, 1996, ANN NY ACAD SCI, V784, P325, DOI 10.1111/j.1749-6632.1996.tb16247.x; OSBORNE CK, 1976, P NATL ACAD SCI USA, V73, P4536, DOI 10.1073/pnas.73.12.4536; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1998, J STEROID BIOCHEM, V65, P169, DOI 10.1016/S0960-0760(98)00021-1; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Richards RG, 1998, J BIOL CHEM, V273, P11962, DOI 10.1074/jbc.273.19.11962; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; STEWART AJ, 1992, BRIT J CANCER, V66, P640, DOI 10.1038/bjc.1992.330; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; Stoica A, 2000, J CELL BIOCHEM, V76, P605, DOI 10.1002/(SICI)1097-4644(20000315)76:4<605::AID-JCB9>3.0.CO;2-T; Stoica A, 2000, J ENDOCRINOL, V165, P371, DOI 10.1677/joe.0.1650371; SUTHERLAND RL, 1983, CANCER RES, V43, P3998; Thornton JM, 1992, SEED SCI RES, V2, P41, DOI 10.1017/S0960258500001094; VANDERBURG B, 1990, CANCER RES, V50, P7770; VANDERBURG B, 1988, J CELL PHYSIOL, V134, P101, DOI 10.1002/jcp.1041340112; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; White MF, 1998, CURR TOP MICROBIOL, V228, P179; Yee D, 2000, J MAMMARY GLAND BIOL, V5, P107, DOI 10.1023/A:1009575518338; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472	56	82	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25823	25833		10.1074/jbc.M100925200	http://dx.doi.org/10.1074/jbc.M100925200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11337496	hybrid			2022-12-25	WOS:000169823300026
J	Mitrovic, AD; Plesko, F; Vandenberg, RJ				Mitrovic, AD; Plesko, F; Vandenberg, RJ			Zn2+ inhibits the anion conductance of the glutamate transporter EAAT4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL GLIAL-CELLS; RAT-BRAIN; CHLORIDE CHANNEL; ZINC; NEURONS; EXPRESSION; ASPARTATE; SUBTYPES; CURRENTS; AFFINITY	Glutamate transport by the excitatory amino acid transporters (EAATs) is coupled to the co-transport of 3 Na+ ions and 1 H+ and the counter-transport of 1 K+ ion, which ensures that extracellular glutamate concentrations are maintained in the submicromolar range. In addition to the coupled ion fluxes, glutamate transport activates an uncoupled anion conductance that does not influence the rate or direction of transport but may have the capacity to influence the excitability of the cell. Free Zn2+ ions are often co-localized with glutamate in the central nervous system and have the capacity to modulate the dynamics of excitatory neurotransmission. In this study we demonstrate that Zn2+ ions inhibit the uncoupled anion conductance and also reduce the affinity of L-aspartate for EAAT4. The molecular basis for this effect was investigated using site-directed mutagenesis. Two histidine residues in the extracellular loop between transmembrane domains three and four of EAAT4 appear to confer Zn2+ inhibition of the anion conductance.	Univ Sydney, Dept Pharmacol, Sydney, NSW 2006, Australia	University of Sydney	Vandenberg, RJ (corresponding author), Univ Sydney, Dept Pharmacol, Sydney, NSW 2006, Australia.	robv@pharmacol.usyd.edu.au	Vandenberg, Robert John/E-6018-2016	Vandenberg, Robert John/0000-0003-1523-4814				ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Billups B, 1996, J NEUROSCI, V16, P6722; BUSSELBERG D, 1994, J NEUROPHYSIOL, V71, P1491, DOI 10.1152/jn.1994.71.4.1491; DAWSON RMC, 1986, DATA BIOCH RES, P76; Eliasof S, 1996, P NATL ACAD SCI USA, V93, P4153, DOI 10.1073/pnas.93.9.4153; Eskandari S, 2000, P NATL ACAD SCI USA, V97, P8641, DOI 10.1073/pnas.97.15.8641; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; Furuta A, 1997, NEUROSCIENCE, V81, P1031, DOI 10.1016/S0306-4522(97)00252-2; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; Jackson M, 2001, NATURE, V410, P89, DOI 10.1038/35065091; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; Lehre KP, 1998, J NEUROSCI, V18, P8751, DOI 10.1523/jneurosci.18-21-08751.1998; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; Lin CLG, 2001, NATURE, V410, P84, DOI 10.1038/35065084; Marie H, 1999, J PHYSIOL-LONDON, V520, P393, DOI 10.1111/j.1469-7793.1999.00393.x; MILEDI R, 1989, J PHYSIOL-LONDON, V417, P173, DOI 10.1113/jphysiol.1989.sp017796; Otis TS, 1997, SCIENCE, V277, P1515, DOI 10.1126/science.277.5331.1515; PETERS S, 1987, SCIENCE, V236, P589, DOI 10.1126/science.2883728; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; REGAN L, 1995, TRENDS BIOCHEM SCI, V20, P280, DOI 10.1016/S0968-0004(00)89044-1; SARANTIS M, 1988, NATURE, V332, P451, DOI 10.1038/332451a0; Spiridon M, 1998, J PHYSIOL-LONDON, V506, P363, DOI 10.1111/j.1469-7793.1998.363bw.x; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; Vandenberg RJ, 1997, MOL PHARMACOL, V51, P809, DOI 10.1124/mol.51.5.809; Vandenberg RJ, 1998, MOL PHARMACOL, V54, P189, DOI 10.1124/mol.54.1.189; Wadiche JI, 1998, J NEUROSCI, V18, P7650; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; Weiss JH, 2000, TRENDS PHARMACOL SCI, V21, P395, DOI 10.1016/S0165-6147(00)01541-8; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	33	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26071	26076		10.1074/jbc.M011318200	http://dx.doi.org/10.1074/jbc.M011318200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11352900	hybrid			2022-12-25	WOS:000169823300059
J	Wang, HY; Altman, Y; Fang, D; Elly, C; Dai, Y; Shao, Y; Liu, YC				Wang, HY; Altman, Y; Fang, D; Elly, C; Dai, Y; Shao, Y; Liu, YC			Cbl promotes ubiquitination of the T cell receptor zeta through an adaptor function of Zap-70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; SYK TYROSINE KINASE; NEGATIVE REGULATOR; C-CBL; ANTIGEN RECEPTOR; PHOSPHORYLATION SITE; SIGNAL-TRANSDUCTION; RING FINGER; ACTIVATION; PROTEIN	Triggering of the T cell antigen receptor (TCR). CD3 complex induces its ubiquitination, However, the molecular events that lead to ubiquitin conjugation to these cell surface molecules have not been defined, Here we report that Cbl, a RING-type E3 ubiquitin-protein ligase, promotes ubiquitination of TCR zeta chain, which requires its functional variant Src homology 2 domain and an intact RING finger. The tyrosine kinase Zap-70, which binds to both TCR zeta and Cbl, plays an adaptor role in these events, Mutations in TCR zeta, Zap-70, or Cbl that disrupt the interaction between TCR zeta and Zap-70 or between Zap-70 and Cbl reduce ubiquitination of TCR zeta Our results suggest a novel mechanism by which Cbl negatively regulates T cell development and activation by inducing ubiquitination of the TCR CD3 components.	La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA	La Jolla Institute for Immunology	Liu, YC (corresponding author), La Jolla Inst Allergy & Immunol, Div Cell Biol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.	yuncail@liai.org	Fang, Deyu/I-7245-2013	Fang, Deyu/0000-0002-4211-2751; LIU, YUN-CAI/0000-0002-0996-7109	NIDDK NIH HHS [R01DK-56588] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Cenciarelli C, 1996, J BIOL CHEM, V271, P8709, DOI 10.1074/jbc.271.15.8709; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; FANG D, 2001, J BIOL CHEM, V276, P15547; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOU D, 1994, J BIOL CHEM, V269, P14244; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Jose ES, 2000, IMMUNITY, V12, P161, DOI 10.1016/S1074-7613(00)80169-7; Krummel MF, 2000, SCIENCE, V289, P1349, DOI 10.1126/science.289.5483.1349; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Love PE, 2000, IMMUNITY, V12, P591, DOI 10.1016/S1074-7613(00)80210-1; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; Ota S, 2000, J BIOL CHEM, V275, P414, DOI 10.1074/jbc.275.1.414; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; PANTALEO G, 1987, J EXP MED, V166, P619, DOI 10.1084/jem.166.2.619; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Rao N, 2000, J IMMUNOL, V164, P4616, DOI 10.4049/jimmunol.164.9.4616; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829; Sosinowski T, 2000, J EXP MED, V191, P463, DOI 10.1084/jem.191.3.463; Tang J, 1999, P NATL ACAD SCI USA, V96, P9775, DOI 10.1073/pnas.96.17.9775; Valitutti S, 1997, J EXP MED, V185, P1859, DOI 10.1084/jem.185.10.1859; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	36	133	136	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26004	26011		10.1074/jbc.M010738200	http://dx.doi.org/10.1074/jbc.M010738200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11353765	hybrid			2022-12-25	WOS:000169823300050
J	Xu, BE; Stippec, S; Robinson, FL; Cobb, MH				Xu, BE; Stippec, S; Robinson, FL; Cobb, MH			Hydrophobic as well as charged residues in both MEK1 and ERK2 are important for their proper docking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; RIBOSOMAL S6 KINASE; MAP KINASE; SIGNAL-TRANSDUCTION; IN-VIVO; PHOSPHORYLATION; SITE; IDENTIFICATION; RESOLUTION; SEQUENCE	Docking between MEK1 and ERK2 is required for their stable interaction and efficient signal transmission. The MEK1 N terminus contains the ERK docking or D domain that consists of conserved hydrophobic and basic residues. We mutated the hydrophobic and basic residues individually and found that loss of either type reduced MEK1 phosphorylation of ERK2 in vitro and its ability to bind to ERK2 in vivo, Moreover, ERK2 was localized in both the cytoplasm and the nucleus when co-expressed with MEK1 that had mutations in either the hydrophobic or the basic residues. We then identified two conserved hydrophobic residues on ERK2 that play roles in docking with MEK1, Mutating these residues to alanine reduced the interaction of ERK2 with MEK1 in cells. These mutations also reduced the phosphorylation of MEK1 by ERK2 but had little effect on phosphorylation of MBP by ERK2, Finally, we generated docking site mutants in ERK2-MEK1 fusion proteins. Although the mutation of the MEK1 D domain significantly reduced ERK2-MEK1 activity, mutations of the putatively complementary acidic residues and hydrophobic residues on ERK2 did not change its activity. However, both types of mutations decreased the phosphorylation of Elk-l caused by ERK2-MEK1 fusion proteins. These findings suggest complex interactions of MEK1 D domains with ERK2 that influence its activation and its effects on substrates.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Cobb, Melanie/0000-0003-0833-5473	NIDDK NIH HHS [DK34128] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034128, R37DK034128] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRUNET A, 1996, SCIENCE, V272, P1653; Christerson LB, 1999, CELL MOTIL CYTOSKEL, V43, P186, DOI 10.1002/(SICI)1097-0169(1999)43:3<186::AID-CM2>3.0.CO;2-1; Dang A, 1998, J BIOL CHEM, V273, P19909, DOI 10.1074/jbc.273.31.19909; Eblen ST, 2001, MOL CELL BIOL, V21, P249, DOI 10.1128/MCB.21.1.249-259.2001; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Resing KA, 1998, BIOCHEMISTRY-US, V37, P463, DOI 10.1021/bi971750x; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SEGER R, 1992, J BIOL CHEM, V267, P14373; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Smith JK, 2000, J BIOL CHEM, V275, P31588, DOI 10.1074/jbc.M005892200; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Wang ZL, 1997, P NATL ACAD SCI USA, V94, P2327, DOI 10.1073/pnas.94.6.2327; Wilsbacher JL, 1999, J BIOL CHEM, V274, P16988, DOI 10.1074/jbc.274.24.16988; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	26	77	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26509	26515		10.1074/jbc.M102769200	http://dx.doi.org/10.1074/jbc.M102769200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11352917	hybrid			2022-12-25	WOS:000169823300114
J	Yang, JQ; Kawai, Y; Hanson, RW; Arinze, IJ				Yang, JQ; Kawai, Y; Hanson, RW; Arinze, IJ			Sodium butyrate induces transcription from the G alpha(i2) gene promoter through multiple Sp1 sites in the promoter and by activating the MEK-ERK signal transduction pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE INHIBITORS; LLC-PK1 RENAL-CELLS; CHAIN FATTY-ACIDS; RNA-POLYMERASE-II; EMBRYONAL CARCINOMA-CELLS; HUMAN K562 CELLS; PROTEIN-KINASE; ALPHA-SUBUNIT; MAP KINASE; PROTOONCOGENE TRANSCRIPTION	Sodium butyrate, an erythroid differentiation inducer and a histone deacetylase inhibitor, increases G alpha (i2), levels in differentiating K562 cells, Here we show that sodium butyrate induces Gal, gene transcription via sequences at -50/-36 and -92/-85 in the G alpha (i), gene promoter. Both sequences contain core sequence motif for Spl binding; electrophoretic mobility shift as well as supershift assays confirmed binding to Spl, Transcription from the G alpha (i2) gene promoter was also activated by two other histone deacetylase inhibitors, trichostatin A and Helminthsporium carbonium toxin (HC toxin), which also induce erythroblastic differentiation in K562 cells. However, hydroxyurea, a potent erythroid differentiation inducer in these cells, did not activate transcription from this gene promoter, indicating that promoter activation is inducer-specific, Mutations within the Spl sites at -50/-36 and -92/-85 in the Gai, gene promoter substantially decreased transcriptional activation by sodium butyrate, trichostatin A, or HC toxin, Transfection with constitutively activated ERKs indicated that this promoter can be activated through the MEK-ERK signal transduction pathway. Inhibition of the MEK-ERK pathway with U0126 or reduction in the expression of endogenous ERK with an antisense oligonucleotide to ERK significantly inhibited sodium butyrate- and HC toxin-induced transcription but had no effect on trichostatin A-induced transcription, Inhibition of the JNK and p38 MAPKs, using selective inhibitors, had no effect on sodium butyrate-induced transcription. In cells in which sodium butyrate induction of promoter activation had been inhibited by various concentrations of U0126, constitutively activated ERK2 reversed this inhibition. These results show that the MEK-ERK signal transduction pathway is important in butyrate signaling, which eventually converges in the cell nucleus.	Meharry Med Coll, Dept Biochem, Nashville, TN 37208 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Meharry Medical College; Case Western Reserve University	Arinze, IJ (corresponding author), Meharry Med Coll, Dept Biochem, 1005 David B Todd Jr Blvd, Nashville, TN 37208 USA.	i.arinze@worldnet.att.net			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025541] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 25541] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADUNYAH SE, 1995, BBA-GENE STRUCT EXPR, V1263, P123; Ajenjo N, 2000, J BIOL CHEM, V275, P7189, DOI 10.1074/jbc.275.10.7189; AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; Benvenuto G, 1996, MOL CELL BIOL, V16, P2736; BIRREN BW, 1986, NUCLEIC ACIDS RES, V14, P853, DOI 10.1093/nar/14.2.853; BROSCH G, 1995, PLANT CELL, V7, P1941, DOI 10.1105/tpc.7.11.1941; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CONSTANTOULAKIS P, 1989, BLOOD, V74, P1963; Courilleau D, 2000, J BIOL CHEM, V275, P17344, DOI 10.1074/jbc.M000887200; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; CUMMINGS JH, 1981, GUT, V22, P763, DOI 10.1136/gut.22.9.763; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; Davis MG, 2000, BIOCHEM J, V346, P455, DOI 10.1042/0264-6021:3460455; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; DOVER GJ, 1986, BLOOD, V67, P735; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; Eschenhagen T, 1996, BASIC RES CARDIOL, V91, P41, DOI 10.1007/BF00795361; Espinos E, 1998, MOL BRAIN RES, V56, P118, DOI 10.1016/S0169-328X(98)00036-9; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Galasinski SK, 2000, MOL CELL BIOL, V20, P1923, DOI 10.1128/MCB.20.6.1923-1930.2000; GLAUBER JG, 1991, MOL CELL BIOL, V11, P4690, DOI 10.1128/MCB.11.9.4690; HEERDT BG, 1994, CANCER RES, V54, P3288; HERUTH DP, 1993, J BIOL CHEM, V268, P20466; HOLTZMAN EJ, 1991, J BIOL CHEM, V266, P1763; HOLTZMAN EJ, 1993, J BIOL CHEM, V268, P3964; Janson W, 1997, ONCOGENE, V15, P1395, DOI 10.1038/sj.onc.1201304; Jho EH, 1997, J BIOL CHEM, V272, P24468, DOI 10.1074/jbc.272.39.24468; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Khanna-Gupta A, 2000, BLOOD, V95, P3734; KINANE TB, 1993, J BIOL CHEM, V268, P24669; KINANE TB, 1994, J BIOL CHEM, V269, P27503; Kinane TB, 1995, J BIOL CHEM, V270, P30760, DOI 10.1074/jbc.270.51.30760; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; LAZAR MA, 1990, J BIOL CHEM, V265, P17474; LE HB, 1994, DNA CELL BIOL, V13, P473, DOI 10.1089/dna.1994.13.473; LEDER A, 1975, CELL, V5, P319, DOI 10.1016/0092-8674(75)90107-5; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Liu CT, 1996, CRIT REV ONCOGENESIS, V7, P101, DOI 10.1615/CritRevOncog.v7.i1-2.70; Lu Y, 1999, BBA-GENE STRUCT EXPR, V1444, P85, DOI 10.1016/S0167-4781(98)00257-7; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; McBain JA, 1997, BIOCHEM PHARMACOL, V53, P1357, DOI 10.1016/S0006-2952(96)00904-5; McCaffrey PG, 1997, BLOOD, V90, P2075, DOI 10.1182/blood.V90.5.2075; MERCHANT JL, 1995, J BIOL CHEM, V270, P6314, DOI 10.1074/jbc.270.11.6314; Merchiers P, 1999, FEBS LETT, V456, P149, DOI 10.1016/S0014-5793(99)00942-4; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; Naar AM, 1998, COLD SPRING HARB SYM, V63, P189, DOI 10.1101/sqb.1998.63.189; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Netzker R, 1999, BBA-GENE STRUCT EXPR, V1444, P231, DOI 10.1016/S0167-4781(98)00281-4; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; RIGGS MG, 1977, NATURE, V268, P462, DOI 10.1038/268462a0; RIUS C, 1990, EXP CELL RES, V188, P129, DOI 10.1016/0014-4827(90)90287-K; Rivero JA, 1996, BIOCHEM BIOPH RES CO, V224, P796, DOI 10.1006/bbrc.1996.1102; ROEDIGER WEW, 1980, LANCET, V2, P712; ROEDIGER WEW, 1980, GUT, V21, P793, DOI 10.1136/gut.21.9.793; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SCHEPPACH W, 1992, JPEN-PARENTER ENTER, V16, P43, DOI 10.1177/014860719201600143; Sowa Y, 1999, ANN NY ACAD SCI, V886, P195, DOI 10.1111/j.1749-6632.1999.tb09415.x; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Tsuji Y, 1999, J BIOL CHEM, V274, P7501, DOI 10.1074/jbc.274.11.7501; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; WEINSTEIN LS, 1988, FEBS LETT, V232, P333, DOI 10.1016/0014-5793(88)80764-6; WEINSTEIN LS, 1990, MOL ENDOCRINOL, V4, P958, DOI 10.1210/mend-4-7-958; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; ZHANG DE, 1994, J BIOL CHEM, V269, P11425; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhang YG, 2001, J BIOL CHEM, V276, P14572, DOI 10.1074/jbc.M004615200; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	77	83	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25742	25752		10.1074/jbc.M102821200	http://dx.doi.org/10.1074/jbc.M102821200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11337508	hybrid			2022-12-25	WOS:000169823300016
J	Detich, N; Ramchandani, S; Szyf, M				Detich, N; Ramchandani, S; Szyf, M			A conserved 3 '-untranslated element mediates growth regulation of DNA methyltransferase 1 and inhibits its transforming activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; A+U-RICH ELEMENTS; DEPENDENT REGULATION; CYTOSINE-DNA; CELL-CYCLE; SERUM STIMULATION; SIGNALING PATHWAY; BINDING PROTEIN; COLON-CANCER	Ectopic expression of DNA methyltransferase 1 (DNMT1) has been proposed to play an important role in cancer. dnmt1 mRNA is undetectable in growth-arrested cells but is induced upon entrance into the S phase of the cell cycle, and until now, the mechanisms responsible for this regulation were unknown. In this report, we demonstrate that the 3 ' -untranslated region (3 ' -UTR) of the dnmt1 mRNA can confer a growth-dependent regulation on its own message as well as a heterologous beta -globin mRNA Our results indicate that a 54-nucleotide highly conserved element within the 3 ' -UTR is necessary and sufficient to mediate this regulation. Cell-free mRNA decay experiments demonstrate that this element increases mRNA turnover rates and does so to a greater extent in the presence of extracts prepared from arrested cells. A specific RNA-protein complex is formed with the 3 ' -UTR only in growth-arrested cells, and a UV cross-linking analysis revealed a 40-kDa protein (p40), the binding of which is dramatically increased in growth-arrested cells and is inversely correlated with dnmt1 mRNA levels as cells are induced into the cell cycle. Although ectopic expression of human DNMT1 lacking the 3 ' -UTR can transform NIH-3T3 cells, inclusion of the 3 ' -UTR prevents transformation. These results support the hypothesis that deregulated expression of DNMT1 with the cell cycle is important for cellular transformation.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada	McGill University	Szyf, M (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Sir William Osler Promenade, Montreal, PQ H3G 1Y6, Canada.	mszyf@pharma.mcgill.ca						Araujo FD, 1998, MOL CELL BIOL, V18, P3475, DOI 10.1128/MCB.18.6.3475; ASSONBATRES MA, 1994, P NATL ACAD SCI USA, V91, P1318, DOI 10.1073/pnas.91.4.1318; Atasoy U, 1998, J CELL SCI, V111, P3145; Ausubel FM., 1988, CURRENT PROTOCOLS MO; Baker DM, 2000, J BIOL CHEM, V275, P19985, DOI 10.1074/jbc.M002351200; Baylin SB, 1998, ADV CANCER RES, V72, P141; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; Buzby JS, 1996, BLOOD, V88, P2889, DOI 10.1182/blood.V88.8.2889.bloodjournal8882889; Buzby JS, 1999, J BIOL CHEM, V274, P33973, DOI 10.1074/jbc.274.48.33973; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; De Marzo AM, 1999, CANCER RES, V59, P3855; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Eads CA, 1999, CANCER RES, V59, P2302; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heaton JH, 2001, J BIOL CHEM, V276, P3341, DOI 10.1074/jbc.M006538200; Hew Y, 1999, J BIOL CHEM, V274, P14415, DOI 10.1074/jbc.274.20.14415; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jang BC, 2000, J BIOL CHEM, V275, P39507, DOI 10.1074/jbc.M003224200; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; Joseph B, 1998, J BIOL CHEM, V273, P20511, DOI 10.1074/jbc.273.32.20511; Jurgens B, 1996, CANCER RES, V56, P5698; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; Kessler O, 1996, MOL CELL BIOL, V16, P4426; Knox JD, 2000, J BIOL CHEM, V275, P17986, DOI 10.1074/jbc.C900894199; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Liu YL, 1996, NUCLEIC ACIDS RES, V24, P2718, DOI 10.1093/nar/24.14.2718; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; Maity A, 1997, CELL GROWTH DIFFER, V8, P311; MALTER JS, 1991, J BIOL CHEM, V266, P3167; Melamed M. R., 1990, FLOW CYTOMETRY SORTI; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Milutinovic S, 2000, J BIOL CHEM, V275, P6353, DOI 10.1074/jbc.275.9.6353; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nass SJ, 1999, ONCOGENE, V18, P7453, DOI 10.1038/sj.onc.1203138; Noe V, 1999, J BIOL CHEM, V274, P27807, DOI 10.1074/jbc.274.39.27807; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Robertson KD, 2000, NUCLEIC ACIDS RES, V28, P2108, DOI 10.1093/nar/28.10.2108; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Scheper W, 1996, BIOCHEM J, V318, P195, DOI 10.1042/bj3180195; Searles CD, 1999, CIRC RES, V85, P588, DOI 10.1161/01.RES.85.7.588; Sela-Brown A, 2000, J BIOL CHEM, V275, P7424, DOI 10.1074/jbc.275.10.7424; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; Slack A, 1999, J BIOL CHEM, V274, P10105, DOI 10.1074/jbc.274.15.10105; Spicher A, 1998, MOL CELL BIOL, V18, P7371, DOI 10.1128/MCB.18.12.7371; Staton JM, 2000, J MOL ENDOCRINOL, V25, P17, DOI 10.1677/jme.0.0250017; SURDEJ P, 1994, ANNU REV GENET, V28, P263; SZYF M, 1985, J BIOL CHEM, V260, P8653; Szyf M, 1998, CANCER METAST REV, V17, P219, DOI 10.1023/A:1006023023787; SZYF M, 1991, J BIOL CHEM, V266, P10027; SZYF M, 1994, TRENDS PHARMACOL SCI, V15, P233, DOI 10.1016/0165-6147(94)90317-4; SZYF M, 1984, P NATL ACAD SCI-BIOL, V81, P3278, DOI 10.1073/pnas.81.11.3278; Szyf M, 2001, PROG NUCLEIC ACID RE, V69, P47, DOI 10.1016/S0079-6603(01)69044-5; Szyf M, 2000, ANN NY ACAD SCI, V910, P156; SZYF M, 1990, MOL ENDOCRINOL, V4, P1144, DOI 10.1210/mend-4-8-1144; Tao L, 1997, J MOL BIOL, V273, P509, DOI 10.1006/jmbi.1997.1352; TEUBNER B, 1995, J CELL PHYSIOL, V165, P284, DOI 10.1002/jcp.1041650209; Tholanikunnel BG, 1999, BIOCHEMISTRY-US, V38, P15564, DOI 10.1021/bi9913348; Tillmann-Bogush M, 1999, J BIOL CHEM, V274, P1172, DOI 10.1074/jbc.274.2.1172; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257; Wu J C, 1985, Prog Clin Biol Res, V198, P119; Wu JJ, 1996, CANCER RES, V56, P616; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; Young JI, 2001, J BIOL CHEM, V276, P19610, DOI 10.1074/jbc.M009470200; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; Zhou QM, 1998, MOL CELL BIOL, V18, P815, DOI 10.1128/MCB.18.2.815	84	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24881	24890		10.1074/jbc.M103056200	http://dx.doi.org/10.1074/jbc.M103056200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11335728	hybrid			2022-12-25	WOS:000169800700061
J	Genetta, T; Morisaki, H; Morisaki, T; Holmes, EW				Genetta, T; Morisaki, H; Morisaki, T; Holmes, EW			A novel bipartite intronic splicing enhancer promotes the inclusion of a mini-exon in the AMP deaminase 1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR-2; TRACT BINDING-PROTEIN; ALTERNATIVE EXON; SKELETAL-MUSCLE; RNA; EXPRESSION; RECOGNITION; ELEMENT; SITE; IDENTIFICATION	Alternative splicing of the 12-base exon 2 of the adenosine monophosphate deaminase (AMPD) gene is subject to regulation by both cis- and trans-regulatory signals. The extent of exon 2 inclusion is stage- and cell type-specific and is subject to the physiological state of the cell. In adult skeletal muscle, a cell type that regulates the activity of this allosteric enzyme at several levels, the exon S-plus form of AMPD, predominates. We have performed a systematic analysis of the cis-acting regulatory sequences that reside in the intron immediately downstream of this mini-exon. A complex element comprising sequences that enhance exon 2 inclusion and sequences that counteract this effect resides in the middle of this intron. We demonstrate that the enhancing component is bipartite, with more than a kilobase of sequence separating the two functional sites. The presence of even minimal levels the mini-exon in the fully processed AMPD mRNA requires both of these sites, neither of which appears in any other published splicing enhancer. An RNA binding activity derived from a muscle cell line requires both of the enhancing sites. Mutations in either of the sites that eliminate exon 2 inclusion abrogate this binding activity.	Univ Calif San Diego, Sch Med, Off Dean, La Jolla, CA 92093 USA; Childrens Hosp Philadelphia, Joseph P Stokes Res Inst, Philadelphia, PA 19104 USA; Natl Cardiovasc Ctr, Res Inst, Dept Biosci, Suita, Osaka 5650871, Japan	University of California System; University of California San Diego; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; National Cerebral & Cardiovascular Center - Japan	Holmes, EW (corresponding author), Univ Calif San Diego, Sch Med, Off Dean, Rm 1313 Basic Sci Bldg,9500 Gilman Dr, La Jolla, CA 92093 USA.		Holmes, Edward/GVR-9499-2022		NIDDK NIH HHS [DK12314] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams MD, 1996, CURR OPIN CELL BIOL, V8, P331, DOI 10.1016/S0955-0674(96)80006-8; ASHBY B, 1979, J CELL BIOL, V81, P361, DOI 10.1083/jcb.81.2.361; ASHBY B, 1977, J BIOL CHEM, V252, P1869; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; BLACK DL, 1992, CELL, V69, P795, DOI 10.1016/0092-8674(92)90291-J; BLACK DL, 1995, RNA, V1, P763; Carlo T, 2000, MOL CELL BIOL, V20, P3988, DOI 10.1128/MCB.20.11.3988-3995.2000; Carlo T, 1996, RNA, V2, P342; Carstens RP, 2000, MOL CELL BIOL, V20, P7388, DOI 10.1128/MCB.20.19.7388-7400.2000; Chen CD, 1999, GENE DEV, V13, P593, DOI 10.1101/gad.13.5.593; DELGATTO F, 1995, MOL CELL BIOL, V15, P4825; DelGatto F, 1997, MOL CELL BIOL, V17, P5106, DOI 10.1128/MCB.17.9.5106; Dirksen WP, 2000, J BIOL CHEM, V275, P29170, DOI 10.1074/jbc.M001126200; Graveley BR, 1998, EMBO J, V17, P6747, DOI 10.1093/emboj/17.22.6747; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Guo NH, 2000, J BIOL CHEM, V275, P33641, DOI 10.1074/jbc.M005597200; Hedjran F, 1997, P NATL ACAD SCI USA, V94, P12343, DOI 10.1073/pnas.94.23.12343; HERTEL KJ, 1998, CELL, V98, P449; HISATOME I, 1998, AM J PHYSIOL, V275, P870; HUH GS, 1994, GENE DEV, V8, P1561, DOI 10.1101/gad.8.13.1561; HUH GS, 1993, MOL CELL BIOL, V13, P5301, DOI 10.1128/MCB.13.9.5301; KORETZ JF, 1980, P NATL ACAD SCI-BIOL, V77, P7186, DOI 10.1073/pnas.77.12.7186; Lim LP, 1998, MOL CELL BIOL, V18, P3900, DOI 10.1128/MCB.18.7.3900; Loh E, 1999, CIRCULATION, V99, P1422, DOI 10.1161/01.CIR.99.11.1422; Markovtsov V, 2000, MOL CELL BIOL, V20, P7463, DOI 10.1128/MCB.20.20.7463-7479.2000; MARQUETANT R, 1989, BIOCHEMISTRY-US, V28, P8744, DOI 10.1021/bi00448a010; McCullough AJ, 1997, MOL CELL BIOL, V17, P4562, DOI 10.1128/MCB.17.8.4562; McCullough AJ, 2000, MOL CELL BIOL, V20, P9225, DOI 10.1128/MCB.20.24.9225-9235.2000; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; MINEO I, 1991, MOL CELL BIOL, V11, P5356, DOI 10.1128/MCB.11.10.5356; MINEO I, 1990, MOL CELL BIOL, V10, P5271, DOI 10.1128/MCB.10.10.5271; Modafferi EF, 1997, MOL CELL BIOL, V17, P6537, DOI 10.1128/MCB.17.11.6537; MONTARRAS D, 1989, EMBO J, V8, P2203, DOI 10.1002/j.1460-2075.1989.tb08343.x; MORISAKI H, 1993, J CLIN INVEST, V91, P2275, DOI 10.1172/JCI116455; Morisaki H, 2000, GENE, V246, P365, DOI 10.1016/S0378-1119(00)00078-0; MORISAKI T, 1992, P NATL ACAD SCI USA, V89, P6457, DOI 10.1073/pnas.89.14.6457; Ryan KJ, 1996, MOL CELL BIOL, V16, P4014; Ryan KJ, 2000, J BIOL CHEM, V275, P20618, DOI 10.1074/jbc.M909977199; Sabina R.L., 1990, METABOLIC BASIS INHE, V2, P1769; SABINA RL, 1989, MOL CELL BIOL, V9, P2244, DOI 10.1128/MCB.9.5.2244; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SIEBEL CW, 1995, GENE DEV, V9, P269, DOI 10.1101/gad.9.3.269; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; STERNER DA, 1993, MOL CELL BIOL, V13, P2677, DOI 10.1128/MCB.13.5.2677; WHEELER TJ, 1979, J BIOL CHEM, V254, P8994; ZAHLER AM, 1993, MOL CELL BIOL, V13, P4023, DOI 10.1128/MCB.13.7.4023; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837	49	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25589	25597		10.1074/jbc.M011637200	http://dx.doi.org/10.1074/jbc.M011637200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11331279	hybrid			2022-12-25	WOS:000169800700150
J	Xu, T; Forgac, M				Xu, T; Forgac, M			Microtubules are involved in glucose-dependent dissociation of the yeast vacuolar [H+]-ATPase in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASE; V-ATPASE; PROTON TRANSPORT; SUBUNIT; DOMAIN; INHIBITION; MECHANISM; SYNTHASES; CATALYSIS; PROTEIN	The vacuolar [H+]-ATPases (V-ATPases) are composed of a peripheral V-1 domain and a membrane-embedded V-0 domain. Reversible dissociation of the V-1 and V-0 domains has been observed in both yeast and insects and has been suggested to represent a general regulatory mechanism for controlling V-ATPase activity in vivo. in yeast, dissociation of the V-ATPase is triggered by glucose depletion, but the signaling pathways that connect V-ATPase dissociation and glucose metabolism have not been identified. We have found that nocodazole, an agent that disrupts microtubules, partially blocked dissociation of the V-ATPase in response to glucose depletion in yeast. By contrast, latrunculin, an agent that disrupts actin filaments, had no effect on glucose-dependent dissociation of the V-ATPase complex. Neither nocodazole nor latrunculin blocked reassembly of the V-ATPase upon re-addition of glucose to the medium. The effect of nocodazole appears to be specifically through disruption of microtubules since glucose-dependent dissociation of the V-ATPase was not blocked by nocodazole in yeast strains bearing a mutation in tubulin that renders it resistant to nocodazole. Because nocodazole has been shown to arrest cells in the G(2) phase of the cell cycle, it was of interest to determine whether nocodazole exerted its effect on dissociation of the V-ATPase through cell cycle arrest. Glucose-dependent dissociation of the V-ATPase was examined in four yeast strains bearing temperature-sensitive mutations that arrest cells in different stages of the cell cycle. Because dissociation of the V-ATPase occurred normally at both the permissive and restrictive temperatures in these mutants, the results suggest that in vivo dissociation is not dependent upon cell cycle phase.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Forgac, M (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.	michael.forgac@tufts.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034478, R01GM034478] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34478, R01 GM034478, R37 GM034478] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALISON EM, 1991, METHOD ENZYMOL, V194, P729; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; ARAI H, 1989, BIOCHEMISTRY-US, V28, P3075, DOI 10.1021/bi00433a051; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Breton S, 2000, J BIOL CHEM, V275, P18219, DOI 10.1074/jbc.M909857199; Brown D, 2000, J EXP BIOL, V203, P137; BROWN D, 1991, KIDNEY INT, V40, pS79; Capaldi RA, 2000, J EXP BIOL, V203, P29; CHATTERJEE D, 1992, P NATL ACAD SCI USA, V89, P6257, DOI 10.1073/pnas.89.14.6257; Cross RL, 1996, J BIOENERG BIOMEMBR, V28, P403, DOI 10.1007/BF02113981; FENG Y, 1992, J BIOL CHEM, V267, P5817; FENG Y, 1992, J BIOL CHEM, V267, P19769; FENG Y, 1994, J BIOL CHEM, V269, P13224; Fillingame RH, 2000, J EXP BIOL, V203, P9; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Forgac M, 1998, FEBS LETT, V440, P258, DOI 10.1016/S0014-5793(98)01425-2; Futai M, 1996, J BIOENERG BIOMEMBR, V28, P409, DOI 10.1007/BF02113982; GLUCK SL, 1992, J BIOENERG BIOMEMBR, V24, P351, DOI 10.1007/BF00762528; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; GUTHRIE BA, 1988, J CELL BIOL, V107, P115, DOI 10.1083/jcb.107.1.115; HASEK J, 1986, EUR J CELL BIOL, V41, P150; Kane PM, 1999, J BIOENERG BIOMEMBR, V31, P49, DOI 10.1023/A:1005444513542; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOL CHEM, V267, P447; Lee BS, 1999, J BIOL CHEM, V274, P29164, DOI 10.1074/jbc.274.41.29164; Liu JZ, 1996, BIOCHEMISTRY-US, V35, P10938, DOI 10.1021/bi9608065; Liu Q, 1996, J BIOL CHEM, V271, P2018, DOI 10.1074/jbc.271.4.2018; MacLeod KJ, 1999, J BIOL CHEM, V274, P32869, DOI 10.1074/jbc.274.46.32869; Margolles-Clark E, 1999, J BIOENERG BIOMEMBR, V31, P29, DOI 10.1023/A:1005440412633; Meaden PG, 1999, YEAST, V15, P1211, DOI 10.1002/(SICI)1097-0061(19990915)15:12<1211::AID-YEA448>3.0.CO;2-H; Moriyama Y, 1996, BIOL CHEM H-S, V377, P155; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; Nanda A, 1996, J BIOL CHEM, V271, P15963, DOI 10.1074/jbc.271.27.15963; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; Pedersen PL, 1996, J BIOENERG BIOMEMBR, V28, P389, DOI 10.1007/BF02113979; Richards KL, 2000, MOL BIOL CELL, V11, P1887, DOI 10.1091/mbc.11.5.1887; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; SOLOMON F, 1992, P197; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; SZE H, 1992, J BIOENERG BIOMEMBR, V24, P371, DOI 10.1007/BF00762530; TEICHERT U, 1989, J BIOL CHEM, V264, P16037; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WEINERT TA, 1993, GENETICS, V134, P63; Xu T, 2000, J BIOL CHEM, V275, P22075, DOI 10.1074/jbc.M002983200; ZHANG JM, 1992, J BIOL CHEM, V267, P9773; Zhang JW, 1998, J BIOL CHEM, V273, P18470, DOI 10.1074/jbc.273.29.18470	50	57	57	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24855	24861		10.1074/jbc.M100637200	http://dx.doi.org/10.1074/jbc.M100637200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11331282	hybrid			2022-12-25	WOS:000169800700058
J	Ghosh, I; Sun, L; Xu, MQ				Ghosh, I; Sun, L; Xu, MQ			Zinc inhibition of protein trans-splicing and identification of regions essential for splicing and association of a split intein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERBICIDE SULFOMETURON METHYL; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; ADENOSINE-TRIPHOSPHATASE; ACETOLACTATE SYNTHASE; BRANCHED INTERMEDIATE; HOMING ENDONUCLEASE; CATALYTIC SUBUNIT; DNAE GENE	Two important aspects of protein splicing were investigated by employing the trans-splicing intein from the dnaE gene of Synechocystis sp. PCC6803. First, we demonstrated that both protein splicing and cleavage at the N-terminal splice junction were inhibited in the; presence of zinc ion. The trans-splicing reaction was partially blocked at a concentration of 1-10 muM Zn2+ and completely inhibited at 100 muM Zn2+; the inhibition by zinc was reversed in the presence of ethylenediaminetetraacetic acid. We propose that inactivation of Cys(160) at the C-terminal splice junction by the chelation of zinc affects both the N-S acyl rearrangement and the transesterification steps in the splicing pathway. Furthermore, in vivo and in vitro assays were established for the determination of intein residues and regions required for splicing or association between the N- and C-terminal intein halves. N-terminal truncation of the intein C-terminal segment inhibited both splicing and association activities, suggesting this region is crucial for the formation of an interface between the two intein halves. The replacement of conserved residues in blocks B and F with alanine abolished splicing but allowed for association. This is the first evidence showing that the conserved residues in block F are required for protein splicing.	New England Biolabs Inc, Beverly, MA 01915 USA		Xu, MQ (corresponding author), New England Biolabs Inc, 32 Tozer Rd, Beverly, MA 01915 USA.							Chen LX, 2001, GENE, V263, P39, DOI 10.1016/S0378-1119(00)00568-0; Chong SR, 1996, J BIOL CHEM, V271, P22159, DOI 10.1074/jbc.271.36.22159; COOPER AA, 1993, EMBO J, V12, P2575, DOI 10.1002/j.1460-2075.1993.tb05913.x; DAILEY FE, 1986, J BACTERIOL, V165, P453, DOI 10.1128/jb.165.2.453-460.1986; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; Evans TC, 2000, J BIOL CHEM, V275, P9091, DOI 10.1074/jbc.275.13.9091; Gorbalenya AE, 1998, NUCLEIC ACIDS RES, V26, P1741, DOI 10.1093/nar/26.7.1741; GUAN C, 1988, GENE, V67, P21; Hill CM, 1998, BIOCHEM J, V335, P653, DOI 10.1042/bj3350653; HIRATA R, 1992, BIOCHEM BIOPH RES CO, V188, P40, DOI 10.1016/0006-291X(92)92347-Z; HIRATA R, 1990, J BIOL CHEM, V265, P6726; Ichiyanagi K, 2000, J MOL BIOL, V300, P889, DOI 10.1006/jmbi.2000.3873; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; Kapust RB, 1999, PROTEIN SCI, V8, P1668, DOI 10.1110/ps.8.8.1668; Kawasaki M, 1997, J BIOL CHEM, V272, P15668, DOI 10.1074/jbc.272.25.15668; Klabunde T, 1998, NAT STRUCT BIOL, V5, P31, DOI 10.1038/nsb0198-31; LAROSSA RA, 1984, J BIOL CHEM, V259, P8753; Martin DD, 2001, BIOCHEMISTRY-US, V40, P1393, DOI 10.1021/bi001786g; Mills KV, 2001, J BIOL CHEM, V276, P10832, DOI 10.1074/jbc.M011149200; Paulus H, 2000, ANNU REV BIOCHEM, V69, P447, DOI 10.1146/annurev.biochem.69.1.447; PERLER FB, 1994, NUCLEIC ACIDS RES, V22, P1125, DOI 10.1093/nar/22.7.1125; Perler FB, 1997, CURR OPIN CHEM BIOL, V1, P292, DOI 10.1016/S1367-5931(97)80065-8; Perler FB, 1997, NUCLEIC ACIDS RES, V25, P1087, DOI 10.1093/nar/25.6.1087; Pietrokovski S, 1998, PROTEIN SCI, V7, P64, DOI 10.1002/pro.5560070106; Poland BW, 2000, J BIOL CHEM, V275, P16408, DOI 10.1074/jbc.275.22.16408; Scott CP, 1999, P NATL ACAD SCI USA, V96, P13638, DOI 10.1073/pnas.96.24.13638; Shao Y, 1996, BIOCHEMISTRY-US, V35, P3810, DOI 10.1021/bi952592h; Shingledecker K, 2000, ARCH BIOCHEM BIOPHYS, V375, P138, DOI 10.1006/abbi.1999.1645; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sun L, 2001, APPL ENVIRON MICROB, V67, P1025, DOI 10.1128/AEM.67.3.1025-1029.2001; Wu H, 1998, P NATL ACAD SCI USA, V95, P9226, DOI 10.1073/pnas.95.16.9226; XU MQ, 1993, CELL, V75, P1371, DOI 10.1016/0092-8674(93)90623-X; XU MQ, 1994, EMBO J, V13, P5517, DOI 10.1002/j.1460-2075.1994.tb06888.x; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x; YADAV N, 1986, P NATL ACAD SCI USA, V83, P4418, DOI 10.1073/pnas.83.12.4418	35	52	54	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24051	24058		10.1074/jbc.M011049200	http://dx.doi.org/10.1074/jbc.M011049200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11331276	hybrid			2022-12-25	WOS:000169531100110
J	Lyons, PD; Dunty, JM; Schaefer, EM; Schaller, MD				Lyons, PD; Dunty, JM; Schaefer, EM; Schaller, MD			Inhibition of the catalytic activity of cell adhesion kinase beta by protein-tyrosine phosphatase-PEST-mediated dephosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION; PTP-PEST; SUBSTRATE RECOGNITION; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; PROLINE-RICH; SH3 DOMAIN; PHOSPHORYLATION; PAXILLIN; MIGRATION	Protein-tyrosine phosphatase (PTP)-PEST is a cytoplasmic tyrosine phosphatase that can bind and dephosphorylate the focal adhesion-associated proteins p130(CAS) and paxillin. Focal adhesion kinase (FAK) and cell adhesion kinase beta (CAK beta)/PYK2/CADTK/RAFTK are protein-tyrosine kinases that can colocalize with, bind to, and induce tyrosine phosphorylation of p130(CAS) and paxillin, Thus, we considered the possibility that these kinases might be substrates for PTP-PEST. Using a combination of substrate-trapping assays and overexpression of PTP-PEST in mammalian cells, CAK beta was found to be a substrate for PTP-PEST. Both the major autophosphorylation site of CAK beta (Tyr(402)) and activation loop tyrosine residues, Tyr(579) and Tyr(580), were targeted for dephosphorylation by PTP-PEST. Dephosphorylation of CAK beta by PTP-PEST dramatically inhibited CAK beta kinase activity. In contrast, FAK was a poor substrate for PTP-PEST, and treatment with PTP-PEST had no effect on FAK kinase activity. Tyrosine phosphorylation of paxillin, which is greatly enhanced by CAK beta overexpression, was dramatically reduced upon coexpression of PTP-PEST. Finally, endogenous PTP-PEST and endogenous CAK beta were found to localize to similar cellular compartments in epithelial and smooth muscle cells. These results suggest that CAK beta is a substrate of PTP-PEST and that FAK is a poor PTP-PEST substrate. Further, PTP-PEST can negatively regulate CAK beta signaling by inhibiting the catalytic activity of the kinase.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Biosource Int, Hopkinton, MA 01748 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Schaller, MD (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, 534 Taylor Hall,CB7090, Chapel Hill, NC 27599 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057943] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57943] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andreev J, 1999, MOL CELL BIOL, V19, P2338; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; Astier A, 1997, J BIOL CHEM, V272, P228; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Baldari CT, 1999, BIOL CHEM, V380, P129, DOI 10.1515/BC.1999.020; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Casamassima A, 1997, J BIOL CHEM, V272, P9363; CHAREST A, 1995, GENOMICS, V28, P501, DOI 10.1006/geno.1995.1181; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; Charest A, 1997, ONCOGENE, V14, P1643, DOI 10.1038/sj.onc.1201008; Cheng J, 1996, BLOOD, V88, P1156, DOI 10.1182/blood.V88.4.1156.bloodjournal8841156; Cloutier JF, 1999, J EXP MED, V189, P111, DOI 10.1084/jem.189.1.111; Cooley MA, 2000, MOL BIOL CELL, V11, P3247, DOI 10.1091/mbc.11.9.3247; Cote JF, 1999, J BIOL CHEM, V274, P20550, DOI 10.1074/jbc.274.29.20550; Davidson D, 1997, J BIOL CHEM, V272, P23455, DOI 10.1074/jbc.272.37.23455; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; GRAHAM IL, 1994, J CELL BIOL, V127, P1139, DOI 10.1083/jcb.127.4.1139; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; HIPPEN KL, 1993, BIOCHEMISTRY-US, V32, P12405, DOI 10.1021/bi00097a019; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kumar S, 1999, J BIOL CHEM, V274, P30657, DOI 10.1074/jbc.274.43.30657; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lev S, 1999, MOL CELL BIOL, V19, P2278; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Li X, 1999, J BIOL CHEM, V274, P8917, DOI 10.1074/jbc.274.13.8917; Liu F, 1998, CURR BIOL, V8, P173, DOI 10.1016/S0960-9822(98)70066-1; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; ROGERS SW, 1986, BIOMED BIOCHIM ACTA, V45, P1611; SAKAI R, 1994, J BIOL CHEM, V269, P32740; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Shen Y, 2000, J BIOL CHEM, V275, P1405, DOI 10.1074/jbc.275.2.1405; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tang H, 2000, J BIOL CHEM, V275, P8389, DOI 10.1074/jbc.275.12.8389; Thomas JW, 1999, J BIOL CHEM, V274, P36684, DOI 10.1074/jbc.274.51.36684; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; YANG Q, 1993, J BIOL CHEM, V268, P6622; Yano H, 2000, P NATL ACAD SCI USA, V97, P9076, DOI 10.1073/pnas.97.16.9076; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	62	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24422	24431		10.1074/jbc.M011080200	http://dx.doi.org/10.1074/jbc.M011080200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11337490	hybrid, Green Published			2022-12-25	WOS:000169531100158
J	Cuzzocrea, S; Mazzon, E; Dugo, L; Serraino, I; Ciccolo, A; Centorrino, T; De Sarro, A; Caputi, AP				Cuzzocrea, S; Mazzon, E; Dugo, L; Serraino, I; Ciccolo, A; Centorrino, T; De Sarro, A; Caputi, AP			Protective effects of n-acetylcysteine on lung injury and red blood cell modification induced by carrageenan in the rat	FASEB JOURNAL			English	Article						inflammation; nitric oxide; peroxynitrite; n-acetylcysteine; superoxide	OBSTRUCTIVE PULMONARY-DISEASE; NITRIC-OXIDE SYNTHASE; ADP-RIBOSE SYNTHETASE; DNA STRAND-BREAKS; HYDROGEN-PEROXIDE; INDUCED PLEURISY; KAPPA-B; SUPEROXIDE-DISMUTASE; TRANSCRIPTION FACTOR; LOCAL INFLAMMATION	Oxidative stress has been suggested as a potential mechanism in the pathogenesis of lung inflammation. The pharmacological profile of n-acetylcysteine (NAC), a free radical scavenger, was evaluated in an experimental model of lung injury (carrageenan-induced pleurisy). Injection of carrageenan into the pleural cavity of rats elicited an acute inflammatory response characterized by fluid accumulation in the pleural cavity that contained many neutrophils (PMNs), an infiltration of PMNs in lung tissues and subsequent lipid peroxidation, and increased production of nitrite/nitrate, tumor necrosis factor alpha, and interleukin 1 beta. All parameters of inflammation were attenuated by NAC treatment. Furthermore, carrageenan induced an up-regulation of the adhesion molecules ICAM-1 and P-selectin, as well as nitrotyrosine and poly (ADP-ribose) synthetase (PARS), as determined by immunohistochemical analysis of lung tissues. The degree of staining for the ICAM-1, P-selectin, nitrotyrosine, and PARS was reduced by NAG. In vivo NAC treatment significantly reduced peroxynitrite formation as measured by the oxidation of the fluorescent dihydrorhodamine-123, prevented the appearance of DNA damage, an decrease in mitochondrial respiration, and partially restored the cellular level of NAD+ in ex vivo macrophages harvested from the pleural cavity of rats subjected to carrageenan-induced pleurisy. A significant alteration in the morphology of red blood cells was observed 24 h after carrageenan administration. NAC treatment has the ability to significantly diminish the red blood cell alteration. Our results clearly demonstrate that NAC treatment exerts a protective effect and clearly indicate that NAC offers a novel therapeutic approach for the management of lung injury where radicals have been postulated to play a role.	Univ Messina, Sch Med, Inst Pharmacol, I-98100 Messina, Italy; Univ Messina, Sch Med, Dept Biomorphol, I-98100 Messina, Italy; Univ Messina, Inst Gen Surg, I-98100 Messina, Italy	University of Messina; University of Messina; University of Messina	Cuzzocrea, S (corresponding author), Univ Messina, Sch Med, Inst Pharmacol, Torre Biol Policlin Univ Via C Valeria Gazzi, I-98100 Messina, Italy.		Mazzon, Emanuela/AAL-4334-2020	mazzon, emanuela/0000-0002-5073-717X; Dugo, Laura/0000-0001-5527-0364				ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; BONE RC, 1991, CHEST, V100, P802, DOI 10.1378/chest.100.3.802; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; BRITTON JR, 1995, AM J RESP CRIT CARE, V151, P1383, DOI 10.1164/ajrccm.151.5.7735589; Brown BB, 1995, MOL DIVERS, V1, P4, DOI 10.1007/BF01715804; CARSON DA, 1986, EXP CELL RES, V164, P273, DOI 10.1016/0014-4827(86)90028-5; Cuzzocrea S, 1998, IMMUNOLOGY, V93, P96; Cuzzocrea S, 1998, EUR J PHARMACOL, V342, P67, DOI 10.1016/S0014-2999(97)01417-9; Cuzzocrea S, 1997, J PINEAL RES, V23, P106, DOI 10.1111/j.1600-079X.1997.tb00342.x; DAMOTTA JIB, 1994, BRIT J PHARMACOL, V112, P111; DARLEYUSMAR V, 1995, FEBS LETT, V369, P131, DOI 10.1016/0014-5793(95)00764-Z; DAWSON J, 1991, INT J TISSUE REACT, V13, P171; Dix TA, 1996, BIOCHEMISTRY-US, V35, P4578, DOI 10.1021/bi952010w; DROST EM, 1992, AM J RESP CELL MOL, V6, P287, DOI 10.1165/ajrcmb/6.3.287; DROST EM, 1993, AM REV RESPIR DIS, V148, P1277, DOI 10.1164/ajrccm/148.5.1277; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; Galley HF, 1997, FREE RADICAL BIO MED, V23, P768, DOI 10.1016/S0891-5849(97)00059-2; GROENEVELD ABJ, 1990, CIRC SHOCK, V30, P185; HARRISON PM, 1991, NEW ENGL J MED, V324, P1852, DOI 10.1056/NEJM199106273242604; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; HYSLOP PA, 1988, J BIOL CHEM, V263, P1665; INOUE S, 1995, FEBS LETT, V371, P86, DOI 10.1016/0014-5793(95)00873-8; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; Ischiropoulos H, 1999, METHOD ENZYMOL, V301, P367; KOOY NW, 1994, FREE RADICAL BIO MED, V16, P149, DOI 10.1016/0891-5849(94)90138-4; LAIGHT DW, 1994, EUR J PHARM-ENVIRON, V292, P81, DOI 10.1016/0926-6917(94)90029-9; LINDEN M, 1989, INFLAMMATION, V13, P651, DOI 10.1007/BF00914309; MacMillan-Crow LA, 1999, ARCH BIOCHEM BIOPHYS, V366, P82, DOI 10.1006/abbi.1999.1202; MACNEE W, 1989, NEW ENGL J MED, V321, P924, DOI 10.1056/NEJM198910053211402; MACNEE W, 1993, THORAX, V48, P79, DOI 10.1136/thx.48.1.79; MEISTER A, 1983, SCIENCE, V220, P472, DOI 10.1126/science.6836290; Noguera A, 1998, AM J RESP CRIT CARE, V158, P1664, DOI 10.1164/ajrccm.158.5.9712092; Ogino M, 1996, INFLAMM RES, V45, P335, DOI 10.1007/BF02252946; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Parmentier M, 1999, AM J RESP CRIT CARE, V159, pA286; PESKAR BM, 1991, AGENTS ACTIONS, V33, P240, DOI 10.1007/BF01986569; POSTMA DS, 1988, AM REV RESPIR DIS, V137, P57, DOI 10.1164/ajrccm/137.1.57; POUWELL RJ, 1991, AM SURGEON, V57, P86; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; Rahman I, 1996, AM J RESP CRIT CARE, V154, P1055, DOI 10.1164/ajrccm.154.4.8887607; Rahman I, 1997, THORAX, V52, P565, DOI 10.1136/thx.52.6.565; Repine JE, 1997, AM J RESP CRIT CARE, V156, P341, DOI 10.1164/ajrccm.156.2.9611013; RUBBO H, 1994, J BIOL CHEM, V269, P26066; SALGO MG, 1995, ARCH BIOCHEM BIOPHYS, V322, P500, DOI 10.1006/abbi.1995.1493; Salvemini D, 1999, BRIT J PHARMACOL, V127, P685, DOI 10.1038/sj.bjp.0702604; Salvemini D, 1996, BRIT J PHARMACOL, V118, P829, DOI 10.1111/j.1476-5381.1996.tb15475.x; Salzman AL, 1996, AM J PHYSIOL-GASTR L, V270, pG565, DOI 10.1152/ajpgi.1996.270.4.G565; SCHILLIER HJ, 1993, CRIT CARE MED, V21, P92; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SELBY C, 1991, AM REV RESPIR DIS, V143, P1359, DOI 10.1164/ajrccm/143.6.1359; SRIDHAR MK, 1994, EUR RESPIR J, V7, P720, DOI 10.1183/09031936.94.07040720; Steinberg FM, 1998, AM J CLIN NUTR, V68, P319, DOI 10.1093/ajcn/68.2.319; Szabo C, 1997, J EXP MED, V186, P1041, DOI 10.1084/jem.186.7.1041; SZABO C, 1993, BRIT J PHARMACOL, V108, P786, DOI 10.1111/j.1476-5381.1993.tb12879.x; TRACEY WR, 1995, J PHARMACOL EXP THER, V273, P1295; VILLA LM, 1994, P NATL ACAD SCI USA, V91, P12383, DOI 10.1073/pnas.91.26.12383; Watchorn T., 1998, AM J RESP CRIT CARE, V157, pA889; WEGNER CD, 1992, LUNG, V170, P267, DOI 10.1007/BF00566679; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; WIZEMANN TM, 1994, J LEUKOCYTE BIOL, V56, P759, DOI 10.1002/jlb.56.6.759; Yamakura F, 1998, J BIOL CHEM, V273, P14085, DOI 10.1074/jbc.273.23.14085; ZIMENT I, 1988, BIOMED PHARMACOTHER, V42, P513; Zingarelli B, 1996, J IMMUNOL, V156, P350	69	92	99	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1187	1200		10.1096/fj.00-0526hyp	http://dx.doi.org/10.1096/fj.00-0526hyp			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344087				2022-12-25	WOS:000168655200009
J	Aigner, A; Juhl, H; Malerczyk, C; Tkybusch, A; Benz, CC; Czubayko, F				Aigner, A; Juhl, H; Malerczyk, C; Tkybusch, A; Benz, CC; Czubayko, F			Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation	ONCOGENE			English	Article						HER2; c-erbB2 (neu); HER2-ECD; gastric cancer; breast cancer; ribozyme	EPIDERMAL GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; BREAST-CANCER; OVARIAN-CANCER; GENE ENCODES; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; CARCINOMA-CELLS; FACTOR RECEPTOR; MESSENGER-RNA	Overexpression of the HER2 (neu/c-erbB-2) oncogene frequently coincides with an aggressive clinical course of certain human adenocarcinomas. Expression and secretion of aberrant HER2 splice variants has been reported in various cell lines and tissues and can interfere with the oncogenic HER2 activity. Here we demonstrate, using two different approaches, that expression of a truncated 100 kDa HER2 variant which encodes the extracellular domain of HER2 (HER-ECD) inhibits growth factor-mediated tumour cell proliferation. A HER2-ECD cDNA encoding the truncated variant was overexpressed in MCF7 breast cancer cells, HER2-ECD overexpression decreased spontaneous proliferation of MCF7 cells as well as heregulin-mediated soft agar colony formation, Concomitantly, heregulin-induced phosphorylation of HER4 as well as downstream activation of p44/p42 MAP-kinases was decreased. To confirm these data, ribozymes were targeted to the 3'-untranslated region of the 2.3 kb HER2-ECD mRNA which is spontaneously expressed in MKN7 gastric cancer cells. HER2-ECD-targeted ribozymes downregulated HER2-ECD expression and enhanced EGF-mediated soft agar colony formation of MKN7 cells. In parallel, EGF-induced activation of p44/p42 MAP-kinases and activation of c-Fos expression were increased in ribozyme-transfected MKN7 cells. Finally, in RT-PCR we found a trend towards a progressive loss of 2.3 kb HER2-ECD mRNA expression in more advanced gastric tumours, These data show that the HER2-ECD variant inhibits growth factor-mediated tumour cell proliferation suggesting an important role during the progression of human cancer.	Univ Marburg, Dept Pharmacol & Toxicol, D-35033 Marburg, Germany; Georgetown Univ, Lombardi Canc Ctr, Washington, DC 20007 USA; Univ Hosp Kiel, Dept Surg, D-24105 Kiel, Germany; Univ Calif San Francisco, Div Hematol Oncol, San Francisco, CA 94143 USA	Philipps University Marburg; Georgetown University; University of Kiel; Schleswig Holstein University Hospital; University of California System; University of California San Francisco	Czubayko, F (corresponding author), Univ Marburg, Dept Pharmacol & Toxicol, Karl von Frisch Str 1, D-35033 Marburg, Germany.		Aigner, Achim/R-4429-2017	Aigner, Achim/0000-0002-2778-6256	NATIONAL CANCER INSTITUTE [P30CA051008] Funding Source: NIH RePORTER; NCI NIH HHS [2P30-CA-51008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aigner A, 2000, GROWTH FACTORS, V18, P51, DOI 10.3109/08977190009003233; Allgayer H, 2000, J CLIN ONCOL, V18, P2201, DOI 10.1200/JCO.2000.18.11.2201; Colomer R, 2000, CLIN CANCER RES, V6, P2356; CZUBAYKO F, 1994, J BIOL CHEM, V269, P21358; Doherty JK, 1999, P NATL ACAD SCI USA, V96, P10869, DOI 10.1073/pnas.96.19.10869; FLICKINGER TW, 1992, MOL CELL BIOL, V12, P883, DOI 10.1128/MCB.12.2.883; Gebhardt F, 1998, BIOCHEM BIOPH RES CO, V247, P319, DOI 10.1006/bbrc.1998.8779; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Hsieh SS, 2000, INT J CANCER, V86, P644, DOI 10.1002/(SICI)1097-0215(20000601)86:5<644::AID-IJC7>3.0.CO;2-T; Juhl H, 1997, J BIOL CHEM, V272, P29482, DOI 10.1074/jbc.272.47.29482; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Lee H, 1998, ONCOGENE, V16, P3243, DOI 10.1038/sj.onc.1201866; Lewis GD, 1996, CANCER RES, V56, P1457; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Reiter JL, 1996, NUCLEIC ACIDS RES, V24, P4050, DOI 10.1093/nar/24.20.4050; RUBIN LA, 1985, J IMMUNOL, V135, P3172; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; SCOTT GK, 1993, MOL CELL BIOL, V13, P2247, DOI 10.1128/MCB.13.4.2247; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Souttou B, 1997, J BIOL CHEM, V272, P19588, DOI 10.1074/jbc.272.31.19588; TAVERNIER J, 1992, P NATL ACAD SCI USA, V89, P7041, DOI 10.1073/pnas.89.15.7041; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1998, BBA-REV CANCER, V1377, pM25, DOI 10.1016/S0304-419X(97)00032-2; ZABRECKY JR, 1991, J BIOL CHEM, V266, P1716	30	41	49	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2001	20	17					2101	2111		10.1038/sj.onc.1204305	http://dx.doi.org/10.1038/sj.onc.1204305			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360194				2022-12-25	WOS:000168116700005
J	Zhang, TT; Prives, C				Zhang, TT; Prives, C			Cyclin A-CDK phosphorylation regulates MDM2 protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P53; RING FINGER DOMAIN; DEPENDENT KINASES; S-PHASE; ONCOPROTEIN MDM2; UBIQUITIN LIGASE; CELL-CYCLE; IN-VITRO; RETINOBLASTOMA PROTEIN; EMBRYONIC LETHALITY	The product of the MDM2 gene interacts with and regulates a number of proteins, in particular the tumor suppressor p53. The MDM2 protein is likely to be extensively modified in vivo, and such modification may regulate its functions in cells. We identified a potential cyclin-dependent kinase (CDK) site in murine MDM2,, and found the protein to be efficiently phosphorylated in vitro by cyclin A-containing complexes (cyclin A-CDK2 and cyclin A-CDK1), but MDM2 was either weakly or not phosphorylated by other cyclin-containing complexes. Moreover, a peptide containing a putative, MDM2 cyclin recognition motif specifically inhibited phosphorylation by cyclin A-CDK2. The site of cyclin A-CDK2 phosphorylation was identified as Thr-216 by two-dimensional phosphopeptide mapping and mutational analysis. Phosphorylation of MDM2 at Thr-216 both weakens its interaction with p53 and modestly augments its binding to p19(ARF) Interestingly, an MDM2-specific monoclonal antibody, SMP14, cannot recognize MDM2 phosphorylated at Thr-216. Changes in SMP14 reactivity of MDM2 in staged cell extracts indicate that phosphorylation of MDM2 at Thr-216 in vivo is most prevalent at the onset of S phase when cyclin A first becomes detectable.	Columbia Univ, Dept Sci Biol, New York, NY 10027 USA	Columbia University	Prives, C (corresponding author), Columbia Univ, Dept Sci Biol, New York, NY 10027 USA.	clp3@columbia.edu			NATIONAL CANCER INSTITUTE [R37CA058316, P01CA087497, R01CA058316] Funding Source: NIH RePORTER; NCI NIH HHS [CA87497, CA58316] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1999, MOL CELL BIOL, V19, P1068; Adams PD, 1996, MOL CELL BIOL, V16, P6623; Adkins JN, 2000, BIOCHEMISTRY-US, V39, P13925, DOI 10.1021/bi001524e; Argentini M, 2000, ONCOGENE, V19, P3849, DOI 10.1038/sj.onc.1203737; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bond GL, 2000, MOL CELL BIOL, V20, P5310, DOI 10.1128/MCB.20.14.5310-5320.2000; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; Boyd MT, 2000, J BIOL CHEM, V275, P31883, DOI 10.1074/jbc.M004252200; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325; Dynlacht BD, 1997, MOL CELL BIOL, V17, P3867, DOI 10.1128/MCB.17.7.3867; Endicott JA, 1999, CURR OPIN STRUC BIOL, V9, P738, DOI 10.1016/S0959-440X(99)00038-X; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Gibbs E, 1996, J BIOL CHEM, V271, P22847, DOI 10.1074/jbc.271.37.22847; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Gotz C, 1999, EUR J BIOCHEM, V266, P493, DOI 10.1046/j.1432-1327.1999.00882.x; Guerra B, 1997, ONCOGENE, V14, P2683, DOI 10.1038/sj.onc.1201112; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hay TJ, 2000, FEBS LETT, V478, P183, DOI 10.1016/S0014-5793(00)01850-0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Juven-Gershon T, 1999, MOL MED, V5, P71, DOI 10.1007/BF03402141; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LENG P, 1995, ONCOGENE, V10, P1275; LENG P, 1995, INT J ONCOL, V6, P251; Leveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651; Liang SH, 1998, J BIOL CHEM, V273, P19817, DOI 10.1074/jbc.273.31.19817; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Mayo LD, 1997, CANCER RES, V57, P5013; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; Okamoto K, 1996, MOL CELL BIOL, V16, P6593; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; PRICE BD, 1995, ONCOGENE, V11, P73; Prives C, 1999, J PATHOL, V187, P112; Reinke V, 1999, CELL GROWTH DIFFER, V10, P147; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; Roberts JM, 1999, CELL, V98, P129, DOI 10.1016/S0092-8674(00)81007-7; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SORENSEN SB, 1991, FEBS LETT, V294, P195, DOI 10.1016/0014-5793(91)80667-R; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Wuarin J, 1996, CELL, V85, P785, DOI 10.1016/S0092-8674(00)81261-1; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	85	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29702	29710		10.1074/jbc.M011326200	http://dx.doi.org/10.1074/jbc.M011326200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11359766	hybrid			2022-12-25	WOS:000170558000016
J	Engelmann, K; Baldus, SE; Hanisch, FG				Engelmann, K; Baldus, SE; Hanisch, FG			Identification and topology of variant sequences within individual repeat domains of the human epithelial tumor mucin MUC1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; MOLECULAR-CLONING; ANTIGEN; CDNA; ANTIBODIES; INDUCTION; PEPTIDE; CELLS	This study shows for the first time that the tandemly repeated icosapeptide of human MUC1 underlies a genetic sequence polymorphism at three positions (underlined): P (TD) under bar RPAPGSTAP (P) under bar AHGVTSA. The concerted replacement DT --> ES (sequence variation 1) and the single replacements P -->Q (sequence variation 2), P -->A (sequence variation 3), and P -->T (sequence variation 4) were identified by sequencing of polymerase chain reaction products and studied by minisatellite variant repeat analysis for their incidence and topology in the 5` and 3' peripheral regions of the variable number of tandem repeats domain. Minisatellite variant repeat analyses were performed with 27 individual samples of genomic DNA from human cells and tissues covering 30-60% of the domain. Within the peripheral regions, sequence variations 1-4 occur at high incidence and show a nearly constant repeat topology in all individual normal and tumor samples. Also, individuals who were non-Caucasian or of different ethnic background were found to have the same set of replacements with identical topology. The repeat variant 1 replacing the established tumor target motif DTR with ESR was found in all individuals and appears predominantly in repeat clusters (diads and triads). The largely constant topology of variant repeats is interpreted by the assumption that the variable number of tandem repeats domain has evolved as a recent expansion of sequence variable super-repeats.	Univ Cologne, Fac Med, Inst Biochem 2, D-50931 Cologne, Germany; Univ Cologne, Fac Med, Inst Pathol, D-50931 Cologne, Germany	University of Cologne; University of Cologne	Hanisch, FG (corresponding author), Univ Cologne, Fac Med, Inst Biochem 2, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.							Agrawal B, 1996, J IMMUNOL, V157, P2089; Apostolopoulos V, 1997, J IMMUNOL, V159, P5211; APOSTOLOPOULOS V, 1995, J IMMUNOL, V155, P5089; Conway K, 1996, CANCER RES, V56, P4773; GENDLER S, 1988, J BIOL CHEM, V263, P12820; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; Hanisch FG, 2000, GLYCOBIOLOGY, V10, P439, DOI 10.1093/glycob/10.5.439; HANISCH FG, 2001, IN PRESS GLYCOBIOLOG; JEFFREYS AJ, 1991, NATURE, V354, P204, DOI 10.1038/354204a0; JEFFREYS AJ, 1990, CELL, V60, P473, DOI 10.1016/0092-8674(90)90598-9; JEROME KR, 1991, CANCER RES, V51, P2908; LAN MS, 1990, J BIOL CHEM, V265, P15294; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; Muller S, 1999, J BIOL CHEM, V274, P18165, DOI 10.1074/jbc.274.26.18165; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; Price MR, 1998, TUMOR BIOL, V19, P1, DOI 10.1159/000056500; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; Taylor-Papadimitriou J, 1999, BBA-MOL BASIS DIS, V1455, P301, DOI 10.1016/S0925-4439(99)00055-1; TONDINI C, 1988, CANCER RES, V48, P4107; von Mensdorff-Pouilly S, 2000, INT J CANCER, V86, P702, DOI 10.1002/(SICI)1097-0215(20000601)86:5<702::AID-IJC16>3.0.CO;2-1; vonMensdorffPouilly S, 1996, EUR J CANCER, V32A, P1325, DOI 10.1016/0959-8049(96)00048-2; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x	22	38	53	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27764	27769		10.1074/jbc.M103187200	http://dx.doi.org/10.1074/jbc.M103187200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11350974	hybrid			2022-12-25	WOS:000170093400005
J	Avison, MB; Horton, RE; Walsh, TR; Bennett, PM				Avison, MB; Horton, RE; Walsh, TR; Bennett, PM			Escherichia coli CreBC is a global regulator of gene expression that responds to growth in minimal media	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE REGULON; BETA-LACTAMASES; AEROMONAS-SOBRIA; PHOM; IDENTIFICATION; SEQUENCE; CLONING; KINASE; PHOSPHOTRANSACETYLASE; NUCLEOTIDE	We have identified nine genes, the expression of which are regulated by the CreEC two-component system: the first members of the cre regulon. They are divided into eight transcriptional units, each having a promoter-proximal TTCACnnnnnnTTCAC "cre-tag" motif. The cre regulon genes are: the ackA/pta operon, the products of which collectively catalyze the conversion of acetyl-CoA into acetate and ATP; talA, which encodes an enzyme involved in the mobilization of glyceraldehyde-3-phosphate into the pentose phosphate pathway; radC, which encodes a RecG-like DNA recombination/repair function; malE, which is the first gene in the malEFG maltose transporter operon; trgB, which encodes an ADP-ribose pyrophosphorylase; and three other genes, creD, yidS and yieI, the products of which have not been assigned a function. Expression of each of these cre regulon genes is induced via CreBC during growth in minimal media, with the exception of malE, which is more tightly repressed. The diverse functions encoded by the cre regulon suggest that CreBC is a global regulator that sits right at the heart of metabolic control in Escherichia coli.	Univ Bristol, Bristol Ctr Antimicrobial Res & Evaluat, Dept Pathol & Microbiol, Sch Med Sci, Bristol BS8 1TD, Avon, England	University of Bristol	Avison, MB (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Univ Walk, Bristol BS8 1TD, Avon, England.	Matthewb.Avison@bris.ac.uk	Walsh, Timothy R/F-6519-2010	Walsh, Timothy/0000-0003-4315-4096; Avison, Matthew/0000-0003-1454-8440				Alksne LE, 1997, J BACTERIOL, V179, P2006, DOI 10.1128/jb.179.6.2006-2013.1997; AMEMURA M, 1986, J BACTERIOL, V168, P294, DOI 10.1128/jb.168.1.294-302.1986; AMEMURA M, 1990, J BACTERIOL, V172, P6300, DOI 10.1128/jb.172.11.6300-6307.1990; Avison MB, 2000, J ANTIMICROB CHEMOTH, V46, P695, DOI 10.1093/jac/46.5.695; Avison MB, 2000, J ANTIMICROB CHEMOTH, V46, P879, DOI 10.1093/jac/46.6.879; AVISON MB, 1999, 39 INT C ANT AG CHEM, P88; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BUXTON RS, 1973, MOL GEN GENET, V127, P69, DOI 10.1007/BF00267784; Chang DE, 1999, J BACTERIOL, V181, P6656, DOI 10.1128/JB.181.21.6656-6663.1999; DRURY LS, 1988, MOL MICROBIOL, V2, P109, DOI 10.1111/j.1365-2958.1988.tb00012.x; Dunn CA, 1999, J BIOL CHEM, V274, P32318, DOI 10.1074/jbc.274.45.32318; FELZENSZWALB I, 1992, MUTAT RES, V273, P263, DOI 10.1016/0921-8777(92)90088-K; FELZENSZWALB I, 1984, RADIAT RES, V97, P615, DOI 10.2307/3576153; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; KAKUDA H, 1994, J BIOCHEM-TOKYO, V116, P916, DOI 10.1093/oxfordjournals.jbchem.a124616; Lombardo MJ, 2000, J BACTERIOL, V182, P6287, DOI 10.1128/JB.182.22.6287-6291.2000; LOW KB, 1972, BACTERIOL REV, V36, P587, DOI 10.1128/MMBR.36.4.587-607.1972; MAKINO K, 1989, J MOL BIOL, V210, P551, DOI 10.1016/0022-2836(89)90131-9; MAKINO K, 1984, MOL GEN GENET, V195, P381, DOI 10.1007/BF00341438; Makino K, 1996, J MOL BIOL, V259, P15, DOI 10.1006/jmbi.1996.0298; NIUMSUP P, 1997, 37 INT C ANT AG CHEM, P79; Okamura H, 2000, J MOL BIOL, V295, P1225, DOI 10.1006/jmbi.1999.3379; PRIDMORE RD, 1987, GENE, V56, P309, DOI 10.1016/0378-1119(87)90149-1; RASMUSSEN BA, 1994, ANTIMICROB AGENTS CH, V38, P2078, DOI 10.1128/AAC.38.9.2078; Richet E, 1996, J MOL BIOL, V264, P852, DOI 10.1006/jmbi.1996.0682; SAMBROOK J, 1989, MOL CLONING LABORATO, V1, P53; Saveson CJ, 1999, GENETICS, V152, P5; Sprenger GA, 1995, ARCH MICROBIOL, V164, P324, DOI 10.1007/BF02529978; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; Walsh TR, 1998, ANTIMICROB AGENTS CH, V42, P436; WALSH TR, 1995, J ANTIMICROB CHEMOTH, V36, P41, DOI 10.1093/jac/36.1.41; Wanner B.L., 1996, E COLI SALMONELLA CE, V1, P1357; WANNER BL, 1992, J BACTERIOL, V174, P2124, DOI 10.1128/JB.174.7.2124-2130.1992; WANNER BL, 1987, J BACTERIOL, V169, P900, DOI 10.1128/jb.169.2.900-903.1987; WANNER BL, 1980, GENETICS, V96, P353	35	76	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26955	26961		10.1074/jbc.M011186200	http://dx.doi.org/10.1074/jbc.M011186200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11350954	hybrid			2022-12-25	WOS:000169966900031
J	Thorsteinsson, MV; Kerby, RL; Youn, H; Conrad, M; Serate, J; Staples, CR; Roberts, GP				Thorsteinsson, MV; Kerby, RL; Youn, H; Conrad, M; Serate, J; Staples, CR; Roberts, GP			Redox-mediated transcriptional activation in a CooA variant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTROSCOPY; CAMP RECEPTOR PROTEIN; CARBON-MONOXIDE; RHODOSPIRILLUM-RUBRUM; NITRIC-OXIDE; ESCHERICHIA-COLI; CYCLIC-NUCLEOTIDE; GUANYLATE-CYCLASE; GENE-EXPRESSION; OXYGEN SENSOR	CoOA, the carbon monoxide-sensing transcription factor from Rhodospirillum rubrum, binds CO at a reduced (Fe-II) heme moiety with resulting conformational changes that promote DNA binding, In this study, we report a variant of CooA, M124R, that is active in transcriptional activation in a redox-dependent manner. Where wild-type CooA is active only in the Fe-II + CO form, M124R CooA is active in both Fe-II + CO and Fe-III forms. Analysis of the pH dependence of the activity of Fe-III M124R CooA demonstrated that the activity was also coordination state-dependent with a five-coordinate, high-spin species identified as the active form and Cys(75) as the retained ligand, In contrast, the active Fe-II + CO forms of both wild-type and M124R CooA are six coordinate and low-spin with a protein ligand other than Cys(75), so that WT and Fe-III M124R CooA are apparently achieving an active conformation despite two different heme coordination and ligation states. A hypothesis to explain these results is proposed. This study demonstrates the utility of CooA as a model system for the isolation of functionally interesting heme proteins.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Roberts, GP (corresponding author), Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA.				NIGMS NIH HHS [GM53228] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053228] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; Aono S, 1998, J BIOL CHEM, V273, P25757, DOI 10.1074/jbc.273.40.25757; Ausubel F. M., 1995, SHORT PROTOCOLS MOL, P21; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BURSTYN JN, 1996, BIOCHEMISTRY-US, V35, P5896; Cheng XD, 1998, J BIOL CHEM, V273, P705, DOI 10.1074/jbc.273.2.705; CHENG XD, 1995, BIOCHEMISTRY-US, V34, P10816, DOI 10.1021/bi00034a014; Chiang L W, 1993, PCR Methods Appl, V2, P210; DEDUVE C, 1948, ACTA CHEM SCAND, V2, P264, DOI 10.3891/acta.chem.scand.02-0264; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; Friebe A, 1999, BIOCHEMISTRY-US, V38, P15253, DOI 10.1021/bi9908944; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; He YP, 1996, J BIOL CHEM, V271, P120, DOI 10.1074/jbc.271.1.120; KERBY RL, 1995, J BACTERIOL, V177, P2241, DOI 10.1128/jb.177.8.2241-2244.1995; KILEY PJ, 1991, J BACTERIOL, V173, P16, DOI 10.1128/jb.173.1.16-22.1991; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; LEE FJ, 1994, NUCLEIC ACIDS RES, V22, P2894; Lukat-Rodgers GS, 1998, BIOCHEMISTRY-US, V37, P13543, DOI 10.1021/bi981439v; LukatRodgers GS, 1997, BIOCHEMISTRY-US, V36, P4178, DOI 10.1021/bi9628230; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; Makino R, 1999, J BIOL CHEM, V274, P7714, DOI 10.1074/jbc.274.12.7714; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Matsui T, 1996, BIOCHEMISTRY-US, V35, P13118, DOI 10.1021/bi960459z; McLaughlin BE, 2000, CAN J PHYSIOL PHARM, V78, P343, DOI 10.1139/cjpp-78-4-343; Passner JM, 2000, J MOL BIOL, V304, P847, DOI 10.1006/jmbi.2000.4231; PIERIK AJ, 1991, EUR J BIOCHEM, V195, P505, DOI 10.1111/j.1432-1033.1991.tb15731.x; Schmidt K, 2001, MOL PHARMACOL, V59, P220, DOI 10.1124/mol.59.2.220; SHELVER D, 1995, J BACTERIOL, V177, P2157, DOI 10.1128/jb.177.8.2157-2163.1995; Shelver D, 1999, BIOCHEMISTRY-US, V38, P2669, DOI 10.1021/bi982658j; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; SONO M, 1982, J BIOL CHEM, V257, P5496; SPIRO S, 1994, ANTON LEEUW INT J G, V66, P23, DOI 10.1007/BF00871630; Stone JR, 1998, CHEM BIOL, V5, P255, DOI 10.1016/S1074-5521(98)90618-4; Thorsteinsson MV, 2000, BIOCHEMISTRY-US, V39, P8284, DOI 10.1021/bi000327c; Thorsteinsson MV, 2000, J BIOL CHEM, V275, P39332, DOI 10.1074/jbc.M007691200; Uchida T, 2000, BIOCHEMISTRY-US, V39, P12747, DOI 10.1021/bi0011476; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Yamamoto K, 2001, J BIOL CHEM, V276, P11473, DOI 10.1074/jbc.C100047200	39	16	16	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26807	26813		10.1074/jbc.M102758200	http://dx.doi.org/10.1074/jbc.M102758200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11359778	hybrid			2022-12-25	WOS:000169966900012
J	Zwaagstra, JC; El-Alfy, M; O'Connor-McCourt, MD				Zwaagstra, JC; El-Alfy, M; O'Connor-McCourt, MD			Transforming growth factor (TGF)-beta 1 internalization - Modulation by ligand interaction with TGF-beta receptors types I and II and a mechanism that is distinct from clathrin-mediated endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; DOWN-REGULATION; CELLS; CAVEOLAE; DYNAMIN; EGF; TRANSGLUTAMINASE; CHLOROQUINE	Transforming growth factor-p (TGF-P) internalization was studied by monitoring the uptake of I-125-TGF-beta1 in Mv1Lu cells, which endogenously express TGF-P receptors types I (RI), II (RII), and III (RIII), and 293 cells transfected with RI and RII. At 37 degreesC internalization occurred rapidly, within 10 min of ligand addition. Internalization was optimal in 293 cells expressing both RI and RII, Internalization was prevented by phenylarsine oxide, a nonspecific inhibitor of receptor internalization, but was not affected by reagents that interfere with clathrin-mediated endocytosis such as monodansylcadaverine, K44A dynamin, and inhibitors of endosomal acidification. Electron microscopic examination of Mv1Lu cells treated with I-125-TGF-beta1 at 37 degreesC indicated that internalization occurred via a noncoated vesicular mechanism. Internalization was prevented by prebinding cells with TGF-beta1 at 4 degreesC for 2 h prior to switching the cells to 37 degreesC. This was attributed to a loss of receptor binding, as indicated by a rapid decrease in the amount of TGF-beta1 bound to the cell surface at 37 degreesC and by a reduction in the labeling intensities of RI and RII in I-125-TGF-beta1-cross-linking experiments. Mv1Lu or 293 (RI+RII) cells, prebound with TGF-beta1 at 4 degreesC and subsequently stripped of ligand by an acid wash, nevertheless initiated a signaling response upon transfer to 37 degreesC, suggesting that prebinding promotes formation of stable RI RII complexes that can signal independently of ligand.	Natl Res Council Canada, Biotechnol Res Inst, Cell Surface Recognit Grp, Montreal, PQ H4P 2R2, Canada; Ctr Rech, Mol Endocrinol Lab, Ste Foy, PQ G1V 4G2, Canada	National Research Council Canada	Zwaagstra, JC (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, Cell Surface Recognit Grp, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	john.zwaagstra@nrc.ca						ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Anders RA, 1997, MOL BIOL CELL, V8, P2133, DOI 10.1091/mbc.8.11.2133; Anders RA, 1998, J BIOL CHEM, V273, P23118, DOI 10.1074/jbc.273.36.23118; Beaumont V, 1998, J BIOL CHEM, V273, P33174, DOI 10.1074/jbc.273.50.33174; Bergeron JJM, 1995, BIOSCIENCE REP, V15, P411, DOI 10.1007/BF01204345; Bevan AP, 1997, J BIOL CHEM, V272, P26833, DOI 10.1074/jbc.272.43.26833; Bohm SK, 1997, BIOCHEM J, V322, P1; CAPALA J, 1991, INT J RADIAT BIOL, V60, P497, DOI 10.1080/09553009114552341; CARPENTIER JL, 1994, ANN NY ACAD SCI, V733, P266, DOI 10.1111/j.1749-6632.1994.tb17276.x; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; CHARBY J, 1993, J BIOL CHEM, V268, P17138; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; COOPER JL, 1988, J CELL PHYSIOL, V134, P387, DOI 10.1002/jcp.1041340309; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; FRENCH AR, 1995, J BIOL CHEM, V270, P4334, DOI 10.1074/jbc.270.9.4334; Gekle M, 1999, J PHYSIOL-LONDON, V520, P709, DOI 10.1111/j.1469-7793.1999.00709.x; GRADY EF, 1995, J BIOL CHEM, V270, P4603, DOI 10.1074/jbc.270.9.4603; HERTEL C, 1985, J BIOL CHEM, V260, P2547; HOSOI K, 1993, J CELL PHYSIOL, V157, P1, DOI 10.1002/jcp.1041570102; Jans DA, 1998, BIOESSAYS, V20, P400, DOI 10.1002/(SICI)1521-1878(199805)20:5<400::AID-BIES7>3.0.CO;2-R; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; Kang Y, 2000, BIOCHEMISTRY-US, V39, P13551, DOI 10.1021/bi001196i; KATOH S, 1994, BIOL PHARM BULL, V17, P1003; KOPRIWA BM, 1967, J HISTOCHEM CYTOCHEM, V15, P501, DOI 10.1177/15.9.501; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1986, J CELL PHYSIOL, V128, P216, DOI 10.1002/jcp.1041280212; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; NADLER NJ, 1979, J HISTOCHEM CYTOCHEM, V27, P1531, DOI 10.1177/27.11.512340; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; Ray E, 1996, FEBS LETT, V378, P235, DOI 10.1016/0014-5793(95)01462-4; Sandvig K, 2000, EMBO J, V19, P5943, DOI 10.1093/emboj/19.22.5943; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; Simpson JC, 1998, EXP CELL RES, V239, P293, DOI 10.1006/excr.1997.3921; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Vogler O, 1998, J BIOL CHEM, V273, P12155, DOI 10.1074/jbc.273.20.12155; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WATERS CM, 1990, BIOCHEMISTRY-US, V29, P3563, DOI 10.1021/bi00466a020; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zwaagstra JC, 1999, EXP CELL RES, V252, P352, DOI 10.1006/excr.1999.4640	54	40	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27237	27245		10.1074/jbc.M100033200	http://dx.doi.org/10.1074/jbc.M100033200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356827	hybrid			2022-12-25	WOS:000169966900069
J	Asante-Appiah, E; Ball, K; Bateman, K; Skorey, K; Friesen, R; Desponts, C; Payette, P; Bayly, C; Zamboni, R; Scapin, G; Ramachandran, C; Kennedy, BP				Asante-Appiah, E; Ball, K; Bateman, K; Skorey, K; Friesen, R; Desponts, C; Payette, P; Bayly, C; Zamboni, R; Scapin, G; Ramachandran, C; Kennedy, BP			The YRD motif is a major determinant of substrate and inhibitor specificity in T-cell protein-tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN SENSITIVITY; STRUCTURAL BASIS; MICE; 1B; PHOSPHORYLATION; IDENTIFICATION; MUTATIONS; SELECTION; BINDING; WEIGHT	We have studied T-cell protein-tyrosine phosphatase (TCPTP) as a model phosphatase in an attempt to unravel amino acid residues that may influence the design of specific inhibitors. Residues 48-50, termed the YRD motif, a region that is found in protein-tyrosine phosphatases, but absent in dual-specificity phosphatases was targeted. YRD derivatives of TCPTP were characterized by steady-state kinetics and by inhibition studies with BzN-EJJ-amide, a potent inhibitor of TCPTP, Substitution of Asp(50) to alanine or Arg(49) to lysine, methionine, or alanine significantly affected substrate hydrolysis and led to a substantial decrease in affinity for BzN-EJJ-amide, The influence of residue 49 on substrate/inhibitor selectivity was further investigated by comparing subsite amino acid preferences of TCPTP and its R49K derivative by affinity selection coupled with mass spectrometry, The greatest effect on selectivity was observed on the residue that precedes the phosphorylated tyrosine, Unlike wild-type TCPTP, the R49K derivative preferred tyrosine to aspartic or glutamic acid. BzN-EJJ-amide which retains the preferred specificity requirements of TCPTP and PTP1B was equipotent on both enzymes but greater than 30-fold selective over other phosphatases, These results suggest that Ar-49 and Asp(50) may be targeted for the design of potent and selective inhibitors of TCPTP and PTP1B.	Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada; Merck Frosst Ctr Therapeut Res, Dept Med Chem, Pointe Claire, PQ H9R 4P8, Canada; Merck Res Lab, Dept Endocrinol & Cell Biol, Rahway, NJ 07065 USA	Merck & Company; Merck & Company; Merck & Company	Asante-Appiah, E (corresponding author), Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, POB 1005, Pointe Claire, PQ H9R 4P8, Canada.	Ernest_Asanteappiah@merck.com		Bateman, Kevin/0000-0002-4026-6685				Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; Desmarais S, 1999, BIOCHEM J, V337, P219, DOI 10.1042/0264-6021:3370219; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; Huang Z, 1999, J BIOMOL SCREEN, V4, P327, DOI 10.1177/108705719900400608; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; Huyer G, 1998, ANAL BIOCHEM, V258, P19, DOI 10.1006/abio.1997.2541; Iversen LF, 2000, J BIOL CHEM, V275, P10300, DOI 10.1074/jbc.275.14.10300; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; RUZZENE M, 1993, EUR J BIOCHEM, V211, P289, DOI 10.1111/j.1432-1033.1993.tb19897.x; Sarmiento M, 2000, BIOCHEMISTRY-US, V39, P8171, DOI 10.1021/bi000319w; Sarmiento M, 1998, J BIOL CHEM, V273, P26368, DOI 10.1074/jbc.273.41.26368; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tiganis T, 1999, J BIOL CHEM, V274, P27768, DOI 10.1074/jbc.274.39.27768; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; van Huijsduijnen RH, 1998, GENE, V225, P1; YouTen KE, 1997, J EXP MED, V186, P683, DOI 10.1084/jem.186.5.683; Zhang YL, 2000, J BIOL CHEM, V275, P34205, DOI 10.1074/jbc.M004490200; ZHANG ZY, 1993, ANAL BIOCHEM, V211, P7, DOI 10.1006/abio.1993.1224; Zhang ZY, 1998, CRIT REV BIOCHEM MOL, V33, P1, DOI 10.1080/10409239891204161	31	54	58	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26036	26043		10.1074/jbc.M011697200	http://dx.doi.org/10.1074/jbc.M011697200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11352902	hybrid			2022-12-25	WOS:000169823300054
J	Park, AR; Cho, SK; Yun, UJ; Jin, MY; Lee, SH; Sachetto-Martins, G; Park, OK				Park, AR; Cho, SK; Yun, UJ; Jin, MY; Lee, SH; Sachetto-Martins, G; Park, OK			Interaction of the arabidopsis receptor protein kinase Wak1 with a glycine-rich protein, AtGRP-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL; OXIDATIVE BURST; CROSS-LINKING; GENE; EXPRESSION; CLAVATA3; TRANSDUCTION; SIGNALOSOME; RESISTANCE; PATHWAYS	The Arabidopsis wall-associated receptor kinase, Wak1, is a member of the Wak family (Wak1-5) that links the plasma membrane to the extracellular matrix, By the yeast two-hybrid screen, we found that a glycine-rich extracellular protein, AtGRP-3, binds to the extracellular domain of Wak1, Further in vitro binding studies indicated that AtGRP-3 is the only isoform among the six tested AtGRPs that specifically interacts with Waks, and the cysteine-rich carboxyl terminus of AtGRP-3 is essential for its binding to Wak1, We also show that Wak1 and AtGRP-3 form a complex with a molecular size of similar to 500 kDa in vivo in conjunction with the kinase-associated protein phosphatase, KAPP, that has been shown to interact with a number of plant receptor-like kinases, Binding of AtGRP-3 to Wak1 is shown to be crucial for the integrity of the complex. Wak1 and AtGRP-3 are both induced by salicylic acid treatment. Moreover, exogenously added AtGRP-3 up-regulates the expression of Wak1, AtGRP-3, and PR-1 (for (p) under bar athogenesis-(r) under bar elated) in protoplasts. Taken together, our data suggest that AtGRP-3 regulates Wak1 function through binding to the cell wall domain of Wak1 and that the interaction of Wak1 with AtGRP-3 occurs in a pathogenesis-related process in planta.	Kumho Life & Environm Sci Lab, Puk Gu, Kwangju 500480, South Korea; Univ Fed Rio de Janeiro, Dept Genet, BR-21941970 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro	Park, OK (corresponding author), Kumho Life & Environm Sci Lab, Puk Gu, 1 Oryong Dong, Kwangju 500480, South Korea.	omkim@hotmail.com	Sachetto-Martins, Gilberto/AAT-4095-2021; Sachetto-Martins, Gilberto/AAN-6328-2020					Abel S, 1998, METH MOL B, V82, P209; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; Bowling SA, 1997, PLANT CELL, V9, P1573, DOI 10.1105/tpc.9.9.1573; Brady JD, 1997, PLANT PHYSIOL, V115, P87, DOI 10.1104/pp.115.1.87; Braun DM, 1997, PLANT J, V12, P83, DOI 10.1046/j.1365-313X.1997.12010083.x; Braun DM, 1996, TRENDS BIOCHEM SCI, V21, P70, DOI 10.1016/S0968-0004(96)80185-X; BRISSON LF, 1994, PLANT CELL, V6, P1703, DOI 10.1105/tpc.6.12.1703; Cao H, 1997, CELL, V88, P57, DOI 10.1016/S0092-8674(00)81858-9; Choi G, 1999, NATURE, V401, P610, DOI 10.1038/44176; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; Cosgrove DJ, 1997, ANNU REV CELL DEV BI, V13, P171, DOI 10.1146/annurev.cellbio.13.1.171; DEOLIVEIRA DE, 1990, PLANT CELL, V2, P427, DOI 10.1105/tpc.2.5.427; DEOLIVEIRA DE, 1993, PLANT J, V3, P495, DOI 10.1046/j.1365-313X.1993.03040495.x; Domingo C, 1999, PLANT J, V20, P563, DOI 10.1046/j.1365-313X.1999.00631.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fletcher LC, 1999, SCIENCE, V283, P1911, DOI 10.1126/science.283.5409.1911; Friedrich L, 1995, PLANT MOL BIOL, V29, P959, DOI 10.1007/BF00014969; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; He ZH, 1996, J BIOL CHEM, V271, P19789, DOI 10.1074/jbc.271.33.19789; He ZH, 2000, SCIENCE, V288, P2360, DOI 10.1126/science.288.5475.2360; He ZH, 1998, PLANT J, V14, P55, DOI 10.1046/j.1365-313X.1998.00092.x; He ZH, 1999, PLANT MOL BIOL, V39, P1189, DOI 10.1023/A:1006197318246; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; KELLER B, 1993, PLANT PHYSIOL, V101, P1127, DOI 10.1104/pp.101.4.1127; KOHORN BD, 1992, P NATL ACAD SCI USA, V89, P10989, DOI 10.1073/pnas.89.22.10989; Kohorn BD, 1999, TRENDS CELL BIOL, V9, P381, DOI 10.1016/S0962-8924(99)01643-8; Lamb C, 1997, ANNU REV PLANT PHYS, V48, P251, DOI 10.1146/annurev.arplant.48.1.251; Lease K, 1998, CURR OPIN PLANT BIOL, V1, P388, DOI 10.1016/S1369-5266(98)80261-6; Li JM, 1997, CELL, V90, P929, DOI 10.1016/S0092-8674(00)80357-8; LINTHORST HJM, 1990, PLANT MOL BIOL, V15, P521, DOI 10.1007/BF00019172; McCubbin AG, 2000, ANNU REV CELL DEV BI, V16, P333, DOI 10.1146/annurev.cellbio.16.1.333; MUDD JB, 1997, PLANT RESPONSE AIR P, P267; Pennell R, 1998, CURR OPIN PLANT BIOL, V1, P504, DOI 10.1016/S1369-5266(98)80043-5; Penninckx IAMA, 1996, PLANT CELL, V8, P2309, DOI 10.1105/tpc.8.12.2309; PRASAD TK, 1994, PLANT CELL, V6, P65, DOI 10.1105/tpc.6.1.65; QUIGLEY F, 1991, PLANT MOL BIOL, V17, P949, DOI 10.1007/BF00037079; Sachetto-Martins G, 2000, BBA-GENE STRUCT EXPR, V1492, P1, DOI 10.1016/S0167-4781(00)00064-6; SANDAL NN, 1992, PLANT MOL BIOL, V18, P607, DOI 10.1007/BF00040679; SHOWALTER AM, 1993, PLANT CELL, V5, P9, DOI 10.1105/tpc.5.1.9; Smith HB, 1999, PLANT CELL, V11, P299; Streuli C, 1999, CURR OPIN CELL BIOL, V11, P634, DOI 10.1016/S0955-0674(99)00026-5; Thomma BPHJ, 1998, P NATL ACAD SCI USA, V95, P15107, DOI 10.1073/pnas.95.25.15107; Trotochaud AE, 2000, SCIENCE, V289, P613, DOI 10.1126/science.289.5479.613; Trotochaud AE, 1999, PLANT CELL, V11, P393, DOI 10.1105/tpc.11.3.393; VANHUIJSDUIJNEN RA, 1988, EMBO J, V5, P2057; VANNOCKER S, 1993, PLANT MOL BIOL, V21, P695, DOI 10.1007/BF00014552; Wei N, 1999, TRENDS GENET, V15, P98, DOI 10.1016/S0168-9525(98)01670-9; Wojtaszek P, 1997, BIOCHEM J, V322, P681, DOI 10.1042/bj3220681; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	49	34	37	0	40	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26688	26693		10.1074/jbc.M101283200	http://dx.doi.org/10.1074/jbc.M101283200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11335717	hybrid			2022-12-25	WOS:000169823300135
J	Chatterji, A; Beachy, RN; Fauquet, CM				Chatterji, A; Beachy, RN; Fauquet, CM			Expression of the oligomerization domain of the replication-associated protein (Rep) of Tomato leaf curl New Delhi virus interferes with DNA accumulation of heterologous geminiviruses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; RESISTANCE; ORIGIN; IDENTIFICATION; ORGANIZATION; INFECTIVITY; SEQUENCES; CLEAVAGE; GENOME	The minimal DNA binding domain of the replication-associated protein (Rep) of Tomato leaf curl New Delhi virus was determined by electrophoretic mobility gel shift analysis and co-purification assays. DNA binding activity maps to amino acids 1-160 (Rep-(1-160)) of the Rep protein and overlaps with the protein oligomerization domain. Transient expression of Rep protein (Rep(1-160)) was found to inhibit homologous viral DNA accumulation by 70-86% in tobacco protoplasts and in Nicotiana benthamiana plants. The results obtained showed that expression of N-terminal sequences of Rep protein could efficiently interfere with DNA binding and oligomerization activities during virus infection. Surprisingly, this protein reduced accumulation of the African cassava mosaic virus, Pepper huasteco yellow vein virus and Potato yellow mosaic virus by 22-48%, electrophoretic mobility shift assays and co-purification studies showed that Rep-(1-160) did not bind with high affinity in vitro to the corresponding common region sequences of heterologous geminiviruses. However, Rep-(1-160) formed oligomers with the Rep proteins of the other geminiviruses. These data suggest that the regulation of virus accumulation may involve binding of the Rep to target DNA sequences and to the other Rep molecules during virus replication.	Univ Missouri, Int Lab Trop Agr Biotechnol, Donald Danforth Plant Sci Ctr, CME, St Louis, MO 63121 USA	Donald Danforth Plant Science Center; University of Missouri System; University of Missouri Saint Louis	Fauquet, CM (corresponding author), Univ Missouri, Int Lab Trop Agr Biotechnol, Donald Danforth Plant Sci Ctr, CME, 8001 Nat Bridge Rd,M308, St Louis, MO 63121 USA.	iltab@danforthcenter.org						ARGUELLOASTORGA GR, 1994, VIROLOGY, V203, P90, DOI 10.1006/viro.1994.1458; Bendahmane M, 1997, PLANT MOL BIOL, V33, P351, DOI 10.1023/A:1005715805000; BonillaRamirez GM, 1997, J GEN VIROL, V78, P947, DOI 10.1099/0022-1317-78-4-947; Brown J. K., 1994, FAO (Food and Agriculture Organization of the United Nations) Plant Protection Bulletin, V42, P3; Chatterji A, 1999, J VIROL, V73, P5481, DOI 10.1128/JVI.73.7.5481-5489.1999; Chatterji A, 2000, VIROLOGY, V273, P341, DOI 10.1006/viro.2000.0434; DAY AG, 1991, P NATL ACAD SCI USA, V88, P6721, DOI 10.1073/pnas.88.15.6721; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; DESBIEZ C, 1995, P NATL ACAD SCI USA, V92, P5640, DOI 10.1073/pnas.92.12.5640; EAGLE PA, 1994, PLANT CELL, V6, P1157, DOI 10.1105/tpc.6.8.1157; Fauquet CM, 2000, ARCH VIROL, V145, P1743, DOI 10.1007/s007050070089; FONTES EPB, 1994, J BIOL CHEM, V269, P8459; FONTES EPB, 1994, PLANT CELL, V6, P405, DOI 10.1105/tpc.6.3.405; FRISCHMUTH T, 1991, VIROLOGY, V183, P539, DOI 10.1016/0042-6822(91)90982-H; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HEYRAUD F, 1993, EMBO J, V12, P4445, DOI 10.1002/j.1460-2075.1993.tb06130.x; HEYRAUDNITSCHKE F, 1995, NUCLEIC ACIDS RES, V23, P910, DOI 10.1093/nar/23.6.910; Hong YG, 1996, MOL PLANT MICROBE IN, V9, P219, DOI 10.1094/MPMI-9-0219; HONG YG, 1995, J GEN VIROL, V76, P2415, DOI 10.1099/0022-1317-76-10-2415; JUPIN I, 1995, FEBS LETT, V362, P116, DOI 10.1016/0014-5793(95)00221-T; LAUFS J, 1995, P NATL ACAD SCI USA, V92, P3879, DOI 10.1073/pnas.92.9.3879; Noris E, 1996, VIROLOGY, V224, P130, DOI 10.1006/viro.1996.0514; Orozco BM, 1997, J BIOL CHEM, V272, P9840; PADIDAM M, 1995, J GEN VIROL, V76, P25, DOI 10.1099/0022-1317-76-1-25; SAUNDERS K, 1991, NUCLEIC ACIDS RES, V19, P2325, DOI 10.1093/nar/19.9.2325; Settlage SB, 1996, J VIROL, V70, P6790, DOI 10.1128/JVI.70.10.6790-6795.1996; STANLEY J, 1983, NATURE, V305, P643, DOI 10.1038/305643a0; STANLEY J, 1990, P NATL ACAD SCI USA, V87, P6291, DOI 10.1073/pnas.87.16.6291; STENGER DC, 1991, P NATL ACAD SCI USA, V88, P8029, DOI 10.1073/pnas.88.18.8029; SUNTER G, 1993, VIROLOGY, V195, P275, DOI 10.1006/viro.1993.1374; Umaharan P, 1998, PHYTOPATHOLOGY, V88, P1262, DOI 10.1094/PHYTO.1998.88.12.1262; Verdaguer B, 1998, PLANT MOL BIOL, V37, P1055, DOI 10.1023/A:1006004819398; WATANABE Y, 1987, FEBS LETT, V219, P65, DOI 10.1016/0014-5793(87)81191-2; [No title captured]	34	22	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25631	25638		10.1074/jbc.M100030200	http://dx.doi.org/10.1074/jbc.M100030200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342533	hybrid			2022-12-25	WOS:000169800700155
J	de Meis, L				de Meis, L			Uncoupled ATPase activity and heat production by the sarcoplasmic reticulum Ca2+-ATPase - Regulation by ADP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; ENERGY INTERCONVERSION; ADENOSINE-TRIPHOSPHATE; CA2+ TRANSPORT; HYDROLYSIS; EFFLUX; COLD; THERMOGENESIS; EXPRESSION; RABBIT	Sarcoplasmic reticulum vesicles of rabbit skeletal muscle accumulate Ca2+ at the expense of ATP hydrolysis, The heat released during the hydrolysis of each ATP molecule varies depending on whether or not a Ca2+ gradient is formed across the vesicle membrane. After Ca2+ accumulation, a part of the Ca2+-ATPase activity is not coupled with Ca2+ transport (Yu, X,, and Inesi, G, (1995) J, Biol, Chem. 270, 4361-4367), I now show that both the heat produced during substrate hydrolysis and the uncoupled ATPase activity vary depending on the ADP/ATP ratio in the medium. With a low ratio, the Ca2+ transport is exothermic, and the formation of the gradient increases the amount of heat produced during the hydrolysis of each ATP molecule cleaved. With a high ADP/ATP ratio, the Ca2+ transport is endothermic, and formation of a gradient increased the amount of heat absorbed from the medium. Heat is absorbed from the medium when the Ca2+ efflux is coupled with the synthesis of ATP (5.7 kcal/mol of ATP), When there is no ATP synthesis, the Ca2+ efflux is exothermic (14-16 kcal/Ca2+ mol). It is concluded that in the presence of a low ADP concentration the uncoupled ATPase activity is the dominant route of heat production, With a high ADP/ATP ratio, the uncoupled ATPase activity is abolished, and the Ca2+ transport is endothermic, The possible correlation of these findings with thermogenesis and anoxia is discussed.	Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro	de Meis, L (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, Cidade Univ, BR-21941590 Rio De Janeiro, Brazil.	demeis@bioqmed.ufjr.br						BIANCO AC, 1987, AM J PHYSIOL, V253, pE255, DOI 10.1152/ajpendo.1987.253.3.E255; BLOCK BA, 1994, ANNU REV PHYSIOL, V56, P535; Boss O, 1998, EUR J ENDOCRINOL, V139, P1, DOI 10.1530/eje.0.1390001; Boss O, 1998, J BIOL CHEM, V273, P5, DOI 10.1074/jbc.273.1.5; BUSTO R, 1987, J CEREB BLOOD FLOW M, V7, P129; CHIESI M, 1979, J BIOL CHEM, V254, P370; CHINET A, 1992, J PHYSIOL-LONDON, V455, P663, DOI 10.1113/jphysiol.1992.sp019321; DAGLORIA M, 1976, J BIOL CHEM, V251, P3629; De Meis L, 1998, AM J PHYSIOL-CELL PH, V274, pC1738, DOI 10.1152/ajpcell.1998.274.6.C1738; de Meis L, 1974, Biochemistry, V13, P5032, DOI 10.1021/bi00721a026; de Meis L, 1998, BIOCHEM BIOPH RES CO, V243, P598, DOI 10.1006/bbrc.1997.8028; De Meis L, 2000, AN ACAD BRAS CIENC, V72, P365, DOI 10.1590/S0001-37652000000300010; de Meis L, 2000, BIOCHEM BIOPH RES CO, V276, P35, DOI 10.1006/bbrc.2000.3418; deMeis L, 1996, BBA-BIOENERGETICS, V1275, P105, DOI 10.1016/0005-2728(96)00058-8; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DEMEIS L, 1988, METHOD ENZYMOL, V157, P190; deMeis L, 1997, FEBS LETT, V406, P201, DOI 10.1016/S0014-5793(97)00244-5; DEMEIS L, 1982, J BIOL CHEM, V257, P1289; DEMEIS L, 1991, J BIOL CHEM, V266, P5736; DEMEIS L, 1981, SARCOPLASMIC RETICUL, V2; DIETRICH DLL, 1993, CIRC RES, V73, P1177, DOI 10.1161/01.RES.73.6.1177; DUMONTEIL E, 1993, AM J PHYSIOL, V265, pC507, DOI 10.1152/ajpcell.1993.265.2.C507; DUMONTEIL E, 1995, AM J PHYSIOL-CELL PH, V269, pC955, DOI 10.1152/ajpcell.1995.269.4.C955; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Fortea MI, 2000, J BIOL CHEM, V275, P12521, DOI 10.1074/jbc.275.17.12521; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; GOULD GW, 1987, BIOCHIM BIOPHYS ACTA, V904, P45, DOI 10.1016/0005-2736(87)90085-X; Hamalainen N, 1997, J MUSCLE RES CELL M, V18, P545, DOI 10.1023/A:1018663218477; HASSELBACH W, 1964, PROG BIOPHYS MOL BIO, V14, P167, DOI 10.1016/S0079-6107(64)80006-7; HASSELBACH W, 1978, BIOCHIM BIOPHYS ACTA, V515, P23, DOI 10.1016/0304-4157(78)90007-2; INESI G, 1989, J BIOL CHEM, V264, P5929; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; INESI G, 1980, J BIOL CHEM, V255, P3025; Inesi G, 1978, Ann N Y Acad Sci, V307, P224, DOI 10.1111/j.1749-6632.1978.tb41947.x; JANSKY L, 1995, PHYSIOL REV, V75, P237, DOI 10.1152/physrev.1995.75.2.237; Klingenspor M, 1996, BIOCHEM J, V316, P607, DOI 10.1042/bj3160607; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; MAKINOSE M, 1971, FEBS LETT, V12, P269, DOI 10.1016/0014-5793(71)80195-3; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P906, DOI 10.1016/0005-2736(73)90395-7; Mitidieri F, 1999, J BIOL CHEM, V274, P28344, DOI 10.1074/jbc.274.40.28344; MONTEROLOMELI M, 1992, J BIOL CHEM, V267, P1829; MOTTA HG, 1980, ARCH BIOCHEM BIOPHYS, V203, P395; Ramos RCS, 1999, J NEUROCHEM, V72, P81, DOI 10.1046/j.1471-4159.1999.0720081.x; ROMERO PJ, 1989, J BIOL CHEM, V264, P7869; ROSSI B, 1979, J BIOL CHEM, V254, P2302; SCHWARZENBACH G, 1957, HELV CHIM ACTA, V40, P1886, DOI 10.1002/hlca.19570400640; Simonides WS, 1996, J BIOL CHEM, V271, P32048, DOI 10.1074/jbc.271.50.32048; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; SORENSON MM, 1986, J MEMBRANE BIOL, V90, P219, DOI 10.1007/BF01870128; TANFORD C, 1984, CRC CR REV BIOCH MOL, V17, P123, DOI 10.3109/10409238409113603; VanderLinden CG, 1996, AM J PHYSIOL-CELL PH, V271, pC1908, DOI 10.1152/ajpcell.1996.271.6.C1908; WOOD HG, 1966, J BIOL CHEM, V241, P5692; WOOD SC, 1991, ANNU REV PHYSIOL, V53, P71, DOI 10.1146/annurev.physiol.53.1.71; YU X, 1995, J BIOL CHEM, V270, P4361, DOI 10.1074/jbc.270.9.4361	57	85	86	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25078	25087		10.1074/jbc.M103318200	http://dx.doi.org/10.1074/jbc.M103318200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342561	hybrid			2022-12-25	WOS:000169800700087
J	Hansen, CH; Du, LC; Naur, P; Olsen, CE; Axelsen, KB; Hick, AJ; Pickett, JA; Halkier, BA				Hansen, CH; Du, LC; Naur, P; Olsen, CE; Axelsen, KB; Hick, AJ; Pickett, JA; Halkier, BA			CYP83B1 is the oxime-metabolizing enzyme in the glucosinolate pathway in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOGENIC GLUCOSIDE DHURRIN; ESCHERICHIA-COLI; CYTOCHROME P450S; SORGHUM-BICOLOR; BIOSYNTHESIS; EXPRESSION; L.; BENZYLGLUCOSINOLATE; TRYPTOPHAN; CONVERSION	CYP83B1 from Arabidopsis thaliana has been identified as the oxime-metabolizing enzyme in the biosynthetic pathway of glucosinolates. Biosynthetically active microsomes isolated from Sinapis alba converted p-hydroxyphenylacetaldoxime and cysteine into S-alkylated p-hydroxyphenylacetothiohydroximate, S-(p-hydroxyphenylacetohydroximoyl)-L-cysteine, the next proposed intermediate in the glucosinolate pathway. The production was shown to be dependent on a cytochrome P450 monooxygenase. We searched the genome of A. thaliana for homologues of CYP71E1 (P450ox), the only known oxime-metabolizing enzyme in the biosynthetic pathway of the evolutionarily related cyanogenic glucosides, By a combined use of bioinformatics, published expression data, and knock-out phenotypes, we identified the cytochrome P450 CYP83B1 as the oxime-metabolizing enzyme in the glucosinolate pathway as evidenced by characterization of the recombinant protein expressed in Escherichia coli, The data are consistent with the hypothesis that the oxime-metabolizing enzyme in the cyanogenic pathway (P450ox) was mutated into a "P450mox" that converted oximes into toxic compounds that the plant detoxified into glucosinolates.	Royal Vet & Agr Univ, Plant Biochem Lab, DK-1871 Frederiksberg C, Denmark; Royal Vet & Agr Univ, Dept Chem, DK-1871 Frederiksberg, Denmark; Royal Vet & Agr Univ, Ctr Mol Plant Physiol, DK-1871 Frederiksberg C, Denmark; Swiss Inst Bioinformat, SwissProt Grp, CH-1211 Geneva 4, Switzerland; IACR Rothamsted, Harpenden AL5 2JQ, Herts, England	University of Copenhagen; University of Copenhagen; University of Copenhagen; Swiss Institute of Bioinformatics; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research	Halkier, BA (corresponding author), Royal Vet & Agr Univ, Plant Biochem Lab, Thrvaldsensvej 40, DK-1871 Frederiksberg C, Denmark.		Olsen, Carl E/H-3031-2014; Halkier, Barbara A/H-3196-2014; Axelsen, Kristian B/F-3449-2015	Olsen, Carl E/0000-0002-2275-0596; Halkier, Barbara A/0000-0002-3742-702X; Axelsen, Kristian B/0000-0003-3889-2879				Bak S, 1999, PLANT J, V20, P663, DOI 10.1046/j.1365-313X.1999.00642.x; Bak S, 2001, PLANT CELL, V13, P101, DOI 10.1105/tpc.13.1.101; Bak S, 1998, PLANT MOL BIOL, V36, P393, DOI 10.1023/A:1005915507497; Barlier I, 2000, P NATL ACAD SCI USA, V97, P14819, DOI 10.1073/pnas.260502697; Barnes HJ, 1996, METHOD ENZYMOL, V272, P3, DOI 10.1016/S0076-6879(96)72003-7; Du LC, 1995, P NATL ACAD SCI USA, V92, P12505, DOI 10.1073/pnas.92.26.12505; Ettlinger M.G., 1968, RECENT ADV PHYTOCHEM, V1, P59; Fahey JW, 2001, PHYTOCHEMISTRY, V56, P5, DOI 10.1016/S0031-9422(00)00316-2; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Halkier BA, 1999, NATURALLY OCCURRING GLYCOSIDES, P193; HALKIER BA, 1995, ARCH BIOCHEM BIOPHYS, V322, P369, DOI 10.1006/abbi.1995.1477; Hansen CH, 2001, J BIOL CHEM, V276, P11078, DOI 10.1074/jbc.M010123200; Hull AK, 2000, P NATL ACAD SCI USA, V97, P2379, DOI 10.1073/pnas.040569997; Jefcoate C R, 1978, Methods Enzymol, V52, P258; Jones PR, 2000, RECENT ADV PHYTOCHEM, V34, P191, DOI 10.1016/S0079-9920(00)80008-8; Kahn RA, 1997, PLANT PHYSIOL, V115, P1661, DOI 10.1104/pp.115.4.1661; Kiddle GA, 1999, PLANT CELL ENVIRON, V22, P433, DOI 10.1046/j.1365-3040.1999.00416.x; MATSUO M, 1972, PHYTOCHEMISTRY, V11, P697, DOI 10.1016/0031-9422(72)80034-7; Mikkelsen MD, 2000, J BIOL CHEM, V275, P33712, DOI 10.1074/jbc.M001667200; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; MITZUTANI M, 1998, PLANT MOL BIOL, V37, P39; Reintanz B, 2001, PLANT CELL, V13, P351, DOI 10.1105/tpc.13.2.351; Rodman J.E., 1981, PHYTOCHEMISTRY ANGIO, P43; RODMAN JE, 1991, SYST BOT, V16, P598, DOI 10.2307/2418864; Rodman JE, 1998, AM J BOT, V85, P997, DOI 10.2307/2446366; SCHWIMMER S, 1960, BIOCHIM BIOPHYS ACTA, V42, P316, DOI 10.1016/0006-3002(60)90795-2; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WETTER LR, 1968, CAN J BIOCHEM CELL B, V46, P931, DOI 10.1139/o68-139; Winkler RG, 1998, PLANT PHYSIOL, V118, P743, DOI 10.1104/pp.118.3.743; Wittstock U, 2000, J BIOL CHEM, V275, P14659, DOI 10.1074/jbc.275.19.14659	30	126	134	2	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24790	24796		10.1074/jbc.M102637200	http://dx.doi.org/10.1074/jbc.M102637200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11333274	Green Published, hybrid			2022-12-25	WOS:000169800700051
J	Jones, LC; Whitlock, JP				Jones, LC; Whitlock, JP			Dioxin-inducible transactivation in a chromosomal setting - Analysis of the acidic domain of the Ah receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; STRUCTURAL ELEMENTS; PAS SUPERFAMILY; ALPHA-HELIX; IN-VIVO; PROTEIN; IDENTIFICATION; CLONING; BINDING; CBP	We analyzed the transactivation function of the acidic segment of the Ah receptor (amino acids 515-583) by reconstituting AhR-defective mouse hepatoma cells with mutants. Our data reveal that both hydrophobic and acidic residues are important for transactivation and that these residues are clustered in two regions of the acidic segment of AhR. Both regions are crucial for function, because disruption of either one substantially impairs transactivation of the chromosomal CYP1A1 target gene. Neither region contains an amino acid motif that resembles those reported for other acidic activation domains. Furthermore, proline substitutions in both regions do not impair transactivation in vivo, a finding that implies that cu-helix formation is not required for function.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA; Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol & Oncol, Los Angeles, CA 90048 USA	Stanford University; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Whitlock, JP (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.	jpwhit@stanford.edu			NATIONAL CANCER INSTITUTE [R01CA053887, R35CA053887] Funding Source: NIH RePORTER; NCI NIH HHS [CA 53887] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DahlmanWright K, 1996, BIOCHEMISTRY-US, V35, P1323, DOI 10.1021/bi952409k; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Defossez PA, 1997, NUCLEIC ACIDS RES, V25, P4455, DOI 10.1093/nar/25.22.4455; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FEARON ER, 1992, P NATL ACAD SCI USA, V89, P7958, DOI 10.1073/pnas.89.17.7958; FISHER JM, 1990, J BIOL CHEM, V265, P9676; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Hi R, 1999, J BIOL CHEM, V274, P35152, DOI 10.1074/jbc.274.49.35152; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; JAIN S, 1994, J BIOL CHEM, V269, P31518; Ko HP, 1997, MOL CELL BIOL, V17, P3497, DOI 10.1128/MCB.17.7.3497; Ko HSP, 1996, MOL CELL BIOL, V16, P430; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lee H, 2000, J BIOL CHEM, V275, P29426, DOI 10.1074/jbc.M003107200; LI H, 1994, J BIOL CHEM, V269, P28098; MA Q, 1995, J BIOL CHEM, V270, P12697, DOI 10.1074/jbc.270.21.12697; McAndrew PC, 1998, MOL CELL BIOL, V18, P5818, DOI 10.1128/MCB.18.10.5818; MILLER AG, 1983, J BIOL CHEM, V258, P3523; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; OKEY AB, 1994, TRENDS PHARMACOL SCI, V15, P226, DOI 10.1016/0165-6147(94)90316-6; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Radhakrishnan I, 1999, J MOL BIOL, V287, P859, DOI 10.1006/jmbi.1999.2658; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; SCAMMELL JG, 1995, MOL BRAIN RES, V33, P326, DOI 10.1016/0169-328X(95)00161-K; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; SWIFT S, 1999, CURR PROTOCOL IMMU S, V31; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Uesugi M, 1999, P NATL ACAD SCI USA, V96, P14801, DOI 10.1073/pnas.96.26.14801; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103	49	15	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25037	25042		10.1074/jbc.M102910200	http://dx.doi.org/10.1074/jbc.M102910200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11350970	hybrid			2022-12-25	WOS:000169800700081
J	Ogretmen, B; Schady, D; Usta, J; Wood, R; Kraveka, JM; Luberto, C; Birbes, H; Hannun, YA; Obeid, LM				Ogretmen, B; Schady, D; Usta, J; Wood, R; Kraveka, JM; Luberto, C; Birbes, H; Hannun, YA; Obeid, LM			Role of ceramide in mediating the inhibition of telomerase activity in A549 human lung adenocarcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT GENE; GLUCOSYLCERAMIDE SYNTHASE; REVERSE-TRANSCRIPTASE; TUMOR-CELLS; EXPRESSION; APOPTOSIS; PROLIFERATION; PATHWAY; CANCER; GROWTH	This study was designed to analyze whether ceramide, a bioeffector of growth suppression, plays a role in the regulation of telomerase activity in A549 cells. Telomerase activity was inhibited significantly by exogenous C-6-ceramide, but not by the biologically inactive analog dihydro-C-6-ceramide, in a time- and dose-dependent manner, with 85% inhibition produced by 20 muM C-6-ceramide at 24 h, Moreover, analysis of phosphatidylserine translocation from the inner to the outer plasma membrane by flow cytometry and of poly(ADP-ribose) polymerase degradation by Western blotting showed that ceramide treatment (20 muM for 24 h) had no apoptotic effects. Trypan blue exclusion, [H-3]thymidine incorporation, and cell cycle analyses, coupled with clonogenic cell survival assay on soft agar, showed that ceramide treatment with a 20 muM concentration at 24 h resulted in the cell cycle arrest of the majority of the cell population at G(0)/G(1) with no detectable cell death, These results suggest that the inhibition of telomerase by ceramide is not a consequence of cell death but is correlated with growth arrest. Next, to determine the role of endogenous ceramide in telomerase modulation, A549 cells were transiently transfected with an expression vector containing the full-length bacterial sphingomyelinase cDNA (b-SMase). The overexpression of b-SMase, but not exogenously applied purified b-SMase enzyme, resulted in significantly decreased telomerase activity compared with controls, showing that the increased endogenous ceramide is sufficient for telomerase inhibition. Moreover, treatment of A549 cells with daunorubicin at 1 muM for 6 h resulted in the inhibition of telomerase, which correlated with the elevation of endogenous ceramide levels and growth arrest. Finally, stable overexpression of human glucosylceramide synthase, which attenuates ceramide levels by converting ceramide to glucosylceramide, prevented the inhibitory effects of C-6-ceramide and daunorubicin on telomerase, Therefore, these results provide novel data showing for the first time that ceramide is a candidate upstream regulator of telomerase.	Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pediat, Div Hematol Oncol, Charleston, SC 29425 USA; Amer Univ Beirut, Dept Biochem, Beirut, Lebanon	Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Medical University of South Carolina; Medical University of South Carolina; American University of Beirut	Obeid, LM (corresponding author), Med Univ S Carolina, Dept Med, POB 250779, Charleston, SC 29425 USA.	obeidl@musc.edu		obeid, lina/0000-0002-0734-0847	NCI NIH HHS [CA87584] Funding Source: Medline; NIA NIH HHS [AG16583, AG12467] Funding Source: Medline; NIGMS NIH HHS [GM43825] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R55AG012467, R01AG016583, R29AG012467] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akiyama M, 1999, CANCER LETT, V142, P23, DOI 10.1016/S0304-3835(99)00109-3; Albanell J, 1997, JNCI-J NATL CANCER I, V89, P1609, DOI 10.1093/jnci/89.21.1609; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Connor CE, 2001, CYTOMETRY, V43, P164, DOI 10.1002/1097-0320(20010301)43:3<164::AID-CYTO1044>3.0.CO;2-O; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; Faraoni I, 1997, CLIN CANCER RES, V3, P579; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Hisatake J, 1999, CANCER RES, V59, P4023; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Johnson VL, 1999, EXP CELL RES, V251, P175, DOI 10.1006/excr.1999.4557; Katakura Y, 1997, BIOCHEM BIOPH RES CO, V237, P313, DOI 10.1006/bbrc.1997.7104; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lee JY, 1998, BIOCHEM J, V334, P457, DOI 10.1042/bj3340457; Li J, 1999, FASEB J, V13, pA1420; Liu B, 1997, SEMIN CELL DEV BIOL, V8, P311, DOI 10.1006/scdb.1997.0153; Liu YY, 2000, J BIOL CHEM, V275, P7138, DOI 10.1074/jbc.275.10.7138; Liu YY, 1999, J BIOL CHEM, V274, P1140, DOI 10.1074/jbc.274.2.1140; Mandal M, 1997, J BIOL CHEM, V272, P14183, DOI 10.1074/jbc.272.22.14183; Marchetti A, 1999, CLIN CANCER RES, V5, P2077; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Ogretmen B, 1998, CANCER CHEMOTH PHARM, V42, P441, DOI 10.1007/s002800050843; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; Park KH, 1998, INT J ONCOL, V13, P489; Perry DK, 1998, BBA-MOL CELL BIOL L, V1436, P233, DOI 10.1016/S0005-2760(98)00145-3; Plo I, 1999, FEBS LETT, V452, P150, DOI 10.1016/S0014-5793(99)00631-6; RAO J, 1992, ANAL BIOCHEM, V207, P186, DOI 10.1016/0003-2697(92)90521-8; Sarvesvaran J, 1999, CARCINOGENESIS, V20, P1649, DOI 10.1093/carcin/20.8.1649; Schmelz EM, 1998, NUTRITION, V14, P717, DOI 10.1016/S0899-9007(98)00052-5; Schmelz EM, 1999, CANCER RES, V59, P5768; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shiratsuchi M, 1999, LEUKEMIA LYMPHOMA, V34, P349, DOI 10.3109/10428199909050960; Taga S, 1999, ANN SURG, V230, P715, DOI 10.1097/00000658-199911000-00015; Tepper AD, 2000, J BIOL CHEM, V275, P34810, DOI 10.1074/jbc.M005142200; Ulaner GA, 1998, CANCER RES, V58, P4168; VENABLE ME, 1994, J BIOL CHEM, V269, P26040; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Zhang JD, 1999, J CELL BIOL, V145, P99, DOI 10.1083/jcb.145.1.99; Zhang P, 1997, J BIOL CHEM, V272, P9609	56	95	103	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24901	24910		10.1074/jbc.M100314200	http://dx.doi.org/10.1074/jbc.M100314200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11335714	hybrid			2022-12-25	WOS:000169800700063
J	Schick, BP; Petrushina, I; Brodbeck, KC; Castronuevo, P				Schick, BP; Petrushina, I; Brodbeck, KC; Castronuevo, P			Promoter regulatory elements and DNase I-hypersensitive sites involved in serglycin proteoglycan gene expression in human erythroleukemia, CHRF 288-11, and HL-60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY GRANULE PROTEOGLYCANS; ENDOTHELIAL GROWTH-FACTOR; GLYCOPROTEIN-IIB GENE; MEGAKARYOCYTE-SPECIFIC EXPRESSION; TISSUE-SPECIFIC EXPRESSION; CAMP RESPONSE ELEMENT; CIS-ACTING ELEMENTS; CORE PROTEIN GENE; CYCLIC-AMP; TRANSCRIPTIONAL REGULATION	We have compared regulation of the serglycin gene in human erythroleukemia (HEL) and CHRF 288-11 cells, which have megakaryocytic characteristics, with promyelocytic HL-60 cells, Deletion constructs were prepared from the region -1123/+42 to -20/+42, and putative regulatory sites were mutated. In all three cell lines, the two major regulatory elements for constitutive expression were the (-80)ets site and the cyclic AMP response element (CRE) half-site at -70, A protein from HEL and CHRF, but not HL60, nuclear extracts bound to the (-80)ets site. Another protein from ah three cell lines bound to the (-70)CRE. Phorbol 12-myristate 15-acetate (PMA) and dibutyryl cyclic AMP (dbcAMP) increased expression of the reporter in HEL cells 2.5-3- and 4.5-fold, respectively, from all constructs except those with (-70)CRE mutations. PMA virtually eliminated expression of serglycin mRNA and promoter constructs, but dbcAMP increased expression in HL-60 cells. The effects of PMA and dbcAMP on promoter expression correlated with mRNA expression, The strengths of two DNase hypersensitive sites in the 5 ' -flanking region and the first intron in all three cells correlated with relative endogenous serglycin mRNA expression, An additional DNase I-hypersensitive site in HL60 DNA in the first intron may be related to the high serglycin expression in HL60 relative to HEL or CHRF cells.	Thomas Jefferson Univ, Cardeza Fdn Hematol Res, Jefferson Med Coll, Philadelphia, PA 19107 USA	Jefferson University	Schick, BP (corresponding author), Thomas Jefferson Univ, Cardeza Fdn Hematol Res, Jefferson Med Coll, 1015 Walnut St, Philadelphia, PA 19107 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007821, R01HL029282] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07821, HL-29282] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLIEL PM, 1988, FEBS LETT, V236, P123, DOI 10.1016/0014-5793(88)80298-9; ANGERTH T, 1990, GENE, V93, P235, DOI 10.1016/0378-1119(90)90230-O; Asundi VK, 1998, GENE, V206, P255, DOI 10.1016/S0378-1119(97)00594-5; AVRAHAM S, 1992, J BIOL CHEM, V267, P610; AVRAHAM S, 1989, J BIOL CHEM, V264, P16719; BARBER AJ, 1972, BIOCHIM BIOPHYS ACTA, V286, P312, DOI 10.1016/0304-4165(72)90267-X; Bastian LS, 1996, J BIOL CHEM, V271, P18554, DOI 10.1074/jbc.271.31.18554; BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; BLOCK KL, 1995, STEM CELLS, V13, P135, DOI 10.1002/stem.5530130205; BLOCK KL, 1994, BLOOD, V84, P3385; BOCKAMP EO, 1995, BLOOD, V86, P1502, DOI 10.1182/blood.V86.4.1502.bloodjournal8641502; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRENNAN MJ, 1983, CANCER RES, V43, P4302; CHURCH DJ, 1994, BIOCHEM J, V303, P217, DOI 10.1042/bj3030217; Cook DM, 1996, ONCOGENE, V13, P1789; Deere M, 1999, GENOME RES, V9, P449; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUTERQUECOQUILLAUD M, 1993, ONCOGENE, V8, P1865; EISMAN R, 1990, BLOOD, V76, P336; Eklund KK, 1997, J IMMUNOL, V158, P4373; ELLIOTT JF, 1993, MOL IMMUNOL, V30, P749, DOI 10.1016/0161-5890(93)90146-3; ENGLANDER EW, 1992, DNA CELL BIOL, V11, P61, DOI 10.1089/dna.1992.11.61; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; FUGMAN DA, 1990, BLOOD, V75, P1252; GROVER A, 1987, DIFFERENTIATION, V36, P138, DOI 10.1111/j.1432-0436.1987.tb00188.x; HARRIGAN MT, 1989, MOL CELL BIOL, V9, P3438, DOI 10.1128/MCB.9.8.3438; HASHIMOTO Y, 1995, J BIOL CHEM, V270, P24532, DOI 10.1074/jbc.270.41.24532; Ho HCK, 2001, BIOL REPROD, V64, P1667, DOI 10.1095/biolreprod64.6.1667; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; HUMPHRIES DE, 1992, J BIOL CHEM, V267, P13558; Ikeda T, 1996, GROWTH FACTORS, V13, P151, DOI 10.3109/08977199609003217; Iozzo RV, 1997, J BIOL CHEM, V272, P5219, DOI 10.1074/jbc.272.8.5219; JUCKER M, 1992, ONCOGENE, V7, P943; Kim JS, 1997, MOL BRAIN RES, V51, P154, DOI 10.1016/S0169-328X(97)00227-1; Ko CW, 1996, MOL CELL BIOCHEM, V162, P65; Kolset SO, 1996, J LEUKOCYTE BIOL, V59, P545, DOI 10.1002/jlb.59.4.545; KOLSET SO, 1990, BIOCHIM BIOPHYS ACTA, V1032, P191, DOI 10.1016/0304-419X(90)90004-K; KOZAK UC, 1994, MOL CELL BIOL, V14, P59, DOI 10.1128/MCB.14.1.59; Kulseth MA, 1999, BBA-GEN SUBJECTS, V1428, P225, DOI 10.1016/S0304-4165(99)00096-3; KUNKEL GR, 1981, NUCLEIC ACIDS RES, V9, P6869, DOI 10.1093/nar/9.24.6869; KURAMOCHI S, 1990, EUR J BIOCHEM, V193, P163, DOI 10.1111/j.1432-1033.1990.tb19318.x; LASKIN JD, 1991, LEUK RE, V15, P5515; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; Lok CN, 2000, J BIOL CHEM, V275, P24185, DOI 10.1074/jbc.M000944200; Lowe GN, 1996, ENDOCRINOLOGY, V137, P2208, DOI 10.1210/en.137.6.2208; Ludlow LB, 1996, J BIOL CHEM, V271, P22076, DOI 10.1074/jbc.271.36.22076; MAILLET P, 1992, LEUKEMIA, V6, P1143; MARLEY PD, 1993, EUR J PHARM-MOLEC PH, V244, P7, DOI 10.1016/0922-4106(93)90053-C; MARTIN F, 1993, J BIOL CHEM, V268, P21606; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Mohle R, 1997, P NATL ACAD SCI USA, V94, P663, DOI 10.1073/pnas.94.2.663; MONTGOMERY RI, 1992, P NATL ACAD SCI USA, V89, P11327, DOI 10.1073/pnas.89.23.11327; MURAOSA Y, 1993, MOL CELL BIOL, V13, P7881, DOI 10.1128/MCB.13.12.7881; NagamotoCombs K, 1997, J BIOL CHEM, V272, P6051, DOI 10.1074/jbc.272.9.6051; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; NASO MF, 1994, J BIOL CHEM, V269, P32999; NICODEMUS CF, 1990, J BIOL CHEM, V265, P5889; OPREY J, 1994, MOL CELL BIOL, V14, P851; Pio F, 1996, J BIOL CHEM, V271, P23329, DOI 10.1074/jbc.271.38.23329; Pirok EW, 1997, J BIOL CHEM, V272, P11566, DOI 10.1074/jbc.272.17.11566; Prandini MH, 1996, BLOOD, V88, P2062, DOI 10.1182/blood.V88.6.2062.bloodjournal8862062; RAMACHANDRAN B, 1995, EXP HEMATOL, V23, P49; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; RAVID K, 1991, P NATL ACAD SCI USA, V88, P1521, DOI 10.1073/pnas.88.4.1521; RAYGALLET D, 1995, ONCOGENE, V11, P303; Robinson L, 1997, P NATL ACAD SCI USA, V94, P7170, DOI 10.1073/pnas.94.14.7170; SAKAMOTO KM, 1994, MOL CELL BIOL, V14, P5975, DOI 10.1128/MCB.14.9.5975; Sali A., 1993, J BIOL CHEM, V268, P9203; SCHICK BP, 1995, J CELL PHYSIOL, V165, P96, DOI 10.1002/jcp.1041650113; SCHICK BP, 1988, J BIOL CHEM, V263, P1052; SCHICK BP, 1993, LEUKEMIA, V7, P1955; SCHICK BP, 1991, ARTERIOSCLER THROMB, V11, P191, DOI 10.1161/01.ATV.11.1.191; SCHICK BP, 1992, BIOCHEM J, V282, P651, DOI 10.1042/bj2820651; Schick BP, 2001, BLOOD, V97, P449, DOI 10.1182/blood.V97.2.449; Schick BP, 1997, J CELL PHYSIOL, V172, P87, DOI 10.1002/(SICI)1097-4652(199707)172:1<87::AID-JCP10>3.0.CO;2-L; SCHICK PK, 1989, BLOOD, V73, P1801; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; Shimura H, 1998, MOL ENDOCRINOL, V12, P1473, DOI 10.1210/me.12.10.1473; SPROTT SC, 1991, INT J BIOCHEM, V23, P713, DOI 10.1016/0020-711X(91)90042-L; STELLRECHT CM, 1991, DIFFERENTIATION, V48, P127, DOI 10.1111/j.1432-0436.1991.tb00251.x; STELLRECHT CMM, 1993, J BIOL CHEM, V268, P4078; Stevens R. L., 2000, PROTEOGLYCANS STRUCT, P177; ToyamaSorimachi N, 1997, J BIOL CHEM, V272, P26714, DOI 10.1074/jbc.272.42.26714; TOYAMASORIMACHI N, 1995, J BIOL CHEM, V270, P7437, DOI 10.1074/jbc.270.13.7437; Tsuzuki S, 1997, J BIOCHEM-TOKYO, V122, P17; Ungefroren H, 1996, J BIOL CHEM, V271, P15787, DOI 10.1074/jbc.271.26.15787; Ungefroren H, 1998, J BIOL CHEM, V273, P29230, DOI 10.1074/jbc.273.44.29230; Ungefroren H, 1997, BIOCHEM BIOPH RES CO, V235, P413, DOI 10.1006/bbrc.1997.6801; UZAN G, 1991, J BIOL CHEM, V266, P8932; Wakiya K, 1996, J BIOL CHEM, V271, P30823, DOI 10.1074/jbc.271.48.30823; WATANABE H, 1995, BIOCHEM J, V308, P433, DOI 10.1042/bj3080433; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WHYZMUZIS CA, 1993, BIOCHEM BIOPH RES CO, V194, P118, DOI 10.1006/bbrc.1993.1793; WOLLBERG P, 1994, J BIOL CHEM, V269, P19719	98	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24726	24735		10.1074/jbc.M102958200	http://dx.doi.org/10.1074/jbc.M102958200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11333275	hybrid			2022-12-25	WOS:000169800700043
J	Shetty, S; Idell, S				Shetty, S; Idell, S			Urokinase induces expression of its own receptor in Beas2B lung epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITORS; RNA BINDING-PROTEIN; POSTTRANSCRIPTIONAL REGULATION; MESOTHELIOMA CELLS; MESSENGER-RNA; TUMOR INVASION; BREAST-CANCER; U-PA; METASTASIS; CARCINOMA	Interaction between the urokinase-type plasminogen activator (uPA) and its receptor (uPAR) localizes cellular proteolysis and promotes cellular proliferation and migration. The interaction between uPA and uPAR at the surface of epithelial cells thereby contributes to the pathogenesis of lung inflammation and neoplasia. In this study, we sought to determine if uPA itself alters uPAR expression by lung epithelial cells. uPA enhanced uPAR expression as well as I-125-UpA binding in Beas2B lung epithelial cells in a time- and concentration-dependent manner. The uPA-mediated induction of uPAR is not accomplished through its receptor and requires enzymatic activity. The low molecular weight fragment of uPA, lacking the receptor binding domain, was as potent as intact two-chain uPA in inducing expression of uPAR at the cell surface. Plasmin, the end product of plasminogen activation, did not alter uPA-mediated uPAR expression. Induction of uPAR by uPA represents a novel pathway by which epithelial cells can regulate uPAR-dependent cellular responses that may contribute to stromal remodeling in lung injury or neoplasia.	Univ Texas Hlth Ctr, Dept Med Specialties, Lab C6, Tyler, TX 75708 USA		Shetty, S (corresponding author), Univ Texas Hlth Ctr, Dept Med Specialties, Lab C6, BIomed Res Bldg,11937 US Highway 271, Tyler, TX 75708 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062453] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-62453-01] Funding Source: Medline; PHS HHS [R01 45018-06] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ACHBAROU A, 1994, CANCER RES, V54, P2372; AXELROD JH, 1989, MOL CELL BIOL, V9, P2133, DOI 10.1128/MCB.9.5.2133; BAHUSLAV J, 1995, J EXP MED, V181, P1381; Bhat GJ, 1999, AM J PHYSIOL-LUNG C, V277, pL301, DOI 10.1152/ajplung.1999.277.2.L301; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; BOYD D, 1988, CANCER RES, V48, P3112; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; CHAPMAN HA, 1988, CHEST, V93, P1256, DOI 10.1378/chest.93.6.1256; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DUMLER I, 1993, FEBS LETT, V322, P37, DOI 10.1016/0014-5793(93)81106-A; Dumler I, 1998, J BIOL CHEM, V273, P315, DOI 10.1074/jbc.273.1.315; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; DVORAK HF, 1983, CANCER METAST REV, V2, P41, DOI 10.1007/BF00046905; Ghiso JAA, 1999, EUR J BIOCHEM, V263, P295, DOI 10.1046/j.1432-1327.1999.00507.x; GROSS TJ, 1991, AM J PHYSIOL, V260, pL286, DOI 10.1152/ajplung.1991.260.4.L286; GROSS TJ, 1990, AM J RESP CELL MOL, V3, P449, DOI 10.1165/ajrcmb/3.5.449; HOLLAS W, 1992, THROMB HAEMOSTASIS, V68, P662; HoyerHansen G, 1997, EUR J BIOCHEM, V243, P21, DOI 10.1111/j.1432-1033.1997.0021a.x; IDELL S, 1992, AM J RESP CELL MOL, V7, P414, DOI 10.1165/ajrcmb/7.4.414; IDELL S, 1994, AM J PHYSIOL-LUNG C, V267, pL693, DOI 10.1152/ajplung.1994.267.6.L693; Idell S, 1994, New Horiz, V2, P566; Idell S, 1995, PULMONARY FIBROSIS, P743; JANICKE F, 1991, SEMIN THROMB HEMOST, V17, P303, DOI 10.1055/s-2007-1002624; JIANG Y, 1996, BLOOD, V19, P2775; Koshelnick Y, 1997, J BIOL CHEM, V272, P28563, DOI 10.1074/jbc.272.45.28563; LIOTTA LA, 1991, CANCER INVEST, V9, P543, DOI 10.3109/07357909109018952; LUND LR, 1991, J BIOL CHEM, V266, P5177; LUND LR, 1995, BIOCHEM J, V310, P345, DOI 10.1042/bj3100345; Mazar A P, 1999, Angiogenesis, V3, P15, DOI 10.1023/A:1009095825561; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MITSUBAYASHI S, 1987, UROL RES, V15, P335; PEDERSEN H, 1994, CANCER RES, V54, P120; PEDERSEN H, 1994, CANCER RES, V54, P4671; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; Schmitt M, 1997, THROMB HAEMOSTASIS, V78, P285; Shetty S, 1998, ARCH BIOCHEM BIOPHYS, V356, P265, DOI 10.1006/abbi.1998.0789; Shetty S, 1999, MOL CELL BIOCHEM, V199, P189, DOI 10.1023/A:1006914800447; Shetty S, 1998, AM J PHYSIOL-LUNG C, V274, pL871, DOI 10.1152/ajplung.1998.274.6.L871; Shetty S, 1997, MOL CELL BIOL, V17, P1075, DOI 10.1128/MCB.17.3.1075; SHETTY S, 1995, ANTISENSE RES DEV, V5, P307, DOI 10.1089/ard.1995.5.307; SHETTY S, 1995, AM J PHYSIOL, V268, P972; SPRENGERS ED, 1987, BLOOD, V69, P381; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WALTZ DA, 1993, J CLIN INVEST, V91, P1541, DOI 10.1172/JCI116360; Xing RH, 1997, CANCER RES, V57, P3585	48	42	44	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24549	24556		10.1074/jbc.M101605200	http://dx.doi.org/10.1074/jbc.M101605200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342540	hybrid			2022-12-25	WOS:000169800700019
J	Spodsberg, N; Jacob, R; Alfalah, M; Zimmer, KP; Naim, HY				Spodsberg, N; Jacob, R; Alfalah, M; Zimmer, KP; Naim, HY			Molecular basis of aberrant apical protein transport in an intestinal enzyme disorder	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCRASE-ISOMALTASE DEFICIENCY; LACTASE-PHLORHIZIN HYDROLASE; INTRACELLULAR-TRANSPORT; VIRUS HEMAGGLUTININ; GLYCOSYLATION SITES; EPITHELIAL-CELLS; PLASMA-MEMBRANE; SORTING SIGNALS; O-GLYCOSYLATION; CLEAVAGE	The impaired sorting profile to the apical membrane of human intestinal sucrase-isomaltase is the underlying cause in the pathogenesis of a novel phenotype of intestinal congenital sucrase-isomaltase deficiency. Molecular characterization of this novel phenotype reveals a point mutation in the coding region of the sucrase-isomaltase (SI) gene that results in an amino acid substitution of a glutamine by arginine at residue 117 of the isomaltase subunit. This substitution is located in a domain revealing features of a trefoil motif or a P-dornain in immediate vicinity of the heavily O-glycosylated stalk domain. Expression of the mutant SI phenotype in epithelial Madin-Darby canine kidney cells reveals a randomly targeted SI protein to the apical and basolateral membranes confirming an exclusive role of the Q117R mutation in generating this phenotype. Unlike wild type SI, the mutant protein is completely extractable with Triton X-100 despite the presence of O-glycans that serve in the wild type protein as an apical sorting signal and are required for the association of SI with detergent-insoluble lipid microdomains. Obviously the O-glycans are not adequately recognized in the context of the mutant SI, most likely due to altered folding of the P-domain that ultimately affects the access of the O-glycans to a putative sorting element.	Sch Vet Med, Dept Physiol Chem, D-30559 Hannover, Germany; Univ Munster, Childrens Hosp, D-41489 Munster, Germany	University of Veterinary Medicine Hannover, Foundation; University of Munster	Naim, HY (corresponding author), Sch Vet Med, Dept Physiol Chem, Bunteweg 17, D-30559 Hannover, Germany.		Jacob, Ralf/B-8163-2011; Zimmer, Klaus-Peter/AAY-9261-2020; Zimmer, Klaus-Peter/AAY-9351-2020; Al Falah, Dr. Marwan/C-6281-2011					Alfalah M, 1999, CURR BIOL, V9, P593, DOI 10.1016/S0960-9822(99)80263-2; CHANTRET I, 1992, BIOCHEM J, V285, P915, DOI 10.1042/bj2850915; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DAHLQVIST A, 1968, ANAL BIOCHEM, V22, P99, DOI 10.1016/0003-2697(68)90263-7; FRANSEN JAM, 1991, J CELL BIOL, V115, P45, DOI 10.1083/jcb.115.1.45; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; HAURI HP, 1979, P NATL ACAD SCI USA, V76, P5183, DOI 10.1073/pnas.76.10.5183; HAURI HP, 1985, P NATL ACAD SCI USA, V82, P4423, DOI 10.1073/pnas.82.13.4423; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HOFFMANN W, 1993, TRENDS BIOCHEM SCI, V18, P239, DOI 10.1016/0968-0004(93)90170-R; Huet G, 1998, J CELL BIOL, V141, P1311, DOI 10.1083/jcb.141.6.1311; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; Jacob R, 2000, J BIOL CHEM, V275, P6566, DOI 10.1074/jbc.275.9.6566; Jacob R, 2000, J CLIN INVEST, V106, P281, DOI 10.1172/JCI9677; Jacob R, 2000, J BIOL CHEM, V275, P10630, DOI 10.1074/jbc.275.14.10630; Jacob R, 1999, J BIOL CHEM, V274, P8061, DOI 10.1074/jbc.274.12.8061; KOJIMA N, 1992, BIOCHEM BIOPH RES CO, V182, P1288, DOI 10.1016/0006-291X(92)91872-N; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLOYD ML, 1987, NEW ENGL J MED, V316, P438, DOI 10.1056/NEJM198702193160804; MATLIN K, 1983, J CELL BIOL, V97, P627, DOI 10.1083/jcb.97.3.627; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; Moolenaar CEC, 1997, J CELL SCI, V110, P557; NAIM HY, 1988, J CLIN INVEST, V82, P667, DOI 10.1172/JCI113646; NAIM HY, 1988, J BIOL CHEM, V263, P7242; Nichols BL, 1998, J BIOL CHEM, V273, P3076, DOI 10.1074/jbc.273.5.3076; Ouwendijk J, 1996, J CLIN INVEST, V97, P633, DOI 10.1172/JCI118459; Ouwendijk J, 1998, BBA-MOL BASIS DIS, V1406, P299, DOI 10.1016/S0925-4439(98)00016-7; ROBERTS PC, 1993, J VIROL, V67, P3048, DOI 10.1128/JVI.67.6.3048-3060.1993; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; TREEM WR, 1995, J PEDIATR GASTR NUTR, V21, P1, DOI 10.1097/00005176-199507000-00001; WELPLY JK, 1983, J BIOL CHEM, V258, P1856; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; Wilson PD, 1997, AM J PHYSIOL-RENAL, V272, pF434, DOI 10.1152/ajprenal.1997.272.4.F434	33	28	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23506	23510		10.1074/jbc.C100219200	http://dx.doi.org/10.1074/jbc.C100219200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11340066	hybrid			2022-12-25	WOS:000169531100039
J	Matsuzaki, H; Tamatani, M; Yamaguchi, A; Namikawa, K; Kiyama, H; Vitek, MP; Mitsuda, N; Tohyama, M				Matsuzaki, H; Tamatani, M; Yamaguchi, A; Namikawa, K; Kiyama, H; Vitek, MP; Mitsuda, N; Tohyama, M			Vascular endothelial growth factor rescues hippocampal neurons from glutamate-induced toxicity: signal transduction cascades	FASEB JOURNAL			English	Article									Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Suita, Osaka 5650871, Japan; Asahikawa Med Coll, Dept Anat, Asahikawa, Hokkaido 0788510, Japan; Duke Univ, Med Ctr, Div Neurol, Durham, NC 27710 USA; Japan Sci & Technol, CREST, Tokyo, Japan	Osaka University; Asahikawa Medical College; Duke University; Japan Science & Technology Agency (JST)	Tamatani, M (corresponding author), Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Kiyama, Hiroshi/M-8867-2014; MATSUZAKI, HIDEO/AAE-5246-2020	Kiyama, Hiroshi/0000-0001-5963-046X; MATSUZAKI, HIDEO/0000-0002-6869-1261; Vitek, Michael/0000-0001-8140-8048					0	232	252	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1218	1220		10.1096/fj.00-0495fje	http://dx.doi.org/10.1096/fj.00-0495fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344093				2022-12-25	WOS:000168655200015
J	Sakiyama-Elbert, SE; Panitch, A; Hubbell, JA				Sakiyama-Elbert, SE; Panitch, A; Hubbell, JA			Development of growth factor fusion proteins for cell-triggered drug delivery	FASEB JOURNAL			English	Article									ETH Zurich, Inst Biomed Engn, CH-8044 Zurich, Switzerland; ETH Zurich, Dept Mat, CH-8044 Zurich, Switzerland; Univ Zurich, Zurich, Switzerland; CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; Arizona State Univ, Dept Bioengn, Tempe, AZ 85287 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; California Institute of Technology; Arizona State University; Arizona State University-Tempe	Hubbell, JA (corresponding author), ETH Zurich, Inst Biomed Engn, Moussonstr 18, CH-8044 Zurich, Switzerland.		Panitch, Alyssa/F-4413-2012; Hubbell, Jeffrey A/A-9266-2008; Sakiyama-Elbert, Shelly/A-6753-2008	Hubbell, Jeffrey A/0000-0003-0276-5456; Sakiyama-Elbert, Shelly/0000-0003-4832-5851					0	129	140	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1300	1302		10.1096/fj.00-0564fje	http://dx.doi.org/10.1096/fj.00-0564fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344120				2022-12-25	WOS:000168655200042
J	Zhang, JH; Underwood, LE; D'Ercole, AJ				Zhang, JH; Underwood, LE; D'Ercole, AJ			Hepatic mRNAs up-regulated by starvation: an expression profile determined by suppression subtractive hybridization	FASEB JOURNAL			English	Article									Univ N Carolina, Dept Pediat, Div Endocrinol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Zhang, JH (corresponding author), Univ N Carolina, Dept Pediat, Div Endocrinol, 509 Burnett Womack Bldg,CB 7220, Chapel Hill, NC 27599 USA.								0	14	14	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1261	1263		10.1096/fj.00-0717fje	http://dx.doi.org/10.1096/fj.00-0717fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344107				2022-12-25	WOS:000168655200029
J	Huang, SM; Schonthal, AH; Stallcup, MR				Huang, SM; Schonthal, AH; Stallcup, MR			Enhancement of p53-dependent gene activation by the transcriptional coactivator Zac1	ONCOGENE			English	Article						Zac1; p53; E6 protein; transcriptional coactivator; transcriptional activation	HUMAN-PAPILLOMAVIRUS TYPE-16; ZINC-FINGER PROTEIN; HUMAN BREAST-CANCER; RECEPTOR SIGNALING PATHWAYS; TUMOR-SUPPRESSOR P53; NEGATIVE REGULATOR; E6 ONCOPROTEIN; CELLS; EXPRESSION; GROWTH	A recently discovered potential tumor suppressor protein, Zac1, was previously shown to promote cell cycle arrest and apoptosis, and to act as a positive or negative transcriptional cofactor for nuclear receptors, Since these activities are common to Zac1 and p53, we tested for a functional interaction between these two proteins by investigating possible effects of Zac1 on the transcriptional activator function of p53. Zac1 specifically enhanced the activity of p53-responsive promoters in cells expressing wild type p53, The same promoters were not activated by Zac1 in cells lacking functional p53, but the Zac1 effect was restored by co-expression of p53. Zac1 bound to p53 and enhanced the activity of p53 or its N-terminal transcriptional activation domain fused to the DNA binding domain of Gal4. These results indicate that Zac1 served as a transcriptional coactivator for p53. The enhancement of p53 activity by Zac1 was much more dramatic in HeLa cells than in other cell Lines tested. HeLa cells express human papillomavirus type 18 E6 protein which inactivates and causes the degradation of p53. Physical and functional interactions observed between Zac1 and E6 protein indicated that the dramatic activity of Zac1 in HeLa cells was due not only to Zac1's coactivator effect on p53, but also to the ability of Zac1 to reverse E6 inhibition of p53.	Univ So Calif, Dept Pathol, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Dept Mol Microbiol & Immunol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California; University of Southern California	Stallcup, MR (corresponding author), Univ So Calif, Dept Pathol, HMR 301,2011 Zonal Ave, Los Angeles, CA 90089 USA.		Schonthal, Axel/ABH-3846-2020	Schonthal, Axel/0000-0003-0662-5653	NATIONAL CANCER INSTITUTE [R29CA074278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK055274, R01DK055274] Funding Source: NIH RePORTER; NCI NIH HHS [CA74278] Funding Source: Medline; NIDDK NIH HHS [DK55274] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARTEK J, 1990, ONCOGENE, V5, P893; Bhat MK, 1997, J BIOL CHEM, V272, P28989, DOI 10.1074/jbc.272.46.28989; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CASEY G, 1991, ONCOGENE, V6, P1791; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARVEY M, 1993, ONCOGENE, V8, P2457; Hoffmann A, 1998, ANN NY ACAD SCI, V865, P49, DOI 10.1111/j.1749-6632.1998.tb11162.x; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Huang SM, 2000, MOL CELL BIOL, V20, P1855, DOI 10.1128/MCB.20.5.1855-1867.2000; Kas K, 1998, J BIOL CHEM, V273, P23026, DOI 10.1074/jbc.273.36.23026; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LITTLE JB, 1987, CANCER RES, V47, P4229; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; TAM SW, 1994, ONCOGENE, V9, P2663; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Wu RC, 1997, J BIOL CHEM, V272, P29091, DOI 10.1074/jbc.272.46.29091; Yu CL, 1997, BIOCHEM BIOPH RES CO, V239, P617, DOI 10.1006/bbrc.1997.7522; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999	31	88	88	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2001	20	17					2134	2143		10.1038/sj.onc.1204298	http://dx.doi.org/10.1038/sj.onc.1204298			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360197				2022-12-25	WOS:000168116700008
J	Annis, MG; Zamzami, N; Zhu, WJ; Penn, LZ; Kroemer, G; Leber, B; Andrews, DW				Annis, MG; Zamzami, N; Zhu, WJ; Penn, LZ; Kroemer, G; Leber, B; Andrews, DW			Endoplasmic reticulum localized Bcl-2 prevents apoptosis when redistribution of cytochrome c is a late event	ONCOGENE			English	Article						apoptosis; Bax; Bcl-2; cytochrome c; endoplasmic reticulum	MITOCHONDRIAL PERMEABILITY TRANSITION; CELL-DEATH; CASPASE ACTIVATION; FAMILY PROTEINS; RELEASE; COMPLEX; MYC; DNA; PRO-CASPASE-3; SUPPRESSION	The disruption of mitochondrial function is a key component of apoptosis in most cell types. Localization of Bcl-2 to the outer mitochondrial and endoplasmic reticulum membranes is consistent with a role in the inhibition of many forms of apoptosis, In Rat-1 cells, a Bcl-2 mutant targeted exclusively to the endoplasmic reticulum (Bcl-cb5) was effective at inhibiting apoptosis induced by serum starvation/myc, or ceramide but not apoptosis induced by etoposide, The former conditions cause a decrease in mitochondrial transmembrane potential (Delta psi (m)) as an early event that precedes the release of cytochrome c from mitochondria, By contrast, when cells are exposed to etoposide, a situation in which cytochrome c release and membrane localization of the pro-apoptotic protein Bax precede loss of Delta psi (m), wild type Bcl-2 but not Bcl-cb5 prevents apoptosis, Therefore, Bcl-2 functions in spatially distinct pathways of apoptosis distinguished by the order of cytochrome c release and loss of Delta psi (m).	McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Inst Gustave Roussy, CNRS UMR1599, F-94805 Villejuif, France; McMaster Univ, Dept Med & Lab Med, Hamilton, ON L8N 3Z5, Canada	McMaster University; University of Toronto; UNICANCER; Gustave Roussy; McMaster University	Andrews, DW (corresponding author), McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada.		KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020	KROEMER, Guido/0000-0002-9334-4405; Annis, Matthew/0000-0002-8776-004X; Andrews, David/0000-0002-9266-7157; Leber, Brian/0000-0001-5502-1480; Penn, Linda/0000-0001-8133-5459				Adachi S, 1998, J BIOL CHEM, V273, P19892, DOI 10.1074/jbc.273.31.19892; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; BOYD JM, 1995, ONCOGENE, V11, P1921; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; JANIAK F, 1994, J BIOL CHEM, V269, P9842; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lee ST, 1999, ONCOGENE, V18, P3520, DOI 10.1038/sj.onc.1202716; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Petit PX, 1998, FEBS LETT, V426, P111, DOI 10.1016/S0014-5793(98)00318-4; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scorrano L, 1999, J BIOL CHEM, V274, P24657, DOI 10.1074/jbc.274.35.24657; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Xanthoudakis S, 1999, EMBO J, V18, P2049, DOI 10.1093/emboj/18.8.2049; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	41	108	109	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2001	20	16					1939	1952		10.1038/sj.onc.1204288	http://dx.doi.org/10.1038/sj.onc.1204288			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360178				2022-12-25	WOS:000168043800002
J	Ruteshouser, EC; Ashworth, LK; Huff, V				Ruteshouser, EC; Ashworth, LK; Huff, V			Absence of PPP2R1A mutations in Wilms tumor	ONCOGENE			English	Article						PPP2R1A; protein phosphatase 2A; Wilms tumor; FWT2; tumor suppressor	PROTEIN PHOSPHATASE 2A; BETA-CATENIN; SUPPRESSOR LOCUS; OKADAIC ACID; PPP1R3 GENE; SUBUNIT; EXPRESSION; ANTIGEN; CANCER; AXIN	Evidence from genetic linkage analysis indicates that a gene located at 19q13.4, FWT2, is responsible for predisposition to Wilms tumor in many Wilms tumor families. This region has also been implicated in the etiology of sporadic Wilms tumor through loss of heterozygosity analyses, The PPP2R1A gene, encoding the alpha isoform of the heterotrimeric serine/threonine protein phosphatase 2A (PP2A), is located within the FWT2 candidate region and is altered in breast and lung carcinomas. PPP2R1B, encoding the beta isoform, is mutated in Lung, colon, and breast cancers. These findings suggested that both PPP2R1A and PPP2R1B may be tumor suppressor genes. Additionally, PP2A is important in fetal kidney growth and differentiation and has an expression pattern similar to that of the Wilms tumor suppressor gene WT1, Since PPP2R1A was therefore a compelling candidate for the FWT2 gene, we analysed the coding region of PPP2R1A in DNA and RNA samples from affected members of four Wilms tumor families and 30 sporadic tumors and identified no mutations in PPP2R1A in any of these 34 samples. We conclude that PPP2R1A is not the 19q familial Wilms tumor gene and that mutation of PPP2R1A is not a common event in the etiology of sporadic Wilms tumor.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Pediat, Houston, TX 77030 USA; Univ Calif Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, Livermore, CA 94551 USA	University of Texas System; UTMD Anderson Cancer Center; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System	Huff, V (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Pediat, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA78257, CA34936, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA034936, P30CA016672, R01CA078257] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFSHARI CA, 1993, CANCER RES, V53, P1777; ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRESLOW N, 1993, MED PEDIATR ONCOL, V21, P172, DOI 10.1002/mpo.2950210305; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DEPAOLIROACH AA, 1994, ADV ENZYME REGUL, V34, P199, DOI 10.1016/0065-2571(94)90017-5; Everett AD, 1999, J AM SOC NEPHROL, V10, P1737; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRUBB GR, 1994, LAB INVEST, V71, P472; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P7330; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Huff V, 1997, CANCER RES, V57, P1859; HUFF V, 1990, HUM GENET, V84, P253; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Koesters R, 1999, CANCER RES, V59, P3880; Kohno T, 1999, CANCER RES, V59, P4170; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lin XH, 1998, P NATL ACAD SCI USA, V95, P14693, DOI 10.1073/pnas.95.25.14693; Maiti S, 2000, CANCER RES, V60, P6288; MANNENS M, 1990, CANCER RES, V50, P3279; MAW MA, 1992, CANCER RES, V52, P3094; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; McDonald JM, 1998, CANCER RES, V58, P1387; Miozzo M, 1996, GENOMICS, V37, P310, DOI 10.1006/geno.1996.0565; MIWA H, 1992, J NATL CANCER I, V84, P181, DOI 10.1093/jnci/84.3.181; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; Rahman N, 1996, NAT GENET, V13, P461, DOI 10.1038/ng0896-461; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; SVENNILSON J, 1995, KIDNEY INT, V48, P103, DOI 10.1038/ki.1995.273; Takakura S, 2000, ONCOGENE, V19, P836, DOI 10.1038/sj.onc.1203388; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284	42	8	8	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 12	2001	20	16					2050	2054		10.1038/sj.onc.1204301	http://dx.doi.org/10.1038/sj.onc.1204301			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360189				2022-12-25	WOS:000168043800013
J	Malbec, O; Schmitt, C; Bruhns, P; Krystal, G; Fridman, WH; Daeron, M				Malbec, O; Schmitt, C; Bruhns, P; Krystal, G; Fridman, WH; Daeron, M			Src homology 2 domain-containing inositol 5-phosphatase 1 mediates cell cycle arrest by Fc gamma RIIB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NEGATIVE REGULATION; B-CELLS; C-KIT; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; INHIBITION MOTIF; PHOSPHATASE SHIP; PROGENITOR CELLS; LYMPHOCYTES-B	We previously found that low affinity receptors for the Fc portion of IgG, Fc-/RUB, which are widely expressed by hematopoietic cells, can negatively regulate receptor tyrosine kinase-dependent cell proliferation. We investigated here the mechanisms of this inhibition. We used as experimental models wild-type mast cells, which constitutively express the stem cell factor receptor Kit and Fc gamma RIIB, Fc gamma RIIB-deficient mast cells reconstituted with wild-type or mutated Fc gamma RIIB, and Src homology 2 domain-containing inositol polyphosphate 5-phosphatase 1 (SHIP1)deficient mast cells. We found that, upon coaggregation with Kit, Fc gamma RIIB are tyrosyl-phosphorylated, recruit SHIP1, but not SHIP2, SH2 domain-containing protein tyrosine phosphatase-1 or -2, abrogate Akt phosphorylation, shorten the duration of the activation of mitogen-activated protein kinases of the Ras and Rac pathways, abrogate cyclin induction, prevent cells from entering the cell cycle, and block thymidine incorporation. Fc gamma RIIB-mediated inhibition of Mt-dependent cell proliferation was reduced in SHIP1-deficient mast cells, whereas inhibition of IgE-induced responses was abrogated. Cell proliferation was, however, inhibited by coaggregating Mt with Fc gamma RIIB whose intracytoplasmic domain was replaced with the catalytic domain of SHIP1. These results demonstrate that Fc gamma RIIB use SHIP1 to inhibit pathways shared by receptor tyrosine kinases and immunoreceptors to trigger cell proliferation and cell activation, respectively, but that, in the absence of SHIP1, Fc-/RUB can use other effectors that specifically inhibit cell proliferation.	Inst Curie, INSERM U 255, Lab Immunol Cellulaire & Clin, F-75005 Paris, France; Hop La Pitie Salpetriere, CNRS UMR 7627, Lab Immunol Cellulaire, F-75013 Paris, France; Terry Fox Lab, Vancouver, BC B5Z 1L3, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Daeron, M (corresponding author), Inst Biomed Cordeliers, INSERM U 255, Lab Immunol Cellulaire & Clin, 15 Rue Ecole Med, F-75006 Paris, France.	Marc.Daeron@U255.bhdc.jussieu.fr	Bruhns, Pierre/F-5567-2013	Bruhns, Pierre/0000-0002-4709-8936; Krystal, Gerald/0000-0002-1961-6281; fridman, wolf herman/0000-0002-1332-0973				AMIGORENA S, 1989, EUR J IMMUNOL, V19, P1379, DOI 10.1002/eji.1830190805; AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; Astoul E, 1999, J CELL BIOL, V145, P1511, DOI 10.1083/jcb.145.7.1511; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BENHAMOU M, 1990, J IMMUNOL, V144, P3071; BERLIOZ C, 1995, J VIROL, V69, P2214, DOI 10.1128/JVI.69.4.2214-2222.1995; Bruhns P, 2000, J BIOL CHEM, V275, P37357, DOI 10.1074/jbc.M003518200; Bruhns P, 1999, J IMMUNOL, V162, P3168; Carver DJ, 2000, BLOOD, V96, P1449, DOI 10.1182/blood.V96.4.1449.h8001449_1449_1456; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; DAERON M, 1992, J IMMUNOL, V149, P1365; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DUBREUIL P, 1990, ANN NY ACAD SCI, V599, P58; Fong DC, 1996, IMMUNOL LETT, V54, P83, DOI 10.1016/S0165-2478(96)02654-5; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Jiang A, 1998, J EXP MED, V188, P1297, DOI 10.1084/jem.188.7.1297; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; KIMURA S, 1981, IMMUNOGENETICS, V14, P3, DOI 10.1007/BF00344295; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Latour S, 1996, J IMMUNOL, V157, P189; LATOUR S, 1992, J IMMUNOL, V149, P2155; Lesourne R, 2001, J BIOL CHEM, V276, P6327, DOI 10.1074/jbc.M006537200; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LIU FT, 1980, J IMMUNOL, V124, P2728; Malbec O, 1999, CURR TOP MICROBIOL, V244, P13; Malbec O, 1998, J IMMUNOL, V160, P1647; Malbec O, 1999, J IMMUNOL, V162, P4424; Muraille E, 2000, IMMUNOL LETT, V72, P7, DOI 10.1016/S0165-2478(00)00162-0; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Pearse RN, 1999, IMMUNITY, V10, P753, DOI 10.1016/S1074-7613(00)80074-6; PHILLIPS NE, 1984, J IMMUNOL, V132, P627; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; SAUTES C, 1991, EUR J IMMUNOL, V21, P231, DOI 10.1002/eji.1830210135; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; SINCLAIR NRS, 1971, ADV EXP MED BIOL, V12, P609; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Tridandapani S, 1997, J IMMUNOL, V158, P1125; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720	48	28	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30381	30391		10.1074/jbc.M011094200	http://dx.doi.org/10.1074/jbc.M011094200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11359765	hybrid			2022-12-25	WOS:000170558000102
J	Sanchez-Fernandez, R; Davies, TGE; Coleman, JOD; Rea, PA				Sanchez-Fernandez, R; Davies, TGE; Coleman, JOD; Rea, PA			The Arabidopsis thaliana ABC protein superfamily, a complete inventory	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER; P-GLYCOPROTEIN; GENE-PRODUCT; RESISTANCE; ENCODES; TRANSLOCASE; SENSITIVITY; CONJUGATE; PEPTIDES; PATHWAY	We describe the first complete inventory of ATP-binding cassette (ABC) proteins from a multicellular organism, the model plant Arabidopsis thaliana. By the application of several search criteria, Arabidopsis was found to contain a total of 129 open reading frames (ORFs) capable of encoding ABC proteins, of which 103 possessed contiguous transmembrane spans and were identified as putative intrinsic membrane proteins. Fifty-two of the putative intrinsic membrane proteins contained at least two transmembrane domains (TMDs) and two nucleotide-binding folds (NBFs) and could be classified as belonging to one of five subfamilies of full-molecule transporters. The other 51 putative membrane proteins, all of which were half-molecule transporters, fell into five subfamilies. Of the remaining ORFs identified, all of which encoded proteins lacking TMDs, 11 could be classified into three subfamilies. There were no obvious homologs in other organisms for 15 of the ORFs which encoded a heterogeneous group of non-intrinsic ABC proteins (NA-Ps). Unrooted phylogenetic analyses substantiated the subfamily designations. Notable features of the Arabidopsis ABC superfamily was the presence of a large yeast-Eke PDR subfamily, and the absence of genes encoding bona fide cystic fibrosis transmembrane conductance regulator (CFTR), sulfonylurea receptor (SUR), and heavy metal tolerance factor 1 (HMT1) homologs. Arabidopsis was unusual in its large allocation of ORFs (a minimum of 0.5%) to members of the ABC protein superfamily.	Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA; IACR Rothamsted, Harpenden AL5 2JQ, Herts, England	University of Pennsylvania; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research	Rea, PA (corresponding author), Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA.	parea@sas.upenn.edu	Davies, Thomas/D-6091-2011; Davies, Thomas G. Emyr/C-2795-2017	Davies, Thomas G. Emyr/0000-0002-9452-2947				Allikmets R, 1999, HUM MOL GENET, V8, P743, DOI 10.1093/hmg/8.5.743; Babiychuk E, 1997, P NATL ACAD SCI USA, V94, P12722, DOI 10.1073/pnas.94.23.12722; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BALZI E, 1994, J BIOL CHEM, V269, P2206; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; BISBAL C, 1995, J BIOL CHEM, V270, P13308, DOI 10.1074/jbc.270.22.13308; Costanzo MC, 2000, NUCLEIC ACIDS RES, V28, P73, DOI 10.1093/nar/28.1.73; Csere P, 1998, FEBS LETT, V441, P266, DOI 10.1016/S0014-5793(98)01560-9; DAVIES TGE, 1996, GENE, V199, P195; DEALDANA CRV, 1995, EMBO J, V14, P3184, DOI 10.1002/j.1460-2075.1995.tb07321.x; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; DREESEN TD, 1988, MOL CELL BIOL, V8, P5206, DOI 10.1128/MCB.8.12.5206; DUDLER R, 1992, J BIOL CHEM, V267, P5882; Gelbart WM, 1999, NUCLEIC ACIDS RES, V27, P85, DOI 10.1093/nar/27.1.85; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HAO Z, 2000, CANCER RES, V60, P4779; Henikoff S, 1997, SCIENCE, V278, P609, DOI 10.1126/science.278.5338.609; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Jasinski M, 2001, PLANT CELL, V13, P1095, DOI 10.1105/tpc.13.5.1095; Jedlitschky G, 2000, J BIOL CHEM, V275, P30069, DOI 10.1074/jbc.M005463200; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; Kolaczkowski M, 1996, J BIOL CHEM, V271, P31543, DOI 10.1074/jbc.271.49.31543; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; Kushnir S, 2001, PLANT CELL, V13, P89, DOI 10.1105/tpc.13.1.89; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Liu GS, 2001, J BIOL CHEM, V276, P8648, DOI 10.1074/jbc.M009690200; Liu LX, 1999, J BIOL CHEM, V274, P32738, DOI 10.1074/jbc.274.46.32738; Lu YP, 1998, PLANT CELL, V10, P267, DOI 10.1105/tpc.10.2.267; Lu YP, 1997, P NATL ACAD SCI USA, V94, P8243, DOI 10.1073/pnas.94.15.8243; Martinoia E., 2000, VACUOLAR COMPARTMENT, P221; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; Mitsuhashi N, 2000, J BIOL CHEM, V275, P17536, DOI 10.1074/jbc.275.23.17536; Moller SG, 2001, GENE DEV, V15, P90, DOI 10.1101/gad.850101; MOSSER J, 1994, HUM MOL GENET, V3, P265, DOI 10.1093/hmg/3.2.265; ORTIZ DF, 1992, EMBO J, V11, P3491, DOI 10.1002/j.1460-2075.1992.tb05431.x; ORTIZ DF, 1995, J BIOL CHEM, V270, P4721, DOI 10.1074/jbc.270.9.4721; OSRAM JF, 2000, BIOCHIM BIOPHYS ACTA, V1529, P321; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; Rea PA, 1999, J EXP BOT, V50, P895, DOI 10.1093/jexbot/50.suppl_1.895; Rea PA, 1998, ANNU REV PLANT PHYS, V49, P727, DOI 10.1146/annurev.arplant.49.1.727; Reits EAJ, 2000, NATURE, V404, P774, DOI 10.1038/35008103; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SALT DE, 1995, PLANT PHYSIOL, V107, P1293, DOI 10.1104/pp.107.4.1293; Schinkel AH, 1997, P NATL ACAD SCI USA, V94, P4028, DOI 10.1073/pnas.94.8.4028; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Sidler M, 1998, PLANT CELL, V10, P1623, DOI 10.1105/tpc.10.10.1623; Smart CC, 1996, J BIOL CHEM, V271, P19351, DOI 10.1074/jbc.271.32.19351; Strunnikov AV, 1999, EUR J BIOCHEM, V263, P6, DOI 10.1046/j.1432-1327.1999.00509.x; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; Swofford D.L., 1999, PAUP PHYLOGENETIC AN; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tommasini R, 1998, PLANT J, V13, P773, DOI 10.1046/j.1365-313X.1998.00076.x; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; VOGELILANGE R, 1990, PLANT PHYSIOL, V92, P1086, DOI 10.1104/pp.92.4.1086; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wang W, 1996, PLANT MOL BIOL, V31, P683, DOI 10.1007/BF00042240; Wink M, 1997, ADV BOT RES, V25, P141, DOI 10.1016/S0065-2296(08)60151-2	61	376	425	1	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30231	30244		10.1074/jbc.M103104200	http://dx.doi.org/10.1074/jbc.M103104200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11346655	hybrid			2022-12-25	WOS:000170558000084
J	de Jager, T; Pelzer, T; Muller-Botz, S; Imam, A; Muck, J; Neyses, L				de Jager, T; Pelzer, T; Muller-Botz, S; Imam, A; Muck, J; Neyses, L			Mechanisms of estrogen receptor action in the myocardium - Rapid gene activation via the ERK1/2 pathway and serum response elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CARDIAC-HYPERTROPHY; CORONARY HEART-DISEASE; PROTEIN-KINASE PATHWAY; IMMEDIATE-EARLY GENES; TRANSCRIPTION FACTORS; EGR-1 TRANSCRIPTION; RAT CARDIOMYOCYTES; ENDOTHELIAL-CELLS; ER-ALPHA; C-FOS	We have previously shown that the myocardium is a target tissue for estrogen. Here, we have identified rapid non-nuclear estrogen effects on the expression of the early growth response gene-1 (Egr-1) in cardiomyocytes. Egr-1 mRNA and protein were rapidly and strongly induced by estrogen in an estrogen receptor-dependent manner via the extracellular signal-regulated kinase, ERK1/2. A promoter analysis study of a 1.2-kilobase Egr-1 promoter fragment revealed that the serum response elements (SREs) but not the estrogen response elements or AP-1 sites are responsible for Egr-1 induction by estrogen, identifying a novel mechanism of estrogen receptor-dependent gene activation in the myocardium. Both estrogen receptor-alpha and -beta induced the Egr-1 promoter via the SREs as well as an artificial promoter consisting of only five SREs in cardiomyocytes. Electrophoretic mobility shift assays showed that a protein complex containing serum response factor or an antigenically related protein was recruited to the SREs by estrogen treatment of primary cardiomyocytes. The recruitment of the protein complex was inhibited by the specific estrogen receptor antagonist ICI 182,780 as well as the MEK inhibitor PD 98059. Taken together, these results identify SREs as important promoter control elements for an estrogen receptor-dependent mechanism of gene activation in the myocardium.	Univ Wurzburg, Dept Med, D-97080 Wurzburg, Germany	University of Wurzburg	Neyses, L (corresponding author), Univ Wurzburg, Dept Med, Josef Schneider Str 2, D-97080 Wurzburg, Germany.		Neyses, Ludwig/AGY-7446-2022					Aumais JP, 1996, J BIOL CHEM, V271, P12568, DOI 10.1074/jbc.271.21.12568; Bernal-Mizrachi E, 2000, J BIOL CHEM, V275, P25681, DOI 10.1074/jbc.M003424200; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; Chiu JJ, 1999, CIRC RES, V85, P238, DOI 10.1161/01.RES.85.3.238; Cohen DM, 1996, J BIOL CHEM, V271, P12903, DOI 10.1074/jbc.271.22.12903; Duan RQ, 2001, J BIOL CHEM, V276, P11590, DOI 10.1074/jbc.M005492200; Endoh H, 1997, BIOCHEM BIOPH RES CO, V235, P99, DOI 10.1006/bbrc.1997.6746; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GORDON T, 1978, ANN INTERN MED, V89, P157, DOI 10.7326/0003-4819-89-2-157; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Grohe C, 1997, FEBS LETT, V416, P107, DOI 10.1016/S0014-5793(97)01179-4; GUPTA MP, 1991, J BIOL CHEM, V266, P12813; Hammes A, 1998, CIRC RES, V83, P877; Herrington DM, 1999, ANN INTERN MED, V131, P463, DOI 10.7326/0003-4819-131-6-199909210-00012; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Improta-Brears T, 1999, P NATL ACAD SCI USA, V96, P4686, DOI 10.1073/pnas.96.8.4686; Karas RH, 1995, FEBS LETT, V377, P103, DOI 10.1016/0014-5793(95)01293-1; Kim HP, 1999, BIOCHEM BIOPH RES CO, V263, P257; Kohout TA, 1996, CIRC RES, V78, P971, DOI 10.1161/01.RES.78.6.971; Lim CP, 1998, ONCOGENE, V16, P2915, DOI 10.1038/sj.onc.1201834; Ling Y, 1998, J BIOL CHEM, V273, P10506, DOI 10.1074/jbc.273.17.10506; Marienfeld R, 1997, EUR J IMMUNOL, V27, P1601, DOI 10.1002/eji.1830270703; McCaffrey TA, 2000, J CLIN INVEST, V105, P653, DOI 10.1172/JCI8592; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; NEYSES L, 1993, J HYPERTENS, V11, P927, DOI 10.1097/00004872-199309000-00006; Nuedling S, 1999, FEBS LETT, V454, P271, DOI 10.1016/S0014-5793(99)00816-9; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; PELZER T, 1999, SCI C MOL CELL INT P; Pratt MAC, 1998, MOL CELL BIOCHEM, V189, P119, DOI 10.1023/A:1006827015320; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Russell KS, 2000, P NATL ACAD SCI USA, V97, P5930, DOI 10.1073/pnas.97.11.5930; Saadane N, 1999, BRIT J PHARMACOL, V127, P1165, DOI 10.1038/sj.bjp.0702676; Saadane N, 2000, AM J PHYSIOL-HEART C, V278, pH796, DOI 10.1152/ajpheart.2000.278.3.H796; Schwachtgen JL, 1998, J CLIN INVEST, V101, P2540, DOI 10.1172/JCI1404; Shamim A, 1999, MOL CELL BIOCHEM, V195, P11, DOI 10.1023/A:1006887307568; Singer CA, 1999, J NEUROSCI, V19, P2455; Watters JJ, 2000, MOL ENDOCRINOL, V14, P1872, DOI 10.1210/me.14.11.1872; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; Zhang Z, 1998, AM J PHYSIOL-CELL PH, V275, pC1104, DOI 10.1152/ajpcell.1998.275.4.C1104	41	63	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27873	27880		10.1074/jbc.M010984200	http://dx.doi.org/10.1074/jbc.M010984200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11335712	hybrid			2022-12-25	WOS:000170093400019
J	Bouly, M; Masson, D; Gross, B; Jiang, XC; Fievet, C; Castro, G; Tall, AR; Fruchart, JC; Staels, B; Lagrost, L; Luc, G				Bouly, M; Masson, D; Gross, B; Jiang, XC; Fievet, C; Castro, G; Tall, AR; Fruchart, JC; Staels, B; Lagrost, L; Luc, G			Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; APOLIPOPROTEIN-A-I; ADENOVIRUS-MEDIATED OVEREXPRESSION; TISSUE-SELECTIVE MANNER; ESTER TRANSFER PROTEIN; HUMAN-PLASMA; TRANSGENIC MICE; HEPATIC LIPASE; PARTICLE-SIZE; HDL LEVELS	Fibrate treatment in mice is known to modulate high density lipoprotein (HDL) metabolism by regulating apolipoprotein (apo)AI and apoAII gene expression. In addition to alterations in plasma HDL levels, fibrates induce the emergence of large, cholesteryl ester-rich HDL in treated transgenic mice expressing human apoAI (HuAITg), The mechanisms of these changes may not be restricted to the modulation of apolipoprotein gene expression, and the aim of the present study was to determine whether the expression of factors known to affect HDL metabolism (ie. phospholipid transfer protein (PLTP), lecithin:cholesterol acyltransferase, and hepatic lipase) are modified in fenofibrate-treated mice. Significant rises in plasma PLTP activity were observed after 2 weeks of fenofibrate treatment in both wild-type and HuAITg mice. Simultaneously, hepatic PLTP mRNA levels increased in a dose-dependent fashion. In contrast to PLTP, lecithin: cholesterol acyltransferase mRNA levels in HuAITg mice were not significantly modified by fenofibrate despite a significant decrease in plasma cholesterol esterification activity, Fenofibrate did not induce any change in hepatic lipase activity. Fenofibrate significantly increased HDL size, an effect that was more pronounced in HuAITg mice than in wild-type mice, This effect in wild-type mice was completely abolished in PLTP-deficient mice. Finally, fenofibrate treatment did not influence PLTP activity or hepatic mRNA in peroxisome proliferator-activated receptor-alpha -deficient mice. It is concluded that 1) fenofibrate treatment increases plasma phospholipid transfer activity as the result of up-regulation of PLTP gene expression through a peroxisome proliferator-activated receptor-alpha -dependent mechanism, and 2) increased plasma PLTP levels account for the marked enlargement of HDL in fenofibrate-treated mice.	Inst Pasteur, INSERM U545, Dept Atherosclerosis, F-59019 Lille, France; Univ Lille 2, Fac Pharm, F-59006 Lille, France; Hop Bocage, INSERM U498, Lab Lipoprot Biochem, Dijon, France; Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille; CHU Dijon Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Columbia University	Luc, G (corresponding author), Inst Pasteur, INSERM U545, Dept Atherosclerosis, 1 Rue Prof Calmette, F-59019 Lille, France.		MASSON, David/AAC-8896-2022; MASSON, David/R-4557-2017; Masson, David/R-6633-2019; Staels, Bart/N-9497-2016; Tall, Alan/AAT-8528-2021	MASSON, David/0000-0003-1692-0699; MASSON, David/0000-0003-1692-0699; Staels, Bart/0000-0002-3784-1503; GROSS, BARBARA/0000-0001-5566-0004				Albers JJ, 1996, INT J CLIN LAB RES, V26, P262, DOI 10.1007/BF02602960; ALBERS JJ, 1995, BBA-LIPID LIPID MET, V1258, P27, DOI 10.1016/0005-2760(95)00091-P; Albers JJ, 1999, J LIPID RES, V40, P295; Berthou L, 1996, J CLIN INVEST, V97, P2408, DOI 10.1172/JCI118687; CHEN CH, 1982, J LIPID RES, V23, P680; CHEUNG MC, 1991, J LIPID RES, V32, P383; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P166; DAERR WH, 1982, BIOCHIM BIOPHYS ACTA, V710, P128, DOI 10.1016/0005-2760(82)90142-4; DAMEN J, 1982, BIOCHIM BIOPHYS ACTA, V712, P444, DOI 10.1016/0005-2760(82)90271-5; DECKELBAUM RJ, 1982, J BIOL CHEM, V257, P6509; Ehnholm S, 1998, J LIPID RES, V39, P1248; Foger B, 1997, J BIOL CHEM, V272, P27393, DOI 10.1074/jbc.272.43.27393; Francone OL, 1996, J LIPID RES, V37, P1268; Fruchart JC, 1999, CURR OPIN LIPIDOL, V10, P245, DOI 10.1097/00041433-199906000-00007; HAMILTON RL, 1976, J CLIN INVEST, V58, P667, DOI 10.1172/JCI108513; HENDERSON AD, 1993, CLIN CHEM, V39, P218; HOPKINS GJ, 1985, J LIPID RES, V26, P218; JAUHIAINEN M, 1993, J BIOL CHEM, V268, P4032; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Jiang XC, 1996, J CLIN INVEST, V98, P2373, DOI 10.1172/JCI119050; Lagrost L, 1998, CURR OPIN LIPIDOL, V9, P203, DOI 10.1097/00041433-199806000-00004; LEE SST, 1995, MOL CELL BIOL, V15, P3012; MarquesVidal P, 1997, ATHEROSCLEROSIS, V133, P87, DOI 10.1016/S0021-9150(97)00120-2; NEWNHAM HH, 1990, ATHEROSCLEROSIS, V82, P167, DOI 10.1016/0021-9150(90)90037-J; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; SALTER AM, 1987, BIOCHEM J, V247, P79, DOI 10.1042/bj2470079; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; SHEPHERD J, 1994, ATHEROSCLEROSIS, V110, pS55, DOI 10.1016/0021-9150(94)05380-2; SPEIJER H, 1991, ATHEROSCLEROSIS, V90, P159, DOI 10.1016/0021-9150(91)90110-O; Staels B, 1998, CIRCULATION, V98, P2088, DOI 10.1161/01.CIR.98.19.2088; STAELS B, 1992, ARTERIOSCLER THROMB, V12, P286, DOI 10.1161/01.ATV.12.3.286; STAELS B, 1992, J LIPID RES, V33, P727; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; TU AY, 1993, J BIOL CHEM, V268, P23098; vonEckardstein A, 1996, BBA-LIPID LIPID MET, V1301, P255, DOI 10.1016/0005-2760(96)00050-1; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118	37	77	79	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25841	25847		10.1074/jbc.M101160200	http://dx.doi.org/10.1074/jbc.M101160200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11342537				2022-12-25	WOS:000169823300028
J	Collins, TJ; Lipp, P; Berridge, MJ; Bootman, MD				Collins, TJ; Lipp, P; Berridge, MJ; Bootman, MD			Mitochondrial Ca2+ uptake depends on the spatial and temporal profile of cytosolic Ca2+ signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; CALCIUM OSCILLATIONS; RELEASE; TRANSPORT; STORE; HOMEOSTASIS; MECHANISM; FEEDBACK; CELLS; WAVES	Using confocal imaging of Rhod-2-loaded HeLa cells, we examined the ability of mitochondria to sequester Ca2+ signals arising from different sources. Mitochondrial Ca2+ (Ca-mit(2+)) uptake was stimulated by inositol 1,4,5-trisphosphate (InsP(3))-evoked Ca2+ release, capacitative Ca2+ entry, and Ca2+ leaking from the endoplasmic reticulum, For each Ca2+ source, the relationship between cytosolic Ca2+ (Ca-cyt(2+)) concentration and Ca-mit(2+) was complex. With Ca-cyt(2+) < 300 nM, a slow and persistent Ca-mit(2+) uptake was observed. If Ca-cyt(2+) increased above similar to 400 nM, Ca-mit(2+) uptake accelerated sharply. For equivalent Ca-mit(2+) increases, the rate of Ca-mit(2+) rise was greater with InsP(3)-evoked Ca2+ signals than any other source. Spatial variation of the Ca-mit(2+) response was observed within individual cells. Both the fraction of responsive mitochondria and the amplitude of the Ca-mit(2+) response were graded in direct proportion to stimulus concentration. Trains of repetitive Ca2+ oscillations did not maintain elevated Ca-mit(2+) levels. Only low frequency Ca2+ transients (<1/15 min) evoked repetitive Ca-mit(2+) signals. Our data indicate that there is a lag between Ca-cyt(2+) and Ca-mit(2+) increases but that mitochondria will accumulate calcium when it is elevated over basal levels regardless of its source. Furthermore, in addition to the characteristics of Ca2+ signals, Ca2+ uniporter desensitization and proximity of mitochondria to InsP(3) receptors modulate mitochondrial Ca2+ responses.	Babraham Inst, Mol Signalling Lab, Cambridge CB2 4AT, England; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge	Lipp, P (corresponding author), Babraham Inst, Mol Signalling Lab, Cambridge CB2 4AT, England.	peter.lipp@bbsrc.ac.uk	Bootman, Martin/AAB-3330-2019	Bootman, Martin/0000-0002-6447-3451				Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Boitier E, 1999, J CELL BIOL, V145, P795, DOI 10.1083/jcb.145.4.795; Bootman M, 1997, J PHYSIOL-LONDON, V499, P307, DOI 10.1113/jphysiol.1997.sp021928; BOOTMAN MD, 1994, J BIOL CHEM, V269, P24783; Breitbart H, 1996, BBA-MOL CELL RES, V1312, P79, DOI 10.1016/0167-4889(96)00022-5; Chow S, 1996, CYTOMETRY, V24, P360; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Colegrove SL, 2000, J GEN PHYSIOL, V115, P371, DOI 10.1085/jgp.115.3.371; Collins TJ, 2000, BIOCHEM J, V347, P593, DOI 10.1042/0264-6021:3470593; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; David G, 1999, J NEUROSCI, V19, P7495, DOI 10.1523/JNEUROSCI.19-17-07495.1999; Drummond RM, 1996, PFLUG ARCH EUR J PHY, V431, P473, DOI 10.1007/s004240050025; Duchen MR, 1998, J CELL BIOL, V142, P975, DOI 10.1083/jcb.142.4.975; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; FLATMAN PW, 1984, J MEMBRANE BIOL, V80, P1, DOI 10.1007/BF01868686; GUNTER KK, 1994, J BIOENERG BIOMEMBR, V26, P471, DOI 10.1007/BF00762732; GUNTER TE, 1994, J BIOENERG BIOMEMBR, V26, P465, DOI 10.1007/BF00762731; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Hajnoczky G, 1999, J BIOL CHEM, V274, P14157, DOI 10.1074/jbc.274.20.14157; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; ICHAS F, 1994, FEBS LETT, V348, P211, DOI 10.1016/0014-5793(94)00615-6; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; IGBAVBOA U, 1988, J BIOL CHEM, V263, P1405; Kaftan EJ, 2000, J BIOL CHEM, V275, P25465, DOI 10.1074/jbc.M000903200; KRONER H, 1986, ARCH BIOCHEM BIOPHYS, V251, P525, DOI 10.1016/0003-9861(86)90360-7; Landolfi B, 1998, J CELL BIOL, V142, P1235, DOI 10.1083/jcb.142.5.1235; Lawrie AM, 1996, J BIOL CHEM, V271, P10753, DOI 10.1074/jbc.271.18.10753; LEISEY JR, 1993, AM J PHYSIOL, V265, pH1203; Lipp P, 1997, EMBO J, V16, P7166, DOI 10.1093/emboj/16.23.7166; Maechler P, 1998, J BIOL CHEM, V273, P20770, DOI 10.1074/jbc.273.33.20770; McCarron JG, 1999, J PHYSIOL-LONDON, V516, P149, DOI 10.1111/j.1469-7793.1999.149aa.x; Monteith GR, 1999, AM J PHYSIOL-CELL PH, V276, pC1193, DOI 10.1152/ajpcell.1999.276.5.C1193; Pacher P, 2001, BIOPHYS J, V80, p236A; Racay P, 1996, GEN PHYSIOL BIOPHYS, V15, P193; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; Rutter GA, 1996, P NATL ACAD SCI USA, V93, P5489, DOI 10.1073/pnas.93.11.5489; Sheppard CA, 1997, J NEUROCHEM, V68, P2317; SMITH PM, 1994, BIOCHEM J, V299, P37, DOI 10.1042/bj2990037; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; TOVEY SC, 1998, J PHYSL, V509, P200; WHITE RJ, 1995, J NEUROSCI, V15, P1318	47	158	158	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26411	26420		10.1074/jbc.M101101200	http://dx.doi.org/10.1074/jbc.M101101200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11333261	hybrid			2022-12-25	WOS:000169823300102
J	Han, H; Wang, HZ; Long, H; Nattel, S; Wang, ZG				Han, H; Wang, HZ; Long, H; Nattel, S; Wang, ZG			Oxidative preconditioning and apoptosis in L-cells - Roles of protein kinase B and mitogen-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISCHEMIA-REPERFUSION INJURY; SMOOTH-MUSCLE CELLS; N-TERMINAL KINASE; CARDIOMYOCYTE APOPTOSIS; SIGNALING PATHWAYS; HYDROGEN-PEROXIDE; MAP KINASE; KAPPA-B; STRESS; SURVIVAL	Oxidative stress can cause significant cell death by apoptosis, We performed studies in L-cells to explore whether prior exposure to oxidative stress ("oxidative preconditioning") can protect the cell against the apoptotic consequences of subsequent oxidative insults and to establish the mediators in the preconditioning signaling cascade. Cells were preconditioned with three 5-min exposures to H2O2, followed by 10-h recovery and subsequent exposure to 600 muM H2O2 for 10 h. A Single 10-h exposure to H2O2 induced substantial apoptotic cell death (similar to 90%), as determined by enzyme-linked immunosorbent assay, TUNEL (terminal deoxyribonucleotide transferase-mediated dUTP nick end labeling), and Annexin V methods, but apoptosis was largely prevented in preconditioned cells. The degree of cytoprotection depended on the strength of preconditioning or H(2)O2 concentration (20 similar to 600 muM), Transient increases in mitogen-activated protein kinase (MAPK), p38, and JNK/SAPK activities and sustained protein kinase B (Akt) activation, accompanied by drastically reduced caspase 3 activity, were seen after preconditioning, The expression levels of these kinases were unaltered. Inhibitors of p38 (SB203580) and phosphoinositide 5-kinase (PI3K, LY294002) pathways abolished the protection provided by preconditioning, We conclude that oxidative preconditioning protects cells against apoptosis and that this effect involves MAPK and PI3K/Akt pathways. This system may be important in regulating apoptotic cell death in development and disease states.	Montreal Heart Inst, Res Ctr, Montreal, PQ H1T 1C8, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3A 2T5, Canada	Universite de Montreal; Universite de Montreal; McGill University	Wang, ZG (corresponding author), Montreal Heart Inst, Res Ctr, 5000 Belanger E, Montreal, PQ H1T 1C8, Canada.		wang, zhiguo/AAN-4182-2021; Wang, Zhiguo/GRS-4339-2022; Han, Ho Jae/M-1476-2016	Wang, Zhiguo/0000-0002-0811-2045; Han, Ho Jae/0000-0002-0657-1766; Nattel, Stanley/0000-0002-5565-3311				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Arstall MA, 1998, J MOL CELL CARDIOL, V30, P1019, DOI 10.1006/jmcc.1998.0666; Birkenkamp KU, 1999, LEUKEMIA, V13, P1037, DOI 10.1038/sj.leu.2401447; Chen J, 1997, NEUROLOGY, V48, P306, DOI 10.1212/WNL.48.2.306; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Crowder RJ, 1998, J NEUROSCI, V18, P2933; DEFILY DV, 1993, AM J PHYSIOL, V265, pH700, DOI 10.1152/ajpheart.1993.265.2.H700; DEZEEUW S, 1999, ANN NY ACAD SCI, V874, P179; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HEURTEAUX C, 1995, P NATL ACAD SCI USA, V92, P4666, DOI 10.1073/pnas.92.10.4666; Islam CF, 1997, BRIT J UROL, V79, P842, DOI 10.1046/j.1464-410X.1997.00209.x; Jimenez LA, 1997, AM J PHYSIOL-LUNG C, V273, pL1029, DOI 10.1152/ajplung.1997.273.5.L1029; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KITAGAWA K, 1990, BRAIN RES, V528, P21, DOI 10.1016/0006-8993(90)90189-I; Konishi H, 1999, BIOCHEM BIOPH RES CO, V264, P840, DOI 10.1006/bbrc.1999.1579; Li PF, 1997, CIRCULATION, V96, P3602; Ma XL, 1999, CIRCULATION, V99, P1685, DOI 10.1161/01.CIR.99.13.1685; Maulik N, 1999, FEBS LETT, V443, P331, DOI 10.1016/S0014-5793(98)01719-0; Maulik N, 1998, MOL CELL BIOCHEM, V186, P139, DOI 10.1023/A:1006883717174; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; Obata T, 2000, CRIT CARE MED, V28, pN67, DOI 10.1097/00003246-200004001-00008; PANCY CY, 1997, AM J PHYSIOL, V273, pR887; PANG CY, 1995, CARDIOVASC RES, V29, P782, DOI 10.1016/S0008-6363(96)88613-5; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Peralta C, 1996, BIOCHEM BIOPH RES CO, V229, P264, DOI 10.1006/bbrc.1996.1790; Ping PP, 2000, CIRC RES, V86, P921, DOI 10.1161/01.RES.86.9.921; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Shirai T, 1998, J THORAC CARDIOV SUR, V115, P210, DOI 10.1016/S0022-5223(98)70459-3; STEVENSON MA, 1994, CANCER RES, V54, P12; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Takeshima S, 1997, ACTA PHYSIOL SCAND, V161, P263, DOI 10.1046/j.1365-201X.1997.00218.x; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Turner NA, 1998, J MOL CELL CARDIOL, V30, P1789, DOI 10.1006/jmcc.1998.0743; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Valen G, 1998, FREE RADICAL RES, V29, P235, DOI 10.1080/10715769800300271; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; Verdouw PD, 1996, ANN NY ACAD SCI, V793, P27, DOI 10.1111/j.1749-6632.1996.tb33502.x; von Harsdorf R, 1999, CIRCULATION, V99, P2934, DOI 10.1161/01.CIR.99.22.2934; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	45	70	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26357	26364		10.1074/jbc.M011136200	http://dx.doi.org/10.1074/jbc.M011136200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11331278	hybrid			2022-12-25	WOS:000169823300095
J	Kovalovich, K; Li, W; DeAngelis, R; Greenbaum, LE; Ciliberto, G; Taub, R				Kovalovich, K; Li, W; DeAngelis, R; Greenbaum, LE; Ciliberto, G; Taub, R			Interleukin-6 protects against Fas-mediated death by establishing a critical level of anti-apoptotic hepatic proteins FLIP, Bcl-2, and Bcl-xL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MITOCHONDRIAL PERMEABILITY TRANSITION; CYTOCHROME-C RELEASE; CARBON-TETRACHLORIDE; MOUSE HEPATOCYTES; FACTOR RECEPTOR; DEFICIENT MICE; LIVER-INJURY; RAT-LIVER; ACTIVATION	Previous studies showed that following acute carbon tetrachloride (CCl4) treatment, interleukin-6 null (IL6-/-) mice develop increased hepatocellular injury, defective regeneration, delayed wound healing, and increased hepatocyte apoptosis, Pretreatment with IL-6 prior to CCl4 reduces injury, hepatocyte apoptosis, and accelerates regeneration in both IL-6-/- and +/+ livers. To demonstrate whether IL-6 can prevent liver injury that involves direct stimulation of hepatocyte apoptosis, IL-6-/- and +/+ mice were treated with the Fas agonist, Jo-2 mAb. At low Fas agonist doses, IL-6+/+ mice developed mild hepatic injury and survived, whereas IL-6-/-mice developed severe apoptotic hepatitis within 12 h and died. Pretreatment with IL-6 improved survival in IL-6-/- mice and reduced injury in both IL-6-/- and +/+ livers. The direct anti-apoptotic effects of IL-6 were demonstrated in vitro as IL-6 decreased Fas-mediated apoptosis in both IL-6-/- and +/+ primary hepatocyte cultures, and suggested that IL-6-/- hepatocytes have a pre-existing defect in anti-apoptotic pathways. After Fas activation, IL-6-/- livers demonstrated evidence of both proximal and distal alterations in the apoptotic pathways including elevated caspase 8 and 3 activation-associated fragments, and loss of cytochrome c staining. IL-6-/- livers had reduced pre-existing protein expression of the anti-apoptotic factors Bcl-2 and Bcl-xL as well as more rapid degradation of FLIP following Fas treatment that appeared to be post-transcriptionally regulated. FLIP is a crucial proximal inhibitor of caspase 8 activation in Fas, tumor necrosis factor, and DR3/DR4-mediated apoptosis, and Bcl-2 and Bcl-xL more downstream anti-apoptotic regulators. IL-6 may function as a critical anti-apoptotic factor in the liver by its ability to establish and maintain an adequate level of FLIP and downstream anti-apoptotic factors.	Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA; IRBM, I-00040 Pomezia, Italy	University of Pennsylvania; University of Pennsylvania; Merck & Company	Taub, R (corresponding author), Univ Penn, Sch Med, Dept Genet, 705A Stellar Chance,422 Curie Blvd, Philadelphia, PA 19104 USA.	taubra@mail.med.upenn.edu	Ciliberto, Gennaro/J-4131-2017	Ciliberto, Gennaro/0000-0003-2851-8605	NIDDK NIH HHS [1 F32 DK09732-01, 1 K08 DK 02667-01, DK 49629, P30 DK50306] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009732, R01DK049629, K08DK002667, P30DK050306] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI M, 1995, NAT GENET, V11, P294, DOI 10.1038/ng1195-294; Afford SC, 1999, J EXP MED, V189, P441, DOI 10.1084/jem.189.2.441; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BERGER ML, 1986, HEPATOLOGY, V6, P36, DOI 10.1002/hep.1840060108; BLUETHMANN H, 1994, J LEUKOCYTE BIOL, V56, P565, DOI 10.1002/jlb.56.5.565; Boesen-de Cock JGR, 1999, J BIOL CHEM, V274, P14255, DOI 10.1074/jbc.274.20.14255; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CZAJA MJ, 1995, GASTROENTEROLOGY, V108, P1849, DOI 10.1016/0016-5085(95)90149-3; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; FATTORI E, 1994, J EXP MED, V180, P1243, DOI 10.1084/jem.180.4.1243; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hatano E, 2000, J BIOL CHEM, V275, P11814, DOI 10.1074/jbc.275.16.11814; Hellerbrand C, 1998, HEPATOLOGY, V27, P1285, DOI 10.1002/hep.510270514; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kao CY, 1996, BIOCHEM BIOPH RES CO, V222, P64, DOI 10.1006/bbrc.1996.0698; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Kovalovich K, 2000, HEPATOLOGY, V31, P149, DOI 10.1002/hep.510310123; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; Redondo C, 1996, J CLIN INVEST, V98, P1245, DOI 10.1172/JCI118908; Rouquet N, 1996, CURR BIOL, V6, P1192, DOI 10.1016/S0960-9822(02)70688-X; Shi JL, 1998, AM J PATHOL, V153, P515, DOI 10.1016/S0002-9440(10)65594-0; SLATER TF, 1966, NATURE, V209, P36, DOI 10.1038/209036a0; TAUB R, 1987, J BIOL CHEM, V262, P10893; Tokushige K, 2000, AM J GASTROENTEROL, V95, P2040; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Xu Y, 1998, AM J PHYSIOL-CELL PH, V275, pC1058, DOI 10.1152/ajpcell.1998.275.4.C1058; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	41	233	245	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26605	26613		10.1074/jbc.M100740200	http://dx.doi.org/10.1074/jbc.M100740200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11349125	hybrid			2022-12-25	WOS:000169823300125
J	Gaur, D; Swaminathan, S; Batra, JK				Gaur, D; Swaminathan, S; Batra, JK			Interaction of human pancreatic ribonuclease with human ribonuclease inhibitor - Generation of inhibitor-resistant cytotoxic variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EOSINOPHIL-DERIVED NEUROTOXIN; BOVINE SEMINAL RIBONUCLEASE; AMINO-ACID-SEQUENCE; CATALYTIC PROPERTIES; CRYSTAL-STRUCTURE; CATIONIC PROTEIN; RESOLUTION; ANGIOGENIN; MECHANISM; COMPLEX	Mammalian ribonucleases interact very strongly with the intracellular ribonuclease inhibitor (RI), Eukaryotic cells exposed to mammalian ribonucleases are protected from their cytotoxic action by the intracellular inhibition of ribonucleases by RI. Human pancreatic ribonuclease (HPR) is structurally and functionally very similar to bovine RNase A and interacts with human RI with a high affinity. In the current study, we have investigated the involvement of Lys-7, Gln-11, Asn-71, Asn-88, Gly-89, Ser-90, and Glu-111 in HPR in its interaction with human ribonuclease inhibitor. These contact residues were mutated either individually or in combination to generate mutants K7A, Q11A, N71A, E111A, N88R, G89R, S90R, K7A/E111A, Q11A/E111A, N71A/E111A, K7A/ N71A/E111A, Q11A/N71A/E111A, and K7A/Q11A/N71A/ E111A. Out of these, eight mutants, K7A, Q11A, N71A, S90R, E111A, Q11A/E111A, N71A/E111A, and K7A/N71A/ E111A, showed an ability to evade RI more than the wild type HPR, with the triple mutant K7A/N71A/E111A having the maximum RI resistance. As a result, these variants exhibited higher cytotoxic activity than wild type HPR, The mutation of Gly-89 in HPR produced no change in the sensitivity of HPR for RI, whereas it has been reported that mutating the equivalent residue Gly-88 in RNase A yielded a variant with increased RI resistance and cytotoxicity, Hence, despite its considerable homology with RNase A, HPR shows differences in its interaction with RI. We demonstrate that interaction between human pancreatic ribonuclease and RI can be disrupted by mutating residues that are involved in HPR-RI binding. The inhibitor-resistant cytotoxic HPR mutants should be useful in developing therapeutic molecules.	Natl Inst Immunol, Immunochem Lab, New Delhi 110067, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Batra, JK (corresponding author), Natl Inst Immunol, Immunochem Lab, Aruna Asaf Ali Rd, New Delhi 110067, India.		Batra, Janendra/GWQ-8031-2022	Batra, Janendra/0000-0003-2206-3398				ARDELT W, 1991, J BIOL CHEM, V266, P245; Bal HP, 1997, EUR J BIOCHEM, V245, P465, DOI 10.1111/j.1432-1033.1997.t01-1-00465.x; BARDON A, 1976, BIOCHIM BIOPHYS ACTA, V438, P461, DOI 10.1016/0005-2744(76)90262-X; Beintema J.J., 1997, RIBONUCLEASES STRUCT, P245; BEINTEMA JJ, 1984, ANAL BIOCHEM, V136, P48, DOI 10.1016/0003-2697(84)90306-3; BOIX E, 1994, J BIOL CHEM, V269, P2529; BOND MD, 1988, ANAL BIOCHEM, V173, P166, DOI 10.1016/0003-2697(88)90174-1; BOQUE L, 1994, J BIOL CHEM, V269, P19707; Bretscher LE, 2000, J BIOL CHEM, V275, P9893, DOI 10.1074/jbc.275.14.9893; BUCHNER J, 1992, ANAL BIOCHEM, V205, P263, DOI 10.1016/0003-2697(92)90433-8; Chen CZ, 1997, P NATL ACAD SCI USA, V94, P1761, DOI 10.1073/pnas.94.5.1761; Chen CZ, 1999, BIOCHEMISTRY-US, V38, P9273, DOI 10.1021/bi990762a; CROOK EM, 1960, BIOCHEM J, V74, P234, DOI 10.1042/bj0740234; D'Alessio Giuseppe, 1993, Trends in Cell Biology, V3, P106, DOI 10.1016/0962-8924(93)90166-X; DELCARDAYRE SB, 1995, PROTEIN ENG, V8, P261, DOI 10.1093/protein/8.3.261; Domachowske JB, 1997, J LEUKOCYTE BIOL, V62, P363, DOI 10.1002/jlb.62.3.363; DURACK DT, 1981, P NATL ACAD SCI-BIOL, V78, P5165, DOI 10.1073/pnas.78.8.5165; FONTECILLACAMPS JC, 1994, J BIOL CHEM, V269, P21526; Hofsteenge J., 1997, RIBONUCLEASES STRUCT, P621, DOI [10.1016/b978-012588945-2/50020-0, DOI 10.1016/B978-012588945-2/50020-0]; KAWANOMOTO M, 1992, BIOCHIM BIOPHYS ACTA, V1129, P335, DOI 10.1016/0167-4781(92)90513-Y; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; Kobe B, 1996, J MOL BIOL, V264, P1028, DOI 10.1006/jmbi.1996.0694; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LACCETTI P, 1992, CANCER RES, V52, P4582; LEE FS, 1993, PROG NUCLEIC ACID RE, V44, P1, DOI 10.1016/S0079-6603(08)60215-9; LEHRER RI, 1989, J IMMUNOL, V142, P4428; Leland PA, 1998, P NATL ACAD SCI USA, V95, P10407, DOI 10.1073/pnas.95.18.10407; MIKULSKI SM, 1993, INT J ONCOL, V3, P57; MURTHY BS, 1992, BIOCHEM J, V281, P343, DOI 10.1042/bj2810343; NEWTON DL, 1994, J NEUROSCI, V14, P538; NITTA K, 1994, CANCER RES, V54, P920; Papageorgiou AC, 1997, EMBO J, V16, P5162, DOI 10.1093/emboj/16.17.5162; PAVLOVSKY AG, 1978, FEBS LETT, V92, P258, DOI 10.1016/0014-5793(78)80766-2; Pous J, 2000, J MOL BIOL, V303, P49, DOI 10.1006/jmbi.2000.4506; RICHARDSON RM, 1990, BIOCHEM J, V267, P593, DOI 10.1042/bj2670593; ROSENBERG HF, 1995, J BIOL CHEM, V270, P7876, DOI 10.1074/jbc.270.14.7876; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAXENA SK, 1991, J BIOL CHEM, V266, P21208; Saxena SK, 1996, J BIOL CHEM, V271, P20783, DOI 10.1074/jbc.271.34.20783; SENO M, 1994, BBA-GENE STRUCT EXPR, V1218, P466, DOI 10.1016/0167-4781(94)90208-9; SHAPIRO R, 2000, J MOL BIOL, V362, P487; SORRENTINO S, 1992, J BIOL CHEM, V267, P14859; SORRENTINO S, 1994, ARCH BIOCHEM BIOPHYS, V312, P340, DOI 10.1006/abbi.1994.1318; VESCIA S, 1980, CANCER RES, V40, P3740; WEICKMANN JL, 1981, BIOCHEMISTRY-US, V20, P1272, DOI 10.1021/bi00508a035; WITZEL H, 1962, BIOCHEM BIOPH RES CO, V7, P295, DOI 10.1016/0006-291X(62)90194-8; WU YN, 1993, J BIOL CHEM, V268, P10686; ZEGERS I, 1994, PROTEIN SCI, V3, P2322, DOI 10.1002/pro.5560031217	48	47	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24978	24984		10.1074/jbc.M102440200	http://dx.doi.org/10.1074/jbc.M102440200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342552	hybrid			2022-12-25	WOS:000169800700073
J	Yamagishi, SI; Edelstein, D; Du, XL; Kaneda, Y; Guzman, M; Brownlee, M				Yamagishi, SI; Edelstein, D; Du, XL; Kaneda, Y; Guzman, M; Brownlee, M			Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARNITINE PALMITOYLTRANSFERASE-I; NECROSIS-FACTOR-ALPHA; INSULIN-RESISTANCE; CYTOSKELETAL COMPONENTS; DIABETES-MELLITUS; VASCULAR-DISEASE; OBESE GENE; ATHEROSCLEROSIS; GLUCOSE; MICE	Leptin, a circulating hormone secreted mainly from adipose tissues, is involved in the control of body weight. The plasma concentrations are correlated with body mass index, and are reported to be high in patients with insulin resistance, which is one of the major risk factors for cardiovascular disease. However, the direct effect of leptin on vascular wall cells is not fully understood. In this study, we investigated the effects of leptin on reactive oxygen species (ROS) generation and expression of monocyte chemoattractant protein-1 (MCP-1) in bovine aortic endothelial cells (BAEC). We found that leptin increases ROS generation in BAEC in a dose-dependent manner and that its effects are additive with those of glucose. Rotenone, thenoyltrifluoroacetone (TTEA), carbonyl cyanide m-chlorophenylhydrazone (CCCP), Mn(III)tetrakis (4-benzoic acid) porphyrin (MnTBAP), uncoupling protein-1 (UCP1) HVJ-liposomes, or manganese superoxide dismutase (MnSOD) HVJ-liposomes completely prevented the effect of leptin, suggesting that ROS arise from mitochondrial electron transport. Leptin increased fatty acid orridation by stimulating the activity of carnitine palmitoyltransferase-1 (CPT-1) and inhibiting that of acetyl-CoA carboxylase (ACC), pace-setting enzymes for fatty acid oxidation and synthesis, respectively. Leptin-induced ROS generation, CPT-1 activation, ACC inhibition, and MCP-1 overproduction were found to be completely prevented by either genistein, a tyrosine kinase inhibitor, H-89, a protein kinase A (PKA) inhibitor, or tetradecylglycidate, a CPT-1 inhibitor. Leptin activated PKA, and the effects of leptin were inhibited by the cAMP antagonist Rp-cAMPS, These results suggest that leptin induces ROS generation by increasing fatty acid oxidation via PKA activation, which may play an important role in the progression of atherosclerosis in insulin-resistant obese diabetic patients.	Yeshiva Univ Albert Einstein Coll Med, Dept Med, Ctr Diabet Res, Bronx, NY 10461 USA; Osaka Univ, Sch Med, Div Gene Therapy Sci, Suita, Osaka 5050871, Japan; Univ Complutense Madrid, Sch Biol, Dept Biochem & Mol Biol 1, Madrid 28040, Spain	Yeshiva University; Albert Einstein College of Medicine; Osaka University; Complutense University of Madrid	Brownlee, M (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Med, Ctr Diabet Res, 1300 Morris Pk Ave, Bronx, NY 10461 USA.			Guzman, Manuel/0000-0001-7475-118X				Abe J, 1998, TRENDS CARDIOVAS MED, V8, P59, DOI 10.1016/S1050-1738(97)00133-3; BIJLEVELD C, 1987, BIOCHIM BIOPHYS ACTA, V918, P273; Blazquez C, 1998, J NEUROCHEM, V71, P1597; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Bouloumie A, 1999, FASEB J, V13, P1231, DOI 10.1096/fasebj.13.10.1231; Civelek VN, 1996, BIOCHEM J, V318, P615, DOI 10.1042/bj3180615; Crandall DL, 1999, J CLIN ENDOCR METAB, V84, P3222, DOI 10.1210/jc.84.9.3222; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; Guzman M, 2000, TRENDS ENDOCRIN MET, V11, P49, DOI 10.1016/S1043-2760(99)00223-4; GUZMAN M, 1992, BIOCHEM J, V287, P487, DOI 10.1042/bj2870487; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; KAISER N, 1993, DIABETES, V42, P80, DOI 10.2337/diabetes.42.1.80; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Nyholm B, 1997, EUR J ENDOCRINOL, V136, P173, DOI 10.1530/eje.0.1360173; Panahloo A, 1996, CORONARY ARTERY DIS, V7, P723, DOI 10.1097/00019501-199610000-00005; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Randle PJ, 1998, DIABETES METAB REV, V14, P263, DOI 10.1002/(SICI)1099-0895(199812)14:4&lt;263::AID-DMR233&gt;3.0.CO;2-C; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROLLINS BJ, 1990, AM J PATHOL, V136, P1229; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Rudberg S, 1998, HORM RES, V50, P297, DOI 10.1159/000023294; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; Saeki Y, 1998, GENE THER, V5, P1031, DOI 10.1038/sj.gt.3300711; Shimomura I, 1996, NAT MED, V2, P800, DOI 10.1038/nm0796-800; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; STRALFORS P, 1984, P NATL ACAD SCI-BIOL, V81, P3317, DOI 10.1073/pnas.81.11.3317; Velasco G, 1998, J BIOL CHEM, V273, P21497, DOI 10.1074/jbc.273.34.21497; Wung BS, 1997, CIRC RES, V81, P1, DOI 10.1161/01.RES.81.1.1	33	501	546	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25096	25100		10.1074/jbc.M007383200	http://dx.doi.org/10.1074/jbc.M007383200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342529	hybrid			2022-12-25	WOS:000169800700089
J	Wilstermann, AM; Osheroff, N				Wilstermann, AM; Osheroff, N			Positioning the 3 '-DNA terminus for topoisomerase II-mediated religation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN DNA LIGASES; TARGETED DRUGS; CLEAVAGE; MECHANISM; ENZYME; YEAST; SITE; BREAKPOINTS; ETOPOSIDE; LESIONS	Despite the importance of the topoisomerase II DNA cleavage/rejoining cycle to genomic integrity, the mechanistic details of religation are poorly understood. Topoisomerase II utilizes covalent protein-DNA interactions to align the 5'-termini of cleaved DNA for religation, However, because the enzyme does not form covalent bonds with the 3'-DNA termini, the basis for the alignment of the 3'-ends is less clear. Three major possibilities exist. The 3'-termini may be positioned for religation (i) by base pairing to their complementary DNA strands, (ii) by base stacking to the adjacent residues, or (iii) by noncovalent interactions with topoisomerase II. To distinguish between these possibilities, the ability of human topoisomerase II alpha to religate a series of oligonucleotides with altered base pairing or base stacking at their 3'-termini was determined. Substrates containing modifications that disrupted terminal base pairing or base stacking with-out affecting the 3'-terminal base were resealed at wild-type rates. In contrast, substrates that lacked the terminal base (or contained an altered base) displayed very low rates of religation. On the basis of these results, we propose that topoisomerase II positions the 3'-DNA termini for religation through noncovalent protein-DNA contacts.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med Hematol Oncol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Osheroff, N (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 654 Robinsin Res Bldg, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [T32CA009385] Funding Source: NIH RePORTER; NCI NIH HHS [5 T32 CA09385] Funding Source: Medline; NIGMS NIH HHS [GM3394, GM53960] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson VE, 1999, J BIOL CHEM, V274, P35927, DOI 10.1074/jbc.274.50.35927; Baguley BC, 1998, BBA-GENE STRUCT EXPR, V1400, P213, DOI 10.1016/S0167-4781(98)00137-7; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Berger JM, 1998, BBA-GENE STRUCT EXPR, V1400, P3, DOI 10.1016/S0167-4781(98)00124-9; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; CORBETT AH, 1992, J BIOL CHEM, V267, P683; FELIX CA, 1995, CANCER RES, V55, P4287; Fortune JM, 2000, PROG NUCLEIC ACID RE, V64, P221, DOI 10.1016/S0079-6603(00)64006-0; FREUDENREICH CH, 1993, EMBO J, V12, P2085, DOI 10.1002/j.1460-2075.1993.tb05857.x; FREUDENREICH CH, 1994, P NATL ACAD SCI USA, V91, P11007, DOI 10.1073/pnas.91.23.11007; Hande KR, 1998, BBA-GENE STRUCT EXPR, V1400, P173, DOI 10.1016/S0167-4781(98)00134-1; Hande KR, 1998, EUR J CANCER, V34, P1514, DOI 10.1016/S0959-8049(98)00228-7; Kaufmann SH, 1998, BBA-GENE STRUCT EXPR, V1400, P195, DOI 10.1016/S0167-4781(98)00136-5; Kingma PS, 1997, BIOCHEMISTRY-US, V36, P5934, DOI 10.1021/bi970507v; Kingma PS, 1997, J BIOL CHEM, V272, P1148, DOI 10.1074/jbc.272.2.1148; Kingma PS, 1998, J BIOL CHEM, V273, P17999, DOI 10.1074/jbc.273.29.17999; LEHMAN IR, 1974, SCIENCE, V186, P790; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; Liu QY, 1998, J BIOL CHEM, V273, P20252, DOI 10.1074/jbc.273.32.20252; Nitiss JL, 1998, BBA-GENE STRUCT EXPR, V1400, P63, DOI 10.1016/S0167-4781(98)00128-6; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; OSHEROFF NE, 1998, BIOCH BIOPHYS ACTA, V1400; POMMIER Y, 1997, CANC THERAPEUTICS EX, V1, P153; Pommier Y., 1996, CANC CHEMOTHERAPY BI, P435; PRICHARD CE, 1997, NUCLEIC ACIDS RES, V25, P3403; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; SAENGER W, 1984, PRINCIPLES NUCL ACID, P137; SANDER M, 1983, J BIOL CHEM, V258, P8421; SantaLucia J, 1998, P NATL ACAD SCI USA, V95, P1460, DOI 10.1073/pnas.95.4.1460; Tomkinson AE, 1998, MUTAT RES-DNA REPAIR, V407, P1, DOI 10.1016/S0921-8777(97)00050-5; Tomkinson AE, 1997, BIOESSAYS, V19, P893, DOI 10.1002/bies.950191009; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WASSERMAN RA, 1993, CANCER RES, V53, P3591; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; Xia TB, 1998, BIOCHEMISTRY-US, V37, P14719, DOI 10.1021/bi9809425; ZECHIEDRICH EL, 1989, BIOCHEMISTRY-US, V28, P6229, DOI 10.1021/bi00441a014	37	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17727	17731		10.1074/jbc.M100197200	http://dx.doi.org/10.1074/jbc.M100197200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11359787	hybrid			2022-12-25	WOS:000168866500016
J	Liu, ML; Shibata, MA; Von Lintig, FC; Wang, WL; Cassenaer, S; Boss, GR; Green, JE				Liu, ML; Shibata, MA; Von Lintig, FC; Wang, WL; Cassenaer, S; Boss, GR; Green, JE			Haploid loss of Ki-ras delays mammary tumor progression in C3 (1)/SV40 Tag transgenic mice	ONCOGENE			English	Article						Ki-ras; mammary gland tumor; transgenic mice	GROWTH IN-VITRO; MOUSE; GENE; EXPRESSION; CARCINOMA; ADENOCARCINOMA; IDENTIFICATION; AMPLIFICATION; SUPPRESSION; APOPTOSIS	We have previously demonstrated that amplification and overexpression of the Ki-ras gene is associated with mammary tumor progression in C3(1)/SV40Tag transgenic mice (Liu Et al,, 1998), To further evaluate the functional significance of the Ki-vas proto-oncogene in mammary cancer development, in vivo studies were conducted to examine the effect of Ki-vas gene dosage on tumor progression. The lack of one normal Ki-vas allele C3(1)/SV40Tag transgenic mice resulted in significantly delayed mammary intraepithelial neoplasia (MIN) formation as well as in a decreased number of mammary gland carcinomas, However, despite the retardation of tumor development by reduced Ki-ras gene dosage, overall survival was only modestly affected. This appears to be due to several factors including significant mammary tumor growth associated with Ki-ras gene amplification and over-expression that occurs during the advanced stage of oncogenesis in mice carrying either one or two normal Ki-ras alleles, The retardation of tumor progression due to the haploid loss of Ki-ras did not appear to be related to accelerated apoptosis, or a reduced rate of cell proliferation at the tumor stages examined. These data strongly suggest that the gene dosage of Ki-vas affects tumor promotion at an early stage of mammary tumor progression in this SV40 Tag-induced model of mammary oncogenesis.	NCI, Lab Cell Regulat & Carcinogenesis, Div Basic Sci, NIH, Bethesda, MD 20892 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California San Diego	Green, JE (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, Div Basic Sci, NIH, Bethesda, MD 20892 USA.		Shibata, Masa-Aki/L-1624-2019	Shibata, Masa-Aki/0000-0002-3350-7305; Boss, Gerry/0000-0002-9758-8714				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1986, NUCLEIC ACIDS RES, V14, P1209, DOI 10.1093/nar/14.3.1209; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FILMUS JE, 1985, CANCER RES, V45, P4468; Fueyo J, 1998, NAT MED, V4, P685, DOI 10.1038/nm0698-685; FUJITA J, 1985, P NATL ACAD SCI USA, V82, P3849, DOI 10.1073/pnas.82.11.3849; GARCIA I, 1989, CANCER RES, V49, P6675; GEORGE DL, 1986, P NATL ACAD SCI USA, V83, P1651, DOI 10.1073/pnas.83.6.1651; GRAHAM KA, 1985, CANCER RES, V45, P2201; Green JE, 2000, ONCOGENE, V19, P1020, DOI 10.1038/sj.onc.1203280; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; Liu ML, 1998, ONCOGENE, V17, P2403, DOI 10.1038/sj.onc.1202456; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Maroulakou IG, 1999, ONCOGENE, V18, P5435, DOI 10.1038/sj.onc.1202926; PROSPERI MT, 1990, CANCER LETT, V51, P169, DOI 10.1016/0304-3835(90)90053-Z; SCHEELE JS, 1994, J BIOL CHEM, V269, P18599; Shibata MA, 1996, CANCER RES, V56, P2998; Shibata MA, 2001, CANCER GENE THER, V8, P23, DOI 10.1038/sj.cgt.7700275; Sills RC, 1999, IARC SCI PUBL, P55; TANAKA T, 1986, CANCER RES, V46, P1465; WESTAWAY D, 1986, EMBO J, V5, P301, DOI 10.1002/j.1460-2075.1986.tb04213.x	24	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2001	20	16					2044	2049		10.1038/sj.onc.1204280	http://dx.doi.org/10.1038/sj.onc.1204280			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360188				2022-12-25	WOS:000168043800012
J	Maulon, L; Mari, B; Bertolotto, C; Ricci, JE; Luciano, F; Belhacene, N; Deckert, M; Baier, G; Auberger, P				Maulon, L; Mari, B; Bertolotto, C; Ricci, JE; Luciano, F; Belhacene, N; Deckert, M; Baier, G; Auberger, P			Differential requirements for ERK1/2 and p38 MAPK activation by thrombin in T cells. Role of P59Fyn and PKC epsilon	ONCOGENE			English	Article						T lymphocytes; thrombin; Src kinases; PKCs; MAP kinases	PROTEIN-KINASE-C; RECEPTOR AGONIST PEPTIDE; EPIDERMAL-GROWTH-FACTOR; SRC FAMILY KINASES; TYROSINE KINASE; COUPLED RECEPTORS; IL-2 PROMOTER; CROSS-LINKING; RAS; PHOSPHORYLATION	Activation of the mitogen-activated protein kinase (MAPK) cascade is a well documented mechanism for the G-protein-coupled receptors, Here, we have analysed the requirements for ERKs and p38 MAPK activation by thrombin in Jurkat T cells. We show that thrombin-mediated ERKs activation requires both PTK and PKC activities, whereas p38 MAPK activation is dependent only on PTKs, Thrombin-induced ERK and p38 MAPK activation was more pronounced in p56Lck deficient cells indicating that this PTK exerts a negative control on MAPK activity. Accordingly, overexpression of p50 Csk a kinase that inactivates p56Lck induced constitutive activation of ERKs, Requirement for a Src kinase was evidenced by expression of a constitutively active form of p59Fyn in Jurkat cells. Besides its effect on tyrosine phosphorylation events, thrombin also triggered a rapid and robust redistribution of PKC epsilon and delta from the cytosol to the membrane. Expression of constitutively active and dominant negative PKC epsilon demonstrates the pivotal role of this PKC isoform in ERKs activation by thrombin, These data are consistent with a model where thrombin induces ERK activation via both PKC-dependent and independent pathways, whereas p38 MAPK activation requires only PTKs, The PKC-independent pathway requires Src kinases other than p56Lck more likely p59Fyn, while the PKC-dependent mechanism depends on PKC epsilon.	INSERM, U526, F-06107 Nice 2, France; Univ Innsbruck, Inst Med Biol & Human Genet, A-6020 Innsbruck, Austria; Hop Archet, INSERM U343, Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Innsbruck; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm)	Auberger, P (corresponding author), INSERM, U526, 28 Ave Valombrose, F-06107 Nice 2, France.		Bertolotto, Corine/AAF-6634-2021; Mari, Bernard P/F-8960-2013; Deckert, Marcel/M-4998-2016; RICCI, Jean Ehrland/AAS-4379-2020; Mari, Bernard P/D-7445-2015; Mari, Bernard/Q-5832-2019; Ricci, Jean Ehrland/I-7117-2016; AUBERGER, Patrick/G-1491-2013; Baier, Gottfried/E-8755-2012; Mari, Bernard P/GVS-3100-2022; luciano, frederic/P-6264-2016; Deckert, Marcel/T-3566-2019; Bertolotto-Ballotti, Corine/O-2155-2016	Bertolotto, Corine/0000-0001-6971-7753; Mari, Bernard P/0000-0002-0422-9182; RICCI, Jean Ehrland/0000-0003-1585-8117; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard/0000-0002-0422-9182; Ricci, Jean Ehrland/0000-0003-1585-8117; AUBERGER, Patrick/0000-0002-2481-8275; Mari, Bernard P/0000-0002-0422-9182; luciano, frederic/0000-0001-9253-4998; Deckert, Marcel/0000-0003-2094-559X; Baier, Gottfried/0000-0002-2085-8325				ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; AUTERO M, 1996, MOL CELL BIOL, V16, P1842; Bjorkoy G, 1997, J BIOL CHEM, V272, P11557; BRANCH DR, 1995, J IMMUNOL, V154, P3678; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CONWAY AM, 1999, BIOCHEM J, P171; Deckert M, 1998, IMMUNITY, V9, P595, DOI 10.1016/S1074-7613(00)80657-3; DERY O, 1998, AM J PHYSIOL, P1429; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DIKIC I, 1998, J BIOL CHEM, V269, P31706; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; Ghaffari-Tabrizi N, 1999, EUR J IMMUNOL, V29, P132; GOLDSCHMITH MA, 1998, P NATL ACAD SCI USA, V84, P6879; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Joyce DE, 1997, BLOOD, V90, P1893, DOI 10.1182/blood.V90.5.1893; Kampfer S, 1998, EMBO J, V17, P4046, DOI 10.1093/emboj/17.14.4046; KAWAKAMI Y, 1995, J IMMUNOL, V155, P3556; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Mari B, 1997, FASEB J, V11, P869, DOI 10.1096/fasebj.11.11.9285485; MARI B, 1994, J BIOL CHEM, V269, P8517; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Maulon L, 1998, BLOOD, V91, P4232, DOI 10.1182/blood.V91.11.4232.411k32_4232_4241; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; Ron D, 1999, J BIOL CHEM, V274, P19003, DOI 10.1074/jbc.274.27.19003; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; Satoh K, 1996, BIOCHEM BIOPH RES CO, V225, P1084, DOI 10.1006/bbrc.1996.1299; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Wang XHSN, 1998, BIOCHEM BIOPH RES CO, V253, P33, DOI 10.1006/bbrc.1998.9749; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	43	29	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2001	20	16					1964	1972		10.1038/sj.onc.1204266	http://dx.doi.org/10.1038/sj.onc.1204266			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360180				2022-12-25	WOS:000168043800004
J	Miller, WE; McDonald, PH; Cai, SF; Field, ME; Davis, RJ; Lefkowitz, RJ				Miller, WE; McDonald, PH; Cai, SF; Field, ME; Davis, RJ; Lefkowitz, RJ			Identification of a motif in the carboxyl terminus of beta-arrestin2 responsible for activation of JNK3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; MAP KINASE CASCADE; BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; SIGNAL-TRANSDUCTION; SACCHAROMYCES-CEREVISIAE; SCAFFOLD PROTEINS; CLATHRIN ADAPTER; ENDOCYTOSIS; COMPLEX	Accumulating evidence indicates that the beta -arrestins act as scaffold molecules that couple G-protein-coupled receptors to mitogen-activated protein (MAP) kinase signaling pathways. Recently, we identified the c-Jun N-terminal kinase 3 (JNK3) as a beta -arrestin2-interacting protein in yeast-two hybrid and co-immunoprecipitation studies. beta -Arrestin2 acts as a scaffold to enhance signaling to JNK3 stimulated by overexpression of the MAP3 kinase ASK1 or by agonist activation of the angiotensin 1A receptor. Whereas beta -arrestin1 is a very strong activator of JNK3 signaling, beta -arrestin1 is very weak in this regard. The data also indicate that the specific step enhanced by beta -arresting involves phosphozylation of JNK3 by the MAP2 kinase MKK4. We reasoned that defining the region (or domain) in beta -arrestin2 responsible for high level JNK3 activation would provide insight into the mechanism by which beta -arrestin2 enhances the activity of this signaling pathway. Using chimeric beta -arrestin2, we have determined that sequences in the carboxyl-terminal region of beta -arrestin2 are important for the enhancement of JNK3 phosphorylation. More detailed analysis of the carboxyl-terminal domains of the beta -arrestins indicated that beta -arrestin2, but not beta -arrestin2, contains a sequence (RRSLHL) highly homologous to the conserved docking motif present in many MAP kinase-binding proteins. Replacement of the beta -arrestin2 RRS residues with the corresponding KP residues present in beta -arrestin1 dramatically reduced both JNK3 interaction and enhancement of JNK3 phosphorylation. Conversely, replacement of the HP residues in beta -arrestin1 with RRS significantly increased both JNK3 binding and enhancement of JNK3 phosphorylation. These results delineate a mechanism by which beta -arrestin2 functions as a scaffold protein in the JNK3 signaling pathway and implicate the conserved docking site in beta -arrestin2 as an important factor in binding JNK3 and stimulating the phosphorylation of JNK3 by MKK4.	Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA	Duke University; Howard Hughes Medical Institute; Duke University; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Box 3821, Durham, NC 27710 USA.		Lefkowitz, Robert/AAW-2649-2021	Cai, Sheng/0000-0002-2708-887X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alloway PG, 2000, NEURON, V28, P129, DOI 10.1016/S0896-6273(00)00091-X; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BARAK LS, 1994, J BIOL CHEM, V269, P2790; Bardwell AJ, 2001, J BIOL CHEM, V276, P10374, DOI 10.1074/jbc.M010271200; Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; CHOI KY, 1994, CELL, V78, P499; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DAVIS RJ, 1999, IN PRESS BIOCH SOC S, V64, P1; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Feng YY, 1998, CURR BIOL, V8, P267, DOI 10.1016/S0960-9822(98)70108-3; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; Ito M, 1999, MOL CELL BIOL, V19, P7539; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Kiselev A, 2000, NEURON, V28, P139, DOI 10.1016/S0896-6273(00)00092-1; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Levchenko A, 2000, P NATL ACAD SCI USA, V97, P5818, DOI 10.1073/pnas.97.11.5818; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McDonald PH, 1999, J BIOL CHEM, V274, P10677, DOI 10.1074/jbc.274.16.10677; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yasuda J, 1999, MOL CELL BIOL, V19, P7245	45	94	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27770	27777		10.1074/jbc.M102264200	http://dx.doi.org/10.1074/jbc.M102264200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11356842	hybrid			2022-12-25	WOS:000170093400006
J	Assarsson, M; Andersson, ME; Hogbom, M; Persson, BO; Sahlin, M; Barra, AL; Sjoberg, BM; Nordlund, P; Graslund, A				Assarsson, M; Andersson, ME; Hogbom, M; Persson, BO; Sahlin, M; Barra, AL; Sjoberg, BM; Nordlund, P; Graslund, A			Restoring proper radical generation by azide binding to the iron site of the E238A mutant R2 protein of ribonucleotide reductase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSYL RADICAL-DIIRON(III) COFACTOR; CRYSTAL-STRUCTURE; EPR SPECTROSCOPY; STRUCTURAL BASIS; FE2+ REACTION; MECHANISM; SUBUNIT; MOUSE; IDENTIFICATION; ACTIVATION	The enzyme activity of Escherichia coli ribonucleotide reductase requires the presence of a stable tyrosyl free radical and diiron center in its smaller R2 component. The iron/radical site is formed in a reconstitution reaction between ferrous iron and molecular oxygen in the protein. The reaction is known to proceed via a paramagnetic intermediate X, formally a Fe-III-Fe-IV state. me have used 9.6 GHz and 285 GHz EPR to investigate intermediates in the reconstitution reaction in the iron ligand mutant R2 E238A with or without azide, formate, or acetate present. Paramagnetic intermediates, i.e. a long-living X-like intermediate and a transient tyrosyl radical, were observed only with azide and under none of the other conditions, A crystal structure of the mutant protein R2 E238A/Y122F with a diferrous iron site complexed with azide was determined. Azide was found to be a bridging ligand and the absent Glu-238 ligand was compensated for by azide and an extra coordination from Glu-204, A general scheme for the reconstitution reaction is presented based on EPR and structure results. This indicates that tyrosyl radical generation requires a specific ligand coordination with 4-coordinate Fe1 and 6-coordinate Fe2 after oxygen binding to the diferrous site.	Stockholm Univ, Dept Biochem & Biophys, S-10691 Stockholm, Sweden; Stockholm Univ, Dept Mol Biol, S-10691 Stockholm, Sweden; Stockholm Univ, Dept Funct Genom, S-10691 Stockholm, Sweden; MPI, CNRS, High Field Magnet Lab, F-38042 Grenoble, France	Stockholm University; Stockholm University; Stockholm University; Centre National de la Recherche Scientifique (CNRS)	Graslund, A (corresponding author), Stockholm Univ, Dept Biophys, S-10691 Stockholm, Sweden.	astrid@biophys.su.se		Sjoberg, Britt-Marie/0000-0001-5953-3360; Hogbom, Martin/0000-0001-5574-9383				ABERG A, 1993, BIOCHEMISTRY-US, V34, P14093; Andersson ME, 1999, J AM CHEM SOC, V121, P2346, DOI 10.1021/ja982280c; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARRA AL, 1990, CHEM PHYS LETT, V165, P107, DOI 10.1016/0009-2614(90)87019-N; BOLLINGER JM, 1991, J AM CHEM SOC, V113, P6289, DOI 10.1021/ja00016a066; BOLLINGER JM, 1994, J AM CHEM SOC, V116, P8015, DOI 10.1021/ja00097a008; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; BOLLINGER JM, 1994, J AM CHEM SOC, V116, P8024, DOI 10.1021/ja00097a009; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Burdi D, 1998, J AM CHEM SOC, V120, P12910, DOI 10.1021/ja9824270; Ekberg M, 1996, J BIOL CHEM, V271, P20655, DOI 10.1074/jbc.271.34.20655; GERFEN GJ, 1993, J AM CHEM SOC, V115, P6420, DOI 10.1021/ja00067a071; Hagadorn JR, 1998, J AM CHEM SOC, V120, P13531, DOI 10.1021/ja983333t; LING JS, 1994, J BIOL CHEM, V269, P5595; Logan DT, 1998, BIOCHEMISTRY-US, V37, P10798, DOI 10.1021/bi9806403; Logan DT, 1996, STRUCTURE, V4, P1053, DOI 10.1016/S0969-2126(96)00112-8; Moenne-Loccoz P, 1998, BIOCHEMISTRY-US, V37, P14659, DOI 10.1021/bi981838q; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; NORDLUND P, 1989, FEBS LETT, V258, P251, DOI 10.1016/0014-5793(89)81666-7; ORMO M, 1995, J BIOL CHEM, V270, P6570, DOI 10.1074/jbc.270.12.6570; OTWINOWSKI Z, 1993, P CCP4 STUD WEEK WAR; Persson BO, 1996, J BIOL INORG CHEM, V1, P247, DOI 10.1007/s007750050050; Potsch S, 1999, J BIOL CHEM, V274, P17696, DOI 10.1074/jbc.274.25.17696; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; ROVA U, 1995, BIOCHEMISTRY-US, V34, P4267, DOI 10.1021/bi00013a016; SAHLIN M, 1986, J MAGN RESON, V67, P135, DOI 10.1016/0022-2364(86)90417-8; Schmidt PP, 1998, J BIOL CHEM, V273, P21463, DOI 10.1074/jbc.273.34.21463; Siegbahn PEM, 1997, THEOR CHEM ACC, V97, P289, DOI 10.1007/s002140050264; Sjoberg BM, 1997, STRUCT BOND, V88, P139; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; SJOBERG BM, 1977, J BIOL CHEM, V252, P536; Solomon EI, 2000, CHEM REV, V100, P235, DOI 10.1021/cr9900275; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Sturgeon BE, 1996, J AM CHEM SOC, V118, P7551, DOI 10.1021/ja960399k; Tronrud DE, 1997, METHOD ENZYMOL, V277, P306, DOI 10.1016/S0076-6879(97)77017-4; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; van Dam PJ, 1998, J AM CHEM SOC, V120, P5080, DOI 10.1021/ja9737127; Willems JP, 1997, J AM CHEM SOC, V119, P9816, DOI 10.1021/ja9709942	39	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26852	26859		10.1074/jbc.M008190200	http://dx.doi.org/10.1074/jbc.M008190200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11328804	hybrid			2022-12-25	WOS:000169966900018
J	Han, MH; Han, DKM; Aebersold, RH; Glomset, JA				Han, MH; Han, DKM; Aebersold, RH; Glomset, JA			Effects of protein kinase CK2, extracellular signal-regulated kinase 2, and protein phosphatase 2A on a phosphatidic acid-preferring phospholipase A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION SITES; MASS-SPECTROMETRY; IDENTIFICATION; A(2); A(1); CELLS; ATP	A soluble, phosphatidic acid-preferring phospholipase A1, expressed in mature bovine testes but not in newborn calf testes, may contribute to the formation or function of sperm. Here we incubated a recombinant preparation of the phospholipase in vitro with several enzymes including protein kinase CK2 (CK2), extracellular signal-regulated kinase 2 (ERK2), and protein phosphatase 2A (PP2A) to identify effects that might be of regulatory importance in vivo. Major findings were that 1) CK2 phosphorylated the phospholipase on serines 93, 105, and 716; 2) ERK2 phosphorylated the enzyme on serine 730; 3) there was cross-antagonism between the reactions that phosphorylated serines 716 and 730; 4) PP2A selectively hydrolyzed phosphate groups that were esterified to serines 716 and 730; 5) CK2 alpha formed a stable, MgATP/MgGTP-dependent complex with the phospholipase by a novel mechanism; and 6) the complex showed reduced phospholipase activity and resembled a complex identified in homogenates of macaque testis. These results provide the first available information about the effects of reactions of phosphorylation and dephosphorylation on the behavior of the phospholipase, shed Light on properties of CK2 alpha that may be required for the formation of complexes with its substrates, and raise the possibility that a complex containing CK2 alpha and the phospholipase may play a special biological role in the testis.	Univ Washington, Howard Hughes Med Inst, Res Labs, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Reg Primate Res Ctr, Seattle, WA 98195 USA; Inst Syst Biol, Seattle, WA 98105 USA; Univ Connecticut, Sch Med, Dept Physiol, Farmington, CT 06030 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Institute for Systems Biology (ISB); University of Connecticut	Glomset, JA (corresponding author), Univ Washington, Howard Hughes Med Inst, Res Labs, Box 357370, Seattle, WA 98195 USA.	jglomset@u.washington.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823, P51RR000166] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00166, RR 11823] Funding Source: Medline; PHS HHS [A1 34339] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; AHNERTHILGER G, 1993, NEUROSCIENCE, V53, P547, DOI 10.1016/0306-4522(93)90219-6; Blanquet PR, 2000, PROG NEUROBIOL, V60, P211, DOI 10.1016/S0301-0082(99)00026-X; Braun RE, 2000, INT J ANDROL, V23, P92, DOI 10.1046/j.1365-2605.2000.00027.x; Bunt G, 2000, BIOCHEMISTRY-US, V39, P7847, DOI 10.1021/bi992725p; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; Gygi SP, 1999, ELECTROPHORESIS, V20, P310, DOI 10.1002/(SICI)1522-2683(19990201)20:2<310::AID-ELPS310>3.0.CO;2-M; Haynes PA, 1998, ELECTROPHORESIS, V19, P939, DOI 10.1002/elps.1150190609; HAZEN SL, 1991, J BIOL CHEM, V266, P14526; Higgs HN, 1998, J BIOL CHEM, V273, P5468, DOI 10.1074/jbc.273.10.5468; Higgs HN, 1996, J BIOL CHEM, V271, P10874, DOI 10.1074/jbc.271.18.10874; HIGGS HN, 1994, P NATL ACAD SCI USA, V91, P9574, DOI 10.1073/pnas.91.20.9574; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin QS, 2000, BIOCHEMISTRY-US, V39, P9335, DOI 10.1021/bi000017u; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Luconi M, 1998, BIOL REPROD, V58, P1476, DOI 10.1095/biolreprod58.6.1476; Mudgal P, 1998, MOL REPROD DEV, V50, P178, DOI 10.1002/(SICI)1098-2795(199806)50:2&lt;178::AID-MRD8&gt;3.0.CO;2-H; Niefind K, 1999, NAT STRUCT BIOL, V6, P1100, DOI 10.1038/70033; Oko R, 1998, ANDROLOGIA, V30, P193; OKO RJ, 1991, ANN NY ACAD SCI, V637, P203, DOI 10.1111/j.1749-6632.1991.tb27311.x; REDWOOD CS, 1993, FEBS LETT, V327, P85, DOI 10.1016/0014-5793(93)81045-2; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Wang Z, 2000, BIOCHEMISTRY-US, V39, P11114, DOI 10.1021/bi0006767; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020	26	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27698	27708		10.1074/jbc.M101983200	http://dx.doi.org/10.1074/jbc.M101983200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11328814	hybrid			2022-12-25	WOS:000169966900127
J	Hegde, V; Kelley, MR; Xu, Y; Mian, IS; Deutsch, WA				Hegde, V; Kelley, MR; Xu, Y; Mian, IS; Deutsch, WA			Conversion of the bifunctional 8-oxoguanine/beta-delta apurinic/apyrimidinic DNA repair activities of Drosophila ribosomal protein S3 into the human S3 monofunctional P-elimination catalyst through a single amino acid change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME ENDONUCLEASE-III; ESCHERICHIA-COLI; DAMAGED DNA; DEOXYRIBOSE PHOSPHATE; GLYCOSYLASE ACTIVITY; DELTA-ELIMINATION; BETA-ELIMINATION; STRUCTURAL BASIS; ABASIC SITES; FPG PROTEIN	The Drosophila 53 ribosomal protein has important roles in both protein translation and DNA repair. In regards to the latter activity, it has been shown that 53 contains vigorous N-glycosylase activity for the removal of 8-oxoguanine residues in DNA that leaves baseless sites in their places. Drosophila 53 also possesses an apurinic/apyrimidinic (AP) lyase activity in which the enzyme catalyzes a beta -elimination reaction that cleaves phosphodiester bonds 3' and adjacent to an AP lesion in DNA. In certain situations, this is followed by a delta -elimination reaction that ultimately leads to the formation of a single nucleotide gap in DNA bordered by 5' and 3'-phosphate groups. The human 53 protein, although 80% identical to its Drosophila homolog and shorter by only two amino acids, has only marginal N-glycosylase activity. Its lyase activity only cleaves AP DNA by a beta -elimination reaction, thus further distinguishing itself from the Drosophila 53 protein in lacking a delta -elimination activity. Using a hidden Markov model analysis based on the crystal structures of several DNA repair proteins, the enzymatic differences between Drosophila and human 53 were suggested by the absence of a conserved glutamine residue in human 53 that usually resides at the cleft of the deduced active site pocket of DNA glycosylases. Here we show that the replacement of the Drosophila glutamine by an alanine residue leads to the complete loss of glycosylase activity. Unexpectedly, the delta -elimination reaction at AP sites was also abrogated by a change in the Drosophila glutamine residue. Thus, a single amino acid change converted the Drosophila activity into one that is similar to that possessed by the human 53 protein. In support of this were experiments executed in vivo that showed that human 53 and the Drosophila site-directed glutamine-changed 53 performed poorly when compared with Drosophila wildtype 53 and its ability to protect a bacterial mutant from the harmful effects of DNA-damaging agents.	Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA; Indiana Univ, Sch Med, Dept Pediat, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Dept Cell & Mol Biol, Div Life Sci, Berkeley, CA 94720 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Deutsch, WA (corresponding author), Louisiana State Univ, Pennington Biomed Res Ctr, 6400 Perkins, Baton Rouge, LA 70808 USA.			Kelley, Mark/0000-0002-6120-9532				BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bhagwat M, 1996, BIOCHEMISTRY-US, V35, P659, DOI 10.1021/bi9522662; BORISH ET, 1985, BIOCHEM BIOPH RES CO, V133, P780, DOI 10.1016/0006-291X(85)90972-6; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; CUNNINGHAM RP, 1986, J BACTERIOL, V168, P1120, DOI 10.1128/jb.168.3.1120-1127.1986; Dellinger B, 2000, P COMBUST INST, V28, P2675, DOI 10.1016/S0082-0784(00)80687-6; Deutsch WA, 1997, J BIOL CHEM, V272, P32857, DOI 10.1074/jbc.272.52.32857; Dherin C, 2000, NUCLEIC ACIDS RES, V28, P4583, DOI 10.1093/nar/28.23.4583; Dizdaroglu M, 1996, MUTAT RES-DNA REPAIR, V362, P1, DOI 10.1016/0921-8777(95)00025-9; DODSON ML, 1994, J BIOL CHEM, V269, P32709; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; Hollis T, 2000, EMBO J, V19, P758, DOI 10.1093/emboj/19.4.758; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5; KANE CM, 1981, J BIOL CHEM, V256, P3405; Kelley MR, 2001, MUTAT RES-DNA REPAIR, V485, P107, DOI 10.1016/S0921-8777(00)00067-7; KIM J, 1995, J BIOL CHEM, V270, P13620, DOI 10.1074/jbc.270.23.13620; KOW YW, 1989, BIOCHEMISTRY-US, V28, P3280, DOI 10.1021/bi00434a024; KUHNLEIN U, 1976, P NATL ACAD SCI USA, V73, P1169, DOI 10.1073/pnas.73.4.1169; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; Labahn J, 1996, CELL, V86, P321, DOI 10.1016/S0092-8674(00)80103-8; LATHAM KA, 1995, BIOCHEMISTRY-US, V34, P8796, DOI 10.1021/bi00027a031; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Lindahl T, 1980, Methods Enzymol, V65, P284; MANOHARAN M, 1988, J AM CHEM SOC, V110, P2690, DOI 10.1021/ja00216a074; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MAZUMDER A, 1989, J AM CHEM SOC, V111, P8029, DOI 10.1021/ja00202a062; Mian IS, 1998, J COMPUT BIOL, V5, P57, DOI 10.1089/cmb.1998.5.57; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Nash HM, 1997, CHEM BIOL, V4, P693, DOI 10.1016/S1074-5521(97)90225-8; POGUEGEILE K, 1991, MOL CELL BIOL, V11, P3842, DOI 10.1128/MCB.11.8.3842; Sandigursky M, 1997, J BIOL CHEM, V272, P17480, DOI 10.1074/jbc.272.28.17480; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Yacoub A, 1996, EMBO J, V15, P2306, DOI 10.1002/j.1460-2075.1996.tb00584.x; Yamagata Y, 1996, CELL, V86, P311, DOI 10.1016/S0092-8674(00)80102-6	38	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27591	27596		10.1074/jbc.M101213200	http://dx.doi.org/10.1074/jbc.M101213200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11353770	hybrid			2022-12-25	WOS:000169966900113
J	Omori, K; Idei, A; Akatsuka, H				Omori, K; Idei, A; Akatsuka, H			Serratia ATP-binding cassette protein exporter, Lip, recognizes a protein region upstream of the C terminus for specific secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL ABC-TRANSPORTERS; OUTER-MEMBRANE COMPONENT; ESCHERICHIA-COLI; ERWINIA-CHRYSANTHEMI; PSEUDOMONAS-AERUGINOSA; EXTRACELLULAR LIPASE; CRYSTAL-STRUCTURE; SIGNAL PEPTIDE; AMINO-ACIDS; MARCESCENS	Serratia marcescens ATP-binding cassette (ABC) exporter, the Lip system, secretes lipase (LipA(SM)), metalloproteases, and a cell surface layer protein homologue but not a heme acquisition protein, HasA (HasA(SM)). Secretion of HasA(SM) is limited to the Has(SM) system. However, HasA proteins from Pseudomonas fluorescens (HasA(PF)) and Pseudomonas aeruginosa were exported through the Lip and Has(SM) systems. To investigate the specificity in Lip exporter-mediated secretion, secretion analysis was performed using chimeras containing the HasA(PF), and HasA(SM) sequences. The segment Val-Ala-Leu (designated R1 to R3 sites), which is present close to the C terminus of HasA(PF) but not HasA(SM), was revealed to be involved in the substrate specificity of the Lip exporter. Introduction of amino acid substitutions into the R1-R5 region demonstrated that R1, R3, R4, and R5 sites require some specific amino acid residues for Lip mediated secretion. The amino acid sequence of the region was conserved considerably among the proteins secreted by the Lip exporter, On the contrary, the region was not related to HasA secretion through the Has(SM) system. Interestingly, a typical C-terminal motif, so far regarded as a secretion signal, was not necessary for secretion through either the Lip or the Has(SM) exporter. In LipA(SM) secretion via the Lip system, the typical C-terminal motif was not essential either, but the presence of a sequence similar to Val-Ala-Leu and its location from the C terminus greatly affect the secretion level. Secretion analyses using hybrid exporters and competitors exhibited that the R1-R5 region was recognized by an ABC protein of the Lip exporter, LipB, and that the mutations aborting Lip-mediated secretion in the region resulted in a loss of the affinity to LipB. Thus, a determinant within the secretory protein for Lip-mediated secretion was fully defined.	Tanabe Seiyaku Co Ltd, Discovery Res Lab, Toda, Saitama 3358505, Japan; Tanabe Seiyaku Co Ltd, Discovery Res Lab, Yodogawa Ku, Osaka 5328505, Japan	Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation	Omori, K (corresponding author), Tanabe Seiyaku Co Ltd, Discovery Res Lab, 2-50 Kawagishi-2-Chome, Toda, Saitama 3358505, Japan.							Akatsuka H, 1996, J FERMENT BIOENG, V81, P115, DOI 10.1016/0922-338X(96)87587-8; AKATSUKA H, 1995, J BACTERIOL, V177, P6381, DOI 10.1128/jb.177.22.6381-6389.1995; AKATSUKA H, 1994, J BACTERIOL, V176, P1949, DOI 10.1128/jb.176.7.1949-1956.1994; Akatsuka H, 1997, J BACTERIOL, V179, P4754, DOI 10.1128/jb.179.15.4754-4760.1997; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BAUMANN U, 1994, J MOL BIOL, V242, P244, DOI 10.1006/jmbi.1994.1576; Binet R, 1996, MOL MICROBIOL, V22, P265, DOI 10.1046/j.1365-2958.1996.00103.x; Binet R, 1997, GENE, V192, P7, DOI 10.1016/S0378-1119(96)00829-3; BINET R, 1995, EMBO J, V14, P2298, DOI 10.1002/j.1460-2075.1995.tb07224.x; Duong F, 1996, MOL MICROBIOL, V21, P459, DOI 10.1111/j.1365-2958.1996.tb02555.x; GHIGO JM, 1994, J BIOL CHEM, V269, P8979; Idei A, 1999, J BACTERIOL, V181, P7545, DOI 10.1128/JB.181.24.7545-7551.1999; Izadi-Pruneyre N, 1999, EUR J BIOCHEM, V261, P562, DOI 10.1046/j.1432-1327.1999.00305.x; JARCHAU T, 1994, MOL GEN GENET, V245, P53, DOI 10.1007/BF00279750; Kawai E, 1998, MOL MICROBIOL, V27, P941, DOI 10.1046/j.1365-2958.1998.00739.x; KENNY B, 1992, MOL MICROBIOL, V6, P1477, DOI 10.1111/j.1365-2958.1992.tb00868.x; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; Koronakis V, 1997, MOL MICROBIOL, V23, P617, DOI 10.1046/j.1365-2958.1997.d01-1880.x; LETOFFE S, 1993, J BACTERIOL, V175, P7321; LETOFFE S, 1994, J BACTERIOL, V176, P5372; LETOFFE S, 1990, EMBO J, V9, P1375, DOI 10.1002/j.1460-2075.1990.tb08252.x; LETOFFE S, 1994, P NATL ACAD SCI USA, V91, P9876, DOI 10.1073/pnas.91.21.9876; Letoffe S, 1998, MOL MICROBIOL, V28, P1223, DOI 10.1046/j.1365-2958.1998.00885.x; MACKMAN N, 1986, CURR TOP MICROBIOL, V125, P159; MATSUMAE H, 1993, J FERMENT BIOENG, V75, P93, DOI 10.1016/0922-338X(93)90216-U; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Sakurai N, 1996, LETT APPL MICROBIOL, V23, P23, DOI 10.1111/j.1472-765X.1996.tb00021.x; Sambrook J., 2002, MOL CLONING LAB MANU; TAKAGI T, 1985, J BIOTECHNOL, V3, P59, DOI 10.1016/0168-1656(85)90007-0; WANDERSMAN C, 1990, P NATL ACAD SCI USA, V87, P4776, DOI 10.1073/pnas.87.12.4776; WANDERSMAN C, 1987, J BACTERIOL, V169, P5046, DOI 10.1128/jb.169.11.5046-5053.1987; Young J, 1999, BBA-BIOMEMBRANES, V1461, P177, DOI 10.1016/S0005-2736(99)00158-3; ZHANG F, 1993, P NATL ACAD SCI USA, V90, P4211, DOI 10.1073/pnas.90.9.4211	33	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27111	27119		10.1074/jbc.M101410200	http://dx.doi.org/10.1074/jbc.M101410200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11335719	hybrid			2022-12-25	WOS:000169966900052
J	Schuringa, JJ; Dekker, LV; Vellenga, E; Kruijer, W				Schuringa, JJ; Dekker, LV; Vellenga, E; Kruijer, W			Sequential activation of Rac-1, SEK-1/MKK-4, and protein kinase C delta is required for interleukin-6-induced STAT3 Ser-727 phosphorylation and transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR APRF; SERINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; TYROSINE; PATHWAYS; IDENTIFICATION; ASSOCIATION; BINDING; FAMILY	Activation of signal transducer and activator of transcription 3 (STAT3) by interleukin-6 (IL-6) involves phosphorylation of Tyr-705 and Ser-727, both of which are critical for STAT3 transactivation. Here, we demonstrate that IL-6 activates Rac-1 and SEK-1/MKK-4 of the stress-activated protein kinase pathway, as well as protein kinase C delta (PKC delta), as indicated by PKC delta Thr-505 phosphorylation, However, JNK-1, the end point kinase of the stress-activated protein kinase pathway signal transduction cascade, is not activated by IL-6, PKC delta was found to be associated with SEK-1/MKK-4 in unstimulated HepG2 cells but rapidly dissociates from SEK-1/ MKK-4 upon IL-6 stimulation to become associated with STAT3, Inhibition of PKC delta using rottlerin (6 muM) or by overexpression of dominant negative PKC delta demonstrates that PKC delta kinase activity is required for STAT3 Ser-727 phosphorylation and transactivation but not for STAT3 Tyr-705 phosphorylation or nuclear import. PKC delta signals downstream of Rac-1 and SEK-1/MKK-4, because enhanced STAT3 transactivation induced by overexpression of constitutive active RacV12 was strongly abrogated by rottlerin, whereas IL-B-induced SEK-1/MKK-4 Thr-223 phosphorylation was not affected under these conditions. Studying the kinetics of STAT3 and PKC delta phosphorylation in cytoplasmic and nuclear fractions revealed that STAT3 Tyr-705 phosphorylation and nuclear translocation precedes PKC delta Thr-505 and STAT3 Ser-727 phosphorylation. Furthermore, the IL-6-induced PKC delta Thr-505 and STATE Ser-727 phosphorylation were only observed in nuclear fractions of HepG2 cells, These results demonstrate that IL-6-induced STAT3 transactivation involves the sequential activation of Rac-1 and SEK-1/MKK-4, which leads to nuclear translocation of PKC delta by release from a SEK-1/MKK-4-containing complex. Our results further indicate that PKC delta -mediated STAT3 Ser-727 phosphorylation is mainly a nuclear event.	Ctr Biol, Dept Genet, NL-9751 NN Haren, Netherlands; Univ Groningen Hosp, Dept Hematol, NL-9700 RB Groningen, Netherlands; UCL, Dept Med, Rayne Inst, London WC1E 6JJ, England	University of Groningen; University of London; King's College London; University College London	Kruijer, W (corresponding author), Ctr Biol, Dept Genet, Kerklaan 30, NL-9751 NN Haren, Netherlands.	W.Kruijer@biol.rug.nl	Dekker, Lodewijk/J-6934-2013	Dekker, Lodewijk/0000-0001-5247-3297				Anhuf D, 2000, J IMMUNOL, V165, P2535, DOI 10.4049/jimmunol.165.5.2535; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GRAHAM FL, 1973, MOL CELL BIOL, V2, P607; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Saharinen P, 1997, BLOOD, V90, P4341; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schuringa JJ, 2000, BLOOD, V95, P3765, DOI 10.1182/blood.V95.12.3765; Schuringa JJ, 2000, BIOCHEM J, V347, P89, DOI 10.1042/0264-6021:3470089; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	35	66	68	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27709	27715		10.1074/jbc.M009821200	http://dx.doi.org/10.1074/jbc.M009821200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11335711	hybrid			2022-12-25	WOS:000169966900128
J	Simpson, LL; Maksymowych, AB; Hao, S				Simpson, LL; Maksymowych, AB; Hao, S			The role of zinc binding in the biological activity of botulinum toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETANUS TOXIN; NEUROTRANSMITTER RELEASE; NEUROTOXIN; PROTEINS; CLEAVAGE; SYNAPTOBREVIN; PURIFICATION; CELLS	Botulinum toxin is a zinc-dependent endoprotease that acts on vulnerable cells to cleave polypeptides that are essential for exocytosis. To exert this poisoning effect, the toxin must proceed through a complex sequence of events that involves binding, productive internalization, and intracellular expression of catalytic activity. Results presented in this study show that soluble chelators rapidly strip Zn2+ from its binding site in botulinum toxin, and this stripping of cation results in the loss of catalytic activity in cell-free or broken cell preparations. Stripped toxin is still active against intact neuromuscular junctions, presumably because internalized toxin binds cytosolic Zn2+. In contrast to soluble chelators, immobilized chelators have no effect on bound Zn2+, nor do they alter toxin activity. The latter finding is because of the fact that the spontaneous loss of Zn2+ from its coordination site in botulinum toxin is relatively slow .When exogenous Zn2+ is added to toxin that has been stripped by soluble chelators, the molecule rebinds cation and regains catalytic and neuromuscular blocking activity. Exogenous Zn2+ can restore toxin activity either when the toxin is free in solution on the cell exterior or when it has been internalized and is in the cytosol. The fact that stripped toxin can reach the cytosol means that the loss of bound Zn2+ does not produce conformational changes that block internalization. Similarly, the fact that stripped toxin in the cytosol can be reactivated by ambient Zn2+ or exogenous Zn2+ means that productive internalization does not produce conformational changes that block rebinding of cation.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Mol Pharmacol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Biochem, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University	Simpson, LL (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Philadelphia, PA 19107 USA.	lance.simpson@mail.tju.edu			NIGMS NIH HHS [GM53742] Funding Source: Medline; NINDS NIH HHS [NS22153] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022153] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahmed SA, 2000, J PROTEIN CHEM, V19, P475, DOI 10.1023/A:1026549431380; Coffield JA, 1997, J PHARMACOL EXP THER, V280, P1489; DASGUPTA BR, 1984, TOXICON, V22, P415, DOI 10.1016/0041-0101(84)90085-0; Fu FN, 1998, BIOCHEMISTRY-US, V37, P5267, DOI 10.1021/bi9723966; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HOHNEZELL B, 1993, FEBS LETT, V336, P175, DOI 10.1016/0014-5793(93)81635-D; Humeau Y, 2000, BIOCHIMIE, V82, P427, DOI 10.1016/S0300-9084(00)00216-9; Kiyatkin N, 1997, INFECT IMMUN, V65, P4586, DOI 10.1128/IAI.65.11.4586-4591.1997; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; Montecucco C, 1995, Q REV BIOPHYS, V28, P423, DOI 10.1017/S0033583500003292; MONTECUCCO C, 1986, TRENDS BIOCHEM SCI, V11, P314, DOI 10.1016/0968-0004(86)90282-3; Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Poirier MA, 1998, J BIOL CHEM, V273, P11370, DOI 10.1074/jbc.273.18.11370; SAKAGUCHI G, 1982, PHARMACOL THERAPEUT, V19, P165, DOI 10.1016/0163-7258(82)90061-4; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1992, J BIOL CHEM, V267, P23479; SIMPSON LL, 1988, METHOD ENZYMOL, V165, P76; SIMPSON LL, 1993, J PHARMACOL EXP THER, V267, P720; SIMPSON LL, 1981, PHARMACOL REV, V33, P155; SIMPSON LL, 1980, J PHARMACOL EXP THER, V212, P16; Tonello F, 1997, BIOCHEM J, V322, P507, DOI 10.1042/bj3220507; Wong SH, 1998, MOL BIOL CELL, V9, P1549, DOI 10.1091/mbc.9.6.1549	24	33	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27034	27041		10.1074/jbc.M102172200	http://dx.doi.org/10.1074/jbc.M102172200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11358966				2022-12-25	WOS:000169966900041
J	Suzuki, T; Hiroki, A; Watanabe, T; Yamashita, T; Takei, I; Umezawa, K				Suzuki, T; Hiroki, A; Watanabe, T; Yamashita, T; Takei, I; Umezawa, K			Potentiation of insulin-related signal transduction by a novel protein-tyrosine phosphatase inhibitor, Et-3,4-dephostatin, on cultured 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUCOSE-TRANSPORT; DEPENDENT DIABETES-MELLITUS; PANCREATIC BETA-CELLS; HUMAN SKELETAL-MUSCLE; GROWTH-FACTOR-I; HYPOGLYCEMIC AGENT; NEGATIVE REGULATOR; RECEPTOR KINASE; GENE-EXPRESSION; C-CBL	We previously isolated dephostatin from Streptomyces as a novel inhibitor of CD45-associated protein-tyrosine phosphatase. We prepared Et-3,4-dephostatin as a stable analogue and found it to inhibit PTP-1B and SHPTP-1 protein-tyrosine phosphatases selectively but not to inhibit CD45 and leukocyte common antigen-related phosphatase ones effectively. Et-3,4-dephostatin increased the tyrosine phosphorylation of the insulin receptor and insulin receptor substrate-1 with or without insulin in differentiated 3T3-L1 mouse adipocytes. The increase of tyrosine phosphorylation by Et-3,4-dephostatin was more prominent in 6-h than in 30-min incubation. It also increased phosphorylation and activation of Akt with or without insulin. Et-3,4-dephostatin also enhanced translocation of glucose transporter 4 from the cytoplasm to the membrane and 2-deoxy-glucose transport. Et-3,4-dephostatin-induced glucose uptake was inhibited by SB203580, a p38 inhibitor, but not by PD98059, a MEK inhibitor, or by cycloheximide as insulin-induced uptake. Interestingly, although LY294002, a phosphatidylinositol 3-kinase inhibitor, inhibited the insulin-induced glucose uptake completely, it only partially inhibited the Et-3,4-dephostatin-induced uptake. It also blocked insulin-induced glucose transporter 4 translocation but not the Et-3,4-dephostatin-induced one. The increase in c-Cbl tyrosine phosphorylation caused by Et-3,4 dephostatin was stronger than that in insulin receptor phosphorylation, These observations indicate that a phosphatidylinositol 3-kinase-independent pathway involving c-Cbl is more important in Et-3,4-dephostatin-induced glucose uptake than in insulin-induced uptake, Et-3,4-dephostatin showed an in vivo antidiabetic effect in terms of reducing the high blood glucose level in KK-A(y) mice after oral administration. Thus, Et-3,4-dephostatin potentiated insulin-related signal transductions in cultured mouse adipocytes and showed an antidiabetic effect in mice.	Keio Univ, Fac Sci & Technol, Dept Appl Chem, Kohoku Ku, Yokohama, Kanagawa 2230061, Japan; Inst Microbial Chem, Shinagawa Ku, Tokyo 1410021, Japan; Kaneka Corp, Takasago, Hyogo 6768688, Japan; Keio Univ, Sch Med, Clin Lab Internal Med, Shinjuku Ku, Tokyo 1608582, Japan	Keio University; Kaneka Corporation; Keio University	Umezawa, K (corresponding author), Keio Univ, Fac Sci & Technol, Dept Appl Chem, Kohoku Ku, 3-14-1 Hiyoshi, Yokohama, Kanagawa 2230061, Japan.							ABEL ED, 1995, CURR OPIN ENDOCRINOL, V2, P313; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ARNER P, 1987, DIABETOLOGIA, V30, P437, DOI 10.1007/BF00292549; Asano T, 2000, J BIOL CHEM, V275, P17671, DOI 10.1074/jbc.M910391199; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; CARO JF, 1987, J CLIN INVEST, V79, P1330, DOI 10.1172/JCI112958; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; Donthi RV, 2000, CARDIOVASC DRUG THER, V14, P463, DOI 10.1023/A:1007876703644; Efanova IB, 1998, J BIOL CHEM, V273, P33501, DOI 10.1074/jbc.273.50.33501; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; FANTUS IG, 1994, DIABETES, V43, P375, DOI 10.2337/diabetes.43.3.375; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fujitani S, 1996, METABOLISM, V45, P184, DOI 10.1016/S0026-0495(96)90051-7; Fujiwara S, 1997, BIOCHEM BIOPH RES CO, V238, P213, DOI 10.1006/bbrc.1997.7174; GOLDSTEIN BJ, 1993, RECEPTOR, V3, P1; HARUTA T, 1995, J BIOL CHEM, V270, P27991; IMOTO M, 1993, J ANTIBIOT, V46, P1342, DOI 10.7164/antibiotics.46.1342; Kayali AG, 1998, J BIOL CHEM, V273, P13808, DOI 10.1074/jbc.273.22.13808; KENNER KA, 1993, J BIOL CHEM, V268, P25455; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Kupriyanova TA, 1999, J BIOL CHEM, V274, P1458, DOI 10.1074/jbc.274.3.1458; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Lupher ML, 1998, INT J BIOCHEM CELL B, V30, P439, DOI 10.1016/S1357-2725(97)00075-7; MIMURA K, 1994, DIABETIC MED, V11, P685, DOI 10.1111/j.1464-5491.1994.tb00333.x; Moran A, 1997, J CLIN INVEST, V99, P534, DOI 10.1172/JCI119190; Nishimura M, 1969, EXP ANIMALS, V18, P147, DOI DOI 10.1538/EXPANIM1957.18.4_147; OBERMAIERKUSSER B, 1989, J BIOL CHEM, V264, P9497; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; RIVON V, 1997, BIOCHEM J, V324, P839; ROBERTSON RP, 1994, DIABETES, V43, P1085, DOI 10.2337/diabetes.43.9.1085; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; ROSEN OM, 1978, J BIOL CHEM, V253, P7579; Schoonjans K, 1996, J LIPID RES, V37, P907; STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; Watanabe T, 1995, J ANTIBIOT, V48, P1460, DOI 10.7164/antibiotics.48.1460; Watanabe T, 2000, TETRAHEDRON, V56, P741, DOI 10.1016/S0040-4020(99)01058-3; WHITE MF, 1994, J BIOL CHEM, V269, P1	42	38	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27511	27518		10.1074/jbc.M011726200	http://dx.doi.org/10.1074/jbc.M011726200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11342532	hybrid			2022-12-25	WOS:000169966900102
J	Warnick, CT; Dabbas, B; Ford, CD; Strait, KA				Warnick, CT; Dabbas, B; Ford, CD; Strait, KA			Identification of a p53 response element in the promoter region of the hMSH2 gene required for expression in A2780 ovarian cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA MISMATCH REPAIR; TRANSCRIPTIONAL ACTIVATION; TUMOR-CELLS; BINDING; FAMILY; P73; HETERODIMER; PROTEIN; MEMBER; LINES	Defects in the human MSH2 mismatch repair system have been implicated in cellular mutagenesis, tumorigenesis, and chemotherapeutic resistance. The current studies characterized the 5' upstream proximal promoter region of the hMSH2 gene using transient transfection of A2780 ovarian cancer cells. Serial deletions of a 1.88-kb fragment of the proximal promoter region of the hMSH2 gene revealed that promoter activity was restricted to the first -281 bp. Targeted deletions within this -281 bp region coupled with specific sequence mutagenesis identified a response element for the p53 tumor suppressor protein located between -242 and -222 bp, The -242 hMSH2 p53 element is configured as a direct tandem repeat palindrome with 80% homology to the p53 consensus binding sequence. Co-transfection of an hMSH2 reporter and p53 expression vector into the p53-null cell line SK-OV-3 produced 10-fold enhanced transcription, which was lost when the -242 to -222 p53 binding site was mutated. These results clearly demonstrate the presence of a previously unidentified p53 response element in the hMSH2 proximal promoter. Its location at -242 bp upstream of the start site of transcription is distinct from two previously reported p53 sites at -447 and -416, which transactivate in Saos-2 cells (Scherer, S. J., Maier, S. M., Seifert, M., Hanselmann, R. G., Zang, K. D., Muller-Hermelink, H. K., Angel, P., Welter, C., and Schartl, M. (2000) J. Biol. Chem. 275, 37469-37473). Finally, in sharp contrast to their activity in Saos-2 cells, deletion of the -447 and -416 sites in A2780 cells had no effect on hMSH2 promoter activity. Thus, it appears that p53 regulates hMSH2 expression through multiple cell type-specific DNA response elements.	Latter Day St Hosp, Dept Med, Canc Res Lab, Salt Lake City, UT 84143 USA; Latter Day St Hosp, Dept Pathol, Canc Res Lab, Salt Lake City, UT 84143 USA		Strait, KA (corresponding author), Latter Day St Hosp, Dept Med, Canc Res Lab, 325 8th Ave, Salt Lake City, UT 84143 USA.							Arrowsmith CH, 1999, CELL DEATH DIFFER, V6, P1169, DOI 10.1038/sj.cdd.4400619; BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; Bian JH, 1997, P NATL ACAD SCI USA, V94, P14753, DOI 10.1073/pnas.94.26.14753; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; CARSON DA, 1995, LANCET, V346, P1009, DOI 10.1016/S0140-6736(95)91693-8; CLAVERYS JP, 1986, MICROBIOL REV, V50, P133, DOI 10.1128/MMBR.50.2.133-165.1986; De Laurenzi V, 2000, ANN NY ACAD SCI, V926, P90; delaChapelle A, 1995, ANNU REV GENET, V29, P329, DOI 10.1146/annurev.ge.29.120195.001553; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Fujita M, 1995, INT J CANCER, V64, P361, DOI 10.1002/ijc.2910640602; GUESDON JL, 1979, J HISTOCHEM CYTOCHEM, V27, P1131, DOI 10.1177/27.8.90074; Iwahashi Y, 1998, GENE, V213, P141, DOI 10.1016/S0378-1119(98)00187-5; Jackson P, 1998, ONCOGENE, V16, P283, DOI 10.1038/sj.onc.1201491; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levrero M, 2000, J CELL SCI, V113, P1661; Li GM, 1999, ONCOL RES, V11, P393; MARKS JR, 1991, CANCER RES, V51, P2979; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Prives C, 1999, J PATHOL, V187, P112; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; RUTTENBERG DH, 1999, J BIOL CHEM, V274, P33747; Scherer SJ, 2000, J BIOL CHEM, V275, P37469, DOI 10.1074/jbc.M006990200; Scherer SJ, 1996, BIOCHEM BIOPH RES CO, V221, P722, DOI 10.1006/bbrc.1996.0663; SHEEHY G, 1986, J HISTOTECHNOL, V9, P134; Umar A, 1997, CANCER RES, V57, P3949; Vikhanskaya F, 2000, NUCLEIC ACIDS RES, V28, P513, DOI 10.1093/nar/28.2.513; YAGINUMA Y, 1992, CANCER RES, V52, P4196; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607	37	45	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27363	27370		10.1074/jbc.M103088200	http://dx.doi.org/10.1074/jbc.M103088200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11350971	hybrid			2022-12-25	WOS:000169966900084
J	Carlson, TR; Feng, YZ; Maisonpierre, PC; Mrksich, M; Morla, AO				Carlson, TR; Feng, YZ; Maisonpierre, PC; Mrksich, M; Morla, AO			Direct cell adhesion to the angiopoietins mediated by integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; OVEREXPRESSING ANGIOPOIETIN-1; FIBRONECTIN RECEPTOR; ENDOTHELIAL-CELLS; GROWTH-FACTORS; TIE2 RECEPTOR; IN-VITRO; ANGIOGENESIS; SURFACE; VITRONECTIN	Genetic ablation of angiopoietin-1 (Ang-l) or of its cognate receptor, Tie2, disrupts angiogenesis in mouse embryos. The endothelial cells in growing blood vessels of Ang-l knockout mice have a rounded appearance and are poorly associated with one another and their underlying basement membranes (Dumont, D. J., Gradwohl, G., Fong, G. H., purl, M. C., Gertsenstein, M., Auerbach, A, and Breitman, M. L. (1994) Genes Dev. 8, 1897-1909; Sate, T. N., Tozawa, Y., Deutsch, U., Wolburg-Buchholz, K., Fujiwara, Y., Gendron-Maguire, M., Gridley, T., Wolburg, H., Risau, W., and Qin, Y. (1995) Nature 376, 70-74; Suri, C., Jones, P. F., Patan, S., Bartunkova, S., Maisonpierre, P. C., Davis, S., Sate, T. N., and Yancopoulos, G. D. (1996) Cell 87, 1171-1180). It is therefore possible that Ang-l regulates endothelial cell adhesion. In this study we asked whether Ang-l might act as a direct substrate for cell adhesion. Human umbilical vein endothelial cells (HUVECs) plated for a brief period on different substrates were found to adhere and spread well on Ang-l. Similar results were seen on angiopoietin-2 (Ang-2)-coated surfaces, although cells did not spread well on Ang-2. Ang-l, but not Ang-2, supported HUVEC migration, and this was independent of growth factor activity. When the same experiments were done with fibroblasts that either lacked, or stably expressed, Tie2, results similar to those with HUVECs were seen, suggesting that adhesion to the angiopoietins was independent of Tie2 and not limited to endothelial cells. Interestingly, when integrin-blocking agents were included in these assays, adhesion to either angiopoietin was significantly reduced. Moreover, Chinese hamster ovary-B2 cells lacking the a, integrin subunit did not adhere to Ang-l, but they did adhere to Ang-8. Stable expression of the human a, integrin subunit in these cells rescued adhesion to Ang-l and promoted an increase in adhesion to Ang-a, We also found that Ang-l and Ang-8 bind rather selectively to vitronectin. These results suggest that, beyond their role in modulating Tie2 signaling, Ang-l and Ang-2 can directly support cell adhesion mediated by integrins.	Univ Chicago, Dept Pathol, Comm Canc Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Chem, Chicago, IL 60637 USA; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	University of Chicago; University of Chicago; University of Chicago; Regeneron	Morla, AO (corresponding author), Univ Chicago, Dept Pathol, Comm Canc Biol, MC 1089,5841 S Maryland Ave, Chicago, IL 60637 USA.		Mrksich, Milan/G-2469-2011	Mrksich, Milan/0000-0002-4964-796X	NHLBI NIH HHS [R01 HL-59962] Funding Source: Medline; NIGMS NIH HHS [R01 GM-54621] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059962] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; ASCH E, 1990, J CLIN INVEST, V85, P1372, DOI 10.1172/JCI114581; BAUER JS, 1993, J CELL BIOL, V122, P209, DOI 10.1083/jcb.122.1.209; Bazzoni G, 1999, CURR OPIN CELL BIOL, V11, P573, DOI 10.1016/S0955-0674(99)00023-X; Beckner ME, 1999, CANCER INVEST, V17, P594, DOI 10.3109/07357909909032845; Browder T, 2000, J BIOL CHEM, V275, P1521, DOI 10.1074/jbc.275.3.1521; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; CHRZANOWSKAWODNICKA M, 1994, J CELL SCI, V107, P3643; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; Fujikawa K, 1999, EXP CELL RES, V253, P663, DOI 10.1006/excr.1999.4693; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Huang XL, 1999, BIOCHEM BIOPH RES CO, V264, P133, DOI 10.1006/bbrc.1999.1472; Jain RK, 2000, NAT MED, V6, P131, DOI 10.1038/72212; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Jung SM, 1998, J BIOL CHEM, V273, P14827, DOI 10.1074/jbc.273.24.14827; Kim I, 2000, CIRC RES, V86, P952, DOI 10.1161/01.RES.86.9.952; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Lewis JM, 1996, J CELL BIOL, V134, P1323, DOI 10.1083/jcb.134.5.1323; LUM H, 1994, AM J PHYSIOL, V267, pL223, DOI 10.1152/ajplung.1994.267.3.L223; MACIAG T, 1979, P NATL ACAD SCI USA, V76, P5674, DOI 10.1073/pnas.76.11.5674; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Munger JS, 1998, MOL BIOL CELL, V9, P2627, DOI 10.1091/mbc.9.9.2627; Nishimura M, 1999, FEBS LETT, V448, P254, DOI 10.1016/S0014-5793(99)00381-6; Norde W, 1998, BIOTECHNOL APPL BIOC, V28, P133; Norde W, 2000, J BIOTECHNOL, V79, P259, DOI 10.1016/S0168-1656(00)00242-X; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SCHREINER CL, 1989, J CELL BIOL, V109, P3157, DOI 10.1083/jcb.109.6.3157; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Takakura N, 1998, IMMUNITY, V9, P677, DOI 10.1016/S1074-7613(00)80665-2; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Valenzuela DM, 1999, P NATL ACAD SCI USA, V96, P1904, DOI 10.1073/pnas.96.5.1904; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; YURCHENCO PD, 1994, CURR OPIN CELL BIOL, V6, P674, DOI 10.1016/0955-0674(94)90093-0; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235	46	209	219	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26516	26525		10.1074/jbc.M100282200	http://dx.doi.org/10.1074/jbc.M100282200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11346644	hybrid			2022-12-25	WOS:000169823300115
J	Chen, YA; Scales, SJ; Duvvuri, V; Murthy, M; Patel, SM; Schulman, H; Scheller, RH				Chen, YA; Scales, SJ; Duvvuri, V; Murthy, M; Patel, SM; Schulman, H; Scheller, RH			Calcium regulation of exocytosis in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; MEMBRANE-FUSION; SNARE COMPLEX; CA2+-DEPENDENT EXOCYTOSIS; NEUROTRANSMITTER RELEASE; SECRETORY VESICLES; PROTEIN-KINASE; CALMODULIN; BINDING; CA2+	The calcium (Ca2+) regulation of neurotransmitter release is poorly understood. Here we investigated several aspects of this process in PC12 cells. We first showed that osmotic shock by 1 M sucrose stimulated rapid release of neurotransmitters from intact PC12 cells, indicating that most of the vesicles were docked at the plasma membrane. Second, we further investigated the mechanism of rescue of botulinum neurotoxin E inhibition of release by recombinant SNAP-25 COOH-terminal coil, which is known to be required in the triggering stage. We confirmed here that Ca2+ was required simultaneously with the SNAP-25 peptide, with no significant increase in release if either the peptide or Ca2+ was present during the priming stage as well as the triggering, suggesting that SNARE (soluble N-ethylmaleimide-sensitive fusion protein attachment protein receptor) complex assembly was involved in the final Ca2+-triggered event. Using this rescue system, we also identified a series of acidic surface SNAP-25 residues that rescued better than wild-type when mutated, due to broadened Ca2+ sensitivity, suggesting that this charged patch may interact electrostatically with a negative regulator of membrane fusion, Finally, we showed that the previously demonstrated stimulation of exocytosis in this system by calmodulin required calcium binding, since calmodulin mutants defective in Ca2+-binding were not able to enhance release.	Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University	Scheller, RH (corresponding author), Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.	scheller@gene.com	Duvvuri, Vikas/M-1904-2013; Scales, Suzie J./H-4507-2019	Scales, Suzie J./0000-0003-2544-0283	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH020016] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 08327, GM40600] Funding Source: Medline; NIMH NIH HHS [5T32 MH20016-04] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARTALEJO CR, 1994, NATURE, V367, P72, DOI 10.1038/367072a0; Banerjee A, 1996, J BIOL CHEM, V271, P20227, DOI 10.1074/jbc.271.34.20227; BIRCH KA, 1992, J CELL BIOL, V118, P1501, DOI 10.1083/jcb.118.6.1501; BITTNER MA, 1992, J BIOL CHEM, V267, P16219; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Brunger AT, 2000, CURR OPIN NEUROBIOL, V10, P293, DOI 10.1016/S0959-4388(00)00098-2; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Chen YA, 1999, J BIOL CHEM, V274, P26469, DOI 10.1074/jbc.274.37.26469; Chen YA, 2001, NEURON, V30, P161, DOI 10.1016/S0896-6273(01)00270-7; Coppola T, 1999, EMBO J, V18, P5885, DOI 10.1093/emboj/18.21.5885; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; FRIEDBERG F, 1990, Protein Sequences and Data Analysis, V3, P335; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; Gerona RRL, 2000, J BIOL CHEM, V275, P6328, DOI 10.1074/jbc.275.9.6328; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; Itakura M, 1999, BIOCHEM BIOPH RES CO, V265, P691, DOI 10.1006/bbrc.1999.1756; Kasai H, 1999, TRENDS NEUROSCI, V22, P88, DOI 10.1016/S0166-2236(98)01293-4; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; LITTLETON JT, 1995, TRENDS NEUROSCI, V18, P177; Lonart G, 1998, NEURON, V21, P1141, DOI 10.1016/S0896-6273(00)80631-5; MARSHAK DR, 1996, STRATEGIES PROTEIN P, P74; Martin TFJ, 1997, J BIOL CHEM, V272, P14447, DOI 10.1074/jbc.272.22.14447; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; Pabst S, 2000, J BIOL CHEM, V275, P19808, DOI 10.1074/jbc.M002571200; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; PERSECHINI A, 1989, TRENDS NEUROSCI, V12, P462, DOI 10.1016/0166-2236(89)90097-0; Peters C, 1999, SCIENCE, V285, P1084, DOI 10.1126/science.285.5430.1084; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Quetglas S, 2000, P NATL ACAD SCI USA, V97, P9695, DOI 10.1073/pnas.97.17.9695; Reim K, 2001, CELL, V104, P71, DOI 10.1016/S0092-8674(01)00192-1; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; Scales SJ, 2000, NEURON, V26, P457, DOI 10.1016/S0896-6273(00)81177-0; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STEINHARDT RA, 1982, NATURE, V295, P154, DOI 10.1038/295154a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tokumaru H, 2001, CELL, V104, P421, DOI 10.1016/S0092-8674(01)00229-X; VONRUDEN L, 1993, SCIENCE, V262, P1061, DOI 10.1126/science.8235626; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Yakel JL, 1997, TRENDS PHARMACOL SCI, V18, P124, DOI 10.1016/S0165-6147(97)01046-8; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	48	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26680	26687		10.1074/jbc.M103522200	http://dx.doi.org/10.1074/jbc.M103522200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11359785	hybrid			2022-12-25	WOS:000169823300134
J	Mitsutake, S; Tani, M; Okino, N; Mori, K; Ichinose, S; Omori, A; Iida, H; Nakamura, T; Ito, M				Mitsutake, S; Tani, M; Okino, N; Mori, K; Ichinose, S; Omori, A; Iida, H; Nakamura, T; Ito, M			Purification, characterization, molecular cloning, and subcellular distribution of neutral ceramidase of rat kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR PROLIFERATION; ALKALINE CERAMIDASE; ACID CERAMIDASE; SPHINGOSINE; SPHINGOSINE-1-PHOSPHATE; CHOLESTEROL; PROTEINS; EXPRESSION; COMPLEX; ANTIGEN	Previously, we reported two types of neutral ceramidase in mice, one solubilized by freeze-thawing and one not. The former was purified as a 94-kDa protein from mouse liver, and cloned (Tani, M., Okino, N., Mori, K., Tanigawa, T., Izu, H., and Ito, M. (2000) J. Biol. Chem, 275, 11229-11234), In this paper, we describe the purification, molecular cloning, and subcellular distribution of a 112-kDa membrane-bound neutral ceramidase of rat kidney, which was completely insoluble by freeze-thawing. The open reading frame of the enzyme encoded a polypeptide of 761 amino acids having nine putative N-glycosylation sites and one possible transmembrane domain. In the ceramidase overexpressing HEK293 cells, 133-kDa (Golgi-form) and 113-kDa (endoplasmic reticulum-form) Myc-tagged ceramidases were detected, whereas these two proteins were converted to a 87-kDa protein concomitantly with loss of activity when expressed in the presence of tunicamycin, indicating that the N-glycosylation process is indispensable for the expression of the enzyme activity. Immunohistochemical analysis clearly showed that the ceramidase was mainly localized at the apical membrane of proximal tubules, distal tubules, and collecting ducts in rat kidney, while in liver the enzyme was distributed with endosome-like organelles in hepatocytes. Interestingly, the kidney ceramidase was found to be enriched in the raft microdomains with cholesterol and GM1 ganglioside.	Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Dept Biosci & Biotechnol, Higashi Ku, Fukuoka 8128581, Japan; Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Dept Appl Genet & Pest Management, Higashi Ku, Fukuoka 8128581, Japan; Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 1948511, Japan	Kyushu University; Kyushu University	Ito, M (corresponding author), Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Dept Biosci & Biotechnol, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	makotoi@agr.kyushu-u.ac.jp	Mitsutake, Susumu/A-4082-2012; Okino, Nozomu/AAY-2635-2021; Ito, Makoto/Q-6164-2019	ito, Makoto/0000-0003-3159-7818; Tani, Motohiro/0000-0003-4316-8260				Aguilar RC, 2001, J BIOL CHEM, V276, P13145, DOI 10.1074/jbc.M010591200; ANI M, 2000, J BIOL CHEM, V275, P11229; BENDALL DS, 1960, BIOCHEM J, V74, P444, DOI 10.1042/bj0740444; BERNARDO K, 1995, J BIOL CHEM, V270, P11098, DOI 10.1074/jbc.270.19.11098; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; El Bawab S, 1999, J BIOL CHEM, V274, P27948, DOI 10.1074/jbc.274.39.27948; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; GAMBLE W, 1978, J LIPID RES, V19, P1068; HAKOMORI S, 1995, J BIOCHEM, V118, P1091, DOI 10.1093/oxfordjournals.jbchem.a124992; Hansen GH, 2000, J BIOL CHEM, V275, P5136, DOI 10.1074/jbc.275.7.5136; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; Hatt PD, 1997, EUR J BIOCHEM, V246, P336, DOI 10.1111/j.1432-1033.1997.00336.x; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; Ito M, 2000, METHOD ENZYMOL, V311, P682; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Kupperman E, 2000, NATURE, V406, P192, DOI 10.1038/35018092; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Li CM, 1998, GENOMICS, V50, P267, DOI 10.1006/geno.1998.5334; Mao CG, 2000, J BIOL CHEM, V275, P6876, DOI 10.1074/jbc.275.10.6876; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; NEWMAN LS, 1995, CELL, V82, P773, DOI 10.1016/0092-8674(95)90474-3; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OHTA H, 1995, CANCER RES, V55, P691; OKAZAKI T, 1990, J BIOL CHEM, V265, P3125; Okino N, 1998, J BIOL CHEM, V273, P14368, DOI 10.1074/jbc.273.23.14368; Okino N, 1999, J BIOL CHEM, V274, P36616, DOI 10.1074/jbc.274.51.36616; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; Romiti E, 2000, BIOCHEM BIOPH RES CO, V275, P746, DOI 10.1006/bbrc.2000.3370; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Sambrook H., 1989, MOL CLONING LAB MANU; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; SUGITA M, 1972, SCIENCE, V178, P1100, DOI 10.1126/science.178.4065.1100; SYMONS LJ, 1987, ANAL BIOCHEM, V164, P382, DOI 10.1016/0003-2697(87)90508-2; Tani M, 2000, J BIOL CHEM, V275, P3462, DOI 10.1074/jbc.275.5.3462; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; YADA Y, 1995, J BIOL CHEM, V270, P12677, DOI 10.1074/jbc.270.21.12677; ZHANG H, 1990, J BIOL CHEM, V265, P76	48	90	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26249	26259		10.1074/jbc.M102233200	http://dx.doi.org/10.1074/jbc.M102233200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11328816	hybrid			2022-12-25	WOS:000169823300082
J	MacDonald, NJ; Shivers, WY; Narum, DL; Plum, SM; Wingard, JN; Fuhrmann, SR; Liang, H; Holland-Linn, J; Chen, DHT; Sim, BKL				MacDonald, NJ; Shivers, WY; Narum, DL; Plum, SM; Wingard, JN; Fuhrmann, SR; Liang, H; Holland-Linn, J; Chen, DHT; Sim, BKL			Endostatin binds tropomyosin - A potential modulator of the antitumor activity of endostatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; ANGIOGENESIS INHIBITOR; KINETIC-ANALYSIS; GROWTH-FACTOR; AFFINITY; FIBRONECTIN; CD2	The mechanism of action of Endostatin, an endogenous inhibitor of angiogenesis and tumor growth, remains unknown. We utilized phage-display technology to identify polypeptides that mimic the binding domains of proteins with which Endostatin interacts. A conformed peptide (E37) was identified that shares an epitope with human tropomyosin implicating tropomyosin as an Endostatin-binding protein. We show that recombinant human Endostatin binds tropomyosin in vitro and to tropomyosin-associated microfilaments in a variety of endothelial cell types. The most compelling evidence that tropomyosin modulates the activity of Endostatin was demonstrated when E37 blocked greater than 84% of the tumor-growth inhibitory activity of Endostatin in the B16-BL6 metastatic melanoma model. We conclude that the E37 peptide mimics the Endostatinbinding epitope of tropomyosin and blocks the antitumor activity of Endostatin by competing for Endostatin binding. We postulate that the Endostatin interaction with tropomyosin results in disruption of microfilament integrity leading to inhibition of cell motility, induction of apoptosis, and ultimately inhibition of tumor growth.	EntreMed Inc, Rockville, MD 20850 USA		Sim, BKL (corresponding author), EntreMed Inc, 9640 Med Ctr Dr, Rockville, MD 20850 USA.	kims@entremed.com		Narum, David/0000-0003-3041-5402				Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; Berger AC, 2000, J SURG RES, V91, P26, DOI 10.1006/jsre.2000.5890; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Bloch W, 2000, FASEB J, V14, P2373; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; DeMeester SL, 1998, SURGERY, V124, P362, DOI 10.1016/S0039-6060(98)70142-4; Dhanabal M, 1999, BIOCHEM BIOPH RES CO, V258, P345, DOI 10.1006/bbrc.1999.0595; Dhanabal M, 1999, CANCER RES, V59, P189; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; Dike LE, 1999, IN VITRO CELL DEV-AN, V35, P441; Dixelius J, 2000, BLOOD, V95, P3403, DOI 10.1182/blood.V95.11.3403.011k07_3403_3411; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Huang S, 1998, MOL BIOL CELL, V9, P3179, DOI 10.1091/mbc.9.11.3179; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; INGBER DE, 1990, J CELL BIOL, V110, P1803, DOI 10.1083/jcb.110.5.1803; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; Kesari KV, 1999, CLIN EXP IMMUNOL, V118, P219; Lin J J, 1997, Int Rev Cytol, V170, P1, DOI 10.1016/S0074-7696(08)61619-8; Moldovan L, 2000, CIRC RES, V86, P549, DOI 10.1161/01.RES.86.5.549; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Moses MA, 1999, P NATL ACAD SCI USA, V96, P2645, DOI 10.1073/pnas.96.6.2645; Nicholson MW, 1998, J BIOL CHEM, V273, P763, DOI 10.1074/jbc.273.2.763; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8; Pourati J, 1998, AM J PHYSIOL-CELL PH, V274, pC1283, DOI 10.1152/ajpcell.1998.274.5.C1283; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; Shuster CB, 1998, MICROCIRCULATION, V5, P239; Silkowski H, 1997, EUR BIOPHYS J BIOPHY, V25, P455, DOI 10.1007/s002490050060; Sim B K, 1999, Angiogenesis, V3, P41, DOI 10.1023/A:1009058931769; Sim BKL, 2000, CANCER METAST REV, V19, P181, DOI 10.1023/A:1026551202548; VANDERMERWE PA, 1993, EMBO J, V12, P4945, DOI 10.1002/j.1460-2075.1993.tb06188.x	32	113	139	1	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25190	25196		10.1074/jbc.M100743200	http://dx.doi.org/10.1074/jbc.M100743200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11335715	hybrid			2022-12-25	WOS:000169800700102
J	Haghighi, K; Schmidt, AG; Hoit, B; Brittsan, AG; Yatani, A; Lester, JW; Zhai, J; Kimura, Y; Dorn, GW; MacLennan, DH; Kranias, EG				Haghighi, K; Schmidt, AG; Hoit, B; Brittsan, AG; Yatani, A; Lester, JW; Zhai, J; Kimura, Y; Dorn, GW; MacLennan, DH; Kranias, EG			Superinhibition of sarcoplasmic reticulum function by phospholamban induces cardiac contractile failure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEFT-VENTRICULAR FUNCTION; HEART-FAILURE; GENDER-DIFFERENCES; AORTIC-STENOSIS; CA2+ CHANNELS; CALCIUM; CA2+-ATPASE; GENE; PHOSPHORYLATION; HYPERTROPHY	To determine whether selective impairment of cardiac sarcoplasmic reticulum (SR) Ca2+ transport may drive the progressive functional deterioration leading to heart failure, transgenic mice, overexpressing a phospholamban Val(49) --> Gly mutant (2-fold), which is a superinhibitor of SR Ca2+-ATPase affinity for Ca2+, were generated, and their cardiac phenotype was examined longitudinally. At 3 months of age, the increased EC50 level of SR Ca2+ uptake for Ca2+ (0.67 +/- 0.09 mum) resulted in significantly higher depression of cardiomyocyte rates of shortening (57%), relengthening (31%), and prolongation of the Ca2+ signal decay time (165%) than overexpression (2-fold) of wild type phospholamban (68%, 64%, and 125%, respectively), compared with controls (100%). Echocardiography also revealed significantly depressed function and impaired beta -adrenergic responses in mutant hearts. The depressed contractile parameters were associated with left ventricular remodeling, recapitulation of fetal gene expression, and hypertrophy, which progressed to dilated cardiomyopathy with interstitial tissue fibrosis and death by 6 months in males. Females also had ventricular hypertrophy at 3 months but exhibited normal systolic function up to 12 months of age. These results suggest a causal relationship between defective SR Ca2+ cycling and cardiac remodeling leading to heart failure, with a gender-dependent influence on the time course of these alterations.	Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Div Cardiol, Cincinnati, OH 45267 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada	University System of Ohio; University of Cincinnati; Case Western Reserve University; University of Toronto	Kranias, EG (corresponding author), Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Div Cardiol, 231 A Sabin Way, Cincinnati, OH 45267 USA.	Litsa.Kranias@uc.edu			NHLBI NIH HHS [HL-64018, HL-26057, HL52318] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL026057, R01HL064018, R01HL026057, P50HL052318] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams KF, 1999, CIRCULATION, V99, P1816, DOI 10.1161/01.CIR.99.14.1816; Bristow MR, 1998, LANCET, V352, P8; BUTTRICK P, 1992, CIRCULATION, V86, P1336, DOI 10.1161/01.CIR.86.4.1336; Chien KR, 2000, J CLIN INVEST, V105, P1339, DOI 10.1172/JCI10079; Chien KR, 1999, CELL, V98, P555, DOI 10.1016/S0092-8674(00)80043-4; Chu GX, 1996, CIRC RES, V79, P1064, DOI 10.1161/01.RES.79.6.1064; Cornea RL, 2000, J BIOL CHEM, V275, P41487, DOI 10.1074/jbc.M008195200; DONNER R, 1983, AM J CARDIOL, V51, P946, DOI 10.1016/S0002-9149(83)80171-4; FELDMAN AM, 1993, CIRC RES, V73, P184, DOI 10.1161/01.RES.73.1.184; Grohe C, 1997, FEBS LETT, V416, P107, DOI 10.1016/S0014-5793(97)01179-4; GROSSMAN W, 1980, AM J MED, V69, P576, DOI 10.1016/0002-9343(80)90471-4; Hasenfuss G, 1998, CARDIOVASC RES, V39, P60, DOI 10.1016/S0008-6363(98)00110-2; HOIT BD, 1995, CIRC RES, V77, P632, DOI 10.1161/01.RES.77.3.632; Houser SR, 2000, J MOL CELL CARDIOL, V32, P1595, DOI 10.1006/jmcc.2000.1206; JONES LR, 1993, J BIOL CHEM, V268, P11486; Ju YK, 1999, J PHYSIOL-LONDON, V516, P793, DOI 10.1111/j.1469-7793.1999.0793u.x; Kadambi VJ, 1996, J CLIN INVEST, V97, P533, DOI 10.1172/JCI118446; Kadokami T, 2000, J CLIN INVEST, V106, P589, DOI 10.1172/JCI9307; Kimura Y, 1996, J BIOL CHEM, V271, P21726, DOI 10.1074/jbc.271.36.21726; Kimura Y, 1998, J BIOL CHEM, V273, P14238, DOI 10.1074/jbc.273.23.14238; KOENIG H, 1982, CIRC RES, V50, P782, DOI 10.1161/01.RES.50.6.782; Koss KL, 1997, BASIC RES CARDIOL, V92, P17, DOI 10.1007/BF00794064; Koss KL, 1996, CIRC RES, V79, P1059, DOI 10.1161/01.RES.79.6.1059; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; Lorell BH, 2000, CIRCULATION, V102, P470; Luo WS, 1998, J BIOL CHEM, V273, P4734, DOI 10.1074/jbc.273.8.4734; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; Masaki H, 1997, AM J PHYSIOL-HEART C, V272, pH606, DOI 10.1152/ajpheart.1997.272.2.H606; MEYER M, 1995, CIRCULATION, V92, P778, DOI 10.1161/01.CIR.92.4.778; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; MORGAN JP, 1991, NEW ENGL J MED, V325, P625; SCHAIBLE TF, 1984, CIRC RES, V54, P38, DOI 10.1161/01.RES.54.1.38; Schmidt U, 1999, AM J PHYSIOL-HEART C, V277, pH474, DOI 10.1152/ajpheart.1999.277.2.H474; Schwinger RHG, 1999, J MOL CELL CARDIOL, V31, P479, DOI 10.1006/jmcc.1998.0897; SHAM JSK, 1995, P NATL ACAD SCI USA, V92, P121, DOI 10.1073/pnas.92.1.121; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; TADA M, 1982, MOL CELL BIOCHEM, V46, P73; Tada M, 1998, ANN NY ACAD SCI, V853, P116, DOI 10.1111/j.1749-6632.1998.tb08261.x; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; WEGENER AD, 1989, J BIOL CHEM, V264, P11468; Weinberg EO, 1997, CIRCULATION, V95, P1592; Weinberg EO, 1999, J AM COLL CARDIOL, V34, P264, DOI 10.1016/S0735-1097(99)00165-5; Zhai J, 2000, J BIOL CHEM, V275, P10538, DOI 10.1074/jbc.275.14.10538; Zvaritch E, 2000, J BIOL CHEM, V275, P14985, DOI 10.1074/jbc.275.20.14985	44	94	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24145	24152		10.1074/jbc.M102403200	http://dx.doi.org/10.1074/jbc.M102403200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11328820	hybrid			2022-12-25	WOS:000169531100122
J	Yu, ZB; Lai, CM; Maoui, M; Banville, D; Shen, SH				Yu, ZB; Lai, CM; Maoui, M; Banville, D; Shen, SH			Identification and characterization of S2V, a novel putative siglec that contains two V set Ig-like domains and recruits protein-tyrosine phosphatases SHPs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BINDING-SITE; HEMATOPOIETIC-CELL PHOSPHATASE; MYELIN-ASSOCIATED GLYCOPROTEIN; INHIBITORY RECEPTOR; SH2 DOMAIN; MOLECULAR-CLONING; SIALOADHESIN; ACTIVATION; MEMBER; CD33	We describe the molecular cloning and characterization of S2V, a novel sialic acid binding immunoglobulin-like lectin. The cDNA of S2V encodes a type 1 transmembrane protein with four extracellular immunoglobulin-like (Pg-like) domains and a cytoplasmic tail bearing a typical immunoreceptor tyrosine-based inhibitory motif (ITIM) and an ITIM-like motif. A unique feature of S2V is the presence of two V-set Ig-like domains responsible for the binding to sialic acid, whereas all other known siglecs possess only one. S2V is predominantly expressed in macrophage. In vivo S2V was tyrosine-phosphorylated. when co-expressed with exogenous c-Src kinase. Upon tyrosine phosphorylation, S2V recruits both Src homology 2 (SK2) domain-containing protein-tyrosine phosphatases SHP-1 and SHP-2, two important inhibitory regulators of immunoreceptor signal transduction. These findings suggest that S2V is involved in the negative regulation of the signaling in macrophage by functioning as an inhibitory receptor. When expressed in COS-7 cells, S2V was able to mediate sialic acid-dependent binding to human red blood cells, suggesting that S2V may function through cell-cell interaction.	Natl Res Council Canada, Biotechnol Res Inst, Pharmaceut Sector, Montreal, PQ H4P 2R2, Canada; Univ Montreal, Dept Pathol & Microbiol, St Hyacinthe, PQ J2S 7C6, Canada	National Research Council Canada; Universite de Montreal	Shen, SH (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, Pharmaceut Sector, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	shi.shen@nrc.ca						Angata T, 2000, J BIOL CHEM, V275, P22127, DOI 10.1074/jbc.M002775200; Angata T, 2000, GLYCOBIOLOGY, V10, P431, DOI 10.1093/glycob/10.4.431; ARQUINT M, 1987, P NATL ACAD SCI USA, V84, P600, DOI 10.1073/pnas.84.2.600; Bakker ABH, 2000, HUM IMMUNOL, V61, P18, DOI 10.1016/S0198-8859(99)00160-3; Blery M, 2000, HUM IMMUNOL, V61, P51, DOI 10.1016/S0198-8859(99)00157-3; BOUCHARD P, 1994, J BIOL CHEM, V269, P19585; Bruhns P, 1999, J IMMUNOL, V162, P3168; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Cornish AL, 1998, BLOOD, V92, P2123, DOI 10.1182/blood.V92.6.2123.418k20_2123_2132; Crocker PR, 1996, BIOCHEM SOC T, V24, P150, DOI 10.1042/bst0240150; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; DAVID M, 1995, MOL CELL BIOL, V15, P7050; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; Falco M, 1999, J EXP MED, V190, P793, DOI 10.1084/jem.190.6.793; Floyd H, 2000, J BIOL CHEM, V275, P861, DOI 10.1074/jbc.275.2.861; Hua CT, 1998, J BIOL CHEM, V273, P28332, DOI 10.1074/jbc.273.43.28332; Keegan K, 1996, ONCOGENE, V12, P1537; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KonKozlowski M, 1996, J BIOL CHEM, V271, P3856; LAI C, 1987, P NATL ACAD SCI USA, V84, P4337, DOI 10.1073/pnas.84.12.4337; May AP, 1998, MOL CELL, V1, P719, DOI 10.1016/S1097-2765(00)80071-4; Meyaard L, 1997, IMMUNITY, V7, P283, DOI 10.1016/S1074-7613(00)80530-0; Mousseau DD, 2000, J BIOL CHEM, V275, P4467, DOI 10.1074/jbc.275.6.4467; NATH D, 1995, J BIOL CHEM, V270, P26184, DOI 10.1074/jbc.270.44.26184; Nicoll G, 1999, J BIOL CHEM, V274, P34089, DOI 10.1074/jbc.274.48.34089; Patel N, 1999, J BIOL CHEM, V274, P22729, DOI 10.1074/jbc.274.32.22729; Paul SP, 2000, BLOOD, V96, P483; POWELL LD, 1995, J BIOL CHEM, V270, P14234; SALZER JL, 1987, J CELL BIOL, V104, P957, DOI 10.1083/jcb.104.4.957; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SIMMONS D, 1988, J IMMUNOL, V141, P2797; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; Tamir I, 2000, CURR OPIN IMMUNOL, V12, P307, DOI 10.1016/S0952-7915(00)00092-3; Tang S, 1997, J CELL BIOL, V138, P1355, DOI 10.1083/jcb.138.6.1355; Tangye SG, 1999, J IMMUNOL, V162, P6981; Taylor VC, 1999, J BIOL CHEM, V274, P11505, DOI 10.1074/jbc.274.17.11505; Ulyanova T, 1999, EUR J IMMUNOL, V29, P3440, DOI 10.1002/(SICI)1521-4141(199911)29:11<3440::AID-IMMU3440>3.3.CO;2-3; vanderMerwe PA, 1996, J BIOL CHEM, V271, P9273, DOI 10.1074/jbc.271.16.9273; Vinson M, 1996, J BIOL CHEM, V271, P9267, DOI 10.1074/jbc.271.16.9267; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; Yu ZB, 1998, J BIOL CHEM, V273, P3687, DOI 10.1074/jbc.273.6.3687; Yu ZB, 2001, BIOCHEM J, V353, P483, DOI 10.1042/0264-6021:3530483; Zhang JQ, 2000, J BIOL CHEM, V275, P22121, DOI 10.1074/jbc.M002788200; Zhang JY, 1999, J IMMUNOL, V162, P6359	50	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23816	23824		10.1074/jbc.M102394200	http://dx.doi.org/10.1074/jbc.M102394200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11328818	hybrid			2022-12-25	WOS:000169531100080
J	Ammit, AJ; Hastie, AT; Edsall, LC; Hoffman, RK; Amrani, Y; Krymskaya, VP; Kane, SA; Peters, SP; Penn, RB; Spiegel, S; Panettieri, RA				Ammit, AJ; Hastie, AT; Edsall, LC; Hoffman, RK; Amrani, Y; Krymskaya, VP; Kane, SA; Peters, SP; Penn, RB; Spiegel, S; Panettieri, RA			Sphingosine 1-phosphate modulates human airway smooth muscle cell functions that promote inflammation and airway remodeling in asthma	FASEB JOURNAL			English	Article									Univ Penn, Med Ctr, Dept Med, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Div Pulm & Crit Care Med, Philadelphia, PA 19107 USA; Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	University of Pennsylvania; Jefferson University; Georgetown University; Jefferson University	Panettieri, RA (corresponding author), Univ Penn, Med Ctr, Dept Med, Pulm Allergy & Crit Care Div, 805 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.		Amrani, Yassine/Q-6323-2019; panettieri, reynold/AAG-9485-2019; Amrani, Yassine/A-1826-2013	Amrani, Yassine/0000-0002-7042-6926; Ammit, Alaina/0000-0003-0555-2544					0	259	268	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1212	1214		10.1096/fj.00-0742fje	http://dx.doi.org/10.1096/fj.00-0742fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344091				2022-12-25	WOS:000168655200013
J	Navarro-Antolin, J; Lopez-Munoz, MJ; Klatt, P; Soria, J; Michel, T; Lamas, S				Navarro-Antolin, J; Lopez-Munoz, MJ; Klatt, P; Soria, J; Michel, T; Lamas, S			Formation of peroxynitrite in vascular endothelial cells exposed to cyclosporine A	FASEB JOURNAL			English	Article									CSIC, Ctr Invest Biol, E-28006 Madrid, Spain; CSIC, Inst Reina Sofia Invest Nefrol, E-28006 Madrid, Spain; CSIC, Inst Catalisis & Petroleoquim, E-28006 Madrid, Spain; Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Catalisis y Petroleoquimica (ICP); Harvard University; Brigham & Women's Hospital; Harvard Medical School	Lamas, S (corresponding author), CSIC, Ctr Invest Biol, C Velazquez 144, E-28006 Madrid, Spain.		Lamas, Santiago/G-7308-2015	Lamas, Santiago/0000-0001-5166-4155; Lopez-Munoz, Maria-Jose/0000-0002-8323-7315					0	45	49	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1291	1293		10.1096/fj.00-0636fje	http://dx.doi.org/10.1096/fj.00-0636fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344117				2022-12-25	WOS:000168655200039
J	Zangger, K; Oz, G; Haslinger, E; Kunert, O; Armitage, IM				Zangger, K; Oz, G; Haslinger, E; Kunert, O; Armitage, IM			Nitric oxide selectively releases metals from the amino-terminal domain of metallothioneins: potential role at inflammatory sites	FASEB JOURNAL			English	Article									Graz Univ, Inst Pharmaceut Chem, A-8010 Graz, Austria; Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	University of Graz; University of Minnesota System; University of Minnesota Twin Cities	Zangger, K (corresponding author), Graz Univ, Inst Chem Organ & Bioorgan Chem, Heinrichstr 28, A-8010 Graz, Austria.		Oz, Gulin/L-1306-2016	Oz, Gulin/0000-0002-5769-183X; Kunert, Olaf/0000-0002-7091-5973; Zangger, Klaus/0000-0003-1682-1594					0	84	88	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1303	1305		10.1096/fj.00-0641fje	http://dx.doi.org/10.1096/fj.00-0641fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344121				2022-12-25	WOS:000168655200043
J	Weggen, S; Preuss, U; Pietsch, T; Hilger, N; Klawitz, I; Scheidtmann, KH; Wiestler, OD; Bayer, TA				Weggen, S; Preuss, U; Pietsch, T; Hilger, N; Klawitz, I; Scheidtmann, KH; Wiestler, OD; Bayer, TA			Identification of amplified genes from SV40 large T antigen-induced rat PNET cell lines by subtractive cDNA analysis and radiation hybrid mapping	ONCOGENE			English	Article						SV40 large T antigen; amplification; suppression subtractive hybridization; radiation hybrid mapping; cytosolic branched chain aminotransferase	PRIMITIVE NEUROECTODERMAL TUMORS; C-MYC; BINDING; IMMORTALIZATION; TUMORIGENESIS; EXPRESSION; MODELS; MAPS; UNR	Primitive neuroectodermal tumors (PNETs) such as human medulloblastomas are genetically heterogeneous and therefore poorly understood, In a rat model the SV40 large T antigen was used to induce neoplasms with characteristic features of PNETs, Tumor development requires a latency period of 8-11 months implicating secondary genetic alterations. To identify such secondary alterations we performed comparative analyses of two phenotypically identical PNET-derived eel lines. Indeed, these cell Lines displayed distinct high-level amplification sites. Using a combination of subtractive cDNA analysis and radiation hybrid mapping we have now identified genes in the amplicon regions of the two cell lines. Interestingly, one of these genes encodes the rat homolog of a cytosolic branched chain aminotransferase (BCAT(C)) previously shown to be amplified in a mouse teratocarcinoma cell line. We propose that this simple cloning strategy may serve as a powerful tool for the isolation of genes implicated in known chromosomal aberrations in primary tumors and tumor cell lines.	Univ Bonn, Genet Inst, D-53117 Bonn, Germany; Univ Bonn, Inst Psychol, D-53117 Bonn, Germany; Univ Bonn, Med Ctr, Dept Psychiat, D-53105 Bonn, Germany; Univ Bonn, Med Ctr, Dept Neuropathol, D-53105 Bonn, Germany	University of Bonn; University of Bonn; University of Bonn; University of Bonn	Preuss, U (corresponding author), Univ Bonn, Genet Inst, Roemerstr 164, D-53117 Bonn, Germany.							Banga SS, 1997, ONCOGENE, V14, P313, DOI 10.1038/sj.onc.1200842; Bayer TA, 1999, ACTA NEUROPATHOL, V97, P607, DOI 10.1007/s004010051036; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BenYosef T, 1996, ONCOGENE, V13, P1859; BOEHNKE M, 1991, AM J HUM GENET, V49, P1174; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; DESTOPPELAAR JM, 1994, CYTOGENET CELL GENET, V67, P23, DOI 10.1159/000133718; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; EIBL RH, 1994, AM J PATHOL, V144, P556; Ferrer N, 1999, DNA CELL BIOL, V18, P209, DOI 10.1089/104454999315420; FREDERIKSEN K, 1988, NEURON, V1, P439, DOI 10.1016/0896-6273(88)90175-4; FUNG KM, 1995, J NEUROPATH EXP NEUR, V54, P285, DOI 10.1097/00005072-199505000-00001; Furth PA, 1998, DEV BIOL STAND, V94, P281; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HALL TR, 1993, J BIOL CHEM, V268, P3092; HELD WA, 1994, CANCER RES, V54, P6489; HELD WA, 1994, CANCER RES, V54, P6496; Hutson SM, 1995, J BIOL CHEM, V270, P30344, DOI 10.1074/jbc.270.51.30344; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; JEFFERS M, 1990, NUCLEIC ACIDS RES, V18, P4891; Kappler R, 1999, CARCINOGENESIS, V20, P1433, DOI 10.1093/carcin/20.8.1433; Kholodilov NG, 2000, MOL BRAIN RES, V75, P281, DOI 10.1016/S0169-328X(99)00318-6; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; LUDLOW JW, 1995, VIRUS RES, V35, P113, DOI 10.1016/0168-1702(94)00094-S; McCormick Frank, 1999, Trends in Cell Biology, V9, pM53, DOI 10.1016/S0962-8924(99)01668-2; MORIYAMA T, 1994, FEBS LETT, V353, P305, DOI 10.1016/0014-5793(94)01064-1; NIWA O, 1990, NUCLEIC ACIDS RES, V18, P6709, DOI 10.1093/nar/18.22.6709; Salewski H, 1999, CANCER RES, V59, P1980; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sargent LM, 1997, CANCER RES, V57, P3451; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; Steen RG, 1999, GENOME RES, V9, pAP1; Weggen S, 1997, BRAIN PATHOL, V7, P731, DOI 10.1111/j.1750-3639.1997.tb01059.x	33	9	9	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2001	20	16					2023	2031		10.1038/sj.onc.1204287	http://dx.doi.org/10.1038/sj.onc.1204287			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360186				2022-12-25	WOS:000168043800010
J	Li, N; Zhang, WP; Wan, T; Zhang, J; Chen, TY; Yu, YZ; Wang, JL; Cao, XT				Li, N; Zhang, WP; Wan, T; Zhang, J; Chen, TY; Yu, YZ; Wang, JL; Cao, XT			Cloning and characterization of Siglec-10, a novel sialic acid binding member of the Ig superfamily, from human dendritic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; PROTEIN-TYROSINE PHOSPHATASES; MOLECULAR-CLONING; INHIBITORY RECEPTOR; SIALOADHESIN FAMILY; NEGATIVE REGULATOR; B-CELLS; CD22; IDENTIFICATION; CD33	The Siglecs (sialic acid-binding Ig-like lectins) are a subfamily of I-type lectins, which specifically recognize sialic acids. Nine members of the family have been identified thus far. We have obtained a novel cDNA clone from a human dendritic cell cDNA library encoding a protein with sequence and structural features of the Siglec family, hence designated as Siglec-10. The full-length Siglec-10 cDNA encodes a type I transmembrane protein containing four extracellular immunoglobulinlike domains, a transmembrane region, and a cytoplasmic tail with two classical immunoreceptor tyrosine-based inhibitory motifs. The N-terminal V-set Ig domain has most of the amino acid residues typical of the Siglecs. Siglec-10 shows the closest homology to Siglec-5 and Siglec-3/CD33. Various cells and cell lines including monocytes and dendritic cells express Siglec-10. High levels of mRNA expression were seen in peripheral blood leukocytes, spleen, and liver. When expressed on COS-7 cells, Siglec-10 was able to bind human red blood cells and soluble sialoglycoconjugates in a sialic acid-dependent manner. The identification of Siglec-1-0 as a new Siglec family member and its expression profile, together with its sialic acid-dependent binding capacity, suggest that it may be involved in cell-cell recognition by interacting with sialylated ligands expressed on specific cell populations.	Second Mil Med Univ, Inst Immunol, Shanghai 200433, Peoples R China; Zhejiang Univ, Inst Immunol, Hangzhou 310031, Zhejiang, Peoples R China	Naval Medical University; Zhejiang University	Cao, XT (corresponding author), Second Mil Med Univ, Inst Immunol, 800 Xiangyin Rd, Shanghai 200433, Peoples R China.	caoxt@public3.sta.net.cn	yu, yizhi/ADP-7854-2022					Angata T, 2000, J BIOL CHEM, V275, P22127, DOI 10.1074/jbc.M002775200; Angata T, 2000, GLYCOBIOLOGY, V10, P431, DOI 10.1093/glycob/10.4.431; Bolland S, 1999, ADV IMMUNOL, V72, P149, DOI 10.1016/S0065-2776(08)60019-X; Borges L, 1997, J IMMUNOL, V159, P5192; Cao XT, 2000, J IMMUNOL, V165, P2588, DOI 10.4049/jimmunol.165.5.2588; Cornish AL, 1998, BLOOD, V92, P2123, DOI 10.1182/blood.V92.6.2123.418k20_2123_2132; Crocker P R, 1998, Glycobiology, V8, pv; Crocker PR, 1996, BIOCHEM SOC T, V24, P150, DOI 10.1042/bst0240150; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; Dupont B, 1997, TISSUE ANTIGENS, V49, P557, DOI 10.1111/j.1399-0039.1997.tb02802.x; Falco M, 1999, J EXP MED, V190, P793, DOI 10.1084/jem.190.6.793; Floyd H, 2000, J BIOL CHEM, V275, P861, DOI 10.1074/jbc.275.2.861; Foussias G, 2000, GENOMICS, V67, P171, DOI 10.1006/geno.2000.6208; FREEMAN SD, 1995, BLOOD, V85, P2005, DOI 10.1182/blood.V85.8.2005.bloodjournal8582005; Hua CT, 1998, J BIOL CHEM, V273, P28332, DOI 10.1074/jbc.273.43.28332; Huber M, 1999, J BIOL CHEM, V274, P335, DOI 10.1074/jbc.274.1.335; JARAMILLO ML, 1994, J BIOL CHEM, V269, P27240; KELM S, 1994, GLYCOCONJUGATE J, V11, P576, DOI 10.1007/BF00731309; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; Kikly KK, 2000, J ALLERGY CLIN IMMUN, V105, P1093, DOI 10.1067/mai.2000.107127; LAW CL, 1995, J IMMUNOL, V155, P3368; May VR, 1998, NEUROREHABILITATION, V11, P1; Munday J, 2001, BIOCHEM J, V355, P489, DOI 10.1042/0264-6021:3550489; NATH D, 1995, J BIOL CHEM, V270, P26184, DOI 10.1074/jbc.270.44.26184; Newman PJ, 1999, J CLIN INVEST, V103, P5, DOI 10.1172/JCI5928; Nicoll G, 1999, J BIOL CHEM, V274, P34089, DOI 10.1074/jbc.274.48.34089; Nitschke L, 1997, CURR BIOL, V7, P133, DOI 10.1016/S0960-9822(06)00057-1; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; Otipoby KL, 1996, NATURE, V384, P634, DOI 10.1038/384634a0; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Patel N, 1999, J BIOL CHEM, V274, P22729, DOI 10.1074/jbc.274.32.22729; PEDRAZA L, 1990, J CELL BIOL, V111, P2651, DOI 10.1083/jcb.111.6.2651; PEIPER SC, 1988, BLOOD, V72, P314; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; SGROI D, 1993, J BIOL CHEM, V268, P7011; Takei Y, 1997, CYTOGENET CELL GENET, V78, P295, DOI 10.1159/000134676; Tang S, 1997, J CELL BIOL, V138, P1355, DOI 10.1083/jcb.138.6.1355; Taylor VC, 1999, J BIOL CHEM, V274, P11505, DOI 10.1074/jbc.274.17.11505; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tropak MB, 1997, J NEUROCHEM, V68, P1753; Ulyanova T, 1999, EUR J IMMUNOL, V29, P3440, DOI 10.1002/(SICI)1521-4141(199911)29:11<3440::AID-IMMU3440>3.3.CO;2-3; Unkeless JC, 1997, CURR OPIN IMMUNOL, V9, P338, DOI 10.1016/S0952-7915(97)80079-9; vanderMerwe PA, 1996, J BIOL CHEM, V271, P9273, DOI 10.1074/jbc.271.16.9273; Vely F, 1997, J IMMUNOL, V159, P2075; Vinson M, 1996, J BIOL CHEM, V271, P9267, DOI 10.1074/jbc.271.16.9267; Wende H, 1999, MAMM GENOME, V10, P154, DOI 10.1007/s003359900961; Zhang JQ, 2000, J BIOL CHEM, V275, P22121, DOI 10.1074/jbc.M002788200	49	73	78	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28106	28112		10.1074/jbc.M100467200	http://dx.doi.org/10.1074/jbc.M100467200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11358961	hybrid			2022-12-25	WOS:000170093400049
J	Potapova, O; Basu, S; Mercola, D; Holbrook, NJ				Potapova, O; Basu, S; Mercola, D; Holbrook, NJ			Protective role for c-Jun in the cellular response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; ACTIVATION DOMAIN; CYCLE PROGRESSION; INDUCED APOPTOSIS; PROTEIN-KINASE; MEK KINASE-1; PHOSPHORYLATION; INDUCTION; AP-1; JNK	c-Jun, a member of the activation protein 1 (AP-1) family of transcription factors, has been implicated in the regulation of many important biological processes including cell cycle progression, transformation, differentiation, and apoptosis. Accordingly, its expression and function are upregulated in response to diverse stimuli including mitogens and a wide range of stresses. Transcriptional activation of the e-Jun protein is dependent on its phosphorylation at Ser-63 and Ser-73, process mediated by c-Jun N-terminal kinase. Active c-Jun is required for AP-1 transactivation and c-Jun-mediated transformation, but its role during stress remains unclear as both pro-apoptotic and pro-survival effects of e-Jun have been observed. Here we investigated the importance of c-Jun N-terminal phosphorylation in influencing the sensitivity of human T98G glioblastoma cells to a variety of cytotoxic agents. Stable expression of a nonphosphorylatable dominant negative protein c-Jun(S63A,S73A) markedly inhibited the activation of AP-1-driven transcription and greatly increased the cytotoxic effects of DNA-damaging agents associated with enhanced apoptosis. However, the same cells expressing the mutant Jun protein did not differ from parental cells in their sensitivity to several non-DNA-damaging cytotoxic agents. Our results suggest that activated e-Jun has a selective role in protecting human tumor cells from apoptosis induced by DNA damage.	NIA, Cell Stress & Aging Sect, Cellular & Mol Biol Lab, Baltimore, MD 21224 USA; Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Holbrook, NJ (corresponding author), NIA, Cell Stress & Aging Sect, Cellular & Mol Biol Lab, Box 12,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		mercola, dan/L-4182-2013; Roszak, Joanna/F-4003-2010	mercola, dan/0000-0002-0281-9840; 				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Bost F, 2000, METHOD ENZYMOL, V314, P342; Brewer JW, 1999, P NATL ACAD SCI USA, V96, P8505, DOI 10.1073/pnas.96.15.8505; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Fritz G, 1999, ONCOGENE, V18, P1033, DOI 10.1038/sj.onc.1202394; GALANG CK, 1994, ONCOGENE, V9, P2913; Gibson S, 1999, J BIOL CHEM, V274, P10916, DOI 10.1074/jbc.274.16.10916; Hayakawa J, 1999, J BIOL CHEM, V274, P31648, DOI 10.1074/jbc.274.44.31648; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Huang Y, 2000, J BIOL CHEM, V275, P18234, DOI 10.1074/jbc.M909431199; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; OLIVE PL, 1990, JNCI-J NATL CANCER I, V82, P779, DOI 10.1093/jnci/82.9.779; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Pourquier P, 1998, BIOCHEM PHARMACOL, V55, P1963, DOI 10.1016/S0006-2952(98)00006-9; Sanchez-Perez I, 1999, FEBS LETT, V453, P151, DOI 10.1016/S0014-5793(99)00690-0; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056	32	95	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28546	28553		10.1074/jbc.M102075200	http://dx.doi.org/10.1074/jbc.M102075200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11352915	hybrid			2022-12-25	WOS:000170093400107
J	Klein, RC; Prorok, M; Galdzicki, Z; Castellino, FJ				Klein, RC; Prorok, M; Galdzicki, Z; Castellino, FJ			The amino acid residue at sequence position 5 in the conantokin peptides partially governs subunit-selective antagonism of recombinant N-methyl-D-aspartate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; 3 DIFFERENT SUBUNITS; NMDA-RECEPTOR; IN-VITRO; MOLECULAR CHARACTERIZATION; HIPPOCAMPAL-NEURONS; MAMMALIAN-CELLS; ZINC INHIBITION; RAT-BRAIN; BINDING	Whole cell voltage clamp recordings mere performed to assess the ability of conantokin-G: (con-G), conantokin-T (con-T), and a 17-residue truncated form of conantokin-R (con-R[1-17]) to inhibit N-methyl-n-aspartate (NMDA)evoked currents in human embryonic kidney 293 cells transiently expressing various combinations of NR1a, NR1b, NR2A, and NR2B receptor subunits. Con-T and conR[1-17] attenuated ion currents in cells expressing NR1a/ NR2A or NR1a/NR2B, Con-G,did not affect NMDA-evoked ionic currents in cells expressing NR1a/NR2A, but it showed inhibitory activity in cells expressing NR1a/NR2B receptors and the triheteromeric combination of NR1a/ NR2A/NR2B. An Ala-rich con-G analog, con-G[Q6G/gamma 7K/ N8A/gamma 10A/gamma 14A/K15A/S16A/N17A] (Ala/con-G, where gamma is Gla), in which all nonessential amino acids were altered to Ala residues, manifested subunit specificity similar to that of con-G, suggesting that the replaced residues are not responsible for selectivity in the con-G framework. A sarcosine-containing con-T truncation analog, con-T[1-9/ G1Src/Q6G], inhibited currents in NR1a/NR2A and NR1a/ NR2B receptors, eliminating residues 10-21 as mediators of the broad subunit selectivity of con-T, In contrast to the null effects of con-G and Ala/con-G at a NR1a/NR2A-containing receptor, some inhibition (similar to 40%) of NMDA-evoked currents was effected by these peptides in cells expressing NR1b/NR2A. This finding suggests that the presence of exon 5 in NR1b plays a role in the activity of the conantokins, Analysis of various conantokin analogs demonstrated that Leu(5) of con-G is an important determinant of conantokin selectivity, Taken as a whole, these results suggest that the important molecular determinants on conantokins responsible for NMDA receptor activity and specificity are discretely housed in specific residues of these peptides, thus allowing molecular manipulation of the NMDA receptor inhibitory properties of the conantokins.	Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; Univ Notre Dame, WM Keck Ctr Transgene Res, Notre Dame, IN 46556 USA; Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA	University of Notre Dame; University of Notre Dame; Uniformed Services University of the Health Sciences - USA	Castellino, FJ (corresponding author), Univ Notre Dame, Dept Chem & Biochem, 229 Nieuwland Sci Hall, Notre Dame, IN 46556 USA.				NHLBI NIH HHS [HL-19982] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019982] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams AC, 2000, EUR J PHARMACOL, V404, P303, DOI 10.1016/S0014-2999(00)00640-3; Blandl T, 1998, FEBS LETT, V435, P257, DOI 10.1016/S0014-5793(98)01077-1; Blandl T, 2000, FEBS LETT, V470, P139, DOI 10.1016/S0014-5793(00)01309-0; Blandl T, 2001, J BIOL CHEM, V276, P7391, DOI 10.1074/jbc.M006648200; BULLER AL, 1994, J NEUROSCI, V14, P5471; CHAZOT PL, 1994, J BIOL CHEM, V269, P24403; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen NS, 1997, MOL PHARMACOL, V51, P1015, DOI 10.1124/mol.51.6.1015; COLPITTS TL, 1993, INT J PEPT PROT RES, V41, P567; Donevan SD, 2000, MOL PHARMACOL, V58, P614, DOI 10.1124/mol.58.3.614; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; HAACK JA, 1990, J BIOL CHEM, V265, P6025; Hawkins LM, 1999, J BIOL CHEM, V274, P27211, DOI 10.1074/jbc.274.38.27211; ISHII T, 1993, J BIOL CHEM, V268, P2836; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; Kendrick SJ, 1996, J NEUROCHEM, V67, P608; Klein RC, 1999, NEUROSCI LETT, V273, P171, DOI 10.1016/S0304-3940(99)00649-7; Klein RC, 1999, NEUROPHARMACOLOGY, V38, P1819, DOI 10.1016/S0028-3908(99)00065-9; Laube B, 1997, NEURON, V18, P493, DOI 10.1016/S0896-6273(00)81249-0; Laurie DJ, 1997, MOL BRAIN RES, V51, P23, DOI 10.1016/S0169-328X(97)00206-4; LAURIE DJ, 1994, EUR J PHARM-MOLEC PH, V268, P335, DOI 10.1016/0922-4106(94)90058-2; Luo JH, 1997, MOL PHARMACOL, V51, P79, DOI 10.1124/mol.51.1.79; LYNCH DR, 1995, J NEUROCHEM, V64, P1462; MCINTOSH JM, 1984, J BIOL CHEM, V259, P4343; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; PRIESTLEY T, 1995, MOL PHARMACOL, V48, P841; Prorok M, 1996, BIOCHEMISTRY-US, V35, P16528, DOI 10.1021/bi9621122; Prorok M, 1998, J BIOL CHEM, V273, P19573, DOI 10.1074/jbc.273.31.19573; Prorok M, 1996, INT J PEPT PROT RES, V48, P281; SKOLNICK P, 1992, J NEUROCHEM, V59, P1516, DOI 10.1111/j.1471-4159.1992.tb08468.x; SKOLNICK P, 1994, PHARM TOXICOLOGY BAS, P155; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; Sun LX, 1998, FEBS LETT, V441, P392, DOI 10.1016/S0014-5793(98)01590-7; Tovar KR, 1999, J NEUROSCI, V19, P4180; Traynelis SF, 1998, J NEUROSCI, V18, P6163; WAFFORD KA, 1993, NEUROREPORT, V4, P1347, DOI 10.1097/00001756-199309150-00015; Warder SE, 1998, J BIOL CHEM, V273, P7512, DOI 10.1074/jbc.273.13.7512; Warder SE, 2001, J NEUROCHEM, V77, P812, DOI 10.1046/j.1471-4159.2001.00281.x; White HS, 2000, J PHARMACOL EXP THER, V292, P425; Williams AJ, 2000, J PHARMACOL EXP THER, V294, P378	41	52	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26860	26867		10.1074/jbc.M102428200	http://dx.doi.org/10.1074/jbc.M102428200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11335724	hybrid			2022-12-25	WOS:000169966900019
J	Ohndorf, UM; Steegborn, C; Knijff, R; Sondermann, P				Ohndorf, UM; Steegborn, C; Knijff, R; Sondermann, P			Contributions of the individual domains in human La protein to its RNA 3 '-end binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III TRANSCRIPTS; TERMINATION FACTOR LA; CRYSTAL-STRUCTURE; AUTOANTIGEN-LA; RECOGNITION MOTIFS; MESSENGER-RNA; SEX-LETHAL; SS-B; ANGSTROM RESOLUTION; NUCLEAR ANTIGEN	The autoantigen La regulates the maturation of RNA polymerase III transcripts by binding to their poly(U) termination signal, The modular protein harbors a N-terminal RNA recognition motif (RRM), RRM1, and in the C-terminal domain, a second, atypical RRM2, in addition to a phosphorylation site, and a putative nucleotide binding site. This study presents a detailed investigation into the RNA 3'-end binding properties of La by using binding titration and competition assays with subsequent gel mobility shift analysis. Two truncation mutants containing one (La-RRM1) or both(La-RRM1-RRM2) RNA-binding domains were constructed, overexpressed, and purified. A K-d value of 25 +/- 10 nM for La binding to a nonameric RNA ligand with the oligouridylate recognition sequence was obtained, discriminating with a specificity ratio of similar to 100 for this probe over a RNA ligand with a 3'-poly(A) stretch. The N-terminal La-RRM1 region was identified as the major contributor of these properties to La, manifested in a 5-fold lower K-d of 5 +/-3 nM and a slightly increased specificity ratio of 120 for the RNA ligand, The atypical RRM2 in the C-terminal domain of La has an unprecedented negative effect on 3'-end RNA recognition, as indicated by a higher Ltd value of 90 +/- 10 nM for the La-RRM1-RRM2 mutant but comparable specificity. Thus the C-terminal regions beyond RRM2 positively modulate the RNA binding affinity of La. Negative regulation, however, occurs through Ser(366) phosphorylation decreasing the binding affinity by 2-fold. ATP had no influence on RNA complex formation. The functional implications of these findings for the mechanism of action of La are discussed.	Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Planegg, Germany	Max Planck Society	Ohndorf, UM (corresponding author), Max Planck Inst Biochem, Abt Strukturforsch, Klopferspitz 18A, D-82152 Planegg, Germany.							Ali N, 1997, P NATL ACAD SCI USA, V94, P2249, DOI 10.1073/pnas.94.6.2249; Allain FHT, 2000, EMBO J, V19, P6870, DOI 10.1093/emboj/19.24.6870; BACHMANN M, 1990, CELL, V60, P85, DOI 10.1016/0092-8674(90)90718-T; BACHMANN M, 1986, BIOL CHEM H-S, V367, P671, DOI 10.1515/bchm3.1986.367.2.671; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; CHAMBERS JC, 1988, J BIOL CHEM, V263, P18043; CHAN EKL, 1989, J AUTOIMMUN, V2, P321, DOI 10.1016/0896-8411(89)90159-5; CHANG YN, 1994, J VIROL, V68, P7008, DOI 10.1128/JVI.68.11.7008-7020.1994; Craig AWB, 1997, MOL CELL BIOL, V17, P163, DOI 10.1128/MCB.17.1.163; Crowder SM, 1999, P NATL ACAD SCI USA, V96, P4892, DOI 10.1073/pnas.96.9.4892; Dember LM, 1996, J BIOL CHEM, V271, P2783, DOI 10.1074/jbc.271.5.2783; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; Fan H, 1997, CELL, V88, P707, DOI 10.1016/S0092-8674(00)81913-3; Fan H, 1998, MOL CELL BIOL, V18, P3201, DOI 10.1128/MCB.18.6.3201; Goodier JL, 1997, MOL CELL BIOL, V17, P5823, DOI 10.1128/MCB.17.10.5823; GORLACH M, 1994, J BIOL CHEM, V269, P23074; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; Heise T, 1999, J VIROL, V73, P5767, DOI 10.1128/JVI.73.7.5767-5776.1999; Huhn P, 1997, NUCLEIC ACIDS RES, V25, P410, DOI 10.1093/nar/25.2.410; Intine RVA, 2000, MOL CELL, V6, P339, DOI 10.1016/S1097-2765(00)00034-4; James MC, 1999, EUR J BIOCHEM, V266, P151, DOI 10.1046/j.1432-1327.1999.00839.x; KANAAR R, 1995, EMBO J, V14, P4530, DOI 10.1002/j.1460-2075.1995.tb00132.x; Kuhn U, 1996, J MOL BIOL, V256, P20, DOI 10.1006/jmbi.1996.0065; LIN S, 1972, J MOL BIOL, V72, P671, DOI 10.1016/0022-2836(72)90184-2; LOHMAN TM, 1992, METHOD ENZYMOL, V212, P400; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; Maraia RJ, 1996, P NATL ACAD SCI USA, V93, P3383, DOI 10.1073/pnas.93.8.3383; Maraia RJ, 2001, MOL CELL BIOL, V21, P367, DOI 10.1128/MCB.21.2.367-379.2001; MATHEWS MB, 1984, MOL CELL BIOL, V4, P1134, DOI 10.1128/MCB.4.6.1134; MATTIOLI M, 1974, ARTHRITIS RHEUM-US, V17, P421, DOI 10.1002/art.1780170413; McLaren RS, 1997, MOL CELL BIOL, V17, P3028, DOI 10.1128/MCB.17.6.3028; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Pannone BK, 1998, EMBO J, V17, P7442, DOI 10.1093/emboj/17.24.7442; PFEIFLE J, 1987, BIOCHIM BIOPHYS ACTA, V928, P217, DOI 10.1016/0167-4889(87)90124-8; PIZER LI, 1983, MOL CELL BIOL, V3, P1235, DOI 10.1128/MCB.3.7.1235; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; PRUIJN GJM, 1995, EUR J BIOCHEM, V232, P611, DOI 10.1111/j.1432-1033.1995.tb20851.x; PRUIJN GJM, 1991, NUCLEIC ACIDS RES, V19, P5173, DOI 10.1093/nar/19.19.5173; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; Rosenblum JS, 1998, J CELL BIOL, V143, P887, DOI 10.1083/jcb.143.4.887; SCHERLY D, 1990, EMBO J, V9, P3675, DOI 10.1002/j.1460-2075.1990.tb07579.x; Scofield RH, 1999, MOL IMMUNOL, V36, P1093, DOI 10.1016/S0161-5890(99)00095-4; Shamoo Y, 1997, NAT STRUCT BIOL, V4, P215, DOI 10.1038/nsb0397-215; Simons FHM, 1996, EXP CELL RES, V224, P224, DOI 10.1006/excr.1996.0132; Sobel SG, 1999, MOL BIOL CELL, V10, P3849, DOI 10.1091/mbc.10.11.3849; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; TOPFER F, 1993, J IMMUNOL, V150, P3091; VANVENROOIJ WJ, 1993, MOL BIOL REP, V18, P113, DOI 10.1007/BF00986765; Varani G, 1998, ANNU REV BIOPH BIOM, V27, P407, DOI 10.1146/annurev.biophys.27.1.407; Wolin SL, 1999, GENE DEV, V13, P1, DOI 10.1101/gad.13.1.1; Xu RM, 1997, STRUCTURE, V5, P559, DOI 10.1016/S0969-2126(97)00211-6	53	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27188	27196		10.1074/jbc.M102891200	http://dx.doi.org/10.1074/jbc.M102891200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11342556	hybrid			2022-12-25	WOS:000169966900062
J	Burtelow, MA; Roos-Mattjus, PMK; Rauen, M; Babendure, JR; Karnitz, LM				Burtelow, MA; Roos-Mattjus, PMK; Rauen, M; Babendure, JR; Karnitz, LM			Reconstitution and molecular analysis of the hRad9-hHus1-hRad1 (9-1-1) DNA damage responsive checkpoint complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE RAD1(+); REPLICATION-FACTOR-C; HUMAN HOMOLOG; SACCHAROMYCES-CEREVISIAE; STRUCTURAL HOMOLOG; CELLULAR-RESPONSE; PROTEIN COMPLEX; CONTROL GENE; KINASE; HUS1	DNA damage activates cell cycle checkpoint signaling pathways that coordinate cell cycle arrest and DNA repair. Three of the proteins involved in checkpoint signaling, Rad1, Hus1, and Rad9, have been shown to interact by immunoprecipitation and yeast two-hybrid studies. However, it is not known how these proteins interact and assemble into a complex. In the present study we demonstrated that in human cells all the hRad9 and hHus1 and approximately one-half of the cellular pool of hRad1 interacted as a stable, biochemically discrete complex, with an apparent molecular mass of 160 kDa. This complex was reconstituted by co-expression of all three recombinant proteins in a heterologous system, and the reconstituted complex exhibited identical chromatographic behavior as the endogenous complex. Interaction studies using differentially tagged proteins demonstrated that the proteins did not self-multimerize. Rather, each protein had a binding site for the other two partners, with the N terminus of hRad9 interacting with hRad1, the N terminus of hRad1 interacting with hHus1, and the N terminus of hHus1 interacting with the C terminus of hRad9's predicted PCNA-like region. Collectively, these analyses suggest a model of how these three proteins assemble to form a functional checkpoint complex, which we dubbed the 9-1-1 complex.	Mayo Clin & Mayo Fdn, Div Dev Oncol Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Radiat Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Pharmacol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Karnitz, LM (corresponding author), Mayo Clin & Mayo Fdn, Div Dev Oncol Res, Guggenheim 13, Rochester, MN 55905 USA.			Roos-Mattjus, Pia/0000-0002-7187-2012	NATIONAL CANCER INSTITUTE [R01CA084321, R56CA084321] Funding Source: NIH RePORTER; NCI NIH HHS [CA-84321] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bao SD, 1999, CANCER RES, V59, P2023; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Bluyssen HAR, 1998, GENOMICS, V54, P331, DOI 10.1006/geno.1998.5582; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Cai RL, 2000, J BIOL CHEM, V275, P27909; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Caspari T, 1999, BIOCHIMIE, V81, P173, DOI 10.1016/S0300-9084(99)80050-9; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; Dahlen M, 1998, MOL BIOL CELL, V9, P611, DOI 10.1091/mbc.9.3.611; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Dean FB, 1998, GENOMICS, V54, P424, DOI 10.1006/geno.1998.5587; Freire R, 1998, GENE DEV, V12, P2560, DOI 10.1101/gad.12.16.2560; Green CM, 2000, CURR BIOL, V10, P39, DOI 10.1016/S0960-9822(99)00263-8; Hang HY, 2000, GENOMICS, V65, P24, DOI 10.1006/geno.2000.6142; Kostrub CF, 1998, EMBO J, V17, P2055, DOI 10.1093/emboj/17.7.2055; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Li L, 1999, ONCOGENE, V18, P1689, DOI 10.1038/sj.onc.1202469; Lieberman HB, 1996, P NATL ACAD SCI USA, V93, P13890, DOI 10.1073/pnas.93.24.13890; Longhese MP, 1998, EMBO J, V17, P5525, DOI 10.1093/emboj/17.19.5525; Lowndes NF, 2000, CURR OPIN GENET DEV, V10, P17, DOI 10.1016/S0959-437X(99)00050-7; Marathi UK, 1998, GENOMICS, V54, P344, DOI 10.1006/geno.1998.5589; Martinho RG, 1998, EMBO J, V17, P7239, DOI 10.1093/emboj/17.24.7239; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; Parker AE, 1998, J BIOL CHEM, V273, P18340, DOI 10.1074/jbc.273.29.18340; Parker AE, 1998, J BIOL CHEM, V273, P18332, DOI 10.1074/jbc.273.29.18332; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; THELEN MP, 1994, J BIOL CHEM, V269, P747; Udell CM, 1998, NUCLEIC ACIDS RES, V26, P3971, DOI 10.1093/nar/26.17.3971; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Weiss RS, 2000, GENE DEV, V14, P1886	41	117	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25903	25909		10.1074/jbc.M102946200	http://dx.doi.org/10.1074/jbc.M102946200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11340080	hybrid			2022-12-25	WOS:000169823300037
J	Cottet, S; Dupraz, P; Hamburger, F; Dolci, W; Jaquet, M; Thorens, B				Cottet, S; Dupraz, P; Hamburger, F; Dolci, W; Jaquet, M; Thorens, B			SOCS-1 protein prevents Janus kinase/STAT-dependent inhibition of beta cell insulin gene transcription and secretion in response to interferon-gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; NITRIC-OXIDE PRODUCTION; RAT PANCREATIC-ISLETS; IFN-GAMMA; IN-VIVO; DIABETES-MELLITUS; TYROSINE PHOSPHORYLATION; LENTIVIRAL VECTOR; INDUCIBLE GENE; FATTY-ACIDS	In the pathogenesis of type I diabetes mellitus, activated leukocytes infiltrate pancreatic islets and induce beta cell dysfunction and destruction. Interferon (IFN)-gamma, tumor necrosis factor-ru and interleukin (IL)-1 beta play important, although not completely defined, roles in these mechanisms, Here, using the highly differentiated beta Tc-Tet insulin-secreting cell line, we showed that IFN-gamma dose- and time-dependently suppressed insulin synthesis and glucose-stimulated secretion. As described previously IFN-gamma, in combination with IL-1 beta, also induces inducible NO synthase expression and apoptosis (Dupraz, P,, Cottet, S,, Hamburger, F., Dolci, W,, Felley-Bosco, E,, and Thorens, B, (2000) J, Biol. Chem. 275, 37672-37678), To assess the role of the Janus kinase/signal transducer and activator of transcription (STAT) pathway in IFN-gamma intracellular signaling, we stably overexpressed SOCS-1 (suppressor of cytokine signaling-1) in the beta cell line. We demonstrated that SOCS-1 suppressed cytokine-induced STAT-1 phosphorylation and increased cellular accumulation, This was accompanied by a suppression of the effect of IFN-gamma on: (i) reduction in insulin promoter-luciferase reporter gene transcription, (ii) decrease in insulin mRNA and peptide content, and (iii) suppression of glucose-stimulated insulin secretion, Furthermore, SOCS-1 also suppressed the cellular effects that require the combined presence of IL-1 beta and IFN-gamma:: induction of nitric oxide production and apoptosis, Together our data demonstrate that IFN-gamma is responsible for the cytokine-induced defect in insulin gene expression and secretion and that this effect can be completely blocked by constitutive inhibition of the Janus kinase/STAT pathway.	Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	University of Lausanne	Thorens, B (corresponding author), Univ Lausanne, Inst Pharmacol & Toxicol, 27 Rue Bugnon, CH-1005 Lausanne, Switzerland.							Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Baldeon ME, 1997, DIABETES, V46, P770, DOI 10.2337/diabetes.46.5.770; CAMPBELL IL, 1990, MOL BIOL MED, V7, P299; CAMPBELL IL, 1988, J IMMUNOL, V141, P2325; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dunger A, 1996, DIABETES, V45, P183, DOI 10.2337/diabetes.45.2.183; Dupraz P, 1999, GENE THER, V6, P1160, DOI 10.1038/sj.gt.3300922; Dupraz P, 2000, J BIOL CHEM, V275, P37672, DOI 10.1074/jbc.M005150200; EFRAT S, 1995, P NATL ACAD SCI USA, V92, P3576, DOI 10.1073/pnas.92.8.3576; EIZIRIK DL, 1994, J CLIN INVEST, V93, P1968, DOI 10.1172/JCI117188; Eizirik DL, 1996, DIABETOLOGIA, V39, P875; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Galsgaard ED, 1996, MOL ENDOCRINOL, V10, P652, DOI 10.1210/me.10.6.652; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; Gremlich S, 1997, J BIOL CHEM, V272, P3216, DOI 10.1074/jbc.272.6.3216; Gremlich S, 1997, J BIOL CHEM, V272, P30261, DOI 10.1074/jbc.272.48.30261; Guillam MT, 1997, NAT GENET, V17, P327, DOI 10.1038/ng1197-327; Heitmeier MR, 1999, J BIOL CHEM, V274, P29266, DOI 10.1074/jbc.274.41.29266; Hultgren B, 1996, DIABETES, V45, P812, DOI 10.2337/diabetes.45.6.812; Ito S, 1999, BLOOD, V93, P1456, DOI 10.1182/blood.V93.5.1456; Kallmann BA, 1997, DIABETES, V46, P237, DOI 10.2337/diabetes.46.2.237; KATZ JD, 1995, SCIENCE, V268, P1185, DOI 10.1126/science.7761837; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; OLSON LK, 1993, J CLIN INVEST, V92, P514, DOI 10.1172/JCI116596; RABINOVITCH A, 1994, DIABETOLOGIA, V37, P733, DOI 10.1007/BF00404328; RABINOVITCH A, 1994, J CLIN ENDOCR METAB, V79, P1058, DOI 10.1210/jc.79.4.1058; Rabinovitch A, 1998, DIABETES METAB REV, V14, P129, DOI 10.1002/(SICI)1099-0895(199806)14:2<129::AID-DMR208>3.0.CO;2-V; Rabinovitch A, 1998, BIOCHEM PHARMACOL, V55, P1139, DOI 10.1016/S0006-2952(97)00492-9; RAGO R, 1990, ANAL BIOCHEM, V191, P31; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; Sakamoto H, 1998, BLOOD, V92, P1668, DOI 10.1182/blood.V92.5.1668.417k09_1668_1676; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; STERNESJO J, 1995, AUTOIMMUNITY, V20, P185, DOI 10.3109/08916939508993349; SUAREZPINZON WL, 1994, ENDOCRINOLOGY, V134, P1006, DOI 10.1210/en.134.3.1006; Suzuki R, 1998, ONCOGENE, V17, P2271, DOI 10.1038/sj.onc.1202143; Thomas HE, 1998, J CLIN INVEST, V102, P1249, DOI 10.1172/JCI2899; vonHerrath MG, 1997, J EXP MED, V185, P531, DOI 10.1084/jem.185.3.531; Wang B, 1997, P NATL ACAD SCI USA, V94, P13844, DOI 10.1073/pnas.94.25.13844; Wilson SB, 1998, NATURE, V391, P177, DOI 10.1038/34419; YAGI N, 1995, DIABETES, V44, P744, DOI 10.2337/diabetes.44.7.744; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998; Zufferey R, 1999, J VIROL, V73, P2886, DOI 10.1128/JVI.73.4.2886-2892.1999; Zumsteg U, 2000, DIABETES, V49, P39, DOI 10.2337/diabetes.49.1.39	55	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25862	25870		10.1074/jbc.M103235200	http://dx.doi.org/10.1074/jbc.M103235200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11342558	hybrid			2022-12-25	WOS:000169823300031
J	Izem, L; Morton, RE				Izem, L; Morton, RE			Cholesteryl ester transfer protein biosynthesis and cellular cholesterol homeostasis are tightly interconnected	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-TRANSFER PROTEIN; MESSENGER-RNA LEVELS; HORMONE-SENSITIVE LIPASE; HUMAN ADIPOSE-TISSUE; STEROL UP-REGULATION; TRANSGENIC MICE; HUMAN-PLASMA; GENE-EXPRESSION; MONOCLONAL-ANTIBODY; RABBIT PLASMA	Cholesteryl ester transfer protein (CETP) mediates triglyceride and cholesteryl ester (CE) transfer between lipoproteins, and its activity is strongly modulated by dietary cholesterol. To better understand the regulation of CETP synthesis and the relationship between CETP levels and cellular lipid metabolism, we selected the SW872 adipocytic cell line as a model. These cells secrete CETP in a time-dependent manner at levels exceeding those observed for Caco-2 or HepG2 cells. The addition of LDL, 25OH-cholesterol, oleic acid, or acetylated LDL to SW872 cells increased CETP secretion (activity and mass) up to 6-fold. In contrast, CETP production was decreased by almost 60% after treatment with lipoprotein-deficient serum or P-cyclodextrin, These effects, which were paralleled by changes in CETP mRNA, show that CETP biosynthesis in SW872 cells directly correlates with cellular lipid status. To investigate a possible, reciprocal relationship between CETP expression and cellular lipid homeostasis, CETP biosynthesis in SW872 cells was suppressed with CETP antisense oligonucleotides. Antisense oligonucleotides reduced CETP secretion (activity and mass) by 60% compared with sense-treated cells. When CETP synthesis was suppressed for 24 h, triglyceride synthesis was unchanged, but cholesterol biosynthesis was reduced by 20%, and acetate incorporation into CE increased 31%, After 3 days of suppressed CETP synthesis, acetate incorporation into the CE pool increased 3-fold over control. This mirrored a similar increase in CE mass. The efflux of free cholesterol to HDL was the same in sense and antisense-treated cells; however, HDL-induced CE hydrolysis in antisense-treated cells was diminished a-fold even though neutral CE hydrolase activity was unchanged. Thus, CETP-compromised SW872 cells display a phenotype characterized by inefficient mobilization of CE stores leading to CE accumulation. These results strongly suggest that CETP expression levels contribute to normal cholesterol homeostasis in adipocytic cells. Overall, these studies demonstrate that lipid homeostasis and CETP expression are tightly coupled.	Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Morton, RE (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, 9500 Euclid Ave,NC10, Cleveland, OH 44195 USA.				NHLBI NIH HHS [HL60934] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060934] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGELLON LB, 1992, J BIOL CHEM, V267, P22336; Atger VM, 1997, J CLIN INVEST, V99, P773, DOI 10.1172/JCI119223; Benoist F, 1997, J BIOL CHEM, V272, P23572, DOI 10.1074/jbc.272.38.23572; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Bruce C, 1998, ANNU REV NUTR, V18, P297, DOI 10.1146/annurev.nutr.18.1.297; Chouinard RA, 1998, J BIOL CHEM, V273, P22409, DOI 10.1074/jbc.273.35.22409; CLEVIDENCE BA, 1984, ARTERIOSCLEROSIS, V4, P196, DOI 10.1161/01.ATV.4.3.196; Dessi M, 1997, MOL CELL BIOCHEM, V177, P107, DOI 10.1023/A:1006823601032; DRAYNA D, 1987, NATURE, V327, P632, DOI 10.1038/327632a0; EGAN JJ, 1992, P NATL ACAD SCI USA, V89, P8537, DOI 10.1073/pnas.89.18.8537; FAUST RA, 1987, ARTERIOSCLEROSIS, V7, P267, DOI 10.1161/01.ATV.7.3.267; FAUST RA, 1988, J BIOL CHEM, V263, P8786; FRAENKELCONRAT H, 1957, METHOD ENZYMOL, V4, P247, DOI 10.1016/0076-6879(57)04059-8; Gauthier B, 1999, ATHEROSCLEROSIS, V142, P301, DOI 10.1016/S0021-9150(98)00245-7; HASHIMOTO S, 1984, BIOCHEM BIOPH RES CO, V120, P586, DOI 10.1016/0006-291X(84)91295-6; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HESLER CB, 1987, J BIOL CHEM, V262, P2275; INAZU A, 1992, BIOCHEMISTRY-US, V31, P2352, DOI 10.1021/bi00123a021; JIANG XC, 1992, J CLIN INVEST, V90, P1290, DOI 10.1172/JCI115993; JIANG XC, 1991, J BIOL CHEM, V266, P4631; JIANG XC, 1993, J BIOL CHEM, V268, P27406; KRAEMER FB, 1993, J LIPID RES, V34, P663; KURUSHIMA H, 1995, BBA-LIPID LIPID MET, V1258, P251, DOI 10.1016/0005-2760(95)00122-S; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luo Y, 2000, J CLIN INVEST, V105, P513, DOI 10.1172/JCI8573; MARTIN LJ, 1993, J LIPID RES, V34, P437; MCPHERSON R, 1991, ARTERIOSCLER THROMB, V11, P797, DOI 10.1161/01.ATV.11.4.797; MENDEZ AJ, 1986, ANAL BIOCHEM, V156, P386, DOI 10.1016/0003-2697(86)90269-1; MORTON RE, 1981, J BIOL CHEM, V256, P1992; MORTON RE, 1983, J BIOL CHEM, V258, P1751; MORTON RE, 1988, J LIPID RES, V29, P1367; PAPE ME, 1991, ARTERIOSCLER THROMB, V11, P1759, DOI 10.1161/01.ATV.11.6.1759; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; QUIG DW, 1990, ANNU REV NUTR, V10, P169, DOI 10.1146/annurev.nu.10.070190.001125; QUINET E, 1991, J CLIN INVEST, V87, P1559, DOI 10.1172/JCI115169; QUINET EM, 1990, J CLIN INVEST, V85, P357, DOI 10.1172/JCI114446; Radeau T, 1995, J LIPID RES, V36, P2552; RAVNIK SE, 1992, BIOL REPROD, V47, P1126, DOI 10.1095/biolreprod47.6.1126; Richardson MA, 1996, J LIPID RES, V37, P1162; Sattler W, 1996, LIPIDS, V31, P1303, DOI 10.1007/BF02587917; Serdyuk AP, 1997, METABOLISM, V46, P833, DOI 10.1016/S0026-0495(97)90131-1; SHEN GX, 1995, AM J PHYSIOL, V269, P99; SON YSC, 1986, ARTERIOSCLEROSIS, V6, P345, DOI 10.1161/01.ATV.6.3.345; SPEIJER H, 1991, ATHEROSCLEROSIS, V90, P159, DOI 10.1016/0021-9150(91)90110-O; SPERKER B, 1993, EUR J BIOCHEM, V218, P945, DOI 10.1111/j.1432-1033.1993.tb18451.x; SWENSON TL, 1987, J BIOL CHEM, V262, P16271; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; TOLLEFSON JH, 1985, J BIOL CHEM, V260, P5887; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; WHITLOCK ME, 1989, J CLIN INVEST, V84, P129, DOI 10.1172/JCI114132; Yang TP, 1996, J BIOL CHEM, V271, P12603, DOI 10.1074/jbc.271.21.12603; YEN FT, 1989, J CLIN INVEST, V83, P2018, DOI 10.1172/JCI114112; ZILVERSMIT DB, 1975, BIOCHIM BIOPHYS ACTA, V409, P393, DOI 10.1016/0005-2760(75)90036-3	55	35	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26534	26541		10.1074/jbc.M103624200	http://dx.doi.org/10.1074/jbc.M103624200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11352921	hybrid			2022-12-25	WOS:000169823300117
J	Atshaves, BP; Storey, SM; McIntosh, AL; Petrescu, AD; Lyuksyutova, OI; Greenberg, AS; Schroeder, F				Atshaves, BP; Storey, SM; McIntosh, AL; Petrescu, AD; Lyuksyutova, OI; Greenberg, AS; Schroeder, F			Sterol carrier protein-2 expression modulates protein and lipid composition of lipid droplets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-CELL FIBROBLASTS; DIFFERENTIATION-RELATED PROTEIN; FATTY ACYL-COENZYME; CHOLESTEROL TRANSPORT; MEMBRANE-STRUCTURE; STORAGE DISEASE; BINDING SITE; IN-VIVO; ACID; STEROIDOGENESIS	Despite the critical role lipid droplets play in maintaining energy reserves and lipid stores for the cell, little is known about the regulation of the lipid or protein components within the lipid droplet. Although immunofluorescence of intact cells as well as Western analysis of isolated lipid droplets revealed that sterol carrier protein-2 (SCP-S) was not associated with lipid droplets, SCP-S expression significantly altered the structure of the lipid droplet. First, the targeting of fatty acid and cholesterol to the lipid droplets was significantly decreased. Second, the content of several proteins important for lipid droplet function was differentially increased (perilipin A), reduced severalfold (adipose differentiation-related protein (ADRP), vimentin), or almost completely eliminated (hormone-sensitive lipase and proteins > 93 kDa) in the isolated lipid droplet. Third, the distribution of lipids within the lipid droplets was significantly altered. Double labeling of cells with 12-(N-methyl)-N-[(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-octadecanoic acid (NBD-stearic acid) and antisera to ADRP showed that 70, 24, and 13% of lipid droplets contained ADRP, NBD-stearic acid, or both, respectively. SCP-2 expression decreased the level of ADRP in the lipid droplet but increased the proportion wherein ADRP and NBD-stearic acid colocalized by 3-fold. SCP-S expression also decreased the lipid droplet fatty acid and cholesterol mass (nmol/mg protein) by 5.2-and 6.6-fold, respectively. Finally, SCP-2 expression selectively altered the pattern of esterified fatty acids in favor of polyunsaturated fatty acids within the lipid droplet. Displacement studies showed differential binding affinity of ADRP for cholesterol and fatty acids. These data suggested that SCP-2 and ADRP play a significant role in regulating fatty acid and cholesterol targeting to lipid droplets as well as in determining their lipid and protein components.	Texas A&M Univ, Dept Physiol & Pharmacol, College Stn, TX 77843 USA; Tufts Univ, Program Obes Metab, JM USDA, Human Nutr Res Ctr Aging, Boston, MA 02111 USA	Texas A&M University System; Texas A&M University College Station; Tufts University; United States Department of Agriculture (USDA)	Schroeder, F (corresponding author), Texas A&M Univ, Dept Physiol & Pharmacol, TVMC, College Stn, TX 77843 USA.	Fschroeder@cvm.tamu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41406] Funding Source: Medline; NIGMS NIH HHS [GM31651] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atshaves BP, 1999, J LIPID RES, V40, P610; Atshaves BP, 2000, J BIOL CHEM, V275, P36852, DOI 10.1074/jbc.M003434200; Atshaves BP, 1998, AM J PHYSIOL-CELL PH, V274, pC633, DOI 10.1152/ajpcell.1998.274.3.C633; Avdulov NA, 1999, BBA-MOL CELL BIOL L, V1437, P37, DOI 10.1016/S0005-2760(98)00178-7; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; Baum CL, 1997, J BIOL CHEM, V272, P6490, DOI 10.1074/jbc.272.10.6490; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Brasaemle DL, 2000, BBA-MOL CELL BIOL L, V1483, P251, DOI 10.1016/S1388-1981(99)00179-1; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHANDERBHAN R, 1982, J BIOL CHEM, V257, P8928; CHANDERBHAN RF, 1986, ENDOCR RES, V12, P351, DOI 10.3109/07435808609035445; Chanderbhan RF, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P197; Chao H, 1999, BBA-MOL CELL BIOL L, V1439, P371, DOI 10.1016/S1388-1981(99)00109-2; Choi YS, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P109; CLARKE SD, 1993, PROG LIPID RES, V32, P139, DOI 10.1016/0163-7827(93)90013-M; COLLES SM, 1995, LIPIDS, V30, P795, DOI 10.1007/BF02533954; EDELSTEIN RA, 1988, AM J GASTROENTEROL, V83, P687; Fielding CJ, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P273; Fong TH, 1997, J CELL BIOCHEM, V65, P67; Fong TH, 1996, J CELL BIOCHEM, V63, P366, DOI 10.1002/(SICI)1097-4644(19961201)63:3<366::AID-JCB12>3.0.CO;2-F; Frolov A, 2000, J BIOL CHEM, V275, P12769, DOI 10.1074/jbc.275.17.12769; Frolov A, 1996, J BIOL CHEM, V271, P31878, DOI 10.1074/jbc.271.50.31878; Fuchs M, 1997, FASEB J, V11, pA1060; Fuchs M, 1998, BIOCHEM J, V336, P33, DOI 10.1042/bj3360033; GADELLA TWJ, 1991, BIOCHIM BIOPHYS ACTA, V1070, P237, DOI 10.1016/0005-2736(91)90170-D; GADELLA TWJ, 1994, EUR J BIOCHEM, V220, P1019, DOI 10.1111/j.1432-1033.1994.tb18707.x; Gallegos AM, 2000, CHEM PHYS LIPIDS, V105, P9, DOI 10.1016/S0009-3084(99)00128-0; GALLEGOS AM, 2001, IN PRESS PROG LIPID; GALLEGOS AM, 2001, IN PRESS BIOCHEMISTR; GALLEGOS AM, 2001, IN PRSS CHEM PHYS LI; Gao J, 1999, J BIOL CHEM, V274, P16825, DOI 10.1074/jbc.274.24.16825; HARA A, 1978, ANAL BIOCHEM, V90, P420, DOI 10.1016/0003-2697(78)90046-5; HIGUCHI K, 1970, J CELL PHYSIOL, V75, P65, DOI 10.1002/jcp.1040750108; Huang H, 1999, BIOCHEMISTRY-US, V38, P13231, DOI 10.1021/bi990870x; Huang H, 1999, BIOCHEM J, V344, P593, DOI 10.1042/0264-6021:3440593; Igal RA, 1996, J BIOL CHEM, V271, P16644, DOI 10.1074/jbc.271.28.16644; INCERPI S, 1992, ARCH BIOCHEM BIOPHYS, V298, P35, DOI 10.1016/0003-9861(92)90090-J; JEFFERSON JR, 1991, J BIOL CHEM, V266, P5486; JEFFERSON JR, 1990, J BIOL CHEM, V265, P11062; JIANG HP, 1992, P NATL ACAD SCI USA, V89, P7856, DOI 10.1073/pnas.89.17.7856; Jump DB, 1999, ANNU REV NUTR, V19, P63, DOI 10.1146/annurev.nutr.19.1.63; KELLER GA, 1989, J CELL BIOL, V108, P1353, DOI 10.1083/jcb.108.4.1353; Leonard AN, 1998, J LIPID RES, V39, P1981; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; MARZO A, 1971, CLIN CHEM, V17, P145; McArthur MJ, 1999, J LIPID RES, V40, P1371; McGarry JD, 1999, DIABETOLOGIA, V42, P128, DOI 10.1007/s001250051130; MENDISHANDAGAMA SMLC, 1995, TISSUE CELL, V27, P483, DOI 10.1016/S0040-8166(05)80056-4; Moncecchi D, 1996, BBA-LIPID LIPID MET, V1302, P110, DOI 10.1016/0005-2760(96)00044-6; Murphy EJ, 1998, AM J PHYSIOL-GASTR L, V275, pG237, DOI 10.1152/ajpgi.1998.275.2.G237; Murphy EJ, 2000, J LIPID RES, V41, P788; Murphy EJ, 1997, BBA-LIPID LIPID MET, V1345, P283, DOI 10.1016/S0005-2760(97)00003-9; MyersPayne SC, 1996, J NEUROCHEM, V66, P313; NAGY L, 1990, ENDOCRINOLOGY, V126, P2267, DOI 10.1210/endo-126-5-2267; NICHOLS JW, 1987, J BIOL CHEM, V262, P14172; PENTCHEV PG, 1994, BBA-MOL BASIS DIS, V1225, P235, DOI 10.1016/0925-4439(94)90001-9; PFEIFER SM, 1993, J STEROID BIOCHEM, V47, P167, DOI 10.1016/0960-0760(93)90071-4; Puglielli L, 1996, BIOCHEM J, V317, P681, DOI 10.1042/bj3170681; Schoer JK, 2000, BIOCHEMISTRY-US, V39, P7662, DOI 10.1021/bi992686h; Schroeder F, 1996, P SOC EXP BIOL MED, V213, P150, DOI 10.3181/00379727-213-44047; Schroeder F, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P213; SCHROEDER F, 1995, BIOCHEMISTRY-US, V34, P11919, DOI 10.1021/bi00037a033; SCHROEDER F, 1991, P SOC EXP BIOL MED, V196, P235; Schroeder F, 2000, J BIOL CHEM, V275, P25547, DOI 10.1074/jbc.M000431200; SCHROEDER F, 2001, IN PRESS EXP BIOL ME; Seedorf U, 1998, GENE DEV, V12, P1189, DOI 10.1101/gad.12.8.1189; Serrero G, 2000, BBA-MOL CELL BIOL L, V1488, P245, DOI 10.1016/S1388-1981(00)00128-1; SERVETNICK DA, 1995, J BIOL CHEM, V270, P16970, DOI 10.1074/jbc.270.28.16970; SOKOL J, 1988, J BIOL CHEM, V263, P3411; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Sparrow CP, 1999, J LIPID RES, V40, P1747; SPIEGELMAN BM, 1993, CELL, V73, P625, DOI 10.1016/0092-8674(93)90243-J; Starodub O, 2000, AM J PHYSIOL-CELL PH, V279, pC1259, DOI 10.1152/ajpcell.2000.279.4.C1259; Stolowich N, 1999, J BIOL CHEM, V274, P35425, DOI 10.1074/jbc.274.50.35425; Stolowich NJ, 1997, BIOCHEMISTRY-US, V36, P1719, DOI 10.1021/bi962317a; Wang SM, 1997, J CELL BIOCHEM, V67, P84, DOI 10.1002/(SICI)1097-4644(19971001)67:1<84::AID-JCB9>3.0.CO;2-S; WOODFORD JK, 1995, CHEM PHYS LIPIDS, V76, P73, DOI 10.1016/0009-3084(95)02436-M; YAMAMOTO R, 1991, P NATL ACAD SCI USA, V88, P463, DOI 10.1073/pnas.88.2.463; YEAGLE PL, 1988, BIOL CHOLESTEROL, P121; ZANLUNGO S, 2000, GASTROENTEROLOGY, V118, P135	82	64	67	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25324	25335		10.1074/jbc.M100560200	http://dx.doi.org/10.1074/jbc.M100560200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11333258	hybrid			2022-12-25	WOS:000169800700119
J	De Felice, FG; Houzel, JC; Garcia-Abreu, J; Louzada, PRF; Afonso, RC; Meirelles, MNL; Lent, R; Neto, VM; Ferreira, ST				De Felice, FG; Houzel, JC; Garcia-Abreu, J; Louzada, PRF; Afonso, RC; Meirelles, MNL; Lent, R; Neto, VM; Ferreira, ST			Inhibition of Alzheimer's disease beta-amyloid aggregation, neurotoxicity, and in vivo deposition by nitrophenols: implications for Alzheimer's therapy	FASEB JOURNAL			English	Article									Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21944590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Anat, BR-21944590 Rio De Janeiro, Brazil; FIOCRUZ, Inst Oswaldo Cruz, Dept Ultraestrutura & Biol Celular, BR-21045900 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Fundacao Oswaldo Cruz	Ferreira, ST (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21944590 Rio De Janeiro, Brazil.		De Felice, Fernanda G/M-1074-2017; Houzel, Jean Christophe/M-7936-2019; Abreu, Jose G/ABB-1199-2021; Houzel, Jean Christophe/G-3723-2010; Abreu, Jose G/G-6159-2010; Moura-Neto, VIVALDO/V-9913-2019; Ferreira, Sergio/AAZ-1576-2020	Houzel, Jean Christophe/0000-0001-5128-438X; Abreu, Jose G/0000-0002-1363-1755; Houzel, Jean Christophe/0000-0001-5128-438X; Abreu, Jose G/0000-0002-9875-7786; Moura-Neto, VIVALDO/0000-0002-6266-043X; Ferreira, Sergio/0000-0001-7160-9866					0	95	109	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1297	1299		10.1096/fj.00-0676fje	http://dx.doi.org/10.1096/fj.00-0676fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344119				2022-12-25	WOS:000168655200041
J	Jewell, UR; Kvietikova, I; Scheid, A; Bauer, C; Wenger, RH; Gassmann, M				Jewell, UR; Kvietikova, I; Scheid, A; Bauer, C; Wenger, RH; Gassmann, M			Induction of HIF-1 alpha in response to hypoxia is instantaneous	FASEB JOURNAL			English	Article									Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland	University of Zurich	Gassmann, M (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.		Wenger, Roland H./B-7953-2009; Jewell, Ursula/AAH-4132-2019	Wenger, Roland H./0000-0001-7592-4839; 					0	429	450	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1312	1314		10.1096/fj.00-0732fje	http://dx.doi.org/10.1096/fj.00-0732fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344124				2022-12-25	WOS:000168655200046
J	Lindstrom, MS; Klangby, U; Wiman, KG				Lindstrom, MS; Klangby, U; Wiman, KG			p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53	ONCOGENE			English	Article						pl4ARF; MDM2; p53; nucleolus; Bmi-1; burkitt lymphoma	TUMOR-SUPPRESSOR GENE; B-CELL; INK4A/ARF LOCUS; C-MYC; MUTATIONS; ONCOGENE; P19(ARF); ASSOCIATION; METHYLATION; P16(INK4A)	The hallmark of Burkitt lymphoma (BL) is a constitutively activated c-myc gene that drives tumor cell growth. A majority of BL-derived cell lines also carry mutant p53, In addition, the p16INK4a promoter is hypermethylated in most BL biopsies and BL cell lines, leading to silencing of this gene, Activation of c-myc and/or cell cycle dysregulation can induce ARF expression and p53-dependent apoptosis, We therefore investigated the p14ARF-MDM2-p53 pathway in BL cell lines. p14ARF was expressed and localized to nucleoli in all BL carrying mutant p53, Three out of seven BL carrying wt p53 had a homozygous deletion of the CDKN2A locus that encodes both p14ARF and p16INK4a. Three BL carrying wild type p53 retained the CDKN2A locus and overexpressed MDM2, DNA sequencing revealed a point mutation in CDKN2A exon 2 in one of these BL, Seraphine, However, this point mutation did not affect p14ARF's nucleolar localization or ability to induce p53, The Bmi-1 protein that negatively regulates the p14ARF promoter and co-operates with c-myc in tumorigenesis was expressed at low to moderate levels in all BL analysed. Our results indicate that inactivation of the ARF-MDM2-p53 pathway is an essential step during the development of Burkitt lymphoma, presumably as a mechanism to escape c-myc induced apoptosis.	Karolinska Hosp, Canc Ctr Karolinska, Dept Oncol Pathol, Karolinska Inst, SE-17176 Stockholm, Sweden; AB Sangtec Med, SE-16102 Bromma, Sweden	Karolinska Institutet; Karolinska University Hospital	Wiman, KG (corresponding author), Karolinska Hosp, Canc Ctr Karolinska, Dept Oncol Pathol, Karolinska Inst, SE-17176 Stockholm, Sweden.		Lindström, Mikael S/AAA-1451-2019; Wiman, Klas/AAB-8399-2021	Lindström, Mikael S/0000-0003-1148-8497; Wiman, Klas/0000-0002-7113-524X				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; Baur AS, 1999, BLOOD, V94, P1773, DOI 10.1182/blood.V94.5.1773.417a12_1773_1781; BHATIA KG, 1992, CANCER RES, V52, P4273; Capoulade C, 1998, ONCOGENE, V16, P1603, DOI 10.1038/sj.onc.1201702; Cherney BW, 1997, CANCER RES, V57, P2508; CORDONCARDO C, 1994, CANCER RES, V54, P794; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; ESTELLER M, 2000, CANCER RES, V60, P29; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; Gao CF, 1999, BIOCHEM BIOPH RES CO, V264, P860, DOI 10.1006/bbrc.1999.1611; Gardie B, 1998, BLOOD, V91, P1016, DOI 10.1182/blood.V91.3.1016.1016_1016_1020; Gronbaek K, 2000, LEUKEMIA, V14, P1727, DOI 10.1038/sj.leu.2401901; Gutierrez MI, 1997, ANN ONCOL, V8, P987, DOI 10.1023/A:1008265304712; Gutierrez MI, 1999, CANCER RES, V59, P696; HAUPT Y, 1993, ONCOGENE, V8, P3161; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Klangby U, 1998, BLOOD, V91, P1680, DOI 10.1182/blood.V91.5.1680.1680_1680_1687; KLEIN G, 1993, GENE, V135, P189, DOI 10.1016/0378-1119(93)90065-B; Kumar R, 1998, GENE CHROMOSOME CANC, V23, P273, DOI 10.1002/(SICI)1098-2264(199811)23:3<273::AID-GCC11>3.0.CO;2-N; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pinyol M, 2000, AM J PATHOL, V156, P1987, DOI 10.1016/S0002-9440(10)65071-7; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; STRANKS G, 1995, BLOOD, V85, P893, DOI 10.1182/blood.V85.4.893.bloodjournal854893; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Voncken JW, 1999, J CELL SCI, V112, P4627; VOUSDEN KH, 1993, J GEN VIROL, V74, P803, DOI 10.1099/0022-1317-74-5-803; WATANABE T, 1994, BLOOD, V84, P3158; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WIMAN KG, 1991, ONCOGENE, V6, P1633; Zhang SL, 1998, P NATL ACAD SCI USA, V95, P2429, DOI 10.1073/pnas.95.5.2429; Zhang SL, 2001, MOL CELL BIOL, V21, P310, DOI 10.1128/MCB.21.1.310-318.2001; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	48	74	79	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2001	20	17					2171	2177		10.1038/sj.onc.1204303	http://dx.doi.org/10.1038/sj.onc.1204303			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360201				2022-12-25	WOS:000168116700012
J	Dreier, B; Beerli, RR; Segal, DJ; Flippin, JD; Barbas, CF				Dreier, B; Beerli, RR; Segal, DJ; Flippin, JD; Barbas, CF			Development of zinc finger domains for recognition of the 5 '-ANN-3 ' family of DNA sequences and their use in the construction of artificial transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLLING GENE-EXPRESSION; CRYSTAL-STRUCTURE; PHAGE DISPLAY; FACTOR IIIA; FACTOR SP1; PROTEIN; COMPLEX; ACTIVATION; AFFINITY; DESIGN	In previous studies we have developed Cys(2)-His(2) zinc finger domains that specifically recognized each of the 16 5'-GNN-3' DNA target sequences and could be used to assemble six-finger proteins that bind 18-base pair DNA sequences (Beerli, R. R., Dreier, B., and Barbas, C. F., III (2000) Proc. Nad. Acad. Sci. U. S. A. 97,1495-1500). Such proteins provide the basis for the construction of artificial transcription factors to study gene/function relationships in the post-genomic era. Central to the universal application of this approach is the development of zinc finger domains that specifically recognize each of the 64 possible DNA triplets. Here we describe the construction of a novel phage display library that enables the selection of zinc finger domains recognizing the 5' ANN-3' family of DNA sequences. Library selections provided domains that in most cases showed binding specificity for the 3-base pair target site that they were selected to bind. These zinc finger domains were used to construct 6-finger proteins that specifically bound their 18-base pair target site with affinities in the pm to low nm range. When fused to regulatory domains, these proteins containing various numbers of 5'-ANN-3' domains were capable of specific transcriptional regulation of a reporter gene and the endogenous human ERBB-2 and ERBB-3 genes. These results suggest that modular DNA recognition by zinc finger domains is not limited to the 5'-GNN-3' family of DNA sequences and can be extended to the 5'-ANN-3' family. The domains characterized in this work provide for the rapid construction of artificial transcription factors, thereby greatly increasing the number of sequences and genes that can be targeted by DNA-binding proteins built from pre-defined zinc finger domains.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Barbas, CF (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, BCC-515,N Torrey Pines Rd, La Jolla, CA 92037 USA.	carlos@scripps.edu	Segal, David/V-9126-2019; Segal, David/B-6646-2013	Segal, David/0000-0001-8962-3105; Segal, David/0000-0001-8962-3105	NCI NIH HHS [CA86258] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086258] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BARBAS CF, 1991, METHODS COMPANION ME, V2, P119; Beerli RR, 2000, J BIOL CHEM, V275, P32617, DOI 10.1074/jbc.M005108200; Beerli RR, 1998, P NATL ACAD SCI USA, V95, P14628, DOI 10.1073/pnas.95.25.14628; Beerli RR, 2000, P NATL ACAD SCI USA, V97, P1495, DOI 10.1073/pnas.040552697; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; Choo Y, 2000, CURR OPIN STRUC BIOL, V10, P411, DOI 10.1016/S0959-440X(00)00107-X; Corbi N, 1997, FEBS LETT, V417, P71, DOI 10.1016/S0014-5793(97)01257-X; Dreier B, 2000, J MOL BIOL, V303, P489, DOI 10.1006/jmbi.2000.4133; Elrod-Erickson M, 1998, STRUCTURE, V6, P451, DOI 10.1016/S0969-2126(98)00047-1; ElrodErickson M, 1996, STRUCTURE, V4, P1171, DOI 10.1016/S0969-2126(96)00125-6; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; Foster MP, 1997, NAT STRUCT BIOL, V4, P605, DOI 10.1038/nsb0897-605; Gogos JA, 1996, P NATL ACAD SCI USA, V93, P2159, DOI 10.1073/pnas.93.5.2159; Greisman HA, 1997, SCIENCE, V275, P657, DOI 10.1126/science.275.5300.657; HARWERTH IM, 1992, J BIOL CHEM, V267, P15160; Houbaviy HB, 1996, P NATL ACAD SCI USA, V93, P13577, DOI 10.1073/pnas.93.24.13577; HYDEDERUYSCHER RP, 1995, NUCLEIC ACIDS RES, V23, P4457, DOI 10.1093/nar/23.21.4457; Isalan M, 1998, BIOCHEMISTRY-US, V37, P12026, DOI 10.1021/bi981358z; Isalan M, 1997, P NATL ACAD SCI USA, V94, P5617, DOI 10.1073/pnas.94.11.5617; Jamieson AC, 1996, P NATL ACAD SCI USA, V93, P12834, DOI 10.1073/pnas.93.23.12834; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kim CA, 1996, NAT STRUCT BIOL, V3, P940, DOI 10.1038/nsb1196-940; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; Liu PQ, 2001, J BIOL CHEM, V276, P11323, DOI 10.1074/jbc.M011172200; Liu Q, 1997, P NATL ACAD SCI USA, V94, P5525, DOI 10.1073/pnas.94.11.5525; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; Narayan VA, 1997, J BIOL CHEM, V272, P7801, DOI 10.1074/jbc.272.12.7801; NARDELLI J, 1992, NUCLEIC ACIDS RES, V20, P4137, DOI 10.1093/nar/20.16.4137; Nolte RT, 1998, P NATL ACAD SCI USA, V95, P2938, DOI 10.1073/pnas.95.6.2938; Pabo CO, 2000, J MOL BIOL, V301, P597, DOI 10.1006/jmbi.2000.3918; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Rader C, 1997, CURR OPIN BIOTECH, V8, P503, DOI 10.1016/S0958-1669(97)80075-4; Segal DJ, 2000, CURR OPIN CHEM BIOL, V4, P34, DOI 10.1016/S1367-5931(99)00048-4; Segal DJ, 1999, P NATL ACAD SCI USA, V96, P2758, DOI 10.1073/pnas.96.6.2758; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; Wolfe SA, 1999, J MOL BIOL, V285, P1917, DOI 10.1006/jmbi.1998.2421; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183; WU H, 1995, P NATL ACAD SCI USA, V92, P344, DOI 10.1073/pnas.92.2.344; Wuttke DS, 1997, J MOL BIOL, V273, P183, DOI 10.1006/jmbi.1997.1291; Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200; ZweidlerMcKay PA, 1996, MOL CELL BIOL, V16, P4024	45	228	288	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29466	29478		10.1074/jbc.M102604200	http://dx.doi.org/10.1074/jbc.M102604200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11340073	hybrid			2022-12-25	WOS:000170346000109
J	Alderton, F; Rakhit, S; Kong, KC; Palmer, T; Sambi, B; Pyne, S; Pyne, NJ				Alderton, F; Rakhit, S; Kong, KC; Palmer, T; Sambi, B; Pyne, S; Pyne, NJ			Tethering of the platelet-derived growth factor ss receptor to G-protein-coupled receptors - A novel platform for integrative signaling by these receptor classes in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AIRWAY SMOOTH-MUSCLE; MEDIATED TYROSINE PHOSPHORYLATION; SPHINGOSINE 1-PHOSPHATE RECEPTOR; KINASE ACTIVATION; PHOSPHOINOSITIDE 3-KINASE; G(BETA-GAMMA) SUBUNITS; STIMULATION; PATHWAY; ASSOCIATION; REQUIRES	Here we provide evidence to show that the platelet-derived growth factor beta receptor is tethered to endogenous G-protein-coupled receptor(s) in human embryonic kidney 293 cells. The tethered receptor complex provides a platform on which receptor tyrosine kinase and G-protein-coupled receptor signals can be integrated to produce more efficient stimulation of the p42/p44 mitogen-activated protein kinase pathway. This was based on several lines of evidence. Fix st, we have shown that pertussis toxin (which uncouples G-protein-coupled receptors from inhibitory G-proteins) reduced the platelet-derived growth factor stimulation of p42/p44 mitogen-activated protein kinase. Second, transfection of cells with inhibitory G-protein a subunit increased the activation of p42/p44 mitogen-activated protein kinase by platelet-derived growth factor. Third, platelet-derived growth factor stimulated the tyrosine phosphorylation of the inhibitory G-protein a subunit, which was blocked by the platelet-derived growth factor kinase inhibitor, tyrphostin AG 1296. We have also shown that the platelet-derived growth factor beta receptor forms a tethered complex with Myc-tagged endothelial differentiation gene 1 (a G-protein-coupled receptor whose agonist is sphingosine I-phosphate) in cells co-transfected with these receptors. This facilitates platelet-derived growth factor-stimulated tyrosine phosphorylation of the inhibitory G-protein a subunit and increases p42/p44 mitogen-activated protein kinase activation. In addition, we found that G-protein-coupled receptor kinase 2 and beta -arrestin I can associate with the platelet-derived growth factor beta receptor. These proteins play an important role in regulating endocytosis of G-protein-coupled receptor signal complexes, which is required for activation of p42/p44 mitogen-activated protein kinase. Thus, platelet-derived growth factor beta receptor signaling may be initiated by G-protein-coupled receptor kinase 2/beta -arrestin I that has been recruited to the platelet-derived growth factor beta receptor by its tethering to a G-protein-coupled receptor(s). These results provide a model that may account for the co-mitogenic effect of certain G-protein-coupled receptor agonists with platelet-derived growth factor on DNA synthesis.	Univ Strathclyde, Dept Physiol & Pharmacol, Strathclyde Inst Biomed Sci, Glasgow G4 0NR, Lanark, Scotland; Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland	University of Strathclyde; University of Glasgow	Pyne, NJ (corresponding author), Univ Strathclyde, Dept Physiol & Pharmacol, Strathclyde Inst Biomed Sci, 27 Taylor St, Glasgow G4 0NR, Lanark, Scotland.		Pyne, Susan/AAF-5001-2019	Pyne, Susan/0000-0002-6608-9584; Pyne, Nigel/0000-0002-5657-4578				Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Conway AM, 1999, BIOCHEM J, V337, P171, DOI 10.1042/0264-6021:3370171; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Fedorov YV, 1998, MOL CELL BIOL, V18, P5780, DOI 10.1128/MCB.18.10.5780; Graler MH, 1998, GENOMICS, V53, P164, DOI 10.1006/geno.1998.5491; Hallak H, 2000, J BIOL CHEM, V275, P2255, DOI 10.1074/jbc.275.4.2255; HLA T, 1990, J BIOL CHEM, V265, P9308; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Karoor V, 1998, J BIOL CHEM, V273, P33035, DOI 10.1074/jbc.273.49.33035; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; KRUPINSKI J, 1988, J BIOL CHEM, V263, P12333; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; LUTTRELL L, 1990, J BIOL CHEM, V265, P16873; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; OBRIEN RM, 1987, FEBS LETT, V212, P281, DOI 10.1016/0014-5793(87)81361-3; OKAZAKI H, 1993, BIOCHEM BIOPH RES CO, V190, P1104, DOI 10.1006/bbrc.1993.1163; Rakhit S, 2000, MOL PHARMACOL, V58, P413, DOI 10.1124/mol.58.2.413; Rakhit S, 1999, BIOCHEM J, V338, P643, DOI 10.1042/0264-6021:3380643; Rakhit S, 2001, MOL PHARMACOL, V60, P63, DOI 10.1124/mol.60.1.63; ROTHENBERG PL, 1988, J BIOL CHEM, V263, P15546; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Wang HY, 2000, J BIOL CHEM, V275, P36086, DOI 10.1074/jbc.M004404200; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351	28	139	141	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28578	28585		10.1074/jbc.M102771200	http://dx.doi.org/10.1074/jbc.M102771200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11359779	hybrid			2022-12-25	WOS:000170093400111
J	Boren, J; Lookene, A; Makoveichuk, E; Xiang, SQ; Gustafsson, M; Liu, HQ; Talmud, P; Olivecrona, G				Boren, J; Lookene, A; Makoveichuk, E; Xiang, SQ; Gustafsson, M; Liu, HQ; Talmud, P; Olivecrona, G			Binding of low density lipoproteins to lipoprotein lipase is dependent on lipids but not on apolipoprotein B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TO-RETENTION HYPOTHESIS; N-TERMINAL 17-PERCENT; HEPARAN-SULFATE; EXPRESSION; SURFACE; INCREASES; PLASMA; LDL; ATHEROSCLEROSIS; PROTEOGLYCANS	Lipoprotein lipase (LPL) efficiently mediates the binding of lipoprotein particles to lipoprotein receptors and to proteoglycans at cell surfaces and in the extracellular matrix. It has been proposed that LPL increases the retention of atherogenic Lipoproteins in the vessel wall and mediates the uptake of lipoproteins in cells, thereby promoting lipid accumulation and plaque formation. We investigated the interaction between LPL and low density lipoproteins (LDLs) with special reference to the protein-protein interaction between LPL and apolipoprotein B (apoB). Chemical modification of lysines and arginines in apoB or mutation of its main proteoglycan binding site did not abolish the interaction of LDL with LPL as shown by surface plasmon resonance (SPR) and by experiments with THP-I macrophages. Recombinant LDL with either apoB100 or apoB48 bound with similar affinity. In contrast, partial delipidation of LDL markedly decreased binding to LPL. In cell culture experiments, phosphatidylcholine-containing liposomes competed efficiently with LDL for binding to LPL. Each LDL particle bound several (up to 15) LPL dimers as determined by SPR and by experiments with THP-I macrophages. A recombinant NH2-terminal fragment of apoB (apoB17) bound with low affinity to LPL as shown by SPR, but this interaction was completely abolished by partial delipidation of apoB17. me conclude that the LPL-apoB interaction is not significant in brid,bing LDL to cell surfaces and matrix components; the main interaction is between LPL and the LDL lipids.	Gothenburg Univ, Wallenberg Lab, S-41345 Gothenburg, Sweden; Umea Univ, Dept Med Biosci, S-90187 Umea, Sweden; NICPB, EE-12618 Tallinn, Estonia; UCL, Rayne Inst, Dept Med, Div Cardiovasc Genet, London WC1E 6JJ, England	University of Gothenburg; Umea University; National Institute of Chemical Physics & Biophysics (NICPB); University of London; King's College London; University College London	Boren, J (corresponding author), Sahlgrens Univ Hosp, Wallenberg Lab, S-41545 Gothenburg, Sweden.	jan.boren@wlab.wall.gu.se	Talmud, Philippa J/C-4402-2008	Talmud, Philippa/0000-0002-5560-1933				AUWERX JH, 1988, BIOCHEMISTRY-US, V27, P2651, DOI 10.1021/bi00408a003; Babaev VR, 1999, J CLIN INVEST, V103, P1697, DOI 10.1172/JCI6117; Beisiegel U, 1996, ATHEROSCLEROSIS, V124, P1, DOI 10.1016/0021-9150(95)05792-7; BENGTSSON G, 1980, EUR J BIOCHEM, V106, P549, DOI 10.1111/j.1432-1033.1980.tb04602.x; BENGTSSONOLIVECRONA G, 1991, METHOD ENZYMOL, V197, P345; Boren J, 1996, GENOME RES, V6, P1123, DOI 10.1101/gr.6.11.1123; Boren J, 1998, J CLIN INVEST, V101, P1084, DOI 10.1172/JCI1847; Boren J, 1998, J CLIN INVEST, V101, P2658, DOI 10.1172/JCI2265; BOREN J, 1992, J BIOL CHEM, V267, P9858; Camejo G, 1998, ATHEROSCLEROSIS, V139, P205, DOI 10.1016/S0021-9150(98)00107-5; Choi SY, 1997, J LIPID RES, V38, P77; CHOI SY, 1995, J BIOL CHEM, V270, P8081, DOI 10.1074/jbc.270.14.8081; Clee SM, 2000, J LIPID RES, V41, P521; EDWARDS IJ, 1993, J LIPID RES, V34, P1155; ELOVSON J, 1988, J LIPID RES, V29, P1461; ESTERBAUER H, 1987, J LIPID RES, V28, P495; Gaus K, 1999, J COLLOID INTERF SCI, V217, P111, DOI 10.1006/jcis.1999.6333; Goldberg IJ, 1996, J LIPID RES, V37, P693; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; HELMKAMP RW, 1967, INT J APPL RADIAT IS, V18, P747, DOI 10.1016/0020-708X(67)90012-9; Hendriks WL, 1996, BIOCHEM J, V314, P563, DOI 10.1042/bj3140563; HERSCOVITZ H, 1991, P NATL ACAD SCI USA, V88, P7313, DOI 10.1073/pnas.88.16.7313; Herscovitz H, 2001, J LIPID RES, V42, P51; Hussain MM, 2000, J BIOL CHEM, V275, P29324, DOI 10.1074/jbc.M005317200; Innerarity T L, 1986, Methods Enzymol, V129, P542; INNERARITY TL, 1978, BIOCHEMISTRY-US, V17, P1440, DOI 10.1021/bi00601a013; IVERIUS PH, 1976, J BIOL CHEM, V251, P7791; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Leitinger N, 1999, ARTERIOSCL THROM VAS, V19, P1291, DOI 10.1161/01.ATV.19.5.1291; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; Lookene A, 1997, BIOCHEMISTRY-US, V36, P5267, DOI 10.1021/bi962699k; Lookene A, 1996, BIOCHEMISTRY-US, V35, P12155, DOI 10.1021/bi960008e; MacPhee CE, 1997, J LIPID RES, V38, P1649; Makoveichuk E, 1998, BIOCHEM BIOPH RES CO, V252, P703, DOI 10.1006/bbrc.1998.9596; Mann WA, 1999, ATHEROSCLEROSIS, V145, P61, DOI 10.1016/S0021-9150(99)00015-5; MARCEL YL, 1988, ARTERIOSCLEROSIS, V8, P832, DOI 10.1161/01.ATV.8.6.832; McNamara JR, 1996, J LIPID RES, V37, P1924; Mead JR, 1999, FEBS LETT, V462, P1, DOI 10.1016/S0014-5793(99)01495-7; Merkel M, 1998, P NATL ACAD SCI USA, V95, P13841, DOI 10.1073/pnas.95.23.13841; OBRIEN KD, 1992, J CLIN INVEST, V89, P1544, DOI 10.1172/JCI115747; Olin KL, 1999, J BIOL CHEM, V274, P34629, DOI 10.1074/jbc.274.49.34629; OLIVECRONA G, 1995, CURR OPIN LIPIDOL, V6, P291, DOI 10.1097/00041433-199510000-00009; Olivecrona T, 1999, LIPOPROTEINS IN HEALTH AND DISEASE, P223; Olivecrona T., 1987, LIPOPROTEIN LIPASE, P15; Pang L, 1996, J BIOL CHEM, V271, P19518, DOI 10.1074/jbc.271.32.19518; Pentikainen MO, 2000, J BIOL CHEM, V275, P5694, DOI 10.1074/jbc.275.8.5694; Podrez EA, 2000, J LIPID RES, V41, P1455; RENIER G, 1993, ARTERIOSCLER THROMB, V13, P190, DOI 10.1161/01.ATV.13.2.190; SAXENA U, 1995, ARTERIOSCL THROM VAS, V15, P1240, DOI 10.1161/01.ATV.15.8.1240; SAXENA U, 1992, J CLIN INVEST, V89, P373, DOI 10.1172/JCI115595; Semenkovich CF, 1998, J LIPID RES, V39, P1141; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; WALLINDER L, 1984, BIOCHIM BIOPHYS ACTA, V795, P513, DOI 10.1016/0005-2760(84)90181-4; Wang XS, 2000, ATHEROSCLEROSIS, V150, P357, DOI 10.1016/S0021-9150(99)00413-X; Weinberg RB, 2000, J LIPID RES, V41, P1419; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; Williams KJ, 1998, CURR OPIN LIPIDOL, V9, P471, DOI 10.1097/00041433-199810000-00012; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P10143, DOI 10.1073/pnas.88.22.10143; YOUNG SG, 1986, P NATL ACAD SCI USA, V83, P1101, DOI 10.1073/pnas.83.4.1101; Zechner R, 1997, CURR OPIN LIPIDOL, V8, P77, DOI 10.1097/00041433-199704000-00005	61	40	41	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26916	26922		10.1074/jbc.M011090200	http://dx.doi.org/10.1074/jbc.M011090200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11331277	hybrid			2022-12-25	WOS:000169966900026
J	Zhang, HF; Lu, SL; Morrison, SL; Tomlinson, S				Zhang, HF; Lu, SL; Morrison, SL; Tomlinson, S			Targeting the functional antibody-decay-accelerating factor fusion proteins to a cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT-SYSTEM; FACTOR-I; CD59; INHIBITION; C9; TRANSPLANTATION; INFLAMMATION; ACTIVATION; CLONING; DISEASE	Recombinant soluble complement inhibitors hold promise for the treatment, of inflammatory disease and disease states associated with transplantation. Targeting complement inhibitors to the site of complement activation and disease may enhance their efficacy and safety. Data presented show that targeting of decay-accelerating factor (DAF, an inhibitor of complement activation) to a cell surface by means of antibody fragments is feasible and that cell-targeted DAF provides significantly enhanced protection from complement deposition and lysis compared with soluble untargeted DAF. An extracellular region of DAF was joined to an antibody combining site with specificity for the hapten dansyl, at the end of either C(H)1 or C(H)3 Tg regions. The recombinant IgG-DAF chimeric proteins retained antigen specificity and bound to dansylated Chinese hamster ovary cells. Both soluble C(H)1-DAF and C(H)3-DAF were effective at inhibiting complement-mediated lysis of untargeted Chinese hamster ovary cells at molar concentrations within the range reported by others for soluble DAF. However, when targeted to a dansyl-labeled cell membrane, C(H)1-DAF was significantly more potent at inhibiting complement deposition and complement-mediated lysis. Cell-bound C(H)1-DAF also provided cells with protection from complement lysis after removal of unbound C(H)1-DAF. Of further importance, the insertion of a nonfunctional protein domain of DAF (the N-terminal short consensus repeat) between C(H)1 and the functional DAF domain increased activity of the fusion protein. In contrast to C(H)1-DAF, C(H)3-DAF was not significantly better at protecting targeted versus untargeted cells from complement, indicating that a small targeting vehicle is preferable to a large one. We have previously shown that for effective functioning of soluble complement inhibitor CD59, binding of CD59 to the cell surface close to the site of complement activation is required. Significantly, such a constraint did:not apply for effective DAF function.	Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA; Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA	Medical University of South Carolina; University of California System; University of California Los Angeles	Tomlinson, S (corresponding author), Med Univ S Carolina, Dept Microbiol & Immunol, BSB 201,173 Ashley Ave, Charleston, SC 29425 USA.	tomlinss@musc.edu			NIAID NIH HHS [AI 34451] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034451, R29AI034451] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Asghar SS, 2000, FRONT BIOSCI-LANDMRK, V5, pE63, DOI 10.2741/asghar; Brodbeck WG, 1996, J IMMUNOL, V156, P2528; Byrne G, 1997, TRANSPLANTATION, V63, P149, DOI 10.1097/00007890-199701150-00027; CARAS IW, 1987, NATURE, V325, P545, DOI 10.1038/325545a0; Christiansen D, 1996, EUR J IMMUNOL, V26, P578, DOI 10.1002/eji.1830260312; COYNE KE, 1992, J IMMUNOL, V149, P2906; FODOR WL, 1995, J IMMUNOL, V155, P4135; Harlow E., 1988, ANTIBODIES LAB MANUA; Higgins PJ, 1997, J IMMUNOL, V158, P2872; HOURCADE D, 1989, ADV IMMUNOL, V45, P381, DOI 10.1016/S0065-2776(08)60697-5; Kirschfink M, 1997, IMMUNOPHARMACOLOGY, V38, P51, DOI 10.1016/S0162-3109(97)00057-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW SKA, 1995, IN FOCUS, P46; MEDOF ME, 1984, J EXP MED, V160, P1558, DOI 10.1084/jem.160.5.1558; MEDOF ME, 1987, P NATL ACAD SCI USA, V84, P2007, DOI 10.1073/pnas.84.7.2007; MERI S, 1990, IMMUNOLOGY, V71, P1; MORAN P, 1992, J IMMUNOL, V149, P1736; Morgan BP, 1996, BIOCHEM SOC T, V24, P224, DOI 10.1042/bst0240224; Morgan BP, 1998, BIOCHEM SOC T, V26, P49, DOI 10.1042/bst0260049; NINOMIYA H, 1992, J BIOL CHEM, V267, P13675; POON PH, 1995, J BIOL CHEM, V270, P8571, DOI 10.1074/jbc.270.15.8571; ROLLINS SA, 1990, J IMMUNOL, V144, P3478; RYAN US, 1995, NAT MED, V1, P967, DOI 10.1038/nm0995-967; SHIN SU, 1994, J BIOL CHEM, V269, P4979; SHIN SU, 1990, P NATL ACAD SCI USA, V87, P5322, DOI 10.1073/pnas.87.14.5322; Squinto SP, 1996, CURR OPIN BIOTECH, V7, P641, DOI 10.1016/S0958-1669(96)80076-0; Wang H, 1999, TRANSPLANTATION, V68, P1643, DOI 10.1097/00007890-199912150-00007; WANG Y, 1995, P NATL ACAD SCI USA, V92, P8955, DOI 10.1073/pnas.92.19.8955; Wang Y, 1996, P NATL ACAD SCI USA, V93, P8563, DOI 10.1073/pnas.93.16.8563; Yu JH, 1997, J EXP MED, V185, P745, DOI 10.1084/jem.185.4.745; Zhang HF, 1999, J CLIN INVEST, V103, P55, DOI 10.1172/JCI4607	31	23	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27290	27295		10.1074/jbc.M100436200	http://dx.doi.org/10.1074/jbc.M100436200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11352906	hybrid			2022-12-25	WOS:000169966900075
J	Hartness, ME; Lewis, A; Searle, GJ; O'Kelly, I; Peers, C; Kemp, PJ				Hartness, ME; Lewis, A; Searle, GJ; O'Kelly, I; Peers, C; Kemp, PJ			Combined antisense and pharmacological approaches implicate hTASK as an airway O-2 sensing K+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; NADPH-OXIDASE; CHEMORECEPTOR CELLS; ION CHANNELS; RAT; ACID; PH; EXPRESSION; MODULATION; HYPOXIA	Neuroepithelial bodies act as airway oxygen sensors. The lung carcinoma line H146 is an established model for neuroepithelial body cells. Although O-2 sensing in both cells is via NADPH oxidase H2O2/free radical production and acute hypoxia promotes K+ channel closure and cell depolarization, the identity of the K+ channel is still controversial. However, recent data point toward the involvement of a member of the tandem P domain family of K+ channels. Reverse transcription-polymerase chain reaction screening indicates that all known channels other than hTWIK1 and hTRAAK are expressed in H146 cells. Our detailed pharmacological characterization of the O-2-sensitive K+ current described herein is compatible with the involvement of hTASK1 or hTASK3 (pH dependence, tetraethylammonium and dithiothreitol insensitivity, blockade by arachidonic acid, and halothane activation). Furthermore, we have used antisense oligodeoxynucleotides directed against hTASK1 and hTASK3 to suppress almost completely the hTASK1 protein and show that these cells no longer respond to acute hypoxia; this behavior was not mirrored in liposome-only or missense-treated cells. Finally, we have used Zn2+ treatment as a maneuver able to discriminate between these two homologues of hTASK and show that the most likely candidate channel for O-2 sensing in these cells is hTASK3.	Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Cardiovasc Res Inst, Leeds LS2 9JT, W Yorkshire, England	University of Leeds; University of Leeds	Kemp, PJ (corresponding author), Univ Leeds, Sch Biomed Sci, Worsley Med & Dent Bldg, Leeds LS2 9JT, W Yorkshire, England.	p.z.kemp@leeds.ac.uk	Hartness, Matthew/ABE-6961-2021; Kemp, Paul/A-4634-2010	Kemp, Paul/0000-0003-2773-973X; Peers, Chris/0000-0002-8354-346X				Buckler KJ, 2000, J PHYSIOL-LONDON, V525, P135, DOI 10.1111/j.1469-7793.2000.00135.x; Conforti L, 2000, J PHYSIOL-LONDON, V524, P783, DOI 10.1111/j.1469-7793.2000.00783.x; Decher N, 2001, FEBS LETT, V492, P84, DOI 10.1016/S0014-5793(01)02222-0; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; Fu XW, 2000, P NATL ACAD SCI USA, V97, P4374, DOI 10.1073/pnas.97.8.4374; Fu XW, 1999, J PHYSIOL-LONDON, V514, P139, DOI 10.1111/j.1469-7793.1999.139af.x; GAZDAR AF, 1988, CANCER RES, V48, P4078; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Kim Y, 2000, J BIOL CHEM, V275, P9340, DOI 10.1074/jbc.275.13.9340; LAUWERYNS JM, 1973, Z ZELLFORSCH MIK ANA, V145, P521, DOI 10.1007/BF00306722; Leonoudakis D, 1998, J NEUROSCI, V18, P868; Lesage F, 1996, EMBO J, V15, P6400, DOI 10.1002/j.1460-2075.1996.tb01031.x; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; LESAGE F, 2000, AM J PHYSL, V793; Lopes CMB, 2000, J BIOL CHEM, V275, P16969, DOI 10.1074/jbc.M001948200; LopezBarneo J, 1996, TRENDS NEUROSCI, V19, P435; Maingret F, 1999, J BIOL CHEM, V274, P26691, DOI 10.1074/jbc.274.38.26691; Meadows HJ, 2001, NEUROPHARMACOLOGY, V40, P551, DOI 10.1016/S0028-3908(00)00189-1; Millar JA, 2000, P NATL ACAD SCI USA, V97, P3614, DOI 10.1073/pnas.050012597; Mojet MH, 1997, J PHYSIOL-LONDON, V504, P175, DOI 10.1111/j.1469-7793.1997.175bf.x; NECKERS L, 1993, AM J PHYSIOL, V265, pL1, DOI 10.1152/ajplung.1993.265.1.L1; O'Kelly I, 1998, AM J PHYSIOL-LUNG C, V275, pL709, DOI 10.1152/ajplung.1998.275.4.L709; O'Kelly I, 1999, AM J PHYSIOL-LUNG C, V276, pL96, DOI 10.1152/ajplung.1999.276.1.L96; O'Kelly I, 2000, J BIOL CHEM, V275, P7684, DOI 10.1074/jbc.275.11.7684; Patel AJ, 1999, NAT NEUROSCI, V2, P422, DOI 10.1038/8084; Peers C, 1997, TRENDS PHARMACOL SCI, V18, P405; Rajan S, 2000, J BIOL CHEM, V275, P16650, DOI 10.1074/jbc.M000030200; Rashid AJ, 2001, J NEUROSCI, V21, P125, DOI 10.1523/JNEUROSCI.21-01-00125.2001; Reyes R, 1998, J BIOL CHEM, V273, P30863, DOI 10.1074/jbc.273.47.30863; Rudy B, 1999, ANN NY ACAD SCI, V868, P304, DOI 10.1111/j.1749-6632.1999.tb11295.x; Rychkov GY, 1997, J PHYSIOL-LONDON, V501, P355, DOI 10.1111/j.1469-7793.1997.355bn.x; Stengl M, 1998, J PHYSIOL-LONDON, V511, P827, DOI 10.1111/j.1469-7793.1998.827bg.x; Wang DS, 1996, P NATL ACAD SCI USA, V93, P13182, DOI 10.1073/pnas.93.23.13182; Youngson C, 1997, MICROSC RES TECHNIQ, V37, P101, DOI 10.1002/(SICI)1097-0029(19970401)37:1<101::AID-JEMT10>3.3.CO;2-S; YOUNGSON C, 1993, NATURE, V365, P153, DOI 10.1038/365153a0	39	96	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26499	26508		10.1074/jbc.M010357200	http://dx.doi.org/10.1074/jbc.M010357200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11344164	hybrid			2022-12-25	WOS:000169823300113
J	Kakio, A; Nishimoto, S; Yanagisawa, K; Kozutsumi, Y; Matsuzaki, K				Kakio, A; Nishimoto, S; Yanagisawa, K; Kozutsumi, Y; Matsuzaki, K			Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSOLUBLE MEMBRANE COMPARTMENT; SYNAPTIC PLASMA-MEMBRANES; A-BETA; PRECURSOR PROTEIN; FIBRIL FORMATION; DISEASE; PEPTIDE; BINDING; AGGREGATION; VESICLES	GM1 ganglioside-bound amyloid beta -protein (GM1/A beta), found in brains exhibiting early pathological changes of Alzheimer's disease (AD) including diffuse plaques, has been suggested to be involved in the initiation of amyloid fibril formation in vivo by acting as a seed. To elucidate the molecular mechanism underlying GM1/A beta formation, the effects of lipid composition on the binding of A beta to GM1-containing lipid bilayers were examined in detail using fluorescent dye-labeled human A beta-(1-40). Increases in not only GM1 but also cholesterol contents in the lipid bilayers facilitated the binding of A beta to the membranes by altering the binding capacity but not the binding affinity. An increase in membrane-bound A beta concentration triggered its conformational transition from helix-rich to beta -sheet-rich structures. Excimer formation of fluorescent dye-labeled GM1 suggested that A beta recognizes a GM1 "cluster" in membranes, the formation of which is facilitated by cholesterol, The results of the present study strongly suggested that increases in intramembrane cholesterol content, which are likely to occur during aging, appear to be a risk factor for amyloid fibril formation.	Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Engn, Dept Energy & Hydrocarbon Chem, Sakyo Ku, Kyoto 6068501, Japan; Natl Inst Longev Sci, Dept Dementia Res, Morioka, Obu 4748522, Japan; RIKEN, Glycochain Express Lab, Suprabiomol Syst Res, Frontier Res Syst, Wako, Saitama 3510198, Japan	Kyoto University; Kyoto University; RIKEN	Matsuzaki, K (corresponding author), Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068501, Japan.							Avdulov NA, 1997, J NEUROCHEM, V69, P1746; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; Brown RE, 1998, J CELL SCI, V111, P1; BURDICK D, 1992, J BIOL CHEM, V267, P546; CERNY S, 1983, CHEM PHYSICS SOLID S, V2, P1; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; ChooSmith LP, 1997, FEBS LETT, V402, P95, DOI 10.1016/S0014-5793(96)01504-9; ChooSmith LP, 1997, J BIOL CHEM, V272, P22987, DOI 10.1074/jbc.272.37.22987; EPAND RM, 1983, BIOCHEMISTRY-US, V22, P5074, DOI 10.1021/bi00291a005; Esler WP, 2000, BIOCHEMISTRY-US, V39, P6288, DOI 10.1021/bi992933h; Ferraretto A, 1997, BIOCHEMISTRY-US, V36, P9232, DOI 10.1021/bi970428j; FORSTER T, 1969, ANGEW CHEM INT EDIT, V8, P333, DOI 10.1002/anie.196903331; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Hasegawa K, 1999, BIOCHEMISTRY-US, V38, P15514, DOI 10.1021/bi991161m; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; Igbavboa U, 1997, J NEUROCHEM, V69, P1661; Igbavboa U, 1996, J NEUROCHEM, V66, P1717; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P112; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Matsuzaki K, 1999, BIOCHEMISTRY-US, V38, P4137, DOI 10.1021/bi982345o; MATSUZAKI K, 1989, BIOCHIM BIOPHYS ACTA, V981, P130, DOI 10.1016/0005-2736(89)90090-4; MATSUZAKI K, 1994, BIOCHEMISTRY-US, V33, P3342, DOI 10.1021/bi00177a027; MCDANIEL R, 1985, BIOCHIM BIOPHYS ACTA, V819, P153, DOI 10.1016/0005-2736(85)90169-5; McLaurin J, 1998, J BIOL CHEM, V273, P4506, DOI 10.1074/jbc.273.8.4506; McLaurin J, 1996, J BIOL CHEM, V271, P26482, DOI 10.1074/jbc.271.43.26482; Mizuno T, 1999, J BIOL CHEM, V274, P15110, DOI 10.1074/jbc.274.21.15110; Morishima-Kawashima M, 1998, BIOCHEMISTRY-US, V37, P15247, DOI 10.1021/bi981843u; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; Racchi M, 1997, BIOCHEM J, V322, P893, DOI 10.1042/bj3220893; SCHWARZ G, 1989, BIOCHIMIE, V71, P1, DOI 10.1016/0300-9084(89)90125-9; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; SOTO C, 1995, J BIOL CHEM, V270, P3063, DOI 10.1074/jbc.270.7.3063; Takakuwa T, 1985, ANAL SCI, V1, P215, DOI DOI 10.2116/ANALSCI.1.215; Terzi E, 1997, BIOCHEMISTRY-US, V36, P14845, DOI 10.1021/bi971843e; THOMPSON TE, 1985, BIOCHIM BIOPHYS ACTA, V817, P229, DOI 10.1016/0005-2736(85)90024-0; Tseng BP, 1999, BIOCHEMISTRY-US, V38, P10424, DOI 10.1021/bi990718v; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; Wieprecht T, 1999, BIOCHEMISTRY-US, V38, P10377, DOI 10.1021/bi990913+; Wieprecht T, 2000, BIOCHEMISTRY-US, V39, P442, DOI 10.1021/bi992146k; YANAGISAWA K, 1995, NAT MED, V1, P1062, DOI 10.1038/nm1095-1062; Yanagisawa K, 1997, FEBS LETT, V420, P43, DOI 10.1016/S0014-5793(97)01484-1; Yanagisawa K, 1998, NEUROBIOL AGING, V19, pS65, DOI 10.1016/S0197-4580(98)00032-3	47	324	337	0	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24985	24990		10.1074/jbc.M100252200	http://dx.doi.org/10.1074/jbc.M100252200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342534	hybrid			2022-12-25	WOS:000169800700074
J	Parfenyev, AN; Salminen, A; Halonen, P; Hachimori, A; Baykov, AA; Lahti, R				Parfenyev, AN; Salminen, A; Halonen, P; Hachimori, A; Baykov, AA; Lahti, R			Quaternary structure and metal ion requirement of family II pyrophosphatases from Bacillus subtilis, Streptococcus gordonii, and Streptococcus mutans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI INORGANIC PYROPHOSPHATASE; ESCHERICHIA-COLI; MANGANESE; SUBSTITUTIONS; ENCODES; ENZYME; FORMS	Pyrophosphatase (PPase) from Bacillus subtilis has recently been found to be the first example of a family II soluble PPase with a unique requirement for Mn2+. In the present work, we cloned and overexpressed in Escherichia coli putative genes for two more family II PPases (from Streptococcus mutans and Streptococcus gordonii), isolated the recombinant proteins, and showed them to be highly specific and active PPases (catalytic constants of 1700-3300 s(-1) at 25 degreesC in comparison with 200-400 s(-1) for family I). All three family II PPases were found to be dimeric manganese metalloenzymes, dissociating into much less active monomers upon removal of Mn2+. The dimers were found to have one high affinity manganese-specific site (K-d of 0.2-3 nM for Mn2+ and 10-80 muM for Mg2+) and two or three moderate affinity sites (K-d, similar to 1 mM for both cations) per subunit, Mn2+ binding to the high affinity site, which occurs with a half-time of less than 10 s at 1.5 mM Mn2+, dramatically shifts the monomer <----> dimer equilibrium in the direction of the dimer, further activates the dimer, and allows substantial activity (60-180 s(-1)) against calcium pyrophosphate, a potent inhibitor of family I PPases.	Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia; Moscow MV Lomonosov State Univ, Sch Chem, Moscow 119899, Russia; Turku Univ, Dept Biochem, FIN-20500 Turku, Finland; Shinshu Univ, Fac Text Sci & Technol, Inst High Polymer Res, Ueda, Nagano 3868856, Japan	Lomonosov Moscow State University; Lomonosov Moscow State University; Finland National Institute for Health & Welfare; University of Turku; Shinshu University	Baykov, AA (corresponding author), Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia.		Baykov, Alexander/AAH-5301-2021; Baykov, Alexander A/C-7981-2012	Baykov, Alexander/0000-0002-2495-8200				AVAEVA SM, 2000, BIOKHIMIYA, V65, P442; Baykov A A, 1999, Prog Mol Subcell Biol, V23, P127; BAYKOV AA, 1981, ANAL BIOCHEM, V116, P1, DOI 10.1016/0003-2697(81)90313-4; Baykov AA, 1995, J BIOL CHEM, V270, P30804, DOI 10.1074/jbc.270.51.30804; BEIGHTON D, 1980, MICROBIOS, V28, P149; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARNEY J, 1951, J BACTERIOL, V62, P145, DOI 10.1128/JB.62.2.145-148.1951; CHEN J, 1990, J BACTERIOL, V172, P5686, DOI 10.1128/jb.172.10.5686-5689.1990; CHERNYAK BY, 1982, ANAL BIOCHEM, V123, P101; CHERVENKA CH, 1972, METHODS ANAL ULTRACE, P23; COOPERMAN BS, 1992, TRENDS BIOCHEM SCI, V17, P262, DOI 10.1016/0968-0004(92)90406-Y; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; Fabrichniy IP, 1997, BIOCHEMISTRY-US, V36, P7746, DOI 10.1021/bi9629844; GLASS RL, 1973, ARCH ORAL BIOL, V18, P1099, DOI 10.1016/0003-9969(73)90083-6; Harutyunyan EH, 1997, BIOCHEMISTRY-US, V36, P7754, DOI 10.1021/bi962637u; Heikinheimo P, 1996, STRUCTURE, V4, P1491, DOI 10.1016/S0969-2126(96)00155-4; Heikinheimo P, 2001, P NATL ACAD SCI USA, V98, P3121, DOI 10.1073/pnas.061612498; KAPYLA J, 1995, BIOCHEMISTRY-US, V34, P792, DOI 10.1021/bi00003a012; Kornberg A., 1962, HORIZONS BIOCH, P251; Kuhn NJ, 1998, ARCH BIOCHEM BIOPHYS, V354, P47, DOI 10.1006/abbi.1998.0629; Kuhn NJ, 2000, ARCH BIOCHEM BIOPHYS, V379, P292, DOI 10.1006/abbi.2000.1860; KURGANOV BI, 1982, ALLOSTERIC ENZYMES K, P151; KURILOVA SA, 1984, BIOORG KHIM+, V10, P1153; LOESCHE WJ, 1986, MICROBIOL REV, V50, P353, DOI 10.1128/MMBR.50.4.353-380.1986; LUNDIN M, 1991, J BIOL CHEM, V266, P12168; MARTIN ME, 1986, J BIOL CHEM, V261, P9361; Merckel MC, 2001, STRUCTURE, V9, P289, DOI 10.1016/S0969-2126(01)00587-1; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; MOE OA, 1972, J BIOL CHEM, V247, P7315; Salminen A, 1999, J BIOL CHEM, V274, P33898, DOI 10.1074/jbc.274.48.33898; Sambrook J., 2002, MOL CLONING LAB MANU; Shintani T, 1998, FEBS LETT, V439, P263, DOI 10.1016/S0014-5793(98)01381-7; TONO H, 1967, J BIOL CHEM, V242, P2375; TONO H, 1967, J BACTERIOL, V93, P1819, DOI 10.1128/JB.93.6.1819-1824.1967; USHIRO I, 1991, J DENT RES, V70, P1422, DOI 10.1177/00220345910700110501; Velichko IS, 1998, BIOCHEMISTRY-US, V37, P734, DOI 10.1021/bi9714823; Young TW, 1998, MICROBIOL-SGM, V144, P2563, DOI 10.1099/00221287-144-9-2563	37	60	64	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24511	24518		10.1074/jbc.M101829200	http://dx.doi.org/10.1074/jbc.M101829200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342544	hybrid			2022-12-25	WOS:000169800700014
J	Tanha, J; Xu, P; Chen, ZG; Ni, F; Kaplan, H; Narang, SA; MacKenzie, CR				Tanha, J; Xu, P; Chen, ZG; Ni, F; Kaplan, H; Narang, SA; MacKenzie, CR			Optimal design features of camelized human single-domain antibody libraries	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN ANTIBODIES; IMPROVED CARBOHYDRATE-BINDING; SMALL RECOGNITION UNITS; PHAGE DISPLAY LIBRARY; B O-ANTIGEN; V-H DOMAIN; ESCHERICHIA-COLI; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; NMR-SPECTROSCOPY	We have constructed a human V-H library based on a camelized V-H sequence, The library was constructed with complete randomization of 19 of the 23 CDR3 residues and was penned against two monoclonal antibody targets to generate V-H sequences for determination of the antigen contact residue positions. Furthermore, the feasibility and desirability of introducing a disulfide bridge between CDR1 and CDR3 was investigated. Sequences derived from the library showed a bias toward the use of C-terminal CDR3 residues as antigen contact residues. Mass spectrometric analyses indicated that CDR1-CDR3 disulfide formation was universal. However, surface plasmon resonance and NMR data showed that the CDR3 constraint imposed by the disulfide bridge was not always desirable. Very high yields of soluble protein products and lack of protein aggregation, as demonstrated by the quality of the H-1-N-15 HSQC spectra, indicated that the V-H sequence for library construction was a good choice. These results should be useful in the design of V-H libraries with optimal features.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; Viventia Biotech Inc, Winnipeg, MB R3T 3Z1, Canada	National Research Council Canada; National Research Council Canada	MacKenzie, CR (corresponding author), Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada.	roger.mackenzie@nrc.ca	Ni, Feng/AAN-6388-2020					ANAND NN, 1991, GENE, V100, P39, DOI 10.1016/0378-1119(91)90347-E; ANAND NN, 1991, J BIOL CHEM, V266, P21874; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; CONSTANTINE KL, 1993, J BIOMOL NMR, V3, P41; CONSTANTINE KL, 1992, BIOCHEMISTRY-US, V31, P5033, DOI 10.1021/bi00136a017; DAN MD, 1995, J NEUROSURG, V82, P475, DOI 10.3171/jns.1995.82.3.0475; Davies J, 1996, PROTEIN ENG, V9, P531, DOI 10.1093/protein/9.6.531; DAVIES J, 1994, FEBS LETT, V339, P285, DOI 10.1016/0014-5793(94)80432-X; DAVIES J, 1995, BIO-TECHNOL, V13, P475, DOI 10.1038/nbt0595-475; Decanniere K, 1999, STRUCTURE, V7, P361, DOI 10.1016/S0969-2126(99)80049-5; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DENG SJ, 1995, P NATL ACAD SCI USA, V92, P4992, DOI 10.1073/pnas.92.11.4992; DENG SJ, 1994, J BIOL CHEM, V269, P9533; Desmyter A, 1996, NAT STRUCT BIOL, V3, P803, DOI 10.1038/nsb0996-803; Ghahroudi MA, 1997, FEBS LETT, V414, P521, DOI 10.1016/S0014-5793(97)01062-4; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; Harrison JL, 1996, METHOD ENZYMOL, V267, P83; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Kabat EA, 1991, SEQUENCES PROTEINS I; KNAPPIK A, 1994, BIOTECHNIQUES, V17, P754; Lauwereys M, 1998, EMBO J, V17, P3512, DOI 10.1093/emboj/17.13.3512; MACKENZIE CR, 1994, BIO-TECHNOL, V12, P390, DOI 10.1038/nbt0494-390; MacKenzie R, 1998, J IMMUNOL METHODS, V220, P39, DOI 10.1016/S0022-1759(98)00143-4; MICELI RM, 1994, J IMMUNOL METHODS, V167, P279, DOI 10.1016/0022-1759(94)90097-3; MUYLDERMANS S, 1994, PROTEIN ENG, V7, P1129, DOI 10.1093/protein/7.9.1129; Nguyen VK, 2000, EMBO J, V19, P921, DOI 10.1093/emboj/19.5.921; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Reiter Y, 1999, J MOL BIOL, V290, P685, DOI 10.1006/jmbi.1999.2923; Riechmann L, 1996, J MOL BIOL, V259, P957, DOI 10.1006/jmbi.1996.0373; RIECHMANN L, 1995, J BIOMOL NMR, V6, P141, DOI 10.1007/BF00211778; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sheriff S, 1996, NAT STRUCT BIOL, V3, P733, DOI 10.1038/nsb0996-733; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; SLATTER M, 1999, PROGR NMR SPECTROSC, V34, P93; Spinelli S, 1996, NAT STRUCT BIOL, V3, P752, DOI 10.1038/nsb0996-752; Voordijk S, 2000, J MOL BIOL, V300, P963, DOI 10.1006/jmbi.2000.3890; Vu KB, 1997, MOL IMMUNOL, V34, P1121, DOI 10.1016/S0161-5890(97)00146-6; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; [No title captured]	40	59	96	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24774	24780		10.1074/jbc.M100770200	http://dx.doi.org/10.1074/jbc.M100770200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11335716	hybrid			2022-12-25	WOS:000169800700049
J	Kashani-Poor, N; Zwicker, M; Kerscher, S; Brandt, U				Kashani-Poor, N; Zwicker, M; Kerscher, S; Brandt, U			A central functional role for the 49-kDa subunit within the catalytic core of mitochondrial complex I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; QUINONE OXIDOREDUCTASE; NICKEL HYDROGENASES; BINDING	We have analyzed a series of eleven mutations in the 49-kDa protein of mitochondrial complex I (NADH:ubiquinone oxidoreductase) from Yarrowia lipolytica to identify functionally important domains in this central subunit. The mutations were selected based on sequence homology with the large subunit of [NiFe] hydrogenases, None of the mutations affected assembly of complex I, all decreased or abolished ubiquinone reductase activity. Several mutants exhibited decreased sensitivities toward ubiquinone-analogous inhibitors. Unexpectedly, seven mutations affected the properties of iron-sulfur cluster N2, a prosthetic group not located in the 49-kDa subunit, In three of these mutants cluster N2 was not detectable by electron-paramagnetic resonance spectroscopy. The fact that the small subunit of hydrogenase is homologous to the PSST subunit of complex I proposed to host cluster N2 offers a straightforward explanation for the observed, unforeseen effects on this iron-sulfur cluster. We propose that the fold around the hydrogen reactive site of [NiFe] hydrogenase is conserved in the 49-kDa subunit of complex I and has become part of the inhibitor and ubiquinone binding region. We discuss that the fourth ligand of iron-sulfur cluster N2 missing in the PSST subunit may be provided by the 49-kDa subunit.	Univ Frankfurt Klinikum, Inst Biochem 1, ZBC, Dept Biochem 1, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital	Brandt, U (corresponding author), Univ Frankfurt Klinikum, Inst Biochem 1, ZBC, Dept Biochem 1, Theodor Stern Kai 7,Haus 25B, D-60590 Frankfurt, Germany.	brandt@zbc.klinik.uni-frankfurt.de	Brandt, Ulrich/C-4406-2008; Brandt, Ulrich/GLV-1242-2022	Brandt, Ulrich/0000-0003-1869-6811; Brandt, Ulrich/0000-0003-1869-6811				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Ahlers PM, 2000, J BIOL CHEM, V275, P23577, DOI 10.1074/jbc.M002074200; ALBRACHT SPJ, 1993, BIOCHIM BIOPHYS ACTA, V1144, P221, DOI 10.1016/0005-2728(93)90176-G; ALBRACHT SPJ, 1994, BBA-BIOENERGETICS, V1188, P167, DOI 10.1016/0005-2728(94)90036-1; Barth G, 1996, NONCONVENTIONAL YEAS, P313, DOI [DOI 10.1007/978-3-642-79856-6_10, 10.1007/978-3-642-79856-6_10]; Brandt U, 1997, BBA-BIOENERGETICS, V1318, P79, DOI 10.1016/S0005-2728(96)00141-7; Brandt U, 1998, BBA-BIOENERGETICS, V1364, P85; Chevallet M, 1997, EUR J BIOCHEM, V250, P451, DOI 10.1111/j.1432-1033.1997.0451a.x; Darrouzet E, 1998, FEBS LETT, V431, P34, DOI 10.1016/S0014-5793(98)00719-4; Djafarzadeh R, 2000, BBA-BIOENERGETICS, V1459, P230, DOI 10.1016/S0005-2728(00)00154-7; Friedrich T, 1998, BBA-BIOENERGETICS, V1365, P215, DOI 10.1016/S0005-2728(98)00070-X; Gray MW, 1999, SCIENCE, V283, P1476, DOI 10.1126/science.283.5407.1476; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; INGLEDEW WJ, 1980, BIOCHEM J, V186, P111, DOI 10.1042/bj1860111; Kerscher S, 2001, J BIOENERG BIOMEMBR, V33, P187, DOI 10.1023/A:1010726818165; Kerscher SJ, 1999, J CELL SCI, V112, P2347; Kunkel A, 1998, EUR J BIOCHEM, V252, P467, DOI 10.1046/j.1432-1327.1998.2520467.x; Lancaster CRD, 1999, BIOCHEM SOC T, V27, P591, DOI 10.1042/bst0270591; Loeffen J, 2001, ANN NEUROL, V49, P195, DOI 10.1002/1531-8249(20010201)49:2<195::AID-ANA39>3.0.CO;2-M; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OHNISHI T, 1993, J BIOENERG BIOMEMBR, V25, P325, DOI 10.1007/BF00762457; Prieur I, 2001, BBA-BIOENERGETICS, V1504, P173, DOI 10.1016/S0005-2728(01)00158-X; Rich P, 1999, BIOCHEM SOC T, V27, P561, DOI 10.1042/bst0270561; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schuler F, 1999, P NATL ACAD SCI USA, V96, P4149, DOI 10.1073/pnas.96.7.4149; SLED VD, 1993, BIOCHIM BIOPHYS ACTA, V1141, P262, DOI 10.1016/0005-2728(93)90051-G; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482	29	114	116	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24082	24087		10.1074/jbc.M102296200	http://dx.doi.org/10.1074/jbc.M102296200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11342550	hybrid			2022-12-25	WOS:000169531100114
J	Kallio, J; Pesonen, U; Kaipio, K; Karvonen, MK; Jaakkola, U; Heinonen, OJ; Uusitupa, MIJ; Koulu, M				Kallio, J; Pesonen, U; Kaipio, K; Karvonen, MK; Jaakkola, U; Heinonen, OJ; Uusitupa, MIJ; Koulu, M			Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans	FASEB JOURNAL			English	Article									Univ Turku, Dept Pharmacol & Clin Pharmacol, FIN-20520 Turku, Finland; Univ Turku, Dept Physiol, Paavo Nurmi Ctr, FIN-20520 Turku, Finland; Univ Kuopio, Dept Clin Nutr, FIN-70211 Kuopio, Finland	University of Turku; University of Turku; University of Eastern Finland	Kallio, J (corresponding author), Univ Turku, Dept Pharmacol & Clin Pharmacol, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.		Uusitupa, Matti Ilmari Julius/AAX-4929-2020; Heinonen, Olli/AAG-7298-2019	Heinonen, Olli/0000-0002-1722-1729; Pesonen, Ullamari/0000-0002-9962-212X					0	116	119	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1242	1244		10.1096/fj.00-0436fje	http://dx.doi.org/10.1096/fj.00-0436fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344101				2022-12-25	WOS:000168655200023
J	Affourtit, C; Krab, K; Leach, GR; Whitehouse, DG; Moore, AL				Affourtit, C; Krab, K; Leach, GR; Whitehouse, DG; Moore, AL			New insights into the regulation of plant succinate dehydrogenase - On the role of the protonmotive force	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL MATRIX; ALTERNATIVE OXIDASE; ELECTRON-TRANSPORT; LIGHT-SCATTERING; ADENYLATE KINASE; QUINONE POOL; MEMBRANE; CONTRACTION; RESPIRATION; CARRIER	Regulation of succinate dehydrogenase was investigated using tightly coupled potato tuber mitochondria in a novel fashion by simultaneously measuring the oxygen uptake rate and the ubiquinone (Q) reduction level. We found that the activation level of the enzyme is unambiguously reflected by the kinetic dependence of the succinate oxidation rate upon the Q-redox poise. Kinetic results indicated that succinate dehydrogenase is activated by both ATP (K-1/2 similar to 3 mum) and ADP. The carboxyatractyloside insensitivity of these stimulatory effects indicated that they occur at the cytoplasmic side of the mitochondrial inner membrane. Importantly, our novel approach revealed that the enzyme is also activated by oligomycin (K-1/2 similar to 16 nm). Time-resolved kinetic measurements of succinate dehydrogenase activation by succinate furthermore revealed that the activity of the enzyme is negatively affected by potassium. The succinate-induced activation (+/-K+) is prevented by the presence of an uncoupler. Together these results demonstrate that in vitro activity of succinate dehydrogenase is modulated by the protonmotive force. We speculate that the widely recognized activation of the enzyme by adenine nucleotides in plants is mediated in this manner. A mechanism that could account for such regulation is suggested and ramifications for its in vivo relevance are discussed.	Univ Sussex, Sch Biol Sci, Dept Biochem, Brighton BN1 9QG, E Sussex, England; Free Univ Amsterdam, Fac Biol, BioCtr Amsterdam, Dept Mol Cell Physiol, NL-1081 HV Amsterdam, Netherlands	University of Sussex; University of Amsterdam; Vrije Universiteit Amsterdam	Affourtit, C (corresponding author), Univ Sussex, Sch Biol Sci, Dept Biochem, Brighton BN1 9QG, E Sussex, England.	C.Affourtit@sussex.ac.uk	Affourtit, Charles/I-3958-2019	Affourtit, Charles/0000-0003-1776-9943				Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; ACKRELL BAC, 1977, J BIOL CHEM, V252, P1582; ACKRELL BAC, 1977, J BIOL CHEM, V252, P6963; ACKRELL BAC, 1974, J BIOL CHEM, V249, P2021; ACKRELL BAC, 1977, FEBS LETT, V75, P249, DOI 10.1016/0014-5793(77)80097-5; ACKRELL BAC, 1975, J BIOL CHEM, V250, P7114; Affourtit C, 1999, J BIOL CHEM, V274, P6212, DOI 10.1074/jbc.274.10.6212; AFFOURTIT C, 2001, BIOCHIM BIOPHYS ACTA, V1504, P59; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BEAVIS AD, 1993, J BIOL CHEM, V268, P997; Casolo V, 1998, PLANT SCI, V136, P149, DOI 10.1016/S0168-9452(98)00114-9; DOUCE R, 1986, BIOCHIM BIOPHYS ACTA, V850, P64, DOI 10.1016/0005-2728(86)90009-5; DRANSFIELD DT, 1993, AM J PHYSIOL, V264, pC663, DOI 10.1152/ajpcell.1993.264.3.C663; FRICAUD AC, 1992, BIOCHIM BIOPHYS ACTA, V1099, P253, DOI 10.1016/0005-2728(92)90035-Z; GARLID KD, 1985, J BIOL CHEM, V260, P3434; GUTMAN, 1971, BIOCHEMISTRY-US, V10, P4763, DOI 10.1021/bi00801a025; GUTMAN M, 1971, BIOCHEM BIOPH RES CO, V42, P1016, DOI 10.1016/0006-291X(71)90005-2; GUTMAN M, 1971, BIOCHEMISTRY-US, V10, P2726; Heldt HW, 1987, BIOCH PLANTS, V12, P49; Jezek P, 1996, J BIOL CHEM, V271, P32743, DOI 10.1074/jbc.271.51.32743; KEARNEY EB, 1972, BIOCHEM BIOPH RES CO, V49, P1115, DOI 10.1016/0006-291X(72)90328-2; KEARNEY EB, 1974, J BIOL CHEM, V249, P2016; KEARNEY EB, 1972, BIOCHEM BIOPH RES CO, V46, P531, DOI 10.1016/S0006-291X(72)80171-2; KEARNEY EB, 1957, J BIOL CHEM, V229, P363; KLINGENBERG M, 1989, ARCH BIOCHEM BIOPHYS, V270, P1, DOI 10.1016/0003-9861(89)90001-5; KRAB K, 1995, J BIOENERG BIOMEMBR, V27, P387, DOI 10.1007/BF02110001; Krab K, 2000, EUR J BIOCHEM, V267, P869, DOI 10.1046/j.1432-1327.2000.01065.x; KRAB K, 1995, BIOCHEM SOC T, V23, pS289, DOI 10.1042/bst023289s; Leach GR, 1996, BIOCHEM J, V317, P313, DOI 10.1042/bj3170313; LIENHARD GE, 1973, J BIOL CHEM, V248, P1121; MOORE AL, 1988, FEBS LETT, V235, P76, DOI 10.1016/0014-5793(88)81237-7; MOORE AL, 1982, PLANT PHYSIOL, V70, P1271, DOI 10.1104/pp.70.5.1271; OESTREIC.G, 1973, PLANT PHYSIOL, V52, P622, DOI 10.1104/pp.52.6.622; Pastore D, 1999, J BIOL CHEM, V274, P26683, DOI 10.1074/jbc.274.38.26683; RUSTIN P, 1991, BIOCHEM J, V274, P249, DOI 10.1042/bj2740249; SINGER TP, 1973, PLANT PHYSIOL, V52, P616, DOI 10.1104/pp.52.6.616; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; VANDENBERGEN CWM, 1994, EUR J BIOCHEM, V226, P1071; VERCESI AE, 1995, NATURE, V375, P24, DOI 10.1038/375024a0; WHITEHOUSE DG, 1989, PLANT PHYSIOL, V91, P487, DOI 10.1104/pp.91.2.487	40	38	44	2	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32567	32574		10.1074/jbc.M103111200	http://dx.doi.org/10.1074/jbc.M103111200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11350973	hybrid, Green Published			2022-12-25	WOS:000170746000027
J	Charpilienne, A; Nejmeddine, M; Berois, M; Parez, N; Neumann, E; Hewat, E; Trugnan, G; Cohen, J				Charpilienne, A; Nejmeddine, M; Berois, M; Parez, N; Neumann, E; Hewat, E; Trugnan, G; Cohen, J			Individual rotavirus-like particles containing 120 molecules of fluorescent protein are visible in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-LIKE PARTICLES; 3-DIMENSIONAL RECONSTRUCTION; CAPSID PROTEINS; VP2; EXPRESSION; MICROSCOPY; IMMUNITY; EPITOPE; MODEL; LAYER	Rotaviruses are large, complex icosahedral particles consisting of three concentric capsid layers. When the innermost capsid protein VP2 is expressed in the baculovirus-insect cell system it assembles as core-like particles. The amino terminus region of VP2 is dispensable for assembly of virus-like particles (VLP). Coexpression of VP2 and VP6 produces double layered VLP. We hypothesized that the amino end of VP2 could be extended without altering the auto assembly properties of VP2. Using the green fluorescent protein (GFP) or the DsRed protein as model inserts we have shown that the chimeric protein GFP (or DsRed)-VP2 auto assembles perfectly well and forms fluorescent VLP (GFP-VLP2/6 or DsRed-VLP2/6) when coexpressed with VP6. The presence of GFP inside the core does not prevent the assembly of the outer capsid layer proteins VP7 and VP4 to give VLP2/6/7/4. Cryo-electron microscopy of purified GFP-VLP2/6 showed that GFP molecules are located at the 5-fold vertices of the core. It is possible to visualize a single fluorescent VLP in living cells by confocal fluorescent microscopy. In vitro VLP2/6 did not enter into permissive cells or in dendritic cells. In contrast, fluorescent VLP2/6/7/4 entered the cells and then the fluorescence signal disappear rapidly. Presented data indicate that fluorescent VLP are interesting tools to follow in real time the entry process of rotavirus and that chimeric VLP could be envisaged as "nanoboxes" carrying macromolecules to living cells.	INRA, F-78352 Jouy En Josas, France; Univ Paris 06, INSERM, U538, F-75571 Paris 12, France; Hop Armand Trousseau, Virol Lab, EA 2391, UFR St Antoine, Paris, France; Inst Biol Struct, Lab Microscopie Elect Struct, F-38027 Grenoble 1, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Cohen, J (corresponding author), INRA, F-78352 Jouy En Josas, France.			Nejmeddine, Mohamed/0000-0003-0160-2727				Baird GS, 2000, P NATL ACAD SCI USA, V97, P11984, DOI 10.1073/pnas.97.22.11984; Baker TS, 1996, J STRUCT BIOL, V116, P120, DOI 10.1006/jsbi.1996.0020; Ball JM, 1996, ARCH VIROL, P243; BELYAEV AS, 1992, VIROLOGY, V190, P840, DOI 10.1016/0042-6822(92)90922-C; Canque B, 2000, BLOOD, V96, P3748, DOI 10.1182/blood.V96.12.3748.h8003748_3748_3756; CRAWFORD SE, 1994, J VIROL, V68, P5945, DOI 10.1128/JVI.68.9.5945-5952.1994; CROWTHER RA, 1971, PHILOS T R SOC B, V261, P221, DOI 10.1098/rstb.1971.0054; FRANCO MA, 1993, J GEN VIROL, V74, P2579, DOI 10.1099/0022-1317-74-12-2579; Fuller SD, 1996, J STRUCT BIOL, V116, P48, DOI 10.1006/jsbi.1996.0009; GEORGI A, 1990, P NATL ACAD SCI USA, V87, P6579, DOI 10.1073/pnas.87.17.6579; Gilbert JM, 1997, J VIROL, V71, P4555, DOI 10.1128/JVI.71.6.4555-4563.1997; Gilbert SC, 1997, NAT BIOTECHNOL, V15, P1280, DOI 10.1038/nbt1197-1280; Greenstone HL, 1998, P NATL ACAD SCI USA, V95, P1800, DOI 10.1073/pnas.95.4.1800; Grimes JM, 1998, NATURE, V395, P470, DOI 10.1038/26694; Hewat EA, 1996, EMBO J, V15, P1515, DOI 10.1002/j.1460-2075.1996.tb00495.x; Hill CL, 1999, NAT STRUCT BIOL, V6, P565, DOI 10.1038/9347; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; Kratz PA, 1999, P NATL ACAD SCI USA, V96, P1915, DOI 10.1073/pnas.96.5.1915; LABBE M, 1994, J GEN VIROL, V75, P3423, DOI 10.1099/0022-1317-75-12-3423; LABBE M, 1991, J VIROL, V65, P2946; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT S, 1994, J VIROL, V68, P6794, DOI 10.1128/JVI.68.10.6794-6798.1994; Lawton JA, 1997, J VIROL, V71, P7353, DOI 10.1128/JVI.71.10.7353-7360.1997; Liprandi F, 1997, VIROLOGY, V237, P430, DOI 10.1006/viro.1997.8803; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; MIYAMURA K, 1994, P NATL ACAD SCI USA, V91, P8507, DOI 10.1073/pnas.91.18.8507; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; ONeal CM, 1997, J VIROL, V71, P8707, DOI 10.1128/JVI.71.11.8707-8717.1997; Patterson GH, 1997, BIOPHYS J, V73, P2782, DOI 10.1016/S0006-3495(97)78307-3; PEARSON LD, 1993, IMMUNOL CELL BIOL, V5, P381; Prasad BVV, 1996, NATURE, V382, P471, DOI 10.1038/382471a0; PRASAD BVV, 1988, J MOL BIOL, V199, P269, DOI 10.1016/0022-2836(88)90313-0; Rollo EE, 1999, J IMMUNOL, V163, P4442; Ruiz MC, 1996, J VIROL, V70, P4877, DOI 10.1128/JVI.70.8.4877-4883.1996; SAXTON WO, 1982, J MICROSC-OXFORD, V127, P127, DOI 10.1111/j.1365-2818.1982.tb00405.x; Sedlik C, 1997, P NATL ACAD SCI USA, V94, P7503, DOI 10.1073/pnas.94.14.7503; YOSHIMURA A, 1984, J VIROL, V51, P497, DOI 10.1128/JVI.51.2.497-504.1984; ZENG CQY, 1994, VIROLOGY, V201, P55, DOI 10.1006/viro.1994.1265; Zeng CQY, 1998, J VIROL, V72, P201, DOI 10.1128/JVI.72.1.201-208.1998	39	128	130	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29361	29367		10.1074/jbc.M101935200	http://dx.doi.org/10.1074/jbc.M101935200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11356839	hybrid, Green Published			2022-12-25	WOS:000170346000097
J	Andrews, RK; Gardiner, EE; Asazuma, N; Berlanga, O; Tulasne, D; Nieswandt, B; Smith, AI; Berndt, MC; Watson, SP				Andrews, RK; Gardiner, EE; Asazuma, N; Berlanga, O; Tulasne, D; Nieswandt, B; Smith, AI; Berndt, MC; Watson, SP			A novel viper venom metalloproteinase, alborhagin, is an agonist at the platelet collagen receptor GPVI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE LECTIN; BOTHROPS-JARARACA VENOM; VON-WILLEBRAND-FACTOR; GLYCOPROTEIN-VI; GAMMA-CHAIN; TRIMERESURUS-ALBOLABRIS; PHOSPHOLIPASE C-GAMMA-2; IB; ACTIVATION; PROTEINS	The interaction of platelet membrane glycoprotein VI (GPVI) with collagen can initiate (patho)physiological thrombus formation. The viper venom C-type lectin family proteins convulxin and alboaggregin-A activate platelets by interacting with GPVI. In this study, we isolated from white-lipped tree viper (Trimeresurus albolabris) venom, alborhagin, which is functionally related to convulxin because it activates platelets but is structurally different and related to venom metalloproteinases. Alborhagin-induced platelet aggregation (EC50, <7.5 <mu>g/ml) was inhibitable by an anti-alpha IIb beta3 antibody, CRC64, and the Src family kinase inhibitor PP1, suggesting that alborhagin activates platelets, leading to alpha IIb,beta3-dependent aggregation. Additional evidence suggested that, like convulxin, alborhagin activated platelets by a mechanism involving GPVI. First, alborhagin- and convulxin-treated platelets showed a similar tyrosine phosphorylation pattern, including a similar level of phospholipase C gamma2 phosphorylation. Second, alborhagin induced GPVI-dependent responses in GPVI-transfected K562 and Jurkat cells. Third, alborhagin-dependent aggregation of mouse platelets was inhibited by the anti-GPVI monoclonal antibody JAQ1. Alborhagin had minimal effect on convulxin binding to GPVI-expressing cells, indicating that these venom proteins may recognize distinct binding sites. Characterization of alborhagin as a GPVI agonist that is structurally distinct from convulxin demonstrates the versatility of snake venom toxins and provides a novel probe for GPVI-dependent platelet activation.	Baker Med Res Inst, Hazel & Pip Appel Vasc Biol Lab, Melbourne, Vic 8008, Australia; Baker Med Res Inst, Peptide Biol Lab, Melbourne, Vic 8008, Australia; Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; Univ Witten Herdecke, Ferdinand Sauerbruch Klinikum Wuppertal, D-42117 Wuppertal, Germany	Baker Heart and Diabetes Institute; Baker Heart and Diabetes Institute; University of Oxford; Witten Herdecke University	Andrews, RK (corresponding author), Baker Med Res Inst, Hazel & Pip Appel Vasc Biol Lab, POB 6492,St Kilda Rd Cent, Melbourne, Vic 8008, Australia.	rkandrews@hotmail.com	Gardiner, Elizabeth/P-8716-2019; Tulasne, David/AAR-5287-2020; Tulasne, David/A-8705-2008; Gardiner, Elizabeth/E-7774-2011; Berndt, Michael C/D-5580-2012; Watson, Stephen P/Q-6292-2016	Gardiner, Elizabeth/0000-0001-9453-9688; Tulasne, David/0000-0002-6764-7242; Watson, Stephen P/0000-0002-7846-7423; Smith, Ian/0000-0002-4143-2892				Andrews RK, 1996, BIOCHEMISTRY-US, V35, P12629, DOI 10.1021/bi960704e; ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8317, DOI 10.1021/bi00447a009; Andrews RK, 1997, INT J BIOCHEM CELL B, V29, P91, DOI 10.1016/S1357-2725(96)00122-7; Andrews RK, 2000, TOXICON, V38, P775, DOI 10.1016/S0041-0101(99)00187-7; Asazuma N, 2000, J BIOL CHEM, V275, P33427, DOI 10.1074/jbc.M001439200; Asazuma N, 2001, BLOOD, V97, P3989, DOI 10.1182/blood.V97.12.3989; Berlanga O, 2000, BLOOD, V96, P2740; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; Briddon SJ, 1999, BIOCHEM J, V338, P203, DOI 10.1042/0264-6021:3380203; DELUCA M, 1995, J BIOL CHEM, V270, P26734, DOI 10.1074/jbc.270.45.26734; DELUCA M, 1995, BIOCHEM BIOPH RES CO, V206, P570, DOI 10.1006/bbrc.1995.1081; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; Falati S, 1999, BLOOD, V94, P1648, DOI 10.1182/blood.V94.5.1648.417k31_1648_1656; FUJIMURA Y, 1991, BIOCHEMISTRY-US, V30, P1957, DOI 10.1021/bi00221a032; Hers I, 2000, EUR J BIOCHEM, V267, P2088, DOI 10.1046/j.1432-1327.2000.01214.x; Ichinohe T, 1997, J BIOL CHEM, V272, P63; JandrotPerrus M, 1997, J BIOL CHEM, V272, P27035, DOI 10.1074/jbc.272.43.27035; Jeon OH, 1999, EUR J BIOCHEM, V263, P526, DOI 10.1046/j.1432-1327.1999.00525.x; KHASPEKOVA SG, 1993, BRIT J HAEMATOL, V85, P332, DOI 10.1111/j.1365-2141.1993.tb03175.x; KINI RM, 1992, TOXICON, V30, P265, DOI 10.1016/0041-0101(92)90869-7; Kini RM, 1996, TOXICON, V34, P1287, DOI 10.1016/S0041-0101(96)00107-9; Kowalska MA, 1998, THROMB HAEMOSTASIS, V79, P609; KROLL MH, 1993, J BIOL CHEM, V268, P3520; Kulkarni S, 2000, J CLIN INVEST, V105, P783, DOI 10.1172/JCI7569; Leduc M, 1998, BIOCHEM J, V333, P389, DOI 10.1042/bj3330389; Navdaev A, 2001, J BIOL CHEM, V276, P20882, DOI 10.1074/jbc.M101585200; Navdaev A, 2001, BLOOD, V97, P2333, DOI 10.1182/blood.V97.8.2333; Nieswandt B, 2000, J BIOL CHEM, V275, P23998, DOI 10.1074/jbc.M003803200; Nieswandt B, 2001, J EXP MED, V193, P459, DOI 10.1084/jem.193.4.459; PAINE MJI, 1992, J BIOL CHEM, V267, P22869; Pasquet JM, 1999, BIOCHEM J, V342, P171, DOI 10.1042/0264-6021:3420171; PENG ML, 1992, THROMB HAEMOSTASIS, V67, P702; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SCHOLEY JM, 1980, NATURE, V287, P233, DOI 10.1038/287233a0; Schulte V, 2001, J BIOL CHEM, V276, P364, DOI 10.1074/jbc.M007536200; TAKEYA H, 1990, J BIOL CHEM, V265, P16068; Ward CM, 1996, BIOCHEMISTRY-US, V35, P4929, DOI 10.1021/bi952456c; Ward CM, 1996, TOXICON, V34, P1203, DOI 10.1016/0041-0101(96)00115-8; Watson SP, 1999, THROMB HAEMOSTASIS, V82, P365; WEISS HJ, 1995, THROMB HAEMOSTASIS, V74, P117	41	57	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28092	28097		10.1074/jbc.M011352200	http://dx.doi.org/10.1074/jbc.M011352200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11344165	hybrid			2022-12-25	WOS:000170093400047
J	Lian, GW; Ding, L; Chen, M; Liu, Z; Zhao, DQ; Ni, JZ				Lian, GW; Ding, L; Chen, M; Liu, Z; Zhao, DQ; Ni, JZ			Preparation and properties of a selenium-containing catalytic antibody as type I deiodinase mimic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; IODOTHYRONINE DEIODINASE; PARTIAL-PURIFICATION; 5'-DEIODINASE; MICROSOMES; THYROXINE; ENZYME; KIDNEY	Conversion of thyroxine (T-4) to 3,5,3'-triiodothyronine is an essential first step in controlling thyroid hormone action. Type I deiodinase (DI) can catalyze the conversion to produce the bulk of serum 3,5,3'-triiodothyronine. Acting as a mimic of DI, a selenium-containing catalytic antibody (Se-4C5) prepared by converting the serine residues of monoclonal antibody 4C5 raised against T4 into selenocysteines, can catalyze the deiodination of T4 with dithiothreitol (DTT) as cosubstrate. The mimic enzyme Se-4C5 exhibited a much greater deiodinase activity than model compound ebselen and another selenium-containing antibody Se-Hp4 against GSH. The coupling of selenocysteine with the combining pocket of antibody 4C5 endowed Se-4C5 with enzymatic activity. To probe the catalytic mechanism of the catalytic antibody, detailed kinetic studies were carried out in this paper. Investigations into the deiodinative reaction revealed the relationship between the initial velocity and substrate concentration. The characteristic parallel Dalziel plots demonstrated that Se-4C5-catalyzed reaction mechanism was ping-pong one, involving at least one covalent enzyme intermediate. The kinetic properties of the catalytic antibody were similar to those of DI, with K-m values for T-4 and DTT of approximately 0.8 muM and 1.8 muM, respectively, and a V-m value of 270 pmol per mg of protein per min. The activity could be sensitively inhibited by 6-propyl-2-thiouracil (PTU) with a K-i value of similar to 120 muM at 2.0 muM T-4 concentration. The PTU inhibition was progressively alleviated with the increasing concentration of added DTT, revealing that PTU was a competitive inhibitor for DTT.	Changchun Univ Agr & Anim Husb Sci, Inst Mil Vet Sci, Changchun 130021, Peoples R China; Chinese Acad Sci, Changchun Inst Appl Chem, Lab Rare Earth Chem & Phys, Changchun 130022, Peoples R China	Jilin University; Chinese Academy of Sciences; Changchun Institute of Applied Chemistry, CAS	Ding, L (corresponding author), Chinese Acad Sci, Changchun Inst Appl Chem, Lab Rare Earth Chem & Phys, Changchun 130022, Peoples R China.		Chen, Mo/E-8234-2010					AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; BELL IM, 1993, BIOCHEMISTRY-US, V32, P3754, DOI 10.1021/bi00065a030; BERRY MJ, 1991, J BIOL CHEM, V266, P14155; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; CAVALLINI D, 1966, NATURE, V212, P294, DOI 10.1038/212294a0; CHIU D, 1977, ARCH BIOCHEM BIOPHYS, V184, P209, DOI 10.1016/0003-9861(77)90344-7; Ding L, 1998, BIOCHEM J, V332, P251, DOI 10.1042/bj3320251; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; GOSWAMI A, 1984, J CLIN INVEST, V74, P2097, DOI 10.1172/JCI111634; GOSWAMI A, 1990, BIOCHEM BIOPH RES CO, V173, P6, DOI 10.1016/S0006-291X(05)81013-7; HUMMEL BCW, 1985, BIOCHIM BIOPHYS ACTA, V841, P173, DOI 10.1016/0304-4165(85)90019-4; JANGHORBANI M, 1989, ANAL CHEM, V61, P701, DOI 10.1021/ac00182a013; KLAYMAN DL, 1973, J AM CHEM SOC, V95, P197, DOI 10.1021/ja00782a034; KOELER G, 1975, NATURE, V256, P495; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; LEONARD JL, 1978, ENDOCRINOLOGY, V103, P2137, DOI 10.1210/endo-103-6-2137; Leonard JL, 1986, THYROID HORMONE META, P189; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LOWERY OH, 1951, J BIOL CHEM, V193, P265; MOL JA, 1988, MOL CELL ENDOCRINOL, V55, P159, DOI 10.1016/0303-7207(88)90130-X; MPOKO CN, 1985, CLIN CHIM ACTA, V146, P215, DOI 10.1016/0009-8981(85)90061-0; OPPENHEIMER JH, 1987, ENDOCR REV, V8, P288, DOI 10.1210/edrv-8-3-288; Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086; Schultz PG, 1998, P NATL ACAD SCI USA, V95, P14590, DOI 10.1073/pnas.95.25.14590; VISSER TJ, 1975, BIOCHEM J, V150, P489, DOI 10.1042/bj1500489; WENDEL A, 1975, BIOCHIM BIOPHYS ACTA, V377, P211, DOI 10.1016/0005-2744(75)90303-4; Wentworth P, 1998, CURR OPIN CHEM BIOL, V2, P138, DOI 10.1016/S1367-5931(98)80046-X	28	15	18	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28037	28041		10.1074/jbc.M101942200	http://dx.doi.org/10.1074/jbc.M101942200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11350963	hybrid			2022-12-25	WOS:000170093400040
J	Mayer, IA; Verma, A; Grumbach, IM; Uddin, S; Lekmine, F; Ravandi, F; Majchrzak, B; Fujita, S; Fish, EN; Platanias, LC				Mayer, IA; Verma, A; Grumbach, IM; Uddin, S; Lekmine, F; Ravandi, F; Majchrzak, B; Fujita, S; Fish, EN; Platanias, LC			The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; ACTIVATED PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVATION; SERINE PHOSPHORYLATION; STRUCTURAL BASIS; ADAPTER PROTEIN; STAT PROTEINS; I INTERFERONS; GENE; CRKL	The mechanisms by which interferon-alpha (IFN-alpha) mediates its anti-leukemic effects in chronic myelogenous leukemia (CML) cells are not known. We determined whether p38 MAPK is activated by IFN-alpha in BCR-ABLexpressing cells and whether its function is required for the generation of growth inhibitory responses. IFN-alpha treatment induced phosphorylation/activation of p38 in the IFN-alpha -sensitive KT-1 cell line, but not in IFN-alpha -resistant K562 cells. Consistent with this, IFN-alpha treatment of KT-1 (but not K562) cells induced activation of the small GTPase Racl, which functions as an upstream regulator of p38. In addition, IFN-alpha -dependent phosphorylationfactivation of p38 was induced by treatment of primary granulocytes isolated from the peripheral blood of patients with CAIL. To define the functional role of the Rac1/p38 ALkPK pathway in IFN-alpha signaling, the effects of pharmacological inhibition of p38 on the induction of IFN-alpha responses were determined. Treatment of KT-1 cells with the p38-specific inhibitors SB203580 and SB202190 reversed the growth inhibitory effects of IFN-alpha. On the other hand, the MEK kinase inhibitor PD09SO59 had no effects, further demonstrating the specificity of these findings. To directly determine the significance of IFN-alpha -dependent activation of p38 in the induction of the anti-leukemic effects of IFN-alpha, we evaluated the effects of p38 inhibition on leukemic colony formation in bone marrow samples of patients with CML. IFN-alpha inhibited leukemic granulocyte/ macrophage colony formation in a dose-dependent manner, whereas concomitant treatment with p38 inhibitors reversed such an inhibition. Thus, the Rac1-/p38 MAPK pathway is activated by IFN-alpha in BCR-ABL-expressing cells and appears to play a key role in the generation of the growth inhibitory effects of IFN-alpha in CAIL cells.	Univ Illinois, Hematol Oncol Sect, MBRB, Dept Med, Chicago, IL 60607 USA; W Side Vet Affairs Med Ctr, Chicago, IL 60607 USA; Univ Toronto, Dept Immunol, Toronto, ON M5S 3E2, Canada; Univ Toronto, UNiv Network, Toronto Res Inst, Div Cell & Mol Biol, Toronto, ON M5S 3E2, Canada; Ehime Univ, Dept Internal Med 1, Matsuyama, Ehime 7910295, Japan	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Toronto; University of Toronto; Ehime University	Platanias, LC (corresponding author), Univ Illinois, Hematol Oncol Sect, MBRB, Dept Med, MC-734,Rm 3150,900 S Ashland Ave, Chicago, IL 60607 USA.			Uddin, Shahab/0000-0003-1886-6710; Grumbach, Isabella/0000-0002-2285-3157	NATIONAL CANCER INSTITUTE [R29CA073381, R01CA077816] Funding Source: NIH RePORTER; NCI NIH HHS [CA73381, CA77816] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; FISH EN, 1992, J INTERFERON RES, V12, P257, DOI 10.1089/jir.1992.12.257; Fish EN, 1999, J BIOL CHEM, V274, P571, DOI 10.1074/jbc.274.2.571; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; GOEBERT M, 1997, EMBO J, V16, P3563; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Grumbach IM, 2001, BRIT J HAEMATOL, V112, P327, DOI 10.1046/j.1365-2141.2001.02556.x; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Pane F, 1999, BLOOD, V94, P2200, DOI 10.1182/blood.V94.7.2200.419a33_2200_2207; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Pfeffer LM, 1998, CANCER RES, V58, P2489; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Platanias LC, 1999, EXP HEMATOL, V27, P1315, DOI 10.1016/S0301-472X(99)00060-0; Salojin KV, 1999, J IMMUNOL, V163, P844; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; Stadler M, 1995, ONCOGENE, V11, P2565; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Uddin S, 2000, J BIOL CHEM, V275, P27634; Uddin S, 1997, J IMMUNOL, V158, P2390; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; Uddin S, 1997, BLOOD, V90, P2574; Wang ZL, 1998, STRUCTURE, V6, P1117, DOI 10.1016/S0969-2126(98)00113-0; WETZLER M, 1995, AM J MED, V99, P402, DOI 10.1016/S0002-9343(99)80189-2; Wilson KP, 1997, CHEM BIOL, V4, P423, DOI 10.1016/S1074-5521(97)90194-0; Yanagisawa K, 1998, BLOOD, V91, P641, DOI 10.1182/blood.V91.2.641.641_641_648; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	42	124	129	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28570	28577		10.1074/jbc.M011685200	http://dx.doi.org/10.1074/jbc.M011685200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11353767	hybrid			2022-12-25	WOS:000170093400110
J	Marin, EP; Krishna, AG; Sakmar, TP				Marin, EP; Krishna, AG; Sakmar, TP			Rapid activation of transducin by mutations distant from the nucleotide-binding site - Evidence for a mechanistic model of receptor-catalyzed nucleotide exchange by G proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ALPHA-SUBUNIT; STRUCTURAL DETERMINANTS; TRANSITION-STATE; RHODOPSIN; RAS; PHOSPHODIESTERASE; G(I-ALPHA-1); G(S-ALPHA); PEPTIDES	G proteins act as molecular switches in which information flow depends on whether the bound nucleotide is GDP ("off") or GTP ("on"). We studied the basal and receptor-catalyzed nucleotide exchange rates of site-directed mutants of the alpha subunit of transducin, We identified three amino acid residues (Thr-325, Val-328, and Phe-332) in which mutation resulted in dramatic increases (up to 165-fold) in basal nucleotide exchange rates in addition to enhanced receptor-catalyzed nucleotide exchange rates. These three residues are located on the inward facing surface of the alpha5 helix, which lies between the carboxyl-terminal tail and a loop contacting the nucleotide-binding pocket, Mutation of amino acid residues on the outward facing surface of the same alpha5 helix caused a decrease in receptor-catalyzed nucleotide exchange. We propose that the alpha5 helix comprises a functional microdomain in G proteins that affects basal nucleotide release rates and mediates receptor-catalyzed nucleotide exchange at a distance from the nucleotide-binding pocket.	Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University	Sakmar, TP (corresponding author), Rockefeller Univ, Biochem & Mol Biol Lab, 1230 York Ave, New York, NY 10021 USA.	sakmar@rockvax.rockefeller.edu	Sakmar, Thomas P/D-1833-2015	Sakmar, Thomas P/0000-0002-2836-8953; Aradhyam, Gopala Krishna/0000-0001-8232-3935	NIGMS NIH HHS [GM07982, GM07739] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; Bohm A, 1997, CURR OPIN BIOTECH, V8, P480, DOI 10.1016/S0958-1669(97)80072-9; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DENKER BM, 1992, J BIOL CHEM, V267, P9998; DENKER BM, 1995, BIOCHEMISTRY-US, V34, P5544, DOI 10.1021/bi00016a028; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Heck M, 2001, J BIOL CHEM, V276, P10000, DOI 10.1074/jbc.M009475200; Iiri T, 1998, NATURE, V394, P35, DOI 10.1038/27831; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; Kisselev OG, 1998, P NATL ACAD SCI USA, V95, P4270, DOI 10.1073/pnas.95.8.4270; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lichtarge O, 1996, P NATL ACAD SCI USA, V93, P7507, DOI 10.1073/pnas.93.15.7507; Marin EP, 2001, J BIOL CHEM, V276, P23873, DOI 10.1074/jbc.M101197200; Marsh SR, 1998, MOL PHARMACOL, V53, P981; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; MENON ST, 2001, IN PRESS PHYSL REV; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Min KC, 2000, PROTEIN EXPRES PURIF, V20, P514, DOI 10.1006/prep.2000.1326; MIXONMB, 1995, SCIENCE, V20, P954; Muradov KG, 2000, BIOCHEMISTRY-US, V39, P3937, DOI 10.1021/bi992156l; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; Osawa S, 1995, J BIOL CHEM, V270, P31052, DOI 10.1074/jbc.270.52.31052; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Posner BA, 1998, J BIOL CHEM, V273, P21752, DOI 10.1074/jbc.273.34.21752; QUILLIAM LA, 1995, P NATL ACAD SCI USA, V92, P1272, DOI 10.1073/pnas.92.5.1272; RAMDAS L, 1991, BIOCHEMISTRY-US, V30, P11637, DOI 10.1021/bi00114a005; SAKMAR TP, 1988, NUCLEIC ACIDS RES, V16, P6361, DOI 10.1093/nar/16.14.6361; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; Sprang SR, 1998, CELL, V95, P155, DOI 10.1016/S0092-8674(00)81746-8; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014	45	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27400	27405		10.1074/jbc.C100198200	http://dx.doi.org/10.1074/jbc.C100198200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356823	hybrid			2022-12-25	WOS:000169966900089
J	Castric, P; Cassels, FJ; Carlson, RW				Castric, P; Cassels, FJ; Carlson, RW			Structural characterization of the Pseudomonas aeruginosa 1244 pilin glycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTTRANSLATIONAL MODIFICATION; CAMPYLOBACTER FLAGELLIN; NEISSERIA-MENINGITIDIS; STREPTOCOCCUS-SANGUIS; MENINGOCOCCAL PILIN; TWITCHING MOTILITY; SOMATIC ANTIGENS; GLYCOSYLATION; GLYCOPROTEIN; GENE	An antigenic similarity between lipopolysaccharide (LPS) and glycosylated pilin of Pseudomonas aeruginosa 1244 was noted. We purified a glycan-containing molecule from proteolytically digested pill and showed it to be composed of three sugars and serine. This glycan competed with pure pill and LPS for reaction with an LPS-specific monoclonal antibody, which also inhibited twitching motility by P. aeruginosa bearing glycosylated pill. One-dimensional NMR analysis of the glycan indicated the sugars to be 5N beta OHC(4)7NfmPse, Xyl, and FucNAc. The complete proton assignments of these sugars as well as the serine residue were determined by COSY and TOCSY. Electrospray ionization mass spectrometry (MS) determined the mass of this molecule to be 771.5. The ROESY NMR spectrum, tandem MS/MS analysis, and methylation analysis provided information on linkage and the sequence of oligosaccharide components. These data indicated that the molecule had the following structure: alpha -5N beta OHC(4)7NFmPse-(2 -->4)-beta -Xyl-(1 -->3)-beta -FucNAc-(1 -->3)-beta -Ser.	Duquesne Univ, Dept Biol Sci, Pittsburgh, PA 15282 USA; Walter Reed Army Med Ctr, Dept Enter Infect, Washington, DC 20307 USA; Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA	Duquesne University; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; University System of Georgia; University of Georgia	Castric, P (corresponding author), Duquesne Univ, Dept Biol Sci, Pittsburgh, PA 15282 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R15AI043317] Funding Source: NIH RePORTER; NIAID NIH HHS [R15 AI43317] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANGYAL SJ, 1979, CARBOHYD RES, V77, P37, DOI 10.1016/S0008-6215(00)83791-X; BOCK K, 1994, J BIOL CHEM, V269, P7137; BODEY GP, 1983, REV INFECT DIS, V5, P279; BRADLEY DE, 1980, CAN J MICROBIOL, V26, P146, DOI 10.1139/m80-022; Brimer CD, 1998, J BACTERIOL, V180, P3209, DOI 10.1128/JB.180.12.3209-3217.1998; Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; CASSELS FJ, 1989, J BACTERIOL, V171, P4019, DOI 10.1128/jb.171.7.4019-4025.1989; CASTRIC P, 1995, MICROBIOL-UK, V141, P1247, DOI 10.1099/13500872-141-5-1247; CASTRIC PA, 1994, INFECT IMMUN, V62, P371, DOI 10.1128/IAI.62.2.371-376.1994; CASTRIC PA, 1969, J BIOL CHEM, V244, P4089; CASTRIC PA, 1989, MOL GEN GENET, V216, P75, DOI 10.1007/BF00332233; Comolli JC, 1999, INFECT IMMUN, V67, P3625, DOI 10.1128/IAI.67.7.3625-3630.1999; CROSS AS, 1993, J INFECT DIS, V167, P112, DOI 10.1093/infdis/167.1.112; Davey ME, 2000, MICROBIOL MOL BIOL R, V64, P847, DOI 10.1128/MMBR.64.4.847-867.2000; DOBOS KM, 1995, INFECT IMMUN, V63, P2846, DOI 10.1128/IAI.63.8.2846-2853.1995; Doig P, 1996, MOL MICROBIOL, V19, P379, DOI 10.1046/j.1365-2958.1996.370890.x; ERICKSON PR, 1993, J BIOL CHEM, V268, P23780; FROST LS, 1977, J BACTERIOL, V131, P259, DOI 10.1128/JB.131.1.259-269.1977; GHEBREGZABHER M, 1976, J CHROMATOGR, V127, P133, DOI 10.1016/S0021-9673(00)80168-5; Hahn HP, 1997, GENE, V192, P99, DOI 10.1016/S0378-1119(97)00116-9; HAMADEH RM, 1995, INFECT IMMUN, V63, P4900, DOI 10.1128/IAI.63.12.4900-4906.1995; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; IRVIN RT, 1990, MICROBIAL CELL SURFA, P137; Kang PJ, 1997, MOL MICROBIOL, V24, P1249; KNIREL YA, 1990, CRIT REV MICROBIOL, V17, P273, DOI 10.3109/10408419009105729; KNIREL YA, 1987, EUR J BIOCHEM, V163, P639, DOI 10.1111/j.1432-1033.1987.tb10913.x; Lanyi B., 1978, METHOD MICROBIOL, V10, P93; LECHNER J, 1989, ANNU REV BIOCHEM, V58, P173, DOI 10.1146/annurev.bi.58.070189.001133; LEE KK, 1994, MOL MICROBIOL, V11, P705, DOI 10.1111/j.1365-2958.1994.tb00348.x; LIU PV, 1983, INT J SYST BACTERIOL, V33, P256, DOI 10.1099/00207713-33-2-256; LOGAN SM, 1989, J BACTERIOL, V171, P3031, DOI 10.1128/jb.171.6.3031-3038.1989; Marceau M, 1998, MOL MICROBIOL, V27, P705, DOI 10.1046/j.1365-2958.1998.00706.x; MCMICHAEL JC, 1992, J GEN MICROBIOL, V138, P2687, DOI 10.1099/00221287-138-12-2687; O'Toole GA, 1998, MOL MICROBIOL, V30, P295, DOI 10.1046/j.1365-2958.1998.01062.x; PARANCHYCH W, 1988, ADV MICROB PHYSIOL, V29, P53, DOI 10.1016/S0065-2911(08)60346-X; PARANCHYCH W, 1979, CAN J MICROBIOL, V25, P1175, DOI 10.1139/m79-182; PARGE HE, 1995, NATURE, V378, P32, DOI 10.1038/378032a0; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAMPHAL R, 1991, INFECT IMMUN, V59, P1307, DOI 10.1128/IAI.59.4.1307-1311.1991; Sadoff J C, 1985, Antibiot Chemother (1971), V36, P134; SCHAUER R, 1985, TRENDS BIOCHEM SCI, V10, P357, DOI 10.1016/0968-0004(85)90112-4; Stimson E, 1996, BIOCHEM J, V316, P29, DOI 10.1042/bj3160029; STIMSON E, 1995, MOL MICROBIOL, V17, P1201, DOI 10.1111/j.1365-2958.1995.mmi_17061201.x; STROM MS, 1993, ANNU REV MICROBIOL, V47, P565, DOI 10.1146/annurev.micro.47.1.565; Szymanski CM, 1999, MOL MICROBIOL, V32, P1022, DOI 10.1046/j.1365-2958.1999.01415.x; VIRJI M, 1993, MOL MICROBIOL, V10, P1013, DOI 10.1111/j.1365-2958.1993.tb00972.x; WIELAND F, 1985, J BIOL CHEM, V260, P5180; WIELAND F, 1983, P NATL ACAD SCI-BIOL, V80, P5470, DOI 10.1073/pnas.80.18.5470; York WS, 1985, METHOD ENZYMOL, P3, DOI DOI 10.1016/0076-6879(86)18062-1	49	158	169	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26479	26485		10.1074/jbc.M102685200	http://dx.doi.org/10.1074/jbc.M102685200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11342554	hybrid			2022-12-25	WOS:000169823300110
J	Desmyter, A; Decanniere, K; Muyldermans, S; Wyns, L				Desmyter, A; Decanniere, K; Muyldermans, S; Wyns, L			Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANONICAL STRUCTURES; CRYSTAL-STRUCTURE; VH DOMAINS; CONFORMATIONS; FRAGMENTS; SEQUENCES; SELECTION; PROGRAM; CRYSTALLOGRAPHY; IMMUNOGLOBULINS	Detailed knowledge on antibody-antigen recognition is scarce given the unlimited antibody specificities of which only few have been investigated at an atomic level. We report the crystal structures of an antibody fragment derived from a camel heavy chain antibody against carbonic anhydrase, free and in complex with antigen. Surprisingly, this single-domain antibody interacts with nanomolar affinity with the antigen through its third hypervariable loop (19 amino acids long), providing a flat interacting surface of 620 Angstrom (2). For the first time, a single-domain antibody is observed with its first hypervariable loop adopting a type-1 canonical structure. The second hypervariable loop, of unique size due to a somatic mutation, reveals a regular p-turn, The third hypervariable loop covers the remaining hypervariable loops and the side of the domain that normally interacts with the variable domain of the light chain, Specific amino acid substitutions and reoriented side chains reshape this side of the domain and increase its hydrophilicity, Of interest is the substitution of the conserved Trp-103 by Arg because it opens new perspectives to 'humanize' a camel variable domain of heavy chain of heavy chain antibody (VHH) or to 'camelize' a human or a mouse variable domain of heavy chain of conventional antibody (VH).	Free Univ Brussels VIB, Dept Ultrastruct, B-1640 Rhode St Genese, Belgium	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel	Desmyter, A (corresponding author), Free Univ Brussels VIB, Dept Ultrastruct, Paardenstr 65, B-1640 Rhode St Genese, Belgium.	aldesmtr@vub.ac.be	Muyldermans, Serge/AAC-7374-2019; Muyldermans, Serge V/C-6418-2016	Muyldermans, Serge/0000-0002-3678-3575; Muyldermans, Serge V/0000-0002-3678-3575				AlLazikani B, 1997, J MOL BIOL, V273, P927, DOI 10.1006/jmbi.1997.1354; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger A. T., 1992, SYSTEM XRAY CRYSTALL; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; Chothia C, 1998, J MOL BIOL, V278, P457, DOI 10.1006/jmbi.1998.1653; CHOTHIA C, 1985, J MOL BIOL, V186, P651, DOI 10.1016/0022-2836(85)90137-8; CHOTHIA C, 1992, J MOL BIOL, V227, P799, DOI 10.1016/0022-2836(92)90224-8; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; Davies J, 1996, PROTEIN ENG, V9, P531, DOI 10.1093/protein/9.6.531; DAVIES J, 1995, BIO-TECHNOL, V13, P475, DOI 10.1038/nbt0595-475; Decanniere K, 1999, STRUCTURE, V7, P361, DOI 10.1016/S0969-2126(99)80049-5; Decanniere K, 2000, J MOL BIOL, V300, P83, DOI 10.1006/jmbi.2000.3839; Desmyter A, 1996, NAT STRUCT BIOL, V3, P803, DOI 10.1038/nsb0996-803; FAN ZC, 1992, J MOL BIOL, V228, P188, DOI 10.1016/0022-2836(92)90500-J; Frenken LGJ, 2000, J BIOTECHNOL, V78, P11, DOI 10.1016/S0168-1656(99)00228-X; Ghahroudi MA, 1997, FEBS LETT, V414, P521, DOI 10.1016/S0014-5793(97)01062-4; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; Harmsen MM, 2000, MOL IMMUNOL, V37, P579, DOI 10.1016/S0161-5890(00)00081-X; Hoogenboom HR, 1998, IMMUNOTECHNOLOGY, V4, P1, DOI 10.1016/S1380-2933(98)00007-4; Hubbard SJ, 1993, NACCESS COMPUTER PRO; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; KABAT EA, 1991, J IMMUNOL, V147, P1709; Kabat EA, 1991, US PUBLIC HLTH SERVI; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Lauwereys M, 1998, EMBO J, V17, P3512, DOI 10.1093/emboj/17.13.3512; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Morea V, 1998, J MOL BIOL, V275, P269, DOI 10.1006/jmbi.1997.1442; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Muyldermans S, 1999, J MOL RECOGNIT, V12, P131, DOI 10.1002/(SICI)1099-1352(199903/04)12:2<131::AID-JMR454>3.0.CO;2-M; MUYLDERMANS S, 1994, PROTEIN ENG, V7, P1129, DOI 10.1093/protein/7.9.1129; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nguyen VK, 2000, EMBO J, V19, P921, DOI 10.1093/emboj/19.5.921; OTWINOWSKI Z, 1993, P CCP4 STUD WEEK, P107; Padlan EA, 1996, ADV PROTEIN CHEM, V49, P57, DOI 10.1016/S0065-3233(08)60488-X; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; Riechmann L, 1996, J MOL BIOL, V259, P957, DOI 10.1006/jmbi.1996.0373; Riechmann L, 1999, J IMMUNOL METHODS, V231, P25, DOI 10.1016/S0022-1759(99)00138-6; Schaffitzel C, 1999, J IMMUNOL METHODS, V231, P119, DOI 10.1016/S0022-1759(99)00149-0; Sheriff S, 1996, NAT STRUCT BIOL, V3, P733, DOI 10.1038/nsb0996-733; Shirai H, 1999, FEBS LETT, V455, P188, DOI 10.1016/S0014-5793(99)00821-2; Shirai H, 1996, FEBS LETT, V399, P1, DOI 10.1016/S0014-5793(96)01252-5; Spinelli S, 1996, NAT STRUCT BIOL, V3, P752, DOI 10.1038/nsb0996-752; Spinelli S, 2000, BIOCHEMISTRY-US, V39, P1217, DOI 10.1021/bi991830w; Transue TR, 1998, PROTEINS, V32, P515, DOI 10.1002/(SICI)1097-0134(19980901)32:4<515::AID-PROT9>3.0.CO;2-E; van der Linden R, 2000, J IMMUNOL METHODS, V240, P185, DOI 10.1016/S0022-1759(00)00188-5; van der Linden RHJ, 1999, BBA-PROTEIN STRUCT M, V1431, P37, DOI 10.1016/S0167-4838(99)00030-8; Vu KB, 1997, MOL IMMUNOL, V34, P1121, DOI 10.1016/S0161-5890(97)00146-6	50	126	231	10	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26285	26290		10.1074/jbc.M102107200	http://dx.doi.org/10.1074/jbc.M102107200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11342547	hybrid			2022-12-25	WOS:000169823300086
J	Hirota, K; Murata, M; Itoh, T; Yodoi, J; Fukuda, K				Hirota, K; Murata, M; Itoh, T; Yodoi, J; Fukuda, K			Redox-sensitive transactivation of epidermal growth factor receptor by tumor necrosis factor confers the NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; EGF RECEPTOR; HYDROGEN-PEROXIDE; TYROSINE PHOSPHORYLATION; TRANSCRIPTIONAL ACTIVITY; SIGNAL-TRANSDUCTION; OXIDATIVE STRESS; KINASE-ALPHA; THIOREDOXIN; APOPTOSIS	Cross-communication between different signaling systems allows the integration of the great diversity of stimuli that a cell receives under varying physiological situations. In this paper we have explored the possibility that tumor necrosis factor (TNF) receptor signal cross-talks with epidermal growth factor (EGF) receptor signal on the nuclear factor-kappaB (NF-kappaB) activation pathway. We have demonstrated that overexpression of the EGF receptor (EGFR) in NIH3T3 cells significantly enhances TNF-induced NF-kappaB-dependent luciferase activity even without EGF, that EGF treatment has a synergistic effect on the induction of the reporter activity, and that this enhancement is suppressed by AG1478, EGFR-specific tyrosine kinase inhibitor. We also have shown that TNF induces tyrosine phosphorylation and internalization of the overexpressed EGFR in NIH3T3 cells and the endogenously expressed EGFR in A431 cells and that the transactivation by TNF is suppressed by N-acetyl-L-cysteine or overexpression of an endogenous reducing molecule, thioredoxin, but not by phosphatidylinositol 3-kinase inhibitors and protein kinase C inhibitor. Taken together, this evidence strongly suggests that EGFR transactivation by TNF, which is regulated in a redox-dependent manner, is playing a pivotal role in TNF-induced NF-kappaB activation.	Kyoto Univ, Kyoto Univ Hosp, Dept Anesthesia, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Integrat Brain Sci, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Inst Virus Res, Dept Biol Responses, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University; Kyoto University; Kyoto University	Hirota, K (corresponding author), Kyoto Univ, Kyoto Univ Hosp, Dept Anesthesia, Sakyo Ku, 54 Shogoin Kawaharacho, Kyoto 6068507, Japan.		Hirota, Kiichi/E-9181-2010	Hirota, Kiichi/0000-0003-1110-0827				Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Barbier AJ, 1999, J BIOL CHEM, V274, P14067, DOI 10.1074/jbc.274.20.14067; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; Hirota K, 2000, BIOCHEM BIOPH RES CO, V274, P177, DOI 10.1006/bbrc.2000.3106; Hirota K, 2001, FEBS LETT, V489, P134, DOI 10.1016/S0014-5793(01)02094-4; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; IZUMI H, 1994, EXP CELL RES, V214, P654, DOI 10.1006/excr.1994.1303; Kamata H, 2000, EUR J BIOCHEM, V267, P1933, DOI 10.1046/j.1432-1327.2000.01194.x; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Obata H, 1996, BIOCHEM BIOPH RES CO, V224, P27, DOI 10.1006/bbrc.1996.0979; Ozes ON, 1999, NATURE, V401, P82; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; SULCINER DJ, 1996, MOL CELL BIOL, V16, P7155; Sun L, 1998, ONCOGENE, V16, P2095, DOI 10.1038/sj.onc.1201731; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Takeuchi J, 2000, ANTIOXID REDOX SIGN, V2, P83, DOI 10.1089/ars.2000.2.1-83; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	49	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25953	25958		10.1074/jbc.M011021200	http://dx.doi.org/10.1074/jbc.M011021200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11337489	hybrid			2022-12-25	WOS:000169823300043
J	Ma, R; Pluznick, J; Kudlacek, P; Sansom, SC				Ma, R; Pluznick, J; Kudlacek, P; Sansom, SC			Protein kinase C activates store-operated Ca2+ channels in human glomerular mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; SMOOTH-MUSCLE; INTRACELLULAR CA2+; SIGNALING COMPLEX; HUMAN-NEUTROPHILS; XENOPUS OOCYTES; T-LYMPHOCYTES; TRP; DEPLETION; INFLUX	Store-operated Ca2+ channels (SOC) are expressed in cultured human mesangial cells and activated by epidermal growth factor through a pathway involving protein kinase C (PKC), We used fura-2 fluorescence and patch clamp experiments to determine the role of PKC in mediating the activation of SOC after depletion of internal stores by thapsigargin, The measurements of intracellular Ca2+ concentration ([Ca2+],) revealed that the thapsigargin-induced Ca2+ entry pathway was abolished by calphostin C, a protein kinase C inhibitor, The PKC activator, phorbol 12-myristate 13-acetate (PMA), promoted a Ca2+ influx that was significantly attenuated by calphostin C and La3+ but not by diltiazem, Neither PMA nor calphostin C altered the thapsigargin-induced initial transient rise in [Ca2+](i-). In cell-attached patch clamp experiments, the thapsigargin-induced activation of SOC was potentiated by PMA and abolished by both calphostin C and staurosporine. However, SOC was unaffected by thapsigargin when clamping [Ca2+](i) with 1,2-bis (o-Aminophenoxy)ethane-N,N,N ' ,N ' tetraacetic acid tetra(acetoxymethyl)ester. In the absence of thapsigargin, PMA and phorbol 12, 13-didecanoate evoked a significant increase in NP, of SOC, whereas calphostin C did not affect base-line channel activity, In inside-out patches, SOC activity ran down immediately upon excision but was reactivated significantly after adding the catalytic subunit of 0.1 unit/ml of PKC plus 100 mum ATP, Neither ATP alone nor ATP with heat-inactivated PKC rescued a rundown of SOC, Metavanadate, a general protein phosphatase inhibitor, also enhanced SOC activity in inside-out patches. Bath [Ca2+] did not significantly affect the channel activity in inside-out patch, These results indicate that the depletion of Ca2+ stores activates SOC by PRC-mediated phosphorylation of the channel proteins or a membrane-associated complex.	Univ Nebraska, Med Ctr, Dept Physiol & Biophys, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Sansom, SC (corresponding author), Univ Nebraska, Med Ctr, Dept Physiol & Biophys, 984575 Nebraska Med Ctr, Omaha, NE 68198 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049561] Funding Source: NIH RePORTER; NHLBI NIH HHS [1T32HL07888] Funding Source: Medline; NIDDK NIH HHS [DK-49561] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; BODE HP, 1994, FEBS LETT, V339, P307, DOI 10.1016/0014-5793(94)80436-2; Bonev AD, 1996, J GEN PHYSIOL, V108, P315, DOI 10.1085/jgp.108.4.315; Camello C, 1999, J PHYSIOL-LONDON, V516, P399, DOI 10.1111/j.1469-7793.1999.0399v.x; CARMINES PK, 1993, AM J PHYSIOL, V265, pF677, DOI 10.1152/ajprenal.1993.265.5.F677; Chang EY, 1997, J IMMUNOL, V159, P2624; DONNADIEU E, 1992, J BIOL CHEM, V267, P25864; Gibson A, 1998, TRENDS PHARMACOL SCI, V19, P266; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Huber A, 1998, FEBS LETT, V425, P317, DOI 10.1016/S0014-5793(98)00248-8; Huber A, 1996, EMBO J, V15, P7036, DOI 10.1002/j.1460-2075.1996.tb01095.x; Kerschbaum HH, 1999, SCIENCE, V283, P836, DOI 10.1126/science.283.5403.836; Kondo I, 2000, JPN J PHARMACOL, V82, P210, DOI 10.1254/jjp.82.210; Kwak YG, 1999, J BIOL CHEM, V274, P25355, DOI 10.1074/jbc.274.36.25355; LAGAST H, 1984, J CLIN INVEST, V73, P878, DOI 10.1172/JCI111284; Leinweber B, 2000, J BIOL CHEM, V275, P40329, DOI 10.1074/jbc.M008257200; Lo CF, 1999, ANN NY ACAD SCI, V868, P431, DOI 10.1111/j.1749-6632.1999.tb11307.x; LUCKHOFF A, 1994, BIOPHYS J, V67, P177, DOI 10.1016/S0006-3495(94)80467-9; Ma R, 2001, J AM SOC NEPHROL, V12, P47, DOI 10.1681/ASN.V12147; Ma R, 2000, AM J PHYSIOL-RENAL, V278, pF954, DOI 10.1152/ajprenal.2000.278.6.F954; Maasch C, 2000, FASEB J, V14, P1653, DOI 10.1096/fj.14.11.1653; MCCARTHY SA, 1989, BIOCHEM J, V264, P357, DOI 10.1042/bj2640357; Mene P, 1996, J AM SOC NEPHROL, V7, P983; MENE P, 1994, KIDNEY INT, V46, P122, DOI 10.1038/ki.1994.251; Montell C, 1997, MOL PHARMACOL, V52, P755, DOI 10.1124/mol.52.5.755; MONTERO M, 1993, J BIOL CHEM, V268, P13055; Nagahama T, 2000, KIDNEY INT, V57, P215, DOI 10.1046/j.1523-1755.2000.00822.x; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Okoro EO, 1999, J PHARM PHARMACOL, V51, P953, DOI 10.1211/0022357991773221; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PETERSEN CCH, 1994, J BIOL CHEM, V269, P32246; Pfaff IL, 1999, J AM SOC NEPHROL, V10, P1861; Putney JW, 1999, BIOESSAYS, V21, P38; Ribeiro CMP, 2000, CELL CALCIUM, V27, P175, DOI 10.1054/ceca.2000.0108; Ribeiro CMP, 1996, J BIOL CHEM, V271, P21522, DOI 10.1074/jbc.271.35.21522; Schubert R, 1999, AM J PHYSIOL-CELL PH, V276, pC648, DOI 10.1152/ajpcell.1999.276.3.C648; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TORNQUIST K, 1993, BIOCHEM J, V290, P443; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC920, DOI 10.1152/ajpcell.1994.267.4.C920; Wu XY, 2000, AM J PHYSIOL-CELL PH, V278, pC526, DOI 10.1152/ajpcell.2000.278.3.C526; Yamazaki J, 1999, BIOPHYS J, V76, P1972, DOI 10.1016/S0006-3495(99)77356-X; Yano KJ, 1999, ENDOCRINOLOGY, V140, P4622, DOI 10.1210/en.140.10.4622; Yao Y, 1997, J GEN PHYSIOL, V109, P703, DOI 10.1085/jgp.109.6.703; Yoshiji H, 1999, CANCER RES, V59, P4413; Zhu X, 1998, NEWS PHYSIOL SCI, V13, P211; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	50	43	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25759	25765		10.1074/jbc.M011241200	http://dx.doi.org/10.1074/jbc.M011241200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11352899	hybrid			2022-12-25	WOS:000169823300018
J	Reffey, SB; Wurthner, JU; Parks, WT; Roberts, AB; Duckett, CS				Reffey, SB; Wurthner, JU; Parks, WT; Roberts, AB; Duckett, CS			X-linked inhibitor of apoptosis protein functions as a cofactor in transforming growth factor-beta signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR RECEPTOR; PROGRAMMED CELL-DEATH; TGF-BETA; CYTOCHROME-C; TRANSCRIPTIONAL REGULATION; BACULOVIRUS IAP; SMAD4 COOPERATE; GENE-EXPRESSION; KINASE RECEPTOR	X-linked inhibitor of apoptosis protein (XIAP) is a potent suppressor of apoptotic cell death, which functions by directly inhibiting caspases, the principal effecters of apoptosis. Here we report that XIAP can also function as a cofactor in the regulation of gene expression by transforming growth factor-beta (TGF-beta), XIAP, but not the related proteins c-IAP1 or c-IAP2, associated with several members of the type I class of the TGF-beta receptor superfamily and potentiated TGF-beta -induced signaling, Although XIAP-mediated activation of c-Jun N-terminal kinase and nuclear factor kappaB was found to require the TGF-beta signaling intermediate Smad4, the ability of XIAP to suppress apoptosis was found to be Smad4-independent, These data implicate a role for XIAP in TGF-beta -mediated signaling that is distinct from its anti-apoptotic functions.	NCI, Metab Branch, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; NCI, Lab Cell Regulat & Carcinogenesis, Canc Res Ctr, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Duckett, CS (corresponding author), NCI, Metab Branch, Canc Res Ctr, NIH, 10 Ctr Dr,Room 6B-05, Bethesda, MD 20892 USA.			Parks, W. Tony/0000-0001-7341-3277; Duckett, Colin/0000-0001-9413-2263				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; Duckett CS, 1997, GENE DEV, V11, P2810, DOI 10.1101/gad.11.21.2810; Duckett CS, 1998, MOL CELL BIOL, V18, P608, DOI 10.1128/MCB.18.1.608; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Freathy C, 2000, HEPATOLOGY, V32, P750, DOI 10.1053/jhep.2000.18329; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hawkins CJ, 1996, P NATL ACAD SCI USA, V93, P13786, DOI 10.1073/pnas.93.24.13786; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hofer-Warbinek R, 2000, J BIOL CHEM, V275, P22064, DOI 10.1074/jbc.M910346199; Huang HK, 2000, J BIOL CHEM, V275, P26661; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lopez-Rovira T, 2000, J BIOL CHEM, V275, P28937, DOI 10.1074/jbc.M909923199; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Massague J, 2000, GENE DEV, V14, P627; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Nagata S, 1996, CURR BIOL, V6, P1241, DOI 10.1016/S0960-9822(02)70706-9; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Oeda E, 1998, J BIOL CHEM, V273, P9353, DOI 10.1074/jbc.273.16.9353; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PERKINS ND, 1994, J VIROL, V68, P6820, DOI 10.1128/JVI.68.10.6820-6823.1994; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sanna MG, 1998, P NATL ACAD SCI USA, V95, P6015, DOI 10.1073/pnas.95.11.6015; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Uren AG, 1998, TRENDS BIOCHEM SCI, V23, P159, DOI 10.1016/S0968-0004(98)01198-0; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	70	122	126	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26542	26549		10.1074/jbc.M100331200	http://dx.doi.org/10.1074/jbc.M100331200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11356828	hybrid			2022-12-25	WOS:000169823300118
J	Valenzuela-Fernandez, A; Palanche, T; Amara, A; Magerus, A; Altmeyer, R; Delaunay, T; Virelizier, JL; Baleux, F; Galzi, JL; Arenzana-Seisdedos, F				Valenzuela-Fernandez, A; Palanche, T; Amara, A; Magerus, A; Altmeyer, R; Delaunay, T; Virelizier, JL; Baleux, F; Galzi, JL; Arenzana-Seisdedos, F			Optimal inhibition of X4 HIV isolates by the CXC chemokine stromal cell-derived factor 1 alpha requires interaction with cell surface heparan sulfate proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR CXCR4; ENVELOPE GLYCOPROTEIN; DENDRITIC CELLS; LYMPHOCYTE CHEMOATTRACTANT; GASTROINTESTINAL-TRACT; EPITHELIAL-CELLS; RHESUS MACAQUES; FACTOR-I; T-CELLS; SDF-1	The chemokine stromal cell-derived factor 1 (SDF-1) is the natural ligand for CXC chemokine receptor 4 (CXCR4), SDF-1 inhibits infection of CD4+ cells by X4 (CXCR4-dependent) human immunodeficiency virus (HIV) strains. We previously showed that SDF-1 alpha interacts specifically with heparin or heparan sulfates (HSs), Herein, we delimited the boundaries of the MS-binding domain located in the first beta -strand of SDF-1 alpha as the critical residues. We also provide evidence that binding to cell surface heparan sulfate proteoglycans (MSPGs) determines the capacity of SDF-1 alpha to prevent the fusogenic activity of HIV-1 X4 isolates in leukocytes. Indeed, SDF-1 alpha mutants lacking the capacity to interact with HSPGs showed a substantially reduced capacity to prevent cell-to-cell fusion mediated by X4 HIV envelope glycoproteins. Moreover, the enzymatic removal of cell surface MS diminishes the HIV-inhibitory capacity of the chemokine to the levels shown by the HS-binding-disabled mutant counterparts, The mechanisms underlying the optimal HIV-inhibitory activity of SDF-1 alpha when attached to MSPGs were investigated, Combining fluorescence resonance energy transfer and laser confocal microscopy, we demonstrate the concomitant binding of SDF-1 alpha to CXCR4 and MSPGs at the cell membrane. Using FRET between a Texas Red-labeled SDF-1 alpha and an enhanced green fluorescent protein-tagged CXCR4, we show that binding of SDF-1 alpha to cell surface HSPGs modifies neither the kinetics of occupancy nor activation in real time of CXCR4 by the chemokine. Moreover, attachment to HSPGs does not modify the potency of the chemokine to promote internalization of CXCR4, Attachment to cellular MSPGs may co-operate in the optimal anti-HIV activity of SDF-1 alpha by increasing the local concentration of the chemokine in the surrounding environment of CXCR4, thus facilitating sustained occupancy and down-regulation of the HIV coreceptor.	Inst Pasteur, Unite Immunol Virale, F-75724 Paris 15, France; Inst Pasteur, Unite Chim Organ, F-75724 Paris 15, France; Ecole Super Biotecnol Strasbourg, Dept Recepteurs & Prot Membranaires, CNRS UPR 9050, F-67400 Illkirch Graffenstaden, France; INRA, Stn Pathol Vegetale, F-33833 Villenave Dornon, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); INRAE	Arenzana-Seisdedos, F (corresponding author), Inst Pasteur, Unite Immunol Virale, 28 Rue Dr Roux, F-75724 Paris 15, France.	farenzan@pasteur.fr	Valenzuela-Fernández, Agustín/P-1638-2019; Valenzuela-Fernández, Agustín/B-6219-2014; Amara, Ali/E-8803-2017; Arenzana-Seisdedos, Fernando/E-5835-2016; Magerus-Chatinet, Aude/I-6245-2017; AMARA, Ali/ABX-9903-2022	Valenzuela-Fernández, Agustín/0000-0002-2585-8703; Valenzuela-Fernández, Agustín/0000-0002-2585-8703; Magerus-Chatinet, Aude/0000-0001-7365-699X; AMARA, Ali/0000-0002-0283-1815				Agace WW, 2000, CURR BIOL, V10, P325, DOI 10.1016/S0960-9822(00)00380-8; Agace WW, 2000, EUR J IMMUNOL, V30, P819, DOI 10.1002/1521-4141(200003)30:3<819::AID-IMMU819>3.0.CO;2-Y; Amara A, 1999, J BIOL CHEM, V274, P23916, DOI 10.1074/jbc.274.34.23916; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Amzazi S, 1998, VIROLOGY, V252, P96, DOI 10.1006/viro.1998.9452; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; BERNFIELD M, 1990, PHILOS T R SOC B, V327, P171, DOI 10.1098/rstb.1990.0052; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1998, J EXP MED, V187, P753, DOI 10.1084/jem.187.5.753; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Bohm SK, 1997, BIOCHEM J, V322, P1; Brelot A, 2000, J BIOL CHEM, V275, P23736, DOI 10.1074/jbc.M000776200; Burns JM, 1999, P NATL ACAD SCI USA, V96, P14499, DOI 10.1073/pnas.96.25.14499; Chabot DJ, 1999, J VIROL, V73, P6598, DOI 10.1128/JVI.73.8.6598-6609.1999; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; CLAVEL F, 1994, J VIROL, V68, P1179, DOI 10.1128/JVI.68.2.1179-1185.1994; Coulomb-L'Hermine A, 1999, P NATL ACAD SCI USA, V96, P8585, DOI 10.1073/pnas.96.15.8585; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Doranz BJ, 1999, J VIROL, V73, P2752, DOI 10.1128/JVI.73.4.2752-2761.1999; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Gleichmann M, 2000, EUR J NEUROSCI, V12, P1857, DOI 10.1046/j.1460-9568.2000.00048.x; GranelliPiperno A, 1996, J EXP MED, V184, P2433, DOI 10.1084/jem.184.6.2433; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; Harouse JM, 1999, SCIENCE, V284, P816, DOI 10.1126/science.284.5415.816; HEIDMANN T, 1979, EUR J BIOCHEM, V94, P255, DOI 10.1111/j.1432-1033.1979.tb12893.x; Heveker N, 1998, CURR BIOL, V8, P369, DOI 10.1016/S0960-9822(98)70155-1; Hu JJ, 2000, J VIROL, V74, P6087, DOI 10.1128/JVI.74.13.6087-6095.2000; Ianelli CJ, 1998, J BIOL CHEM, V273, P23367, DOI 10.1074/jbc.273.36.23367; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Michael NL, 1999, NAT MED, V5, P740, DOI 10.1038/10462; Miller CJ, 1999, J INFECT DIS, V179, pS413, DOI 10.1086/314795; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; NEUBIG RR, 1993, MOL PHARMACOL, V43, P734; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Ohshiro Y, 1996, MICROBIOL IMMUNOL, V40, P827, DOI 10.1111/j.1348-0421.1996.tb01148.x; Oravecz T, 1997, J IMMUNOL, V159, P4587; Pablos JL, 1999, AM J PATHOL, V155, P1577, DOI 10.1016/S0002-9440(10)65474-0; Puri A, 1998, P NATL ACAD SCI USA, V95, P14435, DOI 10.1073/pnas.95.24.14435; SANDERSON RD, 1988, P NATL ACAD SCI USA, V85, P9562, DOI 10.1073/pnas.85.24.9562; Scarlatti G, 1997, NAT MED, V3, P1259, DOI 10.1038/nm1197-1259; SCHWARTZ O, 1994, VIROLOGY, V198, P360, DOI 10.1006/viro.1994.1042; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Tanabe S, 1997, J IMMUNOL, V159, P905; TERSMETTE M, 1989, LANCET, V1, P983; Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427; Vollmer JY, 1999, J BIOL CHEM, V274, P37915, DOI 10.1074/jbc.274.53.37915; Wagner L, 1998, NATURE, V391, P908, DOI 10.1038/36129; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	53	68	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26550	26558		10.1074/jbc.M100411200	http://dx.doi.org/10.1074/jbc.M100411200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11352904	hybrid, Green Published			2022-12-25	WOS:000169823300119
J	Warny, M; Aboudola, S; Robson, SC; Sevigny, J; Communi, D; Soltoff, SP; Kelly, CP				Warny, M; Aboudola, S; Robson, SC; Sevigny, J; Communi, D; Soltoff, SP; Kelly, CP			P2Y(6) nucleotide receptor mediates monocyte interleukin-8 production in response to UDP or lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE DIPHOSPHOKINASE; PERITONEAL-MACROPHAGES; PURINERGIC RECEPTOR; IL-1-BETA RELEASE; ATP; ACTIVATION; EXPRESSION; IDENTIFICATION; CELLS; MODULATION	Extracellular nucleotides are autocrine and paracrine cellular mediators that signal through P2 nucleotide receptors. Monocytic cells express several P2Y receptors but the role of these G protein-coupled receptors in monocytes is not known. Here, we present evidence that P2Y(6) regulates chemokine production and release in monocytes, We find that UDP, a selective P2Y(6) agonist, stimulates interleukin (IL)-8 release in human THP-1 monocytic cells whereas other nucleotides are relatively inactive. P2 receptor antagonists or P2Y(6) antisense oligonucleotides inhibit IL-8 release induced by UDP, Furthermore, UDP specifically activated IL-8 production in astrocytoma 1321N1 cells transfected with human P2Y(6). Since lipopolysaccharide has been suggested to activate P2 receptors via nucleotide release, we tested whether IL-8 production stimulated by lipopolysaccharide might result from P2Y(6) activation. P2 antagonists or apyrase, an enzyme which hydrolyzes nucleotides including UDP, inhibit IL-8 production induced by lipopolysaccharide but not by other stimuli. Furthermore, IL-8 gene expression activated by lipopolysaccharide is enhanced by P2Y(6) overexpression and inhibited by P2Y(6) antisense oligonucleotides. Thus, UDP activates IL-8 production via P2Y(6) in monocytic cells. Furthermore, lipopolysaccharide mediates IL-8 production at least in part by autocrine P2Y(6) activation. These findings indicate a novel role for P2Y(6) in innate immune defenses.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gastroenterol, Boston, MA 02215 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Signal Transduct Div, Boston, MA 02215 USA; Free Univ Brussels, Sch Med, Inst Interdisciplinary Res, B-1070 Brussels, Belgium	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Warny, M (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gastroenterol, Dana Bldg,Rm 501,330 Brookline Ave, Boston, MA 02215 USA.	mwarny@caregroup.harvard.edu	Sevigny, Jean/E-8039-2012; Robson, Simon C./AAA-8537-2021; Sévigny, Jean/AGH-9323-2022	Sevigny, Jean/0000-0003-2922-1600; Sévigny, Jean/0000-0003-2922-1600	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057307, R01HL063972] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058858, R21DK054290] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL63972, R01HL57307] Funding Source: Medline; NIDDK NIH HHS [R01DK54290, R01DK58858] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ajuebor MN, 1999, J IMMUNOL, V162, P1685; Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Balboa MA, 1999, J BIOL CHEM, V274, P36764, DOI 10.1074/jbc.274.51.36764; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; Beigi RD, 2000, J IMMUNOL, V165, P7189, DOI 10.4049/jimmunol.165.12.7189; Berchtold S, 1999, FEBS LETT, V458, P424, DOI 10.1016/S0014-5793(99)01197-7; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; BURNSTOCK G, 1998, P2 NUCLEOTIDE RECEPT, P3; Chen BC, 1998, J BIOL CHEM, V273, P29754, DOI 10.1074/jbc.273.45.29754; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Clifford EE, 1997, AM J PHYSIOL-CELL PH, V273, pC973, DOI 10.1152/ajpcell.1997.273.3.C973; Communi D, 1996, BIOCHEM BIOPH RES CO, V222, P303, DOI 10.1006/bbrc.1996.0739; Evans RJ, 1998, P2 NUCLEOTIDE RECEPT, P43; Ferrari D, 1999, J BIOL CHEM, V274, P13205, DOI 10.1074/jbc.274.19.13205; Ferrari D, 1997, J EXP MED, V185, P579, DOI 10.1084/jem.185.3.579; Ferrari D, 1997, J IMMUNOL, V159, P1451; Gerszten RE, 1999, NATURE, V398, P718, DOI 10.1038/19546; Grahames CBA, 1999, BRIT J PHARMACOL, V127, P1915, DOI 10.1038/sj.bjp.0702732; HARDEN TK, 1998, P2 NUCLEOTIDE RECEPT, P109; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; Hu Y, 1998, J BIOL CHEM, V273, P27170, DOI 10.1074/jbc.273.42.27170; Imai M, 2000, BIOCHEM BIOPH RES CO, V270, P272, DOI 10.1006/bbrc.2000.2410; Jin JG, 1998, BRIT J PHARMACOL, V123, P789, DOI 10.1038/sj.bjp.0701665; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; Lazarowski ER, 1997, J BIOL CHEM, V272, P20402, DOI 10.1074/jbc.272.33.20402; Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; Mulero JJ, 1999, J BIOL CHEM, V274, P20064, DOI 10.1074/jbc.274.29.20064; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; ROBSON SC, 2001, IN PRESS DRUG DEV RE; Sevigny J, 1997, BBA-GEN SUBJECTS, V1334, P73, DOI 10.1016/S0304-4165(96)00079-7; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Soltoff SP, 1998, J BIOL CHEM, V273, P2653, DOI 10.1074/jbc.273.5.2653; Somers GR, 1998, LAB INVEST, V78, P1375; Sperlagh B, 1998, NEUROCHEM INT, V33, P209, DOI 10.1016/S0197-0186(98)00025-4; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Warny M, 2000, J CLIN INVEST, V105, P1147, DOI 10.1172/JCI7545; WARNY M, 2000, AM J PHYSIOL, V276, pC717; WERNER A, 1991, J CHROMATOGR, V553, P205, DOI 10.1016/S0021-9673(01)88490-9; Yang H, 2000, J BIOL CHEM, V275, P20861, DOI 10.1074/jbc.M002896200	41	122	128	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26051	26056		10.1074/jbc.M102568200	http://dx.doi.org/10.1074/jbc.M102568200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11349132	hybrid			2022-12-25	WOS:000169823300056
J	West, KL; Ito, Y; Birger, Y; Postnikov, Y; Shirakawa, H; Bustin, M				West, KL; Ito, Y; Birger, Y; Postnikov, Y; Shirakawa, H; Bustin, M			HMGN3a and HMGN3b, two protein isoforms with a tissue-specific expression pattern, expand the cellular repertoire of nucleosome-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOBILITY-GROUP PROTEINS; GROUP CHROMOSOMAL-PROTEINS; HUMAN CDNA SEQUENCE; MULTIGENE FAMILY; FUNCTIONAL GENE; HISTONE H1; NF-Y; CHROMATIN; HMG-14; TRANSCRIPTION	HMGN1 (HMG-14) and HMGN2 (HMG-17) are nuclear proteins that bind specifically to nucleosomes reduce the compactness of the chromatin fiber, and enhance transcription from chromatin templates. Here we report that many vertebrates contain an additional type of HMGN protein named HMGN3 (Trip 7), The human HMGN3 gene is located on chromosome 6 and spans 32 kilobase pairs, which is nearly 10-fold longer than the closely related HMGN2 gene. However, the intron/exon boundaries of the HMGN3 gene are identical to those of HMGN1 and HMGN2. Unique within the HMGN family, the HMGN3 transcript undergoes alternative splicing and generates two different variants, HMGN3a and HMGN3b. The shorter variant, HMGN3b, arises from an additional splice site that truncates exon V and causes a frameshift. The resulting HMGN3b protein lacks the majority of the C-terminal chromatin-unfolding domain. Both splice variants are found in many vertebrates from frogs to man and are expressed in many tissues. The pattern of tissue-specific expression differs considerably from those of HMGN1 and HMGN2 at both the mRNA and the protein level. Our results expand the multiplicity of the HMGN protein family and raise the possibility that these nucleosome-binding proteins function as co-activators in tissue-specific gene expression.	NCI, Div Basic Sci, Prot Sect,Lab Metab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	West, KL (corresponding author), NCI, Div Basic Sci, Prot Sect,Lab Metab, NIH, Bldg 37,Rm 3C12, Bethesda, MD 20892 USA.	klmarsh@pop.nci.nih.gov	Shirakawa, Hitoshi/D-1406-2009; Bustin, Michael/G-6155-2015	Bustin, Michael/0000-0002-5147-7242; West, Katherine/0000-0002-5994-8969; SHIRAKAWA, HITOSHI/0000-0002-4828-5274				ALFONSO PJ, 1994, J MOL BIOL, V236, P189, DOI 10.1006/jmbi.1994.1128; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; Bergel M, 2000, J BIOL CHEM, V275, P11514, DOI 10.1074/jbc.275.15.11514; BUSTIN M, 1989, METHOD ENZYMOL, V170, P214; BUSTIN M, 1995, SEMIN CELL BIOL, V6, P247, DOI 10.1006/scel.1995.0033; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Cook T, 1999, ANN NY ACAD SCI, V880, P94, DOI 10.1111/j.1749-6632.1999.tb09513.x; COOPER E, 1983, ENDOCRINOLOGY, V112, P1816, DOI 10.1210/endo-112-5-1816; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; de la Barre AE, 2000, EMBO J, V19, P379, DOI 10.1093/emboj/19.3.379; Ding HF, 1997, MOL CELL BIOL, V17, P5843, DOI 10.1128/MCB.17.10.5843; FLETCHER TM, 1995, J BIOL CHEM, V270, P25359, DOI 10.1074/jbc.270.43.25359; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Herrera JE, 1999, MOL CELL BIOL, V19, P3466; Hock R, 1998, EMBO J, V17, P6992, DOI 10.1093/emboj/17.23.6992; Hock R, 1998, J CELL BIOL, V143, P1427, DOI 10.1083/jcb.143.6.1427; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; KORNBERG RD, 1989, METHOD ENZYMOL, V170, P3; LANDSMAN D, 1986, J BIOL CHEM, V261, P6082; LANDSMAN D, 1986, J BIOL CHEM, V261, P7479; LANDSMAN D, 1989, NUCLEIC ACIDS RES, V17, P2301, DOI 10.1093/nar/17.6.2301; LANDSMAN D, 1989, J BIOL CHEM, V264, P3421; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEVYWILSON B, 1981, P NATL ACAD SCI-BIOL, V78, P2189, DOI 10.1073/pnas.78.4.2189; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MARDIAN JKW, 1980, SCIENCE, V209, P1534, DOI 10.1126/science.7433974; Minucci S, 1999, SEMIN CELL DEV BIOL, V10, P215, DOI 10.1006/scdb.1999.0303; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; PARANJAPE SM, 1995, GENE DEV, V9, P1978, DOI 10.1101/gad.9.16.1978; PASH J, 1990, P NATL ACAD SCI USA, V87, P3836, DOI 10.1073/pnas.87.10.3836; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; POSTNIKOV YV, 1995, J MOL BIOL, V252, P423, DOI 10.1006/jmbi.1995.0508; POSTNIKOV YV, 1994, NUCLEIC ACIDS RES, V22, P4520, DOI 10.1093/nar/22.21.4520; Postnikov YV, 1997, J MOL BIOL, V274, P454, DOI 10.1006/jmbi.1997.1391; Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001; SANDEEN G, 1980, NUCLEIC ACIDS RES, V8, P3757, DOI 10.1093/nar/8.17.3757; Shirakawa H, 2000, J BIOL CHEM, V275, P37937, DOI 10.1074/jbc.M000989200; Shirakawa H, 2000, J BIOL CHEM, V275, P6368, DOI 10.1074/jbc.275.9.6368; SPAULDING SW, 1991, MOL ENDOCRINOL, V5, P42, DOI 10.1210/mend-5-1-42; STERNER R, 1981, J BIOL CHEM, V256, P8892; Thomas JO, 1999, CURR OPIN CELL BIOL, V11, P312, DOI 10.1016/S0955-0674(99)80042-8; Trieschmann L, 1998, P NATL ACAD SCI USA, V95, P5468, DOI 10.1073/pnas.95.10.5468; TRIESCHMANN L, 1995, MOL CELL BIOL, V15, P6663; TRIESCHMANN L, 1995, EMBO J, V14, P1478, DOI 10.1002/j.1460-2075.1995.tb07134.x; Vestner B, 1998, J BIOL CHEM, V273, P9409, DOI 10.1074/jbc.273.16.9409; Weigmann N, 1997, DNA CELL BIOL, V16, P1207, DOI 10.1089/dna.1997.16.1207; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Wolffe AP, 1998, PROG NUCLEIC ACID RE, V61, P379, DOI 10.1016/S0079-6603(08)60832-6	55	38	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25959	25969		10.1074/jbc.M101692200	http://dx.doi.org/10.1074/jbc.M101692200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11356838	hybrid			2022-12-25	WOS:000169823300044
J	Carvalho, J; Bertram, PG; Wente, SR; Zheng, XFS				Carvalho, J; Bertram, PG; Wente, SR; Zheng, XFS			Phosphorylation regulates the interaction between Gln3p and the nuclear import factor Srp1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPORT; SACCHAROMYCES-CEREVISIAE; GENE-PRODUCT; PORE COMPLEX; NUCLEOCYTOPLASMIC TRANSPORT; RAPAMYCIN TOR; PROTEIN; YEAST; CRM1; IDENTIFICATION	Gln3p is a GATA-type transcription activator of nitrogen catabolite repressible (NCR) genes. Gln3p was recently found to be hyperphosphorylated in a TOR-dependent manner and resides in the cytoplasm in high quality nitrogen. In contrast, during nitrogen starvation or rapamycin treatment, Gln3p becomes rapidly dephosphorylated and accumulates in the nucleus, thereby activating nitrogen catabolite repression genes. However, a detailed mechanistic understanding is lacking for the regulation of Gln3p nucleocytoplasmic distribution, In this study, we applied a functional genomics approach to identify the nuclear transport factors for Gln3p, We found that yeast karyopherin alpha /Srp1p and Crm1p are required for the nuclear import and export of Gln3p, respectively. Similarly, the Ran GTPase pathway is also involved in the nuclear translocation of Gln3p, Finally, we show that Srp1p preferentially interacts with the hypophosphorylated versus the hyperphosphorylated Gln3p. These findings define a possible mechanism for regulated nucleocytoplasmic transport of Gln3p by phosphorylation in vivo.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Zheng, XFS (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, Campus Box 8069,1030 CSRBNT,660 S Euclid Ave, St Louis, MO 63110 USA.	zheng@pathology.wustl.edu						Alarcon CM, 1999, MOL BIOL CELL, V10, P2531, DOI 10.1091/mbc.10.8.2531; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; BELANGER KD, 1994, J CELL BIOL, V126, P619, DOI 10.1083/jcb.126.3.619; Bertram PG, 1998, CURR BIOL, V8, P1259, DOI 10.1016/S0960-9822(07)00535-0; Bertram PG, 2000, J BIOL CHEM, V275, P35727, DOI 10.1074/jbc.M004235200; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; CAFFERKEY R, 1994, GENE, V141, P133, DOI 10.1016/0378-1119(94)90141-4; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; Coffman JA, 1996, MOL CELL BIOL, V16, P847; Corbett AH, 1997, MICROBIOL MOL BIOL R, V61, P193, DOI 10.1128/.61.2.193-211.1997; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; COURCHESNE WE, 1988, J BACTERIOL, V170, P708, DOI 10.1128/jb.170.2.708-713.1988; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; DeVit MJ, 1999, CURR BIOL, V9, P1231, DOI 10.1016/S0960-9822(99)80503-X; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Hodge CA, 1999, EMBO J, V18, P5778, DOI 10.1093/emboj/18.20.5778; Hood JK, 1998, J BIOL CHEM, V273, P35142, DOI 10.1074/jbc.273.52.35142; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; KADOWAKI T, 1994, J CELL BIOL, V126, P649, DOI 10.1083/jcb.126.3.649; Kaffman A, 1998, GENE DEV, V12, P2673, DOI 10.1101/gad.12.17.2673; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Komeili A, 2000, J CELL BIOL, V151, P863, DOI 10.1083/jcb.151.4.863; Komeili A, 2000, CURR OPIN CELL BIOL, V12, P355, DOI 10.1016/S0955-0674(00)00100-9; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; Kuge S, 1998, GENES CELLS, V3, P521, DOI 10.1046/j.1365-2443.1998.00209.x; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Kuruvilla FG, 1999, CHEM BIOL, V6, pR129, DOI 10.1016/S1074-5521(99)80070-2; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; LANFORD RE, 1985, VIROLOGY, V147, P72, DOI 10.1016/0042-6822(85)90228-4; LORENZ MC, 1995, J BIOL CHEM, V270, P27531, DOI 10.1074/jbc.270.46.27531; MAGASANIK B, 1992, MOL CELLULAR BIOL YE, V2, P283; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MELCHIOR F, 1993, MOL BIOL CELL, V4, P569, DOI 10.1091/mbc.4.6.569; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Seedorf M, 1997, P NATL ACAD SCI USA, V94, P8590, DOI 10.1073/pnas.94.16.8590; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; STAN R, 1994, J BIOL CHEM, V269, P32027; STANBROUGH M, 1995, P NATL ACAD SCI USA, V92, P9450, DOI 10.1073/pnas.92.21.9450; TRAGLIA HM, 1989, MOL CELL BIOL, V9, P2989, DOI 10.1128/MCB.9.7.2989; Wente SR, 2000, SCIENCE, V288, P1374, DOI 10.1126/science.288.5470.1374; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; XIAO ZX, 1993, MOL CELL BIOL, V13, P4691, DOI 10.1128/MCB.13.8.4691; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	69	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25359	25365		10.1074/jbc.M103050200	http://dx.doi.org/10.1074/jbc.M103050200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11331291	hybrid			2022-12-25	WOS:000169800700123
J	Waugh, DJJ; Gaivin, RJ; Zuscik, MJ; Gonzalez-Cabrera, P; Ross, SA; Yun, J; Perez, DM				Waugh, DJJ; Gaivin, RJ; Zuscik, MJ; Gonzalez-Cabrera, P; Ross, SA; Yun, J; Perez, DM			Phe-308 and Phe-312 in transmembrane domain 7 are major sites of alpha(1)-adrenergic receptor antagonist binding - Imidazoline agonists bind like antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; PROTEIN-COUPLED RECEPTOR; EXTRACELLULAR LOOP; BETA(2)-ADRENERGIC RECEPTOR; IDENTIFICATION; SUBTYPE; ACTIVATION; RESIDUES; SELECTIVITY; AFFINITY	Although agonist binding in adrenergic receptors is fairly well understood and involves residues located in transmembrane domains 3 through 6, there are few residues reported that are involved in antagonist binding. In fact, a major docking site for antagonists has never been reported in any G-protein coupled receptor. It has been speculated that antagonist binding is quite diverse depending upon the chemical structure of the antagonist, which can be quite different from agonists, We now report the identification of two phenylalanine residues in transmembrane domain 7 of the alpha (1a)-adrenergic receptor (Phe-312 and Phe-308) that are a major site of antagonist affinity. Mutation of either Phe-308 or Phe-312 resulted in significant losses of affinity (4-1200-fold) for the antagonists prazosin, WB4101, BMY7378, (+) niguldipine, and 5-methylurapidil, with no changes in affinity for phenethylamine-type agonists such as epinephrine, methoxamine, or phenylephrine, Interestingly, both residues are involved in the binding of all imidazoline-type agonists such as oxymetazoline, cirazoline, and clonidine, confirming previous evidence that this class of ligand binds differently than phenethylamine-type agonists and may be more antagonist-like, which may explain their partial agonist properties. In modeling these interactions with previous mutagenesis studies and using the current backbone structure of rhodopsin, we conclude that antagonist binding is docked higher in the pocket closer to the extracellular surface than agonist binding and appears skewed toward transmembrane domain 7.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Perez, DM (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, NB5,9500 Euclid Ave, Cleveland, OH 44195 USA.			Zuscik, Michael/0000-0003-0461-8708; WAUGH, DAVID/0000-0002-4022-3765	NHLBI NIH HHS [R01 HL61438] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061438] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARAK LS, 1994, J BIOL CHEM, V269, P2790; Chen JY, 1999, ELECTROCHEM COMMUN, V1, P274, DOI 10.1016/S1388-2481(99)00056-9; DIXON RAF, 1989, PROTEINS, V6, P267, DOI 10.1002/prot.340060309; GUAN XM, 1992, MOL PHARMACOL, V41, P695; Guarino RD, 1996, CELL SIGNAL, V8, P323, DOI 10.1016/0898-6568(96)00066-6; Hamaguchi N, 1996, BIOCHEMISTRY-US, V35, P14312, DOI 10.1021/bi961024e; Hwa J, 1996, J BIOL CHEM, V271, P6322, DOI 10.1074/jbc.271.11.6322; HWA J, 1995, J BIOL CHEM, V270, P23189, DOI 10.1074/jbc.270.39.23189; LI X, 1996, EUR J PHARMACOL, V300, P1; MARULLO S, 1990, EMBO J, V9, P1471, DOI 10.1002/j.1460-2075.1990.tb08264.x; MINNEMAN KP, 1994, MOL PHARMACOL, V46, P929; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Perez DM, 1996, MOL PHARMACOL, V49, P112; PEREZ DM, 1994, MOL PHARMACOL, V46, P823; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; Porter JE, 1996, J BIOL CHEM, V271, P28318, DOI 10.1074/jbc.271.45.28318; RUFFOLO RR, 1977, J PHARM PHARMACOL, V29, P378, DOI 10.1111/j.2042-7158.1977.tb11344.x; RUFFOLO RR, 1983, EUR J PHARMACOL, V86, P471, DOI 10.1016/0014-2999(83)90199-1; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4383; SURYANARAYANA S, 1991, J BIOL CHEM, V266, P15488; Waugh DJJ, 2000, J BIOL CHEM, V275, P11698, DOI 10.1074/jbc.275.16.11698; Wurch T, 1998, MOL PHARMACOL, V54, P1088, DOI 10.1124/mol.54.6.1088; Zhao MM, 1996, MOL PHARMACOL, V50, P1118; Zhao MM, 1998, MOL PHARMACOL, V53, P524, DOI 10.1124/mol.53.3.524	25	52	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25366	25371		10.1074/jbc.M103152200	http://dx.doi.org/10.1074/jbc.M103152200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11331292	Green Published, hybrid			2022-12-25	WOS:000169800700124
J	Latasa, MU; Boukaba, A; Garcia-Trevijano, ER; Torres, L; Rodriguez, JL; Caballeria, J; Lu, SC; Lopez-Rodas, G; Franco, L; Mato, JM; Avila, MA				Latasa, MU; Boukaba, A; Garcia-Trevijano, ER; Torres, L; Rodriguez, JL; Caballeria, J; Lu, SC; Lopez-Rodas, G; Franco, L; Mato, JM; Avila, MA			Hepatocyte growth factor induces MAT2A expression and histone acetylation in rat hepatocytes: role in liver regeneration	FASEB JOURNAL			English	Article									Univ Navarra, Fac Med, Edificio Castanos, Dept Med Interna,Unidad Hepatol & Terapia Gen, Pamplona 31008, Spain; Univ Valencia, Dept Bioquim & Biol Mol, E-46100 Valencia, Spain; Hosp Clin & Prov, Serv Hepatol, Barcelona 08036, Spain; Univ So Calif, Sch Med, Dept Med, Ctr Liver Dis Res, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Med, Div Gastrointestinal Liver Dis, Los Angeles, CA 90033 USA	University of Navarra; University of Valencia; University of Barcelona; Hospital Clinic de Barcelona; University of Southern California; University of Southern California	Mato, JM (corresponding author), Univ Navarra, Fac Med, Edificio Castanos, Dept Med Interna,Unidad Hepatol & Terapia Gen, Pamplona 31008, Spain.		MATO, JOSE/A-5187-2011; Torres, Luis/AAB-2403-2019; Avila, Matias A/Y-6342-2019; Ruiz García-Trevijano, Elena R./ABE-1014-2021; LOPEZ-RODAS, GERARDO/I-1349-2015	MATO, JOSE/0000-0003-1264-3153; Avila, Matias A/0000-0001-6570-3557; Ruiz García-Trevijano, Elena R./0000-0002-3985-1270; LOPEZ-RODAS, GERARDO/0000-0001-8367-653X; Latasa, Maria Ujue/0000-0002-0878-1337; Franco, Luis/0000-0001-9610-6448					0	48	49	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1248	1250		10.1096/fj.00-0556fjev1	http://dx.doi.org/10.1096/fj.00-0556fjev1			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344103				2022-12-25	WOS:000168655200025
J	Lin, J; Jinno, S; Okayama, H				Lin, J; Jinno, S; Okayama, H			Cdk6-cyclin D3 complex evades inhibition by inhibitor proteins and uniquely controls cell's proliferation competence	ONCOGENE			English	Article						Cdk6; cyclin D3; CKI; proliferation competence	CYCLIN-DEPENDENT KINASE-6; CDK INHIBITORS; TYROSINE PHOSPHORYLATION; VIRAL CYCLIN; PROGRESSION; EXPRESSION; P27(KIP1); ANCHORAGE; FAMILY; GROWTH	Mammalian cells require a cyclin D-dependent kinase for the cell cycle start, yet many mesenchymal cells express three seemingly redundant D cyclins and similarly, seemingly redundant Cdk4 and Cdk6 as their kinase partners, We have found that the Cdk6-cyclin D3 complex is unique among the D cyclin and kinase combinations in the ability to promote the cell cycle start. In an anchorage-minus G(1)-arrested rat fibroblast, only Cdk6-D3 retains kinase activity due mainly to its ability to evade inhibition by p27(KIPI) and p21(CIPI) with a resemblance to viral cyclin-bound Cdk6, Rodent fibroblasts engineered to overexpress both Cdk6 and cyclin D3 highly resist serum starvation- or cell-cell contact-imposed G(1)-arrest, In BALB/c 3T3 cells, D3 is constitutively expressed, but Cdk6 is markedly induced with concomitant activation upon stimulation with a growth-promoting factor. These results suggest a role for the Cdk6-D3 complex in regulating cell's proliferation ability in response to external stimuli.	Univ Tokyo, Grad Sch Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Okayama, H (corresponding author), Univ Tokyo, Grad Sch Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan.							Belyavskyi M, 1998, P NATL ACAD SCI USA, V95, P11205, DOI 10.1073/pnas.95.19.11205; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chilosi M, 1998, AM J PATHOL, V152, P209; Dong F, 1998, MOL BIOL CELL, V9, P2081, DOI 10.1091/mbc.9.8.2081; Dong F, 1998, J BIOL CHEM, V273, P6190, DOI 10.1074/jbc.273.11.6190; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Henzinger T, 1998, J BIOL CHEM, V273, P14958, DOI 10.1074/jbc.273.24.14958; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jinno S, 1999, ONCOGENE, V18, P565, DOI 10.1038/sj.onc.1202347; Jinno S, 1999, P NATL ACAD SCI USA, V96, P13197, DOI 10.1073/pnas.96.23.13197; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KUME K, 1992, NEW BIOL, V4, P504; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; Okayama H, 1996, ADV CANCER RES, V69, P17, DOI 10.1016/S0065-230X(08)60859-3; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; Schulze-Gahmen U, 1999, STRUCTURE, V7, P245, DOI 10.1016/S0969-2126(99)80035-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Swanton C, 1997, NATURE, V390, P184, DOI 10.1038/36606; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; Van Dyk LF, 1999, J VIROL, V73, P5110, DOI 10.1128/JVI.73.6.5110-5122.1999; Wagner EF, 1998, J IMMUNOL, V161, P1123	27	36	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2001	20	16					2000	2009		10.1038/sj.onc.1204375	http://dx.doi.org/10.1038/sj.onc.1204375			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360184				2022-12-25	WOS:000168043800008
J	Drain, J; Bishop, JR; Hajduk, SL				Drain, J; Bishop, JR; Hajduk, SL			Haptoglobin-related protein mediates trypanosome lytic factor binding to trypanosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; NORMAL HUMAN SERUM; BRUCEI-BRUCEI; AFRICAN TRYPANOSOMES; RECEPTOR; LYSIS; IDENTIFICATION; ENDOCYTOSIS; COMPLEX; FORMS	Trypanosome lytic factor (TLF-1) is an unusual high density lipoprotein (HDL) found inhuman serum that is toxic to Trypanosoma brucei bruce! and may be critical in preventing human infections by this parasite. TLF-1 is composed of four major apolipoproteins: apolipoprotein AI, apolipoprotein AII, paraoxonase, and the primate-specific haptoglobin-related protein (Hpr). Hpr is greater than 90% homologous to haptoglobin (Hp), an abundant acute phase serum protein. Killing of trypanosomes by TLF-1 requires cell sin-face binding, endocytosis, and subsequent lysosomal targeting. Low temperature binding studies reveal two receptors for TLF-1: one that is high affinity/low capacity (K-d similar to 12 nM, 350 receptors per cell) and another that binds with low affinity/ high capacity (K-d similar to 1 muM, 60,000 receptors per cell). The low affinity binding is competed by nonlytic human HDL and is likely to be apolipoprotein Al-mediated. Purified human Hpr and human Hp bind to trypanosomes, are internalized, and are targeted to the lysosome. Furthermore,. Hpr shows competition for TLF-1 binding, and a monoclonal antibody against Hpr prevents both TLF-1 uptake and trypanosome killing. Based on these results, we propose that Hpr mediates the high affinity binding of TLF-1 to T. b. brucei through a haptoglobin-like receptor.	Univ Alabama, Sch Med, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Hajduk, SL (corresponding author), Univ Alabama, Sch Med, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027316] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27316] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALTZ T, 1985, EMBO J, V4, P1273, DOI 10.1002/j.1460-2075.1985.tb03772.x; BONKOVSKY HL, 1991, AM J MED SCI, V301, P32, DOI 10.1097/00000441-199101000-00006; BOWMAN BH, 1982, ADV HUM GENET, V12, P189; COPPENS I, 1987, J PROTOZOOL, V34, P465, DOI 10.1111/j.1550-7408.1987.tb03216.x; Dobryszycka W, 1997, EUR J CLIN CHEM CLIN, V35, P647; GILLETT MPT, 1992, BIOCHIM BIOPHYS ACTA, V1123, P239, DOI 10.1016/0005-2760(92)90002-D; GRAB DJ, 1993, EUR J CELL BIOL, V62, P114; GUTTERIDGE JMC, 1987, BIOCHIM BIOPHYS ACTA, V917, P219, DOI 10.1016/0005-2760(87)90125-1; HAGER KM, 1994, J CELL BIOL, V126, P155, DOI 10.1083/jcb.126.1.155; HAJDUK SL, 1989, J BIOL CHEM, V264, P5210; HAJDUK SL, 1992, PARASITOL TODAY, V8, P95, DOI 10.1016/0169-4758(92)90247-Y; Kelley RJ, 1999, MOL BIOCHEM PARASIT, V98, P17, DOI 10.1016/S0166-6851(98)00155-8; KIMURA H, 1975, J BIOCHEM-TOKYO, V77, P909, DOI 10.1093/oxfordjournals.jbchem.a130814; LANHAM SM, 1968, NATURE, V218, P1273, DOI 10.1038/2181273a0; Lee MGS, 1999, MOL BIOCHEM PARASIT, V100, P153, DOI 10.1016/S0166-6851(99)00009-2; LORENZ P, 1994, T ROY SOC TROP MED H, V88, P487, DOI 10.1016/0035-9203(94)90443-X; MAEDA N, 1985, J BIOL CHEM, V260, P6698; MCEVOY SM, 1988, J BIOL CHEM, V263, P15740; Miller YI, 1997, BIOCHEMISTRY-US, V36, P12189, DOI 10.1021/bi970258a; Muranjan M, 1998, J BIOL CHEM, V273, P3884, DOI 10.1074/jbc.273.7.3884; OKUDA M, 1992, BIOCHIM BIOPHYS ACTA, V1136, P143, DOI 10.1016/0167-4889(92)90249-B; Raper J, 1996, J EXP MED, V183, P1023, DOI 10.1084/jem.183.3.1023; Raper J, 1996, MOL BIOCHEM PARASIT, V76, P337, DOI 10.1016/0166-6851(95)02551-0; Sambrook J., 2002, MOL CLONING LAB MANU; SEED JR, 1990, J PROTOZOOL, V37, P393, DOI 10.1111/j.1550-7408.1990.tb01163.x; SHIMAMURA M, 2001, IN PRESS MOL BIOCH P; SMITH AB, 1995, P NATL ACAD SCI USA, V92, P10262, DOI 10.1073/pnas.92.22.10262; SMITH AB, 1995, SCIENCE, V268, P284, DOI 10.1126/science.7716520; STEVERDING D, 1995, J CELL BIOL, V131, P1173, DOI 10.1083/jcb.131.5.1173; VADIVELOO PK, 1992, BIOCHEM J, V284, P145, DOI 10.1042/bj2840145	30	77	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30254	30260		10.1074/jbc.M010198200	http://dx.doi.org/10.1074/jbc.M010198200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11352898	hybrid			2022-12-25	WOS:000170558000086
J	Okuyama, H; Shimahara, Y; Kawada, N; Seki, S; Kristensen, DB; Yoshizato, K; Uyama, N; Yamaoka, Y				Okuyama, H; Shimahara, Y; Kawada, N; Seki, S; Kristensen, DB; Yoshizato, K; Uyama, N; Yamaoka, Y			Regulation of cell growth by redox-mediated extracellular proteolysis of platelet-derived growth factor receptor ss	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STELLATE CELLS; ACTIVATION; PROTEINS	Redox-regulated processes are important elements in various cellular functions. Reducing agents, such as N-acetyl-L-cysteine- (NAC), are known to regulate signal transduction and cell growth through their radical scavenging action. However, recent studies have shown that reactive oxygen species are not always involved in ligand-stimulated intracellular signaling. Here, we report a novel mechanism by which NAC blocks platelet-derived growth factor (PDGF)-induced signaling pathways in hepatic stellate cells, a fibrogenic player in the liver. Unlike in vascular smooth muscle cells, we found that reducing agents, including NAC, triggered extracellular proteolysis of PDGF receptor-beta, leading to desensitization of hepatic stellate cells toward PDGF-BB. This effect was mediated by secreted mature cathepsin B. In addition, type II transforming growth factor-beta receptor was also down-regulated. Furthermore, these events seemed to cause a dramatic improvement of rat liver fibrosis. These results indicated that redox processes impact the cell's response to growth factors by regulating the turnover of growth factor receptors and that "redox therapy" is promising for fibrosis-related disease.	Kyoto Univ, Grad Sch Med, Dept Surg Gastroenterol, Sakyo Ku, Kyoto 6068397, Japan; Osaka City Univ, Grad Sch Med, Dept Hepatol, Abeno Ku, Osaka 5458585, Japan; Japan Sci & Technol Corp, Reg Sci Promoter Program, Hiroshima Proteome Lab, Hiroshima 7390046, Japan; JST, Hiroshima Prefecture Collaborat Reg Ent Advanceme, Hiroshima Tissue Regenerat Project, Hiroshima 7390046, Japan; Hiroshima Univ, Grad Sch Sci, Dept Biol Sci, Hiroshima 7398526, Japan	Kyoto University; Osaka Metropolitan University; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Hiroshima University	Okuyama, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Surg Gastroenterol, Sakyo Ku, Kyoto 6068397, Japan.	yokuyama@f8.dion.ne.jp	kawada, norifumi/AAS-1367-2020					Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Bonizzi G, 1996, EUR J BIOCHEM, V242, P544, DOI 10.1111/j.1432-1033.1996.0544r.x; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; BUTTLE DJ, 1992, ARCH BIOCHEM BIOPHYS, V299, P377, DOI 10.1016/0003-9861(92)90290-D; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; George J, 1999, P NATL ACAD SCI USA, V96, P12719, DOI 10.1073/pnas.96.22.12719; HILL PA, 1994, J CELL BIOCHEM, V56, P118, DOI 10.1002/jcb.240560116; KASAI Y, 1988, P NATL ACAD SCI USA, V85, P146; Kawada N, 1999, J HEPATOL, V30, P1057, DOI 10.1016/S0168-8278(99)80260-8; KAWADA N, 1993, EUR J BIOCHEM, V213, P815, DOI 10.1111/j.1432-1033.1993.tb17824.x; KELLY GS, 1997, ALT MED REV, V3, P114; Kirschke H, 1998, LYSOSOMAL CYSTEINE P; Kristensen DB, 2000, HEPATOLOGY, V32, P268; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; LAUTERBURG BH, 1983, J CLIN INVEST, V71, P980, DOI 10.1172/JCI110853; Leto G, 1997, ONCOLOGY, V54, P79; Li D, 1999, J GASTROEN HEPATOL, V14, P618, DOI 10.1046/j.1440-1746.1999.01928.x; MORI S, 1993, J BIOL CHEM, V268, P577; Mort JS, 1997, INT J BIOCHEM CELL B, V29, P715, DOI 10.1016/S1357-2725(96)00152-5; Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120; NISHIMURA Y, 1990, ACTA HISTOCHEM CYTOC, V23, P53, DOI 10.1267/ahc.23.53; OKAMOTO T, 1999, OXIDAT STRESS DIS, V3, P261; PINZANI M, 1989, J CLIN INVEST, V84, P1786, DOI 10.1172/JCI114363; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; SASADA T, 1999, OXIDAT STRESS DIS, V3, P1; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F	27	32	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28274	28280		10.1074/jbc.M102995200	http://dx.doi.org/10.1074/jbc.M102995200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11346654	hybrid, Green Submitted			2022-12-25	WOS:000170093400072
J	Dmitriev, OY; Fillingame, RH				Dmitriev, OY; Fillingame, RH			Structure of Ala(20) -> Prs/Pro(64) -> Ala substituted subunit c of Escherichia coli ATP synthase in which the essential proline is switched between transmembrane helices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING H+ TRANSPORT; CROSS-LINKING; PROTON TRANSLOCATION; MEMBRANE DOMAIN; ALPHA-HELIX; POLAR LOOP; F-0; OLIGOMER; EPSILON; F0F1	The structure of the A20P/P64A mutated subunit c of Escherichia coli ATP synthase, in which the essential proline has been switched from residue 64 of the second transmembrane helix (TMH) to residue 20 of the first TMH, has been solved by N-15,H-1 MMR in a monophasic chloroform/methanol/water (4:4:1) solvent mixture. The cA20P/P64A mutant grows as well as wild type, and the F0F1 complex is fully functional in ATPase-coupled H+ pumping. Residues 20 and 64 lie directly opposite to each other in the hairpin-like structure of wild type subunit c, and the prolinyl 64 residue is thought to induce a slight bend in TMH-2 such that it wraps around a more straightened TMH-1. In solution, the A20P/P64A substituted subunit c also forms a hairpin of two alpha -helices, with residues 41-45 forming a connecting loop as in the case of the wild type protein, but, in this case, Pro(20) induces a bend in TMH-1, which then packs against a more straightened TMH-2. The essential prolinyl residue, whether at position 64 or 20, lies close to the aspartyl 61 H+ binding site. The prolinyl residue may introduce structural flexibility in this region of the protein, which may be necessary for the proposed movement of the alpha -helical segments during the course of the H+ pumping catalytic cycle.	Univ Wisconsin, Sch Med, Dept Biomol Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Fillingame, RH (corresponding author), Univ Wisconsin, Sch Med, Dept Biomol Chem, 1300 Univ Ave, Madison, WI 53706 USA.	rhfillin@facstaff.wisc.edu	Dmitriev, Oleg/AAB-7830-2019		NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR008438, S10RR002781, P41RR002301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023105, R01GM023105] Funding Source: NIH RePORTER; NCRR NIH HHS [RR02301, RR08438, RR02781] Funding Source: Medline; NIGMS NIH HHS [GM23105] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Altendorf K, 2000, J EXP BIOL, V203, P19; AssadiPorter FM, 1995, BIOCHEMISTRY-US, V34, P16186, DOI 10.1021/bi00049a034; BAX A, 1994, METHOD ENZYMOL, V239, P79; Biggin PC, 1997, BIOPHYS J, V72, P627, DOI 10.1016/S0006-3495(97)78701-0; BIRKENHAGER R, 1995, EUR J BIOCHEM, V230, P58, DOI 10.1111/j.1432-1033.1995.tb20534.x; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; Capaldi RA, 2000, J EXP BIOL, V203, P29; Dmitriev O, 1999, J BIOL CHEM, V274, P15598, DOI 10.1074/jbc.274.22.15598; Dmitriev OY, 1999, P NATL ACAD SCI USA, V96, P7785, DOI 10.1073/pnas.96.14.7785; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; Fillingame RH, 1999, SCIENCE, V286, P1687, DOI 10.1126/science.286.5445.1687; Fillingame RH, 2000, BBA-BIOENERGETICS, V1458, P387, DOI 10.1016/S0005-2728(00)00089-X; Fillingame RH, 2000, J EXP BIOL, V203, P9; FILLINGAME RH, 1975, J BACTERIOL, V124, P870, DOI 10.1128/JB.124.2.870-883.1975; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FIMMEL AL, 1983, BIOCHEM J, V213, P451, DOI 10.1042/bj2130451; FRAGA D, 1990, THESIS U WISCONSIN M; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; GIRVIN ME, 1993, BIOCHEMISTRY-US, V32, P12167, DOI 10.1021/bi00096a029; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; Groth G, 1997, FEBS LETT, V410, P117, DOI 10.1016/S0014-5793(97)00529-2; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hermolin J, 1999, J BIOL CHEM, V274, P17011, DOI 10.1074/jbc.274.24.17011; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Jones PC, 2000, J BIOL CHEM, V275, P11355, DOI 10.1074/jbc.275.15.11355; Jones PC, 1998, J BIOL CHEM, V273, P29701, DOI 10.1074/jbc.273.45.29701; Jones PC, 1998, J BIOL CHEM, V273, P17178, DOI 10.1074/jbc.273.27.17178; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEBEL D, 1978, ANAL BIOCHEM, V85, P86, DOI 10.1016/0003-2697(78)90277-4; MOSHER ME, 1985, J BIOL CHEM, V260, P4807; Nakamoto RK, 1999, ANNU REV BIOPH BIOM, V28, P205, DOI 10.1146/annurev.biophys.28.1.205; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SANKARARAMAKRISHNAN R, 1993, PROTEINS, V15, P26, DOI 10.1002/prot.340150105; Schulenberg B, 1999, J BIOL CHEM, V274, P34233, DOI 10.1074/jbc.274.48.34233; Seelert H, 2000, NATURE, V405, P418, DOI 10.1038/35013148; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; Singh S, 1996, FEBS LETT, V397, P30, DOI 10.1016/S0014-5793(96)01127-1; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Takeyasu K, 1996, FEBS LETT, V392, P110, DOI 10.1016/0014-5793(96)00796-X; Valiyaveetil FI, 1997, J BIOL CHEM, V272, P32635, DOI 10.1074/jbc.272.51.32635; VIK SB, 1994, J BIOL CHEM, V269, P30364; WARREN WS, 1993, SCIENCE, V262, P2005, DOI 10.1126/science.8266096; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; WILLIAMS KA, 1991, BIOCHEMISTRY-US, V30, P8919, DOI 10.1021/bi00101a001; Woolf TB, 1997, BIOPHYS J, V73, P2376, DOI 10.1016/S0006-3495(97)78267-5; YUN RH, 1991, PROTEINS, V10, P219, DOI 10.1002/prot.340100306; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609	56	8	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27449	27454		10.1074/jbc.M100762200	http://dx.doi.org/10.1074/jbc.M100762200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11331283	hybrid			2022-12-25	WOS:000169966900095
J	Yamazaki, S; Muta, T; Takeshige, K				Yamazaki, S; Muta, T; Takeshige, K			A novel I kappa B protein, I kappa B-zeta, induced by proinflammatory stimuli, negatively regulates nuclear factor-kappa B in the nuclei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-2; INNATE IMMUNE-RESPONSE; ZINC-FINGER PROTEIN; DROSOPHILA TOLL; ALPHA; ACTIVATION; TNF; EXPRESSION; APOPTOSIS; INHIBITOR	The transcription factor nuclear factor-kappaB (NF-kappaB) plays crucial roles in a wide variety of cellular functions and its activity is strictly regulated by cytosolic inhibitors known as I kappa Bs. We here report a new member of the I kappaB protein family, I kappaB-zeta, harboring six ankyrin repeats at its carboxyl terminus. I kappaB-zeta mRNA is strongly induced after stimulation by lipopolysaccharide. The induction of I kappaB-zeta is also observed by stimulation with interleukin-1 beta but not by tumor necrosis factor-alpha. In contrast to cytosolic I kappaB-alpha, -beta, and -epsilon, the induced I kappaB-zeta localizes in the nucleus via its amino-terminal region, which shows no homology with other proteins. Transiently expressed I kappaB-zeta inhibits the NF-kappaB activity without affecting the nuclear translocation of NF-kappaB upon stimulation. The expressed I kappaB-zeta preferentially associates with the NF-kappaB subunit p50 rather than p65 and recombinant I kappaB-zeta proteins inhibit the DNA binding of the p65/p50 heterodimer and the p50/p50 homodimer, Thus, I kappaB-zeta negatively regulates NF-kappaB activity in the nucleus, possibly in order to prevent excessive inflammation. Moreover, transfection of I kappaB-zeta renders cells more susceptible to apoptosis induced by tumor necrosis factor-alpha. The proapoptotic activity of I kappaB-zeta further suggests that it might be one of key regulators for inflammation and other biologically relevant processes.	Kyushu Univ, Grad Sch Med Sci, Dept Mol & Cellular Biochem, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University	Muta, T (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol & Cellular Biochem, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.			Yamazaki, Soh/0000-0001-5038-1567				Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akira S, 2000, BIOCHEM SOC T, V28, P551, DOI 10.1042/bst0280551; Aliprantis AO, 2000, EMBO J, V19, P3325, DOI 10.1093/emboj/19.13.3325; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Haruta H, 2001, J BIOL CHEM, V276, P12485, DOI 10.1074/jbc.C100075200; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; Irie T, 2000, FEBS LETT, V467, P160, DOI 10.1016/S0014-5793(00)01146-7; Jaattela M, 1996, J IMMUNOL, V156, P1166; Kitamura H, 2000, FEBS LETT, V485, P53, DOI 10.1016/S0014-5793(00)02185-2; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Medvedev AE, 2000, J IMMUNOL, V164, P5564, DOI 10.4049/jimmunol.164.11.5564; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Na SY, 1998, J BIOL CHEM, V273, P30933, DOI 10.1074/jbc.273.47.30933; Na SY, 1999, J BIOL CHEM, V274, P28491, DOI 10.1074/jbc.274.40.28491; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; SCOTT ML, 1993, GENE DEV, V7, P1226; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Ulevitch RJ, 2000, IMMUNOL RES, V21, P49, DOI 10.1385/IR:21:2-3:49; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; Yamamoto H, 1997, BIOCHEM J, V325, P223, DOI 10.1042/bj3250223	31	221	242	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27657	27662		10.1074/jbc.M103426200	http://dx.doi.org/10.1074/jbc.M103426200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356851	hybrid			2022-12-25	WOS:000169966900121
J	Zeng, HY; Dvorak, HF; Mukhopadhyay, D				Zeng, HY; Dvorak, HF; Mukhopadhyay, D			Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) receptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; TUMOR-CELLS; ANGIOGENESIS; FLT-1; EXPRESSION; 3-KINASE; KDR; IDENTIFICATION	Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) achieves its multiple functions by activating two receptor tyrosine kinases, Flt-1 (VEGF receptor-1) and KDR (VEGF receptor-2), both of which are selectively expressed on primary vascular endothelium. To dissect the respective signaling pathways and biological functions mediated by these receptors in primary endothelial cells with these two receptors intact, we developed a chimeric receptor system in which the N terminus of the epidermal growth factor receptor was fused to the transmembrane domain and intracellular domain of KDR (EGDR) and Flt-1 (EGLT). We observed that KDR, but not Flt-1, was responsible for VPF/VEGF-induced human umbilical vein endothelial cell (HUVEC) proliferation and migration. Moreover, Flt-1 showed an inhibitory effect on KDR-mediated proliferation, but not migration. We also demonstrated that the inhibitory function of Flt-1 was mediated through the phosphatidylinositol 3-kinase (PI-3K)-dependent pathway because inhibitors of PI-3K as well as a dominant negative mutant of p85 (PI-3K subunit) reversed the inhibition, whereas a constitutively activated mutant of p110 introduced the inhibition to HUVEC-EGDR. We also observed that, in VPF/VEGF-stimulated HUVECs, the Flt-1/EGLT-mediated down-modulation of KDR/EGDR signaling was at or before intracellular Ca2+ mobilization, but after KDR/EGDR phosphorylation. By mutational analysis, we further identified that the tyrosine 794 residue of Flt-1 was essential for its antiproliferative effect. Taken together, these studies contribute significantly to our understanding of the signaling pathways and biological functions triggered by KDR and Flt-1 and describe a unique mechanism in which PI-3K acts as a mediator of antiproliferation in primary vascular endothelium.	Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Mukhopadhyay, D (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, RN270H,330 Brookline Ave, Boston, MA 02215 USA.				NATIONAL CANCER INSTITUTE [R01CA050453, R01CA078383, R29CA078383] Funding Source: NIH RePORTER; NCI NIH HHS [CA50453, CA78383] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENEZRA M, 1993, BLOOD, V81, P3324; Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; BROCK TA, 1991, AM J PATHOL, V138, P213; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dvorak H.F., 1984, DEV ONCOL, V22, P96; DVORAK HF, 1990, PROG CLIN BIOL RES, V354, P317; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; DVORAK HF, 1979, J IMMUNOL, V122, P166; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Folkman J, 1996, SCI AM, V275, P150, DOI 10.1038/scientificamerican0996-150; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gagnon ML, 2000, P NATL ACAD SCI USA, V97, P2573, DOI 10.1073/pnas.040337597; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Petrova TV, 1999, EXP CELL RES, V253, P117, DOI 10.1006/excr.1999.4707; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SENGER DR, 1986, CANCER RES, V46, P5629; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; VLODAVSKY I, 1991, J CELL BIOCHEM, V45, P167, DOI 10.1002/jcb.240450208; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988	39	245	268	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26969	26979		10.1074/jbc.M103213200	http://dx.doi.org/10.1074/jbc.M103213200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11350975	hybrid			2022-12-25	WOS:000169966900033
J	Davis, TL; Rabinovitz, I; Futscher, BW; Schnolzer, M; Burger, F; Liu, YG; Kulesz-Martin, M; Cress, AE				Davis, TL; Rabinovitz, I; Futscher, BW; Schnolzer, M; Burger, F; Liu, YG; Kulesz-Martin, M; Cress, AE			Identification of a novel structural variant of the alpha(6) integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL EPIDERMOLYSIS-BULLOSA; SUBUNIT CYTOPLASMIC DOMAIN; CELL-ADHESION MOLECULES; EXTRACELLULAR-MATRIX; LIGAND-BINDING; LAMININ RECEPTOR; ALPHA-6-BETA-4 INTEGRIN; FIBRONECTIN RECEPTOR; MONOCLONAL-ANTIBODY; TISSUE DISTRIBUTION	The alpha P-6 integrin is a 140-kDa (nonreduced) laminin receptor. We have identified a novel 70-kDa (nonreduced) form of the alpha (6) integrin called alpha P-6 for the latin word parvus, meaning small. The variant was immunoprecipitated from human cells using four different alpha (6)-specific monoclonal antibodies but not with alpha (3) or alpha (5) antibodies. The alpha P-6 integrin contained identical amino acid sequences within exons 13-25, corresponding to the extracellular "stalk region" and the cytoplasmic tail of the alpha (6) integrin. The light chains of alpha P-6 and alpha P-6 were identical as judged by alpha (6)A-specific antibodies and electrophoretic properties. The alpha P-6 variant paired with either beta (1) or beta (4) subunits and was retained on the cell surface three times longer than alpha (6). Reverse transcription/polymerase chain reaction analysis revealed a single polymerase chain reaction product. The alpha P-6 variant was found in human prostate (DU145H, LnCaP, PC3) and colon (SW480) cancer cell lines but not in normal prostate (PrEC), breast cancer (MCF-7), or lung cancer (H69) cell lines or a variant of a prostate carcinoma cell line (PC3-N), Protein levels of alpha P-6 increased 3-fold during calcium-induced terminal differentiation in a normal mouse keratinocyte model system. A novel form of the alpha (6) integrin exists on cell surfaces that contains a dramatically altered extracellular domain.	Univ Arizona, Arizona Canc Ctr, Dept Radiat Oncol, Tucson, AZ 85724 USA; Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85724 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA	Arizona Center Cancer Care; University of Arizona; University of Arizona; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Helmholtz Association; German Cancer Research Center (DKFZ); Oregon Health & Science University	Cress, AE (corresponding author), Univ Arizona, Arizona Canc Ctr, Dept Radiat Oncol, 1501 N Campbell Ave, Tucson, AZ 85724 USA.	cress@azcc.arizona.edu	Cress, Anne/V-6527-2019	Cress, Anne/0000-0001-6194-0061	NATIONAL CANCER INSTITUTE [P30CA023074, P01CA056666, R01CA075152, R01CA031101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER; NCI NIH HHS [CA75152, CA23074, P30 CA023074, R01 CA075152, CA31101, P01 CA056666-120002, P01 CA056666, R01 CA075152-08, P30 CA023074-22] Funding Source: Medline; NIEHS NIH HHS [ES06694, P30 ES006694] Funding Source: Medline; PHS HHS [P01-56666] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDREW SM, 1992, BRIT J DERMATOL, V127, P359, DOI 10.1111/j.1365-2133.1992.tb00454.x; BEDNARCZYK JL, 1992, J BIOL CHEM, V267, P25274; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; Berthet V, 2000, J BIOL CHEM, V275, P33308, DOI 10.1074/jbc.M004834200; Breitkreutz D, 1998, EUR J CELL BIOL, V75, P273, DOI 10.1016/S0171-9335(98)80123-4; Brown TA, 1996, J INVEST DERMATOL, V107, P384, DOI 10.1111/1523-1747.ep12363370; Bullock TNJ, 1996, J EXP MED, V184, P1319, DOI 10.1084/jem.184.4.1319; Callebaut I, 1998, CELL MOL LIFE SCI, V54, P880, DOI 10.1007/s000180050216; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER HM, 1991, J CELL BIOL, V115, P843, DOI 10.1083/jcb.115.3.843; Cress AE, 2000, BIOTECHNIQUES, V29, P776, DOI 10.2144/00294st03; CRESS AE, 1995, CANCER METAST REV, V14, P219, DOI 10.1007/BF00690293; DAMSKY CH, 1994, DEVELOPMENT, V120, P3657; Delwel GO, 1997, BIOCHEM J, V324, P263, DOI 10.1042/bj3240263; DROZ D, 1994, LAB INVEST, V71, P710; EINHEBER S, 1993, J CELL BIOL, V123, P1223, DOI 10.1083/jcb.123.5.1223; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; ENGELBERGKULKA H, 1993, TRENDS BIOCHEM SCI, V18, P294, DOI 10.1016/0968-0004(93)90039-P; FALCIONI R, 1988, CANCER RES, V48, P816; FILARDO EJ, 1994, J BIOL CHEM, V269, P4641; FRIEDRICHS K, 1995, CANCER RES, V55, P901; Fulop V, 1998, CELL, V94, P161, DOI 10.1016/S0092-8674(00)81416-6; GAIETTA G, 1994, J CELL SCI, V107, P3339; GeorgesLabouesse E, 1996, NAT GENET, V13, P370, DOI 10.1038/ng0796-370; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GIL SG, 1994, J INVEST DERMATOL, V103, pS31, DOI 10.1111/1523-1747.ep12398953; HEMLER ME, 1988, J BIOL CHEM, V263, P7660; Hennings H, 1980, Curr Probl Dermatol, V10, P3; HESSLE H, 1984, DIFFERENTIATION, V26, P49, DOI 10.1111/j.1432-0436.1984.tb01372.x; HOGERVORST F, 1993, J CELL BIOL, V121, P179, DOI 10.1083/jcb.121.1.179; HOGERVORST F, 1991, EUR J BIOCHEM, V199, P425, DOI 10.1111/j.1432-1033.1991.tb16140.x; HONDA T, 1995, J CLIN ENDOCR METAB, V80, P2899, DOI 10.1210/jc.80.10.2899; Humphries MJ, 1996, CURR OPIN CELL BIOL, V8, P632, DOI 10.1016/S0955-0674(96)80104-9; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; Irie A, 1997, P NATL ACAD SCI USA, V94, P7198, DOI 10.1073/pnas.94.14.7198; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; Jaspars LH, 1996, CELL ADHES COMMUN, V4, P269, DOI 10.3109/15419069609010771; KAWAGUCHI S, 1993, J BIOL CHEM, V268, P16279; KNOX JD, 1994, AM J PATHOL, V145, P167; KOUKOULIS GK, 1993, VIRCHOWS ARCH B, V63, P373, DOI 10.1007/BF02899286; KULESZMARTIN MF, 1988, CARCINOGENESIS, V9, P171, DOI 10.1093/carcin/9.1.171; KULESZMARTIN MF, 1980, CARCINOGENESIS, V1, P995, DOI 10.1093/carcin/1.12.995; LESSEY BA, 1995, AM J PATHOL, V146, P717; LIEBERT M, 1993, HYBRIDOMA, V12, P67, DOI 10.1089/hyb.1993.12.67; Lu CF, 1997, J IMMUNOL, V159, P268; MECHTERSHEIMER G, 1993, VIRCHOWS ARCH A, V422, P203, DOI 10.1007/BF01621803; MIETTINEN M, 1993, AM J PATHOL, V142, P1009; Mould AP, 2000, J BIOL CHEM, V275, P20324, DOI 10.1074/jbc.M000572200; NAGLE RB, 1995, AM J PATHOL, V146, P1498; Niessen CM, 1996, J CELL SCI, V109, P1695; Oxvig C, 1998, P NATL ACAD SCI USA, V95, P4870, DOI 10.1073/pnas.95.9.4870; Paoli M, 1999, NAT STRUCT BIOL, V6, P926; PARKER CM, 1993, J BIOL CHEM, V268, P7028; PATEY N, 1994, CELL ADHES COMMUN, V2, P159, DOI 10.3109/15419069409004434; Pattaramalai S, 1996, EXP CELL RES, V222, P281, DOI 10.1006/excr.1996.0036; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PELTONEN J, 1989, J CLIN INVEST, V84, P1916, DOI 10.1172/JCI114379; Price AA, 1997, J EXP MED, V186, P1725, DOI 10.1084/jem.186.10.1725; Pulkkinen L, 1997, LAB INVEST, V76, P823; Putz E, 1999, CANCER RES, V59, P241; RABINOVITZ I, 1995, CLIN EXP METASTAS, V13, P481, DOI 10.1007/BF00118187; Sastry SK, 1999, J CELL BIOL, V144, P1295, DOI 10.1083/jcb.144.6.1295; SHAW LM, 1993, J CELL BIOL, V123, P1017, DOI 10.1083/jcb.123.4.1017; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shimizu H, 1996, ARCH DERMATOL, V132, P919, DOI 10.1001/archderm.132.8.919; SIMON EE, 1990, AM J PHYSIOL, V259, pF783, DOI 10.1152/ajprenal.1990.259.5.F783; SONNENBERG A, 1990, J CELL SCI, V96, P207; Sonnenberg A, 1993, Curr Top Microbiol Immunol, V184, P7; SONNENBERG A, 1987, J BIOL CHEM, V262, P10376; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; Sterk LMT, 2000, J CELL BIOL, V149, P969, DOI 10.1083/jcb.149.4.969; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TAMURA RN, 1991, P NATL ACAD SCI USA, V88, P10183, DOI 10.1073/pnas.88.22.10183; TERPE HJ, 1994, HISTOCHEMISTRY, V101, P41, DOI 10.1007/BF00315830; Tran NL, 1999, AM J PATHOL, V155, P787, DOI 10.1016/S0002-9440(10)65177-2; VANWAES C, 1991, CANCER RES, V51, P2395; VIDAL F, 1995, NAT GENET, V10, P229, DOI 10.1038/ng0695-229; vonBredow DC, 1997, EXP CELL RES, V236, P341, DOI 10.1006/excr.1997.3711; Wagner S, 1997, STROKE, V28, P858, DOI 10.1161/01.STR.28.4.858; WATT FM, 1993, DEVELOPMENT, P185; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WEINEL RJ, 1995, GASTROENTEROLOGY, V108, P523, DOI 10.1016/0016-5085(95)90082-9; WEINEL RJ, 1992, INT J CANCER, V52, P827, DOI 10.1002/ijc.2910520526; Witkowski CM, 2000, CARCINOGENESIS, V21, P325, DOI 10.1093/carcin/21.2.325; WITKOWSKI CM, 1993, J CANCER RES CLIN, V119, P637, DOI 10.1007/BF01215981	89	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26099	26106		10.1074/jbc.M102811200	http://dx.doi.org/10.1074/jbc.M102811200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11359780	Green Accepted, hybrid			2022-12-25	WOS:000169823300063
J	Mao, CG; Xu, RJ; Szulc, ZM; Bielawska, A; Galadari, SH; Obeid, LM				Mao, CG; Xu, RJ; Szulc, ZM; Bielawska, A; Galadari, SH; Obeid, LM			Cloning and characterization of a novel human alkaline ceramidase - A mammalian enzyme that hydrolyzes phytoceramide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC STRESS-RESPONSE; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; PSEUDOMONAS-AERUGINOSA; NEUTRAL CERAMIDASE; ANCHORED PROTEINS; FUMONISIN B-1; CELL-GROWTH; SPHINGOLIPIDS; INHIBITION	Ceramidases are enzymes involved in regulating cellular levels of ceramides, sphingoid bases, and their phosphates, Based on sequence homology to the yeast alkaline ceramidases YPC1p (Mao, C,, Xu, R,, Bielawska, A., and Obeid, L, M, (2000) J. Biol, Chem. 275, 6876-6884) and YDC1p (Mao, C,, Xu, R,, Bielawska, A., Szulc, Z, M,, and Obeid, L, RI. (2000) J. Biol Chem, 275, 31369-31378), we report the identification and cloning of a cDNA encoding for a novel human alkaline ceramidase (aPHC) that hydrolyzes phytoceramide selectively, Northern blot analysis showed that aPHC was ubiquitously expressed, with the highest expression in placenta. Green fluorescent protein tagging showed that it was localized in both the Golgi apparatus and endoplasmic reticulum. Overexpression of aPHC in mammalian cells elevated in vitro ceramidase activity toward N-4-nitrobenz-2-oxa-1,3-diazole-C-12-phytoceramide. Its expression in a yeast mutant strain devoid of any ceramidase activity restored the ceramidase activity and caused an increase in the hydrolysis of phytoceramide in yeast cells, thus leading to the decreased biosynthesis of sphingolipids. These data collectively suggest that, similar to the yeast phytoceramidase YPC1p, aPHC has phytoceramidase activity both in vitro and in cells; hence, it is a functional homolog of the yeast phytoceramidase YPC1p, However, in contrast to YPC1p, aPHC exhibited no reverse activity of ceramidase either in vitro or in cells. Biochemical characterization showed that aPHC had a pH optimum of 9.5, was activated by Ca2+, but was inhibited by Zn2+ and sphingosine, Substrate specificity showed that aPHC hydrolyzed phytoceramide preferentially, Together, these data demonstrate that aPHC is a novel human alkaline phytoceramidase, the first mammalian alkaline ceramidase to be identified as being specific for the hydrolysis of phytoceramide.	Med Univ S Carolina, Ralph H Johnson Vet Affairs Hosp, Div Gen Internal Med, Charleston, SC 29425 USA; United Arab Emirates Univ, Fac Med & Hlth Sci, Dept Biochem, Abu Dhabi, U Arab Emirates	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; United Arab Emirates University	Mao, CG (corresponding author), Dept Med, 114 Doughty St,Rm 605 STB,POB 250779, Charleston, SC 29425 USA.		Galadari, Sehamuddin/AAK-6039-2020; xu, rui/GRX-5734-2022	obeid, lina/0000-0002-0734-0847				Ardail D, 2001, FEBS LETT, V488, P160, DOI 10.1016/S0014-5793(00)02332-2; Birt DF, 1998, NUTR CANCER, V31, P119, DOI 10.1080/01635589809514690; Bleck O, 1999, J INVEST DERMATOL, V113, P894, DOI 10.1046/j.1523-1747.1999.00809.x; Brini M, 2000, CELL MOL LIFE SCI, V57, P354, DOI 10.1007/PL00000698; Chung N, 2000, J BIOL CHEM, V275, P17229, DOI 10.1074/jbc.C000229200; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Dickson RC, 1999, BBA-MOL CELL BIOL L, V1438, P305, DOI 10.1016/S1388-1981(99)00068-2; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; El Bawab S, 1999, J BIOL CHEM, V274, P27948, DOI 10.1074/jbc.274.39.27948; El Bawab S, 2001, J BIOL CHEM, V276, P16758, DOI 10.1074/jbc.M009331200; English D, 2001, CARDIOVASC RES, V49, P588, DOI 10.1016/S0008-6363(00)00230-3; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hannun YA, 1997, ADV EXP MED BIOL, V407, P145; Hannun YA, 1997, BIOCHEM SOC T, V25, P1171, DOI 10.1042/bst0251171; HASSLER DF, 1993, ADV LIPID RES, V26, P49; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; Kim S, 2000, GENETICS, V156, P1519; Kita K, 2000, BBA-MOL CELL BIOL L, V1485, P111, DOI 10.1016/S1388-1981(00)00029-9; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; Mao CG, 1999, BIOCHEM J, V342, P667, DOI 10.1042/0264-6021:3420667; Mao CG, 2000, J BIOL CHEM, V275, P6876, DOI 10.1074/jbc.275.10.6876; Mao CG, 2000, J BIOL CHEM, V275, P31369, DOI 10.1074/jbc.M003683200; MARCHESINI S, 1990, CHEM PHYS LIPIDS, V53, P165, DOI 10.1016/0009-3084(90)90042-P; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; MIKAMI M, 1992, BIOCHIM BIOPHYS ACTA, V1125, P104, DOI 10.1016/0005-2760(92)90162-O; Nikolova-Karakashian M, 2000, METHOD ENZYMOL, V311, P194; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; Okino N, 1999, J BIOL CHEM, V274, P36616, DOI 10.1074/jbc.274.51.36616; Pyne S, 2000, PHARMACOL THERAPEUT, V88, P115, DOI 10.1016/S0163-7258(00)00084-X; RODER B, 1990, CHEM PHYS LIPIDS, V53, P85, DOI 10.1016/0009-3084(90)90136-F; Schmelz EM, 1998, NUTRITION, V14, P717, DOI 10.1016/S0899-9007(98)00052-5; Schmelz EM, 1998, TOXICOL APPL PHARM, V148, P252, DOI 10.1006/taap.1997.8356; Selzner M, 2001, CANCER RES, V61, P1233; Skrzypek M, 1997, J BACTERIOL, V179, P1513, DOI 10.1128/jb.179.5.1513-1520.1997; Smith ER, 2000, METHOD ENZYMOL, V312, P361; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; Sutterlin C, 1997, J CELL SCI, V110, P2703; Takamatsu Kiyoshi, 1992, Keio Journal of Medicine, V41, P161; TamiyaKoizumi K, 1997, BIOCHEM MOL BIOL INT, V41, P1179; Tani M, 2000, J BIOL CHEM, V275, P11229, DOI 10.1074/jbc.275.15.11229; Tani M, 2000, J BIOL CHEM, V275, P3462, DOI 10.1074/jbc.275.5.3462; WU WI, 1995, J BIOL CHEM, V270, P13171, DOI 10.1074/jbc.270.22.13171	44	115	124	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26577	26588		10.1074/jbc.M102818200	http://dx.doi.org/10.1074/jbc.M102818200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11356846	hybrid			2022-12-25	WOS:000169823300122
J	Kline, JB; Clevenger, CV				Kline, JB; Clevenger, CV			Identification and characterization of the prolactin-binding protein in human serum and milk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; PLASMA-MEMBRANE GLYCOPROTEINS; GH-BINDING; (GH)-BINDING PROTEIN; LACTOGENIC HORMONES; EXTRACELLULAR DOMAIN; ESCHERICHIA-COLI; SINGLE-GENE; EXPRESSION; RAT	The actions of prolactin (PRL) are mediated by its receptor, a member of the superfamily of single transmembrane cytokine receptors, High affinity binding proteins for the closely related growth hormone have been found in the sera of several species including humans and are generated by alternative splicing or proteolysis of the growth hormone receptor extracellular domain (ECD), In contrast, no conclusive evidence has been presented that an analogous prolactin-binding protein (PRLBP) is expressed in human serum. Using both monoclonal and polyclonal antibodies generated against hPRL and the ECD of the human prolactin receptor, co-immunoprecipitation analyses of human serum identified a 32-kDa hPRLBP capable of binding both hPRL and human growth hormone. A measurable fraction of circulating PRL (36%) was associated with the hPRLBP, Despite well documented sex differences in serum hPRL levels, there were no significant differences in the levels of hPRLBP found in the sera of normal adult males and females (15.3 +/- 1.3 ng/ml versus 13.4 +/- 0.8 ng/ml, respectively (mean +/- S,E,)). Immunoprecipitation studies also detected the PRLBP in human milk albeit at lower concentrations than found in sera. Deglycosylation did not alter its electrophoretic mobility, indicating an absence of carbohydrate moieties and suggesting that the hPRLBP spans most of the PRLR ECD, a result confirmed by limited proteolysis and mass spectrometry. The potential function of this serum chaperone was assessed in vitro by the addition of recombinant hPRLBP to the culture medium of the PRL-dependent Nb2 T-cell line. These studies revealed that the hPRLBP antagonizes PRL action, inhibiting PRL-driven growth in a dose-dependent manner.	Univ Penn, Med Ctr, Dept Pathol & Lab Med, Stellar Chance Labs 513, Philadelphia, PA 19104 USA	University of Pennsylvania	Clevenger, CV (corresponding author), Univ Penn, Med Ctr, Dept Pathol & Lab Med, Stellar Chance Labs 513, 422 Curie Blvd, Philadelphia, PA 19104 USA.				NATIONAL CANCER INSTITUTE [R01CA069294] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009727] Funding Source: NIH RePORTER; NCI NIH HHS [2R01 CA69294] Funding Source: Medline; NIDDK NIH HHS [1F32 DK09727] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amit T, 1997, MOL CELL ENDOCRINOL, V130, P167, DOI 10.1016/S0303-7207(97)00088-9; Barnard R, 1997, J ENDOCRINOL, V153, P1, DOI 10.1677/joe.0.1530001; BAUMANN G, 1986, J CLIN ENDOCR METAB, V62, P134, DOI 10.1210/jcem-62-1-134; BAUMANN G, 1987, J CLIN ENDOCR METAB, V64, P657, DOI 10.1210/jcem-64-4-657; BAUMANN G, 1988, ENDOCRINOLOGY, V122, P976, DOI 10.1210/endo-122-3-976; BAUMANN G, 1990, J CLIN ENDOCR METAB, V71, P470, DOI 10.1210/jcem-71-2-470; BAUMBACH WR, 1989, GENE DEV, V3, P1199, DOI 10.1101/gad.3.8.1199; BIGNON C, 1994, J BIOL CHEM, V269, P3318; BOUTIN JM, 1989, MOL ENDOCRINOL, V3, P1455, DOI 10.1210/mend-3-9-1455; Buteau H, 1998, MOL ENDOCRINOL, V12, P544, DOI 10.1210/me.12.4.544; CARMIGNAC DF, 1992, J ENDOCRINOL, V135, P447, DOI 10.1677/joe.0.1350447; Clark RG, 1996, ENDOCRINOLOGY, V137, P4308, DOI 10.1210/en.137.10.4308; DORATO A, 1992, ENDOCRINOLOGY, V131, P1734, DOI 10.1210/en.131.4.1734; EDENS A, 1994, ENDOCRINOLOGY, V135, P2802, DOI 10.1210/en.135.6.2802; FRASER IS, 1989, J CLIN ENDOCR METAB, V69, P585, DOI 10.1210/jcem-69-3-585; GARGOSKY SE, 1995, ENDOCRINE, V3, P813, DOI 10.1007/BF02935686; Gertler A, 1996, J BIOL CHEM, V271, P24482, DOI 10.1074/jbc.271.40.24482; HERINGTON AC, 1986, J CLIN INVEST, V77, P1817, DOI 10.1172/JCI112507; IINO T, 1986, J GEN VIROL, V67, P1373, DOI 10.1099/0022-1317-67-7-1373; Leav I, 1999, AM J PATHOL, V154, P863, DOI 10.1016/S0002-9440(10)65333-3; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LIM L, 1990, ENDOCRINOLOGY, V127, P1287, DOI 10.1210/endo-127-3-1287; MANNOR DA, 1991, J CLIN ENDOCR METAB, V73, P30, DOI 10.1210/jcem-73-1-30; MERCADO M, 1994, J CLIN ENDOCR METAB, V79, P1637, DOI 10.1210/jc.79.6.1637; PEETERS S, 1977, ENDOCRINOLOGY, V101, P1164, DOI 10.1210/endo-101-4-1164; Rycyzyn MA, 2000, MOL ENDOCRINOL, V14, P1175, DOI 10.1210/me.14.8.1175; SAITO Y, 1995, J BIOCHEM, V118, P521, DOI 10.1093/oxfordjournals.jbchem.a124939; SMITH WC, 1989, MOL ENDOCRINOL, V3, P984, DOI 10.1210/mend-3-6-984; SOTIROPOULOS A, 1993, ENDOCRINOLOGY, V132, P1863, DOI 10.1210/en.132.4.1863; TAKANO E, 1988, BIOCHEMISTRY-US, V27, P1964, DOI 10.1021/bi00406a024; TALAMANTES F, 1994, P SOC EXP BIOL MED, V206, P254; TAR A, 1990, J CLIN ENDOCR METAB, V71, P1202, DOI 10.1210/jcem-71-5-1202; TAUBER R, 1989, EUR J BIOCHEM, V186, P55, DOI 10.1111/j.1432-1033.1989.tb15177.x; TAUBER R, 1983, P NATL ACAD SCI-BIOL, V80, P4026, DOI 10.1073/pnas.80.13.4026; TCHELET A, 1995, J ENDOCRINOL, V144, P393, DOI 10.1677/joe.0.1440393; TRIVEDI B, 1988, ENDOCRINOLOGY, V123, P2201, DOI 10.1210/endo-123-5-2201; WALKER AM, 1992, J PSYCHIATR NEUROSCI, V17, P61; WALKER AM, 1995, P NATL ACAD SCI USA, V92, P3278, DOI 10.1073/pnas.92.8.3278; WATERS MJ, 1980, ENDOCRINOLOGY, V107, P816, DOI 10.1210/endo-107-3-816; YMER SI, 1985, MOL CELL ENDOCRINOL, V41, P153, DOI 10.1016/0303-7207(85)90018-8; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0; ZHANG FP, 1995, J ENDOCRINOL, V147, P497, DOI 10.1677/joe.0.1470497	42	59	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24760	24766		10.1074/jbc.M011786200	http://dx.doi.org/10.1074/jbc.M011786200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11337493	hybrid			2022-12-25	WOS:000169800700047
J	Ma, XR; Karra, S; Guo, W; Lindner, DJ; Hu, JD; Angell, JE; Hofmann, ER; Reddy, SPM; Kalvakolanu, DV				Ma, XR; Karra, S; Guo, W; Lindner, DJ; Hu, JD; Angell, JE; Hofmann, ER; Reddy, SPM; Kalvakolanu, DV			Regulation of interferon and retinoic acid-induced cell death activation through thioredoxin reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; DEPENDENT PROTEIN-KINASE; INDUCED APOPTOSIS; MOLECULAR-CLONING; REDOX REGULATION; CYTOCHROME-C; VITAMIN-A; GROWTH; RECEPTOR; EXPRESSION	Interferons (IFNs) and retinoids are potent biological response modifiers. The IFN-beta and all-trans-retinoic acid combination, but not these single agents individually, induces death in several tumor cell lines. To elucidate the molecular basis for these actions, we have employed an antisense knockout approach to identify the gene products that mediate cell death and isolated several genes associated with retinoid-IFN-induced mortality (GRIMs), One of the GRIM cDNAs, GRIM-12, was identical to human thioredoxin reductase (TR). To define the functional relevance of TR to cell death and to define its mechanism of death-modulating functions, we generated mutants of TR and studied their influence on the IFN/RA-induced death regulatory functions of caspases, Wild-type TR activates cell death that was inhibited in the presence of caspase inhibitors or catalytically inactive caspases, A mutant TR, lacking the active site cysteines, inhibits the cell death induced by caspase 8. IFN/all-trans-retinoic acid-induced cytochrome c release from the mitochondrion was promoted in the presence of wild type and was inhibited in the presence of mutant TR, We find that TR modulates the activity of caspase 8 to promote death. This effect is in part caused by the stimulation of death receptor gene expression. These studies identify a new mechanism of cell death regulation by the IFN/all-trans-retinoic acid combination involving redox enzymes.	Univ Maryland, Sch Med, Greenebaum Canc Ctr, Dept Microbiol & Immunol,Mol & Cellular Biol Prog, Baltimore, MD 21201 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Environm Sci, Baltimore, MD USA	University System of Maryland; University of Maryland Baltimore; Johns Hopkins University	Kalvakolanu, DV (corresponding author), Univ Maryland, Sch Med, Greenebaum Canc Ctr, Dept Microbiol & Immunol,Mol & Cellular Biol Prog, Baltimore, MD 21201 USA.	dkalvako@umaryland.edu	Lindner, Daniel/ABB-5440-2020		NCI NIH HHS [CA 78282, CA 71401] Funding Source: Medline; NHLBI NIH HHS [HL-58122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078282, R01CA071401] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL058122, R01HL058122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Casso D, 1996, MOL GEN GENET, V252, P518, DOI 10.1007/BF02172398; Chelbi-Alix MK, 1998, J VIROL, V72, P1043, DOI 10.1128/JVI.72.2.1043-1051.1998; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Gaboli M, 1998, LEUKEMIA LYMPHOMA, V30, P11, DOI 10.3109/10428199809050925; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; Gallegos A, 1996, CANCER RES, V56, P5765; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gongora C, 1997, J BIOL CHEM, V272, P19457, DOI 10.1074/jbc.272.31.19457; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; HARTMAN H, 1993, P NATL ACAD SCI USA, V90, P2271, DOI 10.1073/pnas.90.6.2271; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Hofman ER, 1998, MOL CELL BIOL, V18, P6493, DOI 10.1128/MCB.18.11.6493; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; IRMIER M, 1997, NATURE, V388, P190; Kalvakolanu DV, 2000, HISTOL HISTOPATHOL, V15, P523, DOI 10.14670/HH-15.523; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Kurooka H, 1997, GENOMICS, V39, P331, DOI 10.1006/geno.1996.4493; Kuwata T, 2000, BLOOD, V95, P3349, DOI 10.1182/blood.V95.11.3349; Lee HY, 1998, J CLIN INVEST, V101, P1012, DOI 10.1172/JCI1329; Lee KK, 1998, J BIOL CHEM, V273, P19160, DOI 10.1074/jbc.273.30.19160; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Levy-Strumpf N, 1998, ONCOGENE, V17, P3331, DOI 10.1038/sj.onc.1202588; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Lindner DJ, 1997, CLIN CANCER RES, V3, P931; Lipton SA, 1999, CELL DEATH DIFFER, V6, P943, DOI 10.1038/sj.cdd.4400580; Liu R, 1998, J BIOL CHEM, V273, P16985, DOI 10.1074/jbc.273.27.16985; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; LOVE JM, 1994, CURR OPIN CELL BIOL, V6, P825, DOI 10.1016/0955-0674(94)90051-5; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Matikainen S, 1997, CELL GROWTH DIFFER, V8, P687; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; Mohr S, 1997, BIOCHEM BIOPH RES CO, V238, P387, DOI 10.1006/bbrc.1997.7304; MOORE DM, 1994, SEMIN HEMATOL, V31, P31; MULLER EGD, 1991, J BIOL CHEM, V266, P9194; Nagy L, 1998, CELL DEATH DIFFER, V5, P11, DOI 10.1038/sj.cdd.4400337; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; Pearson GD, 1998, J BIOL CHEM, V273, P5431, DOI 10.1074/jbc.273.10.5431; Pelicano L, 1997, ONCOGENE, V15, P2349, DOI 10.1038/sj.onc.1201410; Pierce RH, 2000, AM J PATHOL, V157, P221, DOI 10.1016/S0002-9440(10)64533-6; Raveh T, 1996, J BIOL CHEM, V271, P25479, DOI 10.1074/jbc.271.41.25479; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; RUBARTELLI A, 1995, CANCER RES, V55, P675; SALZ HK, 1994, GENETICS, V136, P1075; Sen CK, 1999, CELL DEATH DIFFER, V6, P481, DOI 10.1038/sj.cdd.4400514; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; Sun SY, 1999, ONCOGENE, V18, P2357, DOI 10.1038/sj.onc.1202543; Sun SY, 2000, CLIN CANCER RES, V6, P1563; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; Ueda S, 1998, J IMMUNOL, V161, P6689; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wang ZG, 1998, SCIENCE, V279, P1547; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Xiao WH, 1997, J BIOL CHEM, V272, P9742, DOI 10.1074/jbc.272.15.9742; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355	77	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24843	24854		10.1074/jbc.M100380200	http://dx.doi.org/10.1074/jbc.M100380200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11331281	hybrid			2022-12-25	WOS:000169800700057
J	Nomura, M; Kaji, A; Ma, WY; Zhong, SP; Liu, GM; Bowden, CT; Miyamoto, K; Dong, ZG				Nomura, M; Kaji, A; Ma, WY; Zhong, SP; Liu, GM; Bowden, CT; Miyamoto, K; Dong, ZG			Mitogen and stress-activated protein kinase 1 mediates activation of Akt by ultraviolet B irradiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; N-TERMINAL KINASE; GLYCOGEN-SYNTHASE KINASE-3; SERINE THREONINE KINASES; TUMOR-SUPPRESSOR GENE; NECROSIS-FACTOR-ALPHA; P38 MAP KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; CELL-SURVIVAL; GROWTH-FACTOR	In this study, we investigated the mechanism by which UVB irradiation activates Akt (also known as protein kinase B (PKB)) in mouse epidermal JB6 cells. Treatment with a phosphatidylinositol 3-kinase inhibitor, LY 294002, or expression of a dominant negative mutant of p85 (regulatory component of phosphatidylinositol 3-kinase) inhibited UVB-induced Akt activation. Interestingly, Akt activation by UVB was attenuated by treatment with PD 98059, a specific mitogen-activated protein kinase/extracellular signal-regulated protein kinase (Erk) kinase 1 inhibitor, or SE 202190, a specific p38 kinase inhibitor. Furthermore, the expression of a dominant negative mutant of Erk2 or p38 kinase, but not that of c-dun N-terminal kinase 1 (JNK1), blocked UVB-induced Akt activation. The expression of a dominant negative mutant of p85 or treatment with LY 294002 also inhibited UVB-induced Erk phosphorylation. The UVB-activated mitogen-activated protein kinase members, which were immunoprecipitated from cells exposed to UVB, did not phosphorylate Akt, Instead, Akt was phosphorylated at both threonine 308 and serine 473 and activated by UVB-activated mitogen- and stress-activated protein kinase 1 (Msk1). The expression of a Msk1 C-terminal kinase-dead mutant inhibited UVB-induced phosphorylation and activation of Akt. These data thus suggested that UVB-induced Akt activation was mediated through Msk1, which is a downstream kinase of the Erk and p38 kinase signaling pathways.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; Univ Arizona, Arizona Canc Ctr, Dept Radiat Oncol, Tucson, AZ 85721 USA; Kanazawa Univ, Hosp Pharm, Kanazawa, Ishikawa 9200934, Japan	University of Minnesota System; Arizona Center Cancer Care; University of Arizona; Kanazawa University	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@smig.net			NCI NIH HHS [CA27502, CA74916, CA81064] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA027502, R29CA074916, R01CA081064, R37CA081064] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ANANTHASWAMY HN, 1990, PHOTOCHEM PHOTOBIOL, V52, P1119, DOI 10.1111/j.1751-1097.1990.tb08452.x; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cadet J, 1997, BIOL CHEM, V378, P1275; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Davies MA, 1999, CANCER RES, V59, P2551; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; ELDER DE, 1989, J INVEST DERMATOL S, V92, P297; Ferby IM, 1996, J BIOL CHEM, V271, P11684, DOI 10.1074/jbc.271.20.11684; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; Huang CS, 1997, J BIOL CHEM, V272, P4187, DOI 10.1074/jbc.272.7.4187; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Huang CS, 1999, ONCOGENE, V18, P2828, DOI 10.1038/sj.onc.1202639; Kabuyama Y, 1998, FEBS LETT, V441, P297, DOI 10.1016/S0014-5793(98)01565-8; Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEY RD, 1993, P NATL ACAD SCI USA, V90, P4337, DOI 10.1073/pnas.90.10.4337; Li DM, 1997, CANCER RES, V57, P2124; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Matsuda N, 2000, PHOTOCHEM PHOTOBIOL, V72, P334, DOI 10.1562/0031-8655(2000)072<0334:DAOEAJ>2.0.CO;2; MATSUI MS, 1995, PHOTOCARCINOGENESIS, P21; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Meier P, 1998, CELL, V95, P295, DOI 10.1016/S0092-8674(00)81760-2; Merienne K, 2000, ONCOGENE, V19, P4221, DOI 10.1038/sj.onc.1203712; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; New L, 1999, J BIOL CHEM, V274, P1026, DOI 10.1074/jbc.274.2.1026; Nomura T, 1997, CANCER RES, V57, P2081; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Scheid MP, 1996, J BIOL CHEM, V271, P18134, DOI 10.1074/jbc.271.30.18134; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Smith ML, 1997, P NATL ACAD SCI USA, V94, P12255, DOI 10.1073/pnas.94.23.12255; STABERG B, 1983, J INVEST DERMATOL, V81, P517, DOI 10.1111/1523-1747.ep12522855; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Tyrrell R M, 1996, EXS, V77, P255; Tyrrell RM, 1996, BIOESSAYS, V18, P139, DOI 10.1002/bies.950180210; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	80	65	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25558	25567		10.1074/jbc.M101164200	http://dx.doi.org/10.1074/jbc.M101164200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11350959	hybrid			2022-12-25	WOS:000169800700147
J	Wong, GE; Zhu, XL; Prater, CE; Oh, E; Evans, JP				Wong, GE; Zhu, XL; Prater, CE; Oh, E; Evans, JP			Analysis of fertilin alpha (ADAM1)-mediated sperm-egg cell adhesion during fertilization and identification of an adhesion-mediating sequence in the disintegrin-like domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH DOMAIN; IN-VITRO FERTILIZATION; INTEGRIN ALPHA-6-BETA-1; POTENTIAL ROLE; ADAM 2; HUMAN FIBRONECTIN; SURFACE PROTEIN; MOUSE EGGS; BINDING; BETA	Fertilin alpha (also known as ADAM1) is a member of the ADAM ((A) under bar (d) under bar isintegrin and (A) under bar (m) under bar etalloprotease domain) family of proteins. In this study, we examine the mechanism of mouse fertilin alpha 's in adhesion of sperm to the egg plasma membrane during fertilization. We find that recombinant forms of fertilin alpha corresponding to either the disintegrin-like domain or the cysteine-rich domain and the EGF-like repeat can perturb sperm-egg binding, suggesting that both of these domains can participate in fertilin alpha -mediated adhesion events. In further examination of the fertilin alpha disintegrin-like domain, we find that a subdomain of disintegrin-like domain with the sequence DLEECDCG outside the putative disintegrin loop but with homology to the fertilin beta disintegrin loop can inhibit the binding of both sperm and recombinant fertilin a to eggs, suggesting that this is an adhesion-mediating motif of the fertilin a disintegrin-like domain. This sequence also inhibits the binding of recombinant fertilin p to eggs and thus is the first peptide sequence found to block two different sperm ligands, Finally, a monoclonal antibody to the tetraspanin protein CD9, KMC.8, inhibited the binding of recombinant fertilin a to eggs in one type of binding assay, suggesting that, under certain conditions, fertilin a may interact with a KMC.8-sensitive binding site on the egg plasma membrane.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Div Reprod Biol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Evans, JP (corresponding author), Johns Hopkins Univ, Sch Publ Hlth, Dept Biochem & Mol Biol, Div Reprod Biol, 615 N Wolfe St, Baltimore, MD 21205 USA.	jpevans@jhsph.edu		Prater, Chrissy/0000-0002-4247-2351	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD037696, R01HD037696] Funding Source: NIH RePORTER; NCI NIH HHS [CA09110] Funding Source: Medline; NICHD NIH HHS [R29 HD037696-04, R29 HD037696, HD 37696, HD07276] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; AOTA S, 1994, J BIOL CHEM, V269, P24756; Bigler D, 2000, J BIOL CHEM, V275, P11576, DOI 10.1074/jbc.275.16.11576; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; Cal S, 2000, MOL BIOL CELL, V11, P1457, DOI 10.1091/mbc.11.4.1457; Chen MS, 1999, P NATL ACAD SCI USA, V96, P11830, DOI 10.1073/pnas.96.21.11830; Chen MS, 1999, J CELL BIOL, V144, P549, DOI 10.1083/jcb.144.3.549; Cho CH, 2000, DEV BIOL, V222, P289, DOI 10.1006/dbio.2000.9703; Dustin ML, 1998, CELL ADHES COMMUN, V6, P255, DOI 10.3109/15419069809004481; Eto B, 2000, J BIOL CHEM, V275, P34922, DOI 10.1074/jbc.M001953200; Evans Janice P., 1999, Frontiers in Bioscience, V4, pD114, DOI 10.2741/Evans; Evans JP, 1997, DEV BIOL, V187, P94, DOI 10.1006/dbio.1997.8612; Evans JP, 1997, DEV BIOL, V187, P79, DOI 10.1006/dbio.1997.8611; EVANS JP, 1995, J CELL SCI, V108, P3267; Evans JP, 1998, BIOL REPROD, V59, P145, DOI 10.1095/biolreprod59.1.145; Hardy CM, 1997, BIOL REPROD, V57, P879, DOI 10.1095/biolreprod57.4.879; Iba K, 1999, AM J PATHOL, V154, P1489, DOI 10.1016/S0002-9440(10)65403-X; Iba K, 2000, J CELL BIOL, V149, P1143, DOI 10.1083/jcb.149.5.1143; Jia LG, 2000, ARCH BIOCHEM BIOPHYS, V373, P281, DOI 10.1006/abbi.1999.1517; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Linder B, 1997, DEV GROWTH DIFFER, V39, P243; Lum L, 1997, DEV BIOL, V191, P131, DOI 10.1006/dbio.1997.8609; MARDON HJ, 1994, FEBS LETT, V340, P197, DOI 10.1016/0014-5793(94)80137-1; McLane MA, 1998, P SOC EXP BIOL MED, V219, P109, DOI 10.3181/00379727-219-44322; Miller BJ, 2000, J CELL BIOL, V149, P1289, DOI 10.1083/jcb.149.6.1289; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; Nath D, 2000, J CELL SCI, V113, P2319; Nath D, 1999, J CELL SCI, V112, P579; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; PRIMAKOFF P, 1987, J CELL BIOL, V104, P141, DOI 10.1083/jcb.104.1.141; Pyluck A, 1997, BIOORG MED CHEM LETT, V7, P1053, DOI 10.1016/S0960-894X(97)00160-1; Redick SD, 2000, J CELL BIOL, V149, P521, DOI 10.1083/jcb.149.2.521; Redkar AA, 1999, J ANDROL, V20, P500; Schlondorff J, 1999, J CELL SCI, V112, P3603; Shilling FM, 1997, DEV BIOL, V186, P155, DOI 10.1006/dbio.1997.8586; Waters SI, 1997, BIOL REPROD, V56, P1245, DOI 10.1095/biolreprod56.5.1245; Whitten WK, 1971, ADV BIOSCI, V6, P129, DOI DOI 10.1016/B978-0-08-017571-3.50013-9; Yuan RY, 1997, J CELL BIOL, V137, P105, DOI 10.1083/jcb.137.1.105; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345; Zhu XL, 2000, J BIOL CHEM, V275, P7677, DOI 10.1074/jbc.275.11.7677	40	32	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24937	24945		10.1074/jbc.M101637200	http://dx.doi.org/10.1074/jbc.M101637200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342541	hybrid			2022-12-25	WOS:000169800700068
J	Zhu, Z; Ma, B; Homer, RJ; Zheng, T; Elias, JA				Zhu, Z; Ma, B; Homer, RJ; Zheng, T; Elias, JA			Use of the tetracycline-controlled transcriptional silencer (tTS) to eliminate transgene leak in inducible overexpression transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LUNG INJURY; GENE-EXPRESSION; MAMMALIAN-CELLS; EUKARYOTIC CELLS; REGULATED SYSTEM; GROWTH-FACTOR; MURINE LUNG; IL-13; INTERLEUKIN-13; INFLAMMATION	The doxycycline-inducible reverse tetracycline transactivator (rtTA) is frequently used to overexpress transgenes in a temporally regulated fashion in vivo, These systems are, however, often limited by the levels of transgene expression in the absence of dox administration. The tetracycline-controlled transcriptional silencer (tTS), a fusion protein containing the tet repressor and the KRAB-AB domain of the kid-1 transcriptional repressor, is inhibited by doxycycline, We hypothesized that tTS would tighten control of transgene expression in rtTA-based systems. To test this hypothesis we generated mice in which the CC10 promoter targeted tTS to the lung, bred these mice with CC10-rtTA-interleukin 13 (IL-13) mice in which IL-13 was overexpressed in an inducible lung-specific fashion, and compared the IL-13 production and phenotypes of parental mice and the triple transgenic CC10-rtTA/tTS-IL-13 progeny of these crosses. In the CC10-rtTA-IL-13 mice, IL-13, mucus metaplasia, inflammation, alveolar enlargement, and enhanced lung volumes were noted at base line and increased greatly after doxycycline administration. In the triple transgenic tTS animals, IL-13 and the IL-13-induced phenotype could not be appreciated without doxycycline. In contrast, tTS did not alter the induction of IL-13 or the generation of the IL-13 phenotype by doxycycline, Thus, tTS effectively eliminated the baseline leak without altering the inducibility of rtTA-regulated transgenes in vivo. Optimal "off/on" regulation of transgene expression can be accomplished with the combined use of tTS and rtTA.	Yale Univ, Sch Med, Dept Internal Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Vet Affairs Connecticut Hlth Care Syst, Pathol & Lab Med Serv, West Haven, CT 06516 USA	Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Elias, JA (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Pulm & Crit Care Med Sect, 333 Cedar St,105 LCI, New Haven, CT 06520 USA.	jack.elias@yale.edu	homer, robert/P-3884-2019	homer, robert/0000-0002-2055-5885	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056389, R01HL061904, R01HL064242, P50HL056389] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-64242, HL-61904, HL-56389] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baron U, 2000, METHOD ENZYMOL, V327, P401, DOI 10.1016/S0076-6879(00)27292-3; Baron U, 1999, P NATL ACAD SCI USA, V96, P1013, DOI 10.1073/pnas.96.3.1013; Cohn L, 1999, J IMMUNOL, V162, P6178; Corne J, 2000, J CLIN INVEST, V106, P783, DOI 10.1172/JCI9674; de Vries JE, 1998, J ALLERGY CLIN IMMUN, V102, P165, DOI 10.1016/S0091-6749(98)70080-6; DEUSCHLE U, 1995, MOL CELL BIOL, V15, P1907; EFRAT S, 1995, P NATL ACAD SCI USA, V92, P3576, DOI 10.1073/pnas.92.8.3576; Forster K, 1999, NUCLEIC ACIDS RES, V27, P708, DOI 10.1093/nar/27.2.708; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; Gallia GL, 1998, ONCOGENE, V16, P1879, DOI 10.1038/sj.onc.1201706; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GOSSEN M, 1993, TRENDS BIOCHEM SCI, V18, P471, DOI 10.1016/0968-0004(93)90009-C; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; HOGAN B, 1986, MANIPULATING MOUSE E; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; KORFHAGEN TR, 1994, J CLIN INVEST, V93, P1691, DOI 10.1172/JCI117152; Minty A, 1997, EUR CYTOKINE NETW, V8, P203; MIYAZAKI Y, 1995, J CLIN INVEST, V96, P250, DOI 10.1172/JCI118029; Ray P, 1997, J CLIN INVEST, V100, P2501, DOI 10.1172/JCI119792; SCHILZ R, 1996, AIRWAYS SMOOTH MUSCL, P241; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; Tang WL, 1996, J CLIN INVEST, V98, P2845, DOI 10.1172/JCI119113; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Tichelaar JW, 2000, J BIOL CHEM, V275, P11858, DOI 10.1074/jbc.275.16.11858; Urlinger S, 2000, P NATL ACAD SCI USA, V97, P7963, DOI 10.1073/pnas.130192197; Wang ZD, 2000, J EXP MED, V192, P1587, DOI 10.1084/jem.192.11.1587; Ward NS, 2000, AM J RESP CELL MOL, V22, P535, DOI 10.1165/ajrcmb.22.5.3808; Waxman AB, 1998, J CLIN INVEST, V101, P1970, DOI 10.1172/JCI1337; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; Zheng T, 2000, J CLIN INVEST, V106, P1081, DOI 10.1172/JCI10458; Zhou L, 1996, DEV BIOL, V175, P227, DOI 10.1006/dbio.1996.0110; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	34	104	125	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25222	25229		10.1074/jbc.M101512200	http://dx.doi.org/10.1074/jbc.M101512200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11331286	hybrid			2022-12-25	WOS:000169800700106
J	Frigeri, A; Nicchia, GP; Desaphy, JF; Pierno, S; De Luca, A; Camerino, DC; Svelto, M				Frigeri, A; Nicchia, GP; Desaphy, JF; Pierno, S; De Luca, A; Camerino, DC; Svelto, M			Muscle loading modulates aquaporin-4 expression in skeletal muscle	FASEB JOURNAL			English	Article									Univ Bari, Dept Gen & Environm Physiol, I-70126 Bari, Italy; Univ Bari, Dept Pharmacobiol, Pharmacol Unit, I-70126 Bari, Italy	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	Frigeri, A (corresponding author), Univ Bari, Dept Gen & Environm Physiol, Via Amendola 165-A, I-70126 Bari, Italy.		frigeri, Antonio/AAC-6336-2022; Desaphy, Jean-Francois/T-6191-2019; Svelto, Maria/P-6186-2014	Desaphy, Jean-Francois/0000-0001-8816-9369; De Luca, Annamaria/0000-0002-5652-7341; Svelto, Maria/0000-0002-5584-9541; Frigeri, Antonio/0000-0002-5284-2934; Conte, Diana/0000-0003-0162-9698; Pierno, Sabata/0000-0003-3121-2666	Telethon [983] Funding Source: Medline	Telethon(Fondazione Telethon)			0	45	45	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1282	1284		10.1096/fj.00-0525fje	http://dx.doi.org/10.1096/fj.00-0525fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344114				2022-12-25	WOS:000168655200036
J	Pfeifer, H; Conrad, M; Roethlein, D; Kyriakopoulos, A; Brielmeier, M; Bornkamm, GW; Behne, D				Pfeifer, H; Conrad, M; Roethlein, D; Kyriakopoulos, A; Brielmeier, M; Bornkamm, GW; Behne, D			Identification of a specific sperm nuclei selenoenzyme necessary for protamine thiol cross-linking during sperm maturation	FASEB JOURNAL			English	Article									Hahn Meitner Inst Kernforsch Berlin GmbH, Dept Mol Trace Element Res Life Sci, D-14109 Berlin, Germany; GSF, Res Ctr Environm & Hlth, Inst Clin Mol Biol & Tumor Genet, D-81377 Munich, Germany	Helmholtz Association; Helmholtz-Zentrum fuer Materialien und Energie GmbH (HZB); Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Behne, D (corresponding author), Hahn Meitner Inst Kernforsch Berlin GmbH, Dept Mol Trace Element Res Life Sci, Glienicker Str 100, D-14109 Berlin, Germany.		Conrad, Marcus/E-8792-2015; Brielmeier, Markus/M-7352-2014	Conrad, Marcus/0000-0003-1140-5612; Brielmeier, Markus/0000-0002-8715-869X					0	208	218	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1236	1238		10.1096/fj.00-0655fje	http://dx.doi.org/10.1096/fj.00-0655fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344099	Bronze			2022-12-25	WOS:000168655200021
J	Stark, LA; Din, FVN; Zwacka, RM; Dunlop, MG				Stark, LA; Din, FVN; Zwacka, RM; Dunlop, MG			Aspirin-induced activation of the NF-kappa B signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells	FASEB JOURNAL			English	Article									Western Gen Hosp, MRC, Human Genet Unit, Colon Canc Genet Grp, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh, Dept Oncol, Div Clin & Mol Med, Colon Canc Genet Grp, Edinburgh, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Stark, LA (corresponding author), Western Gen Hosp, MRC, Human Genet Unit, Colon Canc Genet Grp, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.		Dunlop, Malcolm G/F-1973-2011; Din, Farhat/A-1944-2015	Dunlop, Malcolm G/0000-0002-3033-5851; Zwacka, Ralf/0000-0003-2821-0387					0	164	172	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1273	1275		10.1096/fj.00-0529fje	http://dx.doi.org/10.1096/fj.00-0529fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344111				2022-12-25	WOS:000168655200033
J	Zhang, CH; Hein, TW; Wang, W; Chang, CI; Kuo, L				Zhang, CH; Hein, TW; Wang, W; Chang, CI; Kuo, L			Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide-mediated vasodilatory function	FASEB JOURNAL			English	Article									Texas A&M Univ Syst, Hlth Sci Ctr, Cardiovasc Res Inst, Dept Med Physiol, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Kuo, L (corresponding author), Texas A&M Univ Syst, Hlth Sci Ctr, Cardiovasc Res Inst, Dept Med Physiol, College Stn, TX 77843 USA.			Kuo, Lih/0000-0002-4912-6910					0	169	174	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1264	1266		10.1096/fj.00-0681fje	http://dx.doi.org/10.1096/fj.00-0681fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344108				2022-12-25	WOS:000168655200030
J	Nozaki, S; Sledge, GW; Nakshatri, H				Nozaki, S; Sledge, GW; Nakshatri, H			Repression of GADD153/CHOP by NF-kappa B: a possible cellular defense against endoplasmic reticulum stress-induced cell death	ONCOGENE			English	Article						NF-kappa B; GADD153/CHOP; apoptosis; transcription repression; endoplasmic reticulum stress	HUMAN BREAST-CANCER; DAMAGE-INDUCIBLE GENES; INDUCED APOPTOSIS; MESSENGER-RNA; C/EBP-BETA; GROWTH ARREST; MAMMARY-GLAND; BINDING-SITE; DNA-BINDING; NUDE-MICE	Exposure of mammalian cells to ultraviolet light, nutrient deprived culture media, hypoxia, environmental toxicants such as methyl mercury, methyl methanesulfonate, crocodilite asbestos or the agents that disrupt the function of endoplasmic reticulum (ER) leads to activation of the pro-apoptotic transcription factor GADD153/CHOP. Paradoxically, several of these agents also induce the anti-apoptotic transcription factor NF-kappaB. In this report, we demonstrate that NF-kappaB inhibits GADD153 activation in breast cancer cells exposed to nutrient deprived media, tunicamycin (which blocks protein folding in ER) or calcium ionopore (which depletes calcium stores in ER), Basal and calcium ionopore-induced GADD153 expression was more pronounced in fibroblasts obtained from mouse embryos lacking in p65 subunit of NF-kappaB compared to fibroblasts from wild type Littermate embryos. Moreover, p65-/-fibroblasts were killed more efficiently by calcium ionopore and tunicamycin but not hydrogen peroxide compared to wild type fibroblasts, We also show that parthenolide, a NF-kappaB inhibitor, sensitizes breast cancer tells to tunicamycin, Transient transfection assay revealed that the p65 subunit but not the p50 subunit of NF-kappaB represses GADD153 promoter activity, These results establish a correlation between repression of proapoptotic genes by NF-kappaB and increased cell survival during ER stress as well as identify a distinct NF-kappaB regulated cell survival pathway.	Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pathol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Surg, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Nakshatri, H (corresponding author), Indiana Canc Res Inst, R4-202,1044 W Walnut St, Indianapolis, IN 46202 USA.			Nakshatri, Harikrishna/0000-0001-8876-0052				Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BARTEK J, 1990, ONCOGENE, V5, P893; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Brickman JM, 1999, P NATL ACAD SCI USA, V96, P10679, DOI 10.1073/pnas.96.19.10679; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; CORNETTA K, 1994, CLIN EXP METASTAS, V12, P3, DOI 10.1007/BF01784328; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Gately DP, 1996, J BIOL CHEM, V271, P20588, DOI 10.1074/jbc.271.34.20588; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; Huang JD, 1995, GENE DEV, V9, P3177, DOI 10.1101/gad.9.24.3177; Huang QH, 1999, BIOCHEM J, V341, P225, DOI 10.1042/0264-6021:3410225; Johnson NF, 1997, ENVIRON HEALTH PERSP, V105, P913, DOI 10.2307/3433303; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Kaltschmidt B, 2000, EUR J BIOCHEM, V267, P3828, DOI 10.1046/j.1432-1327.2000.01421.x; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kim R, 1999, ANTICANCER RES, V19, P1779; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LESOONWOOD LA, 1995, HUM GENE THER, V6, P395, DOI 10.1089/hum.1995.6.4-395; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; Los G, 1999, CLIN CANCER RES, V5, P1610; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; NOURBAKHSH M, 1993, EMBO J, V12, P451, DOI 10.1002/j.1460-2075.1993.tb05677.x; Ou YC, 1997, TOXICOL APPL PHARM, V147, P31, DOI 10.1006/taap.1997.8235; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; Patel NM, 2000, ONCOGENE, V19, P4159, DOI 10.1038/sj.onc.1203768; Ravi R, 1998, CANCER RES, V58, P4531; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Schmitt-Ney M, 2000, J BIOL CHEM, V275, P40839, DOI 10.1074/jbc.M007440200; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; Summerton J, 1999, BBA-GENE STRUCT EXPR, V1489, P141, DOI 10.1016/S0167-4781(99)00150-5; Tetsuka T, 2000, J BIOL CHEM, V275, P4383, DOI 10.1074/jbc.275.6.4383; Ubeda M, 1999, MOL CELL BIOL, V19, P7589; Valentine SA, 1998, MOL CELL BIOL, V18, P6584, DOI 10.1128/MCB.18.11.6584; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	57	97	108	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2001	20	17					2178	2185		10.1038/sj.onc.1204292	http://dx.doi.org/10.1038/sj.onc.1204292			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360202				2022-12-25	WOS:000168116700013
J	Qian, R; Chen, C; Colley, KJ				Qian, R; Chen, C; Colley, KJ			Location and mechanism of alpha 2,6-sialyltransferase dimer formation - Role of cysteine residues in enzyme dimerization, localization, activity and processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; ENDOPLASMIC-RETICULUM; GOLGI RETENTION; SIGNAL ANCHOR; MEDIAL GOLGI; DOMAIN; CELLS; SIALYLTRANSFERASES; OLIGOSACCHARIDES; GLYCOSYLATION	A significant proportion of the alpha2,6-sialyltransferase of protein Asn-linked glycosylation (ST6Gal 1) forms di. sulfide-bonded dimers that exhibit decreased activity, but retain the ability to bind asialoglycoprotein substrates. Here, we have investigated the subcellular location and mechanism of ST6Gal I dimer formation, as well as the role of Cys residues in the enzyme's trafficking, localization, and catalytic activity. Pulse-chase analysis demonstrated that the ST6Gal I disulfide-bonded dimer forms in the endoplasmic reticulum. Mutagenesis experiments showed that Cys-24 in the transmembrane region is required for dimerization, while catalytic domain Cys residues are required for trafficking and catalytic activity. Replacement of Cys-181 and Cys-332 generated proteins that are largely retained in the endoplasmic reticulum and minimally active or inactive, respectively. Replacement of Cys-350 or Cys-361 inactivated the enzyme without compromising its localization or processing, suggesting that these amino acids are part of the enzyme's active site. Replacement of Cys-139 or Cys-403 generated proteins that are catalytically active and appear to be more stably localized in the Golgi, since they exhibited decreased cleavage and secretion. The Cys-139 mutant also exhibited increased dimer formation suggesting that ST6Gal I dimers may be critical in the oligomerization process involved in stable ST6Gal I Golgi localization.	Univ Illinois, Coll Med, Dept Biochem & Mol Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Colley, KJ (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Biol, 1819 W Polk St,M-C 536, Chicago, IL 60612 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048134, R29GM048134] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48134] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angata K, 2001, J BIOL CHEM, V276, P15369, DOI 10.1074/jbc.M100576200; AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; Borsig L, 1998, GLYCOBIOLOGY, V8, P259, DOI 10.1093/glycob/8.3.259; BOSSHART H, 1992, EUR J BIOCHEM, V208, P341, DOI 10.1111/j.1432-1033.1992.tb17192.x; Chen C, 2000, GLYCOBIOLOGY, V10, P531, DOI 10.1093/glycob/10.5.531; Chen C, 2000, J BIOL CHEM, V275, P13819, DOI 10.1074/jbc.275.18.13819; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; DATTA A, 2001, J BIOL CHEM, V276, P15696; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; Datta AK, 1998, J BIOL CHEM, V273, P9608, DOI 10.1074/jbc.273.16.9608; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P2, DOI 10.1093/glycob/3.1.2; Geremia RA, 1997, GLYCOBIOLOGY, V7, pR5; JACKIEWICZ E, 1996, J BIOL CHEM, V271, P26395; KUROSAWA N, 1994, J BIOL CHEM, V269, P19048; Li JH, 2000, J BIOL CHEM, V275, P41476, DOI 10.1074/jbc.M007480200; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; Ma JY, 1997, J BIOL CHEM, V272, P672; Ma JY, 1996, J BIOL CHEM, V271, P7758, DOI 10.1074/jbc.271.13.7758; Ma JY, 1999, J BIOL CHEM, V274, P8046, DOI 10.1074/jbc.274.12.8046; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; NAVARATNAM N, 1988, EUR J BIOCHEM, V171, P623, DOI 10.1111/j.1432-1033.1988.tb13833.x; Opat AS, 2000, J BIOL CHEM, V275, P11836, DOI 10.1074/jbc.275.16.11836; Ouzzine M, 2000, J BIOL CHEM, V275, P28254; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169; YAMAGUCHI N, 1995, J BIOL CHEM, V270, P12170, DOI 10.1074/jbc.270.20.12170; Zhu GF, 1997, GLYCOBIOLOGY, V7, P987, DOI 10.1093/glycob/7.7.987	31	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28641	28649		10.1074/jbc.M103664200	http://dx.doi.org/10.1074/jbc.M103664200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11356854	hybrid			2022-12-25	WOS:000170346000003
J	Pesesse, X; Dewaste, V; De Smedt, F; Laffargue, M; Giuriato, S; Moreau, C; Payrastre, B; Erneux, C				Pesesse, X; Dewaste, V; De Smedt, F; Laffargue, M; Giuriato, S; Moreau, C; Payrastre, B; Erneux, C			The Src homology 2 domain containing inositol 5-phosphatase SHIP2 is recruited to the epidermal growth factor (EGF) receptor and dephosphorylates phosphatidylinositol 3,4,5-trisphosphate in EGF-stimulated COS-7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE B; SH2 DOMAIN; POLYPHOSPHATE 5-PHOSPHATASE; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; PHOSPHATASE SHIP; SIGNALING PATHWAY; MOLECULAR-CLONING; ACTIVATION; ASSOCIATION	The lipid phosphatase SHIP2 (Src homology 2 domain containing inositol 5-phosphatase 2) has been shown to be expressed in nonhemopoietic and hemopoietic cells. It has been implicated in signaling events initiated by several extracellular signals, such as epidermal growth factor (EGF) and insulin. In COS-7 cells, SHIP2 was tyrosine-phosphorylated at least at two separated tyrosine phosphorylation sites in response to EGF. SHIP2 was coimmunoprecipitated with the EGF receptor (EGFR) and also with the adaptor protein Shc. A C-terminal truncated form of SHIP2 that lacks the 366 last amino acids, referred to as tSHIP2, was also precipitated with the EGFR when transfected in COS-7 cells. The Src homology 2 domain of SHIP2 was unable to precipitate the EGFR in EGF-stimulated cells. Moreover, when transfected in COS-7 cells, it could not be detected in immunoprecipitates of the EGFR When the His-tagged. full-length enzyme was expressed in COS-7 cells and stained with anti-His(6) monoclonal antibody, a signal was observed at plasma membranes in EGF-stimulated cells that colocalize with the EGFR by double staining. Upon stimulation by EGF, phosphatidylinositol 3,4,5-trisphosphate and protein kinase B activity were decreased in SHIP2-transfected COS-7 cells as compared with the vector alone. SHIP2 appears therefore in a tyrosine-phosphorylated complex with at least two other proteins, the EGFR and Shc.	Free Univ Brussels, Interdisciplinary Res Inst, B-1070 Brussels, Belgium; Hop Purpan, INSERM, U326, F-31059 Toulouse, France	Universite Libre de Bruxelles; Vrije Universiteit Brussel; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Pesesse, X (corresponding author), Free Univ Brussels, Interdisciplinary Res Inst, Campus Erasme,Bldg C,808 Route Lennik, B-1070 Brussels, Belgium.	xpesesse@ulb.ac.be	Giuriato, Sylvie/A-9113-2010; Laffargue, Muriel/AAE-7849-2021	Giuriato, Sylvie/0000-0003-3274-3397; Laffargue, Muriel/0000-0003-1833-639X; , Bernard/0000-0002-8693-0190				Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Blero D, 2001, BIOCHEM BIOPH RES CO, V282, P839, DOI 10.1006/bbrc.2001.4639; Brauweiler AM, 2000, IMMUNOL REV, V176, P69; Brown RA, 1999, J BIOL CHEM, V274, P14529, DOI 10.1074/jbc.274.21.14529; Bruyns C, 1999, BIOL CHEM, V380, P969, DOI 10.1515/BC.1999.120; Carver DJ, 2000, BLOOD, V96, P1449, DOI 10.1182/blood.V96.4.1449.h8001449_1449_1456; Chattopadhyay A, 1999, J BIOL CHEM, V274, P26091, DOI 10.1074/jbc.274.37.26091; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; Coffer PJ, 1998, BIOCHEM J, V335, P1; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Dixon JE, 1996, RECENT PROG HORM RES, V51, P405; Drayer AL, 1996, BIOCHEM BIOPH RES CO, V225, P243, DOI 10.1006/bbrc.1996.1161; Erneux C, 1998, BBA-MOL CELL BIOL L, V1436, P185, DOI 10.1016/S0005-2760(98)00132-5; Giuriato S, 1997, J BIOL CHEM, V272, P26857, DOI 10.1074/jbc.272.43.26857; GIURIATO S, 2001, J BIOL CHEM, V282, P839; Gratacap MP, 1998, J BIOL CHEM, V273, P24314, DOI 10.1074/jbc.273.38.24314; Habib T, 1998, J BIOL CHEM, V273, P18605, DOI 10.1074/jbc.273.29.18605; Harmer SL, 1999, J BIOL CHEM, V274, P12183, DOI 10.1074/jbc.274.17.12183; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Ishihara H, 1999, BIOCHEM BIOPH RES CO, V260, P265, DOI 10.1006/bbrc.1999.0888; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Kudo M, 2000, MOL BRAIN RES, V75, P172, DOI 10.1016/S0169-328X(99)00311-3; Laffargue M, 1999, J BIOL CHEM, V274, P32835, DOI 10.1074/jbc.274.46.32835; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu L, 1997, J BIOL CHEM, V272, P8983; Liu Q, 1997, GENOMICS, V39, P109, DOI 10.1006/geno.1996.4374; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; Mason JM, 2000, J BIOL CHEM, V275, P4398, DOI 10.1074/jbc.275.6.4398; Mitchell CA, 1996, BIOCHEM SOC T, V24, P994, DOI 10.1042/bst0240994; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Muraille E, 2000, IMMUNOL LETT, V72, P7, DOI 10.1016/S0165-2478(00)00162-0; Muraille E, 1999, BIOCHEM J, V342, P697, DOI 10.1042/0264-6021:3420697; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; Pesesse X, 1998, FEBS LETT, V437, P301, DOI 10.1016/S0014-5793(98)01255-1; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; Phee H, 2000, J BIOL CHEM, V275, P19090, DOI 10.1074/jbc.M001093200; Poe JC, 2000, J BIOL CHEM, V275, P17420, DOI 10.1074/jbc.M001892200; Prasad N, 2001, MOL CELL BIOL, V21, P1416, DOI 10.1128/MCB.21.4.1416-1428.2001; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rohrschneider LR, 2000, GENE DEV, V14, P505; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; Schurmans S, 1999, GENOMICS, V62, P260, DOI 10.1006/geno.1999.5995; Shaw M, 1999, FEBS LETT, V461, P120, DOI 10.1016/S0014-5793(99)01434-9; Stefan M, 2001, J BIOL CHEM, V276, P3017, DOI 10.1074/jbc.M009333200; Taylor V, 2000, MOL CELL BIOL, V20, P6860, DOI 10.1128/MCB.20.18.6860-6871.2000; Tridandapani S, 1997, MOL CELL BIOL, V17, P4305, DOI 10.1128/MCB.17.8.4305; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 1999, EMBO J, V18, P1292, DOI 10.1093/emboj/18.5.1292; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8	57	63	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28348	28355		10.1074/jbc.M103537200	http://dx.doi.org/10.1074/jbc.M103537200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11349134	hybrid			2022-12-25	WOS:000170093400081
J	Hall, BE; Yang, SS; Boriack-Sjodin, PA; Kuriyan, J; Bar-Sagi, D				Hall, BE; Yang, SS; Boriack-Sjodin, PA; Kuriyan, J; Bar-Sagi, D			Structure-based mutagenesis reveals distinct functions for Ras switch 1 and switch 2 in Sos-catalyzed guanine nucleotide exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; FACTOR CDC25(MM); HOMOLOGY DOMAIN; ARF GTPASE; IN-VIVO; ACTIVATION; RESIDUES; PROTEINS; GRB2; IDENTIFICATION	Ras GTPases function as binary switches in signaling pathways controlling cell growth and differentiation. The guanine nucleotide exchange factor Sos mediates the activation of Ras in response to extracellular signals. We have previously solved the crystal structure of nucleotide-free Ras in complex with the catalytic domain of Sos (Boriack-Sjodin, P.A., Margarit, S.M., Bar-Sagi, D., and Kuriyan, J. (1998) Nature 394, 337-343), The structure demonstrates that Sos induces conformational changes in two loop regions of Ras known as switch 1 and switch 2, In this study, we have employed site-directed mutagenesis to investigate the functional significance of the conformational changes for the catalytic function of Sos. Switch 2 of Ras is held in a very tight embrace by Sos, with almost every external side chain coordinated by Sos. Mutagenesis of contact residues at the switch 2-Sos interface shows that only a small set of side chains affect binding, with the most important contact being mediated by tyrosine 64, which is buried in a hydrophobic pocket of Sos in the Ras Sos complex. Substitutions of Ras and Sos side chains that are inserted into the Mg2+- and nucleotide phosphate-binding site of switch 2 (Ras Ala(59) and Sos Leu(938) and Glu(942)) have no effect on the catalytic function of Sos. These results indicate that the interaction of Sos with switch 2 is necessary for tight binding, but is not the critical driving force for GDP displacement. The structural distortion of switch 1 induced by Sos is mediated by a small number of specific contacts between highly conserved residues on both Ras and Sos. Mutations of a subset of these residues (Ras Tyr(32) and Tyr(40)) result in an increase in the intrinsic rate of nucleotide dissociation from Ras and impair the binding of Ras to Sos. Based on this analysis, me propose that the interactions of Sos with the snitch 1 and switch 2 regions of Ras have distinct functional consequences: the interaction with switch 2 mediates the anchoring of Ras to Sos, whereas the interaction with switch 1 leads to disruption of the nucleotide-binding site and GDP dissociation.	SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Grad Program Mol Pharmacol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Grad Program Mol & Cellular Biol, Stony Brook, NY 11794 USA; Rockefeller Univ, Labs Mol Biophys, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University	Bar-Sagi, D (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Life Sci Bldg, Stony Brook, NY 11794 USA.			Bar-Sagi, Dafna/0000-0003-2597-8948	NCI NIH HHS [CA28146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BARSAGI D, 1994, TRENDS ENDOCRIN MET, V5, P165, DOI 10.1016/1043-2760(94)90014-0; Beraud-Dufour S, 1998, EMBO J, V17, P3651, DOI 10.1093/emboj/17.13.3651; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Byrne JL, 1996, ONCOGENE, V13, P2055; CHARDIN P, 1994, CYTOGENET CELL GENET, V66, P68, DOI 10.1159/000133667; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Corbalan-Garcia S, 1998, MOL CELL BIOL, V18, P880, DOI 10.1128/MCB.18.2.880; Day GJ, 1998, MOL CELL BIOL, V18, P7444, DOI 10.1128/MCB.18.12.7444; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FASANO O, 1988, EMBO J, V7, P3375, DOI 10.1002/j.1460-2075.1988.tb03210.x; Feltham JL, 1997, BIOCHEMISTRY-US, V36, P8755, DOI 10.1021/bi970694x; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; HOWE LR, 1993, ONCOGENE, V8, P2583; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; Jefferson AB, 1998, ONCOGENE, V16, P2303, DOI 10.1038/sj.onc.1201891; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; Kim JH, 1998, ONCOGENE, V16, P2597, DOI 10.1038/sj.onc.1201822; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Leonardsen L, 1996, ONCOGENE, V13, P2177; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU BX, 1993, ONCOGENE, V8, P3081; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; PARK WM, 1994, MOL CELL BIOL, V14, P8117, DOI 10.1128/MCB.14.12.8117; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; Shimizu T, 2000, J BIOL CHEM, V275, P18311, DOI 10.1074/jbc.M910274199; van den Berghe N, 1999, J BIOL CHEM, V274, P11078, DOI 10.1074/jbc.274.16.11078; Vanoni M, 1999, J BIOL CHEM, V274, P36656, DOI 10.1074/jbc.274.51.36656; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zhang BL, 2000, J BIOL CHEM, V275, P25299, DOI 10.1074/jbc.M001027200	47	99	101	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27629	27637		10.1074/jbc.M101727200	http://dx.doi.org/10.1074/jbc.M101727200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11333268	hybrid			2022-12-25	WOS:000169966900118
J	Komori, K; Ishino, Y				Komori, K; Ishino, Y			Replication protein A in Pyrococcus furiosus is involved in homologous DNA recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; STRAND EXCHANGE; FUNCTIONAL DOMAINS; CRYSTAL-STRUCTURE; POLYMERASE-ALPHA; RAD52 PROTEIN; SUBUNIT; IDENTIFICATION; COMPLEX; RPA	Single-stranded DNA-binding protein in Bacteria and replication protein A (RPA) in Eukarya play crucial roles in DNA replication, repair, and recombination processes. We identified an RPA complex from the hyperthermophilic archaeon, Pyrococcus furiosus. Unlike the single-peptide RPAs from the methanogenic archaea, Methanococcus jannaschii and Methanothermobacter thermoautotrophicus, P, furiosus RPA (PfuRPA) exists as a stable hetero-oligomeric complex consisting of three subunits, RPA41, RPA14, and RPA32, The amino acid sequence of RPA41 has some similarity to those of the eukaryotic RPA70 subunit and the M. jannaschii RPA, On the other hand, RPA14 and RPA32 do not share homology with any known open reading frames from Bacteria and Eukarya, However, six of eight archaea, whose total genome sequences have been published, have the open reading frame homologous to RPA32. The PfuRPA complex, but not each subunit alone, specifically bound to a single-stranded DNA and clearly enhanced the efficiency of an in vitro strand-exchange reaction by the P, furiosus RadA protein. Moreover, immunoprecipitation analyses showed that PfuRPA interacts with the recombination proteins, RadA and Hjc, as well as replication proteins, DNA polymerases, primase, proliferating cell nuclear antigen, and replication factor C in P, furiosus cells. These results indicate that PfuRPA plays important roles in the homologous DNA recombination in P. furiousus.	Biomol Engn Res Inst, Dept Biol Mol, Suita, Osaka 5650874, Japan		Ishino, Y (corresponding author), Biomol Engn Res Inst, Dept Biol Mol, 6-2-3 Furuedai, Suita, Osaka 5650874, Japan.	ishino@beri.co.jp		Ishino, Yoshizumi/0000-0001-9419-0826				Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Bochkarev A, 1999, EMBO J, V18, P4498, DOI 10.1093/emboj/18.16.4498; Bochkareva E, 1998, J BIOL CHEM, V273, P3932, DOI 10.1074/jbc.273.7.3932; Bochkareva E, 2000, J BIOL CHEM, V275, P27332; Bocquier AA, 2001, CURR BIOL, V11, P452, DOI 10.1016/S0960-9822(01)00119-1; Braun KA, 1997, BIOCHEMISTRY-US, V36, P8443, DOI 10.1021/bi970473r; Bullock PA, 1997, CRIT REV BIOCHEM MOL, V32, P503, DOI 10.3109/10409239709082001; Bycroft M, 1997, CELL, V88, P235, DOI 10.1016/S0092-8674(00)81844-9; Cann IKO, 2001, J BACTERIOL, V183, P2614, DOI 10.1128/JB.183.8.2614-2623.2001; Cann IKO, 1999, J BACTERIOL, V181, P6591, DOI 10.1128/JB.181.21.6591-6599.1999; Cann IKO, 1998, P NATL ACAD SCI USA, V95, P14250, DOI 10.1073/pnas.95.24.14250; Chedin F, 1998, TRENDS BIOCHEM SCI, V23, P273, DOI 10.1016/S0968-0004(98)01243-2; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; Golub EI, 1998, NUCLEIC ACIDS RES, V26, P5388, DOI 10.1093/nar/26.23.5388; GOMES XV, 1995, J BIOL CHEM, V270, P4534, DOI 10.1074/jbc.270.9.4534; Gomes XV, 1996, BIOCHEMISTRY-US, V35, P10558, DOI 10.1021/bi9607517; Gupta RC, 1998, P NATL ACAD SCI USA, V95, P9843, DOI 10.1073/pnas.95.17.9843; Hayashi I, 1999, NUCLEIC ACIDS RES, V27, P4695, DOI 10.1093/nar/27.24.4695; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; Kelly TJ, 1998, P NATL ACAD SCI USA, V95, P14634, DOI 10.1073/pnas.95.25.14634; Kelman Z, 1999, J BIOL CHEM, V274, P28751, DOI 10.1074/jbc.274.40.28751; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; Kil YV, 2000, J BACTERIOL, V182, P130, DOI 10.1128/JB.182.1.130-134.2000; Kim DK, 1996, J BIOL CHEM, V271, P15124, DOI 10.1074/jbc.271.25.15124; Komori K, 2000, J BIOL CHEM, V275, P33791, DOI 10.1074/jbc.M004556200; Komori K, 1999, NUCLEIC ACIDS RES, V27, P4167, DOI 10.1093/nar/27.21.4167; Komori K, 1999, P NATL ACAD SCI USA, V96, P8873, DOI 10.1073/pnas.96.16.8873; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Lin YL, 1996, J BIOL CHEM, V271, P17190, DOI 10.1074/jbc.271.29.17190; Lin YL, 1998, J BIOL CHEM, V273, P1453, DOI 10.1074/jbc.273.3.1453; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; Mer G, 2000, CELL, V103, P449, DOI 10.1016/S0092-8674(00)00136-7; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Pfuetzner RA, 1997, J BIOL CHEM, V272, P430; Philipova D, 1996, GENE DEV, V10, P2222, DOI 10.1101/gad.10.17.2222; RADDING CM, 1991, J BIOL CHEM, V266, P5355; Raghunathan S, 1997, P NATL ACAD SCI USA, V94, P6652, DOI 10.1073/pnas.94.13.6652; Seitz EM, 1998, GENE DEV, V12, P1248, DOI 10.1101/gad.12.9.1248; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Spies M, 2000, EUR J BIOCHEM, V267, P1125, DOI 10.1046/j.1432-1327.2000.01108.x; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; UEMORI T, 1993, NUCLEIC ACIDS RES, V21, P259, DOI 10.1093/nar/21.2.259; Wadsworth RIM, 2001, NUCLEIC ACIDS RES, V29, P914, DOI 10.1093/nar/29.4.914; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189	55	73	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25654	25660		10.1074/jbc.M102423200	http://dx.doi.org/10.1074/jbc.M102423200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11342551	hybrid			2022-12-25	WOS:000169823300005
J	Thiede, B; Dimmler, C; Siejak, F; Rudel, T				Thiede, B; Dimmler, C; Siejak, F; Rudel, T			Predominant identification of RNA-binding proteins in Fas-induced apoptosis by proteome analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESOLUTION 2-DIMENSIONAL ELECTROPHORESIS; LYMPHOMA CELL-LINE; HNRNP A/B PROTEINS; IN-VIVO; MEDIATED APOPTOSIS; MASS-SPECTROMETRY; IMMUNE PRIVILEGE; SPLICING FACTORS; DEATH; CASPASES	Proteome analysis of Jurkat T cells was performed in order to identify proteins that are modified during apoptosis, Subtractive analysis of two-dimensional gel patterns of apoptotic and nonapoptotic cells revealed differences in 45 protein spots. 37 protein spots of 21 different proteins were identified by peptide mass fingerprinting using matrix-assisted laser desorption/ionization mass spectrometry, The hnRNPs A0, A2/B1, A3, K and R; the splicing factors p54(nrb), SRp30c, ASF-2, and KH-type splicing regulatory protein (FUSE-binding protein 2); and alpha NAG, NS1-associated protein 1, and poly(A)-binding protein 4 were hitherto unknown to be involved in apoptosis, The putative cleavage sites of the majority of the proteins could be calculated by the molecular masses and isoelectric points in the two-dimensional electrophoresis gel, the peptide mass fingerprints, and after translation by treatment with recombinant caspase-3, Remarkably, 15 of the 21 identified proteins contained the RNP or KH motif, the best characterized RNA-binding motifs.	Max Planck Inst Infektionsbiol, Abt Mol Biol, D-10117 Berlin, Germany	Max Planck Society	Rudel, T (corresponding author), Max Planck Inst Infektionsbiol, Abt Mol Biol, Schumannstr 21-22, D-10117 Berlin, Germany.							AEBERSOLD R, 1990, ELECTROPHORESIS, V11, P517, DOI 10.1002/elps.1150110702; Anderson NL, 1998, ELECTROPHORESIS, V19, P1853, DOI 10.1002/elps.1150191103; Appel RD, 1996, ELECTROPHORESIS, V17, P540, DOI 10.1002/elps.1150170324; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Bai YD, 1999, NUCLEIC ACIDS RES, V27, P1126, DOI 10.1093/nar/27.4.1126; Blackstock WP, 1999, TRENDS BIOTECHNOL, V17, P121, DOI 10.1016/S0167-7799(98)01245-1; Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; Brockstedt E, 1999, J PROTEIN CHEM, V18, P225, DOI 10.1023/A:1020636308270; Brockstedt E, 1998, J BIOL CHEM, V273, P28057, DOI 10.1074/jbc.273.43.28057; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; Celis JE, 1998, FEBS LETT, V430, P64, DOI 10.1016/S0014-5793(98)00527-4; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; GATTOKONCZAK F, 1999, MOL CELL BIOL, V19, P251; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; Gerner C, 2000, J BIOL CHEM, V275, P39018, DOI 10.1074/jbc.M006495200; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; Griffith TS, 1997, IMMUNOL TODAY, V18, P240, DOI 10.1016/S0167-5699(97)81663-5; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; Jiang ZH, 1998, P NATL ACAD SCI USA, V95, P9155, DOI 10.1073/pnas.95.16.9155; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; Jungblut PR, 1999, ELECTROPHORESIS, V20, P2100; JUNGBLUT PR, 1990, J BIOCHEM BIOPH METH, V21, P47, DOI 10.1016/0165-022X(90)90044-D; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; KLOSE J, 1975, HUMANGENETIK, V26, P231; KLOSE J, 1995, ELECTROPHORESIS, V16, P1034, DOI 10.1002/elps.11501601175; Lemkin PF, 1997, ELECTROPHORESIS, V18, P461, DOI 10.1002/elps.1150180321; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MAYEDA A, 1994, EMBO J, V13, P5483, DOI 10.1002/j.1460-2075.1994.tb06883.x; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; O'Connell J, 1999, IMMUNOL TODAY, V20, P46, DOI 10.1016/S0167-5699(98)01382-6; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Reed JC, 1999, NAT BIOTECHNOL, V17, P1064, DOI 10.1038/15048; Ren Y, 1998, CELL DEATH DIFFER, V5, P563, DOI 10.1038/sj.cdd.4400407; Rickers A, 1998, EUR J IMMUNOL, V28, P296, DOI 10.1002/(SICI)1521-4141(199801)28:01<296::AID-IMMU296>3.0.CO;2-4; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Siomi H, 1997, CURR OPIN GENET DEV, V7, P345, DOI 10.1016/S0959-437X(97)80148-7; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Stegh AH, 2000, MOL CELL BIOL, V20, P5665, DOI 10.1128/MCB.20.15.5665-5679.2000; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Thiede B, 2000, ELECTROPHORESIS, V21, P2713, DOI 10.1002/1522-2683(20000701)21:13<2713::AID-ELPS2713>3.0.CO;2-U; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wilkins MR, 1996, BIO-TECHNOL, V14, P61, DOI 10.1038/nbt0196-61; Williams KL, 1999, ELECTROPHORESIS, V20, P678, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<678::AID-ELPS678>3.0.CO;2-R; Yates JR, 1998, J MASS SPECTROM, V33, P1	58	110	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26044	26050		10.1074/jbc.M101062200	http://dx.doi.org/10.1074/jbc.M101062200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11352910	hybrid, Green Published			2022-12-25	WOS:000169823300055
J	Wasiak, S; Quinn, CC; Ritter, B; de Heuvel, E; Baranes, D; Plomann, M; McPherson, PS				Wasiak, S; Quinn, CC; Ritter, B; de Heuvel, E; Baranes, D; Plomann, M; McPherson, PS			The Ras/Rac guanine nucleotide exchange factor mammalian son-of-sevenless interacts with PACSIN 1/syndapin I, a regulator of endocytosis and the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; N-WASP; KINASE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; BINDING-PROTEIN; EGF RECEPTOR; SH3 DOMAINS; HUMAN SOS1; RAS; GRB2	Mammalian Son-of-sevenless (mSos) functions as a guanine nucleotide exchange factor for Res and Rac, thus regulating signaling to mitogen-activated protein kinases and actin dynamics. In the current study, we have identified a new mSos-binding protein of 50 kDa (p50) that interacts with the mSos1 proline-rich domain. Mass spectrometry analysis and immunodepletion studies reveal p50 as PACSIN 1/syndapin I, a Src homology 3 domain-containing protein functioning in endocytosis and regulation of actin dynamics. In addition to PACSIN 1, which is neuron-specific, mSos also interacts with PACSIN 2, which is expressed in neuronal and nonneuronal tissues. PACSIN 2 shows enhanced binding to the mSos proline-rich domain in pull-down assays from brain extracts as compared with lung extracts, suggesting a tissue-specific regulation of the interaction. Proline to leucine mutations within the Src homology 3 domains of PACSIN 1 and 2 abolish their binding to mSos, demonstrating the specificity of the interactions. In situ, PACSIN 1 and mSos1 are co-expressed in growth cones and actin-rich filopodia in hippocampal and dorsal root ganglion neurons, and the two proteins coimmunoprecipitate from brain extracts. Moreover, epidermal growth factor treatment of COS-7 cells causes co-localization of PACSIN 1 and mSos1 in actin-rich membrane ruffles, and their interaction is regulated through epidermal growth factor-stimulated mSos1 phosphorylation, These data suggest that PACSINs may function with mSos1 in regulation of actin dynamics.	McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06510 USA; Univ Cologne, Inst Biochem, D-50931 Cologne, Germany; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada	McGill University; Yale University; University of Cologne; McGill University	McPherson, PS (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, 3801 Rue Univ, Montreal, PQ H3A 2B4, Canada.			Ritter, Brigitte/0000-0002-0094-0460	NINDS NIH HHS [NS22807] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS022807] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; Baranes D, 1998, NEURON, V21, P813, DOI 10.1016/S0896-6273(00)80597-8; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; Bretscher MS, 1998, CURR BIOL, V8, P721, DOI 10.1016/S0960-9822(98)70281-7; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Carlier MF, 2000, J BIOL CHEM, V275, P21946, DOI 10.1074/jbc.M000687200; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Glogauer M, 2000, J CELL BIOL, V150, P785, DOI 10.1083/jcb.150.4.785; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Haugh JM, 1999, J BIOL CHEM, V274, P34350, DOI 10.1074/jbc.274.48.34350; Lamarche-Vane N, 1998, J BIOL CHEM, V273, P29172, DOI 10.1074/jbc.273.44.29172; Lanzetti L, 2000, NATURE, V408, P374, DOI 10.1038/35042605; Leprince C, 1997, J BIOL CHEM, V272, P15101, DOI 10.1074/jbc.272.24.15101; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 2001, TRAFFIC, V2, P375, DOI 10.1034/j.1600-0854.2001.002006375.x; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Modregger J, 2000, J CELL SCI, V113, P4511; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Plomann M, 1998, EUR J BIOCHEM, V256, P201, DOI 10.1046/j.1432-1327.1998.2560201.x; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Qualmann B, 2000, J CELL BIOL, V148, P1047, DOI 10.1083/jcb.148.5.1047; Qualmann B, 1999, MOL BIOL CELL, V10, P501, DOI 10.1091/mbc.10.2.501; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ritter B, 1999, FEBS LETT, V454, P356, DOI 10.1016/S0014-5793(99)00830-3; RodriguezViciana P, 1996, PHILOS T ROY SOC B, V351, P225, DOI 10.1098/rstb.1996.0020; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8; Tong XK, 2000, J BIOL CHEM, V275, P29894, DOI 10.1074/jbc.M004096200; Tong XK, 2000, EMBO J, V19, P1263, DOI 10.1093/emboj/19.6.1263; VAN AL, 1997, GENE DEV, V11, P2295; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Zhao H, 1998, J BIOL CHEM, V273, P12061, DOI 10.1074/jbc.273.20.12061; Zheng JQ, 1996, J NEUROSCI, V16, P1140	51	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26622	26628		10.1074/jbc.M100591200	http://dx.doi.org/10.1074/jbc.M100591200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11352907	hybrid			2022-12-25	WOS:000169823300127
J	Zhang, H; Zhu, ZN; Vidanes, G; Mbangkollo, D; Liu, YL; Siede, W				Zhang, H; Zhu, ZN; Vidanes, G; Mbangkollo, D; Liu, YL; Siede, W			Characterization of DNA damage-stimulated self-interaction of Saccharomyces cerevisiae checkpoint protein Rad17p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE RAD1(+); CELL-CYCLE ARREST; BUDDING YEAST; RAD9 CHECKPOINT; FISSION YEAST; STRAND BREAKS; MEC1-DEPENDENT PHOSPHORYLATION; SLIDING CLAMP; GENE-PRODUCT; G(1) ARREST	Saccharomyces cerevisiae Rad17p is necessary for cell cycle checkpoint arrests in response to DNA damage. Its known interactions with the checkpoint proteins Mec3p and Ddc1p in a PCNA-like complex indicate a sensor role in damage recognition. In a novel application of the yeast two-hybrid system and by immunoprecipitation, we show here that Rad17p is capable of increased self-interaction following DNA damage introduced by 4-nitroquinoline-N-oxide, camptothecin or partial inactivation of DNA ligase I. Despite overlap of regions required for Rad17p interactions with Rad17p or Mec3p, single amino acid substitutions revealed that Rad17p(.)Rad17p complex formation is independent of Mec3p. E128K (rad17-1) was found to inhibit Rad17p interaction with Mec3p but not with Rad17p. On the other hand, Phe-121 is essential for Rad17p self-interaction, and its function in checkpoint arrest but not for Mec3p interaction. These differential effects indicate that Rad17p-Rad17p interaction plays a role that is independent of the Rad17p(.)Mec3p(.)Ddc1p complex, although our results are also compatible with Rad17p-mediated supercomplex formation of the Rad17p(.)Mec3(.)pDdc1p heterotrimer in response to DNA damage.	Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta, GA 30322 USA	Emory University; Emory University	Siede, W (corresponding author), Emory Univ, Sch Med, Winship Canc Inst, B5111,1365 B Clifton Rd, Atlanta, GA 30322 USA.				NATIONAL CANCER INSTITUTE [R01CA087381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055381] Funding Source: NIH RePORTER; NCI NIH HHS [CA87381] Funding Source: Medline; NIGMS NIH HHS [GM55381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aboussekhra A, 1996, EMBO J, V15, P3912, DOI 10.1002/j.1460-2075.1996.tb00765.x; Ahmed S, 2000, NATURE, V403, P159, DOI 10.1038/35003120; BAILLY V, 1992, P NATL ACAD SCI USA, V89, P8273, DOI 10.1073/pnas.89.17.8273; Bashkirov VI, 2000, MOL CELL BIOL, V20, P4393, DOI 10.1128/MCB.20.12.4393-4404.2000; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Bessho T, 2000, J BIOL CHEM, V275, P7451, DOI 10.1074/jbc.275.11.7451; Bluyssen HAR, 1998, GENOMICS, V54, P331, DOI 10.1006/geno.1998.5582; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Caspari T, 1999, BIOCHIMIE, V81, P173, DOI 10.1016/S0300-9084(99)80050-9; Chang MS, 1999, J BIOL CHEM, V274, P36544, DOI 10.1074/jbc.274.51.36544; Cohen-Fix O, 1997, P NATL ACAD SCI USA, V94, P14361, DOI 10.1073/pnas.94.26.14361; Costanzo V, 2000, MOL CELL, V6, P649, DOI 10.1016/S1097-2765(00)00063-0; de la Torre-Ruiz MA, 1998, EMBO J, V17, P2687, DOI 10.1093/emboj/17.9.2687; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; Edwards RJ, 1999, NAT CELL BIOL, V1, P393, DOI 10.1038/15623; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Emili A, 1998, MOL CELL, V2, P183, DOI 10.1016/S1097-2765(00)80128-8; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; Freire R, 1998, GENE DEV, V12, P2560, DOI 10.1101/gad.12.16.2560; Gartner A, 2000, MOL CELL, V5, P435, DOI 10.1016/S1097-2765(00)80438-4; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; Green CM, 2000, CURR BIOL, V10, P39, DOI 10.1016/S0960-9822(99)00263-8; Guo ZJ, 2000, MOL BIOL CELL, V11, P1535, DOI 10.1091/mbc.11.5.1535; Hang HY, 2000, GENOMICS, V65, P24, DOI 10.1006/geno.2000.6142; HARPER JW, 1993, CELL, V75, P805; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Kaiser C., 1994, METHODS YEAST GENETI; Kiser GL, 1996, MOL BIOL CELL, V7, P703, DOI 10.1091/mbc.7.5.703; Kondo T, 1999, MOL CELL BIOL, V19, P1136; Kostrub CF, 1998, EMBO J, V17, P2055, DOI 10.1093/emboj/17.7.2055; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Liu Y, 2000, MOL GEN GENET, V262, P1132, DOI 10.1007/PL00008656; Longhese MP, 1998, EMBO J, V17, P5525, DOI 10.1093/emboj/17.19.5525; Lowndes NF, 2000, CURR OPIN GENET DEV, V10, P17, DOI 10.1016/S0959-437X(99)00050-7; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; Marathi UK, 1998, GENOMICS, V54, P344, DOI 10.1006/geno.1998.5589; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; MEYN MS, 1995, CANCER RES, V55, P5991; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; Naiki T, 2000, MOL CELL BIOL, V20, P5888, DOI 10.1128/MCB.20.16.5888-5896.2000; Navas TA, 1996, GENE DEV, V10, P2632, DOI 10.1101/gad.10.20.2632; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; Neecke H, 1999, EMBO J, V18, P4485, DOI 10.1093/emboj/18.16.4485; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Osmani SA, 1997, TRENDS CELL BIOL, V7, P283, DOI 10.1016/S0962-8924(97)01086-6; Paciotti V, 2000, GENE DEV, V14, P2046; Paciotti V, 1998, EMBO J, V17, P4199, DOI 10.1093/emboj/17.14.4199; Parker AE, 1998, J BIOL CHEM, V273, P18332, DOI 10.1074/jbc.273.29.18332; Pellicioli A, 1999, EMBO J, V18, P6561, DOI 10.1093/emboj/18.22.6561; PRINTEN JA, 1994, GENETICS, V138, P609; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; ROSE MD, 1987, METHOD ENZYMOL, V152, P481; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; SCHIESTL RH, 1989, MOL CELL BIOL, V9, P1882, DOI 10.1128/MCB.9.5.1882; Shimomura T, 1998, MOL CELL BIOL, V18, P5485, DOI 10.1128/MCB.18.9.5485; Siede W, 1996, J BACTERIOL, V178, P5841, DOI 10.1128/jb.178.19.5841-5843.1996; SIEDE W, 1994, GENETICS, V138, P271; Siede W, 1996, NUCLEIC ACIDS RES, V24, P1669, DOI 10.1093/nar/24.9.1669; Soulier J, 1999, CURR BIOL, V9, P551, DOI 10.1016/S0960-9822(99)80242-5; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; THELEN MP, 1994, J BIOL CHEM, V269, P747; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; Udell CM, 1998, NUCLEIC ACIDS RES, V26, P3971, DOI 10.1093/nar/26.17.3971; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Visintin R, 2000, CURR OPIN CELL BIOL, V12, P372, DOI 10.1016/S0955-0674(00)00102-2; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Wan SH, 1999, YEAST, V15, P821, DOI 10.1002/(SICI)1097-0061(199907)15:10A<821::AID-YEA422>3.3.CO;2-R; Weinert T, 1998, CURR OPIN GENET DEV, V8, P185, DOI 10.1016/S0959-437X(98)80140-8; WEINERT TA, 1993, GENETICS, V134, P63; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; Xin H, 2000, NUCLEIC ACIDS RES, V28, P2847, DOI 10.1093/nar/28.14.2847; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8	79	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26715	26723		10.1074/jbc.M103682200	http://dx.doi.org/10.1074/jbc.M103682200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11356855	hybrid			2022-12-25	WOS:000169823300139
J	Macia, E; Chabre, M; Franco, M				Macia, E; Chabre, M; Franco, M			Specificities for the small G proteins ARF1 and ARF6 of the guanine nucleotide exchange factors ARNO and EFA6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PLASMA-MEMBRANE; SEC7 DOMAIN; ACTIN CYTOSKELETON; CHROMAFFIN CELLS; BINDING; MYRISTOYLATION; CYTOHESIN-1; ACTIVATION; EXPRESSION	ARF1 and ARF6 are distant members of the ADP-ribosylation factor (ARF) small G-protein subfamily. Their distinct cellular functions must result from specificity of interaction with different effecters and regulators, including guanine nucleotide exchange factors (GEFs), ARF nucleotide-binding site opener (ARNO), and EFA6 are analogous ARF-GEFs, both comprising a catalytic "Sec7" domain and a pleckstrin homology domain. In vivo ARNO, like ARF1, is mostly cytosolic, with minor localizations at the Golgi and plasma membrane; EFA6, like ARF6, is restricted to the plasma membrane. However, depending on conditions, ARNO appears active on ARF6 as well as on ARF1, Here we analyze the origin of these ARF-GEF selectivities. In vitro, in the presence of phospholipid membranes, ARNO activates ARF1 preferentially and ARF6 slightly, whereas EFA6 activates ARF6 exclusively; the stimulation efficiency of EFA6 on ARF6 is comparable with that of ARNO on ARF1, These selectivities are determined by the GEFs Sec7 domains alone, without the pleckstrin homology and N-terminal domains, and by the ARF core domains, without the myristoylated N-terminal helix; they are not modified upon permutation between ARF1 and ARF6 of the few amino acids that differ within the switch regions. Thus selectivity for ARF1 or ARF6 must depend on subtle folding differences between the ARFs switch regions that interact with the Sec7 domains.	CNRS, Inst Pharmacol Mol & Cellulaire, UMR 6097, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Franco, M (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UMR 6097, 660 Route des Lucioles, F-06560 Valbonne, France.	franco@ipmc.cnrs.fr	Macia, Eric/AAW-2964-2021; Franco, Michel/ABH-4993-2020; FRANCO, michel/AAA-9735-2021	Franco, Michel/0000-0003-1853-8661; macia, eric/0000-0003-3686-2000				Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; Beraud-Dufour S, 1998, EMBO J, V17, P3651, DOI 10.1093/emboj/17.13.3651; Beraud-Dufour S, 1999, J BIOL CHEM, V274, P37629, DOI 10.1074/jbc.274.53.37629; Caumon AS, 2000, J BIOL CHEM, V275, P15637, DOI 10.1074/jbc.M908347199; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Chavrier P, 2001, METHOD ENZYMOL, V329, P272; Claude A, 1999, J CELL BIOL, V146, P71, DOI 10.1083/jcb.146.1.71; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Franco M, 1998, P NATL ACAD SCI USA, V95, P9926, DOI 10.1073/pnas.95.17.9926; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; Franco M, 1996, J BIOL CHEM, V271, P1573, DOI 10.1074/jbc.271.3.1573; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; Frank SR, 1998, MOL BIOL CELL, V9, P3133, DOI 10.1091/mbc.9.11.3133; Galas MC, 1997, J BIOL CHEM, V272, P2788, DOI 10.1074/jbc.272.5.2788; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; KAHN RA, 1986, J BIOL CHEM, V261, P7906; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Knorr T, 2000, EUR J BIOCHEM, V267, P3784, DOI 10.1046/j.1432-1327.2000.01416.x; Langille SE, 1999, J BIOL CHEM, V274, P27099, DOI 10.1074/jbc.274.38.27099; Lee SY, 2000, J CELL SCI, V113, P1883; Macia E, 2000, BIOCHEMISTRY-US, V39, P5893, DOI 10.1021/bi992795w; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; Menetrey J, 2000, NAT STRUCT BIOL, V7, P466; Monier S, 1998, J CELL SCI, V111, P3427; Nagel WG, 1998, MOL BIOL CELL, V9, P1981, DOI 10.1091/mbc.9.8.1981; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Yang CZ, 1998, J BIOL CHEM, V273, P4006, DOI 10.1074/jbc.273.7.4006	41	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24925	24930		10.1074/jbc.M103284200	http://dx.doi.org/10.1074/jbc.M103284200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342560	hybrid			2022-12-25	WOS:000169800700066
J	Raharjo, SB; Emoto, N; Ikeda, K; Sato, R; Yokoyama, M; Matsuo, M				Raharjo, SB; Emoto, N; Ikeda, K; Sato, R; Yokoyama, M; Matsuo, M			Alternative splicing regulates the endoplasmic reticulum localization or secretion of soluble secreted endopeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; II MEMBRANE-PROTEINS; NEUTRAL ENDOPEPTIDASE-24.11; MOLECULAR-IDENTIFICATION; CLEAVAGE-SECRETION; GENE-EXPRESSION; GROWTH-FACTOR; CELL-SURFACE; TRANSMEMBRANE; RETENTION	A subfamily of zinc metalloproteases, represented by Neutral endopeptidase (EC 3.4.24.11) and endothelin-converting enzyme, is involved in the metabolism of a variety of biologically active peptides. Recently, we cloned and characterized a novel member of this metalloprotease family termed soluble secreted endopeptidase (SEP), which hydrolyzes many vasoactive peptides, Here we report that alternative splicing of the mouse SEP gene generates two polypeptides, SEPDelta and SEP. After synthesis, both isoforms are inserted into the endoplasmic reticulum (ER) as type II membrane proteins. SEPDelta then becomes an ER resident, whereas SEP, which differs by only the presence of 23 residues at the beginning of its luminal domain, is proteolytically cleaved by membrane secretase(s) in the ER and transported into the extracellular compartment. An analysis of the chimeric proteins between SEP Delta and bovine endothelin-converting enzyme-1b (bECE-1b) demonstrated that the retention of SEPDelta in the ER is mediated by the luminal domain. In addition, the dissection of the chimeric bECE-1b/SEP insertion showed that its insertion domain is obviously responsible for its secretion. A series of mutagenesis in this region revealed that the minimal requirement for cleavage was found to be a WDERTVV motif. Our results suggest that the unique subcellular localization and secretion of SEP proteins provide a novel model of protein trafficking within the secretory pathway.	Kobe Univ, Grad Sch Med, Dept Internal Med, Div Cardiovasc & Resp Med, Kobe, Hyogo 6500017, Japan; Kobe Univ, Grad Sch Med, Div Mol Med, Int Ctr Med Res, Kobe, Hyogo 6500017, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo 1138657, Japan	Kobe University; Kobe University; University of Tokyo	Emoto, N (corresponding author), Kobe Univ, Grad Sch Med, Dept Internal Med, Div Cardiovasc & Resp Med, 7-5-1 Kusunoki,Chuo, Kobe, Hyogo 6500017, Japan.			Emoto, Noriaki/0000-0001-6673-2616; ikeda, Koji/0000-0002-9972-7255; raharjo, sunu budhi/0000-0001-5749-8231				Ahn K, 1998, ARCH BIOCHEM BIOPHYS, V359, P258, DOI 10.1006/abbi.1998.0913; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; CHEN CY, 1992, J IMMUNOL, V148, P2817; CREEMERS JWM, 1995, J BIOL CHEM, V270, P2695, DOI 10.1074/jbc.270.6.2695; Deng P, 1996, J BIOL CHEM, V271, P16338, DOI 10.1074/jbc.271.27.16338; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Emoto N, 1999, J BIOL CHEM, V274, P1509, DOI 10.1074/jbc.274.3.1509; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; Fu J, 2000, J BIOL CHEM, V275, P3984, DOI 10.1074/jbc.275.6.3984; Ghaddar G, 2000, BIOCHEM J, V347, P419, DOI 10.1042/0264-6021:3470419; HANLEY JM, 1983, J BIOL CHEM, V258, P7858; Honsho M, 1998, J BIOL CHEM, V273, P20860, DOI 10.1074/jbc.273.33.20860; Ikeda K, 1999, J BIOL CHEM, V274, P32469, DOI 10.1074/jbc.274.45.32469; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; Lee S, 1999, BLOOD, V94, P1440, DOI 10.1182/blood.V94.4.1440.416k01_1440_1450; Lipman ML, 1998, J BIOL CHEM, V273, P13729, DOI 10.1074/jbc.273.22.13729; Mottola G, 2000, J BIOL CHEM, V275, P24070, DOI 10.1074/jbc.M910400199; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; Nohturfft A, 1999, P NATL ACAD SCI USA, V96, P11235, DOI 10.1073/pnas.96.20.11235; Pei DQ, 2000, J BIOL CHEM, V275, P33988, DOI 10.1074/jbc.M006493200; RAMCHANDRAN R, 1995, BIOCHEMISTRY-US, V34, P12645, DOI 10.1021/bi00039a021; RAMCHANDRAN R, 1994, J BIOL CHEM, V269, P2125; ROBERTS SB, 1994, J BIOL CHEM, V269, P3111; ROQUES BP, 1993, PHARMACOL REV, V45, P87; Sadhukhan R, 1998, P NATL ACAD SCI USA, V95, P138, DOI 10.1073/pnas.95.1.138; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Sato K, 1997, P NATL ACAD SCI USA, V94, P9693, DOI 10.1073/pnas.94.18.9693; Sato R, 1999, J BIOL CHEM, V274, P24714, DOI 10.1074/jbc.274.35.24714; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; Szczesna-Skorupa E, 2000, ARCH BIOCHEM BIOPHYS, V374, P128, DOI 10.1006/abbi.1999.1628; Tang BL, 1997, EUR J CELL BIOL, V73, P98; VALDENAIRE O, 1995, J BIOL CHEM, V270, P29794; Valdenaire O, 2000, BIOCHEM SOC T, V28, P426, DOI 10.1042/0300-5127:0280426; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	38	20	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25612	25620		10.1074/jbc.M101703200	http://dx.doi.org/10.1074/jbc.M101703200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342542	hybrid			2022-12-25	WOS:000169800700153
J	Eriksson, EE; Xie, X; Werr, J; Thoren, P; Lindbom, L				Eriksson, EE; Xie, X; Werr, J; Thoren, P; Lindbom, L			Direct viewing of atherosclerosis in vivo: plaque invasion by leukocytes is initiated by the endothelial selectins	FASEB JOURNAL			English	Article						intravital; atherosclerosis; inflammation; selectin; neutrophils	CELL-ADHESION MOLECULE-1; P-SELECTIN; T-LYMPHOCYTES; FOAM CELLS; MACROPHAGES; EXPRESSION; LOCALIZATION; LESIONS; ACCUMULATION; PLATELETS	Leukocyte infiltration in atherosclerosis has been extensively investigated by using histological techniques on fixed tissues. In this study, intravital microscopic observations of leukocyte recruitment in the aorta of atherosclerotic mice were performed. Interactions between leukocytes and atherosclerotic endothelium were highly transient, thereby limiting the ability for rolling leukocytes to firmly adhere. Leukocyte rolling was abolished by function inhibition of P-selectin (P<0.001, n=8), whereas antibody blockage of E-selectin (n=10) decreased rolling leukocyte flux to 51 +/- 9.9% (mean+/-SE, P<0.01) and increased leukocyte rolling velocity to 162 +/- 18% (P<0.01) of pretreatment values. Notably, function inhibition of the integrin at, subunit (n=5) had no effect on rolling flux (107+/-25%, P=0.782) or rolling velocity (89+/-6.1%, P=0.147), despite endothelial expression of vascular cell adhesion molecule 1 (VCAM-1). Leukocytes interacting with atherosclerotic endothelium were predominantly neutrophils, because treatment with antineutrophil serum decreased rolling and neutrophil counts in peripheral blood to the same extent. In conclusion, we present the first direct observations of atherosclerosis in vivo. We show that transient dynamics of leukocyte-endothelium interactions are important regulators of arterial leukocyte recruitment and that leukocyte rolling in atherosclerosis is critically dependent on the endothelial selectins. This experimental technique and the data presented introduce a novel perspective for the study of pathophysiological events involved in large-vessel disease.	Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden	Karolinska Institutet	Eriksson, EE (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden.	einar.eriksson@fyfa.ki.se		Lindbom, Lennart/0000-0001-9243-257X				ARFORS KE, 1987, BLOOD, V69, P338; Barnathan ES, 1997, AM J PATHOL, V150, P1009; CARLOS TM, 1994, BLOOD, V84, P2068; Collins RG, 2000, J EXP MED, V191, P189, DOI 10.1084/jem.191.1.189; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; Diacovo TG, 1998, J EXP MED, V187, P197, DOI 10.1084/jem.187.2.197; Dong ZM, 1998, J CLIN INVEST, V102, P145, DOI 10.1172/JCI3001; Eriksson EE, 2000, CIRC RES, V86, P526, DOI 10.1161/01.RES.86.5.526; Gautam N, 2000, J EXP MED, V191, P1829, DOI 10.1084/jem.191.11.1829; GERRITY RG, 1981, AM J PATHOL, V103, P181; HANSSON GK, 1991, ARTERIOSCLER THROMB, V11, P745, DOI 10.1161/01.ATV.11.3.745; Iiyama K, 1999, CIRC RES, V85, P199, DOI 10.1161/01.RES.85.2.199; Jung U, 1997, MICROCIRCULATION-LON, V4, P311, DOI 10.3109/10739689709146794; Jung U, 1998, J CLIN INVEST, V102, P1526, DOI 10.1172/JCI119893; KISHIKAWA H, 1993, VIRCHOWS ARCH A, V423, P433, DOI 10.1007/BF01606532; Kunkel EJ, 2000, J IMMUNOL, V164, P3301, DOI 10.4049/jimmunol.164.6.3301; Kunkel EJ, 1997, AM J PHYSIOL-HEART C, V272, pH1391, DOI 10.1152/ajpheart.1997.272.3.H1391; Kunkel EJ, 1996, CIRC RES, V79, P1196, DOI 10.1161/01.RES.79.6.1196; LAWRENCE MB, 1993, J IMMUNOL, V151, P6338; LEHR HA, 1994, LAB INVEST, V71, P380; Lei X, 1996, ATHEROSCLEROSIS, V125, P81, DOI 10.1016/0021-9150(96)05863-7; LEY K, 1995, J EXP MED, V181, P669, DOI 10.1084/jem.181.2.669; Lorenzon P, 1998, J CELL BIOL, V142, P1381, DOI 10.1083/jcb.142.5.1381; Nakashima Y, 1998, ARTERIOSCL THROM VAS, V18, P842, DOI 10.1161/01.ATV.18.5.842; OBrien KD, 1996, CIRCULATION, V93, P672, DOI 10.1161/01.CIR.93.4.672; Ramos CL, 1999, CIRC RES, V84, P1237, DOI 10.1161/01.RES.84.11.1237; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sakai A, 1997, ARTERIOSCL THROM VAS, V17, P310, DOI 10.1161/01.ATV.17.2.310; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SQUIER MKT, 1995, J LEUKOCYTE BIOL, V57, P2, DOI 10.1002/jlb.57.1.2; TRILLO AA, 1982, ATHEROSCLEROSIS, V43, P259, DOI 10.1016/0021-9150(82)90027-2; van der Wal AC, 1999, CARDIOVASC RES, V41, P334, DOI 10.1016/S0008-6363(98)00276-4; Wang N, 1996, J BIOL CHEM, V271, P8837, DOI 10.1074/jbc.271.15.8837; Yoshida M, 1998, J IMMUNOL, V161, P933	34	109	110	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2001	15	7					1149	1157		10.1096/fj.00-0537com	http://dx.doi.org/10.1096/fj.00-0537com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344083				2022-12-25	WOS:000168655200005
J	Degryse, B; Orlando, S; Resnati, M; Rabbani, SA; Blasi, F				Degryse, B; Orlando, S; Resnati, M; Rabbani, SA; Blasi, F			Urokinase/urokinase receptor and vitronectin/alpha(v)beta(3) integrin induce chemotaxis and cytoskeleton reorganization through different signaling pathways	ONCOGENE			English	Article						urokinase; integrins; chemotaxis; cytoskeleton	SMOOTH-MUSCLE CELLS; UROKINASE RECEPTOR; PLASMINOGEN-ACTIVATOR; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; KINASE FUNCTIONS; GROWTH-FACTORS; MIGRATION; VITRONECTIN; ADHESION	Vitronectin (VN) and pro-urokinase (pro-uPA) stimulated migration of rat smooth muscle cells in a dose-dependent and additive way, and induced motile-type changes in cell morphology together with a complete reorganization of the actin filaments and of the microtubules, All these effects were inhibited by pertussis toxin, or by antibodies directed against the urokinase receptor (uPAR) or against the VN receptor alpha (v)beta (3) suggesting that an association between the two receptors is required to mediate both signals. Investigation of the signaling pathways showed that increasing the intracellular cAMP resulted in a selective inhibition of VN-induced cell migration. On the other hand, PD 98059, an inhibitor of MEK, differentially inhibited the pro-uPA but not the VN-induced cell migration. Phosphorylation and nuclear translocation of Erk by pro-uPA was directly observed. We conclude that the signaling pathways of pro-uPA and VN must be at least in part different.	Univ Vita Salute San Raffaele, Dept Mol Pathol & Med, I-20132 Milan, Italy; Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Montreal, PQ H3A 1A1, Canada	Vita-Salute San Raffaele University; McGill University; Royal Victoria Hospital; McGill University	Blasi, F (corresponding author), Univ Vita Salute San Raffaele, Dept Mol Pathol & Med, Via Olgettina 58, I-20132 Milan, Italy.		Massimo, Resnati/AAN-5854-2020	Massimo, Resnati/0000-0002-4804-4569; rabbani, shafaat/0000-0001-5594-3899; Blasi, Francesco/0000-0001-9406-1784				BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; Bilato C, 1997, J CLIN INVEST, V100, P693, DOI 10.1172/JCI119582; Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; BOYLE MDP, 1987, J IMMUNOL, V139, P169; BROWN SL, 1994, CARDIOVASC RES, V28, P1815, DOI 10.1093/cvr/28.12.1815; Byzova TV, 1998, THROMB HAEMOSTASIS, V80, P726; Carriero MV, 1999, CANCER RES, V59, P5307; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; Chavakis T, 1998, BLOOD, V91, P2305, DOI 10.1182/blood.V91.7.2305.2305_2305_2312; CHOI ET, 1994, J VASC SURG, V19, P125, DOI 10.1016/S0741-5214(94)70127-X; CIAMBRONE GJ, 1992, J BIOL CHEM, V267, P13617; CLYMAN RI, 1992, EXP CELL RES, V200, P272, DOI 10.1016/0014-4827(92)90173-6; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; Degryse B, 1999, BLOOD, V94, P649, DOI 10.1182/blood.V94.2.649.414k34_649_662; DELROSSO M, 1992, EXP CELL RES, V203, P427; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Dumler I, 1999, J BIOL CHEM, V274, P24059, DOI 10.1074/jbc.274.34.24059; Fazioli F, 1997, EMBO J, V16, P7279, DOI 10.1093/emboj/16.24.7279; FIBBI G, 1988, EXP CELL RES, V179, P385, DOI 10.1016/0014-4827(88)90277-7; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Graves LM, 1996, TRENDS ENDOCRIN MET, V7, P43, DOI 10.1016/1043-2760(95)00204-9; GUDEWICZ PW, 1987, BIOCHEM BIOPH RES CO, V147, P1176, DOI 10.1016/S0006-291X(87)80193-6; Gyetko MR, 1996, J CLIN INVEST, V97, P1818, DOI 10.1172/JCI118611; Howe AK, 2000, NAT CELL BIOL, V2, P593, DOI 10.1038/35023536; HoyerHansen G, 1997, EUR J BIOCHEM, V243, P21, DOI 10.1111/j.1432-1033.1997.0021a.x; Kanse SM, 1996, EXP CELL RES, V224, P344, DOI 10.1006/excr.1996.0144; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KJOELLER L, 1997, EXP CELL RES, V232, P420; Konakova M, 1998, EUR J BIOCHEM, V253, P421, DOI 10.1046/j.1432-1327.1998.2530421.x; Kusch A, 2000, J BIOL CHEM, V275, P39466, DOI 10.1074/jbc.M003626200; Lin TH, 1997, J BIOL CHEM, V272, P8849; May AE, 1998, J EXP MED, V188, P1029, DOI 10.1084/jem.188.6.1029; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Nguyen DHD, 2000, J BIOL CHEM, V275, P19382, DOI 10.1074/jbc.M909575199; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; PLOUG M, 1994, BIOCHEMISTRY-US, V33, P8991, DOI 10.1021/bi00196a017; Preissner KT, 1998, THROMB RES, V89, P1, DOI 10.1016/S0049-3848(97)00298-3; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Sidenius N, 2000, FEBS LETT, V470, P40, DOI 10.1016/S0014-5793(00)01282-5; Simon DI, 2000, J BIOL CHEM, V275, P10228, DOI 10.1074/jbc.275.14.10228; Simon DI, 1996, BLOOD, V88, P3185, DOI 10.1182/blood.V88.8.3185.bloodjournal8883185; Slepian MJ, 1998, CIRCULATION, V97, P1818, DOI 10.1161/01.CIR.97.18.1818; Stahl A, 1997, INT J CANCER, V71, P116, DOI 10.1002/(SICI)1097-0215(19970328)71:1<116::AID-IJC19>3.3.CO;2-Z; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; TARUI T, 2000, J BIOL CHEM, V276, P3938; WALTZ DA, 1994, J BIOL CHEM, V269, P14746; Webb DJ, 2000, J CELL SCI, V113, P123; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Xue W, 1997, CANCER RES, V57, P1682; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393	58	91	97	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 12	2001	20	16					2032	2043		10.1038/sj.onc.1204261	http://dx.doi.org/10.1038/sj.onc.1204261			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360187	Bronze			2022-12-25	WOS:000168043800011
J	Mani, SS; Batni, S; Whitaker, L; Chen, SM; Engbretson, G; Knox, BE				Mani, SS; Batni, S; Whitaker, L; Chen, SM; Engbretson, G; Knox, BE			Xenopus rhodopsin promoter - Identification of immediate upstream sequences necessary for high level, rod-specific transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; LEUCINE-ZIPPER; HOMEODOMAIN PROTEIN; TRANSGENIC MICE; CELL-CULTURES; FACTOR NRL; PHOTORECEPTOR; RETINA; ELEMENT; SITES	To understand the mechanisms that control the cell-specific visual pigment gene transcription, the Xenopus rhodopsin 5' regulatory region has been characterized in vivo using transient transfection of Xenopus embryos and transgenesis. The principal control sequences were located within -233/+41, a region with significant conservation with mammalian rhodopsin genes. DNase footprinting indicated seven distinct regions that contain potential cis-acting elements. Sequences near the initiation site (-45/+41, basal region) were essential, but not sufficient, for rod-specific transcription. Two negative regulatory regions were found, one between -233 to -202, with no apparent similarity to known elements, and a second Ret-l-like CAAT (-136/-122) motif. Deletion of either sequence led to a 2-3-fold increase in expression levels, without a change in rod specificity. Sequences between -170 to -146, which contain an E-box motif, were necessary for high level expression in transgenic tadpoles but not in transient transfections. Sequences between -84 and -58, which contained an NRE-like consensus were found to be necessary for high level expression in both assays. Although expression levels were modulated by various proximal sequences in the rhodopsin promoter, none of the tested sequences were found to be necessary for rod specificity. Promoter constructs with a consensus BAT-1 sequence in conjunction with an NRE-like element upstream of the basal promoter directed low level green fluorescent protein expression in the central nervous system in transgenic tadpoles. These results suggest that rod cell-specific expression of rhodopsin is controlled by redundant elements in the proximal promoter.	SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA; SUNY Upstate Med Univ, Dept Ophthalmol, Syracuse, NY 13210 USA; Washington Univ, Sch Med, Dept Ophthalmol, St Louis, MO 63110 USA; Syracuse Univ, Dept Bioengn & Neurosci, Syracuse, NY 13244 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Washington University (WUSTL); Syracuse University	Knox, BE (corresponding author), SUNY Upstate Med Univ, Dept Biochem & Mol Biol, 750 E Adams St, Syracuse, NY 13210 USA.				NATIONAL EYE INSTITUTE [R01EY012975, R01EY011256, R01EY009409, R55EY009409, R01EY012543, R56EY000667, R01EY000667] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY012543, EY12975, EY00667, EY09409, EY11256] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ahmad I, 1995, Brain Res Dev Brain Res, V90, P184; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Batni S, 1996, J BIOL CHEM, V271, P3179, DOI 10.1074/jbc.271.6.3179; Batni S, 2000, METHOD ENZYMOL, V316, P50; Bingham PM, 1997, CELL, V90, P385, DOI 10.1016/S0092-8674(00)80496-1; Boatright JH, 1997, EXP EYE RES, V64, P269, DOI 10.1006/exer.1996.0222; Bobola N, 1999, MECH DEVELOP, V82, P165, DOI 10.1016/S0925-4773(98)00162-2; BOBOLA N, 1995, J BIOL CHEM, V270, P1289, DOI 10.1074/jbc.270.3.1289; Chau KY, 2000, J NEUROSCI, V20, P7317; Chen SM, 1996, J BIOL CHEM, V271, P28549, DOI 10.1074/jbc.271.45.28549; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; DESJARDIN LE, 1993, J BIOL CHEM, V268, P6953; DesJardin LE, 1996, INVEST OPHTH VIS SCI, V37, P154; DOWLING JE, 1987, RETINA APPROACHABLE, P12; GOURAS P, 1994, VISUAL NEUROSCI, V11, P1227, DOI 10.1017/S0952523800007021; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KIKUCHI T, 1993, MOL CELL BIOL, V13, P4400, DOI 10.1128/MCB.13.7.4400; Kimura A, 2000, J BIOL CHEM, V275, P1152, DOI 10.1074/jbc.275.2.1152; Knox BE, 1998, FEBS LETT, V423, P117, DOI 10.1016/S0014-5793(98)00018-0; Kroll KL, 1996, DEVELOPMENT, V122, P3173; Kumar R, 1996, J BIOL CHEM, V271, P29612, DOI 10.1074/jbc.271.47.29612; KUMAR R, 1995, MOL GENETICS OCULAR, P139; LEM J, 1991, NEURON, V6, P201, DOI 10.1016/0896-6273(91)90356-5; Martinez JA, 1998, BIOCHEM BIOPH RES CO, V250, P175, DOI 10.1006/bbrc.1998.9261; Mitton KP, 2000, J BIOL CHEM, V275, P29794, DOI 10.1074/jbc.M003658200; MOHUN TJ, 1989, EMBO J, V8, P1153, DOI 10.1002/j.1460-2075.1989.tb03486.x; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; Nie ZQ, 1996, J BIOL CHEM, V271, P2667, DOI 10.1074/jbc.271.5.2667; NIEUWKOOP PD, 1967, NORMAL TABLE XENOPUS, P162; PalBhadra M, 1997, CELL, V90, P479, DOI 10.1016/S0092-8674(00)80508-5; PERRON M, 1999, CELL LINEAGE FATE DE, P353, DOI DOI 10.1016/B978-012505255-9/50024-9; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; SAMBROOK J, 1992, MOL CLONING LAB MANU; SAXEN LAURI, 1954, ANN ACAD SCI FENNICAE SER A, V23, P1; SOKAL RR, 1995, BIOMETRY, P229; STIEMKE MM, 1994, DEV BIOL, V162, P169, DOI 10.1006/dbio.1994.1076; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; Tomic-Canic M, 1996, Methods Mol Biol, V57, P259; TREISMAN JE, 1988, MOL CELL BIOL, V8, P1570, DOI 10.1128/MCB.8.4.1570; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; WOODFORD BJ, 1994, EXP EYE RES, V58, P631, DOI 10.1006/exer.1994.1058; YARFITZ S, 1994, J BIOL CHEM, V269, P14329; Yokoyama S, 1996, GENES CELLS, V1, P787, DOI 10.1046/j.1365-2443.1996.d01-273.x; YU X, 1993, BIOCHEM BIOPH RES CO, V191, P76, DOI 10.1006/bbrc.1993.1186; ZACK DJ, 1991, NEURON, V6, P187, DOI 10.1016/0896-6273(91)90355-4	47	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36557	36565		10.1074/jbc.M101685200	http://dx.doi.org/10.1074/jbc.M101685200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11333267	hybrid			2022-12-25	WOS:000171194500069
J	Gizard, F; Lavallee, B; DeWitte, F; Hum, DW				Gizard, F; Lavallee, B; DeWitte, F; Hum, DW			A novel zinc finger protein TReP-132 interacts with CBP/p300 to regulate human CYP11A1 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							SIDE-CHAIN CLEAVAGE; STEROIDOGENIC FACTOR-I; NUCLEAR RECEPTOR COACTIVATORS; AUG INITIATOR CODON; BOVINE LUTEAL CELLS; DNA-BINDING DOMAIN; ADRENAL Y1 CELLS; TRANSCRIPTIONAL ACTIVATION; MESSENGER-RNA; TRANSLATIONAL CONTROL	The human CYP11A1 gene is expressed specifically in steroidogenic tissues and encodes cytochrome P450sec, which catalyzes the first step in steroid synthesis. A region of the 5 ' -flanking DNA of the gene from nucleotides -155 to -131 (-155/-131) is shown to activate transcription in steroidogenic human placental JEG-3 (1) and adrenal NCI-H295 cells. Using this region of the gene as probe, a cDNA clone of 4.4 kilobase pairs was isolated by screening JEG-3 cell and human placental cDNA expression libraries. The open reading frame encodes three zinc fingers of the C2H2 subtype, and separate regions rich in glutamate, proline, and glutamine, which are indicative of a DNA-binding protein involved in gene transcription. Expression of the cDNA in vitro and in HeLa cells yields a protein of 132 kDa, which concurs with the predicted size. Northern blot analysis demonstrate expression of two TReP-132 transcripts of 4.4 and 7.5 kilobase pairs in the thymus, adrenal cortex, and testis; and expression is also found in the steroidogenic JEG-3, NCI-H295, and MCF-7 cell lines. Immunocytochemistry analysis demonstrates localization of the HA-tagged TReP-132 protein in the nucleus. The expression of exogenous TReP-132 in HeLa cells was demonstrated to interact with the -155/-131 region in bandshift analysis. Transfection of the cDNA in placental JEG-3 and adrenal NCI-H295 cells increases expression of a reporter construct controlled by the P450sec gene 5 ' -flanking region from nucleotides -1676 to +49. Moreover, a chimeric protein generated by fusion of TReP-132 with the Gal4 DNA-binding domain was able to significantly increase promoter activity of a reporter construct via Gal4-binding sites upstream of the E1b minimal promoter. Coexpression of CREB-binding protein (CBP)/p300 with TReP-132 has an additive effect on promoter activity, and the proteins were demonstrated to interact physically. Thus, these results together indicate the isolation of a novel zinc-finger transcriptional regulating protein of 132 kDa (TReP-132) involved in the regulation of P450sec gene expression.	Genfit, F-59120 Loos, France; Univ Laval, Oncol & Mol Endocrinol Res Ctr, Quebec City, PQ G1K 7P4, Canada	Laval University	Hum, DW (corresponding author), Genfit, Parc Eurasante,885 Ave Eugene Avinee, F-59120 Loos, France.	dean.hum@genfit.com						ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; CAO JH, 1994, VIROLOGY, V205, P151, DOI 10.1006/viro.1994.1630; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chau YM, 1997, BIOL REPROD, V57, P765, DOI 10.1095/biolreprod57.4.765; CHEN CT, 1995, DNA CELL BIOL, V14, P803, DOI 10.1089/dna.1995.14.803; Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407; Chou SJ, 1996, J BIOL CHEM, V271, P22125, DOI 10.1074/jbc.271.36.22125; CHUNG B, 1986, P NATL ACAD SCI USA, V83, P8962, DOI 10.1073/pnas.83.23.8962; CLEMENS JW, 1994, ENDOCRINOLOGY, V134, P1499, DOI 10.1210/en.134.3.1499; CONLEY AJ, 1994, J MOL ENDOCRINOL, V12, P155, DOI 10.1677/jme.0.0120155; Craig AWB, 1998, NATURE, V392, P520, DOI 10.1038/33198; Crawford PA, 1997, MOL CELL BIOL, V17, P3997, DOI 10.1128/MCB.17.7.3997; Durocher F, 1998, PHARMACOGENETICS, V8, P49, DOI 10.1097/00008571-199802000-00007; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; GUO IC, 1994, J BIOL CHEM, V269, P6362; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; HANUKOGLU I, 1989, FOLLICULAR DEV OVULA, P233; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HONDA S, 1993, J BIOL CHEM, V268, P7494; Huang NW, 2000, J BIOL CHEM, V275, P2852, DOI 10.1074/jbc.275.4.2852; HUM DW, 1988, J BIOL CHEM, V263, P15946; HUM DW, 1993, ENDOCRINOLOGY, V132, P546, DOI 10.1210/en.132.2.546; HUM DW, 1995, DNA CELL BIOL, V14, P451, DOI 10.1089/dna.1995.14.451; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; INOUE H, 1991, EUR J BIOCHEM, V195, P563, DOI 10.1111/j.1432-1033.1991.tb15738.x; INOUE H, 1988, EUR J BIOCHEM, V171, P435, DOI 10.1111/j.1432-1033.1988.tb13808.x; Ito M, 1998, MOL ENDOCRINOL, V12, P290, DOI 10.1210/me.12.2.290; Janknecht R, 1996, ONCOGENE, V12, P1961; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Juengel JL, 1998, ENDOCRINE, V9, P227, DOI 10.1385/ENDO:9:3:227; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; Kobayashi A, 1996, J BIOL CHEM, V271, P12310, DOI 10.1074/jbc.271.21.12310; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JS, 1996, MOL CELL BIOL, V16, P4312; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Liu Z, 1999, MOL CELL ENDOCRINOL, V153, P183, DOI 10.1016/S0303-7207(99)00036-2; Liu Z, 1997, MOL ENDOCRINOL, V11, P127, DOI 10.1210/me.11.2.127; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Mamluk R, 1999, BIOL REPROD, V60, P628, DOI 10.1095/biolreprod60.3.628; MATHENY C, 1994, J BIOL CHEM, V269, P8176; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; MELLON SH, 1993, BRAIN RES, V629, P283, DOI 10.1016/0006-8993(93)91332-M; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; Mesiano S, 1996, J CLIN ENDOCR METAB, V81, P340, DOI 10.1210/jc.81.1.340; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Monte D, 1998, J BIOL CHEM, V273, P4585, DOI 10.1074/jbc.273.8.4585; Montminy M, 1997, NATURE, V387, P654, DOI 10.1038/42594; MOORE CCD, 1990, MOL CELL BIOL, V10, P6013, DOI 10.1128/MCB.10.11.6013; MOORE CCD, 1992, MOL ENDOCRINOL, V6, P2045, DOI 10.1210/me.6.12.2045; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MOROHASHI K, 1993, MOL ENDOCRINOL, V7, P1196, DOI 10.1210/me.7.9.1196; MORRIS JF, 1991, ONCOGENE, V6, P2339; ONATE SA, 1995, SCIENCE, V270, P1354; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; Pedone PV, 1996, P NATL ACAD SCI USA, V93, P2822, DOI 10.1073/pnas.93.7.2822; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Preiss T, 1998, RNA, V4, P1321, DOI 10.1017/S1355838298980669; Radtke F, 1996, BIOL CHEM H-S, V377, P47, DOI 10.1515/bchm3.1996.377.1.47; Rodriguez H, 1997, J CLIN ENDOCR METAB, V82, P365, DOI 10.1210/jc.82.2.365; Ruan HJ, 1996, J BIOL CHEM, V271, P29576, DOI 10.1074/jbc.271.47.29576; Sandhoff TW, 1998, ENDOCRINOLOGY, V139, P4820, DOI 10.1210/en.139.12.4820; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; SIMPSON ER, 1990, MOL CELL ENDOCRINOL, V70, pC25, DOI 10.1016/0303-7207(90)90151-W; Sjottem E, 1997, J MOL BIOL, V267, P490, DOI 10.1006/jmbi.1997.0893; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; SONENBERG N, 1994, CURR OPIN GENET DEV, V4, P310, DOI 10.1016/S0959-437X(05)80059-0; STROMSTEDT M, 1995, MOL BRAIN RES, V34, P75, DOI 10.1016/0169-328X(95)00140-N; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; TAKAYAMA K, 1994, J BIOCHEM-TOKYO, V116, P193, DOI 10.1093/oxfordjournals.jbchem.a124493; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; TANAKA M, 1994, MOL CELL BIOL, V14, P6046, DOI 10.1128/MCB.14.9.6046; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VANTVEER LJ, 1992, P NATL ACAD SCI USA, V89, P8971, DOI 10.1073/pnas.89.19.8971; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WATANABE N, 1994, EUR J BIOCHEM, V222, P825, DOI 10.1111/j.1432-1033.1994.tb18929.x; Waterman MR, 1996, ENDOCR RES, V22, P615, DOI 10.1080/07435809609043755; Waterman MR, 1986, CYTOCHROME P450 STRU, P345; Westin S, 2000, ADV PHARMACOL, V47, P89; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	101	40	45	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33881	33892		10.1074/jbc.M100113200	http://dx.doi.org/10.1074/jbc.M100113200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11349124	hybrid			2022-12-25	WOS:000170910200081
J	Zhu, QZ; Yao, JH; Wani, G; Wani, MA; Wani, AA				Zhu, QZ; Yao, JH; Wani, G; Wani, MA; Wani, AA			Mdm2 mutant defective in binding p300 promotes ubiquitination but not degradation of p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING-FINGER DOMAIN; DNA-REPAIR; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL ACTIVITY; IN-VIVO; PROTEIN; E1A; PROTEASOME; STABILIZATION; ACCUMULATION	Turnover of the p53 tumor suppressor protein is mediated by Mdm2 through the ubiquitin proteolysis pathway. p300, a co-activator for p53, also participates in this process by complexing with Mdm2. We now report that the mutant Mdm2, defective in p53 binding, does not promote p53 ubiquitination and degradation in vivo or inhibit p53 transcriptional activation. By contrast, the mutant Mdm2, defective in p300 binding, still retains its activity to promote p53 ubiquitination and to inhibit p53 transcriptional activation but fails in promoting p53 degradation. We also show that both wild-type Mdm2 and the mutant Mdm2, defective in p300 binding, can promote the ubiquitination of cancer-derived p53 mutants, but only wild-type Mdm2 can cause their degradation. Furthermore, adenoviral oncoprotein, 12S.E.1A, but not its deletion mutant that lacks p300 binding, was shown to decrease in vivo ubiquitination of mutant p53. Taken together, these results provide genetic evidence that p300 plays a pivotal role in the regulation of Mdm2-mediated p53 turnover by integrating the cellular ubiquitination and proteolytic processes.	Mol Carcinogenesis Lab, Columbus, OH 43210 USA; James Canc Hosp, Dept Radiol, Columbus, OH 43210 USA; James Canc Hosp, Biochem Program, Columbus, OH 43210 USA; Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA	James Cancer Hospital & Solove Research Institute; Ohio State University; James Cancer Hospital & Solove Research Institute; Ohio State University; James Cancer Hospital & Solove Research Institute; Ohio State University	Wani, AA (corresponding author), Mol Carcinogenesis Lab, 103 Wiseman Hall,400 W 12th Ave, Columbus, OH 43210 USA.	wani.2@osu.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002388] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES2388] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LUNA RMD, 1995, NATURE, V378, P203; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Nakajima T, 1998, J BIOL CHEM, V273, P20036, DOI 10.1074/jbc.273.32.20036; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; SANCHEZPRIETO R, 1995, ONCOGENE, V11, P675; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Turnell AS, 2000, EMBO J, V19, P4759, DOI 10.1093/emboj/19.17.4759; Venkatachalam S, 1997, ONCOGENE, V14, P801, DOI 10.1038/sj.onc.1200890; Wani MA, 1999, CARCINOGENESIS, V20, P765, DOI 10.1093/carcin/20.5.765; Wani MA, 2000, CANCER RES, V60, P2273; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461; Yuan ZM, 1999, J BIOL CHEM, V274, P1883, DOI 10.1074/jbc.274.4.1883; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhu QZ, 2000, MOL CARCINOGEN, V28, P215; Zhu QZ, 2000, J BIOL CHEM, V275, P11492, DOI 10.1074/jbc.275.15.11492; Zhu QZ, 2001, CANCER RES, V61, P64	48	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29695	29701		10.1074/jbc.M102634200	http://dx.doi.org/10.1074/jbc.M102634200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11340074	hybrid			2022-12-25	WOS:000170558000015
J	Blazyk, J; Wiegand, R; Klein, J; Hammer, J; Epand, RM; Epand, RF; Maloy, WL; Kari, UP				Blazyk, J; Wiegand, R; Klein, J; Hammer, J; Epand, RM; Epand, RF; Maloy, WL; Kari, UP			A novel linear amphipathic beta-sheet cationic antimicrobial peptide with enhanced selectivity for bacterial lipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; PHOSPHOLIPID-BILAYERS; MEMBRANE INTERFACES; CYTOLYTIC ACTIVITY; PORE FORMATION; MAGAININ-2; ANALOGS; PROTEINS; DESIGN; PGLA	All known naturally occurring linear cationic peptides adopt an amphipathic alpha -helical conformation upon binding to lipids as an initial step in the induction of cell leakage. We designed an 18-residue peptide, (KIGAKI)(3)-NH2, that has no amphipathic character as an alpha -helix but can form a highly amphipathic beta -sheet. When bound to lipids, (KIGAKI)(3)-NH2 did indeed form a beta -sheet structure as evidenced by Fourier transform infrared and circular dichroism spectroscopy. The antimicrobial activity of this peptide was compared with that of (KIAGKIA)(3)-NH2, and it was better than that of GMASKA-GAIAGKIAKVALKAL-NH2 (PGLa) and (KLAGLAK)(3)NH2, all of which form amphipathic alpha -helices when bound to membranes. (KIGAKI)(3)-NH2 was much less effective at inducing leakage in lipid vesicles composed of mixtures of the acidic lipid, phosphatidylglycerol, and the neutral lipid, phosphatidylcholine, as compared with the other peptides. However, when phosphatidylethanolamine replaced phosphatidylcholine, the lytic potency of PGLa and the alpha -helical model peptides was reduced, whereas that of (KIGAKI)(3)-NH2 was improved. Fluorescence experiments using analogs containing a single tryptophan residue showed significant differences between (KIGAKI)(3)-NH2 and the alpha -helical peptides in their interactions with lipid vesicles. Because the data suggest enhanced selectivity between bacterial and mammalian lipids, linear amphipathic beta -sheet peptides such as (KIGAKI)3-NH2 warrant further investigation as potential antimicrobial agents.	Ohio Univ, Coll Osteopath Med, Dept Biomed Sci, Athens, OH 45701 USA; Ohio Univ, Coll Arts & Sci, Dept Chem & Biochem, Athens, OH 45701 USA; McMaster Univ, Hlth Sci Ctr, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; Genaera Corp, Plymouth Meeting, PA USA	University System of Ohio; Ohio University; University System of Ohio; Ohio University; McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba	Blazyk, J (corresponding author), Ohio Univ, Coll Osteopath Med, Dept Biomed Sci, Athens, OH 45701 USA.		, Richard/R-2316-2019	, Richard/0000-0002-9602-9558	NIAID NIH HHS [AI47165] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R15AI047165] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bechinger B, 1998, BIOPHYS J, V74, P981, DOI 10.1016/S0006-3495(98)74021-4; BECHINGER B, 1993, PROTEIN SCI, V2, P2077, DOI 10.1002/pro.5560021208; BLONDELLE SE, 1992, BIOCHEMISTRY-US, V31, P12688, DOI 10.1021/bi00165a020; Castano S, 2000, BBA-BIOMEMBRANES, V1463, P65, DOI 10.1016/S0005-2736(99)00175-3; CHEN HC, 1988, FEBS LETT, V236, P462, DOI 10.1016/0014-5793(88)80077-2; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CUERVO JH, 1990, PEPTIDES CHEM STRUCT, P124; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; Epand RM, 1999, BBA-BIOMEMBRANES, V1462, P11, DOI 10.1016/S0005-2736(99)00198-4; Epand RM, 1998, BBA-REV BIOMEMBRANES, V1376, P353, DOI 10.1016/S0304-4157(98)00015-X; Hirsh DJ, 1996, BIOCHEMISTRY-US, V35, P12733, DOI 10.1021/bi961468a; HOFFMANN W, 1983, EMBO J, V2, P711, DOI 10.1002/j.1460-2075.1983.tb01489.x; Hong J, 1999, BIOCHEMISTRY-US, V38, P16963, DOI 10.1021/bi991850y; JACKSON M, 1992, BIOCHEMISTRY-US, V31, P7289, DOI 10.1021/bi00147a012; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; LUDTKE SJ, 1994, BBA-BIOMEMBRANES, V1190, P181, DOI 10.1016/0005-2736(94)90050-7; Ludtke SJ, 1996, BIOCHEMISTRY-US, V35, P13723, DOI 10.1021/bi9620621; MALOY WL, 1995, BIOPOLYMERS, V37, P105, DOI 10.1002/bip.360370206; Matsuzaki K, 1996, BIOCHEMISTRY-US, V35, P11361, DOI 10.1021/bi960016v; MATSUZAKI K, 1994, BIOCHEMISTRY-US, V33, P3342, DOI 10.1021/bi00177a027; Matsuzaki K, 1998, BIOCHEMISTRY-US, V37, P11856, DOI 10.1021/bi980539y; MISHRA VK, 1994, J BIOL CHEM, V269, P7185; Oh JE, 1999, J PEPT RES, V53, P41, DOI 10.1111/j.1399-3011.1999.tb01615.x; ONO S, 1990, BIOCHIM BIOPHYS ACTA, V1022, P237, DOI 10.1016/0005-2736(90)90119-9; Oren Z, 1997, J BIOL CHEM, V272, P14643, DOI 10.1074/jbc.272.23.14643; Oren Z, 1999, EUR J BIOCHEM, V259, P360, DOI 10.1046/j.1432-1327.1999.00047.x; OSTERMAN DG, 1985, J CELL BIOCHEM, V29, P57, DOI 10.1002/jcb.240290202; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P9482, DOI 10.1021/bi00154a022; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; Sitaram N, 1999, BBA-BIOMEMBRANES, V1462, P29, DOI 10.1016/S0005-2736(99)00199-6; SORAVIA E, 1988, FEBS LETT, V228, P337, DOI 10.1016/0014-5793(88)80027-9; TYTLER EM, 1993, J BIOL CHEM, V268, P22112; White SH, 1998, METHOD ENZYMOL, V295, P62; Wieprecht T, 2000, BIOCHEMISTRY-US, V39, P442, DOI 10.1021/bi992146k; Wieprecht T, 1996, BIOCHEMISTRY-US, V35, P10844, DOI 10.1021/bi960362c; WILLIAMS RW, 1990, BIOCHEMISTRY-US, V29, P4490, DOI 10.1021/bi00470a031; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; Yau WM, 1998, BIOCHEMISTRY-US, V37, P14713, DOI 10.1021/bi980809c; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	39	129	134	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27899	27906		10.1074/jbc.M102865200	http://dx.doi.org/10.1074/jbc.M102865200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11352918	hybrid			2022-12-25	WOS:000170093400022
J	Hong, SH; Park, SJ; Kong, HJ; Shuman, JD; Cheong, JH				Hong, SH; Park, SJ; Kong, HJ; Shuman, JD; Cheong, JH			Functional interaction of bZIP proteins and the large subunit of replication factor C in liver and adipose cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING-PROTEIN; C/EBP-ALPHA GENE; TERMINAL ADIPOCYTE DIFFERENTIATION; EUKARYOTIC DNA-REPLICATION; ACTIVATED RECEPTOR-GAMMA; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTORS; NUCLEAR ANTIGEN; LEUCINE-ZIPPER; EXPRESSION	The transcription factor CCAAT/enhancer-binding protein-vt (C/EBP alpha) has a vital role in cell growth and differentiation. To delineate further a mechanism for C/EBP alpha -mediated differentiation, we screened C/EBP alpha -interacting proteins through far-Western screening. One of the strongest interactions was with RFC140, the large subunit of the replication factor C complex. C/EBPa specifically interacted with RFC140 from rat liver nuclear extract as determined by a combination of affinity chromatography and co-immunoprecipitation. Subsequent far-Western blotting showed that the bZIP domain of C/EBPa interacted with the DNA-binding region of RFC140. Overexpression of RFC140 in mammalian cells increased the transactivation activity of C/EBPa on both minimal and native promoters. Consistent with the enhanced transactivation, a complex of C/EBP alpha and RFC140 proteins with the cognate DNA element was detected in vitro. The specific interaction between C/EBP alpha and RFC140 was detected in the terminal differentiation of 3T3-LI preadipocytes to adipocytes. The synergistic transcription effect of these two proteins increased the promoter activity and protein expression of peroxisome proliferator-activated receptor-gamma, which is a main regulator of adipocyte differentiation. Our results demonstrate that the specific transcription factor C/EBPa and the general DNA replication factor RFC140 interact functionally and physically. This observation highlights a unique mechanism by which the levels of the general replication factor can strongly modulate the functional activity of the specific transcription factor as a coactivator.	Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea; NCI, Regulat Cell Growth Lab, Frederick Canc Res & Dev Ctr, NIH, Frederick, MD 21701 USA	Chonnam National University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Cheong, JH (corresponding author), Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea.							Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BUNZ F, 1993, P NATL ACAD SCI USA, V90, P11014, DOI 10.1073/pnas.90.23.11014; Cayrol C, 1996, EMBO J, V15, P2748, DOI 10.1002/j.1460-2075.1996.tb00635.x; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; DIEHL AM, 1994, GASTROENTEROLOGY, V106, P1625, DOI 10.1016/0016-5085(94)90420-0; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; GUO K, 1995, MOL CELL BIOL, V15, P3823; Hansen JB, 1999, J BIOL CHEM, V274, P2386, DOI 10.1074/jbc.274.4.2386; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; HOWELL EA, 1994, MOL CELL BIOL, V14, P255, DOI 10.1128/MCB.14.1.255; Jiang MS, 2000, P NATL ACAD SCI USA, V97, P12519, DOI 10.1073/pnas.220426097; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEVAVASSEUR F, 1995, FEBS LETT, V363, P132, DOI 10.1016/0014-5793(95)00305-S; Lyle RE, 1996, BIOCHEM BIOPH RES CO, V228, P709, DOI 10.1006/bbrc.1996.1721; MCGEHEE RE, 1995, MOL ENDOCRINOL, V9, P487, DOI 10.1210/me.9.4.487; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; NAGY P, 1994, J CELL BIOL, V126, P223, DOI 10.1083/jcb.126.1.223; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Podust VN, 1998, J BIOL CHEM, V273, P31992, DOI 10.1074/jbc.273.48.31992; Puigserver P, 1998, EUR J CELL BIOL, V77, P117, DOI 10.1016/S0171-9335(98)80079-4; RAMOS RA, 1992, SCIENCE, V251, P288; RANA B, 1995, J BIOL CHEM, V270, P18123, DOI 10.1074/jbc.270.30.18123; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; Sabourin LA, 2000, CLIN GENET, V57, P16, DOI 10.1034/j.1399-0004.2000.570103.x; Shuman JD, 1997, J BIOL CHEM, V272, P12793, DOI 10.1074/jbc.272.19.12793; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; Tang QQ, 1999, MOL CELL BIOL, V19, P4855; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	42	21	21	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28098	28105		10.1074/jbc.M010912200	http://dx.doi.org/10.1074/jbc.M010912200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11356826	hybrid			2022-12-25	WOS:000170093400048
J	He, H; Levitzki, A; Zhu, HJ; Walker, F; Burgess, A; Maruta, H				He, H; Levitzki, A; Zhu, HJ; Walker, F; Burgess, A; Maruta, H			Platelet-derived growth factor requires epidermal growth factor receptor to activate p21-activated kinase family kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL MOTILITY; RAS; SRC; EXPRESSION; TRANSMODULATION; PROTEINS; AFFINITY; ALPHA; GENE; PP1	The platelet-derived growth factor (PDGF) receptor (PDGFR) transactivates the epidermal growth factor (EGF) receptor (ErbB1) to stimulate the cell migration of fibroblasts through an unknown mechanism (Li, J., Rim, Y.N. & Bertics, P. (2000) J. Biol. Chem. 275, 2951-2958). In this paper we provide evidence that the transactivation of the EGF receptor (EGFR) by PDGFR is essential for PDGF to activate pal-activated kinase (PAK) family kinases. Fetal calf serum (10%) transiently stimulates the PAK activity in NIH 3T3 fibroblasts. The activation of PAK was completely inhibited by either PDGFR-specific inhibitor (AG1295) or EGFR-specific inhibitor (AG1478), suggesting that serum requires either the PDGF- or EGF-dependent pathway or the combination of both to activate PAK, PDGF-induced activation of PAR is completely inhibited by either AG1295 or AG1478, indicating that PDGF requires both PDGFR and EGFR for PAK activation. In support of this notion, a mouse embryo fibroblast cell line derived from the EGFR -/- mouse (from Dr. Erwin Wagner) doesn't activate PAT( in response to PDGF. Expression of human EGFR in this cell line restores the ability of the PDGF to induce PAK activation. Our results indicate that PDGF activates PAK through transactivation of ErbB1.	Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia; Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Hebrew University of Jerusalem	He, H (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, POB 2008, Melbourne, Vic 3050, Australia.	Hong.He@ludwig.edu.au		Zhu, Hong-Jian/0000-0002-1478-995X				Bagrodia S, 1999, J BIOL CHEM, V274, P22393, DOI 10.1074/jbc.274.32.22393; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; COLLINS MKL, 1983, J BIOL CHEM, V258, P1689; Daniels RH, 1999, J BIOL CHEM, V274, P6047, DOI 10.1074/jbc.274.10.6047; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Dharmawardhane S, 2000, MOL BIOL CELL, V11, P3341, DOI 10.1091/mbc.11.10.3341; DOWNWARD J, 1998, MOL B INT U, V3, P171; GLICK AB, 1991, MOL CARCINOGEN, V4, P210, DOI 10.1002/mc.2940040308; He H, 2000, CANCER J, V6, P243; He H, 2001, CANCER J, V7, P191; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Li J, 2000, J BIOL CHEM, V275, P2951, DOI 10.1074/jbc.275.4.2951; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Maruta H, 1999, MICROSC RES TECHNIQ, V47, P61; MARUTA H, 1991, J BIOL CHEM, V266, P11661; Mincione G, 1996, J CELL BIOCHEM, V60, P437, DOI 10.1002/(SICI)1097-4644(19960315)60:4<437::AID-JCB1>3.0.CO;2-T; NORMANNO N, 1994, P NATL ACAD SCI USA, V91, P2790, DOI 10.1073/pnas.91.7.2790; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; SUSA M, 1992, J BIOL CHEM, V267, P22951; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VALGEIRSDOTTIR S, 1995, J BIOL CHEM, V270, P10161, DOI 10.1074/jbc.270.17.10161; WALKER F, 1988, BIOCHEM J, V256, P109, DOI 10.1042/bj2560109; WALKER F, 1991, J BIOL CHEM, V266, P2746; Zhu HJ, 1999, J BIOL CHEM, V274, P32258, DOI 10.1074/jbc.274.45.32258	31	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26741	26744		10.1074/jbc.C100229200	http://dx.doi.org/10.1074/jbc.C100229200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356824	hybrid			2022-12-25	WOS:000169966900003
J	Kilic, G; Doctor, RB; Fitz, JG				Kilic, G; Doctor, RB; Fitz, JG			Insulin stimulates membrane conductance in a liver cell line - Evidence for insertion of ion channels through a phosphoinositide 3-kinase-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED-RAT-LIVER; FROG NEUROMUSCULAR-JUNCTION; PATCH-CLAMP TECHNIQUES; MOTOR-NERVE TERMINALS; PHOSPHATIDYLINOSITOL 3-KINASE; INTRACELLULAR CALCIUM; HEPATOCYTE COUPLETS; SECRETORY PROTEINS; PLASMA-MEMBRANE; APICAL DOMAIN	Activation of insulin receptors stimulates a rapid increase in the ion permeability of liver cells. To evaluate whether this response involves insertion of ion channels,plasma membrane turnover was measured in a model liver cell line using the fluorescent membrane marker FM1-43. Under basal conditions, the rate of constitutive membrane turnover was similar to2%min(-1) and balanced exocytosis and endocytosis maintainer; the total cell membrane area constant. Exposure to insulin stimulated a transient increase in membrane turnover of up to 10-fold above constitutive rates. The response was concentration-dependent (0.001-10 muM). Insulin also caused a parallel increase in membrane conductance as measured by whole-cell patch clamp recording due to opening of Cl-- and K+-selective ion channels. The insulin-stimulated membrane turnover did not appear to involve the constitutive recycling compartments, suggesting that a distinct pool of vesicles may be involved. The effects of insulin on membrane turnover and membrane conductance were inhibited by blockers of phosphoinositide 3-kinase LY294002 and wortmannin or by disrupting microtubule assembly with nocodazole. Taken together, these findings indicate that insulin stimulates recruitment of new membranes through phosphoinositide 3-kinase-dependent mechanisms. Thus, regulated insertion of a separate population of ion channel-containing vesicles may represent one mechanism for mediating the changes in membrane conductance that are essential for the cellular response to insulin.	Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Kilic, G (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Campus Box B158,Rm 6416,4200 E 9th Ave, Denver, CO 80262 USA.	gordan.kilic@uchsc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK046082, R01DK046082, R01DK043278] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43278, DK46082] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAWQATI Q, 1989, METHOD ENZYMOL, V172, P49; Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; BARNARD GF, 1984, J CLIN INVEST, V74, P173, DOI 10.1172/JCI111399; Benzeroual K, 1997, AM J PHYSIOL-GASTR L, V272, pG1425, DOI 10.1152/ajpgi.1997.272.6.G1425; Benzeroual K, 2000, BBA-MOL CELL RES, V1495, P14, DOI 10.1016/S0167-4889(99)00147-0; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; BOYER JL, 1995, GASTROENTEROLOGY, V109, P1600, DOI 10.1016/0016-5085(95)90649-5; BRUCK R, 1992, AM J PHYSIOL, V262, pG806, DOI 10.1152/ajpgi.1992.262.5.G806; BRUCK R, 1993, AM J PHYSIOL, V265, pG347, DOI 10.1152/ajpgi.1993.265.2.G347; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; FITZ JG, 1994, AM J PHYSIOL, V266, pG544, DOI 10.1152/ajpgi.1994.266.4.G544; Folli F, 1997, GASTROENTEROLOGY, V113, P954, DOI 10.1016/S0016-5085(97)70192-6; FOLLI F, 1992, J BIOL CHEM, V267, P22171; Graf J, 1996, J HEPATOL, V24, P53; HADDAD P, 1991, AM J PHYSIOL, V261, pG340, DOI 10.1152/ajpgi.1991.261.2.G340; HALLBRUCKER C, 1991, PFLUG ARCH EUR J PHY, V418, P519, DOI 10.1007/BF00497781; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hamm-Alvarez SF, 1998, PHYSIOL REV, V78, P1109, DOI 10.1152/physrev.1998.78.4.1109; Hao MM, 2000, J BIOL CHEM, V275, P15279, DOI 10.1074/jbc.275.20.15279; Harvey J, 2000, J BIOL CHEM, V275, P4660, DOI 10.1074/jbc.275.7.4660; HEATON JH, 1984, J BIOL CHEM, V259, P2396; Kanzaki M, 1999, NAT CELL BIOL, V1, P165, DOI 10.1038/11086; Kavalali ET, 1999, P NATL ACAD SCI USA, V96, P12893, DOI 10.1073/pnas.96.22.12893; KELLY KL, 1992, J BIOL CHEM, V267, P3423; Klingauf J, 1998, NATURE, V394, P581, DOI 10.1038/29079; LINDAU M, 1988, PFLUG ARCH EUR J PHY, V411, P137, DOI 10.1007/BF00582306; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Mathe L, 2000, CAN J GASTROENTEROL, V14, P389, DOI 10.1155/2000/574820; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Richards DA, 2000, NEURON, V27, P551, DOI 10.1016/S0896-6273(00)00065-9; Roelofsen H, 1998, J CELL SCI, V111, P1137; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Ryan TA, 1997, NATURE, V388, P478, DOI 10.1038/41335; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; SAUCAN L, 1994, J CELL BIOL, V125, P733, DOI 10.1083/jcb.125.4.733; SAUCAN L, 1992, HEPATOLOGY, V15, P714, DOI 10.1002/hep.1840150427; SCHARSCHMIDT BF, 1986, P NATL ACAD SCI USA, V83, P9488, DOI 10.1073/pnas.83.24.9488; Shimoni Y, 1999, J PHYSIOL-LONDON, V514, P735, DOI 10.1111/j.1469-7793.1999.735ad.x; STEINMAN RM, 1976, J CELL BIOL, V68, P665, DOI 10.1083/jcb.68.3.665; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; SUNG CK, 1992, BIOCHEM BIOPH RES CO, V189, P1024, DOI 10.1016/0006-291X(92)92306-I; Terzic A, 1996, J PHYSIOL-LONDON, V492, P395, DOI 10.1113/jphysiol.1996.sp021316; THOMSEN OO, 1983, AM J PHYSIOL, V245, pG59, DOI 10.1152/ajpgi.1983.245.1.G59; THOMSEN OO, 1982, SCAND J GASTROENTERO, V17, P687, DOI 10.3109/00365528209181080; THOMSEN OO, 1982, SCAND J GASTROENTERO, V17, P297; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Wu LG, 1996, NEURON, V17, P769, DOI 10.1016/S0896-6273(00)80208-1	49	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26762	26768		10.1074/jbc.M100992200	http://dx.doi.org/10.1074/jbc.M100992200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11349127	hybrid			2022-12-25	WOS:000169966900006
J	Tsukihashi, Y; Kawaichi, M; Kokubo, T				Tsukihashi, Y; Kawaichi, M; Kokubo, T			Requirement for yeast TAF145 function in transcriptional activation of the RPS5 promoter that depends on both core promoter structure and upstream activating sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TATA BOX-BINDING; IN-VIVO; TFIID COMPLEX; ACETYLTRANSFERASE ACTIVITY; COACTIVATOR REQUIREMENTS; SACCHAROMYCES-CEREVISIAE; TAF(II)250 SUBUNIT; CYCLIN GENES; DNA	The general transcription factor TFIID has been shown to be involved in both core promoter recognition and the transcriptional activation of eukaryotic genes. We recently isolated TAF145 (one of TFIID subunits) temperature-sensitive mutants in yeast, in which transcription of the TUB2 gene is impaired at restrictive temperatures due to a defect in core promoter recognition. Here, we show in these mutants that the transcription of the RPS5 gene is impaired, mostly due to a defect in transcriptional activation rather than to a defect in core promoter recognition, although the latter is slightly affected as well. Surprisingly, the RPS5 core promoter can be activated by various activation domains fused to a GAL4 DNA binding domain, but not by the original upstream activating sequence (UAS) of the RPS5 gene. In addition, a heterologous CYC1 core promoter can be activated by RPS5-UAS at normal levels even in these mutants. These observations indicate that a distinct combination of core promoters and activators may exploit alternative activation pathways that vary in their requirement for TAF145 function. In addition, a particular function of TAF145 that is deleted in our mutants appears to be involved in both core promoter recognition and transcriptional activation.	Nara Inst Sci & Technol, Div Gene Funct Anim, Nara 6300101, Japan	Nara Institute of Science & Technology	Kokubo, T (corresponding author), Yokohama City Univ, Grad Sch Integrated Sci, Div Mol & Cellular Biol, Tsurumi Ku, 1-7-29 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	kokubo@tsurumi.yohohama-cu.ac.jp						Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; Chen Z, 2000, MOL CELL BIOL, V20, P5064, DOI 10.1128/MCB.20.14.5064-5076.2000; Chi TH, 1996, GENE DEV, V10, P2540, DOI 10.1101/gad.10.20.2540; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; Dunphy EL, 2000, MOL CELL BIOL, V20, P1134, DOI 10.1128/MCB.20.4.1134-1139.2000; EMAMI KH, 1995, MOL CELL BIOL, V15, P5906; Graham IR, 1999, MOL CELL BIOL, V19, P7481; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Green MR, 2000, TRENDS BIOCHEM SCI, V25, P59, DOI 10.1016/S0968-0004(99)01527-3; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; Komarnitsky PB, 1998, MOL CELL BIOL, V18, P5861, DOI 10.1128/MCB.18.10.5861; Komarnitsky PB, 1999, GENE DEV, V13, P2484, DOI 10.1101/gad.13.19.2484; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kotani T, 2000, P NATL ACAD SCI USA, V97, P7178, DOI 10.1073/pnas.120074297; Kotani T, 1998, J BIOL CHEM, V273, P32254, DOI 10.1074/jbc.273.48.32254; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kutach AK, 2000, MOL CELL BIOL, V20, P4754, DOI 10.1128/MCB.20.13.4754-4764.2000; Lascaris RF, 1999, BIOINFORMATICS, V15, P267, DOI 10.1093/bioinformatics/15.4.267; Lee DK, 1999, GENE DEV, V13, P2934, DOI 10.1101/gad.13.22.2934; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Li B, 2000, EMBO J, V19, P4091, DOI 10.1093/emboj/19.15.4091; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; Lieberman PM, 1997, MOL CELL BIOL, V17, P6624, DOI 10.1128/MCB.17.11.6624; LUNDBLACK V, 1998, CURRENT PROTOCOLS MO, V2; Luo X, 1996, MOL CELL BIOL, V16, P1367; Martinez E, 1998, MOL CELL BIOL, V18, P6571, DOI 10.1128/MCB.18.11.6571; Michel B, 1998, MOL CELL, V2, P663, DOI 10.1016/S1097-2765(00)80164-1; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; O'Brien T, 2000, P NATL ACAD SCI USA, V97, P2456, DOI 10.1073/pnas.97.6.2456; O'Brien T, 1998, MOL CELL, V1, P905, DOI 10.1016/S1097-2765(00)80089-1; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Patikoglou GA, 1999, GENE DEV, V13, P3217, DOI 10.1101/gad.13.24.3217; Pham AD, 2000, SCIENCE, V289, P2357, DOI 10.1126/science.289.5488.2357; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Ranish JA, 1999, GENE DEV, V13, P49, DOI 10.1101/gad.13.1.49; Reese JC, 2000, J BIOL CHEM, V275, P17391, DOI 10.1074/jbc.M001635200; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Sakurai H, 1999, BIOCHEM BIOPH RES CO, V261, P734, DOI 10.1006/bbrc.1999.1113; Sanders SL, 2000, J BIOL CHEM, V275, P13895, DOI 10.1074/jbc.275.18.13895; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; Tsukihashi Y, 2000, MOL CELL BIOL, V20, P2385, DOI 10.1128/MCB.20.7.2385-2399.2000; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; Weissman JDJ, 2000, J BIOL CHEM, V275, P10160, DOI 10.1074/jbc.275.14.10160; Willy PJ, 2000, SCIENCE, V290, P982, DOI 10.1126/science.290.5493.982; Xiao WM, 1997, J VIROL, V71, P1757, DOI 10.1128/JVI.71.3.1757-1765.1997	61	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25715	25726		10.1074/jbc.M102416200	http://dx.doi.org/10.1074/jbc.M102416200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11337503	hybrid			2022-12-25	WOS:000169823300013
J	Branum, ME; Reardon, JT; Sancar, A				Branum, ME; Reardon, JT; Sancar, A			DNA repair excision nuclease attacks undamaged DNA - A potential source of spontaneous mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MISMATCH REPAIR; REPLICATION FIDELITY; MAMMALIAN-CELLS; BASE DAMAGE; TRANSCRIPTION; EXCINUCLEASE; RECOGNITION; MECHANISM; LESIONS	Nucleotide excision repair is a general repair system that eliminates many dissimilar lesions from DNA. In an effort to understand substrate determinants of this repair system, we tested DNAs with minor backbone modifications using the ultrasensitive excision assay. We found that a phosphorothioate and a methylphosphonate were excised with low efficiency. Surprisingly, we also found that fragments of 23-28 nucleotides and of 12-13 nucleotides characteristic of human and Escherichia coli excision repair, respectively, were removed from undamaged DNA at a significant rate. Considering the relative abundance of undamaged DNA in comparison to damaged DNA in the course of the life of an organism, we conclude that, in general, excision from and resynthesis of undamaged DNA may exceed the excision and resynthesis caused by DNA damage. As resynthesis is invariably associated with mutations, we propose that gratuitous repair may be an important source of spontaneous mutations.	Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Sancar, A (corresponding author), Univ N Carolina, Sch Med, Dept Biochem & Biophys, Mary Ellen Jones Bldg,CB 7260, Chapel Hill, NC 27599 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32833] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bacolla A, 2001, J BIOL CHEM, V276, P18597, DOI 10.1074/jbc.M100845200; Beletskii A, 1996, P NATL ACAD SCI USA, V93, P13919, DOI 10.1073/pnas.93.24.13919; Berdal KG, 1998, EMBO J, V17, P363, DOI 10.1093/emboj/17.2.363; Buschta-Hedayat N, 1999, P NATL ACAD SCI USA, V96, P6090, DOI 10.1073/pnas.96.11.6090; CARON PR, 1988, NUCLEIC ACIDS RES, V16, P7855, DOI 10.1093/nar/16.16.7855; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; DATTA A, 1995, SCIENCE, V268, P1616, DOI 10.1126/science.7777859; DAVIS BD, 1989, P NATL ACAD SCI USA, V86, P5005, DOI 10.1073/pnas.86.13.5005; DIZDAROGLU M, 1993, FEBS LETT, V315, P1, DOI 10.1016/0014-5793(93)81120-O; Douki T, 1997, CARCINOGENESIS, V18, P2385, DOI 10.1093/carcin/18.12.2385; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; FIX DF, 1987, MOL GEN GENET, V209, P78, DOI 10.1007/BF00329839; Gordienko I, 1998, EMBO J, V17, P626, DOI 10.1093/emboj/17.2.626; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; Hanawalt PC, 2001, MUTAT RES-DNA REPAIR, V485, P3, DOI 10.1016/S0921-8777(00)00071-9; Hess MT, 1997, P NATL ACAD SCI USA, V94, P6664, DOI 10.1073/pnas.94.13.6664; Holmquist GP, 1998, MUTAT RES-FUND MOL M, V400, P59, DOI 10.1016/S0027-5107(98)00051-7; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Matsunaga T, 1996, J BIOL CHEM, V271, P11047, DOI 10.1074/jbc.271.19.11047; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Moolenaar GF, 1998, J BIOL CHEM, V273, P34896, DOI 10.1074/jbc.273.52.34896; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; Reardon JT, 1997, NUCLEIC ACIDS RES, V25, P1015, DOI 10.1093/nar/25.5.1015; Reardon JT, 1997, P NATL ACAD SCI USA, V94, P9463, DOI 10.1073/pnas.94.17.9463; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Senturker S, 1999, FREE RADICAL BIO MED, V27, P370, DOI 10.1016/S0891-5849(99)00069-6; SMITH CA, 1993, J BIOL CHEM, V268, P11143; THOMAS DC, 1985, J BIOL CHEM, V260, P9875; VANHOUTEN B, 1987, J BACTERIOL, V169, P540, DOI 10.1128/jb.169.2.540-545.1987; Wakasugi M, 1998, P NATL ACAD SCI USA, V95, P6669, DOI 10.1073/pnas.95.12.6669; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; Wyatt MD, 1999, BIOESSAYS, V21, P668, DOI 10.1002/(SICI)1521-1878(199908)21:8<668::AID-BIES6>3.3.CO;2-4; Ye N, 1999, MUTAT RES-DNA REPAIR, V435, P43, DOI 10.1016/S0921-8777(99)00022-1	37	85	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25421	25426		10.1074/jbc.M101032200	http://dx.doi.org/10.1074/jbc.M101032200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11353769	hybrid			2022-12-25	WOS:000169800700132
J	Kawakami, K; Takeshita, F; Puri, RK				Kawakami, K; Takeshita, F; Puri, RK			Identification of distinct roles for a dileucine and a tyrosine internalization motif in the interleukin (IL)-13 binding component IL-13 receptor alpha 2 chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCER GP130; CARCINOMA CELL-LINES; DI-LEUCINE MOTIF; CYTOPLASMIC DOMAIN; TRANSFERRIN RECEPTOR; PSEUDOMONAS EXOTOXIN; IL-13R-ALPHA-1 CHAIN; JANUS KINASE; GAMMA-CHAIN; IN-VITRO	Interleukin (IL)-13 receptor alpha2 (IL-13R alpha2) chain is an essential binding component for IL-13-mediated ligand binding. Recently, we have demonstrated that this receptor chain also plays an important role in the internalization of IL-13. To study the mechanism of IL-13 internalization, we generated mutated IL-13R alpha2 chains that targeted trileucine residues (Leu(335), Leu(336), and Leu(337)) in the transmembrane domain and a tyrosine motif (Tyr(343)) in the intracellular domain and transfected these cDNAs in COS-7 cells. Cells that expressed a C-terminally truncated IL-13R alpha2 chain (Delta 335) did not bind IL-13, suggesting that the trileucine region modulates IL-13 binding. Truncation of IL-13R alpha2 chain with a mutation in the trileucine region resulted in significantly decreased internalization compared with wild type IL-13R alpha2 chain transfected cells. COS-7 cells transfected with tyrosine motif mutants exhibited a similar internalization level compared with wild type IL-13R alpha2 chain transfected cells; however, dissociation of cell surface IL-13 was faster compared with wild type IL-13R alpha2 transfectants. These results were further confirmed by determining the cytotoxicity of a chimeric protein composed of IL-13 and a mutated form of Pseudomonas exotoxin (IL13-PE38QQR) to cells that expressed IL-13R alpha2 chain mutants. We further demonstrate that the IL-13R alpha2 chain is not ubiquitinated and that internalization of IL-13R alpha2 did not depend on ubiquitination, Together, our findings suggest that the dileucine motif in the trileucine region and tyrosine motif participate in IL-13R alpha2 internalization in distinct manners.	US FDA, NIH, Lab Mol Tumor Biol,Ctr Biol Evaluat & Res, Div Cellular & Gene Therapies, Bethesda, MD 20892 USA; US FDA, Ctr Biol Evaluat & Res, Retroviral Immunol Sect, Div Viral Prod, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Puri, RK (corresponding author), US FDA, NIH, Lab Mol Tumor Biol,Ctr Biol Evaluat & Res, Div Cellular & Gene Therapies, Bldg 29B,Rm 2NN10,29 Lincoln Dr,MSC 4555, Bethesda, MD 20892 USA.	puri@cber.fda.gov						Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DEBINSKI W, 1995, J BIOL CHEM, V270, P16775, DOI 10.1074/jbc.270.28.16775; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; Feng NP, 1998, LAB INVEST, V78, P591; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; Garippa RJ, 1996, J BIOL CHEM, V271, P20660, DOI 10.1074/jbc.271.34.20660; Govers P, 1998, J BIOL CHEM, V273, P16426, DOI 10.1074/jbc.273.26.16426; Hamer I, 1997, J BIOL CHEM, V272, P21685, DOI 10.1074/jbc.272.35.21685; Hart PH, 1999, EUR J IMMUNOL, V29, P2087, DOI 10.1002/(SICI)1521-4141(199907)29:07<2087::AID-IMMU2087>3.0.CO;2-J; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; Hunter MG, 1999, BLOOD, V93, P440, DOI 10.1182/blood.V93.2.440.402k23_440_446; Kawakami K, 2000, HUM GENE THER, V11, P1829, DOI 10.1089/10430340050129459; Kawakami K, 2001, BLOOD, V97, P2673, DOI 10.1182/blood.V97.9.2673; KEEGAN AD, 1995, P NATL ACAD SCI USA, V92, P7681, DOI 10.1073/pnas.92.17.7681; Kil SJ, 1999, J BIOL CHEM, V274, P3141, DOI 10.1074/jbc.274.5.3141; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Kuznetsov VA, 1999, BIOPHYS J, V77, P154, DOI 10.1016/S0006-3495(99)76879-7; Levin I, 1998, FEBS LETT, V427, P164, DOI 10.1016/S0014-5793(98)00414-1; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Miloux B, 1997, FEBS LETT, V401, P163, DOI 10.1016/S0014-5793(96)01462-7; Murata T, 1998, INT J MOL MED, V1, P551; Murata T, 1997, INT J CANCER, V70, P230, DOI 10.1002/(SICI)1097-0215(19970117)70:2<230::AID-IJC15>3.0.CO;2-M; Murata T, 1997, CELL IMMUNOL, V175, P33, DOI 10.1006/cimm.1996.1051; Murata T, 1996, J IMMUNOL, V156, P2972; Murata T, 1997, BIOCHEM BIOPH RES CO, V238, P90, DOI 10.1006/bbrc.1997.7248; Nakamura K, 1999, MOL PHARMACOL, V56, P728; Nakatsu F, 2000, J BIOL CHEM, V275, P26213, DOI 10.1074/jbc.M907720199; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; Obiri NI, 1997, J BIOL CHEM, V272, P20251, DOI 10.1074/jbc.272.32.20251; Obiri NI, 1997, J IMMUNOL, V158, P756; Ohmori Y, 1996, J IMMUNOL, V157, P2058; Oshima Y, 2000, J BIOL CHEM, V275, P14375, DOI 10.1074/jbc.275.19.14375; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; Puri RK, 1996, BLOOD, V87, P4333, DOI 10.1182/blood.V87.10.4333.bloodjournal87104333; PYTOWSKI B, 1995, J BIOL CHEM, V270, P9067, DOI 10.1074/jbc.270.16.9067; SHIN JY, 1991, J BIOL CHEM, V266, P10658; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; Thiel S, 1998, BIOCHEM J, V330, P47, DOI 10.1042/bj3300047; Thiel S, 1999, BIOCHEM J, V339, P15, DOI 10.1042/0264-6021:3390015; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; Urban JF, 1998, IMMUNITY, V8, P255, DOI 10.1016/S1074-7613(00)80477-X; Yu CL, 1997, J BIOL CHEM, V272, P14017, DOI 10.1074/jbc.272.22.14017	51	39	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25114	25120		10.1074/jbc.M100936200	http://dx.doi.org/10.1074/jbc.M100936200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11352909	hybrid			2022-12-25	WOS:000169800700092
J	LeGros, L; Halim, AB; Chamberlin, ME; Geller, A; Kotb, M				LeGros, L; Halim, AB; Chamberlin, ME; Geller, A; Kotb, M			Regulation of the human MAT2B gene encoding the regulatory beta subunit of methionine adenosyltransferase, MAT II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE SYNTHETASE; RAT-LIVER; HUMAN-ERYTHROCYTES; HUMAN-LYMPHOCYTES; EXPRESSION; TRANSCRIPTION; ACTIVATION; ISOZYMES; CLONING; CELLS	Methionine adenosyltransferase (MAT) catalyzes the biosynthesis of S-adenosylmethionine (AdoMet), a key molecule in transmethylation reactions and polyamine biosynthesis, The MAT II isozyme consists of a catalytic alpha2 and a regulatory beta subunit. Down-regulation of the MAT II beta subunit expression causes a 6-10-fold increase in intracellular AdoMet levels. To understand the mechanism by which the beta subunit expression is regulated, we cloned the MAT2B gene, determined its organization, characterized its 5 ' -flanking sequences, and elucidated the in vitro and in vivo regulation of its promoter. Transcription of the MAT2B gene initiates at position -203 relative to the translation start site, Promoter deletion analysis defined a minimal promoter between positions +52 and +93 base pairs, a GC-rich region, Inclusion of the sequences between -4 and +52 enhanced promoter activity; this was primarily because of an Sp1 recognition site at +9/+15, The inclusion of sequences up to position -115 provided full activity; this was attributed to a TATA at -32, The Sp1 site at position +9 was key for the formation of protein DNA complexes. Mutation of both the Sp1 site at +9 and the TATA at -32 reduced promoter activity to its minimal level. Supershift assays showed no effect of the anti-Spl antibody on complex formation, whereas the anti-Sp3 antibody had a strong effect on protein DNA complex formation, suggesting that Sp3 is one of the main factors binding to this Sp1 site. Chromatin immunoprecipitation assays supported the involvement of both Sp1 and Sp3 in complexes formed on the MAT2B promoter. The data show that the 5 ' -untranslated sequences play an important role in regulating the MAT2B gene and identifies the Sp1 site at +9 as a potential target for modulating MAT2B expression, a process that can have a major effect on intracellular AdoMet levels.	Univ Tennessee, Ctr Hlth Sci, Dept Surg, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Microbiol & Immunol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Biochem, Memphis, TN 38163 USA; Vet Affairs Med Ctr, Memphis, TN 38104 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center	Kotb, M (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Surg, 956 Court Ave,Suite A-202, Memphis, TN 38163 USA.				NIGMS NIH HHS [GM-54892-09] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CANTONI GL, 1953, J BIOL CHEM, V204, P403; DELAROSA J, 1992, J BIOL CHEM, V267, P10699; DELAROSA J, 1995, J BIOL CHEM, V270, P21860; DELAROSA J, 1992, CANCER RES, V52, P3361; FINKELSTEIN JD, 1975, BIOCHEM BIOPH RES CO, V66, P81, DOI 10.1016/S0006-291X(75)80297-X; Gil B, 1996, HEPATOLOGY, V24, P876; Halim AB, 1999, J BIOL CHEM, V274, P29720, DOI 10.1074/jbc.274.42.29720; Halim AB, 2001, J BIOL CHEM, V276, P9784, DOI 10.1074/jbc.M002347200; Hiroki T, 1997, EUR J BIOCHEM, V250, P653, DOI 10.1111/j.1432-1033.1997.00653.x; HOFFMAN JL, 1983, METHOD ENZYMOL, V94, P223; HORIKAWA S, 1990, J BIOL CHEM, V265, P13683; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; KOTB M, 1985, J BIOL CHEM, V260, P3923; KOTB M, 1990, BIOCHIM BIOPHYS ACTA, V1039, P253, DOI 10.1016/0167-4838(90)90193-J; KOTB M, 1990, BIOCHIM BIOPHYS ACTA, V1040, P137, DOI 10.1016/0167-4838(90)90068-Q; Kotb M, 1997, TRENDS GENET, V13, P51, DOI 10.1016/S0168-9525(97)01013-5; KOTB M, 1993, PHARMACOL THERAPEUT, V59, P125, DOI 10.1016/0163-7258(93)90042-C; LANGKAMPHENKEN B, 1994, BBA-GEN SUBJECTS, V1201, P397, DOI 10.1016/0304-4165(94)90068-X; LeGros HL, 1997, J BIOL CHEM, V272, P16040, DOI 10.1074/jbc.272.25.16040; LeGros HL, 2000, J BIOL CHEM, V275, P2359, DOI 10.1074/jbc.275.4.2359; LIAU MC, 1979, CANCER RES, V39, P162; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MATO JM, 1994, ADV EXP MED BIOL, V368, P113; Mingorance J, 1997, INT J BIOCHEM CELL B, V29, P485, DOI 10.1016/S1357-2725(96)00151-3; MITSUI KI, 1988, J BIOL CHEM, V263, P11211; MUDD SH, 1973, ADENOSYLTRANSFERASES, P121; Mudd SH, 1995, DISORDERS TRANSSULFU; ODEN KL, 1983, BIOCHEMISTRY-US, V22, P2978, DOI 10.1021/bi00281a030; OKADA G, 1981, BIOCHEMISTRY-US, V20, P934, DOI 10.1021/bi00507a045; PAJARES MA, 1992, FEBS LETT, V309, P1, DOI 10.1016/0014-5793(92)80726-W; PISSOWOTZKI K, 1991, MOL GEN GENET, V231, P113, DOI 10.1007/BF00293829; SAKATA SF, 1993, J BIOL CHEM, V268, P13978; SULLIVAN DM, 1983, BIOCHEMISTRY-US, V22, P1636, DOI 10.1021/bi00276a017; SUMA Y, 1986, J BIOCHEM, V100, P67, DOI 10.1093/oxfordjournals.jbchem.a121707; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; TABOR CW, 1984, ADV ENZYMOL RAMB, V56, P251; UBAGAI T, 1995, J CLIN INVEST, V96, P1943, DOI 10.1172/JCI118240; Wang J, 2000, BIOTECHNIQUES, V29, P976, DOI 10.2144/00295bm09; Yang Y, 2000, J BIOL CHEM, V275, P38863, DOI 10.1074/jbc.M007906200	40	43	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24918	24924		10.1074/jbc.M102816200	http://dx.doi.org/10.1074/jbc.M102816200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11337507	hybrid			2022-12-25	WOS:000169800700065
J	Tomita, K; Saijo, K; Yamasaki, S; Iida, T; Nakatsu, F; Arase, H; Ohno, H; Shirasawa, T; Kuriyama, T; O'Shea, JJ; Saito, T				Tomita, K; Saijo, K; Yamasaki, S; Iida, T; Nakatsu, F; Arase, H; Ohno, H; Shirasawa, T; Kuriyama, T; O'Shea, JJ; Saito, T			Cytokine-independent Jak3 activation upon T cell receptor (TCR) stimulation through direct association of Jak3 and the TCR complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING JAK3; SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; GAMMA-CHAIN; IL-2 RECEPTOR; LYMPHOID DEVELOPMENT; INTERFERON-ALPHA; GENETIC-EVIDENCE; CD3 COMPLEX; INTERLEUKIN-2	Jak3 is responsible for growth signals by various cytokines such as interleukin (IL)-2, IL-4, and IL-7 through association with the common gamma chain (gammac) in lymphocytes. We found that T cells from Jak3-deficient mice exhibit impairment of not only cytokine signaling but also early activation signals and that Jak3 is phosphorylated upon T cell receptor (TCR) stimulation. TCR-mediated phosphorylation of Jak3 is independent of IL-2 receptor/gammac but is dependent on Lck and ZAP-70. Jak3 was found to be assembled with the TCR complex, particularly through direct association with CD3 zeta via its JH4 region, which is a different region from that for gammac association. These results suggest that Jak3 plays a role not only in cell growth but also in T cell activation and represents cross-talk of a signaling molecule between TCR and growth signals.	Chiba Univ, Grad Sch Med, Dept Mol Genet, Chuo Ku, Chiba 2608790, Japan; Tokyo Metropolitan Inst Gerontol, Dept Neurophysiol, Itabashi Ku, Tokyo 1730015, Japan; Chiba Univ, Sch Med, Inst Pulm Canc Res, Dept Internal Med,Chuo Ku, Chiba 2608790, Japan; NIAMS, Lymphocyte Cell Biol Sect, NIH, Bethesda, MD 20892 USA	Chiba University; Tokyo Metropolitan Institute of Gerontology; Chiba University; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Saito, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Mol Genet, Chuo Ku, 1-8-1 Inohana, Chiba 2608790, Japan.		Saito, Takashi/C-9684-2009; Ohno, Hiroshi/L-7899-2014; Arase, Hisashi/C-8442-2009	Saito, Takashi/0000-0001-9495-3547; Ohno, Hiroshi/0000-0001-8776-9661; Arase, Hisashi/0000-0002-1153-3166	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041106, ZIAAR041106] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; Chen M, 1997, P NATL ACAD SCI USA, V94, P6910, DOI 10.1073/pnas.94.13.6910; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; GOLDSMITH MA, 1987, P NATL ACAD SCI USA, V84, P6879, DOI 10.1073/pnas.84.19.6879; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; Malaviya R, 1999, J BIOL CHEM, V274, P27028, DOI 10.1074/jbc.274.38.27028; MALISSEN B, 1993, CURR OPIN IMMUNOL, V5, P324, DOI 10.1016/0952-7915(93)90049-X; Miyatake S, 1997, EUR J IMMUNOL, V27, P1816, DOI 10.1002/eji.1830270733; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Moriggl R, 1999, IMMUNITY, V11, P225, DOI 10.1016/S1074-7613(00)80097-7; Nakano H, 1996, J BIOL CHEM, V271, P6483, DOI 10.1074/jbc.271.11.6483; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Park SY, 1995, IMMUNITY, V3, P771, DOI 10.1016/1074-7613(95)90066-7; Petricoin EF, 1997, NATURE, V390, P629, DOI 10.1038/37648; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; Saijo K, 1997, J EXP MED, V185, P351, DOI 10.1084/jem.185.2.351; Shiratori T, 1997, IMMUNITY, V6, P583, DOI 10.1016/S1074-7613(00)80346-5; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Takase K, 1997, J IMMUNOL, V159, P741; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; Thomis DC, 1997, J IMMUNOL, V159, P4708; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; Viola A, 1997, J EXP MED, V186, P1775, DOI 10.1084/jem.186.10.1775; Wakizaka K, 1998, EUR J IMMUNOL, V28, P636, DOI 10.1002/(SICI)1521-4141(199802)28:02<636::AID-IMMU636>3.0.CO;2-A; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Welte T, 1999, SCIENCE, V283, P222, DOI 10.1126/science.283.5399.222; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	42	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25378	25385		10.1074/jbc.M011363200	http://dx.doi.org/10.1074/jbc.M011363200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11349123	hybrid			2022-12-25	WOS:000169800700126
J	Weisman, R; Finkelstein, S; Choder, M				Weisman, R; Finkelstein, S; Choder, M			Rapamycin blocks sexual development in fission yeast through inhibition of the cellular function of an FKBP12 homolog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; RYANODINE RECEPTOR FUNCTION; CIS-TRANS-ISOMERASES; TGF-BETA FAMILY; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; CYCLOPHILIN-A; FK506-BINDING PROTEIN; TRANSCRIPTION FACTOR; PROLYL ISOMERASE	FKBP12 is a ubiquitous and a highly conserved prolyl isomerase that binds the immunosuppressive drugs FK506 and rapamycin, Members of the FKBP12 family have been implicated in many processes that include intracellular protein folding, transport, and assembly. In the budding yeast Saccharomyces cerevisiae and in human T cells, rapamycin forms a complex with FKBP12 that inhibits cell cycle progression by inhibition of the TOR kinases, We reported previously that rapamycin does not inhibit the vegetative growth of the fission yeast Schizosaccharomyces pombe; however, it specifically inhibits its sexual development. Here we show that disruption of the S, pombe FKBP12 homolog, fkh1(+), at its chromosomal locus results in a mating-deficient phenotype that is highly similar to that obtained by treatment of wild type cells with rapamycin, A screen for fkh1 mutants that can confer rapamycin resistance identified five amino acids in Fkh1 that are critical for the effect of rapamycin in S, pombe, All five amino acids are located in the putative rapamycin binding pocket. Together, our findings indicate that Fkh1 has an important role in sexual development and serves as the target for rapamycin action in S. pombe.	Tel Aviv Univ, Fac Life Sci, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel	Tel Aviv University	Weisman, R (corresponding author), Tel Aviv Univ, Fac Life Sci, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel.	ronitt@post.tau.ac.il	weisman, ronit/D-3741-2016; weisman, ronit/R-6969-2016					Alarcon CM, 1997, MOL CELL BIOL, V17, P5968, DOI 10.1128/MCB.17.10.5968; ATKISON P, 1995, LANCET, V345, P894, DOI 10.1016/S0140-6736(95)90011-X; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Cardenas ME, 1999, CLIN MICROBIOL REV, V12, P583, DOI 10.1128/CMR.12.4.583; CARDENAS ME, 1994, EMBO J, V13, P5944, DOI 10.1002/j.1460-2075.1994.tb06940.x; Cardenas ME, 1998, TRENDS BIOTECHNOL, V16, P427, DOI 10.1016/S0167-7799(98)01239-6; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; CLIPSTONE NA, 1993, ANN NY ACAD SCI, V696, P20; COSTELLO G, 1986, CURR GENET, V11, P119, DOI 10.1007/BF00378203; Davey J, 1998, YEAST, V14, P1529, DOI 10.1002/(SICI)1097-0061(199812)14:16<1529::AID-YEA357>3.0.CO;2-0; DEMARTIN R, 1990, NUCLEIC ACIDS RES, V18, P4917, DOI 10.1093/nar/18.16.4917; DEVOTI J, 1991, EMBO J, V10, P3759, DOI 10.1002/j.1460-2075.1991.tb04945.x; Dolinski K, 1997, P NATL ACAD SCI USA, V94, P13093, DOI 10.1073/pnas.94.24.13093; Dolinski K, 1997, MOL BIOL CELL, V8, P2267, DOI 10.1091/mbc.8.11.2267; Dolinski KJ, 1999, GENETICS, V151, P935; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; FROMANT M, 1995, ANAL BIOCHEM, V224, P347, DOI 10.1006/abio.1995.1050; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Gothel SF, 1999, CELL MOL LIFE SCI, V55, P423, DOI 10.1007/s000180050299; Hall MN, 1996, BIOCHEM SOC T, V24, P234, DOI 10.1042/bst0240234; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Himukai R, 1999, J BIOCHEM, V126, P879, DOI 10.1093/oxfordjournals.jbchem.a022530; Huse M, 1999, CELL, V96, P425, DOI 10.1016/S0092-8674(00)80555-3; Ivery MTG, 2000, MED RES REV, V20, P452, DOI 10.1002/1098-1128(200011)20:6<452::AID-MED2>3.0.CO;2-6; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; Kato T, 1996, FEBS LETT, V378, P207, DOI 10.1016/0014-5793(95)01442-X; KE HM, 1991, P NATL ACAD SCI USA, V88, P9483, DOI 10.1073/pnas.88.21.9483; KE HM, 1992, J MOL BIOL, V228, P539, DOI 10.1016/0022-2836(92)90841-7; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Kunz J, 2000, MOL MICROBIOL, V37, P1480, DOI 10.1046/j.1365-2958.2000.02105.x; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LORENZ MC, 1995, J BIOL CHEM, V270, P27531, DOI 10.1074/jbc.270.46.27531; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MOCHIZUKI N, 1992, MOL GEN GENET, V233, P17, DOI 10.1007/BF00587556; MORENO S, 1991, METHOD ENZYMOL, V194, P795; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PRENTICE HL, 1992, NUCLEIC ACIDS RES, V20, P621, DOI 10.1093/nar/20.3.621; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; SCHONBRUNNER ER, 1991, J BIOL CHEM, V266, P3630; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; Shou WN, 1998, NATURE, V391, P489, DOI 10.1038/35146; Snaith HA, 1999, GENETICS, V152, P839; Takeda T, 1995, EMBO J, V14, P6193, DOI 10.1002/j.1460-2075.1995.tb00310.x; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; TIMERMAN AP, 1995, J BIOL CHEM, V270, P2451, DOI 10.1074/jbc.270.6.2451; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; TROPSCHUG M, 1990, NATURE, V346, P674, DOI 10.1038/346674a0; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; Weisman R, 1996, EMBO J, V15, P447, DOI 10.1002/j.1460-2075.1996.tb00377.x; Weisman R, 2001, J BIOL CHEM, V276, P7027, DOI 10.1074/jbc.M010446200; Weisman R, 1997, J BACTERIOL, V179, P6325, DOI 10.1128/jb.179.20.6325-6334.1997; YANG WM, 1995, J BIOL CHEM, V270, P15187, DOI 10.1074/jbc.270.25.15187; Yao DY, 2000, J BIOL CHEM, V275, P13149, DOI 10.1074/jbc.275.17.13149; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	68	39	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24736	24742		10.1074/jbc.M102090200	http://dx.doi.org/10.1074/jbc.M102090200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11335722	hybrid			2022-12-25	WOS:000169800700044
J	Liang, JS; Ginsberg, HN				Liang, JS; Ginsberg, HN			Microsomal triglyceride transfer protein binding and lipid transfer activities are independent of each other, but both are required for secretion of apolipoprotein B lipoproteins from liver cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; ABETALIPOPROTEINEMIA GENE; ENDOPLASMIC-RETICULUM; DISULFIDE-ISOMERASE; AMINO-TERMINUS; HEPG2 CELLS; DEGRADATION; B100; INHIBITION; RESPONSIVENESS	Recent studies indicate that microsomal triglyceride transfer protein (MTP) and apolipoprotein B (apoB) interact physically via two specific binding sites located within the amino-terminal globular region of apoB100. The first site is thought to be within the first 5.8% of the amino-terminal sequence, and the second site is between 9 and 16% of the amino-terminal sequence. It is not clear from prior studies whether these sites have unique or overlapping functions. Furthermore, there are no data differentiating between lipid transfer and potential chaperone functions of MTP. In the present study we have attempted to further characterize the physiologic interaction between apoB and MTP and to determine the relationship between the binding and lipid transfer aspects of the interaction. HepG2 cells were transiently transfected with apoB cDNAs, and MTP binding to apoB polypeptides was determined by two-step immunoprecipitation. MTP bound equally well to apoB polypeptides with (apoB13, 1.6, beta, apoB34, and apoB42) or without (apoB16, apoB13, and 16 or apoB13, 13, and 16) beta sheet domains. When proteasomal degradation of newly synthesized apoB polypeptides was blocked, MTP binding to all of the apoB polypeptides was only modestly affected by lipid availability and was independent of MTP-associated lipid transfer. Furthermore, MTP did not bind directly to a portion of the first 13 sheet domain. We created two apoB constructs (apoB16(del) and apoB34(del)) by deleting the first 210 amino acids of apoB16 and apoB34. These apoB polypeptides, therefore, lacked the putative first MTP binding site. MTP binding to apoB16(del) and apoB34(del) was decreased significantly. However, the secretion of apoB16(del) was not different from apoB16, whereas the secretion of apoB34(del) was impaired significantly. Our results indicate that the interact-ion between MTP and apoB involves independent binding and lipid transfer activities but that both activities are required for the secretion of apolipoprotein B from liver cells.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Columbia University	Ginsberg, HN (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St, New York, NY 10032 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055638, T32HL007343] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55638, T32HL07343] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bakillah A, 1998, BIOCHEMISTRY-US, V37, P3727, DOI 10.1021/bi972629t; Bakillah A, 2000, BIOCHEMISTRY-US, V39, P4892, DOI 10.1021/bi9924009; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; BOREN J, 1994, J BIOL CHEM, V269, P25879; Bradbury P, 1999, J BIOL CHEM, V274, P3159, DOI 10.1074/jbc.274.5.3159; Chang BHJ, 1999, J BIOL CHEM, V274, P6051, DOI 10.1074/jbc.274.10.6051; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; DIXON JL, 1993, J LIPID RES, V34, P167; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; Haghpassand M, 1996, J LIPID RES, V37, P1468; HEINEMANN T, 1994, J LIPID RES, V35, P2200; Huang XF, 1997, J BIOL CHEM, V272, P31872, DOI 10.1074/jbc.272.50.31872; Hussain MM, 1998, J BIOL CHEM, V273, P25612, DOI 10.1074/jbc.273.40.25612; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; Liang JS, 1998, J BIOL CHEM, V273, P35216, DOI 10.1074/jbc.273.52.35216; Mann CJ, 1999, J MOL BIOL, V285, P391, DOI 10.1006/jmbi.1998.2298; McLeod RS, 1996, J BIOL CHEM, V271, P18445, DOI 10.1074/jbc.271.31.18445; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SWIFT LL, 1995, J LIPID RES, V36, P395; Taghibiglou C, 2000, J BIOL CHEM, V275, P8416, DOI 10.1074/jbc.275.12.8416; Tietge UJF, 1999, J LIPID RES, V40, P2134; Tran K, 1998, J BIOL CHEM, V273, P7244, DOI 10.1074/jbc.273.13.7244; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; WETTERAU JR, 1985, CHEM PHYS LIPIDS, V38, P205, DOI 10.1016/0009-3084(85)90068-4; WETTERAU JR, 1986, BIOCHIM BIOPHYS ACTA, V875, P610, DOI 10.1016/0005-2760(86)90084-6; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	37	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28606	28612		10.1074/jbc.M100294200	http://dx.doi.org/10.1074/jbc.M100294200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11358959	hybrid			2022-12-25	WOS:000170093400114
J	Wang, XT; McCullough, KD; Wang, XJ; Carpenter, G; Holbrook, NJ				Wang, XT; McCullough, KD; Wang, XJ; Carpenter, G; Holbrook, NJ			Oxidative stress-induced phospholipase C-gamma l activation enhances cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE; FACTOR RECEPTOR; HYDROGEN-PEROXIDE; PROTEIN-KINASE; SIGNALING PATHWAYS; INDUCED APOPTOSIS; PHOSPHORYLATION; SRC; C-GAMMA-1	Phospholipase C-gamma1 (PLC-gamma1) is rapidly activated in response to growth factor stimulation and plays an important role in regulating cell proliferation and differentiation through the generation of the second messengers diacylglycerol and inositol 1,4,5-trisphosphate, leading to the activation of protein kinase C (PKC) and increased levels of intracellular calcium, respectively. Given the existing overlap between signaling pathways that are activated in response to oxidant injury and those involved in responding to proliferative stimuli, we investigated the role of PLC-gamma1 during the cellular response to oxidative stress. Treatment of normal mouse embryonic fibroblasts (MEF) with H2O2 resulted in time- and concentration-dependent tyrosine phosphorylation of PLC-gamma1. Phosphorylation could be blocked by pharmacological inhibitors of Src family tyrosine kinases or the epidermal growth factor receptor tyrosine kinase, but not by inhibitors of the platelet-derived growth factor receptor or phosphatidylinositol 3-kinase. To investigate the physiologic relevance of H2O2-induced tyrosine phosphorylation of PLC-gamma1, we compared survival of normal MEF and PLC-gamma1-deficient MEF following exposure to H2O2. Treatment of PLC-gamma1-deficient MEF with H2O2 resulted in rapid cell death, whereas normal MEF were resistant to the stress. Pretreatment of normal MEF with a selective pharmacological inhibitor of PLC-gamma1, or inhibitors of inositol trisphosphate receptors and PKC, increased their sensitivity to H2O2, whereas treatment of PLC-gamma1-deficient MEF with agents capable of directly activating PKC and enhancing calcium mobilization significantly improved their survival. Finally, reconstitution of PLC-gamma1 protein expression in PLC-gamma1-deficient MEF restored cell survival following H2O2 treatment. These findings suggest an important protective function for PLC-gamma1 activation during the cellular response to oxidative stress.	NIA, Cell Stress & Aging Sect, Cellular & Mol Biol Lab, NIH, Baltimore, MD 21224 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Vanderbilt University; Vanderbilt University	Holbrook, NJ (corresponding author), NIA, Cell Stress & Aging Sect, Cellular & Mol Biol Lab, NIH, Box 12,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.				NATIONAL CANCER INSTITUTE [R01CA075195] Funding Source: NIH RePORTER; NCI NIH HHS [CA75195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Barker SA, 1998, MOL BIOL CELL, V9, P483, DOI 10.1091/mbc.9.2.483; BLAKE RA, 1993, BIOCHEM J, V290, P471, DOI 10.1042/bj2900471; Bridges AJ, 1996, J MED CHEM, V39, P267, DOI 10.1021/jm9503613; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Chen W, 1998, MOL CELL BIOL, V18, P5178, DOI 10.1128/MCB.18.9.5178; Cotgreave I A, 1997, Adv Pharmacol, V38, P205; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Ji GS, 1998, MOL BIOL CELL, V9, P749, DOI 10.1091/mbc.9.4.749; Ji QS, 1999, MOL CELL BIOL, V19, P4961; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; Khare S, 1997, J CLIN INVEST, V99, P1831, DOI 10.1172/JCI119350; Kim H, 2000, J BIOL CHEM, V275, P18266, DOI 10.1074/jbc.275.24.18266; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Klotz LO, 2000, BIOCHEM J, V352, P219, DOI 10.1042/0264-6021:3520219; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Lee YH, 1999, BBA-MOL CELL BIOL L, V1440, P235, DOI 10.1016/S1388-1981(99)00128-6; Lee YH, 2000, LIFE SCI, V67, P827, DOI 10.1016/S0024-3205(00)00677-9; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LIAO F, 1993, BIOCHEM BIOPH RES CO, V191, P1028, DOI 10.1006/bbrc.1993.1320; Liao HJ, 2001, J BIOL CHEM, V276, P8627, DOI 10.1074/jbc.C100030200; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; QIN SF, 1995, BIOCHEM J, V308, P347, DOI 10.1042/bj3080347; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; Rao GN, 1996, ONCOGENE, V13, P713; RHEE SG, 1992, J BIOL CHEM, V267, P12393; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; Wagner BA, 2000, J BIOL CHEM, V275, P22461, DOI 10.1074/jbc.M001434200; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706; Zanella CL, 1996, CANCER RES, V56, P5334	40	126	128	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28364	28371		10.1074/jbc.M102693200	http://dx.doi.org/10.1074/jbc.M102693200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11350969	hybrid			2022-12-25	WOS:000170093400083
J	Kabayama, K; Ito, N; Honke, K; Igarashi, Y; Inokuchi, J				Kabayama, K; Ito, N; Honke, K; Igarashi, Y; Inokuchi, J			Suppression of integrin expression and tumorigenicity by sulfation of lactosylceramide in 3LL Lewis lung carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBRONECTIN RECEPTOR; RENAL-CANCER CELLS; CEREBROSIDE SULFOTRANSFERASE; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; RAT-BRAIN; SYNTHASE; SURFACE; PROTEIN; GLYCOSPHINGOLIPIDS	To investigate the cellular functions of sulfated glycosphingolipids, we introduced the cerebroside sulfotransferase (CST) gene into J5 cells, a subclone of 3LL, Lewis lung carcinoma cells. The J5 cells lack acidic glycosphingolipids but accumulate their common biosynthetic precursor, lactosylceramide. We established the stable CST transfectants, J5/CST-1 and J5/CST-2 clones, highly expressing sulfated lactosylceramide (SM3). Both clones exhibited more spherical morphology in comparison to mock transfectant, and their adhesiveness to fibronectin and laminin was significantly lower. The loss of cell-substratum interactions in these SM3-expressing cells could be attributed to decreased expression of integrins (alpha (5), alpha (6), and beta (1)) on the cell surface and their whole cellular levels. However, the levels of H-2K(b) and H-2D(b) antigens remained unchanged. Reverse transcriptase-polymerase chain reaction and Northern blot analyses for these integrins exhibited significant decrease of beta (1) gene expression in J5/CST-1 and 2, but there was no change in the levels of alpha (5) and alpha (6) transcripts. Deglycosylation by endoglycosidase H treatment clearly demonstrated that the precursor form of beta (1) integrin, possessing high mannose oligosaccharide chains, was preferentially decreased in the CST transfectants. These results demonstrate that endogenous SM3 negatively regulates beta (1) integrin expression at the transcriptional level, and the decrease of alpha integrin proteins in the CST transfectants was due to the posttranscriptional modification. We suggest the putative importance of the intracellular pre-beta (1) integrin pool for normal integrin maturation and subsequent function. Although the rates of cell proliferation in vitro for mock and CST transfectants were similar, tumorigenicity of J5/ CST-1 and -2 cells inoculated into syngeneic C57/BL6 mice was greatly decreased or even absent. This was probably due to global loss of the efficient cell-matrix interactions, which are essential for the development of malignant tumors in vivo. Thus, we showed the evidence that cellular SM3 negatively regulates the cell substratum interaction, resulting in the loss of tumorigenicity.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan	Hokkaido University; Osaka University	Inokuchi, J (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Kita Ku, Kita 12 jo,Nishi 6 chome, Sapporo, Hokkaido 0600812, Japan.		Kabayama, Kazuya/ABD-5748-2020; Inokuchi, Jin-ichi/AAW-9964-2020	Kabayama, Kazuya/0000-0002-7583-5454; Inokuchi, Jin-ichi/0000-0002-0703-5746				AKIYAMA SK, 1989, J BIOL CHEM, V264, P18011; AKIYAMA SK, 1987, J BIOL CHEM, V262, P17536; BENJAMINS JA, 1982, J NEUROCHEM, V38, P233, DOI 10.1111/j.1471-4159.1982.tb10875.x; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; BERDITCHEVSKI F, 1995, J BIOL CHEM, V270, P17784, DOI 10.1074/jbc.270.30.17784; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Chester MA, 1997, PURE APPL CHEM, V69, P2475, DOI 10.1351/pac199769122475; Claas C, 2001, J BIOL CHEM, V276, P7974, DOI 10.1074/jbc.M008650200; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; Cornish-Bowden A, 1998, CARBOHYD RES, V312, P167; Frank M, 1998, J NEUROSCI, V18, P4901; FUJITA S, 1992, JPN J CANCER RES, V83, P1317, DOI 10.1111/j.1349-7006.1992.tb02764.x; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Gong JG, 1997, CELL GROWTH DIFFER, V8, P83; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HEINO J, 1989, J BIOL CHEM, V264, P380; Hirahara Y, 2000, EUR J BIOCHEM, V267, P1909, DOI 10.1046/j.1432-1327.2000.01139.x; HIRAIWA N, 1990, CANCER RES, V50, P2917; Honke K, 1996, J BIOCHEM-TOKYO, V119, P421; Honke K, 1997, J BIOL CHEM, V272, P4864, DOI 10.1074/jbc.272.8.4864; Honke K, 2001, J BIOL CHEM, V276, P267, DOI 10.1074/jbc.M005666200; INOKUCHI J, 1993, CLIN EXP METASTAS, V11, P27, DOI 10.1007/BF00880063; INOKUCHI J, 2000, GLYCOCONJ J, V17, P1; Ishii A, 1998, J BIOL CHEM, V273, P31652, DOI 10.1074/jbc.273.48.31652; Ishizuka I, 1997, PROG LIPID RES, V36, P245, DOI 10.1016/S0163-7827(97)00011-8; JASPERS M, 1988, FEBS LETT, V231, P402, DOI 10.1016/0014-5793(88)80859-7; Keusch JJ, 2000, J BIOL CHEM, V275, P25308, DOI 10.1074/jbc.M002629200; Keusch JJ, 2000, J BIOL CHEM, V275, P25315, DOI 10.1074/jbc.M002630200; Kim LT, 1997, P SOC EXP BIOL MED, V214, P123; KOBATA A, 1979, ANAL BIOCHEM, V100, P1, DOI 10.1016/0003-2697(79)90102-7; KOBAYASHI T, 1993, BRIT J CANCER, V67, P76, DOI 10.1038/bjc.1993.12; KOBAYASHI T, 1994, INT J CANCER, V56, P281, DOI 10.1002/ijc.2910560223; KOIVISTO L, 1994, BIOCHEM J, V300, P771, DOI 10.1042/bj3000771; Kojima Y, 2000, J BIOL CHEM, V275, P15152, DOI 10.1074/jbc.M909620199; LENTER M, 1994, J BIOL CHEM, V269, P12263; Mannion BA, 1996, J IMMUNOL, V157, P2039; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; Ono M, 2000, BIOCHEM BIOPH RES CO, V279, P744, DOI 10.1006/bbrc.2000.4030; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; Radford KJ, 1996, BIOCHEM BIOPH RES CO, V222, P13, DOI 10.1006/bbrc.1996.0690; ROBERTS DD, 1988, ARCH BIOCHEM BIOPHYS, V267, P405, DOI 10.1016/0003-9861(88)90046-X; SACCHI A, 1989, CANCER RES, V49, P2615; SheikhHamad D, 1997, AM J PHYSIOL-CELL PH, V273, pC902, DOI 10.1152/ajpcell.1997.273.3.C902; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SLUPSKY JR, 1989, J BIOL CHEM, V264, P12289; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; Stroeken PJM, 1998, CANCER RES, V58, P1569; Svennerholm L, 1980, Adv Exp Med Biol, V125, P11; Svineng G, 1999, J CELL SCI, V112, P4751; Tachibana I, 1997, J BIOL CHEM, V272, P29181, DOI 10.1074/jbc.272.46.29181; TADANO K, 1979, BIOCHIM BIOPHYS ACTA, V575, P421; TAKI T, 1994, ANAL BIOCHEM, V221, P312, DOI 10.1006/abio.1994.1418; TENNEKOON G, 1983, J CELL BIOL, V97, P1107, DOI 10.1083/jcb.97.4.1107; Togayachi A, 2001, J BIOL CHEM, V276, P22032, DOI 10.1074/jbc.M011369200; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97	56	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26777	26783		10.1074/jbc.M100428200	http://dx.doi.org/10.1074/jbc.M100428200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11352905	hybrid			2022-12-25	WOS:000169966900008
J	Kupke, T				Kupke, T			Molecular characterization of the 4 '-phosphopantothenoylcysteine decarboxylase domain of bacterial Dfp flavoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; OXIDATIVE DECARBOXYLATION; PURIFICATION; BIOSYNTHESIS; SUBSTRATE; PROTEINS; ATHAL3; GENE	The NH2-terminal domain of the bacterial flavoprotein Dfp catalyzes the decarboxylation of (R)-4'-phospho-N-pantothenoylcysteine to 4'-phosphopantetheine, a key step in coenzyme A biosynthesis, Dfp proteins, LanD proteins (for example EpiD, which is involved in epidermin biosynthesis), and the salt tolerance protein AtHAL3a from Arabidopsis thaliana are homooligomeric flavin-containing Cys decarboxylases (HFCD protein family), The crystal structure of the peptidyl-cysteine decarboxylase EpiD complexed with a pentapeptide substrate has recently been determined. The peptide is bound by an NH2-terminal substrate binding helix, residue Asn(117), which contacts the cysteine residue of the substrate, and a COOH-terminal substrate recognition clamp, The conserved motif G-G/S-I-A-X-Y-K of the Dfp proteins aligns partly with the substrate binding helix of EpiD. Point mutations within this motif resulted in loss of coenzyme binding (G14S) or in significant decrease of Dfp activity (G15A, I16L, A17D, K20N, K20Q), Exchange of Asn(125) of Dfp, which corresponds to Asn(117) of EpiD, and exchange of Cys(158), which is within the proposed substrate recognition clamp of Dfp, led to inactivity of the enzyme, Molecular analysis of the conditional lethality of the Escherichia coli dfp-707 mutant revealed that the single point mutation G11D of Dfp is related to decreased amounts of soluble Dfp protein at 37 degreesC.	Univ Tubingen, Lehrstuhl Mikrobielle Genet, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Kupke, T (corresponding author), Univ Tubingen, Lehrstuhl Mikrobielle Genet, Morgenstelle 15, D-72076 Tubingen, Germany.		Zhang, Ning/F-1387-2014	Kupke, Thomas/0000-0003-2341-1710				Albert A, 2000, STRUCTURE, V8, P961, DOI 10.1016/S0969-2126(00)00187-8; Begley TP, 2001, VITAM HORM, V61, P157; Blaesse M, 2000, EMBO J, V19, P6299, DOI 10.1093/emboj/19.23.6299; Espinosa-Ruiz A, 1999, PLANT J, V20, P529, DOI 10.1046/j.1365-313X.1999.00626.x; Geerlof A, 1999, J BIOL CHEM, V274, P27105, DOI 10.1074/jbc.274.38.27105; JACKOWSKI S, 1996, ESCHERICHIA COLI SAL, V1, P687; Kupke T, 2000, J BIOL CHEM, V275, P31838, DOI 10.1074/jbc.M004273200; KUPKE T, 1992, J BACTERIOL, V174, P5354, DOI 10.1128/JB.174.16.5354-5361.1992; KUPKE T, 1994, J BIOL CHEM, V269, P5653; Kupke T, 2001, J BIOL CHEM, V276, P19190, DOI 10.1074/jbc.M100776200; KUPKE T, 1995, J BIOL CHEM, V270, P11282, DOI 10.1074/jbc.270.19.11282; Mishra PK, 2001, J BACTERIOL, V183, P2774, DOI 10.1128/JB.183.9.2774-2778.2001; SCANDURRA R, 1987, FEBS LETT, V212, P79, DOI 10.1016/0014-5793(87)81560-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEVASTOPOULOS CG, 1977, P NATL ACAD SCI USA, V74, P3485, DOI 10.1073/pnas.74.8.3485; SONG WJ, 1992, J BACTERIOL, V174, P6411, DOI 10.1128/JB.174.20.6411-6417.1992; SPITZER ED, 1988, J BACTERIOL, V170, P872, DOI 10.1128/jb.170.2.872-876.1988; SPITZER ED, 1985, J BACTERIOL, V164, P994, DOI 10.1128/JB.164.3.994-1003.1985; Strauss E, 2001, J BIOL CHEM, V276, P13513, DOI 10.1074/jbc.C100033200; VANPOELJE PD, 1990, ANNU REV BIOCHEM, V59, P29, DOI 10.1146/annurev.bi.59.070190.000333	20	30	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27597	27604		10.1074/jbc.M103342200	http://dx.doi.org/10.1074/jbc.M103342200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11358972	hybrid			2022-12-25	WOS:000169966900114
J	Menendez-Arias, L; Abraha, A; Quinones-Mateu, ME; Mas, A; Camarasa, MJ; Arts, EJ				Menendez-Arias, L; Abraha, A; Quinones-Mateu, ME; Mas, A; Camarasa, MJ; Arts, EJ			Functional characterization of chimeric reverse transcriptases with polypeptide subunits of highly divergent HIV-1 group M and O strains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; (-)-STRAND DNA-SYNTHESIS; P51 SUBUNIT; TEMPLATE-PRIMER; NONNUCLEOSIDE INHIBITORS; ANGSTROM RESOLUTION; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; DRUG-RESISTANCE; TSAO	Human immunodeficiency virus (HPV)-1 strains have been divided into three groups: main (M), outlier (O), and non-M non-O (N). Biochemical analyses of HIV-1 reverse transcriptase (RT) have been performed predominantly with enzymes derived from HIV-1 group M:subtype B laboratory strains. This study was designed to optimize the expression and to characterize the enzymatic properties of HIV-1 group O RTs as well as chimeric RTs composed of group M and O p66 and p51 subunits. The DNA-dependent DNA polymerase activity on a short heteropolymeric template-primer was similar with all enzymes, i.e. the HIV-1 group O and M and chimeric RTs. Our data revealed that the 51-kDa subunit in the chimeric heterodimer p66(M:B)/p51(O) confers increased heterodimer stability and partial resistance to non-nucleoside RT inhibitors. Chimeric:RTs (p66(M:B)/p51(O) and p66(O)/p51(M:B)) were unable to initiate reverse transcription from tRNA(3)(Lys) using HIV-1 group O or group M:subtype B RNA templates. In contrast, HIV-1 group O and M RTs supported (-)-strand DNA synthesis from tRNA(3)(Lys) hybridized to any of their corresponding HIV-1 RNA templates. HIV-2 RT could not initiate-reverse transcription on tRNA(3)(Lys)-primed HIV-1 genomic RNA. These findings suggest that the initiation event is conserved between HIV-1 groups, but not HIV types.	Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain; Case Western Reserve Univ, Dept Med, Div Infect Dis, Cleveland, OH 44106 USA; CSIC, Inst Quim Med, E-28006 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Case Western Reserve University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Medica (IQM); CSIC - Instituto de Quimica Organica General (IQOG)	Menendez-Arias, L (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain.		Quinones-Mateu, Miguel/H-3846-2019; Mas, Antonio/F-2505-2011; Camarasa, María-José/B-6340-2015; Camarasa, María-José/N-8845-2019; Menendez Arias, Luis/G-2436-2016; Arias, Luis Menendez/N-7447-2016	Mas, Antonio/0000-0003-2563-570X; Camarasa, María-José/0000-0002-4978-6468; Camarasa, María-José/0000-0002-4978-6468; Arias, Luis Menendez/0000-0002-1251-6640; Arts, Eric/0000-0002-4880-7968; Quinones-Mateu, Miguel/0000-0001-9170-5601	NHLBI NIH HHS [KO1-HL67610-01] Funding Source: Medline; NIAID NIH HHS [R01-AI31147, AI36219] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K01HL067610] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036219, R01AI031147] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amacker M, 1998, J MOL BIOL, V278, P757, DOI 10.1006/jmbi.1998.1739; Arts EJ, 1996, J BIOL CHEM, V271, P9054, DOI 10.1074/jbc.271.15.9054; Arts EJ, 1996, P NATL ACAD SCI USA, V93, P10063, DOI 10.1073/pnas.93.19.10063; Arts EJ, 1998, J BIOL CHEM, V273, P14523, DOI 10.1074/jbc.273.23.14523; ARTS EJ, 1994, J BIOL CHEM, V269, P16571; BALZARINI J, 1993, P NATL ACAD SCI USA, V90, P6952, DOI 10.1073/pnas.90.15.6952; CAMARASA MJ, 1992, J MED CHEM, V35, P2721, DOI 10.1021/jm00093a002; Chiba J, 1996, J GEN VIROL, V77, P2921, DOI 10.1099/0022-1317-77-12-2921; Descamps D, 1997, J VIROL, V71, P8893, DOI 10.1128/JVI.71.11.8893-8898.1997; DIVITA G, 1993, FEBS LETT, V324, P153, DOI 10.1016/0014-5793(93)81383-B; DIVITA G, 1994, J BIOL CHEM, V269, P13080; Divita G, 1995, BIOCHEMISTRY-US, V34, P16337, DOI 10.1021/bi00050a014; Dufour E, 1998, EUR J BIOCHEM, V251, P487, DOI 10.1046/j.1432-1327.1998.2510487.x; Ghosh M, 1996, BIOCHEMISTRY-US, V35, P8553, DOI 10.1021/bi952773j; GOEL R, 1993, BIOCHEMISTRY-US, V32, P13012, DOI 10.1021/bi00211a009; Harris D, 1998, BIOCHEMISTRY-US, V37, P5903, DOI 10.1021/bi9728452; HOTTIGER M, 1994, J BIOL CHEM, V269, P986; HOWARD KJ, 1991, J BIOL CHEM, V266, P23003; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; HUANG SC, 1992, BIOCHEM BIOPH RES CO, V184, P986, DOI 10.1016/0006-291X(92)90688-H; ISEL C, 1993, J BIOL CHEM, V268, P25269; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JACQUES PS, 1994, J BIOL CHEM, V269, P1388; JONCKHEERE H, 1994, J BIOL CHEM, V269, P25255; JOYCE CM, 1995, J BACTERIOL, V177, P6321, DOI 10.1128/jb.177.22.6321-6329.1995; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LOYA S, 1994, AIDS RES HUM RETROV, V10, P939, DOI 10.1089/aid.1994.10.939; MartinHernandez AM, 1996, EMBO J, V15, P4434, DOI 10.1002/j.1460-2075.1996.tb00816.x; MartinHernandez AM, 1997, NUCLEIC ACIDS RES, V25, P1383, DOI 10.1093/nar/25.7.1383; Mas A, 2000, EMBO J, V19, P5752, DOI 10.1093/emboj/19.21.5752; Menendez-Arias L, 1998, BIOCHEMISTRY-US, V37, P16636, DOI 10.1021/bi981830g; MISHIMA Y, 1995, EMBO J, V14, P2679, DOI 10.1002/j.1460-2075.1995.tb07266.x; MULLER B, 1991, J BIOL CHEM, V266, P14709; Palmer S, 1998, AIDS RES HUM RETROV, V14, P157, DOI 10.1089/aid.1998.14.157; PEREZPEREZ MJ, 1992, J MED CHEM, V35, P2988, DOI 10.1021/jm00094a009; PEREZPEREZ MJ, 1992, TETRAHEDRON LETT, V33, P3029, DOI 10.1016/S0040-4039(00)79591-8; Quinones-Mateu ME, 1998, J VIROL, V72, P9002; QuinonesMateu ME, 1997, VIROLOGY, V236, P364, DOI 10.1006/viro.1997.8748; QUINONESMATEU ME, 2000, AIDS REV, V2, P190; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; Sluis-Cremer N, 2000, BIOCHEMISTRY-US, V39, P1427, DOI 10.1021/bi991682+; Tachedjian G, 2000, P NATL ACAD SCI USA, V97, P6334, DOI 10.1073/pnas.97.12.6334; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WANG J, 1994, P NATL ACAD SCI USA, V91, P7242, DOI 10.1073/pnas.91.15.7242; Wohrl BM, 1997, J BIOL CHEM, V272, P17581, DOI 10.1074/jbc.272.28.17581; Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11	48	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27470	27479		10.1074/jbc.M104342200	http://dx.doi.org/10.1074/jbc.M104342200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11353775	hybrid			2022-12-25	WOS:000169966900098
J	Grundmann, O; Mosch, HU; Braus, GH				Grundmann, O; Mosch, HU; Braus, GH			Repression of GCN4 mRNA translation by nitrogen starvation in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID BIOSYNTHETIC GENES; EXCHANGE FACTOR EIF2B; PROTEIN-KINASE; TRANSFER-RNA; TRANSCRIPTIONAL ACTIVATOR; CATABOLITE REPRESSION; PSEUDOHYPHAL DIFFERENTIATION; INVASIVE GROWTH; AMINO-ACIDS; YEAST	Saccharomyces cerevisiae activates a regulatory network called "general control" that provides the cell with sufficient amounts of protein precursors during amino acid starvation, We investigated how starvation for nitrogen affects the general control regulatory system, because amino acid biosynthesis is part of nitrogen metabolism. Amino acid limitation results in the synthesis of the central transcription factor Gcn4p, which binds to specific DNA-binding motif sequences called Gcn4-protein-responsive elements (GCREs) that are present in the promoter regions of its target genes. Nitrogen starvation increases GCN4 transcription but efficiently represses expression of both a synthetic GCRE6::lacZ reporter gene and the natural amino acid biosynthetic gene ARO4. Repression of Gcn4p-regulated transcription by nitrogen starvation is independent of the ammonium sensing systems that include Mep2p and Gpa2p or Ure2p and Gln3p but depends on the four upstream open reading frames in the GCN4 mRNA leader sequence. Efficient translation of GCN4 mRNA is completely blocked by nitrogen starvation, even when cells are simultaneously starved for amino acids and eukaryotic initiation factor-2 alpha is fully phosphorylated by Gcn2p. Our data suggest that nitrogen starvation regulates translation of GCN4 by a novel mechanism that involves the four upstream open reading frames but that still acts independently of eukaryotic initiation factor-2 alpha phosphorylation by Gcn2p.	Univ Gottingen, Inst Microbiol & Genet, D-37077 Gottingen, Germany	University of Gottingen	Braus, GH (corresponding author), Univ Gottingen, Inst Microbiol & Genet, Grisebachstr 8, D-37077 Gottingen, Germany.	gbraus@gwdg.de	Braus, Gerhard/ABC-6293-2021; Braus, Gerhard H/G-3999-2012	Braus, Gerhard/0000-0002-3117-5626; Braus, Gerhard H/0000-0002-3117-5626				Albrecht G, 1998, J BIOL CHEM, V273, P12696, DOI 10.1074/jbc.273.21.12696; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUS G, 1989, EMBO J, V8, P939, DOI 10.1002/j.1460-2075.1989.tb03455.x; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DRYSDALE CM, 1995, MOL CELL BIOL, V15, P1220, DOI 10.1128/MCB.15.3.1220; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; Erdman S, 1998, J CELL BIOL, V140, P461, DOI 10.1083/jcb.140.3.461; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; HANNIG EM, 1988, MOL CELL BIOL, V8, P4808, DOI 10.1128/MCB.8.11.4808; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; Hinnebusch A. G., 1992, MOL CELLULAR BIOL YE, P319, DOI DOI 10.1016/J.ACA.2008.01.060; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HINNEBUSCH AG, 1990, PROG NUCLEIC ACID RE, V38, P195; HINNEBUSCH AG, 1985, MOL CELL BIOL, V5, P2349, DOI 10.1128/MCB.5.9.2349; HINNEBUSCH AG, 1992, MOL CELLULAR BIOL YE, V3, P319; Hoffmann B, 1999, MOL MICROBIOL, V31, P807, DOI 10.1046/j.1365-2958.1999.01219.x; Hofman-Bang J, 1999, MOL BIOTECHNOL, V12, P35, DOI 10.1385/MB:12:1:35; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; Kubler E, 1997, J BIOL CHEM, V272, P20321, DOI 10.1074/jbc.272.33.20321; KUNZLER M, 1992, GENE, V113, P67, DOI 10.1016/0378-1119(92)90670-K; Lorenz MC, 1998, GENETICS, V150, P1443; Lorenz MC, 1997, EMBO J, V16, P7008, DOI 10.1093/emboj/16.23.7008; Lorenz MC, 1998, EMBO J, V17, P1236, DOI 10.1093/emboj/17.5.1236; Marini AM, 1997, MOL CELL BIOL, V17, P4282, DOI 10.1128/MCB.17.8.4282; MEUSSDOERFFER F, 1983, J BIOL CHEM, V258, P6293; MIRANDE M, 1988, J BIOL CHEM, V263, P18443; Mosch HU, 1999, MOL BIOL CELL, V10, P1325, DOI 10.1091/mbc.10.5.1325; MOSCH HU, 1990, EMBO J, V9, P2951, DOI 10.1002/j.1460-2075.1990.tb07487.x; MOSCH HU, 1991, J BIOL CHEM, V266, P20453; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; Pavitt GD, 1997, MOL CELL BIOL, V17, P1298, DOI 10.1128/MCB.17.3.1298; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; ROSE M, 1983, METHOD ENZYMOL, V101, P167; ROUSSOU I, 1988, MOL CELL BIOL, V8, P2132, DOI 10.1128/MCB.8.5.2132; Schnappauf G, 1997, P NATL ACAD SCI USA, V94, P8491, DOI 10.1073/pnas.94.16.8491; SIKORSKI RS, 1989, GENETICS, V122, P19; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Stanhill A, 1999, MOL CELL BIOL, V19, P7529; ter Schure EG, 2000, FEMS MICROBIOL REV, V24, P67, DOI 10.1016/S0168-6445(99)00030-3; THIREOS G, 1984, P NATL ACAD SCI-BIOL, V81, P5096, DOI 10.1073/pnas.81.16.5096; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; WEK SA, 1995, MOL CELL BIOL, V15, P4497; WENZEL TJ, 1995, NUCLEIC ACIDS RES, V23, P883, DOI 10.1093/nar/23.5.883; WIAME JM, 1985, ADV MICROB PHYSIOL, V26, P1, DOI 10.1016/S0065-2911(08)60394-X; Yang RJ, 2000, MOL CELL BIOL, V20, P2706, DOI 10.1128/MCB.20.8.2706-2717.2000; Yang WM, 1996, MOL CELL BIOL, V16, P6603	51	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25661	25671		10.1074/jbc.M101068200	http://dx.doi.org/10.1074/jbc.M101068200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11356835	hybrid			2022-12-25	WOS:000169823300006
J	Ngo, TH; Hoylaerts, MF; Knockaert, I; Brouwers, E; Declerck, PJ				Ngo, TH; Hoylaerts, MF; Knockaert, I; Brouwers, E; Declerck, PJ			Identification of a target site in plasminogen activator inhibitor-1 that allows neutralization of its inhibitory properties concomitant with an allosteric up-regulation of its antiadhesive properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; CELL-ADHESION; BIOLOGICAL SAMPLES; BINDING DOMAIN; VITRONECTIN; PAI-1; MIGRATION; TYPE-1; PURIFICATION; LOCALIZATION	The serpin plasminogen activator inhibitor-1 (PAI-1) has a dual function: 1) it plays an important role as a direct inhibitor of the plasminogen activation system, and 2) its interaction with the adhesive glycoprotein vitronectin suggests a role in tissue remodeling and metastasis, independent from its proteinase inhibitory properties. Unique to this serpin is the close association between its conformational and functional properties. Indeed, PAI-1 can occur in an active and a latent conformation, but both functions are exclusively present in the active conformation. We report here the epitope localization and functional effects of a monoclonal antibody (MA-124K1) that inhibits rat PAI-1 activity and simultaneously increases the binding of inactive PAI-1 to vitronectin (the affinity constant of PAI-1 for vitronectin is 2 x 10(7) M-1 in the absence of MA-124K1 and 160 x 10(7) M-1 in the presence of MA-124K1). To the best of our knowledge, this is the first monoclonal antibody dissociating the proteinase inhibitory properties from the vitronectin binding properties in PAI-1. Mutation of Glu(212) and/or Glu(220) in rat PAI-1 to Ala results in a strongly reduced affinity or absence of binding to MA-124K1. The three-dimensional structure of PAI-1 reveals that these residues constitute a conformational epitope close to the reactive-site loop and compatible with the effect of MA-124K1 on the inhibitory properties of PAI-1, However, the vitronectin binding site is localized at the opposite site of the molecule, indicating that the effect of MA-124K1 involves an allosteric modulation of the vitronectin binding site. Cell culture experiments revealed a significant reduction of cell attachment and migration in the presence of MA-124K1, providing evidence for the functional relevance of this antibody-mediated up-regulation of the vitronectin binding properties of PAI-1. In conclusion, a novel mechanism for interference with PAI-1 functions has been identified and is of importance in the modulation of cell migration and related events (e.g, tumor metastasis).	Katholieke Univ Leuven, Lab Pharmaceut Biol & Phytopharmacol, Fac Pharmaceut Sci, B-3000 Louvain, Belgium; Catholic Univ Louvain, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium	KU Leuven; Universite Catholique Louvain	Declerck, PJ (corresponding author), Katholieke Univ Leuven, Lab Pharmaceut Biol & Phytopharmacol, Fac Pharmaceut Sci, Van Evenstr 4, B-3000 Louvain, Belgium.	paul.declerck@farm.kuleuven.ac.be	Declerck, Paul J/A-2330-2017	Declerck, Paul J/0000-0003-1259-9105; Hoylaerts, Marc/0000-0002-6474-3933				Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Bijnens AP, 2000, J BIOL CHEM, V275, P6375, DOI 10.1074/jbc.275.9.6375; Bijnens AP, 1997, THROMB HAEMOSTASIS, V77, P350; Bijnens AP, 2001, THROMB HAEMOSTASIS, V85, P866; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; CHERVITZ SA, 1995, J BIOL CHEM, V270, P24043, DOI 10.1074/jbc.270.41.24043; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEBROCK S, 1995, FEBS LETT, V376, P243, DOI 10.1016/0014-5793(95)01289-0; Debrock S, 1998, THROMB HAEMOSTASIS, V79, P597; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; DECLERCK PJ, 1994, J INTERN MED, V236, P425, DOI 10.1111/j.1365-2796.1994.tb00820.x; FA M, 1995, BIOCHEMISTRY-US, V34, P13833, DOI 10.1021/bi00042a015; Gils A, 1996, BIOCHEMISTRY-US, V35, P7474, DOI 10.1021/bi960079d; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONSSON U, 1993, ANN BIOL CLIN-PARIS, V51, P19; Kjoller L, 1997, EXP CELL RES, V232, P420, DOI 10.1006/excr.1997.3540; Kumar R, 1999, J BIOL CHEM, V274, P24737, DOI 10.1074/jbc.274.35.24737; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; Lawrence DA, 1997, J BIOL CHEM, V272, P7676, DOI 10.1074/jbc.272.12.7676; Loskutoff DJ, 1999, APMIS, V107, P54, DOI 10.1111/j.1699-0463.1999.tb01526.x; Morshauser RC, 1999, J MOL BIOL, V289, P1387, DOI 10.1006/jmbi.1999.2776; Nar H, 2000, J MOL BIOL, V297, P683, DOI 10.1006/jmbi.2000.3604; Ngo TH, 1999, THROMB HAEMOSTASIS, V82, P1510; Ngo TH, 1998, FIBRINOLYSIS PROTEOL, V12, P335, DOI 10.1016/S0268-9499(98)80390-1; Ngo TH, 1998, THROMB HAEMOSTASIS, V79, P808, DOI 10.1055/s-0037-1615069; Ngo TH, 1997, FIBRINOLYSIS PROTEOL, V11, P37, DOI 10.1016/S0268-9499(97)80007-0; Oosterhof GON, 1997, EUR UROL, V32, P91, DOI 10.1159/000480887; PADMANABHAN J, 1995, THROMB HAEMOSTASIS, V73, P829; SEIFFERT D, 1991, P NATL ACAD SCI USA, V88, P9402, DOI 10.1073/pnas.88.21.9402; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; Seiffert D, 1997, J BIOL CHEM, V272, P13705, DOI 10.1074/jbc.272.21.13705; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Sugiura Y, 1999, CANCER RES, V59, P1327; VANMEIJER M, 1994, FEBS LETT, V352, P342, DOI 10.1016/0014-5793(94)00990-2; Wiman B, 1999, SCAND J CLIN LAB INV, V59, P23; WIMAN B, 1988, FEBS LETT, V242, P125, DOI 10.1016/0014-5793(88)80999-2	36	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26243	26248		10.1074/jbc.M008241200	http://dx.doi.org/10.1074/jbc.M008241200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11342530	hybrid			2022-12-25	WOS:000169823300081
J	Shimizu, K; Chiba, S; Saito, T; Kumano, K; Takahashi, T; Hirai, H				Shimizu, K; Chiba, S; Saito, T; Kumano, K; Takahashi, T; Hirai, H			Manic fringe and lunatic fringe modify different sites of the Notch2 extracellular region, resulting in different signaling modulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APICAL ECTODERMAL RIDGE; HUMAN JAGGED1; LIGAND; HOMOLOG; GENE; EXPRESSION; DELTA; SERRATE; GLYCOSYLTRANSFERASE; MUTATIONS	Three mammalian fringe proteins are implicated in controlling Notch activation by Delta/Serrate/Lag2 ligands during tissue boundary formation, It was proved recently that they are glycosyltransferases that initiate elongation of O-linked fucose residues attached to epidermal growth factor-like sequence repeats in the extracellular domain of Notch molecules. Here we demonstrate the existence of functional diversity among the mammalian fringe proteins. Although both manic fringe (mFng) and lunatic fringe (1Fng) decreased the binding of Jagged1 to Notch2 and not that of Delta1, the decrease by mFng was greater in degree than that by 1Fng, We also found that both fringe proteins reduced Jagged1-triggered Notch2 signaling, whereas neither affected Delta1-triggered Notch2 signaling. However, the decrease in Jagged1-triggered Notch2 signaling by mFng was again greater than that by 1Fng, Furthermore, we observed that each fringe protein acted on a different site of the extracellular region of Notch2, Taking these findings together, we propose that the difference in modulatory function of multiple fringe proteins may result from the distinct amino acid sequence specificity targeted by these glycosyltransferases.	Tokyo Univ Hosp, Grad Sch Med, Dept Cell Therapy & Transplantat Med, Bunkyo Ku, Tokyo 1138655, Japan; Tokyo Univ Hosp, Grad Sch Med, Dept Hematol & Oncol, Tokyo 1138655, Japan	University of Tokyo; University of Tokyo	Hirai, H (corresponding author), Tokyo Univ Hosp, Grad Sch Med, Dept Cell Therapy & Transplantat Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	hhirai-tky@umin.ac.jp		Takahashi, Tokiharu/0000-0002-5785-8660				ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Cho KO, 1998, NATURE, V396, P272, DOI 10.1038/24394; Cohen B, 1997, NAT GENET, V16, P283, DOI 10.1038/ng0797-283; de Celis JF, 2000, DEVELOPMENT, V127, P1291; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; Dunwoodie SL, 1997, DEVELOPMENT, V124, P3065; Evrard YA, 1998, NATURE, V394, P377, DOI 10.1038/28632; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Hicks C, 2000, NAT CELL BIOL, V2, P515, DOI 10.1038/35019553; Johnston SH, 1997, DEVELOPMENT, V124, P2245; Ju BG, 2000, NATURE, V405, P191, DOI 10.1038/35012090; Klein T, 1998, DEVELOPMENT, V125, P2951; Klueg KM, 1999, J CELL SCI, V112, P3289; KOPAN R, 1993, J CELL BIOL, V121, P631, DOI 10.1083/jcb.121.3.631; LARDELLI M, 1994, MECH DEVELOP, V46, P123, DOI 10.1016/0925-4773(94)90081-7; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243; Li LH, 1998, IMMUNITY, V8, P43, DOI 10.1016/S1074-7613(00)80457-4; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Luo B, 1997, MOL CELL BIOL, V17, P6057, DOI 10.1128/MCB.17.10.6057; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Rauskolb C, 1999, NATURE, V401, P476, DOI 10.1038/46786; REAUME AG, 1992, DEV BIOL, V154, P377, DOI 10.1016/0012-1606(92)90076-S; Shawber C, 1996, DEV BIOL, V180, P370, DOI 10.1006/dbio.1996.0310; Shimizu K, 2000, MOL CELL BIOL, V20, P6913, DOI 10.1128/MCB.20.18.6913-6922.2000; Shimizu K, 1999, J BIOL CHEM, V274, P32961, DOI 10.1074/jbc.274.46.32961; Shutter JR, 2000, GENE DEV, V14, P1313; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; Valsecchi V, 1997, MECH DEVELOP, V69, P203, DOI 10.1016/S0925-4773(97)00146-9; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; Yuan YP, 1997, CELL, V88, P9, DOI 10.1016/S0092-8674(00)81852-8; Zhang NA, 1998, NATURE, V394, P374, DOI 10.1038/28625	38	95	102	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25753	25758		10.1074/jbc.M103473200	http://dx.doi.org/10.1074/jbc.M103473200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11346656	hybrid			2022-12-25	WOS:000169823300017
J	Hall, JA; Maloney, PC				Hall, JA; Maloney, PC			Transmembrane segment 11 of UhpT, the sugar phosphate carrier of Escherichia coli, is an alpha-helix that carries determinants of substrate selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAHELICAL SALT BRIDGE; LACTOSE PERMEASE; TRANSLOCATION PATHWAY; STREPTOCOCCUS-LACTIS; MELIBIOSE CARRIER; TRANSPORT SYSTEM; ANION-EXCHANGE; SITE; BINDING; IDENTIFICATION	In Escherichia coli, transport of hexose 6-phosphates is mediated by the P-i-linked antiport carrier, UhpT, a member of the major facilitator superfamily, We showed earlier that Lys(391), a member of an intrahelical salt bridge (Asp(388)/Lys(391)) in the eleventh transmembrane segment (TM11) of this transporter, can function as a determinant of substrate selectivity (Hall, J, A., Fann, M.-C., and Maloney, P. C. (1999) J. Biol. Chem. 274, 6148-6153), Here, we examine in detail the role of TM11 in setting substrate preference. Derivatives having an uncompensated cationic charge at either position 388 or 391 (the D388C, D388V, or D388K/K391C variants) are gain-of-function mutants in which phosphoenolpyruvate, not sugar g-phosphate, is the preferred organic substrate. By contrast, when an uncompensated anionic charge is placed at position 388 (K391C), we observed behavior consistent with an increased preference for monovalent rather than divalent sugar 6-phosphate. Because positions 388 and 391 lie deep within the UhpT hydrophobic sector, these findings suggested that an extended length of TM11 may be accessible to external substrates and probes. To explore this issue, we used a panel of TM11 single cysteine variants to examine the transport of glucose 6-phosphate in the presence and absence of the membrane-impermeant, thiol-reactive agent p-chloromercuribenzosulfonate (PCMBS). Accessibility to PCMBS, together with the pattern of substrate protection against PCMBS inhibition, leads us to conclude that TM11 spans the membrane as an a-helix, with approximately two-thirds of its surface lining a substrate translocation pathway. We suggest that this feature is a general property of carrier proteins in the major facilitator superfamily and that for this reason residues in TM11 will serve to carry determinants of substrate selectivity.	Johns Hopkins Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine	Maloney, PC (corresponding author), Johns Hopkins Sch Med, Dept Physiol, 725 N Wolfe St, Baltimore, MD 21205 USA.				NIGMS NIH HHS [F32 GM19421, GM24195] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019421, R01GM024195, R56GM024195] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBUDKAR SV, 1986, P NATL ACAD SCI USA, V83, P280, DOI 10.1073/pnas.83.2.280; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; EVANS PR, 1981, PHILOS T ROY SOC B, V293, P53, DOI 10.1098/rstb.1981.0059; Fann MC, 1998, J MEMBRANE BIOL, V164, P187, DOI 10.1007/s002329900404; Fann MC, 1998, J BIOL CHEM, V273, P33735, DOI 10.1074/jbc.273.50.33735; Franco PJ, 1999, J BACTERIOL, V181, P6377, DOI 10.1128/JB.181.20.6377-6386.1999; FRIEDRICH MJ, 1987, J BACTERIOL, V169, P3556, DOI 10.1128/jb.169.8.3556-3563.1987; FRILLINGOS S, 1995, BIOCHEMISTRY-US, V34, P9368, DOI 10.1021/bi00029a012; Fu DX, 1998, J BIOL CHEM, V273, P17962, DOI 10.1074/jbc.273.28.17962; Fu DX, 2001, J BIOL CHEM, V276, P8753, DOI 10.1074/jbc.M008417200; Fu DX, 1997, J BIOL CHEM, V272, P2129; GOSWITZ VC, 1995, PROTEIN SCI, V4, P534; GOTT P, 1988, MOL MICROBIOL, V2, P655, DOI 10.1111/j.1365-2958.1988.tb00074.x; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; Hall JA, 1999, J BIOL CHEM, V274, P6148, DOI 10.1074/jbc.274.10.6148; HARLOW E, 1988, ANTIBODIES LAB MANUA, P486; HE MM, 1995, BIOCHEMISTRY-US, V34, P15661, DOI 10.1021/bi00048a009; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFSTEE BHJ, 1959, NATURE, V184, P1296, DOI 10.1038/1841296b0; ISLAND MD, 1992, J BACTERIOL, V174, P2754, DOI 10.1128/JB.174.9.2754-2762.1992; JOHANSON RA, 1985, J BIOL CHEM, V260, P1465; KABACK HR, 1994, J EXP BIOL, V196, P183; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; KYTE J, 1995, STRUCTURE PROTEIN CH, P59; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JI, 1996, BBA-BIOMEMBRANES, V1278, P111, DOI 10.1016/0005-2736(95)00209-X; LEUCKE H, 1990, NATURE, V347, P402; LODI PJ, 1994, BIOCHEMISTRY-US, V33, P2809, DOI 10.1021/bi00176a009; LUNDQVIST T, 1989, J BIOL CHEM, V264, P7078; MALONEY PC, 1990, MICROBIOL REV, V54, P1; MALONEY PC, 1994, CURR OPIN CELL BIOL, V6, P571, DOI 10.1016/0955-0674(94)90079-5; MALONEY PC, 1984, J BACTERIOL, V158, P238, DOI 10.1128/JB.158.1.238-245.1984; MALONEY PC, 1996, ESCHERICHIA COLI SAL, P1130; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; Matos M, 1996, J BIOL CHEM, V271, P18571, DOI 10.1074/jbc.271.31.18571; Matsuzaki S, 1999, BBA-BIOMEMBRANES, V1420, P63, DOI 10.1016/S0005-2736(99)00087-5; Miller J. H., 1972, EXPT MOL GENETICS, P431; Mueckler M, 1999, J BIOL CHEM, V274, P10923, DOI 10.1074/jbc.274.16.10923; PADAN E, 1976, EUR J BIOCHEM, V63, P533, DOI 10.1111/j.1432-1033.1976.tb10257.x; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Paulsen IT, 1998, J MOL BIOL, V277, P573, DOI 10.1006/jmbi.1998.1609; POOLMAN B, 1993, BIOCHIM BIOPHYS ACTA, V1183, P5, DOI 10.1016/0005-2728(93)90003-X; Quiocho FA, 1997, STRUCTURE, V5, P997, DOI 10.1016/S0969-2126(97)00253-0; Rosenberg H., 1987, ION TRANSPORT PROKAR, P205; SHARFF AJ, 1993, BIOCHEMISTRY-US, V32, P10553, DOI 10.1021/bi00091a004; SKARZYNSKI T, 1987, J MOL BIOL, V193, P171, DOI 10.1016/0022-2836(87)90635-8; Someya Y, 2000, J BIOL CHEM, V275, P210, DOI 10.1074/jbc.275.1.210; SONNA LA, 1988, J BIOL CHEM, V263, P6625; Varela MF, 1996, BBA-BIOENERGETICS, V1276, P21, DOI 10.1016/0005-2728(96)00030-8; Varela MF, 1997, J BACTERIOL, V179, P5570, DOI 10.1128/jb.179.17.5570-5573.1997; Venkatesan P, 1998, P NATL ACAD SCI USA, V95, P9802, DOI 10.1073/pnas.95.17.9802; Voss J, 1997, BIOCHEMISTRY-US, V36, P15055, DOI 10.1021/bi971726j; Voss J, 1996, BIOCHEMISTRY-US, V35, P12915, DOI 10.1021/bi9608774; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; WESTON LA, 1987, J BACTERIOL, V169, P3546, DOI 10.1128/jb.169.8.3546-3555.1987; Williams KA, 2000, NATURE, V403, P112, DOI 10.1038/47534; YAN RT, 1993, CELL, V75, P37, DOI 10.1016/S0092-8674(05)80082-0; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973	59	18	18	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25107	25113		10.1074/jbc.M102017200	http://dx.doi.org/10.1074/jbc.M102017200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11349129	hybrid			2022-12-25	WOS:000169800700091
J	Zauberman, A; Lapter, S; Zipori, D				Zauberman, A; Lapter, S; Zipori, D			Smad proteins suppress CCAAT/enhancer-binding protein (C/EBP) beta- and STAT3-mediated transcriptional activation of the haptoglobin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; TUMOR-SUPPRESSOR; ACTIVIN-A; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; SKI ONCOPROTEIN; RESTRICTIN-P; CELL-GROWTH; RECEPTOR	Activin A, a member of the transforming growth factor beta (TGF beta) superfamily, blocks interleukin (IL)-6 biological functions. The molecular basis of the influence of this TGF beta signaling on the IL-6 receptor triggered cascade is unknown. We studied IL-g-induced secretion of the acute phase protein haptoglobin by hepatoma cells. Overexpression of the C/EBP beta gene, a downstream effector in the IL-6 pathway, activated transcription from the haptoglobin promoter. This was abolished by either a constitutively active form of activin A type IB receptor (CAactRIB) or by a combination of Smad3 and Smad4, Similarly, Smads abolished transcriptional activation by co-stimulation with IL-6 and STAT3. The transcription co-activator p300 partially overcame the suppressive effect of Smads. Electrophoretic mobility shift assays indicated that C/EBP beta binding to haptoglobin promoter DNA was reduced by over-expression of CAactRIB and Smad4. We thus show that Smad proteins operate as transcription inhibitors on target genes of the IL-6 induced pathway. The effect of Smads is exerted on components of the transcription activation complex and may also involve interference with DNA binding. This study thus depicts molecular sites of interaction between the TGF beta superfamily and the IL-6 signaling cascades.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Zipori, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.							Akira S, 1997, INT J BIOCHEM CELL B, V29, P1401, DOI 10.1016/S1357-2725(97)00063-0; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BAUMANN H, 1991, J BIOL CHEM, V266, P20390; Boudreau F, 1998, DNA CELL BIOL, V17, P669, DOI 10.1089/dna.1998.17.669; BRETON J, 1995, EUR J BIOCHEM, V227, P573, DOI 10.1111/j.1432-1033.1995.tb20427.x; Bright JJ, 1998, J IMMUNOL, V161, P1772; BROSH N, 1995, J BIOL CHEM, V270, P29594, DOI 10.1074/jbc.270.49.29594; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KISHIMOTO T, 1992, INT J IMMUNOPHARMACO, V14, P431; Lebrun JJ, 1999, MOL ENDOCRINOL, V13, P15, DOI 10.1210/me.13.1.15; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359-6101(99)00025-8; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Sternberg D, 1995, GROWTH FACTORS, V12, P277, DOI 10.3109/08977199509028966; Sudarshan C, 1999, J IMMUNOL, V162, P2974; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; WANG L, 1995, J BIOL CHEM, V270, P23159, DOI 10.1074/jbc.270.39.23159; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yu SJ, 1999, BIOCHEM BIOPH RES CO, V259, P544, DOI 10.1006/bbrc.1999.0808; Zauberman A, 1997, ONCOGENE, V15, P1705, DOI 10.1038/sj.onc.1201348; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; ZIPORI D, 1986, P NATL ACAD SCI USA, V83, P4547, DOI 10.1073/pnas.83.12.4547	52	52	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24719	24725		10.1074/jbc.M005813200	http://dx.doi.org/10.1074/jbc.M005813200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11331273	hybrid			2022-12-25	WOS:000169800700042
J	Henn, AD; Berleth, ES; Mihich, E; Ehrke, MJ				Henn, AD; Berleth, ES; Mihich, E; Ehrke, MJ			Changes in cytosolic and membrane TNF inhibitory protein-B1 (TIP-B1) levels associated with protection from TNF-induced cytotoxicity	FASEB JOURNAL			English	Article									Roswell Pk Canc Inst, Grace Canc Drug Ctr, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Ehrke, MJ (corresponding author), Roswell Pk Canc Inst, Grace Canc Drug Ctr, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.								0	6	7	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1315	1317		10.1096/fj.00-0543fje	http://dx.doi.org/10.1096/fj.00-0543fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344125	Bronze			2022-12-25	WOS:000168655200047
J	Langen, RCJ; Schols, AMWJ; Kelders, MCJM; Wouters, EFM; Janssen-Heininger, MW				Langen, RCJ; Schols, AMWJ; Kelders, MCJM; Wouters, EFM; Janssen-Heininger, MW			Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappa B	FASEB JOURNAL			English	Article						cachexia; muscle wasting; TNF-alpha; NF-kappa B; myogenic differentiation	TUMOR-NECROSIS-FACTOR; OBSTRUCTIVE PULMONARY-DISEASE; APOPTOSIS-RELATED PROTEINS; CHRONIC HEART-FAILURE; FACTOR-ALPHA; TRANSCRIPTION FACTORS; SKELETAL-MUSCLE; RHEUMATOID-ARTHRITIS; GENE-EXPRESSION; PROSTATE-CANCER	Muscle wasting is often associated with chronic inflammation, Because tumor necrosis factor alpha (TNF-alpha) has been implicated as a major mediator of cachexia, its effects on C2C12 myocytes were examined, TNF-alpha activated nuclear factor-kappaB (NF-kappaB) and interfered with the expression of muscle proteins in differentiating myoblasts, Introduction of a mutant form of inhibitory protein kappaB alpha (I kappaB alpha) restored myogenic differentiation in myoblasts treated with TNF-alpha or interleukin 1 beta, Conversely, activation of NF-kappaB by overexpression of I kappaB kinase was sufficient to block myogenesis, illustrating the causal link between NF-kappaB activation and inhibition of myogenic differentiation. The inhibitory effects of TNF-alpha on myogenic differentiation were reversible, indicating that the effects of the cytokine were not due to nonspecific toxicity, Treatment of differentiated myotubes with TNF-alpha did not result in a striking loss of muscle-specific proteins, which shows that myogenesis was selectively affected in the myoblast stage by TNF-alpha, An important finding was that NF-kappaB was activated to the same extent in differentiating and differentiated cells, illustrating that once myocytes have differentiated they become refractory to the effects of NF-kappaB activation, These results demonstrate that inflammatory cytokines may contribute to muscle wasting through the inhibition of myogenic differentiation via a NF-kappaB-dependent pathway.	Univ Vermont, Dept Pathol, Burlington, VT 05405 USA; Maastricht Univ, Dept Pulmonol, Maastricht, Netherlands	University of Vermont; Maastricht University	Janssen-Heininger, MW (corresponding author), Univ Vermont, Dept Pathol, Med Alumni Bldg A143, Burlington, VT 05405 USA.		Wouters, Emiel/ABD-6200-2021					Anker SD, 1997, LANCET, V349, P1050, DOI 10.1016/S0140-6736(96)07015-8; Anker SD, 1997, LANCET, V349, P1258; Argiles JM, 1999, MED RES REV, V19, P223, DOI 10.1002/(SICI)1098-1128(199905)19:3<223::AID-MED3>3.0.CO;2-N; BELEC L, 1995, J ACQ IMMUN DEF SYND, V8, P212; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buck M, 1996, EMBO J, V15, P1753, DOI 10.1002/j.1460-2075.1996.tb00524.x; COONEY R, 1994, AM J PHYSIOL-ENDOC M, V267, pE636, DOI 10.1152/ajpendo.1994.267.5.E636; CORNELIUS P, 1991, J BIOL CHEM, V266, P4023; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; DIFRANCIA M, 1994, AM J RESP CRIT CARE, V150, P1453, DOI 10.1164/ajrccm.150.5.7952575; FONG Y, 1989, AM J PHYSIOL, V256, pR659, DOI 10.1152/ajpregu.1989.256.3.R659; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Janssen YMW, 1997, AM J PHYSIOL-LUNG C, V273, pL789, DOI 10.1152/ajplung.1997.273.4.L789; Ji SQ, 1998, J INTERF CYTOK RES, V18, P879, DOI 10.1089/jir.1998.18.879; Kaliman P, 1999, J BIOL CHEM, V274, P17437, DOI 10.1074/jbc.274.25.17437; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; KIRCHBERGER M, 1991, PHYSL BASIS MED PRAC, P62; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; KOTLER DP, 1989, AM J CLIN NUTR, V50, P444, DOI 10.1093/ajcn/50.3.444; Layne MD, 1999, EXP CELL RES, V249, P177, DOI 10.1006/excr.1999.4465; Lehtinen SK, 1996, BIOCHEM BIOPH RES CO, V229, P36, DOI 10.1006/bbrc.1996.1754; Li YP, 1998, FASEB J, V12, P871, DOI 10.1096/fasebj.12.10.871; LLOVERA M, 1994, FEBS LETT, V338, P311, DOI 10.1016/0014-5793(94)80290-4; MacLachlan TK, 1998, J CELL BIOCHEM, V71, P461, DOI 10.1002/(SICI)1097-4644(19981215)71:4<461::AID-JCB1>3.0.CO;2-0; MILLER SC, 1988, MOL CELL BIOL, V8, P2295, DOI 10.1128/MCB.8.6.2295; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; MORRISON WL, 1988, CLIN SCI, V75, P415, DOI 10.1042/cs0750415; Nakashima J, 1998, CLIN CANCER RES, V4, P1743; NAKASHIMA J, 1995, CANCER RES, V55, P4881; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; ROUBENOFF R, 1992, J RHEUMATOL, V19, P1505; Schols AMWJ, 1998, AM J RESP CRIT CARE, V157, P1791, DOI 10.1164/ajrccm.157.6.9705017; Sugiura T, 1999, ARTHRITIS RHEUM, V42, P291, DOI 10.1002/1529-0131(199902)42:2<291::AID-ANR11>3.0.CO;2-1; Szalay K, 1997, EUR J CELL BIOL, V74, P391; SZASZ G, 1976, CLIN CHEM, V22, P650; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; Tews DS, 1997, NEUROPATH APPL NEURO, V23, P331, DOI 10.1046/j.1365-2990.1997.5998059.x; Tews DS, 1997, J NEUROPATH EXP NEUR, V56, P150, DOI 10.1097/00005072-199702000-00005; Thaloor D, 1999, AM J PHYSIOL-CELL PH, V277, pC320, DOI 10.1152/ajpcell.1999.277.2.C320; Vary TC, 1996, SHOCK, V6, P13, DOI 10.1097/00024382-199607000-00004; VREUGDENHIL G, 1992, EUR J CLIN INVEST, V22, P488, DOI 10.1111/j.1365-2362.1992.tb01495.x; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang YJ, 2000, MOL CELL BIOL, V20, P4505, DOI 10.1128/MCB.20.13.4505-4512.2000; WILSON DO, 1989, AM REV RESPIR DIS, V139, P1435, DOI 10.1164/ajrccm/139.6.1435; WINTER B, 1993, J BIOL CHEM, V268, P9869; YABLONKAREUVENI Z, 1995, MICROSC RES TECHNIQ, V30, P366, DOI 10.1002/jemt.1070300504; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Zhao SP, 1997, INT J CARDIOL, V58, P257, DOI 10.1016/S0167-5273(96)02873-2; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	52	317	323	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1169	1180		10.1096/fj.00-0463	http://dx.doi.org/10.1096/fj.00-0463			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344085				2022-12-25	WOS:000168655200007
J	Nielsen, KH; Gredsted, L; Broach, JR; Willumsen, BM				Nielsen, KH; Gredsted, L; Broach, JR; Willumsen, BM			Sensitivity of wild type and mutant ras alleles to Ras specific exchange factors: Identification of factor specific requirements	ONCOGENE			English	Article						Ras exchange; Ras V103E; Sos1; GRF; GRP; S. cerevisiae	MURINE SARCOMA-VIRUS; NUCLEOTIDE-RELEASING FACTOR; SACCHAROMYCES-CEREVISIAE CDC25; GTPASE ACTIVATING PROTEIN; P21 TRANSFORMING PROTEIN; MOLECULAR-CLONING; MAMMALIAN RAS; R-RAS; N-RAS; FUNCTIONAL INTERACTION	We have investigated the productive interaction between the four mammalian Ras proteins (H-, N-, KA- and KB-Ras) and their activators, the mammalian exchange factors mSos1, GRF1 and GRP, by using a modified Saccharomyces cerevisiae whose growth is dependent on activation of a mammalian Ras protein by its activator. All four mammalian Ras proteins were activated with similar efficiencies by the individual exchange factors. The H-Ras mutant V103E, which is competent for membrane localization, nucleotide binding, intrinsic and stimulated GTPase activity as well as intrinsic exchange, was defective for activation by all factors tested, suggesting that the integrity of this residue is necessary for catalyzed exchange. However, when other H-Ras mutants were studied, some distinct sensitivities to the exchange factors were observed. GRP-mediated, but not mSos1-mediated, exchange was blocked in additional mutants, suggesting different structural requirements for GRP, Analysis of Ras-mediated gene activation in murine fibroblasts confirmed these results.	Univ Copenhagen, Dept Mol Cell Biol, DK-1353 Copenhagen, Denmark; Princeton Univ, Lewis Thomas Lab 303, Princeton, NJ 08544 USA	University of Copenhagen; Princeton University	Willumsen, BM (corresponding author), Univ Copenhagen, Dept Mol Cell Biol, Oester Farimagsgade 2A, DK-1353 Copenhagen, Denmark.		Willumsen, Berthe M/H-1903-2012	Willumsen, Berthe M/0000-0002-2277-6999; Broach, James/0000-0003-1197-0312	NCI NIH HHS [CA41086] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA041086] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; BROACH JR, 1991, TRENDS GENET, V7, P28, DOI 10.1016/0168-9525(91)90018-L; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COX AD, 1994, ONCOGENE, V9, P3281; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DEVENDITTIS E, 1986, EMBO J, V5, P3657, DOI 10.1002/j.1460-2075.1986.tb04696.x; DHAR R, 1982, SCIENCE, V217, P934, DOI 10.1126/science.6287572; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOWE LR, 1993, ONCOGENE, V8, P2583; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Jones MK, 1998, J BIOL CHEM, V273, P1782, DOI 10.1074/jbc.273.3.1782; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Leonardsen L, 1996, ONCOGENE, V13, P2177; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; Moreira JMA, 1998, EMBO J, V17, P6028, DOI 10.1093/emboj/17.20.6028; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; Nielsen KH, 1997, MOL CELL BIOL, V17, P7132, DOI 10.1128/MCB.17.12.7132; ORITA S, 1993, J BIOL CHEM, V268, P25542; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PILZ RB, 1984, J BIOL CHEM, V259, P2927; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rose MD., 1990, METHODS YEAST GENETI; SEGAL M, 1995, EUR J BIOCHEM, V228, P96, DOI 10.1111/j.1432-1033.1995.tb20235.x; SEGAL M, 1992, J BIOL CHEM, V267, P22747; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TATCHELL K, 1986, J BACTERIOL, V166, P364, DOI 10.1128/jb.166.2.364-367.1986; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; THEVELEIN JM, 1994, YEAST, V10, P1753, DOI 10.1002/yea.320101308; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TSUCHIDA N, 1982, SCIENCE, V217, P937, DOI 10.1126/science.6287573; VELU TJ, 1989, J VIROL, V63, P1384, DOI 10.1128/JVI.63.3.1384-1392.1989; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WILLUMSEN BM, 1991, MOL CELL BIOL, V11, P6026, DOI 10.1128/MCB.11.12.6026; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WILLUMSEN BM, 1995, METHOD ENZYMOL, V250, P269	61	9	13	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2001	20	17					2091	2100		10.1038/sj.onc.1204306	http://dx.doi.org/10.1038/sj.onc.1204306			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360193	Bronze			2022-12-25	WOS:000168116700004
J	Zhao, HH; Herrera, RE; Coronado-Heinsohn, E; Yang, MC; Ludes-Meyers, JH; Seybold-Tilson, KJ; Nawaz, Z; Yee, D; Barr, FG; Diab, SG; Brown, PH; Fuqua, SAW; Osborne, CK				Zhao, HH; Herrera, RE; Coronado-Heinsohn, E; Yang, MC; Ludes-Meyers, JH; Seybold-Tilson, KJ; Nawaz, Z; Yee, D; Barr, FG; Diab, SG; Brown, PH; Fuqua, SAW; Osborne, CK			Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR FKHR; PAX3-FKHR FUSION PROTEIN; ALVEOLAR RHABDOMYOSARCOMA; BREAST-CANCER; HORMONE-RECEPTOR; CHROMOSOMAL TRANSLOCATIONS; STEROID-RECEPTORS; THYROID-HORMONE; CO-REPRESSOR; N-COR	In a search for novel transcriptional intermediary factors for the estrogen receptor (ER), we used the ligand-binding domain and hinge region of ER as bait in a yeast two-hybrid screen of a cDNA library derived from tamoxifen-resistant MCF-7 human breast tumors from an in vivo athymic nude mouse model. Here we report the isolation and characterization of the forkhead homologue in rhabdomyosarcoma (FKHR), a recently described member of the hepatocyte nuclear factor 3/forkhead homeotic gene family, as a nuclear hormone receptor (NR) intermediary protein. FKHR interacts with both steroid and nonsteroid NRs, although the effect of ligand on this interaction varies by receptor type. The interaction of FKHR with ER is enhanced by estrogen, whereas its interaction with thyroid hormone receptor and retinoic acid receptor is ligand-independent. In addition, FKHR differentially regulates the transactivation mediated by different NRs. Transient transfection of FKHR into mammalian cells dramatically represses transcription mediated by the ER, glucocorticoid receptor, and progesterone receptor. In contrast, FKHR stimulates rather than represses retinoic acid receptor- and thyroid hormone receptor-mediated transactivation. Most intriguingly, overexpression of FKHR dramatically inhibits the proliferation of ER-dependent MCF-7 breast cancer cells. Therefore, FKHR represents a bifunctional NR intermediary protein that can act as either a coactivator or corepressor, depending on the receptor type.	Univ Texas, Hlth Sci Ctr, Dept Med, Div Oncol, San Antonio, TX 78284 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Texas System; University of Texas Health San Antonio; Baylor College of Medicine; Baylor College of Medicine; University of Pennsylvania	Herrera, RE (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Oncol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.		Roszak, Joanna/F-4003-2010	Yee, Douglas/0000-0002-3387-4009	NCI NIH HHS [P50CA58183, P30CA54174, CA64202] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058183, R01CA064202, P30CA054174] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BARR FG, 1995, JAMA-J AM MED ASSOC, V273, P553, DOI 10.1001/jama.273.7.553; Barr FG, 1997, INT J BIOCHEM CELL B, V29, P1449, DOI 10.1016/S1357-2725(97)00095-2; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Bennicelli JL, 1996, P NATL ACAD SCI USA, V93, P5455, DOI 10.1073/pnas.93.11.5455; BIEGEL JA, 1995, GENE CHROMOSOME CANC, V12, P186, DOI 10.1002/gcc.2870120305; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Douarin BL, 1996, EMBO J, V15, P6701; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; FUQUA SAW, 1995, ENDOCR-RELAT CANCER, V2, P19, DOI 10.1677/erc.0.0020019; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; HANSEN RK, 1998, BREAST CANC MOL GENE, P1; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HROMAS R, 1995, CRIT REV ONCOL HEMAT, V20, P129, DOI 10.1016/1040-8428(94)00151-I; Huang NW, 1998, EMBO J, V17, P3398, DOI 10.1093/emboj/17.12.3398; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Kelly KM, 1997, J CLIN ONCOL, V15, P1831, DOI 10.1200/JCO.1997.15.5.1831; Kelly KM, 1996, CANCER, V78, P1320, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1320::AID-CNCR22>3.3.CO;2-F; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; MacGregor JI, 1998, PHARMACOL REV, V50, P151; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; OSBORNE CK, 1985, CANCER RES, V45, P584; Osborne CK, 1996, BREAST, V5, P181, DOI 10.1016/S0960-9776(96)90090-9; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; OSBORNE CK, 1996, SCI AM SCI MED S, V3, P31; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; SHAPIRO DN, 1993, CANCER RES, V53, P108; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; SUBLETT JE, 1995, ONCOGENE, V11, P545; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Tomizawa M, 2000, J BIOL CHEM, V275, P7289, DOI 10.1074/jbc.275.10.7289; TONETTI DA, 1995, ANTI-CANCER DRUG, V6, P498, DOI 10.1097/00001813-199508000-00002; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Vogt PK, 1997, VIROLOGY, V238, P1, DOI 10.1006/viro.1997.8846; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; Zhang X, 1998, MOL ENDOCRINOL, V12, P513, DOI 10.1210/me.12.4.513	57	147	150	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27907	27912		10.1074/jbc.M104278200	http://dx.doi.org/10.1074/jbc.M104278200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11353774	hybrid			2022-12-25	WOS:000170093400023
J	Bernard, D; Quatannens, B; Vandenbunder, B; Abbadie, C				Bernard, D; Quatannens, B; Vandenbunder, B; Abbadie, C			Rel/NF-kappa B transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-INDUCED APOPTOSIS; INDUCED CELL-DEATH; TRANSFORMED KERATINOCYTES; CD95-INDUCED APOPTOSIS; EMBRYONIC LETHALITY; LIVER DEGENERATION; DEFICIENT MICE; JNK ACTIVATION; T-LYMPHOCYTES; FAS-LIGAND	Rel/nuclear factor (NF)-kappaB transcription factors play a major role in the regulation of programmed cell death. A few anti-apoptotic Rel/NF-kappaB target genes have been characterized; they act either downstream in the apoptotic pathway or upstream, for example at the tumor necrosis factor (TNF) receptor Level. We found using DNA arrays, reverse transcription-polymerase chain reaction, and immunofluorescence that Rel/NF-kappaB factors up-regulate DcR1, a receptor for TNF-related apoptosis-inducing ligand (TRAIL), a cytokine of the TNF family that induces apoptosis in tumor cells. Four related receptors bind TRAIL, two death receptors (DR4 and DR5) that signal apoptosis and two decoy receptors (DcR1 and DcR2) that act as dominant negative inhibitors of TRAIL-mediated apoptosis. DcR1 is devoid of an intracellular domain and is anchored at the cell surface membrane by a glycophospholipid. Our results indicate that overexpression of cRel or activation of endogenous Rel/NF-kappaB factors by TNF alpha in HeLa cells up-regulates DcR1 without changing the expression of DcR2, DR4, and DR5 and makes cells resistant against TRAIL-induced apoptosis. This resistance is a consequence of DcR1 upregulation,,because it was abolished when DcR1 was removed from the cell surface by a phosphatidylinositol phospholipase C. Therefore, Rel/NF-kappaB transcription factors could regulate the sensitivity of cells to TRAIL, by: controlling the ratio of TRAIL-decoy to -death receptors.	Univ Lille 2, CNRS,FRE 2353, IPL, Inst Biol Lille, F-59021 Lille, France; Univ Lille 2, CNRS,Unite Mixte Rech 8526, Inst Pasteur Lille, Inst Biol Lille, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Abbadie, C (corresponding author), Univ Lille 2, CNRS,FRE 2353, IPL, Inst Biol Lille, 1 Rue Calmette,BP 447, F-59021 Lille, France.		ABBADIE, Corinne/F-4949-2018; Bernard, David/D-6265-2018	ABBADIE, Corinne/0000-0002-8174-2393; Bernard, David/0000-0002-1557-2074				ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bernard D, 2001, CANCER RES, V61, P2656; BROWNELL E, 1989, ONCOGENE, V4, P935; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; Foo SY, 1999, TRENDS GENET, V15, P229; Goke R, 2000, CELL IMMUNOL, V201, P77, DOI 10.1006/cimm.2000.1650; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Hu WH, 1999, J BIOL CHEM, V274, P30603, DOI 10.1074/jbc.274.43.30603; HUGUET C, 1997, CELL DEATH DIFFER, V4, P1; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; Kothny-Wilkes G, 1999, J BIOL CHEM, V274, P28916, DOI 10.1074/jbc.274.41.28916; Kothny-Wilkes G, 1998, J BIOL CHEM, V273, P29247, DOI 10.1074/jbc.273.44.29247; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Leverkus M, 2000, CANCER RES, V60, P553; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOMBARDI L, 1995, NUCLEIC ACIDS RES, V23, P2328, DOI 10.1093/nar/23.12.2328; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Marsters SA, 1999, RECENT PROG HORM RES, V54, P225; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; PEPIN N, 1994, VIROLOGY, V204, P706, DOI 10.1006/viro.1994.1586; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Rudolph D, 2000, GENE DEV, V14, P854; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Schneider P, 2000, Pharm Acta Helv, V74, P281, DOI 10.1016/S0031-6865(99)00038-2; Sheikh MS, 1999, ONCOGENE, V18, P4153, DOI 10.1038/sj.onc.1202763; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; VAN AD, 1996, SCIENCE, V274, P787; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wu GS, 1999, ONCOGENE, V18, P6411, DOI 10.1038/sj.onc.1203025; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Zhang XD, 2000, FEBS LETT, V482, P193, DOI 10.1016/S0014-5793(00)02042-1; Zhang XD, 1999, CANCER RES, V59, P2747; ZIEGLER E, 1995, J VIROL, V69, P3465, DOI 10.1128/JVI.69.6.3465-3474.1995; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382; Zong WX, 1998, CELL DEATH DIFFER, V5, P963, DOI 10.1038/sj.cdd.4400441	59	107	118	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27322	27328		10.1074/jbc.M011183200	http://dx.doi.org/10.1074/jbc.M011183200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11350953	hybrid			2022-12-25	WOS:000169966900079
J	Buczynski, G; Slepenkov, SV; Sehorn, MG; Witt, SN				Buczynski, G; Slepenkov, SV; Sehorn, MG; Witt, SN			Characterization of a lidless form of the molecular chaperone DnaK - Deletion of the lid increases peptide on- and off-rate constants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL-CHANGES; GLUTATHIONE-S-TRANSFERASE; SUBSTRATE-BINDING; ESCHERICHIA-COLI; ATP HYDROLYSIS; BACTERIOPHAGE-LAMBDA; HSP70; PROTEIN; OLIGOMERIZATION; DISSOCIATION	The C-terminal, polypeptide binding domain of the 70-kDa molecular chaperone DnaK is composed of a unique lidlike subdomain that appears to hinder steric access to the peptide binding site. We have expressed, purified, and characterized a lidless form of DnaK to test the influence of the lid on the ATPase activity, on interdomain communication, and on the kinetics of peptide binding. The principal findings are that loss of the lid creates an activated form of DnaK which is not equivalent to ATP-bound DnaK. For example, at 25 degreesC the NR peptide (NRLLLTG) dissociates from the ADP and ATP states of DnaK with observed off-rate constants of 0.001 and 4.8 s(-1), respectively. In contrast, for DnaK that lacks most of the helical lid, residues 518-638, the NR peptide dissociates with observed off-rate constants of 0.1 and 188 s(-1). These results show that the loss of the lid does not interfere with interdomain communication, that the beta -sandwich peptide binding domain can exist in two discrete conformations, and that the lid functions to increase the lifetime of a DnaK peptide complex. We discuss several mechanisms to explain how the lid affects the lifetime of a DnaK peptide complex.	Louisiana State Univ, Dept Biochem & Mol Biol, Hlth Sci Ctr, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Witt, SN (corresponding author), Louisiana State Univ, Dept Biochem & Mol Biol, Hlth Sci Ctr, 1501 Kings Highway, Shreveport, LA 71130 USA.		Witt, Stephan N/M-7922-2013; Slepenkov, Sergey/D-4039-2016	Witt, Stephan N/0000-0002-6462-2840; 				Bevington PR, 1969, DATA REDUCTION ERROR; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; FARR CD, 1995, BIOCHEMISTRY-US, V34, P15574, DOI 10.1021/bi00047a024; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; Fouchaq B, 1999, EUR J BIOCHEM, V259, P379, DOI 10.1046/j.1432-1327.1999.00053.x; GAO BC, 1994, BIOCHEMISTRY-US, V33, P2048, DOI 10.1021/bi00174a010; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Haugland R.P., 1992, HDB FLUORESCENT PROB; Hiromi K., 1979, KINETICS FAST ENZYME; Maru Y, 1996, J BIOL CHEM, V271, P15353, DOI 10.1074/jbc.271.26.15353; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; MORSHAUSER RC, 1995, BIOCHEMISTRY-US, V34, P6261, DOI 10.1021/bi00019a001; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Pellecchia M, 2000, NAT STRUCT BIOL, V7, P298; Russell R, 1998, BIOCHEMISTRY-US, V37, P596, DOI 10.1021/bi972025p; SAITO H, 1977, J MOL BIOL, V113, P1, DOI 10.1016/0022-2836(77)90038-9; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Slepenkov SV, 1998, BIOCHEMISTRY-US, V37, P16749, DOI 10.1021/bi981738k; Slepenkov SV, 1998, BIOCHEMISTRY-US, V37, P1015, DOI 10.1021/bi9720484; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; TACK BF, 1980, J BIOL CHEM, V255, P8842; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; Tudyka T, 1997, PROTEIN SCI, V6, P2180; WELCH WJ, 1998, MOL CHAPERONES LIFE, P71; YOCHEM J, 1978, MOL GEN GENET, V164, P9, DOI 10.1007/BF00267593; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	29	67	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27231	27236		10.1074/jbc.M100237200	http://dx.doi.org/10.1074/jbc.M100237200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11352903	hybrid			2022-12-25	WOS:000169966900068
J	Christenson, LK; Stouffer, RL; Strauss, JF				Christenson, LK; Stouffer, RL; Strauss, JF			Quantitative analysis of the hormone-induced hyperacetylation of histone H3 associated with the steroidogenic acute regulatory protein gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; PERI-OVULATORY INTERVAL; MACAQUE GRANULOSA-CELLS; LEYDIG TUMOR-CELLS; BINDING-PROTEIN; STAR GENE; FACTOR-I; TRANSCRIPTIONAL REGULATION; RAPID ACCUMULATION; CORPUS-LUTEUM	Transcriptional regulation of steroidogenic acute regulatory protein (StAR) determines adrenal and gonadal cell steroidogenesis. Chromatin immunoprecipitation assays were combined with quantitative real-time polymerase chain reaction to assess histone acetylation associated with the StAR promoter. MA-10 cells treated with 8-bromo-cAMP had increased acetylated histone H3 associated with the proximal (but not distal) StAR promoter, nascent StAR transcripts, and progesterone production within 15 min, whereas StAR mRNA increased at 30 min. At 360 min, steroidogenesis remained elevated, but mRNA, nascent RNA, and StAR promoter-associated H3 acetylation all declined. StAR promoter-associated H4 acetylation was unchanged by 8-bromo-cAMP treatment of MA-10 cells. In vivo analysis of macaque and human granulosa cells showed that luteinization was associated with increased StAR promoter-associated H3 acetylation. We conclude that acetylation of H3 (but not H4) associated with the proximal promoter is associated with StAR gene transcription, that chromatin modification occurs in discrete regions of the promoter, that the initial steroidogenic response to 8-bromo-cAMP occurs prior to increased StAR mRNA accumulation, and that MA-10 cell StAR gene transcription and promoter-associated H3 acetylation are biphasic during a 6-h treatment period. The union of the chromatin immunoprecipitation assay with quantitative real-time polymerase chain reaction described and validated here should enhance the analysis of gene expression.	Univ Penn, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA; Oregon Reg Primate Res Ctr, Div Reprod Sci, Beaverton, OR 97006 USA	University of Pennsylvania; Pennsylvania Medicine; Oregon Health & Science University; Oregon National Primate Research Center	Christenson, LK (corresponding author), Univ Penn, Ctr Res Reprod & Womens Hlth, 1349 Biomed Res Bldg II-III,421 Curie Blvd, Philadelphia, PA 19104 USA.	lchriste@mail.med.upenn.edu	Christenson, Lane K/G-6435-2013		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD020869] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD018185] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000163] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00163] Funding Source: Medline; NICHD NIH HHS [HD20869, HD06274, U54 HD18185] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		*APPL BIOS, 1997, APPL BIOS B, V2; Arakane F, 1997, J BIOL CHEM, V272, P32656, DOI 10.1074/jbc.272.51.32656; ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; Bauer MP, 2000, MOL CELL ENDOCRINOL, V168, P119, DOI 10.1016/S0303-7207(00)00316-6; Bennett MK, 1999, J BIOL CHEM, V274, P13025, DOI 10.1074/jbc.274.19.13025; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Caron KM, 1997, P NATL ACAD SCI USA, V94, P11540, DOI 10.1073/pnas.94.21.11540; Chaffin CL, 1999, HUM REPROD, V14, P642, DOI 10.1093/humrep/14.3.642; Chaffin CL, 2000, MOL HUM REPROD, V6, P11, DOI 10.1093/molehr/6.1.11; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Christenson LK, 1997, J CLIN ENDOCR METAB, V82, P2135, DOI 10.1210/jc.82.7.2135; Christenson LK, 1999, J BIOL CHEM, V274, P26591, DOI 10.1074/jbc.274.37.26591; Christenson LK, 2001, ENDOCRINOLOGY, V142, P28, DOI 10.1210/endo.142.1.7867; Christenson LK, 2000, BBA-MOL CELL BIOL L, V1529, P175, DOI 10.1016/S1388-1981(00)00147-5; Clark BJ, 1997, ENDOCRINOLOGY, V138, P4893, DOI 10.1210/en.138.11.4893; CLARK BJ, 1995, MOL ENDOCRINOL, V9, P1346, DOI 10.1210/me.9.10.1346; Davie JR, 1999, J CELL BIOCHEM, P141; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; Hazzard TM, 1999, MOL HUM REPROD, V5, P1115, DOI 10.1093/molehr/5.12.1115; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; LaVoie HA, 1999, ENDOCRINOLOGY, V140, P146, DOI 10.1210/en.140.1.146; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luger K, 1998, CURR OPIN GENET DEV, V8, P140, DOI 10.1016/S0959-437X(98)80134-2; MCALLISTER JM, 1994, J CLIN ENDOCR METAB, V79, P106, DOI 10.1210/jc.79.1.106; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; PON LA, 1988, ENDOCRINOLOGY, V123, P1942, DOI 10.1210/endo-123-4-1942; PON LA, 1986, J BIOL CHEM, V261, P3309; PON LA, 1986, ENDOCR RES, V12, P429, DOI 10.3109/07435808609035449; Reinhart AJ, 1999, MOL CELL ENDOCRINOL, V151, P161, DOI 10.1016/S0303-7207(98)00257-3; Reinhart AJ, 1999, MOL ENDOCRINOL, V13, P729, DOI 10.1210/me.13.5.729; Rust W, 1998, J MOL ENDOCRINOL, V21, P189, DOI 10.1677/jme.0.0210189; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Seger R, 2001, J BIOL CHEM, V276, P13957, DOI 10.1074/jbc.M006852200; Silverman E, 1999, J BIOL CHEM, V274, P17987, DOI 10.1074/jbc.274.25.17987; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sugawara T, 2000, ENDOCRINOLOGY, V141, P2895, DOI 10.1210/en.141.8.2895; Sugawara T, 1997, BIOCHEMISTRY-US, V36, P7249, DOI 10.1021/bi9628984; Wang XY, 2001, J BIOL CHEM, V276, P12764, DOI 10.1074/jbc.M100501200; Wang XY, 2000, J BIOL CHEM, V275, P35013, DOI 10.1074/jbc.M004998200; Wooton-Kee CR, 2000, ENDOCRINOLOGY, V141, P1345, DOI 10.1210/en.141.4.1345; Zazopoulos E, 1997, NATURE, V390, P311, DOI 10.1038/36899	46	78	80	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27392	27399		10.1074/jbc.M101650200	http://dx.doi.org/10.1074/jbc.M101650200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11346648	hybrid			2022-12-25	WOS:000169966900088
J	Hii, CST; Moghadammi, N; Dunbar, A; Ferrante, A				Hii, CST; Moghadammi, N; Dunbar, A; Ferrante, A			Activation of the phosphatidylinositol 3-kinase-Akt/protein kinase B signaling pathway in arachidonic acid-stimulated human myeloid and endothelial cells - Involvement of the ErbB receptor family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); POLYUNSATURATED FATTY-ACIDS; P38 MAP KINASE; PROTEIN-KINASE; GROWTH-FACTOR; HUMAN NEUTROPHILS; PHOSPHOINOSITIDE 3-KINASE; DIFFERENTIAL ACTIVATION; SUPEROXIDE-PRODUCTION; REGULATED KINASES	Although arachidonic acid has been demonstrated to stimulate a wide variety of cellular functions, the responsible mechanisms remain poorly defined. We now report that arachidonic acid stimulated the activity of class Ia phosphatidylinositol S-kinase (PI3K) in human umbilical vein endothelial cells, HL60 cells, and human neutrophils. Pretreatment of endothelial cells with AG-1478, an inhibitor of the ErbB receptor family, resulted in the suppression of PI3K activation by arachidonic acid. The fatty acid enhanced the tyrosine phosphorylation of ErbB4 but not of ErbB2 or ErbB3. The ability of arachidonic acid to stimulate PI3K activity in neutrophils was suppressed by indomethacin and nordihydroguaiaretic acid, inhibitors of the cyclooxygenases and lipoxygenases, respectively, but not by 17-octadecynoic acid, an inhibitor of omega -hydroxylation of arachidonic acid by cytochrome P450 monooxygenases. Consistent with this, the activity of PI3K in neutrophils was stimulated by 5-hydroxyeicosatetraenoic acid. Arachidonic acid also transiently stimulated the phosphorylation of Akt on Thr-308 and Ser-473. Although PI3K was not required for the activation of the mitogen-activated protein kinases, ERK1, ERM2, and p38, in arachidonic acid-stimulated neutrophils, the:fatty acid acted via PI3K to stimulate the respiratory burst. These results not only define a novel mechanism through which some of the actions of arachidonic acid are mediated but also demonstrate that, in addition to ErbB1 (epidermal growth factor receptor), ErbB4 can also be transactivated by a non-epidermal growth factor-like ligand.	Womens & Childrens Hosp, Dept Immunopathol, Adelaide, SA 5006, Australia; CSIRO, Mol & Cellular Biol Lab, Cooperat Res Ctr Tissue Growth & Repair, Div Hlth Sci & Nutr, Thebarton, SA 5031, Australia; Univ Adelaide, Dept Paediat, Adelaide, SA 5005, Australia; Univ S Australia, Sch Pharmaceut Mol & Biomed Sci, Adelaide, SA 5001, Australia	Womens & Childrens Hospital Australia; Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of Adelaide; University of South Australia	Hii, CST (corresponding author), Womens & Childrens Hosp, Dept Immunopathol, 72 King William Rd, Adelaide, SA 5006, Australia.	chii01@mail.staff.adelaide.edu.au						Anderson KM, 1997, J BIOL CHEM, V272, P30504, DOI 10.1074/jbc.272.48.30504; AYLSWORTH CF, 1986, CANCER RES, V46, P4527; BADWEY JA, 1981, J BIOL CHEM, V256, P2640; Balsinde J, 2000, J BIOL CHEM, V275, P4783, DOI 10.1074/jbc.275.7.4783; BAND AM, 1992, J MOL ENDOCRINOL, V8, P95, DOI 10.1677/jme.0.0080095; Bertagnolo V, 1999, CANCER RES, V59, P542; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; Burgermeister E, 2000, EUR J PHARMACOL, V388, P195, DOI 10.1016/S0014-2999(99)00816-X; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chang LC, 1999, FEBS LETT, V454, P165, DOI 10.1016/S0014-5793(99)00717-6; Cui XL, 1997, P NATL ACAD SCI USA, V94, P3771, DOI 10.1073/pnas.94.8.3771; DECOURSEY TE, 1993, BIOPHYS J, V65, P1590, DOI 10.1016/S0006-3495(93)81198-6; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; Dulin NO, 1998, HYPERTENSION, V32, P1089, DOI 10.1161/01.HYP.32.6.1089; Egeblad M, 2001, BIOCHEM BIOPH RES CO, V281, P25, DOI 10.1006/bbrc.2001.4302; FERRANTE A, 1982, J IMMUNOL METHODS, V48, P81, DOI 10.1016/0022-1759(82)90212-5; FINSTAD HS, 1994, BLOOD, V84, P3799, DOI 10.1182/blood.V84.11.3799.bloodjournal84113799; Gabrilovich D. I., 1999, NEUTROPHILS NEW OUTL, P79; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Haeggstrom JZ, 1999, CURR INFLAMMAT RES, P51; Hazan-Halevy I, 2000, J BIOL CHEM, V275, P12416, DOI 10.1074/jbc.275.17.12416; Hii CST, 1999, INFECT IMMUN, V67, P1297, DOI 10.1128/IAI.67.3.1297-1302.1999; HII CST, 1995, J BIOL CHEM, V270, P4201, DOI 10.1074/jbc.270.9.4201; Hii CST, 1998, J BIOL CHEM, V273, P19277, DOI 10.1074/jbc.273.30.19277; Hii CST, 2001, IMMUNOLOGY, V102, P59, DOI 10.1046/j.1365-2567.2001.01156.x; HII CST, 1995, CARCINOGENESIS, V16, P1505, DOI 10.1093/carcin/16.7.1505; Hii CST, 1999, ADV EXP MED BIOL, V469, P365; Huang ZH, 1997, CIRC RES, V80, P149, DOI 10.1161/01.RES.80.2.149; Knall C, 1996, J BIOL CHEM, V271, P2832, DOI 10.1074/jbc.271.5.2832; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; Kunapuli P, 1998, J BIOL CHEM, V273, P22442, DOI 10.1074/jbc.273.35.22442; Laffargue M, 1999, J BIOL CHEM, V274, P32835, DOI 10.1074/jbc.274.46.32835; LAVIOLETTE M, 1986, J CLIN INVEST, V77, P54, DOI 10.1172/JCI112301; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Marcil J, 1999, BIOCHEM J, V337, P185, DOI 10.1042/0264-6021:3370185; McMahon B, 2000, J BIOL CHEM, V275, P27566; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; Metzler B, 1998, J BIOL CHEM, V273, P33320, DOI 10.1074/jbc.273.50.33320; MURAKAMI K, 1985, FEBS LETT, V192, P189, DOI 10.1016/0014-5793(85)80105-8; ONODA T, 1989, J NAT PROD, V52, P1252, DOI 10.1021/np50066a009; Paine E, 2000, J BIOL CHEM, V275, P11284, DOI 10.1074/jbc.275.15.11284; Panaretou C, 1997, J BIOL CHEM, V272, P2477; Rao GN, 1999, J BIOL CHEM, V274, P12925, DOI 10.1074/jbc.274.18.12925; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; Rizzo MT, 1996, BLOOD, V88, P3792, DOI 10.1182/blood.V88.10.3792.bloodjournal88103792; Robinson BS, 1997, IMMUNOLOGY, V91, P274, DOI 10.1046/j.1365-2567.1997.d01-2227.x; Robinson BS, 1998, BIOCHEM J, V336, P611, DOI 10.1042/bj3360611; Russell KS, 1999, AM J PHYSIOL-HEART C, V277, pH2205, DOI 10.1152/ajpheart.1999.277.6.H2205; Sajan MP, 1999, J BIOL CHEM, V274, P30495, DOI 10.1074/jbc.274.43.30495; Schwartz Z, 1999, ENDOCRINOLOGY, V140, P2991, DOI 10.1210/en.140.7.2991; SHIKANO M, 1994, BBA-LIPID LIPID MET, V1212, P211, DOI 10.1016/0005-2760(94)90255-0; Smirnov SV, 1996, CIRC RES, V79, P20, DOI 10.1161/01.RES.79.1.20; Stuhlmeier KM, 1997, J BIOL CHEM, V272, P24679, DOI 10.1074/jbc.272.39.24679; Sun WY, 2000, J BIOL CHEM, V275, P24421, DOI 10.1074/jbc.M003148200; Suzuki K, 2000, BIOCHEM BIOPH RES CO, V272, P111, DOI 10.1006/bbrc.2000.2737; Syrbu SI, 1999, J IMMUNOL, V162, P2334; Tang DG, 1997, INT J CANCER, V72, P1078, DOI 10.1002/(SICI)1097-0215(19970917)72:6<1078::AID-IJC24>3.0.CO;2-#; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vinante F, 1999, BLOOD, V94, P3169, DOI 10.1182/blood.V94.9.3169.421k30_3169_3177; Wieland SJ, 1996, J BIOL CHEM, V271, P19037, DOI 10.1074/jbc.271.32.19037; WOLF BA, 1986, J BIOL CHEM, V261, P3501; Wymann MP, 2000, IMMUNOL TODAY, V21, P260, DOI 10.1016/S0167-5699(00)01649-2	65	39	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27246	27255		10.1074/jbc.M103250200	http://dx.doi.org/10.1074/jbc.M103250200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11359783	hybrid			2022-12-25	WOS:000169966900070
J	Cammarano, MS; Minden, A				Cammarano, MS; Minden, A			Dbl and the Rho GTPases activate NF kappa B by I kappa B kinase (IKK)-dependent and IKK-independent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; C-JUN; RAS TRANSFORMATION; PROTEIN-KINASE; CELLULAR-TRANSFORMATION; CYCLIN D1; TRANSCRIPTIONAL ACTIVITY; FOCAL COMPLEXES; FAMILY GTPASES; TAX PROTEIN	Dbl is a guanine nucleotide exchange factor that activates the Rho family GTPases Cdc42, Rac, and Rho, Dbl and all three GTPases are strong activators of transcription factor NF kappaB, which has been shown to have an important role in Dbl-induced oncogenic transformation, Here we show that although Dbl activation of NF kappaB requires Cdc42, Rac, and Rho, the different GTPases activate NF kappaB by different mechanisms. Whereas Rac stimulates the activity of the I kappaB kinase IKK beta, Cdc42 and Rho activate NF kappaB without activating either IKK alpha or IKK beta, Like Dbl, Rac activation of IKK beta is mediated by the serine/threonine kinases NIK but not MEKK. This differs from Rac activation of the JNK pathway, which was previously shown to be mediated by MEKK, The pathway leading from Rho and Cdc42 to NF kappaB is more elusive, but our results suggest that it involves an IKK alpha /IKK beta -independent mechanism. Finally, we show that the signaling enzymes that mediate NF kappaB activation by Dbl and the Rho GTPases are also necessary for malignant transformation induced by oncogenic Dbl.	Columbia Univ, Sherman Fairchild Ctr, Dept Biol Sci MC 2460, New York, NY 10027 USA	Columbia University	Minden, A (corresponding author), Columbia Univ, Sherman Fairchild Ctr, Dept Biol Sci MC 2460, Rm 813,1212 Amsterdam Ave, New York, NY 10027 USA.				NATIONAL CANCER INSTITUTE [R01CA076342] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA76342] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baichwal V. R., 1997, CURR BIOL, V7, P94; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dutartre H, 1996, J CELL SCI, V109, P367; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HART MJ, 1994, J BIOL CHEM, V269, P62; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VAN AD, 1996, SCIENCE, V274, P787; VAN AL, 1997, GENE DEV, V11, P2295; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	70	73	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25876	25882		10.1074/jbc.M011345200	http://dx.doi.org/10.1074/jbc.M011345200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11337492	hybrid			2022-12-25	WOS:000169823300033
J	Takeuchi, K; Shibamoto, S; Nagamine, K; Shigemori, I; Omura, S; Kitamura, N; Ito, F				Takeuchi, K; Shibamoto, S; Nagamine, K; Shigemori, I; Omura, S; Kitamura, N; Ito, F			Signaling pathways leading to transcription and translation cooperatively regulate the transient increase in expression of c-Fos protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE-GROWTH-FACTOR; TUMOR NECROSIS FACTOR; TERNARY COMPLEX-FORMATION; RECEPTOR TYROSINE KINASE; SCATTER FACTOR-RECEPTOR; MESSENGER-RNA; EGF-RECEPTOR; PHAS-I; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE	The mechanisms by which growth factors trigger signal transduction pathways leading to the regulation of c-Fos expression are of great interest. in this study we investigated the effect of hepatocyte growth factor (HGF/SF) and epidermal growth factor (EGF) on the expression of c-fos and its product, c-Fos, in human epithelial cell line MKN74, The expression level of c-Fos protein in HGF/SF-stimulated cells was 5-10-fold higher than that in EGF-stimulated cells, whereas the level of c-fos mRNA induced by HGF/SF was similar to that by EGF, The hyperphosphorylation of eukaryotic initiation factor 4E-binding protein 1 (4E-BP1), indicative of an increased number of translation initiation complexes, was detected only in HGF/SF-induced MKN74 cells. Activation of phosphatidylinositol-3 ' -OH kinase and FKBP12-rapamycin associated mammalian target of rapamycin (FRAP/mTOR) was observed after the treatment with HGF/SF, Pretreatment with an inhibitor of either one, i.e. LY294002 for phosphatidylinositol-3 ' -OH kinase or rapamycin for FRAP/mTOR, completely inhibited 4E-BP1 phosphorylation and decreased the c-Fos synthesis induced by HGF/SF down to the level found in EGF-induced cells. These results suggest that the phosphorylation of 4E-BP1 is stimulated by HGF/SF in a manner requiring both phosphatidy-linositol-3 ' -OH kinase-dependent and FRAP/mTOR-dependent pathways, thereby stimulating c-fos mRNA translation. Regulation of the translation process of c-fos mRNA in addition to the immediate activation of c-fos transcription is necessary for the transient increase in the level of c-Fos protein to stimulate cell proliferation.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Dept Life Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Kitasato Inst, Res Ctr Biol Funct, Minato Ku, Tokyo 1088642, Japan; Setsunan Univ, Fac Pharmaceut Sci, Dept Biochem, Hirakata, Osaka 5730101, Japan	Tokyo Institute of Technology; Setsunan University	Shibamoto, S (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way,MS 40, S San Francisco, CA 94080 USA.			Ito, Fumiaki/0000-0002-4129-4899				Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; CHATANI Y, 1992, BIOCHEM BIOPH RES CO, V185, P860, DOI 10.1016/0006-291X(92)91706-V; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; KIM HH, 1994, J BIOL CHEM, V269, P24747; Kleijn M, 1998, EUR J BIOCHEM, V253, P531, DOI 10.1046/j.1432-1327.1998.2530531.x; Kleijn M, 1996, FEBS LETT, V396, P165, DOI 10.1016/0014-5793(96)01097-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN JX, 1987, J BIOL CHEM, V262, P11908; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MADER S, 1995, MOL CELL BIOL, V15, P4990; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; Mendez R, 1996, MOL CELL BIOL, V16, P2857; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; Nagamine K, 1996, EUR J BIOCHEM, V236, P476, DOI 10.1111/j.1432-1033.1996.t01-1-00476.x; NALDINI L, 1991, ONCOGENE, V6, P501; NISHIBE S, 1989, J BIOL CHEM, V264, P10335; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; OMURA S, 1991, J ANTIBIOT, V44, P117, DOI 10.7164/antibiotics.44.117; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; SASSONECORSI P, 1987, NATURE, V326, P507, DOI 10.1038/326507a0; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHIBAMOTO S, 1992, CELL STRUCT FUNCT, V17, P185, DOI 10.1247/csf.17.185; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; SONENBERG N, 1978, P NATL ACAD SCI USA, V75, P4843, DOI 10.1073/pnas.75.10.4843; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; STRAIN AJ, 1991, J CLIN INVEST, V87, P1853, DOI 10.1172/JCI115207; Tanimura S, 1998, ONCOGENE, V17, P57, DOI 10.1038/sj.onc.1201905; TSUJIMOTO M, 1986, J IMMUNOL, V136, P2441; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990	56	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26077	26083		10.1074/jbc.M102704200	http://dx.doi.org/10.1074/jbc.M102704200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11352916	hybrid			2022-12-25	WOS:000169823300060
J	Yarnell, AT; Oh, S; Reinberg, D; Lippard, SJ				Yarnell, AT; Oh, S; Reinberg, D; Lippard, SJ			Interaction of FACT, SSRP1, and the high mobility group (HMG) domain of SSRP1 with DNA damaged by the anticancer drug cisplatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; YEAST PROTEIN; LARGE SUBUNIT; TRANSCRIPTION; ADDUCTS; BINDING; REPAIR; CDC68; RECOGNITION; POB3	The structure-specific recognition protein SSRP1, initially isolated from expression screening of a human B-cell cDNA library for proteins that bind to cisplatin (cis-diamminedichloroplatinum(II))-modified DNA, contains a single DNA-binding high mobility group (HMG) domain. Human SSRP1 purifies as a heterodimer of SSRP1 and Spt16 (FACT) that alleviates the nucleosomal block to transcription elongation by RNAPII in vitro. The affinity and specificity of FACT, SSRP1, and the isolated HMG domain of SSRP1 for cisplatin-damaged DNA were investigated by gel mobility shift assays, FACT exhibits both affinity and specificity for DNA damaged globally with cisplatin compared with unmodified DNA or DNA damaged globally with the clinically ineffective trans-DDP isomer, FACT binds the major 1,2-d(GpG) intrastrand cisplatin adduct, but its isolated SSRP1 subunit fails to form discrete, high affinity complexes with cisplatin-modified DNA under similar conditions. These results suggest that Spt16 primes SSRP1 for cisplatin-damaged DNA recognition by unveiling its HMG domain, As expected, the isolated HMG domain of SSRP1 is sufficient for specific binding to cisplatin-damaged DNA and binds the major cisplatin 1,1-d(GpG) intrastrand cross-link, The affinity and specificity of FACT for cisplatin-modified DNA as well as its importance for transcription of chromatin, suggests that the interaction of FACT and cisplatin-damaged DNA may be crucial to the anticancer mechanism of cisplatin.	MIT, Dept Chem, Cambridge, MA 02139 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Howard Hughes Med Inst, Div Nucleic Acids Enzymol,Dept Biochem, Piscataway, NJ 08854 USA	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center	Lippard, SJ (corresponding author), MIT, Dept Chem, Rm 18-590, Cambridge, MA 02139 USA.	lippard@lippard.mit.edu		Reinberg, Danny/0000-0003-4288-2016	NATIONAL CANCER INSTITUTE [R01CA034992, R37CA034992] Funding Source: NIH RePORTER; NCI NIH HHS [CA34992] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BILLINGS PC, 1992, BIOCHEM BIOPH RES CO, V188, P1286, DOI 10.1016/0006-291X(92)91371-V; Brewster NK, 1998, J BIOL CHEM, V273, P21972, DOI 10.1074/jbc.273.34.21972; BROWN SJ, 1993, SCIENCE, V261, P603, DOI 10.1126/science.8342024; BRUHN SL, 1993, NUCLEIC ACIDS RES, V21, P1643, DOI 10.1093/nar/21.7.1643; BRUHN SL, 1992, P NATL ACAD SCI USA, V89, P2307, DOI 10.1073/pnas.89.6.2307; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CHOW CS, 1995, BIOCHEMISTRY-US, V34, P2956, DOI 10.1021/bi00009a027; CHOW CS, 1994, BIOCHEMISTRY-US, V33, P15124, DOI 10.1021/bi00254a023; DONAHUE BA, 1990, BIOCHEMISTRY-US, V29, P5872, DOI 10.1021/bi00476a032; Dunham SU, 1997, BIOCHEMISTRY-US, V36, P11428, DOI 10.1021/bi9709452; Evans DRH, 1998, GENETICS, V150, P1393; FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025; Fleck O, 1998, J BIOL CHEM, V273, P30398, DOI 10.1074/jbc.273.46.30398; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HANSEN JC, 1994, P NATL ACAD SCI USA, V91, P2339, DOI 10.1073/pnas.91.6.2339; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; HUGHES EN, 1992, J BIOL CHEM, V267, P13520; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; Jordan P, 1998, NUCLEIC ACIDS RES, V26, P2831, DOI 10.1093/nar/26.12.2831; LEPRE CA, 1990, NUCLEIC ACIDS MOL BI, P9, DOI DOI 10.1007/978-3-642-84150-7_2; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LYCAN D, 1994, MOL CELL BIOL, V14, P7455, DOI 10.1128/MCB.14.11.7455; McANulty MM, 1996, BIOCHEMISTRY-US, V35, P6089, DOI 10.1021/bi952877u; McANulty MM, 1996, MUTAT RES-DNA REPAIR, V362, P75, DOI 10.1016/0921-8777(95)00037-2; Mitsui A, 1999, P NATL ACAD SCI USA, V96, P6054, DOI 10.1073/pnas.96.11.6054; Okuhara K, 1999, CURR BIOL, V9, P341, DOI 10.1016/S0960-9822(99)80160-2; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; Pil P., 1997, ENCY CANC, P392; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; Ratner JN, 1998, J BIOL CHEM, V273, P5184, DOI 10.1074/jbc.273.9.5184; Sandman KE, 1999, CHEM BIOL, V6, P541, DOI 10.1016/S1074-5521(99)80086-6; Santisteban MS, 1997, EMBO J, V16, P2493, DOI 10.1093/emboj/16.9.2493; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; TAKAHARA PM, 1995, NATURE, V377, P649, DOI 10.1038/377649a0; TONEY JH, 1989, P NATL ACAD SCI USA, V86, P8328, DOI 10.1073/pnas.86.21.8328; TREIBER DK, 1994, P NATL ACAD SCI USA, V91, P5672, DOI 10.1073/pnas.91.12.5672; Trimmer EE, 1998, BIOCHEMISTRY-US, V37, P352, DOI 10.1021/bi971675q; Wittmeyer J, 1999, BIOCHEMISTRY-US, V38, P8961, DOI 10.1021/bi982851d; WOLFFE AP, 1994, CURR OPIN GENET DEV, V4, P245, DOI 10.1016/S0959-437X(05)80051-6; XU QL, 1993, MOL CELL BIOL, V13, P7553, DOI 10.1128/MCB.13.12.7553; Zamble DB, 1996, BIOCHEMISTRY-US, V35, P10004, DOI 10.1021/bi960453+; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7; Zhai XQ, 1998, BIOCHEMISTRY-US, V37, P16307, DOI 10.1021/bi981708h	46	83	89	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25736	25741		10.1074/jbc.M101208200	http://dx.doi.org/10.1074/jbc.M101208200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11344167	hybrid			2022-12-25	WOS:000169823300015
J	Lopes, CMB; Zilberberg, N; Goldstein, SAN				Lopes, CMB; Zilberberg, N; Goldstein, SAN			Block of Kcnk3 by protons - Evidence that 2-p-domain potassium channel subunits function as homodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN K+ CHANNEL; 2 PORE DOMAINS; EXTRACELLULAR K+; LEAK CHANNEL; TASK-1; SELECTIVITY; EXPRESSION; FAMILY; TANDEM; REGION	KCNK subunits have two pore-forming P domains and four predicted transmembrane segments. To assess the number of subunits in each pore, we studied external proton block of Kcnk3, a subunit prominent in rodent heart and brain. Consistent with a pore-blocking mechanism, inhibition was dependent on voltage, potassium concentration, and a histidine in the first P domain (P1H). Thus, at pH 6.8 with 20 mM potassium half the current passed by P1H channels was blocked (apparently via two sites similar to 10% into the electrical field) whereas channels with an asparagine substitution (P1N) were fully active. Furthermore, pore blockade by barium was sensitive to pH in P1H but not P1N channels. Although linking two Kcnk3 subunits in tandem to produce P1H-P1H and P1N-P1N channels bearing four P domains did not alter these attributes, the mixed tandems P1H-P1N and P1N-P1H were half-blocked at pH similar to6.4, apparently via a single site. This implicates a dimeric structure for Kcnk3 channels with two (and only two) P1 domains in each pore and argues that P2 domains also contribute to pore formation.	Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06536 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06536 USA	Yale University; Yale University	Goldstein, SAN (corresponding author), 295 Congress Ave, New Haven, CT 06536 USA.		Zilberberg, Noam/F-2005-2012; Goldstein, Steven A./E-9817-2015	Goldstein, Steven A./0000-0001-5207-5061; Zilberberg, Noam/0000-0002-7848-2391				Bockenhauer D, 2001, NAT NEUROSCI, V4, P486, DOI 10.1038/87434; Buckler KJ, 2000, J PHYSIOL-LONDON, V525, P135, DOI 10.1111/j.1469-7793.2000.00135.x; Czirjak G, 2000, MOL ENDOCRINOL, V14, P863, DOI 10.1210/me.14.6.863; Decher N, 2001, FEBS LETT, V492, P84, DOI 10.1016/S0014-5793(01)02222-0; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Goldman DE, 1943, J GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37; Goldstein SAN, 1996, P NATL ACAD SCI USA, V93, P13256, DOI 10.1073/pnas.93.23.13256; Goldstein SAN, 2001, NAT REV NEUROSCI, V2, P175, DOI 10.1038/35058574; HODGKIN AL, 1952, J PHYSIOL-LONDON, V116, P424, DOI 10.1113/jphysiol.1952.sp004716; Ilan N, 2001, BIOPHYS J, V80, P241, DOI 10.1016/S0006-3495(01)76010-9; Jiang YX, 2000, J GEN PHYSIOL, V115, P269, DOI 10.1085/jgp.115.3.269; KETCHUM KA, 1995, NATURE, V376, P690, DOI 10.1038/376690a0; Kim Y, 1999, AM J PHYSIOL-HEART C, V277, pH1669, DOI 10.1152/ajpheart.1999.277.5.H1669; Kim Y, 2000, J BIOL CHEM, V275, P9340, DOI 10.1074/jbc.275.13.9340; Lesage F, 1996, EMBO J, V15, P6400, DOI 10.1002/j.1460-2075.1996.tb01031.x; Lopes CMB, 2000, J BIOL CHEM, V275, P16969, DOI 10.1074/jbc.M001948200; Loukin SH, 1997, EMBO J, V16, P4817, DOI 10.1093/emboj/16.16.4817; Millar JA, 2000, P NATL ACAD SCI USA, V97, P3614, DOI 10.1073/pnas.050012597; Morrill JA, 1999, J GEN PHYSIOL, V114, P71, DOI 10.1085/jgp.114.1.71; NEYTON J, 1988, J GEN PHYSIOL, V92, P569, DOI 10.1085/jgp.92.5.569; Sabirov RZ, 1997, J GEN PHYSIOL, V110, P665, DOI 10.1085/jgp.110.6.665; Talley EM, 2000, NEURON, V25, P399, DOI 10.1016/S0896-6273(00)80903-4; Vergani P, 1997, FEBS LETT, V405, P337, DOI 10.1016/S0014-5793(97)00211-1; Vergani P, 1998, EMBO J, V17, P7190, DOI 10.1093/emboj/17.24.7190; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; Zilberberg N, 2000, J GEN PHYSIOL, V116, P721, DOI 10.1085/jgp.116.5.721	28	103	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24449	24452		10.1074/jbc.C100184200	http://dx.doi.org/10.1074/jbc.C100184200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11358956	hybrid			2022-12-25	WOS:000169800700005
J	Macdonald, JR; Bachinger, HP				Macdonald, JR; Bachinger, HP			HSP47 binds cooperatively to triple helical type I collagen but has little effect on the thermal stability or rate of refolding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; MOLECULAR CHAPERONE HSP47; ENDOPLASMIC-RETICULUM; PROCOLLAGEN; REQUIREMENTS; PURIFICATION; GLYCOPROTEIN; RECOGNITION; EXPRESSION; SECRETION	HSP47, a collagen-specific molecular chaperone, interacts with unfolded and folded procollagens. Binding of chicken HSP47 to native bovine type I collagen was studied by fluorescence quenching and cooperative binding with a collagen concentration at half saturation (K-half) of 1.4 x 10(-7) M, and a Hill coefficient of 4.3 was observed. Similar results are observed for the binding of mouse HSP47 recombinantly expressed in Escherichia coli, Chicken HSP47 binds equally well to native type II and type III procollagen without the carboxyl-terminal propeptide (pN type III collagen), but binding to triple helical collagen-like peptides is much weaker. Weak binding occurred to both hydroxylated and nonhydroxylated collagen-like peptides, and a significant chain length dependence was observed. Binding of HSP47 to native type I collagen had no effect on the thermal stability of the triple helix. Refolding of type I collagen in the presence of HSP47 showed minor changes, but these are probably not biologically significant. Binding of HSP47 to bovine pN type III collagen has only minor effects on the thermal stability of the triple helix and does not influence the refolding kinetics of the triple helix.	Shriners Hosp Children, Res Unit, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Bachinger, HP (corresponding author), Shriners Hosp Children, Res Unit, 3101 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	hpb@shcc.org		Macdonald, Randy/0000-0001-7203-1234				BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; Bonfanti L, 1998, CELL, V95, P993, DOI 10.1016/S0092-8674(00)81723-7; HIRAYOSHI K, 1991, MOL CELL BIOL, V11, P4036, DOI 10.1128/MCB.11.8.4036; Hosokawa N, 1998, J BIOCHEM-TOKYO, V124, P654, DOI 10.1093/oxfordjournals.jbchem.a022162; KAMBE K, 1994, J HISTOCHEM CYTOCHEM, V42, P833, DOI 10.1177/42.7.8014466; Koide T, 1999, J BIOL CHEM, V274, P34523, DOI 10.1074/jbc.274.49.34523; Koide T, 2000, J BIOL CHEM, V275, P27957; Nagai N, 2000, J CELL BIOL, V150, P1499, DOI 10.1083/jcb.150.6.1499; Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/0968-0004(96)80881-4; NAGATA K, 1988, BIOCHEM BIOPH RES CO, V153, P428, DOI 10.1016/S0006-291X(88)81242-7; Nagata K, 1998, MATRIX BIOL, V16, P379, DOI 10.1016/S0945-053X(98)90011-7; NATSUME T, 1994, J BIOL CHEM, V269, P31224; SAGA S, 1987, J CELL BIOL, V105, P517, DOI 10.1083/jcb.105.1.517; Satoh M, 1996, J CELL BIOL, V133, P469, DOI 10.1083/jcb.133.2.469; SAUK JJ, 1994, J BIOL CHEM, V269, P3941; SMITH T, 1995, J BIOL CHEM, V270, P18323, DOI 10.1074/jbc.270.31.18323; Tanaka Y, 1996, EXP EYE RES, V63, P383, DOI 10.1006/exer.1996.0128; Tasab M, 2000, EMBO J, V19, P2204, DOI 10.1093/emboj/19.10.2204; Thomson CA, 2000, BIOCHEM J, V349, P877, DOI 10.1042/bj3490877; Tomita M, 1999, J BIOCHEM, V126, P1118, DOI 10.1093/oxfordjournals.jbchem.a022557; VAILLANCOURT JP, 1991, BIOCHEM J, V274, P793, DOI 10.1042/bj2740793	21	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25399	25403		10.1074/jbc.M102471200	http://dx.doi.org/10.1074/jbc.M102471200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11333272	hybrid			2022-12-25	WOS:000169800700129
J	Morrison, BH; Bauer, JA; Kalvakolanu, DV; Lindner, DJ				Morrison, BH; Bauer, JA; Kalvakolanu, DV; Lindner, DJ			Inositol hexakisphosphate kinase 2 mediates growth suppressive and apoptotic effects of interferon-beta in ovarian carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE HEMATOPOIETIC-CELLS; HUMAN-LEUKOCYTE INTERFERONS; DIPHOSPHOINOSITOL PENTAKISPHOSPHATE; PROTEIN-KINASE; INTERLEUKIN-6 SUPPRESS; IN-VITRO; EXPRESSION; IDENTIFICATION; RECOMBINANT; ALPHA	Interferons (IFNs) regulate the expression of genes that mediate their antiviral, antitumor, and immunomodulatory actions. We have previously shown that IFN-beta suppresses growth of human ovarian carcinoma xenografts in vivo and induces apoptosis of ovarian carcinoma cells in vitro. To investigate mechanisms of IFN-beta -induced apoptosis we employed an antisense technical knockout approach to identify gene products that mediate cell death and have isolated several regulators of interferon-induced death (RIDs). In this investigation, we have characterized one of the RIDs, RID-2. Sequence analysis revealed that RID-2 was identical to human inositol hexakisphosphate kinase 2 (IP6K2). IP6K2 is post-transcriptionally induced by IFN-beta in ovarian carcinoma cells. A mutant IP6K2 with substitutions in the putative inositol phosphate binding domain abrogates IFN-beta -induced apoptosis. These studies identify a novel function for IP6K2 in cell growth regulation and apoptosis.	Univ Maryland, Sch Med, Greenebaum Canc Ctr, Dept Microbiol & Immunol, Baltimore, MD 21201 USA; Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Ctr Canc Drug Dev & Discovery,Taussig Canc Ctr, Cleveland, OH 44195 USA	University System of Maryland; University of Maryland Baltimore; Cleveland Clinic Foundation	Lindner, DJ (corresponding author), 9500 Euclid Ave,R40, Cleveland, OH 44195 USA.		Lindner, Daniel/ABB-5440-2020	Bauer, Joseph/0000-0003-4972-6008	NCI NIH HHS [CA78282, CA71401, R01 CA095020-01A1, R01 CA078282] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095020, R01CA078282, R01CA071401] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBER GN, 1995, MOL CELL BIOL, V15, P3138; Blackshaw S, 2000, FASEB J, V14, P1375, DOI 10.1096/fj.14.10.1375; DAMELL JE, 1997, SCIENCE, V277, P1630; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; EVINGER M, 1981, ARCH BIOCHEM BIOPHYS, V210, P319, DOI 10.1016/0003-9861(81)90195-8; GREINER JW, 1987, SCIENCE, V235, P895, DOI 10.1126/science.3580039; GREINER JW, 1984, CANCER RES, V44, P3208; GRESSER I, 1969, P NATL ACAD SCI USA, V63, P51, DOI 10.1073/pnas.63.1.51; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Huang CF, 1998, BIOCHEMISTRY-US, V37, P14998, DOI 10.1021/bi981920l; Kalvakolanu DV, 2000, HISTOL HISTOPATHOL, V15, P523, DOI 10.14670/HH-15.523; Kinoshita S, 1998, PHARMACEUT RES, V15, P1851, DOI 10.1023/A:1011953906065; KUMAR R, 1992, P NATL ACAD SCI USA, V89, P6599, DOI 10.1073/pnas.89.14.6599; Lindner DJ, 1997, J INTERF CYTOK RES, V17, P681, DOI 10.1089/jir.1997.17.681; MEISSNER PS, 1987, P NATL ACAD SCI USA, V84, P4171, DOI 10.1073/pnas.84.12.4171; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; ORTALDO JR, 1983, J BIOL CHEM, V258, P5011; RAMET M, 1995, CARCINOGENESIS, V16, P2117, DOI 10.1093/carcin/16.9.2117; Raveh T, 1996, J BIOL CHEM, V271, P25479, DOI 10.1074/jbc.271.41.25479; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; Saiardi A, 2000, J BIOL CHEM, V275, P24686, DOI 10.1074/jbc.M002750200; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Samuel CE, 1997, INT J HEMATOL, V65, P227; SHEARS SB, 1995, J BIOL CHEM, V270, P10489, DOI 10.1074/jbc.270.18.10489; Silverman R., 1997, RIBONUCLEASES STRUCT, P515; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; STEPHENS L, 1993, J BIOL CHEM, V268, P4009; Togashi S, 1997, BIOCHEM J, V326, P221, DOI 10.1042/bj3260221; Voglmaier SM, 1996, P NATL ACAD SCI USA, V93, P4305, DOI 10.1073/pnas.93.9.4305; Vyas P, 2000, P NATL ACAD SCI USA, V97, P13696, DOI 10.1073/pnas.250476397; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; YAGINUMA Y, 1992, CANCER RES, V52, P4196	37	123	133	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24965	24970		10.1074/jbc.M101161200	http://dx.doi.org/10.1074/jbc.M101161200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11337497	Green Accepted, hybrid			2022-12-25	WOS:000169800700071
J	Denning, G; Jamieson, L; Maquat, LE; Thompson, EA; Fields, AP				Denning, G; Jamieson, L; Maquat, LE; Thompson, EA; Fields, AP			Cloning of a novel phosphatidylinositol kinase-related kinase - Characterization of the human SMG-1 RNA surveillance protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CHECKPOINTS; MESSENGER-RNA; PHOSPHOINOSITIDE 3-KINASE; MAMMALIAN TARGET; FKBP12-RAPAMYCIN-ASSOCIATED PROTEIN; CAENORHABDITIS-ELEGANS; G(1) PROGRESSION; MEDIATED DECAY; HUMAN HOMOLOG; UPF1 PROTEIN	We have cloned and characterized a new member of the phosphatidylinositol kinase (PIK)-related kinase family. This gene, which we term human SMG-1 (hSMG- 1), is orthologous to Caenorhabditis elegans SMG-1, a protein that functions in nonsense-mediated mRNA decay (NMD). cDNA sequencing revealed that hSMG-1 encodes a protein of 3031 amino acids containing a conserved kinase domain, a C-terminal domain unique to the PIK-related kinases and an FKBP12-rapamycin binding-like domain similar to that found in the PIK-related kinase mTOR. Immunopurified FLAG-tagged hSMG-1 exhibits protein kinase activity as measured by autophosphorylation and phosphorylation of the generic PIK-related kinase substrate PHAS-1. hSMG-1 kinase activity is inhibited by high nanomolar concentrations of wortmannin (IC50 = 105 nM) but is not inhibited by a FISBP12-rapamycin complex. Mutation of conserved residues within the kinase domain of hSMG-1 abolishes both autophosphorylation and substrate phosphorylation, demonstrating that hSMG-1 exhibits intrinsic protein kinase activity. hSMG-1 phosphorylates purified hUpf1 protein, a phosphoprotein that plays a critical role in NMD, at sites that are also phosphorylated in whole cells. Eased on these data, we conclude that hSMG-1 is the human orthologue to C. elegans SMG-1. Our data indicate that hSMG-1 may function in NMD by directly phosphorylating hUpf1 protein at physiologically relevant sites.	Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA; Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Rochester	Fields, AP (corresponding author), Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, 301 Univ Blvd, Galveston, TX 77555 USA.	afields@utmb.edu		Maquat, Lynne/0000-0002-2789-2075	NCI NIH HHS [R01 CA56869] Funding Source: Medline; NIDDK NIH HHS [DK33938] Funding Source: Medline; NIGMS NIH HHS [GM59614] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059614] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Applequist SE, 1997, NUCLEIC ACIDS RES, V25, P814, DOI 10.1093/nar/25.4.814; Bentley NJ, 1997, BIOL CHEM, V378, P1267; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Bosotti R, 2000, TRENDS BIOCHEM SCI, V25, P225, DOI 10.1016/S0968-0004(00)01563-2; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; Cutler NS, 1999, MOL CELL ENDOCRINOL, V155, P135, DOI 10.1016/S0303-7207(99)00121-5; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; Frischmeyer PA, 1999, HUM MOL GENET, V8, P1893, DOI 10.1093/hmg/8.10.1893; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Hilleren P, 1999, ANNU REV GENET, V33, P229, DOI 10.1146/annurev.genet.33.1.229; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Ishikawa K, 1997, DNA Res, V4, P307, DOI 10.1093/dnares/4.5.307; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Lelivelt MJ, 1999, MOL CELL BIOL, V19, P6710; Lew JE, 1998, MOL CELL BIOL, V18, P6121, DOI 10.1128/MCB.18.10.6121; Li SL, 1998, IMMUNITY, V8, P135, DOI 10.1016/S1074-7613(00)80466-5; Maquat LE, 2001, CELL, V104, P173, DOI 10.1016/S0092-8674(01)00202-1; MAQUAT LE, 1995, RNA, V1, P453; Mitrovich QM, 2000, GENE DEV, V14, P2173, DOI 10.1101/gad.819900; Moriarty PM, 1998, MOL CELL BIOL, V18, P2932, DOI 10.1128/MCB.18.5.2932; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; Page MF, 1999, MOL CELL BIOL, V19, P5943; Pal M, 2001, RNA, V7, P5, DOI 10.1017/S1355838201000127; Perlick HA, 1996, P NATL ACAD SCI USA, V93, P10928, DOI 10.1073/pnas.93.20.10928; PULAK R, 1993, GENE DEV, V7, P1885, DOI 10.1101/gad.7.10.1885; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Sarkaria JN, 1998, CANCER RES, V58, P4375; Sun XL, 1998, P NATL ACAD SCI USA, V95, P10009, DOI 10.1073/pnas.95.17.10009; Vilella-Bach M, 1999, J BIOL CHEM, V274, P4266, DOI 10.1074/jbc.274.7.4266; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Wymann MP, 1996, MOL CELL BIOL, V16, P1722	42	122	128	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22709	22714		10.1074/jbc.C100144200	http://dx.doi.org/10.1074/jbc.C100144200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11331269	hybrid			2022-12-25	WOS:000169412700098
J	Burke, B; Lipman, RSA; Shiba, K; Musier-Forsyth, K; Hou, YM				Burke, B; Lipman, RSA; Shiba, K; Musier-Forsyth, K; Hou, YM			Divergent adaptation of tRNA recognition by Methanococcus jannaschii prolyl-tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ACCEPTOR STEM; AMINOACYLATION; TRNA(PRO); EVOLUTION; COMPLEX; GENOME; CODE	Analysis of prolyl-tRNA synthetase (ProRS) across all three taxonomic domains (Eubacteria, Eucarya, and Archaea) reveals that the sequences are divided into two distinct groups. Recent studies show that Escherichia coti ProRS, a member of the "prokaryotic-like" group, recognizes specific tRNA bases at both the acceptor and anticodon ends, whereas human ProRS, a member of the "eukaryotic-like" group, recognizes nucleotide bases primarily in the anticodon, The archaeal Methanococcus jannaschii ProRS is a member of the eukaryotic-like group, although its tRNA(Pro) possesses prokaryotic features in the acceptor stem, We show here that, in some respects, recognition of tRNA(Pro) by M. jannaschii ProRS parallels that of human, with a strong emphasis on the anticodon and only weak recognition of the acceptor stem. However, our data also indicate differences in the details of the anticodon recognition between these two eukaryotic-like synthetases. Although the human enzyme places a stronger emphasis on G35, the M. jannaschii enzyme places a stronger emphasis on G36, a feature that is shared by E. coli ProRS. These results, interpreted in the context of an extensive sequence alignment., provide evidence of divergent adaptation by M. jannaschii ProRS; recognition of the tRNA acceptor end is eukaryotic-like, whereas the details of the anticodon recognition are prokaryotic-like, This divergence may be a reflection of the unusual dual function of this enzyme, which catalyzes specific aminoacylation with proline as well as with cysteine.	Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA; Thomas Jefferson Univ, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA; Japanese Fdn Canc Res, Inst Canc, Dept Cell Biol, Toshima Ku, Tokyo 170, Japan	University of Minnesota System; University of Minnesota Twin Cities; Jefferson University; Japanese Foundation for Cancer Research	Hou, YM (corresponding author), Univ Minnesota, Dept Chem, 207 Pleasant St SE, Minneapolis, MN 55455 USA.	Ya-Ming.Hou@mail.tju.edu	Shiba, Kiyotaka/I-9588-2014	Shiba, Kiyotaka/0000-0001-6459-0204; Hou, Ya-Ming/0000-0001-6546-2597	NIGMS NIH HHS [GM49928, GM56662] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049928, R01GM056662, R55GM049928, R29GM049928] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Bunjun S, 2000, P NATL ACAD SCI USA, V97, P12997, DOI 10.1073/pnas.230444397; Burke B, 2000, BIOCHEMISTRY-US, V39, P15540, DOI 10.1021/bi001835p; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; Chihade JW, 1998, BIOCHEMISTRY-US, V37, P9193, DOI 10.1021/bi9804636; Cusack S, 1998, STRUCTURE, V6, P101, DOI 10.1016/S0969-2126(98)00011-2; Cusack S, 1996, EMBO J, V15, P2834, DOI 10.1002/j.1460-2075.1996.tb00644.x; Eiler S, 1999, EMBO J, V18, P6532, DOI 10.1093/emboj/18.22.6532; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P1, DOI 10.1021/bi00672a001; Giege R, 1998, NUCLEIC ACIDS RES, V26, P5017, DOI 10.1093/nar/26.22.5017; Goldgur Y, 1997, STRUCTURE, V5, P59, DOI 10.1016/S0969-2126(97)00166-4; HIPPS D, 1995, P NATL ACAD SCI USA, V92, P5550, DOI 10.1073/pnas.92.12.5550; HOU YM, 1993, P NATL ACAD SCI USA, V90, P6776, DOI 10.1073/pnas.90.14.6776; Lipman RSA, 2000, BIOCHEMISTRY-US, V39, P7792, DOI 10.1021/bi0004955; LIU HJ, 1995, NUCLEIC ACIDS RES, V23, P165, DOI 10.1093/nar/23.1.165; QUINN CL, 1995, BIOCHEMISTRY-US, V34, P12489, DOI 10.1021/bi00039a001; RIPMASTER TL, 1995, P NATL ACAD SCI USA, V92, P4932, DOI 10.1073/pnas.92.11.4932; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; Shiba K, 1997, J BIOL CHEM, V272, P22809, DOI 10.1074/jbc.272.36.22809; SHIBA K, 1995, BIOCHEMISTRY-US, V34, P10340, DOI 10.1021/bi00033a004; Stathopoulos C, 2000, SCIENCE, V287, P479, DOI 10.1126/science.287.5452.479; Steer BA, 1999, BIOCHEMISTRY-US, V38, P4965, DOI 10.1021/bi990038s; Stehlin C, 1998, BIOCHEMISTRY-US, V37, P8605, DOI 10.1021/bi980364s; Wakasugi K, 1998, EMBO J, V17, P297, DOI 10.1093/emboj/17.1.297; Yaremchuk A, 2000, EMBO J, V19, P4745, DOI 10.1093/emboj/19.17.4745	25	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20286	20291		10.1074/jbc.M100456200	http://dx.doi.org/10.1074/jbc.M100456200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11342535	hybrid			2022-12-25	WOS:000169135100084
J	Moll, M; Klenk, HD; Herrler, G; Maisner, A				Moll, M; Klenk, HD; Herrler, G; Maisner, A			A single amino acid change in the cytoplasmic domains of measles virus glycoproteins H and F alters targeting, endocytosis, and cell fusion in polarized Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE COFACTOR PROTEIN; COATED PITS; INTERNALIZATION SIGNAL; EPITHELIAL-CELLS; SORTING SIGNALS; MDCK CELLS; HEMAGGLUTININ; RECEPTOR; ENVELOPE; RECOGNITION	As we have shown previously, release of measles virus (MV) from polarized epithelial cells is not determined by the viral envelope proteins H and F, Although virus budding is restricted to the apical surfaces, both proteins were abundantly expressed on the basolateral surface of Madin-Darby canine kidney cells. In this report, we provide evidence that the basolateral expression of the viral proteins is of biological importance for the MV infection of polarized epithelial cells. We demonstrate that both MV glycoproteins possess a basolateral targeting signal that is dependent upon the unique tyrosine in the cytoplasmic tails. These tyrosines are shown to be also part of an endocytosis signal. In MV-infected cells, internalization of the glycoproteins was not observed, indicating that recognition of the endocytosis signals is disturbed by viral factors. In contrast, basolateral transport was not substantially hindered, resulting in efficient cell-to-cell fusion of polarized Madin-Darby canine kidney cells. Thus, recognition of the signals for endocytosis and polarized transport is differently regulated in infected cells. Mutation of the basolateral sorting signal in one of the MV glycoproteins prevented fusion of polarized cells. These results suggest that basolateral expression of the MV glycoproteins favors virus spread in epithelia.	Univ Marburg, Inst Virol, D-35037 Marburg, Germany; Tierarztlichen Hsch Hannover, Inst Virol, D-30559 Hannover, Germany	Philipps University Marburg; University of Veterinary Medicine Hannover, Foundation	Maisner, A (corresponding author), Univ Marburg, Inst Virol, Robert Koch Str 17, D-35037 Marburg, Germany.			Moll, Markus/0000-0003-4592-3063				Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; Cathomen T, 1995, VIROLOGY, V214, P628, DOI 10.1006/viro.1995.0075; Cathomen T, 1998, J VIROL, V72, P1224, DOI 10.1128/JVI.72.2.1224-1234.1998; Cathomen T, 1998, EMBO J, V17, P3899, DOI 10.1093/emboj/17.14.3899; DAVIS CG, 1986, CELL, V45, P14; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; Egan MA, 1996, J VIROL, V70, P6547, DOI 10.1128/JVI.70.10.6547-6556.1996; FULLER S, 1984, CELL, V38, P65, DOI 10.1016/0092-8674(84)90527-0; GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0; GONZALEZ A, 1987, P NATL ACAD SCI USA, V84, P3738, DOI 10.1073/pnas.84.11.3738; GRAEVE L, 1989, J CELL BIOL, V109, P2809, DOI 10.1083/jcb.109.6.2809; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; Lazarovits J, 1996, J CELL BIOL, V134, P339, DOI 10.1083/jcb.134.2.339; Leser GP, 1996, MOL BIOL CELL, V7, P155, DOI 10.1091/mbc.7.1.155; Lin S, 1997, J BIOL CHEM, V272, P26300, DOI 10.1074/jbc.272.42.26300; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; Maisner A, 1997, J BIOL CHEM, V272, P20793, DOI 10.1074/jbc.272.33.20793; Maisner A, 2000, J GEN VIROL, V81, P441, DOI 10.1099/0022-1317-81-2-441; Maisner A, 1998, J VIROL, V72, P5276, DOI 10.1128/JVI.72.6.5276-5278.1998; MCQUEEN N, 1986, P NATL ACAD SCI USA, V83, P9318, DOI 10.1073/pnas.83.24.9318; Naim HY, 2000, EMBO J, V19, P3576, DOI 10.1093/emboj/19.14.3576; NAIM HY, 1994, J BIOL CHEM, V269, P3928; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; OWENS RJ, 1991, P NATL ACAD SCI USA, V88, P3987, DOI 10.1073/pnas.88.9.3987; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROTH MG, 1980, J VIROL, V35, P547, DOI 10.1128/JVI.35.2.547-550.1980; ROTH MG, 1983, CELL, V33, P435, DOI 10.1016/0092-8674(83)90425-7; ROTH MG, 1987, J CELL BIOL, V104, P769, DOI 10.1083/jcb.104.3.769; ROTH MG, 1986, J CELL BIOL, V103, P2607; ROUX L, 1985, J GEN VIROL, V66, P987, DOI 10.1099/0022-1317-66-5-987; Sauter MM, 1996, J CELL BIOL, V132, P795, DOI 10.1083/jcb.132.5.795; SIMONS K, 1980, J GEN VIROL, V50, P1, DOI 10.1099/0022-1317-50-1-1; Spielhofer P, 1998, J VIROL, V72, P2150, DOI 10.1128/JVI.72.3.2150-2159.1998; Tatsuo H, 2000, NATURE, V406, P893, DOI 10.1038/35022579; Teuchert M, 1999, J BIOL CHEM, V274, P19979, DOI 10.1074/jbc.274.28.19979; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; TUCKER SP, 1993, ADV VIRUS RES, V42, P187, DOI 10.1016/S0065-3527(08)60086-X; VEY M, 1992, VIROLOGY, V188, P408, DOI 10.1016/0042-6822(92)90775-K; WILD TF, 1991, J GEN VIROL, V72, P429; YOKODE M, 1992, J CELL BIOL, V117, P39, DOI 10.1083/jcb.117.1.39; [No title captured]	45	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17887	17894		10.1074/jbc.M010183200	http://dx.doi.org/10.1074/jbc.M010183200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11359789	hybrid			2022-12-25	WOS:000168866500038
J	Pang, TX; Su, XH; Wakabayashi, S; Shigekawa, R				Pang, TX; Su, XH; Wakabayashi, S; Shigekawa, R			Calcineurin homologous protein as an essential cofactor for Na+/H+ exchangers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-BINDING PROTEIN; MOLECULAR-CLONING; IDENTIFICATION; DOMAIN; GROWTH; NHE1; PH; EXPRESSION; INHIBITION; ANTIPORTER	The Na+/H+ exchangers (NHEs) comprise a family of transporters that catalyze cell functions such as regulation of the pH and volume of a cell and epithelial absorption of Na+ and bicarbonate. Ubiquitous calcineurin B homologous protein (CHP or p22) is co-localized and co-immunoprecipitated with expressed NHE1, NHE2, or NHE3 independently of its myristoylation and Ca2+ binding, and its binding site was identified as the jux-tamembrane region within the carboxyl-terminal cytoplasmic domain of exchangers. CHP binding-defective mutations of NHE1-3 or CHP depletion by injection of the competitive CHP-binding region of NHE1 into Xeno-pus oocytes resulted in a dramatic reduction (> 90%) in the Na+/H+ exchange activity. The data suggest that CHP serves as an essential cofactor, which supports the physiological activity of NHE family members.	Natl Cardiovasc Ctr, Res Inst, Dept Mol Physiol, Suita, Osaka 5658565, Japan	National Cerebral & Cardiovascular Center - Japan	Wakabayashi, S (corresponding author), Natl Cardiovasc Ctr, Res Inst, Dept Mol Physiol, Fujishiro Dai 5-7-1, Suita, Osaka 5658565, Japan.							Aharonovitz O, 2000, J CELL BIOL, V150, P213, DOI 10.1083/jcb.150.1.213; Baird NR, 1999, J BIOL CHEM, V274, P4377, DOI 10.1074/jbc.274.7.4377; Barroso MR, 1996, J BIOL CHEM, V271, P10183, DOI 10.1074/jbc.271.17.10183; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; Busch S, 1997, BBA-BIOMEMBRANES, V1325, P13, DOI 10.1016/S0005-2736(97)00011-4; COUNILLON L, 1994, BIOCHEMISTRY-US, V33, P10463, DOI 10.1021/bi00200a030; Cox GA, 1997, CELL, V91, P139, DOI 10.1016/S0092-8674(01)80016-7; Ikeda T, 1997, J BIOCHEM-TOKYO, V121, P295; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Lin X, 1996, P NATL ACAD SCI USA, V93, P12631, DOI 10.1073/pnas.93.22.12631; Lin X, 1999, J BIOL CHEM, V274, P36125, DOI 10.1074/jbc.274.51.36125; Meyer T, 1999, NAT CELL BIOL, V1, pE93, DOI 10.1038/12090; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Schultheis PJ, 1998, J CLIN INVEST, V101, P1243, DOI 10.1172/JCI1249; Timm S, 1999, MOL BIOL CELL, V10, P3473, DOI 10.1091/mbc.10.10.3473; Wakabayashi S, 2000, J BIOL CHEM, V275, P7942, DOI 10.1074/jbc.275.11.7942; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WATANABE Y, 1995, J BIOL CHEM, V270, P456, DOI 10.1074/jbc.270.1.456; Yoshida T, 1998, J BIOL CHEM, V273, P1583, DOI 10.1074/jbc.273.3.1583; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010	26	146	161	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17367	17372		10.1074/jbc.M100296200	http://dx.doi.org/10.1074/jbc.M100296200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11350981	hybrid			2022-12-25	WOS:000168730400103
J	Cozzi, PJ; Malhotra, S; Mcauliffe, P; Kooby, DA; Federoff, HJ; Huryk, B; Johnson, P; Scardino, PT; Heston, WDW; Fong, Y				Cozzi, PJ; Malhotra, S; Mcauliffe, P; Kooby, DA; Federoff, HJ; Huryk, B; Johnson, P; Scardino, PT; Heston, WDW; Fong, Y			Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model	FASEB JOURNAL			English	Article									Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, George M OBrien Urol Res Ctr, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA; Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA; NeuroVir Therapeut Inc, Vancouver, BC, Canada	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Rochester; University of Rochester	Fong, Y (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA.								0	68	76	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1306	1308		10.1096/fj.00-0533fje	http://dx.doi.org/10.1096/fj.00-0533fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344122				2022-12-25	WOS:000168655200044
J	Santos, J; Herranz, M; Fernandez, M; Vaquero, C; Lopez, P; Fernandez-Piqueras, J				Santos, J; Herranz, M; Fernandez, M; Vaquero, C; Lopez, P; Fernandez-Piqueras, J			Evidence of a possible epigenetic inactivation mechanism operating on a region of mouse chromosome 19 in gamma-radiation-induced thymic lymphomas	ONCOGENE			English	Article						Pten; Cd95; Jak2; epigenetic inactivation; gamma-irradiation; mouse thymic lymphomas; chromosome 19	TUMOR-SUPPRESSOR GENE; T-CELL LYMPHOMAS; INHIBITOR P15(INK4B); PROSTATE-CANCER; FREQUENT LOSS; DISTAL PART; PTEN/MMAC1; MUTATION; PTEN; MICE	Loss of heterozygosity (LOH) analysis, performed in 68 gamma -radiation-induced primary thymic lymphomas of F1 hybrid mice, provided evidence of significant LOH on chromosome 19 in a region defined by the D19Mit106 (22 cM) and D19Mit100 (27 cM) markers (Thymic Lymphoma Suppressor Region 8, TLSR8), Cd95 and Pten, two genes mapped at this region, were inactivated in a vast majority of these tumors (85.3% for Cd95 and 61.8% for Pten), Moreover, altered expression of Cd95 and Pten occurred concomitantly in 34 of 68 (50%) thymic lymphomas suggesting a coordinated mechanism of inactivation of these genes. Surprisingly, we also found that Jak2, a proto-oncogene located between Cd95 and Pten, was simultaneously inactivated in a significant fraction of the tumors analysed (24 of 34, 70.6%). Taken together these findings and the lack of mutations in the coding sequences of the mentioned genes clearly suggest a possible regional epigenetic inactivation mechanism on mouse chromosome 19 operating during the development of these tumors.	Univ Autonoma Madrid, Fac Ciencias, Dept Biol, Lab Genet Mol Humana, E-28049 Madrid, Spain	Autonomous University of Madrid	Fernandez-Piqueras, J (corresponding author), Univ Autonoma Madrid, Fac Ciencias, Dept Biol, Lab Genet Mol Humana, E-28049 Madrid, Spain.		LORENZO, CONCEPCION VAQUERO/L-2827-2017; Herranz, Michel/L-2561-2016; Santos, Javier/ABF-5755-2021	Santos, Javier/0000-0002-4168-6251				Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Butler LM, 2000, BRIT J CANCER, V82, P131; Cairns P, 1997, CANCER RES, V57, P4997; Dahia PLM, 1998, ONCOGENE, V16, P2403, DOI 10.1038/sj.onc.1201762; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dubrova YE, 2000, NATURE, V405, P37, DOI 10.1038/35011135; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; FEINBERG AP, 1995, J NATL CANC I MONOGR, V17, P21; Herranz M, 1999, CANCER RES, V59, P2068; Liu R, 2000, ONCOGENE, V19, P571, DOI 10.1038/sj.onc.1203364; Malumbres M, 1999, ONCOGENE, V18, P385, DOI 10.1038/sj.onc.1202299; Malumbres M, 1997, ONCOGENE, V14, P1361, DOI 10.1038/sj.onc.1200969; Matsumoto Y, 1998, ONCOGENE, V16, P2747, DOI 10.1038/sj.onc.1201810; Melendez B, 1999, ONCOGENE, V18, P4166, DOI 10.1038/sj.onc.1202826; Okumoto M, 1999, CANCER LETT, V135, P223, DOI 10.1016/S0304-3835(98)00305-X; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Sachs RK, 2000, TRENDS GENET, V16, P143, DOI 10.1016/S0168-9525(99)01960-5; Santos J, 1998, ONCOGENE, V17, P925, DOI 10.1038/sj.onc.1202009; Santos J, 1996, ONCOGENE, V12, P669; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Yu CL, 1997, J IMMUNOL, V159, P5206	24	23	23	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2001	20	17					2186	2189		10.1038/sj.onc.1204297	http://dx.doi.org/10.1038/sj.onc.1204297			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360203				2022-12-25	WOS:000168116700014
J	Munoz, P; Baus, F; Piette, J				Munoz, P; Baus, F; Piette, J			Ku antigen is required to relieve G2 arrest caused by inhibition of DNA topoisomerase II activity by the bisdioxopiperazine ICRF-193	ONCOGENE			English	Article						cell cycle; DNA topoisomerase II; Ku antigen; DNA replication	DEPENDENT PROTEIN-KINASE; CELL-CYCLE; MAMMALIAN-CELLS; V(D)J RECOMBINATION; M-PHASE; CHROMOSOME STRUCTURE; ENZYME; SEGREGATION; CHECKPOINT; MECHANISM	Ku antigen is necessary for DNA double-strand break (DSB) repair through its ability to bind DNA ends with high affinity and to recruit the catalytic subunit of DNA-PK to the DSBs, Ku-deficient cells are hypersensitive to agents causing DSBs in DNA but also to the DNA topoisomerase II (topo II) inhibitor ICRF-193, which does not induce DSBs, This suggests a new role of Ku antigen, that is independent of DSB repair by DNA-PK. Here we characterize the basis for the hypersensitivity of Ku-deficient cells to ICRF-193, Chromosome condensation and segregation, which are dependent on topo II, but also the catalytic activity of topo II in Late S-G2 were inhibited to a comparable extent when ICRF-193 was applied to Ku-deficient cells or wild-type cells. However, mutant cells arrested in G2 by ICRF-193 treatment were unable to progress into M phase upon drug removal, although drug-trapped topo II complexes were removed from DNA and the two isoforms of topo II recovered their catalytic activity as in wild-type cells, The reversibility of G2 arrest was recovered by complementation of mutant cells with a human Ku86 cDNA, Notably, chromosome condensation was abnormal in Ku-deficient cells after suppression of the G2 arrest by caffeine, even in the absence of ICRF-193, These results reflect the involvement of Ku-antigen in the cellular response to topo II inhibition, more particularly in relieving G2 arrest caused by topo II inhibition in late S/G2 and the subsequent recovery of chromosome condensation.	Inst Genet Mol Montpellier, CNRS, UMR 5535, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Piette, J (corresponding author), Inst Genet Mol Montpellier, CNRS, UMR 5535, IFR 24,1919 Route Mende, F-34293 Montpellier 5, France.							Anderson H, 1996, CELL GROWTH DIFFER, V7, P83; ANDOH T, 1993, BIOTECHNOL APPL BIOC, V18, P165; Andoh T, 1998, BBA-GENE STRUCT EXPR, V1400, P155, DOI 10.1016/S0167-4781(98)00133-X; Andreassen PR, 1997, J CELL BIOL, V136, P29, DOI 10.1083/jcb.136.1.29; Austin CA, 1998, BIOESSAYS, V20, P215, DOI 10.1002/(SICI)1521-1878(199803)20:3<215::AID-BIES5>3.0.CO;2-Q; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CHEN GL, 1984, J BIOL CHEM, V259, P3560; CLARKE DJ, 1993, J CELL SCI, V105, P563; Cooper MP, 2000, GENE DEV, V14, P907; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; Duguet M, 1997, J CELL SCI, V110, P1345; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; Errami A, 1996, MOL CELL BIOL, V16, P1519; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; GORBSKY GJ, 1994, CANCER RES, V54, P1042; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341; Jensen LH, 2000, J BIOL CHEM, V275, P2137, DOI 10.1074/jbc.275.3.2137; Kaufmann WK, 1998, MUTAT RES-FUND MOL M, V400, P153, DOI 10.1016/S0027-5107(98)00041-4; Kimura K, 1996, J BIOL CHEM, V271, P21439, DOI 10.1074/jbc.271.35.21439; KIMURA K, 1994, J BIOL CHEM, V269, P1173; Meyer KN, 1997, J CELL BIOL, V136, P775, DOI 10.1083/jcb.136.4.775; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MIMORI T, 1986, J BIOL CHEM, V261, P375; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; Munoz P, 1998, MOL CELL BIOL, V18, P5797, DOI 10.1128/MCB.18.10.5797; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Patel S, 2000, MOL PHARMACOL, V58, P560, DOI 10.1124/mol.58.3.560; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; Shen JC, 2000, TRENDS GENET, V16, P213, DOI 10.1016/S0168-9525(99)01970-8; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; SUNDIN O, 1980, CELL, V21, P103, DOI 10.1016/0092-8674(80)90118-X; TANABE K, 1991, CANCER RES, V51, P4903; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Warburton PE, 1997, BIOESSAYS, V19, P97, DOI 10.1002/bies.950190203; Weinert T, 1998, CURR OPIN GENET DEV, V8, P185, DOI 10.1016/S0959-437X(98)80140-8; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; Wu L, 1999, CURR BIOL, V9, pR518, DOI 10.1016/S0960-9822(99)80325-X; ZDZIENICKA MZ, 1988, MUTAT RES, V194, P239	47	7	7	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 12	2001	20	16					1990	1999		10.1038/sj.onc.1204262	http://dx.doi.org/10.1038/sj.onc.1204262			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360183				2022-12-25	WOS:000168043800007
J	Soler, C; Valdes, R; Garcia-Manteiga, J; Xaus, J; Comalada, M; Casado, FJ; Modolell, M; Nicholson, B; MacLeod, C; Felipe, A; Celada, A; Pastor-Anglada, M				Soler, C; Valdes, R; Garcia-Manteiga, J; Xaus, J; Comalada, M; Casado, FJ; Modolell, M; Nicholson, B; MacLeod, C; Felipe, A; Celada, A; Pastor-Anglada, M			Lipopolysaccharide-induced apoptosis of macrophages determines the up-regulation of concentrative nucleoside transporters Cnt1 and Cnt2 through tumor necrosis factor-alpha-dependent and -independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE PRODUCTION; ADENOSINE-INDUCED APOPTOSIS; MOLECULAR-BIOLOGY; TNF-ALPHA; SYNTHASE EXPRESSION; EXTRACELLULAR ATP; IFN-GAMMA; RECEPTOR; HL-60; INDUCTION	In murine bone marrow macrophages, lipopolysaccharide (LPS) induces apoptosis through the autocrine production of tumor necrosis factor-alpha (TNF-alpha), as demonstrated by the fact that macrophages from TNF-alpha receptor I knock-out mice did not undergo early apoptosis. In these conditions LPS up-regulated the two concentrative high affinity nucleoside transporters here shown to be expressed in murine bone marrow macrophages, concentrative nucleoside transporter (CNT) 1 and 2, in a rapid manner that is nevertheless consistent with the de novo synthesis of carrier proteins. This effect was not dependent on the presence of macrophage colony-stimulating factor, although LPS blocked the macrophage colony-stimulating factor-mediated up-regulation of the equilibrative nucleoside transport system es. TNF-alpha mimicked the regulatory response of nucleoside transporters triggered by LPS, but macrophages isolated from TNF-alpha receptor I knock-out mice similarly up-regulated nucleoside transport after LPS treatment. Although NO is produced by macrophages after LPS treatment, NO is not involved in these regulatory responses because LPS up-regulated CNT1 and CNT2 transport activity and expression in macrophages from inducible nitric oxide synthase and cationic amino acid transporter (CAT) 2 knock-out mice, both of which lack inducible nitric oxide synthesis. These data indicate that the early proapoptotic responses of macrophages, involving the up-regulation of CNT transporters, follow redundant regulatory pathways in which TNF-alpha- dependent- and -independent mechanisms are involved. These observations also support a role for CNT transporters in determining extracellular nucleoside availability and modulating macrophage apoptosis.	Univ Barcelona, Dept Bioquim & Biol Mol, Regulat Transport Syst Grp, Fac Biol, E-08028 Barcelona, Spain; Univ Barcelona, Dept Fisiol Biol Macrofag, E-08028 Barcelona, Spain; Max Planck Inst Immunobiol, D-79108 Freiburg, Germany; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	University of Barcelona; University of Barcelona; Max Planck Society; University of California System; University of California San Diego; University of California System; University of California San Diego	Pastor-Anglada, M (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Regulat Transport Syst Grp, Fac Biol, Diagonal 645, E-08028 Barcelona, Spain.	mpastor@porthos.bio.ub.es	Felipe, Antonio/M-8297-2015; Soler, Concepció/L-1185-2014; Manteiga, Jose Manuel Garcia/AAN-1954-2020; Celada, Antonio/I-1714-2016	Felipe, Antonio/0000-0002-7294-6431; Soler, Concepció/0000-0001-6502-5012; Manteiga, Jose Manuel Garcia/0000-0002-5481-040X; Casado Merediz, Francisco Javier/0000-0003-0192-841X; Celada, Antonio/0000-0003-3883-2171	NATIONAL CANCER INSTITUTE [R01CA081376] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA81376] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINA JE, 1993, J IMMUNOL, V150, P5080; Baldwin SA, 1999, MOL MED TODAY, V5, P216, DOI 10.1016/S1357-4310(99)01459-8; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; Cass C E, 1999, Pharm Biotechnol, V12, P313; CELADA A, 1984, J EXP MED, V160, P55, DOI 10.1084/jem.160.1.55; Dawicki DD, 1997, AM J PHYSIOL-LUNG C, V273, pL485, DOI 10.1152/ajplung.1997.273.2.L485; del Santo B, 1998, HEPATOLOGY, V28, P1504, DOI 10.1002/hep.510280609; Denlinger LC, 1996, J BIOL CHEM, V271, P337, DOI 10.1074/jbc.271.1.337; Dragan Y, 2000, HEPATOLOGY, V32, P239, DOI 10.1053/jhep.2000.9546; Dresser MJ, 2000, DRUG METAB DISPOS, V28, P1135; Ferrari D, 1997, J IMMUNOL, V159, P1451; GREENBLATT MS, 1992, BLOOD, V80, P1339; Hasko G, 2000, BRIT J PHARMACOL, V129, P909, DOI 10.1038/sj.bjp.0703134; Hasko G, 2000, J IMMUNOL, V164, P1013, DOI 10.4049/jimmunol.164.2.1013; Hasko G, 1996, J IMMUNOL, V157, P4634; Hasko G, 2000, FASEB J, V14, P2065, DOI 10.1096/fj.99-0508com; Hu Y, 1998, J BIOL CHEM, V273, P27170, DOI 10.1074/jbc.273.42.27170; Humphreys BD, 1996, J IMMUNOL, V157, P5627; Kim KT, 1998, J CANCER RES CLIN, V124, P471, DOI 10.1007/s004320050201; LEIST M, 1995, J IMMUNOL, V154, P1307; Mata JF, 2001, MOL PHARMACOL, V59, P1542, DOI 10.1124/mol.59.6.1542; Murray J, 1997, BLOOD, V90, P2772, DOI 10.1182/blood.V90.7.2772.2772_2772_2783; Nicholson B, 2001, J BIOL CHEM, V276, P15881, DOI 10.1074/jbc.M010030200; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Pastor-Anglada M, 1998, BIOCHEM CELL BIOL, V76, P771, DOI 10.1139/bcb-76-5-771; Pastor-Anglada M, 1998, TRENDS PHARMACOL SCI, V19, P424, DOI 10.1016/S0165-6147(98)01253-X; Pastor-Anglada M, 2001, MOL MEMBR BIOL, V18, P81, DOI 10.1080/096876800110033783; Pastor-Anglada M, 2001, DRUG DEVELOP RES, V52, P431, DOI 10.1002/ddr.1144; Peyot ML, 2000, CIRC RES, V86, P76, DOI 10.1161/01.RES.86.1.76; Rathbone MP, 1999, PROG NEUROBIOL, V59, P663, DOI 10.1016/S0301-0082(99)00017-9; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Sajjadi FG, 1996, J IMMUNOL, V156, P3435; SALKOWSKI CA, 1995, J IMMUNOL, V155, P3168; SARIH M, 1993, BIOCHEM BIOPH RES CO, V191, P503, DOI 10.1006/bbrc.1993.1246; Soler C, 2000, J LEUKOCYTE BIOL, V67, P345, DOI 10.1002/jlb.67.3.345; SOLER C, 2001, IN PRESS FASEB J; Sperlagh B, 1998, NEUROCHEM INT, V33, P209, DOI 10.1016/S0197-0186(98)00025-4; TANAKA Y, 1994, EXP CELL RES, V213, P242, DOI 10.1006/excr.1994.1196; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; WAKADE TD, 1995, J PHYSIOL-LONDON, V488, P123, DOI 10.1113/jphysiol.1995.sp020951; Wang J, 1997, PHARM RES-DORDR, V14, P1524, DOI 10.1023/A:1012113931332; Xaus J, 2000, BLOOD, V95, P3823; Xaus J, 1999, J IMMUNOL, V162, P3607	44	67	70	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30043	30049		10.1074/jbc.M101807200	http://dx.doi.org/10.1074/jbc.M101807200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11346649	hybrid, Green Published			2022-12-25	WOS:000170558000059
J	de Gregorio, R; Iniguez, MA; Fresno, M; Alemany, S				de Gregorio, R; Iniguez, MA; Fresno, M; Alemany, S			Cot kinase induces cyclooxygenase-2 expression in T cells through activation of the nuclear factor of activated T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GENE-EXPRESSION; TRANSCRIPTION FACTORS; SIGNALING PATHWAYS; INVOLVEMENT; INDUCTION; ONCOPROTEIN; INHIBITION; ONCOGENE	Cyclooxygenase-2 (COX-2) is induced in human T lymphocytes upon T cell receptor triggering. Here we report that Cot kinase, a mitogen-activated protein kinase kinase kinase involved in T cell activation, up-regulates COX-2 gene expression in Jurkat T cells. Induction of COX-2 promoter activity by Cot kinase occurred mainly through activation of the nuclear factor of activated T cells (NFAT). Mutation of the distal (-105/-97) and proximal (-76/-61) NEAT response elements in the COX-2 promoter abolished the activation induced by Cot kinase. Even more, coexpression of a dominant negative version of NFAT inhibited Cot kinase-mediated COX-2 promoter activation, whereas cotransfection of a constitutively active version of the calcium-dependent phosphatase calcineurin synergizes with Cot kinase in the up-regulation of COX-2 promoter-driven transcription. Strikingly, Cot kinase increased transactivation mediated by a GAL4-NFAT fusion protein containing the N-terminal transactivation domain of NFATp. In contrast to phorbol ester plus calcium ionophore A23187, Cot kinase increases both COX-2 promoter activity and NFAT-mediated transactivation in a cyclosporin A-independent manner. These data indicate that Cot kinase up-regulates COX-2 promoter-driven transcription through the NFAT response elements, being the Cot kinase-induced NFAT-dependent transactivation presumably implicated in this up-regulation.	Univ Autonoma Madrid, Fac Med, CSIC, Inst Invest Biomed, E-28029 Madrid, Spain; Univ Autonoma Madrid, Ctr Biol Mol, CSIC, E-28029 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Alemany, S (corresponding author), Univ Autonoma Madrid, Fac Med, CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.		Alemany, Susana/J-6307-2014; Peña, Miguel Angel Iñiguez/J-8518-2012	Alemany, Susana/0000-0002-4089-7620; Peña, Miguel Angel Iñiguez/0000-0001-8262-6119; Fresno Escudero, Manuel/0000-0002-9223-5477				Adderley SR, 1999, J BIOL CHEM, V274, P5038, DOI 10.1074/jbc.274.8.5038; AOKI M, 1991, ONCOGENE, V6, P1515; AOKI M, 1993, J BIOL CHEM, V268, P22723; ARENZANASEISDEDOS F, 1993, J VIROL, V67, P6596, DOI 10.1128/JVI.67.11.6596-6604.1993; Avots A, 1999, IMMUNITY, V10, P515, DOI 10.1016/S1074-7613(00)80051-5; Ballester A, 1998, J BIOL CHEM, V273, P14099, DOI 10.1074/jbc.273.23.14099; Ballester A, 1997, J IMMUNOL, V159, P1613; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Brueggemeier RW, 1999, CANCER LETT, V140, P27, DOI 10.1016/S0304-3835(99)00050-6; CHAN AML, 1993, ONCOGENE, V8, P1329; Chen CC, 2000, J IMMUNOL, V165, P2719, DOI 10.4049/jimmunol.165.5.2719; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Crofford LJ, 1997, ARTHRITIS RHEUM-US, V40, P226, DOI 10.1002/art.1780400207; DuBois RN, 1996, GASTROENTEROLOGY, V110, P1259, DOI 10.1053/gast.1996.v110.pm8613017; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; Garcia-Rodriguez C, 2000, EUR J IMMUNOL, V30, P2432, DOI 10.1002/1521-4141(2000)30:8<2432::AID-IMMU2432>3.0.CO;2-F; Hagemann D, 1999, ONCOGENE, V18, P1391, DOI 10.1038/sj.onc.1202431; Hernandez GL, 2001, J EXP MED, V193, P607, DOI 10.1084/jem.193.5.607; Hida T, 1998, CANCER RES, V58, P3761; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Iniguez MA, 1999, J IMMUNOL, V163, P111; Iniguez MA, 2000, J BIOL CHEM, V275, P23627, DOI 10.1074/jbc.M001381200; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; Jones MK, 1999, NAT MED, V5, P1418; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Luo C, 1996, MOL CELL BIOL, V16, P3955; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; Nakao S, 2000, MOL CELL BIOCHEM, V209, P113, DOI 10.1023/A:1007155525020; Newton R, 1997, BIOCHEM BIOPH RES CO, V237, P28, DOI 10.1006/bbrc.1997.7064; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANO H, 1995, CANCER RES, V55, P3785; Sawaoka H., 1998, AM J PHYSIOL, V274, P1061; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Sheng GG, 1997, GASTROENTEROLOGY, V113, P1883, DOI 10.1016/S0016-5085(97)70007-6; SIVER PA, 1984, P NATL ACAD SCI USA, V81, P5951; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838; Tsatsanis C, 1998, ONCOGENE, V17, P2609, DOI 10.1038/sj.onc.1202460; Tsatsanis C, 1998, P NATL ACAD SCI USA, V95, P3827, DOI 10.1073/pnas.95.7.3827; von Knethen A, 1999, MOL BIOL CELL, V10, P361, DOI 10.1091/mbc.10.2.361; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yan ZP, 2000, J BIOL CHEM, V275, P4949, DOI 10.1074/jbc.275.7.4949; Zhang F, 1998, J BIOL CHEM, V273, P2424, DOI 10.1074/jbc.273.4.2424; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451	57	70	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27003	27009		10.1074/jbc.M100885200	http://dx.doi.org/10.1074/jbc.M100885200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356833	hybrid			2022-12-25	WOS:000169966900037
J	Sakurai, K; Katoh, M; Fujimoto, Y				Sakurai, K; Katoh, M; Fujimoto, Y			Alloxan-induced mitochondrial permeability transition triggered by calcium, thiol oxidation, and matrix ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-NUCLEOTIDES; APOPTOSIS; MEMBRANE; TRANSPORT; RELEASE; PORE; MECHANISMS; REDUCTION; INDUCTION; CELLS	In addition to their critical function in energy metabolism, mitochondria contain a permeability transition pore, which is regulated by adenine nucleotides. We investigated conditions required for ATP to induce a permeability transition in mammalian mitochondria. Mitochondrial smelling associated,with mitochondria permeability transition (MPT) was initiated by adding succinate to a rat liver mitochondrial suspension containing alloxan, a diabetogenic agent. If alloxan was added immediately with or 5 min after adding succinate, MPT was strikingly decreased, MPT induced by alloxan was inhibited by EGTA and several agents causing thiol oxidation, suggesting that alloxan leads to permeability transition through a mechanism dependent on Ca2+ uptake and sulfhydryl oxidation; Antimycin A and cyanide, inhibitors of electron transfer, carbonyl cyanide m-chlorophenylhydrazone, and oligomycin all-inhibited MPT. During incubation with succinate, alloxan depleted ATP in mitochondria after an initial transient increase. However, in a mitochondrial suspension containing EGTA, ATP significantly increased in the presence of alloxan to a level greater than that of the control, These results suggest the involvement of energized transport of Ca2+ in the MPT initiation, Addition of exogenous ATP, however, did not trigger MPT in the presence of alloxan and had no effect on MPT induced by alloxan. We conclude that alloxan-induced MPT requires mitochondrial energization, oxidation of protein thiols, and matrix ATP to promote energized uptake of Ca2+.	Hokkaido Coll Pharm, Dept Biochem, Otaru, Hokkaido 0470264, Japan		Sakurai, K (corresponding author), Hokkaido Coll Pharm, Dept Biochem, 7-1 Katsuraoka Cho, Otaru, Hokkaido 0470264, Japan.	ks51@hokuyakudai.ac.jp						ASIMAKIS GK, 1981, AM J PHYSIOL, V241, pH672, DOI 10.1152/ajpheart.1981.241.5.H672; AUSTIN J, 1984, J BIOL CHEM, V259, P154; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BOQUIST L, 1984, DIABETOLOGIA, V27, P379, DOI 10.1007/BF00304854; Bortner CD, 1999, J BIOL CHEM, V274, P21953, DOI 10.1074/jbc.274.31.21953; Constantini P., 1996, J BIOL CHEM, V271, P6746; CROMPTON M, 1990, INTRACELLULAR CALCIU, P183; Eguchi Y, 1997, CANCER RES, V57, P1835; FARBER JL, 1982, LAB INVEST, V47, P114; FREI B, 1985, J BIOL CHEM, V260, P7394; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gunter TE, 1998, BBA-BIOENERGETICS, V1366, P5, DOI 10.1016/S0005-2728(98)00117-0; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kowaltowski AJ, 1998, J BIOL CHEM, V273, P12766, DOI 10.1074/jbc.273.21.12766; Kowaltowski AJ, 1997, BBA-BIOENERGETICS, V1318, P395, DOI 10.1016/S0005-2728(96)00111-9; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kushnareva YE, 2000, ARCH BIOCHEM BIOPHYS, V376, P377, DOI 10.1006/abbi.2000.1730; LAPIDUS RG, 1994, J BIOL CHEM, V269, P18931; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; MALAISSE WJ, 1982, BIOCHEM PHARMACOL, V31, P3527, DOI 10.1016/0006-2952(82)90571-8; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; NICHOLLS D, 1982, BIOCHIM BIOPHYS ACTA, V683, P57, DOI 10.1016/0304-4173(82)90013-1; Novgorodov SA, 1996, J BIOENERG BIOMEMBR, V28, P139, DOI 10.1007/BF02110644; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; RIGOBELLO MP, 1995, ARCH BIOCHEM BIOPHYS, V319, P225, DOI 10.1006/abbi.1995.1286; Rodriguez-Zavala JS, 1998, J BIOL CHEM, V273, P7850, DOI 10.1074/jbc.273.14.7850; Sakurai K, 1998, MOL PHARMACOL, V54, P1024, DOI 10.1124/mol.54.6.1024; Sakurai K, 2000, FREE RADICAL BIO MED, V28, P273, DOI 10.1016/S0891-5849(99)00236-1; SAKURAI K, 1990, CHEM PHARM BULL, V38, P993; SanchezAlcazar JA, 1997, J BIOL CHEM, V272, P30167, DOI 10.1074/jbc.272.48.30167; Schweizer M, 1996, BIOCHEMISTRY-US, V35, P4524, DOI 10.1021/bi952708+; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Simbula G, 1997, AM J PHYSIOL-CELL PH, V273, pC479, DOI 10.1152/ajpcell.1997.273.2.C479; SKREDE S, 1968, BIOCHEM J, V108, P693, DOI 10.1042/bj1080693; SUSIN SA, 1998, BIOCHIM BIOPHYS ACTA, V1633, P151; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZARATTI M, 1995, BIOCHIM BIOPHYS ACTA, V1241, P139	42	20	20	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26942	26946		10.1074/jbc.M102029200	http://dx.doi.org/10.1074/jbc.M102029200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11342546	hybrid			2022-12-25	WOS:000169966900029
J	Borges, K; Dingledine, R				Borges, K; Dingledine, R			Functional organization of the GluR1 glutamate receptor promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURON-SPECIFIC EXPRESSION; VENTRAL TEGMENTAL AREA; MESSENGER-RNA; CORE PROMOTER; IN-VITRO; GENE; AMPA; ACID; TRANSCRIPTION; INCREASES	The GluR1 glutamate receptor subunit is expressed in most brain areas and plays a major role in excitatory synaptic transmission. We cloned and sequenced 5 kilobase pairs of the rat GluR1 promoter and identified multiple transcriptional start sites between -295 and -202 (relative to the first ATG). Similar to other glutamate receptor subunit promoters, the GluR1 promoter lacks TATA and CAAT elements in that region but binds Spl proteins at two sites. Promoter activity of GluR1 fragments cloned into pGL3 was assessed by immunocytochemistry and by measuring luciferase activity after transfection into primary cultures of rat cortical neurons and glia. GluR1 promoter activity was stronger in neurons, with neuronal specificity appearing to reside mainly within the neuronal expression-enhancing regions, -1395 to -743 and -253 to -48. The latter region contains 4 sites that bound recombinant cAMP-response element-binding proteins and a glial silencing region between -253 and -202. In both neurons and dia, promoter activity was increased by a 64-base pair GA repeat upstream of the initiation sites and reduced by a 57-base pair region that contained an N box. In contrast to the GluR2 promoter the regulatory regions are mainly located outside of the GluR1 initiation region.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA	Emory University	Borges, K (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 1510 Clifton Rd, Atlanta, GA 30322 USA.	kborges@pharm.emory.edu	dingledine, Ray/F-5173-2011; Borges, Karin/B-4276-2011	Borges, Karin/0000-0001-7448-0770; Dingledine, Ray/0000-0001-7128-4520				Abbott KL, 2000, J MOL CELL CARDIOL, V32, P391, DOI 10.1006/jmcc.1999.1085; AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; BESSIS A, 1995, NEUROSCIENCE, V69, P807, DOI 10.1016/0306-4522(95)00303-Z; Cammarota M, 1998, EUR J NEUROSCI, V10, P2669, DOI 10.1046/j.1460-9568.1998.t01-1-00254.x; Carlton SM, 1998, NEUROSCI LETT, V242, P21, DOI 10.1016/S0304-3940(98)00036-6; CHENG B, 1995, J NEUROCHEM, V65, P2525; Chew LJ, 1997, J NEUROSCI, V17, P227, DOI 10.1523/JNEUROSCI.17-01-00227.1997; CHIN LS, 1994, J BIOL CHEM, V269, P18507; Churchill L, 1999, J NEUROCHEM, V72, P2397, DOI 10.1046/j.1471-4159.1999.0722397.x; CONDORELLI DF, 1993, J NEUROCHEM, V61, P2133, DOI 10.1111/j.1471-4159.1993.tb07451.x; Dingledine R, 1999, PHARMACOL REV, V51, P7; EGGEN BJL, 1994, MOL BRAIN RES, V23, P221, DOI 10.1016/0169-328X(94)90229-1; Fitzgerald LW, 1996, J NEUROSCI, V16, P274; FITZGERALD LW, 1995, J NEUROSCI, V15, P2453, DOI 10.1523/JNEUROSCI.15-03-02453.1995; Gallo V, 2000, TRENDS PHARMACOL SCI, V21, P252, DOI 10.1016/S0165-6147(00)01494-2; GARCIALADONA FJ, 1994, MOL BRAIN RES, V21, P75, DOI 10.1016/0169-328X(94)90380-8; Gecz J, 1999, GENOMICS, V62, P356, DOI 10.1006/geno.1999.6032; Harant H, 1996, J BIOL CHEM, V271, P26954, DOI 10.1074/jbc.271.43.26954; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; LUEDERS KK, 1982, NUCLEIC ACIDS RES, V10, P7715, DOI 10.1093/nar/10.23.7715; Mathern GW, 1998, J NEUROPATH EXP NEUR, V57, P615, DOI 10.1097/00005072-199806000-00008; Myers SJ, 1998, J NEUROSCI, V18, P6723; Myers SJ, 1999, ANNU REV PHARMACOL, V39, P221, DOI 10.1146/annurev.pharmtox.39.1.221; MYERS SJ, 1998, SOC NEUR ABSTR, V23, P923; Nayak A, 1998, NATURE, V394, P680, DOI 10.1038/29305; Naylor P, 1996, MOL BRAIN RES, V35, P349, DOI 10.1016/0169-328X(95)00264-S; NEDIVI E, 1992, J NEUROSCI, V12, P691; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; PELLEGRINIGIAMPIETRO DE, 1992, NEUROSCI LETT, V144, P65, DOI 10.1016/0304-3940(92)90717-L; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Sasner M, 1996, J BIOL CHEM, V271, P21316, DOI 10.1074/jbc.271.35.21316; SUCHER NJ, 1993, J BIOL CHEM, V268, P22299; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; VERDOORN TA, 1988, MOL PHARMACOL, V34, P298; Weber JRM, 1998, J NEUROSCI, V18, P5264, DOI 10.1523/JNEUROSCI.18-14-05264.1998; Weber JRM, 1997, J NEUROSCI, V17, P7583; Wood MW, 1996, J BIOL CHEM, V271, P8115, DOI 10.1074/jbc.271.14.8115; Yaworsky PJ, 1997, J BIOL CHEM, V272, P25112, DOI 10.1074/jbc.272.40.25112; Yeo J F, 1997, Int J Neurosci, V90, P9; Yoshida Y, 1996, J BIOL CHEM, V271, P30167, DOI 10.1074/jbc.271.47.30167; Zilles K, 1999, NEUROSCIENCE, V94, P1051, DOI 10.1016/S0306-4522(99)00392-9	44	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25929	25938		10.1074/jbc.M009105200	http://dx.doi.org/10.1074/jbc.M009105200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11340067	hybrid			2022-12-25	WOS:000169823300040
J	Chen, CB; Wallis, R				Chen, CB; Wallis, R			Stoichiometry of complexes between mannose-binding protein and its associated serine proteases - Defining functional units for complement activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RA-REACTIVE FACTOR; CLASSICAL PATHWAY; IMMUNE-SYSTEM; LECTIN; MANNAN; SERUM; EQUILIBRIUM; COMPONENT; ZYMOSAN; C1S	Serum mannose-binding protein (MBP) initiates the lectin branch of the complement cascade by binding to sugars on the surfaces of microorganisms and activating two MBP-associated serine proteases (MASP-1 and MASP-2). Rat serum MBP consists of oligomers containing up to four copies of a subunit that is composed of three identical polypeptide chains. Biophysical analysis of intact and truncated MASPs indicates that each MASP is a homodimer that is stabilized through interactions involving an N-terminal CUB domain. The binding sites for MBP are formed from the three N-terminal MASP domains, in which two CUB modules interact with MBP. Each MASP dimer contains binding sites for two MBP subunits. Both sites must be occupied by subunits from a single MBP oligomer to form a stable complex. Thus, the smallest functional unit for complement activation consists of MBP dimers bound to MASP-1 or MASP-2 homodimers. Trimers and tetramers of MBP form complexes containing up to two MASPs. The results reveal how MASP-1 and MASP-2 can function independently to activate the complement cascade.	Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England	University of Oxford	Wallis, R (corresponding author), Univ Oxford, Dept Biochem, Glycobiol Inst, S Parks Rd, Oxford OX1 3QU, England.			Wallis, Russell/0000-0002-8705-5295				Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Eftink MR, 1997, METHOD ENZYMOL, V278, P221; Endo Y, 1998, J IMMUNOL, V161, P4924; IKEDA K, 1987, J BIOL CHEM, V262, P7451; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P537, DOI 10.1016/0076-6879(90)85044-O; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LIPSCOMBE RJ, 1995, IMMUNOLOGY, V85, P660; LU J, 1990, J IMMUNOL, V144, P2287; Minton AP, 1997, PROG COLL POL SCI S, V107, P11; REID KBM, 1983, BIOCHEM SOC T, V11, P1; Rivas G, 1999, METHODS, V19, P194, DOI 10.1006/meth.1999.0851; SIM RB, 1991, IMMUNOL TODAY, V12, P307, DOI 10.1016/0167-5699(91)90004-D; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Stover CM, 1999, J IMMUNOL, V163, P6848; Stover CM, 1999, J IMMUNOL, V162, P3481; SUPER M, 1990, CLIN EXP IMMUNOL, V79, P144; TAKADA F, 1993, BIOCHEM BIOPH RES CO, V196, P1003, DOI 10.1006/bbrc.1993.2349; Takahashi M, 1999, INT IMMUNOL, V11, P859, DOI 10.1093/intimm/11.5.859; TAKAYAMA Y, 1994, J IMMUNOL, V152, P2308; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; Thielens NM, 2001, J IMMUNOL, V166, P5068, DOI 10.4049/jimmunol.166.8.5068; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; Wallis R, 1999, J BIOL CHEM, V274, P3580, DOI 10.1074/jbc.274.6.3580; Wallis R, 1997, BIOCHEM J, V325, P391, DOI 10.1042/bj3250391; Wallis R, 2000, J BIOL CHEM, V275, P30962, DOI 10.1074/jbc.M004030200; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; YOKOTA Y, 1995, J BIOCHEM-TOKYO, V117, P414, DOI 10.1093/jb/117.2.414	32	88	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25894	25902		10.1074/jbc.M103539200	http://dx.doi.org/10.1074/jbc.M103539200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11337510	hybrid			2022-12-25	WOS:000169823300036
J	Milisav, I; Moro, F; Neupert, W; Brunner, M				Milisav, I; Moro, F; Neupert, W; Brunner, M			Modular structure of the TIM23 preprotein translocase of mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; INNER MEMBRANE; INTERMEMBRANE SPACE; CARRIER PROTEINS; MATRIX HSP70; COMPLEX; SYSTEM; HSP70-TIM44; MACHINERY; TRANSPORT	The TIM23 complex mediates import into mitochondria of nuclear encoded preproteins with a matrix-targeting signal. It is composed of the integral membrane proteins Tim17 and Tim23 and the peripheral membrane protein Tim44, which recruits mitochondrial Hsp70 to the sites of protein import. We have analyzed the functions of these constituents using a combined genetic and biochemical approach. Depletion of either Tim17 or Tim23 led to loss of import competence of mitochondria and to a reduction in the number of preprotein-conducting channels. Upon depletion of Tim44, mitochondria also lost their ability to import proteins but maintained normal numbers of import channels. In the absence of Tim44 precursor protein was specifically recognized. The presequence was translocated in a Delta psi -dependent manner across the inner membrane and cleaved by matrix-processing peptidase, However, the preprotein did not move further into the matrix but rather underwent retrograde sliding out of the TIM23 complex. Thus, the TIM23 complex is composed of functionally independent modules. Tim17 and Tim23 are necessary for initiating translocation, whereas Tim44 and mitochondrial Hsp70 are indispensable for complete transport of preproteins and for unfolding of folded domains of preproteins.	Univ Munich, Inst Phys Chem, D-80336 Munich, Germany	University of Munich	Brunner, M (corresponding author), Univ Munich, Inst Phys Chem, Goethestr 33, D-80336 Munich, Germany.		Moro Pérez, Fernando/P-3891-2015	Moro Pérez, Fernando/0000-0002-3568-3388; Brunner, Michael/0000-0001-9798-3047				Azem A, 1997, J BIOL CHEM, V272, P20901, DOI 10.1074/jbc.272.33.20901; Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; Bauer MF, 2000, TRENDS CELL BIOL, V10, P25, DOI 10.1016/S0962-8924(99)01684-0; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; Bomer U, 1998, EMBO J, V17, P4226, DOI 10.1093/emboj/17.15.4226; Creighton T. E., 1996, PROTEINS STRUCTURES; DAUM G, 1982, J BIOL CHEM, V257, P3028; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; Kaldi K, 1998, EMBO J, V17, P1569, DOI 10.1093/emboj/17.6.1569; Kerscher O, 1997, J CELL BIOL, V139, P1663, DOI 10.1083/jcb.139.7.1663; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; MARTIN J, 1991, J BIOL CHEM, V266, P18051; Martin J, 1997, CURR OPIN STRUC BIOL, V7, P41, DOI 10.1016/S0959-440X(97)80006-1; Moro F, 1999, EMBO J, V18, P3667, DOI 10.1093/emboj/18.13.3667; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PFANNER N, 1997, CURR BIOL, V7, P100; Rapoport TA, 1999, BIOL CHEM, V380, P1143, DOI 10.1515/BC.1999.145; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; Ryan MT, 2000, INT J BIOCHEM CELL B, V32, P13, DOI 10.1016/S1357-2725(99)00114-4; Schneider HC, 1996, EMBO J, V15, P5796, DOI 10.1002/j.1460-2075.1996.tb00966.x; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; Sirrenberg C, 1997, J BIOL CHEM, V272, P29963, DOI 10.1074/jbc.272.47.29963; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; Ungermann C, 1996, EMBO J, V15, P735, DOI 10.1002/j.1460-2075.1996.tb00409.x; Voisine C, 1999, CELL, V97, P565, DOI 10.1016/S0092-8674(00)80768-0; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6; Voos W, 1996, EMBO J, V15, P2668, DOI 10.1002/j.1460-2075.1996.tb00627.x	35	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25856	25861		10.1074/jbc.M102132200	http://dx.doi.org/10.1074/jbc.M102132200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11344168	hybrid			2022-12-25	WOS:000169823300030
J	Nitiss, JL; Nitiss, KC; Rose, A; Waltman, JL				Nitiss, JL; Nitiss, KC; Rose, A; Waltman, JL			Overexpression of type I topoisomerases sensitizes yeast cells to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE TYROSINE; CLEAVABLE COMPLEXES; REPLICATION FORKS; ABASIC SITES; MECHANISM; GENE; POLY(ADP-RIBOSYLATION); INVOLVEMENT; RESISTANCE; EXPRESSION	DNA topoisomerases play essential roles in many DNA metabolic processes. It has been suggested that topoisomerases play an essential role in DNA repair. Topoisomerases can introduce DNA damage upon exposure to drugs that stabilize the covalent protein-DNA intermediate of the topoisomerase reaction. Lesions in DNA are also able to trap topoisomerase-DNA intermediates, suggesting that topoisomerases have the potential to either assist in DNA repair by locating sites of damage or exacerbating DNA damage by generation of additional damage at the site of a lesion. We have shown that overexpression of yeast topoisomerase I (TOP1) conferred hypersensitivity to methyl methanesulfonate and other DNA-damaging agents, whereas expression of a catalytically inactive enzyme did not. Overexpression of topoisomerase II did not change the sensitivity of cells to these DNA-damaging agents, Yeast cells lacking TOP1 were not more resistant to DNA damage than cells expressing wild type levels of the enzyme, Yeast topoisomerase I covalent complexes can be trapped efficiently on UV-damaged DNA. We suggest that TOP1 does not participate in the repair of DNA damage in yeast cells. However, the enzyme has the potential of exacerbating DNA damage by forming covalent DNA-protein complexes at sites of DNA damage.	St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Nitiss, JL (corresponding author), St Jude Childrens Res Hosp, Dept Mol Pharmacol, 332 N Lauderdale St, Memphis, TN 38105 USA.	john.nitiss@stjude.org	Nitiss, John/E-9974-2010	Nitiss, John/0000-0002-1013-4972	NCI NIH HHS [CA21765, CA52814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, R01CA052814] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; BHATIA K, 1990, CARCINOGENESIS, V11, P123, DOI 10.1093/carcin/11.1.123; BJORNSTI MA, 1989, CANCER RES, V49, P6318; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; BOOTHMAN DA, 1994, CANCER RES, V54, P4618; BOREHAM DR, 1990, RADIAT RES, V123, P203, DOI 10.2307/3577546; BRILL SJ, 1987, NATURE, V326, P414, DOI 10.1038/326414a0; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CORBETT AH, 1991, J BIOL CHEM, V266, P19666; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; DANKS MK, 1988, BIOCHEMISTRY-US, V27, P8861, DOI 10.1021/bi00424a026; Desai SD, 1997, J BIOL CHEM, V272, P24159, DOI 10.1074/jbc.272.39.24159; ENG WK, 1989, J BIOL CHEM, V264, P13373; FERRO AM, 1984, J BIOL CHEM, V259, P547; FERRO AM, 1984, COLD SPRING HARB SYM, V49, P683, DOI 10.1101/SQB.1984.049.01.077; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HSIANG YH, 1989, CANCER RES, V49, P5077; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; Kimura K, 1999, CELL, V98, P239, DOI 10.1016/S0092-8674(00)81018-1; KINGMA PS, 1995, J BIOL CHEM, V270, P21441, DOI 10.1074/jbc.270.37.21441; Kingma PS, 1998, BBA-GENE STRUCT EXPR, V1400, P223, DOI 10.1016/S0167-4781(98)00138-9; KNAB AM, 1995, J BIOL CHEM, V270, P6141, DOI 10.1074/jbc.270.11.6141; Kretz-Remy C, 1999, BIOCHEM CELL BIOL, V77, P299, DOI 10.1139/bcb-77-4-299; KROGH S, 1991, NUCLEIC ACIDS RES, V19, P1235, DOI 10.1093/nar/19.6.1235; Lanza A, 1996, J BIOL CHEM, V271, P6978, DOI 10.1074/jbc.271.12.6978; LIU LF, 1983, J BIOL CHEM, V258, P5365; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; Nitiss JL, 1998, CONT CANC RES, P517; Nitiss JL, 1998, BBA-GENE STRUCT EXPR, V1400, P63, DOI 10.1016/S0167-4781(98)00128-6; Nitiss JL, 1998, BIOCHEMISTRY-US, V37, P3078, DOI 10.1021/bi9723257; NITISS JL, 1992, CANCER RES, V52, P4467; Pommier Y, 2000, P NATL ACAD SCI USA, V97, P2040, DOI 10.1073/pnas.040397497; Postow L, 1999, BIOESSAYS, V21, P805, DOI 10.1002/(SICI)1521-1878(199910)21:10<805::AID-BIES1>3.0.CO;2-7; Pouliot JJ, 1999, SCIENCE, V286, P552, DOI 10.1126/science.286.5439.552; Pourquier P, 1997, J BIOL CHEM, V272, P26441, DOI 10.1074/jbc.272.42.26441; Pourquier P, 1999, J BIOL CHEM, V274, P8516, DOI 10.1074/jbc.274.13.8516; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; Pourquier P, 1998, J BIOL CHEM, V273, P27245, DOI 10.1074/jbc.273.42.27245; Rubin E H, 1996, Cancer Treat Res, V87, P243; RUBY SW, 1985, MOL CELL BIOL, V5, P75, DOI 10.1128/MCB.5.1.75; Subramanian D, 1998, CANCER RES, V58, P976; TRASK DK, 1984, EMBO J, V3, P671, DOI 10.1002/j.1460-2075.1984.tb01865.x; TSAO YP, 1993, CANCER RES, V53, P5908; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Yang SW, 1996, P NATL ACAD SCI USA, V93, P11534, DOI 10.1073/pnas.93.21.11534; YEH YC, 1994, J BIOL CHEM, V269, P15498; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G; Zhu J, 1996, MOL CELL BIOL, V16, P1805	53	32	33	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26708	26714		10.1074/jbc.M102674200	http://dx.doi.org/10.1074/jbc.M102674200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11353773	hybrid			2022-12-25	WOS:000169823300138
J	Uchiyama, M; Griffiths, D; Arai, K; Masai, H				Uchiyama, M; Griffiths, D; Arai, K; Masai, H			Essential role of Sna41/Cdc45 in loading of DNA polymerase alpha onto minichromosome maintenance proteins in fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL REPLICATION ORIGINS; S-PHASE; SCHIZOSACCHAROMYCES-POMBE; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; MCM PROTEIN; BUDDING YEAST; COMPLEX; CDC45P; GENE	Assembly of replication complexes at the replication origins is strictly regulated. Cdc45p is known to be a part of the active replication complexes. In Xenopus egg extracts, Cdc45p was shown to be required for loading of DNA polymerase alpha onto chromatin. The fission yeast cdc45 homologue was identified as a suppressor for nda8 and named snag41. Nevertheless, it is not known how Cdc45p facilitates loading of DNA polymerase ru onto chromatin, particularly to prereplicative complexes. To gain novel insight into the function of this protein in fission yeast, we characterized the fission yeast Cdc45 homologue, Sna41p, We have constructed C-terminally epitope-tagged Sna41p and Pol alphap and replaced the endogenous genes with the corresponding tagged genes. Analyses of protein-protein interactions in vivo by the use of these tagged strains revealed the following: Sna41p interacts with Pol alphap throughout the cell cycle, whereas it interacts with Mis5p/Mcm6p in the chromatin fractions at the G(1)-S boundary through S phase. In an initiation-defective sna41 mutant, sna41(goal), interaction of Pol alphap with Mis5p is not observed, although Pol alphap loading onto the chromatin that occurs before G, START is not affected. These results show that fission yeast Sna41p facilitates the loading of Pol alphap onto minichromosome maintenance proteins. Our results are consistent with a model in which loading of Pol alphap onto replication origins occurs through two steps, namely, loading onto chromatin at preSTART and association with prereplicative complexes at G(1)-S through Sna41p, which interacts with minichromosome maintenance proteins in a cell cycle-dependent manner.	CREST, Tokyo 1088639, Japan; Imperial Canc Res Fund, London WC2A 3PX, England; Univ Tokyo, Inst Med Sci, Dept Mol & Dev Biol, Tokyo 1088639, Japan	Japan Science & Technology Agency (JST); Cancer Research UK; University of Tokyo	Masai, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Cell Biol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 113, Japan.							Aparicio OM, 1999, P NATL ACAD SCI USA, V96, P9130, DOI 10.1073/pnas.96.16.9130; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Aves SJ, 1998, CURR GENET, V34, P164, DOI 10.1007/s002940050382; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Brown GW, 1997, P NATL ACAD SCI USA, V94, P6142, DOI 10.1073/pnas.94.12.6142; Brown GW, 1999, P NATL ACAD SCI USA, V96, P8443, DOI 10.1073/pnas.96.15.8443; Brown GW, 1998, J BIOL CHEM, V273, P22083, DOI 10.1074/jbc.273.34.22083; Chuang RY, 1999, P NATL ACAD SCI USA, V96, P2656, DOI 10.1073/pnas.96.6.2656; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Desdouets C, 1998, EMBO J, V17, P4139, DOI 10.1093/emboj/17.14.4139; FOIANI M, 1995, MOL CELL BIOL, V15, P883; FRANCESCONI S, 1993, NUCLEIC ACIDS RES, V21, P3821, DOI 10.1093/nar/21.16.3821; Grallert B, 1996, GENE DEV, V10, P2644, DOI 10.1101/gad.10.20.2644; Griffiths DJF, 2001, MOL BIOL CELL, V12, P115, DOI 10.1091/mbc.12.1.115; HAGAN IM, 1988, J CELL SCI, V89, P343; Hopwood B, 1996, P NATL ACAD SCI USA, V93, P12309, DOI 10.1073/pnas.93.22.12309; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; Kukimoto I, 1999, EUR J BIOCHEM, V265, P936, DOI 10.1046/j.1432-1327.1999.00791.x; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Maiorano D, 1996, EMBO J, V15, P861, DOI 10.1002/j.1460-2075.1996.tb00421.x; MASAI H, 1995, EMBO J, V14, P3094, DOI 10.1002/j.1460-2075.1995.tb07312.x; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; MIYAKE S, 1993, MOL BIOL CELL, V4, P1003, DOI 10.1091/mbc.4.10.1003; Miyake S, 1998, GENES CELLS, V3, P157, DOI 10.1046/j.1365-2443.1998.00177.x; Mizuno T, 1998, MOL CELL BIOL, V18, P3552, DOI 10.1128/MCB.18.6.3552; MuziFalconi M, 1996, P NATL ACAD SCI USA, V93, P1566, DOI 10.1073/pnas.93.4.1566; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Newlon CS, 1997, CELL, V91, P717, DOI 10.1016/S0092-8674(00)80459-6; Ogawa Y, 1999, MOL CELL BIOL, V19, P7228; OKAZAKI K, 1990, NUCLEIC ACIDS RES, V18, P6485, DOI 10.1093/nar/18.22.6485; Okishio N, 1996, J CELL SCI, V109, P319; Okuno Y, 1997, NUCLEIC ACIDS RES, V25, P530, DOI 10.1093/nar/25.3.530; PARK H, 1993, MOL BIOL CELL, V4, P145, DOI 10.1091/mbc.4.2.145; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; Sherman DA, 1998, NUCLEIC ACIDS RES, V26, P3955, DOI 10.1093/nar/26.17.3955; Sherman DA, 1998, MOL BIOL CELL, V9, P1833, DOI 10.1091/mbc.9.7.1833; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; TAKAHASHI K, 1994, MOL BIOL CELL, V5, P1145, DOI 10.1091/mbc.5.10.1145; Takeda T, 1999, MOL CELL BIOL, V19, P5535; Tanaka TU, 1998, EMBO J, V17, P5182, DOI 10.1093/emboj/17.17.5182; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Tercero JA, 2000, EMBO J, V19, P2082, DOI 10.1093/emboj/19.9.2082; UCHIYAMA M, 2001, IN PRESS MOL GEN GEN; Voitenleitner C, 1999, MOL CELL BIOL, V19, P646; WANG TSF, 1996, DNA REPLICATION EUKA, P461; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	49	30	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26189	26196		10.1074/jbc.M100007200	http://dx.doi.org/10.1074/jbc.M100007200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11344166	hybrid			2022-12-25	WOS:000169823300074
J	O'Flaherty, JT; Chadwell, BA; Kearns, MW; Sergeant, S; Daniel, LW				O'Flaherty, JT; Chadwell, BA; Kearns, MW; Sergeant, S; Daniel, LW			Protein kinases C translocation responses to low concentrations of arachidonic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; DIBUTYRATE BINDING-SITES; HUMAN NEUTROPHILS; PHORBOL ESTERS; NADPH OXIDASE; OLEIC-ACID; ACTIVATION; CELLS; ISOFORMS; PHOSPHORYLATION	Arachidonic acid (AA) directly activates protein kinases C (PKC) and may thereby serve as a regulatory signal during cell stimulation. The effect, however, requires a greater than or equal to 20 muM concentration of the fatty acid. We find that human polymorphonuclear neutrophils (PMN) equilibrated with a ligand for the diacylglycerol receptor on PKC, [H-3]phorbol dibutyrate (PDB), increased binding of [3H]PDB within 15 s of exposure to greater than or equal to 10-30 nM Ak Other unsaturated fatty acids, but not a saturated fatty acid, likewise stimulated PDB binding. These responses, similar to those caused by chemotactic factors, resulted from a rise in the number of diacylglycerol receptors that were plasma membrane-associated and therefore accessible to PDB. Unlike chemotactic factors, however, AA was fully active on cells overloaded with Ca2+ chelators, The major metabolites of AA made by PMN, leukotriene B-4 and 5-hydroxyicosatetraenoate, did not mimic Ak and an AA antimetabolite did not block responses to Ak AA also induced PMN to translocate cytosolic PKC alpha, beta (II), and delta to membranes. This response paralleled PDB binding with respect to dose requirements, time, Ca2+-independence, resistance to an AA antimetabolite, and induction by another unsaturated fatty acid but not by a saturated fatty acid. Finally, HEK 293 cells transfected with vectors encoding PKC beta (1) or PKC delta fused to the reporter enhanced green fluorescent protein (EGFP) were studied, AA caused EGFP-PKC beta translocation from cytosol to plasma membrane at greater than or equal to0.5 muM, and EGFP-PKC delta translocation from cytosol to nuclear and, to a lesser extent, plasma membrane at as little as 30 nM. We conclude that AA induces PKC translocations to specific membrane targets at concentrations 2-4 orders of magnitude below those activating the enzymes. These responses, at least as they occur in PMN, do not require changes in cell Ca2+ or oxygenation of the fatty acid. AA seems more suited for signaling the movement than activation of PKC.	Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University	O'Flaherty, JT (corresponding author), Wake Forest Univ, Sch Med, Dept Internal Med, Infect Dis Sect, Med Ctr Blvd, Winston Salem, NC 27156 USA.	joflaher@wfubmc.edu			NHLBI NIH HHS [1RO1 HL56710] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056710] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Barry OP, 1997, J CLIN INVEST, V99, P2118, DOI 10.1172/JCI119385; Barry OP, 1999, J BIOL CHEM, V274, P7545, DOI 10.1074/jbc.274.11.7545; BROWN JH, 1990, SYM SOC EXP BIOL, V44, P147; Capodici C, 1998, J CLIN INVEST, V102, P165, DOI 10.1172/JCI592; COMBADIERE C, 1993, BIOCHEM J, V289, P695, DOI 10.1042/bj2890695; DANG PMC, 1995, BIOCHEM BIOPH RES CO, V212, P664, DOI 10.1006/bbrc.1995.2020; Daniele JJ, 1999, PROSTAG OTH LIPID M, V57, P341, DOI 10.1016/S0090-6980(98)00084-7; Dekker LV, 2000, BIOCHEM J, V347, P285, DOI 10.1042/0264-6021:3470285; DIAZGUERRA MJM, 1991, J BIOL CHEM, V266, P23568; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; Feng X, 2000, J BIOL CHEM, V275, P17024, DOI 10.1074/jbc.275.22.17024; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; Hayashi A, 1999, BBA-MOL CELL RES, V1450, P99, DOI 10.1016/S0167-4889(99)00040-3; HII CST, 1995, J BIOL CHEM, V270, P4201, DOI 10.1074/jbc.270.9.4201; Hii CST, 1998, J BIOL CHEM, V273, P19277, DOI 10.1074/jbc.273.30.19277; Hii CST, 1999, ADV EXP MED BIOL, V469, P365; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; Huang XP, 1997, J CELL SCI, V110, P1625; Huang ZH, 1997, BIOCHEM J, V325, P553, DOI 10.1042/bj3250553; Kazanietz MG, 2000, MOL CARCINOGEN, V28, P5, DOI 10.1002/(SICI)1098-2744(200005)28:1<5::AID-MC2>3.0.CO;2-G; Kent JD, 1996, J IMMUNOL, V157, P4641; Keranen LM, 1997, J BIOL CHEM, V272, P25959, DOI 10.1074/jbc.272.41.25959; KHAN WA, 1993, J BIOL CHEM, V268, P5063; KHAN WA, 1995, CELL SIGNAL, V7, P171, DOI 10.1016/0898-6568(94)00089-T; Khwaja A, 1999, BLOOD, V94, P291, DOI 10.1182/blood.V94.1.291.413k10_291_301; Laudanna C, 1998, J BIOL CHEM, V273, P30306, DOI 10.1074/jbc.273.46.30306; Lennartz MR, 1999, INT J BIOCHEM CELL B, V31, P415, DOI 10.1016/S1357-2725(98)00108-3; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; Lu Y, 1999, CELL SIGNAL, V11, P275, DOI 10.1016/S0898-6568(98)00061-8; Maasch C, 2000, FASEB J, V14, P1653, DOI 10.1096/fj.14.11.1653; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; Matthews SA, 2000, EMBO J, V19, P2935, DOI 10.1093/emboj/19.12.2935; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mochly-Rosen D, 1998, FASEB J, V12, P35; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; Murray NR, 1998, J BIOL CHEM, V273, P11514, DOI 10.1074/jbc.273.19.11514; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; Nixon JB, 1999, J IMMUNOL, V163, P4574; Nowicki S, 2000, AM J PHYSIOL-CELL PH, V279, pC1812, DOI 10.1152/ajpcell.2000.279.6.C1812; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; OFlaherty JT, 1996, J BIOL CHEM, V271, P17821, DOI 10.1074/jbc.271.30.17821; OFLAHERTY JT, 1990, J BIOL CHEM, V265, P21619; OFLAHERTY JT, 1990, J BIOL CHEM, V265, P9146; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; Padma M, 1999, PROSTAG LEUKOTR ESS, V60, P55, DOI 10.1054/plef.1998.0008; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; Raeder EMB, 1999, BLOOD, V93, P686, DOI 10.1182/blood.V93.2.686.402k27_686_693; RAIS S, 1994, BIOCHEM PHARMACOL, V47, P1797, DOI 10.1016/0006-2952(94)90308-5; Reeves EP, 1999, BIOCHEM J, V344, P859, DOI 10.1042/0264-6021:3440859; Ron D, 1999, J BIOL CHEM, V274, P19003, DOI 10.1074/jbc.274.27.19003; Sanchez P, 1998, MOL CELL BIOL, V18, P3069, DOI 10.1128/MCB.18.5.3069; SASAKI Y, 1993, FEBS LETT, V320, P47, DOI 10.1016/0014-5793(93)81655-J; Sergeant S, 1997, J IMMUNOL, V159, P2877; Shirai Y, 1998, JPN J PHARMACOL, V78, P411, DOI 10.1254/jjp.78.411; Shirai Y, 1998, J CELL BIOL, V143, P511, DOI 10.1083/jcb.143.2.511; Shirai Y, 2000, J BIOL CHEM, V275, P24760, DOI 10.1074/jbc.M003151200; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; SZAMEL M, 1989, J IMMUNOL, V143, P2806; Vallentin A, 2000, J BIOL CHEM, V275, P6014, DOI 10.1074/jbc.275.8.6014; Wang QMJ, 1999, J BIOL CHEM, V274, P37233, DOI 10.1074/jbc.274.52.37233; Wang YX, 1999, J BIOL CHEM, V274, P13859, DOI 10.1074/jbc.274.20.13859; WIJKANDER J, 1995, J BIOL CHEM, V270, P26543, DOI 10.1074/jbc.270.44.26543; WOLF M, 1985, J BIOL CHEM, V260, P5718; Yaney GC, 2000, ENDOCRINOLOGY, V141, P1989, DOI 10.1210/en.141.6.1989	68	62	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24743	24750		10.1074/jbc.M101093200	http://dx.doi.org/10.1074/jbc.M101093200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11328812	hybrid			2022-12-25	WOS:000169800700045
J	Song, LN; Huse, B; Rusconi, S; Simons, SS				Song, LN; Huse, B; Rusconi, S; Simons, SS			Transactivation specificity of glucocorticoid versus progesterone receptors - Role of functionally different interactions of transcription factors with amino- and carboxyl-terminal receptor domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; TUMOR VIRUS PROMOTER; PARTIAL AGONIST ACTIVITY; HUMAN ESTROGEN-RECEPTOR; BREAST-CANCER CELLS; NUCLEAR RECEPTOR; ANDROGEN RECEPTOR; GENE-EXPRESSION; DNA-BINDING; STEROID-RECEPTORS	A major unanswered question of glucocorticoid and progesterone action is how different whole cell responses arise when both of the cognate receptors can bind to, and activate, the same hormone response elements. We have documented previously that the EC,, of agonist complexes, and the partial agonist activity of antagonist complexes, of both glucocorticoid receptors (GRs) and progesterone receptors (PRs) are modulated by increased amounts of homologous receptor and of coregulators. We now ask whether these components can differentially alter GR and PR transcriptional properties. To remove possible cell-specific differences, we have examined both receptors in the common environment of a line of mouse mammary adenocarcinoma (1470.2) cells, In order to segregate the responses that might be due to unequal nucleosome reorganization by the two receptors from those reflecting interactions with other components, we chose a transiently transfected reporter containing a simple glucocorticoid response element (i.e. GREtkLUC), No significant differences are found with elevated levels of either receptor. However, major, qualitative differences are seen with the corepressors SMRT and NCoR, which afford opposite responses with GR and PR. Studies with chimeric GR/PR receptors indicate that no one segment of PR or G;R is responsible for these properties and that the composite response likely involves interactions with both the amino and carboxyl termini of receptors, Collectively, the data suggest that GR and PR induction of responsive genes in a given cell can be differentially controlled, in part, by unequal interactions of multiple receptor domains with assorted nuclear cofactors.	NIDDK, Steroid Hormones Sect, LMCB, NIH, Bethesda, MD 20892 USA; Univ Fribourg, CH-1700 Fribourg, Switzerland	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Fribourg	Simons, SS (corresponding author), NIDDK, Steroid Hormones Sect, LMCB, NIH, Bldg 8,Rm B2A-07, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK057800, Z01DK057800] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alen P, 1999, MOL CELL BIOL, V19, P6085; Alen P, 1999, MOL ENDOCRINOL, V13, P117, DOI 10.1210/me.13.1.117; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; ARCHER TK, 1994, MOL ENDOCRINOL, V8, P568, DOI 10.1210/me.8.5.568; ARCHER TK, 1994, MOL ENDOCRINOL, V8, P1154, DOI 10.1210/me.8.9.1154; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Auger AP, 2000, P NATL ACAD SCI USA, V97, P7551, DOI 10.1073/pnas.97.13.7551; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Chen SY, 2000, J BIOL CHEM, V275, P30106, DOI 10.1074/jbc.M005418200; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Endoh H, 1999, MOL CELL BIOL, V19, P5363; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Folkers GE, 1998, J BIOL CHEM, V273, P32200, DOI 10.1074/jbc.273.48.32200; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Giannoukos G, 2001, MOL ENDOCRINOL, V15, P255, DOI 10.1210/me.15.2.255; Glass CK, 2000, GENE DEV, V14, P121; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Huang SM, 2000, MOL CELL BIOL, V20, P1855, DOI 10.1128/MCB.20.5.1855-1867.2000; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; Kaul S, 2000, MOL ENDOCRINOL, V14, P1010, DOI 10.1210/me.14.7.1010; Kinyamu HK, 2000, J BIOL CHEM, V275, P20061, DOI 10.1074/jbc.M001142200; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; Kumar R, 1999, J BIOL CHEM, V274, P24737, DOI 10.1074/jbc.274.35.24737; KUPFER SR, 1993, J BIOL CHEM, V268, P17519; Lambert JR, 1998, J BIOL CHEM, V273, P32708, DOI 10.1074/jbc.273.49.32708; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; LEE HL, 1994, MOL CELL BIOL, V14, P32, DOI 10.1128/MCB.14.1.32; Li DS, 1999, MOL CELL BIOL, V19, P7191; LIEBERMAN BA, 1993, MOL ENDOCRINOL, V7, P515, DOI 10.1210/me.7.4.515; Liu Z, 1999, P NATL ACAD SCI USA, V96, P9485, DOI 10.1073/pnas.96.17.9485; Massaad C, 2000, BIOCHEM J, V350, P123, DOI 10.1042/0264-6021:3500123; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Misiti S, 1998, ENDOCRINOLOGY, V139, P2493, DOI 10.1210/en.139.5.2493; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; MYMRYK JS, 1995, GENE DEV, V9, P1366, DOI 10.1101/gad.9.11.1366; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nelson CC, 1999, MOL ENDOCRINOL, V13, P2090, DOI 10.1210/me.13.12.2090; Ordentlich P, 1999, P NATL ACAD SCI USA, V96, P2639, DOI 10.1073/pnas.96.6.2639; OSHIMA H, 1993, J BIOL CHEM, V268, P26858; OSHIMA H, 1992, MOL ENDOCRINOL, V6, P416, DOI 10.1210/me.6.3.416; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; PONS M, 1981, J ORG CHEM, V46, P3262, DOI 10.1021/jo00329a024; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Reichardt HM, 2000, MOL CELL BIOL, V20, P9009, DOI 10.1128/MCB.20.23.9009-9017.2000; RICOUSSE SL, 1996, P NATL ACAD SCI USA, V93, P5072; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; Sarlis NJ, 1999, J STEROID BIOCHEM, V68, P89, DOI 10.1016/S0960-0760(99)00021-7; Schoenmakers E, 2000, J BIOL CHEM, V275, P12290, DOI 10.1074/jbc.275.16.12290; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Shim WS, 1999, P NATL ACAD SCI USA, V96, P208, DOI 10.1073/pnas.96.1.208; SIMONS SS, 1980, J ORG CHEM, V45, P3084, DOI 10.1021/jo01303a030; SIMONS SS, 1992, MOL ENDOCRINOL, V6, P995, DOI 10.1210/me.6.7.995; SIMONS SS, 1984, BIOCHEMISTRY-US, V23, P6876, DOI 10.1021/bi00321a092; Smith CL, 2000, MOL ENDOCRINOL, V14, P956, DOI 10.1210/me.14.7.956; Smith CL, 1997, J BIOL CHEM, V272, P14227, DOI 10.1074/jbc.272.22.14227; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P11202, DOI 10.1073/pnas.90.23.11202; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; STRAHLE U, 1989, NATURE, V339, P629, DOI 10.1038/339629a0; Subramaniam N, 1999, J BIOL CHEM, V274, P18121, DOI 10.1074/jbc.274.25.18121; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; Szapary D, 1996, J BIOL CHEM, V271, P30576, DOI 10.1074/jbc.271.48.30576; Szapary D, 1999, MOL ENDOCRINOL, V13, P2108, DOI 10.1210/me.13.12.2108; SZAPARY D, 1993, MOL ENDOCRINOL, V7, P941, DOI 10.1210/me.7.8.941; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Tetel MJ, 1999, MOL ENDOCRINOL, V13, P910, DOI 10.1210/me.13.6.910; Thackray VG, 1998, J STEROID BIOCHEM, V66, P171, DOI 10.1016/S0960-0760(98)00044-2; Thackray VG, 2000, ENDOCRINOLOGY, V141, P3912, DOI 10.1210/en.141.10.3912; Trapp T, 1996, J BIOL CHEM, V271, P9879, DOI 10.1074/jbc.271.17.9879; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Wong JM, 1998, EMBO J, V17, P520, DOI 10.1093/emboj/17.2.520; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; Xu M, 1996, J BIOL CHEM, V271, P21430, DOI 10.1074/jbc.271.35.21430; Yang ZH, 1999, J BIOL CHEM, V274, P37131, DOI 10.1074/jbc.274.52.37131; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Zhang X, 1998, MOL ENDOCRINOL, V12, P513, DOI 10.1210/me.12.4.513	89	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24806	24816		10.1074/jbc.M102610200	http://dx.doi.org/10.1074/jbc.M102610200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11333273	hybrid, Green Submitted			2022-12-25	WOS:000169800700053
J	Wang, YT; Yin, LY; Hillgartner, FB				Wang, YT; Yin, LY; Hillgartner, FB			The homeodomain proteins PBX and MEIS1 are accessory factors that enhance thyroid hormone regulation of the malic enzyme gene in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COOPERATIVE DNA-BINDING; CHICK-EMBRYO HEPATOCYTES; TRANSCRIPTIONAL CONTROL; RESPONSE ELEMENTS; RECEPTOR-ALPHA; HOMEOBOX GENES; HOX PROTEINS; EXPRESSION; TRIIODOTHYRONINE; DOMAIN	Triiodothyronine (T3) stimulates a robust increase (40-fold) in transcription of the malic enzyme gene in chick embryo hepatocytes. Previous work has shown that optimal T3 regulation of malic enzyme transcription is dependent on the presence of an accessory element (designated as region E) that immediately flanks a cluster of five T3 response elements in the malic enzyme gene. Here, we have analyzed the binding of nuclear proteins to region E and investigated the mechanism by which region E enhances T3 responsiveness. In nuclear extracts hom hepatocytes, region E binds heterodimeric complexes consisting of the homeodomain proteins PBX and MEIS1, Region E contains four consecutive PBX/MEIS1 half-sites, PBX-MEIS1 heterodimers bind the first and second half-sites, the third and fourth half-sites, and the first and fourth half-sites. The configuration conferring the greatest increase in T3 responsiveness consists of the first and fourth half-sites that are separated by 7 nucleotides. Stimulation of T3 response element functions by region E does not require the presence of additional melic enzyme sequences. In pull-down experiments, PBX1a and PBX1b specifically bind the nuclear T3 receptor-or, and this interaction is enhanced by the presence of T3, A T3 receptor-ct region containing the DNA binding domain plus nanking sequences famine acids 21-157) is necessary and sufficient for binding to PBX1a and PBX1b, These results indicate that PBX-MEIS1 complexes interact with nuclear T3 receptors to enhance T3 regulation of malic enzyme transcription in hepatocytes.	W Virginia Univ, Dept Biochem, Sch Med, Morgantown, WV 26506 USA	West Virginia University	Hillgartner, FB (corresponding author), W Virginia Univ, Dept Biochem, Sch Med, POB 9142, Morgantown, WV 26506 USA.	fbhillgartner@hsc.wvu.edu						Abramovich C, 2000, J BIOL CHEM, V275, P26172, DOI 10.1074/jbc.M001323200; BAILLIE RA, 1993, J NUTR BIOCHEM, V4, P431, DOI 10.1016/0955-2863(93)90074-7; Berthelsen J, 1996, J BIOL CHEM, V271, P3822; Berthelsen J, 1998, EMBO J, V17, P1423, DOI 10.1093/emboj/17.5.1423; Bischof LJ, 1998, J BIOL CHEM, V273, P7941, DOI 10.1074/jbc.273.14.7941; Burglin TR, 1997, NUCLEIC ACIDS RES, V25, P4173, DOI 10.1093/nar/25.21.4173; Casares F, 1998, NATURE, V392, P723, DOI 10.1038/33706; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407; DESVERGNE B, 1994, MOL CELL ENDOCRINOL, V100, P125, DOI 10.1016/0303-7207(94)90291-7; Fang XX, 1998, ARCH BIOCHEM BIOPHYS, V349, P138, DOI 10.1006/abbi.1997.0406; Fang XX, 2000, MOL CELL ENDOCRINOL, V164, P41, DOI 10.1016/S0303-7207(00)00238-0; Ferretti E, 2000, DEVELOPMENT, V127, P155; Ferretti E, 1999, MECH DEVELOP, V83, P53, DOI 10.1016/S0925-4773(99)00031-3; Glass CK, 2000, GENE DEV, V14, P121; Gonzalez-Manchon C, 1999, GENE, V226, P111, DOI 10.1016/S0378-1119(98)00543-5; GOODRIDG.AG, 1973, J BIOL CHEM, V248, P1924; GOODRIDGE AG, 1968, BIOCHEM J, V108, P663, DOI 10.1042/bj1080663; GOODRIDGE AG, 1976, J BIOL CHEM, V251, P3027; GOODRIDGE AG, 1968, BIOCHEM J, V108, P667, DOI 10.1042/bj1080667; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Goudet G, 1999, J BIOL CHEM, V274, P4067, DOI 10.1074/jbc.274.7.4067; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; Herzig S, 2000, J BIOL CHEM, V275, P27989; HILLGARTNER FB, 1992, J BIOL CHEM, V267, P12299; Hodnett DW, 1996, ARCH BIOCHEM BIOPHYS, V334, P309, DOI 10.1006/abbi.1996.0460; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; Jump DB, 1997, J BIOL CHEM, V272, P27778, DOI 10.1074/jbc.272.44.27778; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Knoepfler PS, 1999, NUCLEIC ACIDS RES, V27, P3752, DOI 10.1093/nar/27.18.3752; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; Knoepfler PS, 1997, ONCOGENE, V14, P2521, DOI 10.1038/sj.onc.1201097; KRUSE F, 1995, MOL CELL BIOL, V15, P4385; Lee Y, 1997, MOL CELL BIOL, V17, P2745, DOI 10.1128/MCB.17.5.2745; LU QA, 1995, MOL CELL BIOL, V15, P3786; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; MA XJ, 1990, J BIOL CHEM, V265, P18435; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; Moore DD, 1995, GLOB MOB SURV; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Ogo A, 1997, ARCH BIOCHEM BIOPHYS, V348, P226, DOI 10.1006/abbi.1997.0372; Ogo A, 1997, ARCH BIOCHEM BIOPHYS, V338, P193, DOI 10.1006/abbi.1996.9838; ONATE SA, 1995, SCIENCE, V270, P1354; Palomino T, 1998, FASEB J, V12, P1201, DOI 10.1096/fasebj.12.12.1201; Park EA, 1999, J BIOL CHEM, V274, P211, DOI 10.1074/jbc.274.1.211; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; Penkov D, 2000, J BIOL CHEM, V275, P16681, DOI 10.1074/jbc.M909345199; Popperl H, 2000, MOL CELL, V6, P255, DOI 10.1016/S1097-2765(00)00027-7; RONCERO C, 1992, J BIOL CHEM, V267, P14918; SALATI LM, 1991, J BIOL CHEM, V266, P4010; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAMUELS HH, 1989, ANNU REV PHYSIOL, V51, P623, DOI 10.1146/annurev.ph.51.030189.003203; SCHAUFELE F, 1992, MOL ENDOCRINOL, V6, P656, DOI 10.1210/me.6.4.656; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Smith JE, 1997, GENOMICS, V43, P99, DOI 10.1006/geno.1997.4766; Subramaniam N, 1998, J BIOL CHEM, V273, P23567, DOI 10.1074/jbc.273.36.23567; Swift GH, 1998, MOL CELL BIOL, V18, P5109, DOI 10.1128/MCB.18.9.5109; Thurmond DC, 1998, J BIOL CHEM, V273, P1613, DOI 10.1074/jbc.273.3.1613; Toresson H, 2000, MECH DEVELOP, V94, P183, DOI 10.1016/S0925-4773(00)00324-5; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; Yeagley D, 2000, J BIOL CHEM, V275, P17814, DOI 10.1074/jbc.M909842199; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	65	15	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23838	23848		10.1074/jbc.M102166200	http://dx.doi.org/10.1074/jbc.M102166200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11331288	hybrid, Green Published			2022-12-25	WOS:000169531100083
J	Kawai, S; Vora, S; Das, S; Gachie, E; Becker, B; Neufeld, AH				Kawai, S; Vora, S; Das, S; Gachie, E; Becker, B; Neufeld, AH			Modeling of risk factors for the degeneration of retinal ganglion cells after ischemia/reperfusion in rats: effects of age, caloric restriction, diabetes, pigmentation, and glaucoma	FASEB JOURNAL			English	Article									Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA	Washington University (WUSTL)	Neufeld, AH (corresponding author), Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, Box 8096,660 S Euclid Ave, St Louis, MO 63110 USA.								0	59	59	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1285	1287		10.1096/fj.00-0666fje	http://dx.doi.org/10.1096/fj.00-0666fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344115				2022-12-25	WOS:000168655200037
J	Bai, JN; Brody, JR; Kadkol, SHS; Pasternack, GR				Bai, JN; Brody, JR; Kadkol, SHS; Pasternack, GR			Tumor suppression and potentiation by manipulation of pp32 expression	ONCOGENE			English	Article						pp32; oncogene; transformation	PROTEIN; PHOSPHATASE; GENE; IDENTIFICATION; INHIBITION; ACTIVATION	Alternative use of genes of the closely-related pp32 family is a common occurrence in human prostate cancer, pp32r1 and pp32r2, the oncogenic members of the pp32 family, are expressed in prostatic adenocarcinoma, while adjacent benign prostate continues to express pp32, This study focuses upon the role of pp32 in tumor suppression, We demonstrate that antisense inhibition of pp32 in NIH3T3 cells leads to a variety of phenotypic changes associated with transformation including reduced serum dependence and loss of contact inhibition. NIH3T3 cells with antisense-inhibited pp32 are not tumorigenic, but are markedly more susceptible to oncogenic stimuli such as vas, In contrast, constitutive expression of pp32 abolishes ras mediated transformation in vitro and tumorigenesis in vivo. These data demonstrate, from the functional aspect, that pp32 acts as a tumor suppressor. Furthermore, inactivation of pp32 function through alternative gene use may be a critical event in tumor evolution and progression.	Johns Hopkins Univ, Sch Med, Dept Pathol, Div Mol Pathol, Baltimore, MD 21205 USA	Johns Hopkins University	Pasternack, GR (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Div Mol Pathol, Room 512 Ross,720 Rutland Ave, Baltimore, MD 21205 USA.				NCI NIH HHS [R01 CA54404] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054404] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Brody JR, 1999, J BIOL CHEM, V274, P20053, DOI 10.1074/jbc.274.29.20053; Chen TH, 1996, MOL BIOL CELL, V7, P2045, DOI 10.1091/mbc.7.12.2045; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; Gusev Y, 1996, CELL PROLIFERAT, V29, P643, DOI 10.1111/j.1365-2184.1996.tb00978.x; HAMILTON SR, 1988, J PATHOL, V154, P205, DOI 10.1002/path.1711540302; Kadkol SS, 1999, NAT MED, V5, P275, DOI 10.1038/6488; Kadkol SS, 1998, PROSTATE, V34, P231, DOI 10.1002/(SICI)1097-0045(19980215)34:3<231::AID-PROS11>3.0.CO;2-F; KADKOL SS, 1999, J MOL DIAGN, V1, P58; LEE TH, 1994, MOL BIOL CELL, V5, P323, DOI 10.1091/mbc.5.3.323; Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y; Mathupala SP, 1997, J BIOL CHEM, V272, P22776, DOI 10.1074/jbc.272.36.22776; Millard SS, 2000, MOL CELL BIOL, V20, P5947, DOI 10.1128/MCB.20.16.5947-5959.2000; Mills JC, 1998, J CELL SCI, V111, P625; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; WEINBERG RA, 1989, BIOCHEMISTRY-US, V28, P8263, DOI 10.1021/bi00447a001; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917	20	60	63	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2001	20	17					2153	2160		10.1038/sj.onc.1204294	http://dx.doi.org/10.1038/sj.onc.1204294			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360199				2022-12-25	WOS:000168116700010
J	Atkinson, SF; Bettinger, T; Seymour, LW; Behr, JP; Ward, CM				Atkinson, SF; Bettinger, T; Seymour, LW; Behr, JP; Ward, CM			Conjugation of folate via gelonin carbohydrate residues retains ribosomal-inactivating properties of the toxin and permits targeting to folate receptor positive cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICIN-A CHAIN; PROTEIN-SYNTHESIS; IN-VIVO; INTACT-CELLS; TUMOR; DEGLYCOSYLATION; HORMONOTOXINS; IMMUNOTOXINS; ENDOCYTOSIS; INHIBITION	Conjugation of folate to proteins permits receptor-mediated endocytosis via the folate receptor (FR) and delivery of the conjugate into the cytoplasm of cells. Since many cancers up-regulate the FR it has enabled the targeting of toxins to tumor cells resulting in specific cell death. However, current conjugation methods rely on chemistries that can affect certain catalytic subunits, such as the A-chain of the plant toxin gelonin. As a result many folate-targeted tons are a compromise between receptor/ligand interaction and toxin activity. We describe the first example of folate conjugated to a protein via carbohydrate residues, using a novel SH-folate intermediate. The folate-gelonin conjugate retains over 99% of toxin activity in a cell-free translational assay compared with unmodified gelonin and is able to bind the FR at the same affinity as free folic acid (10(-10) M). Additionally, the conjugate exhibits prolonged inhibition of protein synthesis in FR positive cell lines in vitro. Folate linked to gelonin via amino conjugation exhibits the same affinity for FR as free folic acid but the toxin is 225-fold less active in a cell-free translational assay. The effect of different conjugation methods on toxin activity and the implications for folate targeting of other glycoproteins are discussed.	Christie Hosp NHS Trust, Paterson Inst Canc Res, Dept Immunol, Manchester M20 4BX, Lancs, England; Univ Birmingham, CRC Inst Canc Studies, Birmingham B15 2TA, W Midlands, England; Fac Pharm, UMR 7514, F-67401 Illkirch Graffenstaden, France	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Birmingham; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Ward, CM (corresponding author), Christie Hosp NHS Trust, Paterson Inst Canc Res, Dept Immunol, Wilmslow Rd, Manchester M20 4BX, Lancs, England.	wardcm@hotmail.com		Ward, Christopher/0000-0001-7389-4488				BLAKEY DC, 1987, CANCER RES, V47, P947; EIKLID K, 1980, EXP CELL RES, V126, P321, DOI 10.1016/0014-4827(80)90270-0; Fu QL, 2001, BIOCONJUGATE CHEM, V12, P271, DOI 10.1021/bc000100u; FULTON RJ, 1988, CANCER RES, V48, P2618; FULTON RJ, 1988, CANCER RES, V48, P2626; Gabizon A, 1999, BIOCONJUGATE CHEM, V10, P289, DOI 10.1021/bc9801124; Koivunen E, 1999, METH MOL B, V129, P3; Kreitman RJ, 1998, ADV DRUG DELIVER REV, V31, P53, DOI 10.1016/S0169-409X(97)00094-X; Leamon CP, 2001, DRUG DISCOV TODAY, V6, P44, DOI 10.1016/S1359-6446(00)01594-4; LEAMON CP, 1992, J BIOL CHEM, V267, P24966; Leamon CP, 1999, J DRUG TARGET, V7, P157, DOI 10.3109/10611869909085499; LEE RJ, 1994, J BIOL CHEM, V269, P3198; MAGNUSSON S, 1993, BIOCHEM J, V291, P749, DOI 10.1042/bj2910749; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; ROSENBLUM MG, 1992, MOL BIOTHER, V4, P122; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; Sforzini S, 1995, J Hematother, V4, P429, DOI 10.1089/scd.1.1995.4.429; Sharma S, 1999, MOL CELL BIOCHEM, V200, P133, DOI 10.1023/A:1007043218769; Shinoda T, 1998, J PHARM SCI, V87, P1521, DOI 10.1021/js980215v; SINGH V, 1989, BIOCHEM J, V263, P417, DOI 10.1042/bj2630417; SINGH V, 1991, BIOCHEM INT, V24, P677; SINGH V, 1991, BIOCHEM INT, V25, P531; SINGH V, 1994, MOL CELL BIOCHEM, V130, P91, DOI 10.1007/BF01084272; STIRPE F, 1980, J BIOL CHEM, V255, P6947; Toffoli G, 1997, INT J CANCER, V74, P193, DOI 10.1002/(SICI)1097-0215(19970422)74:2<193::AID-IJC10>3.0.CO;2-F; TUREK JJ, 1993, J CELL SCI, V106, P423; Wang S, 1997, BIOCONJUGATE CHEM, V8, P673, DOI 10.1021/bc9701297; Wang S, 1998, J CONTROL RELEASE, V53, P39, DOI 10.1016/S0168-3659(97)00236-8; Ward CM, 2000, J DRUG TARGET, V8, P119, DOI 10.3109/10611860008996857; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5; YAZDI PT, 1995, CANCER RES, V55, P3763	31	74	104	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27930	27935		10.1074/jbc.M102825200	http://dx.doi.org/10.1074/jbc.M102825200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11359781	Green Published, hybrid			2022-12-25	WOS:000170093400026
J	Martinez, J; Ren, YG; Nilsson, P; Ehrenberg, M; Virtanen, A				Martinez, J; Ren, YG; Nilsson, P; Ehrenberg, M; Virtanen, A			The mRNA cap structure stimulates rate of poly(A) removal and amplifies processivity of degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; IN-VITRO; POLY(A)-BINDING PROTEIN; TRANSLATION INITIATION; BINDING-PROTEIN; POLY(A)-SPECIFIC RIBONUCLEASE; CRYSTAL-STRUCTURE; DNA-REPLICATION; XENOPUS OOCYTES	Poly(A) -specific ribonuclease (PARN) is an oligomeric, processive, and cap-interacting 3' exonuclease. We have studied how the m(7)G(5')ppp(5')G cap structure affects the activity of PARN. It is shown that the cap has four distinct effects: (i) It stimulates the rate of deadenylation if provided in cis; (ii) it inhibits deadenylation if provided at high concentration in trans; (iii) it stimulates deadenylation if provided at low concentration in trans; and (iv) it increases the processivity of PARN when provided in cis. It is shown that the catalytic and cap binding sites on PARN are separate. The important roles of the 7-methyl group and the inverted guanosine residue of the cap are demonstrated. An active deadenylation complex, consisting of the poly(A)-tailed RNA substrate and PARN, has been identified. Complex formation does not require a cap structure on the RNA substrate. The multiple effects of cap are all accounted for by a simple, kinetic model that takes the processivity of PARN into account.	Uppsala Univ, Dept Cell & Mol Biol, SE-75124 Uppsala, Sweden	Uppsala University	Virtanen, A (corresponding author), Uppsala Univ, Dept Cell & Mol Biol, Box 596, SE-75124 Uppsala, Sweden.			Martinez, Javier/0000-0001-9152-7323				ASTROM J, 1991, EMBO J, V10, P3067, DOI 10.1002/j.1460-2075.1991.tb07858.x; ASTROM J, 1992, J BIOL CHEM, V267, P18154; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; Boeck R, 1998, MOL CELL BIOL, V18, P5062, DOI 10.1128/MCB.18.9.5062; Boeck R, 1996, J BIOL CHEM, V271, P432, DOI 10.1074/jbc.271.1.432; BRAWERMAN G, 1981, CRC CR REV BIOCH MOL, V10, P1, DOI 10.3109/10409238109114634; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; Brewer G, 1998, J BIOL CHEM, V273, P34770, DOI 10.1074/jbc.273.52.34770; Brown CE, 1996, MOL CELL BIOL, V16, P5744; Caponigro G, 1996, MICROBIOL REV, V60, P233, DOI 10.1128/MMBR.60.1.233-249.1996; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; Couttet P, 1997, P NATL ACAD SCI USA, V94, P5628, DOI 10.1073/pnas.94.11.5628; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; Dehlin E, 2000, EMBO J, V19, P1079, DOI 10.1093/emboj/19.5.1079; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Dunckley T, 1999, EMBO J, V18, P5411, DOI 10.1093/emboj/18.19.5411; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Ford LP, 1997, MOL CELL BIOL, V17, P398, DOI 10.1128/MCB.17.1.398; Gallie DR, 1998, BIOCHEM BIOPH RES CO, V245, P295, DOI 10.1006/bbrc.1998.8427; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; Gao M, 2000, MOL CELL, V5, P479, DOI 10.1016/S1097-2765(00)80442-6; Gao M, 2001, EMBO J, V20, P1134, DOI 10.1093/emboj/20.5.1134; GORLACH M, 1994, EXP CELL RES, V211, P400, DOI 10.1006/excr.1994.1104; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Haghighat A, 1997, J BIOL CHEM, V272, P21677, DOI 10.1074/jbc.272.35.21677; Hsu PC, 2000, BIOCHEMISTRY-US, V39, P13730, DOI 10.1021/bi000623p; Keck JL, 2000, CHEM BIOL, V7, pR63, DOI 10.1016/S1074-5521(00)00094-6; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Korner CG, 1997, J BIOL CHEM, V272, P10448; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; Kovall R, 1997, SCIENCE, V277, P1824, DOI 10.1126/science.277.5333.1824; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Kuhn U, 1996, J MOL BIOL, V256, P20, DOI 10.1006/jmbi.1996.0065; LaGrandeur TE, 1998, EMBO J, V17, P1487, DOI 10.1093/emboj/17.5.1487; LARIMER FW, 1992, GENE, V120, P51, DOI 10.1016/0378-1119(92)90008-D; Martinez J, 2000, J BIOL CHEM, V275, P24222, DOI 10.1074/jbc.M001705200; Mian IS, 1997, NUCLEIC ACIDS RES, V25, P3187, DOI 10.1093/nar/25.16.3187; Mitchell P, 2000, CURR OPIN GENET DEV, V10, P193, DOI 10.1016/S0959-437X(00)00063-0; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; Morino S, 1996, EUR J BIOCHEM, V239, P597, DOI 10.1111/j.1432-1033.1996.0597u.x; MUHLRAD D, 1992, GENE DEV, V6, P2100, DOI 10.1101/gad.6.11.2100; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MUHLRAD D, 1994, NATURE, V370, P578, DOI 10.1038/370578a0; Preiss T, 1999, CURR OPIN GENET DEV, V9, P515, DOI 10.1016/S0959-437X(99)00005-2; ROSS J, 1986, J MOL BIOL, V188, P579, DOI 10.1016/S0022-2836(86)80008-0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; Sachs AB, 2000, NAT STRUCT BIOL, V7, P356, DOI 10.1038/75120; SHATKIN AJ, 1987, BIOESSAYS, V7, P275, DOI 10.1002/bies.950070611; STEVENS A, 1980, J BIOL CHEM, V255, P3080; TABOR S, 1987, J BIOL CHEM, V262, P16212; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; Virtanen A, 1997, Prog Mol Subcell Biol, V18, P199; Wahle E, 1999, FEMS MICROBIOL REV, V23, P277, DOI 10.1016/S0168-6445(99)00008-X; Wormington M, 1996, EMBO J, V15, P900, DOI 10.1002/j.1460-2075.1996.tb00424.x; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	59	79	101	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27923	27929		10.1074/jbc.M102270200	http://dx.doi.org/10.1074/jbc.M102270200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11359775	hybrid			2022-12-25	WOS:000170093400025
J	Abe, M; Nishida, I; Minemura, M; Qadota, H; Seyama, Y; Watanabe, T; Ohya, Y				Abe, M; Nishida, I; Minemura, M; Qadota, H; Seyama, Y; Watanabe, T; Ohya, Y			Yeast 1,3-beta-glucan synthase activity is inhibited by phytosphingosine localized to the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID ELONGATION; SACCHAROMYCES-CEREVISIAE; 1,3-BETA-D-GLUCAN SYNTHASE; SECRETORY PATHWAY; MEMBRANE-PROTEIN; PLASMA-MEMBRANES; OUTER-MEMBRANE; GENE ENCODES; IN-VITRO; TRANSPORT	1,3-beta -D-Glucan, a major filamentous component of the cell wall in the budding yeast Saccharomyces cerevisiae, is synthesized by 1,3-beta -glucan synthase (GS), Although a yeast gene whose product is required for GS activity in vitro, GNS1, was isolated and characterized, its role in GS function has remained unknown. In the current study we show that Delta gns1 cells accumulate a non-competitive and non-proteinous inhibitor(s) in the membrane fraction. Investigations of inhibitory activity on GS revealed that the inhibitor(s) is mainly present in the sphingolipid fraction. It is shown that Delta gns1 cells contain phytosphingosine (PHS), an intermediate in the sphingolipid biosynthesis, 30-fold more than wild-type cells do. The membrane fraction isolated from Delta sur2 cells contains an increased amount of dihydrosphingosine (DRS) and also exhibits reduced GS activity. Among constituents of the sphingolipid fraction, PHS and DHS show striking inhibition in a non-competitive manner. The intracellular level of DHS is much lower than that of PHS in wild-type cells, suggesting that PHS is the primary inhibitor of GS in vivo. The localization of PHS to the endoplasmic reticulum in wild-type cells coincides with that of the inhibitor(s) in Delta gns1 cells. Taken together, our results indicate that PHS is a potent inhibitor of yeast GS in vivo.	Univ Tokyo, Dept Integrated Biosci, Grad Sch Frontier Sci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Dept Biol Sci, Grad Sch Sci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Dept Physiol Chem & Metab, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan; Nippon Roche Res Ctr, Dept Mycol, Kanagawa 2478530, Japan; Japan Sci & Technol Corp, Unit Proc & Combined Circuit, PRESTO, Osaka 5650082, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Roche Holding; Japan Science & Technology Agency (JST)	Ohya, Y (corresponding author), Univ Tokyo, Dept Integrated Biosci, Grad Sch Frontier Sci, Bunkyo Ku, Tokyo 1130033, Japan.	ohya@k.u-tokyo.ac.jp	Nishida, Ikuo/W-8007-2019; Abe, Mitsuhiro/C-3602-2017; Nishida, Ikuo/E-3339-2010	Nishida, Ikuo/0000-0002-9669-4005				ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; ARIS JP, 1991, METHOD ENZYMOL, V194, P735; BANDLOW W, 1972, BIOCHIM BIOPHYS ACTA, V282, P105, DOI 10.1016/0005-2736(72)90315-X; BASCO RD, 1994, BIOCHEM J, V304, P917, DOI 10.1042/bj3040917; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHU FK, 1983, ARCH BIOCHEM BIOPHYS, V223, P543, DOI 10.1016/0003-9861(83)90619-7; CID VJ, 1995, MICROBIOL REV, V59, P345, DOI 10.1128/MMBR.59.3.345-386.1995; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; David D, 1998, J CELL BIOL, V143, P1167, DOI 10.1083/jcb.143.5.1167; Dickson RC, 1999, BBA-MOL CELL BIOL L, V1438, P305, DOI 10.1016/S1388-1981(99)00068-2; Dickson RC, 1997, J BIOL CHEM, V272, P29620, DOI 10.1074/jbc.272.47.29620; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; ELSHERBEINI M, 1995, J BACTERIOL, V177, P3227, DOI 10.1128/jb.177.11.3227-3234.1995; ESMON PC, 1987, J BIOL CHEM, V263, P8832; Gennis R, 1989, BIOMEMBRANES MOL STR, P199; Govindan B, 1995, J EXP ZOOL, V273, P401, DOI 10.1002/jez.1402730505; Grilley MM, 1998, J BIOL CHEM, V273, P11062, DOI 10.1074/jbc.273.18.11062; Grote E, 2000, MOL BIOL CELL, V11, P4051, DOI 10.1091/mbc.11.12.4051; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; HECHTBERGER P, 1994, EUR J BIOCHEM, V225, P641, DOI 10.1111/j.1432-1033.1994.00641.x; Helliwell SB, 1998, CURR BIOL, V8, P1211, DOI 10.1016/S0960-9822(07)00511-8; HURT EC, 1988, EUR J CELL BIOL, V46, P554; Inoue SB, 1999, J BIOL CHEM, V274, P38119, DOI 10.1074/jbc.274.53.38119; INOUE SB, 1995, EUR J BIOCHEM, V231, P845, DOI 10.1111/j.1432-1033.1995.tb20770.x; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; LEBER R, 1994, YEAST, V10, P1421, DOI 10.1002/yea.320101105; Lupashin VV, 1996, J CELL BIOL, V132, P277, DOI 10.1083/jcb.132.3.277; Mazur P, 1996, J BIOL CHEM, V271, P14604, DOI 10.1074/jbc.271.24.14604; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; MECHLER B, 1987, EMBO J, V6, P2157, DOI 10.1002/j.1460-2075.1987.tb02483.x; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; Panaretou B, 1996, Methods Mol Biol, V53, P117; PATTON JL, 1991, J BACTERIOL, V173, P3101, DOI 10.1128/JB.173.10.3101-3108.1991; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; RIEZMAN H, 1983, EMBO J, V2, P2161, DOI 10.1002/j.1460-2075.1983.tb01717.x; Robertson J, 1999, J VAC SCI TECHNOL B, V17, P659, DOI 10.1116/1.590613; Saba JD, 1997, J BIOL CHEM, V272, P26087, DOI 10.1074/jbc.272.42.26087; Sakumoto NM, 1999, YEAST, V15, P1669, DOI 10.1002/(SICI)1097-0061(199911)15:15<1669::AID-YEA480>3.0.CO;2-6; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SATO K, 1995, MOL BIOL CELL, V6, P1459, DOI 10.1091/mbc.6.11.1459; SCHATZ G, 1964, BIOCHIM BIOPHYS ACTA, V81, P448, DOI 10.1016/0926-6569(64)90130-0; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; SIKORSKI RS, 1989, GENETICS, V122, P19; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Smits GJ, 1999, CURR OPIN MICROBIOL, V2, P348; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; TAKITA Y, 1995, MOL GEN GENET, V246, P269, DOI 10.1007/BF00288599; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163; Wolff AM, 1996, YEAST, V12, P823, DOI 10.1002/(SICI)1097-0061(199607)12:9<823::AID-YEA975>3.0.CO;2-J; YOSHIHISA T, 1988, J BIOL CHEM, V263, P5158	57	24	26	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26923	26930		10.1074/jbc.M102179200	http://dx.doi.org/10.1074/jbc.M102179200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11337502	hybrid			2022-12-25	WOS:000169966900027
J	Benndorf, R; Sun, XK; Gilmont, RR; Biedermann, KJ; Molloy, MP; Goodmurphy, CW; Cheng, H; Andrews, PC; Welsh, MJ				Benndorf, R; Sun, XK; Gilmont, RR; Biedermann, KJ; Molloy, MP; Goodmurphy, CW; Cheng, H; Andrews, PC; Welsh, MJ			HSP22, a new member of the small heat shock protein superfamily, interacts with mimic of phosphorylated HSP27 ((3D)HSP27)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; SMALL STRESS PROTEIN; ACTIN POLYMERIZATION; INTRACELLULAR-LOCALIZATION; SERTOLI CELLS; IN-VIVO; KINASE; IDENTIFICATION; MUSCLE; RAT	Most of the members of the superfamily of mammalian small heat shock or stress proteins are abundant in muscles where they play a role in muscle function and maintenance of muscle integrity. One member of this protein superfamily, human HSP27, is rapidly phosphorylated on three serine residues (Ser(15), Ser(78), and Ser(82)) during cellular response to a number of extracellular factors. To understand better the role of HSP27, we performed a yeast two-hybrid screen of a human heart cDNA library for HSP27-interacting proteins. By using the triple aspartate mutant, a mimic of phosphorylated HSP27, as 'bait" construct, a protein with a molecular mass of 21.6 kDa was identified as an HSP27-binding protein. Sequence analysis revealed that this new protein shares an overall sequence identity of 33% with human HSP27. This protein also contains the alpha -crystallin domain in its C-terminal half, a hallmark of the superfamily of small stress proteins. Thus, the new protein itself is a member of this protein superfamily, and consequently we designated it HSP22. According to the two-hybrid data, HSP22 interacts preferentially with the triple aspartate form of HSP27 as compared with wild-type HSP27. HSP22 is expressed predominantly in muscles. In vitro, HSP22 is phosphorylated by protein kinase C (at residues Ser(14) and Thr(63)) and by p44 mitogen-activated protein kinase (at residues Ser(27) and Thr(87)) but not by MAPKAPK-2.	Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Plast & Reconstruct Surg, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Benndorf, R (corresponding author), Univ Michigan, Sch Med, Dept Cell & Dev Biol, 1335 Catherine St, Ann Arbor, MI 48109 USA.	rbenndo@umich.edu	Goodmurphy, Craig/AAO-8264-2021; Welsh, Michael/B-1968-2008	Goodmurphy, Craig/0000-0002-7778-1998; Molloy, Mark/0000-0003-4679-5868; Andrews, Philip/0000-0001-6843-5420	NCI NIH HHS [R01CA77078-01] Funding Source: Medline; NHGRI NIH HHS [R01HG01709-01] Funding Source: Medline; NIEHS NIH HHS [ES06265] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077078] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001709] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006265] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; Beall A, 1999, J BIOL CHEM, V274, P11344, DOI 10.1074/jbc.274.16.11344; Benndorf R, 2000, METH MOL B, V99, P431; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; BITAR KN, 1991, BIOCHEM BIOPH RES CO, V181, P1192, DOI 10.1016/0006-291X(91)92065-R; Boelens WC, 1998, BBA-PROTEIN STRUCT M, V1388, P513, DOI 10.1016/S0167-4838(98)00215-5; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; Carr SA, 1996, ANAL BIOCHEM, V239, P180, DOI 10.1006/abio.1996.0313; Davidson SM, 2000, DEV BIOL, V218, P146, DOI 10.1006/dbio.1999.9596; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Der Perng M, 1999, J BIOL CHEM, V274, P33235, DOI 10.1074/jbc.274.47.33235; Eaton P, 2000, J MOL CELL CARDIOL, V32, P961, DOI 10.1006/jmcc.2000.1136; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; Golenhofen N, 1999, J MOL CELL CARDIOL, V31, P569, DOI 10.1006/jmcc.1998.0892; Hawkins J, 2000, ARCH BIOCHEM BIOPHYS, V382, P310, DOI 10.1006/abbi.2000.2005; INAGUMA Y, 1995, J BIOCHEM-TOKYO, V117, P1238, DOI 10.1093/oxfordjournals.jbchem.a124850; Jansen G, 1996, NAT GENET, V13, P316, DOI 10.1038/ng0796-316; KANTOROW M, 1994, P NATL ACAD SCI USA, V91, P3112, DOI 10.1073/pnas.91.8.3112; Kato K, 1998, J BIOL CHEM, V273, P28346, DOI 10.1074/jbc.273.43.28346; KATO K, 1994, J BIOL CHEM, V269, P11274; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P201, DOI 10.1016/0304-4165(91)90062-L; KATO K, 1994, J BIOL CHEM, V269, P15302; KATO K, 1992, J BIOL CHEM, V267, P7718; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Krief S, 1999, J BIOL CHEM, V274, P36592, DOI 10.1074/jbc.274.51.36592; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LANDRY J, 1992, J BIOL CHEM, V267, P794; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; Liu CH, 2000, J BIOL CHEM, V275, P18724, DOI 10.1074/jbc.M001981200; Liu CH, 1999, BIOCHEM BIOPH RES CO, V255, P256, DOI 10.1006/bbrc.1999.0174; LONGONI S, 1990, MOL CELL BIOCHEM, V97, P121, DOI 10.1007/BF00221053; Lutsch G, 1997, CIRCULATION, V96, P3466; Martin JL, 1997, CIRCULATION, V96, P4343; MEHLEN P, 1994, EUR J BIOCHEM, V221, P327, DOI 10.1111/j.1432-1033.1994.tb18744.x; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Piotrowicz RS, 1997, J BIOL CHEM, V272, P25920, DOI 10.1074/jbc.272.41.25920; PITTENGER GL, 1992, ENDOCRINOLOGY, V130, P3207, DOI 10.1210/en.130.6.3207; Preville X, 1998, J CELL BIOCHEM, V69, P436, DOI 10.1002/(SICI)1097-4644(19980615)69:4<436::AID-JCB5>3.0.CO;2-O; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; Sakamoto K, 2000, BIOCHEM BIOPH RES CO, V269, P137, DOI 10.1006/bbrc.2000.2233; Schafer C, 1999, AM J PHYSIOL-CELL PH, V277, pC1032; Schneider GB, 1998, J CELL PHYSIOL, V177, P575, DOI 10.1002/(SICI)1097-4652(199812)177:4<575::AID-JCP8>3.0.CO;2-1; Smith CC, 2000, J BIOL CHEM, V275, P25690, DOI 10.1074/jbc.M002140200; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Sugiyama Y, 2000, J BIOL CHEM, V275, P1095, DOI 10.1074/jbc.275.2.1095; Suzuki A, 1998, J CELL BIOL, V140, P1113, DOI 10.1083/jcb.140.5.1113; van de Klundert FAJM, 1998, EUR J CELL BIOL, V75, P38, DOI 10.1016/S0171-9335(98)80044-7; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; VOORTER CEM, 1989, FEBS LETT, V259, P50; Wang KY, 1996, EUR J BIOCHEM, V242, P56, DOI 10.1111/j.1432-1033.1996.0056r.x; Wieske M, 2001, EUR J BIOCHEM, V268, P2083, DOI 10.1046/j.1432-1327.2001.02082.x; Yamboliev IA, 2000, AM J PHYSIOL-HEART C, V278, pH1899, DOI 10.1152/ajpheart.2000.278.6.H1899; Yoshida K, 1999, CELL STRUCT FUNCT, V24, P181, DOI 10.1247/csf.24.181; Zavialov A, 1998, INT J BIOL MACROMOL, V22, P163, DOI 10.1016/S0141-8130(98)00014-2; ZHU Y, 1994, J BIOL CHEM, V269, P22379	63	96	108	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26753	26761		10.1074/jbc.M103001200	http://dx.doi.org/10.1074/jbc.M103001200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11342557	hybrid			2022-12-25	WOS:000169966900005
J	Ku, NO; Omary, MB				Ku, NO; Omary, MB			Effect of mutation and phosphorylation of type I keratins on their caspase-mediated degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMOLYSIS-BULLOSA SIMPLEX; INTERMEDIATE FILAMENTS; CULTURED-CELLS; ANTIGEN TPS; APOPTOSIS; DISEASE; PROTEINS; CYTOKERATINS; EPITHELIA; CLEAVAGE	Type I keratins K18 and K19 undergo caspase-mediated degradation during apoptosis, Two known K18 caspase cleavage sites are aspartates in the consensus sequences VEVDA and DALDS, located within the rod domain and tail domain, respectively. Several K14 (another type I keratin) mutations within the caspase cleavage motif have been described inpatients with epidermolysis bullosa simplex. Here we use extensive mutational analysis to show that K19 and K14 are caspase substrates and that the ability to undergo caspase-mediated digestion of K18, K19, or K14 is highly dependent on the location and nature of the mutation within the caspase cleavage motif, Caspase cleavage of K14 occurs at the aspartate of VEMDA, a consensus sequence found in type I keratins K12-17 with similar but not identical sequences in K18 and K19. For K18, apoptosis-induced cleavage occurs sequentially, first at (393)DALD and then at (VEVD)-V-234. Hyperphosphorylation of K18 protects from caspase-3 in vitro digestion at (VEVD)-V-234 but not at (393)DALD. Hence, keratins K12-17 are likely caspase substrates during apoptosis. Keratin hyperphosphorylation, which occurs early in apoptosis, protects from caspase-mediated K18 digestion in a cleavage site-specific manner. Mutations in epidermolysis bullosa simplex patients could interfere with K14 degradation during apoptosis, depending on their location.	Vet Affairs Med Ctr, Dept Med, Palo Alto, CA 94304 USA; Stanford Univ, Palo Alto, CA 94304 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University	Omary, MB (corresponding author), Vet Affairs Med Ctr, Dept Med, Mail Code 154J,3801 Miranda Ave, Palo Alto, CA 94304 USA.			Omary, Bishr/0000-0002-8624-2347	NIDDK NIH HHS [DK47918] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047918] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Badock V, 2001, CELL DEATH DIFFER, V8, P308, DOI 10.1038/sj.cdd.4400812; Bjorklund B, 1978, Antibiot Chemother (1971), V22, P16; Caulin C, 1997, J CELL BIOL, V138, P1379, DOI 10.1083/jcb.138.6.1379; CHEN H, 1995, J INVEST DERMATOL, V105, P629, DOI 10.1111/1523-1747.ep12323846; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Gniadecki R, 1998, ARCH DERMATOL RES, V290, P528, DOI 10.1007/s004030050347; Herrmann H, 2000, CURR OPIN CELL BIOL, V12, P79, DOI 10.1016/S0955-0674(99)00060-5; HUMPHRIES MM, 1993, HUM MUTAT, V2, P37, DOI 10.1002/humu.1380020107; Irvine AD, 1999, BRIT J DERMATOL, V140, P815, DOI 10.1046/j.1365-2133.1999.02810.x; Ku NO, 1999, AM J PHYSIOL-GASTR L, V277, pG1108, DOI 10.1152/ajpgi.1999.277.6.G1108; Ku NO, 1997, J BIOL CHEM, V272, P33197, DOI 10.1074/jbc.272.52.33197; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Leers MPG, 1999, J PATHOL, V187, P567, DOI 10.1002/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-J; Liao J, 1997, J BIOL CHEM, V272, P17565, DOI 10.1074/jbc.272.28.17565; MacFarlane M, 2000, J CELL BIOL, V148, P1239, DOI 10.1083/jcb.148.6.1239; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Muller FB, 1998, J INVEST DERMATOL, V111, P900, DOI 10.1046/j.1523-1747.1998.00374.x; Omary M B, 1998, Subcell Biochem, V31, P105; Prasad S, 1999, INT J ONCOL, V14, P563; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Rosenthal DS, 1998, J INVEST DERMATOL, V111, P64, DOI 10.1046/j.1523-1747.1998.00250.x; RUGG EL, 1993, NAT GENET, V5, P294, DOI 10.1038/ng1193-294; Rydlander L, 1996, EUR J BIOCHEM, V241, P309, DOI 10.1111/j.1432-1033.1996.00309.x; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; Slesak B, 2000, CANCER, V89, P83, DOI 10.1002/1097-0142(20000701)89:1<83::AID-CNCR12>3.0.CO;2-J; Stennicke HR, 2000, BIOCHEM J, V350, P563, DOI 10.1042/0264-6021:3500563; Stigbrand T, 2001, TUMOR BIOL, V22, P1, DOI 10.1159/000030148; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Talanian RV, 1997, J BIOL CHEM, V272, P9677; TINNEMANS MMFJ, 1995, EUR J CELL BIOL, V68, P35; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Valik D, 2000, BRIT J CANCER, V82, P1756; van Dalen A, 1999, INT J BIOL MARKER, V14, P45, DOI 10.1177/172460089901400109; vanDalen A, 1996, ANTICANCER RES, V16, P2345; vanEngeland M, 1997, EXP CELL RES, V235, P421, DOI 10.1006/excr.1997.3738; WEBER K, 1984, EMBO J, V3, P2707, DOI 10.1002/j.1460-2075.1984.tb02198.x	40	75	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26792	26798		10.1074/jbc.M103315200	http://dx.doi.org/10.1074/jbc.M103315200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356849	hybrid			2022-12-25	WOS:000169966900010
J	Miller, JT; Ehresmann, B; Hubscher, U; Le Grice, SFJ				Miller, JT; Ehresmann, B; Hubscher, U; Le Grice, SFJ			A novel interaction of tRNA(Lys,3) with the feline immunodeficiency virus RNA genome governs initiation of minus strand DNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE TRANSCRIPTION; PRIMER-BINDING-SITE; EFFICIENT INITIATION; SECONDARY STRUCTURE; POSTTRANSCRIPTIONAL MODIFICATIONS; TY1 RETROTRANSPOSON; GENETIC-ANALYSIS; TYPE-1; COMPLEMENTARY; TRNA(3)(LYS)	Complementarity between nucleotides at the 5' terminus of tRNA(Lys,3) and the U5-IR loop of the feline immunodeficiency virus RNA genome suggests a novel intermolecular interaction controls initiation of minus strand synthesis in a manner analogous to other retroviral systems. Base pairing of this tRNA-viral RNA duplex was confirmed by nuclease mapping of the RNA genome containing full-length or 5'-deleted variants of tRNA(Lys,3) hybridized to the primer-binding site. A major pause in RNA-dependent DNA synthesis occurred 14 nucleotides ahead of the primer-binding site with natural and synthetic tRNA(Lys,3) primers, indicating it was not a consequence of tRNA base modifications. The majority of the paused complexes resulted in dissociation of the reverse transcriptase from the template/primer, as demonstrated by an assay limited to a single binding event. Hybridization of a tRNA mutant whose 5' nucleotides are deleted relieved pausing at this position and subsequently allowed high level DNA synthesis. Additional experiments with tRNA-DNA chimeric primers were used to localize the stage of minus strand synthesis at which the tRNA-viral RNA interaction was disrupted. Finally, replacing nucleotides of the feline immunodeficiency virus US-IR loop with the (A), sequence of its human immunodeficiency virus (HIV)-1 counterpart also relieved pausing, but did not induce pausing immediately downstream of the primer-binding site previously noted during initiation of HIV-1 DNA synthesis. These combined observations provide further evidence of cis-acting sequences immediately adjacent to the primer-binding site controlling initiation of minus strand DNA synthesis in retroviruses and retrotransposons.	NCI, HIV Drug Resistance Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; CNRS, Inst Biol Mol & Cellulaire, F-67084 Strasbourg, France; Univ Zurich Irchel, Inst Vet Biochem, CH-8057 Zurich, Switzerland	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Zurich	Le Grice, SFJ (corresponding author), NCI, HIV Drug Resistance Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA.	slegrice@mail.ncifcrf.gov						AIYAR A, 1994, J VIROL, V68, P611, DOI 10.1128/JVI.68.2.611-618.1994; AIYAR A, 1992, J VIROL, V66, P2464, DOI 10.1128/JVI.66.4.2464-2472.1992; Amacker M, 1998, J MOL BIOL, V278, P757, DOI 10.1006/jmbi.1998.1739; Arts EJ, 1996, J BIOL CHEM, V271, P9054, DOI 10.1074/jbc.271.15.9054; Arts EJ, 1996, P NATL ACAD SCI USA, V93, P10063, DOI 10.1073/pnas.93.19.10063; Auxilien S, 1999, J BIOL CHEM, V274, P4412, DOI 10.1074/jbc.274.7.4412; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; Beard WA, 1996, J BIOL CHEM, V271, P12213, DOI 10.1074/jbc.271.21.12213; Boulme F, 1998, FEBS LETT, V430, P165, DOI 10.1016/S0014-5793(98)00649-8; Brule F, 2000, NUCLEIC ACIDS RES, V28, P634, DOI 10.1093/nar/28.2.634; COBRINIK D, 1988, J VIROL, V62, P3622, DOI 10.1128/JVI.62.10.3622-3630.1988; Coffin J, 1997, RETROVIRUSES; CORDELL B, 1979, J BIOL CHEM, V254, P1866; Cullen BR, 1998, VIROLOGY, V249, P203, DOI 10.1006/viro.1998.9331; Fosse P, 1996, BIOCHEMISTRY-US, V35, P16601, DOI 10.1021/bi9613786; Friant S, 1998, MOL CELL BIOL, V18, P799, DOI 10.1128/MCB.18.2.799; Friant S, 1996, NUCLEIC ACIDS RES, V24, P441, DOI 10.1093/nar/24.3.441; Gabus C, 1998, EMBO J, V17, P4873, DOI 10.1093/emboj/17.16.4873; Gotte M, 1999, J BIOL CHEM, V274, P11159, DOI 10.1074/jbc.274.16.11159; Isel C, 1998, NUCLEIC ACIDS RES, V26, P1198, DOI 10.1093/nar/26.5.1198; ISEL C, 1993, J BIOL CHEM, V268, P25269; Isel C, 1999, EMBO J, V18, P1038, DOI 10.1093/emboj/18.4.1038; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; Isel C, 1996, EMBO J, V15, P917, DOI 10.1002/j.1460-2075.1996.tb00426.x; Kang SM, 1999, J VIROL, V73, P1818, DOI 10.1128/JVI.73.3.1818-1827.1999; Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060; KATI WM, 1992, J BIOL CHEM, V267, P25988; KEENEY JB, 1995, MOL CELL BIOL, V15, P217, DOI 10.1128/MCB.15.1.217; Lanchy JM, 1998, J BIOL CHEM, V273, P24425, DOI 10.1074/jbc.273.38.24425; Lanchy JM, 2000, J BIOL CHEM, V275, P12306, DOI 10.1074/jbc.275.16.12306; Lanchy JM, 1996, BIOCHIMIE, V78, P1087, DOI 10.1016/S0300-9084(97)86734-X; LeGrice SFJ, 1995, METHOD ENZYMOL, V262, P130, DOI 10.1016/0076-6879(95)62015-X; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; Li Y, 1997, VIROLOGY, V238, P273, DOI 10.1006/viro.1997.8837; Li Y, 1997, J VIROL, V71, P6315, DOI 10.1128/JVI.71.9.6315-6322.1997; Liang C, 1997, J VIROL, V71, P5750, DOI 10.1128/JVI.71.8.5750-5757.1997; LINIAL ML, 1990, CURR TOP MICROBIOL, V157, P125; Morris S, 1999, J VIROL, V73, P6307, DOI 10.1128/JVI.73.8.6307-6318.1999; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; REIN A, 1994, ARCH VIROL, P513; Roebuck KA, 1999, GENE EXPRESSION, V8, P67; Souquet M, 1998, BIOCHEMISTRY-US, V37, P12144, DOI 10.1021/bi9731596; Stello T, 1999, NUCLEIC ACIDS RES, V27, P4823, DOI 10.1093/nar/27.24.4823; TALBOTT RL, 1989, P NATL ACAD SCI USA, V86, P5743, DOI 10.1073/pnas.86.15.5743; Tisne C, 2000, RNA, V6, P1403, DOI 10.1017/S1355838200000947; Wakefield JK, 1996, VIROLOGY, V220, P290, DOI 10.1006/viro.1996.0317; WAKEFIELD JK, 1995, J VIROL, V69, P6021, DOI 10.1128/JVI.69.10.6021-6029.1995; Wakefield JK, 1996, J VIROL, V70, P966, DOI 10.1128/JVI.70.2.966-975.1996; WOHRL BM, 1995, BIOCHEMISTRY-US, V34, P5343; WOHRL BM, 1995, SCIENCE, V267, P96, DOI 10.1126/science.7528942; Zhang ZJ, 1998, AIDS RES HUM RETROV, V14, P979, DOI 10.1089/aid.1998.14.979; Zhang ZJ, 1998, RNA, V4, P394; Zhang ZJ, 1996, VIROLOGY, V226, P306, DOI 10.1006/viro.1996.0658; Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11	56	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27721	27730		10.1074/jbc.M100513200	http://dx.doi.org/10.1074/jbc.M100513200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11353768	Green Accepted, hybrid			2022-12-25	WOS:000169966900130
J	Gwizdek, C; Bertrand, E; Dargemont, C; Lefebvre, JC; Blanchard, JM; Singer, RH; Doglio, A				Gwizdek, C; Bertrand, E; Dargemont, C; Lefebvre, JC; Blanchard, JM; Singer, RH; Doglio, A			Terminal minihelix, a novel RNA motif that directs polymerase III transcripts to the cell cytoplasm - Terminal minihelix and RNA export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-ASSOCIATED RNA; ADENOVIRUS VA RNA1; PRE-MESSENGER-RNA; NUCLEAR EXPORT; NUCLEOCYTOPLASMIC TRANSPORT; SACCHAROMYCES-CEREVISIAE; RO RIBONUCLEOPROTEINS; XENOPUS-LAEVIS; PROTEINS; LOCALIZATION	Determining the cia-acting elements controlling nuclear export of RNA is critical, because they specify which RNA will be selected for transport. We have characterized the nuclear export motif of the adenoviral VA1 RNA a small cytoplasmic RNA transcribed by RNA polymerase III. Using a large panel of VA1 mutants in both transfected COS cells and injected Xenopus oocytes, we showed that the terminal stem of VA1 is necessary and sufficient for its export. Surprisingly, we found that the nucleotide sequence within the terminal stem is not important. Rather, the salient features of this motif are its length and its relative position within the RNA. Such stems thus define a novel and degenerate cytoplasmic localization motif that we termed the minihelix, This motif is found in a variety of polymerase III transcripts, and cross-competition analysis in Xenopus oocytes revealed that export of one such RNA, like hY1 RNA, is specifically competed by VA1 or artificial minihelix, Taken together these results show that the minihelix defines a new cia-acting export element and that this motif could be exported via a novel and specific nuclear export pathway.	Fac Med Nice, Virol Lab U526, F-06107 Nice 2, France; Inst Genet Mol Montpellier, F-34293 Montpellier, France; Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA; Inst Jacques Monod, Lab Transport Nucleocytoplasm, F-75251 Paris 5, France	UDICE-French Research Universities; Universite Cote d'Azur; Universite de Montpellier; Yeshiva University; Albert Einstein College of Medicine; UDICE-French Research Universities; Universite Paris Cite	Doglio, A (corresponding author), Fac Med Nice, Virol Lab U526, Ave Valombrose, F-06107 Nice 2, France.		DOGLIO, Alain/ABF-2581-2020	bertrand, edouard/0000-0002-9642-7994; DOGLIO, Alain/0000-0002-5456-5598	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057071] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57071, GM54887] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arts GJ, 1998, EMBO J, V17, P7430, DOI 10.1093/emboj/17.24.7430; Barcellini-Couget S, 1998, ANTISENSE NUCLEIC A, V8, P379, DOI 10.1089/oli.1.1998.8.379; BATAILLE N, 1990, J CELL BIOL, V111, P1571, DOI 10.1083/jcb.111.4.1571; Bertrand E, 1997, RNA, V3, P75; BHAT RA, 1983, MOL CELL BIOL, V3, P1996, DOI 10.1128/MCB.3.11.1996; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; CAGNON L, 1995, J ACQ IMMUN DEF SYND, V9, P349; Chen XG, 2000, GENE DEV, V14, P777; Custodio N, 1999, EMBO J, V18, P2855, DOI 10.1093/emboj/18.10.2855; Dahlberg JE, 1998, CURR OPIN CELL BIOL, V10, P400, DOI 10.1016/S0955-0674(98)80017-3; Grosshans H, 2000, J STRUCT BIOL, V129, P288, DOI 10.1006/jsbi.2000.4226; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HAMM J, 1989, EMBO J, V8, P4179, DOI 10.1002/j.1460-2075.1989.tb08603.x; HAMM J, 1990, METHOD ENZYMOL, V181, P273; Hellmuth K, 1998, MOL CELL BIOL, V18, P6374, DOI 10.1128/MCB.18.11.6374; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; HOWE JG, 1988, J VIROL, V62, P2790, DOI 10.1128/JVI.62.8.2790-2798.1988; Izaurralde E, 1998, RNA, V4, P351; IZAURRALDE E, 1997, EMBO J, V16; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; KHANNAGUPTA A, 1989, P NATL ACAD SCI USA, V86, P1791, DOI 10.1073/pnas.86.6.1791; Kim J, 1996, BIOCHEMISTRY-US, V35, P13753, DOI 10.1021/bi960913z; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Kutay U, 1998, MOL CELL, V1, P359, DOI 10.1016/S1097-2765(00)80036-2; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; Lipowsky G, 1999, RNA, V5, P539, DOI 10.1017/S1355838299982134; Ma YL, 1996, J VIROL, V70, P5083, DOI 10.1128/JVI.70.8.5083-5099.1996; MATHEWS MB, 1991, J VIROL, V65, P5657, DOI 10.1128/JVI.65.11.5657-5662.1991; MATTAJ IW, 1998, CURR BIOL, V67, P265; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MELLITS KH, 1988, EMBO J, V7, P2849, DOI 10.1002/j.1460-2075.1988.tb03141.x; MELLITS KH, 1992, J VIROL, V66, P2369, DOI 10.1128/JVI.66.4.2369-2377.1992; MELLITS KH, 1990, CELL, V61, P843, DOI 10.1016/0092-8674(90)90194-J; Nakielny S, 1997, CURR OPIN CELL BIOL, V9, P420, DOI 10.1016/S0955-0674(97)80016-6; OBRIEN CA, 1993, P NATL ACAD SCI USA, V90, P7250, DOI 10.1073/pnas.90.15.7250; OMALLEY RP, 1986, CELL, V44, P391, DOI 10.1016/0092-8674(86)90460-5; PEERY T, 1993, J VIROL, V67, P3534, DOI 10.1128/JVI.67.6.3534-3543.1993; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; ROE BA, 1975, BIOCHEM BIOPH RES CO, V66, P1097, DOI 10.1016/0006-291X(75)90470-2; ROSA MD, 1981, MOL CELL BIOL, V1, P785, DOI 10.1128/MCB.1.9.785; Samarsky DA, 1998, EMBO J, V17, P3747, DOI 10.1093/emboj/17.13.3747; Sarkar S, 1999, P NATL ACAD SCI USA, V96, P14366, DOI 10.1073/pnas.96.25.14366; Sarkar S, 1998, MOL BIOL CELL, V9, P3041, DOI 10.1091/mbc.9.11.3041; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SCHWEMMLE M, 1992, P NATL ACAD SCI USA, V89, P10292, DOI 10.1073/pnas.89.21.10292; Simons FHM, 1996, RNA, V2, P264; Stutz F, 1998, GENE DEV, V12, P3303, DOI 10.1101/gad.12.21.3303; Terns MP, 1998, METHOD CELL BIOL, V53, P559; VANGELDER CWG, 1994, NUCLEIC ACIDS RES, V22, P2498, DOI 10.1093/nar/22.13.2498; VANHORN DJ, 1995, RNA, V1, P293; WICKENS MP, 1983, J MOL BIOL, V163, P1, DOI 10.1016/0022-2836(83)90027-X; ZACHARIAS M, 1995, J MOL BIOL, V247, P486, DOI 10.1006/jmbi.1995.0155; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436; Zuker M, 1998, RNA, V4, P669, DOI 10.1017/S1355838298980116	54	33	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25910	25918		10.1074/jbc.M100493200	http://dx.doi.org/10.1074/jbc.M100493200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11342536	hybrid, Green Published			2022-12-25	WOS:000169823300038
J	Vaughan, PS; Leszyk, JD; Vaughan, KT				Vaughan, PS; Leszyk, JD; Vaughan, KT			Cytoplasmic dynein intermediate chain phosphorylation regulates binding to dynactin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN; TRANSPORT; COMPLEX; SUBUNIT; IDENTIFICATION; MICROTUBULES; PROTEINS; LOCALIZATION; HOMOLOGY; SPECTRIN	Previously, we identified dynactin as a cargo receptor or adaptor for cytoplasmic dynein, mediated by an interaction between the dynein intermediate chain and p150(Glued), To test phosphorylation as a potential regulatory mechanism for this interaction, we analyzed cytoplasmic dynein by two-dimensional gel analysis and detected two intermediate chain variants, one of which was eliminated by phosphatase treatment. Overlay assays demonstrated that p150(Glued) bound dephosphorylated but not phosphorylated intermediate chains, We then subjected the purified cytoplasmic dynein intermediate chain to mass spectrometry and identified a single phosphorylated tryptic fragment corresponding to the p150(Glued)-binding domain. Fragmentation and retention time analysis mapped the phosphorylation site to serine 84. Site-directed mutants designed to mimic the dephosphorylated or phosphorylated intermediate chain disrupted both in vitro phosphorylation and in vivo phosphorylation of transfected proteins. Mutants mimicking the dephosphorylated form bound p150Glued in vitro and overexpression perturbed transport of dynein-dependent membranes. Mutants mimicking the phosphorylated form displayed diminished p150(Glued) binding in vitro and did not disrupt dynein-mediated transport when expressed in vivo. These findings represent the first mapping of an intermediate chain phosphorylation site and suggest that this phosphorylation plays an important role in regulating the binding of cytoplasmic dynein to dynactin.	Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA; Univ Massachusetts, Sch Med, Dept Biochem, Worcester, MA 01605 USA	University of Notre Dame; University of Massachusetts System; University of Massachusetts Worcester	Vaughan, KT (corresponding author), Univ Notre Dame, Dept Biol Sci, POB 369, Notre Dame, IN 46556 USA.	vaughan.4@nd.edu						ALLAN V, 1995, J CELL BIOL, V128, P879, DOI 10.1083/jcb.128.5.879; ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; Annan RS, 1996, ANAL CHEM, V68, P3413, DOI 10.1021/ac960221g; Annan RS, 2001, ANAL CHEM, V73, P393, DOI 10.1021/ac001130t; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; Bowman AB, 1999, J CELL BIOL, V146, P165; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; CARTER AN, 1997, CURRENT PROTOCOLS MO; COLLINS CA, 1989, CELL MOTIL CYTOSKEL, V14, P491, DOI 10.1002/cm.970140407; CORTHESYTHEULAZ I, 1992, J CELL BIOL, V118, P1333, DOI 10.1083/jcb.118.6.1333; Dell KR, 2000, TRAFFIC, V1, P38, DOI 10.1034/j.1600-0854.2000.010107.x; DILLMAN JF, 1994, J CELL BIOL, V127, P1671, DOI 10.1083/jcb.127.6.1671; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; GILL SR, 1994, MOL BIOL CELL, V5, P645, DOI 10.1091/mbc.5.6.645; Goldstein LSB, 2000, ANNU REV NEUROSCI, V23, P39, DOI 10.1146/annurev.neuro.23.1.39; Holleran EA, 1996, J CELL BIOL, V135, P1815, DOI 10.1083/jcb.135.6.1815; Holleran EA, 1998, INT REV CYTOL, V182, P69, DOI 10.1016/S0074-7696(08)62168-3; Huang CYF, 1999, J BIOL CHEM, V274, P14262, DOI 10.1074/jbc.274.20.14262; HUGHES SM, 1995, J CELL SCI, V108, P17; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; Karki S, 1997, J BIOL CHEM, V272, P5887, DOI 10.1074/jbc.272.9.5887; King SJ, 2000, NAT CELL BIOL, V2, P20, DOI 10.1038/71338; Kumar S, 2000, J BIOL CHEM, V275, P31798, DOI 10.1074/jbc.M000449200; LIN SXH, 1994, J CELL BIOL, V127, P1009, DOI 10.1083/jcb.127.4.1009; LIN SXH, 1992, J CELL SCI, V101, P125; Lo KWH, 2001, J BIOL CHEM, V276, P14059, DOI 10.1074/jbc.M010320200; Mok YK, 2001, J BIOL CHEM, V276, P14067, DOI 10.1074/jbc.M011358200; Muresan V, 2001, MOL CELL, V7, P173, DOI 10.1016/S1097-2765(01)00165-4; Niclas J, 1996, J CELL BIOL, V133, P585, DOI 10.1083/jcb.133.3.585; PASCHAL BM, 1992, J CELL BIOL, V118, P1133, DOI 10.1083/jcb.118.5.1133; Pfister KK, 1996, MOL BIOL CELL, V7, P331, DOI 10.1091/mbc.7.2.331; Pfister KK, 1996, J BIOL CHEM, V271, P1687, DOI 10.1074/jbc.271.3.1687; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Reese EL, 2000, J CELL BIOL, V151, P155, DOI 10.1083/jcb.151.1.155; Reilein AR, 1998, J CELL BIOL, V142, P803, DOI 10.1083/jcb.142.3.803; Rogers SL, 1997, P NATL ACAD SCI USA, V94, P3720, DOI 10.1073/pnas.94.8.3720; Shima DT, 1997, J CELL BIOL, V137, P1211, DOI 10.1083/jcb.137.6.1211; Steffen W, 1997, MOL BIOL CELL, V8, P2077, DOI 10.1091/mbc.8.10.2077; Steffen W, 1996, J STRUCT BIOL, V117, P227, DOI 10.1006/jsbi.1996.0087; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Tam BM, 2000, J CELL BIOL, V151, P1369, DOI 10.1083/jcb.151.7.1369; Tynan SH, 2000, J BIOL CHEM, V275, P32769, DOI 10.1074/jbc.M001537200; Tynan SH, 2000, J BIOL CHEM, V275, P32763, DOI 10.1074/jbc.M001536200; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; WatermanStorer CM, 1997, P NATL ACAD SCI USA, V94, P12180, DOI 10.1073/pnas.94.22.12180; WILKERSON CG, 1995, J CELL BIOL, V129, P169, DOI 10.1083/jcb.129.1.169; Yano H, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-03-j0003.2001; Young A, 2000, MOL BIOL CELL, V11, P2047, DOI 10.1091/mbc.11.6.2047	50	102	106	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26171	26179		10.1074/jbc.M102649200	http://dx.doi.org/10.1074/jbc.M102649200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11340075	hybrid			2022-12-25	WOS:000169823300072
J	Ji, C; Kozak, KR; Marnett, LJ				Ji, C; Kozak, KR; Marnett, LJ			I kappa B kinase, a molecular target for inhibition by 4-hydroxy-2-nonenal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; LIPID-PEROXIDATION; DEOXYGUANOSINE ADDUCTS; DNA LESIONS; C-MYC; ACTIVATION; PHOSPHORYLATION; ALPHA; PROTEIN; IKK	In unstimulated cells, transcription factor NF-kappaB is retained in the cytoplasm by interaction with the inhibitory protein, I kappaB alpha. Appropriate cellular stimuli inactivate I kappaB alpha by phosphorylation, ubiquination, and proteolytic degradation, which allows NF-kappaB to translocate to the nucleus and modulate gene expression. 4-Hydroxy-2-nonenal (HNE), a major lipid peroxidation product, inhibits activation of NF-kappaB in the human colorectal carcinoma cell line (RKO) and human lung carcinoma cell line (H1299), Pretreatment of cells with HNE dose-dependently suppresses tetradecanoylphorbol acetate (TPA)/ionomycin (IM)-induced NF-kappaB DNA binding activity and transactivation of luciferase-based reporter constructs. HNE pretreatment has no affect on TPA/IM-induced AP-1 DNA binding activity. HNE inhibits TPA/ IM-induced degradation of I kappaB alpha in both H1299 and Jurkat T cells. The accumulation of I kappaB alpha parallels the inhibition of its phosphorylation. At doses that inhibit I kappaB alpha degradation, HNE inhibits I kappaB kinase (IKK) activity by direct reaction with IKK, Covalent adducts of HNE to IKK are detected on Western blots using antibodies against IKK or HNE-protein conjugates, Addition of dithiothreitol prevents HNE modification of IKK. Thus, HNE is an endogenous inhibitor of NF-kappaB activation that acts by preventing IKK activation and subsequent I kappaB alpha degradation.	Vanderbilt Univ, Sch Med, Dept Biochem, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Ctr Mol Toxicol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Marnett, LJ (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, Vanderbilt Ingram Canc Ctr, 221 Kirkland Hall, Nashville, TN 37232 USA.	marnett@toxicology.mc.vanderbilt.edu			NATIONAL CANCER INSTITUTE [R35CA047479] Funding Source: NIH RePORTER; NCI NIH HHS [CA47479] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; BARRERA G, 1987, TOXICOL PATHOL, V15, P238, DOI 10.1177/019262338701500219; Barrera G, 1996, BIOCHEM BIOPH RES CO, V227, P589, DOI 10.1006/bbrc.1996.1550; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; CHAUDHARY AK, 1994, SCIENCE, V265, P1580, DOI 10.1126/science.8079172; Chung FL, 2000, CANCER RES, V60, P1507; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; ESTERBAUER H, 1993, AM J CLIN NUTR, V57, P779, DOI 10.1093/ajcn/57.5.779S; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; FAZIO VM, 1992, CANCER RES, V52, P4866; FRIGUET B, 1994, J BIOL CHEM, V269, P21639; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; Ji C, 1998, CARCINOGENESIS, V19, P1275, DOI 10.1093/carcin/19.7.1275; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Kirichenko A, 1996, TOXICOL APPL PHARM, V141, P416, DOI 10.1006/taap.1996.0307; Kruman I, 1997, J NEUROSCI, V17, P5089; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Li L, 1999, AM J PHYSIOL-LUNG C, V277, pL550, DOI 10.1152/ajplung.1999.277.3.L550; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Liu W, 2000, J CELL SCI, V113, P635; Marnett LJ, 1999, MUTAT RES-FUND MOL M, V424, P83, DOI 10.1016/S0027-5107(99)00010-X; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; NATH RG, 1994, P NATL ACAD SCI USA, V91, P7491, DOI 10.1073/pnas.91.16.7491; Page S, 1999, J BIOL CHEM, V274, P11611, DOI 10.1074/jbc.274.17.11611; Parola M, 1998, J CLIN INVEST, V102, P1942, DOI 10.1172/JCI1413; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Schauenstein E., 1977, ALDEHYDES BIOL SYSTE; Soh YJ, 2000, MOL PHARMACOL, V58, P535, DOI 10.1124/mol.58.3.535; Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6	48	159	166	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18223	18228		10.1074/jbc.M101266200	http://dx.doi.org/10.1074/jbc.M101266200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11359792	hybrid			2022-12-25	WOS:000168866500082
J	Kumar, S; Bharti, A; Mishra, NC; Raina, D; Kharbanda, S; Saxena, S; Kufe, D				Kumar, S; Bharti, A; Mishra, NC; Raina, D; Kharbanda, S; Saxena, S; Kufe, D			Targeting of the c-Ab1 tyrosine kinase to mitochondria in the necrotic cell death response to oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; C-ABL; APOPTOTIC RESPONSE; DNA; GENERATION; NUCLEAR; P73	The ubiquitously expressed c-Abl tyrosine kinase is activated in the response of cells to genotoxic and oxidative stress. The present study demonstrates that reactive oxygen species (ROS) induce targeting of c-Abl to mitochondria. We show that ROS-induced localization of c-Abl to mitochondria is dependent on activation of protein kinase C (PKC)S and the c-Abl kinase function. Targeting of c-Abl to mitochondria is associated with ROS-induced loss of mitochondrial transmembrane potential. The results also demonstrate that c-Abl is necessary for ROS-induced depletion of ATP and the activation of a necrosis-like cell death. These findings indicate that the c-Abl kinase targets to mitochondria in response to oxidative stress and thereby mediates mitochondrial dysfunction and cell death.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Lovelace Resp Res Inst, Albuquerque, NM 87115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Lovelace Respiratory Research Institute	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu			NCI NIH HHS [CA42802] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042802] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; Gong JG, 1999, NATURE, V399, P806; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 2000, MOL CELL BIOL, V20, P4979, DOI 10.1128/MCB.20.14.4979-4989.2000; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Li TK, 1999, GENE DEV, V13, P1553, DOI 10.1101/gad.13.12.1553; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Nicotera P, 1998, TOXICOL LETT, V103, P139; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; ROEDERER M, 1990, P NATL ACAD SCI USA, V87, P4884, DOI 10.1073/pnas.87.12.4884; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	28	93	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17281	17285		10.1074/jbc.M101414200	http://dx.doi.org/10.1074/jbc.M101414200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11350980	hybrid			2022-12-25	WOS:000168730400091
J	Harris, MB; Ju, H; Venema, VJ; Liang, HY; Zou, R; Michell, BJ; Chen, ZP; Kemp, BE; Venema, RC				Harris, MB; Ju, H; Venema, VJ; Liang, HY; Zou, R; Michell, BJ; Chen, ZP; Kemp, BE; Venema, RC			Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; CYCLOSPORINE-A; AKT; PATHWAY; HYPERTENSION; PROSTACYCLIN; INHIBITOR; LY294002	Endothelial nitric-oxide synthase (eNOS) is phosphorylated at Ser-1179 (bovine sequence) by Akt after growth factor or shear stress stimulation of endothelial cells, resulting in increased eNOS activity. Purified eNOS is also phosphorylated at Thr-497 by purified AMP-activated protein kinase, resulting in decreased eNOS activity, We investigated whether bradykinin (BK) stimulation of bovine aortic endothelial cells (BAECs) regulates eNOS through Akt activation and Ser-1179 or Thr-497 phosphorylation. Akt is transiently activated in BK-stimulated BAECs. Activation is blocked completely by wortmannin and LY294002, inhibitors of phosphatidylinositol 3-kinase, suggesting that Akt activation occurs downstream from phosphatidylinositol 3-kinase, BK stimulates a transient phosphorylation of eNOS at Ser-1179 that is correlated temporally with a transient dephosphorylation of eNOS at Thr-497. Phosphorylation at Ser-1179, but not dephosphorylation at Thr-497, is blocked by wortmannin and LY294002. BK also stimulates a transient nitric oxide (NO) release from BAECs with a time-course similar to Ser-1179 phosphorylation and Thr-497 dephosphorylation, NO release is not altered by wortmannin. BK-stimulated dephosphorylation of Thr-497 and NO release are blocked by the calcineurin inhibitor, cyclosporin A. These data suggest that BK activation of eNOS in BAECs primarily involves deinhibition of the enzyme through calcineurin-mediated dephosphorylation at Thr-497.	Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pediat, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA; St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; St. Vincent's Institute of Medical Research	Venema, RC (corresponding author), Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA.		Harris, M. Brennan/F-7772-2015; Kemp, Bruce/G-9602-2019; Kemp, Bruce E/L-2633-2014	Harris, M. Brennan/0000-0002-2908-1647; Kemp, Bruce/0000-0001-6735-5082; Kemp, Bruce E/0000-0001-6735-5082	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062152, R29HL057201, R01HL057201] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62152, HL57201] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bernier SG, 2000, J BIOL CHEM, V275, P30707, DOI 10.1074/jbc.M005116200; BOULANGER C, 1990, J CLIN INVEST, V85, P587, DOI 10.1172/JCI114477; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Coffer PJ, 1998, BIOCHEM J, V335, P1; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1989, J BIOL CHEM, V264, P21435; Cooke JP, 1997, ANNU REV MED, V48, P489, DOI 10.1146/annurev.med.48.1.489; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; HAMILTON DV, 1982, TRANSPLANT P, V14, P597; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; IGNARRO LJ, 1989, CIRC RES, V65, P1, DOI 10.1161/01.RES.65.1.1; ISHII K, 1991, AM J PHYSIOL, V261, pH598, DOI 10.1152/ajpheart.1991.261.2.H598; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Marrero MB, 1999, BIOCHEM J, V343, P335, DOI 10.1042/0264-6021:3430335; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Oriji GK, 1998, HYPERTENSION, V32, P849, DOI 10.1161/01.HYP.32.5.849; PAPAPETROPOULOS A, 1997, J CLIN INVEST, V100, P313; RADOMSKI MW, 1987, BRIT J PHARMACOL, V92, P639, DOI 10.1111/j.1476-5381.1987.tb11367.x; SCOTTBURDEN T, 1993, CIRCULATION, V87, P51; SUDHIR K, 1994, CIRCULATION, V90, P3018, DOI 10.1161/01.CIR.90.6.3018; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; Zeng GY, 1996, J CLIN INVEST, V98, P894, DOI 10.1172/JCI118871	32	347	357	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16587	16591		10.1074/jbc.M100229200	http://dx.doi.org/10.1074/jbc.M100229200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11340086	hybrid			2022-12-25	WOS:000168623100136
J	Zhuge, Y; Xu, JH				Zhuge, Y; Xu, JH			Rad mediates type I collagen-dependent MMP-2 activation - Role in cell invasion across collagen barrier	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; GELATINASE-A; TISSUE INHIBITOR; PROGELATINASE-A; EXTRACELLULAR-MATRIX; TUMOR PROGRESSION; INTERSTITIAL COLLAGENASE; NORMAL FIBROBLASTS; ENDOTHELIAL-CELLS; BREAST-CARCINOMA	Cell migration and proteolysis are two essential processes during tumor invasion and metastasis. Matrix metalloproteinase (MMP)-2 (type IV collagenase; gelatinase A), is implicated in tumor metastasis as well as in primary tumor growth. The Rho family of small GTPases regulates the dynamics of actin cytoskeleton associated with cell motility. In this report, we provide evidence that Rac1, one member of Rho-related small GTPases, is a mediator of MMP-2 activation in HT1080 fibrosarcoma cells cultured in three-dimensional collagen gel (3D-col) and that MMP-2 activation is required for Rac1-promoted cell invasion through collagen barrier. Stable expression of dominant negative (Rac1V12N17) and constitutively active Rac1 (Rac1V12), respectively, in HT1080 cells demonstrates that Rac1 promoted cell invasiveness across type I collagen and collagen-dependent MMP-2 activation. Active Rac1 is sufficient to induce MMP-2 activation in cells cultured in fibrin gel, an extracellular matrix component that does not support MMP-2 activation. The Rac1-dependent MMP-2 activation occurred in a cell-associated fashion and required MMP activities. Because the cell membrane-mediated MMP-2 activation requires MT1-MMP and low amount of issue inhibitor of matrix metalloproteinase-2 (TIMP-2), their expression was examined. Rac1 modulated MT1-MMP mRNA level and the accumulation of a 43-kDa form of MT1-MMP protein, in correlation with MMP-2 activation profile. However, TIMP-2 expression was independent of Rac1 activity. The coordinate modulation of MMP-2 activity and MT1-MMP expression/processing by Rac1 is consistent with cell collagenolytic activity. The C-terminal hemopexin-like domain of MMP-2, which interferes with the cell membrane activation of MMP-2, reduced Rac1-promoted cell invasiveness as monitored by collagen invasion assay. These results suggest that collagen-dependent MMP-2 activation and MT1-MMP expression/processing contribute to Rac-promoted tumor cell invasion through interstitial collagen barrier.	SUNY Stony Brook, Sch Med, Dept Dermatol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Xu, JH (corresponding author), SUNY Stony Brook, Sch Med, Dept Dermatol, Stony Brook, NY 11794 USA.				NIAMS NIH HHS [5K01AR02036, 1RO1AR4657101] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR002036, R01AR046571] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; ALBINI A, 1987, CANCER RES, V47, P3239; ANGLIKER H, 1993, BIOCHEM J, V293, P75, DOI 10.1042/bj2930075; Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; AZZAM HS, 1992, CANCER RES, V52, P4540; BIRKEDALHANSEN H, 1987, METHOD ENZYMOL, V144, P140; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Deryugina EI, 1998, CANCER RES, V58, P3743; Ellerbroek SM, 1999, CANCER RES, V59, P1635; EMONARD HP, 1992, CANCER RES, V52, P5845; Friedl P, 1997, CANCER RES, V57, P2061; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Gilles C, 1997, LAB INVEST, V76, P651; Gogly B, 1998, ANAL BIOCHEM, V255, P211, DOI 10.1006/abio.1997.2318; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HERRON GS, 1986, J BIOL CHEM, V261, P2814; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; HOWARD EW, 1991, J BIOL CHEM, V266, P13070; HUHTALA P, 1990, GENOMICS, V6, P554, DOI 10.1016/0888-7543(90)90486-E; Imai K, 1996, CANCER RES, V56, P2707; Imren S, 1996, CANCER RES, V56, P2891; Itoh T, 1998, CANCER RES, V58, P1048; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Kubota S, 1997, INT J CANCER, V70, P106; Kurschat P, 1999, J BIOL CHEM, V274, P21056, DOI 10.1074/jbc.274.30.21056; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lee AY, 1997, P NATL ACAD SCI USA, V94, P4424, DOI 10.1073/pnas.94.9.4424; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; LEVY AT, 1991, CANCER RES, V51, P439; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Lohi J, 1996, EUR J BIOCHEM, V239, P239, DOI 10.1111/j.1432-1033.1996.0239u.x; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; Maquoi E, 2000, J BIOL CHEM, V275, P11368, DOI 10.1074/jbc.275.15.11368; Maquoi E, 1998, FEBS LETT, V424, P262, DOI 10.1016/S0014-5793(98)00187-2; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MONSKY WL, 1993, CANCER RES, V53, P3159; MOOKHTIAR KA, 1986, ANAL BIOCHEM, V158, P322, DOI 10.1016/0003-2697(86)90557-9; MORTON DL, 1997, CANC MED, P2467; MURPHY G, 1994, J BIOL CHEM, V269, P6632; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Rajavashisth TB, 1999, J BIOL CHEM, V274, P11924, DOI 10.1074/jbc.274.17.11924; Ridley A, 2000, J CELL BIOL, V150, pF107, DOI 10.1083/jcb.150.4.F107; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, J BIOCHEM-TOKYO, V119, P209; Seftor REB, 1999, CANCER METAST REV, V18, P359, DOI 10.1023/A:1006317125454; SELTZER JL, 1994, EXP CELL RES, V213, P365, DOI 10.1006/excr.1994.1211; Seltzer JL, 1999, J INVEST DERMATOL, V112, P993, DOI 10.1046/j.1523-1747.1999.00616.x; Stanton H, 1998, J CELL SCI, V111, P2789; Steffensen B, 1998, J BIOL CHEM, V273, P20622, DOI 10.1074/jbc.273.32.20622; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; WARD RV, 1994, BIOCHEM J, V304, P263, DOI 10.1042/bj3040263; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WOLF C, 1993, P NATL ACAD SCI USA, V90, P1843, DOI 10.1073/pnas.90.5.1843; Xu JH, 1998, J CELL BIOL, V140, P709, DOI 10.1083/jcb.140.3.709; Xu JH, 1996, J CELL BIOL, V132, P239, DOI 10.1083/jcb.132.1.239; Xu JH, 1996, J CELL BIOL, V134, P1301, DOI 10.1083/jcb.134.5.1301	79	155	166	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16248	16256		10.1074/jbc.M010190200	http://dx.doi.org/10.1074/jbc.M010190200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11340084	hybrid			2022-12-25	WOS:000168623100091
J	Sindram, D; Porte, RJ; Hoffman, MR; Bentley, RC; Clavien, PA				Sindram, D; Porte, RJ; Hoffman, MR; Bentley, RC; Clavien, PA			Synergism between platelets and leukocytes in inducing endothelial cell apoptosis in the cold ischemic rat liver: a Kupffer cell-mediated injury	FASEB JOURNAL			English	Article									Duke Univ, Med Ctr, Dept Surg, Hepatobiliary & Liver Transplant Lab, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Univ Zurich, Dept Visceral & Transplantat Surg, CH-8006 Zurich, Switzerland	Duke University; Duke University; University of Zurich	Clavien, PA (corresponding author), Univ Zurich Hosp, Dept Visceral & Transplantat Surg, CH-8091 Zurich, Switzerland.			Hoffman, Maureane/0000-0001-7123-0100					0	96	108	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1230	1232		10.1096/fj.00-0554fje	http://dx.doi.org/10.1096/fj.00-0554fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344097				2022-12-25	WOS:000168655200019
J	Constantino, S; Santos, R; Lacronique, V; Bouchaert, I; Monni, R; Bernard, O; Gisselbrecht, S; Gouilleux, F				Constantino, S; Santos, R; Lacronique, V; Bouchaert, I; Monni, R; Bernard, O; Gisselbrecht, S; Gouilleux, F			Constitutively active STAT5 variants induce growth and survival of hematopoietic cells through a PI 3-kinase/Akt dependent pathway	ONCOGENE			English	Article						STAT5; PI 3-kinase; TEL-JAK2; survival	PERIPHERAL-BLOOD CELLS; BCR-ABL ONCOGENE; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; INDEPENDENT PATHWAYS; CYCLE PROGRESSION; FUSION PROTEIN; ACTIVATION; RECEPTOR; KINASE	Signal Transducer and Activator of Transcription (STATs) are important mediators of cytokine and growth factor-induced signal transduction, STAT5A and STAT5B have been shown to play a role in survival and proliferation of hematopoietic cells both in vitro and in viro and to contribute to the growth and viability of cells transformed by the TEL-JAK2 oncoprotein, In this study, we investigated the molecular mechanisms by which constitutively active STAT5 proteins induce cell proliferation and survival of Ba/F3 cell lines expressing either dominant positive STAT5A or STAT5B variants or TEL-JAK2 or TEL-ABL fusion proteins. Our results showed that active STAT5 constitutively interacted with p85, the regulatory subunit of the PT 3-kinase, A constitutive activity of the PI 3-kinase/Akt pathway was observed in these cells and required for their cell cycle progression. In contrast, while activity of the PI 3-kinase/Akt pathway was required for survival of Ba/F3 cells expressing the constitutively active forms of STAT5A or STAT5B, it was dispensable for cells transformed by TEL-JAK2 or TEL-ABL fusion proteins, suggesting that additional survival pathways take place in these transformed cells.	Hop Cochin, INSERM, U363, Inst Cochin Genet Mol, F-75014 Paris, France; INSERM, U434, CEPH, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Gouilleux, F (corresponding author), Hop Cochin, INSERM, U363, Inst Cochin Genet Mol, 27 Rue Fbg St Jacques, F-75014 Paris, France.		Penard-Lacronique, Virginie/R-1938-2019; Santos, Susana/AAM-8902-2021; Penard-Lacronique, Virginie/E-5729-2016; Bernard, Olivier A./E-5721-2016	Penard-Lacronique, Virginie/0000-0001-9435-7331; Penard-Lacronique, Virginie/0000-0001-9435-7331; Gouilleux, Fabrice/0000-0001-6047-1718; Bernard, Olivier/0000-0002-0463-9747; Constantino Rosa Santos, Susana/0000-0002-5711-1292				BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Chai SK, 1997, J IMMUNOL, V159, P4720; Craddock BL, 1997, J BIOL CHEM, V272, P29281, DOI 10.1074/jbc.272.46.29281; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; DATTA K, 1995, MOL CELL BIOL, V15, P2304; DEL PL, 1997, SCIENCE, V278, P687; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Ihle JN, 1998, ANN NY ACAD SCI, V865, P1, DOI 10.1111/j.1749-6632.1998.tb11157.x; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Kieslinger M, 2000, GENE DEV, V14, P232; Kuribara R, 1999, MOL CELL BIOL, V19, P2754; Lacronique V, 2000, BLOOD, V95, P2076, DOI 10.1182/blood.V95.6.2076; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Santos SCR, 2000, ONCOGENE, V19, P1164, DOI 10.1038/sj.onc.1203418; Shuai K, 1996, ONCOGENE, V13, P247; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; TOKER A, 1994, J BIOL CHEM, V269, P32358; Verdier F, 1997, J BIOL CHEM, V272, P26173, DOI 10.1074/jbc.272.42.26173; Voss J, 2000, ONCOGENE, V19, P1684, DOI 10.1038/sj.onc.1203467; Yamauchi T, 1998, J BIOL CHEM, V273, P15719, DOI 10.1074/jbc.273.25.15719; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	39	63	62	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2001	20	17					2080	2090		10.1038/sj.onc.1204308	http://dx.doi.org/10.1038/sj.onc.1204308			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360192	Green Published			2022-12-25	WOS:000168116700003
J	Furuta, M; Zhou, A; Webb, G; Carroll, R; Ravazzola, M; Orci, L; Steiner, DF				Furuta, M; Zhou, A; Webb, G; Carroll, R; Ravazzola, M; Orci, L; Steiner, DF			Severe defect in proglucagon processing in islet A-cells of prohormone convertase 2 null mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PANCREATIC-ISLETS; PROPROTEIN CONVERTASES; PC2; GLUCAGON; PEPTIDES; LOCALIZATION; PROINSULIN; EXPRESSION; MECHANISM; SEQUENCE	Mice homozygous for a deletion in the gene encoding prohormone convertase 2 (PC2) are generally healthy but have mild hypoglycemia and flat glucose-tolerance curves. Their islets show marked alpha (A)-cell hyperplasia, suggesting a possible defect in glucagon processing (Furuta, M., Yano, H., Zhou, A., Rouille, Y,, Holst, J., Carroll, R., Ravazzola, M., Orci, L., Furuta, H., and Steiner, D. (1997) Proc. Natl. Acad. Sci. U.S.A. 94, 6646-6651). In this report we have examined the biosynthesis and processing of proglucagon in isolated islets from these mice via pulse-chase labeling and find that proglucagon undergoes essentially no processing in chase periods up to 8 h in duration. Only a small percent of cleavage at the sensitive interdomain site (residues 71 and 72) appears to occur. These observations thus conclusively demonstrate the essentiality of PC2 for the production of glucagon in the islet A-cells, Ultrastructural and immunocytochemical studies indicate the presence of large amounts of proglucagon in atypical appearing secretory granules in the hyperplastic and hypertrophic A-cells, along with morphological evidence of high rates of proglucagon secretion in PC2 null islets. These findings provide strong evidence that active glucagon is required to maintain normal blood glucose levels, counterbalancing the action of insulin at all times.	Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Geneva, Sch Med, Dept Morphol, CH-1211 Geneva, Switzerland	University of Chicago; Howard Hughes Medical Institute; University of Chicago; University of Geneva	Steiner, DF (corresponding author), Univ Chicago, Dept Biochem & Mol Biol, 5841 S Maryland Ave, Chicago, IL 60637 USA.			Zhou, An/0000-0002-9358-8012	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013914, R01DK013914, P60DK020595] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK13914, DK 20595] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARRETT A, 1998, HDB PROTEOLYTIC ENZY, P342; BELL GI, 1983, NATURE, V302, P716, DOI 10.1038/302716a0; Berman Y, 2000, J NEUROCHEM, V75, P1763, DOI 10.1046/j.1471-4159.2000.0751763.x; Brand CL, 1996, DIABETES, V45, P1076, DOI 10.2337/diabetes.45.8.1076; Day R, 1998, J BIOL CHEM, V273, P829, DOI 10.1074/jbc.273.2.829; DeBie I, 1996, J CELL BIOL, V135, P1261, DOI 10.1083/jcb.135.5.1261; Dhanvantari S, 1996, MOL ENDOCRINOL, V10, P342, DOI 10.1210/me.10.4.342; Furuta M, 1998, J BIOL CHEM, V273, P3431, DOI 10.1074/jbc.273.6.3431; Furuta M, 1997, P NATL ACAD SCI USA, V94, P6646, DOI 10.1073/pnas.94.13.6646; HEINRICH G, 1984, J BIOL CHEM, V259, P4082; HOLST JJ, 1994, J BIOL CHEM, V269, P18827; Johanning K, 1998, J BIOL CHEM, V273, P22672, DOI 10.1074/jbc.273.35.22672; LERNMARK A, 1976, J CELL BIOL, V71, P606, DOI 10.1083/jcb.71.2.606; MARCINKIEWICZ M, 1994, ENDOCRINOLOGY, V135, P1651, DOI 10.1210/en.135.4.1651; MAXWELL MH, 1978, J MICROSC-OXFORD, V112, P253, DOI 10.1111/j.1365-2818.1978.tb01174.x; Muller L, 2000, PROG NUCLEIC ACID RE, V63, P69, DOI 10.1016/S0079-6603(08)60720-5; PAZELT C, 1979, NATURE, V282, P260; Rothenberg ME, 1996, MOL ENDOCRINOL, V10, P331, DOI 10.1210/me.10.4.331; Rouille Y, 1997, FEBS LETT, V413, P119, DOI 10.1016/S0014-5793(97)00892-2; Rouille Y, 1997, J BIOL CHEM, V272, P32810, DOI 10.1074/jbc.272.52.32810; ROUILLE Y, 1994, P NATL ACAD SCI USA, V91, P3242, DOI 10.1073/pnas.91.8.3242; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; ROUILLE Y, 1995, J BIOL CHEM, V270, P26488, DOI 10.1074/jbc.270.44.26488; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; Seidah NG, 1998, ANN NY ACAD SCI, V839, P9, DOI 10.1111/j.1749-6632.1998.tb10727.x; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; Tanaka S, 1996, ARCH HISTOL CYTOL, V59, P261, DOI 10.1679/aohc.59.261; Viale A, 1999, J BIOL CHEM, V274, P6536, DOI 10.1074/jbc.274.10.6536; Villeneuve P, 2000, J COMP NEUROL, V424, P461, DOI 10.1002/1096-9861(20000828)424:3<461::AID-CNE5>3.0.CO;2-J; Wang J, 2001, DIABETES, V50, P534, DOI 10.2337/diabetes.50.3.534; Westphal CH, 1999, CELL, V96, P689, DOI 10.1016/S0092-8674(00)80579-6; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	32	126	128	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27197	27202		10.1074/jbc.M103362200	http://dx.doi.org/10.1074/jbc.M103362200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356850	hybrid			2022-12-25	WOS:000169966900063
J	Rozanov, DV; Deryugina, EI; Ratnikov, BI; Monosov, EZ; Marchenko, GN; Quigley, JP; Strongin, AY				Rozanov, DV; Deryugina, EI; Ratnikov, BI; Monosov, EZ; Marchenko, GN; Quigley, JP; Strongin, AY			Mutation analysis of membrane type-1 matrix metalloproteinase (MT1-MMP) - The role of the cytoplasmic tail Cys(574), the active site Glu(240), and furin cleavage motifs in oligomerization, processing, and self-proteolysis of MT1-MMP expressed in breast carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE INHIBITOR; 1-MATRIX METALLOPROTEINASE; GELATINASE-A; INTEGRIN ALPHA-V-BETA-3; EXTRACELLULAR-MATRIX; EFFICIENT ACTIVATION; COLLAGEN MATRIX; IV COLLAGENASE; PRO-GELATINASE; PROGELATINASE	Membrane type-1 matrix metalloproteinase (MT1-MMP) is a key enzyme in the activation pathway of matrix prometalloproteinase-2 (pro-MMP-8). Both activation and autocatalytic maturation of pro-MMP-2 in trans suggest that MT1-MMP should exist as oligomers on the cell surface. To better understand the functions of MT1-MIMP, we designed mutants with substitutions in the active site (E240A), the cytoplasmic tail (C574A), and the RRXR furin cleavage motifs (R89A, ARAA, and R89A/ ARAA) of the enzyme. The mutants were expressed in MCF7 breast carcinoma cells that are deficient in both MMP-2 and MT1-MMP, Our results supported the existence of MT1-MMP oligomers and demonstrated that a disulfide bridge involving the Cys(574) Of the enzyme's cytoplasmic tail covalently links MT1-MMP monomers on the MCF7 cell surface, The presence of MT1-MMP oligomers also was shown for the enzyme naturally expressed in HT1080 fibrosarcoma cells. The single (R89A and ARAA) and double (RS9A/ARAA) furin cleavage site mutants of MT1-MMP were processed in MCF7 cells into the mature proteinase capable of activating pro-MMP-2 and stimulating cell locomotion. This suggested that furin cleavage is not a prerequisite for the conversion of pro-MT1-MMP into the functionally active enzyme. A hydroxamate class inhibitor (GM6001, or Ilomastat) blocked activation of MT1-MIMP in MCF7 cells but not in HT1080 cells. This implied that a matrixin-like proteinase sensitive to hydroxamates could be involved in a furin-independent, alternative pathway of MT1-MMP activation in breast carcinoma cells. The expression of the wild type MT1-MMP enhanced cell invasion and migration, indicating a direct involvement of this enzyme in cell locomotion. In contrast, both the C574A and E240A mutations render MT1-MMP inefficient in stimulating cell migration and invasion, In addition, the C574A mutation negatively affected cell adhesion, thereby indicating critical interactions involving the cytosolic part of MT1-MMP and the intracellular milieu.	Burnham Inst, La Jolla, CA 92037 USA; Scripps Res Inst, Vasc Biol Dept, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute; Scripps Research Institute	Strongin, AY (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	strongin@burnham.org	Strongin, Alex/R-6609-2019	Strongin, Alex/0000-0003-3765-3016	NATIONAL CANCER INSTITUTE [R01CA077470, R01CA083017] Funding Source: NIH RePORTER; NCI NIH HHS [CA77470, CA83017] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belien ATJ, 1999, J CELL BIOL, V144, P373, DOI 10.1083/jcb.144.2.373; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Cao J, 2000, J BIOL CHEM, V275, P29648, DOI 10.1074/jbc.M001920200; Cao JA, 1996, J BIOL CHEM, V271, P30174, DOI 10.1074/jbc.271.47.30174; Caterina JJ, 2000, J BIOL CHEM, V275, P26416, DOI 10.1074/jbc.M001271200; Chen WT, 1999, ANN NY ACAD SCI, V878, P361, DOI 10.1111/j.1749-6632.1999.tb07695.x; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P6684, DOI 10.1021/bi00187a039; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Deryugina EI, 1998, CANCER RES, V58, P3743; Deryugina EI, 2000, INT J CANCER, V86, P15, DOI 10.1002/(SICI)1097-0215(20000401)86:1<15::AID-IJC3>3.0.CO;2-B; Ellerbroek SM, 1999, CANCER RES, V59, P1635; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; GALARDY RE, 1994, ANN NY ACAD SCI, V732, P315, DOI 10.1111/j.1749-6632.1994.tb24746.x; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Jo Y, 2000, BIOCHEM J, V345, P511, DOI 10.1042/bj3450511; Kazes I, 2000, BLOOD, V96, P3064, DOI 10.1182/blood.V96.9.3064.h8003064_3064_3069; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Kurschat P, 1999, J BIOL CHEM, V274, P21056, DOI 10.1074/jbc.274.30.21056; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Llano E, 1999, CANCER RES, V59, P2570; Maquoi E, 2000, J BIOL CHEM, V275, P11368, DOI 10.1074/jbc.275.15.11368; Maquoi E, 1998, FEBS LETT, V424, P262, DOI 10.1016/S0014-5793(98)00187-2; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; Nabeshima K, 2000, CANCER RES, V60, P3364; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; OGATA Y, 1992, J BIOL CHEM, V267, P3581; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Polette M, 1998, INT J BIOCHEM CELL B, V30, P1195, DOI 10.1016/S1357-2725(98)00083-1; Quaranta V, 2000, J CELL BIOL, V149, P1167, DOI 10.1083/jcb.149.6.1167; Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066; Ratnikov B, 2000, ANAL BIOCHEM, V286, P149, DOI 10.1006/abio.2000.4798; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato T, 1999, BRIT J CANCER, V80, P1137, DOI 10.1038/sj.bjc.6690477; Sato T, 1999, ANN NY ACAD SCI, V878, P713, DOI 10.1111/j.1749-6632.1999.tb07770.x; Sato T, 1997, J CELL SCI, V110, P589; Sato T, 1999, J BIOL CHEM, V274, P37280, DOI 10.1074/jbc.274.52.37280; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Shofuda K, 1998, J BIOCHEM-TOKYO, V124, P462, DOI 10.1093/oxfordjournals.jbchem.a022136; Stanton H, 1998, J CELL SCI, V111, P2789; Steele DL, 2000, PROTEIN ENG, V13, P397, DOI 10.1093/protein/13.6.397; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Urena JM, 1999, J CELL SCI, V112, P773; Valtanen H, 2000, PROTEIN EXPRES PURIF, V19, P66, DOI 10.1006/prep.2000.1216; Velasco G, 2000, CANCER RES, V60, P877; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; Xu ZJ, 1999, J BIOL CHEM, V274, P21149, DOI 10.1074/jbc.274.30.21149; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	63	145	149	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25705	25714		10.1074/jbc.M007921200	http://dx.doi.org/10.1074/jbc.M007921200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11335709	hybrid			2022-12-25	WOS:000169823300012
J	Schwanbeck, R; Gymnopoulos, M; Petry, I; Piekielko, A; Szewczuk, Z; Heyduk, T; Zechel, K; Wisniewski, JR				Schwanbeck, R; Gymnopoulos, M; Petry, I; Piekielko, A; Szewczuk, Z; Heyduk, T; Zechel, K; Wisniewski, JR			Consecutive steps of phosphorylation affect conformation and DNA binding of the Chironomus high mobility group A protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP CHROMOSOMAL-PROTEINS; 4-WAY JUNCTION DNA; CASEIN KINASE-II; HMG-I; REGIONS FLANKING; BOX DOMAIN; I/Y; IDENTIFICATION; PROMOTER; ACRYLODAN	The high mobility group (HMG) proteins of the AT-hook family (HMGA) lie downstream in regulatory networks with protein kinase CI Cdc2 kinase, MAP kinase, and casein kinase 2 (CK2) as final effecters. In the cells of the midge Chironomus, almost all of the HMGA protein (cHMGA) is phosphorylated by CK2 at two adjacent sites. 40% of the protein population is additionally modified by MAP kinase, Using spectroscopic and protein footprinting techniques, we analyzed how individual and consecutive steps of phosphorylation change the conformation of an HMGA protein and affect its contacts with poly(dA-dT). poly(dA-dT) and a fragment of the interferon-beta promoter. We demonstrate that phosphorylation of cHMGA by CK2 alters its conformation and modulates its DNA binding properties such that a subsequent phosphorylation by Cdc2 kinase changes the organization of the protein-DNA complex. In contrast, consecutive phosphorylation by MAP kinase, which results in a dramatic change in cHMGA conformation, has no direct effect on the complex. Because the phosphorylation of the HMGA proteins attenuates binding affinity and reduces the extent of contacts between the DNA and protein, it is likely that this process mirrors the dynamics and diversity of regulatory processes in chromatin.	Univ Gottingen, Zool Inst Entwicklungsbiol 3, D-37073 Gottingen, Germany; Uniwersytet Wroclawski, Wydziat Chem, PL-50388 Wroclaw, Poland; St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Max Planck Inst Biophys Chem, Dept Biochem, D-37077 Gottingen, Germany; MDS Proteom AS, DK-5230 Odense M, Denmark	University of Gottingen; University of Wroclaw; Saint Louis University; Max Planck Society	Wisniewski, JR (corresponding author), MDS Proteom AS, Staermosegardsvej 6, DK-5230 Odense M, Denmark.		Schwanbeck, Ralf/A-2648-2008; Szewczuk, Zbigniew/A-2243-2013; Piekielko-Witkowska, Agnieszka/V-1011-2019; Petry-Podgorska, Inga/I-3886-2014	Schwanbeck, Ralf/0000-0003-0925-929X; Piekielko-Witkowska, Agnieszka/0000-0002-5348-0760; Szewczuk, Zbigniew/0000-0001-5884-9363				Amirand C, 1998, J CELL SCI, V111, P3551; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; Badea M G, 1979, Methods Enzymol, V61, P378; Baichoo N, 1997, BIOCHEMISTRY-US, V36, P10830, DOI 10.1021/bi970714v; Banks GC, 2000, BIOCHEMISTRY-US, V39, P8333, DOI 10.1021/bi000378+; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CLAUS P, 1994, J BIOL CHEM, V269, P33042; Cmarik JL, 1998, ONCOGENE, V16, P3387, DOI 10.1038/sj.onc.1201888; DISNEY JE, 1989, J CELL BIOL, V109, P1975, DOI 10.1083/jcb.109.5.1975; ELTON TS, 1986, ANAL BIOCHEM, V157, P53, DOI 10.1016/0003-2697(86)90195-8; EPPS DE, 1992, J BIOL CHEM, V267, P3129; FERRANTI P, 1992, J BIOL CHEM, V267, P22486; Frank O, 1998, J BIOL CHEM, V273, P20015, DOI 10.1074/jbc.273.32.20015; Ghidelli S, 1997, CHROMOSOMA, V105, P369, DOI 10.1007/BF02529752; HEYDUK E, 1994, BIOCHEMISTRY-US, V33, P9643, DOI 10.1021/bi00198a033; Heyduk E, 1997, J BIOL CHEM, V272, P19763, DOI 10.1074/jbc.272.32.19763; Heyduk T, 1996, P NATL ACAD SCI USA, V93, P10162, DOI 10.1073/pnas.93.19.10162; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LEGER H, 1995, MOL CELL BIOL, V15, P3738; LEHRER SS, 1988, BIOCHEMISTRY-US, V27, P5899, DOI 10.1021/bi00416a012; Louie DF, 2000, PROTEIN SCI, V9, P170; LUND T, 1987, EUR J BIOCHEM, V166, P21, DOI 10.1111/j.1432-1033.1987.tb13477.x; Maher JF, 1996, P NATL ACAD SCI USA, V93, P6716, DOI 10.1073/pnas.93.13.6716; MARRIOTT G, 1988, BIOCHEMISTRY-US, V27, P6214, DOI 10.1021/bi00417a004; Martelli AM, 1998, J HISTOCHEM CYTOCHEM, V46, P863, DOI 10.1177/002215549804600710; MEISNER H, 1995, PROTEIN KINASE FACTS, P240; NISSEN MS, 1995, J BIOL CHEM, V270, P4355, DOI 10.1074/jbc.270.9.4355; PALVIMO J, 1989, FEBS LETT, V257, P101, DOI 10.1016/0014-5793(89)81796-X; Piekielko A, 2001, J BIOL CHEM, V276, P1984, DOI 10.1074/jbc.M004065200; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; Rachofsky EL, 2001, BIOCHEMISTRY-US, V40, P957, DOI 10.1021/bi001665g; REEVES R, 1990, J BIOL CHEM, V265, P8573; Renner U, 2000, BBA-GEN SUBJECTS, V1475, P99, DOI 10.1016/S0304-4165(00)00054-4; RODRIGUEZALFAGEME C, 1980, CHROMOSOMA, V78, P1; Schwanbeck R, 2000, J BIOL CHEM, V275, P1793, DOI 10.1074/jbc.275.3.1793; Schwanbeck R, 1997, J BIOL CHEM, V272, P27476, DOI 10.1074/jbc.272.43.27476; Schwanbeck R, 2000, BIOCHEMISTRY-US, V39, P14419, DOI 10.1021/bi0011274; Slama-Schwok A, 2000, BIOPHYS J, V78, P2543, DOI 10.1016/S0006-3495(00)76799-3; WANG DZ, 1995, J BIOL CHEM, V270, P22924, DOI 10.1074/jbc.270.39.22924; Wisniewski Jacek R., 1998, Zoologica Poloniae, V43, P5; Wisniewski JR, 1999, J BIOL CHEM, V274, P20116; WISNIEWSKI JR, 1994, J BIOL CHEM, V269, P10713; Wisniewski JR, 1997, EUR J BIOCHEM, V243, P151, DOI 10.1111/j.1432-1033.1997.0151a.x; WISNIEWSKI JR, 1994, EUR J BIOCHEM, V225, P687, DOI 10.1111/j.1432-1033.1994.00687.x; Wisniewski JR, 2000, INT J MOL MED, V6, P409; Xiao DM, 2000, J NEUROCHEM, V74, P392, DOI 10.1046/j.1471-4159.2000.0740392.x; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Yie JM, 1997, MOL CELL BIOL, V17, P3649, DOI 10.1128/MCB.17.7.3649; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0; Zweidler A, 1978, Methods Cell Biol, V17, P223, DOI 10.1016/S0091-679X(08)61145-0	52	18	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26012	26021		10.1074/jbc.M011053200	http://dx.doi.org/10.1074/jbc.M011053200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11335713	hybrid			2022-12-25	WOS:000169823300051
J	Wang, XS; Babu, JR; Harden, JM; Jablonski, SA; Gazi, MH; Lingle, WL; de Groen, PC; Yen, TJ; van Deursen, JMA				Wang, XS; Babu, JR; Harden, JM; Jablonski, SA; Gazi, MH; Lingle, WL; de Groen, PC; Yen, TJ; van Deursen, JMA			The mitotic checkpoint protein hBUB3 and the mRNA export factor hRAE1 interact with GLE2p-binding sequence (GLEBS)-containing proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; SPINDLE ASSEMBLY CHECKPOINT; POLE BODY DUPLICATION; NUCLEOCYTOPLASMIC TRANSPORT; BUDDING YEAST; RNA EXPORT; FISSION YEAST; GENE; KINETOCHORES; RAN	The mRNA export factor RAE1 (also called GLE2) and the mitotic checkpoint protein BUB3 share extensive sequence homology in yeast as well as higher eukaryotes, although the biological relevance of their similarity is unclear. Previous work in HeLa cells has shown that human (h)RAE1 binds the nuclear pore complex protein hNUP98 via a short NUP98 motif called GLEBS (for GLE2p-binding Sequence). Here we report that the two known binding partners of hBUB3, the mitotic checkpoint proteins hBUB1 and hBUBR1, both carry a region with remarkable similarity to the GLEBS motif of hNUP98. We show that the GLEBS-like motifs of mouse (m)BUB1 and mBUBR1 are sufficient for mBUB3 binding. mBUB3 lacks affinity for the hNUP98 GLEBS, demonstrating its binding specificity for GLEBS motifs of mitotic checkpoint proteins. Interestingly, mRAE1 does not exclusively bind to the GLEBS motif of hNUP98 and can cross-interact with the mBUB1 GLEBS. We show that full-length RAE1 and BUB1 proteins interact in mammalian cells and accumulate both at the kinetochores of prometaphase chromosomes. Our findings demonstrate that GLEBS motifs reside in mammalian nucleoporins and mitotic checkpoint proteins and apparently serve as specific binding sites for either BUB3, RAE1, or both.	Mayo Clin, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA; Mayo Clin, Dept Expt Pathol, Rochester, MN 55905 USA; Mayo Clin, Dept Gastroenterol & Hepatol, Rochester, MN 55905 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Fox Chase Cancer Center	van Deursen, JMA (corresponding author), Mayo Clin, Dept Pediat & Adolescent Med, 200 1st St SW, Rochester, MN 55905 USA.			Ramesh Babu, Jeganathan/0000-0002-3719-932X; Yen, Tim/0000-0003-2159-0997	NATIONAL CANCER INSTITUTE [P30CA021765, R01CA077262] Funding Source: NIH RePORTER; NCI NIH HHS [CA-21765, R01 CA77262-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Bachi A, 2000, RNA, V6, P136, DOI 10.1017/S1355838200991994; Bailer SM, 1998, EMBO J, V17, P1107, DOI 10.1093/emboj/17.4.1107; Bernard P, 1998, J CELL BIOL, V143, P1775, DOI 10.1083/jcb.143.7.1775; BROWN JA, 1995, J BIOL CHEM, V270, P7411, DOI 10.1074/jbc.270.13.7411; Burke DJ, 2000, CURR OPIN GENET DEV, V10, P26, DOI 10.1016/S0959-437X(99)00040-4; Campbell MS, 2001, J CELL SCI, V114, P953; Carazo-Salas RE, 1999, NATURE, V400, P178, DOI 10.1038/22133; Chan GKT, 2000, NAT CELL BIOL, V2, P944, DOI 10.1038/35046598; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; CHOI YD, 1984, P NATL ACAD SCI-BIOL, V81, P7471, DOI 10.1073/pnas.81.23.7471; Davenport JW, 1999, GENOMICS, V55, P113, DOI 10.1006/geno.1998.5629; Farr KA, 1998, MOL CELL BIOL, V18, P2738, DOI 10.1128/MCB.18.5.2738; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Jablonski SA, 1998, CHROMOSOMA, V107, P386, DOI 10.1007/s004120050322; Kalab P, 1999, CURR BIOL, V9, P481, DOI 10.1016/S0960-9822(99)80213-9; Kalitsis P, 2000, GENE DEV, V14, P2277, DOI 10.1101/gad.827500; Kasper LH, 1999, MOL CELL BIOL, V19, P764; Kraemer D, 1997, P NATL ACAD SCI USA, V94, P9119, DOI 10.1073/pnas.94.17.9119; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Martinez-Exposito MJ, 1999, P NATL ACAD SCI USA, V96, P8493, DOI 10.1073/pnas.96.15.8493; Melchior F, 1998, TRENDS CELL BIOL, V8, P175, DOI 10.1016/S0962-8924(98)01252-5; Murphy R, 1996, MOL BIOL CELL, V7, P1921, DOI 10.1091/mbc.7.12.1921; Nachury MV, 2001, CELL, V104, P95, DOI 10.1016/S0092-8674(01)00194-5; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nakielny S, 1997, CURR OPIN CELL BIOL, V9, P420, DOI 10.1016/S0955-0674(97)80016-6; NEER EJ, 1994, METHOD ENZYMOL, V237, P226; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Pritchard CEJ, 1999, J CELL BIOL, V145, P237, DOI 10.1083/jcb.145.2.237; ROBERTS BT, 1994, MOL CELL BIOL, V14, P8282, DOI 10.1128/MCB.14.12.8282; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Stutz F, 1998, GENE DEV, V12, P3303, DOI 10.1101/gad.12.21.3303; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; vanDeursen J, 1996, EMBO J, V15, P5574, DOI 10.1002/j.1460-2075.1996.tb00942.x; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; Whalen WA, 1997, YEAST, V13, P1167, DOI 10.1002/(SICI)1097-0061(19970930)13:12<1167::AID-YEA154>3.3.CO;2-F; Wiese C, 2001, SCIENCE, V291, P653, DOI 10.1126/science.1057661; Wilde A, 1999, SCIENCE, V284, P1359, DOI 10.1126/science.284.5418.1359; WINEY M, 1991, COLD SH Q B, V56, P705; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518; Zhang CM, 1999, J CELL SCI, V112, P2453	50	98	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26559	26567		10.1074/jbc.M101083200	http://dx.doi.org/10.1074/jbc.M101083200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11352911	hybrid			2022-12-25	WOS:000169823300120
J	Douglas, DN; Dolinsky, VW; Lehner, R; Vance, DE				Douglas, DN; Dolinsky, VW; Lehner, R; Vance, DE			A role for sp1 in the transcriptional regulation of hepatic triacylglycerol hydrolase in the mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTERYL ESTER HYDROLASE; MOLECULAR-CLONING; DEVELOPMENTAL EXPRESSION; BINDING-SITES; DNA-BINDING; IN-VIVO; PROMOTER; RAT; GENE; ACTIVATION	Microsomal triacylglycerol hydrolase (TGH) hydrolyzes stored triacylglycerol in cultured hepatoma cells (Lehner, R., and Vance, D, E, (1999) Biochem. J. 343, 1-10). We studied expression of TGH in murine liver and found both protein and mRNA increased dramatically at 27 days after birth. Nuclear run-on assays demonstrated that this was due to increased transcription. We cloned 542 base pairs upstream of the transcriptional start site of the murine TGH gene. Electrophoretic mobility shift assays demonstrated enhanced binding of hepatic nuclear proteins from 27-day-old mice to the murine TGH promoter, yielding three differentially migrating complexes. DNase I footprint analysis localized these complexes to two distinct regions: site A contains a putative Sp binding site, and site B contains a degenerate E box. We transfected primary murine hepatocytes with a series of 5 ' -deletion constructs upstream of the reporter luciferase cDNA Positive control elements were identified in a segment containing site A Competitive electrophoretic mobility shift assays and supershift assays demonstrated that site A binds Sp1 and Sp3. Transcriptional activation assays in Schneider SL-2 insect cells demonstrated that Spl is a potent activator of the TGH promoter. These experiments directly link increased TGH expression at the time of weaning to transcriptional regulation by Sp1.	Univ Alberta, Dept Biochem, Heritage Med Res Ctr 328, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Pediat, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Cell Biol, Canadian Inst Hlth Res, Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta; Institute for Work & Health; University of Alberta	Vance, DE (corresponding author), Univ Alberta, Dept Biochem, Heritage Med Res Ctr 328, Edmonton, AB T6G 2S2, Canada.	dennis.vance@ualberta.ca		Lehner, Richard/0000-0002-6008-1805				Ahlgren R, 1999, J BIOL CHEM, V274, P19422, DOI 10.1074/jbc.274.27.19422; ALEMANY J, 1992, BIOCHEM BIOPH RES CO, V183, P659, DOI 10.1016/0006-291X(92)90533-Q; ALEXSON SEH, 1994, J BIOL CHEM, V269, P17118; ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; BORELLINI F, 1991, J BIOL CHEM, V266, P15850; Bratke J, 1999, BIOCHEM J, V339, P563, DOI 10.1042/0264-6021:3390563; CHEN HM, 1993, J BIOL CHEM, V268, P8230; Chun RF, 1998, J VIROL, V72, P2615, DOI 10.1128/JVI.72.4.2615-2629.1998; COLEMAN RA, 1988, J LIPID RES, V29, P33; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DEMMER LA, 1986, P NATL ACAD SCI USA, V83, P8102, DOI 10.1073/pnas.83.21.8102; DERYCKERE F, 1994, BIOTECHNIQUES, V16, P405; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DOLINSKY VW, 2001, IN PRESS BIOCH BIOPH; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EPERON IC, 1994, RNA PROCESSING PRACT, V1, P57; Ghosh S, 1995, BBA-LIPID LIPID MET, V1259, P305, DOI 10.1016/0005-2760(95)00184-0; Ghosh S, 1998, AM J PHYSIOL-GASTR L, V274, pG662, DOI 10.1152/ajpgi.1998.274.4.G662; Gibbons GF, 2000, BBA-MOL CELL BIOL L, V1483, P37, DOI 10.1016/S1388-1981(99)00182-1; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JOHANSSON MBN, 1983, BIOL NEONATE, V44, P278, DOI 10.1159/000241728; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kumar AP, 1998, BIOCHEM BIOPH RES CO, V252, P517, DOI 10.1006/bbrc.1998.9676; Langmann T, 1997, BBA-GENE STRUCT EXPR, V1350, P65, DOI 10.1016/S0167-4781(96)00142-X; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Lehner R, 1999, BIOCHEM J, V343, P1, DOI 10.1042/0264-6021:3430001; Lehner R, 1999, BIOCHEM J, V338, P761, DOI 10.1042/0264-6021:3380761; Lehner R, 1997, BIOCHEMISTRY-US, V36, P1861, DOI 10.1021/bi962186d; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MARZLUFF WF, 1985, TRANSCRIPTION TRANSL, P89; Natarajan R, 1999, J LIPID RES, V40, P2091; Natarajan R, 1998, BIOCHEM BIOPH RES CO, V243, P349, DOI 10.1006/bbrc.1997.8030; Noti JD, 1997, J BIOL CHEM, V272, P24038, DOI 10.1074/jbc.272.38.24038; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; PETERS J, 1978, BIOCHEM GENET, V16, P553, DOI 10.1007/BF00484219; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RAY BK, 1994, GENE, V147, P253, DOI 10.1016/0378-1119(94)90076-0; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; Rolfe FG, 1997, J IMMUNOL METHODS, V202, P143, DOI 10.1016/S0022-1759(96)00245-1; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Satoh T, 1998, ANNU REV PHARMACOL, V38, P257, DOI 10.1146/annurev.pharmtox.38.1.257; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; Shi Y, 1997, BBA-REV CANCER, V1332, pF49, DOI 10.1016/S0304-419X(96)00044-3; SPANOPOULOU E, 1991, MOL CELL BIOL, V11, P2216, DOI 10.1128/MCB.11.4.2216; WIGGINS D, 1992, BIOCHEM J, V284, P457, DOI 10.1042/bj2840457; YANG LY, 1995, J LIPID RES, V36, P125; ZHANG DE, 1994, J BIOL CHEM, V269, P11425; Zutter MM, 1997, BLOOD, V90, P678, DOI 10.1182/blood.V90.2.678.678_678_689	51	17	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25621	25630		10.1074/jbc.M103874200	http://dx.doi.org/10.1074/jbc.M103874200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11337511	hybrid			2022-12-25	WOS:000169800700154
J	Harvey, NL; Daish, T; Mills, K; Dorstyn, L; Quinn, LM; Read, SH; Richardson, H; Kumar, S				Harvey, NL; Daish, T; Mills, K; Dorstyn, L; Quinn, LM; Read, SH; Richardson, H; Kumar, S			Characterization of the Drosophila caspase, DAMM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; STRUCTURAL BASIS; APOPTOTIC ACTIVITY; ACTIVATION; PROTEIN; DRONC; IDENTIFICATION; INHIBITION; EXPRESSION; PRODOMAIN	Caspases are main effecters of apoptosis in metazoans, Genome analysis indicates that there are seven caspases in Drosophila, six of which have been previously characterized. Here we describe the cloning and characterization of the last Drosophila caspase, DAMM. Similar to mammalian effector caspases, DAMM lacks a long prodomain, We show that the DAMM precursor, along with the caspases DRONC and DECAY, is partially processed in cells undergoing apoptosis, Recombinant DAMM produced in Escherichia coli shows significant catalytic activity on a pentapeptide caspase substrate. Low levels of damm mRNA are ubiquitously expressed in Drosophila embryos during early stages of development. Relatively high levels of damm mRNA are detected in larval salivary glands and midgut, and in adult egg chambers. Ectopic expression of DAMM in cultured cells induces apoptosis, and similarly, transgenic overexpression of DAMM, but not of a catalytically inactive DAMM mutant, in Drosophila results in a rough eye phenotype, We demonstrate that expression of the catalytically inactive DAMM mutant protein significantly suppresses the rough eye phenotype due to the overexpression of HID, suggesting that DAMM may be required in a hid-mediated cell death pathway.	Inst Med & Vet Sci, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia; Peter MacCallum Canc Inst, Melbourne, Vic 8006, Australia	Institute Medical & Veterinary Science Australia; Peter Maccallum Cancer Center	Kumar, S (corresponding author), Inst Med & Vet Sci, Hanson Ctr Canc Res, POB 14,Rundle Mall,Frome Rd, Adelaide, SA 5000, Australia.	sharad-.kumar@imvs.sa.gov.au	Dorstyn, Loretta/F-3673-2013; Kumar, Sharad/AAX-7787-2020; Richardson, Helena E/A-8080-2013	Dorstyn, Loretta/0000-0001-9886-0989; Kumar, Sharad/0000-0001-7126-9814; Richardson, Helena E/0000-0003-3852-4953; Harvey, Natasha/0000-0001-9839-8966; Quinn, Leonie/0000-0002-3911-6508				ABRAMS JM, 1993, DEVELOPMENT, V117, P29; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chen P, 1996, J BIOL CHEM, V271, P25735, DOI 10.1074/jbc.271.42.25735; Chen P, 1998, DEV BIOL, V201, P202, DOI 10.1006/dbio.1998.9000; Colussi PA, 2000, J CELL BIOL, V148, P703, DOI 10.1083/jcb.148.4.703; Colussi PA, 1998, J BIOL CHEM, V273, P26566, DOI 10.1074/jbc.273.41.26566; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Dorstyn L, 1997, CELL DEATH DIFFER, V4, P570, DOI 10.1038/sj.cdd.4400281; Dorstyn L, 1999, J BIOL CHEM, V274, P30778, DOI 10.1074/jbc.274.43.30778; Doumanis J, 2001, CELL DEATH DIFFER, V8, P387, DOI 10.1038/sj.cdd.4400864; EDGAR BA, 1986, CELL, V44, P871, DOI 10.1016/0092-8674(86)90009-7; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Elrod-Erickson M, 2000, CURR BIOL, V10, P781, DOI 10.1016/S0960-9822(00)00569-8; Fraser AG, 1997, EMBO J, V16, P6192, DOI 10.1093/emboj/16.20.6192; Fraser AG, 1997, EMBO J, V16, P2805, DOI 10.1093/emboj/16.10.2805; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Harvey KF, 1998, J BIOL CHEM, V273, P13524, DOI 10.1074/jbc.273.22.13524; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; Hawkins CJ, 2000, J BIOL CHEM, V275, P27084; Hawkins CJ, 1999, P NATL ACAD SCI USA, V96, P2885, DOI 10.1073/pnas.96.6.2885; Hay BA, 2000, CELL DEATH DIFFER, V7, P1045, DOI 10.1038/sj.cdd.4400765; HAY BA, 1994, DEVELOPMENT, V120, P2121; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Jiang CG, 1997, DEVELOPMENT, V124, P4673; Kaiser WJ, 1998, FEBS LETT, V440, P243, DOI 10.1016/S0014-5793(98)01465-3; Kanuka H, 1999, P NATL ACAD SCI USA, V96, P145, DOI 10.1073/pnas.96.1.145; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kumar S, 1999, CELL DEATH DIFFER, V6, P1060, DOI 10.1038/sj.cdd.4400600; Kumar S, 2000, CELL DEATH DIFFER, V7, P1039, DOI 10.1038/sj.cdd.4400756; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; Leulier F, 2000, EMBO REP, V1, P353, DOI 10.1093/embo-reports/kvd073; McCall K, 1998, SCIENCE, V279, P230, DOI 10.1126/science.279.5348.230; Meier P, 2000, EMBO J, V19, P598, DOI 10.1093/emboj/19.4.598; NICHOLSON DW, 1999, CELL DEATH DIFFER, V6, P1551; Quinn LM, 2000, J BIOL CHEM, V275, P40416, DOI 10.1074/jbc.M002935200; RICHARDSON H, 1995, DEVELOPMENT, V121, P3371; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Shaham S, 1998, J BIOL CHEM, V273, P35109, DOI 10.1074/jbc.273.52.35109; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Stennicke HR, 1999, CELL DEATH DIFFER, V6, P1054, DOI 10.1038/sj.cdd.4400599; Talanian RV, 1997, J BIOL CHEM, V272, P9677; WOLFF T, 1991, DEVELOPMENT, V113, P825; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593	48	64	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25342	25350		10.1074/jbc.M009444200	http://dx.doi.org/10.1074/jbc.M009444200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11337486	hybrid			2022-12-25	WOS:000169800700121
J	Jacob, KK; Stanley, FM				Jacob, KK; Stanley, FM			Elk-1, C/EBP alpha, and Pit-1 confer an insulin-responsive phenotype on prolactin promoter expression in Chinese hamster ovary cells and define the factors required for insulin-increased transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT/ENHANCER-BINDING-PROTEIN; GENE-EXPRESSION; REGULATORY ELEMENT; NUCLEAR-PROTEIN; THYROID-HORMONE; GROWTH-HORMONE; DNA-BINDING; DOMAIN; ETS; PHOSPHORYLATION	The transcription factor(s) that mediate insulin-increased gene transcription are not well defined. These studies use phenotypic conversion of Rat2 and Chinese hamster ovary (CHO) cells with transcription factors to identify components required for regulation of prolactin promoter activity and its control by insulin. The pituitary-derived GH4 cells contain all of the transcription factors required for insulin-increased prolactin-chloramphenicol acetyltransferase (CAT) expression while HeLa cells require only Pit-1, a pituitary-specific factor. However, Rate and CHO cells require additional factors. We had determined previously that the transcription factor that mediates insulin-increased prolactin gene expression was likely an Ets-related protein. Elk-1 and Sap-1 were the only Ets-related transcription factors tested as chimeras with LexA DNA-binding domain that were able to mediate insulin-increased expression of a LexA-CAT reporter plasmid, Elk-1 and Sap-1 are expressed in GH4 and HeLa cells but Rate and CHO cells express Sap-1, but not Elk-1, Expression of Elk-1 made Rats cells (but not CHO cells) insulin responsive. C/EBP alpha also binds to the prolactin promoter at a sequence overlapping the binding site for Elk-1, Expression of both C/EBP alpha and Pit-1 in CHO cells is required for high basal transcription of prolactin-CAT. Expression of Elk-1 converts CHO cells into a phenotype in which prolactin gene expression is increased by insulin treatment. Finally, antisense mediated reduction of Elk-1 in GH4 cells decreased insulin-increased prolactin gene expression and confirmed the requirement for Elk-1 for insulin-increased prolactin gene expression. Thus, both C/EBP alpha and Pit-1 were required for high basal transcription while insulin sensitivity required Elk-1.	NYU Med Ctr, Dept Med, Sch Med, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA	New York University; New York University	Stanley, FM (corresponding author), NYU Med Ctr, Dept Med, Sch Med, TH 450,550 1st Ave, New York, NY 10016 USA.			Stanley, Frederick/0000-0002-3684-2168	NIDDK NIH HHS [DK43365] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043365] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COFFER P, 1994, ONCOGENE, V9, P911; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Gille H, 1996, MOL CELL BIOL, V16, P1094; Hemati N, 1997, J BIOL CHEM, V272, P25913, DOI 10.1074/jbc.272.41.25913; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HUANG JH, 1994, MOL CELL BIOL, V14, P4475, DOI 10.1128/MCB.14.7.4475; Jacob KK, 1998, J BIOL CHEM, V273, P4800, DOI 10.1074/jbc.273.8.4800; JACOB KK, 1995, J BIOL CHEM, V270, P27773, DOI 10.1074/jbc.270.46.27773; Jacob KK, 1999, ENDOCRINOLOGY, V140, P4542, DOI 10.1210/en.140.10.4542; JACOB KK, 1994, J BIOL CHEM, V269, P25515; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; LAMARCO KL, 1989, GENE DEV, V3, P1372, DOI 10.1101/gad.3.9.1372; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Ouyang LH, 1996, J BIOL CHEM, V271, P10425, DOI 10.1074/jbc.271.18.10425; Park EA, 1999, J BIOL CHEM, V274, P211, DOI 10.1074/jbc.274.1.211; PARK EA, 1993, J BIOL CHEM, V268, P613; Partridge M, 1996, ANTISENSE NUCLEIC A, V6, P169, DOI 10.1089/oli.1.1996.6.169; Roesler WJ, 1998, J BIOL CHEM, V273, P14950, DOI 10.1074/jbc.273.24.14950; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; STANLEY F, 1988, J BIOL CHEM, V263, P13444; STANLEY F, 1989, MOL ENDOCRINOL, V3, P1627, DOI 10.1210/mend-3-10-1627; STANLEY FM, 1992, J BIOL CHEM, V267, P16719; Stein CA, 1999, NAT BIOTECHNOL, V17, P209, DOI 10.1038/6909; TAE HJ, 1994, J BIOL CHEM, V269, P10475; Verbeek W, 1999, BLOOD, V93, P3327, DOI 10.1182/blood.V93.10.3327; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x	34	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24931	24936		10.1074/jbc.M102826200	http://dx.doi.org/10.1074/jbc.M102826200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11340077	hybrid			2022-12-25	WOS:000169800700067
J	Zhou, TY; Chiang, CM				Zhou, TY; Chiang, CM			The intronless and TATA-less human TAF(II)55 gene contains a functional initiator and a downstream promoter element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTION FACTOR AP-2; LONG TERMINAL REPEAT; BOX-BINDING PROTEIN; DNA-BINDING; MAMMALIAN-CELLS; CORE PROMOTERS; CHROMOSOMAL LOCALIZATION; DEPENDENT TRANSCRIPTION; TFIID SUBUNITS	Human TAF(II)55 (hTAF(II)55) is a component of the multisubunit general transcription factor TFIID and has been shown to mediate the functions of many transcriptional activators via direct protein-protein interactions. To uncover the regulatory properties of the general transcription machinery, we have isolated the hTAF(II)55 gene and dissected the regulatory elements and the core promoter responsible for hTAF(II)55 gene expression. Surprisingly, the hTAF(II)55 gene has a single uninterrupted open reading frame and is the only intronless general transcription factor identified so far. Its expression is driven by a TATA-less promoter that contains a functional initiator and a downstream promoter element, as illustrated by both transfection assays and mutational analyses. Moreover, this core promoter can mediate the activity of a transcriptional activator that is artificially recruited to the promoter in a heterologous context. Interestingly, in the promoter-proximal region there are multiple Sp1-binding sites juxtaposed to a single AP2-binding site, indicating that Sp1 and AP2 may regulate the core promoter activity of the hTAF(II)55 gene. These findings indicate that a combinatorial regulation of a general transcription factor-encoding gene can be conferred by both ubiquitous and cell type-specific transcriptional regulators.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University	Chiang, CM (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, 10900 Euclid Ave, Cleveland, OH 44106 USA.	c-chiang@biochemistry.cwru.edu			NATIONAL CANCER INSTITUTE [R01CA081017] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059643] Funding Source: NIH RePORTER; NCI NIH HHS [CA81017] Funding Source: Medline; NIGMS NIH HHS [GM59643] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benson LQ, 1999, J BIOL CHEM, V274, P28794, DOI 10.1074/jbc.274.40.28794; BOAM DSW, 1995, J BIOL CHEM, V270, P19487, DOI 10.1074/jbc.270.33.19487; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; CHALUT C, 1995, GENE, V161, P277, DOI 10.1016/0378-1119(95)00209-O; CHANG DJ, 1990, J BIOL CHEM, V265, P9496; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHIANG CM, 1991, J VIROL, V65, P3317, DOI 10.1128/JVI.65.6.3317-3329.1991; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; Gentles AJ, 1999, TRENDS GENET, V15, P47, DOI 10.1016/S0168-9525(98)01648-5; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Grueneberg DA, 1997, GENE DEV, V11, P2482, DOI 10.1101/gad.11.19.2482; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; Hou SY, 2000, MOL CELL BIOL, V20, P113, DOI 10.1128/MCB.20.1.113-125.2000; HUANG ZM, 1995, MOL CELL BIOL, V15, P3864; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Ince TA, 1995, J BIOL CHEM, V270, P30249, DOI 10.1074/jbc.270.51.30249; INOSTROZA JA, 1992, CELL, V70, P477; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; Kaufmann J, 1996, GENE DEV, V10, P873, DOI 10.1101/gad.10.7.873; Kaufmann J, 1998, MOL CELL BIOL, V18, P233, DOI 10.1128/MCB.18.1.233; KEDES LH, 1979, ANNU REV BIOCHEM, V48, P837, DOI 10.1146/annurev.bi.48.070179.004201; Kutach AK, 2000, MOL CELL BIOL, V20, P4754, DOI 10.1128/MCB.20.13.4754-4764.2000; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lavigne AC, 1996, J BIOL CHEM, V271, P19774, DOI 10.1074/jbc.271.33.19774; Lavigne AC, 1999, MOL CELL BIOL, V19, P5486; LEWIN B, 2000, GENES, V7, P37; Lewis BA, 2000, P NATL ACAD SCI USA, V97, P7172, DOI 10.1073/pnas.120181197; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Martinez E, 1998, MOL CELL BIOL, V18, P6571, DOI 10.1128/MCB.18.11.6571; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Mermelstein F, 1996, GENE DEV, V10, P1033, DOI 10.1101/gad.10.8.1033; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; Moqtaderi Z, 1996, P NATL ACAD SCI USA, V93, P14654, DOI 10.1073/pnas.93.25.14654; NAGATA S, 1980, NATURE, V287, P401, DOI 10.1038/287401a0; Novina CD, 1996, TRENDS GENET, V12, P351, DOI 10.1016/0168-9525(96)10034-2; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Pipaon C, 1999, MOL CELL BIOL, V19, P2734; Purrello M, 1998, ONCOGENE, V16, P1633, DOI 10.1038/sj.onc.1201673; Qureshi SA, 1998, MOL CELL, V1, P389, DOI 10.1016/S1097-2765(00)80039-8; Ren B, 1998, EMBO J, V17, P1076, DOI 10.1093/emboj/17.4.1076; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SCHEER E, 1995, GENOMICS, V29, P269, DOI 10.1006/geno.1995.1243; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; Shibuya T, 1999, GENETICS, V152, P869; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Trubetskoy AM, 1999, J VIROL, V73, P3477, DOI 10.1128/JVI.73.4.3477-3483.1999; vanderKnaap JA, 1997, P NATL ACAD SCI USA, V94, P11827, DOI 10.1073/pnas.94.22.11827; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Weis L, 1997, MOL CELL BIOL, V17, P2973, DOI 10.1128/MCB.17.6.2973; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Willy PJ, 2000, SCIENCE, V290, P982, DOI 10.1126/science.290.5493.982; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; Wu SY, 1996, BIOTECHNIQUES, V21, P718; Wu SY, 1999, J BIOL CHEM, V274, P23480, DOI 10.1074/jbc.274.33.23480; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604; Zhang MQ, 1998, GENOME RES, V8, P319, DOI 10.1101/gr.8.3.319	82	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25503	25511		10.1074/jbc.M102875200	http://dx.doi.org/10.1074/jbc.M102875200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11340078	hybrid			2022-12-25	WOS:000169800700141
J	Motteran, L; Pilone, MS; Molla, G; Ghisla, S; Pollegioni, L				Motteran, L; Pilone, MS; Molla, G; Ghisla, S; Pollegioni, L			Cholesterol oxidase from Brevibacterium sterolicum - The relationship between covalent flavinylation and redox properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES-HYGROSCOPICUS; CRYSTAL-STRUCTURE; FAD-BINDING; FAMILY	Brevibacterium sterolicum possesses two forms of cholesterol oxidase, one containing noncovalently bound FAD, the second containing a FAD covalently linked to His(69) of the protein backbone. The functional role of the histidyl-FAD bond in the latter cholesterol oxidase was addressed by studying the properties of the H69A mutant in which the FAD is bound tightly, but not covalently, and by comparison with native enzyme. The mutant retains catalytic activity, but with a turnover rate decreased 35-fold; the isomerization step of the intermediate 3-ketosteroid to the final product is also preserved. Stabilization of the flavin semiquinone and binding of sulfite are markedly decreased, this correlates with a lower midpoint redox potential (-204 mV compared with -101 mV for wild-type). Reconstitution with 8-chloro-FAD led to a holoenzyme form of H69A cholesterol oxidase with a midpoint redox potential of -160 mV, In this enzyme form, flavin semiquinone is newly stabilized, and a 3.5-fold activity increase is observed, this mimicking the thermodynamic effects induced by the covalent flavin linkage. It is concluded that the flavin 8 alpha -linkage to a (Nl)histidine is a pivotal factor in the modulation of the redox properties of this cholesterol oxidase to increase its oxidative power.	Univ Insubria, Dept Struct & Funct Biol, I-21100 Varese, Italy; Univ Constance, Fac Biol, D-78434 Constance, Germany	University of Insubria; University of Konstanz	Pollegioni, L (corresponding author), Univ Insubria, Dept Struct & Funct Biol, Via JH Dunant 3, I-21100 Varese, Italy.	loredano.pollegioni@uninsubria.it		Molla, Gianluca/0000-0003-3688-3397; POLLEGIONI, LOREDANO/0000-0003-1733-7243				[Anonymous], [No title captured]; CAVENER DR, 1992, J MOL BIOL, V223, P811, DOI 10.1016/0022-2836(92)90992-S; Clark W.M., 1960, OXIDATION REDUCTION, P184; Croteau N, 1996, J STRUCT BIOL, V116, P317, DOI 10.1006/jsbi.1996.0047; EDMONDSON DE, 1973, J BIOL CHEM, V248, P8144; Fraaije MW, 1999, J BIOL CHEM, V274, P35514, DOI 10.1074/jbc.274.50.35514; Fraaije MW, 1998, TRENDS BIOCHEM SCI, V23, P206, DOI 10.1016/S0968-0004(98)01210-9; Gadda G, 1997, EUR J BIOCHEM, V250, P369, DOI 10.1111/j.1432-1033.1997.0369a.x; GHISLA S, 1986, BIOCHEM J, V239, P1; GIBSON QH, 1964, J BIOL CHEM, V239, P3927; KASS IJ, 1995, BIOCHEM BIOPH RES CO, V206, P688, DOI 10.1006/bbrc.1995.1097; MacLachlan J, 2000, J STEROID BIOCHEM, V72, P169, DOI 10.1016/S0960-0760(00)00044-3; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MASSEY V, 1991, FLAVINS AND FLAVOPROTEINS 1990, P59; MASSEY V, 1964, FED PROC, V3, P18; Mewies M, 1998, PROTEIN SCI, V7, P7, DOI 10.1002/pro.5560070102; MINNAERT K, 1965, BIOCHIM BIOPHYS ACTA, V110, P42, DOI 10.1016/S0926-6593(65)80093-5; MULLER F, 1991, CHEM BIOCH FLAVOENZY, V1, P261; Mullis K B, 1991, PCR Methods Appl, V1, P1; Pollegioni L, 1999, BIOTECHNOL APPL BIOC, V30, P27; Pollegioni L, 1999, EUR J BIOCHEM, V264, P140, DOI 10.1046/j.1432-1327.1999.00586.x; Sampson NS, 1998, BIOCHEMISTRY-US, V37, P5770, DOI 10.1021/bi973067g; STINSON RA, 1973, BIOCHEM J, V131, P719, DOI 10.1042/bj1310719; VRIELINK A, 1991, J MOL BIOL, V219, P533, DOI 10.1016/0022-2836(91)90192-9; WIERENGA RK, 1983, J MOL BIOL, V167, P725, DOI 10.1016/S0022-2836(83)80106-5; WILLIAMSON G, 1985, BIOCHEMISTRY-US, V24, P7790, DOI 10.1021/bi00347a043; Yue QK, 1999, BIOCHEMISTRY-US, V38, P4277, DOI 10.1021/bi982497j	27	59	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18024	18030		10.1074/jbc.M010953200	http://dx.doi.org/10.1074/jbc.M010953200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11359791	Green Published, hybrid			2022-12-25	WOS:000168866500055
J	Schipke, CG; Ohlemeyer, C; Matyash, M; Nolte, C; Kettenmann, H; Kirchhoff, F				Schipke, CG; Ohlemeyer, C; Matyash, M; Nolte, C; Kettenmann, H; Kirchhoff, F			Astrocytes of the mouse neocortex express functional N-methyl-D-aspartate receptors	FASEB JOURNAL			English	Article									Max Planck Inst Expt Med, D-37075 Gottingen, Germany; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Max Planck Society; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Kirchhoff, F (corresponding author), Max Planck Inst Expt Med, Hermann Rein Str 3, D-37075 Gottingen, Germany.		Kirchhoff, Frank/B-9335-2008; Kettenmann, Helmut/AAJ-5142-2021	Kirchhoff, Frank/0000-0002-2324-2761; Kettenmann, Helmut/0000-0001-8208-0291; Nolte, Christiane/0000-0001-5398-3440					0	151	157	2	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1270	1272		10.1096/fj.00-0439fje	http://dx.doi.org/10.1096/fj.00-0439fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344110				2022-12-25	WOS:000168655200032
J	Hamilton, M; Liao, JH; Cathcart, MK; Wolfman, A				Hamilton, M; Liao, JH; Cathcart, MK; Wolfman, A			Constitutive association of c-N-Ras with c-Raf-1 and protein kinase C epsilon in latent signaling modules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; GROWTH-FACTORS; RAF-1 KINASE; HA-RAS; ACTIVATION; INHIBITION; PATHWAY; SERINE; PHOSPHORYLATION; CELLS	Phorbol ester stimulation of the MAPK cascade is believed to be mediated through the protein kinase C (PKC)dependent activation of Raf-1. Although several studies suggest that phorbol ester stimulation of MAPK is insensitive to dominant-negative Ras, a requirement for Ras in Raf-1 activation by PKC has been suggested recently. We now demonstrate that in normal, quiescent mouse fibroblasts, endogenous c-N-Ras is constitutively associated with both c-Raf-1 and PKC epsilon in a biochemically silent, but latent, signaling module. Chemical inhibition of novel PKCs blocks phorbol 12-myristate 13-acetate (PMA)-mediated activation of MAPKs. Down-regulation of PKC epsilon protein levels by antisense oligodeoxyribonucleotides blocks MAPK activation in response to PMA stimulation, demonstrating that PKC epsilon activity is required for MAPK activation by PMA. c-Raf-1 activity in immunoprecipitated c-N-Ras.c-Raf-1.PKC epsilon complexes is stimulated by PMA and is inhibited by GF109203X, thereby linking c-Raf-1 activation in this complex to PKC activation. These observations suggest that in quiescent cells Ras is organized into ordered, inactive signaling modules. Furthermore, the regulation of the MAPK cascade by both Ras and PKC is intimately linked, converging at the plasma membrane through their association with c-Raf-1.	Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Wolfman, A (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, 9500 Euclid Ave,NC10, Cleveland, OH 44195 USA.	hamilton-mark@lilly.com; wolfmaa@ccf.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062644] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62644] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barnard D, 1998, ONCOGENE, V17, P1539, DOI 10.1038/sj.onc.1202061; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; BISSONNETTE M, 1994, AM J PHYSIOL, V267, pG465, DOI 10.1152/ajpgi.1994.267.3.G465; Cacace AM, 1996, ONCOGENE, V13, P2517; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; Fucini RV, 1999, J BIOL CHEM, V274, P18651, DOI 10.1074/jbc.274.26.18651; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Hamilton M, 1998, ONCOGENE, V16, P1417, DOI 10.1038/sj.onc.1201653; Hamilton M, 1998, J BIOL CHEM, V273, P28155, DOI 10.1074/jbc.273.43.28155; Hausken ZE, 1996, BIOCHEM SOC T, V24, P986, DOI 10.1042/bst0240986; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAPPALAINEN K, 1994, BBA-BIOMEMBRANES, V1196, P201, DOI 10.1016/0005-2736(94)00224-X; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Mineo C, 1997, J BIOL CHEM, V272, P10345; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Perletti GP, 1998, ONCOGENE, V16, P3345, DOI 10.1038/sj.onc.1201871; RAPP UR, 1991, ONCOGENE, V6, P495; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Tamada M, 1997, ONCOGENE, V15, P2959, DOI 10.1038/sj.onc.1201582; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; Therrien M, 1998, CELL, V95, P343, DOI 10.1016/S0092-8674(00)81766-3; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Ueffing M, 1997, ONCOGENE, V15, P2921, DOI 10.1038/sj.onc.1201477; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wielbo D, 1997, BIOCHEM BIOPH RES CO, V232, P794, DOI 10.1006/bbrc.1997.6329; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	54	69	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29079	29090		10.1074/jbc.M102001200	http://dx.doi.org/10.1074/jbc.M102001200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11358964	hybrid			2022-12-25	WOS:000170346000061
J	Baird, CL; Gordon, MS; Andrenyak, DM; Marecek, JF; Lindsley, JE				Baird, CL; Gordon, MS; Andrenyak, DM; Marecek, JF; Lindsley, JE			The ATPase reaction cycle of yeast DNA topoisomerase II - Slow rates of ATP resynthesis and P-i release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEADY-STATE ANALYSIS; N-TERMINAL FRAGMENT; GYRASE-B PROTEIN; INORGANIC-PHOSPHATE; DOUBLE HELIX; TRANSPORT; HYDROLYSIS; MECHANISM; CATALYSIS; ETOPOSIDE	DNA topoisomerase II catalyzes the transport of one DNA duplex through a transient break in a second duplex using a complex ATP hydrolysis mechanism. Two key rates in the ATPase mechanism, ATP resynthesis and phosphate release, were investigated using O-18 exchange and stopped-flow phosphate release experiments, respectively. The O-18 exchange results showed that the rate of ATP resynthesis on the topoisomerase II active site was slow compared with the rate of phosphate release. When topoisomerase II was bound to DNA, phosphate was released slowly, with a lag. Since each of the preceding steps is known to occur rapidly, phosphate release is apparently a rate-determining step. The length of the lag phase was unaffected by etoposide, indicating that inhibiting DNA religation inhibits the ATPase reaction cycle at some step following phosphate release. By combining the O-18 exchange and phosphate release results, the rate constant for ATP resynthesis can be calculated as similar to0.5 s(-1). These data support the mechanism of sequential hydrolysis of two ATP by DNA topoisomerase II.	Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA; Univ Utah, Sch Med, Ctr Human Toxicol, Salt Lake City, UT 84132 USA; SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Lindsley, JE (corresponding author), Univ Utah, Sch Med, Dept Biochem, 50 N Med Dr, Salt Lake City, UT 84132 USA.		Baird, Cheryl L/F-6569-2011; Baird, Cheryl/AGM-0065-2022		NIGMS NIH HHS [GM51194, 5T32GM08753] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051194, T32GM008753] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; ALI JA, 1995, BIOCHEMISTRY-US, V34, P9801, DOI 10.1021/bi00030a018; Baird CL, 1999, P NATL ACAD SCI USA, V96, P13685, DOI 10.1073/pnas.96.24.13685; Berger JM, 1998, CURR OPIN STRUC BIOL, V8, P26, DOI 10.1016/S0959-440X(98)80006-7; Brune M, 1998, BIOCHEMISTRY-US, V37, P10370, DOI 10.1021/bi9804277; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; Fass D, 1999, NAT STRUCT BIOL, V6, P322; Fortune JM, 2000, PROG NUCLEIC ACID RE, V64, P221, DOI 10.1016/S0079-6603(00)64006-0; Gutfreund H, 1995, KINETICS LIFE SCI; Hackney D D, 1980, Methods Enzymol, V64, P60; HACKNEY DD, 1980, J BIOL CHEM, V255, P5320; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7299, DOI 10.1021/bi9729108; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7292, DOI 10.1021/bi9729099; HUTTON RL, 1979, J BIOL CHEM, V254, P9990; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEVY HM, 1959, J BIOL CHEM, V234, P1102; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; Maxwell A, 1999, BIOCHEM SOC T, V27, P48, DOI 10.1042/bst0270048; Morris SK, 1999, J BIOL CHEM, V274, P30690, DOI 10.1074/jbc.274.43.30690; Olland S, 1999, J BIOL CHEM, V274, P21688, DOI 10.1074/jbc.274.31.21688; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; SHUKLA KK, 1980, J BIOL CHEM, V255, P1344; SLEEP JA, 1978, J BIOL CHEM, V253, P5235; STEMPEL KE, 1986, METHOD ENZYMOL, V126, P618; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884	32	40	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27893	27898		10.1074/jbc.M102544200	http://dx.doi.org/10.1074/jbc.M102544200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11353771	hybrid			2022-12-25	WOS:000170093400021
J	Figueroa, C; Taylor, J; Vojtek, AB				Figueroa, C; Taylor, J; Vojtek, AB			Prenylated Rab acceptor protein is a receptor for prenylated small GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLYL-CYCLASE; PLASMA-MEMBRANE; TRANSFORMATION; IDENTIFICATION; LOCALIZATION; TRAFFICKING; ASSOCIATION; PATHWAY; CLONING; KINASE	Localization of Ras and Ras-like proteins to the correct subcellular compartment is essential for these proteins to mediate their biological effects. Many members of the Ras superfamily (Ha-Ras, N-Ras, TC21, and RhoA) are prenylated in the cytoplasm and then transit through the endomembrane system on their way to the plasma membrane. The proteins that aid in the trafficking of the small GTPases have not been well characterized. We report here that prenylated Rab acceptor protein (PRA1), which others previously identified as a prenylation-dependent receptor for Rab proteins, also interacts with Ha-Ras, RhoA, TC21, and Rap1a. The interaction of these small GTPases with PRA1 requires their post-translational modification by prenylation. The prenylation-dependent association of PRA1 with multiple GTPases is conserved in evolution; the yeast PRA1 protein associates with both Ha-Ras and RhoA. Earlier studies reported the presence of PRA1 in the Golgi, and we show here that PRA1 co-localizes with Ha-Ras and RhoA in the Golgi compartment. We suggest that PRA1 acts as an escort protein for small GTPases by binding to the hydrophobic isoprenoid moieties of the small GTPases and facilitates their trafficking through the endomembrane system.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Vojtek, AB (corresponding author), Univ Michigan, Dept Biol Chem, 3323 MSRB 3,Box 0606, Ann Arbor, MI 48109 USA.							ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Allal C, 2000, J BIOL CHEM, V275, P31001, DOI 10.1074/jbc.M005264200; Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Bartels DJ, 1999, MOL CELL BIOL, V19, P6775, DOI 10.1128/mcb.19.10.6775; BHATTACHARYA S, 1995, P NATL ACAD SCI USA, V92, P2984, DOI 10.1073/pnas.92.7.2984; Booden MA, 1999, J BIOL CHEM, V274, P1423, DOI 10.1074/jbc.274.3.1423; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Bucci C, 1999, BIOCHEM BIOPH RES CO, V258, P657, DOI 10.1006/bbrc.1999.0651; Chantry D, 1997, J BIOL CHEM, V272, P19236, DOI 10.1074/jbc.272.31.19236; Chen Z, 2000, J BIOL CHEM, V275, P41251, DOI 10.1074/jbc.M006687200; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Collins SP, 2000, BIOCHEM J, V345, P673, DOI 10.1042/0264-6021:3450673; Fenster SD, 2000, NEURON, V25, P203, DOI 10.1016/S0896-6273(00)80883-1; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; Gelb MH, 1997, SCIENCE, V275, P1750, DOI 10.1126/science.275.5307.1750; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; Graham SM, 1996, MOL CELL BIOL, V16, P6132; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1995, METHOD ENZYMOL, V255, P60; Hutt DM, 2000, J BIOL CHEM, V275, P18511, DOI 10.1074/jbc.M909309199; JANOUEIXLEROSEY I, 1995, J BIOL CHEM, V270, P14801, DOI 10.1074/jbc.270.24.14801; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; Magee T, 1999, CELL, V98, P9, DOI 10.1016/S0092-8674(00)80601-7; Martincic I, 1997, J BIOL CHEM, V272, P26991, DOI 10.1074/jbc.272.43.26991; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; VOJTEK AB, 1993, J CELL SCI, V105, P777; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	33	81	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28219	28225		10.1074/jbc.M101763200	http://dx.doi.org/10.1074/jbc.M101763200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11335720	hybrid			2022-12-25	WOS:000170093400065
J	Groves, MR; Mant, A; Kuhn, A; Koch, J; Dubel, S; Robinson, C; Sinning, I				Groves, MR; Mant, A; Kuhn, A; Koch, J; Dubel, S; Robinson, C; Sinning, I			Functional characterization of recombinant chloroplast signal recognition particle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYLAKOID MEMBRANE-PROTEIN; METHIONINE-RICH DOMAIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; CONSERVED GTPASE; 54-KDA SUBUNIT; SPOT-SYNTHESIS; BINDING-SITE; SEQUENCE; RECEPTOR	The signal recognition particle (SRP) is a ubiquitous system for the targeting of membrane and secreted proteins. The chloroplast SRP (cpSRP) is unique among SRPs in that it possesses no RNA and is functional in post-translational as well as co-translational targeting. We have expressed and purified the two components of the Arabidopsis thaliana chloroplast signal recognition particle (cpSRP) involved in post-translational transport: cpSRP54 and the chloroplast-specific protein, cpSRP43. Recombinant cpSRP supports the efficient arc vitro insertion of pea preLhcb1 into isolated thylakoid membranes. Recombinant cpSRP is a stable heterodimer with a molecular mass of similar to 100 kDa as determined by analytical ultracentrifugation, gel filtration analysis, and dynamic light scattering. The interactions of the components of the recombinant heterodimer and pea preLhcb1 were probed using an immobilized peptide library (pepscan) approach. These data confirm two previously reported interactions with the L18 region and the third transmembrane helix of Lhcb1 and suggest that the interface of the cpSRP43 and epSRP54 proteins is involved in substrate binding. Additionally, cpSRP components are shown to recognize peptides from the cleavable, N-terminal chloroplast transit peptide of preLhcb1. The interaction of cpSRP43 with epSRP54 was probed in a similar experiment with a peptide library representing cpSPR54. The C terminus of cpSRP54 is essential for the formation of the stable cpSRP complex and cpSPR43 interacts with distinct regions of the M domain of cpSRP54.	European Mol Biol Lab, Struct Biol Programme, D-69117 Heidelberg, Germany; Univ Heidelberg, Zentrum Biochem, D-69120 Heidelberg, Germany; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; Univ Heidelberg, Inst Mol Genet, D-69120 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL); Ruprecht Karls University Heidelberg; University of Warwick; Ruprecht Karls University Heidelberg	Sinning, I (corresponding author), European Mol Biol Lab, Struct Biol Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Sinning, Irmgard/A-2982-2010	Dubel, Stefan/0000-0001-8811-7390; Groves, Matthew/0000-0001-9859-5177; Mant, Alexandra/0000-0001-7169-209X				Ball LJ, 1997, EMBO J, V16, P2473, DOI 10.1093/emboj/16.9.2473; Batey RT, 2000, SCIENCE, V287, P1232, DOI 10.1126/science.287.5456.1232; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Brix J, 2000, J MOL BIOL, V303, P479, DOI 10.1006/jmbi.2000.4120; BROCK IW, 1993, PLANT MOL BIOL, V23, P717, DOI 10.1007/BF00021527; CLARK SE, 1990, PLANT CELL, V2, P173, DOI 10.1105/tpc.2.2.173; Clemons WM, 1999, J MOL BIOL, V292, P697, DOI 10.1006/jmbi.1999.3090; Cowieson NP, 2000, CURR BIOL, V10, P517, DOI 10.1016/S0960-9822(00)00467-X; CREETH J. M., 1967, PROGR BIOPHYS MOL BIOL, V17, P217, DOI 10.1016/0079-6107(67)90008-9; Dalbey RE, 2000, ANNU REV CELL DEV BI, V16, P51, DOI 10.1146/annurev.cellbio.16.1.51; DeLille J, 2000, P NATL ACAD SCI USA, V97, P1926, DOI 10.1073/pnas.030395197; Fekkes P, 1999, MICROBIOL MOL BIOL R, V63, P161, DOI 10.1128/MMBR.63.1.161-173.1999; FerreDAmare AR, 1997, METHOD ENZYMOL, V276, P157, DOI 10.1016/S0076-6879(97)76056-7; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; FRANKLIN AE, 1993, J BIOL CHEM, V268, P22175; Freymann DM, 1997, NATURE, V385, P361, DOI 10.1038/385361a0; GROVES MR, 2001, IN PRESS IMMOBILIZED; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Heins L, 1998, TRENDS PLANT SCI, V3, P56, DOI 10.1016/S1360-1385(97)01161-8; High S, 1997, J BIOL CHEM, V272, P11622; HOFFMAN NE, 1994, PLANT PHYSIOL, V105, P295, DOI 10.1104/pp.105.1.295; Jagath JR, 1998, BIOCHEMISTRY-US, V37, P15408, DOI 10.1021/bi981523a; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; Keenan RJ, 1998, CELL, V94, P181, DOI 10.1016/S0092-8674(00)81418-X; Klimyuk VI, 1999, PLANT CELL, V11, P87, DOI 10.1105/tpc.11.1.87; Knoblauch NTM, 1999, J BIOL CHEM, V274, P34219, DOI 10.1074/jbc.274.48.34219; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; Lee HC, 2001, P NATL ACAD SCI USA, V98, P3471, DOI 10.1073/pnas.051484198; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; LUTCKE H, 1995, EUR J BIOCHEM, V228, P531, DOI 10.1111/j.1432-1033.1995.0531m.x; LUTCKE H, 1992, EMBO J, V11, P1543, DOI 10.1002/j.1460-2075.1992.tb05199.x; Montoya G, 2000, STRUCTURE, V8, P515, DOI 10.1016/S0969-2126(00)00131-3; Montoya G, 1997, NATURE, V385, P365, DOI 10.1038/385365a0; Moser C, 1997, P NATL ACAD SCI USA, V94, P11339, DOI 10.1073/pnas.94.21.11339; Nilsson R, 1999, EMBO J, V18, P733, DOI 10.1093/emboj/18.3.733; PAYAN LA, 1991, J CELL BIOL, V112, P603, DOI 10.1083/jcb.112.4.603; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Reineke U, 1999, CURR TOP MICROBIOL, V243, P23; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; Schuenemann D, 1999, BIOCHEM BIOPH RES CO, V254, P253, DOI 10.1006/bbrc.1998.9923; Schuenemann D, 1998, P NATL ACAD SCI USA, V95, P10312, DOI 10.1073/pnas.95.17.10312; Thompson SJ, 1999, J BIOL CHEM, V274, P4059, DOI 10.1074/jbc.274.7.4059; Tu CJ, 2000, J BIOL CHEM, V275, P13187, DOI 10.1074/jbc.C000108200; Tu CJ, 1999, J BIOL CHEM, V274, P27219, DOI 10.1074/jbc.274.38.27219; VANDERVERE PS, 1995, P NATL ACAD SCI USA, V92, P7177, DOI 10.1073/pnas.92.16.7177; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x	48	61	63	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27778	27786		10.1074/jbc.M103470200	http://dx.doi.org/10.1074/jbc.M103470200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11356852	hybrid, Green Published			2022-12-25	WOS:000170093400007
J	Moritz, OL; Tam, BM; Papermaster, DS; Nakayama, T				Moritz, OL; Tam, BM; Papermaster, DS; Nakayama, T			A functional rhodopsin-green fluorescent protein fusion protein localizes correctly in transgenic Xenopus laevis retinal rods and is expressed in a time-dependent pattern	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT RETINITIS-PIGMENTOSA; POSITION-EFFECT VARIEGATION; MATRIX-ATTACHMENT REGIONS; BOVINE RHODOPSIN; OUTER SEGMENT; DROSOPHILA-MELANOGASTER; CYTOPLASMIC TAIL; GENE; KINASE; HETEROCHROMATIN	To study rhodopsin biosynthesis and transport in vivo, we engineered a fusion protein (rho-GFP) of bovine rhodopsin (rho) and green fluorescent protein (GFP). rho-GFP expressed in COS-1 cells bound 11-cis retinal, generating a pigment with spectral properties of rhodopsin (A(max) at 500 nm) and GFP (A(max) at 488 nm). rho-GFP activated transducin at 50% of the wild-type activity, whereas phosphorylation of rho-GFP by rhodopsin kinase was 10% of wild-type levels. We expressed rho-GFP in the rod photoreceptors of Xenopus laevis using the X. laevis principal opsin promoter. Like rhodopsin, rho-GFP localized to rod outer segments, indicating that rho-GFP was recognized by membrane transport mechanisms. In contrast, a rho-GFP variant lacking the C-terminal outer segment localization signal distributed to both outer and inner segment membranes. Confocal microscopy of transgenic retinas revealed that transgene expression levels varied between cells, an effect that is probably analogous to position-effect variegation. Furthermore, rho-GFP concentrations varied along the length of individual rods, indicating that expression levels varied within single cells on a daily or hourly basis. These results have implications for transgenic models of retinal degeneration and mechanisms of position-effect variegation and demonstrate the utility of rho-GYP as a probe for rhodopsin transport and temporal regulation of promoter function.	Univ Connecticut, Ctr Hlth, Dept Neurosci, Farmington, CT 06032 USA; Vertex Pharmaceut Inc, Cambridge, MA 02139 USA	University of Connecticut; Vertex Pharmaceuticals	Moritz, OL (corresponding author), Univ Connecticut, Ctr Hlth, Dept Neurosci, Farmington, CT 06032 USA.			Moritz, Orson L/0000-0002-6183-6499	NEI NIH HHS [EY-06891, EY-12421] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012421] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adler R., 1986, RETINA MODEL CELL BI, P297; AUSUBEL FM, 1992, CURRENT PROTOCOLS MO, P2; Batni S, 1996, J BIOL CHEM, V271, P3179, DOI 10.1074/jbc.271.6.3179; BERSON EL, 1993, INVEST OPHTH VIS SCI, V34, P1659; BESHARSE JC, 1977, J CELL BIOL, V75, P507, DOI 10.1083/jcb.75.2.507; BHATTACHARYA S, 1992, J BIOL CHEM, V267, P6763; BORJIGIN J, 1994, J BIOL CHEM, V269, P14715; BROWN NG, 1992, EUR J BIOCHEM, V208, P659, DOI 10.1111/j.1432-1033.1992.tb17232.x; Chuang JZ, 1998, J CELL BIOL, V142, P1245, DOI 10.1083/jcb.142.5.1245; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Deretic D, 1998, P NATL ACAD SCI USA, V95, P10620, DOI 10.1073/pnas.95.18.10620; Deretic D, 1996, J BIOL CHEM, V271, P2279, DOI 10.1074/jbc.271.4.2279; DORER DR, 1994, CELL, V77, P993, DOI 10.1016/0092-8674(94)90439-1; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P588; Festenstein R, 1996, SCIENCE, V271, P1123, DOI 10.1126/science.271.5252.1123; Green ES, 2000, INVEST OPHTH VIS SCI, V41, P1546; Hafezi F, 2000, BRIT J OPHTHALMOL, V84, P922, DOI 10.1136/bjo.84.8.922; HAROSI FI, 1975, J GEN PHYSIOL, V66, P357, DOI 10.1085/jgp.66.3.357; KAPLAN MW, 1981, INVEST OPHTH VIS SCI, V21, P395; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; KAUFMAN RJ, 1987, MOL CELL BIOL, V7, P1568, DOI 10.1128/MCB.7.4.1568; KAUSHAL S, 1994, BIOCHEMISTRY-US, V33, P6121, DOI 10.1021/bi00186a011; KELLEHER DJ, 1990, J BIOL CHEM, V265, P2632; Knox BE, 1998, FEBS LETT, V423, P117, DOI 10.1016/S0014-5793(98)00018-0; Kroll KL, 1996, DEVELOPMENT, V122, P3173; LEIBMAN P, 1968, VISION RES, V8, P761; LEM J, 1991, NEURON, V6, P201, DOI 10.1016/0896-6273(91)90356-5; LI TS, 1995, P NATL ACAD SCI USA, V92, P3551, DOI 10.1073/pnas.92.8.3551; MCKNIGHT RA, 1992, P NATL ACAD SCI USA, V89, P6943, DOI 10.1073/pnas.89.15.6943; Milot E, 1996, CELL, V87, P105, DOI 10.1016/S0092-8674(00)81327-6; Moritz OL, 1999, INVEST OPHTH VIS SCI, V40, P3276; Muller HJ, 1930, J GENET, V22, P299, DOI 10.1007/BF02984195; NAKAYAMA TA, 1991, J BIOL CHEM, V266, P4269; Namciu SJ, 1998, MOL CELL BIOL, V18, P2382, DOI 10.1128/MCB.18.4.2382; OHGURO H, 1994, BIOCHEMISTRY-US, V33, P1023, DOI 10.1021/bi00170a022; OLSSON JE, 1992, NEURON, V9, P815, DOI 10.1016/0896-6273(92)90236-7; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; Palczewski K, 1997, CURR OPIN NEUROBIOL, V7, P500, DOI 10.1016/S0959-4388(97)80029-3; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1988, BIOCHEMISTRY-US, V27, P2306, DOI 10.1021/bi00407a010; PAPERMASTER DS, 1985, INVEST OPHTH VIS SCI, V26, P1386; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; Piston DW, 1999, METHOD CELL BIOL, V58, P31; SHI W, 1995, J BIOL CHEM, V270, P2112, DOI 10.1074/jbc.270.5.2112; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; SUNG CH, 1993, J BIOL CHEM, V268, P26645; SUNG CH, 1994, J NEUROSCI, V14, P5818; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Talbert PB, 2000, GENETICS, V154, P259; Tam BM, 2000, J CELL BIOL, V151, P1369, DOI 10.1083/jcb.151.7.1369; TOWNESANDERSON E, 1985, J CELL BIOL, V100, P175, DOI 10.1083/jcb.100.1.175; WEISS ER, 1995, BIOCHEM BIOPH RES CO, V216, P755, DOI 10.1006/bbrc.1995.2686; Yeagle P L, 1996, Mol Vis, V2, P12; Yeagle PL, 1997, BIOCHEMISTRY-US, V36, P9649, DOI 10.1021/bi970908a; ZACK DJ, 1991, NEURON, V6, P187, DOI 10.1016/0896-6273(91)90355-4	55	74	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28242	28251		10.1074/jbc.M101476200	http://dx.doi.org/10.1074/jbc.M101476200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11350960	hybrid			2022-12-25	WOS:000170093400068
J	Snyder, PM; Olson, DR; McDonald, FJ; Bucher, DB				Snyder, PM; Olson, DR; McDonald, FJ; Bucher, DB			Multiple WW domains, but not the C2 domain, are required for inhibition of the epithelial Na+ channel by human Nedd4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIDDLES-SYNDROME; SODIUM-CHANNELS; PY MOTIF; EXPRESSION; SUBUNITS; CLONING	The epithelial Na+ channel (ENaC) absorbs Na+ across the apical membrane of epithelia. The activity of ENaC is controlled by its interaction with Nedd4; mutations that disrupt this interaction increase Na+ absorption, causing an inherited form of hypertension (Liddle's syndrome). Nedd4 contains an N-terminal C2 domain, a C-terminal ubiquitin ligase domain, and multiple WW domains. The C2 domain is thought to be involved in the Ca2+-dependent localization of Nedd4 at the cell surface. However, we found that the C2 domain was not required for human Nedd4 (hNedd4) to inhibit ENaC in both Xenopus oocytes and Fischer rat thyroid epithelia. Rather, hNedd4 lacking the C2 domain inhibited ENaC more potently than wild-type hNedd4. Earlier work indicated that the WW domains bind to PY motifs in the C terminus of ENaC. However, it is not known which WW domains mediate this interaction. Glutathione S-transferase-fusion proteins of WW domains 2-4 each bound to alpha, beta, and gamma ENaC in vitro. The interactions were abolished by mutation of two residues. WW domain 3 (but not the other WW domains) was both necessary and sufficient for the binding of hNedd4 to alpha ENaC. WW domain 3 was also required for the inhibition of ENaC by hNedd4; inhibition was nearly abolished when WW domain 3 was mutated. However, the interaction between ENaC and WW domain 3 alone was not sufficient for inhibition. Moreover, inhibition was decreased by mutation of WW domain 2 or WW domain 4. Thus, WW domains 2-4 each participate in the functional interaction between hNedd4 and ENaC in intact cells.	Univ Iowa, Coll Med, Dept Internal Med, EMRB 371, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Otago, Dept Physiol, Dunedin, New Zealand	University of Iowa; University of Iowa; University of Otago	Snyder, PM (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, EMRB 371, Iowa City, IA 52242 USA.	psnyder@blue.weeg.uiowa.edu			NHLBI NIH HHS [HL-58812, HL-03575] Funding Source: Medline; NIDDK NIH HHS [DK-52617] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058812, R29HL058812] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK052617] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; BENOS DJ, 1995, J MEMBRANE BIOL, V143, P1; Espanel X, 1999, J BIOL CHEM, V274, P17284, DOI 10.1074/jbc.274.24.17284; Farr TJ, 2000, BIOCHEM J, V345, P503, DOI 10.1042/0264-6021:3450503; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; Kumar S, 1997, GENOMICS, V40, P435, DOI 10.1006/geno.1996.4582; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Plant PJ, 2000, J CELL BIOL, V149, P1473, DOI 10.1083/jcb.149.7.1473; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; SHEPPARD DN, 1994, AM J PHYSIOL, V266, pL405, DOI 10.1152/ajplung.1994.266.4.L405; Snyder PM, 2000, J CLIN INVEST, V105, P45, DOI 10.1172/JCI7869; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325	21	74	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28321	28326		10.1074/jbc.M011487200	http://dx.doi.org/10.1074/jbc.M011487200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11359767	hybrid			2022-12-25	WOS:000170093400078
J	Gong, PF; Hu, B; Stewart, D; Ellerbe, M; Figueroa, YG; Blank, V; Beckman, BS; Alam, J				Gong, PF; Hu, B; Stewart, D; Ellerbe, M; Figueroa, YG; Blank, V; Beckman, BS; Alam, J			Cobalt induces heme oxygenase-1 expression by a hypoxia-inducible factor-independent mechanism in Chinese hamster ovary cells - Regulation by Nrf2 and MafG transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT RESPONSE ELEMENT; GENE-EXPRESSION; OXIDATIVE STRESS; CARBON-MONOXIDE; MESSENGER-RNA; DEPENDENT TRANSCRIPTION; NF-E2-RELATED FACTOR-2; ERYTHROPOIETIN GENE; HEAVY-METALS; SUBUNIT GENE	We have shown previously that activation of the heme oxygenase-1 (ho-1) gene by hypoxia in aortic smooth muscle cells is mediated by hypoxia-inducible factor-1 (HIF-1). In mutant (Ka13) Chinese hamster ovary cells lacking RIF activity, accumulation of ho-1 mRNA in response to hypoxia and the hypoxia-mimetic CoCl2 was similar to that observed in wild type (K1) cells. These results support the existence of HIF-dependent and HIF-independent mechanisms for ho-1 gene activation by hypoxia and CoCl2. In Ka13 cells, CoCl2 stimulated expression of a luciferase reporter gene under the control of a 15-kilobase pair mouse ho-1 promoter (pHO15luc). Mutation analyses identified the cobalt-responsive sequences as the stress-response elements (StREs). In electrophoretic mobility shift, assays, two specific StRE-protein complexes were observed using extracts from Ka13 cells. In response to cobalt, the level of the slower migrating complex X increased, whereas that of complex Y decreased, in a time-dependent manner. Members of the AP-1 superfamily of basic-leucine zipper factors bind to the StRE. Antibody supershift electrophoretic mobility shift assays did not detect Jun, Fos, or ATF/CREB proteins but identified Nrf2 and the small Maf protein, MafG, as components of complex X. Furthermore, dominant-negative mutants of Nrf2 and small Maf, but not of other bZIP factors, attenuated cobalt-mediated gene activation. Additional experiments demonstrated that induction by cobalt does not result from increased expression of MafG or regulated nuclear translocation of Nrf2 but is dependent on cellular oxidative stress. Unlike cobalt, hypoxia did not stimulate pHO15luc expression and did not increase StRE binding activity, indicating distinct mechanisms for ho-1 gene activation by cobalt and hypoxia in Chinese hamster ovary cells.	Alton Ochsner Med Fdn, Dept Mol Genet, New Orleans, LA 70121 USA; Tulane Univ, Sch Med, Dept Pharmacol, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; McGill Univ, Dept Med, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada	Ochsner Health System; Tulane University; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Lady Davis Institute; McGill University	Alam, J (corresponding author), Alton Ochsner Med Fdn, Dept Mol Genet, 1516 Jefferson Hwy, New Orleans, LA 70121 USA.		Alam, Jawed/F-2596-2010	Alam, Jawed/0000-0001-6520-482X	NIDDK NIH HHS [DK-43135] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043135] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM NG, 1991, J CELL BIOCHEM, V47, P43, DOI 10.1002/jcb.240470106; Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Alam J, 2000, J BIOL CHEM, V275, P27694; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; ALAM J, 1995, J BIOL CHEM, V270, P11977, DOI 10.1074/jbc.270.20.11977; ALAM J, 1989, J BIOL CHEM, V264, P6371; ALAM J, 2000, CURRENT PROTOCOLS TO, V1; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; Blank V, 1997, BLOOD, V89, P3925, DOI 10.1182/blood.V89.11.3925; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crawford DR, 1996, FREE RADICAL BIO MED, V21, P521, DOI 10.1016/0891-5849(96)00160-8; CzyzykKrzeska MF, 1997, KIDNEY INT, V51, P585, DOI 10.1038/ki.1997.84; DHAKSHINAMOORTH, 2000, CURR TOP CELL REGUL, V36, P201; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; Durante W, 1998, INT J MOL MED, V2, P255; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; GOLDBERG MA, 1991, SEMIN HEMATOL, V28, P35; Gong PF, 2000, IND HEALTH, V38, P224, DOI 10.2486/indhealth.38.224; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Hayes JD, 2000, BIOCHEM SOC T, V28, P33, DOI 10.1042/bst0280033; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Huang LE, 1997, KIDNEY INT, V51, P548, DOI 10.1038/ki.1997.76; Inamdar NM, 1996, BIOCHEM BIOPH RES CO, V221, P570, DOI 10.1006/bbrc.1996.0637; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1999, FREE RADICAL RES, V31, P319, DOI 10.1080/10715769900300881; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; ITOH K, 1998, GENE DEV, V13, P67; KATAYOSE D, 1993, BIOCHEM BIOPH RES CO, V191, P587, DOI 10.1006/bbrc.1993.1258; Kim YC, 2001, J BIOL CHEM, V276, P18399, DOI 10.1074/jbc.M100103200; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; KRYLOV D, 1995, EMBO J, V14, P5329, DOI 10.1002/j.1460-2075.1995.tb00217.x; Lee JM, 2001, BIOCHEM BIOPH RES CO, V280, P286, DOI 10.1006/bbrc.2000.4106; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LIN JHC, 1990, EUR J BIOCHEM, V192, P577, DOI 10.1111/j.1432-1033.1990.tb19263.x; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Murata M, 1999, J CELL PHYSIOL, V180, P105, DOI 10.1002/(SICI)1097-4652(199907)180:1<105::AID-JCP12>3.0.CO;2-5; MURPHY BJ, 1991, BRIT J CANCER, V64, P69, DOI 10.1038/bjc.1991.241; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; Panchenko MV, 2000, AM J PHYSIOL-CELL PH, V278, pC92, DOI 10.1152/ajpcell.2000.278.1.C92; Pioli C, 1999, EUR J IMMUNOL, V29, P856, DOI 10.1002/(SICI)1521-4141(199903)29:03<856::AID-IMMU856>3.0.CO;2-P; PRESTERA T, 1995, MOL MED, V1, P827, DOI 10.1007/BF03401897; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; RONDON IJ, 1991, J BIOL CHEM, V266, P16594; Semenza GL, 1997, KIDNEY INT, V51, P553, DOI 10.1038/ki.1997.77; Suzuki T, 2001, BIOCHEM BIOPH RES CO, V280, P4, DOI 10.1006/bbrc.2000.4064; Wenger RH, 2000, J EXP BIOL, V203, P1253; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Wild AC, 1998, BIOCHEM J, V332, P373, DOI 10.1042/bj3320373; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360	59	131	136	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27018	27025		10.1074/jbc.M103658200	http://dx.doi.org/10.1074/jbc.M103658200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356853	hybrid			2022-12-25	WOS:000169966900039
J	Kim, JH; Shin, DY; Han, MH; Choi, MU				Kim, JH; Shin, DY; Han, MH; Choi, MU			Mutational and kinetic evaluation of conserved His-123 in dual specificity protein-tyrosine phosphatase vaccinia H1-related phosphatase - Participation of Tyr-78 and Thr-73 residues in tuning the orientation of His-123	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE STRUCTURES; CRYSTAL-STRUCTURE; CATALYZED REACTION; VHR; INTERMEDIATE; DEPHOSPHORYLATION; VISUALIZATION; TUNGSTATE; DOMAIN; PTP1	Active-site cysteine strategically positioned in the P-loop of protein-tyrosine phosphatases has been suggested to be further stabilized by hydrogen bonding arrays radiating out from the P-loop to neighboring residues. In this work, we investigated the structural, role of histidine array in HC(X)(5)RS motif of the (v) under bar accinia (H) under bar1-(r) under bar elated protein phosphatase (VHR), using site-directed mutagenesis in conjunction with an extensive kinetic analysis. Conserved His-123 was mutated along with neighboring residues Tyr-78 and Thr-73. The increased pK(alpha) values of active-site Cys-124 found in Y78F and T73A mutants (6.51 and 6.75, respectively) were comparable to those of H123A and H123F mutants. Kinetic evaluation of Y78F and T73A mutants further implicates that the mutations perturb the relative position of Cys-124 within the P-loop. These results imply that Tyr-78 and Thr-73 make up an essential part of the Hi-123 array and structurally tune the Cys-124 position. Tyr-78 of VHR turns out to be the invariant Tyr reported in several protein-tyrosine phosphatases by a structure-based sequence alignment, Therefore, orientation of the imidazole ring of His-123 by the invariant Tyr-78 is crucial for maintaining the proper position of Cys-124 in the P-loop.	Seoul Natl Univ, Sch Chem & Mol Engn, Seoul 151747, South Korea; Seoul Natl Univ, Ctr Mol Catalysis, Seoul 151747, South Korea; Korea Res Inst Biosci & Biotechnol, Mol Funct Prot Res Unit, Taejon 305333, South Korea	Seoul National University (SNU); Seoul National University (SNU); Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Choi, MU (corresponding author), Seoul Natl Univ, Sch Chem & Mol Engn, Seoul 151747, South Korea.							BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BENDER ML, 1967, J CHEM EDUC, V44, P84, DOI 10.1021/ed044p84; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Chen L, 1996, BIOCHEMISTRY-US, V35, P9349, DOI 10.1021/bi960700+; CORMACK B, 1995, SHORT PROTOCOLS MOL; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; Evans B, 1996, BIOCHEMISTRY-US, V35, P13609, DOI 10.1021/bi9605651; Fauman EB, 1996, J BIOL CHEM, V271, P18780, DOI 10.1074/jbc.271.31.18780; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; Hengge AC, 1996, BIOCHEMISTRY-US, V35, P7084, DOI 10.1021/bi960255i; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; JOHNSON P, 1992, J BIOL CHEM, V267, P8035; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lohse DL, 1997, BIOCHEMISTRY-US, V36, P4568, DOI 10.1021/bi963094r; Pannifer ADB, 1998, J BIOL CHEM, V273, P10454, DOI 10.1074/jbc.273.17.10454; Peters GH, 1998, BIOCHEMISTRY-US, V37, P5383, DOI 10.1021/bi971187i; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Todd JL, 1999, J BIOL CHEM, V274, P13271, DOI 10.1074/jbc.274.19.13271; WALSH C, 1979, ENZYMATIC REACTIONS, P41; Yang J, 1998, J BIOL CHEM, V273, P28199, DOI 10.1074/jbc.273.43.28199; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; Zhang ZY, 1995, BIOCHEMISTRY-US, V34, P16088, DOI 10.1021/bi00049a024; Zhao Y, 1996, BIOCHEMISTRY-US, V35, P11797, DOI 10.1021/bi960471r; Zhao Y, 1998, J BIOL CHEM, V273, P5484, DOI 10.1074/jbc.273.10.5484; ZHOU GC, 1994, J BIOL CHEM, V269, P28084	34	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27568	27574		10.1074/jbc.M010526200	http://dx.doi.org/10.1074/jbc.M010526200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11346639	hybrid			2022-12-25	WOS:000169966900110
J	Nakagawa, T; Bulger, M; Muramatsu, M; Ito, T				Nakagawa, T; Bulger, M; Muramatsu, M; Ito, T			Multistep chromatin assembly on supercoiled plasmid DNA by nucleosome assembly protein-1 and ATP-utilizing chromatin assembly and remodeling factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLATION; MAMMALIAN-CELLS; CORE PARTICLE; TRANSCRIPTION; BINDING; ISWI; INVITRO; COMPLEX; PURIFICATION; DISRUPTION	We examine in vitro nucleosome assembly by nucleosome assembly protein-1 (NAP-1) and ATP-utilizing chromatin assembly and remodeling factor (ACF). In contrast to previous studies that used relaxed, circular plasmids as templates, we have found that negatively supercoiled templates reveal the distinct roles of NAP-1 and ACF in histone deposition and the formation of an ordered nucleosomal array. NAP-1 can efficiently deposit histones onto supercoiled plasmids. Furthermore, NAP-1 exhibits a greater affinity for histones H2A-H2B than does naked DNA, but in the presence of H3-H4, H2A-H2B are transferred from NAP-1 to the plasmid templates. These observations underscore the importance of a high affinity between H2A-H2B and NAP-1 for ordered transfer of core histones onto DNA. In addition, recombinant ACF composed of imitation snitch and Acf1 can extend closely packed nucleosomes, which suggests that recombinant ACF can mobilize nucleosomes. In the assembly reaction with a supercoiled template, ACF need not be added simultaneously with MAP-1. Regularly spaced nucleosomes are generated even when recombinant ACF is added after core histones are transferred completely onto the DNA. Atomic force microscopy, however; suggests that NAP-1 alone fails to accomplish the formation of fine nucleosomal core particles, which are only formed in the presence of ACF. These results suggest a model for the ordered deposition of histones and the arrangement of nucleosomes during chromatin assembly in vivo.	Saitama Med Sch, Div Gene Struct & Funct, Res Ctr Genom Med, Moroyama, Saitama 3500495, Japan; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Saitama Medical University; Fred Hutchinson Cancer Center	Ito, T (corresponding author), Saitama Med Sch, Div Gene Struct & Funct, Res Ctr Genom Med, Moroyama, Saitama 3500495, Japan.	tito@saitama-med.ac.jp						Adams CR, 1999, CURR OPIN GENET DEV, V9, P185, DOI 10.1016/S0959-437X(99)80028-8; ANNUNZIATO AT, 1995, BIOCHEMISTRY-US, V34, P2916, DOI 10.1021/bi00009a023; BULGER M, 1995, P NATL ACAD SCI USA, V92, P11726, DOI 10.1073/pnas.92.25.11726; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; Chang L, 1997, BIOCHEMISTRY-US, V36, P469, DOI 10.1021/bi962069i; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; ISHIMI Y, 1983, J BIOCHEM-TOKYO, V94, P735, DOI 10.1093/oxfordjournals.jbchem.a134414; ISHIMI Y, 1987, EUR J BIOCHEM, V162, P19, DOI 10.1111/j.1432-1033.1987.tb10535.x; Ito T, 2000, GENE DEV, V14, P1899; Ito T, 1997, GENES CELLS, V2, P593, DOI 10.1046/j.1365-2443.1997.1500348.x; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Ito T, 1996, MOL CELL BIOL, V16, P3112; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Ito T, 1996, J BIOL CHEM, V271, P25041, DOI 10.1074/jbc.271.40.25041; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kaufman PD, 1996, CURR OPIN CELL BIOL, V8, P369, DOI 10.1016/S0955-0674(96)80012-3; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; KELLOGG DR, 1995, J CELL BIOL, V130, P675, DOI 10.1083/jcb.130.3.675; KLEINSCHMIDT JA, 1990, EMBO J, V9, P1309, DOI 10.1002/j.1460-2075.1990.tb08240.x; Kornberg RD, 1999, CURR OPIN GENET DEV, V9, P148, DOI 10.1016/S0959-437X(99)80022-7; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LEUBA SH, 1994, P NATL ACAD SCI USA, V91, P11621, DOI 10.1073/pnas.91.24.11621; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; McQuibban GA, 1998, J BIOL CHEM, V273, P6582, DOI 10.1074/jbc.273.11.6582; PFAFFLE P, 1990, J BIOL CHEM, V265, P16821; Pollard KJ, 1998, BIOESSAYS, V20, P771, DOI 10.1002/(SICI)1521-1878(199809)20:9<771::AID-BIES10>3.0.CO;2-V; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147; van Holde K.E., 1988, CHROMATIN; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; Wolffe A., 1998, CHROMATIN STRUCTURE; WORCEL A, 1978, CELL, V15, P969, DOI 10.1016/0092-8674(78)90280-5; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171	45	64	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27384	27391		10.1074/jbc.M101331200	http://dx.doi.org/10.1074/jbc.M101331200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11333264	hybrid			2022-12-25	WOS:000169966900087
J	Qi, XY; Grabowski, GA				Qi, XY; Grabowski, GA			Differential membrane interactions of saposins A and C - Implications for the functional specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID BETA-GLUCOSIDASE; SPHINGOLIPID ACTIVATOR PROTEIN-2; ARYLSULFATASE-A ACTIVITY; GAUCHER DISEASE; NK-LYSIN; METACHROMATIC LEUKODYSTROPHY; DEFICIENCY; PATIENT; SAP-2; DEGRADATION	Saposins are small, heat-stable glycoprotein activators of lysosomal glycosphingolipid hydrolases that derive from a single precursor, prosaposin, by proteolytic cleavage. Three of these saposins (B, C, and D) share common structural features including a lack of tryptophan,a single glycosylation sequence, the presence of three conserved disulfide bonds, and a common multi-amphipathic helical bundle motif, SaposinA contains an additional glycosylation site and a single tryptophan, The oligosaccharides on saposins are not required for in vitro activation functions. Saposins A and C were produced in Escherichia coli to contain single tryptophans at various locations to serve as intrinsic fluorescence reporters, i.e. as topological probes, for interaction with phospholipid membranes. Maximum emission shifts, aqueous and solid quenching, and resonance energy transfer were quantified by fluorescence spectroscopy. Amphipathic helices at the amino- and carboxyl termini of saposins A and C were shown to insert into the lipid bilayer to about five carbon bond lengths. In comparison, the middle region of saposins A or C were either embedded in the bilayer or solvent-exposed, respectively. Conformational changes of saposin C induced by phosphatidylserine interaction suggested the reorientation of functional helical domains. Differential interaction models are proposed for the membrane-bound saposins A and C. By site-directed mutagenesis of saposin A and C, their membrane topological structures were correlated with their activation effects on acid beta -glucosidase. These findings show that proper orientation of the middle segment of saposin C tee the outside of the membrane surface is critical for its specific and multivalent interaction with acid beta -glucosidase. Such membrane interactions and orientations of the saposins determine the proximity of their activation and/or binding sites to lysosomal hydrolases or lipoid substrates.	Childrens Hosp Res Fdn, Div Human Genet, Cincinnati, OH 45229 USA; Dept Pediat, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Qi, XY (corresponding author), Div & Program Human Genet, 3333 Burnet Ave, Cincinnati, OH 45229 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036729, R01DK057690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034071] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36729, DK 57690] Funding Source: Medline; NINDS NIH HHS [NS 34071] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSSON M, 1995, EMBO J, V14, P1615; BERENT SL, 1981, BIOCHIM BIOPHYS ACTA, V664, P572, DOI 10.1016/0005-2760(81)90134-X; CHRISTOMANOU H, 1989, KLIN WOCHENSCHR, V67, P999, DOI 10.1007/BF01716064; CHRISTOMANOU H, 1986, BIOL CHEM H-S, V367, P879, DOI 10.1515/bchm3.1986.367.2.879; FUJIBAYASHI S, 1985, AM J HUM GENET, V37, P741; FUJIBAYASHI S, 1986, BIOCHIM BIOPHYS ACTA, V875, P554; FUJIBAYASHI S, 1986, J BIOL CHEM, V261, P5339; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; GRABOWSKI GA, 1990, CRIT REV BIOCHEM MOL, V25, P385, DOI 10.3109/10409239009090616; GREENBERG P, 1990, BIOCHIM BIOPHYS ACTA, V1039, P12, DOI 10.1016/0167-4838(90)90220-A; Harzer K, 1997, FEBS LETT, V417, P270, DOI 10.1016/S0014-5793(97)01302-1; HIRAIWA M, 1993, ARCH BIOCHEM BIOPHYS, V303, P326, DOI 10.1006/abbi.1993.1291; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Kervinen J, 1999, EMBO J, V18, P3947, DOI 10.1093/emboj/18.14.3947; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; KLEIN A, 1994, BIOCHEM BIOPH RES CO, V200, P1440, DOI 10.1006/bbrc.1994.1612; LAKOWICZ JR, 1999, PRINCIPLES FLUORESCE, P388; Liepinsh E, 1997, NAT STRUCT BIOL, V4, P793, DOI 10.1038/nsb1097-793; MORIMOTO S, 1988, BIOCHEM BIOPH RES CO, V156, P403, DOI 10.1016/S0006-291X(88)80855-6; MORIMOTO S, 1989, P NATL ACAD SCI USA, V86, P3389, DOI 10.1073/pnas.86.9.3389; MORIMOTO S, 1990, P NATL ACAD SCI USA, V87, P3493, DOI 10.1073/pnas.87.9.3493; MUNFORD RS, 1995, J LIPID RES, V36, P1653; NAKANO T, 1989, J BIOCHEM-TOKYO, V105, P152, DOI 10.1093/oxfordjournals.jbchem.a122629; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; Qi XY, 1999, BIOCHEMISTRY-US, V38, P6284, DOI 10.1021/bi990079o; Qi XY, 1998, BIOCHEMISTRY-US, V37, P11544, DOI 10.1021/bi980785+; QI XY, 1994, J BIOL CHEM, V269, P16746; Qi XY, 1996, J BIOL CHEM, V271, P6874, DOI 10.1074/jbc.271.12.6874; RAFI MA, 1993, SOMAT CELL MOLEC GEN, V19, P1, DOI 10.1007/BF01233949; Regis S, 1999, EUR J HUM GENET, V7, P125, DOI 10.1038/sj.ejhg.5200266; REINER O, 1989, J MOL NEUROSCI, V1, P225; RORMAN EG, 1989, GENOMICS, V5, P486, DOI 10.1016/0888-7543(89)90014-1; Ruysschaert JM, 1998, FEBS LETT, V425, P341, DOI 10.1016/S0014-5793(98)00261-0; SANO A, 1988, BIOCHEM BIOPH RES CO, V154, P1197, DOI 10.1016/0006-291X(88)90267-7; SCHLOTE W, 1991, EUR J PEDIATR, V150, P584, DOI 10.1007/BF02072213; SCHNABEL D, 1992, J BIOL CHEM, V267, P3312; SCHNABEL D, 1991, FEBS LETT, V284, P57, DOI 10.1016/0014-5793(91)80760-Z; SHECHTER E, 1971, BIOCHIM BIOPHYS ACTA, V241, P431, DOI 10.1016/0005-2736(71)90043-5; Vaccaro AM, 1995, J BIOL CHEM, V270, P30576, DOI 10.1074/jbc.270.51.30576; Vaccaro AM, 1997, J BIOL CHEM, V272, P16862, DOI 10.1074/jbc.272.27.16862; VACCARO AM, 1995, J BIOL CHEM, V270, P9953, DOI 10.1074/jbc.270.17.9953; VANDENBUSSCHE G, 1992, BIOCHEMISTRY-US, V31, P9169, DOI 10.1021/bi00153a008; WENGER DA, 1989, AM J MED GENET, V33, P255, DOI 10.1002/ajmg.1320330223; WHITSETT JA, 1995, PHYSIOL REV, V75, P749, DOI 10.1152/physrev.1995.75.4.749	44	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27010	27017		10.1074/jbc.M101075200	http://dx.doi.org/10.1074/jbc.M101075200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356836	hybrid			2022-12-25	WOS:000169966900038
J	Urban, G; Golden, T; Aragon, IV; Scammell, JG; Dean, NM; Honkanen, RE				Urban, G; Golden, T; Aragon, IV; Scammell, JG; Dean, NM; Honkanen, RE			Identification of an estrogen-inducible phosphatase (PP5) that converts MCF-7 human breast carcinoma cells into an estrogen-independent phenotype when expressed constitutively	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRATRICOPEPTIDE REPEAT DOMAIN; CYCLIN E-CDK2 ACTIVATION; C-MYC; CANCER-CELLS; PROTEIN-KINASE; SERINE/THREONINE PHOSPHATASE; ANTISENSE OLIGONUCLEOTIDES; ONCOGENE EXPRESSION; CATALYTIC SUBUNIT; MOLECULAR-CLONING	The proliferation of many estrogen receptor (ER)-positive breast cancer cells depends on estradiol, and tumors arising from these cells are often responsive initially to treatment with Selective ER modulators, which produce an antiestrogen effect. However, tumors that are refractory to the antiestrogenic effects of selective ER modulators often reemerge, and the prognosis for these patients is poor because of the lack of additional effective therapy, Accordingly, deciphering the cellular events associated with estrogen-dependent growth and the subsequent outgrowth of tumors with san estrogen-independent phenotype is of considerable interest. Here me show that the expression of PP5, an evolutionarily conserved Ser/Thr phosphatase that functions as an inhibitor of glucocorticoid- and p53-induced signaling cascades leading to growth suppression, is responsive to 17 beta -estradiol (E-2) in ER-positive human breast carcinoma cells (MCF-7). Northern analysis revealed that E-2-induced PP5 expression is blocked by treatment with tamoxifen, and a consensus ER recognition element was identified in the PP5 promoter, The PP5-ER recognition element associates with human ERs and confers E-2-induced transcriptional activation to reporter plasmids. The specific inhibition of PP5-expression ablates E-2-mediated proliferation in MCF-7 cells without having an apparent effect on E-2-induced expression of c-myc or cyclin DI. Thus, although critical for cell growth, PP5 likely acts either downstream or independently of c-Myc and Cyclin D1. To further characterize the role of PP5 in E-2-regulated growth control, we constructed stable MCF-7 cell lines in which the expression of PP5 was placed under the control of tetracycline-regulated transactivator and operator plasmids, Studies with these cells revealed that the constitutive overexpression of PP5 affords E-2-dependent MCF-7 cells with the ability to proliferate in E-2-depleted media. Together, these studies indicate that E-2-induced PP5 expression functions to enhance E-2-initiated signaling cascades leading to cell division and that aberrant PP5 expression may contribute to the development of MCF-7 cells with an estrogen-independent phenotype.	Univ S Alabama, Dept Biochem & Mol Biol, Mobile, AL 36688 USA; Univ S Alabama, Dept Pharmacol & Comparat Med, Mobile, AL 36688 USA; ISIS Pharmaceut, Carlsbad, CA 92008 USA	University of South Alabama; University of South Alabama; Isis Pharmaceuticals Inc	Honkanen, RE (corresponding author), Univ S Alabama, Dept Biochem, Mobile, AL 36688 USA.	honkanen@sungcg.usouthal.edu			NATIONAL CANCER INSTITUTE [R29CA060750, R01CA060750] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR013200] Funding Source: NIH RePORTER; NCI NIH HHS [CA60750] Funding Source: Medline; NCRR NIH HHS [RR13200] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Altucci L, 1996, ONCOGENE, V12, P2315; AMARA JF, 1983, ENDOCRINOLOGY, V112, P1141, DOI 10.1210/endo-112-3-1141; ARINO J, 1988, P NATL ACAD SCI USA, V85, P4252, DOI 10.1073/pnas.85.12.4252; BARKER HM, 1994, BBA-MOL CELL RES, V1220, P212, DOI 10.1016/0167-4889(94)90138-4; Bastians H, 1996, J CELL SCI, V109, P2865; BECKER W, 1994, J BIOL CHEM, V269, P22586; BINDAL RD, 1988, J MED CHEM, V31, P1978, DOI 10.1021/jm00118a020; Borthwick EB, 2001, FEBS LETT, V491, P279, DOI 10.1016/S0014-5793(01)02177-9; Chen MS, 1996, J BIOL CHEM, V271, P32315, DOI 10.1074/jbc.271.50.32315; CHINKERS M, 1994, P NATL ACAD SCI USA, V91, P11075, DOI 10.1073/pnas.91.23.11075; Dean NM, 1997, ANTISENSE NUCLEIC A, V7, P229, DOI 10.1089/oli.1.1997.7.229; DEAN NM, 1994, J BIOL CHEM, V269, P16416; Driscoll MD, 1998, J BIOL CHEM, V273, P29321, DOI 10.1074/jbc.273.45.29321; DUBIK D, 1987, CANCER RES, V47, P6517; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Foekens JA, 1999, BRIT J CANCER, V79, P300, DOI 10.1038/sj.bjc.6990048; FOEKENS JA, 1995, J NATL CANCER I, V87, P751, DOI 10.1093/jnci/87.10.751; FOEKENS JA, 1994, BRIT J CANCER, V70, P1217, DOI 10.1038/bjc.1994.476; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Huang XZ, 1997, GENOMICS, V44, P336, DOI 10.1006/geno.1997.4891; *INT AG RES CANC, 1992, PUBL WHO, V120; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KATZENELLENBOGE.BS, 1977, BREAST CANC RES TREA, V44, P23; LEUNG BS, 1987, J CELL BIOCHEM, V34, P213, DOI 10.1002/jcb.240340307; LIPPMAN M, 1976, CANCER RES, V36, P4595; Lukas J, 1996, MOL CELL BIOL, V16, P6917; MURPHY LJ, 1987, ENDOCRINOLOGY, V120, P1882, DOI 10.1210/endo-120-5-1882; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; NICHOLSON S, 1989, LANCET, V1, P182; Ollendorf V, 1997, J BIOL CHEM, V272, P32011, DOI 10.1074/jbc.272.51.32011; Osborne CK, 1996, SCI MED, V3, P32; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1998, J STEROID BIOCHEM, V65, P169, DOI 10.1016/S0960-0760(98)00021-1; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PTASHNE M, 1989, SCIENCE, V254, P371; RABIN DS, 1990, BIOL REPROD, V42, P74, DOI 10.1095/biolreprod42.1.74; RAVDIN PM, 1992, J CLIN ONCOL, V10, P1284, DOI 10.1200/JCO.1992.10.8.1284; SCAMMELL JG, 1986, ENDOCRINOLOGY, V119, P1543, DOI 10.1210/endo-119-4-1543; Scott JA, 1991, ENDOCRINE DEPENDENT, P179; SHERMAN CD, 1990, MANUAL CLIN ONCOLOGY, P253; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sinclair C, 1999, J BIOL CHEM, V274, P23666, DOI 10.1074/jbc.274.33.23666; Smith CL, 1998, BIOL REPROD, V58, P627, DOI 10.1095/biolreprod58.3.627; SONG Q, 1993, GENE, V129, P291, DOI 10.1016/0378-1119(93)90282-8; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; SUTHERLAND RL, 1983, EUR J CANCER CLIN ON, V19, P307, DOI 10.1016/0277-5379(83)90127-X; WATSON PH, 1991, CANCER RES, V51, P3996; Wilcken NRC, 1997, CLIN CANCER RES, V3, P849; Zhao SY, 1997, PHOTOCHEM PHOTOBIOL, V66, P727, DOI 10.1111/j.1751-1097.1997.tb03214.x; Zuo Z, 1999, BIOCHEMISTRY-US, V38, P8849, DOI 10.1021/bi990842e; Zuo Z, 1998, J BIOL CHEM, V273, P12250, DOI 10.1074/jbc.273.20.12250; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	57	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27638	27646		10.1074/jbc.M103512200	http://dx.doi.org/10.1074/jbc.M103512200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11331294	hybrid			2022-12-25	WOS:000169966900119
J	Marks, DL; Dominguez, M; Wu, KJ; Pagano, RE				Marks, DL; Dominguez, M; Wu, KJ; Pagano, RE			Identification of active site residues in glucosylceramide synthase - A nucleotide-binding/catalytic motif conserved with processive beta-glycosyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-BUTYLDEOXYNOJIRIMYCIN; CRYSTAL-STRUCTURE; GLYCOSPHINGOLIPID BIOSYNTHESIS; LYSOSOMAL STORAGE; SEQUENCE-ANALYSIS; HIGHER-PLANTS; DISEASE MICE; INHIBITOR; GLUCOSYLTRANSFERASE; TOPOLOGY	Glucosylceramide synthase (GCS) transfers glucose from UDP-Glc to ceramide, catalyzing the first glycosylation step in the formation of higher order glycosphingolipids, The amino acid sequence of GCS was reported to be dissimilar from other proteins, with no identifiable functional domains. We previously identified His-193 of rat GCS as an important residue in UDP-Glc and GCS inhibitor binding; however, little else is known about the GCS active site. Here, we identify key residues of the GCS active site by performing biochemical and site-directed mutagenesis studies of rat GCS expressed in bacteria. First, we found that Cys-207 was the primary residue involved in GCS N-ethylmaleimide sensitivity. Next, we showed by multiple alignment that the region of GCS flanking His-193 and Cys-SO? (amino acids 89-278) contains a D1,D2,D3,(Q/R)XXRW motif found in the putative active site of processive beta -glycosyltransferases (e,g, cellulose, chitin, and hyaluronan syntheses). Site-directed mutagenesis studies demonstrated that most of the highly conserved residues were essential for GCS activity. We also note that GCS and processive beta -glycosyltransferases are topologically similar, possessing cytosolic active sites, with putative transmembrane domains immediately N-terminal to the conserved domain. These results provide the first extensive information on the GCS active site and show that GCS and processive beta -glycosyltransferases possess a conserved substrate-binding/catalytic domain.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Thorac Dis Res Unit, Rochester, MN 55905 USA	Mayo Clinic	Pagano, RE (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Thorac Dis Res Unit, 200 1st St SW,Stabile 8, Rochester, MN 55905 USA.	Pagano.Richard@mayo.edu			NIGMS NIH HHS [GM22942] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022942, R01GM022942] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe A, 2000, J CLIN INVEST, V105, P1563, DOI 10.1172/JCI9711; ABE A, 1995, J LIPID RES, V36, P611; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andersson U, 2000, BIOCHEM PHARMACOL, V59, P821, DOI 10.1016/S0006-2952(99)00384-6; Barny MA, 1996, MOL MICROBIOL, V19, P443, DOI 10.1046/j.1365-2958.1996.382911.x; Blanton RL, 2000, P NATL ACAD SCI USA, V97, P2391, DOI 10.1073/pnas.040565697; Butters TD, 2000, CHEM REV, V100, P4683, DOI 10.1021/cr990292q; Campbell J A, 1998, BIOCHEM J, V329, P929; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; COSTE H, 1986, BIOCHIM BIOPHYS ACTA, V858, P6, DOI 10.1016/0005-2736(86)90285-3; Cox T, 2000, LANCET, V355, P1481, DOI 10.1016/S0140-6736(00)02161-9; Delmer DP, 1999, ANNU REV PLANT PHYS, V50, P245, DOI 10.1146/annurev.arplant.50.1.245; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Ha S, 2000, PROTEIN SCI, V9, P1045, DOI 10.1110/ps.9.6.1045; Hakamori S, 1998, ACTA ANAT, V161, P79; Hakomori S, 1998, GLYCOBIOLOGY, V8, pXI; Ichikawa S, 1998, TRENDS CELL BIOL, V8, P198, DOI 10.1016/S0962-8924(98)01249-5; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; IELPI L, 1990, J BIOL CHEM, V265, P2843; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; Jeyakumar M, 1999, P NATL ACAD SCI USA, V96, P6388, DOI 10.1073/pnas.96.11.6388; Kapitonov D, 1999, GLYCOBIOLOGY, V9, P961, DOI 10.1093/glycob/9.10.961; Keenleyside WJ, 1996, J BIOL CHEM, V271, P28581, DOI 10.1074/jbc.271.45.28581; Lavie Y, 1997, J BIOL CHEM, V272, P1682, DOI 10.1074/jbc.272.3.1682; Lee L, 1999, J BIOL CHEM, V274, P14662, DOI 10.1074/jbc.274.21.14662; Llull D, 1999, J EXP MED, V190, P241, DOI 10.1084/jem.190.2.241; Marks DL, 1999, J BIOL CHEM, V274, P451, DOI 10.1074/jbc.274.1.451; Marks DL, 2000, METHOD ENZYMOL, V311, P50; Maurer BJ, 2000, JNCI-J NATL CANCER I, V92, P1897, DOI 10.1093/jnci/92.23.1897; NAGAHASHI S, 1995, J BIOL CHEM, V270, P13961, DOI 10.1074/jbc.270.23.13961; Paul P, 1996, J BIOL CHEM, V271, P2287, DOI 10.1074/jbc.271.4.2287; Pear JR, 1996, P NATL ACAD SCI USA, V93, P12637, DOI 10.1073/pnas.93.22.12637; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Platt FM, 1997, SCIENCE, V276, P428, DOI 10.1126/science.276.5311.428; PLATT FM, 1994, J BIOL CHEM, V269, P8362; Radin NS, 1999, BIOCHEM PHARMACOL, V57, P589; RADIN NS, 1994, MOL CHEM NEUROPATHOL, V21, P111, DOI 10.1007/BF02815346; Saxena IM, 1997, CELLULOSE, V4, P33, DOI 10.1023/A:1018411101036; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Spicer AP, 1996, J BIOL CHEM, V271, P23400, DOI 10.1074/jbc.271.38.23400; Stasinopoulos SJ, 1999, GLYCOBIOLOGY, V9, P31, DOI 10.1093/glycob/9.1.31; Tifft CJ, 2000, GLYCOBIOLOGY, V10, P1249, DOI 10.1093/glycob/10.12.1249; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; VRIELINK A, 1994, EMBO J, V13, P3413, DOI 10.1002/j.1460-2075.1994.tb06646.x; Wang-Gillam A, 2000, J BIOL CHEM, V275, P1433, DOI 10.1074/jbc.275.2.1433; Wu KJ, 1999, BIOCHEM J, V341, P395, DOI 10.1042/0264-6021:3410395	49	39	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26492	26498		10.1074/jbc.M102612200	http://dx.doi.org/10.1074/jbc.M102612200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11337504	hybrid			2022-12-25	WOS:000169823300112
J	Moller, T; Contos, JJ; Musante, DB; Chun, J; Ransom, BR				Moller, T; Contos, JJ; Musante, DB; Chun, J; Ransom, BR			Expression and function of lysophosphatidic acid receptors in cultured rodent microglial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-BRAIN-BARRIER; G-PROTEIN; SPHINGOSINE 1-PHOSPHATE; CALCIUM MOBILIZATION; MOLECULAR-CLONING; MOUSE-BRAIN; PROLIFERATION; ASTROCYTES; IDENTIFICATION; CONDUCTANCE	Microglia are the resident tissue macrophages of the central nervous system. They are rapidly activated by a variety of insults; and recently, receptors linked to cytoplasmic Ca2+ signals have been implicated in such events. One potential class of receptors are those recognizing lysophosphatidic acid (LPA). LPA is a phospholipid signaling molecule that has been shown to cause multiple cellular responses, including increases in cytoplasmic calcium. We examined whether any of the known LPA receptor genes (lp(A1)/Edg2, lp(A2)/Edg4, and lp(A3)/Edg7) are expressed by cultured mouse or rat microglia. Reverse transcriptase-polymerase chain reaction indicated that mouse microglia predominantly expressed the Ip,, gene, whereas rat microglia predominantly expressed Ip,, Although LPA induced increases in the cytoplasmic Ca2+ concentration in both microglial preparations, the responses differed substantially. The Ca2+ signal in rat microglia occurred primarily through Ca2+ influx via the plasma membrane, whereas the Ca2+ signal in mouse microglia was due to release from intracellular stores. Only at high concentrations was an additional influx component recruited. Additionally, LPA induced increased metabolic activity in mouse (but not rat) microglial cells, Our findings provide evidence for functional LPA receptors on microglia, Thus, LPA might play an important role as a mediator of microglial activation in response to central nervous system injury.	Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Calif San Diego, Sch Med, Dept Pharmacol, San Diego, CA 92093 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of California System; University of California San Diego	Moller, T (corresponding author), Univ Washington, Sch Med, Dept Neurol, 1959 NE Pacific St,POB 356465, Seattle, WA 98195 USA.		Ransom, Bruce/ABE-4606-2021	Ransom, Bruce R./0000-0002-9658-0294	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015589] Funding Source: NIH RePORTER; NINDS NIH HHS [NS15589] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		An SZ, 1998, MOL PHARMACOL, V54, P881, DOI 10.1124/mol.54.5.881; An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; Chun J, 1999, CRIT REV NEUROBIOL, V13, P151, DOI 10.1615/CritRevNeurobiol.v13.i2.20; Chun Jerold, 1999, Cell Biochemistry and Biophysics, V30, P213, DOI 10.1007/BF02738068; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Contos JJA, 2000, GENOMICS, V64, P155, DOI 10.1006/geno.2000.6122; Dubin AE, 1999, J NEUROSCI, V19, P1371; DURIEUX ME, 1992, AM J PHYSIOL, V263, P896; During MJ, 2000, SCIENCE, V287, P1453, DOI 10.1126/science.287.5457.1453; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Ikeda H, 1998, BIOCHEM BIOPH RES CO, V248, P436, DOI 10.1006/bbrc.1998.8983; Im DS, 2000, MOL PHARMACOL, V57, P753, DOI 10.1124/mol.57.4.753; Ishii I, 2000, MOL PHARMACOL, V58, P895, DOI 10.1124/mol.58.5.895; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; Keller JN, 1997, J NEUROCHEM, V69, P1073; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; Lee H, 2000, AM J PHYSIOL-CELL PH, V278, pC612, DOI 10.1152/ajpcell.2000.278.3.C612; Manning TJ, 1997, GLIA, V20, P163, DOI 10.1002/(SICI)1098-1136(199706)20:2<163::AID-GLIA8>3.0.CO;2-A; Manning TJ, 1998, J NEUROSCI RES, V53, P343, DOI 10.1002/(SICI)1097-4547(19980801)53:3<343::AID-JNR8>3.0.CO;2-A; Moller T, 2000, BRAIN RES, V853, P49, DOI 10.1016/S0006-8993(99)02244-1; Moller T, 1997, J NEUROSCI, V17, P615; MOLLER T, 1988, NEUROREPORT, V10, P2929; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Nietgen GW, 1997, ANESTHESIOLOGY, V86, P1112, DOI 10.1097/00000542-199705000-00015; Ramakers GJA, 1998, EXP CELL RES, V245, P252, DOI 10.1006/excr.1998.4224; Repp H, 1998, N-S ARCH PHARMACOL, V358, P509, DOI 10.1007/PL00005286; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIGHI M, 1989, EUR J IMMUNOL, V19, P1443, DOI 10.1002/eji.1830190815; Rosskopf D, 1998, AM J PHYSIOL-CELL PH, V274, pC1573, DOI 10.1152/ajpcell.1998.274.6.C1573; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; Saito S, 1997, NEUROSCI LETT, V229, P73, DOI 10.1016/S0304-3940(97)00397-2; Schulze C, 1997, J NEUROCHEM, V68, P991; SCHUMACHER KA, 1979, THROMB HAEMOSTASIS, V42, P631; Selmaj K, 1996, SPRINGER SEMIN IMMUN, V18, P57, DOI 10.1007/BF00792609; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TIGYI G, 1995, AM J PHYSIOL-HEART C, V268, pH2048, DOI 10.1152/ajpheart.1995.268.5.H2048; TOKUMURA A, 1978, LIPIDS, V13, P572, DOI 10.1007/BF02533598; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WALZ W, 1993, J NEUROSCI, V13, P4403; Weiner JA, 1998, J COMP NEUROL, V398, P587	48	102	103	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25946	25952		10.1074/jbc.M102691200	http://dx.doi.org/10.1074/jbc.M102691200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11340076	hybrid			2022-12-25	WOS:000169823300042
J	Whitaker, GB; Limberg, BJ; Rosenbaum, JS				Whitaker, GB; Limberg, BJ; Rosenbaum, JS			Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF(121)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-BINDING DOMAIN; 2 VEGF RECEPTORS; TYROSINE KINASE; CONE COLLAPSE; CONTAINING PROTEIN; FACTOR ISOFORMS; SEMAPHORIN-III; FLT-1 RECEPTOR; IN-VIVO; CELLS	The two most abundant secreted isoforms of vascular endothelial growth factor A (VEGF(165) and VEGF(121)) are formed as a result of differential splicing of the VEGF-A gene. VEGF(165) and VEGF(121) share similar affinities at the isolated VEGF receptor (VEGFR)-2 but have been previously demonstrated to have differential ability to activate VEGFR-2-mediated effects on endothelial cells. Herein we investigate whether the recently described VEGF(165) isoform-specific receptor neuropilin-1 (Npn-1) is responsible for the difference in potency observed for these ligands, We demonstrate that although VEGFR-2 and Npn-1 form a complex, this complex does not result in an increase in VEGF(165) binding affinity. Therefore, the differential activity of VEGF(165) and VEGF(121) cannot be explained by a differential binding affinity for the complex. Using an antagonist that competes for VEGF(165) binding at the VEGFR-2(.)Npn-1 complex, we observe specific antagonism of VEGF(165)-meditated phosphorylation of VEGFR-2 without affecting the VEGF(121) response. These data indicate that the formation of the complex is responsible for the increased potency of VEGF(165) versus VEGF(121). Taken together, these data suggest a receptor-clustering role for Npn-1, as opposed to Npn-1 behaving as an affinity-converting subunit.	Procter & Gamble Pharmacuet, Hlth Care Res Ctr, Dept Cardiovasc Res, Mason, OH 45040 USA	Procter & Gamble	Rosenbaum, JS (corresponding author), Procter & Gamble Pharmacuet, Hlth Care Res Ctr, Dept Cardiovasc Res, 8700 Mason Montgomery Rd, Mason, OH 45040 USA.							Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; Borges E, 2000, J BIOL CHEM, V275, P39867, DOI 10.1074/jbc.M007040200; Cai HB, 1999, J NEUROSCI, V19, P6519; Cao YH, 1997, BIOCHEM BIOPH RES CO, V235, P493, DOI 10.1006/bbrc.1997.6813; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; De Vries L, 1998, P NATL ACAD SCI USA, V95, P12340, DOI 10.1073/pnas.95.21.12340; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; ENOMOTO T, 1994, BIOCHEM BIOPH RES CO, V202, P1716, DOI 10.1006/bbrc.1994.2133; Fairbrother WJ, 1998, STRUCT FOLD DES, V6, P637, DOI 10.1016/S0969-2126(98)00065-3; FERRARA N, 1995, NATURE, V121, P1089; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fong GH, 1999, DEVELOPMENT, V126, P3015; Fong TAT, 1999, CANCER RES, V59, P99; Fuh G, 2000, J BIOL CHEM, V275, P26690; Gagnon ML, 2000, P NATL ACAD SCI USA, V97, P2573, DOI 10.1073/pnas.040337597; Gilboa L, 2000, MOL BIOL CELL, V11, P1023, DOI 10.1091/mbc.11.3.1023; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Horowitz JR, 1997, ARTERIOSCL THROM VAS, V17, P2793, DOI 10.1161/01.ATV.17.11.2793; Ikeda M, 2000, J PATHOL, V191, P426; Ishida S, 2000, INVEST OPHTH VIS SCI, V41, P1649; Jin Z, 1997, J NEUROSCI, V17, P6256; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533; Kasahara Y, 2000, J CLIN INVEST, V106, P1311, DOI 10.1172/JCI10259; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; Keck RG, 1997, ARCH BIOCHEM BIOPHYS, V344, P103, DOI 10.1006/abbi.1997.0145; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Kiessling LL, 2000, CURR OPIN CHEM BIOL, V4, P696, DOI 10.1016/S1367-5931(00)00153-8; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Li B, 2000, J BIOL CHEM, V275, P29823, DOI 10.1074/jbc.M002015200; LILLIEN L, 1995, NATURE, V377, P158, DOI 10.1038/377158a0; MACEWAN DJ, 1995, MOL PHARMACOL, V48, P316; Machein MR, 1999, HUM GENE THER, V10, P1117, DOI 10.1089/10430349950018111; Mak JCW, 2000, MOL PHARMACOL, V57, P857; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; Miao HQ, 2000, CANCER METAST REV, V19, P29, DOI 10.1023/A:1026579711033; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; MOTULSKY HJ, 1987, FASEB J, V1, P365, DOI 10.1096/fasebj.1.5.3315805; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Ortega N, 1997, AM J PATHOL, V151, P1215; PAJUSOLA K, 1994, ONCOGENE, V9, P3545; PARK JE, 1994, J BIOL CHEM, V269, P25646; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; Raper JA, 2000, CURR OPIN NEUROBIOL, V10, P88, DOI 10.1016/S0959-4388(99)00057-4; Rossignol M, 2000, GENOMICS, V70, P211, DOI 10.1006/geno.2000.6381; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Starovasnik MA, 1999, J MOL BIOL, V293, P531, DOI 10.1006/jmbi.1999.3134; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Takaoka A, 2000, SCIENCE, V288, P2357, DOI 10.1126/science.288.5475.2357; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Tordjman R, 1999, BLOOD, V94, P2301, DOI 10.1182/blood.V94.7.2301.419k24_2301_2309; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Wilson S, 1996, J PHARMACOL EXP THER, V279, P214; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071; Zhu ZP, 1999, INVEST NEW DRUG, V17, P195, DOI 10.1023/A:1006314501634	69	234	259	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25520	25531		10.1074/jbc.M102315200	http://dx.doi.org/10.1074/jbc.M102315200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11333271	hybrid			2022-12-25	WOS:000169800700143
J	Ikemoto, M; Nikawa, T; Takeda, S; Watanabe, C; Kitano, T; Baldwin, KM; Izumi, R; Nonaka, I; Towatari, T; Teshima, S; Rokutan, K; Kishi, K				Ikemoto, M; Nikawa, T; Takeda, S; Watanabe, C; Kitano, T; Baldwin, KM; Izumi, R; Nonaka, I; Towatari, T; Teshima, S; Rokutan, K; Kishi, K			Space shuttle flight (STS-90) enhances degradation of rat myosin heavy chain in association with activation of ubiquitin-proteasome pathway	FASEB JOURNAL			English	Article									Univ Tokushima, Sch Med, Dept Nutr, Tokushima 7708503, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Tokyo 1878502, Japan; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Natl Space Dev Agcy Japan, Tokyo 1050013, Japan; Natl Ctr Neurol & Psychiat, Dept Neuromuscular Res, Tokyo 1878551, Japan; Univ Tokushima, Inst Enzyme Res, Div Enzyme Chem, Tokushima 7708503, Japan	Tokushima University; National Center for Neurology & Psychiatry - Japan; University of California System; University of California Irvine; Japan Aerospace Exploration Agency (JAXA); National Center for Neurology & Psychiatry - Japan; Tokushima University	Nikawa, T (corresponding author), Univ Tokushima, Sch Med, Dept Nutr, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.			Ikemoto-Uezumi, Madoka/0000-0003-2771-9851					0	127	132	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1279	1281		10.1096/fj.00-0629fje	http://dx.doi.org/10.1096/fj.00-0629fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344113	Bronze			2022-12-25	WOS:000168655200035
J	Menegazzi, M; Tedeschi, E; Dussin, D; De Prati, AC; Cavalieri, E; Mariotto, S; Suzuki, H				Menegazzi, M; Tedeschi, E; Dussin, D; De Prati, AC; Cavalieri, E; Mariotto, S; Suzuki, H			Anti-interferon gamma action of epigallocatechin-3-gallate mediated by specific inhibition of STAT1 activation	FASEB JOURNAL			English	Article									Univ Verona, Dept Neurosci & Vis, Biochem Sect, I-37134 Verona, Italy	University of Verona	Suzuki, H (corresponding author), Univ Verona, Dept Neurosci & Vis, Biochem Sect, Str Grazie 8, I-37134 Verona, Italy.		mariotto, sofia/AAH-5473-2019; Menegazzi, Marta/AAE-7079-2019	Menegazzi, Marta/0000-0003-1310-9227					0	62	64	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1309	1311		10.1096/fj.00-0519fje	http://dx.doi.org/10.1096/fj.00-0519fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344123				2022-12-25	WOS:000168655200045
J	Yan, MS; Qiang, WN; Liu, N; Shen, JJ; Lynn, WS; Wong, PKY				Yan, MS; Qiang, WN; Liu, N; Shen, JJ; Lynn, WS; Wong, PKY			The ataxia-telangiectasia gene product may modulate DNA turnover and control cell fate by regulating cellular redox in lymphocytes	FASEB JOURNAL			English	Article						ATM protein kinase; differentiation; thiol; cellular redox activity; DNA turnover	ATM-DEFICIENT MICE; IONIZING-RADIATION; V(D)J RECOMBINATION; INDUCED APOPTOSIS; OXIDATIVE DAMAGE; PROTEIN; CHECKPOINT; PATHWAYS; DEPLETION; RESCUE	The ATM kinase, when activated postnatally, exerts multiple functions to prevent the onset of ataxia-telangiectasia (AT), Using freshly isolated thymocytes from Atm-/- mice that were under stress during postnatal differentiation, we noted that thiol redox activity, as indicated by reduction of the tebrazolium MTS, and DNA turnover activity, as indicated by incorporation of [H-3]thymidine into DNA, were both greatly increased compared with activities in thymocytes from Atm+/+ mice, This increased thymidine incorporation could be suppressed by the thiol N-acetylcysteine, In primary noncycling splenocytes, mitogens proportionally increased both the rate of [H-3]thymidine incorporation and the rate of reduction of MTS, The mitogen-induced activities in splenocytes were not affected by ATM but were suppressed by the calcineurin-dependent inhibitor FK-506, which has no effect on these activities in thymocytes, These findings suggest that increased [H-3]thymidine incorporation and reducing power indicate increased cell cycling in mitogenically stimulated splenocytes, whereas these two indicators represent increased FK-506-independent DNA turnover activities in thymocytes, Thus, a primary function of ATM is to activate the redox-sensitive checkpoint required for down-regulation of DNA turnover activities in developing lymphocytes, Cell-cycling checkpoints in undamaged quiescent lymphocytes are not activated by ATM with mitogenic stimulation. ATM may suppress abnormal DNA turnover and the resultant oncogenesis by regulating cellular thiol redox pathways.	Univ Texas, MD Anderson Canc Ctr, Div Res, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Wong, PKY (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Res, Sci Pk,POB 389, Smithville, TX 78957 USA.	pwong@sprdl.mdacc.tmc.edu	Qiang, Wenan/AAA-7633-2021	Qiang, Wenan/0000-0001-5068-7128	NCI NIH HHS [CA16672] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Barlow C, 1999, P NATL ACAD SCI USA, V96, P9915, DOI 10.1073/pnas.96.17.9915; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barlow C, 1997, NAT GENET, V17, P462, DOI 10.1038/ng1297-462; Barlow C, 1998, NAT GENET, V18, P298, DOI 10.1038/ng0398-298b; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Brown KD, 1999, AM J HUM GENET, V64, P46, DOI 10.1086/302223; Colussi C, 2000, FASEB J, V14, P2266, DOI 10.1096/fj.00-0074com; Costanzo V, 2000, MOL CELL, V6, P649, DOI 10.1016/S1097-2765(00)00063-0; DANSKA JS, 1994, SCIENCE, V266, P450, DOI 10.1126/science.7524150; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; GOODWIN CJ, 1995, J IMMUNOL METHODS, V179, P95, DOI 10.1016/0022-1759(94)00277-4; Hande MP, 2001, HUM MOL GENET, V10, P519, DOI 10.1093/hmg/10.5.519; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Huang STJ, 1999, FASEB J, V13, P467, DOI 10.1096/fasebj.13.3.467; Kim GD, 1999, J BIOL CHEM, V274, P31127, DOI 10.1074/jbc.274.44.31127; Lee Y, 2000, GENE DEV, V14, P2576, DOI 10.1101/gad.837100; Liao MJ, 1999, GENE DEV, V13, P1246, DOI 10.1101/gad.13.10.1246; Liyanage M, 2000, BLOOD, V96, P1940, DOI 10.1182/blood.V96.5.1940.h8001940_1940_1946; Lynn WS, 1997, NEUROIMMUNOMODULAT, V4, P277, DOI 10.1159/000097348; MEYN MS, 1995, CANCER RES, V55, P5991; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Plug AW, 1997, NAT GENET, V17, P457, DOI 10.1038/ng1297-457; Rolig RL, 2000, TRENDS NEUROSCI, V23, P417, DOI 10.1016/S0166-2236(00)01625-8; Rotman G, 1997, CANCER SURV, V29, P285; Rybczynska M, 1996, BBA-LIPID LIPID MET, V1302, P231, DOI 10.1016/0005-2760(96)00067-7; SAHA K, 1993, VIROLOGY, V195, P211, DOI 10.1006/viro.1993.1362; Tanaka T, 1997, LAB INVEST, V77, P145; Vit JP, 2000, INT J RADIAT BIOL, V76, P841, DOI 10.1080/09553000050029002; Watters D, 1999, J BIOL CHEM, V274, P34277, DOI 10.1074/jbc.274.48.34277	31	28	29	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2001	15	7					1132	1138		10.1096/fj.00-0601com	http://dx.doi.org/10.1096/fj.00-0601com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344081				2022-12-25	WOS:000168655200003
J	Paweletz, CP; Charboneau, L; Bichsel, VE; Simone, NL; Chen, T; Gillespie, JW; Emmert-Buck, MR; Roth, MJ; Petricoin, EF; Liotta, LA				Paweletz, CP; Charboneau, L; Bichsel, VE; Simone, NL; Chen, T; Gillespie, JW; Emmert-Buck, MR; Roth, MJ; Petricoin, EF; Liotta, LA			Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front	ONCOGENE			English	Article						laser capture microdissection; protein microarrays; apoptosis; Akt; mitogen activated protein kinase; tumor progression	PROSTATIC INTRAEPITHELIAL NEOPLASIA; GLYCOGEN-SYNTHASE KINASE-3; PROTEOMIC ANALYSIS; GENE-EXPRESSION; GROWTH; APOPTOSIS; AKT; IMMUNOASSAY; SPECIFICITY	Protein arrays are described for screening of molecular markers and pathway targets in patient matched human tissue during disease progression. In contrast to previous protein arrays that immobilize the probe, our reverse phase protein array immobilizes the whole repertoire of patient proteins that represent the state of individual tissue cell populations undergoing disease transitions. A high degree of sensitivity, precision and linearity was achieved, making it possible to quantify the phosphorylated status of signal proteins in human tissue cell subpopulations, Using this novel protein microarray we have longitudinally analysed the state of pro-survival checkpoint proteins at the microscopic transition stage from patient matched histologically normal prostate epithelium to prostate intraepithelial neoplasia (PIN) and then to invasive prostate cancer. Cancer progression was associated with increased phosphorylation of Akt (P < 0.04), suppression of apoptosis pathways (P < 0.03), as well as decreased phosphorylation of ERK (P < 0.01), At the transition from histologically normal epithelium to PIN we observed a statistically significant surge in phosphorylated Akt (P < 0.03) and a concomitant suppression of downstream apoptosis pathways which proceeds the transition into invasive carcinoma.	NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; US FDA, Ctr Biol Evaluat & Res, Tissue Prote Unit, Bethesda, MD 20892 USA; NCI, Canc Prevent Studies Branch, NIH, Bethesda, MD 20892 USA; NCI, Pathogenet Unit, Pathol Lab, NIH, Bethesda, MD 20892 USA; NCI, Canc Genome Anat Project, Off Director, NIH, Bethesda, MD 20892 USA; Georgetown Univ, Dept Chem, Washington, DC 20057 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Georgetown University	Liotta, LA (corresponding author), NCI, Pathol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.			Simone, Nicole/0000-0002-7662-7470				Arenkov P, 2000, ANAL BIOCHEM, V278, P123, DOI 10.1006/abio.1999.4363; BOSTWICK DG, 1995, CANCER-AM CANCER SOC, V75, P1823, DOI 10.1002/1097-0142(19950401)75:7+<1823::AID-CNCR2820751612>3.0.CO;2-7; Buckholz Richard G., 1999, Journal of Molecular Microbiology and Biotechnology, V1, P135; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DeRisi J, 1996, NAT GENET, V14, P457; Dimmeler S, 2000, CIRC RES, V86, P4, DOI 10.1161/01.RES.86.1.4; EKINS RP, 1991, CLIN CHEM, V37, P1955; Emili AQ, 2000, NAT BIOTECHNOL, V18, P393, DOI 10.1038/74442; Emmert-Buck MR, 2000, MOL CARCINOGEN, V27, P158, DOI 10.1002/(SICI)1098-2744(200003)27:3<158::AID-MC2>3.0.CO;2-2; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Englert CR, 2000, CANCER RES, V60, P1526; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Frey RS, 1997, CANCER RES, V57, P628; Ge H, 2000, Nucleic Acids Res, V28, pe3, DOI 10.1093/nar/28.2.e3; Gioeli D, 1999, CANCER RES, V59, P279; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Haab BB, 2001, GENOME BIOL, V2; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jones VW, 1998, ANAL CHEM, V70, P1233, DOI 10.1021/ac971125y; Koch M, 2000, VIRCHOWS ARCH, V436, P413, DOI 10.1007/s004280050468; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Krajewska M, 1996, AM J PATHOL, V148, P1567; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Lueking A, 1999, ANAL BIOCHEM, V270, P103, DOI 10.1006/abio.1999.4063; MacBeath G, 1999, J AM CHEM SOC, V121, P7967, DOI 10.1021/ja991083q; MALINDZAK D., 1997, PROTEOME RES NEW FRO; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Ornstein DK, 2000, ELECTROPHORESIS, V21, P2235, DOI 10.1002/1522-2683(20000601)21:11<2235::AID-ELPS2235>3.3.CO;2-1; PAGE MJ, 2000, PNAS, V96, P12589; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Paweletz CP, 2000, CANCER RES, V60, P6293; Rowe CA, 1999, ANAL CHEM, V71, P3846, DOI 10.1021/ac981425v; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Xie W, 2000, PROSTATE, V44, P31; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zheng DQ, 2000, J BIOL CHEM, V275, P24565, DOI 10.1074/jbc.M002646200; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	39	754	806	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2001	20	16					1981	1989		10.1038/sj.onc.1204265	http://dx.doi.org/10.1038/sj.onc.1204265			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360182				2022-12-25	WOS:000168043800006
J	Faber, C; Scharpf, M; Becker, T; Sticht, H; Rosch, P				Faber, C; Scharpf, M; Becker, T; Sticht, H; Rosch, P			The structure of the coliphage HK022 nun protein-lambda-phage boxB RNA complex - Implications for the mechanism of transcription termination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTATO CARBOXYPEPTIDASE INHIBITOR; ARGININE-RICH MOTIF; BACTERIOPHAGE-LAMBDA; NMR-SPECTROSCOPY; ANTITERMINATION; BINDING; RECOGNITION; WATER	Nun protein from coliphage HK022 binds to phage boxB RNA and functions, in contrast to phage lambda N protein, as a transcriptional termination The basic Nun-(10-44) peptide contains the boxB RNA binding arginine rich motif, ARM. The peptide binds boxB RNA and competes with the phage lambda ARM peptide N-(1-36) as indicated by nuclear magnetic resonance (NMR) spectroscopy titrations. In two-dimensional nuclear Overhauser enhancement spectroscopy experiments boxB RNA in complex with Nun-(20-44) exhibits the same pattern of resonances as it does in complex with N peptides containing the ARM, and we could show that Nun-(20-44) forms a bent a-helix upon binding to the boxB RNA. The structure of the boxB RNA-bound Nun-(20-44) was determined on the basis of 191 intra- and 30 intermolecular distance restraints. Ser-24 is anchored to the lower RNA stem, and stacking of Tyr-39 and A7 is clearly experimentally indicated. Arg-28 shows numerous contacts to the RNA stem. Leu-22, IIe30, Trp-33, IIe-37, and Leu-41 form a hydrophobic surface, which could be a recognition site for additional host factors such as NusG. Such a hydrophobic surface area is not present in N-(1-36) bound to boxB RNA.	Univ Bayreuth, Lehrstuhl Biopolymere, D-95447 Bayreuth, Germany	University of Bayreuth	Rosch, P (corresponding author), Univ Bayreuth, Lehrstuhl Biopolymere, Univ Str 30, D-95447 Bayreuth, Germany.		Rösch, Paul/I-5445-2014; Faber, Cornelius/Q-2689-2016	Rösch, Paul/0000-0003-3330-2446; Faber, Cornelius/0000-0001-7683-7710; Sticht, Heinrich/0000-0001-5644-045X				BRUNGER AT, 1996, X PLOR VERSION 3 851; Cai ZP, 1998, NAT STRUCT BIOL, V5, P203, DOI 10.1038/nsb0398-203; Cavanagh J., 1996, PROTEIN NMR SPECTROS; CHATTOPADHYAY S, 1995, P NATL ACAD SCI USA, V92, P4061, DOI 10.1073/pnas.92.9.4061; Chattopadhyay S, 1995, P NATL ACAD SCI USA, V92, P12131, DOI 10.1073/pnas.92.26.12131; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; DAS A, 1993, ANNU REV BIOCHEM, V62, P893; FRANKLIN NC, 1985, J MOL BIOL, V181, P75, DOI 10.1016/0022-2836(85)90325-0; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; HOLAK TA, 1989, FEBS LETT, V242, P218, DOI 10.1016/0014-5793(89)80473-9; Kuszewski J, 1996, PROTEIN SCI, V5, P1067; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; Legault P, 1998, CELL, V93, P289, DOI 10.1016/S0092-8674(00)81579-2; LIVE DH, 1984, J AM CHEM SOC, V106, P1939, DOI 10.1021/ja00319a006; Luscombe NM, 1997, NUCLEIC ACIDS RES, V25, P4940, DOI 10.1093/nar/25.24.4940; MOGRIDGE J, 1995, GENE DEV, V9, P2831, DOI 10.1101/gad.9.22.2831; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; ROBERT J, 1987, CELL, V51, P483, DOI 10.1016/0092-8674(87)90644-1; SAYLE R, 1995, RASMOL V 2 6 MOL VIS; Scharpf M, 2000, EUR J BIOCHEM, V267, P2397, DOI 10.1046/j.1432-1327.2000.01251.x; Su LL, 1997, BIOCHEMISTRY-US, V36, P12722, DOI 10.1021/bi971408k; *TRIP INC, SYBYL VERS 6 5; Varani G, 1996, PROG NUCL MAG RES SP, V29, P51, DOI 10.1016/0079-6565(96)01028-X; VARANI G, 1991, Q REV BIOPHYS, V24, P479, DOI 10.1017/S0033583500003875; Watnick RS, 1999, SCIENCE, V286, P2337, DOI 10.1126/science.286.5448.2337; Watnick RS, 1998, P NATL ACAD SCI USA, V95, P1546, DOI 10.1073/pnas.95.4.1546; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K, 1986, NMR PROTEINS NUCL AC	30	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32064	32070		10.1074/jbc.M102975200	http://dx.doi.org/10.1074/jbc.M102975200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11356847	hybrid, Green Submitted			2022-12-25	WOS:000170613500082
J	Singh, SK; Rozycki, J; Ortega, J; Ishikawa, T; Lo, J; Steven, AC; Maurizi, MR				Singh, SK; Rozycki, J; Ortega, J; Ishikawa, T; Lo, J; Steven, AC; Maurizi, MR			Functional domains of the ClpA and ClpX molecular chaperones identified by limited proteolysis and deletion analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE FUSION PROTEIN; ATP-DEPENDENT PROTEASES; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ARCHAEAL CHAPERONIN; TERMINAL DOMAIN; DEGRADATION; THERMOSOME; TARGETS; COMPLEX	Escherichia coli ClpA and ClpX are ATP-dependent protein unfoldases that each interact with the protease, ClpP, to promote specific protein degradation. We have used limited proteolysis and deletion analysis to probe the conformations of ClpA and ClpX and their interactions with ClpP and substrates. ATP gammaS binding stabilized ClpA and ClpX such that that cleavage by lysylendopeptidase C occurred at only two sites. Both proteins were cleaved within in a loop preceding an a-helix-rich C-terminal domain. Although the loop varies in size and composition in Clp ATPases, cleavage occurred within and around a conserved triad, IG(FIL). Binding of ClpP blocked this cleavage, and prior cleavage at this site rendered both ClpA and ClpX defective in binding and activating ClpP, suggesting that this site is involved in interactions with ClpP. ClpA was also cut at a site near the junction of the two ATPase domains, whereas the second cleavage site in ClpX lay between its N-terminal and ATPase domains. ClpP did not block cleavage at these other sites. The N-terminal domain of ClpX dissociated upon cleavage, and the remaining ClpX DeltaN remained as a hexamer, associated with ClpP, and expressed ATPase, chaperone, and proteolytic activity. A truncated mutant of ClpA lacking its N-terminal 153 amino acids also formed a hexamer, associated with ClpP, and expressed these activities. We propose that the N-terminal domains of ClpX and ClpA lie on the outside ring surface of the holoenzyme complexes where they contribute to substrate binding or perform a gating function affecting substrate access to other binding sites and that a loop on the opposite face of the ATPase rings stabilizes interactions with ClpP and is involved in promoting ClpP proteolytic activity.	NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; NIAMS, Struct Biol Lab, NIH, Bethesda, MD 20892 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Massachusetts Institute of Technology (MIT)	Maurizi, MR (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 37,1B07, Bethesda, MD 20892 USA.	mmaulizi@helix.nih.gov	Ishikawa, Takashi/E-5023-2017	Ishikawa, Takashi/0000-0002-1976-7477				Beuron F, 1998, J STRUCT BIOL, V123, P248, DOI 10.1006/jsbi.1998.4039; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Bochtler M, 1997, P NATL ACAD SCI USA, V94, P6070, DOI 10.1073/pnas.94.12.6070; Carrascosa JL, 2001, MICRON, V32, P43, DOI 10.1016/S0968-4328(00)00027-5; CONWAY JF, 1993, J STRUCT BIOL, V111, P222, DOI 10.1006/jsbi.1993.1052; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; Gottesman S, 1995, COLD SPRING HARB SYM, V60, P533, DOI 10.1101/SQB.1995.060.01.057; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; Grimaud R, 1998, J BIOL CHEM, V273, P12476, DOI 10.1074/jbc.273.20.12476; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Hoskins JR, 2000, P NATL ACAD SCI USA, V97, P8892, DOI 10.1073/pnas.97.16.8892; Ishikawa T, 2000, NATURE, V408, P667, DOI 10.1038/35047165; ISHIKAWA T, 2001, IN PRESS P NATL ACAD, V98; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Kim YI, 2000, MOL CELL, V5, P639, DOI 10.1016/S1097-2765(00)80243-9; Kim YI, 2001, NAT STRUCT BIOL, V8, P230, DOI 10.1038/84967; Kocsis E, 1995, ULTRAMICROSCOPY, V60, P219, DOI 10.1016/0304-3991(95)00070-2; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Lo JH, 2001, PROTEIN SCI, V10, P551, DOI 10.1110/ps.41401; MAURIZI MR, 1994, METHOD ENZYMOL, V244, P314; Maurizi MR, 1998, BIOCHEMISTRY-US, V37, P7778, DOI 10.1021/bi973093e; May AP, 1999, NAT CELL BIOL, V1, P175, DOI 10.1038/11097; Neuwald AF, 1999, GENOME RES, V9, P27; Ortega J, 2000, MOL CELL, V6, P1515, DOI 10.1016/S1097-2765(00)00148-9; PARK SK, 1993, J BIOL CHEM, V268, P20170; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schoehn G, 2000, J MOL BIOL, V301, P323, DOI 10.1006/jmbi.2000.3952; Singh SK, 2000, P NATL ACAD SCI USA, V97, P8898, DOI 10.1073/pnas.97.16.8898; SINGH SK, 1994, J BIOL CHEM, V269, P29537; Singh SK, 1999, BIOCHEMISTRY-US, V38, P14906, DOI 10.1021/bi991615f; Smith CK, 1999, P NATL ACAD SCI USA, V96, P6678, DOI 10.1073/pnas.96.12.6678; Sousa MC, 2000, CELL, V103, P633, DOI 10.1016/S0092-8674(00)00166-5; Wang J, 2001, STRUCTURE, V9, P177, DOI 10.1016/S0969-2126(01)00570-6; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; Yu RC, 1999, MOL CELL, V4, P97, DOI 10.1016/S1097-2765(00)80191-4; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	41	107	112	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29420	29429		10.1074/jbc.M103489200	http://dx.doi.org/10.1074/jbc.M103489200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11346657	hybrid			2022-12-25	WOS:000170346000104
J	Liao, YH; Satoh, T; Gao, XL; Jin, TG; Hu, CD; Kataoka, T				Liao, YH; Satoh, T; Gao, XL; Jin, TG; Hu, CD; Kataoka, T			RA-GEF-1, a guanine nucleotide exchange factor for Rap1, is activated by translocation induced by association with Rap1-GTP and enhances rap1-dependent B-Raf activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; KINASE ACTIVATION; CELL-ADHESION; MAP KINASE; G-PROTEIN; HA-RAS; FAMILY; DOMAIN; SIGNAL; GTPASE	We previously identified RA-GEF-1, a novel guanine nucleotide exchange factor (GEF) for Rap1 with the ability to associate with Rap1.GTP at its Ras/Rap1-associating (RA) domain. Because it possesses a PSD-95/DlgA/ZO-1 (PDZ) domain, it was also named PDZ-GEF. In this report, we have examined the role of the RA domain of this protein in Rap1-mediated cellular responses. A mutant of RA-GEF-1 (RA-GEF-1 Delta RA) carrying a 21-residue deletion at its RA domain fully retains the in vitro GEF activity toward Rap1 but completely loses the Rap1 binding activity. In contrast, RA-GEF-1 Delta RA, expressed in COS-7 cells, exhibits a 3-fold reduction in its in vivo GEF activity toward Rap I compared with wild-type RA-GEF-1 as examined by the Rap1 pull-down assay. Correspondingly, when coexpressed with wild-type Rap1, RA-GEF-1 Delta RA is unable to further activate B-Raf, whereas RA-GEF-1 stimulates B-Raf as efficiently as activated Rap1. Consistent with these observations, coexpression of activated Rap1 induces translocation of RA-GEF-1, which is otherwise located in the cytoplasm, to the perinuclear compartment, where Rap1 is also predominantly localized. This localization almost coincides with that of the Golgi apparatus, which was detected by anti-trans-Golgi-network 38 antibody. RA-GEF-1 Delta RA fails to show the translocation. These results indicate that RA-GEF-1 defines a novel category of GEF that is translocated to a particular subcellular compartment by association with the GTP-bound form of a small GTPase and catalyzes activation of the GDP-bound form present in the compartment, thereby causing an amplification of cellular responses induced by the small GTPase.	Kobe Univ, Grad Sch Med, Dept Mol & Cellular Biol, Div Mol Biol,Chuo Ku, Kobe, Hyogo 6500017, Japan	Kobe University	Kataoka, T (corresponding author), Kobe Univ, Grad Sch Med, Dept Mol & Cellular Biol, Div Mol Biol,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	kataoka@kobe-u.ac.jp	Satoh, Takaya/K-2628-2014					BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; Huang L, 1997, NAT STRUCT BIOL, V4, P609, DOI 10.1038/nsb0897-609; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; Ichiba T, 1999, FEBS LETT, V457, P85, DOI 10.1016/S0014-5793(99)01012-1; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; Liao YH, 1999, J BIOL CHEM, V274, P37815, DOI 10.1074/jbc.274.53.37815; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Matsubara K, 1999, ONCOGENE, V18, P1303, DOI 10.1038/sj.onc.1202425; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; Ohtsuka T, 1999, BIOCHEM BIOPH RES CO, V265, P38, DOI 10.1006/bbrc.1999.1619; Okada T, 1999, MOL CELL BIOL, V19, P6057; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pham N, 2000, CURR BIOL, V10, P555, DOI 10.1016/S0960-9822(00)00473-5; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Schmidt A, 2001, MOL CELL BIOL, V21, P438, DOI 10.1128/MCB.21.2.438-448.2001; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wienecke R, 1996, ONCOGENE, V13, P913; York RD, 2000, MOL CELL BIOL, V20, P8069, DOI 10.1128/MCB.20.21.8069-8083.2000; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	38	49	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28478	28483		10.1074/jbc.M101737200	http://dx.doi.org/10.1074/jbc.M101737200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11359771	hybrid			2022-12-25	WOS:000170093400098
J	Gustin, JA; Maehama, T; Dixon, JE; Donner, DB				Gustin, JA; Maehama, T; Dixon, JE; Donner, DB			The PTEN tumor suppressor protein inhibits tumor necrosis factor-induced nuclear factor kappa B activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE 3-OH KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; IKK-BETA; TRANSCRIPTION FACTOR; EMBRYONIC LETHALITY; GERMLINE MUTATIONS; CELLULAR-SURVIVAL; INDUCED APOPTOSIS; PROSTATE-CANCER; TNF-ALPHA	Nuclear factor kappaB (NF-kappaB) transcriptionally activates genes that promote immunity and cell survival. Activation of NF-kappaB is induced by an I kappaB kinase (IKK) complex that phosphorylates and promotes dissociation of I kappaB from NF-kappaB, which then translocates into the nucleus. Activation of phosphatidylinositol (PI) 3-kinase/Akt signaling by tumor necrosis factor (TNF) activates IKK and NF-kappaB. The present study shows that PTEN, a tumor suppressor that inhibits PI 3-kinase function, impairs TNF activation of Akt and the IKK complex in 293 cells. Transient expression of PTEN suppressed IKK activation and TNF-induced NF-kappaB DNA binding and transactivation. Studies were conducted with PC-3 prostate cancer cells that do not express PTEN and DU145 prostate cancer cells that express PTEN. TNF activated Akt in PC-3 cells, but not in DU145 cells, and the ability of TNF to activate NF-kappaB was blocked by pharmacological inhibition of PI 3-kinase activity in PC-3 cells, but not in DU145 cells. Expression of PTEN in PC-3 cells to a level comparable with that endogenously present in DU145 cells inhibited TNF activation of NF-kappaB. The cell type-specific ability of PTEN to negatively regulate the PI 3-kinase/AKT/NF-kappaB pathway may be important to its tumor suppressor activity.	Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; University of Michigan System; University of Michigan	Donner, DB (corresponding author), Indiana Univ, Sch Med, Walther Oncol Ctr, 1044 W Walnut St, Indianapolis, IN 46202 USA.	ddonner@IUPUI.edu	Maehama, Tomohiko/AAX-8926-2020; Maehama, Tomohiko/HGB-4896-2022	Maehama, Tomohiko/0000-0002-9685-2317	NCI NIH HHS [CA 67891, CA 73023] Funding Source: Medline; NIDDK NIH HHS [DK 18849] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA067891, R01CA073023, R01CA067891] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018849] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1998, BBA-MOL CELL BIOL L, V1436, P151, DOI 10.1016/S0005-2760(98)00133-7; Andjelic S, 2000, J IMMUNOL, V165, P3860, DOI 10.4049/jimmunol.165.7.3860; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Beutler B, 1998, BLOOD CELL MOL DIS, V24, P216, DOI 10.1006/bcmd.1998.0187; Bonizzi G, 1999, BIOCHEM PHARMACOL, V57, P713, DOI 10.1016/S0006-2952(98)00353-0; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kouba DJ, 2001, J BIOL CHEM, V276, P6214, DOI 10.1074/jbc.M004511200; Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Maier D, 1998, ONCOGENE, V16, P3331, DOI 10.1038/sj.onc.1201832; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Manna SK, 2000, FEBS LETT, V473, P113, DOI 10.1016/S0014-5793(00)01501-5; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; McMenamin ME, 1999, CANCER RES, V59, P4291; Myers MP, 1997, AM J HUM GENET, V61, P1234, DOI 10.1086/301659; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; O'Mahony A, 2000, MOL CELL BIOL, V20, P1170, DOI 10.1128/MCB.20.4.1170-1178.2000; Ozes ON, 1999, NATURE, V401, P82; Peraldi P, 1998, MOL CELL BIOCHEM, V182, P169, DOI 10.1023/A:1006865715292; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Sabbatini P, 1999, J BIOL CHEM, V274, P24263, DOI 10.1074/jbc.274.34.24263; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; Yamamoto Y, 2000, MOL CELL BIOL, V20, P3655, DOI 10.1128/MCB.20.10.3655-3666.2000; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	61	94	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27740	27744		10.1074/jbc.M102559200	http://dx.doi.org/10.1074/jbc.M102559200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11356844	hybrid			2022-12-25	WOS:000169966900132
J	Kessler, E; Fichard, A; Chanut-Delalande, H; Brusel, M; Ruggiero, F				Kessler, E; Fichard, A; Chanut-Delalande, H; Brusel, M; Ruggiero, F			Bone morphogenetic protein-1 (BMP-1) mediates C-terminal processing of procollagen V homotrimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN TOLLOID-LIKE; COLLAGEN CHAIN; PRO-ALPHA-1(V) COLLAGEN; NH2-TERMINAL DOMAIN; MATRIX-FORMS; FURIN; EXPRESSION; CLEAVAGE; CELLS; METALLOPROTEINASES	The processing of the fibrillar procollagen precursors to mature collagens is an essential requirement for fibril formation. The enzymes involved in these events are known as the procollagen N and C proteinases. The latter, which cleaves the C-propeptides of the fibrillar procollagens I-III, is identical to the previously described bone morphogenetic protein-1 (BMP-1). Surprisingly, unlike the other fibrillar collagens, the processing of the C-propeptide domain of the procollagen V homotrimer was found to be mediated by furin rather than BMP-1. However, the presence of putative BMP-1 cleavage sites in the alpha1(V) C-propeptide sequence prompted us to reconsider the procollagen V C-propeptide cleavage by BMP-1. Using a recombinant system to produce substantial amounts of the pro alpha1(V) homotrimer, we have previously shown that the C-propeptide is spontaneously released in the culture medium. The trimeric C-propeptide fragment, resulting from the furin cleavage, still encompassed the predicted BMP-1 cleavage sites. It was purified and tested as a substrate for BMP-1. In parallel, the release of the C-propeptide in the culture medium was inhibited by the addition of a specific furin inhibitor, allowing the re examination of BMP-1 activity on the intact molecule. We showed that BMP-1 does cleave both substrates at one of the two predicted C-proteinase cleavage sites. Our results favor a role for PCP/BMP-1 in physiological C-terminal processing of procollagen V and imply a general mechanism for fibrillar collagen C-terminal processing.	CNRS, Inst Biol & Chim Prot, Unite Mixte Rech 5086, F-69367 Lyon 07, France; Tel Aviv Univ, Sackler Fac Med, Goldschleger Eye Res Inst, Sheba Med Ctr, IL-52621 Tel Hashomer, Israel	Centre National de la Recherche Scientifique (CNRS); Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Ruggiero, F (corresponding author), CNRS, Inst Biol & Chim Prot, Unite Mixte Rech 5086, 7 Passage Vercors, F-69367 Lyon 07, France.			RUGGIERO, Florence/0000-0003-2915-5359; CHANUT-DELALANDE, Helene/0000-0002-1720-2069				ADAR R, 1986, COLLAGEN REL RES, V6, P267; Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; BIRK DE, 1990, J CELL SCI, V95, P649; Blader P, 1997, SCIENCE, V278, P1937, DOI 10.1126/science.278.5345.1937; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; BROEK DL, 1985, J BIOL CHEM, V260, P555; Chernousov MA, 2000, J BIOL CHEM, V275, P28208; Cui YZ, 1998, EMBO J, V17, P4735, DOI 10.1093/emboj/17.16.4735; Fichard A, 1997, J BIOL CHEM, V272, P30083, DOI 10.1074/jbc.272.48.30083; FICHARD A, 1994, MATRIX BIOL, V14, P515; Grassel S, 1996, EUR J BIOCHEM, V242, P576, DOI 10.1111/j.1432-1033.1996.0576r.x; GREENSPAN DS, 1991, J BIOL CHEM, V266, P24727; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; Imamura Y, 2000, J BIOL CHEM, V275, P8749, DOI 10.1074/jbc.275.12.8749; Imamura Y, 1998, J BIOL CHEM, V273, P27511, DOI 10.1074/jbc.273.42.27511; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; Kessler E., 1998, HDB PROTEOLYTIC ENZY, P1236; KIELTY K, 1993, CONNECTIVE TISSUE IT, P103; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; Lonnqvist L, 1998, HUM MOL GENET, V7, P2039, DOI 10.1093/hmg/7.13.2039; Maquoi E, 1998, FEBS LETT, V424, P262, DOI 10.1016/S0014-5793(98)00187-2; MORADIAMELI M, 1994, EUR J BIOCHEM, V221, P987, DOI 10.1111/j.1432-1033.1994.tb18815.x; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; NEAME PJ, 1990, J BIOL CHEM, V265, P20401; NIYIBIZI C, 1993, BIOCHIM BIOPHYS ACTA, V1203, P304, DOI 10.1016/0167-4838(93)90099-D; Ovens A, 2000, J PEPT SCI, V6, P489, DOI 10.1002/1099-1387(200009)6:9<489::AID-PSC282>3.3.CO;2-B; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; Prockop DJ, 1998, MATRIX BIOL, V16, P399, DOI 10.1016/S0945-053X(98)90013-0; Rousseau JC, 1996, J BIOL CHEM, V271, P23743, DOI 10.1074/jbc.271.39.23743; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; Sieron AL, 2000, BIOCHEMISTRY-US, V39, P3231, DOI 10.1021/bi992312o; Steinmann Beat, 1993, P351; STOCKER W, 1995, PROTEIN SCI, V4, P823; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; Takahara K, 1996, GENOMICS, V34, P157, DOI 10.1006/geno.1996.0260; WEIL D, 1987, NUCLEIC ACIDS RES, V15, P181, DOI 10.1093/nar/15.1.181; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	43	37	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27051	27057		10.1074/jbc.M102921200	http://dx.doi.org/10.1074/jbc.M102921200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11358968	hybrid			2022-12-25	WOS:000169966900043
J	Sang, NL; Severino, A; Russo, P; Baldi, A; Giordano, A; Mileo, AM; Paggi, MG; De Luca, A				Sang, NL; Severino, A; Russo, P; Baldi, A; Giordano, A; Mileo, AM; Paggi, MG; De Luca, A			RACK1 interacts with E1A and rescues E1A-induced yeast growth inhibition and mammalian cell apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS TYPE-5 E1A; RETINOBLASTOMA GENE FAMILY; PROTEINS INDUCE APOPTOSIS; REGION 1A PROTEINS; MOLECULAR-CLONING; BETA-SUBUNIT; SACCHAROMYCES-CEREVISIAE; BREAST-CANCER; FISSION YEAST; CYCLE CONTROL	The adenoviral E1A proteins are able to promote proliferation and transformation, inhibit differentiation, induce apoptosis, and suppress tumor growth. The extreme N terminus and conserved region one of E1A, which are indispensable for transcriptional regulation and for binding to p300/CBP, TBP, and pCAF, play essential roles in these abilities. These observations strongly suggest an intrinsic link between E1A-mediated transcriptional regulation and other effects. In this report, we show that E1A inhibits the normal growth of Saccharomyces cerevisiae HF7c, and this inhibition also depends on the domains required for transcriptional regulation. We demonstrate that E1A associates with histone acetyltransferase activity and represses the transactivation activity of transcription factor in S. cerevisiae, suggesting that E1A may suppress the expression of genes required for normal growth. Based on yeast growth rescue, we present a genetic screening strategy that identified RACK1 as an E1A antagonizing factor. Expression of human RACK1 efficiently relieves E1A-mediated growth inhibition in HF7c and protects human tumor cells from E1A-induced apoptosis. Finally, we show that RACK1 decreases E1A-associated histone acetyltransferase activity in yeast and mammalian cells, and physically interacts with E1A Our data demonstrate that RACK1 is a repressor of E1A, possibly by antagonizing the effects of E1A on host gene transcription.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Cardeza Fdn, Philadelphia, PA 19107 USA; Regina Elena Inst Canc Res, Lab Cell Metab & Pharmacokinet, Ctr Expt Res, I-00158 Rome, Italy; Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Anat & Cell Biol, Philadelphia, PA 19107 USA; Regina Elena Inst Canc Res, Biophys Lab, Ctr Expt Res, I-00158 Rome, Italy	Jefferson University; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Jefferson University; Jefferson University; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	De Luca, A (corresponding author), Regina Elena Inst Canc Res, Lab Cell Metab & Pharmacokinet, Ctr Expt Res, Via Messi Oro 156, I-00158 Rome, Italy.	paggi@ifo.it	De Luca, Antonio/AAD-9562-2020; Severino, Anna/S-3417-2019; Mileo, Anna Maria/J-3667-2016; Paggi, Marco G./K-3494-2018; Giordano, Antonio/F-1927-2010; Baldi, Alfonso/ABG-2397-2021	De Luca, Antonio/0000-0002-3905-6154; Severino, Anna/0000-0002-6276-7747; Mileo, Anna Maria/0000-0002-1970-3297; Giordano, Antonio/0000-0002-5959-016X; Baldi, Alfonso/0000-0002-8693-3842	NATIONAL CANCER INSTITUTE [R01CA056304] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 6099-01A1, P01-CA 56304-08] Funding Source: Medline; NINDS NIH HHS [P01 NS 36466] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BERLINGIERI MT, 1993, ONCOGENE, V8, P249; BONDESSON M, 1994, NUCLEIC ACIDS RES, V22, P3053, DOI 10.1093/nar/22.15.3053; Brader KR, 1997, CLIN CANCER RES, V3, P2017; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang JY, 1996, ONCOGENE, V13, P1405; Chang JY, 1997, ONCOGENE, V14, P561, DOI 10.1038/sj.onc.1200861; CHINNADURAI G, 1992, ONCOGENE, V7, P1255; Condorelli G, 1997, J CELL BIOCHEM, V67, P423, DOI 10.1002/(SICI)1097-4644(19971215)67:4<423::AID-JCB1>3.0.CO;2-U; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Deng J, 1998, ONCOGENE, V17, P2167, DOI 10.1038/sj.onc.1202148; DYSON N, 1992, CANCER SURV, V12, P161; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; Frisch SM, 1996, MUTAT RES-FUND MOL M, V350, P261, DOI 10.1016/0027-5107(95)00103-4; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Hoffmann B, 1999, MOL MICROBIOL, V31, P807, DOI 10.1046/j.1365-2958.1999.01219.x; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; Jones N C, 1990, Semin Cancer Biol, V1, P425; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LUDLOW JW, 1995, VIRUS RES, V35, P113, DOI 10.1016/0168-1702(94)00094-S; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MAYOL X, 1993, ONCOGENE, V8, P2561; McLeod M, 2000, MOL CELL BIOL, V20, P4016, DOI 10.1128/MCB.20.11.4016-4027.2000; MILLER ME, 1995, ONCOGENE, V11, P1623; MYMRYK JS, 1994, ONCOGENE, V9, P1187; Mymryk JS, 1996, ONCOGENE, V13, P1581; NEVINS JR, 1995, CURR TOP MICROBIOL, V199, P25; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Okayama H, 1996, ADV CANCER RES, V69, P17, DOI 10.1016/S0065-230X(08)60859-3; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; SanchezPrieto R, 1996, ONCOGENE, V13, P1083; Sang Nianli, 1995, Molecular and Cellular Differentiation, V3, P1; Sang NL, 1996, ANAL BIOCHEM, V233, P142, DOI 10.1006/abio.1996.0020; Sang NL, 1997, DNA CELL BIOL, V16, P1321, DOI 10.1089/dna.1997.16.1321; Sang NL, 1997, J CELL PHYSIOL, V170, P182, DOI 10.1002/(SICI)1097-4652(199702)170:2<182::AID-JCP10>3.0.CO;2-K; Sang NL, 1997, J CELL BIOCHEM, V66, P277, DOI 10.1002/(SICI)1097-4644(19970901)66:3<277::AID-JCB1>3.0.CO;2-M; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; SHENK T, 1991, ADV CANCER RES, V57, P47; TEODORO JG, 1995, ONCOGENE, V11, P467; Ueno NT, 1997, ONCOGENE, V15, P953, DOI 10.1038/sj.onc.1201250; WADA T, 1990, BIOCHEM BIOPH RES CO, V170, P470, DOI 10.1016/0006-291X(90)92115-G; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; YU DH, 1993, CANCER RES, V53, P891; ZIELER HA, 1995, MOL CELL BIOL, V15, P3227	66	53	53	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27026	27033		10.1074/jbc.M010346200	http://dx.doi.org/10.1074/jbc.M010346200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11358958	hybrid			2022-12-25	WOS:000169966900040
J	Mao, CD; Hoang, P; DiCorleto, PE				Mao, CD; Hoang, P; DiCorleto, PE			Lithium inhibits cell cycle progression and induces stabilization of p53 in bovine aortic endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; COLONY-STIMULATING FACTOR; LACKING FUNCTIONAL P53; BETA-CATENIN; VE-CADHERIN; IN-VIVO; MOLECULAR MECHANISM; NEURONAL APOPTOSIS; GROWTH-CONTROL; DNA-DAMAGE	Lithium affects development of various organisms and cell fate through the inhibition of glycogen synthase kinase-3 beta and induction of the Wnt/beta -catenin signaling pathway. In this study, we investigated the effects of lithium on primary bovine aortic endothelial cells (BAEC), Lithium treatment of BAEC induced beta -catenin stabilization but failed to activate the transcriptional activity of the beta -catenin/T-cell factor complex. Lithium caused a sustained G(2)/M cell cycle arrest without affecting cell viability. Reversibility of this cell cycle arrest occurred up to 3 days after treatment but was reduced thereafter. Lithium-treated BAEC exhibited a senescent-like morphology with an increase in cells positive for the senescence-associated-beta -galactosidase activity. Lithium also increased the expression of p21(CiP), a cyclin-dependent kinase inhibitor, both at the protein and RNA levels. No change in p21(Cip) mRNA stability was observed, whereas the transcriptional activity of a p21(Cip) promoter-luciferase construct containing p53 binding sites was increased after lithium treatment. Furthermore, lithium caused increased transcription of a reporter gene under the control of a promoter containing the p53 consensus binding sites both in transiently transfected BAEC and in a stably transfected fibroblast cell line. Lithium caused accumulation of p53 protein in BAEC without affecting p53 mRNA levels. Finally, upregulation of p21(Cip) in response to lithium did not occur in mouse embryonic fibroblasts that were null for p53 alleles, confirming the dependence on a p53 pathway for this lithium effect. These findings demonstrate for the first time that lithium induces also stabilization of the tumor suppressor p53 and reveal a new mechanism that may contribute to the neuroprotective effects of lithium.	Cleveland Clin Fdn, Dept Mol Cardiol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Mao, CD (corresponding author), Cleveland Clin Fdn, Dept Mol Cardiol, Lerner Res Inst, 9500 Euclid Ave,NB50, Cleveland, OH 44195 USA.				NHLBI NIH HHS [HL29582, HL34727] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034727, P01HL029582] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Ahmed Y, 1998, CELL, V93, P1171, DOI 10.1016/S0092-8674(00)81461-0; Barker N, 2000, BIOESSAYS, V22, P961; Bazzoni G, 1999, CURR OPIN CELL BIOL, V11, P573, DOI 10.1016/S0955-0674(99)00023-X; Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583; Blankesteijn WM, 2000, AM J PATHOL, V157, P877, DOI 10.1016/S0002-9440(10)64601-9; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Caveda L, 1996, J CLIN INVEST, V98, P886, DOI 10.1172/JCI118870; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745; Chen RH, 2000, J BIOL CHEM, V275, P17894, DOI 10.1074/jbc.M905336199; Chen RW, 1999, J BIOL CHEM, V274, P6039, DOI 10.1074/jbc.274.10.6039; Chernov MV, 1997, ONCOGENE, V14, P2503, DOI 10.1038/sj.onc.1201104; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; DAVIES JA, 1995, DEV BIOL, V167, P50, DOI 10.1006/dbio.1995.1006; DICORLETO PE, 1985, J CLIN INVEST, V75, P1153, DOI 10.1172/JCI111810; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Duplaa C, 1999, CIRC RES, V84, P1433; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; El-Deiry WS, 1998, CURR TOP MICROBIOL, V227, P121; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fang L, 1999, ONCOGENE, V18, P2789, DOI 10.1038/sj.onc.1202615; Finch RA, 2000, BLOOD, V96, P2262; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Giles JJ, 1999, J ANAT, V194, P197, DOI 10.1046/j.1469-7580.1999.19420197.x; Gradl D, 1999, MOL CELL BIOL, V19, P5576; Guevara NV, 1999, NAT MED, V5, P335, DOI 10.1038/6585; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; HAMMOND WP, 1982, BLOOD, V59, P179; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Ikonomov OC, 1999, AM J PSYCHIAT, V156, P1506, DOI 10.1176/ajp.156.10.1506; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kao KR, 1998, BIOL CELL, V90, P585, DOI 10.1016/S0248-4900(99)80016-1; Kim K, 2000, MOL BIOL CELL, V11, P3509, DOI 10.1091/mbc.11.10.3509; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Krylova O, 2000, J CELL BIOL, V151, P83, DOI 10.1083/jcb.151.1.83; Ladislas R, 2000, Pathol Oncol Res, V6, P3; Logan CY, 1999, DEVELOPMENT, V126, P345; Lucas FR, 1998, J CELL SCI, V111, P1351; Mao C, 2000, ARTERIOSCL THROM VAS, V20, P43, DOI 10.1161/01.ATV.20.1.43; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Matsushita H, 2000, CIRCULATION, V101, P1447, DOI 10.1161/01.CIR.101.12.1447; Mei JM, 2000, CANCER RES, V60, P3379; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Ohteki T, 2000, J EXP MED, V192, P99, DOI 10.1084/jem.192.1.99; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Shimokawa H, 1999, J MOL CELL CARDIOL, V31, P23, DOI 10.1006/jmcc.1998.0841; Smits VAJ, 1999, FEBS LETT, V457, P23, DOI 10.1016/S0014-5793(99)01002-9; Staal FJT, 1999, INT IMMUNOL, V11, P317, DOI 10.1093/intimm/11.3.317; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Torres MA, 2000, J CELL BIOL, V149, P1433, DOI 10.1083/jcb.149.7.1433; Van den Berg DJ, 1998, BLOOD, V92, P3189, DOI 10.1182/blood.V92.9.3189.421k45_3189_3202; Vonica A, 2000, DEV BIOL, V217, P230, DOI 10.1006/dbio.1999.9551; Wei HF, 2000, EUR J PHARMACOL, V392, P117, DOI 10.1016/S0014-2999(00)00127-8; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; WOODGETT JR, 1994, SEMIN CANCER BIOL, V5, P269; Wright M, 1999, BIOCHEM BIOPH RES CO, V263, P384, DOI 10.1006/bbrc.1999.1344; Yonemitsu Y, 1998, CIRC RES, V82, P147; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208	69	70	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26180	26188		10.1074/jbc.M101188200	http://dx.doi.org/10.1074/jbc.M101188200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11337498	hybrid			2022-12-25	WOS:000169823300073
J	McGuire, TF; Trump, DL; Johnson, CS				McGuire, TF; Trump, DL; Johnson, CS			Vitamin D-3-induced apoptosis of murine squamous cell carcinoma cells - Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; VITAMIN-D ANALOGS; 1,25-DIHYDROXYVITAMIN D-3; IN-VITRO; PROSTATE-CANCER; KINASE 1; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; JNK ACTIVATION; PROTEIN-KINASE; TUMOR-CELLS	Vitamin D-3 inhibits cell growth and induces apoptosis in several human cancer lines in vitro and in vivo. However, little is known about the molecular events involved in vitamin D-3-induced apoptosis, Here, we demonstrate that the growth-promoting/pro-survival signaling molecule mitogen-activated protein kinase kinase (MEK) is cleaved in a caspase-dependent manner in murine squamous cell carcinoma (SCC) cells induced to undergo apoptosis by treatment with vitamin D-3. Cleavage resulted in nearly complete loss of full-length MEK and ERK1/2 phosphorylation. ERK1/2 expression was affected only slightly. The phosphorylation and expression of Akt, a kinase regulating a second cell survival pathway, was also inhibited after treatment with vitamin D-3. However, the pro-apoptotic signaling molecule MEKK-1 was up-regulated in both apoptotic and non-apoptotic cells with greater induction and partial N-terminal proteolysis of MEKK-1 observed in apoptotic cells. In contrast to vitamin D-3, cisplatin and etoposide down-regulated Akt levels only modestly, did not promote significant loss of MEK expression, and did not up-regulate MEKK-1. We propose that vitamin D-3 induces apoptosis in SCC cells by a unique mechanism involving selective caspase-dependent MEK cleavage and up-regulation of MEKK-1, Additional evidence is provided that vitamin D-3-induced apoptosis may be mediated via p38 MAPK.	Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Urol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	McGuire, TF (corresponding author), Univ Pittsburgh, Inst Canc, W1002 Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15213 USA.	mcguire@server.pharm.pitt.edu			NCI NIH HHS [CA-67267, CA-85142] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085142, R01CA067267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE E, 1981, P NATL ACAD SCI-BIOL, V78, P4990, DOI 10.1073/pnas.78.8.4990; Blanc C, 2000, CANCER RES, V60, P4386; Blutt SE, 2000, CANCER RES, V60, P779; Blutt SE, 2000, ENDOCRINOLOGY, V141, P10, DOI 10.1210/en.141.1.10; Blutt SE, 1999, P SOC EXP BIOL MED, V221, P89, DOI 10.1046/j.1525-1373.1999.d01-60.x; Campbell MJ, 1997, J MOL ENDOCRINOL, V19, P15, DOI 10.1677/jme.0.0190015; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHO YL, 1991, CANCER RES, V51, P2848; CHOUVET C, 1986, J STEROID BIOCHEM, V24, P373, DOI 10.1016/0022-4731(86)90085-3; Danielsson C, 1998, CELL DEATH DIFFER, V5, P946, DOI 10.1038/sj.cdd.4400437; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Deak JC, 1997, BIOCHEM J, V322, P185, DOI 10.1042/bj3220185; DEL PL, 1997, SCIENCE, V278, P687; Dent P, 1998, LEUKEMIA, V12, P1843, DOI 10.1038/sj.leu.2401222; Diaz GD, 2000, CANCER RES, V60, P2304; EISMAN JA, 1987, CANCER RES, V47, P21; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Evans SRT, 1999, INT J ONCOL, V14, P979; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Fife RS, 1997, CANCER LETT, V120, P65, DOI 10.1016/S0304-3835(97)00298-X; Fioravanti L, 1998, ANTICANCER RES, V18, P1703; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Gebauer G, 2000, INT J ONCOL, V16, P321; Getzenberg RH, 1997, UROLOGY, V50, P999, DOI 10.1016/S0090-4295(97)00408-1; Gross C, 1998, J UROLOGY, V159, P2035, DOI 10.1016/S0022-5347(01)63236-1; Hansen CM, 1997, BIOCHEM PHARMACOL, V54, P1173, DOI 10.1016/S0006-2952(97)00181-0; Hershberger PA, 1999, CANCER RES, V59, P2644; James SY, 1998, BRIT J PHARMACOL, V125, P953, DOI 10.1038/sj.bjp.0702103; Jarpe MB, 1998, ONCOGENE, V17, P1475, DOI 10.1038/sj.onc.1202183; JIANG HP, 1994, ONCOGENE, V9, P3397; Johnson CS, 2000, P AN M AM SOC CLIN, V19, P19; Kawa S, 1997, BRIT J CANCER, V76, P884, DOI 10.1038/bjc.1997.479; Khwaja A, 1997, J CELL BIOL, V139, P1017, DOI 10.1083/jcb.139.4.1017; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Light BW, 1997, CANCER RES, V57, P3759; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Mathiasen IS, 1999, CANCER RES, V59, P4848; McElwain Mariann C., 1995, Molecular and Cellular Differentiation, V3, P31; Narvaez CJ, 1997, ENDOCRINOLOGY, V138, P4690, DOI 10.1210/en.138.11.4690; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Opolski A, 2000, CURR PHARM DESIGN, V6, P755, DOI 10.2174/1381612003400407; Page C, 2000, ANTICANCER RES, V20, P407; Pirianov G, 1999, CELL DEATH DIFFER, V6, P890, DOI 10.1038/sj.cdd.4400563; Rozen F, 1999, INT J ONCOL, V15, P589; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sanchez-Perez I, 1999, FEBS LETT, V453, P151, DOI 10.1016/S0014-5793(99)00690-0; SimboliCampbell M, 1996, J STEROID BIOCHEM, V58, P367, DOI 10.1016/0960-0760(96)00055-6; SimboliCampbell M, 1997, BREAST CANCER RES TR, V42, P31, DOI 10.1023/A:1005772432465; Siow YL, 1997, J BIOL CHEM, V272, P7586, DOI 10.1074/jbc.272.12.7586; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; Sundaram S, 1999, RADIAT RES, V152, P479, DOI 10.2307/3580143; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; TRUMP DL, 2000, P AN M AM SOC CLIN, V19, pA337; VanWeelden K, 1998, ENDOCRINOLOGY, V139, P2102, DOI 10.1210/en.139.4.2102; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Verlinden L, 2000, CANCER RES, V60, P2673; Wang Q, 2000, CANCER RES, V60, P2040; Welsh J, 1998, SUB CELL BIOCHEM, V30, P245; WELSH J, 1994, BIOCHEM CELL BIOL, V72, P537, DOI 10.1139/o94-072; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Widmann C, 1997, ONCOGENE, V15, P2439, DOI 10.1038/sj.onc.1201421; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Wood DE, 1999, J BIOL CHEM, V274, P8309, DOI 10.1074/jbc.274.12.8309; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xie SP, 1999, EUR J CANCER, V35, P1717, DOI 10.1016/S0959-8049(99)00200-2; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; Yu H, 1999, J La State Med Soc, V151, P218; Zhuang SH, 1998, ENDOCRINOLOGY, V139, P1197, DOI 10.1210/en.139.3.1197	74	116	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26365	26373		10.1074/jbc.M010101200	http://dx.doi.org/10.1074/jbc.M010101200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11331275	hybrid			2022-12-25	WOS:000169823300096
J	Palmer, S; Brouillet, JP; Kilbey, A; Fulton, R; Walker, M; Crossley, M; Bartholomew, C				Palmer, S; Brouillet, JP; Kilbey, A; Fulton, R; Walker, M; Crossley, M; Bartholomew, C			Evi-1 transforming and repressor activities are mediated by CtBP Co-repressor proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOCYTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; TERMINAL BINDING-PROTEIN; ZINC-FINGER PROTEIN; CELL-CYCLE CONTROL; TRANSCRIPTIONAL REPRESSION; MYELOID-LEUKEMIA; HISTONE DEACETYLASE; RAT1 FIBROBLASTS; DROSOPHILA CTBP	Ectopic production of the Evil transcriptional repressor zinc finger protein is seen in 4-6% of human acute myeloid leukemias. Overexpression also transforms Rat1 fibroblasts by an unknown mechanism, which is likely to be related to its role in leukemia and which depends upon its repressor activity. We show here that mutant murine Evi-1 proteins, lacking either the N-terminal zinc finger DNA binding domain or both DNA binding zinc finger clusters, function as dominant negative mutants by reverting the transformed phenotype of Evi-1 transformed Rat1 fibroblasts, The dominant negative activity of the non-DNA binding mutants suggests sequestration of transformation-specific cofactors and that recruitment of these cellular factors might mediate Evi-1 transforming activity. C-terminal binding protein (CtBP) co-repressor family proteins bind PLDLS-like motifs, We show that the murine Evi-1 repressor domain has two such sites, PFDLT (site a, amino acids 553-659) and PLDLS (site b, amino acids 584-599), which independently can bind CtBP family co-repressor proteins, with site b binding with higher affinity than site a. Functional analysis of specific CtBP binding mutants show site b is absolutely required to mediate both transformation of Rat1 fibroblasts and transcriptional repressor activity. This is the first demonstration that the biological activity of a mammalian cellular transcriptional repressor protein is mediated by CtBPs. Furthermore, it suggests that CtBP proteins are involved in the development of some acute leukemias and that blocking their ability to specifically interact with EVI1 might provide a target for the development of pharmacological therapeutic agents.	Glasgow Caledonian Univ, Sch Biol & Biomed Sci, Glasgow G4 0BA, Lanark, Scotland; CHU Arnaud Villeneuve, Lab Biol Cellulaire & Hormonale, F-34295 Montpellier 5, France; Univ Montpellier 1, INSERM U 540, Unite Endocrinol Mol & Cellulaire Canc, F-34090 Montpellier, France; Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow 961 1BD, Lanark, Scotland; Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia	Glasgow Caledonian University; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Beatson Institute; University of Sydney	Bartholomew, C (corresponding author), Glasgow Caledonian Univ, Sch Biol & Biomed Sci, City Campus,Cowcaddens Rd, Glasgow G4 0BA, Lanark, Scotland.		Crossley, Merlin/D-7888-2011	Crossley, Merlin/0000-0003-2057-3642				BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; Bartholomew C, 1997, ONCOGENE, V14, P569, DOI 10.1038/sj.onc.1200864; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Cuenco GM, 2000, P NATL ACAD SCI USA, V97, P1760, DOI 10.1073/pnas.030421197; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; FICHELSON S, 1992, LEUKEMIA, V6, P93; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; FUNABIKI T, 1994, ONCOGENE, V9, P1575; Furusawa T, 1999, MOL CELL BIOL, V19, P8581; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Holmes M, 1999, J BIOL CHEM, V274, P23491, DOI 10.1074/jbc.274.33.23491; HORLEIN AJ, 1995, NATURE, V377, P395; Hoyt PR, 1997, MECH DEVELOP, V65, P55, DOI 10.1016/S0925-4773(97)00057-9; Kilbey A, 1998, ONCOGENE, V16, P2287, DOI 10.1038/sj.onc.1201732; Kilbey A, 1999, CELL GROWTH DIFFER, V10, P601; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; KUROKAWA M, 1995, ONCOGENE, V11, P833; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MITANI K, 1995, BRIT J HAEMATOL, V90, P711, DOI 10.1111/j.1365-2141.1995.tb05606.x; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Nibu Y, 1998, EMBO J, V17, P7009, DOI 10.1093/emboj/17.23.7009; Ogawa S, 1996, LEUKEMIA, V10, P788; Peeters P, 1997, CANCER RES, V57, P564; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RUSSELL M, 1994, BLOOD, V84, P1243, DOI 10.1182/blood.V84.4.1243.bloodjournal8441243; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Sundqvist A, 1998, FEBS LETT, V429, P183, DOI 10.1016/S0014-5793(98)00588-2; Suzukawa K, 1997, GENOMICS, V42, P356, DOI 10.1006/geno.1997.4732; Suzukawa K, 1999, LEUKEMIA, V13, P1359, DOI 10.1038/sj.leu.2401483; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Yufu Y, 1996, AM J HEMATOL, V53, P30, DOI 10.1002/(SICI)1096-8652(199609)53:1<30::AID-AJH6>3.0.CO;2-6	49	77	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25834	25840		10.1074/jbc.M102343200	http://dx.doi.org/10.1074/jbc.M102343200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11328817	Green Published, hybrid			2022-12-25	WOS:000169823300027
J	You, ZB; Ouyang, H; Lopatin, D; Polver, PJ; Wang, CY				You, ZB; Ouyang, H; Lopatin, D; Polver, PJ; Wang, CY			Nuclear factor-kappa B-inducible death effector domain-containing protein suppresses tumor necrosis factor-mediated apoptosis by inhibiting caspase-8 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CELL-DEATH; SIGNAL-TRANSDUCTION; IMMUNE ESCAPE; ACTIVATION; FLICE; FAS; EXPRESSION; RECEPTORS; HOMOLOG; THERAPY	Activation of the transcription factor nuclear factor-kappaB (NF-kappaB) has been found to play an essential role in the inhibition of tumor necrosis factor (TNF)-mediated apoptosis, NF-kappaB regulates several antiapoptotic molecules including inhibitors of apoptosis, Bcl-2 family proteins (A1 and Bcl-X-L) and IEX-IL. Here we report that the expression of a small death effector domain (DEI)-containing protein, NDED (NF-kappaB-inducible DED-containing protein), depends on the activation of NF-kappaB, The inhibition of NF-kappaB by IKB alpha a natural inhibitor of NF-kappaB, suppressed NDED mRNA expression induced by TNF, The restoration of NDED in NF-kappaB null cells inhibited TNF-induced apoptosis, Intriguingly, unlike the caspase-8 inhibitor cellular FADD-like interleukin-1 beta converting enzyme-inhibitory protein (c-FLIP), NDED suppressed TNF-mediated apoptosis by inhibiting TNF-induced caspase-8 enzymatic activity but not the processing of caspase-8, Furthermore, NDED could not inhibit etoposide-mediated apoptosis that is independent of caspase-8 activation. Our results provide the first demonstration that NF-kappaB transcriptionally induces the DED-containing protein to suppress TNF-mediated apoptosis by inhibiting caspase-8 activity, which offers new insight into the antiapoptotic mechanism of NF-kappaB.	Univ Michigan, Lab Mol Signaling & Apoptosis, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Dent, Mol & Cellular Biol Program, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Cardiol Restorat Sci & Endodont, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA; Univ Minnesota, Sch Dent, Minneapolis, MN 55455 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Minnesota System; University of Minnesota Twin Cities	Wang, CY (corresponding author), Univ Michigan, Lab Mol Signaling & Apoptosis, Dept Biol & Mat Sci, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013848, R01DE013788] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01-DE13848, R01-DE13788] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Darnay BG, 1999, ANN RHEUM DIS, V58, P2; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Duckett CS, 1997, BBA-REV CANCER, V1332, pR45, DOI 10.1016/S0304-419X(97)00002-4; French LE, 1999, J EXP MED, V190, P891, DOI 10.1084/jem.190.7.891; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Horrevoets AJG, 1999, BLOOD, V93, P3418, DOI 10.1182/blood.V93.10.3418.410k23_3418_3431; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kumar D, 2000, J BIOL CHEM, V275, P2973, DOI 10.1074/jbc.275.4.2973; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mayo MW, 2000, BBA-REV CANCER, V1470, pM55, DOI 10.1016/S0304-419X(00)00002-0; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Owen-Schaub LB, 1998, J EXP MED, V188, P1717, DOI 10.1084/jem.188.9.1717; Ramos JW, 1998, J BIOL CHEM, V273, P33897, DOI 10.1074/jbc.273.51.33897; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	48	104	108	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26398	26404		10.1074/jbc.M102464200	http://dx.doi.org/10.1074/jbc.M102464200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11346652	hybrid			2022-12-25	WOS:000169823300100
J	Chauhan, D; Hideshima, T; Rosen, S; Reed, JC; Kharbanda, S; Anderson, KC				Chauhan, D; Hideshima, T; Rosen, S; Reed, JC; Kharbanda, S; Anderson, KC			Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; ACTIVATION; PROCASPASE-9; CASPASES; PROTEINS; KINASE; IAP; INTERLEUKIN-6; MITOCHONDRIA; SMAC/DIABLO	Smac, a second mitochondria-derived activator of caspases, promotes caspase activation in the cytochrome c (cyto-c)/Apaf-1/caspase-9 pathway. Here, we show that treatment of multiple myeloma (MM) cells with dexamethasone (Dex) triggers the release of Smac from mitochondria to cytosol and activates caspase-9 without concurrent release of cyto-e and Apaf-1 oligomerization. Smac binds to XIAP tan inhibitor of apoptosis protein) and thereby, at least in part, eliminates its inhibitory effect on caspase-9. Interleukin-6, a growth factor for MM, blocks Dex-induced apoptosis and prevents release of Smac, Taken together, these findings demonstrate that Smac plays a functional role in mediating I)ex-induced caspase-9 activation and apoptosis in MM cells.	Harvard Univ, Sch Med, Dana Farber Canc Inst,Dept Adult Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA; Northwestern Univ, Sch Med, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA; Burnham Inst, La Jolla, CA 92037 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Sanford Burnham Prebys Medical Discovery Institute	Anderson, KC (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst,Dept Adult Oncol, Jerome Lipper Multiple Myeloma Ctr, Mayer 557,44 Binney St, Boston, MA 02115 USA.				NCI NIH HHS [CA 78373] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bossy-Wetzel E, 1999, MUTAT RES-DNA REPAIR, V434, P243, DOI 10.1016/S0921-8777(99)00032-4; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Chauhan D, 2001, APOPTOSIS, V6, P47, DOI 10.1023/A:1009620027205; Chauhan D, 2000, J BIOL CHEM, V275, P27845; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mesner PW, 1999, J BIOL CHEM, V274, P22635, DOI 10.1074/jbc.274.32.22635; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; WILLIE AH, 1980, INT REV CYTOL, V68, P251; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	29	174	183	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24453	24456		10.1074/jbc.C100074200	http://dx.doi.org/10.1074/jbc.C100074200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11356822	hybrid			2022-12-25	WOS:000169800700006
J	Mayo, LD; Kessler, KM; Pincheira, R; Warren, RS; Donner, DB				Mayo, LD; Kessler, KM; Pincheira, R; Warren, RS; Donner, DB			Vascular endothelial cell growth factor activates CRE-binding protein by signaling through the KDR receptor tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS TRANSCRIPTION; PERMEABILITY FACTOR; RESPONSE ELEMENT; MAP KINASE; DEVELOPMENTAL EXPRESSION; IN-VIVO; PHOSPHORYLATION; VEGF; TRANSDUCTION; FLT-1	Vascular endothelial cell growth factor (VEGF) plays a crucial role in the development of the cardiovascular system and in promoting angiogenesis associated with physiological and pathological processes. Although a great deal is known of the cytoplasmic signaling pathways activated by VEGF, much less is known of the mechanisms through which VEGF communicates with the nucleus and alters the activity of transcription factors. Binding of VEGF to the KDR/Flk1 receptor tyrosine kinase induces phosphorylation of the CRE-binding protein (CREB) transcription factor on serine 133 and increases CREB DNA binding and transactivation. p38 MAPK/MSK-1 and protein kinase C/p90RSK pathways mediate CREB phosphorylation, Confocal microscopy shows that VEGF-induced phosphorylation of nuclear CREB is blocked by pharmacological inhibition of protein kinase C and p38 mitogen-activated protein kinase signaling. Thus, KDR/Flk1 uses multiple pathways to transmit signals into the nucleus where CREB becomes activated. These results suggest that CREB may play a role in alterations of gene expression important to angiogenesis.	Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; University of California System; University of California San Francisco	Donner, DB (corresponding author), Indiana Univ, Sch Med, Walther Oncol Ctr, 1044 W Walnut St, Indianapolis, IN 46202 USA.	ddonner@IUPUI.edu		Pincheira, Roxana/0000-0003-4277-5245	NCI NIH HHS [CA84018, CA73023] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073023] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Ankoma-Sey V, 1998, ONCOGENE, V17, P115, DOI 10.1038/sj.onc.1201912; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Blendy JA, 1998, J MOL MED-JMM, V76, P104, DOI 10.1007/s001090050197; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; BREIER G, 1992, DEVELOPMENT, V114, P521; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fentzke RC, 1998, J CLIN INVEST, V101, P2415, DOI 10.1172/JCI2950; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; Guo DQ, 2000, J BIOL CHEM, V275, P11216, DOI 10.1074/jbc.275.15.11216; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Ito N, 1998, J BIOL CHEM, V273, P23410, DOI 10.1074/jbc.273.36.23410; JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; KIM J, 1993, NATURE, V262, P841; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MONACCI WT, 1993, AM J PHYSIOL, V264, pC995, DOI 10.1152/ajpcell.1993.264.4.C995; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; PARK JE, 1994, J BIOL CHEM, V269, P25646; Parrizas M, 1997, J BIOL CHEM, V272, P154; Petrova TV, 1999, EXP CELL RES, V253, P117, DOI 10.1006/excr.1999.4707; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1986, CANCER RES, V46, P5629; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; Strawn LM, 1996, CANCER RES, V56, P3540; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wang DF, 2000, J BIOL CHEM, V275, P15905, DOI 10.1074/jbc.M001847200; Warren RS, 1996, J BIOL CHEM, V271, P29483, DOI 10.1074/jbc.271.46.29483; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; Wu LW, 2000, J BIOL CHEM, V275, P6059, DOI 10.1074/jbc.275.9.6059; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; XIE HJ, 1995, J IMMUNOL, V154, P1717; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	71	65	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25184	25189		10.1074/jbc.M102932200	http://dx.doi.org/10.1074/jbc.M102932200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11335727	hybrid			2022-12-25	WOS:000169800700101
J	Swertfeger, DK; Hui, DY				Swertfeger, DK; Hui, DY			Apolipoprotein E receptor binding Versus heparan sulfate proteoglycan binding in its regulation of smooth muscle cell migration and proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; LDL-RECEPTOR; MICE LACKING; LIPOPROTEIN-BINDING; PLASMA-LIPOPROTEINS; SYNTHETIC PEPTIDE; CYTOSOLIC ADAPTER; SURFACE RECEPTORS; APO-E; PROTEIN	This study showed that synthetic peptides containing either a single copy or tandem repeat of the receptor binding domain sequence of apolipoprotein (apo) E, or a peptide containing its C-terminal heparin binding domain, apoE-(211-243), were all effective inhibitors of platelet-derived growth factor (PDGF)-stimulated smooth muscle cell proliferation. In contrast, only the peptide containing a tandem repeating unit of the receptor binding domain sequence of apoE, apoE-(141-155)(2), was capable of inhibiting PDGF-directed smooth muscle cell migration. Peptide containing only a single unit of this sequence, apoE-(141-155), or the apoE-(211-243) peptide were ineffective in inhibiting PDGF-directed smooth muscle cell migration. Additional experiments showed that reductively methylated apoE, which is incapable of receptor binding yet retains its heparin binding capability, was equally effective as apoE in inhibiting PDGF-stimulated smooth muscle cell proliferation, However, reductively methylated apoE was unable to inhibit smooth muscle cell migration toward PDGF, Additionally, the receptor binding domain-specific apoE antibody 1D7 also mitigated the anti-migratory properties of apoE on smooth muscle cells, Finally, pretreatment of cells with heparinase failed to abolish apoE inhibition of smooth muscle cell migration. Taken together, these data documented that apoE inhibition of PDGF-stimulated smooth muscle cell proliferation is mediated by its binding to heparan sulfate proteoglycans, while its inhibition of cell migration is mediated through apoE binding to cell surface receptors.	Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Hui, DY (corresponding author), Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.		Swertfeger, Debi/AAN-6490-2021	Swertfeger, Debi/0000-0002-0570-0271	NHLBI NIH HHS [HL61332] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061332] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CARDIN AD, 1986, BIOCHEM BIOPH RES CO, V134, P783, DOI 10.1016/S0006-291X(86)80489-2; CARDIN AD, 1984, METHOD PHARMACOL, V5, P141; Couchman JR, 1996, J CELL BIOCHEM, V61, P578, DOI 10.1002/(SICI)1097-4644(19960616)61:4<578::AID-JCB11>3.0.CO;2-C; DYER CA, 1991, J BIOL CHEM, V266, P15009; DYER CA, 1988, J BIOL CHEM, V263, P10965; DYER CA, 1991, J BIOL CHEM, V266, P22803; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Hirose J, 2001, J BIOL CHEM, V276, P5228, DOI 10.1074/jbc.M007542200; HUI DY, 1984, J BIOL CHEM, V259, P860; HUI DY, 1981, J BIOL CHEM, V256, P5646; Iozzo RV, 1997, J BIOL CHEM, V272, P5219, DOI 10.1074/jbc.272.8.5219; Ishigami M, 2000, ARTERIOSCL THROM VAS, V20, P1020, DOI 10.1161/01.ATV.20.4.1020; Ishigami M, 1998, J BIOL CHEM, V273, P20156, DOI 10.1074/jbc.273.32.20156; JI ZS, 1993, J BIOL CHEM, V268, P10160; Koyama N, 1998, CIRC RES, V83, P305, DOI 10.1161/01.RES.83.3.305; Law RE, 1996, J CLIN INVEST, V98, P1897, DOI 10.1172/JCI118991; MAHLEY RW, 1979, BIOCHIM BIOPHYS ACTA, V575, P81, DOI 10.1016/0005-2760(79)90133-4; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MIMURA Y, 1995, BIOL PHARM BULL, V18, P1203; Obunike JC, 2000, ARTERIOSCL THROM VAS, V20, P111, DOI 10.1161/01.ATV.20.1.111; Paka L, 1999, J BIOL CHEM, V274, P4816, DOI 10.1074/jbc.274.8.4816; Paka L, 1999, J BIOL CHEM, V274, P36403, DOI 10.1074/jbc.274.51.36403; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; PITAS RE, 1980, J BIOL CHEM, V255, P5454; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; REDDICK RL, 1994, ARTERIOSCLER THROMB, V14, P141, DOI 10.1161/01.ATV.14.1.141; Riddell DR, 1997, J BIOL CHEM, V272, P89; Schneider WJ, 1997, CURR OPIN LIPIDOL, V8, P315, DOI 10.1097/00041433-199710000-00011; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; Swertfeger DK, 2001, FRONT BIOSCI-LANDMRK, V6, pD526, DOI 10.2741/Swertfeg; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; TENSEN CP, 1994, P NATL ACAD SCI USA, V91, P4816, DOI 10.1073/pnas.91.11.4816; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Weiser MCM, 1996, MATRIX BIOL, V15, P331, DOI 10.1016/S0945-053X(96)90136-5; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; WEISGRABER KH, 1983, J BIOL CHEM, V258, P2348; WEISGRABER KH, 1978, J BIOL CHEM, V253, P9053; Yamamoto T, 1996, CURR OPIN LIPIDOL, V7, P298, DOI 10.1097/00041433-199610000-00007; YlaHerttuala S, 1996, CURR OPIN LIPIDOL, V7, P292, DOI 10.1097/00041433-199610000-00006; Zerbinatti CV, 1999, BIOL REPROD, V61, P665, DOI 10.1095/biolreprod61.3.665; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; ZHANG SH, 1994, J CLIN INVEST, V94, P937, DOI 10.1172/JCI117460; Zhu BH, 2000, AM J PATHOL, V157, P1839, DOI 10.1016/S0002-9440(10)64823-7	47	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25043	25048		10.1074/jbc.M102357200	http://dx.doi.org/10.1074/jbc.M102357200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11350966	hybrid			2022-12-25	WOS:000169800700082
J	Vaidyanathan, VV; Puri, N; Roche, PA				Vaidyanathan, VV; Puri, N; Roche, PA			The last exon of SNAP-23 regulates granule exocytosis from mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-INDUCED TRANSLOCATION; SNARE COMPLEX; MEMBRANE-FUSION; CLOSTRIDIAL NEUROTOXINS; T-SNARE; SYNTAXIN; INHIBITION; PROTEINS; BINDING; RELEASE	SNAP-25 and its ubiquitous homolog SNAP-23 are members of the SNARE family of proteins that regulate membrane fusion during exocytosis, Although SNAP-23 has been shown to participate in a variety of intracellular transport processes, the structural domains of SNAP-23 that are required for its interaction with other SNAREs have not been determined. By employing deletion mutagenesis we found that deletion of the aminoterminal 18 amino acids of SNAP-23 (encoded in the first exon) dramatically inhibited binding of SNAP-23 to both the target SNARE syntaxin and the vesicle SNARE vesicle-associated membrane protein(VAMP). By contrast, deletion of the carboxyl-terminal 23 amino acids (encoded in the last exon) of SNAP-23 does not affect SNAP-23 binding to syntaxin but profoundly inhibits its binding to VAMP. To determine the functional relevance of the modular structure of SNAP-23, we overexpressed SNAP-23 in cells possessing the capacity to undergo regulated exocytosis. Expression of human SNAP-23 in a rat mast cell line significantly enhanced exocytosis, and this effect was not observed in transfectants expressing the carboxyl-terminal VAMP-binding mutant of SNAP-23. Despite considerable amino acid identity, we found that human SNAP-23 bound to SNAREs more efficiently than did rat SNAP-23, These data demonstrate that the introduction of a "better" SNARE binder into secretory cells augments exocytosis and defines the carboxyl terminus of SNAP-23 as an essential regulator of exocytosis in mast cells.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Roche, PA (corresponding author), NCI, Expt Immunol Branch, NIH, Bldg 10,Rm 4B36, Bethesda, MD 20892 USA.			Roche, Paul/0000-0002-8949-9172				Anderson HA, 1998, J IMMUNOL, V160, P4850; Araki S, 1997, BIOCHEM BIOPH RES CO, V234, P257, DOI 10.1006/bbrc.1997.6560; BLASI J, 1994, J PHYSIOLOGY-PARIS, V88, P235, DOI 10.1016/0928-4257(94)90086-8; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; Chen D, 2000, BLOOD, V95, P921, DOI 10.1182/blood.V95.3.921.003k17_921_929; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; Foster LJ, 1998, BIOCHEMISTRY-US, V37, P11089, DOI 10.1021/bi980253t; Guo ZH, 1998, CELL, V94, P537, DOI 10.1016/S0092-8674(00)81594-9; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Kawanishi M, 2000, J BIOL CHEM, V275, P8240, DOI 10.1074/jbc.275.11.8240; Leung SM, 1998, J BIOL CHEM, V273, P17732, DOI 10.1074/jbc.273.28.17732; LI H, 1994, GENE, V143, P303; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Low SH, 1998, J CELL BIOL, V141, P1503, DOI 10.1083/jcb.141.7.1503; Low SH, 1998, J BIOL CHEM, V273, P3422, DOI 10.1074/jbc.273.6.3422; Paumet F, 2000, J IMMUNOL, V164, P5850, DOI 10.4049/jimmunol.164.11.5850; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Rea S, 1998, J BIOL CHEM, V273, P18784, DOI 10.1074/jbc.273.30.18784; SADOUL K, 1995, J CELL BIOL, V128, P1019, DOI 10.1083/jcb.128.6.1019; Sadoul K, 1997, J BIOL CHEM, V272, P33023, DOI 10.1074/jbc.272.52.33023; St-Denis JF, 1999, BIOCHEM J, V338, P709, DOI 10.1042/0264-6021:3380709; Steegmaier M, 1998, J BIOL CHEM, V273, P34171, DOI 10.1074/jbc.273.51.34171; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Vaidyanathan VV, 2000, GENE, V247, P181, DOI 10.1016/S0378-1119(00)00100-1; Vogel K, 1999, BIOCHEM BIOPH RES CO, V258, P407, DOI 10.1006/bbrc.1999.0652; Vogel K, 2000, J BIOL CHEM, V275, P2959, DOI 10.1074/jbc.275.4.2959; Wang GY, 1997, J CELL SCI, V110, P505; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wong SH, 1999, MOL BIOL CELL, V10, P119, DOI 10.1091/mbc.10.1.119; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4	33	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25101	25106		10.1074/jbc.M103536200	http://dx.doi.org/10.1074/jbc.M103536200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11350976	hybrid			2022-12-25	WOS:000169800700090
J	Thulin, CD; Savage, JR; McLaughlin, JN; Truscott, SM; Old, WM; Ahn, NG; Resing, KA; Hamm, HE; Bitensky, MW; Willardson, BM				Thulin, CD; Savage, JR; McLaughlin, JN; Truscott, SM; Old, WM; Ahn, NG; Resing, KA; Hamm, HE; Bitensky, MW; Willardson, BM			Modulation of the G protein regulator phosducin by Ca2+/calmodulin-dependent protein kinase II phosphorylation and 14-3-3 protein binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; ROD OUTER SEGMENTS; IN-VIVO; SERINE PHOSPHORYLATION; PHOTORECEPTOR CELLS; CRYSTAL-STRUCTURE; RECEPTOR KINASE; ZETA-ISOFORM; RAT RETINA; LIGHT	Phototransduction is a canonical G protein-mediated cascade of retinal photoreceptor cells that transforms photons into neural responses. Phosducin (Pd) is a G beta gamma -binding protein that is highly expressed in photoreceptors. Pd is phosphorylated in dark-adapted retina and is dephosphorylated in response to light. Dephosphorylated Pd binds G beta gamma with high affinity and inhibits the interaction of G beta gamma with G alpha or Other effecters, whereas phosphorylated Pd does not. These results have led to the hypothesis that Pd down-regulates the light response. Consequently, it is important to understand the mechanisms of regulation of Pd phosphorylation. We have previously shown that phosphorylation of Pd by cAMP-dependent protein kinase moderately inhibits its association with G beta gamma. In this study, we report that Pd was rapidly phosphorylated by Ca2+/calmodulin-dependent kinase II, resulting in 100-fold greater inhibition of G beta gamma binding than cAMP-dependent protein kinase phosphorylation, Furthermore, Pd phosphorylation by Ca2+/calmodulin-dependent kinase II at Ser-54 and Ser-73 led to binding of the phosphoserine-binding protein 14-3-3. Importantly, in vivo decreases in Ca2+. concentration blocked the interaction of Pd with 14-3-3, indicating that Ca2+ controls the phosphorylation state of Ser-54 and Ser-73 in vivo. These results are consistent with a role for Pd in Ca2+-dependent light adaptation processes in photoreceptor cells and also suggest other possible physiological functions.	Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA; Northwestern Univ, Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA; Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA	Brigham Young University; University of Colorado System; University of Colorado Boulder; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; Northwestern University; Boston University	Willardson, BM (corresponding author), Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA.	bmwillardson@chemdept.byu.edu	Hamm, Heidi E/G-2374-2014	OLD, WILLIAM/0000-0002-9499-8478; Willardson, Barry/0000-0002-8503-2268	NATIONAL EYE INSTITUTE [R01EY006062, R01EY012287] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043768] Funding Source: NIH RePORTER; NEI NIH HHS [EY12287, EY06062] Funding Source: Medline; NIAMS NIH HHS [AR43768] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; BAUER PH, 1995, NATURE, V358, P732; BIEMANN K, 1990, METHOD ENZYMOL, V193, P455, DOI 10.1016/0076-6879(90)93433-L; Blackmer T, 2001, SCIENCE, V292, P293, DOI 10.1126/science.1058803; Boekhoff I, 1997, J BIOL CHEM, V272, P4606, DOI 10.1074/jbc.272.7.4606; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; BRONSTEIN J, 1989, BRAIN RES, V495, P83, DOI 10.1016/0006-8993(89)91220-1; BRONSTEIN JM, 1988, J NEUROCHEM, V50, P1438, DOI 10.1111/j.1471-4159.1988.tb03028.x; Chen FY, 1997, BIOCHEM BIOPH RES CO, V233, P370, DOI 10.1006/bbrc.1997.6460; CHENG HC, 1986, J BIOL CHEM, V261, P989; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; CRAFT CM, 1991, GENOMICS, V10, P400, DOI 10.1016/0888-7543(91)90325-9; Detwiler PB, 1996, CURR OPIN NEUROBIOL, V6, P440, DOI 10.1016/S0959-4388(96)80047-X; Dorner C, 1999, J BIOL CHEM, V274, P33654, DOI 10.1074/jbc.274.47.33654; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Gaudet R, 1999, MOL CELL, V3, P649, DOI 10.1016/S1097-2765(00)80358-5; GRAYKELLER MP, 1994, NEURON, V13, P849, DOI 10.1016/0896-6273(94)90251-8; HAMM H, 1990, J GEN PHYSIOL, V95, P545, DOI 10.1085/jgp.95.3.545; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; HAWES BE, 1994, J BIOL CHEM, V269, P29825; HEKMAN M, 1994, FEBS LETT, V343, P120, DOI 10.1016/0014-5793(94)80302-1; Hirooka K, 1997, VISION RES, V37, P2029, DOI 10.1016/S0042-6989(97)00175-2; ISHIDA A, 1995, BIOCHEM BIOPH RES CO, V212, P806, DOI 10.1006/bbrc.1995.2040; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; Koulen P, 1999, P NATL ACAD SCI USA, V96, P9909, DOI 10.1073/pnas.96.17.9909; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; KUO CH, 1989, NEUROSCI LETT, V103, P8, DOI 10.1016/0304-3940(89)90476-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RH, 1990, J BIOL CHEM, V265, P15867; LEE RH, 1990, J BIOL CHEM, V265, P15860; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEE RH, 1984, BIOCHEMISTRY-US, V23, P1972, DOI 10.1021/bi00304a014; LEE RH, 1988, EXP EYE RES, V46, P829, DOI 10.1016/S0014-4835(88)80035-6; LEE RH, 1992, J BIOL CHEM, V267, P25104; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Loew A, 1998, STRUCT FOLD DES, V6, P1007, DOI 10.1016/S0969-2126(98)00102-6; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muller S, 1996, J BIOL CHEM, V271, P11781, DOI 10.1074/jbc.271.20.11781; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nakano K, 2001, P NATL ACAD SCI USA, V98, P4693, DOI 10.1073/pnas.071067198; NEWTON AC, 1993, J BIOL CHEM, V268, P18181; NguyenLegros J, 1996, J NEUROCHEM, V67, P2514; PAGHROEHL K, 1995, J NEUROSCI, V15, P6475; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Pootanakit K, 1999, VISUAL NEUROSCI, V16, P221, DOI 10.1017/S0952523899162035; REIG JA, 1990, J BIOL CHEM, V265, P5816; Rey HL, 1999, J NEUROCHEM, V72, P2345, DOI 10.1046/j.1471-4159.1999.0722345.x; ROSEBOOM PH, 1994, DNA CELL BIOL, V13, P629, DOI 10.1089/dna.1994.13.629; Ruiz-Gomez A, 2000, J BIOL CHEM, V275, P29724, DOI 10.1074/jbc.M001864200; Savage JR, 2000, J BIOL CHEM, V275, P30399, DOI 10.1074/jbc.M005120200; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schulz K, 1996, J BIOL CHEM, V271, P22546, DOI 10.1074/jbc.271.37.22546; Soderling TR, 1996, BBA-PROTEIN STRUCT M, V1297, P131, DOI 10.1016/S0167-4838(96)00105-7; TERASHIMA T, 1994, BRAIN RES, V650, P133, DOI 10.1016/0006-8993(94)90215-1; THULIN CD, 1999, MOL VIS, V5, P40; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wehmeyer A, 1998, LIFE SCI, V62, pPL127, DOI 10.1016/S0024-3205(97)01190-9; WHELAN JP, 1988, J NEUROSCI RES, V20, P263, DOI 10.1002/jnr.490200216; White RR, 1998, J BIOL CHEM, V273, P3166, DOI 10.1074/jbc.273.6.3166; Wilkins JF, 1996, J BIOL CHEM, V271, P19232, DOI 10.1074/jbc.271.32.19232; Willardson BM, 1996, P NATL ACAD SCI USA, V93, P1475, DOI 10.1073/pnas.93.4.1475; WILLARDSON BM, 1993, J BIOL CHEM, V268, P6371; XU J, 1995, P NATL ACAD SCI USA, V92, P2086, DOI 10.1073/pnas.92.6.2086; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yoshida K, 1996, INVEST OPHTH VIS SCI, V37, P174; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhu X, 1998, Mol Vis, V4, P13	77	53	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23805	23815		10.1074/jbc.M101482200	http://dx.doi.org/10.1074/jbc.M101482200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11331285	hybrid			2022-12-25	WOS:000169531100079
J	Kubota, H; Ota, K; Sakaki, Y; Ito, T				Kubota, H; Ota, K; Sakaki, Y; Ito, T			Budding yeast GCN1 binds the GI domain to activate the eIF2 alpha kinase GCN2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGOCYTE NADPH OXIDASE; IMPRINTED GENE IMPACT; FACTOR 2-ALPHA KINASE; INITIATION FACTOR-II; PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; TRANSLATIONAL CONTROL; TRANSFER-RNA; MAMMALIAN-CELLS; ALPHA-SUBUNIT	When starved for a single amino acid, the budding yeast Saccharomyces cerevisiae activates the eukaryotic initiation factor 2 alpha (eIF2 alpha) kinase GCN2 in a GCN1-dependent manner. Phosphorylated eIF2 alpha inhibits general translation but selectively derepresses the synthesis of the transcription factor GCN4, which leads to coordinated induction of genes involved in biosynthesis of various amino acids, a phenomenon called general control response. We recently demonstrated that this response requires binding of GCN1 to the GI domain occurring at the N terminus of GCN2 (Kubota, H,, Sakaki, Y., and Ito, T. (2000) J. Biol. Chem. 275, 20243-20246), Here we provide the first evidence for the involvement of GCN1-GCN2 interaction in activation of GCN2 per se. We identified a C-terminal segment of GCN1 sufficient to bind the GI domain and used a novel dual bait two-hybrid method to identify mutations rendering GCN1 incapable of interacting with GCN2, The yeast bearing such an allele, gcn1-F2291L, fails to display derepression of GCN4 translation and hence general control response, as does a GI domain mutant, gcn2-Y74A,, defective in association with GCN1. Furthermore, we demonstrated that phosphorylation of eIF2 alpha is impaired in both mutants. Since GCN2 is the sole eIF2 alpha kinase in yeast, these findings indicate a critical role of GCN1-GCN2 interaction in activation of the kinase in vivo.	Kanazawa Univ, Canc Res Inst, Div Genome Biol, Kanazawa, Ishikawa 9200934, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo 1088639, Japan	Kanazawa University; University of Tokyo	Ito, T (corresponding author), Kanazawa Univ, Canc Res Inst, Div Genome Biol, 13-1 Takaramachi, Kanazawa, Ishikawa 9200934, Japan.			Ito, Takashi/0000-0001-6097-2803				Anderson J, 1998, GENE DEV, V12, P3650, DOI 10.1101/gad.12.23.3650; Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; DEALDANA CRV, 1995, EMBO J, V14, P3148; Dong JS, 2000, MOL CELL, V6, P269, DOI 10.1016/S1097-2765(00)00028-9; Garcia-Barrio M, 2000, EMBO J, V19, P1887, DOI 10.1093/emboj/19.8.1887; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hagiwara Y, 1997, P NATL ACAD SCI USA, V94, P9249, DOI 10.1073/pnas.94.17.9249; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; HINNEBUSCH AG, 1997, J BIOL CHEM, V272, P2161; Ito T, 2000, P NATL ACAD SCI USA, V97, P1143, DOI 10.1073/pnas.97.3.1143; Ito T, 1996, FEBS LETT, V385, P229, DOI 10.1016/0014-5793(96)00387-0; James P, 1996, GENETICS, V144, P1425; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; Kubota H, 2000, J BIOL CHEM, V275, P20243, DOI 10.1074/jbc.C000262200; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Marton MJ, 1997, MOL CELL BIOL, V17, P4474, DOI 10.1128/MCB.17.8.4474; MARTON MJ, 1993, MOL CELL BIOL, V13, P3541, DOI 10.1128/MCB.13.6.3541; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; Nakamura R, 1998, EUR J BIOCHEM, V251, P583, DOI 10.1046/j.1432-1327.1998.2510583.x; Okamura K, 2000, GENOME RES, V10, P1878, DOI 10.1101/gr.139200; Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451; Qiu HF, 2000, MOL CELL BIOL, V20, P2505, DOI 10.1128/MCB.20.7.2505-2516.2000; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; Sattlegger E, 2000, EMBO J, V19, P6622, DOI 10.1093/emboj/19.23.6622; SCHMITT ME, 1992, GENE DEV, V6, P1975, DOI 10.1101/gad.6.10.1975; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Tavernarakis N, 1996, GENE, V179, P271, DOI 10.1016/S0378-1119(96)00379-4; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; Yamada Y, 1999, BIOCHEM BIOPH RES CO, V256, P162, DOI 10.1006/bbrc.1999.0297; Yang RJ, 2000, MOL CELL BIOL, V20, P2706, DOI 10.1128/MCB.20.8.2706-2717.2000; Zhu SH, 1998, J BIOL CHEM, V273, P1808, DOI 10.1074/jbc.273.3.1808	37	41	44	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17591	17596		10.1074/jbc.M011793200	http://dx.doi.org/10.1074/jbc.M011793200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11350982	hybrid			2022-12-25	WOS:000168730400132
J	Arredondo, M; Munoz, P; Mura, CV; Nunez, MT				Arredondo, M; Munoz, P; Mura, CV; Nunez, MT			HFE inhibits apical iron uptake by intestinal epithelial (Caco-2) cells	FASEB JOURNAL			English	Article									Univ Chile, Fac Ciencias, Dept Biol, Santiago, Chile; Univ Chile, Inst Nutr & Tecnol Alimentos, Santiago 11, Chile; Univ Chile, Millennium Inst Adv Studies Cell Biol & Biotechno, Santiago, Chile	Universidad de Chile; Universidad de Chile; Universidad de Chile	Nunez, MT (corresponding author), Univ Chile, Fac Ciencias, Dept Biol, Casilla 653, Santiago, Chile.		Nunez, Marco/H-6348-2014	Nunez, Marco/0000-0002-1967-8570					0	32	33	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1276	1278		10.1096/fj.00-0578fje	http://dx.doi.org/10.1096/fj.00-0578fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344112				2022-12-25	WOS:000168655200034
J	Nepomuceno-Silva, JL; Yokoyama, K; de Mello, LDB; Mendonca, SM; Paixao, JC; Baron, R; Faye, JC; Buckner, FS; Van Voorhis, WC; Gelb, MH; Lopes, UG				Nepomuceno-Silva, JL; Yokoyama, K; de Mello, LDB; Mendonca, SM; Paixao, JC; Baron, R; Faye, JC; Buckner, FS; Van Voorhis, WC; Gelb, MH; Lopes, UG			TcRho1, a farnesylated Rho family homologue from Trypanosoma cruzi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; ACTIN CYTOSKELETON; SIGNALING PATHWAYS; LEISHMANIA-MAJOR; CELL BIOLOGY; S-PHASE; BRUCEI; CLONING; FARNESYLTRANSFERASE; RAS	Rho GTPases are members of the Ras superfamily and are involved in signal transduction pathways, including maintenance of cell morphology and motility, cell cycle progression, and transcription activation. We report the molecular identification in trypanosomatids (Trypanosoma cruzi) of the first member of the Rho family. The cloned Rho protein, TcRho1, shares similar to 40% homology with other members of the Rho family. Southern blot analysis revealed that TcRHO1 is a single copy gene per haploid genome, and Northern blot assays showed a transcript of 1200 nucleotides in length. Mapping the 5 ' -untranslated region of TcRHO1 transcripts revealed at least five different transcripts derived from differential trans-splicing. Three of the five transcripts contain the trans-splicing site within the coding region of the TcRHO1 gene. TeRho1 also contains the C-terminal sequence CQLF (CAAX motif), which is predicted to direct post-translation prenylation of the cysteine residue. A synthetic peptide containing this C-terminal motif, when tested against Q-Sepharose chromatography fractions from T. cruzi cytosol, was shown to be efficiently farnesylated, but not geranylgeranylated, despite the fact that the CAAX motif with X = Phe specifies geranylgeranylation by mammalian protein geranylgeranyltransferase I. Furthermore, immunoblot analyses of epimastigote protein with anti-S-farnesyleysteine methyl ester and anti-TcRhol antisera strongly suggested that TcRhol is farnesylated in vivo. The farnesylation of proteins such as Rho GTPases could be the basis for the selective cytotoxic action of protein farnesyltransferase inhibitors on trypanosomatids versus mammalian cells.	Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21949 Rio De Janeiro, Brazil; Inst C Regaud, INSERM U397, F-31052 Toulouse, France	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Universidade Federal do Rio de Janeiro; Institut National de la Sante et de la Recherche Medicale (Inserm)	Gelb, MH (corresponding author), Univ Washington, Dept Chem, Seattle, WA 98195 USA.	gelb@chem.washington.edu; lopesu@biof.ufrj.br	Lopes, Ulisses/N-4416-2013; Buckner, Frederick/AAF-3938-2020; Nepomuceno da SIlva, Jose Luciano/L-9657-2013; Lopes, Ulisses Gazos/T-6634-2019	Nepomuceno da SIlva, Jose Luciano/0000-0002-8413-2988; gelb, michael/0000-0001-7000-5219; De Melo, Luiz Dione Barbosa/0000-0003-2445-9943; Buckner, Frederick/0000-0001-7796-6477	NCI NIH HHS [CA52874] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052874] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alberts AS, 1998, EMBO J, V17, P4075, DOI 10.1093/emboj/17.14.4075; ALCINA A, 1988, CELL BIOL INT REP, V12, P979, DOI 10.1016/0309-1651(88)90166-X; Ali BRS, 1999, MOL BIOCHEM PARASIT, V104, P67, DOI 10.1016/S0166-6851(99)00131-0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Baron R, 2000, P NATL ACAD SCI USA, V97, P11626, DOI 10.1073/pnas.97.21.11626; BENAMAR MF, 1988, MOL CELL BIOL, V8, P2166, DOI 10.1128/MCB.8.5.2166; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bringaud F, 1998, MOL BIOCHEM PARASIT, V94, P249, DOI 10.1016/S0166-6851(98)00080-2; Buckner FS, 2000, J BIOL CHEM, V275, P21870, DOI 10.1074/jbc.M000975200; CamargO E. P., 1964, Revista do Instituto de Medicina Tropical de Sao Paulo, V6, P93; CAMPBELLBURK SL, 1995, METHOD ENZYMOL, V255, P3; CAPPAI R, 1993, MOL BIOCHEM PARASIT, V62, P73, DOI 10.1016/0166-6851(93)90179-2; CHAVRIER P, 1992, GENE, V112, P261, DOI 10.1016/0378-1119(92)90387-5; Concepcion JL, 1998, ARCH BIOCHEM BIOPHYS, V352, P114, DOI 10.1006/abbi.1998.0577; CONTRERAS VT, 1985, MOL BIOCHEM PARASIT, V16, P315, DOI 10.1016/0166-6851(85)90073-8; COPPENS I, 1995, MOL BIOCHEM PARASIT, V69, P29, DOI 10.1016/0166-6851(94)00192-P; Cuvillier A, 2000, J CELL SCI, V113, P2065; DAGGER F, 1989, MOL BIOL REP, V13, P197, DOI 10.1007/BF00788171; DAGHER MC, 1995, BIOCHIMIE, V77, P651, DOI 10.1016/0300-9084(96)88180-6; de Mendonca SM, 2000, GENE, V243, P179, DOI 10.1016/S0378-1119(99)00480-1; DEARRUDA MV, 1994, GENE, V139, P123, DOI 10.1016/0378-1119(94)90534-7; DESOUZA W, 1984, INT REV CYTOL, V86, P197, DOI 10.1016/S0074-7696(08)60180-1; DESOUZA W, 1983, J PARASITOL, V69, P138, DOI 10.2307/3281288; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Field H, 1996, MOL BIOCHEM PARASIT, V82, P67, DOI 10.1016/0166-6851(96)02723-5; Field H, 1997, J BIOL CHEM, V272, P10498, DOI 10.1074/jbc.272.16.10498; Field H, 2000, MOL BIOCHEM PARASIT, V106, P21, DOI 10.1016/S0166-6851(99)00192-9; Field H, 1998, J BIOL CHEM, V273, P32102, DOI 10.1074/jbc.273.48.32102; Field H, 1999, J CELL SCI, V112, P147; Field MC, 1999, PARASITOL TODAY, V15, P365, DOI 10.1016/S0169-4758(99)01499-4; FIELD MC, 1995, MOL BIOCHEM PARASIT, V69, P131, DOI 10.1016/0166-6851(94)00209-6; Field MC, 1995, EXP PARASITOL, V81, P313, DOI 10.1006/expr.1995.1122; Gelb MH, 1997, SCIENCE, V275, P1750, DOI 10.1126/science.275.5307.1750; *GEN COMP GROUP IN, GCG WISC SEQ AN SOFT; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; Godbold GD, 1998, BRAZ J MED BIOL RES, V31, P1049, DOI 10.1590/S0100-879X1998000800004; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hirai A, 1997, J BIOL CHEM, V272, P13; Hummel HS, 2000, J BIOL CHEM, V275, P35522, DOI 10.1074/jbc.M002424200; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Johnston DA, 1999, BIOESSAYS, V21, P131, DOI 10.1002/(SICI)1521-1878(199902)21:2<131::AID-BIES7>3.0.CO;2-I; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LaFlamme AC, 1995, MOL BIOCHEM PARASIT, V75, P25, DOI 10.1016/0166-6851(95)02506-5; Leal ST, 2000, EXP PARASITOL, V96, P23, DOI 10.1006/expr.2000.4549; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; MORTARA RA, 1989, J PROTOZOOL, V36, P8; PERRY RP, 1972, BIOCHIM BIOPHYS ACTA, V262, P220, DOI 10.1016/0005-2787(72)90236-5; POMPLIANO DL, 1993, BIOCHEMISTRY-US, V32, P8341, DOI 10.1021/bi00083a038; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; ROSS EM, 1995, RECENT PROG HORM RES, V50, P207; Rowinsky EK, 1999, J CLIN ONCOL, V17, P3631, DOI 10.1200/JCO.1999.17.11.3631; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER A, 1988, J CELL SCI, V90, P307; Sowa MPK, 1999, GENE, V230, P155, DOI 10.1016/S0378-1119(99)00072-4; Sturm NR, 1998, BBA-GENE STRUCT EXPR, V1442, P347, DOI 10.1016/S0167-4781(98)00150-X; Sun JZ, 1998, ONCOGENE, V16, P1467, DOI 10.1038/sj.onc.1201656; SWINDLE J, 1996, MOL BIOL PARASITIC P, P6; Tanaka K, 1998, CURR OPIN CELL BIOL, V10, P112, DOI 10.1016/S0955-0674(98)80093-8; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; VASSELLA E, 1994, NUCLEIC ACIDS RES, V22, P1359, DOI 10.1093/nar/22.8.1359; Vogt A, 1996, ONCOGENE, V13, P1991; Wiese M, 1998, EMBO J, V17, P2619, DOI 10.1093/emboj/17.9.2619; Wilson W, 1997, GENE, V187, P201, DOI 10.1016/S0378-1119(96)00749-4; Winge P, 1997, PLANT MOL BIOL, V35, P483, DOI 10.1023/A:1005804508902; Yokoyama K, 1997, MOL BIOCHEM PARASIT, V87, P61, DOI 10.1016/S0166-6851(97)00043-1; Yokoyama K, 1998, J BIOL CHEM, V273, P26497, DOI 10.1074/jbc.273.41.26497; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; Yokoyama K, 1998, MOL BIOCHEM PARASIT, V94, P87, DOI 10.1016/S0166-6851(98)00053-X	73	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29711	29718		10.1074/jbc.M102920200	http://dx.doi.org/10.1074/jbc.M102920200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11359782	hybrid			2022-12-25	WOS:000170558000017
J	Stricker, TP; Dumin, JA; Dickeson, SK; Chung, L; Nagase, H; Parks, WC; Santoro, SA				Stricker, TP; Dumin, JA; Dickeson, SK; Chung, L; Nagase, H; Parks, WC; Santoro, SA			Structural analysis of the alpha(2) integrin I domain/procollagenase-1 (matrix metalloproteinase-1) interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR; COLLAGENOLYTIC ACTIVITY; BINDING-ACTIVITY; TUMOR INVASION; EXPRESSION; LOCALIZATION; SURFACE; ANGIOGENESIS	Previous studies have established that ligation of keratinocyte alpha (2)beta (1) integrin by type I collagen induces expression of matrix metalloproteinase-1 (MMP-1) and that MMP-1 activity is required for the alpha (2)beta (1) integrin-dependent migration of primary keratinocytes across collagenous matrices. We now present evidence that MMP-1 binds the alpha (2)beta (1) integrin via the I domain of the alpha (2) integrin subunit. Using an enzyme-linked immunosorbent assay with purified human MMP-1 and recombinant alpha (2) integrin I domain, we showed that the alpha (2) integrin I domain specifically bound in a divalent cation-dependent manner to both the pro and active forms of MMP-1, but not to MMP-3 or MMP-13. Although both the I domain and MMP-1 bind divalent cations, MMP-1 bound, in a divalent cation-dependent manner, to alpha (2) integrin I domains containing metal ion-dependent adhesion sites motif mutations that prevent divalent cation binding to the I domain, demonstrating that the metal ion dependence is a function of MMP-1. Using a series of MMP-1-MMP-3 and MMP-1-MMP-13 chimeras, we determined that both the linker domain and the hemopexin-like domain of MMP-1 were required for optimal binding to the I domain. The alpha (2) integrin/MMP-1 interaction described here extends an emerging paradigm in matrix biology involving anchoring of proteinases to the cell surface to regulate their biological activities.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Univ Kansas, Med Ctr, Sch Med, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Univ London Imperial Coll Sci Technol & Med, Sch Med, Kennedy Inst Rheumatol, London W6 8LH, England	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Kansas; University of Kansas Medical Center; Imperial College London; University of Oxford	Santoro, SA (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, Box 8118, St Louis, MO 63110 USA.		Parks, William C./AAH-6786-2021					AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; Bode W, 1999, CELL MOL LIFE SCI, V55, P639, DOI 10.1007/s000180050320; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; BUSIEK DF, 1995, J IMMUNOL, V154, P6484; Caterina JJ, 2000, J BIOL CHEM, V275, P26416, DOI 10.1074/jbc.M001271200; Chung L, 2000, J BIOL CHEM, V275, P29610, DOI 10.1074/jbc.M004039200; Dickeson SK, 1998, CELL MOL LIFE SCI, V54, P556, DOI 10.1007/s000180050184; Dickeson SK, 1999, J BIOL CHEM, V274, P32182, DOI 10.1074/jbc.274.45.32182; Dickeson SK, 1997, J BIOL CHEM, V272, P7661, DOI 10.1074/jbc.272.12.7661; DIMILLA PA, 1993, J CELL BIOL, V122, P729, DOI 10.1083/jcb.122.3.729; Dumin JA, 2001, J BIOL CHEM, V276, P29368, DOI 10.1074/jbc.M104179200; FIELDS GB, 1991, J THEOR BIOL, V153, P585, DOI 10.1016/S0022-5193(05)80157-2; FISHER C, 1994, DEV BIOL, V162, P499, DOI 10.1006/dbio.1994.1104; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; Hewish MJ, 2000, J VIROL, V74, P228, DOI 10.1128/JVI.74.1.228-236.2000; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; LEE JO, 1995, CELL, V80, P681; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; Li SH, 2000, J BIOL CHEM, V275, P35384, DOI 10.1074/jbc.M005139200; Madlener M, 1998, EXP CELL RES, V242, P201, DOI 10.1006/excr.1998.4049; Messent AJ, 1998, J CELL SCI, V111, P1127; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; Mueller SC, 1999, J BIOL CHEM, V274, P24947, DOI 10.1074/jbc.274.35.24947; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Ohman T, 2001, VIRUS RES, V76, P1, DOI 10.1016/S0168-1702(01)00226-X; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; PARKS WC, 1998, MATRIX METALLOPROTEI; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; SAARIALHOKERE UK, 1992, J CLIN INVEST, V90, P1952, DOI 10.1172/JCI116073; SAARIALHOKERE UK, 1993, J INVEST DERMATOL, V100, P335, DOI 10.1111/1523-1747.ep12470032; Stolow MA, 1996, MOL BIOL CELL, V7, P1471, DOI 10.1091/mbc.7.10.1471; STRICKLIN GP, 1993, AM J PATHOL, V143, P1657; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; WOLFE GC, 1993, ARTHRITIS RHEUM-US, V36, P1540, DOI 10.1002/art.1780361108; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Yu Q, 2000, GENE DEV, V14, P163; Yu WH, 2000, J BIOL CHEM, V275, P4183, DOI 10.1074/jbc.275.6.4183	43	71	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29375	29381		10.1074/jbc.M102217200	http://dx.doi.org/10.1074/jbc.M102217200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11359774	hybrid			2022-12-25	WOS:000170346000099
J	Johnson, RA; Ince, TA; Scotto, KW				Johnson, RA; Ince, TA; Scotto, KW			Transcriptional repression by p53 through direct binding a novel DNA element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; GENE-EXPRESSION; MDR1 GENE; NF-Y; DOWN-REGULATION; P-GLYCOPROTEIN; CANCER-CELLS; MUTANT P53; ACTIVATION	The tumor suppressor protein p53 has been well documented as a transcriptional activator involved in the regulation of a number of critical genes involved in the cell cycle, response to DNA damage, and apoptosis, Activation by p53 requires the interaction of the protein with a consensus binding site consisting of two half-sites, each comprising two copies of the sequence PuPuPuC(A/T) arranged head-to-head and separated by 0-13 base pairs. In addition to activation, p53 has been shown to be a potent repressor of transcription. Howl ever; the basis for p53-mediated repression is not well understood and has been proposed to occur indirectly through interactions with other promoter-bound transcription factors. In the present study, we show that p53 can repress transcription directly by binding to a novel head-to-tail (HT) site within the MDR1 promoter. A mutation that disrupted p53 binding to the MDR1 HT site blocked p53-mediated repression of the MDR1 promoter in transfection assays. Replacement of the HT site with a head-to-head (HH) site converted the activity of p53 from repression to activation, indicating that simple recruitment of p53 to the promoter is not sufficient for repression and that the orientation of the binding element determines the fate of p53-regulated promoters.	Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol & Therapeut, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Scotto, KW (corresponding author), Fox Chase Canc Ctr, 7701 Burholme Ave,W269, Philadelphia, PA 19111 USA.			Ince, Tan/0000-0003-0315-6425	NATIONAL CANCER INSTITUTE [R01CA057307, P01CA018856, P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-08748, R01-CA57307, P01-CA18856-15] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CORNWELL MM, 1993, J BIOL CHEM, V268, P19505; Desdouets C, 1996, FEBS LETT, V385, P34, DOI 10.1016/0014-5793(96)00330-4; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Farmer G, 1996, MOL CELL BIOL, V16, P4295; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hu Z, 2000, J BIOL CHEM, V275, P2979, DOI 10.1074/jbc.275.4.2979; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Iotsova V, 1996, CELL GROWTH DIFFER, V7, P629; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Johnstone RW, 2000, TRENDS BIOCHEM SCI, V25, P1, DOI 10.1016/S0968-0004(99)01493-0; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; Kubicka S, 1999, J BIOL CHEM, V274, P32137, DOI 10.1074/jbc.274.45.32137; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MORROW CS, 1994, J BIOL CHEM, V269, P10739; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Ohlsson C, 1998, ENDOCRINOLOGY, V139, P1101, DOI 10.1210/en.139.3.1101; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SAMPATH J, 2000, P AM ASSOC CANC RES, V41, P841; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Sundseth R, 1997, MOL PHARMACOL, V51, P963, DOI 10.1124/mol.51.6.963; Thottassery JV, 1997, P NATL ACAD SCI USA, V94, P11037, DOI 10.1073/pnas.94.20.11037; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TRUANT R, 1993, J BIOL CHEM, V268, P2284; van Veen HW, 1998, ADV EXP MED BIOL, V456, P145; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Watanabe T, 2000, P NATL ACAD SCI USA, V97, P8490, DOI 10.1073/pnas.150104097; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529	40	131	134	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27716	27720		10.1074/jbc.C100121200	http://dx.doi.org/10.1074/jbc.C100121200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11350951	hybrid			2022-12-25	WOS:000169966900129
J	Pinzon-Ortiz, C; Friedman, J; Esko, J; Sinnis, P				Pinzon-Ortiz, C; Friedman, J; Esko, J; Sinnis, P			The binding of the circumsporozoite protein to cell surface heparan sulfate proteoglycans is required for Plasmodium sporozoite attachment to target cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGION-II-PLUS; MALARIA PARASITE; THROMBOSPONDIN; FALCIPARUM; INVASION; HEPATOCYTES; ANTIBODIES; INFECTIVITY; INHIBITOR; CHLORATE	The major surface protein of malaria sporozoites, the circumsporozoite protein, binds to heparan sulfate proteoglycans on the surface of hepatocytes. It has been proposed that this binding event is responsible for the rapid and specific localization of sporozoites to the liver after their injection into the skin by an infected anopheline mosquito. Previous in vitro studies performed under static conditions have failed to demonstrate a significant role for heparan sulfate proteoglycans during sporozoite invasion of cells. We performed sporozoite attachment and invasion assays under more dynamic conditions and found a dramatic decrease in sporozoite attachment to cells in the presence of heparin, In contrast to its effect on attachment, heparin does not appear to have an effect on sporozoite invasion of cells. When substituted heparins were used as competitive inhibitors of sporozoite attachment, we found that sulfation of the glycosaminoglycan chains at both the Nand O-positions was important for sporozoite adhesion to cells. We conclude that the binding of the circumsporozoite protein to hepatic heparan sulfate proteoglycans is likely to function during sporozoite attachment in the liver and that this adhesion event depends on the sulfated glycosaminoglycan chains of the proteoglycans.	NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10010 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	New York University; University of California System; University of California San Diego	Sinnis, P (corresponding author), NYU, Sch Med, Dept Med & Mol Parasitol, 341 E 25th St, New York, NY 10010 USA.			Friedman, Jennifer/0000-0001-5804-9921	NIAID NIH HHS [R01 AI056840, AI44470-02, R01 AI044470] Funding Source: Medline; NIGMS NIH HHS [R01 GM033063, R37 GM033063, GM33063] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056840, R01AI044470] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033063, R37GM033063] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; CERAMI C, 1994, J EXP MED, V179, P695, DOI 10.1084/jem.179.2.695; CHAROENVIT Y, 1987, INFECT IMMUN, V55, P604, DOI 10.1128/IAI.55.3.604-608.1987; Frevert U, 1996, MOL BIOCHEM PARASIT, V76, P257, DOI 10.1016/0166-6851(95)02563-4; FREVERT U, 1993, J EXP MED, V177, P1287, DOI 10.1084/jem.177.5.1287; Gantt S, 2000, INFECT IMMUN, V68, P3667, DOI 10.1128/IAI.68.6.3667-3673.2000; Gantt SM, 1997, J BIOL CHEM, V272, P19205, DOI 10.1074/jbc.272.31.19205; HORTIN GL, 1988, BIOCHEM BIOPH RES CO, V150, P342, DOI 10.1016/0006-291X(88)90526-8; HUMPHRIES DE, 1988, BIOCHEM BIOPH RES CO, V154, P365, DOI 10.1016/0006-291X(88)90694-8; INOUE Y, 1976, CARBOHYD RES, V46, P87, DOI 10.1016/S0008-6215(00)83533-8; INOUE Y, 1976, ANAL BIOCHEM, V71, P46, DOI 10.1016/0003-2697(76)90009-9; JASEJA M, 1989, CAN J CHEM, V67, P1449, DOI 10.1139/v89-221; LINDBLOM A, 1990, GLYCOCONJUGATE J, V7, P545, DOI 10.1007/BF01189076; LYON M, 1994, J BIOL CHEM, V269, P11208; McCormick CJ, 1999, MOL BIOCHEM PARASIT, V100, P111, DOI 10.1016/S0166-6851(99)00052-3; NARDIN EH, 1982, J EXP MED, V156, P20, DOI 10.1084/jem.156.1.20; PANCAKE SJ, 1992, J CELL BIOL, V117, P1351, DOI 10.1083/jcb.117.6.1351; RENIA L, 1988, J IMMUNOL METHODS, V112, P201, DOI 10.1016/0022-1759(88)90358-4; ROBSON KJH, 1995, EMBO J, V14, P3883, DOI 10.1002/j.1460-2075.1995.tb00060.x; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; ROGERS WO, 1992, MOL BIOCHEM PARASIT, V53, P45, DOI 10.1016/0166-6851(92)90005-5; ROGERS WO, 1992, P NATL ACAD SCI USA, V89, P9176, DOI 10.1073/pnas.89.19.9176; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Sinnis P, 1996, J EXP MED, V184, P945, DOI 10.1084/jem.184.3.945; SINNIS P, 1994, J EXP MED, V180, P297, DOI 10.1084/jem.180.1.297; Sinnis P, 1997, TRENDS MICROBIOL, V5, P52, DOI 10.1016/S0966-842X(97)84657-4; Sinnis P, 1998, J IMMUNOL METHODS, V221, P17, DOI 10.1016/S0022-1759(98)00151-3; STEWART MJ, 1986, INFECT IMMUN, V51, P859, DOI 10.1128/IAI.51.3.859-864.1986; Sultan AA, 1997, CELL, V90, P511, DOI 10.1016/S0092-8674(00)80511-5; TAKACS BJ, 1991, J IMMUNOL METHODS, V143, P231, DOI 10.1016/0022-1759(91)90048-K; UNDERHILL CB, 1977, J CELL PHYSIOL, V90, P53, DOI 10.1002/jcp.1040900108; VANDERBERG JP, 1974, J PROTOZOOL, V21, P527, DOI 10.1111/j.1550-7408.1974.tb03693.x; VANDERBERG JP, 1980, MALARIA, V2, P154; Ying P, 1997, EXP PARASITOL, V85, P168, DOI 10.1006/expr.1996.4134; YOSHIDA N, 1980, SCIENCE, V207, P71, DOI 10.1126/science.6985745	37	100	107	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26784	26791		10.1074/jbc.M104038200	http://dx.doi.org/10.1074/jbc.M104038200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11352923	hybrid, Green Accepted			2022-12-25	WOS:000169966900009
J	Tailor, CS; Marin, M; Nouri, A; Kavanaugh, MP; Kabat, D				Tailor, CS; Marin, M; Nouri, A; Kavanaugh, MP; Kabat, D			Truncated forms of the dual function human ASCT2 neutral amino acid transporter/retroviral receptor are translationally initiated at multiple alternative CUG and GUG codons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE RECEPTOR; MURINE LEUKEMIA-VIRUS; FIBROBLAST GROWTH-FACTOR; GLUTAMATE TRANSPORTER; MESSENGER-RNA; MAMMALIAN-CELLS; ENDOGENOUS RETROVIRUS; STRUCTURAL FEATURES; SINGLE-GENE; AUG	The sodium-dependent neutral amino acid transporter type 2 (ASCT2) was recently identified as a cell surface receptor for endogenously inherited retroviruses of cats, baboons, and humans as well as for horizontally transmitted type-D simian retroviruses. By functional cloning, we obtained 10 full-length 2.9-kilobase pair (kbp) cDNAs and two smaller identical 2.1-kbp cDNAs that conferred susceptibility to these viruses. Compared with the 2.9-kbp cDNA, the 2.1-kbp cDNA contains exonic deletions in its 3' noncoding region and a 627-bp 5' truncation that eliminates sequences encoding the amino-terminal portion of the full-length ASCT2 protein. Although expression of the truncated mRNA caused enhanced amino acid transport and viral receptor activities, the AUG codon nearest to its 5' end is flanked by nucleotides that are incompatible with translational initiation and the next in-frame AUG codon is far downstream toward the end of the protein coding sequence. Interestingly, the 5' region of the truncated ASCT2 mRNA contains a closely Linked series of CUG(Leu) and GUG(Val) codons in optimal consensus contexts for translational initiation. By deletion and site-directed mutagenesis, cell-free translation, and analyses of epitope-tagged ASCT2 proteins synthesized intracellularly, we determined that the truncated mRNA encodes multiple ASCT2 isoforms with distinct amino termini that are translationally initiated by a leaky scanning mechanism at these CUG and GUG codons, Although the full-length ASCT2 mRNA contains a 5'-situated AUG initiation codon, a significant degree of leaky scanning also occurred in its translation. ASCT2 isoforms with relatively short truncations were active in both amino acid transport and viral reception, whereas an isoform with a 79-amino acid truncation that lacked the first transmembrane sequence was active only in viral reception. We conclude that ASCT2 isoforms with truncated amino termini are synthesized in mammalian cells by a leaky scanning mechanism that employs multiple alternative CUG and GUG initiation codons.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Kabat, D (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd,Mail Code L224, Portland, OR 97201 USA.	kabat@ohsu.edu			NCI NIH HHS [CA25810, CA83835] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083835, R01CA025810] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; Arnaud E, 1999, MOL CELL BIOL, V19, P505; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; Baklouti F, 1996, BLOOD, V87, P3934, DOI 10.1182/blood.V87.9.3934.bloodjournal8793934; Battini JL, 1999, P NATL ACAD SCI USA, V96, P1385, DOI 10.1073/pnas.96.4.1385; BEJANIN S, 1994, J BIOL CHEM, V269, P21944; Blond JL, 2000, J VIROL, V74, P3321, DOI 10.1128/JVI.74.7.3321-3329.2000; Broer A, 2000, BIOCHEM J, V346, P705, DOI 10.1042/0264-6021:3460705; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; Cunillera N, 1997, J BIOL CHEM, V272, P15381, DOI 10.1074/jbc.272.24.15381; DICKSON C, 1990, ENZYME, V44, P225, DOI 10.1159/000468760; Eskandari S, 2000, P NATL ACAD SCI USA, V97, P8641, DOI 10.1073/pnas.97.15.8641; FALVEY E, 1995, EMBO J, V14, P4307, DOI 10.1002/j.1460-2075.1995.tb00105.x; Gammie AE, 1999, MOL CELL BIOL, V19, P817; George CX, 1999, P NATL ACAD SCI USA, V96, P4621, DOI 10.1073/pnas.96.8.4621; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; Imataka H, 1997, EMBO J, V16, P817, DOI 10.1093/emboj/16.4.817; Kekuda R, 1996, J BIOL CHEM, V271, P18657, DOI 10.1074/jbc.271.31.18657; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Li J, 2000, BBA-BIOMEMBRANES, V1467, P338, DOI 10.1016/S0005-2736(00)00232-7; Liu LM, 1997, J BIOL CHEM, V272, P2984, DOI 10.1074/jbc.272.5.2984; Liu Y, 1997, CELL, V89, P477, DOI 10.1016/S0092-8674(00)80228-7; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; Marin M, 2000, J VIROL, V74, P8085, DOI 10.1128/JVI.74.17.8085-8093.2000; Matsumoto Y, 1999, TOHOKU J EXP MED, V187, P173, DOI 10.1620/tjem.187.173; Mi S, 2000, NATURE, V403, P785, DOI 10.1038/35001608; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; PHILIPPE J, 1995, MOL ENDOCRINOL, V9, P368, DOI 10.1210/me.9.3.368; PILLEMER EA, 1986, J VIROL, V57, P413, DOI 10.1128/JVI.57.2.413-421.1986; PRATS AC, 1989, J MOL BIOL, V205, P363, DOI 10.1016/0022-2836(89)90347-1; RajBhandary UL, 2000, P NATL ACAD SCI USA, V97, P1325, DOI 10.1073/pnas.040579197; Rasko JEJ, 1999, P NATL ACAD SCI USA, V96, P2129, DOI 10.1073/pnas.96.5.2129; Slotboom DJ, 1999, MICROBIOL MOL BIOL R, V63, P293, DOI 10.1128/MMBR.63.2.293-307.1999; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; SUN ZM, 1995, MOL CELL BIOL, V15, P561, DOI 10.1128/MCB.15.1.561; Tailor CS, 1999, P NATL ACAD SCI USA, V96, P927, DOI 10.1073/pnas.96.3.927; Tailor CS, 1997, J VIROL, V71, P9383, DOI 10.1128/JVI.71.12.9383-9391.1997; Tailor CS, 1999, J VIROL, V73, P4470, DOI 10.1128/JVI.73.5.4470-4474.1999; TAIRA M, 1990, J BIOL CHEM, V265, P16491; TAKEUCHI Y, 1994, J VIROL, V68, P8001, DOI 10.1128/JVI.68.12.8001-8007.1994; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; Wimmer B, 1997, P NATL ACAD SCI USA, V94, P13624, DOI 10.1073/pnas.94.25.13624; Yang YL, 1999, NAT GENET, V21, P216, DOI 10.1038/6005; Zerangue N, 1996, J BIOL CHEM, V271, P27991, DOI 10.1074/jbc.271.45.27991	55	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27221	27230		10.1074/jbc.M100737200	http://dx.doi.org/10.1074/jbc.M100737200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11350958	Green Published, hybrid			2022-12-25	WOS:000169966900067
J	Wang, LK; Shuman, S				Wang, LK; Shuman, S			Domain structure and mutational analysis of T4 polynucleotide kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ADENYLATE KINASE; ESCHERICHIA-COLI; DNA HELICASE; LIGASE; GENE; 3'-PHOSPHATASE; POLYMERASE; RESOLUTION; MECHANISM	T4 polynucleotide kinase (Pnk) is the founding member of a family of 5'-kinase/3'-phosphatase enzymes that heal broken termini in RNA or DNA by converting 3'-PO4/5'-OH ends into 3'-OH/5'-PO4 ends, which are then suitable for sealing by RNA or DNA ligases. Here we employed site directed mutagenesis and biochemical methods to dissect the domain structure of the homotetrameric T4 Pnk protein and to localize essential constituents of the apparently separate active sites for the 5'-kinase and 3'-phosphatase activities. We characterized deletion mutants Pnk(42-301) and Pnk(1-181) which correspond to domains defined by proteolysis with chymotrypsin. Pnk(1-181) is a monomer with no 3'-phosphatase and low residual 5'-kinase activity, Pnk(42-301) is a dimer with no 5'-kinase and low residual 3'-phosphatase activity, Four classes of missense mutational effects were observed, (i) Mutations K15A, S16A, and D35A inactivated the 5'-kinase but did not affect the 3'-phosphatase or the tetrameric quaternary structure of T4 Pnk. 5'-kinase activity was ablated by the conservative mutations K15R, K15Q, and D35N; however, kinase activity was restored by the S16T change. (ii) Mutation D167A inactivated the 3'-phosphatase without affecting the 5'-kinase or tetramerization. (iii) Mutation D85A caused a severe decrement in 5'-kinase activity and only a modest effect on the 3'-phosphatase; the nearby N87A mutation resulted in a significantly reduced 3'-phosphatase activity and slightly reduced 5'-kinase activity. D85A and N87A both affected the quaternary structure, resulting in a mixed population of tetramer and dimer species, (iv) Alanine mutations at 11 other conserved positions had no significant effect on either 5'-kinase or 3'-phosphatase activity.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.							AMITSUR M, 1987, EMBO J, V6, P2499, DOI 10.1002/j.1460-2075.1987.tb02532.x; BECKER A, 1967, J BIOL CHEM, V242, P936; Berry MB, 1998, PROTEINS, V32, P276, DOI 10.1002/(SICI)1097-0134(19980815)32:3<276::AID-PROT3>3.0.CO;2-G; BYEON IJL, 1995, BIOCHEMISTRY-US, V34, P3172, DOI 10.1021/bi00010a006; CAMERON V, 1977, BIOCHEMISTRY-US, V16, P5120, DOI 10.1021/bi00642a027; Durantel D, 1998, J GEN VIROL, V79, P629, DOI 10.1099/0022-1317-79-3-629; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JARVEST RL, 1981, BIOCHEM J, V199, P273, DOI 10.1042/bj1990273; Jilani A, 1999, J BIOL CHEM, V274, P24176, DOI 10.1074/jbc.274.34.24176; Karimi-Busheri F, 1999, J BIOL CHEM, V274, P24187, DOI 10.1074/jbc.274.34.24187; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; LILLEHAUG JR, 1975, BIOCHEMISTRY-US, V14, P1221, DOI 10.1021/bi00677a020; Martins A, 1999, J VIROL, V73, P1302, DOI 10.1128/JVI.73.2.1302-1308.1999; MIDGLEY CA, 1985, EMBO J, V4, P2695, DOI 10.1002/j.1460-2075.1985.tb03989.x; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; NOVOGRODSKY A, 1966, J BIOL CHEM, V241, P2933; NOVOGRODSKY A, 1966, J BIOL CHEM, V241, P2923; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PANET A, 1973, BIOCHEMISTRY-US, V12, P5045, DOI 10.1021/bi00749a003; RICHARDSON CC, 1965, P NATL ACAD SCI USA, V54, P158, DOI 10.1073/pnas.54.1.158; Sekiguchi J, 1997, NUCLEIC ACIDS RES, V25, P727, DOI 10.1093/nar/25.4.727; SOLTIS DA, 1982, J BIOL CHEM, V257, P1332; SOLTIS DA, 1982, J BIOL CHEM, V257, P1340; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; VANDESAN.JH, 1973, BIOCHEMISTRY-US, V12, P5050, DOI 10.1021/bi00749a004	28	116	118	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26868	26874		10.1074/jbc.M103663200	http://dx.doi.org/10.1074/jbc.M103663200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11335730	hybrid			2022-12-25	WOS:000169966900020
J	Adachi, T; Wienands, J; Wakabayashi, C; Yakura, H; Reth, M; Tsubata, T				Adachi, T; Wienands, J; Wakabayashi, C; Yakura, H; Reth, M; Tsubata, T			SHP-1 requires inhibitory co-receptors to down-modulate B cell antigen receptor-mediated phosphorylation of cellular substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; KINASE ACTIVATION; LINKER-PROTEIN; SH2 DOMAIN; IG-ALPHA; MOLECULAR-COMPONENTS; NEGATIVE REGULATION; PIR-B; LYMPHOCYTES; CD22	Signaling through the B cell antigen receptor (BCR) is negatively regulated by the SH2 domain-containing protein-tyrosine phosphatase SHP-1, which requires association with tyrosine-phosphorylated proteins for activation. Upon BCR ligation, SHP-1 has been shown to associate with the BCR, the cytoplasmic protein-tyrosine kinases Lyn and Syk, and the inhibitory co-receptors CD22 and CD72, How SHP-1 is activated by BCR ligation and regulates BCR signaling is, however, not fully understood. Here we demonstrate that, in the BCR-expressing myeloma line JS58L mu m3, CD72 expression reduces the BCR ligation-induced phosphorylation of the BCR component Ig alpha /Ig beta and its cytoplasmic effecters Syk and SLP-GS, Substrate phosphorylation was restored by expression of dominant negative mutants of SHP-1, whereas the SHP-1 mutants failed to enhance phosphorylation of the cellular substrates in the absence of CD72, This indicates that SHP-1 is efficiently activated by CD72 but not by other pathways in J558L mu m3 cells and that inhibition of SHP-1 specifically activated by CD72 reverses CD72-induced dephosphorylation of cellular substrates in these cells. Taken together, BCR-induced SHP-1 activation is likely to require inhibitory co-receptors such as CD72, and SHP-1 appears to mediate the negative regulatory effect of CD72 on BCR signaling by dephosphorylating Ig alpha /Ig beta and its downstream signaling molecules Syk and SLP-65.	Tokyo Med & Dent Univ, Med Res Inst, Dept Immunol, Bunkyo Ku, Tokyo 1138510, Japan; Univ Freiburg, Dept Mol Immunol Biol 3, D-79108 Freiburg, Germany; Max Planck Inst Immunol, D-79108 Freiburg, Germany; Tokyo Metropolitan Inst Neurosci, Fuchu, Tokyo 1838526, Japan	Tokyo Medical & Dental University (TMDU); University of Freiburg; Max Planck Society; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science	Tsubata, T (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Immunol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.		Tsubata, Takeshi/AAI-7489-2021	Tsubata, Takeshi/0000-0003-0760-1258				Adachi T, 2000, J IMMUNOL, V164, P1223, DOI 10.4049/jimmunol.164.3.1223; Adachi T, 1998, J IMMUNOL, V160, P4662; Blery M, 1998, P NATL ACAD SCI USA, V95, P2446, DOI 10.1073/pnas.95.5.2446; Chan VWF, 1998, CURR BIOL, V8, P545, DOI 10.1016/S0960-9822(98)70223-4; Coggeshall KM, 1998, CURR OPIN IMMUNOL, V10, P306, DOI 10.1016/S0952-7915(98)80169-6; Cyster JG, 1997, IMMUNITY, V6, P509, DOI 10.1016/S1074-7613(00)80339-8; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; Dustin LB, 1999, J IMMUNOL, V162, P2717; FLASWINKEL H, 1994, EMBO J, V13, P83, DOI 10.1002/j.1460-2075.1994.tb06237.x; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Fujimoto M, 2000, IMMUNITY, V13, P47, DOI 10.1016/S1074-7613(00)00007-8; Hashimoto S, 1999, BLOOD, V94, P2357, DOI 10.1182/blood.V94.7.2357.419k40_2357_2364; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; Jumaa H, 1999, IMMUNITY, V11, P547, DOI 10.1016/S1074-7613(00)80130-2; Kimura T, 1996, MOL CELL BIOL, V16, P1471; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kraus M, 1999, IMMUNITY, V11, P537, DOI 10.1016/S1074-7613(00)80129-6; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; LEPRINCE C, 1993, P NATL ACAD SCI USA, V90, P3236, DOI 10.1073/pnas.90.8.3236; Maeda A, 1999, ONCOGENE, V18, P2291, DOI 10.1038/sj.onc.1202552; Maeda A, 1998, J EXP MED, V187, P1355, DOI 10.1084/jem.187.8.1355; Mizuno K, 2000, J IMMUNOL, V165, P1344, DOI 10.4049/jimmunol.165.3.1344; Nishizumi H, 1998, J EXP MED, V187, P1343, DOI 10.1084/jem.187.8.1343; ORourke L, 1997, CURR OPIN IMMUNOL, V9, P324, DOI 10.1016/S0952-7915(97)80077-5; Pan C, 1999, IMMUNITY, V11, P495, DOI 10.1016/S1074-7613(00)80124-7; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; Pao LI, 1997, J IMMUNOL, V158, P2663; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; PEAKER CJG, 1993, EUR J IMMUNOL, V23, P1358, DOI 10.1002/eji.1830230626; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; Sen G, 1999, EUR J IMMUNOL, V29, P3319; Smith KGC, 1998, J EXP MED, V187, P807, DOI 10.1084/jem.187.5.807; Somani AK, 2001, J BIOL CHEM, V276, P1938, DOI 10.1074/jbc.M006820200; Su YW, 1999, EUR J IMMUNOL, V29, P3702, DOI 10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R; Tedder TF, 1997, ANNU REV IMMUNOL, V15, P481, DOI 10.1146/annurev.immunol.15.1.481; Tooze RM, 1997, IMMUNITY, V7, P59, DOI 10.1016/S1074-7613(00)80510-5; Torres RM, 1999, IMMUNITY, V11, P527, DOI 10.1016/S1074-7613(00)80128-4; Tsubata T, 1999, CURR OPIN IMMUNOL, V11, P249, DOI 10.1016/S0952-7915(99)80041-7; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; Wienands J, 1996, P NATL ACAD SCI USA, V93, P7865, DOI 10.1073/pnas.93.15.7865; WIENANDS J, 1990, EMBO J, V9, P449, DOI 10.1002/j.1460-2075.1990.tb08130.x; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791; Wu YJ, 1998, CURR BIOL, V8, P1009, DOI 10.1016/S0960-9822(07)00421-6; YAKURA H, 1986, J IMMUNOL, V137, P1475; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; Yoshida K, 1999, J BIOL CHEM, V274, P34663, DOI 10.1074/jbc.274.49.34663	52	55	58	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26648	26655		10.1074/jbc.M100997200	http://dx.doi.org/10.1074/jbc.M100997200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11356834	hybrid			2022-12-25	WOS:000169823300130
J	Calvo, AM; Gardner, HW; Keller, NP				Calvo, AM; Gardner, HW; Keller, NP			Genetic connection between fatty acid metabolism and sporulation in Aspergillus nidulans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNGUS GAEUMANNOMYCES-GRAMINIS; ACYL-LIPID DESATURASES; SACCHAROMYCES-CEREVISIAE; SEXUAL DEVELOPMENT; INDUCED EXPRESSION; NEUROSPORA-CRASSA; IDENTIFICATION; CYANOBACTERIUM; SYNECHOCYSTIS; BIOSYNTHESIS	In the Ascomycete fungus Aspergillus nidulans, the ratio of conidia (asexual spores) to ascospores (sexual spores) is affected by linoleic acid moieties including endogenous sporogenic factors called psi factors. Deletion of odeA (Delta odeA), encoding a Delta -12 desaturase that converts oleic acid to linoleic acid, resulted in a strain depleted of polyunsaturated fatty acids (18:2 and 18:3) but increased in oleic acid (18:1) and total percent fatty acid content. Linoleic acid-derived psi factors were absent in this strain but oleic acid-derived psi factors were increased relative to wild type. The Delta odeA strain was reduced in conidial production and mycelial growth; these effects were most noticeable when cultures were grown at 26 degreesC in the dark. Under these environmental conditions, the Delta odeA strain was delayed in ascospore production but produced more ascospores than wild type over time. This suggests a role for oleic acid-derived psi factors in affecting the asexual to sexual spore ratio in A. nidulans, Fatty acid composition and spore development were also affected by veA, a gene previously shown to control light driven conidial and ascospore development. Taken together our results indicate an interaction between veA and odeA alleles for fatty acid metabolism and spore development in A. nidulans.	Texas A&M Univ, Dept Plant Pathol & Microbiol, College Stn, TX 77843 USA; USDA ARS, Natl Ctr Agr Utilizat Res, Peoria, IL 61604 USA	Texas A&M University System; Texas A&M University College Station; United States Department of Agriculture (USDA)	Keller, NP (corresponding author), Univ Wisconsin, Dept Plant Pathol, 882 Russell Labs,1630 Linden Dr, Madison, WI 53706 USA.		Keller, Nancy P./ABC-5911-2021					Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BRODOWSKY ID, 1992, BIOCHIM BIOPHYS ACTA, V1124, P59, DOI 10.1016/0005-2760(92)90126-G; BRODOWSKY ID, 1992, J BIOL CHEM, V267, P14738; BROWSE J, 1993, J BIOL CHEM, V268, P16345; Burow GB, 2000, PLANT MOL BIOL, V42, P689, DOI 10.1023/A:1006361305703; Calvo AM, 1999, APPL ENVIRON MICROB, V65, P3668; CHAMPE SP, 1989, J BACTERIOL, V171, P3982, DOI 10.1128/jb.171.7.3982-3988.1989; CHAMPE SP, 1987, J GEN MICROBIOL, V133, P1383; Fox SR, 2000, LIPIDS, V35, P23, DOI 10.1007/s11745-000-0490-5; Goodrich-Tanrikulu M, 1998, MICROBIOL-UK, V144, P1713, DOI 10.1099/00221287-144-7-1713; Heppard EP, 1996, PLANT PHYSIOL, V110, P311, DOI 10.1104/pp.110.1.311; HYEON B, 1976, CHEM REGUL PLANTS, V11, P69; Kafer E, 1977, Adv Genet, V19, P33, DOI 10.1016/S0065-2660(08)60245-X; KAFER E, 1965, GENETICS, V52, P217; KATAYAMA M, 1978, AGR BIOL CHEM TOKYO, V42, P1431, DOI 10.1080/00021369.1978.10863178; Kis M, 1998, P NATL ACAD SCI USA, V95, P4209, DOI 10.1073/pnas.95.8.4209; Kouba M, 1998, REPROD NUTR DEV, V38, P31, DOI 10.1051/rnd:19980103; Laoteng K, 1999, Mol Cell Biol Res Commun, V1, P36, DOI 10.1006/mcbr.1999.0107; Los DA, 1998, BBA-LIPID LIPID MET, V1394, P3, DOI 10.1016/S0005-2760(98)00091-5; Los DA, 1997, MOL MICROBIOL, V25, P1167, DOI 10.1046/j.1365-2958.1997.5641912.x; MAZUR P, 1990, TETRAHEDRON LETT, V31, P3837, DOI 10.1016/S0040-4039(00)97482-3; MAZUR P, 1991, J CHEM SOC CHEM COMM, P1486, DOI 10.1039/c39910001486; MCDONOUGH VM, 1992, J BIOL CHEM, V267, P5931; MIHARA K, 1990, J BIOCHEM-TOKYO, V108, P1022, DOI 10.1093/oxfordjournals.jbchem.a123301; MILLER BL, 1985, MOL CELL BIOL, V5, P1714, DOI 10.1128/MCB.5.7.1714; MURATA N, 1995, BIOCHEM J, V308, P1; MURATA N, 1989, J BIOENERG BIOMEMBR, V21, P61, DOI 10.1007/BF00762212; Nishiuchi T, 1995, PLANT MOL BIOL, V29, P599, DOI 10.1007/BF00020987; NTAMBI JM, 1995, PROG LIPID RES, V34, P139, DOI 10.1016/0163-7827(94)00010-J; NTAMBI JM, 1992, J BIOL CHEM, V267, P10925; NUKINA M, 1981, AGR BIOL CHEM TOKYO, V45, P2371, DOI 10.1080/00021369.1981.10864892; PRIDMORE RD, 1987, GENE, V56, P309, DOI 10.1016/0378-1119(87)90149-1; ROEDER PE, 1982, BIOCHEMISTRY-US, V21, P4909, DOI 10.1021/bi00263a012; SAKAMOTO T, 1994, PLANT MOL BIOL, V24, P643, DOI 10.1007/BF00023560; Sakamoto T, 1997, MOL MICROBIOL, V23, P1281, DOI 10.1046/j.1365-2958.1997.3071676.x; Sakamoto T, 1997, FEMS MICROBIOL LETT, V152, P313, DOI 10.1016/S0378-1097(97)00217-6; Sakuradani E, 1999, EUR J BIOCHEM, V261, P812, DOI 10.1046/j.1432-1327.1999.00333.x; Sambrook J., 2002, MOL CLONING LAB MANU; SKORY CD, 1992, APPL ENVIRON MICROB, V58, P3527, DOI 10.1128/AEM.58.11.3527-3537.1992; SOMERVILLE C, 1995, P NATL ACAD SCI USA, V92, P6215, DOI 10.1073/pnas.92.14.6215; Tasaka Y, 1996, EMBO J, V15, P6416, DOI 10.1002/j.1460-2075.1996.tb01033.x; Tiku PE, 1996, SCIENCE, V271, P815, DOI 10.1126/science.271.5250.815; WADA H, 1990, PLANT PHYSIOL, V92, P1062, DOI 10.1104/pp.92.4.1062; Xu J, 1999, J BIOL CHEM, V274, P23577, DOI 10.1074/jbc.274.33.23577; YAGER LN, 1992, ASPERGILLUS BIOL IND, P19; Yu JH, 1996, EMBO J, V15, P5184, DOI 10.1002/j.1460-2075.1996.tb00903.x	46	137	155	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25766	25774		10.1074/jbc.M100732200	http://dx.doi.org/10.1074/jbc.M100732200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11352908	hybrid			2022-12-25	WOS:000169823300019
J	Peruzzi, F; Prisco, M; Morrione, A; Valentinis, B; Baserga, R				Peruzzi, F; Prisco, M; Morrione, A; Valentinis, B; Baserga, R			Anti-apoptotic signaling of the insulin-like growth factor-I receptor through mitochondrial translocation of c-Raf and Nedd4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LIGASE NEDD4; PHOSPHATIDYLINOSITOL 3-KINASE; INHIBITS APOPTOSIS; SURVIVAL SIGNALS; WW DOMAINS; BAD; PHOSPHORYLATION; ACTIVATION; SUBSTRATE; GRB10	The type 1 insulin-like growth factor receptor (IGF-IR) sends a strong anti-apoptotic signal by at least three different pathways. By using mutants of the IGF-IR, we showed that one of the pathways depends on residues of the IGF-IR (serines 1280-1283) that interact with 14.3.3 proteins. The result is the activation of Raf-1 and the mitochondrial translocation of both Raf-1 and Nedd4, a target of caspases. A mutant IGF-IR in which the serines at positions 1280-1283 have been mutated to alanine does not protect from apoptosis and fails to translocate Nedd4 or Raf-1 to the mitochondria. This failure is accompanied by a loss of cytochrome c from the mitochondria, The 14.3.3/Raf-1/Nedd4 pathway is operative in the presence or absence of the insulin receptor substrate-1.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Baserga, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,624 BLSB, Philadelphia, PA 19107 USA.	r_baserga@lac.jci.tju.edu	Peruzzi, Francesca/M-9804-2014		NATIONAL CANCER INSTITUTE [P01CA078890] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016291] Funding Source: NIH RePORTER; NCI NIH HHS [CA 78890] Funding Source: Medline; NIA NIH HHS [AG 16291] Funding Source: Medline; NIDDK NIH HHS [KO1 DK 0289-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Baserga R, 1999, CONT ENDOCRINOL, V17, P329; Blakesley VA, 1999, CONT ENDOCRINOL, V17, P143; BOURGERON T, 1992, BIOCHEM BIOPH RES CO, V186, P16, DOI 10.1016/S0006-291X(05)80769-7; Craparo A, 1997, J BIOL CHEM, V272, P11663; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dews M, 2000, ENDOCRINOLOGY, V141, P1289, DOI 10.1210/en.141.4.1289; Dey BR, 1996, MOL ENDOCRINOL, V10, P631, DOI 10.1210/me.10.6.631; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; Furlanetto RW, 1997, BIOCHEM J, V327, P765; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GOTTLIEB RA, 2000, GENE EXPRESSION, V10, P231; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Harvey KF, 1999, TRENDS CELL BIOL, V9, P166, DOI 10.1016/S0962-8924(99)01541-X; Harvey KF, 1998, J BIOL CHEM, V273, P13524, DOI 10.1074/jbc.273.22.13524; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; Jolliffe CN, 2000, BIOCHEM J, V351, P557, DOI 10.1042/0264-6021:3510557; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kosaki A, 1998, J BIOL CHEM, V273, P940, DOI 10.1074/jbc.273.2.940; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; Li SW, 1996, J BIOL CHEM, V271, P12254, DOI 10.1074/jbc.271.21.12254; Morrione A, 1996, CANCER RES, V56, P3165; Morrione A, 1999, J BIOL CHEM, V274, P24094, DOI 10.1074/jbc.274.34.24094; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Nantel A, 1999, J BIOL CHEM, V274, P35719, DOI 10.1074/jbc.274.50.35719; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; Navarro M, 2001, ENDOCRINOLOGY, V142, P1073, DOI 10.1210/en.142.3.1073; Parrizas M, 1997, J BIOL CHEM, V272, P154; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Reuther GW, 1996, VITAM HORM, V52, P149, DOI 10.1016/S0083-6729(08)60410-0; Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; Romano G, 1999, J CELL BIOCHEM, V72, P294, DOI 10.1002/(SICI)1097-4644(19990201)72:2<294::AID-JCB14>3.0.CO;2-0; Rommel C, 1996, ONCOGENE, V12, P609; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Salomoni P, 1998, J EXP MED, V187, P1995, DOI 10.1084/jem.187.12.1995; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Soon L, 1999, MOL CELL BIOL, V19, P3816; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Valentinis B, 2000, J BIOL CHEM, V275, P25451, DOI 10.1074/jbc.M002271200; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	57	64	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25990	25996		10.1074/jbc.M103188200	http://dx.doi.org/10.1074/jbc.M103188200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11352919	hybrid, Green Published			2022-12-25	WOS:000169823300048
J	Eckman, EA; Reed, DK; Eckman, CB				Eckman, EA; Reed, DK; Eckman, CB			Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-DEGRADING ENZYME; MEMBRANE-BOUND METALLOPROTEASE; PRECURSOR PROTEIN; INTRACELLULAR COMPARTMENT; NEUTRAL ENDOPEPTIDASE; EXTRACELLULAR LEVELS; CEREBROSPINAL-FLUID; MOLECULAR-CLONING; BIG ENDOTHELIN-1; HUMAN TISSUES	Deposition of beta -amyloid (A beta) peptides in the brain is an early and invariant feature of all forms of Alzheimer's disease. As with any secreted protein, the extracellular concentration of A beta is determined not only by its production but also by its catabolism. A major focus of Alzheimer's research has been the elucidation of the mechanisms responsible for the generation of A beta, Much less, however, is known about the mechanisms responsible for A beta removal in the brain, In this report, we describe the identification of endothelin-converting enzyme-1 (ECE-1) as a novel A beta -degrading enzyme. We show that treatment of endogenous ECE-expressing cell lines with the metalloprotease inhibitor phosphoramidon causes a 2-3-fold elevation in extracellular A beta concentration that appears to be due to inhibition of intracellular A beta degradation. Furthermore, we show that overexpression of ECE-1 in Chinese hamster ovary cells, which lack endogenous ECE activity, reduces extracellular A beta concentration by up to 90% and that this effect is completely reversed by treatment of the cells with phosphoramidon. Finally, we show that recombinant soluble ECE-1 is capable of hydrolyzing synthetic A beta 40 and A beta 42 in vitro at multiple sites.	Mayo Clin Jacksonville, Jacksonville, FL 32224 USA	Mayo Clinic	Eckman, CB (corresponding author), Mayo Clin Jacksonville, 4500 San Pablo Rd,Birdsall Bldg,Rm 253, Jacksonville, FL 32224 USA.		Eckman, Elizabeth/AAL-7316-2021	Eckman, Elizabeth/0000-0002-5391-4960				Ahn K, 1998, ARCH BIOCHEM BIOPHYS, V359, P258, DOI 10.1006/abbi.1998.0913; Ahn K, 1998, BIOCHEM BIOPH RES CO, V243, P184, DOI 10.1006/bbrc.1998.8081; AHN K, 1995, LIFE SCI, V56, P2331, DOI 10.1016/0024-3205(95)00227-W; ANSORGE S, 1984, BIOMED BIOCHIM ACTA, V43, P39; ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; Azarani A, 1998, BIOCHEM J, V333, P439, DOI 10.1042/bj3330439; Backstrom JR, 1996, J NEUROSCI, V16, P7910; Barnes K, 1997, J NEUROCHEM, V68, P570; Cailler F, 1999, BIOCHEM J, V341, P119, DOI 10.1042/0264-6021:3410119; CHECLER F, 1995, J NEUROCHEM, V65, P1431; Chesneau V, 2000, BIOCHEM J, V351, P509, DOI 10.1042/0264-6021:3510509; CORVOL P, 1995, METHOD ENZYMOL, V248, P283; Davenport AP, 1998, HISTOCHEM J, V30, P359, DOI 10.1023/A:1003236628701; ECKMAN CB, 1995, SOC NEUROSCIENCE; Emoto N, 1999, J BIOL CHEM, V274, P1509, DOI 10.1074/jbc.274.3.1509; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; Fahnoe DC, 2000, J CARDIOVASC PHARM, V36, pS22, DOI 10.1097/00005344-200036051-00009; FULLER SJ, 1995, BIOCHEMISTRY-US, V34, P8091, DOI 10.1021/bi00025a015; Ghaddar G, 2000, BIOCHEM J, V347, P419, DOI 10.1042/0264-6021:3470419; Golde TE, 2000, BBA-MOL BASIS DIS, V1502, P172, DOI 10.1016/S0925-4439(00)00043-0; Gray GA, 1996, PHARMACOL THERAPEUT, V72, P109, DOI 10.1016/S0163-7258(96)00101-5; GRONHAGENRISKA C, 1980, SCAND J CLIN LAB INV, V40, P711, DOI 10.3109/00365518009095586; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Hasegawa H, 1998, FEBS LETT, V428, P304, DOI 10.1016/S0014-5793(98)00554-7; Hoang MV, 1997, BIOCHEM J, V327, P23, DOI 10.1042/bj3270023; HOWELL S, 1995, PEPTIDES, V16, P647, DOI 10.1016/0196-9781(95)00021-B; Ikeda K, 1999, J BIOL CHEM, V274, P32469, DOI 10.1074/jbc.274.45.32469; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Johnson GD, 1999, J BIOL CHEM, V274, P4053, DOI 10.1074/jbc.274.7.4053; Kehoe P, 1999, HUM MOL GENET, V8, P237, DOI 10.1093/hmg/8.2.237; Korth P, 1999, J HISTOCHEM CYTOCHEM, V47, P447, DOI 10.1177/002215549904700403; Korth P, 1997, FEBS LETT, V417, P365, DOI 10.1016/S0014-5793(97)01323-9; KUKKOLA PJ, 1995, J CARDIOVASC PHARM, V26, pS65; KUROCHKIN IV, 1994, FEBS LETT, V345, P33, DOI 10.1016/0014-5793(94)00387-4; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; Parnot C, 1997, HYPERTENSION, V30, P837, DOI 10.1161/01.HYP.30.4.837; Perez A, 2000, NEUROCHEM RES, V25, P247, DOI 10.1023/A:1007527721160; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; Qiu WQ, 1996, J BIOL CHEM, V271, P8443, DOI 10.1074/jbc.271.14.8443; ROQUES BP, 1990, TRENDS PHARMACOL SCI, V11, P245; Russell FD, 1999, CIRC RES, V84, P891; SAWAMURA T, 1991, BIOCHEM BIOPH RES CO, V174, P779, DOI 10.1016/0006-291X(91)91485-U; SCHMIDT M, 1994, FEBS LETT, V356, P238, DOI 10.1016/0014-5793(94)01277-6; Schweizer A, 1997, BIOCHEM J, V328, P871, DOI 10.1042/bj3280871; SHIMADA K, 1995, FEBS LETT, V371, P140, DOI 10.1016/0014-5793(95)00886-E; Soleilhac JM, 1996, EUR J CLIN INVEST, V26, P1011, DOI 10.1046/j.1365-2362.1996.2420580.x; SPILLANTINI MG, 1990, BIOCHEM PHARMACOL, V39, P1353, DOI 10.1016/0006-2952(90)90012-A; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Takaki Y, 2000, J BIOCHEM-TOKYO, V128, P897, DOI 10.1093/oxfordjournals.jbchem.a022839; Tanja O, 2000, BIOCHEM BIOPH RES CO, V271, P565, DOI 10.1006/bbrc.2000.2664; Telemaque S, 1998, J CARDIOVASC PHARM, V31, pS548, DOI 10.1097/00005344-199800001-00158; Turner AJ, 1997, FASEB J, V11, P355, DOI 10.1096/fasebj.11.5.9141502; Turner AJ, 1996, BIOCHEM PHARMACOL, V51, P91, DOI 10.1016/0006-2952(95)02036-5; UMEZAWA S, 1972, Tetrahedron Letters, V1, P97; Valdenaire O, 1999, EUR J BIOCHEM, V264, P341, DOI 10.1046/j.1432-1327.1999.00602.x; VALDENAIRE O, 1995, J BIOL CHEM, V270, P29794; Vekrellis K, 2000, J NEUROSCI, V20, P1657; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; Yamin R, 1999, J BIOL CHEM, V274, P18777, DOI 10.1074/jbc.274.26.18777; Yanagisawa H, 1998, DEVELOPMENT, V125, P825; Yanagisawa H, 2000, J CLIN INVEST, V105, P1373, DOI 10.1172/JCI7447; YOSHIZAWA T, 1992, NEUROPEPTIDES, V22, P85, DOI 10.1016/0143-4179(92)90059-6	62	283	293	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24540	24548		10.1074/jbc.M007579200	http://dx.doi.org/10.1074/jbc.M007579200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11337485	hybrid			2022-12-25	WOS:000169800700018
J	Zhu, XJ; Kahn, RA				Zhu, XJ; Kahn, RA			The Escherichia coli heat labile toxin binds to Golgi membranes and alters golgi and cell morphologies using ADP-ribosylation factor-dependent processes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLERA-TOXIN; BREFELDIN-A; ADENYLATE-CYCLASE; RIBOSYLTRANSFERASE ACTIVITY; MUCOSAL ADJUVANTICITY; DOWNSTREAM EFFECTOR; NUCLEOTIDE-EXCHANGE; PROTEIN COFACTOR; PLASMA-MEMBRANE; PHOSPHOLIPASE-D	The fate of the catalytic subunit of the Escherichia coli heat labile toxin (LTA(1)) was studied after expression in mammalian cells to assess the requirement for ADP-ribosylation factor (ARF) binding to localization and toxicity and ability to compete with endogenous ARF effecters, A progression in LTA(1) localization from cytosol to binding Golgi stacks to condensation of Golgi membranes was found to correlate with the time and level of LTA(1) expression. At the highest levels of LTA(1) expression the staining of LTA and both extrinsic and lumenal Golgi markers all became diffuse, in a fashion reminiscent of the actions of brefeldin A. Thus, LTA(1) binds to the Golgi and can alter its morphology in two distinct ways. However, point mutants of LTA(1) that are defective in the ability to bind activated ARF were also unable to bind Golgi membranes or modify Golgi morphology. Co-expression of mutants of ARF3 that regained binding to these same mutant LTA(1) proteins restored the localization and activities of the toxin, Thus, binding to ARF is required both for the localization of the toxin to the Golgi and for effects on Golgi membranes. A correlation was also seen between the ability of LTA mutants to bind ARF and the increase in cellular cAMP levels. These results demonstrate the importance of ARF binding to the toxicity and cellular effects of the ADP-ribosylating bacterial toxin and reveal that mutants defective in binding ARF retain basal ADP-ribosylation activity but are the least toxic LTA(1) mutants yet described, making them the best candidates for development as mucosal adjuvants.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA	Emory University	Kahn, RA (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd, Atlanta, GA 30322 USA.	rkahn@emory.edu	Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601				AMRTIN ME, 2000, J BIOL CHEM, V275, P19050; Bastiaens PIH, 1996, EMBO J, V15, P4246, DOI 10.1002/j.1460-2075.1996.tb00799.x; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P2669, DOI 10.1073/pnas.75.6.2669; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Cheng E, 1999, VACCINE, V18, P38, DOI 10.1016/S0264-410X(99)00168-1; Cieplak W, 1995, J BIOL CHEM, V270, P30545, DOI 10.1074/jbc.270.51.30545; CLEMENTS JD, 1988, VACCINE, V6, P269, DOI 10.1016/0264-410X(88)90223-X; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; ELSON CO, 1984, J IMMUNOL, V132, P2736; Freytag LC, 1999, CURR TOP MICROBIOL, V236, P215; GILL DM, 1980, J INFECT DIS, V141, P64, DOI 10.1093/infdis/141.1.64; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; GUERRANT RL, 1974, INFECT IMMUN, V10, P320, DOI 10.1128/IAI.10.2.320-327.1974; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kuai J, 2000, J BIOL CHEM, V275, P4022, DOI 10.1074/jbc.275.6.4022; LENCER WI, 1995, J CELL BIOL, V131, P951, DOI 10.1083/jcb.131.4.951; Lencer WI, 1999, BBA-MOL CELL RES, V1450, P177, DOI 10.1016/S0167-4889(99)00070-1; Majoul I, 1998, J CELL BIOL, V143, P601, DOI 10.1083/jcb.143.3.601; Majoul IV, 1996, J CELL BIOL, V133, P777, DOI 10.1083/jcb.133.4.777; MERRITT EA, 1995, CURR OPIN STRUC BIOL, V5, P165, DOI 10.1016/0959-440X(95)80071-9; MOSS J, 1993, J BIOL CHEM, V268, P6383; MOSS J, 1977, J BIOL CHEM, V252, P2455; NASHAR TO, 1993, VACCINE, V11, P235, DOI 10.1016/0264-410X(93)90023-Q; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Rappuoli R, 1999, IMMUNOL TODAY, V20, P493, DOI 10.1016/S0167-5699(99)01523-6; Rodighiero C, 1999, J BIOL CHEM, V274, P3962, DOI 10.1074/jbc.274.7.3962; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SIXMA TK, 1993, J MOL BIOL, V230, P890, DOI 10.1006/jmbi.1993.1209; Snider DP, 1995, CRIT REV IMMUNOL, V15, P317, DOI 10.1615/CritRevImmunol.v15.i3-4.70; Stevens LA, 1999, INFECT IMMUN, V67, P259; Togawa A, 1999, J BIOL CHEM, V274, P12308, DOI 10.1074/jbc.274.18.12308; Williams NA, 1999, IMMUNOL TODAY, V20, P95, DOI 10.1016/S0167-5699(98)01397-8; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289; Zhu XJ, 2000, J BIOL CHEM, V275, P13465, DOI 10.1074/jbc.275.18.13465; Zhu XJ, 2001, BIOCHEMISTRY-US, V40, P4560, DOI 10.1021/bi002628s	43	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25014	25021		10.1074/jbc.M100923200	http://dx.doi.org/10.1074/jbc.M100923200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11333260	hybrid			2022-12-25	WOS:000169800700078
J	Feng, X; Jiang, Y; Meltzer, P; Yen, PM				Feng, X; Jiang, Y; Meltzer, P; Yen, PM			Transgenic targeting of a dominant negative corepressor to liver blocks basal repression by thyroid hormone receptor and increases cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTOR; CANDIDATE PROTOONCOGENE BCL-3; TUMOR-NECROSIS-FACTOR; KAPPA-B PROTEIN; N-COR; TRANSCRIPTIONAL REPRESSION; HISTONE DEACETYLASE; CYCLE CONTROL; PARTIAL-HEPATECTOMY; REGENERATING LIVER	Unliganded thyroid hormone receptors (TRs) interact with corepressors and repress basal transcription of target genes in cotransfection and in vitro studies. Currently, little is known about the function of corepressors in vivo. We thus used a mouse albumin promoter to generate several transgenic mouse lines that overexpressed a dominant negative mutant corepressor, NCoRi, in liver. The transgenic mice had normal liver weight, appearance, and minimal changes in enzyme activity. To study the effects of NCoRi on transcription of hepatic target genes, we examined T-3-regulated gene expression of hypo- and hyperthyroid transgenic mice. In hypothyroid mice, hepatic expression of Spot 14, Bcl-3, glucose 6-phosphatase, and 5'-deiodinase mRNA was higher in transgenic mice than littermate controls whereas these genes were induced to similar levels in T-3-treated mice. Derepression was not observed for malic enzyme mRNA expression in hypothyroid mice. Thus, NCoRi selectively blocked basal transcription of several thyroid hormone-responsive genes but had no effect on ligand-mediated transcription. Additionally, compensatory increases in endogenous SMRT and NCoR mRNA were observed in hypothyroid transgenic mice, Interestingly, hepatocyte proliferation as detected by BrdUrd incorporation was increased in transgenic mice. The gene profile in transgenic mouse livers was studied by cDNA microarray, and several genes related to cell proliferation were induced, In summary, our studies show that NCoR plays important roles in mediating basal repression by TRs and may prevent cellular proliferation in vivo.	NIDDK, Mol Regulat & Neuroendocrinol Sect, Clin Endocrinol Branch, Bethesda, MD 20892 USA; NHRGI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Yen, PM (corresponding author), NIDDK, Mol Regulat & Neuroendocrinol Sect, Clin Endocrinol Branch, Bethesda, MD 20892 USA.		Yen, Paul M/V-9857-2019	Yen, Paul/0000-0002-3790-8114	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK055101] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKERMAN P, 1992, AM J PHYSIOL, V263, pG579, DOI 10.1152/ajpgi.1992.263.4.G579; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Bailey P, 1999, MOL ENDOCRINOL, V13, P1155, DOI 10.1210/me.13.7.1155; Blanchard JM, 2000, BIOCHEM PHARMACOL, V60, P1179, DOI 10.1016/S0006-2952(00)00384-1; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chin WW, 1996, ENDOCRINOLOGY, V137, P387, DOI 10.1210/en.137.2.387; CONOVER CA, 1991, ENDOCRINOLOGY, V129, P710, DOI 10.1210/endo-129-2-710; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Feng X, 2000, MOL ENDOCRINOL, V14, P947, DOI 10.1210/me.14.7.947; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Gauthier K, 1999, EMBO J, V18, P623, DOI 10.1093/emboj/18.3.623; GHAHARY A, 1992, HEPATOLOGY, V15, P1125, DOI 10.1002/hep.1840150625; GILLESPIEA JR, 2000, BIOCHIM BIOPHYS ACTA, V14, P1; Gothe S, 1999, GENE DEV, V13, P1329, DOI 10.1101/gad.13.10.1329; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hollenberg AN, 1996, J BIOL CHEM, V271, P28516, DOI 10.1074/jbc.271.45.28516; Hong SH, 2000, MOL CELL BIOL, V20, P6612, DOI 10.1128/MCB.20.17.6612-6625.2000; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Kawamura T, 1997, HEPATOLOGY, V25, P1014, DOI 10.1002/hep.510250437; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lazar MA, 1999, J INVEST MED, V47, P364; Li H, 1997, MOL ENDOCRINOL, V11, P2025, DOI 10.1210/me.11.13.2025; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; Na SY, 1998, J BIOL CHEM, V273, P30933, DOI 10.1074/jbc.273.47.30933; Na SY, 1999, J BIOL CHEM, V274, P28491, DOI 10.1074/jbc.274.40.28491; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; Park EJ, 1999, P NATL ACAD SCI USA, V96, P3519, DOI 10.1073/pnas.96.7.3519; Payraudeau V, 1998, MOL CELL ENDOCRINOL, V143, P107, DOI 10.1016/S0303-7207(98)00136-1; Phaneuf D, 2000, MOL MED, V6, P96, DOI 10.1007/BF03401777; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rao G, 1996, ONCOGENE, V12, P1165; Rebollo A, 2000, MOL CELL BIOL, V20, P3407, DOI 10.1128/MCB.20.10.3407-3416.2000; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; Servillo G, 1997, ONCOGENE, V14, P1601, DOI 10.1038/sj.onc.1200996; Servillo G, 1998, GENE DEV, V12, P3639, DOI 10.1101/gad.12.23.3639; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Snibson KJ, 1999, LIVER, V19, P242, DOI 10.1111/j.1478-3231.1999.tb00042.x; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; TABOR E, 1994, J MED VIROL, V42, P357, DOI 10.1002/jmv.1890420406; Tagami T, 1997, MOL CELL BIOL, V17, P2642, DOI 10.1128/MCB.17.5.2642; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weiss RE, 1998, ENDOCRINOLOGY, V139, P4945, DOI 10.1210/en.139.12.4945; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Zamir I, 1996, MOL CELL BIOL, V16, P5458; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	60	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15066	15072		10.1074/jbc.M011027200	http://dx.doi.org/10.1074/jbc.M011027200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11328825	hybrid			2022-12-25	WOS:000168528800073
J	Koushik, SV; Wang, J; Rogers, R; Moskophidis, D; Lambert, NA; Creazzo, TL; Conway, SJ				Koushik, SV; Wang, J; Rogers, R; Moskophidis, D; Lambert, NA; Creazzo, TL; Conway, SJ			Targeted inactivation of the sodium-calcium exchanger (Ncx1) results in the lack of a heartbeat and abnormal myofibrillar organization	FASEB JOURNAL			English	Article									Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA; Med Coll Georgia, Augusta Vet Affairs Med Ctr, Augusta, GA 30912 USA; Med Coll Georgia, Dept Cell Biol & Anat, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Conway, SJ (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, 1120 15th St,CB2803, Augusta, GA 30912 USA.								0	188	195	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1209	1211		10.1096/fj.00-0696fje	http://dx.doi.org/10.1096/fj.00-0696fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344090				2022-12-25	WOS:000168655200012
J	Meyer, MG; Park, S; Zeringue, L; Staley, M; McKinstry, M; Kaufman, RI; Zhang, H; Yan, DL; Yennawar, N; Yennawar, H; Farber, GK; Nixon, BT				Meyer, MG; Park, S; Zeringue, L; Staley, M; McKinstry, M; Kaufman, RI; Zhang, H; Yan, DL; Yennawar, N; Yennawar, H; Farber, GK; Nixon, BT			A dimeric two-component receiver domain inhibits the sigma 54-dependent ATPase in DctD	FASEB JOURNAL			English	Article									Penn State Univ, Dept Biochem & Mol Biol, Althouse Lab 6, University Pk, PA 16802 USA; Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of California System; University of California Berkeley	Nixon, BT (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Althouse Lab 6, University Pk, PA 16802 USA.		ID, IMCACAT/D-5867-2014	Yennawar, Hemant P./0000-0003-2869-1109					0	32	32	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1326	1328		10.1096/fj.00-0516fje	http://dx.doi.org/10.1096/fj.00-0516fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344129				2022-12-25	WOS:000168655200051
J	Schmidt-Ott, KM; Xu, AD; Tuschick, S; Liefeldt, L; Kresse, W; Verkhratsky, A; Kettenmann, H; Paul, M				Schmidt-Ott, KM; Xu, AD; Tuschick, S; Liefeldt, L; Kresse, W; Verkhratsky, A; Kettenmann, H; Paul, M			Hypoxia reverses dibutyryl-cAMP-induced stellation of cultured astrocytes via activation of the endothelin system	FASEB JOURNAL			English	Article									Free Univ Berlin, Benjamin Franklin Med Ctr, Inst Clin Pharmacol & Toxicol, D-14195 Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany; Jinan Univ, Dept Neurol, Guangzhou, Peoples R China	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Jinan University	Paul, M (corresponding author), Free Univ Berlin, Benjamin Franklin Med Ctr, Inst Clin Pharmacol & Toxicol, Garystr 5, D-14195 Berlin, Germany.		Schmidt-Ott, Kai/F-4588-2011; Kettenmann, Helmut/AAJ-5142-2021; Verkhratsky, Alexei/J-4527-2013; Paul, Martin/K-5425-2015	Schmidt-Ott, Kai/0000-0002-7700-7142; Verkhratsky, Alexei/0000-0003-2592-9898; Liefeldt, Lutz/0000-0002-3964-4685; Kettenmann, Helmut/0000-0001-8208-0291; Xu, An-Ding/0000-0003-3154-0985					0	10	10	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1227	1229		10.1096/fj.00-0625fje	http://dx.doi.org/10.1096/fj.00-0625fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344096				2022-12-25	WOS:000168655200018
J	Suliman, A; Lam, A; Datta, R; Srivastava, RK				Suliman, A; Lam, A; Datta, R; Srivastava, RK			Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways	ONCOGENE			English	Article						TRAIL; death receptor; FADD; caspase; mitochondria; Bcl-2; Bcl-X-L	CYTOCHROME-C RELEASE; CYTOTOXIC LIGAND TRAIL; PROGRAMMED CELL-DEATH; NF-KAPPA-B; MEDIATED APOPTOSIS; CANCER-CELLS; FAS LIGAND; IONIZING-RADIATION; BACULOVIRUS P35; CD95 APO-1/FAS	Tumor necrosis (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family of cytokines that promotes apoptosis, TRAIL induces apoptosis via death receptors (DR4 and DR5) in a wide variety of tumor cells but not in normal cells. The objectives of this study are to investigate the intracellular mechanisms by which TRAIL induces apoptosis, The death receptor Fas, upon ligand binding, trimerizes and recruits the adaptor protein FADD through the cytoplasmic death domain of Fas, FADD then binds and activates procaspase-8. It is unclear whether FADD is required for TRAIL-induced apoptosis, Here we show that the signaling complex of DR4/DR5 is assembled in response to TRAIL binding. FADD and caspase-8, but not caspase-10, are recruited to the receptor, and cells deficient in either FADD or caspase-8 blocked TRAIL-induced apoptosis, In addition, TRAIL initiates the activation of caspases, the loss of mitochondrial transmembrane potential (Delta psi (m)), the cleavage of BID, and the redistribution of mitochondrial cytochrome c, Treatment of Jurkat cells with cyclosporin A delayed TRAIL-induced Delta psi (m), caspase-3 activation and apoptosis, Similarly, Overexpression of Bcl-2 or Bcl-X-L delayed, but did not inhibit, TRAIL-induced Delta psi (m) and apoptosis, In contrast, XIAP, cowpox virus CrmA and baculovirus p35 inhibited TRAIL-induced apoptosis, These data suggest that death receptors (DR4 and DR5) and Fas receptors induced apoptosis through identical signaling pathway, and TRAIL-induced apoptosis via both mitochondrial-dependent and -independent pathways.	Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	University System of Maryland; University of Maryland Baltimore; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Srivastava, RK (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, 20 N Pine St, Baltimore, MD 21201 USA.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Bertin J, 1996, J VIROL, V70, P6251, DOI 10.1128/JVI.70.9.6251-6259.1996; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; CLEN RJ, 1994, MOL CELL BIOL, V14, P5212; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; Decaudin D, 1997, CANCER RES, V57, P62; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Enari M, 2000, SEIKAGAKU, V72, P6; French LE, 1999, NAT MED, V5, P146, DOI 10.1038/5505; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Golstein P, 1997, CURR BIOL, V7, pR750, DOI 10.1016/S0960-9822(06)90000-1; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Gura T, 1997, SCIENCE, V277, P768, DOI 10.1126/science.277.5327.768; Han ZY, 1999, MOL CELL BIOL, V19, P1381; HAY BA, 1994, DEVELOPMENT, V120, P2121; He LH, 2000, J BIOL CHEM, V275, P12175, DOI 10.1074/jbc.275.16.12175; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Kim EJ, 2001, INT J ONCOL, V18, P187; Kim KH, 2000, CLIN CANCER RES, V6, P335; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1999, CANCER RES, V59, P1693; Krammer P H, 1999, Adv Immunol, V71, P163; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Peter M E, 1999, Results Probl Cell Differ, V23, P25; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 1999, APMIS, V107, P73, DOI 10.1111/j.1699-0463.1999.tb01528.x; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Simonian PL, 1997, BLOOD, V90, P1208, DOI 10.1182/blood.V90.3.1208.1208_1208_1216; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srivastava RK, 1999, J EXP MED, V190, P253, DOI 10.1084/jem.190.2.253; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Srivastava RK, 1999, ONCOGENE, V18, P1755, DOI 10.1038/sj.onc.1202464; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Tanaka M, 1997, J IMMUNOL, V158, P2303; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; TEWARI M, 1995, J BIOL CHEM, V270, P22705, DOI 10.1074/jbc.270.39.22705; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954	87	309	323	0	20	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2001	20	17					2122	2133		10.1038/sj.onc.1204282	http://dx.doi.org/10.1038/sj.onc.1204282			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360196				2022-12-25	WOS:000168116700007
J	Kurokawa, K; Iwashita, T; Murakami, H; Hayashi, H; Kawai, K; Takahashi, M				Kurokawa, K; Iwashita, T; Murakami, H; Hayashi, H; Kawai, K; Takahashi, M			Identification of SNT/FRS2 docking site on RET receptor tyrosine kinase and its role for signal transduction	ONCOGENE			English	Article						SNT/FRS2; RET; SHC; GDNF; MEN2	PHOSPHOTYROSINE-DEPENDENT INTERACTION; FIBROBLAST-GROWTH-FACTOR; NEOPLASIA TYPE 2B; NEUROTROPHIC FACTOR; TRANSFORMING ACTIVITY; CELL-DIFFERENTIATION; ADAPTER PROTEINS; INSULIN-RECEPTOR; PC12 CELLS; NPEY MOTIF	SNT/FRS2 is a lipid anchored docking protein that contains an amino-terminal myristylation signal, followed by a phosphotyrosine-binding (PTB) domain and a carboxy-terminal region with multiple tyrosine residues. Here we show that the SNT/FRS2 PTB domain binds to RET receptor tyrosine kinase activated by glial cell line-derived neurotrophic factor (GDNF) or multiple endocrine neoplasia (MEN) 2 mutations. Analyses by site directed-mutagenesis revealed that it binds to tyrosine 1062 in RET that is also known to be a binding site for the SHC adaptor protein. Whereas SHC bound to RET was associated with GRB2 and GAB1 proteins, SNT/FRS2 was associated with GRB2 only, suggesting that SNT/FRS2 is involved mainly in the activation of the RAS/mitogen activated protein kinase (MAPK) pathway but not the phosphatidylinositol 3-kinase (PI3-K)/AKT pathway. In addition, phosphorylated SNT/FRS2 appeared to directly complex with SHP-2 tyrosine phosphatase. These results suggest that tyrosine 1062 in RET provides a site for the interaction of multiple signaling molecules and that the balance of SHC and SNT/FRS2 binding may affect the nature of the intracellular signaling for cell proliferation, differentiation and survival induced by activated RET.	Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University	Takahashi, M (corresponding author), Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		Kumi, Kawai/I-6275-2014; Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014	Kumi, Kawai/0000-0002-7772-2605; Takahashi, Masahide/0000-0002-2803-2683; 				Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Califano D, 2000, J BIOL CHEM, V275, P19297, DOI 10.1074/jbc.M905866199; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; De Vita G, 2000, CANCER RES, V60, P3727; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; Geneste O, 1999, HUM MOL GENET, V8, P1989, DOI 10.1093/hmg/8.11.1989; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; Ishiguro Y, 1999, ENDOCRINOLOGY, V140, P3992, DOI 10.1210/en.140.9.3992; Iwashita T, 1999, ONCOGENE, V18, P3919, DOI 10.1038/sj.onc.1202742; Iwashita T, 2000, BIOCHEM BIOPH RES CO, V268, P804, DOI 10.1006/bbrc.2000.2227; Iwashita T, 1996, ONCOGENE, V12, P481; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; Murakami H, 1999, ONCOGENE, V18, P1975, DOI 10.1038/sj.onc.1202514; Murakami H, 1999, BIOCHEM BIOPH RES CO, V262, P68, DOI 10.1006/bbrc.1999.1186; Ohiwa M, 1997, BIOCHEM BIOPH RES CO, V237, P747, DOI 10.1006/bbrc.1997.7225; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Wright JH, 1997, MOL BIOL CELL, V8, P1575, DOI 10.1091/mbc.8.8.1575; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987	30	80	81	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 12	2001	20	16					1929	1938		10.1038/sj.onc.1204290	http://dx.doi.org/10.1038/sj.onc.1204290			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360177				2022-12-25	WOS:000168043800001
J	Zhang, ZT; Pak, J; Huang, HY; Shapiro, E; Sun, TT; Pellicer, A; Wu, XR				Zhang, ZT; Pak, J; Huang, HY; Shapiro, E; Sun, TT; Pellicer, A; Wu, XR			Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation	ONCOGENE			English	Article						urothelial carcinoma; progression pathways; Ha-ras oncogene; transgenic mice; uroplakin	TRANSITIONAL-CELL-CARCINOMA; HUMAN BLADDER-TUMORS; URINARY-BLADDER; TRANSGENIC MICE; IN-SITU; GENETIC ALTERATIONS; ONCOGENIC RAS; K-RAS; CANCER; EXPRESSION	Urothelial tumors develop along two distinctive phenotypic pathways (superficial papillary non-invasive tumors versus flat carcinoma in situ lesions), with markedly different biological behavior and prognosis. Although multiple genetic alterations have been identified in human bladder cancer, their cause-effect relationship with the two pathways has not been firmly established, Using a urothelium-specific promoter of the uroplakin TT gene, we showed earlier in transgenic mice that the urothelial expression of SV40T antigen, which inactivates p53 and pRb, induced carcinoma in situ and invasive and metastatic bladder cancer. In striking contrast, we demonstrate here that the urothelial expression of an activated Ha-ras in transgenic mice caused urothelial hyperplasia and superficial papillary non-invasive bladder tumors. These results provide strong, direct experimental evidence that the two phenotypical pathways of bladder tumorigenesis are caused by distinctive genetic defects, Our results indicate that Ha-ras activation can induce urothelial proliferation in vivo; and that urothelial hyperplasia is a precursor of low-grade, superficial papillary bladder tumors. Our transgenic models provide unique opportunities to study the detailed molecular events underlying different types of bladder neoplasms, and can serve as useful preclinical models for evaluating the in vivo efficacy of preventive and therapeutic agents that act on various signaling pathways in bladder cancer.	NYU, Sch Med, Dept Urol, New York, NY 10016 USA; Dept Vet Affairs Med Ctr, New York, NY 10010 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Dept Dermatol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, Dept Microbiol, New York, NY 10016 USA	New York University; New York University; New York University; New York University; New York University	Wu, XR (corresponding author), NYU, Sch Med, Dept Urol, 550 1st Ave,Room Skirball 10U, New York, NY 10016 USA.		MARTINEZ, ANTONIO PELLICER/C-4832-2015; Sun, Tung-Tien/J-4425-2015	Sun, Tung-Tien/0000-0002-6841-1063; Pellicer, Angel/0000-0002-5062-0692; Wu, Xue-Ru/0000-0001-6058-6291	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039753, R01DK056903, P01DK052206] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56903, DK52769, DK52206, DK39753] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; Balazs M, 1997, GENE CHROMOSOME CANC, V19, P84, DOI 10.1002/(SICI)1098-2264(199706)19:2<84::AID-GCC3>3.3.CO;2-U; Benedict WF, 1999, ONCOGENE, V18, P1197, DOI 10.1038/sj.onc.1202452; BOS JL, 1989, CANCER RES, V49, P4682; BRINSTER RL, 1981, CELL, V27, P223, DOI 10.1016/0092-8674(81)90376-7; BRINSTER RL, 1986, HARVEY LECT, V80, P1; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; BURCHILL SA, 1994, BRIT J UROL, V73, P516, DOI 10.1111/j.1464-410X.1994.tb07636.x; BURCHILL SA, 1991, BR J CANCER S13, V63, P62; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; Campbell SC, 1998, CANCER RES, V58, P1298; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Cordon-Cardo C, 1994, Important Adv Oncol, P71; COROMINAS M, 1991, ENVIRON HEALTH PERSP, V93, P19, DOI 10.2307/3431163; CZERNIAK B, 1992, HUM PATHOL, V23, P1199, DOI 10.1016/0046-8177(92)90285-B; DALBAGNI G, 1993, LANCET, V342, P469, DOI 10.1016/0140-6736(93)91595-D; DUNN TL, 1988, J PATHOL, V156, P59, DOI 10.1002/path.1711560112; ENOMOTO T, 1990, CARCINOGENESIS, V11, P2233; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; FITZGERALD JM, 1995, J NATL CANCER I, V87, P129, DOI 10.1093/jnci/87.2.129; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; Grossman H B, 1996, Oncology (Williston Park), V10, P1617; KNOWLES MA, 1993, CANCER RES, V53, P133; KOSS LG, 1992, J CELL BIOCHEM, P23; KUNZE E, 1990, PATHOLOGY TUMOURS LA, V1, P345; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; LEVESQUE P, 1993, INT J CANCER, V55, P785, DOI 10.1002/ijc.2910550516; LIN JH, 1995, P NATL ACAD SCI USA, V92, P679, DOI 10.1073/pnas.92.3.679; MASUI T, 1993, TERATOGEN CARCIN MUT, V13, P225, DOI 10.1002/tcm.1770130504; MESSING EM, 1992, SEMIN SURG ONCOL, V8, P285, DOI 10.1002/ssu.2980080507; Ogawa K, 1998, MOL CARCINOGEN, V21, P70, DOI 10.1002/(SICI)1098-2744(199801)21:1<70::AID-MC9>3.0.CO;2-T; OHTANI M, 1986, CANCER RES, V46, P2001; Olson MF, 2000, SEMIN IMMUNOL, V12, P63, DOI 10.1006/smim.2000.0208; ORLOW I, 1995, J NATL CANCER I, V87, P1524, DOI 10.1093/jnci/87.20.1524; Orntoft TF, 1998, UROL RES, V26, P223, DOI 10.1007/s002400050050; OYASU R, 1995, FOOD CHEM TOXICOL, V33, P747, DOI 10.1016/0278-6915(95)00042-Z; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; RASSOULZADEGAN M, 1987, ONCOGENE RES, V1, P1; Reznikoff CA, 1996, SEMIN ONCOL, V23, P571; ROSIN MP, 1995, CANCER RES, V55, P5213; SAITO S, 1992, Keio Journal of Medicine, V41, P80; SANDGREN EP, 1989, ONCOGENE, V4, P715; SCHALKEN JA, 1992, SEMIN SURG ONCOL, V8, P274, DOI 10.1002/ssu.2980080505; SCHNEIDER BL, 1992, MOL CARCINOGEN, V6, P1, DOI 10.1002/mc.2940060102; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SPRUCK CH, 1994, CANCER RES, V54, P784; STEINBERG GD, 1992, UROL CLIN N AM, V19, P735; THEODORESCU D, 1990, P NATL ACAD SCI USA, V87, P9047, DOI 10.1073/pnas.87.22.9047; Vageli D, 1996, CANCER LETT, V107, P241, DOI 10.1016/0304-3835(96)04372-8; VISVANATHAN KV, 1988, ONCOGENE RES, V3, P77; WAGNER U, 1995, HUM PATHOL, V26, P970, DOI 10.1016/0046-8177(95)90086-1; WALKER BE, 1960, AM J ANAT, V107, P95, DOI 10.1002/aja.1001070202; YAMAMOTO S, 1995, CARCINOGENESIS, V16, P2363, DOI 10.1093/carcin/16.10.2363; YE DW, 1993, UROL RES, V21, P39; Zhang ZT, 1999, CANCER RES, V59, P3512	56	133	137	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2001	20	16					1973	1980		10.1038/sj.onc.1204315	http://dx.doi.org/10.1038/sj.onc.1204315			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360181				2022-12-25	WOS:000168043800005
J	Mummidi, S; Catano, G; Lam, L; Hoefle, A; Telles, V; Begum, K; Jimenez, F; Ahuja, SS; Ahuja, SK				Mummidi, S; Catano, G; Lam, L; Hoefle, A; Telles, V; Begum, K; Jimenez, F; Ahuja, SS; Ahuja, SK			Extensive repertoire of membrane-bound and soluble dendritic cell-specific ICAM-3-grabbing nonintegrin 1 (DC-SIGN1) and DC-SIGN2 isoforms - Inter-individual variation in expression of DC-SIGN transcripts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; C-TYPE LECTIN; PRE-MESSENGER-RNA; TRANSLATIONAL CONTROL; T-CELLS; NUCLEOTIDE-SEQUENCE; GENE-EXPRESSION; LIGAND-BINDING; ANTIGEN; HIV-1	Expression in dendritic cells (DCs) of DC-SIGN, a type II membrane protein with a C-type lectin ectodomain, is thought to play an important role in establishing the initial contact between DCs and resting T cells. DC-SIGN is also a unique type of human immunodeficiency virus-1 (HIV-1) attachment factor and promotes efficient infection in trans of cells that express CD4 and chemokine receptors. We have identified another gene, designated here as DC-SIGN2, that exhibits high sequence homology with DC-SIGN. Here we demonstrate that alternative splicing of DC-SIGN1 (original version) and DC-SIGN2 pre-mRNA generates a large repertoire of DC-SIGN-like transcripts that are predicted to encode membrane-associated and soluble isoforms. The range of DC-SIGN1 mRNA expression was significantly broader than previously reported and included THP-1 monocytic cells, placenta, and peripheral blood mononuclear cells (PBMCs), and there was cell maturation/activation-induced differences in mRNA expression levels. Immunostaining of term placenta with a DC-SIGN1-specific antiserum showed that DC-SIGN1 is expressed on endothelial cells and CC chemokine receptor 5 (CCR5)-positive macrophage-like cells in the villi. DC-SIGN2 mRNA expression was high in the placenta and not detectable in PBMCs. In DCs, the expression of DC-SIGN2 transcripts was significantly lower than that of DC-SIGN1. Notably, there was significant inter-individual heterogeneity in the repertoire of DC-SIGN1 and DC-SIGN2 transcripts expressed. The genes for DC-SIGN1, DC-SIGN2, and CD23, another Type II lectin, colocalize to an similar to 85 kilobase pair region on chromosome 19p13.3, forming a cluster of related genes that undergo highly complex alternative splicing events. The molecular diversity of DC-SIGN-1 and -2 is reminiscent of that observed for certain other adhesive cell surface proteins involved in cell-cell connectivity. The generation of this large collection of polymorphic cell surface and soluble variants that exhibit inter-individual variation in expression levels has important implications for the pathogenesis of HIV-1 infection, as well as for the molecular code required to establish complex interactions between antigen-presenting cells and T cells, i.e. the immunological synapse.	Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol, San Antonio, TX 78229 USA; S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Ahuja, SK (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, Mail Code 7880, San Antonio, TX 78229 USA.	ahujas@uthscsa.edu	Mummidi, Srinivas/H-3335-2017; Mummidi, Srinivas/C-1004-2008; Catano, Gabriel/AAQ-5387-2020	Mummidi, Srinivas/0000-0002-4068-6380; Mummidi, Srinivas/0000-0002-4068-6380; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043279, R01AI046326, R21AI046326, R37AI046326] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43279, AI46326] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; Ahuja SS, 1998, J IMMUNOL, V161, P868; Arinobu Y, 1999, CELL IMMUNOL, V191, P161, DOI 10.1006/cimm.1998.1431; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Black DL, 1998, NEURON, V20, P165, DOI 10.1016/S0896-6273(00)80444-4; Blauvelt A, 1997, J CLIN INVEST, V100, P2043, DOI 10.1172/JCI119737; Bloom TJ, 1996, P NATL ACAD SCI USA, V93, P14188, DOI 10.1073/pnas.93.24.14188; Bocek P, 1997, J IMMUNOL, V158, P3235; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Canque B, 1999, BLOOD, V93, P3866, DOI 10.1182/blood.V93.11.3866.411k43_3866_3875; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; CIAMARELLI A, 1994, J ACQ IMMUN DEF SYND, V7, P230; CLINTON M, 1989, BIOCHEM BIOPH RES CO, V158, P855, DOI 10.1016/0006-291X(89)92801-5; COOK GP, 1995, IMMUNOL TODAY, V16, P237, DOI 10.1016/0167-5699(95)80166-9; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; Corradi JP, 1997, J NEUROSCI, V17, P1406; Cote J, 2001, J BIOL CHEM, V276, P8535, DOI 10.1074/jbc.M008924200; CURTIS BM, 1992, P NATL ACAD SCI USA, V89, P8356, DOI 10.1073/pnas.89.17.8356; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; de Melker AA, 1999, BIOESSAYS, V21, P499, DOI 10.1002/(SICI)1521-1878(199906)21:6<499::AID-BIES6>3.0.CO;2-D; DELESPESSE G, 1991, ADV IMMUNOL, V49, P149; Dietz AB, 2000, BIOCHEM BIOPH RES CO, V275, P731, DOI 10.1006/bbrc.2000.3372; DRICKAMER K, 1995, CURR OPIN STRUC BIOL, V5, P612, DOI 10.1016/0959-440X(95)80052-2; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Eissa NT, 1996, J BIOL CHEM, V271, P27184, DOI 10.1074/jbc.271.43.27184; Fichter M, 1997, ONCOGENE, V14, P2817, DOI 10.1038/sj.onc.1201127; Frank I, 1999, J VIROL, V73, P3449, DOI 10.1128/JVI.73.4.3449-3454.1999; Garcia-Sanz JA, 1998, FASEB J, V12, P299, DOI 10.1096/fasebj.12.3.299; GarciaSanz JA, 1996, J EXP MED, V184, P159, DOI 10.1084/jem.184.1.159; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Gonzalez E, 1999, P NATL ACAD SCI USA, V96, P12004, DOI 10.1073/pnas.96.21.12004; GOODALL GJ, 1986, P NATL ACAD SCI USA, V83, P8926, DOI 10.1073/pnas.83.23.8926; GORDON J, 1994, IMMUNOL TODAY, V15, P411, DOI 10.1016/0167-5699(94)90270-4; Grabowski PJ, 1998, CELL, V92, P709, DOI 10.1016/S0092-8674(00)81399-9; Granelli-Piperno A, 1999, CURR BIOL, V9, P21, DOI 10.1016/S0960-9822(99)80043-8; GranelliPiperno A, 1996, J EXP MED, V184, P2433, DOI 10.1084/jem.184.6.2433; Hebert E, 2000, BIOSCIENCE REP, V20, P213, DOI 10.1023/A:1026484722248; HILL JR, 1993, J BIOL CHEM, V268, P726; IMATAKA H, 1994, J BIOL CHEM, V269, P20668; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; Kacani L, 1998, J VIROL, V72, P6671, DOI 10.1128/JVI.72.8.6671-6677.1998; KIKUTANI H, 1989, CIBA F SYMP, V147, P23; Knight SC, 1997, ANNU REV IMMUNOL, V15, P593, DOI 10.1146/annurev.immunol.15.1.593; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Luo ZD, 1998, J BIOL CHEM, V273, P28486, DOI 10.1074/jbc.273.43.28486; MACKAY CR, 1994, J CELL BIOL, V124, P71, DOI 10.1083/jcb.124.1.71; Mangano A, 2001, J INFECT DIS, V183, P1574, DOI 10.1086/320705; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; Marrack P, 2000, CURR OPIN IMMUNOL, V12, P206, DOI 10.1016/S0952-7915(99)00075-8; Metheny LJ, 1996, EXP CELL RES, V228, P44, DOI 10.1006/excr.1996.0297; Mikulits W, 2000, FASEB J, V14, P1641, DOI 10.1096/fj.14.11.1641; Missler M, 1998, TRENDS GENET, V14, P20, DOI 10.1016/S0168-9525(97)01324-3; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NEEFJES JJ, 1992, IMMUNOL TODAY, V13, P179, DOI 10.1016/0167-5699(92)90123-O; Newell ML, 1998, AIDS, V12, P831, DOI 10.1097/00002030-199808000-00004; Pearson WR, 1997, GENOMICS, V46, P24, DOI 10.1006/geno.1997.4995; PINCHUK LM, 1994, IMMUNITY, V1, P317, DOI 10.1016/1074-7613(94)90083-3; Pohlmann S, 2001, P NATL ACAD SCI USA, V98, P2670, DOI 10.1073/pnas.051631398; RAO SM, 1993, J BIOL CHEM, V268, P22164; Roca X, 1998, AM J PATHOL, V153, P183, DOI 10.1016/S0002-9440(10)65559-9; RUAN HJ, 1994, J BIOL CHEM, V269, P17905; Sancho D, 2000, J IMMUNOL, V165, P3868, DOI 10.4049/jimmunol.165.7.3868; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Shapiro L, 1999, NEURON, V23, P427, DOI 10.1016/S0896-6273(00)80796-5; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Soilleux EJ, 2000, J IMMUNOL, V165, P2937, DOI 10.4049/jimmunol.165.6.2937; Steinman RM, 2000, CELL, V100, P491, DOI 10.1016/S0092-8674(00)80684-4; SUTER U, 1987, NUCLEIC ACIDS RES, V15, P7295, DOI 10.1093/nar/15.18.7295; Tone M, 2001, P NATL ACAD SCI USA, V98, P1751, DOI 10.1073/pnas.98.4.1751; Tsunetsugu-Yokota Y, 1997, VIROLOGY, V239, P259, DOI 10.1006/viro.1997.8895; TSUNETSUGUYOKOTA Y, 1995, J VIROL, V69, P4544, DOI 10.1128/JVI.69.7.4544-4547.1995; Tsytsikov VN, 1996, J BIOL CHEM, V271, P23055, DOI 10.1074/jbc.271.38.23055; Uemura T, 1998, CELL, V93, P1095, DOI 10.1016/S0092-8674(00)81452-X; ULLRICH B, 1995, NEURON, V14, P497, DOI 10.1016/0896-6273(95)90306-2; van der Merwe PA, 2000, SEMIN IMMUNOL, V12, P5, DOI 10.1006/smim.2000.0203; Walker J, 2000, J IMMUNOL METHODS, V239, P167, DOI 10.1016/S0022-1759(00)00181-2; Wang F, 1998, CELL, V93, P47, DOI 10.1016/S0092-8674(00)81145-9; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Weissman D, 1997, CLIN MICROBIOL REV, V10, P358, DOI 10.1128/CMR.10.2.358; Williams SC, 1996, J MOL BIOL, V264, P220, DOI 10.1006/jmbi.1996.0636; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8; YING, 1995, J IMMUNOL, V155, P1637; YOKOTA A, 1988, CELL, V55, P611, DOI 10.1016/0092-8674(88)90219-X; Yokoyama-Kobayashi M, 1999, GENE, V228, P161, DOI 10.1016/S0378-1119(99)00004-9; Yoshikawa T, 1999, MOL IMMUNOL, V36, P1223, DOI 10.1016/S0161-5890(99)00139-X; Zaitseva M, 1997, NAT MED, V3, P1369, DOI 10.1038/nm1297-1369	97	91	105	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33196	33212		10.1074/jbc.M009807200	http://dx.doi.org/10.1074/jbc.M009807200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11337487	hybrid			2022-12-25	WOS:000170746000106
J	Dumin, JA; Dickeson, SK; Stricker, TP; Bhattacharyya-Pakrasi, M; Roby, JD; Santoro, SA; Parks, WC				Dumin, JA; Dickeson, SK; Stricker, TP; Bhattacharyya-Pakrasi, M; Roby, JD; Santoro, SA; Parks, WC			Pro-collagenase-1 (matrix metalloproteinase-1) binds the alpha(2)beta(1) integrin upon release from keratinocytes migrating on type I collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE; TISSUE INHIBITOR; CATALYTIC-ACTIVITY; HUMAN NEUTROPHILS; EXPRESSION; ACTIVATION; ADHESION; LOCALIZATION; COMPONENTS; RECEPTORS	In injured skin, collagenase-1 (matrix metalloproteinase-1 (MMP-1)) is induced in migrating keratinocytes. This site-specific expression is regulated by binding of the alpha (2)beta (1) integrin with dermal type I collagen, and the catalytic activity of MMP-1 is required for keratinocyte migration. Because of this functional association among substrate/ligand, receptor, and proteinase, we assessed whether the integrin also directs the compartmentalization of MMP-1 to its matrix target. Indeed, pro-MMP-1 co-localized to sites of alpha (2)beta (1) contacts in migrating keratinocytes. Furthermore, pro-MMP-1 co-immunoprecipitated with alpha (2)beta (1) from keratinocytes, and alpha (2)beta (1) co-immunoprecipitated with pro-MMP-1. No other MMPs bound alpha (2)beta (1) and no other integrins interacted with MMP-1. Pro-MMP-1 also provided a substrate for alpha (2)beta (1)-dependent adhesion of platelets. Complex formation on keratinocytes was most efficient on native type I collagen and reduced or ablated on denatured or cleaved collagen. Competition studies suggested that the alpha (2) I domain interacts with the linker and hemopexin domains of pro-MMP-1, not with the pro-domain. These data indicate that the interaction of pro-MMP-1 with alpha (2)beta (1) confines this proteinase to points of cell contact with collagen and that the ternary complex of integrin, enzyme, and substrate function together to drive and regulate keratinocyte migration.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Parks, WC (corresponding author), Washington Univ, Sch Med, Dept Pediat, Box 8208,660 S Euclid Ave, St Louis, MO 63110 USA.	parks_w@kids.wustl.edu	Parks, William C./AAH-6786-2021		NHLBI NIH HHS [HL63446] Funding Source: Medline; NIAMS NIH HHS [AR45254] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063446] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR045254] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Campbell EJ, 1999, J CLIN INVEST, V104, P337, DOI 10.1172/JCI6092; Campbell EJ, 2000, J IMMUNOL, V165, P3366, DOI 10.4049/jimmunol.165.6.3366; Caterina JJ, 2000, J BIOL CHEM, V275, P26416, DOI 10.1074/jbc.M001271200; COLLER BS, 1989, BLOOD, V74, P182; Dunsmore SE, 1998, J CLIN INVEST, V102, P1321, DOI 10.1172/JCI1516; HAVERSTICK DM, 1985, BLOOD, V66, P946; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; HERTLE MD, 1992, J CLIN INVEST, V89, P1892, DOI 10.1172/JCI115794; Jeffrey JJ, 1998, BIOL EXTRAC, P15; JUHASZ I, 1993, AM J PATHOL, V143, P1458; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Madlener M, 1998, EXP CELL RES, V242, P201, DOI 10.1006/excr.1998.4049; Mueller SC, 1999, J BIOL CHEM, V274, P24947, DOI 10.1074/jbc.274.35.24947; OWEN CA, 1995, J CELL BIOL, V131, P775, DOI 10.1083/jcb.131.3.775; Owen CA, 1999, J LEUKOCYTE BIOL, V65, P137, DOI 10.1002/jlb.65.2.137; Parks WC, 1999, WOUND REPAIR REGEN, V7, P423, DOI 10.1046/j.1524-475X.1999.00423.x; Partridge CA, 1997, AM J PHYSIOL-LUNG C, V272, pL813, DOI 10.1152/ajplung.1997.272.5.L813; PELLEGRINI G, 1992, J CLIN INVEST, V89, P1783, DOI 10.1172/JCI115782; Pilcher BK, 1999, J BIOL CHEM, V274, P10372, DOI 10.1074/jbc.274.15.10372; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; SAARIALHOKERE UK, 1993, J CLIN INVEST, V92, P2858, DOI 10.1172/JCI116906; SAARIALHOKERE UK, 1994, J CLIN INVEST, V94, P79, DOI 10.1172/JCI117351; SANTORO SA, 1994, METHOD ENZYMOL, V245, P147; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; SIRES UI, 1995, J BIOL CHEM, V270, P1062, DOI 10.1074/jbc.270.3.1062; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STAHLEBACKDAHL M, 1993, AM J PATHOL, V142, P995; Stricker TP, 2001, J BIOL CHEM, V276, P29375, DOI 10.1074/jbc.M102217200; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Sudbeck BD, 1997, MOL BIOL CELL, V8, P811, DOI 10.1091/mbc.8.5.811; SUDBECK BD, 1994, J BIOL CHEM, V269, P30022; Sudbeck BD, 1997, J BIOL CHEM, V272, P22103, DOI 10.1074/jbc.272.35.22103; SYMINGTON BE, 1993, J CELL BIOL, V120, P523, DOI 10.1083/jcb.120.2.523; TAMAI K, 1995, J INVEST DERMATOL, V104, P384, DOI 10.1111/1523-1747.ep12665857; Tarui T, 2001, J BIOL CHEM, V276, P3983, DOI 10.1074/jbc.M008220200; Vaalamo M, 1996, BRIT J DERMATOL, V135, P52; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; YAMADA KM, 1996, MOL CELLULAR BIOL WO, P311; Yu Q, 2000, GENE DEV, V14, P163; Yu WH, 2000, J BIOL CHEM, V275, P4183, DOI 10.1074/jbc.275.6.4183	45	168	173	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29368	29374		10.1074/jbc.M104179200	http://dx.doi.org/10.1074/jbc.M104179200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11359786	hybrid			2022-12-25	WOS:000170346000098
J	Tzarfaty-Majar, V; Lopez-Alemany, R; Feinstein, Y; Gombau, L; Goldshmidt, O; Soriano, E; Munoz-Canoves, P; Klar, A				Tzarfaty-Majar, V; Lopez-Alemany, R; Feinstein, Y; Gombau, L; Goldshmidt, O; Soriano, E; Munoz-Canoves, P; Klar, A			Plasmin-mediated release of the guidance molecule F-spondin from the extracellular matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALARIA CIRCUMSPOROZOITE PROTEIN; FIBROBLAST GROWTH-FACTOR; MELANOMA CELL-ADHESION; HEPARIN-BINDING; NERVOUS-SYSTEM; NEURAL DEVELOPMENT; ENDOTHELIAL-CELLS; NEURITE OUTGROWTH; NEURONAL GROWTH; ACTIVATOR GENE	Serine proteases are implicated in a variety of processes during neurogenesis, including cell migration, axon outgrowth, and synapse elimination. Tissue-type plasminogen activator and urokinase-type activator are expressed in the floor plate during embryonic development. F-spondin, a gene also expressed in the floor plate, encodes a secreted, extracellular matrix-attached protein that promotes outgrowth of commissural axons and inhibits outgrowth of motor axons. F-spondin is processed in vivo to yield an amino half protein that contains regions of homology to reelin and mindin, and a carboxyl half protein that contains either six or four thrombospondin type I repeats (TSRs). We have tested F-spondin to see whether it is subjected to processing by plasmin and to determine whether the processing modulates its biological activity. Plasmin cleaves F-spondin at its carboxyl terminus. By using nested deletion proteins and mutating potential plasmin cleavage sites, we have identified two cleavage sites, the first between the fifth and sixth TSRs, and the second at the fifth TSR. Analysis of the extracellular matrix (ECM) attachment properties of the TSRs revealed that the fifth and sixth TSRs bind to the ECM, but repeats 1-4 do not. Structural functional experiments revealed that two basic motives are required to elicit binding of TSR module to the ECM. We demonstrate further that plasmin releases the ECM-bound F-spondin protein.	Ctr Mol Oncol, Inst Recerca Oncol, Barcelona 08907, Spain; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Anat & Cell Biol, IL-91120 Jerusalem, Israel; Hadassah Hebrew Univ Hosp, Dept Oncol, IL-91120 Jerusalem, Israel; Univ Barcelona, Fac Biol, Dept Anim & Plant Cell Biol, E-08028 Barcelona, Spain	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hadassah University Medical Center; University of Barcelona	Munoz-Canoves, P (corresponding author), Ctr Mol Oncol, Inst Recerca Oncol, Barcelona 08907, Spain.		Munoz-Canoves, Pura/B-3889-2015; Lopez-Alemany, Roser/R-3565-2018; Klar, Avihu/AHC-4770-2022	Lopez-Alemany, Roser/0000-0002-0913-0691; 				Adams JC, 2000, DEV DYNAM, V218, P280; Akassoglou K, 2000, J CELL BIOL, V149, P1157, DOI 10.1083/jcb.149.5.1157; ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; Baranes D, 1998, NEURON, V21, P813, DOI 10.1016/S0896-6273(00)80597-8; BENEZRA M, 1993, BLOOD, V81, P3324; Burstyn-Cohen T, 1998, J NEUROSCI, V18, P8875; Burstyn-Cohen T, 1999, NEURON, V23, P233, DOI 10.1016/S0896-6273(00)80776-X; CAJAL SRY, 1921, TRAB LABOR INVEST BI, V18, P4; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CARROLL PM, 1994, DEVELOPMENT, V120, P3173; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; CHENG HJ, 1994, MOL BIOL CELL, V5, P943, DOI 10.1091/mbc.5.9.943; CHERRY SS, 1995, J BIOL CHEM, V270, P7304; Constam DB, 1996, J CELL BIOL, V134, P181, DOI 10.1083/jcb.134.1.181; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; Debby-Brafman A, 1999, NEURON, V22, P475, DOI 10.1016/S0896-6273(00)80703-5; DEFREITAS MF, 1995, NEURON, V15, P333, DOI 10.1016/0896-6273(95)90038-1; DENT MAR, 1993, EUR J NEUROSCI, V5, P633, DOI 10.1111/j.1460-9568.1993.tb00529.x; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; Feinstein Y, 1999, DEVELOPMENT, V126, P3637; FREVERT U, 1993, J EXP MED, V177, P1287, DOI 10.1084/jem.177.5.1287; Gantt SM, 1997, J BIOL CHEM, V272, P19205, DOI 10.1074/jbc.272.31.19205; Gschwend TP, 1997, MOL CELL NEUROSCI, V9, P207, DOI 10.1006/mcne.1997.0616; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; GUO NH, 1992, J BIOL CHEM, V267, P19349; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; HARPEL PC, 1990, J BIOL CHEM, V265, P11289; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; Huang YY, 1996, P NATL ACAD SCI USA, V93, P8699, DOI 10.1073/pnas.93.16.8699; Irigoyen JP, 1999, CELL MOL LIFE SCI, V56, P104, DOI 10.1007/PL00000615; Jaworski DM, 2000, BRAIN RES, V860, P174, DOI 10.1016/S0006-8993(00)02035-7; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; KAWAKUBO Y, 1994, APPL MICROBIOL BIOT, V41, P413; Kilpelainen I, 2000, J BIOL CHEM, V275, P13564, DOI 10.1074/jbc.275.18.13564; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; KRYSTOSEK A, 1981, SCIENCE, V213, P1532, DOI 10.1126/science.7197054; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; LEFEBVRE O, 1995, DEVELOPMENT, V121, P947; MARS WM, 1993, AM J PATHOL, V143, P949; MCGUIRE PG, 1990, NEURON, V4, P633, DOI 10.1016/0896-6273(90)90121-U; OGRADY RL, 1981, INT J CANCER, V28, P509, DOI 10.1002/ijc.2910280418; Osterwalder T, 1996, EMBO J, V15, P2944, DOI 10.1002/j.1460-2075.1996.tb00657.x; Panetti TS, 1999, J BIOL CHEM, V274, P430, DOI 10.1074/jbc.274.1.430; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; Seeds NW, 1997, CELL TISSUE RES, V290, P367, DOI 10.1007/s004410050942; Seeds NW, 1996, SEMIN NEUROSCI, V8, P405, DOI 10.1006/smns.1996.0049; Seeds NW, 1999, P NATL ACAD SCI USA, V96, P14118, DOI 10.1073/pnas.96.24.14118; SILVERSTEIN RL, 1986, J BIOL CHEM, V261, P9959; SILVERSTEIN RL, 1984, J CLIN INVEST, V74, P1625, DOI 10.1172/JCI111578; SOYOMBO AA, 1994, J BIOL CHEM, V269, P17734; SUMI Y, 1992, DEVELOPMENT, V116, P625; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; TUSZYNSKI GP, 1993, J CELL BIOL, V120, P513, DOI 10.1083/jcb.120.2.513; Tzarfati-Majar V, 2001, P NATL ACAD SCI USA, V98, P4722, DOI 10.1073/pnas.081062398; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079	55	27	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28233	28241		10.1074/jbc.M102585200	http://dx.doi.org/10.1074/jbc.M102585200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11359777	hybrid			2022-12-25	WOS:000170093400067
J	Cohen, S; Orian, A; Ciechanover, A				Cohen, S; Orian, A; Ciechanover, A			Processing of p105 is inhibited by docking of p50 active subunits to the ankyrin repeat domain, and inhibition is alleviated by signaling via the carboxyl-terminal phosphorylation/ubiquitin-ligase binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; UBIQUITIN-PROTEIN LIGASE; GLYCINE-RICH REGION; PRECURSOR P105; NF-KAPPA-B1 PRECURSOR; CONJUGATING ENZYMES; 26S PROTEASOME; DEGRADATION; PROTEOLYSIS; GENERATION	Processing of the p105 precursor to generate the p50 subunit of the nuclear factor kappaB transcription factor is an exceptional case in which the ubiquitin system is involved in Limited processing rather than in complete destruction of the target substrate. A Gly-rich region "stop" signal in the middle of the molecule along with a neighboring downstream ubiquitination, and probably an E3 anchoring domain, have been demonstrated to be important for processing In addition, we have shown that I kappaB kinase-mediated phosphorylation of the C-terminal domain leads to recruitment of the SCFbeta -TrCP ubiquitin ligase with subsequent accelerated ubiquitination and processing/degradation of the precursor (Orian, A, Gonen, H., Bercovich, B,, Fajerman, I., Eytan, E., Israel, A, Mercurio, F,, Iwai, K, Schwartz, A. L., and Ciechanover, A. (2000) EMBO J. 19, 2580-2591), Here we show that processing of p105 molecules that contain more then four ankyrin repeats, but lack the C-terminal phosphorylation/ubiquitin ligase binding domain, is strongly inhibited by docked p50 subunits, Inhibition is caused by interference with the function of the proteasome, as conjugation is not affected. Inhibition is alleviated after I kappaB kinase phosphorylation of the C-terminal domain leads to accelerated, beta -TrCP-mediated ubiquitination and processing/degradation of p105. We suggest that under basal conditions, slow generation of p50 probably involves the mid molecule ubiquitination/E3 recognition motif. Following stimulation, the C-terminal domain is involved in rapid processing/degradation of p105 with release of a large amount of the stored subunits that now become transcriptionally active.	Technion Israel Inst Technol, Fac Med, Dept Biochem, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel; Lady Davis Carmel Med Ctr, Dept Internal Med A, IL-34362 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Clalit Health Services; Carmel Medical Center	Ciechanover, A (corresponding author), Technion Israel Inst Technol, Fac Med, Dept Biochem, POB 9649, IL-31096 Haifa, Israel.		Ciechanover, Aaron J/C-9166-2017					ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; Foo SY, 1999, TRENDS GENET, V15, P229; FUJIMOTO K, 1995, GENE, V165, P183, DOI 10.1016/0378-1119(95)00507-3; Gonen H, 1996, J BIOL CHEM, V271, P302, DOI 10.1074/jbc.271.1.302; Harhaj EW, 1996, ONCOGENE, V12, P2385; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Heissmeyer V, 2001, MOL CELL BIOL, V21, P1024, DOI 10.1128/MCB.21.4.1024-1035.2001; Heusch M, 1999, ONCOGENE, V18, P6201, DOI 10.1038/sj.onc.1203022; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Levitskaya J, 1997, P NATL ACAD SCI USA, V94, P12616, DOI 10.1073/pnas.94.23.12616; LI CCH, 1994, BIOCHEM J, V303, P499, DOI 10.1042/bj3030499; Lin L, 1996, MOL CELL BIOL, V16, P2248; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; MacKichan ML, 1996, J BIOL CHEM, V271, P6084, DOI 10.1074/jbc.271.11.6084; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Orian A, 1999, MOL CELL BIOL, V19, P3664; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; Sharipo A, 1998, NAT MED, V4, P939, DOI 10.1038/nm0898-939; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3	34	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26769	26776		10.1074/jbc.M102448200	http://dx.doi.org/10.1074/jbc.M102448200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11350967	hybrid			2022-12-25	WOS:000169966900007
J	Collins, LL; Lin, DL; Mu, XM; Chang, CS				Collins, LL; Lin, DL; Mu, XM; Chang, CS			Feedback regulation between orphan nuclear receptor TR2 and human papilloma virus type 16	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; CIS-ACTING ELEMENTS; LONG CONTROL REGION; MAJOR LATE PROMOTER; STEROID-RECEPTOR; RESPONSE ELEMENT; GENE-EXPRESSION; GLUCOCORTICOID HORMONES; SV40-TRANSFORMED CELLS; TUMOR-SUPPRESSOR	The human TR2 orphan receptor (TR2), initially isolated from testis and prostate cDNA libraries, is a member of the steroid receptor superfamily. TR2 can regulate several target genes via binding to a consensus response element (AGGTCA) in direct repeat orientation (AGGTCAX((n))AGGTCA, n = 0-6). Here show that TR2 is able to induce the expression of human papilloma virus type 16 (HPV-16) genes via binding to a DR4 response element in the long control region of HPV-16. Additionally, one of the HPV-16 gene products, the E6 oncogene, regulates TR2 gene expression. A likely mechanism for this regulation involves E6-mediate-degradation of the tumor suppressor p53, a protein known to suppress TR2 expression. Together our data provide evidence for feedback regulation between TR2 and HPV-16, which represents a novel regulatory pathway involving a member of the steroid receptor superfamily and the HPV-16 DNA tumor virus.	Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Pathol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Urol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Radiat Oncol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Rochester	Chang, CS (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Rochester, NY 14642 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047258, R01DK056884] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56884, DK47258] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; Boyer SN, 1996, CANCER RES, V56, P4620; CHAN WK, 1989, J VIROL, V63, P3261, DOI 10.1128/JVI.63.8.3261-3269.1989; CHANG C, 1988, BIOCHEM BIOPH RES CO, V155, P971, DOI 10.1016/S0006-291X(88)80591-6; CHANG C, 1989, BIOCHEM BIOPH RES CO, V165, P735, DOI 10.1016/S0006-291X(89)80028-2; Chang CS, 1997, BIOCHEM BIOPH RES CO, V235, P205, DOI 10.1006/bbrc.1997.6760; CHANG CS, 1994, P NATL ACAD SCI USA, V91, P6040, DOI 10.1073/pnas.91.13.6040; Chang CS, 1998, MOL CELL BIOCHEM, V189, P195, DOI 10.1023/A:1006918402474; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CULLING CFA, 1963, HDB HISTOPATHOLOGICA, P179; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GLOSS B, 1989, J VIROL, V63, P1142, DOI 10.1128/JVI.63.3.1142-1152.1989; Hsiao PW, 1999, J BIOL CHEM, V274, P20229, DOI 10.1074/jbc.274.29.20229; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Khare S, 1997, EXP CELL RES, V232, P353, DOI 10.1006/excr.1997.3529; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lee HJ, 1999, MOL CELL BIOCHEM, V194, P199, DOI 10.1023/A:1006903202089; LEE HJ, 1993, BIOCHEM BIOPH RES CO, V194, P97, DOI 10.1006/bbrc.1993.1790; LEE HJ, 1995, J BIOL CHEM, V270, P5434, DOI 10.1074/jbc.270.10.5434; Lee HJ, 1996, J BIOL CHEM, V271, P10405, DOI 10.1074/jbc.271.17.10405; LEE HJ, 1995, J BIOL CHEM, V270, P30129; Lee YF, 1998, J BIOL CHEM, V273, P13437, DOI 10.1074/jbc.273.22.13437; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Lin DL, 1998, ENDOCRINE, V8, P123, DOI 10.1385/ENDO:8:2:123; Lin DL, 1996, J BIOL CHEM, V271, P14649, DOI 10.1074/jbc.271.25.14649; LIN TM, 1995, J BIOL CHEM, V270, P30121; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MITTAL R, 1993, OBSTET GYNECOL, V81, P5; MIZOKAMI A, 1994, MOL ENDOCRINOL, V8, P77, DOI 10.1210/me.8.1.77; Mu XM, 2000, J BIOL CHEM, V275, P23877, DOI 10.1074/jbc.M910158199; MUNGER K, 1989, J VIROL, V63, P4417; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; SIBBET GJ, 1995, J VIROL, V69, P4006, DOI 10.1128/JVI.69.7.4006-4011.1995; Syrjanen SM, 1999, ANN MED, V31, P175, DOI 10.3109/07853899909115976; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Young WJ, 1998, J BIOL CHEM, V273, P20877, DOI 10.1074/jbc.273.33.20877	47	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27316	27321		10.1074/jbc.M104145200	http://dx.doi.org/10.1074/jbc.M104145200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11358973	hybrid			2022-12-25	WOS:000169966900078
J	Suzuki, Y; Nakabayashi, Y; Nakata, K; Reed, JC; Takahashi, R				Suzuki, Y; Nakabayashi, Y; Nakata, K; Reed, JC; Takahashi, R			X-linked inhibitor of apoptosis protein (XIAP) inhibits caspase-3 and-7 in distinct modes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMR STRUCTURE; BIR DOMAIN; MUTAGENESIS; IAPS	The inhibitor of apoptosis proteins (IAP) regulates cell death by inhibiting caspases. The region of X-linked (X) IAP containing the second baculovirus IAP repeat domain (BIR2) is sufficient for inhibiting caspase-3 and -7. In this study,we found that the modes of inhibition of these two caspases were different: caspase-3 is inhibited in a competitive manner whereas caspase-7 inhibition occurs through a mixed competitive and noncompetitive mechanism. Binding assays revealed that the inhibition of caspase-3 by XIAP was totally dependent on the interaction between the active site of caspase-3 and the linker region between the BIR1 and BIR2 domains of XIAP. In contrast, the active site and the NP2-terminal region of caspase-7 bound to the linker region and the BIR2, respectively. Moreover the BIR2 with a mutated linker region, which inhibited caspase-3 very weakly, still bound to and inhibited caspase-7. Furthermore, a chimeric caspase-7/3 comprising the NH2-terminal portion of caspase-7 and COOH-terminal portion of caspase-3 was inhibited by XIAP by a mixed competitive and noncompetitive mechanism. Our results suggest that the Linker region between BIR1 and BIR2 domains is responsible for active site-directed, competitive inhibition of both caspase-3 and -7, whereas the BIR2 itself is involved in noncompetitive inhibition of caspase-7.	RIKEN, Lab Motor Syst Neurodegenerat, Biol Sci Inst, Wako, Saitama 3510198, Japan; Burnham Inst, La Jolla, CA 92037 USA; Tokyo Metropolitan Inst Neurosci, Tokyo 1838526, Japan	RIKEN; Sanford Burnham Prebys Medical Discovery Institute; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science	Takahashi, R (corresponding author), RIKEN, Lab Motor Syst Neurodegenerat, Biol Sci Inst, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.							Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Krajewska M, 1997, CANCER RES, V57, P1605; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Sun CH, 2000, J BIOL CHEM, V275, P33777, DOI 10.1074/jbc.M006226200; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	16	186	208	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27058	27063		10.1074/jbc.M102415200	http://dx.doi.org/10.1074/jbc.M102415200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11359776	hybrid			2022-12-25	WOS:000169966900044
J	Hapke, S; Kessler, H; de Prada, NA; Benge, A; Schmitt, M; Lengyel, E; Reuning, U				Hapke, S; Kessler, H; de Prada, NA; Benge, A; Schmitt, M; Lengyel, E; Reuning, U			Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PLASMINOGEN-ACTIVATOR INHIBITOR-1; PHORBOL ESTER INDUCTION; P65 SUBUNIT; EXTRACELLULAR-MATRIX; VITRONECTIN RECEPTOR; GENE-EXPRESSION; ADHESION; BINDING; FIBRONECTIN	The urokinase type plasminogen activator (uPA), together with its receptor uPAR and the plasminogen activator inhibitor type-1 (PAI-1) plays a pivotal role during tumor invasion and metastasis. Integrins, via interaction with the extracellular matrix (ECM), control cell adhesion and motility, The two systems are functionally linked because uPAR and PAI-1 bind to the ECM component vitronectin (VN), Because integrin signaling alters gene expression patterns, we investigated whether the expression levels of uPA, uPAR, and PAI-1 are affected by ECM/integrin interactions. Expression of uPA, uPAR, and PAI-1 was significantly enhanced when human ovarian cancer cells (OV-MZ-6) were cultivated on fibronectin or collagen type , In contrast, VN induced down-regulation of uPA and uPAR while increasing PAI-1 by up to 4-fold. VN-dependent decrease of uPA protein was paralleled by a significant reduction of uPA promoter activity that was even more pronounced upon alpha (v)beta (3) overexpression and depended on the presence of intact Rel protein-binding sites. The activity of Rel transcription factors was also significantly reduced upon alpha (v)beta (3)-mediated cell adhesion to VN, The activity of the Rel-unresponsive PAI-1 promoter was up to 5-fold induced as a function of alpha (v)beta (3)/VN interaction. Thus, the balance between available concentrations of uPA, uPAR, PAI-1, and integrins in human ovarian cancer cells might provide a switch within the regulation of their invasive phenotype.	Tech Univ Munich, Klin Forschergrp, Frauenklin, Klinikum Rechts Isar, D-81675 Munich, Germany; Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany; Univ Calif San Francisco, Ctr Canc, Dept Obstet Gynecol & Reprod Sci, Canc Res Inst, San Francisco, CA 94143 USA	Technical University of Munich; Technical University of Munich; University of California System; University of California San Francisco	Reuning, U (corresponding author), Tech Univ Munich, Klin Forschergrp, Frauenklin, Klinikum Rechts Isar, Ismaninger Str 22, D-81675 Munich, Germany.	ute.reuning@lrz.tum.de	Kessler, Horst/C-1178-2010; Lengyel, Ernst/D-9220-2014	Lengyel, Ernst/0000-0001-8624-1507				AUMAILLEY M, 1991, FEBS LETT, V291, P50, DOI 10.1016/0014-5793(91)81101-D; Bafetti LM, 1998, J BIOL CHEM, V273, P143, DOI 10.1074/jbc.273.1.143; Bearz A, 1998, BIOCHEM BIOPH RES CO, V243, P732, DOI 10.1006/bbrc.1997.8017; BEHRENDT N, 1995, BIOL CHEM H-S, V376, P269; Besser D, 1996, FIBRINOLYSIS, V10, P215, DOI 10.1016/S0268-9499(96)80018-X; Bewsey KE, 1996, BBA-MOL BASIS DIS, V1317, P55, DOI 10.1016/0925-4439(96)00037-3; Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; CARDARELLI PM, 1994, J BIOL CHEM, V269, P18668; Carreiras F, 1996, GYNECOL ONCOL, V62, P260, DOI 10.1006/gyno.1996.0225; Carreiras F, 1999, GYNECOL ONCOL, V72, P312, DOI 10.1006/gyno.1998.5262; Carriero MV, 1999, CANCER RES, V59, P5307; CHUCHOLOWSKI N, 1992, BIOCHEM SOC T, V20, P208, DOI 10.1042/bst0200208; CIAMBRONE GJ, 1992, J BIOL CHEM, V267, P13617; Deng G, 1996, J BIOL CHEM, V271, P12716, DOI 10.1074/jbc.271.22.12716; DENG G, 1995, THROMB HAEMOSTASIS, V74, P66; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Deryugina EI, 2000, INT J CANCER, V86, P15, DOI 10.1002/(SICI)1097-0215(20000401)86:1<15::AID-IJC3>3.0.CO;2-B; Fischer K, 1998, FEBS LETT, V438, P101, DOI 10.1016/S0014-5793(98)01279-4; Ghosh S, 2000, J BIOL CHEM, V275, P23869, DOI 10.1074/jbc.M000935200; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GRILLI M, 1993, INT REV CYTOL, V143, P1; GUERRINI L, 1995, P NATL ACAD SCI USA, V92, P9077, DOI 10.1073/pnas.92.20.9077; GURRATH M, 1992, EUR J BIOCHEM, V210, P911, DOI 10.1111/j.1432-1033.1992.tb17495.x; Haas M, 1998, J LEUKOCYTE BIOL, V63, P395, DOI 10.1002/jlb.63.3.395; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; Hapke S, 2001, MOL CELL BIOL, V21, P2118, DOI 10.1128/MCB.21.6.2118-2132.2001; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; Irigoyen JP, 1999, CELL MOL LIFE SCI, V56, P104, DOI 10.1007/PL00000615; Kanse SM, 1996, EXP CELL RES, V224, P344, DOI 10.1006/excr.1996.0144; KNUDSEN BS, 1987, J CLIN INVEST, V80, P1082, DOI 10.1172/JCI113164; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; Lauffenburger DA, 1996, NATURE, V383, P390, DOI 10.1038/383390a0; Lengyel E, 1996, J CELL BIOCHEM, V61, P430, DOI 10.1002/(SICI)1097-4644(19960601)61:3<430::AID-JCB10>3.0.CO;2-N; Liapis H, 1997, HUM PATHOL, V28, P443, DOI 10.1016/S0046-8177(97)90033-2; Loskutoff DJ, 1999, APMIS, V107, P54, DOI 10.1111/j.1699-0463.1999.tb01526.x; MOBUS V, 1992, INT J CANCER, V52, P76, DOI 10.1002/ijc.2910520115; Muehlenweg B, 2000, THROMB RES, V98, P73, DOI 10.1016/S0049-3848(99)00238-8; NERLOV C, 1991, ONCOGENE, V6, P1583; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; NIP J, 1995, CANCER METAST REV, V14, P241, DOI 10.1007/BF00690295; NOVAK U, 1991, NUCLEIC ACIDS RES, V19, P3389, DOI 10.1093/nar/19.12.3389; NOWLIN DM, 1993, J BIOL CHEM, V268, P20352; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; PFAFF M, 1994, J BIOL CHEM, V269, P20233; QWARNSTROM EE, 1994, J BIOL CHEM, V269, P30765; REUNING U, 1995, NUCLEIC ACIDS RES, V23, P3887, DOI 10.1093/nar/23.19.3887; Reuning U, 1998, INT J ONCOL, V13, P893; Reuning U, 1999, EUR J BIOCHEM, V259, P143, DOI 10.1046/j.1432-1327.1999.00014.x; RICCIO A, 1988, NUCLEIC ACIDS RES, V16, P2805, DOI 10.1093/nar/16.7.2805; RICCIO A, 1985, NUCLEIC ACIDS RES, V13, P2759, DOI 10.1093/nar/13.8.2759; Ried S, 1999, J BIOL CHEM, V274, P16377, DOI 10.1074/jbc.274.23.16377; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SOKOLOSKI JA, 1993, BLOOD, V82, P625; STACK MS, 1993, CANCER RES, V53, P1998; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; STREULI CH, 1990, J CELL BIOL, V110, P1405; TREMBLE P, 1995, J CELL BIOL, V129, P1707, DOI 10.1083/jcb.129.6.1707; Urtreger AJ, 1999, INT J CANCER, V82, P748, DOI 10.1002/(SICI)1097-0215(19990827)82:5<748::AID-IJC20>3.0.CO;2-R; VANMEIJER M, 1995, FIBRINOLYSIS, V9, P263, DOI 10.1016/S0268-9499(95)80015-8; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Xie B, 1998, J BIOL CHEM, V273, P11576, DOI 10.1074/jbc.273.19.11576; Xue W, 1997, CANCER RES, V57, P1682; YEBRA M, 1995, MOL BIOL CELL, V6, P841, DOI 10.1091/mbc.6.7.841	69	57	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26340	26348		10.1074/jbc.M100181200	http://dx.doi.org/10.1074/jbc.M100181200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11331280	hybrid			2022-12-25	WOS:000169823300093
J	Sakash, JB; Williams, MK; Tsuruta, H; Kantrowitz, ER				Sakash, JB; Williams, MK; Tsuruta, H; Kantrowitz, ER			Domain bridging interactions - A necessary contribution to the function and structure of Escherichia coli aspartate transcarbamoylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONCERTED ALLOSTERIC TRANSITION; QUATERNARY-STRUCTURE; HETEROTROPIC INTERACTIONS; HOMOTROPIC COOPERATIVITY; REGULATORY SUBUNIT; CATALYTIC CHAIN; CLOSURE; BINDING; SITE; CARBAMOYLTRANSFERASE	Aspartate transcarbamoylase undergoes a domain closure in the catalytic chains upon binding of the substrates that initiates the allosteric transition. Interdomain bridging interactions between Glu(50) and both Arg(167) and Arg(234) have been shown to be critical for stabilization of the R state. A hybrid version of the enzyme has been generated in vitro containing one wildtype catalytic subunit, one catalytic subunit in which Glu(50) in each catalytic chain has been replaced by Ala (E50A), and wild-type regulatory subunits. Thus, the hybrid enzyme has one catalytic subunit capable of domain closure and one catalytic subunit incapable of domain closure. The hybrid does not behave as a simple mixture of the constituent subunits; it exhibits lower catalytic activity and higher aspartate affinity than would be expected. As opposed to the wild-type enzyme, the hybrid is inhibited allosterically by CTP at saturating substrate concentrations. As opposed to the E50A holoenzyme, the hybrid is not allosterically activated by ATP at saturating substrate concentrations. Small angle x-ray scattering showed that three of the six interdomain bridging interactions in the hybrid is sufficient to cause the global structural change to the R state, establishing the critical nature of these interactions for the allosteric transition of aspartate transcarbamoylase.	Boston Coll, Dept Chem, Merkert Chem Ctr, Chestnut Hill, MA 02467 USA; Stanford Linear Accelerator Ctr, Stanford, CA 94309 USA	Boston College; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	Kantrowitz, ER (corresponding author), Boston Coll, Dept Chem, Merkert Chem Ctr, Chestnut Hill, MA 02467 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026237] Funding Source: NIH RePORTER; NCRR NIH HHS [P41RR01209] Funding Source: Medline; NIGMS NIH HHS [GM26237] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker DP, 1996, PROTEIN SCI, V5, P2276, DOI 10.1002/pro.5560051114; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P680; DEMBOWSKI NJ, 1993, PROTEIN ENG, V6, P123, DOI 10.1093/protein/6.1.123; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GERHART JC, 1967, J BIOL CHEM, V242, P2886; GERHART JC, 1962, J BIOL CHEM, V237, P891; HERVE G, 1985, J MOL BIOL, V185, P189, DOI 10.1016/0022-2836(85)90190-1; KANTROWITZ ER, 1990, TRENDS BIOCHEM SCI, V15, P53, DOI 10.1016/0968-0004(90)90176-C; KE HM, 1988, J MOL BIOL, V204, P725, DOI 10.1016/0022-2836(88)90365-8; KE HM, 1984, P NATL ACAD SCI USA, V81, P4027; KRAUSE KL, 1987, J MOL BIOL, V193, P527, DOI 10.1016/0022-2836(87)90265-8; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P276, DOI 10.1021/bi00401a042; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P268, DOI 10.1021/bi00401a041; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE BH, 1995, J BIOL CHEM, V270, P15620, DOI 10.1074/jbc.270.26.15620; MANIATIS T, 1982, MOL CLONING LABORATO, P368; MIDDLETON SA, 1988, BIOCHEMISTRY-US, V27, P8653, DOI 10.1021/bi00423a022; NEWTON CJ, 1990, BIOCHEMISTRY-US, V29, P1444, DOI 10.1021/bi00458a015; NEWTON CJ, 1990, P NATL ACAD SCI USA, V87, P2309, DOI 10.1073/pnas.87.6.2309; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; PASTRALANDIS SC, 1981, ANAL BIOCHEM, V118, P358, DOI 10.1016/0003-2697(81)90594-7; Sakash JB, 2000, J BIOL CHEM, V275, P752, DOI 10.1074/jbc.275.2.752; Sakash JB, 1998, BIOCHEMISTRY-US, V37, P281, DOI 10.1021/bi972102g; SILVER RS, 1983, J MOL BIOL, V168, P729, DOI 10.1016/S0022-2836(83)80072-2; STEBBINS JW, 1989, BIOCHEMISTRY-US, V28, P2592, DOI 10.1021/bi00432a037; STEBBINS JW, 1990, BIOCHEMISTRY-US, V29, P3821, DOI 10.1021/bi00468a003; TAUC P, 1994, PROTEIN SCI, V3, P1998, DOI 10.1002/pro.5560031112; TAUC P, 1982, J MOL BIOL, V155, P155, DOI 10.1016/0022-2836(82)90442-9; Tsuruta H, 1998, PROTEINS, V31, P383, DOI 10.1002/(SICI)1097-0134(19980601)31:4<383::AID-PROT5>3.3.CO;2-O; WILD JR, 1989, P NATL ACAD SCI USA, V86, P46, DOI 10.1073/pnas.86.1.46	32	1	1	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26441	26447		10.1074/jbc.M103226200	http://dx.doi.org/10.1074/jbc.M103226200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11352920	hybrid			2022-12-25	WOS:000169823300105
J	Gaudry, CA; Palka, HL; Dusek, RL; Huen, AC; Khandekar, MJ; Hudson, LG; Green, KJ				Gaudry, CA; Palka, HL; Dusek, RL; Huen, AC; Khandekar, MJ; Hudson, LG; Green, KJ			Tyrosine-phosphorylated plakoglobin is associated with desmogleins but not desmoplakin after epidermal growth factor receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CADHERIN CATENIN COMPLEX; MEDIATED CELL-ADHESION; BETA-CATENIN; INTERMEDIATE-FILAMENTS; DESMOSOMAL CADHERINS; CYTOPLASMIC DOMAIN; ALPHA-CATENIN; IN-VITRO; BINDING; DISSOCIATION	Tyrosine phosphorylation of junctional components has been proposed as a mechanism for modulating cell-cell adhesion. Although a correlation exists between the tyrosine phosphorylation of the adherens junction protein beta -catenin and loss of classical cadherin-mediated adhesion, the effects of tyrosine phosphorylation on the function of the adherens junction and desmosome-associated protein plakoglobin is unknown. In the present study, we investigated the effects of epidermal growth factor receptor (EGFR) tyrosine kinase activation on the subcellular distribution of plakoglobin and its association with its junctional binding partners. Long term epidermal growth factor (EGF) treatment of A431 cells revealed a modest decrease in the cytoskeleton-associated pool of plakoglobin (Pg) and a corresponding increase in the cytosolic pool of Pg. After short term EGF treatment, plakoglobin was rapidly phosphorylated, and tyrosine-phosphorylated Pg was distributed predominantly in a membrane-associated Triton X-100-soluble pool, along with a co-precipitating high molecular weight tyrosine-phosphorylated protein identified as desmoglein 2, Analysis of deletion and point mutants defined the primary EGFR-dependent targets as one or more of three C-terminal tyrosine residues. Whereas phosphorylated Pg remained associated with the desmoglein tail after both short and long term EGFR activation, no phosphorylated Pg was found associated with the N-terminal Pg-binding domain (DPNTP) of the intermediate filament-associated protein, desmoplakin, Together these results are consistent with the possibility that EGF-dependent tyrosine phosphorylation of Pg may modulate cell-cell adhesion by compromising the link between desmosomal cadherins and the intermediate filament cytoskeleton.	Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Dermatol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA; Univ New Mexico, Hlth Sci Ctr, Coll Pharm, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol, Albuquerque, NM 87131 USA	Northwestern University; Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center	Green, KJ (corresponding author), Northwestern Univ, Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.	kgreen@nwu.edu			NATIONAL CANCER INSTITUTE [T32CA009560] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042989, R01AR041836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012328] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA09560-10] Funding Source: Medline; NIAMS NIH HHS [R01 AR42989, R01 AR41836] Funding Source: Medline; NIDCR NIH HHS [P01 DE12328] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABERLE H, 1994, J CELL SCI, V107, P3655; Adams CL, 1996, J CELL BIOL, V135, P1899, DOI 10.1083/jcb.135.6.1899; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; Bornslaeger EA, 2001, J CELL SCI, V114, P727; Bornslaeger EA, 1996, J CELL BIOL, V134, P985, DOI 10.1083/jcb.134.4.985; Bryant PJ, 1997, DEV GENET, V20, P75, DOI 10.1002/(SICI)1520-6408(1997)20:2<75::AID-DVG1>3.3.CO;2-G; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fuchs M, 1996, J BIOL CHEM, V271, P16712, DOI 10.1074/jbc.271.28.16712; Fujii K, 1996, EXP CELL RES, V223, P50, DOI 10.1006/excr.1996.0057; Gallicano GI, 1998, J CELL BIOL, V143, P2009, DOI 10.1083/jcb.143.7.2009; GELDERLOOS JA, 1997, CYTOSKELETAL MEMBRAN, P12; Green KJ, 2000, NAT REV MOL CELL BIO, V1, P208, DOI 10.1038/35043032; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huen AC, 2000, MOL BIOL CELL, V11, p174A; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; KANAI Y, 1995, BIOCHEM BIOPH RES CO, V208, P1067, DOI 10.1006/bbrc.1995.1443; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; Kodama S, 1999, J BIOL CHEM, V274, P27682, DOI 10.1074/jbc.274.39.27682; KORMAN NJ, 1989, NEW ENGL J MED, V321, P631, DOI 10.1056/NEJM198909073211002; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; Kowalczyk AP, 1999, J BIOL CHEM, V274, P18145, DOI 10.1074/jbc.274.26.18145; KOWALCZYK AP, 1994, J BIOL CHEM, V269, P31214; Kowalczyk AP, 1999, INT REV CYTOL, V185, P237; Kowalczyk AP, 1997, J CELL BIOL, V139, P773, DOI 10.1083/jcb.139.3.773; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; MATHUR M, 1994, J BIOL CHEM, V269, P14075; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MENG JJ, 1995, MOL BIOL CELL, V6, P2186; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; OCHIAI A, 1994, BIOCHEM BIOPH RES CO, V205, P73, DOI 10.1006/bbrc.1994.2631; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; Ozawa M, 2001, J CELL SCI, V114, P503; Palka HL, 1997, J CELL SCI, V110, P2359; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Rubenstein A, 1997, DEV GENET, V20, P91, DOI 10.1002/(SICI)1520-6408(1997)20:2<91::AID-DVG2>3.0.CO;2-3; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Skoudy A, 1996, BIOCHEM J, V317, P279, DOI 10.1042/bj3170279; Smith EA, 1998, J CELL BIOL, V141, P1229, DOI 10.1083/jcb.141.5.1229; Takeda H, 1995, J CELL BIOL, V131, P1839, DOI 10.1083/jcb.131.6.1839; TROYANOVSKY SM, 1993, CELL, V72, P561, DOI 10.1016/0092-8674(93)90075-2; TROYANOVSKY SM, 1994, P NATL ACAD SCI USA, V91, P10790, DOI 10.1073/pnas.91.23.10790	54	65	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24871	24880		10.1074/jbc.M102731200	http://dx.doi.org/10.1074/jbc.M102731200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11335725	hybrid			2022-12-25	WOS:000169800700060
J	Kumar, R; Shieh, BH				Kumar, R; Shieh, BH			The second PDZ domain of INAD is a type I domain involved in binding to eye protein kinase C - Mutational analysis and naturally occurring variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA PHOTORECEPTORS; DIRECTED MUTAGENESIS; VISUAL TRANSDUCTION; TARGET PROTEINS; RECOGNITION; GENE; DNA; LOCALIZATION; DEACTIVATION; ASSOCIATION	INAD is a scaffolding protein containing five PSD95/ dlg/zonular occludens-1 (PDZ) domains that tether NORPA (phospholipase C beta (4)), the TRP calcium channel, and eye-PKC in Drosophila photoreceptors. We previously showed that eye-PKC interacted with the second PDZ domain (PDZ2) of INAD, Sequence comparison with a prototypical type I PDZ domain predicts that PDZ2 is the best candidate among the five PDZ domains to recognize eye-PKC that contains a type I PDZ ligand, Ile-Thr-Ile-Ile, at its carboxyl terminus. Replacement of Ile(-3) in eye-PKC with charged residues resulted in a drastic reduction of the PDZ2 interaction. Substitution of a conserved His with Arg at the second alpha -helix of PDZ2 led to a reduced binding; however, a Leu replacement resulted in an enhanced eye-PKC association. We isolated and sequenced the InaD gene. The coding sequence of InaD contains nine exons spanning 3 kilobases. Translation of coding sequences from three wildtype alleles revealed three SNPs affecting residues, 282, 319, and 333 of INAD, These polymorphisms are localized in PDZ2. Interestingly, we found two of three PDZ2 variants displayed a greater affinity for eye-PKC, In summary, we evaluated the molecular basis of the eye-PKC and PDZ2 association by mutational analysis and concluded that PDZ2 of INAD is a type I domain important for the eye-PKC interaction.	Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Mol Neurosci, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Shieh, BH (corresponding author), Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA.	bih-hwa.shieh@mcmail.vanderbilt.edu			NEI NIH HHS [EY09743] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009743] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adamski FM, 1998, J BIOL CHEM, V273, P17713, DOI 10.1074/jbc.273.28.17713; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huber A, 1996, J BIOL CHEM, V271, P11710, DOI 10.1074/jbc.271.20.11710; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MISMER D, 1989, GENETICS, V121, P77; Montell C, 1999, ANNU REV CELL DEV BI, V15, P231, DOI 10.1146/annurev.cellbio.15.1.231; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; RANGANATHAN R, 1991, NATURE, V354, P230, DOI 10.1038/354230a0; Rubin GM, 2000, SCIENCE, V287, P2222, DOI 10.1126/science.287.5461.2222; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Scott K, 1998, CURR OPIN NEUROBIOL, V8, P383, DOI 10.1016/S0959-4388(98)80065-2; SHIEH BH, 1995, NEURON, V14, P201, DOI 10.1016/0896-6273(95)90255-4; Shieh BH, 1997, P NATL ACAD SCI USA, V94, P12682, DOI 10.1073/pnas.94.23.12682; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; SMITH DB, 1988, MOL BIOCHEM PARASIT, V27, P249, DOI 10.1016/0166-6851(88)90044-8; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; van Huizen R, 1998, EMBO J, V17, P2285, DOI 10.1093/emboj/17.8.2285; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545	32	9	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24971	24977		10.1074/jbc.M103570200	http://dx.doi.org/10.1074/jbc.M103570200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342563	hybrid			2022-12-25	WOS:000169800700072
J	Dulin, NO; Niu, JX; Browning, DD; Ye, RD; Voyno-Yasenetskaya, T				Dulin, NO; Niu, JX; Browning, DD; Ye, RD; Voyno-Yasenetskaya, T			Cyclic AMP-independent activation of protein kinase A by vasoactive peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CAMP; INHIBITION; RECEPTOR; PHOSPHORYLATION; RELEASE; CASCADE; CYCLASE; CLONING; INFLUX	Protein kinase A (PKA) is an important effector enzyme commonly activated by cAMP. The present study focuses on our finding that the vasoactive peptide endothelin-l (ET1), whose signaling is not coupled to cAMP production, stimulates PKA in two independent cellular models. Using an in vivo assay for PKA activity, we found that ET1 stimulated PKA in HeLa cells overexpressing ET1 receptors and in aortic smooth muscle cells expressing endogenous levels of ET1 receptors, In these cell models, ET1 did not stimulate cAMP production, indicating a novel mechanism for PKA activation. The ET1-induced activation of PKA was found to be dependent on the degradation of inhibitor of kappaB, which was previously reported to bind and inhibit PIKA, ET1 potently stimulated the nuclear factor-kappaB pathway, and this effect was inhibited by overexpression of the inhibitor of kappaB dominant negative mutant (I kappaB alpham) and by treatment with the proteasome inhibitor MG-132. Importantly, I kappaB alpham and MG-132 had similar inhibitory effects on ET1-induced activation of PKA without affecting G(s)-mediated activation of PKA or ET1-induced phosphorylation of mitogen-activated protein kinase. Finally, another vasoactive peptide, angiotensin II, also stimulated PKA in a cAMP-independent manner in aortic smooth muscle cells. These findings suggest that cAMP-independent activation of PKA might be a general response to vasoactive peptides.	Univ Illinois, Dept Pharmacol, Coll Med, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Dulin, NO (corresponding author), Univ Illinois, Dept Pharmacol, Coll Med, M-C 868,Med Sci Bldg,Rm E-407,835 S Wolcott Ave, Chicago, IL 60612 USA.	dulin@uic.edu	Ye, Richard/ABF-2413-2020; voyno-yasenetskaya, tatyana/A-3171-2008; Ye, Richard/O-5223-2016	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620; Browning, Darren/0000-0003-0497-7620	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM056159, R01GM056159] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56159] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI M, 1991, BIOCHEM BIOPH RES CO, V180, P1265, DOI 10.1016/S0006-291X(05)81332-4; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bornfeldt KE, 1999, CELL SIGNAL, V11, P465, DOI 10.1016/S0898-6568(99)00020-0; Browning DD, 2000, J BIOL CHEM, V275, P2811, DOI 10.1074/jbc.275.4.2811; BUTT E, 1994, J BIOL CHEM, V269, P14509; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; Dodge KL, 1998, ENDOCRINOLOGY, V139, P2265, DOI 10.1210/en.139.5.2265; El-Mowafy AM, 1998, BIOCHEM BIOPH RES CO, V251, P494, DOI 10.1006/bbrc.1998.9496; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; Francis SH, 1999, CRIT REV CL LAB SCI, V36, P275, DOI 10.1080/10408369991239213; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; JAMES AF, 1994, NATURE, V370, P297, DOI 10.1038/370297a0; LIN WW, 1993, MOL PHARMACOL, V44, P158; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Mateo AO, 1997, PHARMACOL RES, V36, P339, DOI 10.1006/phrs.1997.0246; MURRAY KJ, 1990, PHARMACOL THERAPEUT, V47, P329, DOI 10.1016/0163-7258(90)90060-F; Orlov SN, 1996, HYPERTENSION, V27, P774, DOI 10.1161/01.HYP.27.3.774; Parris R J, 1997, Vasc Med, V2, P31; Rebsamen MC, 1997, AM J PHYSIOL-ENDOC M, V273, pE922, DOI 10.1152/ajpendo.1997.273.5.E922; SAKAMOTO A, 1991, BIOCHEM BIOPH RES CO, V178, P656, DOI 10.1016/0006-291X(91)90158-4; Schulze-Osthoff K, 1997, IMMUNOBIOLOGY, V198, P35, DOI 10.1016/S0171-2985(97)80025-3; SIMONSON MS, 1990, FASEB J, V4, P2989, DOI 10.1096/fasebj.4.12.2168326; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; TAKAGI Y, 1995, J BIOL CHEM, V270, P10072, DOI 10.1074/jbc.270.17.10072; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Tertyshnikova S, 1998, P NATL ACAD SCI USA, V95, P1613, DOI 10.1073/pnas.95.4.1613; VOGELSANG M, 1994, J CARDIOVASC PHARM, V23, P344, DOI 10.1097/00005344-199402000-00025; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; Wu-Wong JR, 1998, J CARDIOVASC PHARM, V31, pS185, DOI 10.1097/00005344-199800001-00053; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; Yamboliev IA, 1998, PULM PHARMACOL THER, V11, P205, DOI 10.1006/pupt.1998.0139; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhu Y, 1997, AM J PHYSIOL-HEART C, V273, pH119, DOI 10.1152/ajpheart.1997.273.1.H119	37	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					20827	20830		10.1074/jbc.C100195200	http://dx.doi.org/10.1074/jbc.C100195200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11331270	hybrid			2022-12-25	WOS:000169297900007
J	Alves, F; Saupe, S; Ledwon, M; Schaub, F; Hiddemann, W; Vogel, WF				Alves, F; Saupe, S; Ledwon, M; Schaub, F; Hiddemann, W; Vogel, WF			Identification of two novel, kinase-deficient variants of discoidin domain receptor 1: differential expression in human colon cancer cell lines	FASEB JOURNAL			English	Article									Univ Gottingen, Dept Hematol & Oncol, D-37075 Gottingen, Germany; Univ Gottingen, Dept Cardiol & Pneumol, D-37075 Gottingen, Germany; Univ Munich, Univ Hosp Grosshadern, Dept Internal Med 3, D-81377 Munich, Germany; Univ Frankfurt, Georg Speyer Haus Inst Biomed Res, Dept Extracellular Matrix Signaling, D-60596 Frankfurt, Germany	University of Gottingen; University of Gottingen; University of Munich; Goethe University Frankfurt	Alves, F (corresponding author), Univ Gottingen, Dept Hematol & Oncol, Robert Koch Str 40, D-37075 Gottingen, Germany.								0	78	82	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1321	1323		10.1096/fj.00-0626fje	http://dx.doi.org/10.1096/fj.00-0626fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344127				2022-12-25	WOS:000168655200049
J	Liu, ZT; Chang, GQ; Leibowitz, SF				Liu, ZT; Chang, GQ; Leibowitz, SF			Apolipoprotein D interacts with the long-form leptin receptor: a hypothalamic function in the control of energy homeostasis	FASEB JOURNAL			English	Article									Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Leibowitz, SF (corresponding author), Rockefeller Univ, Box 278,1230 York Ave, New York, NY 10021 USA.								0	33	35	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1329	1331		10.1096/fj.00-0530fje	http://dx.doi.org/10.1096/fj.00-0530fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344130				2022-12-25	WOS:000168655200052
J	Robinson, GS; Ju, M; Shih, SC; Xu, X; McMahon, G; Caldwell, RB; Smith, LEH				Robinson, GS; Ju, M; Shih, SC; Xu, X; McMahon, G; Caldwell, RB; Smith, LEH			Nonvascular role for VEGF: VEGFR-1, 2 activity is critical for neural retinal development	FASEB JOURNAL			English	Article									Harvard Univ, Childrens Hosp, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA; SUGEN Inc, S San Francisco, CA USA; Med Coll Georgia, Augusta, GA 30912 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Pfizer; University System of Georgia; Augusta University	Smith, LEH (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Dept Ophthalmol, 300 Longwood Ave, Boston, MA 02115 USA.			Caldwell, Ruth/0000-0003-0168-0354					0	129	140	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1215	1217		10.1096/fj.00-0598fje	http://dx.doi.org/10.1096/fj.00-0598fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344092				2022-12-25	WOS:000168655200014
J	Shah, V; Bharadwaj, S; Kaibuchi, K; Prasad, GL				Shah, V; Bharadwaj, S; Kaibuchi, K; Prasad, GL			Cytoskeletal organization in tropomyosin-mediated reversion of ras-transformation: Evidence for Rho kinase pathway	ONCOGENE			English	Article						tropomyosin; cytoskeleton; Rho kinase	SERUM RESPONSE FACTOR; BINDING PROTEIN-RHO; ACTIN CYTOSKELETON; FOCAL ADHESIONS; GELSOLIN EXPRESSION; NONMUSCLE CALDESMON; STRESS FIBERS; ONCOGENIC RAS; CELLS; SUPPRESSION	Tropomyosin (TM) family of cytoskeletal proteins is implicated in stabilizing actin microfilaments. Many TM isoforms, including tropomyosin-1 (TM1), are downregulated in transformed cells. Previously we demonstrated that TM1 is a suppressor of the malignant transformation, and that TM1 reorganizes microfilaments in the transformed cells, To investigate how TM1 induces microfilament organization in transformed cells, we utilized uas-transformed NIH3T3 (DT) cells, and those transduced to express TM1, and/or TM2, Enhanced expression of TM1 alone, but not TM2, results in re-emergence of microfilaments; TM1, together with TM2 remarkably improves microfilament architecture. TM1 induced cytoskeletal reorganization involves an enhanced expression of caldesmon, but not vinculin, alpha -actinin, or gelsolin, In addition, TM1-induced cytoskeletal reorganization and the revertant phenotype appears to involve re-activation of RhoA controlled pathways in DT cells. RhoA expression, which is suppressed in DT cells, is significantly increased in TM1-expressing cells, without detectable changes in the expression of Pac or Cdc42, Furthermore, expression of a dominant negative Rho kinase, or treatment with Y-27632 disassembled microfilaments in normal NIH3T3 and in TM1 expressing cells. These data suggest that reactivation of Rho kinase directed pathways are critical for TM1-mediated microfilament assemblies.	Wake Forest Univ, Bowman Gray Sch Med, Dept Gen Surg, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA; Wistar Inst Anat & Cell Biol, Philadelphia, PA USA; Nara Inst Sci & Technol, Ikoma, Japan	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; The Wistar Institute; Nara Institute of Science & Technology	Prasad, GL (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Gen Surg, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.							Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Asch HL, 1999, BREAST CANCER RES TR, V55, P179; Ayscough KR, 1998, CURR OPIN CELL BIOL, V10, P102, DOI 10.1016/S0955-0674(98)80092-6; BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; BHATTACHARYA B, 1990, CANCER RES, V50, P2105; Braverman RH, 1996, ONCOGENE, V13, P537; BUTTON E, 1995, CELL MOTIL CYTOSKEL, V30, P247, DOI 10.1002/cm.970300402; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; COOPER HL, 1987, CANCER RES, V47, P4493; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Helfman DM, 1999, MOL BIOL CELL, V10, P3097, DOI 10.1091/mbc.10.10.3097; HENDRICKS M, 1981, P NATL ACAD SCI-BIOL, V78, P5633, DOI 10.1073/pnas.78.9.5633; Huber PAJ, 1997, INT J BIOCHEM CELL B, V29, P1047, DOI 10.1016/S1357-2725(97)00004-6; ISHIKAWA R, 1989, J BIOL CHEM, V264, P16764; ISHIKAWA R, 1989, J BIOL CHEM, V264, P7490; Ishikawa R, 1998, J BIOL CHEM, V273, P26991, DOI 10.1074/jbc.273.41.26991; Izawa I, 1998, ONCOGENE, V17, P2863, DOI 10.1038/sj.onc.1202213; JANCSO A, 1991, J BIOL CHEM, V266, P5891; JANMEY PA, 1995, CURR OPIN CELL BIOL, V7, P111, DOI 10.1016/0955-0674(95)80052-2; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KUMAR A, 1993, INDIAN J HETEROCY CH, V3, P1; LEAVITT J, 1986, MOL CELL BIOL, V6, P2721, DOI 10.1128/MCB.6.7.2721; Lin SK, 1997, MOLECULES, V2, P1, DOI 10.3390/jan97p1; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; Matsumura F, 1993, CURR OPIN CELL BIOL, V5, P70, DOI 10.1016/S0955-0674(05)80010-9; Mielnicki LM, 1999, EXP CELL RES, V249, P161, DOI 10.1006/excr.1999.4461; Momiyama T, 1998, BIOCHEM BIOPH RES CO, V242, P429, DOI 10.1006/bbrc.1997.7959; Montaner S, 1999, J BIOL CHEM, V274, P8506, DOI 10.1074/jbc.274.13.8506; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; NOVY RE, 1993, CELL MOTIL CYTOSKEL, V26, P248, DOI 10.1002/cm.970260308; NOVY RE, 1991, J BIOL CHEM, V266, P16917; PITTENGER MF, 1995, J CELL SCI, V108, P3253; PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8; PRASAD GL, 1994, EUR J BIOCHEM, V224, P1, DOI 10.1111/j.1432-1033.1994.tb19988.x; Prasad GL, 1999, ONCOGENE, V18, P2027, DOI 10.1038/sj.onc.1202264; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; PRASAD GL, 1991, BIOCHEM BIOPH RES CO, V177, P1068, DOI 10.1016/0006-291X(91)90647-P; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; Shah V, 1998, SOMAT CELL MOLEC GEN, V24, P273, DOI 10.1023/B:SCAM.0000007130.08611.fc; Spencer JA, 1999, ONCOGENE, V18, P7319, DOI 10.1038/sj.onc.1203121; Treisman R, 1998, COLD SPRING HARB SYM, V63, P643, DOI 10.1101/sqb.1998.63.643; WARREN KS, 1995, J CELL BIOL, V129, P697, DOI 10.1083/jcb.129.3.697; Warren KS, 1996, CELL MOTIL CYTOSKEL, V34, P215, DOI 10.1002/(SICI)1097-0169(1996)34:3<215::AID-CM5>3.0.CO;2-8; Zohar M, 1998, ONCOGENE, V17, P991, DOI 10.1038/sj.onc.1202022	56	38	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2001	20	17					2112	2121		10.1038/sj.onc.1204291	http://dx.doi.org/10.1038/sj.onc.1204291			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360195				2022-12-25	WOS:000168116700006
J	Riballo, E; Doherty, AJ; Dai, Y; Stiff, T; Oettinger, MA; Jeggo, PA; Kysela, B				Riballo, E; Doherty, AJ; Dai, Y; Stiff, T; Oettinger, MA; Jeggo, PA; Kysela, B			Cellular and biochemical impact of a mutation in DNA ligase IV conferring clinical radiosensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; V(D)J RECOMBINATION; CRYSTAL-STRUCTURE; REPAIR; FIBROBLASTS; GENES; CELLS; LINE	DNA ligase IV functions in DNA non-homologous end-joining, in V(D)J recombination, and during brain development. We previously reported a homozygous mutation (R278H) in DNA ligase IV in a developmentally normal leukemia patient who over-responded to radiotherapy. The impact of this hypomorphic mutation has been evaluated using cellular, biochemical, and structural approaches. Structural modeling using T7 DNA ligase predicts that the activity and conformational stability of the protein is likely to be impaired. We show that wild type DNA ligase IV-Xrcc4 is an efficient double-stranded ligase with distinct optimal requirements for adenylate complex formation versus rejoining. The mutation impairs the formation of an adenylate complex as well as reducing the rejoining activity. Additionally, it imparts temperature-sensitive activity to the protein consistent with the predictions of the structural modeling. At the cellular level, the mutation confers a unique V(D)J recombination phenotype affecting the fidelity of signal joint formation with little effect on the frequency of the reaction. These findings suggest that hypomorphic mutations in ligase IV may allow normal development but confer marked radiosensitivity.	Univ Sussex, MRC, Cell Mutat Unit, Brighton BN1 9RR, E Sussex, England; Univ Cambridge, Wellcome Trust Ctr Mol Mechanisms, Inst Med Res, Cambridge CB2 2XY, England; Univ Cambridge, Dept Haematol, Cambridge CB2 2XY, England; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA	University of Sussex; University of Cambridge; University of Cambridge; Harvard University; Massachusetts General Hospital	Jeggo, PA (corresponding author), Univ Sussex, MRC, Cell Mutat Unit, Brighton BN1 9RR, E Sussex, England.	p.a.jeggo@sussex.ac.uk; b.kysela@sussex.ac.uk		Doherty, Aidan/0000-0002-6370-1109				ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; ARLETT CF, 1988, INT J RADIAT BIOL, V54, P911, DOI 10.1080/09553008814552321; BADIE C, 1995, CANCER RES, V55, P1232; Badie C, 1997, CANCER RES, V57, P4600; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Doherty AJ, 2000, NUCLEIC ACIDS RES, V28, P4051, DOI 10.1093/nar/28.21.4051; Featherstone C, 1999, CURR BIOL, V9, pR759, DOI 10.1016/S0960-9822(00)80005-6; Gauss GH, 1996, MOL CELL BIOL, V16, P258; Gauss GH, 1998, EUR J IMMUNOL, V28, P351, DOI 10.1002/(SICI)1521-4141(199801)28:01<351::AID-IMMU351>3.0.CO;2-#; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; KODAMA K, 1991, NUCLEIC ACIDS RES, V19, P6093, DOI 10.1093/nar/19.22.6093; KYSELA BP, 1995, RADIAT RES, V144, P276, DOI 10.2307/3578946; Lee KJ, 2000, J BIOL CHEM, V275, P34787, DOI 10.1074/jbc.M004011200; Lehmann AR, 1998, BIOESSAYS, V20, P146, DOI 10.1002/(SICI)1521-1878(199802)20:2<146::AID-BIES7>3.3.CO;2-5; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PLOWMAN PN, 1990, BRIT J RADIOL, V63, P624, DOI 10.1259/0007-1285-63-752-624; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; Robins P, 1996, J BIOL CHEM, V271, P24257, DOI 10.1074/jbc.271.39.24257; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; Schar P, 1997, GENE DEV, V11, P1912, DOI 10.1101/gad.11.15.1912; Shuman S, 1996, STRUCTURE, V4, P653, DOI 10.1016/S0969-2126(96)00070-6; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P525, DOI 10.1093/nar/26.2.525; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; YANG SW, 1992, J BIOL CHEM, V267, P8117	32	102	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31124	31132		10.1074/jbc.M103866200	http://dx.doi.org/10.1074/jbc.M103866200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11349135	hybrid			2022-12-25	WOS:000170472900071
J	Paul, S; Tramontano, A; Gololobov, G; Zhou, YX; Taguchi, H; Karle, S; Nishiyama, Y; Planque, S; George, S				Paul, S; Tramontano, A; Gololobov, G; Zhou, YX; Taguchi, H; Karle, S; Nishiyama, Y; Planque, S; George, S			Phosphonate ester probes for proteolytic antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; BENCE-JONES PROTEINS; SITE-DIRECTED MUTAGENESIS; TRANSITION-STATE ANALOG; CATALYTIC ANTIBODIES; LIGHT-CHAIN; PHAGE DISPLAY; CRYSTAL-STRUCTURES; ACTIVE-SITE; ANTIGEN	The reactivity of phosphonate ester probes with several available proteolytic antibody (Ab) fragments was characterized. Irreversible, active site-directed inhibition of the peptidase activity was evident. Stable phosphonate diester-Ab adducts were resolved by column chromatography and denaturing electrophoresis. Biotinylated phosphonate esters were applied for chemical capture of phage particles displaying Fv and light chain repertoires. Selected Ab fragments displayed enriched catalytic activity inhibitable by the selection reagent. Somewhat unexpectedly, a phosphonate monoester also formed stable adducts with the Abs. Improved catalytic activity of phage Abs selected by monoester binding was evident. Turnover values (k(cat)) for a selected Fv construct and a light chain against their preferred model peptide substrates were 0.5 and 0.2 min(-1), respectively, and the corresponding Michaelis-Menten constants (K-m) were 10 and 8 mum. The covalent reactivity of Abs with phosphonate esters suggests their ability to recapitulate the catalytic mechanism utilized by classical serine proteases.	Univ Texas, Sch Med, Dept Pathol & Lab Med, Chem Immunol & Therapeut Res Ctr, Houston, TX 77030 USA	University of Texas System	Paul, S (corresponding author), Univ Texas, Sch Med, Dept Pathol & Lab Med, Chem Immunol & Therapeut Res Ctr, 6431 Fannin, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA080312] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059746, R01HL044126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI046029, R01AI031268, R21AI031268] Funding Source: NIH RePORTER; NCI NIH HHS [CA80312] Funding Source: Medline; NHLBI NIH HHS [HL59746, HL44126] Funding Source: Medline; NIAID NIH HHS [AI31268, AI46029] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANAND NN, 1991, J BIOL CHEM, V266, P21874; BALDWIN E, 1989, SCIENCE, V245, P1104, DOI 10.1126/science.2672338; BENCSURA A, 1995, BIOCHEMISTRY-US, V34, P8989, DOI 10.1021/bi00028a007; BONE R, 1991, BIOCHEMISTRY-US, V30, P2263, DOI 10.1021/bi00222a032; Charbonnier JB, 1997, SCIENCE, V275, P1140, DOI 10.1126/science.275.5303.1140; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; GAO QS, 1995, J MOL BIOL, V253, P658, DOI 10.1006/jmbi.1995.0580; Gololobov G, 1999, MOL IMMUNOL, V36, P1215, DOI 10.1016/S0161-5890(99)00141-8; HAREL M, 1991, J MOL BIOL, V221, P909, DOI 10.1016/0022-2836(91)80183-U; Haux JE, 2000, CHEM RES TOXICOL, V13, P646, DOI 10.1021/tx000027w; Hifumi E, 1999, J BIOSCI BIOENG, V88, P323, DOI 10.1016/S1389-1723(00)80018-3; KALAGA R, 1995, J IMMUNOL, V155, P2695; Lacroix-Desmazes S, 1999, NAT MED, V5, P1044, DOI 10.1038/12483; Legendre D, 2000, J MOL BIOL, V296, P87, DOI 10.1006/jmbi.1999.3437; Li L, 1996, MOL IMMUNOL, V33, P593, DOI 10.1016/0161-5890(96)00021-1; LI L, 1995, J IMMUNOL, V154, P3328; Liu E, 1998, MOL IMMUNOL, V35, P1069, DOI 10.1016/S0161-5890(98)00089-3; MATSUURA K, 1994, BIOCHEM BIOPH RES CO, V204, P57, DOI 10.1006/bbrc.1994.2425; Matsuura K, 1996, BIOL CHEM, V377, P587, DOI 10.1515/bchm3.1996.377.9.587; MCCAFFERTY J, 1994, APPL BIOCHEM BIOTECH, V47, P157, DOI 10.1007/BF02787932; MODY R, 1994, INT J PEPT PROT RES, V44, P441; NOSSAL GJV, 1995, ANNU REV IMMUNOL, V13, P1; PAUL S, 1995, J BIOL CHEM, V270, P15257, DOI 10.1074/jbc.270.25.15257; PAUL S, 1991, J BIOL CHEM, V266, P16128; PAUL S, 1989, SCIENCE, V244, P1158, DOI 10.1126/science.2727702; PAUL S, 1992, J BIOL CHEM, V267, P13142; Paul S, 2000, APPL BIOCHEM BIOTECH, V83, P71, DOI 10.1385/ABAB:83:1-3:71; PAUL S, 1990, J BIOL CHEM, V265, P11910; POLLACK SJ, 1989, J AM CHEM SOC, V111, P5961, DOI 10.1021/ja00197a078; RAHIL J, 1994, BIOCHEMISTRY-US, V33, P116, DOI 10.1021/bi00167a015; SAMPSON NS, 1991, BIOCHEMISTRY-US, V30, P2255, DOI 10.1021/bi00222a031; Schowen R., 1988, MECHANISTIC PRINCIPL, P119; SHUSTER AM, 1992, SCIENCE, V256, P665, DOI 10.1126/science.1585181; Sun M, 1997, J MOL BIOL, V271, P374, DOI 10.1006/jmbi.1997.1196; SUN M, 1991, J BIOL CHEM, V266, P15571; Takahashi N, 2000, J IMMUNOL METHODS, V235, P113, DOI 10.1016/S0022-1759(99)00224-0; TAWFIK DS, 1995, P NATL ACAD SCI USA, V92, P2145, DOI 10.1073/pnas.92.6.2145; Thiagarajan P, 2000, BIOCHEMISTRY-US, V39, P6459, DOI 10.1021/bi992588w; TRAMONTANO A, 1986, P NATL ACAD SCI USA, V83, P6736, DOI 10.1073/pnas.83.18.6736; TRAMONTANO A, 1994, APPL BIOCHEM BIOTECH, V47, P257, DOI 10.1007/BF02787939; Tyutyulkova S, 1996, BBA-MOL BASIS DIS, V1316, P217, DOI 10.1016/0925-4439(96)00028-2; TYUTYULKOVA S, 1995, ANTIBODY ENG PROTOCO, P377; WIRSCHING P, 1995, SCIENCE, V270, P1775, DOI 10.1126/science.270.5243.1775; Wong L, 2000, BIOCHEMISTRY-US, V39, P5750, DOI 10.1021/bi992906r; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444	45	61	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28314	28320		10.1074/jbc.M102530200	http://dx.doi.org/10.1074/jbc.M102530200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11346653	hybrid			2022-12-25	WOS:000170093400077
J	Eleftheriou, A; Yoshida, M; Henderson, BR				Eleftheriou, A; Yoshida, M; Henderson, BR			Nuclear export of human beta-catenin can occur independent of CRM1 and the adenomatous polyposis coli tumor suppressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; APC; CANCER; TRANSACTIVATION; LOCALIZATION; EXPRESSION; SIGNALS; IDENTIFICATION; ACTIVATION; TRANSPORT	beta -Catenin is a mediator of the Wnt-signaling pathway. In many cancers, beta -catenin is stabilized and accumulates in the nucleus where it associates with lymphoid-enhancing factor II T-cell transcription factors to activate genes involved in cell transformation. Previously, we showed that adenomatous polyposis coli (APC) protein can regulate beta -catenin localization by nuclear export. In this study, we used in vitro transport assays to test whether cellular beta -catenin can exit the nucleus independent of APC and the CRM1 export receptor, In digitonin-permeabilized SW480 (APC(mut/mut)) tumor cells, nuclear beta -catenin decreased > 60% in export reactions in the absence of exogenous factors, Under similar conditions, nuclear c-ABL was only exported after the addition of cytosolic extract, and the export was blocked by the CRM1-specific inhibitor, leptomycin B, The nuclear export of beta -catenin was not blocked by leptomycin B treatment, revealing a CRM1- and APC-independent pathway. The export of beta -catenin was sensitive to lower temperatures and the removal of ATP, indicating an active process. Ectopically expressed yellow fluorescent protein-beta -catenin also displayed CRM1-independent export. Conversely, the overexpression of the CRM1 transporter moderately stimulated export of nuclear beta -catenin, confirming that beta -catenin exits the nucleus by at least two distinct pathways. The shuttling ability of tumor cell beta -catenin has implications for its regulation and its role in transferring signals between the nucleus and plasma membrane.	Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead Inst Canc Res, Westmead, NSW 2145, Australia; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan	University of Sydney; Westmead Institute for Medical Research; University of Tokyo	Henderson, BR (corresponding author), Westmead Millennium Inst, WICR, Darcy Rd,POB 412, Westmead, NSW 2145, Australia.		Yoshida, Minoru/C-8049-2014	Yoshida, Minoru/0000-0002-4376-5674				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kongkanuntn R, 1999, ONCOGENE, V18, P7219, DOI 10.1038/sj.onc.1203181; Kose S, 1999, J BIOL CHEM, V274, P3946, DOI 10.1074/jbc.274.7.3946; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Lee SJ, 2000, J MOL BIOL, V302, P251, DOI 10.1006/jmbi.2000.4055; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nakielny S, 1998, CURR BIOL, V8, P89, DOI 10.1016/S0960-9822(98)70039-9; Neufeld KL, 2000, P NATL ACAD SCI USA, V97, P12085, DOI 10.1073/pnas.220401797; Neufeld KL, 2000, EMBO REP, V1, P519; Orsulic S, 1999, J CELL SCI, V112, P1237; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polakis P, 2000, GENE DEV, V14, P1837; Porfiri E, 1997, ONCOGENE, V15, P2833, DOI 10.1038/sj.onc.1201462; Prieve MG, 1999, MOL CELL BIOL, V19, P4503; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; van Es JH, 2001, EXP CELL RES, V264, P126, DOI 10.1006/excr.2000.5142; Wiechens N, 2001, CURR BIOL, V11, P18, DOI 10.1016/S0960-9822(00)00045-2; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119	42	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25883	25888		10.1074/jbc.M102656200	http://dx.doi.org/10.1074/jbc.M102656200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11337505	hybrid			2022-12-25	WOS:000169823300034
J	Rohatgi, R; Nollau, P; Ho, HYH; Kirschner, MW; Mayer, BJ				Rohatgi, R; Nollau, P; Ho, HYH; Kirschner, MW; Mayer, BJ			Nck and phosphatidylinositol 4,5-bisphosphate synergistically activate actin polymerization through the N-WASP-Arp2/3 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; SH2/SH3 ADAPTER PROTEIN; SRC HOMOLOGY-3 DOMAINS; N-WASP; 3T3 FIBROBLASTS; ARP2/3 COMPLEX; KINASE PAK1; CDC42; FILOPODIA; SIGNALS	The Wiskott-Aldrich syndrome protein (WASP) and its relative neural WASP (N-WASP) regulate the nucleation of actin filaments through their interaction with the Arp2/3 complex and are regulated in turn by binding to GTP-bound Cdc42 and phosphatidylinositol 4,5-bisphosphate, The Nck Src homology (SH) 2/3 adaptor binds via its SH3 domains to a proline-rich region on WASP and N-WASP and has been implicated in recruitment of these proteins to sites of tyrosine phosphorylation. We show here that Nck SH3 domains dramatically stimulate the rate of nucleation of actin filaments by purified N-WASP in the presence of Arp2/3 in vitro. All three Nck SH3 domains are required for maximal activation, Nck-stimulated actin nucleation by N-WASP Arp2/3 complexes is further stimulated by phosphatidylinositol 4,5-bisphosphate, but not by GTP-Cdc42, suggesting that Nck and Cdc42 activate N-WASP by redundant mechanisms. These results suggest the existence of an Nck-dependent, Cdc42-independent mechanism to induce actin polymerization at tyrosine-phosphorylated Nck binding sites.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02116 USA; Childrens Hosp, Mol Med Lab, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Kirschner, MW (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02116 USA.	marc@hms.harvard.edu			NCI NIH HHS [CA82258] Funding Source: Medline; NIGMS NIH HHS [GM26875] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082258] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026875, R01GM026875] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anton IM, 1998, J BIOL CHEM, V273, P20992, DOI 10.1074/jbc.273.33.20992; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; CARLIER MF, 1990, J BIOL CHEM, V275, P21969; Chen M, 2000, MOL CELL BIOL, V20, P7867, DOI 10.1128/MCB.20.21.7867-7880.2000; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; McCarty JH, 1998, BIOESSAYS, V20, P913, DOI 10.1002/(SICI)1521-1878(199811)20:11<913::AID-BIES6>3.0.CO;2-T; Moreau V, 2000, NAT CELL BIOL, V2, P441, DOI 10.1038/35017080; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Smith JM, 1999, J BIOL CHEM, V274, P27956, DOI 10.1074/jbc.274.39.27956; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5	26	312	320	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26448	26452		10.1074/jbc.M103856200	http://dx.doi.org/10.1074/jbc.M103856200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11340081	hybrid			2022-12-25	WOS:000169823300106
J	Sachdev, P; Jiang, YX; Li, WQ; Miki, T; Maruta, H; Nur-e-Kamal, MSA; Wang, LH				Sachdev, P; Jiang, YX; Li, WQ; Miki, T; Maruta, H; Nur-e-Kamal, MSA; Wang, LH			Differential requirement for Rho family GTPases in an oncogenic insulin-like growth factor-I receptor-induced cell transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; FOCAL ADHESION KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; V-SRC; CYTOSKELETAL REORGANIZATION; GUANOSINE TRIPHOSPHATASES; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; RAS TRANSFORMATION; CYCLE PROGRESSION	Insulin-like growth factor I receptor (IGFR) plays an important role in cell growth and transformation. We dissected the downstream signaling pathways of an oncogenic variant of IGFR, Gag-IGFR, called NM1, Loss of function mutants of NM1, Phe-1136 and dS2, that retain kinase activity but are attenuated in their transforming ability were used to identify signaling pathways that are important for transformation of NIH 3T3 cells. MAPK, phospholipase C gamma, and Stat3 were activated to the same extent by NM1 and its two mutants, suggesting that activation of these pathways, individually or in combination, was not sufficient for NM1-induced cell transformation. The mutant dS2 has decreased IRS-1 phosphorylation levels and IRS-l-associated phosphatidylinositol 3 ' -kinase activity, suggesting that this impairment may be in part responsible for the defectiveness of dS2, We show that Rho family members, RhoA, Rad, and Cdc42 are activated by NM1, and this activation, particularly RhoA and Cdc42, is attenuated in both mutants of NM1, Dominant negative mutants of Rho, Rac, and Cdc42 inhibited NM1-induced cell transformation, as measured by focus and colony forming ability. Dominant negative Rho most potently inhibited the focus forming activity, whereas Cdc42 was most effective in inhibiting the colony forming ability of NM1-expressing cells. Conversely, constitutively activated (ca) Rho is more effective than ca Rac or ca Cdc42 in rescuing the focus forming ability of the mutants. By contrast, ca Cdc42 is most effective in rescuing the colony forming ability of both mutants.	CUNY Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA; Brockton W Roxbury Vet Affairs Med Ctr, Dept Med, Bronx, NY 10468 USA; Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20007 USA; NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia; Univ Med & Dent New Jersey, RW Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ludwig Institute for Cancer Research; Rutgers State University New Brunswick; Rutgers State University Medical Center	Wang, LH (corresponding author), CUNY Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA.				NCI NIH HHS [CA55054] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; Aplin AE, 1999, J CELL SCI, V112, P695; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Berfield AK, 1997, J HISTOCHEM CYTOCHEM, V45, P583, DOI 10.1177/002215549704500410; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Guvakova MA, 1999, EXP CELL RES, V251, P244, DOI 10.1006/excr.1999.4566; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Hirai A, 1997, J BIOL CHEM, V272, P13; Ito T, 1996, MOL CELL BIOL, V16, P943; JIANG Y, 1996, J BIOL CHEM, V271, P60; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; KALEBIC T, 1994, CANCER RES, V54, P5531; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kim BS, 1998, J NEUROCHEM, V71, P1333; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; LI SW, 1994, J BIOL CHEM, V269, P32558; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; Liu Delong, 1994, Journal of Biomedical Science, V1, P65, DOI 10.1007/BF02257980; LIU DL, 1992, J VIROL, V66, P374, DOI 10.1128/JVI.66.1.374-385.1992; LIU DL, 1993, J VIROL, V67, P9, DOI 10.1128/JVI.67.1.9-18.1993; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Martin SS, 1996, ENDOCRINOLOGY, V137, P5045, DOI 10.1210/en.137.11.5045; Mayer T, 1999, ONCOGENE, V18, P2117, DOI 10.1038/sj.onc.1202537; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MEJNE AM, 1997, EXP CELL RES, V234, P477; NEUENSCHWANDER S, 1995, ENDOCRINOLOGY, V136, P4298, DOI 10.1210/en.136.10.4298; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; NOBES CD, 1995, J CELL SCI S, V8, P35; Nur-E-Kamal MSA, 1999, ONCOGENE, V18, P7787; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Pass HI, 1996, CANCER RES, V56, P4044; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P ANTL ACD SCI US, V92, P17811; Resnicoff M, 1998, ANN NY ACAD SCI, V842, P76, DOI 10.1111/j.1749-6632.1998.tb09634.x; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; SANCHEZMARGALET V, 1995, MOL ENDOCRINOL, V9, P435, DOI 10.1210/me.9.4.435; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sasaoka T, 1996, ENDOCRINOLOGY, V137, P4427, DOI 10.1210/en.137.10.4427; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Scrimgeour AG, 1997, ENDOCRINOLOGY, V138, P2552, DOI 10.1210/en.138.6.2552; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; TartareDeckert S, 1996, ENDOCRINOLOGY, V137, P1019, DOI 10.1210/en.137.3.1019; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; YASHIRO T, 1989, ACTA ENDOCRINOL-COP, V121, P112, DOI 10.1530/acta.0.1210112; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	69	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26461	26471		10.1074/jbc.M010995200	http://dx.doi.org/10.1074/jbc.M010995200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11346642	hybrid, Green Submitted			2022-12-25	WOS:000169823300108
J	Beckstead, MJ; Phelan, R; Mihic, SJ				Beckstead, MJ; Phelan, R; Mihic, SJ			Antagonism of inhalant and volatile anesthetic enhancement of glycine receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; GENERAL-ANESTHETICS; GABA(A) RECEPTORS; BINDING-SITES; AMINO-ACID; ALCOHOL; ISOFLURANE; HALOTHANE; MUTATIONS; CHANNELS	Recent studies suggest that alcohols, volatile anesthetics, and inhaled drugs of abuse, which enhance gamma -aminobutyric acid, type A, and glycine receptor-activated ion channel function, may share common or overlapping molecular sites of action on these receptors, To investigate this possibility, these compounds were applied singly and in combination to wild-type glycine cu, receptors expressed in Xenopus laevis oocytes, Data obtained from concentration-response curves of the volatile anesthetic enflurane constructed in the presence and absence of ethanol, chloroform, or toluene were consistent with competition for a common binding pocket on these receptors, A mutant glycine receptor, insensitive to the enhancing effects of ethanol but not anesthetics or inhalants, demonstrated antagonism of anesthetic and inhalent effects on this receptor. Although ethanol (25-200 mM) had no effect on its own in this receptor, it was able to inhibit reversibly the enhancing effect of enflurane, toluene, and chloroform in a concentration-dependent manner. These data suggest the existence of overlapping molecular sites of action for ethanol, inhalants, and volatile anesthetics on glycine receptors and illustrate the feasibility of pharmacological antagonism of the effects of volatile anesthetics.	Univ Texas, Neurobiol Sect, Austin, TX 78712 USA; Univ Texas, Waggoner Ctr Alcohol & Addict Res, Inst Neurosci, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; Wake Forest University; Wake Forest Baptist Medical Center	Beckstead, MJ (corresponding author), Univ Texas, Neurobiol Sect, 2500 Speedway,MBB 1-148, Austin, TX 78712 USA.				NIAAA NIH HHS [F31 AA005605, AA11525] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [F31AA005605, R01AA011525] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Beckstead MJ, 2000, MOL PHARMACOL, V57, P1199; BECKSTEAD MJ, 2000, ALCOHOL CLIN EXP RES, V24, P45; DUBOIS BW, 1993, P NATL ACAD SCI USA, V90, P6478, DOI 10.1073/pnas.90.14.6478; Eckenhoff RG, 1997, PHARMACOL REV, V49, P343; Eger EI, 1999, ANESTH ANALG, V88, P867, DOI 10.1097/00000539-199904000-00035; ELMAGHRABI EA, 1992, P NATL ACAD SCI USA, V89, P4329, DOI 10.1073/pnas.89.10.4329; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; GION H, 1971, ANESTHESIOLOGY, V35, P361, DOI 10.1097/00000542-197110000-00008; Krasowski MD, 2000, BRIT J PHARMACOL, V129, P731, DOI 10.1038/sj.bjp.0703087; Krasowski MD, 1998, MOL PHARMACOL, V53, P530, DOI 10.1124/mol.53.3.530; Lopez MM, 1998, BIOPHYS J, V74, P974, DOI 10.1016/S0006-3495(98)74020-2; Mascia MP, 2000, P NATL ACAD SCI USA, V97, P9305, DOI 10.1073/pnas.160128797; MIHIC SJ, 1994, J BIOL CHEM, V269, P32768; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Neumahr S, 2000, ANESTH ANALG, V90, P1184, DOI 10.1097/00000539-200005000-00035; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; Sigel E, 1997, TRENDS PHARMACOL SCI, V18, P425, DOI 10.1016/S0165-6147(97)90675-1; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; Wick MJ, 1998, P NATL ACAD SCI USA, V95, P6504, DOI 10.1073/pnas.95.11.6504; Yamakura T, 1999, J BIOL CHEM, V274, P23006, DOI 10.1074/jbc.274.33.23006	21	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24959	24964		10.1074/jbc.M011627200	http://dx.doi.org/10.1074/jbc.M011627200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11346643	hybrid			2022-12-25	WOS:000169800700070
J	Bergmeier, W; Bouvard, D; Eble, JA; Mokhtari-Nejad, R; Schulte, V; Zirngibl, H; Brakebusch, C; Fassler, R; Nieswandt, B				Bergmeier, W; Bouvard, D; Eble, JA; Mokhtari-Nejad, R; Schulte, V; Zirngibl, H; Brakebusch, C; Fassler, R; Nieswandt, B			Rhodocytin (aggretin) activates platelets lacking alpha(2)beta(1) integrin, glycoprotein VI, and the ligand-binding domain of glycoprotein Ib alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN-INDUCED AGGREGATION; VON-WILLEBRAND-FACTOR; SNAKE-VENOM PROTEIN; FCR-GAMMA-CHAIN; IMMUNOGLOBULIN SUPERFAMILY; MONOCLONAL-ANTIBODIES; VONWILLEBRAND-FACTOR; NONHUMAN-PRIMATES; ADHESION; RECEPTOR	Although alpha (2)beta (1) integrin (glycoprotein Ia/IIa) has been established as a platelet collagen receptor, its role in collagen-induced platelet activation has been controversial. Recently, it has been demonstrated that rhodocytin (also termed aggretin), a snake venom toxin purified from the venom of Calloselasma rhodostoma, induces platelet activation that can be blocked by monoclonal antibodies against alpha (2)beta (1) integrin, This finding suggested that clustering of alpha (2)beta (1) integrin by rhodocytin is sufficient to induce platelet activation and led to the hypothesis that collagen may activate platelets by a similar mechanism. In contrast to these findings, we provided evidence that rhodocytin does not bind to alpha (2)beta (1) integrin, Here we show that the Cre/loxP-mediated loss of p, integrin on mouse platelets has no effect on rhodocytin-induced platelet activation, excluding an essential role of ru,p, integrin in this process. Furthermore, proteolytic cleavage of the 45-kDa N-terminal domain of glycoprotein (GP) Ib alpha either on normal or on Pi-null platelets had no significant effect on rhodocytin-induced platelet activation. Moreover, mouse platelets lacking both alpha (2)beta (1) integrin and the activating collagen receptor GPVI responded normally to rhodocytin, Finally, even after additional proteolytic removal of the 45-kDa N-terminal domain of GPIb alpha rhodocytin induced aggregation of these platelets. These results demonstrate that rhodocytin induces platelet activation by mechanisms that are fundamentally different from those induced by collagen.	Univ Witten Herdecke, Dept Mol Oncol Gen Surg, D-42117 Wuppertal, Germany; Univ Lund, Dept Expt Pathol, S-22185 Lund, Sweden; Univ Munster, Inst Physiol Chem & Pathobiochem, D-48149 Munster, Germany	Witten Herdecke University; Lund University; University of Munster	Nieswandt, B (corresponding author), Ferdinand Sauerbruch Klinikum Elberfeld, Dept Mol Oncol, Arrenbergerstr 20,Haus 10, D-42117 Wuppertal, Germany.		Bouvard, Daniel/B-1260-2017; Bouvard, Daniel/M-2727-2013	Bouvard, Daniel/0000-0002-0845-6681; Brakebusch, Cord/0000-0002-9342-1634				Andrews RK, 1999, THROMB HAEMOSTASIS, V82, P357, DOI 10.1055/s-0037-1615854; Bergmeier W, 2000, BLOOD, V95, P886, DOI 10.1182/blood.V95.3.886.003k45_886_893; CADROY Y, 1994, BLOOD, V83, P3218; Cauwenberghs N, 2000, ARTERIOSCL THROM VAS, V20, P1347, DOI 10.1161/01.ATV.20.5.1347; CAZENAVE JP, 1983, ANN BIOL CLIN-PARIS, V41, P167; Chung CH, 1999, BIOCHEM BIOPH RES CO, V263, P723, DOI 10.1006/bbrc.1999.1457; Dormann D, 2001, BLOOD, V97, P929, DOI 10.1182/blood.V97.4.929; DU XP, 1994, J BIOL CHEM, V269, P18287; Eble JA, 2001, J BIOL CHEM, V276, P12274, DOI 10.1074/jbc.M009338200; Eilers M, 1999, BIOCHEM BIOPH RES CO, V263, P230, DOI 10.1006/bbrc.1999.1352; Gratacap MP, 2000, BLOOD, V96, P3439, DOI 10.1182/blood.V96.10.3439.h8003439_3439_3446; HUANG TF, 1995, BIOCHEM J, V309, P1021, DOI 10.1042/bj3091021; Inoue K, 1999, BIOCHEM BIOPH RES CO, V256, P114, DOI 10.1006/bbrc.1999.0295; Jandrot-Perrus M, 2000, BLOOD, V96, P1798, DOI 10.1182/blood.V96.5.1798.h8001798_1798_1807; JandrotPerrus M, 1996, SEMIN THROMB HEMOST, V22, P151, DOI 10.1055/s-2007-999003; JandrotPerrus M, 1997, J BIOL CHEM, V272, P27035, DOI 10.1074/jbc.272.43.27035; Jin JG, 1998, P NATL ACAD SCI USA, V95, P8070, DOI 10.1073/pnas.95.14.8070; Kawasaki T, 1996, J BIOL CHEM, V271, P10635, DOI 10.1074/jbc.271.18.10635; KROLL MH, 1991, J CLIN INVEST, V88, P1568, DOI 10.1172/JCI115468; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Liu LB, 1997, J BIOL CHEM, V272, P1997, DOI 10.1074/jbc.272.3.1997; Lopez J A, 1997, Curr Opin Hematol, V4, P323; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; Navdaev A, 2001, J BIOL CHEM, V276, P20882, DOI 10.1074/jbc.M101585200; Nieswandt B, 2000, BLOOD, V96, P2520; Nieswandt B, 2000, J BIOL CHEM, V275, P23998, DOI 10.1074/jbc.M003803200; Nieswandt B, 2001, BLOOD, V97, P3829, DOI 10.1182/blood.V97.12.3829; Nieswandt B, 2001, J EXP MED, V193, P459, DOI 10.1084/jem.193.4.459; Nieswandt B, 2001, EMBO J, V20, P2120, DOI 10.1093/emboj/20.9.2120; Ohlmann P, 2000, BLOOD, V96, P2134, DOI 10.1182/blood.V96.6.2134.h8002134_2134_2139; Paul BZS, 1999, J BIOL CHEM, V274, P29108, DOI 10.1074/jbc.274.41.29108; PENG ML, 1993, BLOOD, V81, P2321; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Potocnik AJ, 2000, IMMUNITY, V12, P653, DOI 10.1016/S1074-7613(00)80216-2; Romo GM, 1999, J EXP MED, V190, P803, DOI 10.1084/jem.190.6.803; SAELMAN EUM, 1994, BLOOD, V83, P1244; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; Schulte V, 2001, J BIOL CHEM, V276, P364, DOI 10.1074/jbc.M007536200; Shin Y, 1998, BIOCHEM BIOPH RES CO, V245, P741, DOI 10.1006/bbrc.1998.8516; Simon DI, 2000, J EXP MED, V192, P193, DOI 10.1084/jem.192.2.193; Sobocka MB, 2000, BLOOD, V95, P2600; Suzuki-Inoue K, 2001, J BIOL CHEM, V276, P1643, DOI 10.1074/jbc.M006191200; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; WARE J, 1993, J BIOL CHEM, V268, P8376	45	69	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25121	25126		10.1074/jbc.M103892200	http://dx.doi.org/10.1074/jbc.M103892200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11352922	hybrid			2022-12-25	WOS:000169800700093
J	Ebisu, K; Nagasawa, T; Watanabe, K; Kakinuma, K; Miyano, K; Tamura, M				Ebisu, K; Nagasawa, T; Watanabe, K; Kakinuma, K; Miyano, K; Tamura, M			Fused p47(phox) and p67(phox) truncations efficiently reconstitute NADPH oxidase with higher activity and stability than the individual components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; CELL-FREE SYSTEM; NEUTROPHIL PLASMA-MEMBRANE; SH3 DOMAIN INTERACTIONS; SRC HOMOLOGY-3 DOMAINS; 1-ETHYL-3-(3-DIMETHYLAMINOPROPYL) CARBODIIMIDE; PHOSPHATIDIC-ACID; ACTIVATION DOMAIN; ESCHERICHIA-COLI; REDUCTASE	Activation of the neutrophil NADPH oxidase occurs via assembly of the cytosolic regulatory proteins p47(phox), p67(phox), and Rac with the membrane-associated flavocytochrome b(558). Following cell-free activation, enzymatic activity is highly labile (Tamura, M,, Takeshita, M,, Curnutte, J. T,, Uhlinger, D, J,, and Lambeth, J, D, (1992) J, Biol, Chem, 267, 7529-7538), To try to stabilize the activity and investigate the nature of the complex, fusion proteins between p47N-(1-286) and p67N-(1-210) were constructed. In a cell-free system, a fusion protein, p67N-p47N, had an 8-fold higher efficiency and produced a higher activity than the individual proteins, and also resulted in an 8-fold improved efficiency for Rac and a lowered K, for NADPH, Of, generating activity was remarkably stabilized by using p67N-p47N, The cytosolic proteins fused in the opposite orientation, p47N-p67N, showed similar activity and stability as individual proteins, but with a 4-fold improved efficiency compared with the individual cytosolic factors. In the system efficiency for Rac and affinity for NADPH were also higher than those with the nonfused components. Interestingly, the p67N-p47N showed nearly full activation in the absence of an anionic amphifile in a cell-free system containing cytochrome b(558) relipidated with phosphatidylinositol- or phosphatidylserine-enriched phospholipid mixtures, From the results we consider multiple roles of anionic amphifiles in a cell-free activation, which could be substituted by our system. The fact that a fusion produces a more stable complex indicates that interactions among components determine the longevity of the complex. Based on the findings we propose a model for the topology among p47N, p67N, and cytochrome b(558) in the active complex.	Ehime Univ, Fac Engn, Dept Appl Chem, Matsuyama, Ehime 7908577, Japan; Univ Tokyo, Fac Sci, Biophoton Informat Labs, MMBS, Kanagawa 2380225, Japan	Ehime University; University of Tokyo	Tamura, M (corresponding author), Ehime Univ, Fac Engn, Dept Appl Chem, Matsuyama, Ehime 7908577, Japan.							ABO A, 1992, J BIOL CHEM, V267, P16767; Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; Cross AR, 1999, J BIOL CHEM, V274, P15519, DOI 10.1074/jbc.274.22.15519; Dang PMC, 1999, BIOCHEMISTRY-US, V38, P5746, DOI 10.1021/bi982750f; DeLeo FR, 1996, J BIOL CHEM, V271, P17013, DOI 10.1074/jbc.271.29.17013; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; deMendez I, 1996, EMBO J, V15, P1211, DOI 10.1002/j.1460-2075.1996.tb00462.x; Erickson RW, 1999, J BIOL CHEM, V274, P22243, DOI 10.1074/jbc.274.32.22243; FISHER CW, 1992, P NATL ACAD SCI USA, V89, P10817, DOI 10.1073/pnas.89.22.10817; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; FUJII H, 1992, BIOCHIM BIOPHYS ACTA, V1136, P239, DOI 10.1016/0167-4889(92)90112-O; Gorzalczany Y, 2000, J BIOL CHEM, V275, P40073, DOI 10.1074/jbc.M006013200; Han CH, 1998, J BIOL CHEM, V273, P16663, DOI 10.1074/jbc.273.27.16663; Hata K, 1998, J BIOL CHEM, V273, P4232, DOI 10.1074/jbc.273.7.4232; Huang J, 1999, J BIOL CHEM, V274, P19731, DOI 10.1074/jbc.274.28.19731; Kreck ML, 1996, BIOCHEMISTRY-US, V35, P15683, DOI 10.1021/bi962064l; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LETO TL, 1991, J BIOL CHEM, V266, P19812; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; MURAKAMI H, 1987, DNA-J MOLEC CELL BIO, V6, P189, DOI 10.1089/dna.1987.6.189; Nisimoto Y, 1999, J BIOL CHEM, V274, P22999, DOI 10.1074/jbc.274.33.22999; Ogata K, 1996, BIOCHEM J, V313, P549, DOI 10.1042/bj3130549; Palicz A, 2001, J BIOL CHEM, V276, P3090, DOI 10.1074/jbc.M007759200; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; SAKAKI T, 1994, BIOCHEMISTRY-US, V33, P4933, DOI 10.1021/bi00182a023; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SHET MS, 1993, P NATL ACAD SCI USA, V90, P11748, DOI 10.1073/pnas.90.24.11748; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; STEIN JM, 1991, BIOCHEM J, V274, P381, DOI 10.1042/bj2740381; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; TAMURA M, 1992, J BIOL CHEM, V267, P7529; TAMURA M, 1989, ARCH BIOCHEM BIOPHYS, V275, P23, DOI 10.1016/0003-9861(89)90345-7; TAMURA M, 1988, J BIOL CHEM, V263, P17621; TAMURA M, 1993, ARCH BIOCHEM BIOPHYS, V305, P477, DOI 10.1006/abbi.1993.1450; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7	42	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24498	24505		10.1074/jbc.M101122200	http://dx.doi.org/10.1074/jbc.M101122200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11333262	hybrid			2022-12-25	WOS:000169800700012
J	Nakamoto, H; Tanaka, N; Ishikawa, N				Nakamoto, H; Tanaka, N; Ishikawa, N			A novel heat shock protein plays an important role in thermal stress management in cyanobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCYSTIS-SP PCC-6803; GROEL-LIKE GENE; BACILLUS-SUBTILIS; SYNECHOCOCCUS-VULCANUS; FUNCTIONAL-ANALYSIS; MOLECULAR-CLONING; PHOTOSYSTEM-I; OPERON; CHAPERONIN; SUBUNIT	A novel heat shock gene, orf7.5, which encodes a putative acidic polypeptide of 63 amino acids, was cloned from the cyanobacterium Synechococcus sp, PCC 7942, Northern blot analysis revealed the presence of 400- and 330-base orf7,5 mRNAs, which were barely detectable in the cells grown at 30 degreesC but increased transiently in response to heat shock at 40 or 45 degreesC, Primer extension analysis showed that the two mRNAs have different 5'-ends. Chloramphenicol enhanced the accumulation of the orf7,5 mRNA, whereas it inhibited the increase in the amount of the groESL mRNA To reveal the role of the orf7,5 gene in thermal stress management, we constructed a stable mutant in which a gene conferring resistance to an antibiotic was inserted into the coding region of the orf7,5 gene. The interruption led to a marked inhibition of growth at 45 degreesC and a decrease in the basal and acquired thermo-tolerances at 50 degreesC in the transformants, indicating that the gene plays a role in thermal stress management. The orf7,5 mutant could be complemented with a return to the wild type phenotype by a DNA fragment containing orf7,5 but not by mutated orf7,5s, in which a nonsense mutation was generated by introducing a frameshift or a point mutation within the orf7,5-coding region. Thus, thermo-tolerance requires an appropriate translation product, not simply a transcript. Accumulation of the groESL transcript in the orf7,5 mutant was strongly reduced, suggesting that the orf7.5 gene product controls the expression of the groESL operon.	Saitama Univ, Dept Biochem & Mol Biol, Urawa, Saitama 3388570, Japan	Saitama University	Nakamoto, H (corresponding author), Saitama Univ, Dept Biochem & Mol Biol, Urawa, Saitama 3388570, Japan.		Nakamoto, Hitoshi/H-5315-2012					BOREBRY G, 1985, J BACTERIOL, V161, P1125; CHITNIS PR, 1991, J BIOL CHEM, V266, P58; EBBOLE DJ, 1987, J BIOL CHEM, V262, P8274; Eriksson MJ, 1996, J BACTERIOL, V178, P4839, DOI 10.1128/jb.178.16.4839-4846.1996; Furuki M, 1996, BBA-PROTEIN STRUCT M, V1294, P106, DOI 10.1016/0167-4838(96)00037-4; Glatz A, 1997, BIOCHEM BIOPH RES CO, V239, P291, DOI 10.1006/bbrc.1997.7463; GOLDEN SS, 1987, METHOD ENZYMOL, V153, P215; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; Lee SY, 1998, CURR MICROBIOL, V37, P403, DOI 10.1007/s002849900400; LEHEL C, 1993, J BIOL CHEM, V268, P1799; LEHEL C, 1992, PLANT MOL BIOL, V18, P327, DOI 10.1007/BF00034959; Mogk A, 1997, EMBO J, V16, P4579, DOI 10.1093/emboj/16.15.4579; Nakamoto H, 1999, PLANT CELL PHYSIOL, V40, P9, DOI 10.1093/oxfordjournals.pcp.a029479; Narberhaus F, 1999, MOL MICROBIOL, V31, P1, DOI 10.1046/j.1365-2958.1999.01166.x; REILLY P, 1988, J BIOL CHEM, V263, P17658; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Roy SK, 1998, J BACTERIOL, V180, P3997, DOI 10.1128/JB.180.15.3997-4001.1998; Sambrook J., 2002, MOL CLONING LAB MANU; SERVANT P, 1995, J BACTERIOL, V177, P2998, DOI 10.1128/jb.177.11.2998-3003.1995; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; Tanaka N, 1999, FEBS LETT, V458, P117, DOI 10.1016/S0014-5793(99)01134-5; Tanaka N, 1997, BBA-PROTEIN STRUCT M, V1343, P335, DOI 10.1016/S0167-4838(97)00159-3; WEBB R, 1990, J BACTERIOL, V172, P5079, DOI 10.1128/jb.172.9.5079-5088.1990; Webb R., 1994, MOL BIOL CYANOBACTER, P751; YUAN G, 1995, J BACTERIOL, V177, P6462, DOI 10.1128/jb.177.22.6462-6468.1995; ZUBER U, 1994, J BACTERIOL, V176, P1359, DOI 10.1128/jb.176.5.1359-1363.1994	26	12	12	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25088	25095		10.1074/jbc.M101717200	http://dx.doi.org/10.1074/jbc.M101717200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342543	hybrid			2022-12-25	WOS:000169800700088
J	Ostrander, DB; Zhang, M; Mileykovskaya, E; Rho, M; Dowhan, W				Ostrander, DB; Zhang, M; Mileykovskaya, E; Rho, M; Dowhan, W			Lack of mitochondrial anionic phospholipids causes an inhibition of translation of protein components of the electron transport chain - A yeast genetic model system for the study of anionic phospholipid function in mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; SACCHAROMYCES-CEREVISIAE; ATP SYNTHASE; PEL1 GENE; RAT-HEART; PHOSPHATIDYLGLYCEROPHOSPHATE SYNTHASE; ACIDIC PHOSPHOLIPIDS; PRECURSOR PROTEINS; ESCHERICHIA-COLI; NUCLEAR GENES	Reduction of mitochondrial cardiolipin (CL) levels has been postulated to compromise directly the function of several essential enzymes and processes of the mitochondria. There is limited genetic evidence for the critical roles with which CL and its precursor phosphatidylglycerol (PG) have been associated. A null allele of the PGS1 gene from Saccharomyces cerevisiae, which encodes the enzyme responsible for the synthesis of the CL precursor PG phosphate, was created in a yeast strain in which PGS1 expression is exogenously regulated by doxycycline. The addition of increasing concentrations of doxycycline to the growth medium causes a proportional decrease to undetectable levels of PGSI transcript, PG phosphate synthase activity, and PG plus CL. The doubling time of this strain with increasing doxycycline increases to senescence in non-fermentable carbon sources or at high temperatures, conditions that do not support growth of the pgs1 Delta strain. Doxycycline addition also causes mitochondrial abnormalities as observed by fluorescence microscopy, Products of four mitochondrial encoded genes (COX1, COX2, COX3, and COB) and one nuclear encoded gene (COX4) associated with the mitochondrial inner membrane are not present when PGSI expression is fully repressed. No translation of these proteins can be detected in cells lacking the PGSI gene product, although transcription and splicing appear unaffected. Protein import of other nuclear encoded proteins remains unaffected. The remaining proteins encoded by mitochondrial DNA are expressed and translated normally. Thus, the molecular basis for the lack of mitochondrial function in pgs1 Delta cells is the failure to translate gene products essential to the electron transport chain.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77225 USA	University of Texas System	Dowhan, W (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, POB 20708, Houston, TX 77225 USA.	William.Dowhan@uth.tmc.edu	Zhang, Mei/G-8690-2014	Mileykovskaya, Eugenia/0000-0002-8775-4467	NHLBI NIH HHS [HL10304] Funding Source: Medline; NIGMS NIH HHS [GM56389] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010304] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056389] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOVITCH DA, 1990, BIOCHIM BIOPHYS ACTA, V1020, P34, DOI 10.1016/0005-2728(90)90090-Q; Achleitner G, 1999, EUR J BIOCHEM, V264, P545, DOI 10.1046/j.1432-1327.1999.00658.x; ADOLPHUS, 1983, EMBO J, V2, P1765, DOI 10.1002/j.1460-2075.1983.tb01655.x; BELENDIUK G, 1978, J BIOL CHEM, V253, P4555; BEREITERHAHN J, 1976, BIOCHIM BIOPHYS ACTA, V423, P1, DOI 10.1016/0005-2728(76)90096-7; Beyer K, 1996, BIOCHEMISTRY-US, V35, P15784, DOI 10.1021/bi9610055; Bobyleva V, 1997, BIOCHEM MOL BIOL INT, V41, P469; Bonilla E, 1999, BBA-BIOENERGETICS, V1410, P171, DOI 10.1016/S0005-2728(98)00165-0; BRANDT A, 1991, METHOD CELL BIOL, V34, P369; Chang SC, 1998, J BIOL CHEM, V273, P9829, DOI 10.1074/jbc.273.16.9829; Chang SC, 1998, J BIOL CHEM, V273, P14933, DOI 10.1074/jbc.273.24.14933; Chen XJ, 2000, INT REV CYTOL, V194, P197; CHUPIN V, 1995, FEBS LETT, V373, P239, DOI 10.1016/0014-5793(95)01054-I; DOWHAN W, 1985, EMBO J, V4, P179, DOI 10.1002/j.1460-2075.1985.tb02334.x; Dzugasova V, 1998, CURR GENET, V34, P297, DOI 10.1007/s002940050399; EBLE KS, 1990, J BIOL CHEM, V265, P19434; EILERS M, 1989, J BIOL CHEM, V264, P2945; FINE JB, 1982, J LIPID RES, V23, P660; Foury F, 1998, FEBS LETT, V440, P325, DOI 10.1016/S0014-5793(98)01467-7; Fox TD, 1996, EXPERIENTIA, V52, P1130, DOI 10.1007/BF01952112; FUJIKI M, 1993, J BIOL CHEM, V268, P1914; GAIGG B, 1995, BBA-BIOMEMBRANES, V1234, P214, DOI 10.1016/0005-2736(94)00287-Y; GALLET PF, 1995, EUR J BIOCHEM, V228, P113, DOI 10.1111/j.1432-1033.1995.tb20238.x; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; GOORMAGHTIGH E, 1982, BIOCHEM BIOPH RES CO, V104, P314, DOI 10.1016/0006-291X(82)91976-3; Graack HR, 1998, BIOCHEM J, V329, P433, DOI 10.1042/bj3290433; GREKSAK M, 1977, FOLIA MICROBIOL, V22, P30, DOI 10.1007/BF02876990; Hell K, 1998, P NATL ACAD SCI USA, V95, P2250, DOI 10.1073/pnas.95.5.2250; Hell K, 1997, FEBS LETT, V418, P367, DOI 10.1016/S0014-5793(97)01412-9; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOFFMANN B, 1994, J BIOL CHEM, V269, P1940; JANITOR M, 1993, CURR GENET, V24, P307, DOI 10.1007/BF00336781; JANITOR M, 1995, YEAST, V11, P1223, DOI 10.1002/yea.320111302; Jiang F, 1997, MOL MICROBIOL, V26, P481, DOI 10.1046/j.1365-2958.1997.5841950.x; Jiang F, 2000, J BIOL CHEM, V275, P22387, DOI 10.1074/jbc.M909868199; Kawasaki K, 1999, J BIOL CHEM, V274, P1828, DOI 10.1074/jbc.274.3.1828; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; Koshkin V, 2000, BIOCHEM J, V347, P687, DOI 10.1042/0264-6021:3470687; KOVAC L, 1977, MOL CELL BIOCHEM, V14, P11, DOI 10.1007/BF01734158; Law R H, 1995, Methods Mol Biol, V37, P293; LEENHOUTS JM, 1993, FEBS LETT, V327, P172, DOI 10.1016/0014-5793(93)80164-P; Lefebvre-Legendre L, 2001, J BIOL CHEM, V276, P6789, DOI 10.1074/jbc.M009557200; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; Ma BJ, 1999, J LIPID RES, V40, P1837; MANOIL C, 1991, METHOD CELL BIOL, V34, P61; OHTSUKA T, 1993, J BIOL CHEM, V268, P22914; OHTSUKA T, 1993, J BIOL CHEM, V268, P22908; Ortiz A, 1999, BIOPHYS J, V77, P2003, DOI 10.1016/S0006-3495(99)77041-4; OSTRANDER DB, 1995, J BIOL CHEM, V270, P27045, DOI 10.1074/jbc.270.45.27045; Ostrander DB, 1997, YEAST, V13, P871, DOI 10.1002/(SICI)1097-0061(199707)13:9<871::AID-YEA127>3.0.CO;2-2; OU WJ, 1988, J BIOCHEM-TOKYO, V103, P589, DOI 10.1093/oxfordjournals.jbchem.a122312; Paradies G, 1999, FEBS LETT, V454, P207, DOI 10.1016/S0014-5793(99)00809-1; Paradies G, 1999, FREE RADICAL BIO MED, V27, P42, DOI 10.1016/S0891-5849(99)00032-5; Paradies G, 1998, FEBS LETT, V424, P155, DOI 10.1016/S0014-5793(98)00161-6; Paradies G, 2000, FEBS LETT, V466, P323, DOI 10.1016/S0014-5793(00)01082-6; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; PEARCE DA, 1995, J BIOL CHEM, V270, P20879, DOI 10.1074/jbc.270.36.20879; RAND RP, 1972, BIOCHIM BIOPHYS ACTA, V225, P484, DOI 10.1016/0005-2736(72)90152-6; Sanchirico ME, 1998, EMBO J, V17, P5796, DOI 10.1093/emboj/17.19.5796; Schapira AHV, 1999, BBA-BIOENERGETICS, V1410, P159, DOI 10.1016/S0005-2728(98)00164-9; Sedlak E, 1999, BIOCHEMISTRY-US, V38, P14966, DOI 10.1021/bi9914053; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SIKORSKI RS, 1989, GENETICS, V122, P19; Stephens AN, 2000, EUR J BIOCHEM, V267, P6443, DOI 10.1046/j.1432-1327.2000.01733.x; SUBIK J, 1974, FEBS LETT, V42, P309, DOI 10.1016/0014-5793(74)80753-2; ULERY TL, 1994, MOL CELL BIOL, V14, P1160, DOI 10.1128/MCB.14.2.1160; vanKlompenburg W, 1997, EMBO J, V16, P4261, DOI 10.1093/emboj/16.14.4261; XIA WM, 1995, P NATL ACAD SCI USA, V92, P783, DOI 10.1073/pnas.92.3.783; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	72	81	81	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25262	25272		10.1074/jbc.M103689200	http://dx.doi.org/10.1074/jbc.M103689200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11335731	hybrid			2022-12-25	WOS:000169800700111
J	Reinelt, S; Marti, M; Dedier, S; Reitinger, T; Folkers, G; de Castro, JAL; Rognan, D				Reinelt, S; Marti, M; Dedier, S; Reitinger, T; Folkers, G; de Castro, JAL; Rognan, D			beta-amino acid scan of a class I major histocompatibility complex-restricted alloreactive T-cell epitope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LEUKOCYTE ANTIGEN; AUTOIMMUNE-DISEASE; 3-DIMENSIONAL STRUCTURE; NONNATURAL PEPTIDES; CTL CLONE; BINDING; MHC; HLA-B27; MOLECULES; ANALOGS	An HLA-B27-restricted self-octapeptide known to react with an alloreactive T-cell receptor has been modified by systematic substitution of a p-amino acid for the natural cy-amino acid residue, over the whole length of the parent epitope, All modified peptides were shown to bind to recombinant HLA-B*2705 and induce stable major histocompatibility complex-peptide complexes, but with some variation depending on the position of the beta -amino acid on the peptide sequence, Alteration of the natural peptide sequence at the two N-terminal positions (positions 1 and 2) decreases binding affinity and thermodynamic stability of the refolded complex, but all other positions (from position 3 to the C-terminal residue) were insensitive to the beta -amino acid substitution. All modified peptides were recognized by an alloreactive T-cell clone specific for the parent epitope with decreased efficiency, to an extent dependent of the position that was modified. Furthermore, the introduction of a single beta -amino acid at the first two positions of the modified peptide was shown to be sufficient to protect them against enzymatic cleavage. Thus, beta -amino acids represent new interesting templates for alteration of T-cell epitopes to design either synthetic vaccines of T-cell receptor antagonists.	CNRS, UMR 7081, Lab Pharmacochim Commun Cellulaire, F-67401 Illkirch, France; Swiss Fed Inst Technol, Dept Appl Biosci, CH-8057 Zurich, Switzerland; Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Centre National de la Recherche Scientifique (CNRS); Swiss Federal Institutes of Technology Domain; ETH Zurich; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Rognan, D (corresponding author), F Hoffman La Roche Ltd, Div Pharmaceut, CH-4070 Basel, Switzerland.		Martí, Mercè/I-2164-2015; Rognan, Didier/B-9939-2014	Martí, Mercè/0000-0002-1846-0043; Folkers, Gerd/0000-0002-3620-705X				Alvarez I, 2000, CURR OPIN RHEUMATOL, V12, P248, DOI 10.1097/00002281-200007000-00003; Ayyoub M, 1998, RAPID COMMUN MASS SP, V12, P557, DOI 10.1002/(SICI)1097-0231(19980515)12:9<557::AID-RCM199>3.3.CO;2-4; BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; COLLINS EJ, 1994, NATURE, V371, P626, DOI 10.1038/371626a0; Dedier S, 2000, J BIOL CHEM, V275, P27055; Falcioni F, 1999, NAT BIOTECHNOL, V17, P562, DOI 10.1038/9865; Garcia-Peydro M, 2000, J IMMUNOL, V165, P5680, DOI 10.4049/jimmunol.165.10.5680; Garcia-Peydro M, 1999, J IMMUNOL, V163, P6060; Guichard G, 2000, J MED CHEM, V43, P3803, DOI 10.1021/jm000909s; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P643; ISHIOKA GY, 1994, J IMMUNOL, V152, P4311; Khare Sanjay D., 1998, Current Opinion in Rheumatology, V10, P282, DOI 10.1097/00002281-199807000-00002; Krebs S, 1998, J PEPT SCI, V4, P378, DOI 10.1002/(SICI)1099-1387(199809)4:6<378::AID-PSC157>3.0.CO;2-B; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; Magee CC, 1997, CURR OPIN IMMUNOL, V9, P669, DOI 10.1016/S0952-7915(97)80047-7; Ottenhoff THM, 1997, J IMMUNOL METHODS, V200, P89, DOI 10.1016/S0022-1759(96)00190-1; Paas-Rozner M, 2000, P NATL ACAD SCI USA, V97, P2168, DOI 10.1073/pnas.040554597; PACE NC, 1997, PROTEIN STRUCTURE PR, P299; Paradela A, 1998, J IMMUNOL, V161, P5481; Persidis A, 1999, NAT BIOTECHNOL, V17, P1038, DOI 10.1038/13748; Poenaru S, 1999, J MED CHEM, V42, P2318, DOI 10.1021/jm981123l; Reinelt S, 2001, J BIOL CHEM, V276, P18472, DOI 10.1074/jbc.M101282200; ROGNAN D, 1995, P NATL ACAD SCI USA, V92, P753, DOI 10.1073/pnas.92.3.753; Seebach D, 1997, CHEM COMMUN, P2015, DOI 10.1039/a704933a; Singer DS, 1997, CRIT REV IMMUNOL, V17, P463; Spack EG, 1997, CRIT REV IMMUNOL, V17, P529; Thurau SR, 1999, IMMUNOL LETT, V68, P205, DOI 10.1016/S0165-2478(99)00071-1; Toda M, 2000, EUR J IMMUNOL, V30, P403; vanderBurg SH, 1996, J IMMUNOL, V156, P3308	29	37	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24525	24530		10.1074/jbc.M102772200	http://dx.doi.org/10.1074/jbc.M102772200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342555	hybrid			2022-12-25	WOS:000169800700016
J	Clark, AF; Kawase, K; English-Wright, S; Lane, D; Steely, HT; Yamamoto, T; Kitazawa, Y; Kwon, YH; Fingert, JH; Swiderski, RE; Mullins, RF; Hageman, GS; Alward, WLM; Sheffield, VC; Stone, EM				Clark, AF; Kawase, K; English-Wright, S; Lane, D; Steely, HT; Yamamoto, T; Kitazawa, Y; Kwon, YH; Fingert, JH; Swiderski, RE; Mullins, RF; Hageman, GS; Alward, WLM; Sheffield, VC; Stone, EM			Expression of the glaucoma gene myocilin (MYOC) in the human optic nerve head	FASEB JOURNAL			English	Article									Alcon Res Ltd, Glaucoma Res R2 41, Ft Worth, TX 76134 USA; Gifu Univ, Dept Ophthalmol, Gifu, Japan; Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA USA; Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Howard Hughes Med Inst, Iowa City, IA 52242 USA	Novartis; Alcon; Gifu University; University of Iowa; University of Iowa; Howard Hughes Medical Institute; University of Iowa	Clark, AF (corresponding author), Alcon Res Ltd, Glaucoma Res R2 41, 6201 S Freeway, Ft Worth, TX 76134 USA.		Mullins, Robert F/I-6717-2013; Alward, Wallace/AAY-4149-2020; Fingert, John/AAX-4750-2021	Fingert, John/0000-0002-0377-0479; Mullins, Robert/0000-0002-5006-0891; Sheffield, Val/0000-0002-6282-0835; Kwon, Young/0000-0002-1116-8250; Stone, Edwin M./0000-0003-3343-4414; Alward, Wallace/0000-0001-6368-9018					0	43	48	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1251	1253		10.1096/fj.00-0663fje	http://dx.doi.org/10.1096/fj.00-0663fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344104				2022-12-25	WOS:000168655200026
J	Moller, P; Loft, S; Lundby, C; Olsen, NV				Moller, P; Loft, S; Lundby, C; Olsen, NV			Acute hypoxia and hypoxic exercise induce DNA strand breaks and oxidative DNA damage in humans	FASEB JOURNAL			English	Article						FPG; high-intensity exercise; ENDO III; reactive oxygen species	TUMOR-NECROSIS-FACTOR; INTERLEUKIN-1 RECEPTOR ANTAGONIST; MODERATE-ALTITUDE; HYPOBARIC HYPOXIA; GENE-EXPRESSION; STRESS; CELLS; ADHESION; MARKERS; MUSCLE	The present study investigated the effect of a single bout of exhaustive exercise on the generation of DNA strand breaks and oxidative DNA damage under normal conditions and at high-altitude hypoxia (4559 meters for 3 days). Twelve healthy subjects performed a maximal bicycle exercise test; lymphocytes were isolated for analysis of DNA strand breaks and oxidatively altered nucleotides, detected by endonuclease III and formamidipyridine glycosylase (FPG) enzymes. Urine was collected for 24 h periods for analysis of 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG), a marker of oxidative DNA damage. Urinary excretion of 8-oxodG increased during the first day in altitude hypoxia, and there were more endonuclease III-sensitive sites on day 3 at high altitude. The subjects had more DNA strand breaks in altitude hypoxia than at sea level. The level of DNA strand breaks further increased immediately after exercise in altitude hypoxia, Exercise-induced generation of DNA strand breaks was not seen at sea level. In both environments, the level of FPG and endonuclease III-sensitive sites remained unchanged immediately after exercise. DNA strand breaks and oxidative DNA damage are probably produced by reactive oxygen species, generated by leakage of the mitochondrial respiration or during a hypoxia-induced inflammation, Furthermore, the presence of DNA strand breaks may play an important role in maintaining hypoxia-induced inflammation processes. Hypoxia seems to deplete the antioxidant system of its capacity to withstand oxidative stress produced by exhaustive exercise.	Univ Copenhagen, Panum Inst, Dept Pharmacol, Inst Publ Hlth, DK-2200 Copenhagen N, Denmark; Copenhagen Univ Hosp, Neurosci Ctr, Dept Neuroanaesthesia, DK-2200 Copenhagen N, Denmark	University of Copenhagen; University of Copenhagen	Moller, P (corresponding author), Univ Copenhagen, Panum Inst, Dept Pharmacol, Inst Publ Hlth, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.	fipm@farmakol.ku.dk		Loft, Steffen/0000-0001-9552-8518				Brenner IKM, 1999, EUR J APPL PHYSIOL O, V80, P452, DOI 10.1007/s004210050617; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; CHANG SW, 1989, LUNG, V167, P269, DOI 10.1007/BF02714956; Chao WH, 1999, J NUTR, V129, P2009, DOI 10.1093/jn/129.11.2009; Collins A, 1997, ENVIRON MOL MUTAGEN, V30, P139, DOI 10.1002/(SICI)1098-2280(1997)30:2<139::AID-EM6>3.0.CO;2-I; Dempsey JA, 1999, J APPL PHYSIOL, V87, P1997, DOI 10.1152/jappl.1999.87.6.1997; Drenth JPH, 1998, EUR J CLIN INVEST, V28, P866; Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619; Espersen GT, 1996, SCAND J MED SCI SPOR, V6, P156; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GHEZZI P, 1991, CYTOKINE, V3, P189, DOI 10.1016/1043-4666(91)90015-6; GINIS I, 1993, J CELL PHYSIOL, V157, P569, DOI 10.1002/jcp.1041570317; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; HARTMANN A, 1994, MUTAGENESIS, V9, P269, DOI 10.1093/mutage/9.3.269; Hartmann A, 1998, FREE RADICAL BIO MED, V24, P245, DOI 10.1016/S0891-5849(97)00249-9; Hartmann G, 2000, CYTOKINE, V12, P246, DOI 10.1006/cyto.1999.0533; Hempel SL, 1996, AM J RESP CELL MOL, V14, P170, DOI 10.1165/ajrcmb.14.2.8630267; KARAKURUM M, 1994, J CLIN INVEST, V93, P1564, DOI 10.1172/JCI117135; Klausen T, 1997, EUR J APPL PHYSIOL, V76, P480, DOI 10.1007/s004210050278; Kleger GR, 1996, J APPL PHYSIOL, V81, P1917, DOI 10.1152/jappl.1996.81.5.1917; KLOKKER M, 1993, J APPL PHYSIOL, V74, P1100, DOI 10.1152/jappl.1993.74.3.1100; KLOKKER M, 1995, J APPL PHYSIOL, V78, P709; Kubo K, 1996, THORAX, V51, P739, DOI 10.1136/thx.51.7.739; Kumar D, 1999, INT J BIOMETEOROL, V42, P201, DOI 10.1007/s004840050105; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Loft S, 1999, METHOD ENZYMOL, V300, P166; Moller P, 1996, CHEM-BIOL INTERACT, V102, P17, DOI 10.1016/0009-2797(96)03729-5; Moller P, 1998, MUTAT RES-DNA REPAIR, V407, P25, DOI 10.1016/S0921-8777(97)00057-8; Natelson BH, 1996, INT J SPORTS MED, V17, P299, DOI 10.1055/s-2007-972850; Niess AM, 1996, INT J SPORTS MED, V17, P397, DOI 10.1055/s-2007-972868; Pavlicek V, 2000, EUR J APPL PHYSIOL, V81, P497, DOI 10.1007/s004210050074; Pfeiffer JM, 1999, WILD ENVIRON MED, V10, P66, DOI 10.1580/1080-6032(1999)010[0066:EOASOU]2.3.CO;2; Poulsen HE, 1999, P NUTR SOC, V58, P1007, DOI 10.1017/S0029665199001329; Poulsen HE, 1996, J SPORT SCI, V14, P343, DOI 10.1080/02640419608727720; Radak Z, 1999, FREE RADICAL BIO MED, V26, P1059, DOI 10.1016/S0891-5849(98)00309-8; Richardson RS, 1999, AM J PHYSIOL-HEART C, V277, pH2247, DOI 10.1152/ajpheart.1999.277.6.H2247; Roach R, 1993, HYPOXIA MOL MED; Roach RC, 2000, J APPL PHYSIOL, V88, P581, DOI 10.1152/jappl.2000.88.2.581; SEN CK, 1994, J APPL PHYSIOL, V76, P2570, DOI 10.1152/jappl.1994.76.6.2570; SHREENIWAS R, 1992, J CLIN INVEST, V90, P2333, DOI 10.1172/JCI116122; SIMONSCHNASS I, 1988, INT J VITAM NUTR RES, V58, P49; Tuo JS, 1999, FREE RADICAL BIO MED, V26, P801, DOI 10.1016/S0891-5849(98)00267-6; VANOTTEREN GM, 1995, AM J RESP CELL MOL, V13, P399, DOI 10.1165/ajrcmb.13.4.7546769; Vasankari TJ, 1997, EUR J APPL PHYSIOL O, V75, P396, DOI 10.1007/s004210050178; Wood JG, 1999, J APPL PHYSIOL, V87, P1734, DOI 10.1152/jappl.1999.87.5.1734	45	181	189	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2001	15	7					1181	1186		10.1096/fj.00-0703com	http://dx.doi.org/10.1096/fj.00-0703com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344086				2022-12-25	WOS:000168655200008
J	Poot, M; Yom, JS; Whang, SH; Kato, JT; Gollahon, KA; Rabinovitch, PS				Poot, M; Yom, JS; Whang, SH; Kato, JT; Gollahon, KA; Rabinovitch, PS			Werner syndrome cells are sensitive to DNA crosslinking drugs	FASEB JOURNAL			English	Article									Univ Washington, Dept Pathol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Poot, M (corresponding author), Univ Washington, Dept Pathol, 1959 NE Pacific Ave,Hlth Sci Bldg,Room K-081, Seattle, WA 98195 USA.		Poot, Martin/F-9427-2010	Yom, Sue/0000-0002-0779-7476					0	125	125	2	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1224	1226		10.1096/fj.00-0611fje	http://dx.doi.org/10.1096/fj.00-0611fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344095				2022-12-25	WOS:000168655200017
J	Varani, K; Rigamonti, D; Sipione, S; Camurri, A; Borea, PA; Cattabeni, F; Abbracchio, MP; Cattaneo, E				Varani, K; Rigamonti, D; Sipione, S; Camurri, A; Borea, PA; Cattabeni, F; Abbracchio, MP; Cattaneo, E			Aberrant amplification of A(2A) receptor signaling in striatal cells expressing mutant huntingtin	FASEB JOURNAL			English	Article									Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy; Univ Ferrara, Dipartimento Med Clin Sperimentale, I-44100 Ferrara, Italy	University of Milan; University of Ferrara	Abbracchio, MP (corresponding author), Univ Milan, Dept Pharmacol Sci, Via Balzaretti 9, I-20133 Milan, Italy.		Abbracchio, Maria Pia/B-9342-2014	Abbracchio, Maria Pia/0000-0002-7833-3388; CATTANEO, ELENA/0000-0002-0755-4917	Telethon [E.0840, E.1116] Funding Source: Medline	Telethon(Fondazione Telethon)			0	72	73	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1245	1247		10.1096/fj.00-0730fje	http://dx.doi.org/10.1096/fj.00-0730fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344102				2022-12-25	WOS:000168655200024
J	Valgardsdottir, R; Brede, G; Eide, LG; Frengen, E; Prydz, H				Valgardsdottir, R; Brede, G; Eide, LG; Frengen, E; Prydz, H			Cloning and characterization of MDDX28, a putative DEAD-box helicase with mitochondrial and nuclear localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-CLUSTER; RNA HELICASE; LCAT GENE; PROTEIN; EXPORT; SEQUENCE; SIGNAL; CRM1; INHIBITION; COMPLEX	A cDNA encoding a novel member of the helicase family, MMDX28, has been cloned from a human testis library. This apparently intronless gene was transcribed in all tissues studied. MDDX28 encodes a protein of 540 amino acids, with similar to 30% homology to other helicases over the core region, containing all the conserved DEAD-box helicase motifs. No homologue is known. MDDX28 has RNA and Mg2+-dependent ATPase activity. Subcellular localization studies of MDDX28 using oligo-clonal antibodies raised against the protein as well as its enhanced green fluorescence protein (EGFP) demonstrated that the protein is localized in the mitochondria and the nucleus. To our knowledge, MDDX28 is the first member of the RNA helicase described with this dual location. The nuclear localization of MDDX28 depended on active RNA polymerase II transcription, suggesting that the protein could be transported to and from the nucleus. This was confirmed further in an interspecies heterokaryon assay, in which MDDX28 was seen to translocate to the nucleus and mitochondria. The mitochondrial uptake of the MDDX28-EGFP-N1 fusion protein was inhibited by carbonyl cyanide p-(trichloro-methoxy)phenylhydrazone. Our results indicate that MDDX28 can be transported between the mitochondria and the nucleus.	Univ Oslo, Ctr Biotechnol, N-0317 Oslo, Norway	University of Oslo	Prydz, H (corresponding author), Univ Oslo, Ctr Biotechnol, POB 1125, N-0317 Oslo, Norway.			Frengen, Eirik/0000-0002-8387-2247				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Frengen E, 2000, GENOMICS, V70, P273, DOI 10.1006/geno.2000.6389; Frengen E, 1997, CYTOGENET CELL GENET, V76, P53, DOI 10.1159/000134515; FRENGEN E, 1995, CYTOGENET CELL GENET, V68, P194, DOI 10.1159/000133912; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gagliardi D, 1999, FEBS LETT, V458, P337, DOI 10.1016/S0014-5793(99)01168-0; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; LARSEN F, 1993, HUM MOL GENET, V2, P1589, DOI 10.1093/hmg/2.10.1589; LARSEN F, 1992, GENET ANAL-BIOMOL E, V9, P80, DOI 10.1016/1050-3862(92)90002-M; LINDELL TJ, 1970, SCIENCE, V170, P447, DOI 10.1126/science.170.3956.447; Luking A, 1998, CRIT REV BIOCHEM MOL, V33, P259, DOI 10.1080/10409239891204233; Missel A, 1997, MOL CELL BIOL, V17, P4895, DOI 10.1128/MCB.17.9.4895; O'Brien TW, 1999, J BIOL CHEM, V274, P36043, DOI 10.1074/jbc.274.51.36043; Omura T, 1998, J BIOCHEM-TOKYO, V123, P1010; OSEOGAWA K, 1999, CURRENT PROTOCOLS HU; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Otterlei M, 1998, NUCLEIC ACIDS RES, V26, P4611, DOI 10.1093/nar/26.20.4611; Pugh GE, 1999, J MOL BIOL, V292, P771, DOI 10.1006/jmbi.1999.3112; Ruggiero FP, 1998, J HISTOCHEM CYTOCHEM, V46, P177, DOI 10.1177/002215549804600206; SERAPHIN B, 1989, NATURE, V337, P84, DOI 10.1038/337084a0; Soltys BJ, 1999, TRENDS BIOCHEM SCI, V24, P174, DOI 10.1016/S0968-0004(99)01390-0; STEINBERG TH, 1990, J BIOL CHEM, V265, P499; STEPIEN PP, 1992, P NATL ACAD SCI USA, V89, P6813, DOI 10.1073/pnas.89.15.6813; SUDO K, 1995, CYTOGENET CELL GENET, V71, P385, DOI 10.1159/000134145; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X	31	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32056	32063		10.1074/jbc.M011629200	http://dx.doi.org/10.1074/jbc.M011629200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11350955	hybrid			2022-12-25	WOS:000170613500081
J	Koch, T; Schulz, S; Pfeiffer, M; Klutzny, M; Schroder, H; Kahl, E; Hollt, V				Koch, T; Schulz, S; Pfeiffer, M; Klutzny, M; Schroder, H; Kahl, E; Hollt, V			C-terminal splice variants of the mouse mu-opioid receptor differ in morphine-induced internalization and receptor resensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED DESENSITIZATION; ACTIVATED PROTEIN-KINASE; BETA-ARRESTIN; CARBOXY-TERMINUS; IN-VIVO; ENDOCYTOSIS; CELLS; PHOSPHORYLATION; THREONINE-394; SPECIFICITY	The main analgesic effects of the opioid alkaloid morphine are mediated by the IL-opioid receptor. In contrast to endogenous opioid peptides, morphine activates the mu -opioid receptor without causing its rapid endocytosis. Recently, three novel C-terminal splice variants (MOR1C, MOR1D, and MOR1E) of the mouse mu -opioid receptor (MOR1) have been identified. In the present study, we show that these receptors differ substantially in their agonist-selective membrane trafficking. MOR1 and MOR1C stably expressed in human embryonic kidney 293 cells exhibited phosphorylation, internalization, and down-regulation in the presence of the opioid peptide [D-Ala(2),Me-Phe(4),Gly(5)-ol]enkephalin (DAMGO) but not in response to morphine. In contrast, MOR1D and MOR1E exhibited robust phosphorylation, internalization, and down-regulation in response to both DAMGO and morphine. DAMGO elicited a similar desensitization (during an 8-h exposure) and resensitization (during a 50-min drug-free interval) of all four mu -receptor splice variants. After morphine treatment, however, MOR1 and MOR1C showed a faster desensitization and no resensitization as compared with MOR1D and MOR1E. These results strongly reinforce the hypothesis that receptor phosphorylation and internalization are required for opioid receptor reactivation thus counteracting agonist-induced desensitization. Our findings also suggest a mechanism by which cell- and tissue-specific C-terminal splicing of the mu -opioid receptor may significantly modulate the development of tolerance to the various effects of morphine.	Otto Von Guericke Univ, Dept Pharmacol & Toxicol, D-39120 Magdeburg, Germany	Otto von Guericke University	Koch, T (corresponding author), Otto Von Guericke Univ, Dept Pharmacol & Toxicol, Leipziger Str 44, D-39120 Magdeburg, Germany.		Schulz, Stefan/A-6928-2017	Schulz, Stefan/0000-0002-5997-8885				Abbadie C, 2000, NEUROSCIENCE, V100, P141, DOI 10.1016/S0306-4522(00)00248-7; Abbadie C, 2000, J COMP NEUROL, V419, P244, DOI 10.1002/(SICI)1096-9861(20000403)419:2<244::AID-CNE8>3.0.CO;2-R; Abbadie C, 2000, NEUROREPORT, V11, P1953, DOI 10.1097/00001756-200006260-00029; Burt RP, 1996, BRIT J PHARMACOL, V117, P224, DOI 10.1111/j.1476-5381.1996.tb15178.x; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Deng HB, 2000, BIOCHEMISTRY-US, V39, P5492, DOI 10.1021/bi991938b; Ferguson SSG, 1998, SEMIN CELL DEV BIOL, V9, P119, DOI 10.1006/scdb.1997.0216; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUIRAMAND J, 1995, J BIOL CHEM, V270, P7354, DOI 10.1074/jbc.270.13.7354; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Koch T, 1998, J BIOL CHEM, V273, P13652, DOI 10.1074/jbc.273.22.13652; Law PY, 2000, MOL PHARMACOL, V58, P388, DOI 10.1124/mol.58.2.388; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Li LY, 1996, MOL PHARMACOL, V50, P599; LUCAS JJ, 1995, TRENDS PHARMACOL SCI, V16, P246, DOI 10.1016/S0165-6147(00)89034-3; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; Pak Y, 1997, J BIOL CHEM, V272, P24961, DOI 10.1074/jbc.272.40.24961; Pan YX, 1999, MOL PHARMACOL, V56, P396, DOI 10.1124/mol.56.2.396; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; Schmidt H, 2000, J NEUROCHEM, V74, P414, DOI 10.1046/j.1471-4159.2000.0740414.x; Schulz S, 1998, EUR J NEUROSCI, V10, P1196, DOI 10.1046/j.1460-9568.1998.00103.x; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; VANETTI M, 1992, FEBS LETT, V311, P290, DOI 10.1016/0014-5793(92)81122-3; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Wolf R, 1999, MOL PHARMACOL, V55, P263, DOI 10.1124/mol.55.2.263; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; ZIMPRICH A, 1995, FEBS LETT, V359, P142, DOI 10.1016/0014-5793(95)00028-8	29	139	150	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31408	31414		10.1074/jbc.M100305200	http://dx.doi.org/10.1074/jbc.M100305200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11359768	hybrid			2022-12-25	WOS:000170472900106
J	Olah, Z; Karai, L; Iadarola, MJ				Olah, Z; Karai, L; Iadarola, MJ			Anandamide activates vanilloid receptor 1 (VR1) at acidic pH in dorsal root ganglia neurons and cells ectopically expressing VR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSORY NERVES MEDIATE; GATED NA+ CHANNEL; CAPSAICIN-RECEPTOR; ENDOPLASMIC-RETICULUM; INFLAMMATORY MEDIATORS; SUBSTANCE-P; RAT; CALCIUM; CANNABINOIDS; TRANSPORT	The vanilloid receptor type 1 (VR1) is a heat-activated ionophore preferentially expressed in nociceptive neurons of trigeminal and dorsal root ganglia (DRG). VR1, which binds and is activated by capsaicin and other vanilloid compounds, was noted to interact with the endocannabinoid anandamide (ANA) and certain inflammatory metabolites of arachidonic acid in a pH-dependent manner. At pH less than or equal to 6.5 ANA induced Ca-45(2+) uptake either in primary cultures of DRG neurons or cells ectopically expressing C-terminally tagged recombinant forms of VR1 with an EC50 = similar to 10 mum at PH 5.5. Capsazepine, a potent antagonist of vanilloids, inhibited ANA-induced Ca2+ transport in both cell systems. Vanilloids displaced [H-3]ANA in VRI-expressing cells, suggesting competition for binding to VR1. Ratiometric determination of intracellular free calcium and confocal imaging of the VR1-green fluorescent fusion protein revealed that, at low PH (less than or equal to 6.5), ANA could induce an elevation of intracellular free Ca2+ and consequent intracellular membrane changes in DRG neurons or transfected cells expressing VR1. These actions of ANA were similar to the effects determined previously for vanilloids. The ligand-induced changes in Ca2+ at PH less than or equal to 6.5 are consistent with the idea that ANA and other eicosanoids act as endogenous ligands of VR1 in a conditional fashion in vivo. The PH dependence suggests that tissue acidification in inflammation, ischemia, or traumatic injury can sensitize VR1 to eicosanoids and transduce pain from the periphery.	NIDCR, Neuronal Gene Express Unit, Pain & Neurosensory Mechanisms Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Olah, Z (corresponding author), NIDCR, Neuronal Gene Express Unit, Pain & Neurosensory Mechanisms Branch, NIH, Bldg 49,Rm 1A19,49 Convent Dr,MSC-4410, Bethesda, MD 20892 USA.	zoltan.olah@nih.gov			NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000688] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000688] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ballou LR, 2000, P NATL ACAD SCI USA, V97, P10272, DOI 10.1073/pnas.180319297; Bassilana F, 1997, J BIOL CHEM, V272, P28819, DOI 10.1074/jbc.272.46.28819; Baumann TK, 2000, J NEUROSCI, V20; Beltramo M, 1997, SCIENCE, V277, P1094, DOI 10.1126/science.277.5329.1094; Beltramo M, 1999, EUR J PHARMACOL, V364, P75, DOI 10.1016/S0014-2999(98)00821-8; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; BEVAN S, 1994, TRENDS NEUROSCI, V17, P509, DOI 10.1016/0166-2236(94)90149-X; Calignano A, 2000, NATURE, V408, P96, DOI 10.1038/35040576; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; Costa B, 1999, BEHAV PHARMACOL, V10, P327, DOI 10.1097/00008877-199905000-00009; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Dedov VN, 2000, NEUROSCIENCE, V95, P183; Di Marzo V, 1998, FEBS LETT, V436, P449, DOI 10.1016/S0014-5793(98)01175-2; Dirig DM, 1999, BRIT J PHARMACOL, V126, P1333, DOI 10.1038/sj.bjp.0702427; Dux M, 1999, CELL TISSUE RES, V296, P471, DOI 10.1007/s004410051307; Edgemond WS, 1998, MOL PHARMACOL, V54, P180, DOI 10.1124/mol.54.1.180; Grimaldi M, 1999, J BIOL CHEM, V274, P33557, DOI 10.1074/jbc.274.47.33557; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Jaggar SI, 1998, PAIN, V76, P189, DOI 10.1016/S0304-3959(98)00041-4; Jerman JC, 2000, BRIT J PHARMACOL, V130, P916, DOI 10.1038/sj.bjp.0703390; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Jung J, 1999, J NEUROSCI, V19, P529; KESSLER W, 1992, EXP BRAIN RES, V91, P467; Kress M, 1996, NEUROSCI LETT, V211, P5, DOI 10.1016/0304-3940(96)12691-4; Kwak JY, 1998, NEUROSCIENCE, V86, P619, DOI 10.1016/S0306-4522(98)00012-8; Lopshire JC, 1998, J NEUROSCI, V18, P6081; Lopshire JC, 1997, J NEUROPHYSIOL, V78, P3154, DOI 10.1152/jn.1997.78.6.3154; LYNN B, 1991, TRENDS NEUROSCI, V14, P95, DOI 10.1016/0166-2236(91)90067-5; MARRIOTT D, 1991, ADV PROSTAG THROMB L, V21, P739; Martin WJ, 1999, PAIN, V82, P199, DOI 10.1016/S0304-3959(99)00045-7; Melck D, 1999, BIOCHEM BIOPH RES CO, V262, P275, DOI 10.1006/bbrc.1999.1105; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; Noda K, 1997, BRAIN RES, V751, P348, DOI 10.1016/S0006-8993(97)00077-2; Olah Z, 2001, J BIOL CHEM, V276, P11021, DOI 10.1074/jbc.M008392200; OLAH Z, 1994, ANAL BIOCHEM, V221, P94, DOI 10.1006/abio.1994.1384; PETERSEN M, 1993, PAIN, V54, P37, DOI 10.1016/0304-3959(93)90097-9; Piomelli D, 2000, TRENDS PHARMACOL SCI, V21, P218, DOI 10.1016/S0165-6147(00)01482-6; Ralevic V, 2000, BRIT J PHARMACOL, V130, P1483, DOI 10.1038/sj.bjp.0703456; Ribeiro CMP, 2000, CELL CALCIUM, V27, P175, DOI 10.1054/ceca.2000.0108; Richardson JD, 1998, PAIN, V75, P111, DOI 10.1016/S0304-3959(97)00213-3; Robertson JT, 1996, SPINE, V21, P1731, DOI 10.1097/00007632-199608010-00004; Simpson PB, 1998, BRAIN RES REV, V26, P72, DOI 10.1016/S0165-0173(97)00056-8; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; Smart D, 2000, TRENDS PHARMACOL SCI, V21, P134, DOI 10.1016/S0165-6147(00)01459-0; Sterner O, 1999, TRENDS PHARMACOL SCI, V20, P459, DOI 10.1016/S0165-6147(99)01393-0; STEVENS CR, 1991, ANN RHEUM DIS, V50, P124, DOI 10.1136/ard.50.2.124; Subramanian K, 1997, CELL, V89, P963, DOI 10.1016/S0092-8674(00)80281-0; Szolcsanyi J, 2000, TRENDS PHARMACOL SCI, V21, P41, DOI 10.1016/S0165-6147(99)01436-4; Terasaki M, 1996, DEV BIOL, V179, P320, DOI 10.1006/dbio.1996.0263; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Vyklicky L, 1998, J NEUROPHYSIOL, V79, P670, DOI 10.1152/jn.1998.79.2.670; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Welch JM, 2000, P NATL ACAD SCI USA, V97, P13889, DOI 10.1073/pnas.230146497; Yu SP, 1999, SCIENCE, V284, P336, DOI 10.1126/science.284.5412.336; Zimmer A, 1999, P NATL ACAD SCI USA, V96, P5780, DOI 10.1073/pnas.96.10.5780; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761; Zygmunt PM, 2000, TRENDS PHARMACOL SCI, V21, P43, DOI 10.1016/S0165-6147(99)01430-3	60	109	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31163	31170		10.1074/jbc.M101607200	http://dx.doi.org/10.1074/jbc.M101607200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11333266	hybrid			2022-12-25	WOS:000170472900076
J	Liang, QR; De Windt, LJ; Witt, SA; Kimball, TR; Markham, BE; Molkentin, JD				Liang, QR; De Windt, LJ; Witt, SA; Kimball, TR; Markham, BE; Molkentin, JD			The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN GENE; CARDIAC MYOCYTE HYPERTROPHY; SERUM RESPONSE FACTOR; ALPHA-ACTIN PROMOTER; PROTEIN-KINASE-C; BINDING-PROTEINS; EXPRESSION; PATHWAY; HEART; INDUCTION	The zinc finger-containing transcription factors GATA4 and GATA6 are important regulators of basal and inducible gene expression in cardiac and smooth muscle cell types. Here we demonstrate a direct functional role for GATA4 and GATA6 as regulators of cardiomyocyte hypertrophic growth and gene expression. To model the increase in endogenous GATA4 and GATA6 transcriptional activity that occurs in response to hypertrophic stimulation, each factor was overexpressed in cardiomyocytes using recombinant adenovirus. Overexpression of either GATA4 or GATA6 was sufficient to induce cardiomyocyte hypertrophy characterized by enhanced sarcomeric organization, a greater than 2-fold increase in cell surface area, and a significant increase in total protein accumulation. In vivo, transgenic mice with 2.5-fold overexpression of GATA4 within the adult heart demonstrated a slowly progressing increase in heart to body weight ratio, histological features of cardiomyopathy, and activation of hypertrophy-associated genes, suggesting that GATA factors are sufficient regulators of cardiomyocyte hypertrophy in vitro and in vivo. To evaluate the requirement of GATA factors as downstream transcriptional mediators of hypertrophy, a dominant negative GATA4-engrailed repressor fusion-encoding adenovirus was generated. Expression of GATA4-engrailed blocked GATA4- and GATA6-directed transcriptional responses and agonist-induced cardiomyocyte hypertrophy, demonstrating that cardiac-expressed GATA factors are necessary mediators of this process.	Univ Cincinnati, Childrens Hosp,Med Ctr, Div Mol Cardiovasc Biol, Dept Pediat, Cincinnati, OH 45229 USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res Div, Dept Cell Biol, Ann Arbor, MI 48105 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Pfizer	Molkentin, JD (corresponding author), Univ Cincinnati, Childrens Hosp,Med Ctr, Div Mol Cardiovasc Biol, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	jeff.molkentin@chmcc.org	de Windt, Leon/AAO-6395-2020	de Windt, Leon/0000-0002-7793-2856; Molkentin, Jeffery/0000-0002-3558-6529	NHLBI NIH HHS [HL43662, HL60562] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043662, R37HL060562, R01HL060562] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Babu GJ, 2000, J MOL CELL CARDIOL, V32, P1447, DOI 10.1006/jmcc.2000.1185; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Charron F, 1999, MOL CELL BIOL, V19, P4355; Charron F, 1999, SEMIN CELL DEV BIOL, V10, P85, DOI 10.1006/scdb.1998.0281; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Choukroun G, 1998, J CLIN INVEST, V102, P1311, DOI 10.1172/JCI3512; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; Fu YC, 1998, DEVELOPMENT, V125, P4439; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; Hasegawa K, 1997, CIRCULATION, V96, P3943; Hautala N, 2001, CIRCULATION, V103, P730; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6, DOI 10.1016/0735-1097(93)90455-A; Huang WY, 2000, NAT MED, V6, P482, DOI 10.1038/74914; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; Liang FQ, 1999, J CLIN INVEST, V104, P1603, DOI 10.1172/JCI7362; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Molkentin JD, 1996, J MOL CELL CARDIOL, V28, P1211, DOI 10.1006/jmcc.1996.0112; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Morimoto T, 2000, J BIOL CHEM, V275, P13721, DOI 10.1074/jbc.275.18.13721; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Morin S, 2001, MOL CELL BIOL, V21, P1036, DOI 10.1128/MCB.21.4.1036-1044.2001; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; Nagata D, 2000, CIRC RES, V87, P699, DOI 10.1161/01.RES.87.8.699; Palermo J, 1996, CIRC RES, V78, P504, DOI 10.1161/01.RES.78.3.504; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Saadane N, 2000, AM J PHYSIOL-HEART C, V278, pH796, DOI 10.1152/ajpheart.2000.278.3.H796; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; Steinberg SF, 2000, J MOL CELL CARDIOL, V32, P1381, DOI 10.1006/jmcc.2000.1202; Takemoto Y, 1999, J MOL CELL CARDIOL, V31, P2017, DOI 10.1006/jmcc.1999.1033; THUERAUF DJ, 1994, J BIOL CHEM, V269, P17772; Wada H, 2000, J BIOL CHEM, V275, P25330, DOI 10.1074/jbc.M000828200; Xia Y, 2000, J BIOL CHEM, V275, P1855, DOI 10.1074/jbc.275.3.1855; YAMAGATA T, 1995, MOL CELL BIOL, V15, P3830	43	276	296	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30245	30253		10.1074/jbc.M102174200	http://dx.doi.org/10.1074/jbc.M102174200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11356841	hybrid			2022-12-25	WOS:000170558000085
J	Kedei, N; Szabo, T; Lile, JD; Treanor, JJ; Olah, Z; Iadarola, MJ; Blumberg, PM				Kedei, N; Szabo, T; Lile, JD; Treanor, JJ; Olah, Z; Iadarola, MJ; Blumberg, PM			Analysis of the native quaternary structure of vanilloid receptor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROOT GANGLION NEURONS; CAPSAICIN-RECEPTOR; OLIGOMERIC STRUCTURE; CHANNELS; PROTEINS; CALCIUM; BINDING; TARGET; HEAT; TRP	Vanilloid receptor subtype I (VRI) is a ligand-gated channel that can be activated by capsaicin and other vanilloids as well as by protons and heat. In the present study, we have analyzed the oligomeric state of VR1. Co-immunoprecipitation of differently tagged VRI molecules indicated that VRI can form oligomers. Using two different heterologous VR1 expression systems as well as endogenous VRI expressed in dorsal root ganglion cells, we analyzed oligomer formation using perfluorooctanoic acid polyacrylamide gel electrophoresis. Results were confirmed both with chemical cross-linking agents as well as through endogenous cross-linking mediated by transglutaminase. Our results clearly show that VRI forms multimers in each of the expression systems with a homotetramer as a predominant form. The oligomeric structure of VR1 may contribute to the complexity of VRI pharmacology. Finally, differences in glycosylation between the systems were observed, indicating the need for caution in the use of the heterologous expression systems for analysis of VRI properties.	NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA; NIDCR, Neuronal Gene Express Unit, Pain & Neurosensory Mech Branch, NIH, Bethesda, MD 20892 USA; Amgen Corp, Thousand Oaks, CA 91320 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Amgen	Blumberg, PM (corresponding author), NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bldg 37,Rm 3A01,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000688] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000688] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Acs G, 1997, J NEUROSCI, V17, P5622; AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; BEVAN S, 1990, TRENDS PHARMACOL SCI, V11, P330; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; Corey S, 1998, J BIOL CHEM, V273, P5271, DOI 10.1074/jbc.273.9.5271; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; Debyser Z, 1996, PROTEIN SCI, V5, P278; DLUGOSZ AA, 1994, J INVEST DERMATOL, V102, P409, DOI 10.1111/1523-1747.ep12372171; FESUS L, 1993, FEBS LETT, V328, P1, DOI 10.1016/0014-5793(93)80952-Q; Fesus L, 1988, Adv Exp Med Biol, V231, P119; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Guo A, 1999, EUR J NEUROSCI, V11, P946, DOI 10.1046/j.1460-9568.1999.00503.x; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Jerman JC, 2000, BRIT J PHARMACOL, V130, P916, DOI 10.1038/sj.bjp.0703390; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Lagree V, 1998, J BIOL CHEM, V273, P33949, DOI 10.1074/jbc.273.51.33949; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; Oh U, 1996, J NEUROSCI, V16, P1659; Olah Z, 2001, J BIOL CHEM, V276, P11021, DOI 10.1074/jbc.M008392200; OXFORD GS, 2000, 2000 SOC NEUR ANN M, P1689; PATEL SS, 1993, J BIOL CHEM, V268, P10668; Philipp S, 2000, J BIOL CHEM, V275, P23965, DOI 10.1074/jbc.M003408200; Ramjeesingh M, 1999, BIOCHEM J, V342, P119, DOI 10.1042/0264-6021:3420119; Rice R H, 1992, Epithelial Cell Biol, V1, P128; Schumacher MA, 2000, J BIOL CHEM, V275, P2756, DOI 10.1074/jbc.275.4.2756; Suzuki M, 1999, J BIOL CHEM, V274, P6330, DOI 10.1074/jbc.274.10.6330; Szallasi A, 1999, MOL PHARMACOL, V56, P581, DOI 10.1124/mol.56.3.581; SZALLASI A, 1990, BRAIN RES, V524, P106, DOI 10.1016/0006-8993(90)90498-Z; Szallasi A, 1996, PAIN, V68, P195, DOI 10.1016/S0304-3959(96)03202-2; SZALLASI A, 1991, LIFE SCI, V48, P1863, DOI 10.1016/0024-3205(91)90242-4; SZALLASI A, 1993, LIFE SCI, V52, P221; SZOLCSANYI J, 1988, BRAIN RES, V446, P262, DOI 10.1016/0006-8993(88)90885-2; SZOLCSANYI J, 1975, ARZNEIMITTEL-FORSCH, V25, P1877; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Vince JW, 1997, BBA-BIOMEMBRANES, V1326, P295, DOI 10.1016/S0005-2736(97)00033-3; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; Zhu X, 1998, NEWS PHYSIOL SCI, V13, P211	44	252	267	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28613	28619		10.1074/jbc.M103272200	http://dx.doi.org/10.1074/jbc.M103272200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11358970	hybrid			2022-12-25	WOS:000170093400115
J	Kharel, Y; Zhang, YW; Fujihashi, M; Miki, K; Koyama, T				Kharel, Y; Zhang, YW; Fujihashi, M; Miki, K; Koyama, T			Identification of significant residues for homoallylic substrate binding of Micrococcus luteus B-P 26 undecaprenyl diphosphate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN-LENGTH DETERMINATION; SITE-DIRECTED MUTAGENESIS; MOLECULAR-CLONING; BACILLUS-STEAROTHERMOPHILUS; CONSERVED ASPARTATE; CRYSTAL-STRUCTURE; PRENYLTRANSFERASE; EXPRESSION; CONVERSION; MECHANISM	The primary structure of cis-prenyltransferase is totally different from those of trans-prenyltransferases (Shimizu, N., Koyama, T., and Ogura, H. (1998) J. Biol. Chem. 272, 19476-19481). To better understand the molecular mechanism of enzymatic cis-prenyl chain elongation, we selected seven charged residues in the conserved Region V and two of Phe-Ser motif in Region III of undecaprenyl diphosphate synthase of Micrococcus luteus B-P 26 for substitutions by site-directed mutagenesis and examined their effects on substrate binding and catalysis. Kinetic studies indicated that replacements of Arg-197 or Arg-203 with Ser, and Glu-216 with Gln resulted in 7-11-fold increases of K-m values for isopentenyl diphosphate and 18-1200-fold decreases of k(cat) values compared with those of the wild-type enzyme. In addition, two mutants with respect to the Phe-Ser motif in Region III, F73A and S74A, showed 16-32-fold larger K-m values for isopentenyl diphosphate and 12-16-fold lower k(cat) values than those of the wild-type. Furthermore, product analysis indicated that three mutants, F73A, S74A, and E216Q, yielded shorter chain prenyl diphosphates as their main products. These facts together with the protein structural analysis recently carried out (Fujihashi, M., Zhang, Y.-W., Higuchi, Y., Li, X.-Y., Koyama, T., and Miki, K. (2001) Proc. Nad. Acad. Sci. U.S.A. 98, 4337-4342) indicated that the diphosphate moiety of homoallylic substrate is electrostatically recognized by the three charged amino acids, Arg-197, Arg-203, and Glu-216, in Region V and the Phe-Ser motif in Region III, also indispensable for homoallylic substrate binding as well as catalytic function. It was suggested that the undecaprenyl diphosphate synthase takes a different mode for the binding of isopentenyl diphosphate from that of trans-prenyl chain elongating enzymes.	Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan; Kyoto Univ, Grad Sch Sci, Dept Chem, Sakyo Ku, Kyoto 6068502, Japan; RIKEN, Harima Inst, SPring 8, Mikazuki, Hyogo 6795148, Japan	Tohoku University; Kyoto University; Japan Synchrotron Radiation Research Institute; RIKEN	Koyama, T (corresponding author), Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Katahira 2-1-1, Sendai, Miyagi 9808577, Japan.	koyama@tagen.tohoku.ac.jp						Apfel CM, 1999, J BACTERIOL, V181, P483, DOI 10.1128/JB.181.2.483-492.1999; BABA T, 1980, ARCH BIOCHEM BIOPHYS, V200, P474, DOI 10.1016/0003-9861(80)90379-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN AJ, 1994, PROTEIN SCI, V3, P600; DAVISSON VJ, 1986, J ORG CHEM, V51, P4768, DOI 10.1021/jo00375a005; Fujihashi M, 2001, P NATL ACAD SCI USA, V98, P4337, DOI 10.1073/pnas.071514398; JOLY A, 1993, J BIOL CHEM, V268, P26983; Kato JI, 1999, J BACTERIOL, V181, P2733, DOI 10.1128/JB.181.9.2733-2738.1999; Koyama T, 1996, BIOCHEMISTRY-US, V35, P9533, DOI 10.1021/bi960137v; KOYAMA T, 1993, J BIOCHEM-TOKYO, V113, P355, DOI 10.1093/oxfordjournals.jbchem.a124051; KOYAMA T, 1985, METHOD ENZYMOL, V110, P153; Koyama T, 1999, BIOSCI BIOTECH BIOCH, V63, P1671, DOI 10.1271/bbb.63.1671; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MARRERO PF, 1992, J BIOL CHEM, V267, P21873; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ogura K, 1998, CHEM REV, V98, P1263, DOI 10.1021/cr9600464; Ogura K, 1997, Subcell Biochem, V28, P57; Oh SK, 2000, J BIOL CHEM, V275, P18482, DOI 10.1074/jbc.M002000200; Ohnuma S, 1996, J BIOL CHEM, V271, P18831, DOI 10.1074/jbc.271.31.18831; Ohnuma S, 1997, J BIOL CHEM, V272, P5192, DOI 10.1074/jbc.272.8.5192; Ohnuma S, 1998, J BIOL CHEM, V273, P26705, DOI 10.1074/jbc.273.41.26705; Ohnuma SI, 1996, J BIOL CHEM, V271, P10087, DOI 10.1074/jbc.271.17.10087; POULTER CD, 1978, ACCOUNTS CHEM RES, V11, P307, DOI 10.1021/ar50128a004; Sacchettini JC, 1997, SCIENCE, V277, P1788, DOI 10.1126/science.277.5333.1788; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sato M, 1999, MOL CELL BIOL, V19, P471; Schulbach MC, 2000, J BIOL CHEM, V275, P22876, DOI 10.1074/jbc.M003194200; Shimizu N, 1998, J BIOL CHEM, V273, P19476, DOI 10.1074/jbc.273.31.19476; SONG LS, 1994, P NATL ACAD SCI USA, V91, P3044, DOI 10.1073/pnas.91.8.3044; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018; Wang K, 1999, TRENDS BIOCHEM SCI, V24, P445, DOI 10.1016/S0968-0004(99)01464-4	34	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28459	28464		10.1074/jbc.M102057200	http://dx.doi.org/10.1074/jbc.M102057200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11346651	hybrid			2022-12-25	WOS:000170093400095
J	Leng, Y; Chase, TN; Bennett, MC				Leng, Y; Chase, TN; Bennett, MC			Muscarinic receptor stimulation induces translocation of an alpha-synuclein oligomer from plasma membrane to a light vesicle fraction in cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR TRANSLOCATION; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; PHOSPHOLIPASE D2; LEWY BODIES; PROTEIN; BINDING; ACTIVATION; PRECURSOR; COMPONENT	The close correspondence between the distribution of brain alpha -synuclein and that of muscarinic M-1 and M-3 receptors suggests a role for this protein in cholinergic transmission. We thus examined the effect of muscarinic stimulation on alpha -synuclein in SH-SY5Y, a human dopaminergic cell line that expresses this protein. Under basal conditions, alpha -synuclein was detected in all subcellular compartments isolated as follows: plasma membrane, cytoplasm, nucleus, and two vesicle fractions. The lipid fractions contained only a 45-kDa alpha -synuclein oligomer, whereas the cytoplasmic and nuclear fractions contained both the oligomer and the monomer. This finding suggests alpha -synuclein exists physiologically as a lipid-bound oligomer and a soluble monomer. Muscarinic stimulation by carbachol reduced the alpha -synuclein oligomer in plasma membrane over a 30-min period, with a concomitant increase of both the oligomer and the monomer in the cytoplasmic fraction. The oligomer was associated with a light vesicle fraction in cytoplasm that contains uncoated endocytotic vesicles. The carbachol-induced alteration of alpha -synuclein was blocked by atropine. Translocation of the alpha -synuclein oligomer in response to carbachol, stimulation corresponds closely with the time course of ligand-stimulated muscarinic receptor endocytosis. The data suggest that the muscarine receptor stimulated release of the alpha -synuclein oligomer from plasma membrane, and its subsequent association with the endocytotic vesicle fraction may have a role in muscarine receptor endocytosis. We propose that its function may be a transient release of membrane-bound phospholipase D-2 from alpha -synuclein inhibition, thus allowing this lipase to participate in muscarinic receptor endocytosis.	NINDS, Expt Therapeut Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Chase, TN (corresponding author), NINDS, Expt Therapeut Branch, NIH, Bldg 10,Rm 5C-103, Bethesda, MD 20892 USA.	chaset@ninds.nih.gov			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002265] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baba M, 1998, AM J PATHOL, V152, P879; BAUMERT HG, 1989, METHOD ENZYMOL, V172, P584; BENNETT MC, 1999, NEUROSCIENCE, V25, P48; BIEDLER JL, 1978, CANCER RES, V38, P3751; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Fleischer S, 1974, Methods Enzymol, V31, P3; HATTORI H, 1985, J NEUROCHEM, V45, P1578, DOI 10.1111/j.1471-4159.1985.tb07229.x; HEUSER J, 1989, J CELL BIOL, V109, P1457, DOI 10.1083/jcb.109.4.1457; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Klein J, 1996, PROG BRAIN RES, V109, P201; KLEIN J, 1995, J NEUROCHEM, V65, P1445; LEE HC, 1993, P NATL ACAD SCI USA, V90, P10086, DOI 10.1073/pnas.90.21.10086; Lennartz MR, 1999, INT J BIOCHEM CELL B, V31, P415, DOI 10.1016/S1357-2725(98)00108-3; Lu PJ, 1998, BIOCHEMISTRY-US, V37, P5738, DOI 10.1021/bi972551g; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; MAROTEAUX L, 1991, MOL BRAIN RES, V11, P335, DOI 10.1016/0169-328X(91)90043-W; Marshansky V, 1997, ELECTROPHORESIS, V18, P2661, DOI 10.1002/elps.1150181423; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Mezey E, 1998, MOL PSYCHIATR, V3, P493, DOI 10.1038/sj.mp.4000446; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Pronin AN, 2000, J BIOL CHEM, V275, P26515, DOI 10.1074/jbc.M003542200; Slowiejko DM, 1996, J NEUROCHEM, V66, P186; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tanaka K, 1999, J BIOL CHEM, V274, P3919, DOI 10.1074/jbc.274.7.3919; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; TROWBRIDGE IS, 1993, CURR BIOL, V3, P773, DOI 10.1016/0960-9822(93)90028-M; Tsuga H, 1998, J BIOCHEM-TOKYO, V124, P863, DOI 10.1093/oxfordjournals.jbchem.a022191; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; van der Goot FG, 1997, ELECTROPHORESIS, V18, P2689, DOI 10.1002/elps.1150181426; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Yokogawa T, 2000, FEBS LETT, V473, P222, DOI 10.1016/S0014-5793(00)01535-0; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130; Zhou KM, 1998, J CELL SCI, V111, P283	42	58	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28212	28218		10.1074/jbc.M011121200	http://dx.doi.org/10.1074/jbc.M011121200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11337491	hybrid			2022-12-25	WOS:000170093400064
J	He, JQ; Smith, ER; Xu, XX				He, JQ; Smith, ER; Xu, XX			Disabled-2 exerts its tumor suppressor activity by uncoupling c-Fos expression and MAP kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; CARCINOMA-CELLS; DOWN-REGULATION; RAS ACTIVATION; GROWTH-FACTOR; PROTEIN; ELK-1; PATHWAY; DOMAIN; GRB2	Disabled-2 (Dab2) is a putative tumor suppressor in breast and ovarian cancers. Its expression is lost in a majority of tumors, and homozygous deletions have been identified in a small percentage of tumors. Dab2 expression is absent or very low in the majority of breast and ovarian cancer cell Lines, including MCF-7 and SK-Br-3 breast cancer cells. Transfection and expression of Dab2 in MCF-7 and SK-Br-3 cells suppress tumorigenicity. The cells reach a much lower saturation density and have reduced ability to form colonies on agar plates. In examining the signal transduction pathway of Dab2-transfected cells, we found that serum-stimulated c-Fos expression was greatly suppressed; however, the effects of Dab2 on MAPK family kinases were not as consistent. In MCF-2 and SK-Br-3 cells, although c-Fos expression was suppressed, the Erk1/2, JNK, and p38(MAPK) activities were unchanged or even increased. Serum-stimulated c-Fos expression is dependent on MAPK/Erk activity because the MEK inhibitor PD98059 suppresses Erk activity and c-Fos expression. Therefore, Dab2 appears to uncouple MAPK activation and c-fos transcription. Thus, me conclude that Dab2 re-expression suppresses tumorigenicity by reducing c-Fos expression at a site downstream of the activation of MAPK family kinases. Because Dab2 is frequently lost in cancer; the uncoupling of MAPK activation and c-Fos expression may be a favored target for inactivation in tumorigenicity.	Fox Chase Canc Ctr, Ovarian Canc Program, Philadelphia, PA 19111 USA; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA	Fox Chase Cancer Center; Emory University; Emory University	Xu, XX (corresponding author), Fox Chase Canc Ctr, Ovarian Canc Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.				NATIONAL CANCER INSTITUTE [R01CA079716, R01CA075389] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA79716, R01 CA75389] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BUDAY L, 1995, ONCOGENE, V11, P1327; CALLAHAN R, 1989, BREAST CANCER RES TR, V13, P191, DOI 10.1007/BF02106570; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CLARK GJ, 1995, BREAST CANCER RES TR, V35, P133, DOI 10.1007/BF00694753; CorbalanGarcia S, 1996, ONCOGENE, V12, P1063; Cruzalegui FH, 1999, ONCOGENE, V18, P7948, DOI 10.1038/sj.onc.1203362; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; Holt J, 1992, Cancer Treat Res, V63, P301; Johnson C. R., 1992, Computers in Physics, V6, P230; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lin TH, 1997, J BIOL CHEM, V272, P8849; Marais R, 1996, CANCER SURV, V27, P101; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; PAWSON T, 1993, DEV GENET, V14, P333, DOI 10.1002/dvg.1020140502; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Schlaepfer DD, 1996, CELL STRUCT FUNCT, V21, P445, DOI 10.1247/csf.21.445; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sheng ZJ, 2000, ONCOGENE, V19, P4847, DOI 10.1038/sj.onc.1203853; Sugimoto T, 1997, J BIOL CHEM, V272, P29415, DOI 10.1074/jbc.272.47.29415; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; Tian JM, 1999, J BIOL CHEM, V274, P15173, DOI 10.1074/jbc.274.21.15173; Tseng CP, 1998, ENDOCRINOLOGY, V139, P3542, DOI 10.1210/en.139.8.3542; Verheijen MHG, 1999, J BIOL CHEM, V274, P1487, DOI 10.1074/jbc.274.3.1487; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WONG KK, 1993, INT J ONCOL, V3, P13; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; Yang SH, 1999, EMBO J, V18, P5666, DOI 10.1093/emboj/18.20.5666; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	39	35	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26814	26818		10.1074/jbc.M101820200	http://dx.doi.org/10.1074/jbc.M101820200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11359772	hybrid			2022-12-25	WOS:000169966900013
J	Martinez-Julvez, M; Nogues, I; Faro, M; Hurley, JK; Brodie, TB; Mayoral, T; Sanz-Aparicio, J; Hermoso, JA; Stankovich, MT; Medina, M; Tollin, G; Gomez-Moreno, C				Martinez-Julvez, M; Nogues, I; Faro, M; Hurley, JK; Brodie, TB; Mayoral, T; Sanz-Aparicio, J; Hermoso, JA; Stankovich, MT; Medina, M; Tollin, G; Gomez-Moreno, C			Role of a cluster of hydrophobic residues near the FAD cofactor in Anabaena PCC 7119 ferredoxin-NADP(+) reductase for optimal complex formation and electron transfer to ferredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SITE-DIRECTED MUTAGENESIS; NADP+ REDUCTASE; PCC 7119; NADH-CYTOCHROME-B5 REDUCTASE; CHEMICAL-MODIFICATION; TRANSIENT KINETICS; SPINACH FERREDOXIN; NITRATE REDUCTASE; ESCHERICHIA-COLI	In the ferredoxin-NADP(+) reductase (FNR)/ferredoxin (Fd) system, an aromatic amino acid residue on the surface of Anabaena Fd, Phe-65, has been shown to be essential for the electron transfer (ET) reaction. We have investigated further the role of hydrophobic interactions in complex stabilization and ET between these proteins by replacing three hydrophobic residues, Leu-76, Leu-78, and Val-136, situated on the FNR surface in the vicinity of its FAD cofactor. Whereas neither the ability of FNR to accept electrons from NADPH nor its structure appears to be affected by the introduced mutations, different behaviors with Fd are observed. Thus, the ET interaction with Fd is almost completely lost upon introduction of negatively charged side chains. In contrast, only subtle changes are observed upon conservative replacement. Introduction of Ser residues produces relatively sizable alterations of the FAD redox potential, which can explain the modified behavior of these mutants. The introduction of bulky aromatic side chains appears to produce rearrangements of the side chains at the FNR/Fd interaction surface. Thus, subtle changes in the hydrophobic patch influence the rates of ET to and hom Fd by altering the binding constants and the FAD redox potentials, indicating that these residues are especially important in the binding and orientation of Fd for efficient ET. These results are consistent with the structure reported for the Anabaena FNR.Fd complex.	Univ Zaragoza, Fac Ciencias, Dept Bioquim & Biol Mol & Celular, E-50009 Zaragoza, Spain; Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA; CSIC, Grp Cristalog Macromol & Biol Estructural, Inst Quim Fis Rocasolano, E-28006 Madrid, Spain; Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA	University of Zaragoza; University of Arizona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); University of Minnesota System; University of Minnesota Twin Cities	Gomez-Moreno, C (corresponding author), Univ Zaragoza, Fac Ciencias, Dept Bioquim & Biol Mol & Celular, E-50009 Zaragoza, Spain.	gomezm@posta.unizar.es	Nogues, Isabel/AAA-7499-2019; Sanz-Aparicio, Julia/F-6201-2013; Martinez-Julvez, Marta M/G-5392-2012; Martinez-Julvez, Marta/G-3839-2017; Gonzalez, Isabel Nogues/K-2118-2012; Medina, Milagros/F-8310-2012; Hermoso, Juan/J-3433-2012	Sanz-Aparicio, Julia/0000-0002-6849-8621; Martinez-Julvez, Marta M/0000-0001-9047-0046; Martinez-Julvez, Marta/0000-0001-9047-0046; Gonzalez, Isabel Nogues/0000-0002-7475-2411; Medina, Milagros/0000-0001-8743-0182; Hermoso, Juan/0000-0002-1862-8950	NIDDK NIH HHS [DK15057] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015057] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAM J, 1986, J BACTERIOL, V168, P1265, DOI 10.1128/jb.168.3.1265-1271.1986; ALIVERTI A, 1994, FEBS LETT, V343, P247, DOI 10.1016/0014-5793(94)80565-2; Aliverti A, 1998, J BIOL CHEM, V273, P34008, DOI 10.1074/jbc.273.51.34008; AOKI H, 1994, PLANT PHYSIOL, V104, P1473, DOI 10.1104/pp.104.4.1473; Arakaki AK, 1997, FASEB J, V11, P133, DOI 10.1096/fasebj.11.2.9039955; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BATIE CJ, 1984, J BIOL CHEM, V259, P1976; BATIE CJ, 1981, J BIOL CHEM, V256, P7756; BOHME H, 1989, PLANT MOL BIOL, V12, P667, DOI 10.1007/BF00044157; BOWSHER CG, 1996, PLANT PHYSIOL, V112, P861; Brunger A. T., 1993, XPLOR SYSTEM XRAY CR; CASTELLANO EE, 1992, J APPL CRYSTALLOGR, V25, P281, DOI 10.1107/S0021889891012773; CORRELL CC, 1992, SCIENCE, V258, P1604, DOI 10.1126/science.1280857; DeLano WL, 2000, SCIENCE, V287, P1279, DOI 10.1126/science.287.5456.1279; Deng Z, 1999, NAT STRUCT BIOL, V6, P847; Ejdeback M, 2000, BIOCHEMISTRY-US, V39, P5022, DOI 10.1021/bi992757c; FILLAT MF, 1990, NUCLEIC ACIDS RES, V18, P7161, DOI 10.1093/nar/18.23.7161; FOUST GP, 1969, J BIOL CHEM, V244, P964; Gong XS, 2000, EUR J BIOCHEM, V267, P1732, DOI 10.1046/j.1432-1327.2000.01168.x; HAJIREZAEI M, 1997, Y14032 DDBJGENBANKEB; HALL AV, 1994, J BIOL CHEM, V269, P33082; HURLEY JK, 1993, J AM CHEM SOC, V115, P11698, DOI 10.1021/ja00078a006; Hurley JK, 1997, BIOCHEMISTRY-US, V36, P11100, DOI 10.1021/bi9709001; Hurley JK, 1999, PROTEIN SCI, V8, P1614, DOI 10.1110/ps.8.8.1614; HURLEY JK, 1993, BIOCHEMISTRY-US, V32, P9346, DOI 10.1021/bi00087a013; HURLEY JK, 1994, ARCH BIOCHEM BIOPHYS, V312, P480, DOI 10.1006/abbi.1994.1335; Hurley JK, 1996, J AM CHEM SOC, V118, P5526, DOI 10.1021/ja953662a; Hurley JK, 1996, ARCH BIOCHEM BIOPHYS, V333, P243, DOI 10.1006/abbi.1996.0387; Hurley JK, 2000, BIOCHEMISTRY-US, V39, P13695, DOI 10.1021/bi001124r; HYDE GE, 1990, BIOCHEM BIOPH RES CO, V168, P1285, DOI 10.1016/0006-291X(90)91168-R; JELESAROV I, 1994, BIOCHEMISTRY-US, V33, P13321, DOI 10.1021/bi00249a019; JELESAROV I, 1993, EUR J BIOCHEM, V216, P57, DOI 10.1111/j.1432-1033.1993.tb18116.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARPLUS PA, 1994, J BIOENERG BIOMEMBR, V26, P89, DOI 10.1007/BF00763221; KARPLUS PA, 1984, BIOCHEMISTRY-US, V23, P6576, DOI 10.1021/bi00321a046; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMADA HO, 1998, PLANT PHYSIOL, V116, P1192; Kurisu G, 2001, NAT STRUCT BIOL, V8, P117, DOI 10.1038/84097; LESLIE AGW, 1987, P CCP4 STUD WEEK SER, P39; LONG DM, 1992, PHYSIOL PLANTARUM, V85, P561, DOI 10.1111/j.1399-3054.1992.tb04755.x; Martinez-Julvez M, 1998, BIOCHEMISTRY-US, V37, P13604, DOI 10.1021/bi9807411; Martinez-Julvez M, 1999, J BIOL INORG CHEM, V4, P568, DOI 10.1007/s007750050379; Martinez-Julvez M, 1998, BIOCHEMISTRY-US, V37, P17680, DOI 10.1021/bi981718i; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; Mayoral T, 2000, PROTEINS, V38, P60, DOI 10.1002/(SICI)1097-0134(20000101)38:1<60::AID-PROT7>3.0.CO;2-B; Medina M, 1998, BIOCHEMISTRY-US, V37, P2715, DOI 10.1021/bi971795y; Medina M, 2001, J BIOL CHEM, V276, P11902, DOI 10.1074/jbc.M009287200; MEDINA M, 1992, FEBS LETT, V298, P25, DOI 10.1016/0014-5793(92)80014-8; MEDINA M, 1992, ARCH BIOCHEM BIOPHYS, V299, P281, DOI 10.1016/0003-9861(92)90276-3; Morales R, 2000, EMBO REP, V1, P271, DOI 10.1093/embo-reports/kvd057; Morales R, 1999, BIOCHEMISTRY-US, V38, P15764, DOI 10.1021/bi991578s; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NEWMAN BJ, 1988, PLANT MOL BIOL, V10, P511, DOI 10.1007/BF00033606; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISHIDA H, 1995, BIOCHEMISTRY-US, V34, P2763, DOI 10.1021/bi00009a004; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; PORTER TD, 1985, P NATL ACAD SCI USA, V82, P973, DOI 10.1073/pnas.82.4.973; PRZYSIECKI CT, 1985, J BIOL CHEM, V260, P1452; Serre L, 1996, J MOL BIOL, V263, P20, DOI 10.1006/jmbi.1996.0553; SIMONDSEN RP, 1982, BIOCHEMISTRY-US, V21, P6366, DOI 10.1021/bi00268a008; SIMONDSEN RP, 1983, BIOCHEMISTRY-US, V22, P3008, DOI 10.1021/bi00281a034; STANKOVICH MT, 1980, ANAL BIOCHEM, V109, P295, DOI 10.1016/0003-2697(80)90652-1; TOLLIN G, 1995, J BIOENERG BIOMEMBR, V27, P303, DOI 10.1007/BF02110100; Tsai CJ, 1997, PROTEIN SCI, V6, P1426, DOI 10.1002/pro.5560060707; VANDEKAMP M, 1990, EUR J BIOCHEM, V194, P109; VANPOUDEROYEN G, 1994, EUR J BIOCHEM, V222, P583; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; YAO Y, 1984, J BIOCHEM-TOKYO, V95, P1513, DOI 10.1093/oxfordjournals.jbchem.a134759; YUBISUI T, 1984, J BIOCHEM-TOKYO, V96, P579, DOI 10.1093/oxfordjournals.jbchem.a134871; ZANETTI G, 1988, BIOCHEMISTRY-US, V27, P3753, DOI 10.1021/bi00410a035	70	36	38	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27498	27510		10.1074/jbc.M102112200	http://dx.doi.org/10.1074/jbc.M102112200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11342548	hybrid			2022-12-25	WOS:000169966900101
J	Fairchild, TA; Fulton, D; Fontana, JT; Gratton, JP; McCabe, TJ; Sessa, WC				Fairchild, TA; Fulton, D; Fontana, JT; Gratton, JP; McCabe, TJ; Sessa, WC			Acidic hydrolysis as a mechanism for the cleavage of the Glu(298) -> Asp variant of human endothelial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY-ARTERY DISEASE; MYOCARDIAL-INFARCTION; GENE POLYMORPHISM; PEPTIDE-BONDS; PALMITOYLATION; HYPERTENSION; ASSOCIATION; APOPTOSIS; SEVERITY; MUTATION	The 894G -->T polymorphism within exon 7 of the human endothelial nitric-oxide synthase (eNOS) gene codes for glutamate or aspartate, respectively, at residue 298 and has been associated with several diseases of cardiovascular origin. A recent report indicates that Asp(298)-eNOS (E298D) is cleaved intracellularly to 100- and 35-kDa fragments, suggesting a mechanism for reduced endothelial function. Here we have documented the precise cleavage site of the E298D variant as a unique aspartyl-prolyl (Asp(298)-Pro(299)) bond not seen in wild-type eNOS (Glu(298)). W, show that E298D-eNOS, as isolated from cells and in vitro, is susceptible to acidic hydrolysis, and the 100-kDa fragment can be generated ex vivo by increasing temperature at low pH, Importantly, cleavage of E298D was eliminated using a sample buffer system designed to limit acidic hydrolysis of Asp-Pro bonds. These results argue against intracellular processing of E298D-eNOS and suggest that previously described fragmentation of E298D could be a product of sample preparation. We also found that eNOS turnover, NO production, and the susceptibility to cellular stress were not different in cells expressing WT versus E298D-eNOS, Finally, enzyme activities were identical for the respective recombinant enzymes. Thus, intracellular cleavage mechanisms are unlikely to account for associations between the exon 7 polymorphism and cardiovascular diseases.	Yale Univ, Sch Med, Dept Pharmacol, Boyer Ctr Mol Med, New Haven, CT 06536 USA	Yale University	Sessa, WC (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, Boyer Ctr Mol Med, 333 Cedar St, New Haven, CT 06536 USA.		Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938; Gratton, Jean-Philippe/0000-0001-9877-8520	NHLBI NIH HHS [R01 HL61371, R01 HL64793, T32HL10183, R01 HL57665] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057665, R01HL061371, F32HL010183, R01HL064793] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Banasiak KJ, 1998, BRAIN RES, V797, P295, DOI 10.1016/S0006-8993(98)00286-8; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; Cai H, 1999, J MOL MED, V77, P511, DOI 10.1007/s001099900020; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Hibi K, 1998, HYPERTENSION, V32, P521, DOI 10.1161/01.HYP.32.3.521; Hingorani AD, 1999, CIRCULATION, V100, P1515, DOI 10.1161/01.CIR.100.14.1515; Kato N, 1999, HYPERTENSION, V33, P933, DOI 10.1161/01.HYP.33.4.933; Lacolley P, 1998, J HYPERTENS, V16, P31, DOI 10.1097/00004872-199816010-00006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU JW, 1995, BIOCHEMISTRY-US, V34, P12333, DOI 10.1021/bi00038a029; MacLeod MJ, 1999, NEUROLOGY, V53, P418, DOI 10.1212/WNL.53.2.418; MARSDEN PA, 1993, J BIOL CHEM, V268, P14778; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; Miyamoto Y, 1998, HYPERTENSION, V32, P3, DOI 10.1161/01.HYP.32.1.3; Moroi M, 1998, J CLIN INVEST, V101, P1225, DOI 10.1172/JCI1293; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Nakayama M, 2000, AM J CARDIOL, V86, P628, DOI 10.1016/S0002-9149(00)01041-9; PISZKIEW.D, 1970, BIOCHEM BIOPH RES CO, V40, P1173, DOI 10.1016/0006-291X(70)90918-6; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; RITTENHOUSE J, 1984, ANAL BIOCHEM, V138, P442, DOI 10.1016/0003-2697(84)90836-4; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; Rudic RD, 1999, AM J HUM GENET, V64, P673, DOI 10.1086/302304; Tesauro M, 2000, P NATL ACAD SCI USA, V97, P2832, DOI 10.1073/pnas.97.6.2832; Wang XL, 2000, MOL GENET METAB, V70, P241, DOI 10.1006/mgme.2000.3033; Zanchi A, 2000, KIDNEY INT, V57, P405, DOI 10.1046/j.1523-1755.2000.00860.x	28	149	153	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26674	26679		10.1074/jbc.M103647200	http://dx.doi.org/10.1074/jbc.M103647200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11331296	hybrid			2022-12-25	WOS:000169823300133
J	Heaslet, HA; Royer, WE				Heaslet, HA; Royer, WE			Crystalline ligand transitions in Lamprey hemoglobin - Structural evidence for the regulation of oxygen affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PETROMYZON-MARINUS; CO; EQUILIBRIUM; MOLSCRIPT; BINDING; MODEL	The hemoglobins of the Sea Lamprey (Petromyzon marinus) exist in an equilibrium between low affinity oligomers, stabilized by proton binding, and higher affinity monomers, stabilized by oxygen binding, Recent crystallographic analysis revealed that dimerization is coupled with key changes at the ligand binding site with the distal histidine sterically restricting ligand binding in the deoxy dimer but with no significant structural rearrangements on the proximal side. These structural insights led to the hypothesis that oxygen affinity of lamprey hemoglobin is distally regulated. Here we present the 2.9-Angstrom crystal structure of deoxygenated lamprey hemoglobin in an orthorhombic crystal form along with the structure of these crystals exposed to carbon monoxide. The hexameric assemblage in this crystal form is very similar to those observed in the previous deoxy structure. Whereas the hydrogen bonding network and packing contacts formed in the dimeric interface of lamprey hemoglobin are largely unaffected by ligand binding, the binding of carbon monoxide induces the distal histidine to swing to positions that would preclude the formation of a stabilizing hydrogen bond with the bound ligand, These results suggest a dual role for the distal histidine and strongly support the hypothesis that ligand affinity in lamprey hemoglobin is distally regulated.	Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01655 USA; Clark Univ, Dept Chem, Worcester, MA 01610 USA	University of Massachusetts System; University of Massachusetts Worcester; Clark University	Royer, WE (corresponding author), BASF Biores Corp, 100 Res Dr, Worcester, MA 01604 USA.	William.Royer@umassmed.edu		Soutter, Holly/0000-0001-9448-4904	NIDDK NIH HHS [DK43323] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN ME, 1971, J BIOL CHEM, V246, P4790; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barrick D, 1997, NAT STRUCT BIOL, V4, P78, DOI 10.1038/nsb0197-78; BRIEHL RW, 1963, J BIOL CHEM, V238, P2361; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DOHI Y, 1973, J BIOL CHEM, V248, P2354; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; Heaslet HA, 1999, STRUCT FOLD DES, V7, P517, DOI 10.1016/S0969-2126(99)80068-9; HENDRICK.WA, 1968, J MOL BIOL, V33, P829, DOI 10.1016/0022-2836(68)90322-7; HONZATKO RB, 1985, J MOL BIOL, V184, P147, DOI 10.1016/0022-2836(85)90049-X; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kachalova GS, 1999, SCIENCE, V284, P473, DOI 10.1126/science.284.5413.473; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pardanani A, 1997, J BIOL CHEM, V272, P13171, DOI 10.1074/jbc.272.20.13171; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; Qiu Y, 2000, J BIOL CHEM, V275, P13517, DOI 10.1074/jbc.275.18.13517; RIGGS A, 1972, BIOL LAMPREYS, V2, P261; ROMO TD, 1995, PROTEINS, V22, P311, DOI 10.1002/prot.340220403; ROYER WE, 1994, J MOL BIOL, V235, P657, DOI 10.1006/jmbi.1994.1019; Scott EE, 2001, J BIOL CHEM, V276, P5177, DOI 10.1074/jbc.M008282200; Vojtechovsky J, 1999, BIOPHYS J, V77, P2153, DOI 10.1016/S0006-3495(99)77056-6; WALD G, 1951, J GEN PHYSIOL, V35, P45, DOI 10.1085/jgp.35.1.45; Yang F, 1996, J MOL BIOL, V256, P762, DOI 10.1006/jmbi.1996.0123	31	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26230	26236		10.1074/jbc.M101391200	http://dx.doi.org/10.1074/jbc.M101391200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11340069	hybrid			2022-12-25	WOS:000169823300079
J	Idrissi, FZ; Garcia-Reyero, N; Fernandez-Larrea, JB; Pina, B				Idrissi, FZ; Garcia-Reyero, N; Fernandez-Larrea, JB; Pina, B			Alternative mechanisms of transcriptional activation by Rap1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-GENOME-DATABASE; TUMOR VIRUS PROMOTER; DNA-BINDING DOMAIN; ASSEMBLY FACTOR-I; NUCLEOSOMAL DNA; TELOMERE LENGTH; GENE-EXPRESSION; PROTEIN RAP1; YEAST RAP1P; CEREVISIAE	Single Rap1p DNA-binding sites are poor activators of transcription of yeast minimal promoters, even when fully occupied in vivo, This low efficiency is due to two independent repression mechanisms as follows: one that requires the presence of histones, and one that requires Hrs1p, a component of the RNA polymerase II mediator complex. Both repression mechanisms were greatly reduced for constructs with tandemly arranged sites. In these constructs, UASrpg sequences (ACACCCATA-CATTT) activated better than telomere-like sequences (ACACCCACACACCC) in an orientation-dependent manner, Both mutations in the SWI/SNF complex and a deletion of amino acids 597-629 of Rap1p (Tox domain) decreased synergistic effects of contiguous telomeric sites. Conversely, deletion of amino acids 700-798 of Rap1p (Sil domain) made UASrpg and telomeric sites functionally indistinguishable. We propose that the Sil domain masks the main transactivation domain of Rap1p in Rap1p-telomere complexes, where the Tox domain behaves as a secondary activation domain, probably by interacting with chromatin-remodeling complexes. Rap1p DNA-binding sites in ribosomal protein gene promoters are mainly UASrpg-like; their replacement by telomeric sequences in one of these promoters (RPS17B) decreased transcription by two-thirds. The functional differences between UASrpgs and telomeric sequences may thus contribute to the differential expression of Rap1p-regulated promoters in vivo.	CSIC, Dept Biol Mol & Cellular, Inst Biol Mol Barcelona, Ctr Invest & Desenvolupament, ES-08034 Barcelona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB)	Pina, B (corresponding author), CSIC, Dept Biol Mol & Cellular, Inst Biol Mol Barcelona, Ctr Invest & Desenvolupament, Jordi Girona 18, ES-08034 Barcelona, Spain.		Piña, Benjamin/A-1671-2011; Idrissi Azami, Fatima Zohra/P-5627-2015	Piña, Benjamin/0000-0001-9216-2768; Idrissi Azami, Fatima Zohra/0000-0003-3672-7618; Fernandez-Larrea, Juan Bautista/0000-0001-8007-8040				ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; Ball CA, 2000, NUCLEIC ACIDS RES, V28, P77, DOI 10.1093/nar/28.1.77; Bjorklund S, 1996, TRENDS BIOCHEM SCI, V21, P335, DOI 10.1016/0968-0004(96)10051-7; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BUCK SW, 1995, GENE DEV, V9, P370, DOI 10.1101/gad.9.3.370; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; Carr MD, 1996, EUR J BIOCHEM, V235, P721, DOI 10.1111/j.1432-1033.1996.00721.x; Chambers A, 1996, MOL MICROBIOL, V22, P449, DOI 10.1046/j.1365-2958.1996.00134.x; CHAVEZ S, 1995, MOL CELL BIOL, V15, P6987; Chavez S, 1997, P NATL ACAD SCI USA, V94, P2885, DOI 10.1073/pnas.94.7.2885; Cherry JM, 1998, NUCLEIC ACIDS RES, V26, P73, DOI 10.1093/nar/26.1.73; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; CULOTTA VC, 1994, J BIOL CHEM, V269, P25295; DEVLIN C, 1991, MOL CELL BIOL, V11, P3642, DOI 10.1128/MCB.11.7.3642; Enomoto S, 1998, GENE DEV, V12, P219, DOI 10.1101/gad.12.2.219; FREEMAN K, 1995, GENETICS, V141, P1253; GARTENBERG MR, 1992, P NATL ACAD SCI USA, V89, P11461, DOI 10.1073/pnas.89.23.11461; GIARDINA C, 1995, MOL CELL BIOL, V15, P2737; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; GILSON E, 1995, NUCLEIC ACIDS MOL BI, V9, P308; Goncalves PM, 1996, MOL MICROBIOL, V19, P535, DOI 10.1046/j.1365-2958.1996.404939.x; GRAHAM IR, 1994, NUCLEIC ACIDS RES, V22, P124, DOI 10.1093/nar/22.2.124; Graham IR, 1999, MOL CELL BIOL, V19, P7481; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; Ha N, 1996, NUCLEIC ACIDS RES, V24, P1453, DOI 10.1093/nar/24.8.1453; HAHN S, 1985, P NATL ACAD SCI USA, V82, P8562, DOI 10.1073/pnas.82.24.8562; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HARDY CFJ, 1992, MOL CELL BIOL, V12, P1209, DOI 10.1128/MCB.12.3.1209; HARDY CFJ, 1992, GENE DEV, V6, P801, DOI 10.1101/gad.6.5.801; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Idrissi FZ, 1999, BIOCHEM J, V341, P477, DOI 10.1042/0264-6021:3410477; Idrissi FZ, 1998, J MOL BIOL, V284, P925, DOI 10.1006/jmbi.1998.2215; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; KOENIG P, 1996, CELL, V85, P125, DOI 10.1016/S0092-8674(00)81088-0; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Lascaris RF, 1999, BIOINFORMATICS, V15, P267, DOI 10.1093/bioinformatics/15.4.267; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Liang SD, 1996, MOL CELL BIOL, V16, P3773; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; Lopez MC, 1998, P NATL ACAD SCI USA, V95, P14112, DOI 10.1073/pnas.95.24.14112; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCDONNELL DP, 1991, MOL CELL BIOL, V11, P4350, DOI 10.1128/MCB.11.9.4350; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; Morse RH, 2000, TRENDS GENET, V16, P51, DOI 10.1016/S0168-9525(99)01936-8; Myers LC, 1999, P NATL ACAD SCI USA, V96, P67, DOI 10.1073/pnas.96.1.67; Piruat JI, 1997, GENETICS, V147, P1585; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; ROSE M, 1983, J MOL BIOL, V170, P883, DOI 10.1016/S0022-2836(83)80193-4; SCHWABE JWR, 1995, STRUCTURE, V3, P201, DOI 10.1016/S0969-2126(01)00150-2; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Tabtiang RK, 1998, MOL CELL BIOL, V18, P4707, DOI 10.1128/MCB.18.8.4707; Taylor HOB, 2000, J MOL BIOL, V303, P693, DOI 10.1006/jmbi.2000.4161; Van Helden J, 2000, YEAST, V16, P177, DOI 10.1002/(SICI)1097-0061(20000130)16:2<177::AID-YEA516>3.0.CO;2-9; VIGNAIS ML, 1990, J BIOL CHEM, V265, P14669; Wahlin J, 2000, NUCLEIC ACIDS RES, V28, P2292, DOI 10.1093/nar/28.12.2292; Wood JR, 1998, MOL CELL BIOL, V18, P1927, DOI 10.1128/MCB.18.4.1927; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Wotton D, 1997, GENE DEV, V11, P748, DOI 10.1101/gad.11.6.748; WOUDT LP, 1987, NUCLEIC ACIDS RES, V15, P6037, DOI 10.1093/nar/15.15.6037; Wyrick JJ, 1999, NATURE, V402, P418, DOI 10.1038/46567; Yu LN, 1999, MOL CELL BIOL, V19, P5279	67	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26090	26098		10.1074/jbc.M101746200	http://dx.doi.org/10.1074/jbc.M101746200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11358963	hybrid			2022-12-25	WOS:000169823300062
J	Nakatsuka, S; Hayashi, M; Muroyama, A; Otsuka, M; Kozaki, S; Yamada, H; Moriyama, Y				Nakatsuka, S; Hayashi, M; Muroyama, A; Otsuka, M; Kozaki, S; Yamada, H; Moriyama, Y			D-aspartate is stored in secretory granules and released through a Ca2+-dependent pathway in a subset of rat pheochromocytoma PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-SERINE; GLUTAMATE TRANSPORTER; NICOTINIC RECEPTORS; MELATONIN SYNTHESIS; ALPHA-LATROTOXIN; BRAIN; ACID; MICROVESICLES; LOCALIZATION; EXOCYTOSIS	D-Aspartate in mammalian neuronal and neuroendocrine cells is suggested to play a regulatory role(s) in the neuroendocrine function. Although D-aspartate is known to be released from neuroendocrine cells, the mechanism underlying the release is less understood. Rat pheochromocytoma PC12 cells contain an appreciable amount of D-aspartate (257 +/- 31 pmol/10(7) cells). Indirect immunofluorescence microscopy with specific antibodies against D-aspartate indicated that the amino acid is present within a particulate structure, which is co-localized with dopamine and chromogranin A, markers for secretory granules, but not with synaptophysin, a marker for synaptic-like microvesicles. After sucrose density gradient centrifugation of the postnuclear particulate fraction, about 80% of the D-aspartate was recovered in the secretory granule fraction. Upon the addition of KCI, an appreciable amount of D-aspartate (about 40 pmol/10(7) cells at 10 min) was released from cultured cells on incubation in the presence of Ca2+ in the medium. The addition of A23187 also triggered D-aspartate release. Botulinum neurotoxin type E inhibited about 40% of KCl- and Ca2+-dependent D-aspartate release followed by specific cleavage of 25-kDa synaptosomal-associated protein. alpha -latrotoxin increased the intracellular [Ca2+] and caused the Ca2+-dependent D-aspartate release. Bafilomycin Al dissipated the intracellular acidic regions and inhibited 40% of the Ca2+-dependent D-aspartate release. These properties are similar to those of the exocytosis of dopamine. Furthermore, digitonin-permeabilized cells took up radiolabeled D-aspartate depending on MgATP, which is sensitive to bafilomycin Al or 3,5-di-tert-butyl-4-hydroxybenzylidene-malononitrile. Taken together, these results strongly suggest that D-aspartate is stored in secretory granules and then secreted through a Ca2+-dependent exocytotic mechanism. Exocytosis of D-aspartate further supports the role(s) of D-aspartate as a chemical transmitter in neuroendocrine cells.	Okayama Univ, Fac Pharmaceut Sci, Dept Biochem, Okayama 7008530, Japan; Osaka Prefecture Univ, Coll Agr, Dept Vet Sci, Osaka, Japan	Okayama University; Osaka Metropolitan University	Moriyama, Y (corresponding author), Okayama Univ, Fac Pharmaceut Sci, Dept Biochem, 3-1-1 Tsushima Naka, Okayama 7008530, Japan.	moriyama@pheasant.pharm.okayama-u.ac.jp	Yamada, Hiroshi/AGZ-4497-2022; YAMADA, Hiroshi/B-2251-2011	Yamada, Hiroshi/0000-0002-9328-3446; YAMADA, Hiroshi/0000-0002-9328-3446				Araque A, 2000, J NEUROSCI, V20, P666, DOI 10.1523/JNEUROSCI.20-02-00666.2000; Banerjee A, 1996, J BIOL CHEM, V271, P20227, DOI 10.1074/jbc.271.34.20227; BAUERFEIND R, 1993, NEURON, V11, P105, DOI 10.1016/0896-6273(93)90275-V; Bellocchio EE, 2000, SCIENCE, V289, P957, DOI 10.1126/science.289.5481.957; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; COUSIN MA, 1995, J NEUROCHEM, V64, P2097; D'Aniello A, 2000, FASEB J, V14, P699, DOI 10.1096/fasebj.14.5.699; DUNLOP DS, 1986, BIOCHEM BIOPH RES CO, V141, P27, DOI 10.1016/S0006-291X(86)80329-1; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; FELICE LJ, 1978, J NEUROCHEM, V31, P1461, DOI 10.1111/j.1471-4159.1978.tb06573.x; Hashimoto A, 1997, PROG NEUROBIOL, V52, P325, DOI 10.1016/S0301-0082(97)00019-1; HASHIMOTO A, 1992, J CHROMATOGR-BIOMED, V582, P41, DOI 10.1016/0378-4347(92)80300-F; HASHIMOTO A, 1993, J NEUROCHEM, V60, P783, DOI 10.1111/j.1471-4159.1993.tb03219.x; Hayashi T, 1998, J NEUROCHEM, V71, P356; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; IMAI K, 1995, BIOMED CHROMATOGR, V9, P106, DOI 10.1002/bmc.1130090211; Ishio S, 1998, NEUROSCI LETT, V249, P143, DOI 10.1016/S0304-3940(98)00414-5; KAMATA Y, 1993, BIOCHIM BIOPHYS ACTA, V1156, P213, DOI 10.1016/0304-4165(93)90138-X; Kera Y, 1996, COMP BIOCHEM PHYS B, V115, P121, DOI 10.1016/0305-0491(96)00089-2; Lee IS, 1999, BIOCHEM PHARMACOL, V58, P1017, DOI 10.1016/S0006-2952(99)00181-1; Lee JA, 1997, BIOCHEM BIOPH RES CO, V231, P505, DOI 10.1006/bbrc.1996.5902; LIU YJ, 1994, J CELL BIOL, V127, P1419, DOI 10.1083/jcb.127.5.1419; Moriyama Y, 1998, NEUROSCI LETT, V248, P57, DOI 10.1016/S0304-3940(98)00308-5; MORIYAMA Y, 1988, J BIOL CHEM, V263, P8521; MORIYAMA Y, 1995, J BIOL CHEM, V270, P22314, DOI 10.1074/jbc.270.38.22314; NAGATA Y, 1992, BIOCHIM BIOPHYS ACTA, V1115, P208, DOI 10.1016/0304-4165(92)90055-Y; NAITO S, 1985, J NEUROCHEM, V44, P99, DOI 10.1111/j.1471-4159.1985.tb07118.x; NICHOLLS DG, 1989, J NEUROCHEM, V52, P331, DOI 10.1111/j.1471-4159.1989.tb09126.x; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; SCHELL MJ, 1995, P NATL ACAD SCI USA, V92, P3948, DOI 10.1073/pnas.92.9.3948; Schell MJ, 1997, J NEUROSCI, V17, P1604; Schell MJ, 1997, P NATL ACAD SCI USA, V94, P2013, DOI 10.1073/pnas.94.5.2013; Schindelholz B, 2000, EUR J NEUROSCI, V12, P194, DOI 10.1046/j.1460-9568.2000.00913.x; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; Takamori S, 2000, NATURE, V407, P189, DOI 10.1038/35025070; Taylor SC, 2000, J BIOL CHEM, V275, P26786; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; Washbourne P, 1999, J NEUROCHEM, V73, P2424, DOI 10.1046/j.1471-4159.1999.0732424.x; Wolosker H, 2000, NEUROSCIENCE, V100, P183, DOI 10.1016/S0306-4522(00)00321-3; Yamada H, 1996, J PINEAL RES, V21, P175, DOI 10.1111/j.1600-079X.1996.tb00285.x; Yamada H, 1997, J NEUROCHEM, V69, P1491; Yamada H, 1998, J NEUROSCI, V18, P4946; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707	44	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26589	26596		10.1074/jbc.M011754200	http://dx.doi.org/10.1074/jbc.M011754200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11333256	hybrid			2022-12-25	WOS:000169823300123
J	Gineitis, D; Treisman, R				Gineitis, D; Treisman, R			Differential usage of signal transduction pathways defines two types of serum response factor target gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE KINASE; C-FOS PROMOTER; TERNARY COMPLEX FACTORS; ALPHA-ACTIN PROMOTER; GROWTH-FACTOR; RHO-PROTEINS; LYSOPHOSPHATIDIC ACID; TRANSCRIPTIONAL ACTIVATION; MYOGENIC DIFFERENTIATION; 3T3 CELLS	Activation of the transcription factor serum response factor (SRF) is dependent on Rho-controled changes in actin dynamics. We used pathway-specific inhibitors to compare the roles of actin dynamics, extracellular signal-regulated kinase (ERK) signaling, and phosphatidylinositol I-kinase in signaling either to SRF itself or to four cellular SRF target genes. Serum, lysophosphatidic acid, platelet-derived growth factor, and phorbol 12-myristate 13-acetate (PMA) each activated transcription of a stably integrated SRF reporter gene dependent on functional RhoA GTPase, Inhibition of mitogen-activated protein kinase-ERK kinase (MEK) signalling reduced activation of the SRF reporter by all stimuli by about 50%, except for PMA, which was effectively blocked. inhibition of phosphatidylinositol 3-kinase slightly reduced reporter activation by serum and lysophosphatidic acid but substantially inhibited activation by platelet-derived growth factor and PMA. Reporter induction by all stimuli was absolutely dependent on actin dynamics. Regulation of the SRF (srf) and vinculin (ucl) genes was similar to that of the SRF reporter gene; activation by all stimuli was Rho-dependent and required actin dynamics but was largely independent of MEK activity. In contrast, activation of fos and egr1 occurred independently of RhoA and actin polymerization but was almost completely dependent on MEK activation. These results show that at least two classes of SRF target genes can be distinguished on the basis of their relative sensitivity to RhoA-actin and MEK-ERK signaling pathways.	Imperial Canc Res Fund, Transcript Lab, London WC2A 3PX, England	Cancer Research UK	Treisman, R (corresponding author), Imperial Canc Res Fund, Transcript Lab, 44 Lincolns Inn Fields,Rm 401, London WC2A 3PX, England.			Treisman, Richard/0000-0002-9658-0067				Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Barth H, 1998, INFECT IMMUN, V66, P1364, DOI 10.1128/IAI.66.4.1364-1369.1998; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; Beltman J, 1999, J BIOL CHEM, V274, P3772, DOI 10.1074/jbc.274.6.3772; BENZEEV A, 1990, CELL REGUL, V1, P621, DOI 10.1091/mbc.1.9.621; Carnac G, 1998, MOL BIOL CELL, V9, P1891, DOI 10.1091/mbc.9.7.1891; Chen CY, 1996, DEV GENET, V19, P119, DOI 10.1002/(SICI)1520-6408(1996)19:2<119::AID-DVG3>3.0.CO;2-C; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Hahn A, 2000, J BIOL CHEM, V275, P37429, DOI 10.1074/jbc.M000976200; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LAN L, 1987, P NATL ACAD SCI USA, V84, P1182; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Mack CP, 2001, J BIOL CHEM, V276, P341, DOI 10.1074/jbc.M005505200; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCMAHON SB, 1995, MOL CELL BIOL, V15, P1086; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; MOISEYEVA EP, 1993, J BIOL CHEM, V268, P4318; Moore ML, 2001, J BIOL CHEM, V276, P1026, DOI 10.1074/jbc.M009352200; Poser S, 2000, EMBO J, V19, P4955, DOI 10.1093/emboj/19.18.4955; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Reiser COA, 1998, BIOCHEM J, V330, P1107; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sarbassov DD, 1998, MOL ENDOCRINOL, V12, P1870, DOI 10.1210/me.12.12.1870; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Spencer JA, 1996, J BIOL CHEM, V271, P16535, DOI 10.1074/jbc.271.28.16535; Spencer JA, 1999, MOL CELL BIOL, V19, P3977; Spencer JA, 1999, ONCOGENE, V18, P7319, DOI 10.1038/sj.onc.1203121; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wang Y, 2000, ONCOGENE, V19, P1379, DOI 10.1038/sj.onc.1203443; Wang Y, 1998, CELL GROWTH DIFFER, V9, P513; Wei L, 2000, AM J PHYSIOL-HEART C, V278, pH1736, DOI 10.1152/ajpheart.2000.278.6.H1736; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957	60	173	177	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24531	24539		10.1074/jbc.M102678200	http://dx.doi.org/10.1074/jbc.M102678200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342553	hybrid			2022-12-25	WOS:000169800700017
J	Gusarova, V; Caplan, AJ; Brodsky, JL; Fisher, EA				Gusarova, V; Caplan, AJ; Brodsky, JL; Fisher, EA			Apoprotein B degradation is promoted by the molecular chaperones hsp90 and hsp70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; UBIQUITIN-PROTEASOME PATHWAY; RABBIT RETICULOCYTE LYSATE; LOW-DENSITY LIPOPROTEINS; AMINO-TERMINAL DOMAIN; ENDOPLASMIC-RETICULUM; APOLIPOPROTEIN-B; IN-VITRO; INTRACELLULAR DEGRADATION; STEROID-RECEPTOR	Apoprotein B (apoB) is the major protein of liver-derived atherogenic lipoproteins, The net production of apoB can be regulated by presecretory degradation mediated by the ubiquitin-proteasome pathway and cytosolic hsp70. To further explore the mechanisms of apoB degradation, we have established a cell-free system in which degradation can be faithfully recapitulated. Human apoB48 synthesized in vitro was translocated into microsomes, glycosylated, and ubiquitinylated, Subsequent incubation with rat hepatic cytosol led to proteasome-mediated degradation. To explore whether hsp90 is required for apoB degradation, geldanamycin (GA) was added during the degradation assay. GA increased the recovery of microsomal apoB48 similar to3-fold and disrupted the interaction between hsp90 and apoB48, Confirming the hsp90 effect in the cell-free system, we also found that transfection of hsp90 cDNA into rat hepatoma cells enhanced apoB48 degradation. Finally, apoB48 degradation was reconstituted in vitro using cytosol prepared from wild type yeast. Notably, degradation was attenuated when apoB48-containing microsomes were incubated with cytosol supplemented with GA or with cytosol prepared from yeast strains with mutations in the homologues of mammalian hsp70 and hsp90. Overall, our data suggest that hsp90 facilitates the interaction between endoplasmic reticulum-associated apoB and components of the proteasomal pathway, perhaps in cooperation with hsp70.	CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Biochem Mol Biol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Cardiovasc Inst, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Fisher, EA (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Box 1269,1 Gustave Levy Pl, New York, NY 10029 USA.		Caplan, Avrom/GPT-0824-2022	Fisher, Edward/0000-0001-9802-143X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058541] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58541] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELI K, 1994, J BIOL CHEM, V269, P9166; Becker J, 1996, MOL CELL BIOL, V16, P4378; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; Bonifacino J. S., 1998, CURRENT PROTOCOLS CE; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; Chavany C, 1996, J BIOL CHEM, V271, P4974; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1991, J BIOL CHEM, V266, P5080; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Fliss AE, 2000, J STEROID BIOCHEM, V72, P223, DOI 10.1016/S0960-0760(00)00037-6; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Fuller W, 2000, J BIOL CHEM, V275, P37462, DOI 10.1074/jbc.M006278200; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; Goasduff T, 2000, ARCH BIOCHEM BIOPHYS, V379, P321, DOI 10.1006/abbi.2000.1870; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Hayes SA, 1996, J CELL BIOL, V132, P255, DOI 10.1083/jcb.132.3.255; Imamura T, 1998, J BIOL CHEM, V273, P11183, DOI 10.1074/jbc.273.18.11183; Lawson B, 1998, J CELL PHYSIOL, V174, P170, DOI 10.1002/(SICI)1097-4652(199802)174:2<170::AID-JCP4>3.3.CO;2-A; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Liang JS, 2000, J BIOL CHEM, V275, P32003, DOI 10.1074/jbc.M004646200; Linnik KM, 1998, J BIOL CHEM, V273, P21368, DOI 10.1074/jbc.273.33.21368; LITTLE E, 1995, J BIOL CHEM, V270, P9526, DOI 10.1074/jbc.270.16.9526; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; Nganga A, 2000, BIOCHEM J, V352, P865, DOI 10.1042/0264-6021:3520865; Pariyarath R, 2001, J BIOL CHEM, V276, P541, DOI 10.1074/jbc.M007944200; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Rajapandi T, 2000, J BIOL CHEM, V275, P22597, DOI 10.1074/jbc.M002035200; Rusinol AE, 1997, J BIOL CHEM, V272, P8019, DOI 10.1074/jbc.272.12.8019; Rustaeus S, 1998, J BIOL CHEM, V273, P5196, DOI 10.1074/jbc.273.9.5196; Sakata N, 1999, BBA-MOL CELL BIOL L, V1437, P71, DOI 10.1016/S1388-1981(98)00006-7; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; Shaeffer JR, 1996, BIOCHEMISTRY-US, V35, P10886, DOI 10.1021/bi9530705; Shamu CE, 1999, J CELL BIOL, V147, P45, DOI 10.1083/jcb.147.1.45; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Stillemark P, 2000, J BIOL CHEM, V275, P10506, DOI 10.1074/jbc.275.14.10506; Thulasiraman V, 1996, BIOCHEMISTRY-US, V35, P13443, DOI 10.1021/bi9615396; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; WAGNER BJ, 1995, ARCH BIOCHEM BIOPHYS, V323, P455, DOI 10.1006/abbi.1995.0067; WANG H, 1997, CIRCULATION, V96, P1543; WHITE AL, 1992, J BIOL CHEM, V267, P15657; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wilson CM, 2000, J BIOL CHEM, V275, P21224, DOI 10.1074/jbc.M000567200; Wu XJ, 1997, J BIOL CHEM, V272, P11575; Xiong XM, 1999, J BIOL CHEM, V274, P2616, DOI 10.1074/jbc.274.5.2616; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	60	108	110	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24891	24900		10.1074/jbc.M100633200	http://dx.doi.org/10.1074/jbc.M100633200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11333259	hybrid			2022-12-25	WOS:000169800700062
J	Erickson, RL; Hemati, N; Ross, SE; MacDougald, OA				Erickson, RL; Hemati, N; Ross, SE; MacDougald, OA			p300 Coactivates the adipogenic transcription factor CCAAT/enhancer-binding protein alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-MEDIATED PHOSPHORYLATION; RECEPTOR GAMMA-2 PROMOTER; ADIPOSE CELL LINE; ADIPOCYTE DIFFERENTIATION; C/EBP-ALPHA; 3T3-L1 ADIPOCYTES; GENE-EXPRESSION; MAMMALIAN-CELLS; PPAR-GAMMA; ACTIVATION	Despite the knowledge that CCAAT/enhancer-binding protein alpha (C/EBP alpha) plays an important role in preadipocyte differentiation, our understanding of how C/EBP alpha interacts with nuclear proteins to regulate transcription is limited. Based on the hypothesis that evolutionarily conserved regions are functionally important and likely to interact with coactivators, we compared the amino acid sequence of C/EBP alpha from different species (frog to human) and identified four highly conserved regions (CR1-CR4) within the transactivation domain. A series of amino-terminal truncations and internal deletion constructs were made creating forms of C/EBP alpha which lack single or multiple conserved regions. To determine which regions of the C/EBP alpha transactivation domain are important in its ability to induce spontaneous differentiation of 3T3-L1 preadipocytes, we infected preadipocytes with expression vectors encoding the C/EBP alpha conserved region mutants and observed their ability to induce differentiation. We found that CR2 fused to the DNA binding domain is able to induce spontaneous differentiation independent of the other conserved regions. However, CR2 was not necessary for the adipogenic action of C/EBP alpha because a combination of CR1 and CR3 can also induce adipogenesis. Because the transcriptional coactivator p300 participates in the signaling of many transcription factors to the basal transcriptional apparatus, we examined whether functional interaction exists between C/EBP alpha and p300. Cotransfection of p300 with p42C/EBP alpha results in a synergistic increase in leptin promoter activity, indicating that p300 acts as a transcriptional coactivator of C/EBP alpha. Analyses using C/EBP alpha conserved region mutants suggest that multiple regions (CR2 and CR3) of the C/EBP alpha transactivation domain functionally interact with p300.	Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	MacDougald, OA (corresponding author), Univ Michigan, Sch Med, Dept Physiol, 7744 Med Sci Bldg 2,1301 E Catherine, Ann Arbor, MI 48109 USA.	macdouga@umich.edu	Erickson, Robin/AAV-3405-2020	Erickson, Robin/0000-0002-3945-6158; MacDougald, Ormond/0000-0001-6907-7960	NIDDK NIH HHS [DK51563] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051563] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRASIER AR, 1995, CURRENT PROTOCOLS MO, V1; Calkhoven CF, 2000, GENE DEV, V14, P1920; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; Clarke SL, 1997, BIOCHEM BIOPH RES CO, V240, P99, DOI 10.1006/bbrc.1997.7627; Classon M, 2000, P NATL ACAD SCI USA, V97, P10826, DOI 10.1073/pnas.190343597; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Elberg G, 2000, J BIOL CHEM, V275, P27815; ERICKSON RL, 1999, ADIPOCYTE BIOL HORMO, P79; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; Goodman RH, 2000, GENE DEV, V14, P1553; GREEN H, 1979, J CELL PHYSIOL, V101, P169, DOI 10.1002/jcp.1041010119; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Hemati N, 1997, J BIOL CHEM, V272, P25913, DOI 10.1074/jbc.272.41.25913; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Hwang CS, 1996, P NATL ACAD SCI USA, V93, P873, DOI 10.1073/pnas.93.2.873; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; Lin Y, 2000, J BIOL CHEM, V275, P24255, DOI 10.1074/jbc.M002137200; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MACDOUGALD OA, 1995, P NATL ACAD SCI USA, V92, P9034, DOI 10.1073/pnas.92.20.9034; MACDOUGALD OA, 1995, J BIOL CHEM, V270, P647, DOI 10.1074/jbc.270.2.647; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Morrison RF, 1999, J CELL BIOCHEM, P59; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; Osada S, 1996, J BIOL CHEM, V271, P3891; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; Pond CM, 1998, IMMUNOL LETT, V63, P159, DOI 10.1016/S0165-2478(98)00074-1; PREECE A, 1972, MANUAL HISTOGIC TECH; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Rangwala SM, 2000, ANNU REV NUTR, V20, P535, DOI 10.1146/annurev.nutr.20.1.535; Reginato MJ, 1998, J BIOL CHEM, V273, P1855, DOI 10.1074/jbc.273.4.1855; Reitman ML, 2000, TRENDS ENDOCRIN MET, V11, P410, DOI 10.1016/S1043-2760(00)00309-X; Rosen ED, 2000, GENE DEV, V14, P1293; Ross SE, 1999, MOL CELL BIOL, V19, P8433; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wickelgren I, 1998, SCIENCE, V280, P1364, DOI 10.1126/science.280.5368.1364; Williams SC, 1997, GENE EXPRESSION, V6, P371; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	55	93	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16348	16355		10.1074/jbc.M100128200	http://dx.doi.org/10.1074/jbc.M100128200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11340085	hybrid			2022-12-25	WOS:000168623100104
